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I am very grateful to the special group of distinguished scientists who made up the Panel
and Secretariat for this major review of the evidence on food, nutrition, physical activity
and cancer. The vision of WCRF International in convening this Panel and confidence in
letting a strong-willed group of scientists have their way is to be highly commended.
In our view, the evidence reviewed here that led to our recommendations provides a
wonderful opportunity to prevent cancer and improve global health. Individuals and
populations have in their hands the means to lead fuller, healthier lives. Achieving that
will take action, globally, nationally, and locally, by communities, families, and
individuals.
It is worth pausing to put this Report in context. Public perception is often that experts
disagree. Why should the public or policy-makers heed advice if experts differ in their
views? Experts do disagree. That is the nature of science and a source of its strength.
Should we throw up our hands and say one opinion is as good as another? Of course not.
Evidence matters. But not evidence unguided by human thought. Hence the process that
was set up for this review: use a systematic approach to examine all the relevant evidence
using predetermined criteria, and assemble an international group of experts who, having
brought their own knowledge to bear and having debated their disagreements, arrive at
judgements as to what this evidence means. Both parts of the exercise were crucial: the
systematic review and, dare I say it, the wisdom of the experts. 
The elegance of the process was one of the many attractions to me of assuming the role
of chair of the Panel. I could pretend that it was the major reason, and in a way it was, but
the first reason was enjoyment. What a pleasure and a privilege to spend three years in
the company of a remarkable group of scientists, including world leaders in research on
the epidemiology of cancer, as well as leaders in nutrition and public health and the
biology of cancer, to use a relatively new methodology (systematic literature reviews),
supported by a vigorous and highly effective Secretariat, on an issue of profound
importance to global public health: the prevention of cancer by means of healthy patterns
of eating and physical activity. It was quite as enjoyable as anticipated.
Given this heady mix, the reasons why I might have wanted to take on the role of Panel
chair were obvious. I did question the wisdom of WCRF International in inviting me to do
it. Much of my research has been on cardiovascular disease, not cancer. What I described
as my ignorance, WCRF International kindly labelled impartiality.
WCRF also appreciated the parallels between dietary causes of cardiovascular disease
and cancer. There is a great deal of concordance. In general, recommendations in this
Report to prevent cancer will also be of great relevance to cardiovascular disease. The only
significant contradiction is with alcohol. From the point of view of cancer prevention, the
best level of alcohol consumption is zero. This is not the case for cardiovascular disease,
where the evidence suggests that one to two drinks a day are protective. The Panel
therefore framed its recommendation to take this into account. 
The fact that the conclusions and recommendations in this Report are the unanimous
view of the Panel does not imply that, miraculously, experts have stopped disagreeing. The
Panel debated the fine detail of every aspect of its conclusions and recommendations with
remarkable vigour and astonishing stamina. In my view, this was deliberation at its best. If
conclusions could simply fall out of systematic literature reviews, we would not have
needed experts to deliberate. Human judgement was vital; and if human, it cannot be
infallible. But I venture to suggest this process has led to as good an example of evidence-
based public health recommendations as one can find.
Throughout the Panel’s deliberations, it had in mind the global reach of this Report.
Most of the research on diet and cancer comes from high-income countries. But
Preface
vnoncommunicable diseases, including cancer, are now major public health burdens in
every region of the world. An important part of our deliberations was to ensure the
global applicability of our recommendations.
One last point about disagreement among experts: its relevance to the link between
science and policy. A caricature would be to describe science as precise and policy-makers
as indecisive. In a way, the opposite is the case. Science can say: could be, might be,
some of us think this, and some think that. Policy-makers have either to do it or not 
do it — more often, not. Our effort here was to increase the precision of scientific
judgements. As the Report makes clear, many of our conclusions are in the ‘could be’
category. None of our recommendations is based on these ‘could be’ conclusions. All are
based on judgements that evidence was definite or probable. Our recommendations, we
trust, will serve as guides to the population, to scientists, and to opinion-formers.
But what should policy-makers do with our judgements? A year after publication of
this Report, we will publish a second report on policy for diet, nutrition, physical activity,
and the prevention of cancer. As an exercise developing out of this one, we decided to
apply, as far as possible, the same principles of synthesis of evidence to policy-making.
We enhanced the scientific panel that was responsible for this Report with experts in
nutrition and food policy. This policy panel will oversee systematic literature reviews on
food policy, deliberate, and make recommendations.
The current Report and next year’s Policy Report have one overriding aim: to reduce
the global burden of cancer by means of healthier living. 
Michael Marmot
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Introduction
This summary provides an abbreviated version of the full
Report. It highlights the wealth of information and data
studied by the Panel and is designed to give readers an
overview of the key issues contained within the Report,
notably the process, the synthesis of the scientific evidence,
and the resulting judgements and recommendations.  
The first and second Report s
Food, Nutrition and the Prevention of Cancer: a global per-
spective, produced by the World Cancer Research Fund
together with the American Institute for Cancer Research,
has been the most authoritative source on food, nutrition,
and cancer prevention for 10 years. On publication in 1997,
it immediately became recognised as the most authoritative
and influential report in its field and helped to highlight the
importance of research in this crucial area. It became the
standard text worldwide for policy-makers in government
at all levels, for civil society and health professional organ-
isations, and in teaching and research centres of academic
excellence.
Since the mid-1990s the amount of scientific literature on
this subject has dramatically increased. New methods of
analysing and assessing evidence have been developed,
facilitated by advances in electronic technology. There is
more evidence, in particular on overweight and obesity and
on physical activity; food, nutrition, physical activity, and
cancer survivors is a new field. The need for a new report
was obvious; and in 2001 WCRF International in collabora-
tion with AICR began to put in place a global process in
order to produce and publish the Report in November 2007.
How this Report has been achieved
The goal of this Report is to review all the relevant research,
using the most meticulous methods, in order to generate a
comprehensive series of recommendations on food, nutri-
tion, and physical activity, designed to reduce the risk of
cancer and suitable for all societies. This process is also the
basis for a continuous review of the evidence.
Organised into overlapping stages, the process has been
designed to maximise objectivity and transparency, separat-
ing the collection of evidence from its assessment and
judgement. First, an expert task force developed a method
for systematic review of the voluminous scientific literature.
Second, research teams collected and reviewed the litera-
ture based upon this methodology. Third, an expert Panel
has assessed and judged this evidence and agreed recom-
mendations. The results are published in this Report and
summarised here. A more detailed explanation of this
process is given in Chapter 3 and the research teams and
investigators involved are listed on pages viii–xi.
This Report is a guide to future scientific research, cancer
prevention education programmes, and health policy
around the world. It provides a solid evidence base for
policy-makers, health professionals, and informed and
interested people to draw on and work with. 
Overview of the second expert Report
This Report has a number of inter-related general purposes.
One is to explore the extent to which food, nutrition, phys-
ical activity, and body composition modify the risk of can-
cer, and to specify which factors are most important. To the
extent that environmental factors such as food, nutrition,
and physical activity influence the risk of cancer, it is a pre-
ventable disease. The Report specifies recommendations
based on solid evidence which, when followed, will be
expected to reduce the incidence of cancer.    
Part 1 — Background
Chapter 1 shows that patterns of production and con-
sumption of food and drink, of physical activity, and of body
composition have changed greatly throughout human
history. Remarkable changes have taken place as a result 
of urbanisation and industrialisation, at first in Europe,
North America, and other economically advanced coun-
tries, and increasingly in most countries in the world.
Notable variations have been identified in patterns of can-
cer throughout the world. Significantly, studies consistently
show that patterns of cancer change as populations migrate
from one part of the world to another and as countries
become increasingly urbanised and industrialised. Pro-
jections indicate that rates of cancer in general are liable 
to increase. 
Chapter 2 outlines current understanding of the biology
of the cancer process, with special attention to the ways in
which food and nutrition, physical activity, and body com-
position may modify the risk of cancer. Cancer is a disease
of genes, which are vulnerable to mutation, especially over
the long human lifespan. However, evidence shows that
only a small proportion of cancers are inherited.
Environmental factors are most important and can be mod-
ified. These include smoking and other use of tobacco;
infectious agents; radiation; industrial chemicals and pollu-
tion; medication; and also many aspects of food, nutrition,
physical activity, and body composition. 
Summary
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Chapter 3 summarises the types of evidence that the
Panel has agreed are relevant to its work. No single study 
or study type can prove that any factor definitely is a cause
of, or is protective against, any disease. In this chapter,
building on the work of the first report, the Panel shows
that reliable judgements on causation of disease are based
on assessment of a variety of well-designed epidemiologi-
cal and experimental studies. 
The prevention of cancer worldwide is one of the most
pressing challenges facing scientists and public health
policy-makers, among others. These introductory chapters
show that the challenge can be effectively addressed and
suggest that food, nutrition, physical activity, and body
composition play a central part in the prevention of cancer.
Part 2 — Evidence and Judgements
The judgements made by the Panel in Part 2 are based on
independently conducted systematic reviews of the litera-
ture commissioned from academic institutions in the USA,
UK, and continental Europe. The evidence has been metic-
ulously assembled and, crucially, the display of the evi-
dence was separated from assessments derived from that
evidence. Seven chapters present the findings of these
reviews. The Panel’s judgements are displayed in the form
of matrices that introduce five of these chapters, and in the
summary matrix on the fold-out page inside the back cover. 
Chapter 4, the first and longest chapter in Part 2, is con-
cerned with types of food and drink. The judgements of the
Panel are, whenever possible, food- and drink-based,
reflecting the most impressive evidence. Findings on
dietary constituents and micronutrients (for example foods
containing dietary fibre) are identified where appropriate.
Evidence on dietary supplements, and on patterns of diet,
is included in the two final sections of this chapter. 
Chapters 5 and 6 are concerned with physical activity
and with body composition, growth, and development.
Evidence in these areas is more impressive than was the
case up to the mid-1990s; the evidence on growth and
development indicates the importance of an approach to
the prevention of cancer that includes the whole life
course.
Chapter 7 summarises and judges the evidence as
applied to 17 cancer sites, with additional briefer sum-
maries based on narrative reviews of five further body sys-
tems and cancer sites. The judgements shown in the
matrices in this chapter correspond with the judgements
shown in the matrices in the previous chapters. 
Obesity is or may be a cause of a number of cancers.
Chapter 8 identifies what aspects of food, nutrition, and
physical activity themselves affect the risk of obesity and
associated factors. The judgements, which concern the bio-
logical and associated determinants of weight gain, over-
weight, and obesity, are based on a further systematic
literature review, amplified by knowledge of physiological
processes.
The relevance of food, nutrition, physical activity, and
body composition to people living with cancer, and to the
prevention of recurrent cancer, is summarised in Chapter 9.
Improved cancer screening, diagnosis, and medical services
are, in many countries, improving survival rates. So the
number of cancer survivors — people living after diagnosis
of cancer — is increasing. 
The Panel agreed that its recommendations should also
take into account findings on the prevention of other chron-
ic diseases, and of nutritional deficiencies and nutrition-
related infectious diseases, especially of childhood. Chapter
10, also based on a systematic literature review, is a sum-
mary of the findings of expert reports in these areas.  
The research issues identified in Chapter 11 are, in the
view of the Panel, the most promising avenues to explore in
order to refine understanding of the links between food,
nutrition, physical activity, and cancer, and so improve the
prevention of cancer, worldwide. 
Part 3 — Recommendations
Chapter 12, the culmination of the five-year process, pre-
sents the Panel’s public health goals and personal recom-
mendations. These are preceded by a statement of the
principles that have guided the Panel in its thinking. 
The goals and recommendations are based on ‘convinc-
ing’ or ‘probable’ judgements made by the Panel in the chap-
ters in Part 2. These are proposed as the basis for public
policies and for personal choices that, if effectively imple-
mented, will be expected to reduce the incidence of cancer
for people, families, and communities. 
Eight general and two special goals and recommenda-
tions are detailed. In each case a general recommendation
is followed by public health goals and/or personal recom-
mendations, together with further explanation or clarifica-
tion as required. Chapter 12 also includes a summary of the
evidence, justification of the goals and recommendations,
and guidance on how to achieve them. 
The process of moving from evidence to judgements and
to recommendations has been one of the Panel’s main
responsibilities, and has involved discussion and debate
until final agreement has been reached. The goals and rec-
ommendations here have been unanimously agreed. 
The goals and recommendations are followed by the
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Panel’s conclusions on the dietary patterns most likely to
protect against cancer. In order to discern the ‘big picture’ of
healthy and protective diets, it is necessary to integrate a
vast amount of detailed information. The Panel used a
broad, integrative approach that, while largely derived from
conventional ‘reductionist’ research, has sought to find pat-
terns of food and drink consumption, of physical activity,
and of body fatness, that enable recommendations designed
to prevent cancer at personal and population levels.  
The goals and recommendations are designed to be gen-
erally relevant worldwide and the Panel recognises that in
national settings, the recommendations of this Report will
be best used in combination with recommendations, issued
by governments or on behalf of nations, designed to prevent
chronic and other diseases. In addition, the Panel cited
three specific cases where the evidence is strong enough to
be the basis for goals and recommendations, but which cur-
rently are relevant only in discrete geographical regions:
maté in Latin America, Cantonese-style salted fish in the
Pearl River Delta in Southern China, and arsenic contami-
nating water supplies in several locations. Further details on
nutritional patterns and regional and special circumstances
can be found in section 12.3.
The main focus of this Report is on nutritional and other
biological and associated factors that modify the risk of can-
cer. The Panel is aware that as with other diseases, the risk
of cancer is also modified by social, cultural, economic, and
ecological factors. Thus the foods and drinks that people
consume are not purely because of personal choice; likewise
opportunities for physical activity can be constrained.
Identifying the deeper factors that affect cancer risk enables
a wider range of policy recommendations and options to be
identified. This is the subject of a separate report to be pub-
lished in late 2008. 
The public health goals and personal recommendations of
the Panel that follow are offered as a significant contribu-
tion towards the prevention and control of cancer through-
out the world.  
The Panel’s recommendations
The Panel’s goals and recommendations that follow are
guided by several principles, the details of which can be
found in Chapter 12. The public health goals are for
populations, and therefore for health professionals; the
recommendations are for people, as communities, families,
and individuals.  
The Panel also emphasises the importance of not smoking
and avoiding exposure to tobacco smoke.
Format
The goals and recommendations begin with a general state-
ment. This is followed by the population goal and the per-
sonal recommendation, together with any necessary
footnotes. These footnotes are an integral part of the
recommendations. The full recommendations, including
further clarification and qualification, can be found in
Chapter 12.
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Justification
Most populations, and people living in industrialised and
urban settings, have habitual levels of activity below levels
to which humans are adapted.
With industrialisation, urbanisation, and mechanisation,
populations and people become more sedentary. As with
overweight and obesity, sedentary ways of life have been
usual in high-income countries since the second half of the
20th century. They are now common if not usual in most
countries. 
All forms of physical activity protect against some can-
cers, as well as against weight gain, overweight, and obesi-
ty; correspondingly, sedentary ways of life are a cause of
these cancers and of weight gain, overweight, and obesity.
Weight gain, overweight, and obesity are also causes of
some cancers independently of the level of physical activity.
Further details of evidence and judgements can be found in
Chapters 5, 6, and 8. 
The evidence summarised in Chapter 10 also shows that
physical activity protects against other diseases and that
sedentary ways of life are causes of these diseases.
RECOMMENDATION  1
BODY FATNESS
Be as lean as possible within 
the normal range1 of body weight
PUBLIC HEALTH GOALS
Median adult body mass index (BMI) to be 
between 21 and 23, depending on the 
normal range for different populations2
The proportion of the population that is overweight 
or obese to be no more than the current level, 
or preferably lower, in 10 years
PERSONAL RECOMMENDATIONS
Ensure that body weight through 
childhood and adolescent growth projects3 towards the
lower end of the normal BMI range at age 21
Maintain body weight within 
the normal range from age 21
Avoid weight gain and increases in 
waist circumference throughout adulthood
1 ‘Normal range’ refers to appropriate ranges issued by national governments or
the World Health Organization 
2 To minimise the proportion of the population outside the normal range
3 ‘Projects’ in this context means following a pattern of growth (weight and
height) throughout childhood that leads to adult BMI at the lower end of the
normal range. Such patterns of growth are specified in International Obesity
Task Force and WHO growth reference charts
RECOMMENDATION  2
PHYSICAL ACTIVITY
Be physically active as part of everyday life
PUBLIC HEALTH GOALS
The proportion of the population that is sedentary1
to be halved every 10 years
Average physical activity levels (PALs)1 to be above 1.6
PERSONAL RECOMMENDATIONS
Be moderately physically active, equivalent 
to brisk walking,2 for at least 30 minutes every day
As fitness improves, aim for 60 minutes or more 
of moderate, or for 30 minutes or more of 
vigorous, physical activity every day2 3
Limit sedentary habits such as watching television
1 The term ‘sedentary’ refers to a PAL of 1.4 or less. PAL is a way of representing
the average intensity of daily physical activity. PAL is calculated as total energy
expenditure as a multiple of basal metabolic rate 
2 Can be incorporated in occupational, transport, household, or leisure activities 
3 This is because physical activity of longer duration or greater intensity is more
beneficial
Justification
Maintenance of a healthy weight throughout life may be
one of the most important ways to protect against cancer.
This will also protect against a number of other common
chronic diseases.
Weight gain, overweight, and obesity are now generally
much more common than in the 1980s and 1990s. Rates of
overweight and obesity doubled in many high-income coun-
tries between 1990 and 2005. In most countries in Asia and
Latin America, and some in Africa, chronic diseases includ-
ing obesity are now more prevalent than nutritional defi-
ciencies and infectious diseases.
Being overweight or obese increases the risk of some can-
cers. Overweight and obesity also increase the risk of condi-
tions including dyslipidaemia, hypertension and stroke, type
2 diabetes, and coronary heart disease. Overweight in child-
hood and early life is liable to be followed by overweight
and obesity in adulthood. Further details of evidence and
judgements can be found in Chapters 6 and 8. Maintenance
of a healthy weight throughout life may be one of the most
important ways to protect against cancer.
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Justification
Consumption of energy-dense foods and sugary drinks is
increasing worldwide and is probably contributing to the
global increase in obesity.
This overall recommendation is mainly designed to prevent
and to control weight gain, overweight, and obesity. 
Further details of evidence and judgements can be found in
Chapter 8.
‘Energy density’ measures the amount of energy (in kcal
or kJ) per weight (usually 100 g) of food. Food supplies that
are mainly made up of processed foods, which often contain
substantial amounts of fat or sugar, tend to be more energy-
dense than food supplies that include substantial amounts
of fresh foods. Taken together, the evidence shows that it is
not specific dietary constituents that are problematic, so
much as the contribution these make to the energy density
of diets.
Because of their water content, drinks are less energy-
dense than foods. However, sugary drinks provide energy
but do not seem to induce satiety or compensatory reduc-
tion in subsequent energy intake, and so promote overcon-
sumption of energy and thus weight gain.
Justification
An integrated approach to the evidence shows that most
diets that are protective against cancer are mainly made up
from foods of plant origin.
Higher consumption of several plant foods probably protects
against cancers of various sites. What is meant by ‘plant-
based’ is diets that give more emphasis to those plant foods
that are high in nutrients, high in dietary fibre (and so in non-
starch polysaccharides), and low in energy density. Non-
starchy vegetables, and fruits, probably protect against some
cancers. Being typically low in energy density, they probably
also protect against weight gain. Further details of evidence
and judgements can be found in Chapters 4 and 8.
Non-starchy vegetables include green, leafy vegetables,
broccoli, okra, aubergine (eggplant), and bok choy, but not,
for instance, potato, yam, sweet potato, or cassava. Non-
starchy roots and tubers include carrots, Jerusalem arti-
chokes, celeriac (celery root), swede (rutabaga), and turnips.
RECOMMENDATION   3
FOODS AND DRINKS THAT 
PROMOTE WEIGHT GAIN
Limit consumption of energy-dense foods1
Avoid sugary drinks2
PUBLIC HEALTH GOALS
Average energy density of diets3 to be lowered 
towards 125 kcal per 100 g
Population average consumption of sugary drinks2
to be halved every 10 years
PERSONAL RECOMMENDATIONS
Consume energy-dense foods1 4 sparingly
Avoid sugary drinks2
Consume ‘fast foods’5 sparingly, if at all
1 Energy-dense foods are here defined as those with an energy content of more
than about 225–275 kcal per 100 g
2 This principally refers to drinks with added sugars. Fruit juices should also be
limited 
3 This does not include drinks
4 Limit processed energy-dense foods (also see recommendation 4). Relatively
unprocessed energy-dense foods, such as nuts and seeds, have not been shown
to contribute to weight gain when consumed as part of typical diets, and these
and many vegetable oils are valuable sources of nutrients 
5 The term ‘fast foods’ refers to readily available convenience foods that tend to 
be energy-dense and consumed frequently and in large portions
RECOMMENDATION   4
PLANT FOODS
Eat mostly foods of plant origin 
PUBLIC HEALTH GOALS
Population average consumption of non-starchy1
vegetables and of fruits to be at least 600 g (21 oz) daily2
Relatively unprocessed cereals (grains) and/or pulses
(legumes), and other foods that are a natural source of
dietary fibre, to contribute to a population average 
of at least 25 g non-starch polysaccharide daily
PERSONAL RECOMMENDATIONS
Eat at least five portions/servings 
(at least 400 g or 14 oz) of a variety2 of 
non-starchy vegetables and of fruits every day 
Eat relatively unprocessed cereals (grains) 
and/or pulses (legumes) with every meal3
Limit refined starchy foods 
People who consume starchy roots or tubers4
as staples also to ensure intake of sufficient 
non-starchy vegetables, fruits, and pulses (legumes)
1 This is best made up from a range of various amounts of non-starchy vegetables
and fruits of different colours including red, green, yellow, white, purple, and
orange, including tomato-based products and allium vegetables such as garlic
2 Relatively unprocessed cereals (grains) and/or pulses (legumes) to contribute 
to an average of at least 25 g non-starch polysaccharide daily
3 These foods are low in energy density and so promote healthy weight
4 For example, populations in Africa, Latin America, and the Asia-Pacific region
Continued on next page
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Justification
An integrated approach to the evidence also shows that
many foods of animal origin are nourishing and healthy if
consumed in modest amounts.
People who eat various forms of vegetarian diets are at low
risk of some diseases including some cancers, although it is
not easy to separate out these benefits of the diets from
other aspects of their ways of life, such as not smoking,
drinking little if any alcohol, and so forth. In addition, meat
can be a valuable source of nutrients, in particular protein,
iron, zinc, and vitamin B12. The Panel emphasises that this
overall recommendation is not for diets containing no meat
— or diets containing no foods of animal origin. The
amounts are for weight of meat as eaten. As a rough con-
version, 300 g of cooked red meat is equivalent to about
400–450 g raw weight, and 500 g cooked red meat to about
700–750 g raw weight. The exact conversion will depend
on the cut of meat, the proportions of lean and fat, and the
method and degree of cooking, so more specific guidance is
not possible. Red or processed meats are convincing or
probable causes of some cancers. Diets with high levels of
animal fats are often relatively high in energy, increasing
the risk of weight gain. Further details of evidence and
judgements can be found in Chapters 4 and 8.
Justification
The evidence on cancer justifies a recommendation not to
drink alcoholic drinks. Other evidence shows that modest
amounts of alcoholic drinks are likely to reduce the risk of
coronary heart disease.
The evidence does not show a clear level of consumption of
alcoholic drinks below which there is no increase in risk of
the cancers it causes. This means that, based solely on the
evidence on cancer, even small amounts of alcoholic drinks
should be avoided. Further details of evidence and judge-
ments can be found in Chapter 4. In framing the recom-
mendation here, the Panel has also taken into account the
evidence that modest amounts of alcoholic drinks are likely
to protect against coronary heart disease, as described in
Chapter 10.
The evidence shows that all alcoholic drinks have the
same effect. Data do not suggest any significant difference
depending on the type of drink. This recommendation
therefore covers all alcoholic drinks, whether beers, wines,
spirits (liquors), or other alcoholic drinks. The important
factor is the amount of ethanol consumed.
The Panel emphasises that children and pregnant women
should not consume alcoholic drinks.
RECOMMENDATION  5
ANIMAL FOODS
Limit intake of red meat1 and 
avoid processed meat2
PUBLIC HEALTH GOAL
Population average consumption of red meat 
to be no more than 300 g (11 oz) a week, 
very little if any of which to be processed
PERSONAL RECOMMENDATION
People who eat red meat1
to consume less than 500 g (18 oz) a week, 
very little if any to be processed2
1 ‘Red meat’ refers to beef, pork, lamb, and goat from domesticated animals
including that contained in processed foods
2 ‘Processed meat’ refers to meat preserved by smoking, curing or salting, or
addition of chemical preservatives, including that contained in processed foods
RECOMMENDATION  6
ALCOHOLIC DRINKS
Limit alcoholic drinks1
PUBLIC HEALTH GOAL 
Proportion of the population drinking 
more than the recommended limits to be 
reduced by one third every 10 years1 2
PERSONAL RECOMMENDATION
If alcoholic drinks are consumed, 
limit consumption to no more than two drinks a day 
for men and one drink a day for women1 2 3
1 This recommendation takes into account that there is a likely protective effect
for coronary heart disease 
2 Children and pregnant women not to consume alcoholic drinks
3 One ‘drink’ contains about 10–15 grams of ethanol
Recommendation 4, continued from page xviii
The goals and recommendations here are broadly similar
to those that have been issued by other international and
national authoritative organisations (see Chapter 10). They
derive from the evidence on cancer and are supported by
evidence on other diseases. They emphasise the importance
of relatively unprocessed cereals (grains), non-starchy veg-
etables and fruits, and pulses (legumes), all of which contain
substantial amounts of dietary fibre and a variety of
micronutrients, and are low or relatively low in energy den-
sity. These, and not foods of animal origin, are the recom-
mended centre for everyday meals.
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Justification
The strongest evidence on methods of food preservation, pro-
cessing, and preparation shows that salt and salt-preserved
foods are probably a cause of stomach cancer, and that foods
contaminated with aflatoxins are a cause of liver cancer.
Salt is necessary for human health and life itself, but at lev-
els very much lower than those typically consumed in most
parts of the world. At the levels found not only in high-
income countries but also in those where traditional diets
are high in salt, consumption of salty foods, salted foods,
and salt itself is too high. The critical factor is the overall
amount of salt. Microbial contamination of foods and drinks
and of water supplies remains a major public health prob-
lem worldwide. Specifically, the contamination of cereals
(grains) and pulses (legumes) with aflatoxins, produced by
some moulds when such foods are stored for too long in
warm temperatures, is an important public health problem,
and not only in tropical countries.
Salt and salt-preserved foods are a probable cause of
some cancers. Aflatoxins are a convincing cause of liver can-
cer. Further details of evidence and judgements can be
found in Chapter 4.
Justification
The evidence shows that high-dose nutrient supplements
can be protective or can cause cancer. The studies that
demonstrate such effects do not relate to widespread use
among the general population, in whom the balance of
risks and benefits cannot confidently be predicted. A gen-
eral recommendation to consume supplements for cancer
prevention might have unexpected adverse effects.
Increasing the consumption of the relevant nutrients
through the usual diet is preferred.
The recommendations of this Report, in common with its
general approach, are food based. Vitamins, minerals, and
other nutrients are assessed in the context of the foods and
drinks that contain them. The Panel judges that the best
source of nourishment is foods and drinks, not dietary sup-
plements. There is evidence that high-dose dietary supple-
ments can modify the risk of some cancers. Although some
studies in specific, usually high-risk, groups have shown evi-
dence of cancer prevention from some supplements, this
finding may not apply to the general population. Their level
of benefit may be different, and there may be unexpected
and uncommon adverse effects. Therefore it is unwise to
recommend widespread supplement use as a means of can-
cer prevention. Further details of evidence and judgements
can be found in Chapter 4.
In general, for otherwise healthy people, inadequacy of
intake of nutrients is best resolved by nutrient-dense diets
and not by supplements, as these do not increase consump-
tion of other potentially beneficial food constituents. The
Panel recognises that there are situations when supplements
are advisable. See box 12.4.
RECOMMENDATION  7
PRESERVATION, PROCESSING,
PREPARATION 
Limit consumption of salt1 
Avoid mouldy cereals (grains) or pulses (legumes)
PUBLIC HEALTH GOALS
Population average consumption of salt from 
all sources to be less than 5 g (2 g of sodium) a day
Proportion of the population consuming more than 6 g 
of salt (2.4 g of sodium) a day to be halved every 10 years
Minimise exposure to aflatoxins 
from mouldy cereals (grains) or pulses (legumes)
PERSONAL RECOMMENDATIONS
Avoid salt-preserved, salted, or salty foods; 
preserve foods without using salt1
Limit consumption of processed foods with added salt 
to ensure an intake of less than 6 g (2.4 g sodium) a day
Do not eat mouldy cereals (grains) or pulses (legumes)
1 Methods of preservation that do not or need not use salt include refrigeration,
freezing, drying, bottling, canning, and fermentation 
RECOMMENDATION  8
DIETA RY SUPPLEMENTS
Aim to meet nutritional needs 
through diet alone1
PUBLIC HEALTH GOAL
Maximise the proportion of the population achieving
nutritional adequacy without dietary supplements 
PERSONAL RECOMMENDATION
Dietary supplements are not recommended 
for cancer prevention
1 This may not always be feasible. In some situations of illness or dietary
inadequacy, supplements may be valuable
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Justification
The evidence on cancer as well as other diseases shows
that sustained, exclusive breastfeeding is protective for the
mother as well as the child.
This is the first major report concerned with the prevention
of cancer to make a recommendation specifically on breast-
feeding, to prevent breast cancer in mothers and to prevent
overweight and obesity in children. Further details of evi-
dence and judgements can be found in Chapters 6 and 8. 
Other benefits of breastfeeding for mothers and their
children are well known. Breastfeeding protects against
infections in infancy, protects the development of the
immature immune system, protects against other childhood
diseases, and is vital for the development of the bond
between mother and child. It has many other benefits.
Breastfeeding is especially vital in parts of the world where
water supplies are not safe and where impoverished fami-
lies do not readily have the money to buy infant formula
and other infant and young child foods. This recommenda-
tion has a special significance. While derived from the evi-
dence on being breastfed, it also indicates that policies and
actions designed to prevent cancer need to be directed
throughout the whole life course, from the beginning of
life.
Justification
Subject to the qualifications made here, the Panel has
agreed that its recommendations apply also to cancer sur-
vivors. There may be specific situations where this advice
may not apply, for instance, where treatment has compro-
mised gastrointestinal function.
If possible, when appropriate, and unless advised otherwise
by a qualified professional, the recommendations of this
Report also apply to cancer survivors. The Panel has made
this judgement based on its examination of the evidence,
including that specifically on cancer survivors, and also on
its collective knowledge of the pathology of cancer and its
interactions with food, nutrition, physical activity, and body
composition. In no case is the evidence specifically on can-
cer survivors clear enough to make any firm judgements or
recommendations to cancer survivors. Further details of
evidence and judgements can be found in Chapter 9.
Treatment for many cancers is increasingly successful,
and so cancer survivors increasingly are living long enough
to develop new primary cancers or other chronic diseases.
The recommendations in this Report would also be expect-
ed to reduce the risk of those conditions, and so can also be
recommended on that account. 
SPECIAL RECOMMENDATION 1
BREASTFEEDING 
Mothers to breastfeed; children to be breastfed1
PUBLIC HEALTH GOAL
The majority of mothers to breastfeed 
exclusively, for six months2 3
PERSONAL RECOMMENDATION
Aim to breastfeed infants exclusively2
up to six months and continue 
with complementary feeding thereafter3
1 Breastfeeding protects both mother and child 
2 ‘Exclusively’ means human milk only, with no other food or drink, including
water 
3 In accordance with the UN Global Strategy on Infant and Young Child Feeding 
SPECIAL RECOMMENDATION  2
CANCER SURVIVORS1
Follow the recommendations 
for cancer prevention2
RECOMMENDATIONS
All cancer survivors3 to receive nutritional care 
from an appropriately trained professional
If able to do so, and unless otherwise advised, 
aim to follow the recommendations for 
diet, healthy weight, and physical activity2
1 Cancer survivors are people who are living with a diagnosis of cancer, including
those who have recovered from the disease
2 This recommendation does not apply to those who are undergoing active
treatment, subject to the qualifications in the text 
3 This includes all cancer survivors, before, during, and after active treatment 
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The proposals that cancer might be preventable, and that
food, nutrition, physical activity, and body composition
might affect the risk of cancer, were first made before
science emerged in its modern form in the 19th and 20th
centuries. Throughout recorded history, wise choices of
food and drink, and of habitual behaviour, have been
recommended to protect against cancer, as well as other
diseases, and to improve well-being. 
Reports such as this, which incorporate systematic
examination of all relevant types of research, differ from
ancient, historical, and even relatively recent accounts, and
descriptive studies of the type detailed in Chapter 1, not
only in the quantity and quality of evidence, but also in the
reliability of the judgements and recommendations that
derive from it. 
The purpose of this Report
This Report has been commissioned and resourced by the
World Cancer Research Fund (WCRF) International and its
sister organisation the American Institute for Cancer
Research (AICR), who provided the Secretariat that has
supported the Panel responsible for the Report. Panel
members, observers, review centres, and other contributors
are listed on the preceding pages. The five-year project that
has resulted in this Report follows a previous five-year
project that resulted in the first WCRF/AICR report
published in 1997, which was the responsibility of the
former distinguished international multidisciplinary panel
chaired by Professor John Potter.
This Report has two overall general purposes. The first is
to summarise, assess, and judge the most comprehensive
body of evidence yet collected and displayed on the subject
of food, nutrition, physical activity, body composition, and
the risk of cancer, throughout the life-course. The second
purpose is to transform the evidence-derived judgements
into goals and personal recommendations that are a
reliable basis for sound policies and effective actions at
population, community, family, and individual level, in
order to prevent cancer, worldwide. 
What is already known  
The Panel is aware of the general consensus shared by
scientists, health professionals, and policy-makers on the
relationships between food, nutrition, physical activity,
body composition, and the risk of cancer. 
This consensus, based on the findings of a rapidly
growing mass of increasingly well-designed
epidemiological and experimental studies and other
relevant evidence, emerged in the early 1980s. Thus: ‘It is
abundantly clear that the incidence of all the common
cancers in humans is determined by various potentially
controllable external factors. This is surely the most
comforting fact to come out of cancer research, for it
means that cancer is, in large part, a preventable disease’.1
This is the conclusion of a report on diet and the
prevention of cancer published a quarter of a century
before this Report. 
Since the early 1980s, relevant United Nations agencies,
national governments, authoritative non-governmental
organisations, and researchers and other experts in the
field have agreed that food and nutrition, physical activity,
and body composition are individually and collectively
important modifiers of the risk of cancer, and taken
together may be at least as important as tobacco. 
By the mid-1990s the general consensus became more
solidly based on methodical assessment of the totality of
the relevant literature. Thus: ‘It is now established that
cancer is principally caused by environmental factors, of
which the most important are tobacco; diet and factors
related to diet, including body mass and physical activity;
and exposures in the workplace and elsewhere.’ This
statement introduces the recommendations made in the
first WCRF/AICR report. 
Expert reports may be accompanied by guidebooks
written for general readers. Thus: ‘A healthy eating
strategy… is an important part of protecting yourself
against a long list of diseases. These include heart disease,
stroke, several common cancers, cataract formation, other
age-related diseases, and even some types of birth defects.
When combined with not smoking and regular exercise, this
kind of healthy diet can reduce heart disease by 80 per
cent, and stroke and some cancers by 70 percent, compared
with average rates’.2 This is a conclusion of a book written
by a member of the Panel responsible for this Report.
Some general judgements are now well known and not a
matter for serious debate. Cancer in general, and cancers
of different types and sites, are agreed to have various
causes, among which are inherited genetic predisposition
and the increasing likelihood that cells will accumulate
genetic defects as people age. This is discussed in more
detail in Chapter 2. Also, people die less frequently from
nutritional deficiencies, infectious diseases, predation, and
accidents, whereas chronic diseases including cancer —
which are more common in older people — become more
common. 
However, cancer is not an inevitable consequence of
ageing, and people’s susceptibility to it varies.  There is
abundant evidence that the main causes of patterns of
Introduction
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cancer around the world are environmental. This does
indeed mean that at least in principle, most cancer is
preventable, though there is still discussion about the
relative importance of various environmental factors. 
But what are these environmental factors, what is their
relative importance, and how may they vary in different
times in the life-course and in different parts of the world,
and how might they interact with each other? Many
thousand epidemiological and experimental studies have
looked for answers. Some answers are now agreed to be
unequivocal. Thus, smoking is the chief cause of lung
cancer. Alcohol is also an established carcinogen in
humans, as are types of radiation such as those used in
medical treatments and as released by nuclear weapons
and accidents. Certain infectious agents are undoubtedly a
cause of some cancers.  
The need for a new initiative
Many questions, particularly in the field of food, nutrition,
and associated factors, remain. Some are fundamental. Do
statements such as those quoted above remain valid? Do
they apply worldwide? Have the reviews and reports so far
published overlooked key findings? How do the large
prospective studies, meta-analyses, pooling projects, and
randomised controlled trials undertaken and published
since the mid-1990s impact on earlier conclusions and
recommendations? Are there areas in this field that have
been neglected? Is entirely new evidence coming to light? 
Questions such as these led to the commissioning of this
Report by WCRF/AICR in 2001. The Panel responsible for
the Report first convened in 2003, and has met twice a
year until 2007. The terms of reference accepted by the
Panel at its first meeting were to:
• Judge the reviews of the scientific and other literature
prepared for the Panel by the assigned review teams
• Devise a series of dietary, associated, and other
recommendations suitable for all societies, designed to
reduce the risk of cancer
• Evaluate the consistency between such
recommendations and those designed to prevent other
food-related diseases.
The Panel believes that these terms of reference have been
fulfilled. The public policy implications of the
recommendations made in this Report are the subject of a
further report, to be published in late 2008. 
Special features of this Report
This Report in part adapts and builds on the work of the
previous WCRF/AICR report. It also has central features
that are new. It is not simply an ‘update’ of the previous
report. Since the mid-1990s a substantial body of relevant
literature has been published in peer-reviewed journals.
Further, the executive officers of WCRF/AICR, its
Secretariat, and the Panel responsible, decided at the
outset that developments in scientific method since the
mid-1990s, notably in systematic approaches to
synthesising evidence, and as enabled by the electronic
revolution, have been so remarkable that a whole new
process was justified. 
Systematic literature reviews
This process (described in Appendix A) has involved
systematic literature reviews (SLRs), which have been used
as the main basis for the Panel’s judgements in this Report.
These are described in more detail in Chapter 3. They were
undertaken by independent centres of research and review
excellence in North America and Europe, to a common
agreed protocol, itself the product of an expert
Methodology Task Force. As a result, the judgements of the
Panel now are as firmly based as the evidence and the state
of the science allow. Some are new. Some are different
from those previously published. Findings that may at first
reading seem to repeat those of the first report are in fact
the result of an entirely new process. 
Rigorous criteria to assess evidence 
The criteria used in this Report to assess the evidence
presented in the SLRs and from other sources are more
precise and explicit than, and in some respects different
from and more stringent than, those used in the previous
report. During its initial meetings, the Panel reviewed and
agreed these criteria before embarking on the formal
evidence review. More details are given in Chapter 3. 
Nevertheless, readers and users of this Report should be
able to see how and why the development of scientific
method and research since the mid-1990s has resulted in
conclusions and recommendations here that sometimes
vary from, sometimes are much the same as, and
sometimes reinforce those of the previous Report. 
Graphic display of Panel judgements 
The Panel has retained the matrix technique of displaying
its judgements, which introduce the chapters and chapter
sections throughout Part 2 of this Report. This technique,
pioneered in the first report, has been adapted by the
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World Health Organization in its 2003 report on diet,
nutrition, and the prevention of chronic diseases. Some
members of the expert consultation responsible for the
WHO report, including its chair and vice-chair, have served
as members of the Panel responsible for this Report. 
In further adapting the format of the matrices used in
the first report, the Panel was careful to distinguish
between evidence strong enough to justify judgements of
convincing or probable causal relationships, on which
recommendations designed to prevent cancer can be
based, and evidence that is too limited in amount,
consistency, or quality to be a basis for public and personal
health recommendations, but which may nevertheless in
some cases be suggestive of causal relationships. 
Food-based approach
Since the 1990s a broad food- and drink-based approach to
interpreting the evidence on food, nutrition, and the risk of
cancer has increasingly been used, in contrast to the
overwhelming research emphasis on individual food
constituents. The previous report included three chapters
showing the findings on dietary constituents (including
‘energy and related factors’, notably physical activity),
foods and drinks, and food processing (meaning
production, preservation, processing, and preparation), in
that order. 
This Report has taken a food-based approach, as shown
throughout Chapter 4, more closely reflecting the nature of
the evidence. Thus many findings on dietary constituents
and micronutrients, when their dietary sources are from
foods rather than supplements, are here identified as, for
example, findings on ‘foods containing dietary fibre’ or
‘foods containing folate’. Findings on methods of food
processing are, wherever possible, shown as part of the
evidence on the associated foods, so that, for example,
meat processing is integrated with the evidence on meat.
The evidence and judgements focused on cancer are
summarised and displayed in Chapter 7. 
Physical activity
The scope of the work of this Panel is wider than that of
the previous panel. The previous report judged that the
evidence that physical activity protects against cancer of
the colon was convincing. Since then evidence on physical
activity (and physical inactivity, especially when this
amounts to generally sedentary ways of life) has become
more impressive. Correspondingly, the review centres were
requested specifically to examine the literature on physical
activity (and inactivity) as well as on foods and drinks. The
results of this work, and the Panel’s judgements, are shown
in Chapter 5. 
Body fatness 
As with physical inactivity, the evidence that body fatness
— including degrees of fatness throughout the range of
body weight, from underweight and normal to overweight
and obesity, as well as any specific effect of weight gain —
directly influences risk of some cancers has also become
more impressive. The previous report judged that the
evidence that greater body fatness (there termed ‘high
body mass’) is a convincing or probable cause of cancers of
the endometrium, breast (postmenopausal), and kidney.
For this Report, the commissioned SLRs not only included
the evidence linking body fatness directly with cancer, but
a separate review was also commissioned specifically on
the biological and associated determinants of body fatness
itself. The evidence and the Panel’s judgements, which
include assessment of the physiology of energy
metabolism, are summarised in Chapters 6 and 8. 
The Panel is aware that weight gain, overweight, and
obesity, and their antecedent behaviours, are critically
determined by social, cultural, and other environmental
factors. This is one topic for the separate report on policy
implications to be published in late 2008. 
Cancer survivors 
There are increasing numbers of cancer survivors — people
who have at some time been diagnosed with cancer. What
should those people living with cancer do? Particularly
since the 1990s, this question is being asked increasingly,
as more and more people are diagnosed with and treated
for cancer, and are seeking ways in which they can add to
their medical or surgical management to help themselves
to remain healthy. Are the circumstances of people who
have recovered from cancer any different from those of
people who are free from cancer? Questions such as these
are addressed in Chapter 9.  
Life-course approach 
Unlike this Report, the reviews conducted for the first
report did not consider the literature on food and nutrition
in the first two years of life. Increasingly, evidence is
accumulating on the importance of early life-events on
later health. Evidence and judgements on the impact of
birth weight and adult attained height on cancer risk are
presented in Chapter 6, though the detailed processes
underpinning these associations with cancer risk are not
yet clear. Findings on the relationship between not being
breastfed and later overweight and obesity in children are
reported in Chapter 8, and on lactation and lower breast
cancer risk in the mother are reported in Chapter 7. These
findings form part of a general ‘life-course’ approach
summarised in Chapter 2, reflecting an appreciation of the
importance of the accumulation of nutritional and other
experiences throughout life, as well as genetic endowment,
in influencing susceptibility to disease. 
Goals and recommendations
The Panel’s recommendations are set out in Chapter 12
and in abbreviated form in the Summary, on the preceding
pages. 
The previous report agreed 14 recommendations. This
Report makes eight general and two special
recommendations for specific target groups. These are set
out in more detail than in the previous report. As before,
principles that guide the goals and recommendations are
set out. The recommendations themselves are displayed in
boxes and are accompanied by text that justifies them, and
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by practical guidance. The recommendations are addressed
to people, as members of communities and families and
also as individuals. 
Recommendations and options addressed to UN and
other international organisations, national governments,
industry, health professional and civil society organisations,
and the media are set out in the separate report on policy
implications, to be published in late 2008. 
A note of caution 
The Panel is confident that its findings are soundly based,
and that its recommendations, when translated into
effective public policy programmes and personal choices,
will reduce the risk of cancer. That said, the available
evident is imperfect. The Panel’s conclusions derive from
the best evidence now available, which reflects past and
recent research priorities mostly in high-income countries,
though synthesised and judged in as meticulous and
rigorous way as possible. What is here is therefore an
incomplete picture. 
The tendency of reports such as this is to consider
diseases in isolation. In the case of this Report, the
relationship of weight gain, overweight, and obesity on the
risk of some cancers is so clear that determinants of these
factors have also been considered. But the Panel agrees, as
evident in Chapters 10 and 12, that many chronic diseases,
including type 2 diabetes and its precursors, cardiovascular
diseases and their precursors, and also perhaps other
diseases of the digestive, musculoskeletal, and nervous
systems, are to a large extent caused by environmental
factors, including inappropriate food and nutrition,
physical inactivity, overweight and obesity, and associated
factors. Following from this, future reports should consider
the promotion of health and the prevention of disease as a
whole. 
How much cancer is preventable?
As shown in its title, the purpose of this Report is to
prevent cancer. The term ‘prevention’ needs definition. It
does not mean the elimination of cancer. It means
reduction in its occurrence, such that at any age fewer
people have cancer than otherwise would be the case. 
If all factors are taken into account, cancer is mostly a
preventable disease. The authors of a landmark study
published in the early 1980s concluded: ‘It is highly likely
that the United States will eventually have the option of
adopting a diet that reduces its incidence of cancer by
approximately one third, and it is absolutely certain that
another one third could be prevented by abolishing
smoking.’3 Cancers of some sites, notably of the colon, are
generally agreed to be greatly or mostly affected by food
and nutrition. 
Since then, authoritative estimates of the preventability
of cancer by means of food and nutrition and associated
factors have been in broad agreement with the ‘around one
third’ figure. The estimate of the previous WCRF/AICR
Report was that cancer is 30 to 40 per cent preventable
over time, by appropriate food and nutrition, regular
physical activity, and avoidance of obesity. On a global
scale this represents over 3 to 4 million cases of cancer that
can be prevented in these ways, every year. 
In many of its forms, cancer is a disease that can cause
great suffering and claims many lives. The overall
commitment of scientists and other professionals
committed to disease prevention, as exemplified by this
Report, is to reduce the rates not just of cancer, but of all
diseases, so that more people enjoy good health until they
eventually die in old age.
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2This Report has a number of inter-related general purposes. One is to explore
the extent to which food, nutrition, physical activity, and body composition
modify the risk of cancer, and to specify as far as possible the importance of
specific factors. To the extent that environmental factors such as food,
nutrition, and physical activity influence risk of cancer, it is a preventable
disease. The Report specifies recommendations based on solid evidence
which, when followed, will be expected to reduce the incidence of cancer.  
Part 1 of the Report begins with two chapters summarising the first lines of
evidence from observations of human populations, and from experimental
and basic science, pointing to the conclusion that cancer is preventable. The
third chapter summarises the types of evidence that are relevant in
identifying the causes of cancer, and explains the process used by the Panel
to assess the strength of this evidence and to come to judgement. 
Chapter 1 shows that patterns of production and consumption of food and
drink, of physical activity, and of body composition have changed greatly
throughout different periods of human history. Remarkable changes have
taken place as a result of urbanisation and industrialisation, at first in
Europe, North America, and other economically advanced countries, and
increasingly in most countries in the world. 
With the establishment of reliable records in the second half of the 20th
century, notable variations have been identified in patterns of cancer
throughout the world. Some cancers, such as those of the upper
aerodigestive tract, stomach, liver, and cervix, are more common in lower
income countries; others, such as those of the colorectum, breast, ovary,
endometrium, prostate, and lung, are more common in higher income
countries. 
More significant, as shown in Chapter 1, are studies consistently showing
that patterns of cancer change as populations migrate from one part of the
world to another and as countries become increasingly urbanised and
industrialised. Projections indicate that rates of cancer in general are liable
to increase. 
Chapter 2 outlines current understanding of the biology of the cancer
process, with special attention given to the ways in which food and
nutrition, physical activity, and body composition may modify it. 
Cancer is a disease of genes, which are vulnerable to beneficial or harmful
mutation, especially over the long human lifespan. Nutritional factors are
important in determining the likelihood of some mutations, as well as in
changing the functions of genes even without mutation. However, both
epidemiological and experimental evidence shows that only a small
proportion of cancers are inherited. Environmental factors are most
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3important and can be modified. These include smoking and other use of
tobacco; infectious agents; radiation; industrial chemicals and pollution;
medication — and also many aspects of food, nutrition, physical activity, and
body composition. Essentially this is good news. It means that healthy
environments can stop cancer before it starts. The evidence also indicates that
such environments, including the factors that are the subject of this Report,
may be able to check the cancer process after it has started. 
The third chapter summarises the types of evidence that the Panel has agreed
are relevant to its work. No one study can prove that any factor definitely is a
cause of or is protective against any disease. Also while some study designs
are more reliable than others, they often cannot be used to answer many types
of question; so no one kind of study, however careful its methods, can ever
produce definitive results. In this chapter, building on the work of the first
report, the Panel shows that all study designs have strengths and weaknesses,
and that reliable judgements on causation of disease are based on assessment
of a variety of well designed epidemiological and experimental studies. 
The judgements made by the Panel in Part 2 of this Report are based on
independently commissioned and conducted systematic reviews of the
literature. This has ensured that the evidence has been assembled using
methods that are as meticulous as possible, and that the display of the
evidence is separated from assessments derived from this evidence, which are
made in Part 2. 
The prevention of cancer worldwide is one of the most pressing challenges
facing scientists and public health policy-makers, among others. These
introductory chapters show that the challenge can be effectively addressed.
They also suggest that food and nutrition, physical activity, and body
composition all play a central part in the prevention of cancer. 
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International variations
and trends
The first lines of evidence suggesting that cancer is
a largely preventable disease have come from
studies noting variations in cancer incidence across
time and place. The most impressive initial evidence
showing that patterns of cancer are altered by
environmental factors, and are not mainly
genetically determined, comes from studies
describing changes in the rates of different cancers
in genetically identical populations that migrate
from their native countries to other countries. Such
studies consistently show that changes in the rates
of some of the most common cancers, including
those of the stomach, colorectum, breast, and
prostate, can be remarkable, even over one or two
generations. 
This first introductory chapter summarises current
knowledge of the variations in food, nutrition,
physical activity, body composition, and cancer in
different parts of the world. This assessment
provides strong circumstantial evidence that
continues to prompt systematic studies including
interventions of various types, and also reports such
as this, which collect and judge the available
evidence. Such systematic work has already led the
United Nations and other international bodies,
national governments, and authoritative
independent organisations to be confident that
most cancers are largely preventable. 
Patterns of food and drink, of physical activity,
and of body composition have changed remarkably
throughout human history. With industrialisation
and urbanisation, food supplies usually become
more secure, and more food is available for
consumption. In general, diets become more energy
dense, containing fewer starchy foods, more fats
and oils, sugars, and additives, and often more
alcoholic drinks. At the same time, patterns of
physical activity change: populations become
increasingly sedentary, their need for energy from
food drops, and rates of overweight and obesity
increase. 
These changes correlate with changes in the
patterns of cancer throughout the world. Middle-
and low-income regions and countries within Africa,
Asia, and Latin America have generally experienced
comparatively high rates of cancers of the upper
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aerodigestive tract (of the mouth, pharynx, larynx,
nasopharynx, and oesophagus), and of the stomach,
liver (primary), and cervix. Rates of some cancers,
especially stomach cancer, are now generally
decreasing. 
In contrast, high-income countries, and urbanised
and industrialised areas of middle- and low-income
regions and countries, have higher rates of
colorectal cancer and of hormone-related cancers (of
the breast, ovary, endometrium, and prostate). Lung
cancer is now the most common type in the world
because of the increase in tobacco smoking and
exposure to environmental tobacco smoke. Rates of
these cancers, some of which may have been
historically rare, are increasing. 
Globally, the number of people with cancer is
projected to double by the year 2030, with most of
this increase likely to occur in middle- and low-
income countries. Such an increase would only
partly be accounted for by the projected rise in the
size and average age of the global population. This
makes the task of cancer prevention all the more
urgent and important.
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This chapter outlines the historic, recent, and current varia-
tions and trends in food, nutrition, physical activity, over-
weight and obesity, and in patterns of cancer.
People’s diets reflect the times and situations in which they
live. It is only relatively recently in history that urban–indus-
trial ways of life have evolved, with many or most people
living in towns and cities rather than in the countryside. In
much of Africa and Asia, most people still live in rural com-
munities, and peasant–agricultural and urban–industrial
ways of life still coexist in most countries. Such patterns
change very rapidly as countries become increasingly
urbanised and industrialised. 
The different food systems and diets that are part of these
diverse ways of life affect people’s levels of physical activity,
their body composition and stature, their life expectancy, and
patterns of disease, including cancer. With the move to
urban–industrial ways of life, populations have become taller
and heavier, their life expectancy has increased, and they are
usually adequately nourished (although poverty, and even
destitution, remains a major problem in most big cities). On
the other hand, urban populations are at increased risk of
chronic diseases such as obesity, type 2 diabetes, coronary
heart disease, and also some cancers.
This chapter also summarises some available information
on eight common cancers, irrespective of any recognised links
to food, nutrition, and physical activity; these factors are dealt
with later in the Report. Four are endemic in middle- and low-
income countries: cancers of the oesophagus, stomach, liver,
and cervix. Four are endemic in high-income countries, and
are in general increasing in middle- and low-income countries:
cancers of the lung, colon and rectum, breast, and prostate.
Information on the trends and projections of levels of physi-
cal activity, and overweight and obesity, is summarised. 
Descriptive epidemiology, including studies of changing dis-
ease patterns in migrant populations, is covered. These stud-
ies can generate hypotheses about relationships between food,
nutrition, physical activity, and the risk of cancer. However,
they serve mainly as a foundation for studies that provide
stronger evidence. 
The 12 national examples provided throughout this chap-
ter summarise some of the trends in foods and drinks, obesi-
ty, physical activity, and cancer in countries around the world.
These are Egypt and South Africa (Africa); China, India, and
Japan (Asia); the UK, Poland, and Spain (Europe); the USA,
Brazil, and Mexico (the Americas); and Australia (Asia-
Pacific).1-47
1.1  Food systems and diets: historical and
current 
Throughout history, food systems, and thus human diets,
have been and are shaped by climate, terrain, seasons, loca-
tion, culture, and technology. They can be grouped into three
broad types: gatherer–hunter, peasant–agricultural, and
urban–industrial. These and other food systems (for exam-
ple, pastoralist, the semi-mobile farming of herds of large
animals such as sheep and cattle) have their roots in histo-
ry. All have coexisted in recent millennia with the exception
of industrial food systems, which are the consequence of the
industrial revolution that began in Europe in the late 18th
century. These systems still exist in the world today.
1.1.1  Gatherer–hunter 
Since the emergence of Homo sapiens around 250000 years
ago, gatherer–hunter food systems have taken different
forms, depending on the environments in which people lived.
These systems still exist in parts of the world that are remote
from cities and roads. They supply diets that usually include
moderate amounts of starchy foods, and which are high in
dietary fibre and low in sugar, mostly from fruits and
honey.48 Methods of food preparation include pulverising,
drying, and roasting. These diets are usually high in foods
of animal origin (ranging from large animals to insects, and
also fish and other seafood, depending on location), and 
thus in animal protein. It is sometimes thought that 
gatherer–hunter diets are high in fat, which is not the case
because wild animals are lean. Recent analyses suggest that
gathered food generally provides rather more dietary bulk
and energy than hunted food.49
People in gatherer–hunter societies are necessarily physi-
cally active, and are often tall and usually lean (only chiefs,
or old or incapacitated people might be overweight or
obese). The diets of food-secure gatherer–hunter societies
may be diverse and high in micronutrients.50 51 Diets are
liable to become monotonous and deficient in various nutri-
ents, as well as in energy, when food supplies are chronically
insecure, or at times of acute food shortage. It is sometimes
claimed that gatherer–hunter food systems generate diets to
which the human species is best adapted.48 However, life
expectancy in gatherer–hunter societies is and has been usu-
ally relatively low. 
Evidence of cancer has occasionally been found in human
and other fossil and ancient remains.52 Historically, cancer
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In 2004 Egypt had a population of just over
74 million. Nearly the whole population
lives within the Nile Valley and the Nile
Delta, less than 4 per cent of the country’s
total area. Egypt has a lower-middle-income
economy, with a gross domestic product of
4274 international dollars per person (figure
1.3). Life expectancy at birth is 66 years for
men and 70 for women (figure 1.1).46
Chronic diseases account for 83.6 per
cent of deaths, while infectious diseases,
maternal, perinatal, and nutritional condi-
Egypt 
of any type seems to have been uncommon among gather-
er–hunter peoples, if only because their average life
expectancy was low. In modern gatherer–hunter societies,
the incidence of cancer rises after contact with industrialised
and urbanised ways of life, which usually involve shifts in
patterns of diet and physical activity.53 These points gener-
ally also apply to pastoralist societies.
1.1.2  Peasant–agricultural 
In recent millennia, and until very recently in history, almost
all human populations have been rural and mostly peas-
ant–agricultural, and the majority still are in most regions of
Asia, many regions of Africa, and some parts of Latin
America. Peasant–agricultural food systems involving the cul-
tivation of wheat may have first developed around 9000
years ago in the ‘Fertile Crescent’ of the Middle East, includ-
ing the region between the Tigris and Euphrates rivers (with-
in modern Iraq). These systems also developed
independently in Asia, with rice as the staple food, and in
the Americas, with corn (maize) as the staple.54 The key fac-
tor in these systems is land settlement, itself determined by
the cultivation and breeding of crops and also animals, birds,
and fish for human consumption and use.55 In and around
Egypt, people began to make bread from wheat about 6000
years ago.56
Typically, diets derived from these systems are plant-based:
they are high or very high in cereals (grains), complement-
ed with animal sources of protein. These diets are therefore
high in starchy foods and usually in dietary fibre (unless the
cereals are refined). They include varying amounts of foods
of animal origin, and of vegetables and fruits, depending on
relative food security. Surplus food is stored for consump-
tion in winter and during hard times, and methods of food
preparation also include fermentation, used for foods as well
as for the production of alcoholic drinks (see chapters 4.8
and 4.9). 
The dominant indigenous cereal crop varies in different
parts of the world: wheat is grown in the Middle East; bar-
ley, rye, and oats in colder, northern climates; millet and rice
in Asia; maize (corn) in the Americas; and sorghum and teff
in Africa. Indigenous staple crops also include roots and
tubers such as cassava (manioc), yams, potatoes, and also
plantains. Pulses (legumes) are also farmed to ensure agri-
cultural and nutritional balance; and other crops such as
vegetables and fruits are also cultivated. Birds and animals
are domesticated and bred for food, and fish and seafood
contribute to the diets of communities living beside water.57
As with gatherer–hunters, the diets of peasant–agricul-
tural societies may be diverse and high in micronutrients.
Again, when food supplies are chronically insecure, or at
times of acute food shortage (including times of war), diets
are liable to become monotonous and deficient in various
nutrients, as well as in energy.
Peasant–agricultural societies are necessarily physically
active, although not constantly so: the main times of inten-
sive physical work include building field systems, sowing,
harvesting, and storing. The level of energy balance and of
physical activity varies greatly, depending in part on how dif-
Age-standardised rates of common cancers   Egypt
Age-standardised rate per 100 000
Data from International Agency for Research on Cancer20
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tions account for 12.2 per cent; 4.2 per cent
of deaths are due to injuries. The first fig-
ure gives a breakdown of deaths caused by
chronic diseases.46
Bladder cancer is the most common type
of cancer in men, followed by cancers of the
lung and liver.20 In women, the dominant
cancers include those of the breast, cervix,
and bladder (for age-standardised rates of
these cancers, see the second figure).20 The
high incidence of bladder cancer is likely to
be related to bilharzia, a parasitic infection
of the bladder.20 There is also a high inci-
dence of hepatitis C virus, a cause of liver
cancer.20 Also see box 7.8.1 It is predicted
that there will be a 3.5-fold increase in liver
cancer by 2030.12
For the period 1991–1994, 46 per cent of
men and 48 per cent of women between
the ages of 20 and 44 were classified as
sedentary.46 In 2003, women aged 15–49
had a mean body mass index (BMI) of 28.6.
In teenagers (13–19 year olds), average BMI
was 23.9; women in their 30s had a mean
BMI of 29.0, while those over 45 had a BMI
of 31.3. In total, 77.3 per cent of women
aged 15–49 had a BMI of over 25. In 1992,
23.5 per cent of all women had a BMI of
over 30. By 2000, this figure had risen to 41
per cent.46 Fewer data are available for
men, but in 1994, the mean BMI for men
aged 20–44 was 26.6, rising 
to 28.4 for men over 45. In 2002, among 
all men, 45 per cent had a BMI of between
25 and 29.99 and 20 per cent had a BMI of
over 30.15 See figure 1.4 for projections of
the proportions of men and women pre-
dicted to have a BMI of 30 or more in
2015.46
The average amount of available food
energy rose between 1964 and 2004, from
around 2240 to 3290 kcal/person per day
(9400 to 13 800 kJ/person per day).1 Early
dietary studies in Egypt demonstrated that
corn bread was the staple food and that
protein intake was about 100 g/day.15
People from higher-income households
consumed more dairy products and those
from urban households consumed a wider
variety of foods. Between 1950 and 1990,
there was a shift towards a dependence on
wheat rather than other cereals (grains),
and a sustained rise in the consumption of
meat, fish, and dairy products.15
Consumption of sugars and oils increased
substantially and pulses (legumes)
decreased in importance.15 Since the 1970s,
consumption of all major food groups has
increased. However, between 1990 and
1994 there was a 20 per cent decrease in
total household food consumption, because
subsidies were removed and food prices
rose sharply.15 A national study in 1981
found that only 24 per cent of urban and
15 per cent of rural households ate ready-
made foods, and meat was eaten more fre-
quently in urban households compared
with rural households.15 A repeat survey in
1998 found that poultry had become the
main source of animal protein and that
wheat bread was the most popular type,
although homemade wheat-maize bread
was common in rural areas. Another study
highlighted differences in dietary fat
intake: in urban women, 27.5 per cent of
dietary energy came from fat (mainly as
vegetable oil) compared with 22.5 per cent
in rural women.15 Between 1981 and 1998,
people increasingly ate meals away from
home (20.4 per cent of all meals in 1981
compared with 45.8 per cent in 1998).15
ficult it is to cultivate the land. The degree of physical activ-
ity and so of body mass in peasant–agricultural communi-
ties depends mostly on relative food security.58
People in these societies who are prosperous, especially
those who own land farmed by others, may quite often
become overweight or obese. But in general, and largely
because of the nature of their dietary staples, peasant–agri-
culturalists are usually short and lean. This is still evident in
rural peasant communities whose food systems remain tra-
ditional: for instance, in Africa, Latin America, and in Asia,
notably India and China.58
Agriculture enabled the development of towns and then
cities: throughout the world, walled, urban settlements
became surrounded by fields cultivated by peasants. These
people subsisted on the food they produced, and the surplus
fed the community living within the walls. In times of war,
the fortified settlement became a refuge for the farmers. This
crowding of populations into towns and cities caused a sharp
rise in the rates of infectious diseases, mostly notably among
infants and young children, pregnant and lactating women,
and infirm and old people.59
The average life expectancy of peasant–agriculturists 
in general is probably a little longer than that of
gatherer–hunters, with a greater percentage of people
surviving into what would be regarded as late-middle and
old age.
The prevalence and incidence of various cancers in tradi-
tional rural societies is often uncertain, even following the
establishment of cancer registers in many countries: records
are less reliable than those kept in urbanised societies. But
there is reasonable evidence that relatively common cancers
in peasant–agricultural societies include those causally
associated with chronic infections, such as cancers of the
stomach, liver, and cervix.60
1.1.3  Urban–industrial 
Indigenous or traditional peasant–agricultural systems have
coexisted with urban–industrial food systems in most coun-
tries since the creation and growth of cities, and the begin-
ning of the ‘industrial revolution’. This movement started in
Europe in the 18th century, and then spread to North
America and elsewhere. Britain is one exception to this coex-
istence: it was the first country to become mostly urban, with
hired workers replacing peasants on increasingly large and
relatively mechanised farms. The Americas are another
exception: settlers, mostly from Europe, displaced native
populations and developed mechanised agricultural sys-
tems.61 In continental Europe, some balance between rural
and urban ways of life has been preserved. Throughout the
Mediterranean coastal regions, and in the Middle East, mod-
ern food systems have deep, historical roots.62 In most of
Africa and Asia, including countries with large cities, the
basic economies and cultures have remained predominantly
rural, but this is changing.63
Urban–industrial food systems have characteristics distinct
from peasant–agricultural and gatherer–hunter systems.
Their original purpose was to ensure reliable and adequate
supplies of food of an agreed minimum nutritional quality
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to entire populations. Technology has been the main driving
force behind these systems. For instance, various food-preser-
vation techniques were developed as part of the industrial
revolution, and there has been further innovation since that
time. These include bottling, canning, refrigeration, and
packaging; the extensive use of sugar and salt; and tech-
nologies that suppress, convert, or eliminate perishable qual-
ities in fresh foods (see chapters 4.6 and 4.9). The clearing
of land to rear cattle and sheep, and the development of rail-
ways, refrigeration, and other technologies, have made meat,
milk, and their products cheap and plentiful all year round.
Sugar derived from cane is the most profitable edible cash
crop, and sugars and syrups made from cane, beet, and now
also corn are used to sweeten and preserve breakfast foods,
baked foods, desserts, soft drinks, and a vast array of other
manufactured products.64 65 Steel roller mills, invented in the
1870s, separate the components of wheat and enable pro-
duction of uniform quality white bread, which has become
a staple food.66 Hydrogenation, which converts oils to hard
fats (see chapter 4.5), has made margarine a basic item of
food, and provides ingredients used in the manufacturing of
many processed foods.67 Perhaps the most remarkable
change following the industrialisation of food systems has
been the precipitate drop in breastfeeding.68 At various times,
urban–industrial food systems have been adjusted in
response to the then current knowledge of nutrition and pub-
lic health recommendations, notably when food security has
been threatened by wars.69
Urban–industrial food systems generate relatively energy-
dense diets. These are fairly high in meat, and milk and their
products, and in total fats, hardened fats, processed starch-
es and sugars, salt, baked goods, soft drinks, and often also
alcoholic drinks. These diets are relatively low in both
dietary fibre and starchy staple foods, other than products
made from wheat, which has become the dominant cereal
in most countries outside Asia and Africa. Recent advances
in food technology have further altered patterns of food pro-
duction and consumption, particularly in high-income
countries. Patterns of production and consumption of
vegetables and fruits and fish vary between different
urban–industrial food systems, depending on factors such as
climate and geographical location.70
Efficient urban–industrial food systems can ensure the
constant supply of food to all sections of the population,
even to the lowest-income and marginalised groups. In high-
er-income countries and regions, this, together with basic
public health initiatives, has helped to greatly reduce rates
of nutritional deficiencies and other diseases, which people
are more vulnerable to if they have inadequate food supplies.
As a result of these food systems, people have become gen-
erally taller and heavier. 
Since the industrial revolution, as populations have moved
In 2001 South Africa had a population of
nearly 47.5 million.3 The country has a mid-
dle-income economy, with a gross domestic
product of 8506 international dollars per
person (figure 1.3), which masks extreme
socioeconomic inequalities.46 Life expectan-
cy at birth is 47 years for men and 49 for
women (figure 1.1).46
Chronic diseases account for 53.9 per cent
of deaths, while infectious diseases, maternal,
perinatal, and nutritional conditions account
for 40.2 per cent; 5.9 per cent of deaths are
due to injuries. The figure below gives a break-
down of deaths caused by chronic diseases.46
The most common cancers in men are
those of the prostate, lung, oesophagus,
colorectum, and bladder.20 Since HIV and
AIDS became epidemic, Kaposi’s sarcoma
has become more common in both men
and women. For women, the most common
cancers are those of the cervix, breast,
South Africa
Non-communicable causes of death  South Africa
Data from World Health Organization46
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from rural to urban areas, there have been rapid and pro-
found changes in both the nature and quality of their foods
and drinks, and the patterns of diseases they suffer.71
Urban–industrial food systems have evidently improved peo-
ple’s strength and health in early life. They are also a factor
in the doubling of average life expectancy since 1800, and
the increase in global population from around 1 billion in
1800 to 6.5 billion in 2006.72 The range of current life
expectancy in selected countries is illustrated in figure 1.1. 
In the second half of the 20th century, attention focused
on the apparent ill-effects of these food systems on people,
mostly in later life. By the 1980s, it was generally agreed that
these industrialised diets increase the risk of some chronic
diseases, usually of later life, which had become common or
epidemic in higher-income industrialised countries. These
included obesity, type 2 diabetes, and coronary heart disease.
At the same time, in examining patterns of both diet and can-
cer across the world, and among migrants, it was increas-
ingly thought that these diets were partly responsible for
some cancers, notably those of the colon and rectum, breast,
ovary, endometrium, and prostate.73-75
In the last decades of the 20th century, the demographic,
nutritional, and epidemiological transitions that had, until
then, largely been apparent only in higher-income countries
became global. Since the 1990s, and outside Europe, North
America, and other high-income countries, economic glob-
colorectum, lung, and oesophagus (for age-
standardised rates of these cancers, see the
second figure).20 Diseases of poverty and
chronic diseases coexist, but it is predicted
that by 2010, deaths from AIDS will account
for twice as many deaths as those from all
other causes combined.5 41
For the period 2002–2003, 44 per cent of
men and 49 per cent of women aged 18–69
were classified as sedentary (figure 1.6).46
Some regional studies suggest that young
women who did not finish school have low
levels of physical activity.24 There is a lack of
physical education in schools, and poor
environment and high crime rates prevent
leisure activity outside school.24
In 1998 men aged 15–24 had an average
body mass index (BMI) of 21.1; for those
aged 35–65, average BMI remained con-
stant at around 25. Just 7.8 per cent of men
aged 25–34 had a BMI of over 30 compared
with 17.3 per cent of men aged 45–54. In
the same year, women aged 15–24 had an
average BMI of 23.7; for those aged 35–64,
average BMI remained constant at around
29. In women aged 25–34, 27 per cent had
a BMI of over 30 compared with 45 per cent
of women aged 45–64.46 Although under-
nutrition remains a problem among rural
children, obesity and associated diseases are
also prevalent. There has been a miscon-
ception of ‘benign obesity’: being thin is
associated with HIV and AIDS, and moder-
ately overweight women are thought of as
attractive and affluent.24 Overall, in 1998,
21.1 per cent of men and 25.9 per cent of
women had a BMI of at least 25; 10.1 per
cent of men and 27.9 per cent of women
had a BMI of at least 30. See figure 1.4 for
projections of the proportions of men and
women who will have a BMI of 30 or more
in 2015. 
The average amount of available food
energy rose between 1964 and 2004, from
around 2700 to 3000 kcal/person per day
(11400 to 12600 kJ/person per day). In the
same period, sugar consumption dropped
from 420 to 370 kcal/person per day (1800
to 1500 kJ/person per day).1 The National
Food Consumption survey of 1999 found
that stunting was the most common nutri-
tional disorder, affecting almost one fifth of
children aged 1–9, with the lowest levels in
urban areas. There was a similar pattern for
underweight, where 10 per cent of children
aged 1–3 consumed less than half of their
suggested daily dietary needs, and 26 per
cent consumed less than two thirds.25 In
rural areas, adults from lower-income
households were shorter and had a lower
BMI, and commonly consumed foods were
maize, sugar, tea, milk, and brown bread.
Urban households ate less maize porridge
but more vegetables and fruits, animal-
based products, and fats and oils. It was
only in urban areas that fruits and milk
appeared in the top 10 list of foods and
drinks consumed by more than 85 per cent
of people. In men, alcoholic drinks made a
significant contribution to dietary energy
(10–14 per cent). People living in rural areas
obtained a higher proportion of total
dietary energy from carbohydrates, where-
as the most urbanised populations derived
one third of their energy from animal foods
high in protein. 
Urbanisation is generally accompanied
by an improvement in micronutrient
intakes, but this way of life is also associat-
ed with increases in overweight and obesi-
ty.44 Other studies have suggested shifts
towards a Western dietary pattern in peo-
ple living in both urban and rural areas, typ-
ified by a decrease in starchy foods and
dietary fibre consumption, and an increase
in fat. They have also shown that half of 
the population does not eat the locally
recommended four portions of fruits 
and vegetables each day, while a quarter
eats none.10
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alisation is thought to be the single main force shifting
populations from the countryside into cities, changing the
dominant food systems from peasant–agricultural to
urban–industrial, and transforming patterns of disease. This
phenomenon includes the unprecedented and accelerating
movement of money, goods, and ideas. All this has been
made possible by new international, political, and econom-
ic policies, by the creation of supranational regulatory bod-
ies such as the World Trade Organization, and by the
electronic revolution.76-78
People’s levels of physical activity have also changed dra-
matically as a result of the move from peasant–agricultural
to urban–industrial ways of life. In 1950, the UN ‘reference
man’ weighing 65 kg (143 lbs) was estimated to be in ener-
gy balance at an average of 3200 kilocalories (kcal)/day
(13398 kilojoules [kJ]/day); the ‘reference woman’ weighing
55 kg (121 lbs) was estimated to be in energy balance at 2300
kcal/day (9630 kJ/day). Today in the USA, average weights
are much higher, yet the figure for the ‘reference person’ (men
and women combined) is taken to be 2000 kcal/day (8374
kJ/day) for the purposes of nutrition food labelling. The rea-
son for this drop in human energy requirements is because
three of the four settings for physical activity — occupation-
al, household, and transport — (see Chapter 5) have become
increasingly mechanised. Energy-dense food systems, essen-
tial to sustain young populations that walk or cycle to work
that is physically demanding, are unsuitable for ageing pop-
ulations who sit for most of the day, even if they engage in
some recreational physical activity.
There is some evidence that these very recently introduced
urban–industrial food systems have lowered the rates of
nutritional deficiencies and infectious diseases of early life
in middle- to low-income countries and regions. But the
apparent impact on the rates of chronic diseases in these
areas is of increasing public health concern. In most of these
regions, with the exception of sub-Saharan Africa, childhood
overweight, obesity, and type 2 diabetes have become com-
mon and, in some countries, epidemic.70
The Panel emphasises that there is no reason to think that
urban–industrial food systems are intrinsically harmful. They
were first developed using relatively crude technologies, and
at a time when something was known of their positive
impact on growth and strength, but little of their long-term
impact on health. Since then, many new technologies have
been developed, and there is a clearer understanding that
some methods of preserving and processing food are bene-
ficial, whereas others are a factor in increasing the risk of
disease. Future developments can ensure universal food
security, avoid earlier mistakes, and reduce the risk of chron-
ic diseases, including cancer. 
In 2004 China had a population of over 1.3
billion. The one-child policy introduced in
1979 has reduced annual population
growth to 1.07 per cent. The United Nations
estimates that the population will have
increased to nearly 1.5 billion by 2025.46 The
country has a lower-middle-income econo-
my, with a gross domestic product of 5581
international dollars per person (figure
1.3). Life expectancy at birth is 70 years for
men and 74 for women (figure 1.1).46
Chronic diseases account for 78.9 per cent
of deaths, while infectious diseases, mater-
nal, perinatal, and nutritional conditions
account for 11.7 per cent; 9.3 per cent of
deaths are due to injuries.46 The figure
below gives a breakdown of deaths caused
by chronic diseases.46 A study published in
2004 found that there has been a shift
towards nutrition-related chronic diseases
such as type 2 diabetes, cancer, and cardio-
vascular disease.14
Stomach cancer is the most common type
of cancer in men, although it has declined
slightly since 1980.20 Lung cancer has risen
steadily over the same period.20 Liver cancer
has risen since 1990, although levels are now
China
Age-standardised rates of common cancers   China
Age-standardised rate per 100 000
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1.2  Foods and drinks, physical activity,
body composition 
1.2.1  Foods and drinks
Substantial changes have occurred in the patterns of foods
and drinks supplied and consumed throughout the world,
and these changes are becoming increasingly rapid. Also see
Chapter 4. 
Economic development is generally accompanied by
quantitative and qualitative changes in food supplies and
therefore in diets. This ‘nutrition transition’ may reduce the
risk of some dietary deficiencies and improve overall nutri-
tion. But it can also be accompanied by adverse shifts in the
composition of diets, for instance, with a greater proportion
of energy coming from fats and oils, and added sugars. Over
recent years, such dietary changes have been rapid in the
middle- and low-income countries of Asia, Africa, the Middle
East, and Latin America.63 79 80
The Food and Agriculture Organization (FAO) of the UN
records global differences in the availability of food crops and
commodities (box 1.1). These data provide information on
the average amounts of food available for consumption,
rather than actual food consumption. Animal products have
traditionally made up a small proportion of food availabili-
ty in low-income countries; most dietary energy comes from
plant sources such as roots and tubers, cereals (grains), and
fruits. 
However, this pattern is changing, with proportionally
more dietary energy available for consumption now coming
from animal sources. Since the 1960s, estimates for animal
sources for low-income countries have risen from around
160 to 340 kcal/day (670 to 1400 kJ/day). During the same
period, estimates of the energy available for consumption
from plant sources have also risen, from 1900 to 2340
kcal/day (7900 to 9800 kJ/day) (figure 1.2). There have
been similar changes in the availability of both animal and
plant sources of energy in high-income countries. However,
in these cases, the proportion of energy from animal sources
is much greater: around one third or 940 kcal/day (3900
kJ/day).81 The proportion of dietary energy available from
cereals (grains) has remained constant at around 50 per
cent, though dietary energy available from cereals (grains),
in particular rice and wheat, have decreased slightly in low-
income countries. This trend is likely to continue until the
2030s in middle- and low-income countries.81
Large variations exist across the world in the amounts of
fat available for consumption. The highest availability is in
Europe and North America; the lowest is in Africa. The quan-
tity of available fat in diets has increased globally since the
1960s, with the exception of sub-Saharan Africa.81 These
stabilising.20 The incidence of cancer of the
oesophagus has remained stable since the
1980s and cancers of the colorectum are also
relatively common.20 For women, the most
common cancers are those of the lung,
stomach, and breast, which have risen
steadily since the 1980s; of the liver, which
has risen since 1990; and of the oesophagus.
For age-standardised rates of these cancers,
see the second figure.20
For the period 2002–2003, 10 per cent of
men and 12 per cent of women aged 18–69
were classified as sedentary (figure 1.6).46
These figures are likely to increase, with fur-
ther urbanisation and greater use of vehi-
cles for transport. Between 1980 and 2003,
the number of cars produced in China
quadrupled to more than 2 million.84
In 1997 men aged 24–64 had an average
body mass index (BMI) of around 25; just 2.1
per cent of men aged 20–74 had a BMI of
over 30. In the same year, women aged
25–29 had an average BMI of 22.2, and
those aged 35–64 had a BMI of around 25.
Just 3.7 per cent of women had a BMI of
over 30.46 In 2002, 18.9 per cent of men and
women aged 18 and above had a BMI of
over 25, and 2.9 per cent of them had a BMI
of over 30. See figure 1.4 for projections of
the proportions of men and women who
will have a BMI of 30 or more in 2015.
The average amount of available food
energy rose between 1964 and 2004, from
around 1850 to 2940 kcal/person per day
(7760 to 12 290 kJ/person per day). This is
largely due to an increase in the availabili-
ty of fats and oils, meat, and sugar.1 The
1957–1962 famine was followed by a liber-
alisation of food production. Economic
growth has reduced poverty and Chinese
diets now are influenced by the Western
pattern: cereals (grains) and lower-fat mixed
dishes are being replaced with animal foods
and edible fats.14 Recent national nutrition-
al surveys show that energy intake from ani-
mal sources increased from 8 per cent in
1982 to 25 per cent in 2002, and that ener-
gy from fat, particularly among people liv-
ing in urban areas, increased from 25 to 35
per cent over the same period.84 Intake of
cereals (grains) has also decreased substan-
tially since the mid-1980s among urban and
rural populations, with a larger decrease in
the consumption of coarse grains compared
with refined varieties. The biggest drop in
cereal intake has been among people in the
lowest-income groups. Vegetable and fruit
intakes have decreased since 1989, although
they are highest in urban populations. Fat
intake is also increasing and many adults
obtain 30 per cent or more of their overall
energy intake from fat.14 Regional varia-
tions also exist: for example, the dietary pat-
tern around the city of Hangzhou is very
varied, resulting in a diet low in saturated
fatty acids and high in n-3 polyunsaturated
fatty acids; people there eat green, leafy
vegetables with almost every meal.26 The
incidence of nutrition-related diseases and
deaths from these diseases are lower in this
region than in other parts of China.
Snacking contributes minimal energy
intake to Chinese diets (0.9 per cent).
However, snacking and eating food away
from home are increasing among children
from middle- and high-income groups.
Foods commonly eaten away from home
include cereals (grains), vegetables and
fruits, meat, eggs, and fish. Between 1991
and 1997, the proportion of children from
low-income households eating foods away
from home did not change, but there was
an increase among children from higher-
income groups, with a 10 per cent increase
in the consumption of foods from animal
sources eaten away from home. Eating food
prepared away from home accounted for 15
per cent of total energy intake for all
Chinese children during this period.27
Despite these statistics, only 10 per cent of
Chinese children and young people con-
sumed any snacks during the study period,
and there was little evidence then that they
consumed significant amounts of soft
drinks, although this is now changing
rapidly.
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changes are accounted for by an increase in the availability
and consumption of plant oils in lower-income countries.82
Palm oil intake is increasing in South-East Asia, and olive oil
is now consumed widely in Europe and not just in
Mediterranean countries.
Analysis of food balance sheet data suggests that available
energy for consumption has increased steadily on a world-
wide basis. Since the 1960s, this has increased globally by
approximately 450 kcal/person per day (1900 kJ/person per
day), and by more than 600 kcal/person per day (2500
kJ/person per day) in low-income countries.81 Regional dif-
ferences exist. For example, there has been little change in
sub-Saharan Africa, and in Asia the amount of available ener-
gy has risen dramatically: in China by almost 1000 kcal/per-
son per day (4200 kJ/person per day). These data need to
be interpreted with caution, as they do not relate directly to
energy consumption (box 1.1). Global average available
energy is predicted to rise from around 2800 kcal/person per
day (11700 kJ/person per day) (1997–1999 average) to
2940 (12300 kJ) in 2015, and to 3050 (12800 kJ) in 2030.
Again, see box 1.1.
With increasing socioeconomic status, the proportion of
energy in diets from staples such as cereals (grains) and roots
and tubers declines, whereas the proportion of energy from
fats and oil, and animal protein (including from meat, milk,
and eggs) increases. For example, in China, energy intake
from foods of animal origin has increased significantly: the
average Chinese adult now consumes more than 1300
kcal/day (5400 kJ/day) from these foods.83 In low-income
countries between the 1960s and 1990s, consumption of
meat rose by 150 per cent, and of milk and dairy products
by 60 per cent. By 2030, it is predicted that consumption of
animal products could rise by a further 44 per cent, with the
biggest contribution coming from poultry. If stocks of fish can
be maintained, fish consumption is likely to rise by 19–20
kg/person in the same period. Owing to decreases in the cost
of these foods in real terms, low-income countries have high-
er levels of meat and fat consumption at much lower levels
of gross domestic product (GDP) than was the case in coun-
tries that underwent socioeconomic transition in the 1960s
and 1970s. Figure 1.3 shows the GDP of selected countries. 
According to food consumption surveys, only a minority of
the world’s adult population consumes the commonly rec-
ommended minimum daily amount of vegetables and fruits
of 400 g/person. Low-income countries have the lowest
intakes of vegetables and fruits, and vegetables are general-
ly more readily available than fruits.43 In India, for example,
levels of vegetable and fruit intake have remained static at
120–140 g/day. Australia, Japan, and North America have
high levels of intake, for example 300 g/day in Australia. In
Europe, average consumption is between 250 and 350 g/day
— often much higher in Mediterranean countries, for
instance 550 g/day in Spain — and Scandinavian countries
have particularly high fruit intakes.43 Countries in Europe,
Latin America, North America, and South-East Asia have seen
an increase in the availability of vegetables and fruits for con-
Gross domestic product per capita, 2004
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sumption since the 1960s. In contrast, in eastern and cen-
tral Africa, availability has decreased since the mid-1980s. 
Studies in children suggest that their eating patterns vary
around the world. For instance, children living in the USA
and the Philippines consume one third of their daily energy
away from home, and snacks provide one fifth of their daily
energy. In contrast, children living in Russia and China eat
very little food away from the home. Snacks provide about
16 per cent of dietary energy for Russian children, but
account for only 1 per cent in Chinese children.2
A US study showed that between 1977 and 2001, con-
sumption of sweetened drinks increased by 135 per cent.
During the same period, milk consumption decreased by 38
per cent, resulting in an overall daily increase of 278 kcal
(1164 kJ) from drinks.31
1.2.2  Overweight and obesity
There have been rapid changes in rates of overweight and
obesity throughout the world since the 1980s, at the same
time as the urbanisation and industrialisation of middle- and
low-income countries. Such countries often experience the
dual burden of nutritional deficiencies and chronic diseases.
Also see Chapters 6 and 8. 
The most recent estimates suggest that in 2002 there were
1 billion overweight or obese people worldwide, with
Chinese people accounting for approximately one fifth. The
example of China is remarkable. Historically, China, which
is classed as a lower-middle-income economy by the World
Bank, had a lean population. But the prevalence of under-
weight adults has decreased and the numbers of people who
are either overweight or obese have risen considerably. In
2002, there were 184 million overweight and 31 million
obese people in China, out of a population of 1.3 billion.14
The prevalence of overweight and obesity among 7–18 year
olds increased substantially between 1985 and 2000.84
Between 1989 and 1997, one study estimated that the pro-
portion of overweight and obese men in China rose from 6.4
to 14.5 per cent, and in women from 11.5 to 16.2 per cent.85
Another study, in nine Chinese provinces, found that
between 1989 and 2000 there was a 13.7 per cent increase
in the proportion of men, and a 7.9 per cent increase in the
proportion of women, who were overweight or obese.
During the same period, there was an average 2 per cent
decrease in the number of men and women who were clas-
sified as underweight.86
The World Health Organization MONICA Project moni-
tored 10 million adults in 21 countries over a 10-year peri-
od in the 1980s and 1990s. During this time, the mean body
mass index (BMI) increased in most populations, with the
largest increases in regions of Australia and the USA. Over
the course of the project, the overall average BMI increased
by 1.5.87 However, average BMI decreased in Russia and
Central Europe, and in certain regions of Italy and
Switzerland. The UK has one of the highest rates of excess
weight in Europe. This has increased threefold since 1980;
in 2003, 65 per cent of men and 56 per cent of women were
overweight, with 22 per cent of men and 23 per cent of
women classified as obese.88
Historically, food insecurity, undernutrition, and under-
weight, and their likely contribution to infection, have been
The data here on energy, foods, and drinks
are taken from food balance sheets com-
piled by the Food and Agriculture
Organization of the United Nations. These
are statistical data on the production,
trade, and use of agricultural commodities
for all countries. Food balance sheets are
the most common and widely used data
sets for food supply estimates. A food bal-
ance sheet provides estimates of the food
available for human consumption, and an
overall picture of a country’s food supply
during a specified period of time, which
can be compared between countries. 
It follows that these estimates of avail-
ability are not measures of consumption.
They record information about the supply
of food (production, imports, stock
changes, and exports) and about how it is
used (as feed and seed, in processing, and
wastage, as well as food). The amounts of
foods and drinks recorded on these bal-
ance sheets are expressed ‘per person’ (in
kg/person per year or kcal/person per day).
The estimates in food balance sheets
that need to be treated with most caution
are those of energy. Balance sheets over-
estimate food consumption in high-income
countries, where substantial amounts of
food are wasted or fed to pets. They
underestimate consumption in countries
that are not dominated by urban–industri-
al food systems, and where many people
grow their own food, raise animals, or
gather wild food such as fungi and berries.
It follows that balance sheet data showing
increases in food energy over time tend to
reflect economic development and greater
use of money, rather than actual increases
in availability. 
The accuracy of a food balance sheet
also depends on the reliability of the
underlying statistics of supply, use, and
population. Also, the data do not take into
account regional differences, so the infor-
mation may not be representative of the
entire country. In countries where there is
wide variation in income and food access,
for example, the overall supply picture pro-
vided by the balance sheet is of limited use.
In such cases, food balance sheets can be
complemented with national nutrition
surveys or household income/expenditure
surveys. 
Household income/expenditure surveys,
such as the World Bank’s Living Standards
Measurement Study, look at multiple
aspects of household welfare and behav-
iour, and collect data on the quantities of
food purchased by a representative sample
of households. These surveys provide
detailed information about foods con-
sumed in and away from the home over a
limited time period, and can be used to
document differences in regional, geo-
graphical, or household socioeconomic
characteristics. While these surveys are
generally more useful than food balance
sheets for assessing household consump-
tion, they are less readily available. Balance
sheets are often available for a large num-
ber of countries and for most years. 
Food balance sheets, household income/
expenditure surveys, and methods of assess-
ing individual dietary intakes (see Chapter
3) all provide information on food supply
and consumption, and they have different
purposes, uses, and limitations.
Box 1.1 Measurement of food supply and consumption 
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the main nutrition-related public health issues in middle- and
low-income countries. This is no longer the case. Thus,
surveys of women between 1992 and 2000 found that
overweight exceeds underweight in most middle- and low-
income countries, including those in North Africa and the
Middle East, Central Asia, China, and Latin America. Indeed,
there has been a disproportionate increase in, and prevalence
of, obesity among the lowest-income groups in most coun-
tries. It is more likely that people will be overweight if they
live in urban areas compared with rural areas, and countries
with a higher GDP have a greater ratio of overweight to
underweight women.89 North Africa and the Middle East are
two areas of the world with middle- and low-income coun-
tries that are experiencing very high rates of overweight and
obesity, often higher in women than in men.82
The rise of overweight and obesity since the mid-1970s has
been much faster in lower-income countries.63 In Europe and
the USA, the prevalence has risen relatively slowly, by
0.3–0.5 per cent each year; but the figures are two- to four-
fold higher in many low-income countries.90 Projections from
existing data suggest that by 2015, levels of obesity could
be as high as 50 per cent in the USA, between 30 and 40
per cent in the UK and Australia, and more than 20 per cent
in Brazil.46 See figure 1.4. It is estimated that more than 12
million adults in England will be obese by 2010, while 25
per cent of children who live in households with obese par-
ents will become obese themselves.88
1.2.3  Physical activity
Changes in degrees of physical activity throughout the world
have also been rapid since the 1970s, as paid and household
In 2004 India had a population of over 1.1
billion, growing at a rate of about 1.2 per
cent a year; it was the next country after
China to reach the 1-billion mark.46 India
has a low-income economy, with a gross
domestic product of 1830 international
dollars per person (figure 1.3). Life
expectancy at birth is 61 years for men and
63 for women (figure 1.1).46
India
Projected increases in obesityFigure 1.4
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work has become increasingly mechanised, and vehicles are
used more often for transport. Occupational and household
physical activity has reduced dramatically in high-income
countries. Also see Chapters 5, 6 and 8. 
There is as yet no globally accepted, quantified definition
of physical inactivity, or of the extent to which populations
or people should be physically active. In 2002, the WHO
recommended a minimum of 30 minutes moderate-intensi-
ty physical activity most days; it found that at least 60 per
cent of the world’s population fails to achieve this level of
physical activity.91
The proportion of people employed in agriculture can
reflect the level of work-related activity undertaken in a
country, and there may be a linear relationship between the
two.91 Thus, it is likely that, compared with high-income
countries, transport-related and occupational and household
physical activity is higher in low-income countries.
Transport-related physical activity (cycling, walking) is high-
er in those countries with the lowest gross domestic prod-
uct and low car ownership, and this differs little between
men and women. 
Data on physical activity in Africa are limited. Several stud-
ies are available for South Africa, but these cannot be used
to predict or generalise about activity levels across the entire
continent. Some small regional studies have been performed,
in Ethiopia, for example, which provide useful local infor-
mation, but they are not nationally representative. 
Data from Europe, where recreational physical activity
accounts for a greater proportion of total activity, suggest
that approximately half of all walking and cycling trips are
less than 3 km. Therefore, almost half of European adults do
not do enough physical activity getting from one place to
another.91 In Europe, people living in more northerly regions
such as Scandinavia have higher levels of activity than those
living further south, for example, in Mediterranean coun-
tries. Women tend to exercise less than men and this differ-
ence is greatest in southern European countries.42
A study conducted in 1953 demonstrated that more than
half of US school children failed a minimum standard of
Chronic diseases account for 58.1 per
cent of all deaths, while infectious diseases,
maternal, perinatal, and nutritional condi-
tions account for 32.9 per cent; 9 per cent
of deaths are due to injuries.46 The first fig-
ure gives a breakdown of deaths caused by
chronic disease.46
Common cancers in men include those of
the oral cavity and pharynx.20 Although
these cancers have declined since the late
1970s, the incidence remains high.20 Cancers
of the oesophagus and lung have also
decreased slightly in the same period.20 In
women, cancer of the cervix is the most com-
mon type, and has been since the 1970s;
breast cancer has increased steadily during
this time.20 Cancers of the oral cavity and
oesophagus have declined slightly since the
late 1970s (for age-standardised rates of
these cancers, see the second figure).20
For the period 2002–2003, 10 per cent of
men and 16 per cent of women aged 18–69
were classified as sedentary (figure 1.6).46
In 2000 men aged 20–24 had an average
body mass index (BMI) of 20.7, while those
aged 40–54 had an average BMI of 23.6.46
For men aged 20–70, 25.4 per cent had a
BMI of over 25.46 Women aged 20–24 had
an average BMI of 20.9, rising to an aver-
age of 24 at age 30; and women aged
30–69 also had a BMI of around 24.46 In
total, 35.8 per cent of women aged 20–70
had a BMI of over 25.46 A review from 2002
established that the prevalence of
preschool obesity was about 1 per cent, but
stunting remained a problem in over half
of all children.39 Obesity has been uncom-
mon in India and varies with socioeconomic
status, being more common in high-income
households. In the 1970s, 2.1 per cent of
men and 2.9 per cent of women had a BMI
of 25 or more, while less than 0.5 per cent
of men and women had a BMI of 30 or
more.46 By 1998 these figures had risen: 4.4
per cent of men and 4.3 per cent of women
had a BMI of 25 or more.46 See figure 1.4
for projections of the proportions of men
and women who will have a BMI of 30 or
more in 2015.46
The average amount of available food
energy rose between 1964 and 2004, from
around 2050 to 2470 kcal/person per day
(8580 to 10 360 kJ/person per day).1
Recently, though, there have been large
increases in the consumption of animal
products, fats, and sugars. The proportion
of energy from fat has increased each year,
although within India there are differences:
for higher-income groups, 32 per cent of
energy comes from fat, compared with 
17 per cent in lower-income groups.39
Since 1975 there has been a reduction in
cereal (grains) consumption, particularly
coarse grains, although this has not affect-
ed overall energy consumption. This is
probably due to large increases in intakes
of fats and animal protein, and also of milk
and milk products. In lower-income house-
holds, fat comes mainly from vegetable
foods, with very little consumption of ani-
mal fats, whereas in the highest-income
households, the majority of fat is from ani-
mal sources. India is a major producer of
vegetables and fruits, much of which are
exported.
Percentage of adults projected to have insufficient levels of
physical activity or to be inactive in 2020 in selected regions
Projected levels of inactivity in selected
regions in 2020
Figure 1.5
Insufficient Inactive
Africa 45–55 10–20
USA/Canada 35–50 17–30
Latin America 25–45 17–47
Middle East 30–42 15–30
Europe 30–60 15–40
India/Bangladesh 30–42 14–25
New Zealand/Australia/Japan 48–56 15–20
China 40 15–22
Data from Bull et al93
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fitness, compared with less than 10 per cent of European
children.92 Another study in 2001 found that only 0.2 per
cent of US adults were physically active in both occupational
and transport settings, compared with 29 per cent of Chinese
adults.91 In the USA, while socioeconomic status has a large
impact on whether someone participates in recreational
physical activity, there are only small differences between
men and women, and activity levels decline with age. Similar
trends exist for men and women and for socioeconomic sta-
tus in Australia.42
A number of factors will affect levels of physical activity in
future. Economic development has the effect of reducing lev-
els of occupational, household, and transport physical activ-
ity. It reduces the amount of physical activity in the
workplace, often because of a shift from agriculture to man-
ufacturing and service industries. Improved public transport
in middle- and low-income countries reduces transport-
related activity. Similarly, as people gain more disposable
income, they are more likely to own a car, which means that
they will make fewer journeys by bicycle or foot. Recreational
activity is the only area in which physical activity may
increase as economies develop and countries become increas-
ingly urbanised and mechanised, although people may not
necessarily use their leisure time for active pursuits.91
Other factors constrain physical activity in cities, such as
personal safety: crime rates are often high and it may be
unsafe to walk, jog, or cycle in the streets. Furthermore, city
and town planning may not encourage people to be active
— for example, people can only walk, run, ride, and play if
there are sidewalks/pavements, parks, or other areas where
they can move around freely and safely. Cultural and reli-
gious customs may also limit activity levels, particularly for
women.
By 2020 it is predicted that more adults will be physically
In 2004 Japan’s population was just over
128 million, with 79 per cent living in urban
areas.46 The country has a high-income
economy, with a gross domestic product of
30 039 international dollars per person (fig-
ure 1.3). Life expectancy at birth is 79 years
for men and 86 for women (figure 1.1).46
Chronic diseases account for 78.7 per
cent of all deaths, while infectious diseases,
maternal, perinatal, and nutritional condi-
tions account for 10.5 per cent; 10.8 per
cent of deaths are due to injuries. The first
Japan
Sedentary behaviour is defined as less than 30 minutes of
moderate physical activity (equivalent to brisk walking) on fewer
than 5 days/week, or less than 20 minutes of vigorous physical
activity (equivalent to running) on fewer than 3 days/week. Also
defined in terms of ‘metabolic equivalents’ (METs) as achieving
less than 60 MET–hours/week of any combination of activity on
fewer than 5 days/week (also see chapter 5.2)
Sedentary behaviour in adults in selected
countries (age 18–69)
Data from World Health Organization46
Figure 1.6
Men Women
Brazil 28 31
China 10 12
India 10 16
Mexico 17 18
South Africa 44 49
Spain 27 33
Per cent of adults classified as sedentary
Non-communicable causes of death   Japan
Data from World Health Organization46
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Age-standardised rates of common cancers   Japan
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Data from International Agency for Research on Cancer20
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inactive.91 Clearly, levels of physical activity will vary in dif-
ferent areas and countries around the world. In Europe, for
example, the former Soviet Union states and countries in
eastern Europe are at the lower end of the estimates, with
western European countries at the higher end. Indeed, these
figures are expected to rise further in western Europe and it
is estimated that 50–60 per cent of adults will not be suffi-
ciently physically active by 2020. Also see figure 1.5. The per-
centage of adults currently classified as sedentary in selected
national examples is shown in figure 1.6. Using different def-
initions, the amount of adults (aged over 16 years) classi-
fied as sedentary for the UK are 60 per cent of men and 66
per cent of women. For the USA 52 per cent of men and 65
per cent of women (aged over 18 years) are classified as
sedentary.46
1.2.4  Cancer
Patterns of cancer and trends, incidence, and projections vary
greatly in different parts of the world. Also see Chapter 7.
In 2002 there were more than 10 million new cases of can-
cer (excluding non-melanoma skin cancers) recorded world-
wide, and nearly 7 million cancer deaths. By 2020 these
figures are estimated to rise to over 16 million new cases,
with 10 million deaths. There may be more than 20 million
new cases of cancer in 2030.93 Indications suggest that, at
that time, 70 per cent of cancer deaths will be in low-income
countries. 
This projected increase is accounted for by a combination
of factors: the projected increase in global population; an
ageing world population; improved screening, detection, and
treatment, which increases the number of people living with
a diagnosis of cancer (see Chapter 9); the projected increas-
es in tobacco smoking in many countries; and the increase
in the number of people with HIV/AIDS in some countries.
The global age-adjusted incidence of cancer is also likely to
increase. Also see box 1.2. 
Globally, the most commonly diagnosed cancers (exclud-
ing all types of skin cancer) are those of the lung, colon and
rectum, and breast, with lung cancer being the leading cause
of cancer death.94 95 Geographical and socioeconomic dif-
ferences exist for the most common cancers. In low-income
countries, the most prevalent cancers include those of which
infectious agents are a major cause, while in high-income
countries, they include hormone-related cancers. In high-
income countries, and among men, prostate cancer is the
most common type, followed by cancers of the lung, stom-
ach, and colon and rectum. In low-income countries, and
among men, lung cancer is the most common type, followed
by cancers of the oesophagus, stomach, and liver. Breast can-
cer is the most common type among women living in high-
income countries, followed by cancers of the lung, colon and
rectum, and endometrium. Breast cancer is also the most fre-
quent type among women living in low-income countries,
followed by cancers of the lung, stomach, and cervix.94 96
1.2.4.1  Oesophagus 
Oesophageal cancer is the seventh most common type of
cancer worldwide, with more than 460000 new cases record-
figure gives a breakdown of deaths caused
by chronic diseases.46
In men, cancer of the stomach is the most
common type of cancer. This is followed by
colorectal, lung, liver, and prostate cancers,
which have increased since the 1960s.
Cancer of the oesophagus has remained
steady since the 1960s, although the inci-
dence of cancer of the pancreas has
increased since then.20 In women, breast
cancer is the most common type and its inci-
dence has risen since the 1970s.20 Colorectal
cancer is the next most common type, and
this has also increased. Stomach cancer inci-
dence has decreased since the 1960s, but
the rate remains high; lung cancer has risen
steadily since the 1960s.20 The incidence of
cancer of the cervix increased during the
1960s and remained high in the 1970s, but
has since declined (for age-standardised
rates of these cancers, see the second fig-
ure). 20 However, the total numbers of new
cancer cases and cancer deaths are set to
rise because Japan has an ageing popula-
tion. Cancer has been the leading cause of
death in Japan since 1981 and projections
indicate that in 2015 almost 900 000 people
will develop cancer and 450 000 will die
from cancer.47
Regional studies suggest that 68–70 per
cent of men and 70–82 per cent of women,
aged 20–70, are physically inactive. 
In men there has been a steady increase
in body mass index (BMI) since the mid-
1970s. In 2002, 17.5 per cent of men aged
20–29 and around 30 per cent of those
aged 30–60 had a BMI of over 25. Only 7 per
cent of women aged 20–29, 19 per cent of
those aged 40–49, and 25.6 per cent of
those aged 50–59 had a BMI of over 25. See
figure 1.4 for projections of the proportions
of men and women who will have a BMI of
30 or more in 2015. 
The average amount of available food
energy rose between 1964 and 2004, from
around 2570 to 2760 kcal/person per day
(10 780 to 11 540 kJ/person per day). Meat
consumption also increased during this
time.1 Steamed rice was the staple food
until 1950, and accounted for 80 per cent of
energy intake before 1935. Dietary intake
of cereals (grains), almost all rice, has
decreased, from 75 per cent of energy in
the 1940s to 41.3 per cent in 2000. Energy
from fat increased from 6.9 per cent in 1949
to 25 per cent in 1988, and to 26.5 per cent
in 2002. Total fat intake has increased sig-
nificantly following the country’s econom-
ic growth, from 15 g/person per day in the
1940s to 59 g in 1983, remaining at around
this level in 2002. The percentage of ener-
gy in diets from protein has risen from 12.4
per cent in the 1940s to 15.9 per cent in
2000. However, there has been a larger
increase in the percentage of protein from
animal sources: from 18.6 per cent in the
1940s to more than 50 per cent in 2000. In
2002, people were continuing to eat more
green and yellow vegetables, with people
over 50 tending to eat the most vegetables.
Fruit intake peaked in 1975 and has since
decreased and stabilised. In 2002, Japanese
diets did not provide the recommended
intake of calcium: although consumption of
milk and dairy products had increased, con-
sumption of fish and shellfish had declined
slightly. Salt intake remained high, at over
12 g/person per day. 23
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ed in 2002. Because it has a poor survival rate, it is the fifth
most common cause of cancer death, responsible for nearly
390 000 deaths in 2002. 
Incidence rates vary widely between countries. Studies
suggest that cancer of the oesophagus is 100 times 
more common in parts of China than in Europe and 
North America.94 97 Other areas of high risk include southern
and eastern Africa, south-central Asia, and some countries
in South America. 
Geographical variability of exposure to established car-
In 2001 the UK population was nearly 60
million.30 The UK is a high-income economy,
with a gross domestic product of 31300
international dollars per person (figure
1.3). Life expectancy at birth is 76 years for
men and 81 for women (figure 1.1). 
Chronic diseases account for 84 per cent
of all deaths, while infectious diseases,
maternal, perinatal, and nutritional condi-
tions account for 11 per cent; 4.9 per cent
of deaths are due to injuries. The first fig-
ure below gives a breakdown of deaths
caused by chronic diseases.46
Prostate cancer is the most common can-
cer type in men and has increased steadily
since the 1970s.20 Lung cancer incidence
peaked in the 1960s, remained high until
the mid-1980s, and is now declining.20
Colorectal cancer has risen steadily since
1960.20 Bladder cancer, which had been ris-
ing steadily since the 1960s, is now decreas-
ing, and stomach cancer incidence has
declined since the 1960s.20 In women, breast
cancer is the most common type, and
although rates were fairly constant during
the 1960s and 1970s, they have risen steadi-
ly since then.20 The incidence of colorectal
cancer has remained steady since the
1960s.20 Lung cancer rose from the 1960s to
1980s, and has remained steady since
UK
After cancer registers were established in
various countries in the second half of the
20th century, descriptive studies showed
reliably for the first time that rates and
trends of different cancers vary, sometimes
substantially across different countries.
This variation suggested that cancer is not
just genetically inherited and that different
cancers have different causes. 
Many countries publish annual incidence
and mortality rates for cancer. The inci-
dence rate refers to the number of new
cancer cases reported; the mortality rate
refers to the number of deaths from can-
cer. These rates are usually expressed as the
number of new cases (or deaths) each year
for every 100000 people. 
Cancers are not usually diagnosed until
they produce symptoms, so there is a peri-
od of time between the first stages of can-
cer development and its identification. This
length of time can vary greatly, and there
are also considerable differences in survival
times and how types of cancer respond to
treatment. 
Many countries and international agen-
cies track mortality statistics with causes 
of death, and national or regional cancer
registries prepare cancer-incidence statis-
tics. With types of cancer where survival is
high, cancer mortality statistics will not
reflect occurrence rates. But globally, it 
is easier to obtain statistics for mortality
than for incidence, so these are often used
for comparisons between population
groups. 
It can also be difficult to compare can-
cer incidence globally: not all countries and
regions are covered by cancer registries,
and these organisations may use different
definitions and collect different data, both
geographically and over time. 
Box 1.2 Measurement of cancer incidence and mortality 
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cinogens can explain some of these differences. In high-
income countries, alcohol and smoking tobacco are the main
carcinogenic agents, whereas chewing tobacco is more com-
mon in India. Pockets of high incidence occurring in parts
of China and in the Caspian littoral of Iran may be due to
general nutritional deficiencies. Incidence of adenocarcino-
ma of the lower third of the oesophagus is steadily increas-
ing in the USA and Europe, which is likely to be linked to
an increasing incidence of acid reflux from the stomach due
to obesity.94 95 Also see chapter 7.3.
1.2.4.2  Lung 
Lung (pulmonary) cancer has been the most common type
of cancer in the world since 1985, with around 1.35 million
new cases recorded in 2002. It is also the most common
cause of cancer death. In 2002, 1.2 million people died from
lung cancer. 
Between 1985 and 2002, the estimated number of lung
cancer cases worldwide rose by 51 per cent, and the num-
ber of cases in middle- and low-income countries has
increased steadily over recent years. Previous estimates indi-
cated that the majority of lung cancer cases occurred in 
high-income countries (almost 70 per cent in 1980); almost
half were predicted to  occur in middle- and low-income
countries in 2005.94 95 The USA and Europe have the high-
est numbers of lung cancer cases for both men and women,
but the incidence appears to have peaked, and may now 
be declining in the USA and in parts of northern Europe. It
is, however, still increasing in southern and eastern Europe.
Men are more likely to develop lung cancer than women,
almost certainly because, on average, they smoke more than
women. Worldwide, 1 billion men and 250 million women
currently smoke tobacco. It is estimated that throughout the
20th century, 100 million people died from tobacco use.93
Also see chapter 7.4.
1.2.4.3  Stomach
Stomach (gastric) cancer is now the fourth most common
type of cancer worldwide, with around 925000 new cases
recorded in 2002. It is the second most common cause of
death from cancer, with around 700 000 deaths annually.
Until about the mid-1980s, stomach cancer was the most
common type in the world. Since then, rates have fallen sub-
stantially in all high-income countries, and overall rates are
then.20 Cancer of the ovary has increased
slightly since the 1960s, and rates of cancer
of the endometrium have remained the
same since the 1960s (for age-standardised
rates of these cancers, see the second fig-
ure).20 The incidence of childhood cancer
has been rising at an average rate of 1.1
per cent each year and, between 1978 and
1997, the age-standardised incidence
increased from 120 to 141 cases/million chil-
dren.22 Children in the British Isles have the
highest rates of skin cancer in Europe.11
In 2003, 64 per cent of men and 76 per
cent of women aged 16–69 were classified
as sedentary.46 A study to examine exercise
patterns in adults in 1991 and again in 1999
found that only 4 in 10 adults had man-
aged to meet and maintain the current rec-
ommended level of activity, or to increase
their level. During the study period, the
majority either reduced their activity level
or maintained it below the recommended
level, and 15 per cent of the sample was
inactive, both in 1991 and 1999.33
In the UK, body mass index (BMI) has
risen steadily since the mid-1970s. For the
proportions of men and women in 1980
and in 2003 with a BMI of between 25 and
29.9, or of over 30, see the figure on this
page. Also see figure 1.4 for projections of
the proportions of men and women who
will have a BMI of 30 or more in 2015.
The average amount of available 
food energy rose between 1964 and 2004,
from around 3280
to 3480 kcal/person
per day (13 730 to
14 570 kJ/person
per day).1 Consump-
tion of pasta, rice,
cereals (grains),
yogurt, soft drinks,
savoury snacks, and
nuts has increased
since the mid-1980s.
Over the same peri-
od, intakes of fish
and fish dishes and
eggs and egg dishes
have decreased.19
Large studies sug-
gest that fat intake
has decreased be-
cause people now
consume less whole
milk, butter, and red meat, and more veg-
etables and fruits.35 Men surveyed between
2000 and 2001 were more likely to eat
foods containing fats, oils, and sugars, as
well as meat and meat products, and soft
and alcoholic drinks. 
In the same survey, and compared with
older men and all women, young men were
more likely to eat savoury snacks and soft
drinks, and less likely to eat eggs, fish, and
fruit.19 Women ate more fruit, although
only 13 per cent of men and 15 per cent of
women ate the recommended five daily
portions of vegetables and fruits. Instead,
men ate an average of 2.7 portions while
women had 2.9.19 The survey also showed
that vegetable and fruit consumption was
particularly low in young adults, and that
people from low-income households were
less likely to eat fruit and yogurt.19 It
appears that more-educated adults put
dietary guidelines into practice, reducing
the amount of fat in their diets and increas-
ing the amount of vegetables and fruits
they eat.3
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now about 15 per cent lower than in 1985.94-96
Stomach cancer is now much more common in Asia than
in the USA or Europe. Indeed, 42 per cent of cases occur in
China alone.94 97 High-risk areas are China, Japan, eastern
Europe, and Central and South America. Low-risk areas are
South-East Asia, northern and eastern Africa, the USA, and
Australia and New Zealand. In most countries, incidence has
dropped by about 15 per cent compared with 1985.
The bacterium Helicobacter pylori is an established cause
of stomach cancer. Reduction in stomach cancer rates can be
explained partly by reduced exposure to H pylori and part-
ly by increased use of refrigeration to preserve foods.94 97 Also
see chapter 7.5.
1.2.4.4  Liver
Liver (hepatic) cancer is the sixth most common type of can-
cer worldwide, with around 625000 new cases recorded in
2002. The poor prognosis makes it the third most common
cause of cancer death, with around 600000 deaths in 2002. 
In most countries, the incidence of liver cancer is stable
and there is little difference in survival rates between high-
and low-income countries. More than 80 per cent of cases
occur in middle- and low-income countries. Areas with a
high incidence are China (55 per cent of all new cases), sub-
Saharan Africa, and eastern and south-eastern Asia.
Incidence is lower in high-income countries and in Latin
America, although Japan and areas of southern Europe have
intermediate incidence levels.94 96
Exposures to the hepatitis B and C viruses are known to
increase the risk of developing liver cancer; 85 per cent of
cases in low-income countries are attributed to exposures to
these two viruses. Also see chapter 7.8.
1.2.4.5  Colon and rectum 
Colorectal cancer (of the colon or rectum) is the third most
common type of cancer worldwide, with just over 1 million
new cases recorded in 2002. Mortality is approximately half
that of the incidence, and nearly 530000 deaths were
recorded in 2002, making it the fourth most common cause
of death from cancer.
There is a large geographical difference in the global dis-
tribution of colorectal cancers. Incidence varies up to 25-fold
between countries with the highest rates (the USA, Australia
and New Zealand, and in parts of Europe) and those with
the lowest rates (in Africa and Asia). Intermediate levels
occur in South America.
Incidence of colorectal cancer may be stabilising in parts
of northern and western Europe, and possibly declining
gradually in the USA. Elsewhere, however, the incidence is
increasing rapidly, particularly in Japan and in middle- and
low-income countries.94 96
As shown in 1.3, the incidence of colorectal cancer increas-
es quickly when people migrate from low- to high-risk areas
of the world. Indeed, the incidence rate is higher in Japanese
people born in the USA than in white people born in the
USA. Also see chapter 7.9.
In 2004 Poland had a population of around
38.5 million. The country has an upper-mid-
dle-income economy, with a gross domestic
product of 12647 international dollars per
person (figure 1.3).46 Life expectancy at
birth is 71 years for men and 79 for women
(figure 1.1).46
Chronic diseases account for 88.2 per
cent of all deaths, while infectious diseases,
maternal, perinatal, and nutritional condi-
tions account for 3.9 per cent; 7.9 per cent
of deaths are due to injuries. The first fig-
ure gives a breakdown of deaths caused by
chronic diseases.46
Lung cancer is the most common type of
Poland
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1.2.4.6  Breast
Breast cancer is the most common type of cancer in women,
and the third most common cancer overall. Incidence rates
are increasing in most countries, with an estimated 1.15 mil-
lion new cases recorded in 2002. Breast cancer is the sixth
most common cause of death from cancer overall. However,
it is the second most common cause of cancer death in
women, with just over 410000 deaths recorded in 2002.
The incidence of breast cancer is highest in high-income
countries (although not in Japan) and more than half of all
cases occur in these countries. Although breast cancer has
been less common in women living in low-income countries,
age-adjusted incidence is increasing, and the rates of
increase are often greater in these countries.
Globally, estimates indicate that breast cancer incidence
has increased by 0.5 per cent annually since 1990. However,
certain cancer registries, such as those in China and other
parts of Asia, are recording annual increases in incidence of
up to 4 per cent. Rates are low in Africa, with the lowest inci-
dence in central Africa.94 96
Migrant studies show that breast cancer rates change when
women move to a new country. See 1.3. Also see chapter
7.10.
1.2.4.7  Cervix 
Cancer of the cervix is the second most common type of can-
cer among women, and the eighth most common cancer
overall, with around 500000 new cases recorded in 2002.
Cervical cancer is the seventh most common cause of death
from cancer overall, and the third most common in women,
and was responsible for nearly 275000 deaths in 2002.
Over 80 per cent of cases occur in low-income countries.
Areas with the highest incidence rates are sub-Saharan Africa,
the Caribbean, Central and South America, and south-cen-
tral and South-East Asia. Incidence rates are lowest in Europe,
the USA, Japan, China, and Australia and New Zealand.
The incidence has dropped substantially in high-income
countries following the introduction of cervical screening
programmes. The major established cause of cervical cancer
is infection with certain subtypes of human papilloma 
viruses (HPV). Other cofactors (parity, contraception, HIV
infection, and smoking) can also modify the risk of this
cancer in women infected with HPV.94 96 97 Also see 
chapter 7.13.
1.2.4.8  Prostate
Prostate cancer is the third most common type of cancer in
men, and the sixth most common cancer overall, with near-
ly 680 000 new cases recorded in 2002. The majority of cases
are diagnosed in men over the age of 65, and this cancer
accounted for just over 220000 cancer deaths in 2002. This
made it the eighth most common cause of death from can-
cer overall, and the sixth most common in men.
Prostate cancer is more common in high-income countries,
but the incidence remains low in Japan. Incidence rates have
been influenced by screening programmes, which increase
cancer in men and age-adjusted incidence
has remained stable since the 1970s.20 The
incidence of colorectal cancer has increased
since 1990, and both prostate and bladder
cancers have increased slightly since the
1970s.20 Stomach cancer incidence peaked in
the late 1970s and has declined steadily since.
Breast and colorectal cancers are the most
common types in women and their rates
have risen steadily since the 1970s.20 Cancer
of the cervix has remained steady since the
mid-1970s, whereas cancers of the lung,
ovary, and endometrium have increased in
this period (for age-standardised rates of
these cancers, see the second figure).20
In 1996, 31 per cent of men and 32 per
cent of women aged 15–75 were classified
as sedentary.46
In 1996 men aged 15–29 had an average
body mass index (BMI) of 23.1.46 This rose to
25.9 for men aged 30–44, while those aged
45–75 had a BMI of between 26 and 27.46
Only 2.4 per cent of men aged 15–29 had a
BMI of over 30, rising to 10.8 per cent of
those aged 30–44, and 17.5 per cent of 45–59
year olds.46 In the same year, women aged
15–29 had an average BMI of 21.2.46 Women
aged 30–44 had a BMI of 24.1, while those
aged 45–59 had a BMI of 26.7.46 Only 1.5 per
cent of women aged 15–29 had a BMI of
over 30, rising to 22.5 per cent of those aged
45–59, and 23.7 per cent of women aged
60–74.46 In a study of adults in Warsaw, the
average adult BMI remained stable between
1983 and 1993 at approximately 27.46 Overall
in 1996, 10.3 per cent of men and 12.4 per
cent of women had a BMI of 30 or more.46
See figure 1.4 for projections of the propor-
tions of men and women who will have a
BMI of 30 or more in 2015.46
The average amount of available food
energy rose between 1964 and 2004, from
around 3310 to 3520 kcal/person per day
(13850 to 14 730 kJ/person per day). The
amount of energy available from sugars
and meat increased during this period,
while the energy available from animal fats
fell substantially.1 In 1989 Poland began the
transition from a centrally planned to a
market economy. This resulted in dramatic
increases in food prices, and although the
transition gave people a better choice of
foods, there was a decline in food demand
and alterations in dietary patterns.37
Tobacco smoking and alcoholic drink con-
sumption are underlying factors in overall
mortality trends in eastern Europe. An
analysis of national household budget and
individual dietary surveys carried out in the
1990s found that, each day, the average
person ate around 300 g of dairy products
and the same amount of cereals (grains)
and roots and tubers, although consump-
tion of pulses (legumes) was very low.38 A
study of students found that women ate
meat and drank beer less frequently than
men, and they ate more fruit and drank
more milk.8 Another local study, in Warsaw,
reported decreases in intakes of total ener-
gy, dietary cholesterol, and dietary animal
fats, and an increase in vegetable oil intake
between 1984 and 2001.45 Another study
found that between 1990 and 2000, the
proportion of men eating fruit each day
increased from 36 to 42 per cent. Levels of
intake were stable in women, with around
60 per cent eating fruit every day. In con-
trast, over the same decade, only 22–23 per
cent of men limited their fat intake,
although more women did during this peri-
od (an increase from 23 to 45 per cent).40
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diagnosis rates. This has resulted in a huge increase in the
number of recorded cases in the USA in recent years,
although the incidence in several high-income countries has
declined since the 1990s. Prostate cancer incidence is
increasing rapidly in low-income countries, particularly in
Latin American countries (such as Costa Rica, Colombia,
and Ecuador) and in China. Again, this may partly be due
to increased awareness and screening. 
Mortality from prostate cancer is lower (5.8 per cent of
cancer deaths in men),94 and may give a better indication
of actual disease patterns.97 Even so, mortality is approx-
imately 10 times more common in the USA and Europe
than in Asia. Also see chapter 7.14.
1.3  Migrant and other ecological studies
Ecological studies (also called correlation studies) exam-
ine the relationships between environmental factors and
disease outcomes, often in different countries, at an aggre-
gate level (see chapter 3.1.2). These provided the first sys-
tematically gathered evidence suggesting that the principal
causes of cancer are environmental, and that food, nutri-
tion, and physical activity are among these factors. Early
studies showed strong correlations among countries
between, for instance, dietary fat intake and breast can-
cer rates.98
While not providing strong evidence for causation, such
studies generated hypotheses for possible links between
specific nutritional factors and cancers at particular sites,
and for the general proposition that patterns of cancer might
be altered as a result of changing patterns of eating and
other ways of life. Part 2 of this Report explores the degree
In 2004 Spain had a population of over 
43 million. The country has a high-income
economy, with a gross domestic product of
24 325 international dollars per person (fig-
ure 1.3).46 Life expectancy at birth is 77 years
for men and 83 for women (figure 1.1).46
Chronic diseases account for 87.4 per cent
of all deaths, while infectious diseases,
maternal, perinatal, and nutritional condi-
tions account for 5.5 per cent; 6.9 per cent
of deaths are due to injuries. The first figure
below gives a breakdown of deaths due 
Spain
Figure 1.7 Mortality from stomach and colorectal
cancer in European migrants to Australia
Data from McMichael et al102
Stomach cancer Colon cancer Rectal cancer
Length of
residence
(years) <16 >16 <16 >16 <16 >16
Country of
origin
Yugoslavia 2.22 1.23 0.47 0.66 0.46 1.34
England 1.47 1.24 0.99 1.04 1.23 1.04
Scotland 1.84 1.46 1.47 1.24 1.05 1.08
Ireland 1.77 1.21 0.62 1.06 1.17 1.18
Poland 1.69 1.71 1.02 1.14 0.43 1.34
Greece 1.35 1.15 0.36 0.69 0.34 0.7
Italy 1.43 1.49 0.37 0.7 0.48 0.8
Australia 1.0 1.0 1.0 1.0 1.0 1.0
Relative risk of death from cancer of the stomach, colon, and
rectum in European migrants to Australia (1962–1976) compared
with people born in Australia
Non-communicable causes of death   Spain
Data from World Health Organization46
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to which such hypotheses are upheld or refuted by the total-
ity of the relevant published literature, including more robust
observational and also experimental types of study. 
The most compelling evidence, suggesting that the main
causes of cancers of most sites are environmental (due to fac-
tors that people are exposed to) rather than genetically
inherited comes from studies of migrant populations. 
There are many migrant populations. Examples include
people who have migrated from eastern Asia to the
Americas; from the Indian subcontinent to Africa and the
UK; from Europe to Australia; and from Africa to the
Caribbean, and then to the UK. All of these population move-
ments are accompanied by marked changes in patterns of
diet, physical activity, and disease. 
Migrations from Japan to the USA, from the Caribbean to
the UK, and from European countries to Australia have been
to chronic diseases.46
Lung cancer is the most common cancer
type in men and incidence rates have
increased dramatically since the 1970s.20
Rates of colorectal, prostate, bladder, and
oral cancers have risen since records began
in the 1970s.20 Breast cancer is the most
common type in women and the rate has
doubled since the 1970s.20 Colorectal cancer
is the next most common type, which has
seen a steady rise during this period.20
Cancers of the endometrium and cervix
have remained steady since the 1970s, but
cancer of the ovary has risen (for age-stan-
dardised rates of these cancers, see the sec-
ond figure).20
A survey in 1997 found that 76 per cent
of adults aged 16 and over did no regular
exercise during their leisure time29; 46 per
cent of adults were classified as sedentary,
with only 7 per cent of adults recording any
physical activity each week.29
Between 1994 and 1997, men aged
25–34 had an average body mass index
(BMI) of 25, while those aged 35–44 had a
BMI of 26, and 45–75 year olds had a BMI
of 27.46 In total, 35 per cent of men aged
25–64 had a BMI of over 27, and 12.2 per
cent had a BMI of over 30.46 Women aged
25–34 had an average BMI of 23, while
those aged 35–44 had a BMI of 25, and
45–74 year olds had a BMI of between 27
and 28.46 Overall, 25.7 per cent of women
aged 25–64 had a BMI of over 27, and 12.1
per cent had a BMI of over 30.46
Over the period 1977–1993, the propor-
tion of people with energy-intensive jobs
halved. In children aged 6–7, there has
been a marked increase in obesity and over-
weight, higher even than in US children of
the same age. Obesity in adolescents is also
among the highest in the world.29 Between
1990 and 2000, 45 per cent of men and 32.2
per cent of women had a BMI of 25 or
more, and 13.4 per cent of men and 15.8
per cent of women had a BMI of 30 or
more. See figure 1.4 for projections of the
proportions of men and women who will
have a BMI of 30 or more in 2015.46
The average amount of available food
energy rose between 1964 and 2004, from
around 2700 to 3480 kcal/person per day
(11 330 to 14 590 kJ/person per day), due
largely to an increase in the availability of
sugars and meat.1 The Mediterranean-style
diet is often seen as the healthiest in
Europe, but Spanish diets have recently
shifted towards being high in fat and dairy
products, with only moderate amounts of
vegetables. Dairy and fruit intakes are the
highest in Europe, but so is the proportion
of energy in diets from fat.29 Between 1964
and 1990, consumption of plant-based
foods decreased from 1289 to 995 g/person
per day. In the same period, intakes of cere-
als (grains), pulses (legumes), and potatoes
all halved. While consumption of other veg-
etables remained stable, fruit intake dou-
bled to 327 g/person per day. Consumption
of animal products increased from 407 to
743 g/person per day due to a large
increase in the amounts of meat, poultry,
milk, and dairy products in people’s 
diets, although intakes of animal fats
decreased.29
Age-standardised incidence of breast and colorectal cancer is
increased in Asian migrants to Canada compared with source
population
Figure 1.9 Incidence of colorectal cancer in Asian
migrants to USA and their descendants
Data from Flood et al106
Men Women
White USA 89.9 64.3
Chinese USA 66.9 40.9
China 87.8 44.7
Japanese USA 142.5 90.1
Japan 69.3 63.5
Filipino USA 57.2 14.2
Philippines 44.4 25.7
Ethnicity Birth place Incidence rate per 100 000 people
Age-standardised incidence of colorectal cancer is increased in the
descendants of Japanese migrants to the USA
Figure 1.8 Cancer among female Iranian migrants
to British Columbia, Canada
Data from Yavari et al104
Age-standardised incidence in women per 100 000
Cancer Ardabil Kerman Iranian British
province province migrants to Columbia
 (Iran) (Iran) British general
 Columbia
Breast 7.6 16.9 68.5 81.4
Colorectal Not done 5.9 11.6 26.6
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studied in some detail, as have movements of populations
from rural to urban areas within countries. Both types of
migration result in dietary changes, which are followed,
within one or two generations, by changes in disease pat-
terns. Patterns of cancer among migrant groups often change
faster than they do among people who remain in their home
country or among people native to the host country.
In the 1980s, one study demonstrated that breast cancer
incidence increased almost threefold in first-generation
Japanese women who migrated to Hawaii, and up to five-
fold in the second generation. Colorectal cancer incidence
increased almost fourfold in the first generation but did not
increase further with subsequent generations.99 In this same
population, the incidence of stomach cancer dropped by
almost half in the first generation, and dropped further in
the second generation.99
Another study, published in 1980, of European migrants
to Australia demonstrated a reduction in the death rate from
stomach cancer, which corresponded to the length of time
the migrants stayed in Australia. However, their risk of col-
orectal cancer increased proportionally to the length of their
stay.100 See figure 1.7. A later study demonstrated that
deaths from breast cancer among Italian migrants to
Australia were half that of Australian-born women during
the first five years after emigrating. However, after 17 years,
Italian migrants had similar death rates (due to breast can-
cer) to women born in Australia.101
Following migration, the incidence of certain cancers may
increase, whereas the incidence of other cancers may
decrease. Thus among Iranian immigrants to Canada, in
women, breast cancer incidence rate increased fourfold, and
colorectal cancer incidence rate doubled; but there was a
dramatic decrease in cancers of the stomach and oesopha-
gus in both sexes.102 See figure 1.8.
Another study showed that breast cancer incidence
increased threefold within one generation in Polish migrants
In 2004 the USA had a population of almost
300 million. The country has a high-income
economy, with a gross domestic product of
39 901 international dollars per person (fig-
ure 1.3), which masks socioeconomic
inequalities.46 Life expectancy at birth is 75
years for men and 80 for women (figure
1.1).46
Chronic diseases account for 84.7 per
cent of all deaths, while infectious diseases,
maternal, perinatal, and nutritional condi-
tions account for 6.7 per cent; 8.6 per cent
of deaths are due to injuries. The first fig-
ure below gives a breakdown of deaths
caused by chronic diseases.46
Prostate cancer is the most common type
of cancer in men and the incidence rate has
more than doubled since the 1970s.20 Lung
cancer peaked in the early 1980s and has
since declined slightly.20 Rates of colorectal
and bladder cancer have remained stable,
although melanoma has increased steadi-
ly.20 Breast cancer is the most common type
in women, followed by lung cancer, and
both have increased since the 1970s.20 Over
the same period, the incidence of cancers of
the colon and rectum and of the ovary have
remained stable, while cancer of the
endometrium has decreased slightly (for
age-standardised rates of these cancers, see
the second figure below).20
In 2003, 22 per cent of men and 27 per
cent of women aged 20–65 were classi-
fied as sedentary; physical inactivity was
more prevalent among people with a low
income.91
In 2002 men aged 20–24 had an average
body mass index (BMI) of 26.2, while those
aged 25–29 had a BMI of 27, and men aged
30–65 had a BMI of between 27 and 29.46
While 19.7 per cent of men aged 20–24 had
a BMI of over 30, this rose to 23.6 per cent
of those aged 30–34, and 30 per cent of
40–44 year olds.46 Women aged 20–24 had
an average BMI of 26.2, while those aged
USA
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to the USA.103 Japanese, Chinese, and Filipino people who
migrate to the USA have a higher risk of colorectal cancer
than their counterparts who do not migrate. One study of
US-born Japanese men demonstrated incidence rates of col-
orectal cancer twice as high as Japanese men born in coun-
tries other than the USA or Japan and 60 per cent higher
than in white people born in the USA (figure 1.9).104
Data from more recent migrant studies show that cancer
incidence rates generally become similar to those of the
adopted country in second-generation immigrants.17 105 This
is illustrated in first-generation immigrants to Sweden,
where the incidence of all cancers was 5 and 8 per cent lower
for men and women, respectively, compared with native
Swedes.17 By the second generation, however, the incidence
was only marginally below the figures for people native to
Sweden.105
Correlation studies, and migrant studies in particular,
prove that the main determinants of patterns of cancer are
environmental and suggest that patterns of food, nutrition,
and physical activity are important among these causes.
Migrants share a common genetic background, as do their
parents and children: the genetic pool of any population does
not change within a generation or two. But as shown in
Chapter 2, different patterns of environmental exposure can
and do alter patterns of DNA damage and gene expression,
and so cancer, in a relatively short time. 
1.4  Conclusions
Between the early 2000s and 2030, the global absolute num-
ber of cancer cases is projected by UN agencies to double,
most of all in the middle- and low-income countries of Africa
and Asia. Some of this increase can be attributed to the
25–29 had a BMI of 27.4, and 30–65 year
olds had a BMI of between 28 and 30.46
While 23.1 per cent of women aged 20–24
had a BMI of over 30, this rose to 30.9 per
cent of women aged 25–29, and to more
than 40 per cent of those aged 55–64.46 The
obesity epidemic began earlier in the USA
than in other high-income countries.
Between 1906 and 1962, 10.4 per cent of
men and 15 per cent of women had a BMI
of 30 or more.46 By 1999/2000, these figures
had increased to 27.7 per cent of men and
34 per cent of women (see figure).46 In 2002
a US health survey found that almost 75 per
cent of people were trying to prevent
weight gain.106 See figure 1.4 for projec-
tions of the proportions of men and
women who will have a BMI of 30 or more
in 2015.46
The average amount of available food
energy rose between 1964 and 2004, from
around 2930 to 3750 kcal/person per day
(12 250 to 15 690 kJ/person per day).1
Between 1977 and 1996, the average pro-
portion of meals eaten in restaurants or
fast-food outlets rose from 9.6 to 23.5 per
cent, and fast food now accounts for 20 per
cent of dietary energy.2
Vegetable and fruit intakes have
increased since the 1980s across all income
levels, and people now eat more fresh and
frozen vegetables and fruits than canned.
Potatoes are commonly eaten. Bananas 
are the most popular fruit.34 More than 
80 per cent of men and 70 per cent of
women aged 20–64 fail to eat the recom-
mended five daily portions of vegetables
and fruits. Between
1970 and 2000,
average population
consumption of
meat and poultry
per person increas-
ed by 11 per cent:
people ate less beef 
but more poultry.16
Analysis of national
food surveys de-
monstrated that
between 1977 and
2001, people con-
sumed more sweet-
ened drinks and less
milk. The portion
sizes of sweetened
drinks increased and
they contributed
more energy to
diets: an increase
from 50 to 140
kcal/person per day
(210 to 600 kJ/per-
son per day). During
the same period,
fruit drinks increas-
ed from 20 to 45
kcal/person per day
(80 to 190 kJ/person
per day); energy intake from milk dropped
from 140 to 100 kcal/person per day (600 to
410 kJ/person per day), with the largest
drop in milk consumption among those
aged 2–18.31 Another study revealed that 93
per cent of young people ate snack foods
and they consumed one third of their total
energy away from home.2 Energy from soft
drinks, fast foods, and salty snacks doubled
between 1977 and 1996, and soft drinks
now provide 8.5 per cent of total energy in
young people’s diets.2
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In 2004 Mexico had a population of over
107 million. The country has an upper-mid-
dle-income economy, with a gross domes-
tic product of 10158 international dollars
per person (figure 1.3). Life expectancy at
birth is 72 years for men and 77 for women
(figure 1.1).46
Chronic diseases account for 72.4 per
cent of all deaths, while infectious diseases,
maternal, perinatal, and nutritional condi-
tions account for 16.5 per cent; 16.49 per
cent of deaths are due to injuries. The first
figure below gives a breakdown of the
deaths caused by chronic diseases.46
Prostate cancer is the most common type
of cancer in men, followed by lung, stom-
ach, and colorectal cancers. Cancer of the
cervix is the most common type in women,
followed by cancers of the breast, stomach,
and ovary (for age-standardised rates of
these cancers, see the second figure
below).20 Women living in rural areas have
a higher risk of cancer of the cervix com-
pared with those living in urban areas.32
Stomach cancer incidence has risen since
1980, and this increase is more evident in
men.20
In 2002–2003, 17 per cent of men and 18
per cent of women aged 18–69 were clas-
sified as sedentary (figure 1.6).46
Between 1995 and 1999, the prevalence
of overweight and obesity in children rose
from 13.6 per cent to 19.5 per cent.18
Geographically, the highest prevalence of
overweight and obesity is in Mexico City
and in the northern region. Across the
country as a whole, girls are more likely to
be overweight or obese.18 One fifth of
school-age children are overweight or
obese, and the risk of body fatness rises if
their mother has a school education and
higher socioeconomic status.18 Men aged
20–29 had an average body mass index
(BMI) of 25.2, while those aged 30–39 had
a BMI of 26.9, and men aged 40–59 had a
BMI of 27.5. While 11.8 per cent of men
aged 20–29 had a BMI of over 30,46 this
rose to 20.9 per cent of 30–39 year olds.46
Around 25 per cent of men aged between
40 and 69 had a BMI of over 30. Women
aged 20–29 had an average BMI of 25.6.46
This rose to 27.9 for those aged 30–39, and
to 29 for women aged 40–69. While 16.7
per cent of women aged 20–29 had a BMI
of over 30, this rose to 29.6 per cent of
those aged 30–39. Around 40 per cent of
women aged 40–59 had a BMI of over 30.46
See figure 1.4 for projections of the pro-
portions of men and women who will have
a BMI of 30 or more in 2015.46
The average amount of available food
energy rose between 1964 and 2004, from
around 2470 to 3150 kcal/person per day
(10350 to 131780 kJ/person per day).1
In 1999, micronutrient deficiencies re-
mained a problem.36 Undernutrition was
more prevalent in the indigenous popula-
tion, in people of lower socioeconomic
status, and in rural areas and the south.
One in five children under the age of 5
years was stunted, and 2 per cent were
classified as suffering from wasting. Rates
of stunting and wasting were three times
higher in rural than urban areas, and were
higher in the south of the country than the
north.
Folate intakes were lower in urban
areas, in the north of the country, and in
Mexico City, compared with the south and
in rural areas.7 This demonstrates regional
differences in diets, particularly in the
amounts of green, leafy vegetables people
eat. Preschool children in the north and in
Mexico City had the highest intakes of fat
and the lowest intakes of dietary fibre.
Children in the south, those indigenous to
the country, and those of lower socioeco-
nomic status had higher intakes of dietary
fibre and starchy foods, the lowest fat
intakes, and the highest risk of inadequate
micronutrient intakes for vitamin A, vita-
min C, folate, calcium, iron, and zinc.7 In
women, there was a risk of inadequate vit-
amin A, vitamin C, and folate intake.
Consumption of starchy staple foods and
intakes of folate, calcium, and iron were
significantly higher in rural women com-
pared with those living in urban areas.
Saturated fatty acid consumption was
lower in the south, reflecting the greater
contribution of beans and cereals (grains)
in diets.6 Women in urban areas, and those
of higher socioeconomic status, consumed
more cholesterol, saturated fatty acids, and
total fat.6 Across the country as a whole,
dietary fibre consumption was found to be
inadequate, but intakes were higher in
central and south Mexico, mainly because
people’s diets contained beans and cereals
(grains), although their intake of vegeta-
bles and fruits was low.
Mexico
Age-standardised rates of common cancers   Mexico
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In 2004 the population of Australia was
over 20 million. The country has a high-
income economy, with a GDP of 31 454
international dollars per person (figure
1.3).46 Life expectancy at birth is 78 years
for men and 83 for women (figure 1.1).46
Chronic diseases account for 86.9 per
cent of all deaths, while infectious diseases,
maternal, perinatal, and nutritional condi-
tions account for 4.7 per cent; 8.4 per cent
of deaths are due to injuries. The first fig-
ure below gives a breakdown of the deaths
due to chronic diseases.46
In men, prostate cancer is the most com-
mon type and rates have doubled since the
1970s. Colorectal cancer has increased and
lung cancer has declined slightly. There has
been a large increase in the incidence of
melanoma and a slight increase in bladder
cancer. In women, breast cancer is the most
common type and the rate has increased
since the 1970s. Colorectal cancer is the
next most common type, although this has
remained stable. There has been a large
increase in melanoma, and lung cancer has
doubled since the late 1970s, although can-
cer of the endometrium has remained sta-
ble (for age-standardised rates of these
cancers, see the second figure below).20
In 2001, 30 per cent of men and 32 per
cent of women aged 15–75 were classified
as sedentary.46
In the same year, men aged 18–24 had
an average body mass index (BMI) of 24.3,
while those aged 25–29 had a BMI of 25.3,
and men aged 30–75 had a BMI of
between 26 and 27.5.46 Of men aged
18–24, 34.3 per cent had a BMI of over 25.46
This rose to 43.8 per cent of those aged
25–29, and to between 50 and 70 per cent
of men aged 30–75.46 Between 17 and 20
per cent of men aged 35–69 had a BMI of
over 30.46 The average BMI of women aged
18–24 was 22.8.46 This rose to 24.9 for
women aged 30–34, and those aged 40–75
had a BMI of between 25 and 27.1.46 The
proportion of women with a BMI of over 25
increased with age: 19.9 per cent of women
aged 18–24, and 34–55 per cent of those
aged 30–75. Overall, between 15 and 20 per
cent of women aged 30–75 had a BMI of
over 30.46 There has been a steady increase
in BMI since 1980, when 40.6 per cent of
men and 20.2 per cent of women had a BMI
of 25 or more, and 9.3 per cent of men and
8 per cent of women had a BMI of 30 or
more.46 In 2000, 48.2 per cent of men and
29.9 per cent of women had a BMI of 25 or
more, and 19.3 per cent of men and 22.2
per cent of women had a BMI of 30 or
more.46 See figure 1.4 for projections of the
proportions of men and women who will
have a BMI of 30 or more in 2015.46
The average amount of available food
energy remained stable between 1964 and
2004: around 3130 and 3120 kcal/person per
day (13100 and 13070 kJ/person per day),
respectively.1 The most recent National
Nutritional Survey in 1995 found that 90 per
cent of the people surveyed ate cereals
(grains) or cereal products, and milk or milk
products, the day before the interview.
However, half of the men and one third of
the children had not eaten fruit, and 20 per
cent of children had not eaten vegetables
the day before the interview. Fruit con-
sumption was decreasing in adolescents,
although the intake of milk products was
declining only among girls. Fewer adoles-
cents ate cereals (grains) compared with
other age groups, although cereals and
cereal products contributed 34–37 per cent
of their total dietary energy. Cereal products
contributed the greatest amount of food by
weight to adults’ diets, followed by milk and
milk products, then pulses (legumes). Fruit
consumption increased with age, whereas
intakes of cereals (grains), milk, meat, and
poultry decreased. Adults in the Northern
Territory consumed more meat, poultry,
game, and alcoholic drinks, and less veg-
etables and fruits, than people living in
other areas. Men were slightly more likely
to eat food away from home (64 per cent)
compared with women (57 per cent).
Almost one third of adults thought that
they should be eating more fruit, and 25 per
cent thought they should eat fewer high-fat
foods.4 Fruit and vegetable consumption
was highest in 18–39 year-olds, with 40–50
per cent consuming a combination of at
least one portion of fruit and three portions
of vegetables each day, although this
amount then declined steadily with age.
Only 37.6 per cent of children (12–17 year
olds) ate this quantity of vegetables and
fruits and, in total, 37.2 per cent of people
over the age of 12 failed to eat this amount.
A study of people aged 20–75 living in
Queensland found that 63 per cent of par-
ticipants drank too much alcohol, 40 per
cent were not sufficiently physically active,
and less than half ate the recommended lev-
els of fruits and vegetables.13
Australia
Age-standardised rates of common cancers   Australia
Age-standardised rate per 100 000
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In 2004 Brazil had a population of over 185
million. The country has a middle-income
economy, with a gross domestic product of
8140 international dollars per person (fig-
ure 1.3), which masks extreme socioeco-
nomic inequalities.46 Life expectancy at
birth is 67 years for men and 74 for women
(figure 1.1).46
Chronic diseases account for 75.3 per
cent of all deaths, with infectious diseases,
maternal, perinatal, and nutritional con-
ditions accounting for 16.2 per cent; 8.5
per cent of deaths are due to injuries. The
first figure below gives a breakdown of
deaths caused by chronic diseases.46
Prostate cancer is the most common type of
cancer in men. This is followed by lung, stom-
ach, colorectal, and bladder cancers. Breast
cancer is the most common type in women,
followed by cancers of the cervix, colorectum,
stomach, and lung (for age-standardised rates
of these cancers, see the second figure
below).20 Age-standardised mortality rates for
childhood cancers have declined since 1980
and there has been a decrease in mortality
from oral and pharyngeal cancers since the
early 1980s.9 These figures may represent
improved provision of healthcare rather than
changes in incidence.
In 1997, 28 per cent of men and 31 per
cent of women aged 18–69 were classified
as sedentary (figure 1.6).46
In 1997 men aged 20–65 had an average
body mass index (BMI) of between 23 and
25.46 Just 2.1 per cent of men aged 20–24
had a BMI of over 30, rising to 9.1 per cent
of 30–34 year olds, 11.4 per cent of 40–44
year olds, and 12.3 per cent of men aged
50–54.46 Women aged 20–39 had an
average BMI of between 22.5 and 24.9,
while from age 40 onwards, average BMI
remained between 25 and 27.46 Just 5.2
per cent of women aged 20–24 had a BMI
of over 25, rising to 17.4 per cent of those
aged 40–44, and 25.5 per cent of women
aged 60–64.46 The proportion of men and
women with a BMI of 30 or more has
increased steadily since the mid-1970s.46 In
1975, just 2.1 per cent of men and 6 per
cent of women had a BMI of 30 or more;
this rose to 6.4 per cent and 12.4 per cent
in 1996/7.46 See figure 1.4 for projections
of the proportions of men and women
who will have a BMI of 30 or more in
2015.46 In 1975, for every obese woman,
approximately another two were under-
weight. Between 1975 and 1989, the
prevalence of underweight almost halved,
while the prevalence of obesity doubled;
so by 1997 there were two obese women
for every underweight woman.28
The average amount of available food
energy rose between 1964 and 2004, from
2313 to 3157 kcal/person per day (9684 to
13 218 kJ/person per day), largely due to an
increase in the availability of meat and
oils.1 In one study, people living in urban
areas ate more vegetables and fruits than
those living in rural areas; intake increased
with age, schooling, and income. However,
only 41 per cent of adults reported eating
fruit every day and 30 per cent reported
daily vegetable intake.21 Wasting and
stunting in children due to undernutrition
have decreased rapidly since 1975,
although it remains a major problem in
the north-eastern region of the country.
Obesity among children is low, but those
from higher income households in the eco-
nomically developed south-eastern region
are more likely to be overweight.28
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general projected increase in global population; to ageing
populations; and to improved surveillance, detection and, in
the case of prostate cancer, screening and diagnosis.
Nevertheless, at the global level, a real, age-adjusted, popu-
lation-adjusted increase in cancer rates is projected. These
projections show that any global ‘war on cancer’ is not being
won. It follows that soundly based policies and effective pro-
grammes to prevent cancer — which is to say, to decrease
the risk of cancer — need not be accompanied by a decrease
in the overall numbers of people suffering and dying from
cancer.
This ominous prospect should be put in context. First, both
actual numbers and also age-adjusted rates of some cancers
are decreasing in high-income countries, and rates of stom-
ach cancer are generally decreasing worldwide. Second, the
remarkable differences in the numbers of different cancers,
and in their incidence over time, show that most cancer is,
at least in principle, preventable. Third, the theme of this
Report, correlations between changes in patterns of diet,
physical activity, body composition, and changes in patterns
of cancer provide evidence that these factors are important
modifiers of cancer risk. 
Furthermore, as shown in Part 2 of this Report, overall the
evidence is a reliable basis for recommendations designed to
prevent cancer. The evidence shows that, together with expo-
sure to tobacco smoke, key aspects of food and nutrition,
physical activity, and body composition are or may be caus-
es of important cancers of some sites. Unlike tobacco, the evi-
dence also shows that other aspects protect against a number
of common cancers. This indicates that many cancers are
preventable not only in principle, but potentially also in
practice.
Continued from page 25
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The cancer process
Food and nutrition modify the risk of cancers at a
large number of sites. This means that some foods
and drinks, dietary constituents (or their balance in
diets), and methods of food production, processing,
preservation, and preparation influence the
development of some cancers. More recently,
evidence has accumulated about the effects of
physical activity and body composition on the risk of
a number of cancers, suggesting that bioenergetics
is another factor determining cancer risk and tumour
behaviour. 
Since the mid-1990s, great progress has been made
in understanding the cancer process, and which
internal and external factors modify cancer risk.
Mapping of the human genome has enabled the
establishment and development of new disciplines
devoted to understanding biological processes at
the most basic level, including those that prevent
cancer, those that cause cancer, and those that
modify its behaviour. 
Evolution in living organisms depends on the
accumulation of adaptations as a result of changes
in the expression of the genetic information carried
in DNA. Even with no changes in the DNA,
alterations in how the message in the genetic code is
translated can lead to functional changes. More
importantly, the DNA itself is susceptible to
mutation — changes in the genetic code itself — as a
result of damage from external causes such as
radiation or simply due to the process of
metabolism. Such mutations are the essential basis
for human evolution, by producing adaptations that
are beneficial in particular environmental
circumstances. At the same time, some mutations
can contribute to the harmful changes in cells that
eventually lead to cancer. 
The integrity of the genetic information is
protected by many systems that prevent DNA
damage, or remove or repair damaged DNA if it
occurs. Imperfections in these systems limit the
ability to block all damage and allow both helpful
and harmful mutations to occur. Cancers result when
sufficient mutations have accumulated, most
presenting at an age that was rarely reached in the
evolutionary past of human beings. The
development of cancer may be seen as a corollary of
C H A P T E R  2
the ability of humans to evolve and adapt.
Ultimately it is both the genetic information
(genotype) and its expression that control the
characteristics (or phenotype) of an individual. Any
exposure during the life course that affects the
genotype or its expression may also have an effect
on the phenotype. At any point in time, the
phenotype is related not only to the genotype but
also to a host of environmental factors, including
nutritional exposures. This accumulated metabolic
experience may begin during maternal and early life,
and proceed throughout a person’s lifetime. 
The purpose of this second introductory chapter is
to summarise current knowledge and thinking on the
biology of the cancer process, with special reference
to food and nutrition, physical activity, and body
composition. In Part 2 of this Report, epidemiological
and mechanistic evidence is summarised, and the
Panel’s assessments and judgements are made,
based on a balance of all relevant evidence.
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This chapter summarises the wealth of biological evidence
that documents the ability of food and nutrition, physical
activity, and body composition to influence several stages of
the process of the development of cancer.
Nutrients and food constituents have effects that can either
inhibit several events that lead to cancer, or contribute to
cancer development, by altering DNA itself, or by altering
how the genetic message in DNA is translated. Physical 
activity and variations in body composition also appear to
influence cancer risk. Indeed, overall dietary patterns can
indirectly influence cell growth by way of changes in gen-
eral metabolic, regulatory, and endocrine effects.
The normal functioning of all biological processes, includ-
ing those of the human body, depends on the availability of
substrate and nutrients. Good nutrition — defined as appro-
priate provision of food and nutrients from the level of the
whole organism to the cellular and intracellular level — is
needed for normal structure and function. When a person is
not suitably nourished, either through under- or overnutri-
tion, this impacts on the tissue microenvironment, compro-
mising both structure and function.
Understanding the mechanisms underlying cancer devel-
opment is central to improving its prevention and treatment.
The main body of this Report comprises the Panel’s judge-
ments on a series of systematic literature reviews (SLRs) on
evidence linking food, nutrition, and physical activity to can-
cer. All evidence on the mechanisms of the cancer process is
also based on rigorous review criteria. However, the evidence
presented in this chapter is a summary of this literature, and
the references cited are illustrative examples only. Full details
of the methods used for the reviews are contained in the SLR
specification manual. The full SLRs and this manual are con-
tained on the CD included with this Report. 
2.1  Basic concepts and principles
2.1.1 Cancer
Cancer is a group of more than 100 diseases characterised by
uncontrolled cellular growth as a result of changes in the
genetic information of cells. Cells and tissues are complex sys-
tems with critical stages and checkpoints to ensure normal
growth, development, and function. Normally the division, dif-
ferentiation, and death of cells are carefully regulated. All can-
cers start as a single cell that has lost control of its normal
growth and replication processes.
Human adults are made up of around 1013 (or
10 000 000 000 000) cells, which are renewed and replaced
constantly. About 5–10 per cent of cancers result directly
from inheriting genes associated with cancer, but the major-
ity involve alterations or damage accumulated over time to
the genetic material within cells. The causes of damage are
both endogenous (internal) and exogenous (environmental).
Food, nutrition, and physical activity are important envi-
ronmental factors in the development of cancer.
Cancer can also be seen as a group of diseases that affects
many different tissues and types of cell, and can be defined
by their tissue of origin. Approximately 85 per cent of adult
cancers develop from the epithelial cells of the inner and
outer linings of the body and are called carcinomas. Cancers
of glandular tissue such as the breast are called adenocarci-
nomas; cancers from bone and muscle derived from meso-
derm cells (embryonic cells that grow to form muscle, blood,
bone, and connective tissue), are called sarcomas.
Each type of cancer has different characteristics, but one
feature of all these diseases is unregulated cell growth and/or
cell death. Apart from haematological cancers such as
leukaemias, this results in a tumour or mass, and cancerous
cells often invade the surrounding tissue. Spread of cancer
cells from the primary site to other parts of the body is called
metastasis. Benign tumours do not invade or metastasise.
Malignant tumours do not remain localised but can invade
and/or metastasise. 
2.1.2 Genetic material
The genetic material of mammalian cells is composed of dou-
ble-stranded DNA made from four organic bases — cytosine,
guanine, adenine, and thymine — within a helical spine
comprising deoxyribose (a sugar) and phosphate. The com-
bination of a base with phosphate and deoxyribose is called
a nucleotide. Humans have 3 billion base pairs in the DNA
code that encode approximately 30 000 different genes. 
The nucleus of a cell contains DNA, and the information
in the code is ‘read’ to generate proteins in the cytoplasm of
the cell. This is achieved by transcribing the DNA into RNA,
and then translating the information in RNA to synthesise
protein. For transcription, the two DNA strands separate and
an intermediary, complementary copy of the DNA is made
from mRNA (which differs slightly in structure from DNA
and is single stranded). For translation, the RNA leaves the
nucleus and binds to an organelle in the cytoplasm called the
ribosome. The RNA nucleotides encode for 21 different
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amino acids, with the ribosome moving along the RNA mol-
ecule and translating the genetic code into a sequence of
amino acids that build into a protein.
The normal metabolic processes in cells are controlled by
proteins, each of which is a product of a single gene from the
DNA in the nucleus. Although each cell in the body contains
exactly the same genes, cells from different organs have dif-
ferent structures and functions because there is a process of
regulation that determines which genes are expressed; that
is, which genes are turned on and which are not (see 2.2.2).
This differential gene expression varies not only from tissue
to tissue but also from time to time over the course of a per-
son’s life, from embryonic and fetal stages onwards (box 2.1).
Gene expression is regulated by promoter regions of genes in
the DNA, as well as by epigenetic factors — those that alter
gene expression without changing the nucleotide sequence
(see 2.2.3). The availability of nutrients within the immedi-
ate environment influences these processes (figure 2.1).
2.1.3 Nutrigenomics and cancer 
Unravelling links between diet and cancer is complex, as
thousands of dietary components are consumed each day; a
typical diet may provide more than 25000 bioactive food
constituents.1 Assessing intakes of some constituents is dif-
ficult due to wide variations in the amounts of bioactive com-
ponents within a particular food.2 3 Dietary constituents
modify a multitude of processes in both normal and cancer
cells.4 5
The response is further complicated since a single, bio-
active food constituent can modify multiple steps in the
cancer process. Likewise, many of these processes can be
influenced by several food components. Normal and cancer
cells also differ in their responses to bioactive food
components in terms of the
dose (quantity), timing, and
duration of exposure required
to bring about effects. To unrav-
el the contribution of nutrition
to cancer, the biological
processes underpinning cancer
development need to be under-
stood. Extensive evidence exists
for nutritional factors in sever-
al processes related to cancer
development (figure 2.2).
However, because of the com-
plexity of the process, it is not
possible to conclude that mod-
ifying any one, or more, of
these processes influences
cancer risk.
The recent expansion of
knowledge in molecular biolo-
gy has allowed new techniques
to be developed to explain
these mechanisms. Nutri-
genomics is a new field with
profound implications in cancer
prevention and therapy, since it
seeks to clarify the impact of nutrition in the maintenance
of genome stability, and to dissect out the influence of geno-
type in determining our response to diet. Nutrigenomics is
the study of nutritional influences on the phenotypic vari-
ability of individuals based on genomic diversity (figure 2.1).
This determines the sequence and functions of genes, and
studies single nucleotide polymorphisms (SNPs), and ampli-
fications and deletions within the DNA sequence as modi-
fiers of the response to foods and beverages and their
constituents. Nutritional epigenomics is another key deter-
minant of gene expression patterns. It includes non-coding
modification of genes (such as methylation, changes in his-
tone homeostasis, miRNA, and DNA stability) in response
to nutrition. Nutritional transcriptomics is the study of gene
expression patterns at the RNA level, and it can identify
common nutritional response elements in gene promoters
that can be modulated by diet. Proteomics studies the pro-
teins that can be expressed by a cell, many of which can be
influenced by nutrition. Metabolomics studies the range of
metabolic processes in a cell and metabolic regulation in
cells or tissues, which again are heavily influenced by food,
nutrition, and physical activity.
2.2  Cellular processes
The role of nutrition in cancer depends on how it impacts
on fundamental cellular processes including the cell cycle
(figure 2.3; also see 2.5.1). To understand cancer biology,
it is important first to understand normal cellular processes.
The integrity of tissues and organs depends on a regulated
balance between cell proliferation and death, and appro-
priate cell differentiation. This regulation is controlled by
The genetic message in the DNA code is translated into RNA, and then into protein synthesis, 
and so determines metabolic processes. Research methods called ‘-omics’ address these different
stages.
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several types of genes including oncogenes and tumour sup-
pressor genes (box 2.2), and factors in the cellular environ-
ment that influence their expression. Maintenance of the
DNA sequence and structure as cells divide is essential: sev-
eral cellular mechanisms exist to ensure this is achieved. 
2.2.1 Cell signalling
Cells detect and respond to external stimuli and send mess-
ages to other cells through a molecular mechanism known
as cell signalling. 
Cells within a tissue normally communicate with each
other through a network of locally produced chemicals called
cytokines (including some growth factors). Cell proliferation
is a tightly controlled and coordinated process, and is stim-
ulated by growth factors. These soluble proteins can be pro-
duced locally, either from the same cell (autocrine), or from
different cells (paracrine), or as hormones (endocrine) pro-
duced by a distant tissue and transported in the blood.
Growth factors bind to specific receptors on the cell surface
and transmit a signal into the cell, which is relayed to the
nucleus. In the nucleus, genes are switched on to produce
the proteins necessary for cell division.
Getting the growth signal from the outside of the cell to
the nucleus requires a series of steps. The shape of the recep-
tor changes when the growth factor binds to it, which caus-
es part of the receptor to become activated, usually by a
process called phosphorylation. A regulated process of phos-
phorylation and dephosphorylation is necessary for the
appropriate initiation, transmission, and cessation of signals. 
2.2.2 Gene expression 
Gene expression is the process by which the information
within a gene is ‘turned on’ or ‘turned off ’. The information
is used to create the associated proteins and modify the
amounts produced. Also see figure 2.1. 
Transcription factors are proteins involved in the regula-
tion of gene expression and carry the signal from the
cytoplasm to the nucleus. They bind to the promoter regions
of genes and have the effect of either switching gene
expression on or off. There are also nuclear receptors, such
as retinoic acid receptors, that function as transcription
factors by binding directly to specific DNA sequences.
Some so-called ‘housekeeping’ genes are expressed by
almost all cell types. These genes generally encode proteins
that participate in basic cell functions such as metabolic
pathways and synthesis, and processing of DNA, RNA, or pro-
teins. Other genes have more restricted expression, and 
are expressed only in specific cell types, and/or stages of
development.
Gene expression can also be influenced by changes outside
the DNA of genes. DNA is closely organised and tightly pack-
aged in the nucleus of cells. To achieve this, DNA is spooled
around proteins called his-
tones. Histone structure can
be modified either, like DNA
itself, by methylation, or
more commonly by acetyla-
tion (addition of an acetyl
group). Acetylation and
deacetylation (removal) are
mediated by the enzymes
histone acetyl transferase
(HAT) and histone deacety-
lase (HDAC), respectively.
HATs relax the packaged
DNA structure, which is asso-
ciated with enhanced tran-
scription, whereas HDACs
stabilise the structure with
higher levels of packaging,
and so suppress transcrip-
tion. Butyrate, produced in
the colon by bacterial
fermentation of non-starch
polysaccharide (dietary
fibre), diallyl disulphide
from garlic and other allium
vegetables, and sulphora-
phane, a glucosinolate from
cruciferous vegetables, can
behave as histone deacety-
lase inhibitors,16 and act to
maintain DNA stability or
enhance transcription. 
Micro RNAs (miRNAs) are
Food, nutrition, obesity, and physical activity can influence fundamental processes shown here,
which may promote or inhibit cancer development and progression.
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RNA molecules that do not encode proteins; instead they
function as negative regulators of gene expression. Some
mutations in miRNAs have been associated with human can-
cers, and they can function as oncogenes or tumour sup-
pressor genes (box 2.2). miRNAs are short, single-stranded
RNA molecules of approximately 22 nucleotides. For
instance, to silence (turn off) genes, they may bind to com-
plementary mRNA sequences and degrade them before they
have been translated. Profiling miRNA signatures within can-
cer cells may aid the diagnosis, classification, and treatment
of cancer. For example, a certain miRNA that is downregu-
lated in lung cancer is associated with decreased survival.17
Research on the interactions between nutrition and non-cod-
ing RNA molecules is at an early stage but is potentially rel-
evant to cancer.
2.2.3 Epigenetic regulation 
Gene expression can also be altered without changing the
DNA sequence. This is called epigenetic modulation.
Methylation of DNA — the addition of a methyl group
(CH3) — plays a role in gene silencing. Methylation occurs
only to cytosine residues located next to guanine bases in the
DNA sequence. These CpG dinucleotide sequences are found
throughout the genome; in about half of all genes, clusters
of CpG sequences, so-called ‘CpG islands’, are located in the
promoter region that normally functions to promote expres-
sion of the gene. Transcription factors cannot bind to these
sites when methylated and so the gene is silenced. For active
genes, the CpG islands in the promoter regions are general-
ly not methylated. 
Controlled DNA methylation also provides a mechanism
for cell differentiation. In normal cells, genes may be per-
manently silenced so that they can no longer be expressed,
in a way that is transmitted into daughter cells during cell
division (see 2.5.1), so maintaining the particular structur-
al and functional characteristics of the cells of specific 
tissues. 
Dietary constituents contribute to epigenetic modulation
of promoter regions in both normal and malignant cells. For
example, dietary folate and other methyl-donors such as
choline, methionine, and betaine are essential for DNA
synthesis and epigenetic regulation of DNA. Appropriate
gene expression is maintained by appropriate patterns of
methylation; folate is an important determinant of normal
methylation. In addition, dietary constituents such as genis-
tein, which do not provide methyl groups, have also been
reported to modify DNA methylation.
Imbalances or lack of specific dietary constituents may
potentially increase the risk of cancer by inducing an imbal-
ance in DNA precursors, leading to altered DNA synthesis
and repair, and may impair appropriate patterns of DNA
methylation, with consequences for gene expression. For
example, inadequate folate availability means cells tend to
incorporate uracil into DNA in place of thymine. Global
hypomethylation of DNA is an early epigenetic event in cer-
vical carcinogenesis, and the degree of hypomethylation
increases with the grade of cervical cancer.1819 Global
hypomethylation of DNA and site-specific hypermethylation
may also be relevant in colorectal cancer.20 A host of bio-
active food constituents from alcohol to zinc has been
reported to influence DNA methylation patterns.
Nevertheless, it remains to be determined how important
these changes are in the overall cancer process. The poten-
tial cancer-protective effects of green, leafy vegetables (see
chapter 4.2) are often attributed to their folate content.
Folates function as a coenzyme in the metabolism of single-
carbon compounds for nucleic acid synthesis and amino acid
metabolism.
The best understanding of the impact of
endogenous and exogenous factors on the
cancer process will come from studies of
the whole life course, and particularly of
critical periods within it. 
Early nutritional exposure is an impor-
tant determinant of phenotypic expression
during later life and is likely to affect vul-
nerability to chronic diseases, including
cancer.6 During pregnancy, the nutrient
demands of the fetus have to be satisfied.
Although the mother’s dietary intake is
important in maintaining her own nutrient
reserves, it is her nutrition status on enter-
ing pregnancy that determines her capac-
ity to deliver appropriate nutrients to the
fetus. Any stress that modifies her nutri-
tional state, either by changing appetite or
altering nutrient demand, can impact on
the availability of nutrients to the fetus.7 In
experimental models, pregnant rats fed a
low-protein diet resulted in overexposure
of the fetus to maternal glucocorticoids.
This led to a permanent alteration in
hormonal status and metabolic responses in
the offspring.8 9 These effects were attrib-
uted to differential methylation of certain
glucocorticoid genes and could be mitigat-
ed by maternal folic acid supplementation.4
Lower birth weight, followed by expo-
sure to periods of rapid rates of growth,
possibly due to energy-dense diets, is asso-
ciated with development of metabolic
syndrome during adult life.6 This is the clus-
tering of several cardiovascular risk factors
including hypertension, abdominal obesi-
ty, insulin resistance, and type 2 diabetes.
Type 2 diabetes has been associated with
increased prevalence of some cancers, and
risk of cancer shows a graded relationship
with glycated haemoglobin (a measure of
blood glucose control) throughout the nor-
mal range.10 Metabolic syndrome may also
increase cancer risk,11 suggesting that the
metabolic disturbances associated with
this syndrome promote genetic instability. 
Growth and development are dependent
on the supply of adequate energy and
nutrients to match a person’s needs. Famine
exposure in women affects breast dysplasia
later in life: girls exposed to famine before
the age of 10 years have less dysplasia in
later life, whereas those exposed after 18
years of age have more dysplasia than non-
exposed women. This illustrates the impor-
tance of timing of nutrition during key
stages of development.12
Greater body fatness later in life is
linked to development of metabolic syn-
drome and related health problems,
including insulin resistance. The inflam-
matory state associated with obesity also 
promotes cancer.13 In contrast, energy
restriction (box 2.5) delays the onset 
of many age-related diseases, including
cancer.  
Box 2.1 Nutrition over the life course
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2.2.4 Differentiation
Cells become specialised to perform their particular function
through a process known as differentiation. 
Although each cell within the body contains the entire
genome with the same genes, only some genes are active in
any one cell at any one time. Gene expression controls the
subset of genes expressed and the timing of expression, and
this distinguishes one cell type from another by determin-
ing their particular structure and function. 
Hundreds of different cell types arise from one fertilised
egg during development; this is achieved by proliferation
and differentiation of stem cells. Stem cells are unspecialised
but can give rise to different specialised cell types. A small
population of cells within the tumour mass of several forms
of human cancer, which have both the properties of stem
cells and also the characteristics of transformed cells, may
be important for the development of these tumours. As yet,
our understanding of cancer stem cells is basic, although the
concept was proposed as early as 1875.22 Several groups have
now isolated and identified cancer stem cells in both
haematopoietic and epithelial cancers, including cancers of the
breast,23 brain,24 25 ovary,26 prostate,27 colon,28 and stomach.29
It is clear that subtle changes in exposure to bioactive food
constituents can have a profound effect on the differentiation
of these cells.
In early embryos, proliferation of embryonic stem cells
increases the total number of cells. As the organism devel-
ops, cells differentiate and become specialised to their par-
ticular function. Transcription factors specific to that cell type
turn on genes for that particular lineage of cells, so deter-
mining its structure and function.
At various stages of differentiation, cells become sensitive
to different growth factors. In the cancer process, one char-
acteristic of cells that are accumulating DNA damage is that
they become de-differentiated and undergo epithelial-
mesenchymal transition (EMT), characterised by loss of 
cell adhesion and increased cell mobility. In addition, dur-
ing differentiation, other genes can be silenced by chromatin
modification, including DNA methylation and histone mod-
ifications such as methylation and acetylation (see 2.2.2). 
Stem cells are found among differentiated cells in almost
all adult tissues, where they maintain and regenerate tissues.
Examples include haemopoietic stem cells for continuous
generation of red and white blood cells, and stem cells in
the basal layer of the epidermis and at the base of hair fol-
licles in the skin, which can give rise to keratinocytes and
hair follicles. Cellular differentiation also continues in solid
tissues such as mammary tissue, which during pregnancy dif-
ferentiates for later milk production. A systematic review has
shown that long-chain n-3 polyunsaturated fatty acids
(PUFAs) in fish oils promote differentiation of colonic epithe-
lial cells.30 31 Vitamin D and retinoic acid may also promote
differentiation of cells.
2.2.5 DNA damage and repair
Each time a cell divides into two new daughter cells, there
is potential for an error in replication of the DNA (see 2.5.1).
These mutations result in non-functioning genes or in pro-
teins with altered amino acid sequences that can change cell
function.
DNA is continuously exposed to damage from products of
normal intracellular metabolism, including reactive oxygen
species, hydroxyl radicals, and hydrogen peroxide; and also
to damage from external factors such as ultra-violet (UV)
Oncogenes and tumour suppressor genes
are present in all cells, and in their normal,
non-mutated form contribute to the regu-
lation of cell division and death. In cancer,
both types of gene are often mutated, and
these alterations contribute to the cancer
process. The combined effect of activation
of oncogenes and inactivation of tumour
suppressor genes is an important driver of
cancer progression.
Oncogenes increase the rate of transfor-
mation from a normal to a cancerous cell.
Oncogene function is changed by mutation
so that the protein product is produced
either in greater quantities or has increased
activity. The normal, non-mutated form of
an oncogene is called a proto-oncogene. 
More than 100 oncogenes have been
identified, including ERBB2 in breast and
ovarian cancers, members of the Ras family
in cancers of the lung, colorectum, and pan-
creas, and MYC in lymphomas. Ampli-
fication of the ERBB2 gene occurs in around
30 per cent of breast cancers, and RAS muta-
tions occur in approximately 30 per cent of
all human cancers (and in 75–90 per cent of
pancreatic cancers). 
Tumour suppressor genes prevent exces-
sive growth of a cell, either by controlling
cell proliferation or by controlling DNA
repair and genomic stability. Mutation of a
tumour suppressor gene results in the loss
of function of the protein product. 
Common tumour suppressor genes inc-
lude p53 and the retinoblastoma (Rb) gene.
The p53 gene was the first tumour sup-
pressor gene to be identified, and is con-
sidered to be the guardian of the genome.14
Under normal circumstances, p53 is involved
in several processes such as cell prolifera-
tion, DNA repair, apoptosis, and angiogen-
esis. p53 is activated by cellular stresses that
could facilitate tumour development such as
hypoxia, lack of nucleotides, and in partic-
ular, DNA damage. 
In response, p53 can either halt the cell
cycle to allow DNA repair, or induce apop-
tosis. It can bind to the promoter regions of
approximately 300 different genes, thereby
having an important regulatory role in var-
ious molecular pathways. The p53 pathway
is altered in most cancers, and the mutated
protein product cannot protect the
genome, allowing mutations to accumulate. 
In the absence of a functional Rb gene,
the retinoblastoma protein pRb is not made
and its inhibitory role of inactivating cell
cycle transcription factors is absent. This
leads to increased, uncontrolled prolifera-
tion, and thereby increased risk of further
mutations. More than 2000 inactivating
mutations of p53 have been identified in
human tumours. Both p53 and pRb can also
be inactivated by the human papilloma
virus. Development of lung cancer is associ-
ated with loss of function of both genes. Li-
Fraumeni syndrome, a result of a germ line
mutation in p53, leads to inherited 
susceptibility to a wide range of cancers.
Patients with Li-Fraumeni syndrome have 
a 25-fold increased risk of developing cancer
compared with the general population.15
Box 2.2 Oncogenes and tumour suppressor genes
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light, as well as other environmental factors including food,
nutrition, and physical activity (see 2.4). There are several
mechanisms for DNA repair (box 2.3), a vital defence in
maintaining cellular integrity and preventing a cell being
transformed from normal to cancerous. 
Various studies suggest that nutritional status and/or cer-
tain food constituents may influence DNA repair. Data from
observational studies suggest that severe malnutrition can
impair DNA repair.34 Nucleotide excision repair has been
found to be lower in adults with the lowest intakes of
folate.35 Studies of healthy adults consuming kiwi fruits,36
cooked carrots,37 or supplements of coenzyme Q10 (an impor-
tant cofactor in metabolism)38 have demonstrated improved
DNA repair in vitro. Selenium induces base-excision repair
in vitro via p53 activation in cultured fibroblasts.39
Evidence exists that some dietary components can modify
DNA damage and gene expression in exfoliated colonocytes.
For example, the amount of single-strand breaks in exfoli-
ated colorectal mucosal cells was significantly lower in
healthy individuals consuming a vegetarian diet compared
with a diet high in meat.40 Similarly, DNA damage in exfo-
liated lung epithelial cells can be influenced by dietary com-
ponents. Consumption of a lycopene-rich vegetable juice was
associated with significantly decreased damage to the DNA
of lung epithelial cells in healthy volunteers.41
Defects in any of the DNA repair mechanisms can predis-
pose to cancer. Several inherited conditions link such defects
to cancer incidence. For example, patients with hereditary
non-polyposis colorectal cancer have defective mismatch
repair (see chapter 7.9.2).
Although the processes of cell development, signalling,
and DNA repair are tightly controlled, errors will occur dur-
ing the trillions of cell divisions that occur over a lifetime.
This may result in inappropriate proliferation or failure of
damaged cells to die. These changes could provide the
altered cell with a growth advantage over the normal cells
in the tissue. If additional alterations occur, this can result
in a cell with the potential to become cancerous.
2.3  Carcinogen metabolism
The chance of carcinogenesis occurring and then progress-
ing is modified by many factors, including food and nutri-
ion. Dietary constituents that modify carcinogenesis include
selenium, allyl sulphur, sulphuraphane, and isoflavonoids.
Most dietary carcinogens require activation to produce
reactive intermediates that bind to and damage DNA. Phase
I and phase II metabolising enzymes in the liver and in other
tissues are involved in this process. These are enzymes that
catalyse the metabolic detoxification of xenobiotics, drugs,
and carcinogens produced through aerobic metabolism, and
thus protect cells against oxidative stress and reactive elec-
trophilic carcinogen metabolites.
Metabolic activation of carcinogens is generally catalysed
by the cytochrome P450 (CYP) family of phase I enzymes
through oxidation, which usually makes the molecule more
water soluble. Some of the intermediates formed during this
process may be carcinogenic, and can bind to DNA, forming
DNA adducts. These adducts distort the structure of DNA and
disrupt its replication, potentially causing mistranslation.
They can also break the DNA strand, which can result in
mutations or deletions of genetic material.
In addition to P450 enzymes, other systems such as per-
oxidases (including the cyclooxygenases) and certain trans-
ferases, such as N-acetyltransferase and sulphotransferase,
can influence carcinogen bioactivation.42-44
Competing with this metabolic activation of carcinogens
is the detoxification process catalysed by a second group of
enzymes, known as phase II enzymes.45 They catalyse con-
jugation reactions, producing molecules that can be excret-
ed in bile or urine. Examples include acetyltransferases,
glutathione-S-transferases (GSTs), UDP-glucuronyltrans-
ferases, NAD(P)H:quinone oxidoreductase, and sulpho-
transferases. The induction of phase II enzymes is mediated
by the antioxidant response element, which is located in the
promoter region of specific genes.46
Each of these enzymes represents a potential target for
dietary components to influence carcinogen activation.
Specificity in response is evident since isothiocyanates from
cruciferous vegetables have been shown to induce expression
of phase II detoxification enzymes without affecting expres-
sion of phase I enzymes.
The carcinogenic properties of polycyclic hydrocarbons,
aromatic amines, N-nitroso compounds, and aflatoxins
result from the metabolism of these compounds, which
produces carcinogenic by-products. Metabolising enzyme
activity can be modulated by dietary factors. The enzyme
CYP3A4 participates in the metabolism of over half of 
all pharmaceutical agents, and is especially sensitive to
dietary effects. For example, interactions have been report-
ed between grapefruit juice, red wine, garlic, and various
drugs.47 Food–drug interactions involving CYP1A2, CYP2E1,
glucuronysyltransferases, and GSTs have also been
documented.48
The activity of phase I and II enzymes, and thus carcino-
gen metabolism and cancer development, varies between
individuals. SNPs in several phase I and phase II enzymes
have been shown to modulate cancer risk.49 50 There is some
difficulty in synthesising this evidence and some studies may
give false positive results. Nevertheless, the literature shows
tantalising evidence that relates genetic diversity to these
enzymes in various processes linked to cancer development.
Some specific examples of SNPs in cancer are listed below.
GSTs are involved in the metabolism of environmental car-
cinogens and reactive oxygen species. People who lack these
enzymes may be at higher risk for cancer because of a
reduced capacity to dispose of activated carcinogens.51 As
shown in chapter 4.1, aflatoxins — produced by moulds that
contaminate certain types of foods such as cereals (grains)
and peanuts — are carcinogens that are activated by phase
I enzymes in the liver into reactive DNA metabolites that
cause DNA adducts. However, the number of adducts and
therefore the potency of aflatoxin B are influenced by other
enzymes such as GSTs, which eliminate carcinogens before
they can bind to DNA. Individuals with low expression of
GSTs are also at higher risk for colorectal cancer; however,
a diet high in isothiocyanates (derived from glucosinolates
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in cruciferous vegetables) can ameliorate this.52
Epidemiological evidence supports the idea that individ-
uals possessing these genotypes are predisposed to a num-
ber of cancers, including those of the breast, prostate, liver,
and colon53; it also shows that nutrition influences cancer
risk. Thus, an SNP in the methylenetetrahydrofolate reduc-
tase (MTHFR) gene appears to influence folate metabolism
by reducing MTHFR activity, and is associated with a reduc-
tion in the risk of developing colorectal cancer.54 Certain
SNPs in the N-acetyltransferase gene alter the activity of the
enzyme (involved in the metabolic activation of heterocyclic
amines from meat cooked at high temperatures), and may
also increase the risk of colon cancer.
Again, as described in chapter 4.3, people whose diets are
high in red and processed meat and who also carry an insert
variant in CYP2E1, a key activating enzyme of many nitro-
samines, have a greater risk of rectal cancer.55 Consumption
of cruciferous vegetables protects against lung cancer in indi-
viduals lacking the GSTM1 gene.56 In addition, genes that
predispose to obesity may promote obesity-related cancers
(box 2.4).
Dietary components can either be, or be activated into,
potential carcinogens through metabolism, or act to prevent
carcinogen damage. For instance, as summarised in chapter
4.3, high intake of red meat may result in more absorption
of haem iron, greater oxidative stress, and potential for DNA
damage.57 58 In addition, iron overload can also activate
oxidative responsive transcription factors and inflammation
in the colon.59 Red meat consumption is also associated with
the formation of N-nitroso compounds. This increases the
level of nitrogenous residues in the colon and is associated
with the formation of DNA adducts in colon cells.60
Cruciferous vegetables contain glucosinolates, which are
transformed by food preparation into isothiocyanates (ITCs),
which alter the metabolism of carcinogens. Indoles and ITCs,
two major glucosinolate breakdown products, attenuate the
effects of polycyclic aromatic hydrocarbons and nitrosamines
via induction of GSTs and inhibition of cytochrome P450
isoenzymes, respectively.
Human intervention studies with cruciferous vegetables
have demonstrated induction of GSTs by consumption of
Brussels sprouts and red cabbage varieties, but not with
white cabbage and broccoli. The particular isoform of the
enzyme induced may protect against bladder cancer.
Cruciferous vegetables also affect drug metabolism in
humans, and red cabbage leads to specific changes in the
patterns of meat-derived urinary mutagens. ITCs may also
protect against mutations formed by tobacco carcinogens.61
In a variety of animal studies, certain dietary components
have shown a reduction in experimentally induced cancers.
Rats fed ITCs developed significantly fewer oesophageal
cancers due, in part, to inhibition of cytochrome P450-
mediated bioactivation of the carcinogen. Dietary indole-3-
carbinol inhibited spontaneous occurrence of endometrial
adenocarcinoma and preneoplastic lesions in rats.62
Flavonoids (polyphenolic compounds found in plant
foods) may also alter carcinogen metabolism. Quercetin has
been shown to inhibit the expression of cytochrome P450
and phase I enzymes, and may reduce tobacco carcinogen
activation.63
Exposure of vulnerable populations to excess amounts of
dietary constituents, irrespective of whether they are nutri-
ents or not, may actually increase the risk of cancer. In 
one example, consumption of beta-carotene supplements 
in smokers was associated with increased incidence of lung
cancer.64 For most dietary components, there will be an
upper threshold beyond which people may be exposed to
adverse effects. There are also concerns regarding excessive
supplementation with folic acid, iron, copper, iodide, and
selenium.65
2.4  Causes of cancer
A number of different types of exogenous (environmental)
factors are known causes of cancer. These include some
aspects of food and nutrition that are established as car-
cinogenic by the International Agency for Research on
Cancer, although it is difficult to estimate the proportion of
cancers directly attributable to these.74 Known causes of can-
cer include tobacco smoking and its use, infectious agents,
medication, radiation, and industrial chemicals, and also
some factors within the scope of this report — carcinogenic
agents in food and drink. 
Sometimes the extent to which cancer in general, or spe-
cific cancers, may be modified by any factor, are calculated,
and some of these figures are given here. However, these esti-
mates should be treated with some caution. First, they are esti-
mates, and cannot be exact, and so are best given as ranges.
Second, individual causes of cancer often interact with one
another to increase or decrease risk, or are modifiers or pre-
cursors of others; and some act together to produce a multi-
plicative effect. This point is particularly important with food
and nutrition, which may have a substantial effect on the risk
of a cancer with environmental causes other than food, nutri-
tion, and physical activity. Third, it is sometimes assumed that
once all factors that decrease (or increase) risk are added
together, with allowance for unknown factors, such estimates
Mammals have five types of DNA repair system32 33:
• Direct reversal corrects rather than removes damaged DNA
bases. 
• Base-excision repair corrects DNA damage caused by reactive
oxygen species, deamination, and hydroxylation arising from
cellular metabolism and spontaneous depurination.
• Nucleotide-excision repair removes lesions that distort the
structure of the DNA helix, such as pyrimidine dimers and
DNA adducts. 
• Homologous recombination and non-homologous end-
joining repair double-strand breaks. Homologous
recombination is used when a second identical DNA copy is
available, for example after replication; non-homologous
end-joining re-links the ‘broken’ ends of a double-strand
break.
• DNA mismatch repair detects and repairs copying errors
made during replication.
Box 2.3 Mechanisms for DNA repair
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should add up to 100 per cent. This is not so. Reasonable esti-
mates for a number of separate or interactive factors may add
up to well over 100 per cent because of the interactions.
2.4.1  Endogenous causes
2.4.1.1  Inherited germ line mutations 
As mentioned, only a minority (5–10 per cent) of cancers are
linked to single inherited genes. Such inherited alterations
are termed germ line mutations, and are passed on from egg
or sperm DNA. Individuals with inherited germ line muta-
tions will not definitely get cancer but have an increased risk
of developing cancer compared with the general population. 
Often mutations in tumour suppressor genes (box 2.2)
increase the chance of developing cancer at a young age.
These include retinoblastoma (a rare cancer of the eye), Li-
Fraumeni syndrome, multiple endocrine neoplasia type 1,
and kidney cancer in Von Hippel-Lindau disease. Mutations
in the BRCA1 and BRCA2 (breast cancer susceptibility) genes
cause 5–10 per cent of all breast cancer cases. These genes
normally produce DNA repair proteins. Patients with the
syndrome familial adenomatous polyposis coli have a pre-
disposition to colorectal cancer due to mutations in the ade-
nomatosis polyposis coli tumour suppressor gene.75 Other
common cancers, including those of the ovary, prostate, pan-
creas, and endometrium, may be related to inherited muta-
tions, but only in a small percentage of cases.
The other type of genetic mutation — somatic gene
changes — develops during the life course. Such somatic
mutations are not passed on to offspring. This DNA damage
is caused by exposure to external factors such as radiation
or carcinogens, or harmful products of normal aerobic
metabolism.
2.4.1.2 Oxidative stress
Reactive oxygen species generated through normal oxidative
metabolism have the potential to cause extensive DNA dam-
age. The body has several mechanisms, which can scavenge
reactive oxygen species to prevent such damage occurring,
or block the effects.
Reactive oxygen species cause oxidative damage to DNA.
During repair (see 2.2.5), the damaged, oxidised bases are
excreted in the urine. Levels of urinary 8-hydroxy-2'-
deoxyguanosine, an oxidative DNA damage adduct, can be
used as an indicator of oxidative DNA damage in humans
and rodents. Antioxidants can scavenge reactive oxygen
species. Vitamins C and E can donate electrons to free rad-
icals and block their damaging activity. Dietary constituents
such as ITCs and polyphenols can also activate the signalling
pathways that lead to activation of the antioxidant response
element (see 2.3), and upregulation of the expression of
detoxifying enzymes.
2.4.1.3 Inflammation
Inflammation is a physiological response to infection, foreign
bodies, trauma, or chemical or other irritation, and in the
acute phase can be helpful. However, chronic inflammation
can result in DNA damage and cancer promotion. 
Chronically inflamed tissue is infiltrated with a variety of
inflammatory cells that produce a wide variety of bioactive
chemicals. These include cytokines, growth factors, reactive
oxygen and nitrogen species, cyclooxygenase, and lipoxyge-
nase products. A chronic inflammatory environment can
increase proliferation and differentiation, inhibit apoptosis
(programmed cell death), and induce angiogenesis (gener-
ation of new blood vessels). Chronic inflammatory condi-
tions, such as Barrett’s oesophagus and ulcerative colitis,
predispose to cancer. In Barrett’s oesophagus, reflux of acid
can cause the cells lining the gullet to undergo EMT, and
some areas can develop dysplasia and ultimately cancer.
Around 1 per cent of people with Barrett’s oesophagus will
develop oesophageal cancer (this is between 30 and 125
times higher than the general population). Also see chapter
7.3.2. Approximately 5 per cent of patients with ulcerative
colitis, a form of irritable bowel disease, will develop colon
cancer. Also see chapter 7.9.2. Epidemiological and experi-
mental evidence has demonstrated that long-term use of
non-steroidal anti-inflammatory drugs can inhibit cancer
development in a number of tissues including colon,
oesophagus, and breast.76
Cancer induced by inflammation may be susceptible to
nutritional influences. Thus, dietary constituents could be
involved in generation of reactive oxygen species, could
influence antioxidant defences, or could suppress the inflam-
matory process. For example, the glucocorticoid receptor
pathway and the vitamin D receptor are capable of sup-
pressing inflammation.
The immune system can be divided into innate and adap-
tive responses. Innate immunity provides initial defences.
Adaptive immunity develops later and involves activation of
lymphocytes and their differentiation into effector and mem-
ory cells. The ‘immune surveillance’ hypothesis proposes that
both the innate and adaptive immune systems constantly
survey for and eliminate newly formed cancer cells, and that
onset and progression of cancer are kept under control by
the immune system.77 Immunosurveillance requires that the
immune system recognises something different about cancer
cells compared with normal cells within the same tissue –
often different proteins (termed tumour antigens) that are
expressed on the surface of a cancer cell. 
This recognition of ‘altered self ’ allows the immune sys-
tem to generate a response to these tumour antigens. They
can be proteins that are only expressed by cancer cells, and
newly expressed during cancer development; or proteins that
have become mutated during the cancer process and so are
different from the non-mutated protein; or proteins
expressed due to differentiation of cancer cells (termed dif-
ferentiation antigens); or proteins that are normally
expressed by cells but that are expressed at much higher lev-
els by cancer cells. Evasion of immunosurveillance is some-
times referred to as a further hallmark of cancer78 (see 2.5),
although the evidence remains speculative.
Specialised mucosal cells form the interface between the
inside and outside of the body.79 These are normally an effi-
cient barrier against pathogens. The gut barrier consists of
gut-associated lymphoid cells that can sense pathogens, and
participate in innate and adaptive responses.80 The function
of these cells is dependent on nutrition.81 82 For example, n-
3 PUFAs can enhance immunity, whereas high concentrations
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of n-6 unsaturated fatty acids can have a suppressive effect.83
Various factors have been shown to modulate both inflam-
mation and immunity, including vitamins A and E, copper,
selenium, zinc, PUFAs, and epigallocatechin-3-gallate
(EGCG) from green tea.84 Zinc deficiency can lead to abnor-
malities in adaptive immune responses.85
Immune status and chronic inflammation may explain pat-
terns of cancer in different parts of the world. Cancers caused
by infectious agents, such as those of the liver and cervix (see
chapter 7.8 and 7.13) are more common in low-income
countries, where undernutrition may impair people’s
immune responses. Undernutrition, with deficiencies in spe-
cific micronutrients such as vitamin A, riboflavin, vitamin
B12, folic acid, vitamin C, iron, selenium, and zinc, sup-
presses most immune functions and may fail to control
chronic inflammation.86 87 By contrast, hormone-related
cancers such as those of the breast and prostate are more
common in developed countries. 
The cytokine IL-6 can act as a pro- or anti-inflammatory
cytokine. In cancer, IL-6 can either stimulate proliferation or
exert anti-tumour effects by enhancing both innate and
adaptive immunity.88 Dietary phytoestrogens, such as soy
isoflavones, downregulate IL-6 gene expression and thus
potentially influence the development of hormone-related
cancers.89
Circulating levels of IL-6 increase (up to 100-fold)
following exercise; this reduces chronic inflammation 
by reducing pro-inflammatory mediators and elevating 
anti- inflammatory mediators.90 Regular moderate and 
occasional vigorous physical activity has been associated
with enhanced immunity,91 but prolonged and intense 
physical activity can cause immune suppression that 
cannot be counteracted by nutritional supplements or
antioxidants.83 Physical activity does not increase pro-inflam-
matory cytokines, but instead increases anti-inflammatory 
mediators. 
Chronic consumption of alcohol alters both innate and
adaptive immunity. Heavy drinkers are more vulnerable to
infections and, as shown in chapter 4.8, to liver cancer.92 One
possible mechanism is alteration in hepatic metabolism
resulting in functional iron deficiency that impairs immune
function.93-95
2.4.1.4 Hormones
Lifetime exposure to oestrogen — increased by early menar-
che, late menopause, not bearing children, and late (over
30) first pregnancy — raises the risk of, and may be seen as
a cause of, breast, ovarian, and endometrial cancers in
women. The reverse also applies: a reduction in lifetime
exposure to oestrogen due to late menarche, early meno-
pause, bearing children, and early pregnancy may reduce the
risk of hormone-related cancers. Age at menarche and
menopause are influenced by nutrition, with high-energy
diets leading to early puberty and late menopause, and low-
energy diets delaying puberty and advancing menopause.
The oral combined contraceptive pill (containing both
oestrogen and progesterone) has been estimated to halve the
risk of ovarian cancer, if taken for 5 years or more.96 This
protective effect can last for up to 15 years after women stop
taking these oral contraceptives.97 Using any type of oral
contraceptive may also have a slight protective effect against
bowel cancer.98 In contrast, combined oral contraceptives
can cause a slight and transient increase in breast cancer risk,
but only for the duration of use.99 There may also be an
As shown in Chapter 6, the overall evidence
that body fatness is a cause of a number of
cancers is convincing. Some of the mecha-
nisms by which body fatness increases the
risk of cancer are well understood.
Obesity influences the levels of a num-
ber of hormones and growth factors.66
Insulin-like growth factor 1 (IGF-1), insulin,
and leptin are all elevated in obese people,
and can promote the growth of cancer
cells. In addition, insulin resistance is
increased, in particular by abdominal fat-
ness, and the pancreas compensates by
increasing insulin production. This hyper-
insulinaemia increases the risk of cancers of
the colon and endometrium, and possibly
of the pancreas and kidney.13 Increased
circulating leptin levels in obese individ-
uals are associated with colorectal67 and
prostate cancers.68
Sex steroid hormones, including oestro-
gens, androgens, and progesterone, are
likely to play a role in obesity and cancer.
Adipose tissue is the main site of oestrogen
synthesis in men and postmenopausal
women,13. The increased insulin and IGF-1
levels that accompany body fatness result
in increased oestradiol in men and
women,13 and may also result in higher
testosterone levels in women (extreme
obesity can lead to polycystic ovary dis-
ease). Increased levels of sex steroids are
strongly associated with risk of endome-
trial and postmenopausal breast cancers,69
70 and may impact on colon and other can-
cers. As shown in Chapter 6, body fatness
probably protects against premenopausal
breast cancer; this may be because obese
women tend to have anovulatory men-
strual cycles and thus reduced levels of
oestrogen.
Obesity is characterised by a low-grade
chronic inflammatory state, with up to 40
per cent of fat tissue comprising macro-
phages. The adipocyte (fat cell) produces
pro-inflammatory factors, and obese indi-
viduals have elevated concentrations of
circulating tumour necrosis factor (TNF)-
alpha,13 interleukin (IL)-6, and C-reactive
protein, compared with lean people,71
as well as of leptin, which also functions 
as an inflammatory cytokine.72 Such
chronic inflammation can promote cancer
development.
Also as shown in Chapter 6, factors 
that lead to greater adult attained height,
or its consequences, are a cause of a num-
ber of cancers. Adult height is related to
the rate of growth during fetal life and
childhood. The number of cell divisions 
in fetal life and childhood, health and
nutrition status in childhood, and age of
sexual maturity can alter the hormonal
microenvironment, and affect circulating
levels of growth factors, insulin, and
oestrogens.
Taller people have undergone more cell
divisions stimulated by IGF-1 and pituitary-
derived growth hormone,73 and there is
therefore more potential for error during
DNA replication, which may result in
cancer development.
Box 2.4 Body fatness and attained height
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increase in the risk of cervical cancer, although this is part-
ly related to sexual behaviour.100
Studies of women taking oestrogen-only hormone replace-
ment therapy have suggested that the risk of endometrial
cancer is doubled after 5 years of use,101 and the risk of ovari-
an cancer rises by 25 per cent after the same length of use.97 102
However, use of hormone replacement therapy that 
combines oestrogen and progesterone does not increase ovar-
ian cancer risk and may even protect against endometrial
cancer.102 97 101
2.4.2 Exogenous causes
2.4.2.1 Tobacco use 
Tobacco causes an estimated 20 per cent of all cancer deaths,
and an estimated total of 1.2 million in 2002.75 Smokers
have increased risk of a number of different cancers (see
Chapter 7). Worldwide, around 80 per cent of lung cancer
cases in men and 50 per cent in women are caused 
by tobacco smoking.103 104 In 2002, out of all new cases of
cancer in low-income countries, over 1 in 5 in men and
almost 4 per cent in women were attributable to tobacco. 
In high-income countries, one third of all new cancer cases
in men and just over 1 in 8 in women were attributed to
tobacco smoking. 
Cigarette smoke contains at least 80 known mutagenic
carcinogens, including arsenic, cadmium, ammonia,
formaldehyde, and benzopyrene. Each will have a separate
mechanism for causing cancer. For example, following meta-
bolic activation, the activated derivative of benzopyrene,
benzo(a)pyrenediol epoxide, can form DNA adducts in lung
epithelial cells.105
Cigarette smoke is a powerful carcinogen and also a source
of oxidative stress. Compared with non-smokers, active
smokers have lower circulating concentrations of several
antioxidant micronutrients including alpha-carotene, beta-
carotene, cryptoxanthin, and ascorbic acid.106
2.4.2.2 Infectious agents 
Infectious agents, including viruses, bacteria, and parasites,
can induce DNA damage and promote cancer development.
Some infectious agents, including hepatitis viruses, the bac-
terium Helicobacter pylori (H pylori), and parasites, also pro-
mote cancer by causing chronic inflammation (see 2.4.1.3).
Both DNA and RNA viruses can cause cancer, although the
mechanisms differ.75 DNA viruses encode viral proteins that
block tumour suppressor genes, whereas RNA viruses or
retroviruses encode oncogenes (box 2.2). Human papilloma
virus is an established cause of cervical cancer, Epstein-Barr
virus of nasopharyngeal cancer and lymphoma, and hepati-
tis B and C infection of liver cancer.
As summarised in Chapter 7, H pylori is associated with
stomach cancer, liver flukes (from eating raw or undercooked
freshwater fish) with liver cancer, and Schistosoma haema-
tobium infection with bladder cancer. 
In most cases, infection with these agents by itself does not
lead to cancer but is a contributory or necessary factor in 
the cancer process. Multiple factors are thought to be
important in determining why cancer is the result in only
some cases. 
Approximately 1 in 4 cancers in low-income countries are
estimated to be attributable to infection. In 2002, this rep-
resented some 1.9 million cancers or close to 1 in 5 of all
cancers worldwide104. Inadequate nutrition or dietary imbal-
ances can lead to immunodeficiencies and increased sus-
ceptibility to infections. 
Dietary factors may influence host susceptibility to the
viral infection or persistence of the infection. For example,
high folate intake is thought to reduce the susceptibility to
and the persistence of human papilloma virus.107
2.4.2.3 Radiation 
Both ionising radiation and UV radiation damage DNA and
act as carcinogens. This includes radiation used in X-ray
radiographs and in the treatment of cancer. In 1982, the
various forms of radiation were calculated to account for 
3 per cent of all cancer deaths.74
Ionising radiation can cause DNA damage, both directly
by causing breaks in the DNA strands, and indirectly by inter-
acting with water molecules and generating reactive oxygen
species that damage DNA. 
Although sunlight causes DNA damage, it also induces 
production of vitamin D. One of its metabolites, 1-25-hydroxy-
vitamin D, has antiproliferative and pro-differentiation 
effects in some cells mediated through the vitamin D 
receptor. 
Exposure to ionising radiation comes from cosmic radia-
tion (air travel increases exposure), natural radioactivity
present in rocks and soil, medical exposure through X-rays,
or atomic radiation from weapons and nuclear accidents.
Ionising radiation increases the risk of various cancers, in
particular leukaemias, and breast and thyroid cancers. 
UV light from sunlight or sunlamps is divided into three
bands of wavelengths: UVA, UVB, and UVC. UVB is the most
effective carcinogen and is absorbed by bases in the DNA,
causing characteristic patterns of DNA damage. UVA dam-
ages DNA through generation of reactive oxygen species.
UVC in sunlight is absorbed by ozone in the atmosphere 
and does not reach the surface of the earth. UV radiation
causes both malignant melanoma and non-melanoma skin
cancer.
It has been difficult to separate the effects of nutrients on
DNA damage from those on repair, at least in animal or
human studies. There is some evidence that vitamin C and
carotenoids can protect DNA against oxidative damage in
some experimental settings.108
2.4.2.4 Industrial chemicals
Certain industrial chemicals and pesticides persist in 
the environment and become concentrated in the food 
chain. Some of these are within the scope of this Report and
are summarised in Part 2. In 1982, industrial chemicals were
calculated to account for less than 1 per cent of cancer
deaths.74
Polychlorinated biphenyls (PCBs), organic compounds pre-
viously used in plasticisers, adhesives, paints, and various
oils, do not readily degrade. They are soluble in fat rather
than water and thus accumulate in carnivorous fish such as
salmon, and can be absorbed by people who eat these types
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of fish.109 They also accumulate in human milk, and can be
passed to the infant during breastfeeding. There is limited
experimental evidence suggesting that PCBs have sex
steroid activity and alter oestrogen levels, which may con-
tribute to breast cancer risk.109
Arsenic is genotoxic, causes gene mutations, and is car-
cinogenic to humans; arsenic in drinking water is absorbed
from the gastrointestinal tract.75 The Panel’s judgements on
arsenic are summarised in chapter 4.7. Arsenic can modify
the urinary excretion of porphyrins in animals and humans.
It also interferes with the activities of several enzymes of the
haem biosynthetic pathway. There is clear evidence that sele-
nium binds heavy metals such as arsenic and thus modifies
their absorption.75
2.4.2.5 Medication
A number of medical treatments modify the risk of some can-
cers. As indicated in 2.4.2.3, X-rays are carcinogenic, as is
radiation used as cancer treatment.
The most notorious example has been diethylstilboestrol,
once prescribed in pregnancy and now withdrawn, which
caused cancers of the vagina and cervix of female children
born to mothers who received this drug. Treatments that
affect hormonal status have been studied extensively and are
described in 2.4.1.4. Chemotherapy as cancer treatment dur-
ing childhood is followed by an increased risk of lymphoma
in adulthood.110
2.4.2.6 Carcinogenic agents in food
Food may be contaminated with natural or man-made
carcinogenic toxicants. These are within the scope of this
Report, and are assessed and judged in Part 2.
Moulds and the toxins produced by some moulds cause
DNA adducts and are carcinogenic. Aflatoxin B, a product of
the Aspergillus fungus and a common contaminant of cere-
als (grains) and peanuts, is an established cause of liver
cancer (see chapter 4.1). Fumonisin B, a toxin produced by
the fungus Fusarium verticillioides, may be found on maize
and may be carcinogenic, although epidemiological studies
are lacking. 
Some carcinogenic compounds are formed during food
preparation (see chapter 4.3 and 4.9). Heterocyclic amines
are formed by cooking meat at high temperatures, and poly-
cyclic aromatic hydrocarbons can be produced in meat and
fish that has been grilled (broiled) or barbecued (charbroiled)
over a direct flame. Also see box 4.3.4. High environmental
concentrations of polycyclic aromatic hydrocarbons, which
also come from pollution caused by traffic and industry, 
can contaminate other foods such as cereals, vegetables, 
and fruits.
Some N-nitroso compounds are carcinogens, and are
formed in foods containing added nitrates or nitrites; exam-
ples include fish and meat preserved with salting or preser-
vatives, and smoking or drying. These carcinogens can also
be generated from ingested foods containing nitrate or
nitrite. N-nitroso compounds are also produced endoge-
nously in the stomach and colon of people who eat large
amounts of red meat or take nitrite supplements. Also see
box 4.3.2.
2.5  Nutrition and cancer
The majority of cancers are not inherited. Cancer is, how-
ever, a disease of altered gene expression that originates in
changes to DNA, the carrier of genetic information. For a cell
to be transformed from normal to cancerous, it has to acquire
different phenotypic characteristics that result from alter-
ations to the genotype. Most cancers develop to the stage of
being clinically identifiable only years or decades after the
initial DNA damage.
Cancer development, or carcinogenesis, requires a series of
cellular changes. No single gene causes cancer. It is a multi-
step process caused by accumulated errors in the genes that
control cellular processes. One genetic mutation may allow
a single trait (such as increased survival) to be acquired by
a lineage of cells, and descendants of these cells may then
acquire additional genetic mutations. However, cancer only
develops when several genes are altered that confer growth
and survival advantages over neighbouring normal cells.
The capacity of a cell to achieve effective cancer preven-
tion or repair is dependent on the extracellular microenvi-
ronment, including the availability of energy and the
presence of appropriate macro- and micronutrients. Tumours
are not simply masses of cancer cells. Rather, they are het-
erogeneous collections of cancer cells with many other cell
types — so-called stromal cells; cancer cells communicate
with stromal cells within the tumour. The tumour microen-
vironment comprises many cell types including infiltrating
immune cells such as lymphocytes and macrophages,
endothelial cells, nerve cells, and fibroblasts. All these cell
types can produce growth factors, inflammatory mediators,
and cytokines, which can support malignant transformation
and tumour growth, and attenuate host responses. In addi-
tion, factors produced by the cancer cells themselves mod-
ulate the activity and behaviour of the tumour stroma.
Initiation is the exposure of a cell or tissue to an agent that
results in the first genetic mutation. This can be an inherit-
ed mutation or an exogenous or endogenous (produced
through oxidative metabolism) factor. Even without exter-
nal oxidative stress, hundreds of sites within DNA are dam-
aged each day but are normally repaired or eliminated. 
Exposure to the carcinogen initiates DNA damage, usually
via the formation of DNA adducts. If left uncorrected, these
adducts can be transferred to daughter cells during division
and confer the potential for neoplastic (new and abnormal)
growth.
Initiation alone is insufficient for cancer to develop. An ini-
tiated cell must go through a process of clonal expansion
during promotion to become neoplastic; the larger the num-
ber of initiated cells, the greater the risk of progressing to
cancer. Promotion involves exposure of the initiated cell to
a promoting agent. This may allow alterations in the rate of
proliferation or additional DNA damage to occur, leading to
further mutations within the same cell, which alter gene
expression and cellular proliferation. Finally, these initiated
and promoted cells grow and expand to form a tumour mass.
DNA damage continues at this stage and cancer cells often
contain multiple copies of chromosomes. This clear, sequen-
tial process is typical of experimentally induced cancers but
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may be less clear in sporadic cancers in humans. 
At the end of the multistage process of carcinogenesis, the
cell will bear some or all of the hallmarks of cancer111 (figure
2.4). Several genes can contribute to each hallmark and one
gene (for example p53) can contribute to several of the hall-
marks. These hallmarks or traits are shared by most, if not
all, cancer cells. The six hallmarks of cancer cells are self-
sufficiency in growth signals; insensitivity to antigrowth 
signals; limitless replicative potential; evasion of apoptosis;
sustained angiogenesis; and tissue evasion and metastasis.111
Food, nutrition, and physical activity-related factors influ-
ence cellular processes and lead to cells accumulating these
traits (figure 2.5). 
2.5.1 Cell proliferation
Three hallmarks of cancer, namely growth signal autonomy,
evasion of growth inhibitory signals, and unlimited replication,
promote enhanced cell proliferation. Over a normal human
lifetime, approximately 1016 (10000000 000000000) cell
divisions will take place. The sequence of stages of a cell 
dividing into two daughter cells is called the cell cycle (figure
2.3). Normal cells require external signals from growth fac-
tors, which stimulate them to divide. Proliferation of normal
cells depends, in part, on the presence in the cellular envi-
ronment of signals that both promote and inhibit growth, and
the balance between them.
Most cells in adults are not in the process of actively divid-
ing, but are in an inactive or quiescent state termed G. To
re-enter the cell cycle, cells must be stimulated with growth
factors and have sufficient space and nutrients for division. 
During the G1 phase, the cell increases in size, and syn-
thesises RNA and proteins. At the end of the G1 phase, cells
must pass through the G1 checkpoint, which arrests the cycle
if damaged DNA is detected, ensuring that it is not replicat-
ed. During the S phase, DNA is replicated. The S phase ends
when the DNA content of the nucleus has doubled and the
chromosomes have been replicated. 
When DNA synthesis is complete, the cell enters the G2
phase, during which the cell continues to increase in size and
produce new proteins. The G2 checkpoint leads to arrest of
the cell cycle in response to damaged or unreplicated DNA;
otherwise the cell divides into two daughter cells during the
M (mitosis) phase, and the M checkpoint ensures each
daughter cell receives the correct DNA. The cell cycle is con-
trolled by a set of proteins called cyclins and their specific
cyclin-dependent kinases (CDKs). These join to form
cyclin–CDK complexes, which activate transcription factors.
This in turn activates transcription of the genes required for
the next stage of the cell cycle, including the cyclin genes. 
In this section, examples are given to illustrate the known
interactions between nutritional factors and these physio-
logical processes. 
Among the modulators of cell-cycle progression are 
specific nutrients, which can either function as energy
sources or regulate the production and/or function of pro-
teins needed to advance cells through the replicative cycle.
Vitamin A, vitamin B12, folic acid, vitamin D, iron, zinc, and
glucose all contribute to the control of cell cycle progression
(figure 2.3).
2.5.1.1 Growth signal autonomy
Unlike normal cells, cancer cells are not dependent on exter-
nal growth factors to stimulate their division. Instead, they
can generate their own signals or respond to lower concen-
trations of external signals. This frees cancer cells from the
growth constraints of normal cells.
2.5.1.2 Insensitivity to antigrowth signals
Normal cells also receive growth inhibitory signals. Indeed,
most cells of the body are quiescent and not actively divid-
ing. Cells respond to negative environmental signals such as
contact with other cells. Cancer cells have acquired muta-
tions that interfere with these pathways and so do not
respond to growth inhibitory signals.
2.5.1.3 Limitless replicative potential 
Normal cells can divide a finite number of times. Once they
have replicated 60 or 70 times they stop — a process termed
senescence, which is thought to constitute a protective mech-
anism against unlimited proliferation. This preordained num-
ber of cell doublings is controlled by telomeres. Telomeres
are segments of DNA on the ends of chromosomes, which
are shortened during each round of DNA replication.
Eventually when the telomeres are too short, the cell can no
longer divide and it undergoes apoptosis.
By contrast, cancer cells have acquired the ability to main-
tain the length of their telomeres, which means they can
replicate endlessly. Recent work has suggested that senes-
cence can be induced prematurely, particularly in premalig-
nant cells, by activation of the normal, non-mutated forms
of genes such as p53 and Rb.111 This senescence is a normal
active process involving genetic and phenotypic changes that
may protect against cancer development; for example, it may
be one mechanism preventing benign moles from progress-
ing to malignant melanoma. However, in malignant
melanoma, cell markers of senescence are lost.112
In experimental conditions, many constituents of food
such as retinol, calcium, allyl sulphide, n-3 fatty acids, and
genistein are known to influence progression of cells
through the cell cycle. These studies, when conducted in cells
in culture, need to be assessed cautiously because they may
not always adequately reflect events in vivo. However, they
can and do provide evidence additional to that gained from
epidemiological studies. Also see chapter 3.1 and 3.2.
Specific dietary components have effects on cell cycle pro-
gression and proliferation in experimental settings. Some
known or hypothesised benefits of some dietary constituents
are summarised here. 
Vitamin A (in the form of retinol) can lead to cell cycle
arrest.113 Retinoids and carotenoids inhibit proliferation by
binding retinoid receptors on the cell surface. Reduced
expression of retinoid receptors occurs during development
of lung cancer114; retinoic acid receptor silencing is also com-
mon in other malignancies. Retinoic acid, a metabolite of vit-
amin A, has been used as a chemopreventive and therapeutic
agent in cervical cancer.115 Retinoids can inhibit proliferation
of initiated cells by inducing apoptosis or inducing differen-
tiation of abnormal cells back to normal.116 Retinoids may
also cause regression of precancerous lesions in the cervix.117
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Butyrate and diallyl disulphide can act as histone deacety-
lase inhibitors16 (see 2.2.2), and arrest the cell cycle. Folate
is a necessary cofactor for DNA synthesis, and deficiency can
reduce cell proliferation due to decreased DNA synthesis. 
Phenolic compounds, including genistein and EGCG, can
inhibit some cyclins and cyclin-dependent kinases.118
Specifically, in people with oral leukoplakia, green tea (which
contains EGCG) has been associated with significant decreas-
es in the size of cancers and of micronuclei formation in exfo-
liated oral cells.119
Phytoestrogens are found in high concentrations in soya
beans, and have been shown in vitro to exhibit a plethora of
different anti-cancer effects, including inhibiting prolifera-
tion.120 121 Glucosinolates from cruciferous vegetables are con-
verted in the liver to ITCs, which can arrest cell cycle
progression, as well as induce phase 2 enzymes, which can
promote carcinogen excretion (see 2.3). Only about one third
of people have the types of microbial flora in their gut that
are capable of metabolising the dietary isoflavone daidzein
to equol. Compared with Western populations, Asian popu-
lations are more likely to produce equol, and this affects the
expression of genes involved in cell signalling and differen-
tiation, and cell division. Equol can also modulate oestrogen-
responsive genes.122
Calcium has a growth
inhibiting action on normal
and tumour gastrointestinal
cells.123 However, certain
dietary compounds can also
stimulate proliferation in
experimental cell lines, for
example, colonic cells can be
induced to hyperproliferate
by dietary haem iron.124
In a variety of animal
studies, certain dietary com-
ponents have shown reduc-
tions in experimentally
induced cancers. Allyl sul-
phides in garlic inhibit
experimentally induced
colon tumour formation.
Although this is not com-
pletely understood, experi-
ments with diallyl disulphide
suggest a block in the G2/M
phase in the progression of
the cell cycle, and induction
of apoptosis.125
Fish oil supplements
decrease the number of
tumours in experimental
models of colorectal can-
cer.126 Long-chain n-3 PUFAs
in fish oils can limit tumour
cell proliferation30 31 by
modifying signalling path-
ways,127 128 129 for example,
by decreasing signalling of
activated oncogenes.130 Animals that receive a diet supple-
mented with n-3 fatty acids have fewer colonic tumours than
those fed a diet supplemented with corn oil,131 due to dietary
fibre-altering, fatty acid-binding, protein expression in
colonocytes during tumour development.
Various growth factors and hormones involved in normal
cell processes can be used or produced by cancer cells to
maintain or augment uncontrolled cell proliferation. The
receptor for IGF-1 is overexpressed on many cancer cells.
IGF-1 can enhance the growth of a variety of cancer cell
lines132 by stimulating progression of the cell cycle from G1
to S phase.13
Insulin itself can also act as a growth factor for tumour cell
proliferation, both by binding to the insulin receptor on can-
cer cells and by stimulating increased IGF-1 production by the
liver.13 133 Insulin resistance increases with body fatness, in
particular abdominal fatness, and the pancreas compensates
by increasing insulin production. This hyperinsulinaemia is
associated with a risk of cancers of the colon and endometri-
um, and possibly of the pancreas and kidney.13 Leptin, a hor-
mone produced by fat cells, can also stimulate proliferation
of many premalignant and malignant cell types,134 as can a
number of sex steroid hormones (see Chapter 6, and box 2.4).
Nutrition may influence the regulation of the normal cell cycle, which ensures correct DNA
replication. G0 represents resting phase, G1 the growth and preparation of the chromosomes for
replication, S phase the synthesis of DNA, G2 the preparation of the cell for division, and M 
represents mitosis. 
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Physical activity improves insulin sensitivity and decreas-
es levels of insulin.135 However, exercise has little or no long-
term effects on circulating IGF-1 levels.136-138 IGF binding
activity may increase with physical activity, and thus over-
all IGF-1 bioavailability and activity may decrease. Physical
activity decreases serum oestrogen and androgens in post-
menopausal women. In premenopausal women, it decreas-
es circulating oestrogens, increases cycle length, and
decreases ovulation, all of which provide a protective effect
for breast and endometrial cancers. Also see Chapter 5.
In experimental animals, energy restriction leads to a
reduction in cell proliferation66 (box 2.5). At the molecular
level, dietary energy restriction affects levels of cell cycle con-
trol proteins (decreased cyclins, increased levels of cyclin-
dependent kinase inhibitors, and decreased cyclin-dependent
kinases), leading to reduced Rb phosphorylation and inhib-
ited cell cycle progression.139 This, in turn, may directly
inhibit tumour growth and/or indirectly reduce cancer devel-
opment by reducing the number of cell divisions, thus reduc-
ing the chances for incorrect DNA replication or preventing
damaged DNA from being replicated. 
2.5.2  Evasion of apoptosis
Apoptosis is the tightly regulated process of cell death that
controls cell numbers, removes damaged cells, and prevents
damaged cells being replicated, thereby maintaining 
tissue integrity and protecting against cancer. Ultimately,
cells break into small membrane-surrounded fragments
(apoptotic bodies) that are phagocytosed without inducing
inflammation.
Triggers for apoptosis in normal cells include DNA dam-
age, disruption of the cell
cycle, hypoxia, reactive oxy-
gen species, and physical or
chemical insult. Two non-
exclusive pathways, the
intrinsic (mitochondrial)
pathway or the extrinsic
(death-receptor) pathway,
can be activated. Both
involve activation of caspas-
es, a family of protease
enzymes that cleave intra-
cellular proteins.143 In apop-
tosis, p53 functions as a
transcriptional activator of
genes encoding apoptosis
effectors. p53 can also exert
a direct apoptotic effect by
damaging mitochondria.144
Cancer cells have acquired
mutations in genes regulat-
ing apoptosis and therefore
can evade apoptotic signals.
Defects in apoptosis are
often observed in established
cancers. In cancer cells,
many signals that normally
induce apoptosis, such as
damaged DNA or expression of activated oncogenes, are pre-
sent but apoptosis is not induced. This avoidance of apop-
tosis allows further opportunity for additional mutations to
develop. In cancer cells with mutations in p53 or other
members of this family, apoptosis may not occur.
Additionally, mutations in genes that would normally
activate p53 or regulate its activity, or in genes that should
be switched on as a result of p53 activation, can have the
same effect. Cancer cells with upregulated expression of
IGF-1R and increased responses to IGF-1 have decreased
apoptosis.133
In experimental settings, energy restriction creates a pro-
apoptotic environment, adjacent to premalignant and
malignant breast pathologies.145 Long-chain n-3 PUFAs in
fish oils limit tumour cell proliferation, increasing apoptot-
ic potential along the crypt axis, promoting differentiation
and limiting angiogenesis.30 31 126
Reactive oxygen species can induce apoptosis, but it is
also possible that scavenging of reactive oxygen species by
dietary antioxidants can delay or inhibit apoptosis, and thus
favour survival of premalignant cells. Indeed, this could
explain why dietary antioxidant intervention trials have pro-
duced mixed results.146 147
Many dietary components have been shown to induce
apoptosis in cultured cancer cells and in experimental mod-
Cancer cells have different characteristics from normal cells. The six ‘hallmarks’ shown here are the
phenotypic changes that need to be accumulated over time as a result of genetic changes (mutations
and epigenetic factors) in order for a cell to become cancerous.
Maintenance of healthy cells depends on regulated processes,
which can be influenced by factors related to food, nutrition, and
physical activity, either to protect the cell from or to promote
cancer. The evidence for what is shown here comes from a variety
of experimental studies.  
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els of cancer.148 These include EGCG, curcumin, genistein,
indole-3-carbinol, resveratrol, ITCs, lycopene, capsaicin, 
and organosulphur compounds.149 In premalignant cells,
retinoids, polyphenols, and vanilloids stimulate apoptosis.150
Alpha-tocopherol (a form of vitamin E) has been shown both
to induce151 and to protect against apoptosis.152
2.5.3 Sustained angiogenesis 
Angiogenesis, the formation of new blood vessels, is essen-
tial for the supply of nutrients and oxygen to any growing
tissue, including tumours. Most cells within tissues reside
within 100 mm of a capillary blood vessel. The generation
of blood vessels in adults is fairly constant and tightly
controlled by a balance of angiogenesis inducers and
inhibitors. For a cancer to progress to a larger size, it must
acquire the ability to induce angiogenesis. Currently about
35 proteins have been identified as angiogenesis activators
or inhibitors.153
In experimental settings, one of the first dietary compo-
nents for which a beneficial anti-angiogenic effect was
clearly demonstrated was EGCG from green tea.154 Now
some 20 different compounds consisting mainly of flavonoids
and isoflavones (including genistein) are documented as
being able to modulate the angiogenic process. Diets high
in n-6 fatty acids are associated with poor prognosis in breast
cancer patients, whereas those high in n-3 fatty acids appear
to suppress angiogenesis.155 Long-chain n-3 PUFAs in fish 
oils limit angiogenesis in other experimental cancers.3031
Curcumin, quercetin, and resveratrol have all been shown to
inhibit the angiogenic factor, vascular endothelial growth
factor (VEGF), in cultured cancer cells. Garlic extract may
inhibit experimentally induced angiogenesis, as it can sup-
press endothelial cell motility, proliferation, and tube for-
mation.156 Phytoestrogens found in high concentrations in
soya beans have also been shown to inhibit angiogenesis.120
Energy restriction reduces blood vessel density in pre-
malignant and malignant breast pathologies.145 Exercise
increases the levels of a circulating endogenous VEGF-
inhibitor in healthy people, which could decrease plasma
levels of VEGF.157
2.5.4 Tissue invasion and metastasis
Normal cells in solid tissues maintain their position in the
body and generally do not migrate. As a cancer increases, it
eventually reaches the membrane encapsulating the organ.
Tumour cells secrete enzymes such as matrix metallopro-
teases (MMPs), which digest the membrane and allow the
cancer to invade adjacent tissue. Once through the mem-
brane, cancer cells can access other sites via the blood and
lymphatic systems. This migration of cancer cells, or metas-
tasis, is a common characteristic of most cancer deaths. 
There is limited evidence for dietary components to influ-
ence these late stages of cancer, although in vitro, EGCG,
resveratrol, quercetin, curcumin, and genistein can inhibit
one or more MMPs. Vitamin C can inhibit MMP production
by a number of human cancer cell lines and prevent inva-
sion of these lines in vitro.158 Vitamin E can inhibit metas-
tasis of pre-established tumours in mouse models of breast
cancer.159
2.6  Conclusions
Great progress has been made since the mid-1990s in the
understanding of the cancer process. Evidence is accum-
ulating that shows or suggests that food and nutrition, and
physical activity and associated factors, are important in
modification of the cancer process. Moreover, there is
increased evidence that specific dietary patterns, foods and
drinks, and dietary constituents can and do protect against
cancer, not only before the process starts, but also after-
wards. 
Understanding the mechanisms that control cell structure
and function, and so influence the cancer process, will aid
not only understanding of cancer as a whole, but also the
development of preventive strategies.
Restriction of energy intake from food is
the most effective single intervention for
preventing cancer in experimental animals.
It increases the lifespan of rodents, and
suppresses tumour development in mice. In
addition, energy restriction can suppress
the pro-cancer effects of many carcinogens
in experimental animal models.66
Energy restriction leads to a reduction in
cell proliferation.66 This may directly inhib-
it tumour growth, and also indirectly
reduce cancer development by reducing
overall proliferation, thus reducing the
chances for incorrect DNA replication, or
by preventing damaged DNA from being
replicated. Reduced metabolism results in
reduced generation of reactive oxygen
species, and therefore less exposure of
DNA to damaging oxygen radicals.
Dietary energy restriction reduces levels
of circulating IGF-166 140 and insulin, which
are growth factors for many cells, includ-
ing breast cancer.141 IGF-1 stimulates pro-
gression through the cell cycle from G1 to
S phase, and high levels of insulin increase
production of IGF-1.13 Energy restriction
also decreases expression of cyclins and
cyclin-dependent kinases (CDKs), and
increases levels of CDK inhibitors, leading
to reduced Rb phosphorylation and inhib-
ited cell cycle progression.139 Energy restric-
tion also decreases other inflammatory
markers.66 Conversely, increased glucose
levels associated with increased energy
intake are associated with increased DNA
synthesis and levels of some cyclins and
CDKs.113 Energy restriction may also create
a pro-apoptotic environment and reduce
blood vessel density, as shown in pre-
malignant and malignant breast path-
ologies.139 It may also activate other
protective pathways, such as the activation
of protein deacetylases.142
The data on energy restriction must be
interpreted with caution, as all studies
have been performed in experimental ani-
mals and there is an absence of epidemio-
logical and mechanistic data in humans.
Therefore the relevance of these findings
in experimental animals to the human
condition is not yet clear.
Box 2.5 Energy restriction
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Judging the evidence
The task of expert committees responsible for
reports such as this is to collect, discuss, and judge
scientific evidence, as a basis for recommendations
made in the public interest. The purpose of this third
introductory chapter is to summarise the process the
Panel has used in the five years of its work, in order
to ensure that its assessments, judgements, and
recommendations made in the chapters that follow
are reliable. 
As shown in the previous chapters, while cancer is
a disease of cells and tissues, the main determinants
of many cancers are environmental, which means
that most cancers are, at least in theory,
preventable. Environmental factors that modify the
risk of cancer include food and nutrition, physical
activity, and body composition. One purpose of
scientific research in this field is to determine which
aspects of these factors protect against, and which
are causes of, cancers of various sites. Such research
is also concerned with which aspects are most
important — that is, which have the most powerful
or general effects. 
Some of the methods used by the Panel
responsible for this Report are new. Others are
developed from those used elsewhere, including in
the previous report. The best evidence that aspects
of food, nutrition, physical activity, and body fatness
can modify the risk of cancer does not come from
any one type of scientific investigation. It comes
from a combination of different types of
epidemiological and other studies, supported by
evidence of plausible biological mechanisms. Such
comprehensive evidence has been collected in the
form of 20 systematic literature reviews specially
commissioned as the basis for this Report, compiled
by nine independent centres of scientific excellence,
covering 20 cancer sites, the determinants of
obesity, and recommendations made by other
authoritative reports. These reviews amount to a
comprehensive examination of the relevant types of
epidemiological and experimental evidence,
organised using a common methodology. Their
findings, as summarised for and then assessed and
judged by the Panel, are shown in Part 2 of this
Report. The full systematic literature reviews are
contained on the CD included with this Report. 
C H A P T E R  3
Judgements of the Panel are shown in the form of
matrices at the beginning of the chapters of Part 2 of
this Report. Two key judgements in these matrices,
and in the text, are those of ‘convincing’ and
‘probable’. These denote the Panel’s judgements that
the evidence of causality — that a factor either
decreases or increases the risk of cancer — is strong
enough to justify population goals and personal
recommendations, which are made in Part 3. The
criteria agreed by the Panel for grading the evidence
‘convincing’, ‘probable’, or ‘limited’, or else showing
that any substantial effect on the risk of cancer is
unlikely, are also specified in this chapter. 
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Since the mid-1990s, the discipline of epidemiology has
placed increasing emphasis on the use of meta-analyses and
systematic reviews, both of which have informed the Panel
responsible for this Report. Taken together with lines of evi-
dence from other types of study, these provide a reliable basis
for judgements and recommendations designed to improve
public health. 
The task of the Panel, with the supporting Secretariat, has
been to commission, summarise, and display a comprehensive
range of evidence; to assess and judge this evidence; and to
draw conclusions and make recommendations based on this
systematic and transparent process. Also see Appendix A.
This chapter details the nature of the science relevant to
the work of the Panel. It also summarises the processes devel-
oped from initial work done by a Methodology Task Force.
Its findings have been a foundation for the work of the Panel.
The two most important parts of this process are the sys-
tematic literature reviews (SLRs), explained in box 3.4, and
the criteria the Panel has agreed for grading the evidence,
described in box 3.8. These and other methods have deter-
mined the Panel’s approach to gathering, summarising,
assessing, and judging evidence, and agreeing on population
goals and personal recommendations as a basis for the pre-
vention of cancer. 
3.1  Epidemiological evidence
Epidemiological research describes and seeks to explain the
distribution of health and disease within human populations.
The methods used are based mainly on comparative obser-
vations made at the level of whole populations, special
groups (such as migrants), or individuals within populations.
This type of investigation is known as observational. By relat-
ing differences in circumstances and behaviour to differences
in the incidence of disease, associations are identified that
may be causal. In epidemiological studies, an ‘exposure’ is a
factor or condition that may increase or decrease the risk of
disease. In this Report, food, nutrition, physical activity, and
body composition are the ‘exposures’ investigated. The meth-
ods summarised here and applied to cancer are also used to
study and understand other diseases. 
3.1.1  Descriptive studies 
The most basic information about cancer comes from sta-
tistics on cancer incidence and mortality. See chapter 1.2.4,
the introductory passages of the sections of Chapter 7, and
box 7.1.1.
The International Agency for Research on Cancer (IARC),
a branch of the World Health Organization, compiles inter-
national cancer statistics using data from national and
regional cancer registries around the world.1 Cancer inci-
dence rates are usually specified by gender and age. Cancer
mortality rates, generally derived from data collected rou-
tinely on causes of death, are more widely available than
cancer incidence rates. 
Descriptive epidemiology informs cancer surveillance
programmes, and is a basic tool for determining patterns 
of cancer, relative rates of cancer and other diseases, and
changes in patterns and trends over time. Remarkable
changes in the incidence of cancers (for example, the 
general drop in rates of stomach cancer or the increase 
in rates of lung cancer in many middle- and low-income
countries) provide first lines of evidence pointing to causa-
tion due to corresponding changes in environmental 
circumstances. 
Like all types of study, descriptive epidemiology has limi-
tations. Apparent trends in cancer incidence and mortality
may be due in part to changes and developments in screen-
ing, diagnosis, or treatment. For example, the rapid rise in
the recorded incidence of prostate cancer in the USA, the UK,
and other higher-income countries is largely due to wide-
spread use of diagnostic techniques that identify early
evidence of this cancer.
3.1.2  Ecological studies
Ecological studies are designed to explore relationships
between environmental factors and disease amongst popu-
lations rather than individuals.
Within the scope of this Report, ecological studies compare
relationships between estimated levels of consumption of
foods and drinks, levels of physical activity, and degrees of
body fatness with rates of cancer for populations. For exam-
ple, as already mentioned, early observations found impres-
sive correlations between national per capita intake of total
dietary fat and rates of breast cancer mortality, mapped
across many countries,2 leading to the hypothesis that rela-
tively high consumption of total fat was an important cause
of breast cancer.
The findings of ecological studies, together with those 
from migrant and laboratory studies (see 3.1.3 and 3.2), 
were important factors leading to judgements and recom-
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mendations made in reports on diet and cancer published in
the 1980s.3-5
While ecological studies, like other observational studies,
may suggest a relationship between a specific environmen-
tal factor (such as an aspect of food and nutrition) and
disease, the actual causal relationship may be with a differ-
ent ‘confounding’ factor, which may or may not be associat-
ed with the environmental factor being investigated.6 The
example of total fat consumption and breast cancer is a case
in point: total fat consumption, disposable income, and con-
sumption of alcoholic drinks might all correlate with one
another, and also with breast cancer. See box 3.1. 
Ecological studies are often used to identify associations
or trends that warrant further investigation. They have spe-
cial strengths, particularly when conducted between popu-
lations, either internationally, or cross-culturally among
different populations within a country. Thus, the contrast in
dietary intake between countries is often much larger than
the contrast within countries. In addition, average national
diets are likely to be more stable over time than the diets of
communities, families, or individual people. For most coun-
tries, the changes in overall national dietary intakes over a
decade or two are relatively small.
3.1.3  Migrant studies
Migrant studies compare cancer rates for migrants, and for
their offspring, in their current country of residence, with
rates in their country of origin.16 These studies show that
populations migrating between areas with different cancer
incidence rates acquire the rates characteristic of their new
location for some cancers, often after only one or two gen-
erations. This shows that environmental, rather than inher-
ited, factors are primarily responsible for the large differences
in cancer rates in different regions and countries (see chap-
ter 1.3).17 Those diseases for which incidence shifts with
migration, such as cancer, are diseases with evidently impor-
tant environmental causes. 
3.1.4  Case-control studies
In case-control studies, individuals diagnosed with a specif-
ic type of cancer (‘cases’) are compared with otherwise sim-
ilar individuals who have not been diagnosed with cancer
(‘controls’). The control group is a sample of the population
from which the cases arose, and provides an estimate of how
the exposures being studied are distributed in that popula-
tion. Identifying and enrolling appropriate controls is a major
challenge in case-control studies.18-20
Interpretation of epidemiological evidence
on any and all aspects of foods and drinks,
physical activity, body composition, and
associated factors, with the risk of cancer,
is never simple. General considerations
include the following, which need to be
taken into account when evidence is assem-
bled and assessed. This emphasises that
expert judgement is essential. 
Patterns and ranges of intakes. Most stud-
ies are carried out in high-income countries.
Their findings may have limited application
in countries where dietary and physical
activity patterns are different. They may
also be unrevealing in their own countries
if the ranges examined are relatively nar-
row. Some foods that are important dietary
constituents outside high-income countries
are often not examined. 
Classification. Following from the above,
studies usually classify foods and drinks,
and physical activity in ways that corre-
spond to the patterns of high-income coun-
tries. Their findings may over-emphasise
the significance (or insignificance) of foods
and drinks commonly consumed in high-
income countries, and they may overlook
other foods and drinks consumed in 
other parts of the world. The same points
apply to types of physical activity. This 
may impede understanding, not only in
middle- and low-income countries, but also
globally. 
Measurement. Many study exposures are
difficult to determine and are thus mea-
sured imprecisely. It is easier to measure
food intakes than intakes of dietary con-
stituents of foods. This can lead to an
undue degree of importance being given to
studies of aspects of food and nutrition
that happen to be more easily measured. 
Terminology. For some foods and drinks,
and dietary constituents, there are no gen-
erally agreed definitions. Examples include
‘dietary fibre’ and ‘processed meat’. Also,
some common definitions may disguise real
differences: different types of ‘dietary fibre’
have different biological effects. 
Study design. The relative merits of differ-
ent types of epidemiological study design,
and the relative value of epidemiological
evidence compared with experimental evi-
dence, are likely to remain to some extent
a matter of opinion. The special power of
randomised controlled trials (see 3.1.6),
most often used to test the effects of
dietary constituents as opposed to whole
diets, could lead to over-emphasis of the
importance of isolated constituents which,
within the context of food and diets, may
have other effects. 
Confounding. A confounder is a factor
associated with both the outcome (in this
case, cancer) and the exposure being stud-
ied, but is not an effect of the exposure. It
is never possible from observational studies
to eliminate completely the possibility that
an evident effect of a constituent, or aspect
of a food or drink, is at least in part caused
by another factor. 
Reporting bias. Studies reliant on self-
reporting of dietary intake are prone to sys-
tematic bias. People tend to over-report
consumption of foods and drinks they
believe to be healthy, and under-report
foods and drinks they believe to be
unhealthy. Under-reporting of energy
intake has been shown to be associated
with factors such as age, overweight and
obesity, perceived body size, and other per-
sonal characteristics.7-14 Allowance for this
is an inexact science. Also see 3.3.
Production, preservation, processing,
preparation. Studies of foods and drinks,
and of food groups, may neglect the
effects of methods of production, preser-
vation, processing, and preparation (includ-
ing cooking). They are also inclined to
underestimate the significance of foods
and drinks combined in dishes or meals,
and as components of whole dietary
patterns.
Box 3.1 Issues concerning interpretation of the evidence
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Case-control studies are subject to recall bias, which can
occur when participants’ reporting of various exposures
(dietary intake, medication, physical activity, and so on) is
differentially affected by whether they are cases or controls
in the study. Selection bias is an increasing problem in high-
income countries, where participation rates among both case
and control groups may be substantially less than 100 per
cent, and where participation may be related (in different
ways) to various exposures. However, case-control studies
are usually less expensive than cohort studies, and can be
completed over shorter periods of time. 
A ‘nested’ case-control study is carried out within an exist-
ing cohort study (see 3.1.5). In this type of study, all of the
cases in the cohort are compared with a sample of the non-
cases. A nested case-control study has the strengths of a
cohort study — notably that diet is assessed among study
participants prior to the diagnosis of cancer, so avoiding
recall bias — but is less expensive to conduct, since only a
sample of the non-cases are included in the analysis. 
3.1.5  Cohort studies 
In prospective cohort studies (usually simply called cohort
studies), the diets, body compositions, and/or physical activ-
ity levels of a large group (cohort) of people who are
assumed to be healthy are assessed, and the group is fol-
lowed over a period of time. During the follow-up period,
some members of the cohort will develop and be diagnosed
with cancer, while others will not, and comparisons are 
then made between these two groups.  Because measure-
ments are made before any cancer diagnosis, cohort studies
are not subject to recall bias. A single cohort study allows
examination of the effects of diet and physical activity on
multiple types of cancer and other diseases. Also, in cohort
studies, blood and tissue samples are often collected and
stored for future analysis. Finally, cohort studies provide the
opportunity to obtain repeated assessments of participants’
diets at regular intervals, which may improve the dietary
assessment. 
Cohort studies may need to be very large (up to tens or
even hundreds of thousands of participants) to have
sufficient statistical power to identify factors that may
increase cancer risk by as little as 20 or 30 per cent. Also,
meaningful comparisons between cases and non-cases can
be made only for factors that vary sufficiently within the
cohort. 
Cohort studies are expensive, so they have been conduct-
ed mostly in high-income countries. The European
Prospective Investigation into Cancer and Nutrition (EPIC),
started in 1992, is a cohort of more than 520000 men and
women in 10 European countries.21 22 In the US, large cohorts
include the Nurses’ Health Study, established in 1976, and the
Nurses’ Health Study II, established in 1989, each with a
cohort of more than 100000 women.23-25 Increasing numbers
of cohort studies are now being conducted in middle- and
low-income countries.
3.1.6  Randomised controlled trials
A randomised controlled trial (RCT) is an experiment in
which participants are randomly assigned to groups, often
called intervention and control groups, to receive or not
receive an experimental intervention. The main use of RCTs
has generally been to test the efficacy of drugs and other
medical treatments.
In a ‘double blind’ RCT, neither the participants nor the
investigators know to which group (intervention or control)
the participant has been assigned. Blinding is used because
the knowledge of group assignment might influence study
results, but it is usually impossible to achieve with trials
involving physical activity, or those investigating foods and
drinks in their usual form.
An effective use of RCTs is to test the effects of supple-
mentation with specified doses of dietary micronutrients 
(as pills or by other means). However, pharmacological doses
of supplements are often studied — doses much higher 
than can be derived from diets — and results may not be
directly relevant to dietary intakes of that micronutrient. 
Such trials may yield powerful evidence of the effect of a
specific dietary constituent. However, they are often con-
ducted as a result of promising epidemiological studies 
that have shown protective effects of a particular group of
foods, and there is always a possibility that the actual active
agent or combination of agents in the foods has not been
used in the trial. Dietary constituents that are or may be
protective when contained within foods may have unex-
pected effects in isolation, especially at doses higher than
those found in normal diets. For example, in the Alpha-
Tocopherol, Beta-Carotene Cancer Prevention Trial (ATBC
Trial) of male smokers in Finland, high dose beta-carotene
supplementation was associated with increased incidence of
lung cancer.26
RCTs are also used to test interventions designed to change
behaviour, including dietary intakes and physical activity.
Such trials require a high level of commitment by partici-
pants, and learning how to conduct them well is a topic of
active investigation.
A unique and important strength of sufficiently large RCTs
is that confounding variables, both known and unknown,
will on average be distributed equally between the treatment
and control groups, and will therefore not bias the study
results. 
3.1.7  Meta-analysis
Meta-analysis is a method used to combine the results of sev-
eral studies addressing similar questions. Unless an epi-
demiological study is sufficiently large, modest but
potentially important associations can be missed, simply
because of the inadequate statistical power of the individual
study. Meta-analysis is used to provide summaries of select-
ed collections of studies. 
Study-level meta-analysis provides single estimates of
effect using information from multiple studies of the same
design. These summary estimates can provide evidence
regarding the presence or absence of an association, as well
as examining possible dose-response relationships (box 3.2).
Meta-analysis, often displayed graphically on a forest plot
(box 3.3), can also identify heterogeneity between studies.
This heterogeneity can be quantified using a measure called
I2, which ranges from 0 to 100 per cent, and indicates the
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percentage of total variation across studies that is not due
to chance. In general, an I2 of 25 per cent or less indicates
low heterogeneity; around 50 per cent indicates moderate
heterogeneity; and 75 per cent or more indicates high
heterogeneity.27
For this Report, RCTs and ecological, cohort, and case-con-
trol studies have been the subjects of systematic review, and,
when possible (and separately) of study-level meta-analysis.
Studies were included in a meta-analysis only when suffi-
cient data were included in the publication. In addition to
effect measures and their standard errors (or confidence
intervals, see box 3.3), key elements of adequate reporting
included the number of people with and without disease 
for each exposure category, and boundaries of exposure
categories.
The SLRs on which the conclusions of this Report 
are based include original study-level meta-analyses
undertaken by the independent centres of scientific excel-
lence. The Panel considered all studies identified in the SLR,
not just the results of the meta-analyses. Full details of 
the methods used for the meta-analyses are contained in 
the SLR specification manual. The full SLRs and the manu-
al are contained on the CD included with this Report. Also
see box 3.4.
Pooled analysis is a type of meta-analysis where original
individual-level data from various published epidemiologi-
cal studies of the same type — usually prospective cohort
studies — are combined and reanalysed. The combination
of data from multiple studies creates a larger data set and
increased statistical power. Published studies from pooling
projects, in addition to the SLR study-level results generat-
ed specifically for this Report, were taken into account by the
Panel in making its assessments and judgements.
3.2  Experimental evidence 
Epidemiological studies all have strengths and limitations. So
do laboratory and mechanistic studies; their main strength is
control. The environment of these research studies is defined
by chosen experimental conditions: precise manipulations can
be made and relatively exact measures taken. Occasionally
the test participant is a human volunteer, but usually these
studies are conducted in animals (in vivo) or using human
or animal cells grown in the laboratory (in vitro). 
Rodents (usually rats or mice) are the most commonly used
animals in laboratory experiments. Their relatively short life-
span provides comparatively fast results in cancer studies, and
they offer a ‘whole body system’ suited to a wide variety of
tests. Rodent studies can show how nutrients and other com-
pounds might affect the cancer process. But it is known that
some interventions that affect rodents do not affect humans,
or do not affect them in the same ways or to the same degrees,
and vice versa. Also, experiments on animals may be highly
artificial, using special breeds of rodents initially given mas-
sive doses of carcinogenic agents, and then fed nutrients or
other substances at levels far higher than humans would nor-
mally consume, or could ethically be given.
Human or animal cells, sometimes derived from particu-
lar cancers, can be grown in vitro in the laboratory and used
in experiments to help researchers understand mechanisms
that may lead to the development of cancer. The Panel’s deci-
sion on what types of experimental studies were admissible
as evidence for this Report is summarised in box 3.5. 
3.2.1  Human feeding studies 
Human volunteers can be studied in a controlled environ-
ment, such as within a metabolic unit, where their diets and
‘Dose response’ is a term derived from
pharmacology, where it denotes a change
in the effect of a drug according to the
dose used. This concept can be applied to
any exposure, including food, nutrition,
and physical activity. For example, different
amounts of food and drink consumed, or
of physical activity taken, may lead to a dif-
ferent likelihood of any particular out-
come, such as cancer. Such a graded
response, or biological gradient, may show
that higher exposure leads to increased
risk, or to reduced risk, and vice versa. 
Dose responses take different forms. The
effect may be linear, shown in graphic form
as a straight line. There may be a ‘thresh-
old’ below which there is no effect, but
above which there is an effect. This is
shown as a horizontal line that inclines
once the threshold is reached. Or the effect
may be to influence risk one way at both
low and high levels of exposure, but the
other way at intermediate levels of expo-
sure, shown as ‘J’- or ‘U’-shaped curves. 
In such cases, the exposure is evidently
beneficial or harmful only within certain
ranges. 
Throughout Chapters 4–6, this Report
uses two forms of dose-response graph as
a means of displaying graded responses.
These show the direction and shape of the
association, and allow estimates to be
made of levels of exposure that may influ-
ence risk. In order to combine and quanti-
fy study results, the dose-response curves
are also presented with the exposure vari-
able displayed per standard unit of
increase. The demonstration of a biologi-
cal gradient adds weight to evidence that
an exposure may be causal. Diet and phys-
ical activity exposures are continuous vari-
ables, but are often reported in discrete
categories. Although this is done for sta-
tistical reasons and can make effects easi-
er to detect, the number and location of
category boundaries may obscure the true
relationship between exposure and the
outcome, and non-linear effects of expo-
sure may be missed if insufficient cate-
gories are used.
Evidence of dose response is important
when framing recommendations. For
example, if the evidence for cancer showed
no threshold of effect for alcoholic drinks,
such that the risk of cancer increased from
having any amount of alcoholic drink,
however modest, then a recommendation
based on the evidence for cancer would be
to avoid alcoholic drinks. However, if there
is clear evidence of no effect below a cer-
tain level of consumption, then the rec-
ommendation would differ accordingly.
Also see chapter 4.8. 
Box 3.2 Dose response
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activity levels can be highly regulated and measured. In some
studies, subjects live at the metabolic unit for short periods
of time, eating only foods and meals provided as part of the
study. Since the nutrient composition of such diets can be
controlled and manipulated, investigators can study the
effects of various changes in nutrient intakes on factors such
as hormone levels or cell proliferation assays, which may be
important predictors of cancer or other diseases. These are
intermediate markers, however, and relating the results to
cancer occurrence may be problematic.
3.2.2  Live animal models 
Laboratory animals can be used to test the effects of food,
nutrition, and physical activity on the development of can-
cer. Human genes can be added to animals’ DNA (creating
transgenic animal models) or key genes can be removed (cre-
ating ‘knockout’ animal models) to address specific research
questions. Often the animals have tumours produced by irra-
diation, viruses, chemicals, or other carcinogens, or they may
be genetically prone to develop cancer. The effect of dietary
or other interventions on the prevention or progression of
such tumours is then investigated. 
As indicated in 3.2, the strength of these studies is the tight
control of experimental conditions. Their limitations are
their artificiality and the fact that no effect on rodents, how-
ever unequivocal, can be assumed to apply to humans.
Rather like the results of population ecological studies,
results from animal studies provide first lines of evidence
that may prompt more persuasive research; they can also cor-
roborate such findings. 
3.2.3  In vitro studies
In vitro studies are conducted using cells or other test sys-
tems. Human cells, animal cells, mechanistic test systems,
The graphic device known as a ‘forest
plot’ is the usual method of presenting
the results of meta-analysis of a num-
ber of studies. In the forest plot below,
studies are presented that examine the
relationship between alcoholic drinks
and oesophageal cancer. This plot is
also shown as figure 4.8.5.
This plot shows 1 cohort study and
23 estimates from 20 case-control stud-
ies. The horizontal axis of the plot
shows the relative risk (RR) and is
bisected by the vertical axis, which rep-
resents ‘no difference in effect on risk’
between the exposure categories that
are compared (the RR is 1.00). Also 
see 3.4.3. 
The squares represent the results of
each individual study. Each square is
centred on the point estimate of the
RR for that study. The point estimate is
the extent to which any exposure (in
this case, alcoholic drinks) is associated
with the risk of cancer (in this case, of
the oesophagus). The line running
through the squares represents the 95
per cent confidence interval (CI) of the
estimate. Where no line is apparent,
the CI falls within the square. The CI is
an indication of how much random
error underlies the point estimate; it
does not take into account confound-
ing and other forms of systematic bias.15 A
confidence level of 95 per cent indicates a
95 per cent probability that the true pop-
ulation value falls within the CI.28
When the CI does not cross the vertical
axis representing ‘no difference’, the esti-
mate is considered statistically significant.
Looking at the example above, the value
of meta-analysis is demonstrated: of the
20 case-control studies, 6 are non-signifi-
cant or only marginally so, of which 1 sug-
gests a protective effect (that is, it has an
RR of less than 1.00). But taken together,
as shown by the summary diamond, an
overall significant effect, consistent with a
judgement that alcoholic drinks are a
cause of oesophageal cancer, is shown.
There is only one cohort study shown
on the forest plot, and it has a wide CI,
but the estimate is statistically signifi-
cant and consistent with results from
the case-control studies. 
The size of each square on the plot
represents each study’s calculated
weight (influence) on the combined
(summary) estimate (the diamond). The
size of the square is calculated taking 
a number of factors into account, such
as the number of people in the study,
and the event rate (here, the rate of
oesophageal cancer occurrence). The
diamond summarises the meta-analysis.
The width of the diamond represents
the 95 per cent CI of the overall
estimate. Unless indicated otherwise,
random effects models, which do not
assume that the links between exposure
and outcome are the same in different
studies, were used to generate the
forest plots presented in this Report.
The Panel’s judgement for this particu-
lar example is given in chapter 4.8.5. 
The forest plots presented in this Report
do not contain all of the studies identi-
fied in the SLRs. Sometimes, more stud-
ies could be included in a comparison
between those at the highest levels
compared with the lowest levels of
exposure in different studies. This can
give an indication as to whether or not
there is an association between exposure
and outcome. However, because the actu-
al levels of exposure vary between studies,
this cannot give a quantified summary
estimate of effect. The Panel discussed all
studies identified, not just those included
in a meta-analysis. 
Box 3.3 Forest plots
Figure 3.1 Alcoholic drinks and oesophageal cancer;
cohort and case-control studies
Cohort
Kjaerheim 1998 1.26 (1.10–1.44)
Case control
Tuyns 1983 Men 1.12 (1.07–1.17)
Tuyns 1983 Women 1.04 (1.00–1.09)
Decarli 1987 1.04 (1.03–1.05)
La Vecchia 1989 1.01 (0.99–1.03)
Franceschi 1990 1.02 (1.01–1.04)
De Stefani 1990 Men 1.04 (1.03–1.06)
De Stefani 1990 Women 1.13 (0.99–1.29)
Sankaranarayanan 1991 Men 1.02 (1.01–1.03)
Cheng 1992 1.08 (1.07–1.09)
Tavani 1993 1.03 (1.00–1.06)
Tavani 1994 1.02 (1.00–1.04)
Hanaoka 1994 1.24 (1.14–1.33)
Brown 1994 Black men 1.04 (1.03–1.04)
Brown 1994 White men 1.03 (1.05–1.07)
Castelletto 1994 1.05 (1.03–1.07)
Gammon 1997 1.07 (1.05–1.08)
Bosetti 2000 1.03 (1.03–1.03)
Takezaki 2001 1.00 (0.96–1.04)
Sharp 2001 1.00 (0.95–1.05)
Boonyaphiphat 2002 1.05 (1.04–1.07)
Dal Maso 2002 1.03 (1.02–1.04)
Lee 2005 0.99 (0.97–1.00)
Yang 2005 1.05 (1.03–1.06)
Summary estimate 1.04 (1.03–1.05)
F
Relative risk (95% CI)
Relative risk, per drink/week
1 1.50.8 1.25
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and bacterial systems can be used. 
Cell cultures can be primary, where tissue (such as a
tumour biopsy) is taken directly from humans or animals and
then cultured; or secondary, where the original cells are cul-
tured a number of times. Such cell lines are commonly used
in laboratory research, and can become immortal — cultured
again and again. The cells or tissues are subjected to poten-
tial carcinogens, and then markers of damage are measured.
Conducting studies in vitro has two main advantages. 
First, specific, well defined interventions can be tested; and
second, intracellular mechanisms can be examined. However,
these studies do not allow the study of integrated systems,
such as how organs or the whole body responds to the
interventions. Therefore extrapolation of results to humans
is limited. 
3.2.4  Biological pathways 
Epidemiological and experimental evidence indicating a
causal association between an aspect of diet and cancer is
strengthened when there is evidence of a plausible biologi-
cal pathway or mechanism by which the cancer process may
be modified. The Panel agreed that simply identifying such
plausible mechanisms is not sufficient evidence for a causal
relationship; but it also agreed that the case for a causal rela-
tionship is strengthened when there is evidence of biologi-
cal plausibility.
The main basis for the Panel’s work in com-
ing to judgement on the causal relation-
ships between food, nutrition, physical
activity, and cancer is a series of 20 specially
commissioned systematic literature reviews
(SLRs). These have all been conducted
according to a common, detailed specifi-
cation, following recommendations made
by the Methodology Task Force, which
completed its work before the Panel’s first
meeting. The SLRs form the main evidence
basis for the assessments and judgements
made by the Panel in Part 2 of this Report,
on which the Panel’s population goals and
personal recommendations in Part 3 are
based. 
This approach differs from that used to
prepare most other expert reports.
Previously, expert reports concerned with
the prevention of disease, and other top-
ics, have relied on less formal methods to
collect and assess relevant literature. Until
the 1980s, most such reports were assem-
bled by members of panels of scientists
who, assisted by secretariats, wrote drafts
of chapters themselves using their own
knowledge, either with or without addi-
tional research. The panel then reviewed
the draft report until consensus was
achieved. In some cases, report authors
took total responsibility for assembling and
judging the evidence. In the 1990s, more
ambitious reports placed greater emphasis
on secretariats, which tended to take more
responsibility for drafting the report, and
for some original research, as directed by
the panel. More recently, panels have
sometimes been informed by ‘narrative
reviews’ commissioned from specialists and
prepared independently from the panel
process. Such reviews are usually written
from the specialists’ existing knowledge,
and form background ‘substrate’ for the
reports. Narrative reviews may be pub-
lished separately.29
Current practice, when resources allow,
is to separate the process of collecting and
displaying evidence from that of discussing
and judging evidence. Evidence is collect-
ed systematically, after agreeing criteria for
inclusion or exclusion for review. As well as
reducing possible bias, this is a more com-
prehensive and transparent approach. This
process was used by the previous report,
which at the time of its publication was the
most comprehensive in its and allied fields.
This current Report has made a step-
change in this process, by commissioning
independent SLRs, and making full use of
electronic resources.
The Panel, in commissioning the SLRs
and supplementary work, decided to
require evidence from all relevant epi-
demiological and experimental studies,
together with biological findings. The
alternative approach would have been to
agree a hierarchy of epidemiological evi-
dence, perhaps with one study type given
pre-eminent importance. Instead, while
allowing for some types of epidemiologi-
cal study being more or less prone to bias
than others, the Panel has based its con-
clusions and judgements on evidence accu-
mulated from different types of study. For
the Panel to be convinced that a relation-
ship between an exposure and cancer is
causal, or that it is probably causal, consis-
tent evidence from different types of study
was required, with the exception of ran-
domised controlled trials.
The teams responsible for producing the
SLRs gathered relevant studies in a com-
mon, systematic fashion, using a protocol
designed to limit the potential for bias in
deciding which evidence should be includ-
ed or excluded from analysis. 
The first stage of the SLRs was a com-
prehensive search of the scientific literature
and other sources catalogued on electron-
ic databases, using all relevant keywords
and terms. The papers identified were
assessed for relevance using reproducible
criteria. Study characteristics and results
were extracted and recorded. Data from
different studies were combined and
analysed, using meta-analysis when appro-
priate. Key features of selected studies are
presented in graphic form in Chapters 4–6
and 8, to aid comparison and quality assess-
ment. Existing SLRs were also identified to
ensure, as far as possible, that all relevant
papers were included.
An important aspect of an SLR is that all
stages of searching, selection, assessment,
and analysis are prespecified, objective,
reproducible, openly documented, and
subject to peer review at critical stages. As
stated, full details of the approach taken
can be found in the SLR specification man-
ual contained on the CD included with this
Report (together with the SLRs).
The SLRs included evidence published up
to the end of 2005, and the Panel’s con-
clusions are based on these SLRs. To ensure
that the Panel’s recommendations, which
are derived from their conclusions and
judgements, take into account developing
evidence, a further review of studies pub-
lished during 2006 was conducted. This
review was more limited than the full SLRs:
it was confined to exposures that had 
been judged ‘convincing’, ‘probable’, ‘sub-
stantial effect on risk unlikely’, and ‘limit-
ed–suggestive’, based on the SLRs. (See box
3.8 for an explanation of these terms.) At
this second review stage, no further meta-
analyses were performed and a review of
study quality was not included. For these
reasons, the results of this 2006 review
have been noted but have not been used
to alter the Panel’s judgements based on
the full SLRs. A further process has been
established for a continuous review of
evidence published since 2006, after pub-
lication of this Report.
Box 3.4 Systematic literature reviews
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Narrative reviews of experimental studies and of evidence
of plausible biological mechanisms were included in the SLRs
that inform this Report. Summaries of these SLRs are pre-
sented in Part 2, Chapters 4–10. Also see box 3.4.
3.3  Methods of assessment 
Some exposures are easier to measure than others. Thus, it
is relatively easy to assess the impact of tobacco smoking and
exposure to tobacco on cancer risk. Although tobacco smoke
is a mixture of many chemicals, and its interactions with 
the body are complex, tobacco can be considered a single
exposure. 
By contrast, diets are multidimensional exposures and in
free-living populations cannot be measured with complete
accuracy. Moreover, the foods and drinks people consume
every day contain thousands of constituents, some well
known, others unknown and unmeasured. The relationships
between food, nutrition, physical activity, and health and dis-
ease are complex and difficult to untangle. The presence or
absence of effect modification (box 3.6) can create additional
challenges.
3.3.1  Foods, drinks, and nutrients 
People’s dietary intake varies from day to day and over the
course of their lives. There are interrelationships between
food components, between foods in whole diets, and
between diets and other behavioural characteristics such as
physical activity or smoking. There are several methods for
assessing food and drink consumption, all with their own
weaknesses and strengths. 
3.3.1.1   Dietary assessment methods
Food intakes can be measured for populations, groups, or
individuals. The most commonly used techniques for assess-
ing food and drink consumption are diet histories, 24-hour
dietary recalls, food frequency questionnaires, and food diary
or food record methods. Most of the studies included in this
Report used dietary assessment data from individuals,
recorded using food frequency questionnaires. 
Diet histories take the form of unstructured enquiries,
more useful in clinical settings than in research studies.
Dietary recalls may use structured or unstructured methods,
and are often administered many times over the course of a
study. In a 24-hour dietary recall, a record is made of every-
thing a person can recall eating or drinking over the previ-
ous 24 hours. Automated systems for collecting and
analysing dietary recalls have been developed, which facil-
itate the use of this method of assessment in large studies.32
Food frequency questionnaires collect information on food
consumption patterns, typically over the past year. A record
is made of the frequency of consumption of perhaps 100 to
150 items, and often includes information on serving sizes.
Food frequency questionnaires may be designed to gain
detailed information about specific aspects of diets, such as
intakes of fats or dietary fibre, leaving other components less
well characterised. A questionnaire for whole diets cannot
adequately capture the full variety and composition of indi-
vidual diets without becoming unwieldy. Food frequency
questionnaires are inexpensive, however, and are practical
for use in large-scale epidemiological studies.
Food diary or food record methods rely on the participants
in the study recording everything they eat and drink over the
course of one or more days. Participants may be asked to
estimate portion sizes, or weigh foods and drinks. 
All dietary assessment methods that rely on self-reporting
are subject to measurement error. Further errors are intro-
duced by the conversion of food data to nutrient data, using
tables of the chemical composition of foods, which give aver-
age nutrient contents for defined foods. This implicitly
assumes that all participants eat foods that have the same
standard composition and portion size. But in reality, food
composition varies widely, depending on soil quality,
The Panel agreed a ‘hierarchy of robust-
ness’ recommended by the Methodology
Task Force, which completed its work
before the Panel’s first meeting. The ‘hier-
archy of robustness’ was designed to deter-
mine which types of human and animal
experimental study are likely to be most
applicable to human cancer. This was done
for practical and scientific reasons. The
body of experimental literature is very
much larger than the body of epidemio-
logical literature, and an exhaustive sys-
tematic review of this literature would
have been impractical. Also, most experi-
mental work, such as that conducted as a
guide to toxicological regulations, either
has no evident relevance to the work of
the Panel, or else would be unlikely to sig-
nificantly influence judgements derived
from consideration of the collective weight
of evidence from all other types of study.
For these reasons, eight types of exper-
imental evidence were identified and split
into three classes: 
Class 1 
• In vivo data from studies in human
volunteers (controlled human feeding
studies).
• In vivo data from studies using
genetically modified animal models
related to human cancer (such as gene
knockout or transgenic mouse models).
• In vivo data from studies using rodent
cancer models designed to investigate
modifiers of the cancer process. 
Class 2 
• In vitro data from studies using human
cells validated with an in vivo model;
for example, a transgenic model.
• In vitro data from studies using primary
human cells.
• In vitro data from studies using human
cell lines.
Class 3 
• In vitro data from studies on animal cells.
• Data from mechanistic test systems; for
example, isolated enzymes or genes.
For the systematic literature reviews in this
Report, only class 1 evidence was reviewed.
Illustrative evidence from in vitro studies is
included only in Chapter 2.
Box 3.5 Experimental findings
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harvesting conditions, animal feed, storage, and food pro-
cessing, for example. Furthermore, food tables can be incom-
plete: for instance, they may not include information on
phytochemical or fatty acid levels in foods. In many coun-
tries, there may be no records of the composition of tradi-
tional and indigenous foods. 
Multiple-day food records or 24-hour dietary recalls have
been used as reference instruments to check the validity of
food frequency questionnaires.33 34 However, studies using
biomarkers (see 3.3.1.2) have shown that food record and
recall methods are also liable to measurement error, and that
these errors are correlated with errors from food frequency
data. This means that the use of food record or recall meth-
ods to validate food frequency data results in an overesti-
mation of the validity of the food frequency data.35-38
Often, estimated intakes of macro- and micronutrients are
adjusted for energy intake (box 3.7).
3.3.1.2  Biomarkers
‘Recovery’ biomarkers, such as doubly labelled water or 24-
hour urinary nitrogen excretion, can be used to assess the
accuracy of various dietary assessment methods. The dou-
bly labelled water test accurately measures a person’s total
energy expenditure, which equals energy intake when a per-
son is in energy balance.39 Urinary nitrogen excretion is used
as a biomarker of protein consumption.40 Studies using these
recovery biomarkers suggest that measurement errors from
all types of dietary assessment instruments are larger than
previously appreciated.35 38 41
‘Concentration’ biomarkers, such as blood levels of fatty
acids or vitamins, can be used to indirectly estimate dietary
intake of these compounds. However, blood levels are deter-
mined not only by a person’s intake of the compound, but
also by factors such as the compound’s bioavailability and
excretion, intakes of other dietary components, personal
characteristics such as smoking, and individual variation in
metabolism. These determinants — and therefore the rela-
tions between true intakes and the biomarkers — vary
among people, and this can bias observed diet–cancer
associations.9
For some compounds, such as selenium, biomarkers are a
more accurate indicator of dietary intakes than data from
food frequency questionnaires.42 43 Many studies examine
concentration biomarkers as indirect proxies for intake, and
there is growing interest in combining these data with results
from self-report dietary assessment instruments. 
3.3.2  Nutrition status
Nutrition status is not simply a function of dietary intake. It
includes energy and nutrient intakes, and also body nutri-
ent stores and body composition, all of which can be stud-
ied at various levels of complexity. Nutrition status cannot
be completely measured by any one method, and judging
which methods are most useful is an important aspect of the
science in this field.
Some aspects of nutrition status can be assessed relatively
accurately. These include body fatness and measurements of
weight and height at birth, during growth, and in adulthood. 
Nutrition status is affected by other biological and
behavioural factors, and also by social and environmental fac-
tors. Social factors include economic and political drivers of
food supplies, availability of food, and tradition and culture. 
3.3.3  Physical activity
Study of the effects of physical activity on health requires reli-
able and valid measurements of physical activity in whatev-
er setting it occurs — occupational, household, transport,
and recreational — and also of frequency, duration, and
intensity. Effects of physical activity are not just a function
of total overall energy expenditure. A person may expend 
the same amount of energy during a short period of intense
exercise or in a longer period of moderate activity, but 
the physiological effects may be different. Also see 
Chapter 5. 
Assessments of physical activity may use objective bio-
chemical, physiological, or other methods, but these are
expensive and not commonly used in large studies.
Epidemiological studies usually rely on self-completed ques-
tionnaires. These vary in the duration and type of physical
activity, the length and detail of the questionnaire, and how
the physical activity measures are calculated. 
As with food questionnaires, physical activity question-
naires have limitations. Activities may be over-reported when
participants overestimate their recreational activity, for
example, or under-reported, such as when participants do
not take account of everyday activities, such as walking
around their home or office. Many questionnaires ask only
about occupational activity or recreational activity, and there-
fore do not provide a comprehensive account of people’s total
physical activity.
Results from questionnaires are commonly reported in
terms of energy expenditure. This is usually done by assign-
ing an ‘energy cost’ (derived from published guides) to the
energy value of various activities, and multiplying this by the
duration and frequency of the activity. But there are large
variations in the energy values of different activities depend-
ing on age, gender, body mass, skill, and level of fitness;
these can lead to significant errors in estimates. 
3.3.4  Cancer outcomes 
In studies of food, nutrition, physical activity, and cancer,
accurate identification of cancer occurrence is as important
as making accurate measures of food and drink consumption,
and of physical activity. In most epidemiological studies, 
data from cancer registries are used, or else participants
report whether they have been diagnosed as having cancer.
Effect modification (or effect-measure modification) occurs
when a measure of effect for an exposure changes over levels
of another variable (the modifier).30 Effect modifiers can some-
times even change the direction of an effect. For example, a
pooled analysis of seven cohort studies found an association
between body fatness and decreased risk of breast cancer in pre-
menopausal women, but with increased risk in postmenopausal
women.31 In this case, menopausal status modifies the effect of
body fatness on breast cancer risk.
Box 3.6 Effect modification
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Studies may also require participants to undergo clinical
examination, or provide tissue biopsy samples. 
The duration of a study can also affect whether the full
effects of exposures are identified. Relatively short-term
prospective studies may miss any late effects on cancers. This
is one reason why results from studies with long-term fol-
low-up periods are particularly valuable. 
Population-based cancer registries collect cancer incidence
and mortality data for the areas they serve, and produce can-
cer registers. 
In the US, the Surveillance, Epidemiology, and End Results
(SEER) programme collects population-based data on newly
diagnosed cancers from registries that cover approximately
23 per cent of the US population.49 The European Network
of Cancer Registries represents population-based cancer reg-
istries in Europe.50 Population-based registries are becoming
increasingly available in middle- and low-income countries.
In total, 57 countries and 186 cancer registries are repre-
sented in Volume VIII of the Cancer Incidence in Five
Continents series published by IARC.1 Also see box 1.2.
Cancer incidence data are coded in a standardised way,
using International Classification of Disease (ICD) codes that
have been established for oncology.51 These 10-digit codes
specify the site of origin of the tumour (topography), the
tumour or cell type (morphology), the behaviour of the
tumour (malignant, benign, or in situ), and the tumour
grade or degree of differentiation. 
In addition to providing cancer incidence and mortality
statistics, cancer registries are used by researchers to identi-
fy people who are eligible to enrol in a case-control study,
or to collect information on cancer diagnosis relating to peo-
ple who are enrolled in a cohort study.
3.4  Causation and risk 
One of the Panel’s tasks has been to devise a transparent and
objective method that enables evidence of relationships
between diet, physical activity, body fatness, and associated
factors, and cancer of one or more sites, to be judged as
causal, with varying degrees of confidence. 
3.4.1  Inferring causation
The Panel endorses the view of the panel responsible for the
previous report, that causal relationships between food and
nutrition, and physical activity can be confidently inferred
when epidemiological evidence, and experimental and other
biological findings, are consistent, unbiased, strong, graded,
coherent, repeated, and plausible. Individually, none of these
factors is likely to be sufficient to infer a causal relationship
with confidence. Also, individual relationships may be defi-
cient in various respects, but collectively can still be judged
as causal because of their cumulative weight. 
Many types of evidence can contribute to causal inference.
However strong the evidence from any single study, it will
rarely justify a conclusion of causality. Increasing ‘surviv-
ability’ of an observed relationship, when supported by fur-
ther studies, or which produces corroborative evidence in
other categories, as listed above, strengthens the evidence
for a causal relationship.52 53
With regard to food and nutrition, and physical activity,
single exposures are unlikely to act alone to cause or pre-
vent cancer. In general, many factors act together as con-
tributory or component causes, forming a complete causal
process. Component causes can interact biologically, even
when exerting their effects at different times.30
One of the basic principles in controlled
human and animal feeding experiments to
evaluate the effect of a specific dietary fac-
tor is that the diets should be isocaloric
(i.e., total energy intake is the same in both
groups). This is because differences in
energy intake between two groups would
cause one group to gain or lose more
weight than the other. The effects of the
dietary factor being investigated could not
then be distinguished from the effects of
changes in weight. This is important,
because differences in weight themselves
may have different physiological effects. 
In epidemiological studies, there are sim-
ilar reasons to conduct isocaloric analyses.
These use statistical methods to ‘adjust’
intakes of the dietary factor under study
for total energy intake. The rationale for
energy-adjusted intakes is that the
absolute intake of a nutrient is a function
of two factors: first, the total amount of
food consumed, represented by total ener-
gy intake; and second, the composition of
diets. The total amount of food consumed
is determined primarily by body size and
physical activity. 
Body size and physical activity are of
interest in their own right, but their effects
need to be disentangled from the effects
of a specific nutrient. This can be done by
using energy-adjusted nutrient intakes.
Expressed another way, studies designed to
change the intake of a specific nutrient
usually should do so by changing the com-
position of diets rather than total energy
intake. Epidemiological studies therefore
should adjust for energy and not rely on
absolute intakes, which reflect both dietary
composition and variation in total energy
intake due to differences in body size and
physical activity.
The best method to adjust for total
energy intake has been a matter of con-
siderable discussion.44-48 The two basic
approaches are to use the nutrient densi-
ty (for example, expressing intake per unit
of energy or, for macronutrients, as a per-
centage of total energy) or regression
analysis to calculate nutrient residuals. In
an epidemiological analysis, the nutrient
density does not adequately adjust for
total energy intake if energy intake itself
is associated with disease risk. In this case,
total energy intake must be added as a
separate term to the model. Another
method, that of ‘energy partition’, has
been used in some studies, but this is not
an ‘isocaloric’ analysis and thus does not
control for total energy intake. 
An additional advantage of energy-
adjusted nutrient intakes is that they are
often measured with less error than
absolute nutrient intakes. This is because
over- or under-reporting of specific nutri-
ents tends to be strongly correlated with
over- or under-reporting of total energy
intake, especially for macronutrients, being
calculated from the same foods. These
errors are highly correlated, so tend to can-
cel each other when calculating nutrient
densities or energy-adjusted intakes. 
Box 3.7 Energy adjustment
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3.4.2  The ‘portfolio’ approach
Many different types of study, all of which have strengths and
weaknesses, investigate links between food, nutrition, phys-
ical activity, and cancer. Persuasive evidence comes from dif-
ferent types of epidemiological study, supported by
experimental findings that indicate a relevant biological
mechanism. 
The Panel’s judgements, presented in Part 2 of this Report,
are based on its assessment of the evidence available in the
scientific literature, with due consideration given to the
advantages and disadvantages of each type of study design,
and to the quality of individual studies. An inclusive or ‘port-
folio’ approach has been taken, recognising the relative
strengths and weaknesses of different types of study, but in
which no single type of study design is given pre-eminence.
In general, the strongest evidence comes from consistent
findings from different types of studies, preferably also in
diverse populations.
3.4.3  Quantification of risk 
Quantification of the risk of any disease is an essential basis
for public health policy planning. It also guides people in
making their own decisions about how they lead their lives.
It is not enough to know that the risk of cancer is affected
by diet. It is also important to know by how much. For exam-
ple, if consumption of alcohol increases the risk of breast can-
cer, and diets high in vegetables decrease the risk of various
cancers, to what extent may the incidence of cancer on a
population basis be affected by these factors? And on a per-
sonal level, how can people best judge how their current
diets and ways of life, and any changes they might want to
make, are likely to affect their own risk of cancer?
Quantifying risk helps to answer such questions. 
The strength of a relationship between any risk factor and
the occurrence of disease is commonly expressed in terms of
relative risk (RR). In cohort studies, this is the ratio of risk
(or incidence) of a disease among people with a particular
characteristic (say, high consumption of red meat) to that
among people without that characteristic (in this example,
low or no consumption of red meat). In case-control stud-
ies, the odds ratio is used, which is the ratio of the odds of
exposure among cases to the odds of exposure among con-
trols. Relative risks below 1.0 imply a protective effect: so a
relative risk of 0.5 for high compared with low vegetable con-
sumption implies a halving of risk. Relative risks above 1.0
indicate an increased risk. 
Absolute risk is also important. Small RR values, when
consistent, are important when the number of people affect-
ed is large. A large RR of a rare type of cancer amounts to
only a small absolute risk, which may reasonably be con-
sidered not significant, either by public health planners or
by individuals assessing their own choices. By contrast, a
small RR may amount to a large number of cases for a com-
mon type of cancer. For example, an increased risk of 10 per
cent implied by a RR of 1.10 amounts to many extra cases
of colorectal and breast cancer in Europe and North
America, where these cancers are common. Assessment 
of small RRs depends on the size and quality of the 
studies in which such risks are identified. Small RRs may
amount to strong evidence if consistently found in large, well
designed studies. 
3.5  Coming to judgement 
A crucial part of the process that has informed this Report
is the methods used by the Panel in judging whether the evi-
dence that a relationship between aspects of food, nutrition,
physical activity, and body fatness, and cancers of the sites
specified, is or may be causal. The need for evidence from
different types of study and the characteristics looked for in
such studies have been outlined already. Here, the precise
methods used by the Panel are explained. 
The previous report broke new ground in a number of
respects. One was to display panel judgements in the form
of matrices within which panel judgements on causal rela-
tionships, of different degrees of confidence, were shown,
and repeated in the text of the report. This method has been
adapted in other reports.29 Another was the specification of
criteria guiding these judgements. The previous report also
used explicit statements explaining why, on occasion, the
panel had made judgements that did not obviously derive
from the evidence as presented. One general principle was
that of transparency. Readers and users of the previous report
have been able to follow its reasoning, to challenge any
judgements that might seem questionable, and to modify 
or reinforce judgements in the light of further and better
evidence. 
The Panel responsible for this Report decided to adapt
those innovative approaches, and use them as the basis for
its work. Some of the judgements made in this Report are
different from those based on the evidence available a
decade previously, while others confirm or strengthen pre-
vious judgements. 
3.5.1  The matrix approach 
An example of a matrix used in this Report is shown in fig-
ure 3.1. This particular matrix displays the Panel’s judge-
ments on the likelihood that physical activity modifies the
risk of cancers of specified sites. This matrix is used here as
an example, to explain the nature of the matrices displayed
in all chapters in Part 2 of this Report. This matrix and its
judgements are discussed fully in Chapter 5.
The title of the matrix is self-explanatory. In this and other
cases, the introductory words are important: here, the
footnote specifies that the physical activity referred to is of
all types. 
The matrices display the Panel’s judgements on whether
particular aspects of food and nutrition, physical activity, and
body composition do or may modify (or not modify) the risk
of cancers of specific sites. The matrices are of course short-
hand, and the entries cannot convey all nuances. Necessary
clarifications and qualifications are stated in footnotes to the
matrices. 
Matrix entries themselves need to be explained. For exam-
ple, an entry ‘fruits’ or ‘foods containing dietary fibre’ in a
matrix column headed ‘decreases risk’ means that the Panel
has judged that these foods are or may be protective against
59
C H A P T E R  3  •  J U D G I N G  T H E  E V I D E N C E
the cancer specified. The judgements are derived from
analysis of studies in which relatively high intakes of (in this
example) fruits and foods containing dietary fibre are com-
pared with relatively low intakes. The same point applies to
matrix entries ‘physical activity’ and ‘body fatness’ in
columns headed ‘decreases risk’ and ‘increases risk’, respec-
tively, which are derived from analysis of studies of people
whose physical activity levels or degree of body fatness is
relatively high compared with people whose physical activ-
ity levels or degree of body fatness is relatively low. 
In some cases, analysis may show that any effect begins
or ends, or is less apparent, below or above evident ‘thresh-
olds’. For example, it has been thought that alcoholic drinks
increase the risk of some cancers only above certain levels
of consumption. Such amounts would be specified in a foot-
note to the relevant matrices, and could be reflected in Panel
recommendations. When matrices include no such foot-
notes, this is because no lower or upper threshold of effect
has been identified. In such cases, matrix entries showing
or suggesting a causal association should be taken to mean
that the effect is across the whole range of dietary intake,
amounts of physical activity, or degrees of body fatness
found in the studies analysed. The implications of the nature
of the dose-response relationships for recommendations are
further discussed in Chapter 12, in Part 3 of this Report. 
3.5.2 Levels and types of judgement 
The top half of the matrix in figure 3.1 shows that the
evidence of causality, either of decreased risk or increased 
risk, is judged to be convincing, or else probably causal. A
judgement of ‘convincing’ in turn generally justifies a recom-
mendation designed to inform policies and programmes
designed to prevent cancer. A judgement of ‘probable’ also
normally justifies a recommendation. So in the case of the
matrix shown, it follows that the Panel would make a rec-
ommendation on physical activity designed to reduce the risk
of cancer. 
The top two rows of the matrix are separated from the row
below, which shows judgements that the evidence is too lim-
ited, for a variety of reasons (see 3.5.5), to conclude that a
relationship is causal, but that there are enough data to
suggest that such a relationship might exist. Normally, a
judgement of ‘limited — suggestive’ does not justify any rec-
ommendation. The matrices used in Chapter 7 also include
a row showing judgements where the evidence is so limited
(again for a variety of reasons) that no judgement can be
made whether any association exists or not. For this reason,
such judgements of ‘limited — no conclusion’ do not indi-
cate whether the evidence is in the direction of decreasing
or increasing risk. The final, bottom row of the matrix, ‘sub-
stantial effect on risk unlikely’, shows judgements for which
the evidence, equivalent to a judgement of ‘convincing’ or
‘probable’, shows that no causal relationship is likely to exist.
Terms used in the text and matrices to refer to foods and
drinks, physical activity, body fatness, and other factors are
necessarily shorthand. Thus, in chapter 4.2, the matrix dis-
plays judgements that ‘non-starchy vegetables’ probably pro-
tect against a number of cancers. The matrix in chapter 4.8
displays judgements that the evidence that ‘alcoholic drinks’
cause a number of cancers is convincing. What is meant by
‘non-starchy vegetables’ and by ‘alcoholic drinks’ is defined
in the text of these sections.
Further, when ‘non-starchy vegetables’ is used as a matrix
entry and contained in Panel judgements, it means ‘relatively
high consumption of non-starchy vegetables and/or foods
containing them’. The same point applies to many other
matrix entries and also to the accompanying text. 
Within all matrix cells, exposures are listed in the order of
the contents of the Report. There are a number of cancer sites
where a substantial number of related exposures meet the
criteria for matrix entry. The Panel has judged that it is often
appropriate to aggregate such exposures. For example, if
both ‘alcoholic drinks’ and ‘wine’ are judged as exposures
that probably increase the risk of a type of cancer, then 
only ‘alcoholic drinks’ will appear in the matrix for that
cancer site. 
The matrices used in this Report differ from those used in
the previous report in a number of respects. The previous
report used categories of ‘possible’ and ‘insufficient’ defined
differently from the categories of ‘limited — suggestive’ and
‘limited — no conclusion’ used here. Also, the previous report
allowed for different weights of evidence for no causal rela-
tionship, whereas this Report includes just the one judge-
ment of ‘substantial effect on risk unlikely’. The judgements
of ‘convincing’ and ‘probable’, both agreed to be a sufficient
basis for recommendations, are common to both reports,
although the criteria allowing such judgements have been
refined for this Report (see 3.5.5). 
Figure 3.1 Example of a matrix
PHYSICAL ACTIVITY, AND THE RISK OF CANCER
In the judgement of the Panel, physical activity1 modifies the risk of the
following cancers. Judgements are graded according to the strength of
the evidence.
DECREASES RISK INCREASES RISK
Convincing Colon2
Probable Breast
(postmenopause)
Endometrium
Limited — Lung
suggestive Pancreas
Breast (premenopause)
Substantial 
effect on risk None identified
unlikely
1 Physical activity of all types: occupational, household, transport, 
and recreational.
2 Much of the evidence reviewed grouped colon cancer and rectal cancer 
together as ‘colorectal’ cancer. The Panel judges that the evidence is
stronger for colon than for rectum.
For an explanation of the terms used in the matrix, 
please see chapter 3.5.1, the text of this chapter, 
and the glossary.
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3.5.3  The food-based approach
Terms used in the text of this Report and in the matrices
reflect the Panel’s decision that the Report, and its judge-
ments and recommendations, should whenever possible be
based on foods and drinks rather than on nutrients. This
food- (and drink-) based approach is also apparent in the
overall structure of the Report. Chapter 4, the first chapter
in Part 2, on foods and drinks, is the longest chapter. This is
in part because dietary constituents associated with foods are
grouped with these foods. Thus, matrix entries in chapter 4.1
identify ‘foods containing dietary fibre’ (rather than dietary
fibre), and in 4.8 identify ‘alcoholic drinks’ (rather than alco-
hol or ethanol). Chapters 4, 5, and 6 also include material
presented graphically, such as the forest plots described in
box 3.3. 
The food-based approach is also justified because of the
uncertainty that any food constituent is a true causal factor,
rather than simply a marker for the particular foods in which
it is found; or for other dietary constituents found in the
same foods; or other associated health-related factors. In
chapter 4.10, some micronutrients appear in matrices grad-
ed as ‘convincing’ or ‘probable’. These judgements are
derived from the findings of good quality, randomised, con-
trolled trials, sometimes also supported by observational
studies, clearly showing that supplements of these micronu-
trients, rather than the foods containing them, affect the risk
of cancer. 
Sometimes the studies that are the basis for the Panel’s work
have used markers of exposure. Thus, many epidemiological
studies use body mass index as a marker of body fatness.
When there is clear evidence of an underlying mechanism for
body fatness, the Panel has agreed that the term ‘body fatness’
best represents the causal factor. Usually, anthropometric
indices — other examples being waist to hip ratio and waist
This box lists the criteria finally agreed by
the Panel that were necessary to support
the judgements shown in the matrices and
text of the Part 2 chapters. The grades
shown here are ‘convincing’, ‘probable’,
‘limited — suggestive’, ‘limited — no con-
clusion’, and ‘substantial effect on risk
unlikely’. In effect, the criteria define these
terms. 
Convincing
These criteria are for evidence strong
enough to support a judgement of a con-
vincing causal relationship, which justifies
goals and recommendations designed to
reduce the incidence of cancer. 
A convincing relationship should be
robust enough to be highly unlikely to be
modified in the foreseeable future as new
evidence accumulates. All of the following
were generally required:
• Evidence from more than one study type.
• Evidence from at least two independent
cohort studies.
• No substantial unexplained
heterogeneity within or between study
types or in different populations
relating to the presence or absence of
an association, or direction of effect. 
• Good quality studies to exclude with
confidence the possibility that the
observed association results from
random or systematic error, including
confounding, measurement error, and
selection bias.
• Presence of a plausible biological
gradient (‘dose response’) in the
association. Such a gradient need not
be linear or even in the same direction
across the different levels of exposure,
so long as this can be explained
plausibly.
• Strong and plausible experimental
evidence, either from human studies or
relevant animal models, that typical
human exposures can lead to relevant
cancer outcomes.
Probable 
These criteria are for evidence strong
enough to support a judgement of a prob-
able causal relationship, which would gen-
erally justify goals and recommendations
designed to reduce the incidence of cancer. 
All the following were generally
required: 
• Evidence from at least two independent
cohort studies, or at least five case-
control studies.
• No substantial unexplained
heterogeneity between or within study
types in the presence or absence of an
association, or direction of effect. 
• Good quality studies to exclude with
confidence the possibility that the
observed association results from
random or systematic error, including
confounding, measurement error, and
selection bias. 
• Evidence for biological plausibility.
Limited — suggestive 
These criteria are for evidence that is too
limited to permit a probable or convincing
causal judgement, but where there is evi-
dence suggestive of a direction of effect.
The evidence may have methodological
flaws, or be limited in amount, but shows
a generally consistent direction of effect.
This almost always does not justify recom-
mendations designed to reduce the inci-
dence of cancer. Any exceptions to this
require special explicit justification. 
All the following were generally
required:
• Evidence from at least two independent
cohort studies or at least five case-
control studies.
• The direction of effect is generally
consistent though some unexplained
heterogeneity may be present. 
• Evidence for biological plausibility.
Limited — no conclusion
Evidence is so limited that no firm conclu-
sion can be made.
This category represents an entry level,
and is intended to allow any exposure for
which there are sufficient data to warrant
Panel consideration, but where insufficient
evidence exists to permit a more definitive
grading. This does not necessarily mean a
limited quantity of evidence. A body of evi-
dence for a particular exposure might be
graded ‘limited — no conclusion’ for a
number of reasons. The evidence might be
limited by the amount of evidence in terms
of the number of studies available, by
inconsistency of direction of effect, by 
poor quality of studies (for example, lack
of adjustment for known confounders), or
by any combination of these factors.
Exposures that are graded ‘limited — no
conclusion’ do not appear in the matrices
presented in Chapters 4–6, but do appear
in Chapters 7 and 8.
When an exposure is graded ‘limited —
no conclusion’, this does not necessarily
indicate that the Panel has judged that
there is evidence of no relationship. With
Box 3.8 Criteria for grading evidence
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circumference — do not appear in the matrices. 
As exceptions to this approach, the Panel has made judge-
ments on ‘adult attained height’ and ‘greater birth weight’,
as shown in the matrices. Many epidemiological studies have
reported on height and birth weight. It is thought that asso-
ciations between height, birth weight, and cancer risk reflect
some causal association with a combination of genetic, hor-
monal, nutritional, and other factors. Uncertainty as to the
mechanisms underlying the observations with ‘adult attained
height’ and ‘birth weight’ mean that the Panel was not able
to determine the appropriate causal factors to be shown in
the matrices. Instead, the anthropometric markers have been
included, with appropriate footnotes. 
3.5.4   The basis for robust judgements 
The Panel has been particularly careful in deciding the cri-
teria for judgement on causal relationships (or lack of such
relationships). Its decisions here have been enlightened by
the rapid development since the mid-1990s of the technique
of systematic review, using search techniques enabled by the
electronic revolution. 
Since the mid-1990s, about as many studies in the field
of this Report have been published as were published in the
previous 35 years. This development has not just been one
of quantity but also of design and quality. In particular, many
cohort studies have been published in the period analysed
by the SLRs, and some of these have also been pooled. The
Panel agreed that in general, cohort studies provide more
impressive evidence than case-control and other epidemio-
logical study designs, and this decision affected the criteria
for judgement. For this reason, while the best evidence
comes from a number of different study designs, the Panel
agreed that reasonably strong and consistent evidence was
needed from studies where biases could reasonably be
further good quality research, any expo-
sure graded in this way might in the future
be shown to increase or decrease the risk
of cancer. Where there is sufficient evi-
dence to give confidence that an exposure
is unlikely to have an effect on cancer risk,
this exposure will be judged ‘substantial
effect on risk unlikely’.
There are also many exposures for which
there is such limited evidence that no
judgement is possible. In these cases, evi-
dence is recorded in the full SLR reports
contained on the CD included with this
Report. However, such evidence is usually
not included in the summaries and is not
included in the matrices in this printed
Report.
Substantial effect on risk unlikely 
Evidence is strong enough to support a
judgement that a particular food, nutri-
tion, or physical activity exposure is unlike-
ly to have a substantial causal relation to a
cancer outcome. The evidence should be
robust enough to be unlikely to be modi-
fied in the foreseeable future as new evi-
dence accumulates. 
All of the following were generally
required:
• Evidence from more than one study
type. 
• Evidence from at least two independent
cohort studies.
• Summary estimate of effect close to 
1.0 for comparison of high versus low
exposure categories. 
• No substantial unexplained
heterogeneity within or between study
types or in different populations. 
• Good quality studies to exclude, with
confidence, the possibility that the
absence of an observed association
results from random or systematic
error, including inadequate power,
imprecision or error in exposure
measurement, inadequate range of
exposure, confounding, and selection
bias.
• Absence of a demonstrable biological
gradient (‘dose response’). 
• Absence of strong and plausible
experimental evidence, either from
human studies or relevant animal
models, that typical human exposures
lead to relevant cancer outcomes.
Factors that might misleadingly imply an
absence of effect include imprecision of
the exposure assessment, an insufficient
range of exposure in the study population,
and inadequate statistical power. Defects
in these and other study design attributes
might lead to a false conclusion of no
effect.
The presence of a plausible, relevant
biological mechanism does not necessarily
rule out a judgement of ‘substantial effect
on risk unlikely’. But the presence of
robust evidence from appropriate animal
models or in humans that a specific mech-
anism exists, or that typical exposures can
lead to cancer outcomes, argues against
such a judgement. 
Because of the uncertainty inherent in
concluding that an exposure has no effect
on risk, the criteria used to judge an expo-
sure ‘substantial effect on risk unlikely’ are
roughly equivalent to the criteria used
with at least a ‘probable’ level of confi-
dence. Conclusions of ‘substantial effect 
on risk unlikely’ with a lower confidence
than this would not be helpful, and could
overlap with judgements of ‘limited — sug-
gestive’ or ‘limited — no conclusion’. 
Special upgrading factors 
These are factors that form part of the
assessment of the evidence that, when pre-
sent, can upgrade the judgement reached.
So an exposure that might be deemed a
‘limited — suggestive’ causal factor in the
absence, say, of a biological gradient,
might be upgraded to ‘probable’ in its
presence. The application of these factors
(listed below) requires judgement, and the
way in which these judgements affect the
final conclusion in the matrix are stated.
• Presence of a plausible biological
gradient (‘dose response’) in the
association. Such a gradient need not
be linear or even in the same direction
across the different levels of exposure,
so long as this can be explained
plausibly.
• A particularly large summary effect size
(an odds ratio or relative risk of 2.0 or
more, depending on the unit of
exposure) after appropriate control for
confounders.
• Evidence from randomised trials in
humans.
• Evidence from appropriately controlled
experiments demonstrating one or
more plausible and specific mechanisms
actually operating in humans.
• Robust and reproducible evidence from
experimental studies in appropriate
animal models showing that typical
human exposures can lead to relevant
cancer outcomes. 
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excluded. Usually this evidence came from cohort studies
with a prospective design or, where available and appropri-
ate, from randomised controlled trials, to allow a judgement
of ‘convincing’ or ‘probable’. This was not a requirement spec-
ified for the previous report. See box 3.8.
A consequence is that the same amount of evidence for any
particular association has sometimes led to a different judge-
ment and level of matrix entry from the previous report.
Sometimes, in cases where there is a greater quantity of evi-
dence, this might not lead to a ‘higher’ classification, and
could even possibly lead to a ‘lower’ one. These refinements
are intended to give as robust an assessment as possible,
given current understanding. In these respects, the criteria
used by the Panel are more stringent than those pioneered
by the previous panel. 
The Panel agreed that the criteria for their judgements
should be detailed and precise. But such criteria do not 
lead to automatic judgements. However meticulous, they
cannot replace expert judgement. If a reviewer or a Panel
member felt that important considerations had been over-
looked by the overall agreed process, this was discussed, 
and the Panel’s final judgement specified, with reasons 
provided. 
3.5.5  The grading criteria
Specification of criteria for the grading of judgements
enables a common, transparent approach. But as indicated,
any such criteria cannot fully capture the sophistication and
nuances of all the studies considered, or the nature and qual-
ity of different studies. 
In using the criteria specified here, the Panel has taken into
account additional factors including, but not confined to, the
type, number, and size of studies; their design and execu-
tion; the nature of any intervention; the definition of cases
and non-cases; the selection of any comparison group; meth-
ods of characterising exposure and outcome; length and
completeness of follow-up; and the methods used to ascer-
tain cases.
Other factors might lead to one or another grading. Failure
to achieve a higher grade might result from several small
deficits against a number of standards, or from a major short-
fall in one particular aspect of evidence. Panel expertise was
essential in judging whether criteria were met, or ‘upgrad-
ing factors’ (box 3.8) were applicable, as well as deciding
what constituted substantial heterogeneity, high-quality
study design, and so on. The criteria provide a consistent
basis for judgement, not a ‘set of boxes to be ticked’. As well
as these ‘upgrading factors’, particular reasons why any spe-
cific judgement was reached are presented under the rele-
vant exposure and cancer site in Chapters 4–7. 
The following grading criteria specify the quantity, quali-
ty, and nature of evidence that can lead to associations being
graded differently. 
Convincing, probable
In considering the criteria allowing a judgement that the evi-
dence of a causal relationship was convincing, or that the 
evidence showed a probable causal relationship, the Panel
was conscious that both judgements were liable to generate
public health goals and personal recommendations. 
Limited and ‘below’ 
For the two types of ‘limited’ judgement, the evidence falls
short of a ‘higher’ judgement for a variety of reasons. There
are also many exposures for which evidence was so limited
that it did not warrant detailed consideration. In these cases,
evidence is recorded in the full SLR reports contained on the
CD included with this Report. However, this evidence is not
included in the summaries or matrices in this printed Report. 
Absence of a causal relation
The strength of this judgement corresponds to that for ‘con-
vincing’ or ‘probable’ (and replaces the previous report’s ‘no
relationship’ category). This judgement does not reflect the
absence of evidence, which in itself is not evidence of
absence of effect. As with judgements of ‘convincing’ or
‘probable’, evidence from both observational studies and ran-
domised trials contribute to such an inference. 
3.6  Conclusions 
Reports such as this address issues of public importance.
They are informed by a process of collection, display, dis-
cussion, and judgement of evidence as the basis for recom-
mendations made in the public interest. 
We, the members of the Panel responsible for this Report,
have had the responsibility to ensure that the judgements we
have made in Part 2, and the public health goals and per-
sonal recommendations we have specified in Part 3, are
clearly and reliably based on current evidence. 
In the five years of our work, we have built on the work of
the previous report, and have been supported by the findings
of a preliminary Methodology Task Force; by the evidence
gathered and presented by independent SLR centres; by
observers from United Nations and other international organ-
isations; and by the Report’s Secretariat. As far as we know,
the whole process, which has also included eight face-to-face
Panel meetings, each lasting up to four days, is the most com-
prehensive and rigorous of its kind yet undertaken.
As this chapter shows, no method used to ascertain causal
relationships between food, nutrition, physical activity, and
cancer is perfect. But we believe that the integrated and
sometimes innovative approaches we have taken, sum-
marised here, have enabled us to make sound judgements
and reliable recommendations. We have also done our best
to make sure that the methods we have used are explained
and displayed transparently, so they can be readily accessed
and challenged as science develops, or from different points
of view. We believe this best serves science, and also the
cause of cancer prevention.  
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The brief of the Panel, and of the systematic literature review teams that
provided the basis for the Panel’s work, has included the task of presenting a
clear, strong, and reliable foundation for the final recommendations. These in
turn form the basis of sound policies and effective programmes to reduce the
rates of cancer in populations, and the risk of cancer in people, whether as
members of communities, or as families, or as individuals.
In this central part of the Report, seven chapters display the findings of the
independently assembled systematic literature reviews, and the judgements of
the Panel derived from these reviews and other evidence as needed. The Panel’s
judgements are displayed in the form of matrices that introduce five of these
chapters. Judgements of ‘convincing’ and ‘probable’ causal relationships,
shown in the top part of these matrices, are the basis for recommendations
made in Part 3 of the Report. 
Chapter 4, the first and longest chapter that follows, is concerned with types of
food and drink. The judgements of the Panel are generally food- and drink-
based, reflecting the evidence. Findings on dietary constituents and
micronutrients are identified as, for example, on ‘foods containing dietary
fibre’ or ‘foods containing folate’. For consistency, findings on methods of food
processing are, where possible, shown as part of the whole evidence on the
associated foods so that, for example, the processing and preparation of meat
is integrated with the evidence on meat. Evidence specifically on dietary
supplements and on patterns of diet is included in the two final sections of this
chapter. 
Chapters 5 and 6 are concerned with physical activity, and with body
composition, growth, and development. Evidence in these areas is more
impressive than was the case up to the mid-1990s; the evidence on growth and
development indicates the importance of a whole life-course approach to the
prevention of cancer. As with the chapter on foods and drinks, these chapters
include detailed summaries of the evidence collected in the systematic
literature reviews together with graphic representations of the most significant
evidence. 
Chapter 7 summarises and judges the evidence as applied to 17 cancer sites,
with briefer summaries based on narrative reviews on cancers of five other
body systems and sites. The judgements as shown in the matrices in this
chapter correspond with the judgements shown in the matrices in the previous
chapters. 
Chapter 8, in which judgements are also based on the evidence from the
systematic literature reviews amplified by knowledge of physiological
processes, concerns the biological and associated determinants of weight gain,
overweight, and obesity. Before work on this chapter began, the Panel agreed
that a comprehensive review of the evidence would be likely to show that
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obesity is or may be a cause of a number of cancers. It was therefore important
to identify what aspects of food, nutrition, and physical activity themselves
affect the risk of obesity and associated factors. 
Improved screening, diagnosis, and medical services, including therapy and
surgery, are in many countries improving the rates of survival for people with
cancer. The number of cancer survivors — people living after diagnosis of cancer
— is therefore increasing. The relevance of food, nutrition, physical activity, and
body composition to people living with cancer, and to the prevention of
recurrent cancer, is summarised in Chapter 9. 
The Panel agreed that its final recommendations should be principally based on
the evidence concerning cancer, and also should take into account findings on
food, nutrition, physical activity, and the prevention of other chronic diseases,
and of nutritional deficiencies and nutrition-related infectious diseases,
especially of childhood. Chapter 10, which is also based on a systematic
literature review, is a summary of the findings of expert reports in these areas.  
The proposals for further research contained in Chapter 11 are, in the view of
the Panel, the most promising avenues to explore in order to refine
understanding of the links between food, nutrition, physical activity, and
cancer, and so improve the prevention of cancer, worldwide. 
As expected, a comprehensive assessment of all relevant types of evidence
relating to food, nutrition, physical activity, body composition, and the risk of
cancer has proved to be a massive task. The Panel was impressed not only by
the quantity but also the quality of much of the evidence, and the degree to
which a great deal of the evidence was consistent. As a result,
recommendations designed to prevent cancer in general can be made with
confidence. These are contained in Part 3. 
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This chapter, with the following chapters in Part
Two, forms the basis for the population goals and
personal recommendations in Part Three.
The Panel decided that the evidence on food,
nutrition, and cancer is generally most persuasive
for foods rather than for specific nutrients or other
food constituents; and that the evidence from
epidemiological and experimental studies in this
field, usually undertaken to address questions
about cancers of specific or related sites, is most
usefully synthesised in terms of foods and drinks. 
The detailed evidence on foods and drinks is
presented in this chapter, and that on physical
activity and on body composition in the following
two chapters. These three chapters include
summaries of the evidence, including meta-analyses
presented in graphic form, as well as the Panel’s
judgements. Chapter 7 presents the evidence on
cancer sites in more summarised form. 
In this chapter, whenever possible and
appropriate, the evidence on dietary constituents,
and on food production, preservation, processing,
and preparation (including cooking), is integrated
with the evidence on foods and drinks. So here, for
example, the evidence on carotenoids is considered
together with the evidence on vegetables and
fruits; the evidence on methods of cooking meats is
considered with the evidence on red meat and on
processed meats; and the evidence on ethanol is
considered with alcoholic drinks. 
The result is not perfect. There is no single, ideal
way of categorising the evidence on food and
nutrition. But an approach emphasising foods and
drinks is consistent with the generally accepted
view that food-based dietary guidelines and
recommendations are particularly valuable as a
foundation for policies designed to improve public
health. 
The first two sections of this chapter summarise
and judge the evidence on plant foods; the next
two sections that on animal foods; and the
following two sections that on fats and oils, and
sugars and salt. The next two sections concern
drinks, the second of which covers alcoholic drinks.
These are followed by sections concerned with
those aspects of dietary constituents, and with food
production, preservation, processing, and
preparation (including cooking), that have not been
incorporated in previous sections. The final section
summarises evidence on dietary patterns, including
being breastfed.
The pattern that emerges, though different in
some important respects, is largely similar to that
based on the evidence gathered in the mid-1990s,
although the confidence with which various
exposures are judged to cause or protect from
cancer has sometimes changed. 
Foods and drinks
C H A P T E R  4
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These starchy plant foods have been the staple sources of
dietary energy and bulk for humans since the
development of settled communities and agriculture. They
have to be prepared in some way to make them edible. In
whole or relatively unprocessed forms, they are also
sources of dietary fibre and various micronutrients.
Cereals in whole form contain essential fats. When the
outer layers of these foods are removed and they are
refined, most of what remains is starch and protein. 
In general, with industrialisation and urbanisation,
consumption of these foods decreases, and more is
consumed in the form of cereal products, which are
typically more energy-dense and which may contain
substantial amounts of fat, sugar, or salt. Pure starch from
these foods is also used as an ingredient in many
processed foods. Wheat, rice, maize (corn), and potatoes
and their products are now the main cereals and
roots/tubers produced and consumed globally.
Overall, the Panel judges that evidence indicating that
cereals (grains), roots, tubers, or plantains affect the risk
of any cancer, remains insubstantial. 
The Panel judges as follows: 
Foods containing dietary fibre probably protect against
colorectal cancer; and there is limited evidence
suggesting that such foods protect against oesophageal
cancer. Dietary fibre is found in plant foods: vegetables,
fruits, and pulses (legumes) (see chapter 4.2), as well as
in cereals, roots, tubers, and plantains. All these foods are
highest in dietary fibre when in whole or minimally
processed form. 
Foods high in dietary fibre may have a protective effect
because of being bulky and relatively low in energy
density. See chapters 6.1, 7.3, 7.9, and Chapter 8 for
discussion of the role of energy density in weight gain,
overweight, and obesity, and of weight gain, overweight,
and obesity in the risk of some cancers, including those of
the oesophagus and colorectum. 
The Panel also judges that the evidence that foods
contaminated with aflatoxins are a cause of liver cancer is
convincing. Cereals (grains) and peanuts (see chapter
4.2) are the foods most commonly infested by these
fungal toxins. Contamination is most widespread in
CEREALS (GRAINS), STARCHY ROOTS AND TUBERS, PLANTAINS, AND THE RISK OF CANCER
In the judgement of the Panel, the factors listed below modify the risk of cancer. Judgements are graded according to the strength of the evidence.
DECREASES RISK INCREASES RISK
Exposure Cancer site Exposure Cancer site
Convincing Aflatoxins1 Liver
Probable Foods containing Colorectum
dietary fibre2
Limited — Foods containing Oesophagus 
suggestive dietary fibre2
Substantial 
effect on risk None identified
unlikely
1 Foods that may be contaminated with aflatoxins include cereals (grains), and also pulses (legumes), seeds, nuts, and some vegetables and fruits (see chapter 4.2). 
2 Includes both foods naturally containing the constituent and foods which have the constituent added (see chapter 3.5.3). Dietary fibre is contained in plant foods
(see chapter 4.2 and box 4.1.2).
For an explanation of all the terms used in the matrix, please see chapter 3.5.1, the text of this section, and the glossary.
4.1  Cereals (grains), roots, tubers,
and plantains
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countries with hot, damp climates and poor storage
facilities. 
Within the remit of this Report, the strongest evidence,
corresponding to judgements of ‘convincing’ and
‘probable’, shows that foods containing dietary fibre
probably protect against colorectal cancer; and that foods
contaminated with aflatoxins are a convincing cause of
liver cancer. Also see chapter 4.2 for judgements of
probable protective effects of foods containing various
micronutrients also found in cereals, roots, and tubers,
particularly when relatively unprocessed. 
Cereals (grains) are the staple foods in large parts of the world,
supplying most of the energy and bulk in diets. In some regions,
roots, tubers, or plantains are staple foods as well as or instead
of cereals (grains). These generalisations apply to practically
all settled rural and most urban populations. Monotonous
‘poverty diets’ containing very high levels of these foods, par-
ticularly if refined, are low and sometimes inadequate in pro-
tein and other nutrients. Gatherer–hunter and pastoral
communities usually consume less of these starchy foods. Their
nutrient content is variable, largely depending on the degree
to which they are refined. 
Consumption of cereals, roots, and tubers in general gradu-
ally drops with industrialisation and urbanisation, and an
increasing amount of wheat in particular is grown for animal
feed. These foods are increasingly used as a basis for or ingre-
dients in processed products that are often energy-dense, 
high in fats or sugars, and sometimes salt. In lower-income
countries, total population consumption of these foods 
may amount to 60–80 per cent of total energy, and in high-
income countries, usually to less than 30 per cent. Also see
Chapter 1. 
Early reports concerned with nutritional deficiencies gen-
erally did not pay much attention to these foods and instead
gave priority to energy- and nutrient-dense foods of animal
origin, such as milk, eggs, and meat. Beginning in the 1970s,
interest in dietary fibre increased, following informal epi-
demiological findings that diets high in dietary fibre were
associated with a lower risk of a number of chronic diseases.1
2 By the 1990s, it was generally agreed that diets relatively
high in cereals (grains) and other starchy staple foods, prefer-
ably relatively unrefined, protect against obesity, type 2 dia-
betes, coronary heart disease, and perhaps also digestive
disorders.3 4 Evidence that such diets protect against cancer
of any site has been less impressive, but epidemiological
studies tend not to distinguish between degrees of refine-
ment of cereals, roots, and tubers.
This section (4.1) includes cereal products and dietary
fibre. It also includes contamination by aflatoxins, though
this may also affect other plant foods (also see chapter 4.2).
Non-starchy root vegetables such as carrots are included in
chapter 4.2. Micronutrients found in plant foods are includ-
ed in chapter 4.2, though most of these are also found in
cereals (grains), roots, tubers, and plantains.
4.1.1  Definitions, sources
Cereals (grains)
Cereals (grains) are the seeds and energy stores of cultivat-
ed grasses. The main types are wheat, rice, maize (corn),
millet, sorghum, barley, oats, and rye. In some countries,
‘cereal’ is also a term for dry foods made from grains and
other ingredients, often eaten with milk for breakfast. 
Roots, tubers, plantains
Roots and tubers are energy stores of plants. Names and def-
initions can vary around the world — potatoes are tubers,
which are the tips of underground stems that swell with
starch (a polysaccharide) and water. While potatoes are
often classed as vegetables (in the USA, for instance), they
are grouped separately from non-starchy vegetables in this
Report. Sweet potatoes, sometimes called ‘yams’ in North
America, are a type of storage root rather than a tuber, but
true yams are starchy tubers. Cassava (manioc) and yucca
are elongated roots, and sago is a starchy food made from
the pith of some types of palm tree. Taro is cultivated for its
edible leaves, as well as its starchy corm, which is similar to
a tuber. Plantains are one of several fruits used as vegeta-
bles: they grow on trees and look like bananas, but only a
small proportion of the starch is converted to sugar during
the ripening process, which makes them similar to potatoes
to cook with.
Many of the cereals (grains) that we consume are refined. Grains
are first broken into pieces and then refined, sifting away the
bran, germ and, usually, the aleurone layer. This removes most
of the fibre, oil, and B vitamins, as well as approximately 25 per
cent of the protein. Polishing, as often performed on rice,
removes additional nutrients. Many high-income countries
therefore fortify refined cereals, including flour, with B vitamins
and iron. Wholegrain products generally contain the con-
stituents of the grain but, given the absence of an internation-
ally accepted definition, intact grains are present to a variable
extent. The extent to which the grain remains intact influences
physiological processes in the bowel and hence health.
Cereal foods may be eaten in wholegrain form, although con-
sumption in refined forms, such as white rice, bread, or pasta,
is generally much more common, particularly in high-income
countries. Refined grains are considered easier than wholegrains
to cook and to chew; are light in colour — which is attractive
to many consumers; and also have a longer shelf-life than
wholegrain products, as the oil in bran goes rancid relatively
quickly.
Breakfast cereals, particularly in the United States and parts
of Europe, also account for a significant proportion of grain
eaten. Many breakfast cereals, although based on grains
(whole or refined), may contain substantial amounts of added
sugars. Grains are further processed to provide ingredients such
as corn syrup, starch, or alcohol. They also form the basis of
many animal feeds.
Processed grains have a higher glycaemic index than
unprocessed grains and, generally, the greater the degree of
processing, the greater the glycaemic index (box 4.1.3).
Box 4.1.1 Wholegrain and refined
cereals and their products
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The concept of dietary fibre arose from observations of the low
prevalence of colon cancer, diabetes, and coronary heart disease
in parts of Africa amongst people whose diets were high in
unrefined carbohydrates and whose stools were typically bulky,
and often or sometimes semisolid. Considerable efforts have
been dedicated to characterising the dietary components of
what has come to be called dietary fibre that might confer
health benefit. Naturally occurring dietary fibre is only derived
from plant foods. Pulses (legumes) and minimally processed
cereals are particularly concentrated sources, but vegetables and
fruits also contain significant amounts. Dietary fibre isolated
from plant cell walls and in synthetic forms are increasingly
entering the food supply.
High intakes of dietary fibre, variously defined, have been
associated with reduced risk of cardiovascular disease as well as
of some cancers. Definitions of dietary fibre vary. Some are
based on chemical analyses of the components of plant cell
walls, such as non-starch polysaccharide, others on physiologi-
cal effects — the carbohydrates that enter the large bowel hav-
ing escaped digestion in the small intestine being defined as
dietary fibre. The latter definition includes oligosaccharides and
resistant starch. The World Health Organization and Food and
Agriculture Organization have recently proposed that only poly-
saccharides which form part of plant cell walls should be regard-
ed as dietary fibre and that the health benefits of resistant
starch and oligosaccharides are more appropriately considered
separately.
Box 4.1.2 Foods containing dietary fibre
The degree to which different foods and meals raise blood glu-
cose depends not only on the nature of the carbohydrate, but
also on the characteristics of the foods consumed. Glycaemic
index (GI) is a measure of the degree to which a food raises
blood glucose compared with a standard food (usually glucose
or white bread) under standard conditions. The test food must
contain the same amount of available carbohydrate (usually 50
grams) as the standard. GI was originally used as an aid to food
choice in diabetes and has more recently been applied to peo-
ple without diabetes. The rise in blood glucose after consuming
a food depends not only on the GI but also on the amount of
food eaten. A related measure, glycaemic load (GL), takes into
account both the GI of a food as well as the actual amount of
carbohydrate consumed. The GL of a food may be measured
directly or calculated by multiplying the GI of a food by the num-
ber of carbohydrate grams in a serving of the food.
Factors that influence the GI of a food include the type of car-
bohydrate, how the food is processed or cooked, and the other
components present in the food (for example, fat, protein,
fibre). There is some relationship (inverse) between GI and fibre
content, although some foods high in fibre have a high GI and
vice versa. Factors can affect GI by influencing speed of absorp-
tion, for instance higher fat foods tend to have a low GI. The
calculated GI of a mixed meal or whole diet has been shown in
some studies to correlate with the actual GI obtained by feed-
ing a mixed meal. Although the concept of GI has been contro-
versial, the GI and GL of diets have predicted risks of type 2
diabetes and coronary heart disease and related biomarkers,
independent of dietary fibre, in prospective epidemiological
studies, suggesting that GI and GL may be useful markers.
The relevance to cancer might lie in the fact that the rise in
blood glucose after a meal is closely linked to that of insulin,
which apart from its crucial role in carbohydrate and lipid
metabolism, is also one of a family of important growth factors
(also see Chapter 2).
Box 4.1.3 Glycaemic index and load
This section refers to starchy roots, tubers, and plantains.
Carrots, beets, parsnips, turnips, and swedes are non-starchy
roots, and are classified as non-starchy vegetables in this
Report. Also see chapter 4.2. 
4.1.2  Composition
Cereals (grains)
The relative amounts of dietary constituents in cereals and
cereal foods depend largely on the degree of refinement and
other forms of processing (box 4.1.1). Starch makes up
about 70 per cent of the raw weight of the storage tissues
(endosperm) of unprocessed cereal grains. The outer parts
of the grain (the bran and the aleurone layer) contain non-
starch polysaccharide, a type of carbohydrate that charac-
terises dietary fibre (box 4.1.2). 
Cereals also contain variable amounts of protein, oils, B
vitamins, vitamin E and tocotrienols, iron, and various trace
elements, as well as phytochemicals, some of which, such
as the antioxidants, are bioactive (box 4.1.2). The germ is
the embryonic part of cereal plants and contains oils, pro-
teins, and fibre. Various cereals contain other specific com-
ponents. Wheat contains gluten (a mixture of proteins). Rye
has high levels of pentosans and oats contain beta-glucans,
both of which are non-starch polysaccharides, a character-
ising feature of dietary fibre. 
Cereals (grains) and pulses (legumes) may be contami-
nated with aflatoxins. See box 4.1.4. 
Roots, tubers, and plantains
Roots and tubers are less concentrated stores of starch,
although this accounts for almost all of their raw weight
apart from water. Starch content varies from around 15–20
per cent in sweet potatoes to 25–30 per cent in cassava and
yams, which translates into around 80–95 per cent of the
dietary energy of these roots and tubers. Cooking sweet
potatoes makes them taste sweet because an enzyme con-
verts as much as 75 per cent of the starch into maltose (a
disaccharide). Roots and tubers eaten with the skin on are
high in dietary fibre. These foods are generally poor sources
of protein, so although protein deficiency is uncommon,
populations that subsist on these foods, and do not eat pro-
tein-rich pulses (legumes), are at risk of deficiency, especially
children weaned on thin gruels made with these low-protein
foods. They contain variable amounts of other nutrients.
Potatoes contain vitamin C, for example, and the orange
varieties of sweet potatoes contain carotenoids. Yams con-
tain many bioactive compounds and taro corms are high in
vitamin B6, fibre, and manganese.
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4.1.3  Consumption patterns
Cereals and grains
As societies moved to more settled, agricultural ways of life
10–15 000 years ago, cereals became the main staple foods;
the types of cereal crops grown depended largely on climate
and terrain. Wheat, barley, oats, and rye are traditionally sta-
ple foods for people living in the Middle East and Europe;
and with rice in Asia; maize (corn) in the Americas; and
sorghum and millet in Africa. But the market for cereals and
their products is now global, although some, such as
sorghum, remain largely regional. 
The importance of starchy staples in food systems and
diets is broadly connected to economic and industrial devel-
opment. Both in higher-income countries and across the
world, there has been a long-term decline in their con-
sumption. With increasing urbanisation in lower-income
countries, wheat and maize are replacing traditional staple
foods. An important exception is Asia, where rice remains the
staple grain. Cereal cultivation and consumption tends to be
highest in most of Asia and lowest in Oceania, parts of
Europe, and North America.
Globally, cereal foods provide more than 45 per cent of
dietary energy; diets based on these foods tend to be bulky
with a low energy density (see chapter 8.8.4). Cereals pro-
vide more than 50 per cent of dietary energy in low-income
countries, but only around 30 per cent in high-income coun-
tries. While grains contribute roughly 20 per cent of dietary
energy in Australia, North America, and central Europe, they
can provide as much as 70 per cent in parts of Asia (main-
ly from rice). Although more wheat is grown than rice on a
global basis, much of it is used for animal feed. Rice is the
principal food for half of the world’s population.
Cereals are very versatile once they have been processed
from the raw grain. Wheat is mainly milled to make flour
for bread, pastries, cakes, and pasta. Maize (corn) is a sta-
ple food in Latin America and parts of Asia and Africa, where
it is used to make grits, cornmeal (used for polenta as well
as corn breads), corn flour, tortillas, tamales, and corn chips.
It is also the basis of corn starch (a thickener), corn syrup
(a sweetner), and corn oils. Sweetcorn is also eaten as a veg-
etable, either on or off the cob. Rice is usually processed to
remove the bran and aleurone layers, turning ‘brown rice’
into ‘white’. It is also used to make flour (the basis for gluten-
free breads), rice powder, noodles, rice paper, rice milk,
Japanese mochi, and lao-chao (Chinese fermented rice).
Barley is used primarily in Asia (tsampa and miso soya paste)
and in North Africa (soups, porridges, and flat breads).
Whole rye grains are milled and used to make bread in some
north and east European countries. Whole oats are made 
into porridges and used in muesli and baked goods, such 
as biscuits. Fonio, millet, sorghum, teff, and triticale are
traditional crops and staples in parts of Africa and Asia.
Many grains are also fermented to make alcoholic drinks (see
chapter 4.8.1).
Roots, tubers, and plantains
Roots, tubers, and plantains are staple foods in some parts
of the world. For instance, populations in some regions 
of sub-Saharan Africa, Latin America, and Oceania base 
their diets on these foods. Globally, starchy roots provide
around 5 per cent of dietary energy. Consumption is high-
est in the Pacific islands and parts of Africa, with cassava and
yams providing more than 40 per cent of dietary energy in
Ghana. Potatoes can provide as much as 10 per cent of
dietary energy in North America and Europe. Globally, plan-
tains provide less than 0.5 per cent of dietary energy, but
they are locally important in some African, Latin American,
and Caribbean countries, where they can provide more than
15 per cent of dietary energy. Some populations do not rely
on any of these foods — for instance, pastoralist societies
such as the Maasai hunters in East Africa, and the Inuit and
other Arctic populations, maintain their traditional ways of
life and diets.
Mycotoxins are toxins produced by certain
moulds or fungi. Although moulds that
contaminate foods are usually destroyed
by cooking temperatures, the toxins they
produce may remain. Aflatoxins are one
type of mycotoxin. All naturally occurring
aflatoxins are classified as human carcino-
gens (group 1) by the International Agency
for Research on Cancer;  other mycotoxins,
such as fumonisins, are suspected carcino-
gens.5 It is common to find co-contamina-
tion by more than one species of myco-
toxin-producing fungus. In Europe, the
Joint FAO/WHO Expert Committee on Food
Additives and Contaminants recommends
that aflatoxin concentrations in foods be
kept as low as possible.6
The main foods that may be contami-
nated by aflatoxins are all types of cereal
(grain), including wheat, rice, maize (corn),
barley, and oats; and pulses (legumes) —
notably peanuts. Nuts and seeds may also
be contaminated. Feedstuffs for farm ani-
mals may also be contaminated with afla-
toxins, which can then be secreted in milk
or accumulated in tissues.
Aflatoxins, which are produced by
Aspergillus flavus and A. parasiticus, are
most problematic in countries with hot,
damp climates and poor storage facilities.
Under these conditions, foods may become
contaminated with fungi and then accu-
mulate such toxins. Such foods are mar-
keted and consumed in the countries in
which they are produced; they are also
exported to neighbouring countries and
intercontinentally. Aflatoxin contamina-
tion is therefore a international issue. 
Levels of aflatoxin contamination tend
to be highest in countries where rates of
liver cancer are high, such as some African
countries and South-East Asia, including
China. In general, rates are low in Europe,
but relatively high rates of contamination
have on occasion been found in the USA. 
Aflatoxin exposure levels are low in
Europe and Australia, higher in the USA,
and high in many low-income countries.
This is particularly the case in tropical and
subtropical regions where grains and nuts
are stored for long periods under non-ideal
conditions. 
Rates are reduced by inspection, use of
fungicides, and screening of imported
foods. However, monitoring of levels of
aflatoxin contamination in low-income
countries is generally lacking. 
Box 4.1.4 Aflatoxins
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Dietary fibre
Dietary fibre intake, measured as non-starch polysaccharides,
varies from 10–13 grams (g)/day in Japan and the UK to
15–20 g/day or more in Africa and India. Intake among indi-
viduals in a population may vary between 7 and 25 g/day.7
4.1.4  Interpretation of the evidence
Interpretation of the evidence on any and all foods and
drinks, their constituents, their methods of production,
preservation, processing and preparation, and other factors,
with the risk of cancer, is never simple, for general and spe-
cific reasons. 
4.1.4.1  General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6, and 3.7.
‘Relative risk’ (RR) is used in this Report to denote ratio
measures of effect, including ‘risk ratios’, ‘rate ratios’, ‘haz-
ard ratios’, and ‘odds ratios’.
4.1.4.2  Specific 
Some considerations specific to cereals (grains), roots,
tubers, and plantains are as follows. 
Classification. ‘Cereals’ is a broad classification. Different
cereals have different nutritional composition and biological
effects, as do different types of dietary fibre. Any effects 
of specific cereals or their constituents may not become
apparent. 
Patterns and ranges of intake. Little evidence relates to roots,
or  tubers other than potatoes, or plantains, some of which,
such as cassava (manioc) or yams, are staple foods in some
parts of the world. 
Terminology. Potatoes are usually (as here) defined as tubers,
but are sometimes (in the USA especially) included with veg-
etables. Bananas, a significant item in many diets, may be
(as here) defined as a fruit, or else with plantains as a starchy
food. There is no internationally agreed definition for dietary
fibre (box 4.1.1). 
Measurement. Non-starch polysaccharides are measured pre-
cisely by the Englyst method,8 but there are fewer epidemi-
ological data on non-starch polysaccharides specifically than
for dietary fibre. The various analytical techniques used to
assess the fibre content of foods give widely different results. 
Confounding. In high-income countries, high intakes of
wholegrain cereal products tend to go together with other
health-conscious dietary and other habits. Also there is pos-
sible confounding between dietary fibre and other dietary
constituents and in general with ‘healthier’ dietary patterns
and ways of life. Data on dietary fibre come predominantly
from dietary sources, that is, plant-based foods (also see box
4.1.1 and chapter 4.2); therefore, no effect can be attributed
to different types and sources of dietary fibre. 
Production, preservation, processing, preparation. Few stud-
ies distinguish between unrefined and refined cereals and
their products. Many processed foods grouped as cereal
products, such as ready-to-eat breakfast cereals, are high in
added sugars and sometimes salt. The ways in which cere-
als are processed, prepared, and consumed varies greatly in
different cultures.
4.1.5  Evidence and judgements
The full systematic literature review (SLR) is contained on
the CD included with this Report.
4.1.5.1 Cereals (grains)
The evidence was too limited in amount, consistency, or
quality to draw any conclusions.
4.1.5.2 Roots, tubers, and plantains 
The evidence was too limited in amount, consistency, or
quality to draw any conclusions.
4.1.5.3 Foods containing dietary fibre 
Colorectum
Sixteen cohort studies9-37 and 91 case-control studies inves-
tigated dietary fibre and colorectal cancer. The Harvard pool-
ing project also analysed original data from 13 separate
cohort studies.38
An association was apparent from many, though not all,
cohort studies. Ten studies showed decreased risk when com-
paring high with low intake groups,14 19 21 25-29 33 34 which was
statistically significant in one (figure 4.1.1).28 Two reported
non-significant increased risk,36 39 one showed no effect on
risk,30 and one reported no association.18 One study report-
ed non-significant decreased risk in women and non-
significant increased risk in men23; one study reported
non-significant increased risk in women and non-significant
decreased risk in men.37 Meta-analysis was possible on eight
studies, giving a summary effect estimate of 0.90 (95% con-
fidence interval (CI) 0.84–0.97) per 10 g/day increment,
with moderate heterogeneity (figure 4.1.2). A dose-response
relationship was apparent from cohort data.
Because of the abundant prospective data from cohort
studies, case-control studies were not summarised. 
The Harvard pooled analysis from 13 prospective cohort
studies (725 628 participants, followed up for 6 to 20 years,
8081 colorectal cancer cases) gave a significant inverse asso-
ciation in the age-adjusted model (0.84, 95% CI
0.77–0.92).38 However, the association was attenuated 
and no longer statistically significant after adjusting for 
other risk factors (0.94, 95% CI 0.86–1.03). One compari-
son group was statistically significant when maximally
adjusted, others were not. Compared with dietary fibre
intake of 10 to < 15 g/day, the pooled effect estimate was
1.18 (95% CI 1.05–1.31) for less than 10 g/day (low com-
pared with moderate intake). All other measures were not
associated with risk of colorectal cancer. The pooled analy-
sis therefore found that, after accounting for other dietary
risk factors, high dietary fibre intake was not associated 
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with a reduced risk of colorectal cancer. 
Fibre exerts several effects in the gastrointestinal tract but
the precise mechanisms for its probable protective role are
not clearly understood. Fibre dilutes faecal contents, decreas-
es transit time, and increases stool weight.40 Fermentation
products, especially short-chain fatty acids, are produced by
the gut flora from a wide range of dietary carbohydrates that
reach the colon. Short-chain fatty acids, particularly
butyrate, can induce apoptosis and cell cycle arrest, and pro-
mote differentiation. Fibre intake is also strongly correlated
with intake of folate.
A clear dose-response relationship is apparent from
generally consistent cohort studies, supported by
evidence for plausible mechanisms, but residual
confounding could not be excluded. Foods containing
dietary fibre probably protect against colorectal cancer.
The Panel is aware that since the conclusion of the SLR, six
cohort studies41-46 and one case-control study47 have been pub-
lished. This new information does not change the Panel judge-
ment (see box 3.8).
Oesophagus
One cohort study,48 nine case-control studies,49-58 and two
ecological studies59 60 investigated dietary fibre and cancer
of the oesophagus.
There was some evidence of an association between dietary
fibre and reduced oesophageal cancer risk. The single cohort
study reported decreased risk when comparing high with low
intakes, with an effect estimate of 0.50, though no assess-
ment of statistical significance was included.48
The nine case-control studies produced 13 independent
effect estimates. Of these, 11 estimates were of decreased
risk,50-53 55 56 58 61 which were statistically significant in eight.
One estimate indicated no effect on risk54 and one other gave
non-significant increased risk.62 The data were most
consistent when stratified for adenocarcinomas; of six
studies, five reported significant decreased risk; results were
less consistent for squamous cell carcinoma. All studies 
were adjusted for alcohol and smoking except one, which
was adjusted for alcohol but not smoking.50
The ecological studies were inconclusive. Neither was sta-
tistically significant, with one in the direction of increased
and the other of decreased risk.
There is no evidence of a plausible biological mechanism
through which dietary fibre reduces the risk of oesophageal
cancer. It is not possible to conclude whether an as yet
unknown mechanism is responsible for an apparent reduc-
tion in risk, or whether it is due to other components found
in the vegetables and fruits that contain dietary fibre.
There is limited evidence from sparse and inconsistent
case-control studies only, suggesting that foods
containing dietary fibre protect against oesophageal
cancer.
4.1.5.4  Aflatoxins
(Also see box 4.1.4; chapter 4.9; and chapter 7.8). There are
two approaches to measuring aflatoxin intake. The first uses
local food tables to estimate exposure to aflatoxins from diet.
The second approach uses biomarkers of exposure. These are
derived from knowledge of aflatoxin metabolism. In humans,
metabolised products of aflatoxins can be detected in blood,
Figure 4.1.2 Dietary fibre and colorectal cancer;
cohort studies
Heilbrun 1989 Men 0.77 (0.48–1.24)
Bostick 1993  Women 0.88 (0.77–1.01)
Fuchs 1999 Women 0.99 (0.83–1.18)
Terry 2001 Women 1.08 (0.84–1.39)
Colbert 2001 Men 1.02 (0.88–1.18)
Konings 2002 Men 0.95 (0.84–1.07)
Konings 2002 Women 0.85 (0.73–1.00)
Higginbotham 2004 Women 0.83 (0.61–1.13)
Norat 2005 Men 0.77 (0.71–0.83)
Norat 2005 Women 0.89 (0.82–0.97)
Summary estimate 0.90 (0.84–0.97)
510.2 0.5 2
Relative risk (95% CI)
Relative risk, per 10 g/day
Figure 4.1.1 Dietary fibre and colorectal cancer;
cohort studies
Wu 1987 Men 1.19 (0.60–2.11)
Wu 1987 Women 0.64 (0.37–1.11)
Heilbrun 1989 Men 0.71 (0.45–1.13)
Giovannucci 1994 Men 1.08 (0.68–1.71)
Steinmetz 1994 Women 0.80 (0.40–1.91)
Gaard 1996 Men 0.82 (0.46–1.46)
Kato 1997 Women 0.95 (0.79–1.24)
Pietinen 1999 Men 1.00 (0.68–1.58)
Soneham 2000 Women 0.96 (0.70–1.32)
Bingham 2003 0.75 (0.50–0.95)
COL00535 Women 0.94 (0.70–1.26)
IARCIM 1977 Men 0.92 (0.64–1.32)
IARCIM 1977 Women 0.86 (0.52–1.42)
Baron 1997 Women 0.79 (0.45–1.38)
510.2 0.5 2
 Relative risk (95% CI)
Relative risk, highest vs lowest exposure category
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urine, or breastmilk. Biomarkers of exposure are more accu-
rate and precise. 
Liver 
Five cohort studies63-70 and seven case-control studies71-79
assessed associations between biomarkers of exposure to
aflatoxin and hepatocellular carcinoma.
The cohort studies used a variety of different biomarkers
for exposure to aflatoxin, some in blood and some in urine.
Despite this variety, all five studies reported increased risk
for the highest levels when compared to the lowest, and all
of these reported at least one measure that resulted in a sta-
tistically significant increased risk (figure 4.1.3). Studies that
adjusted for hepatitis virus infection tended to show the
greater effects.65 66 There is some evidence of an interaction
whereby the risk is increased by a multiplicative effect if afla-
toxin exposure is combined with hepatitis infection. One
study showed that people with hepatitis virus antibodies and
biomarkers of aflatoxin exposure had a higher risk than those
with hepatitis virus antibodies alone, with an effect estimate
of 10.0 (95% CI 1.6–60.9).65
There is evidence from some of the cohort studies for inter-
action with glutathione-S-transferase (GST) genotype.63 64
GST is an enzyme involved in the metabolic pathway that
‘detoxifies’ aflatoxins. Different genotypes show varying effi-
ciencies at this task. Two genes (GSTT1 and GSTM1) were
assessed separately. For each, it is possible to have a posi-
tive or negative genotype. In each case, a negative genotype
increases risk of hepatocellular carcinoma when exposed to
aflatoxins. There is clear, consistent evidence that
GSTM1/GSTT1 positive genotypes protect against the
increased risk of liver cancer from hepatitis infection com-
bined with aflatoxin exposure, which supports a causal role
for aflatoxins in hepatocellular carcinoma. 
Four case-control studies showed statistically significant
increased risk for the highest levels of biomarkers when com-
pared to the lowest.71 74 78 79 Two studies showed no effect
on risk.73 77 One study showed a non-significant decreased
risk.72 Heterogeneity may be explained by the diversity in
methods of exposure assessment.
A dose-response relationship is apparent from most cohort
studies and some of the case-control studies. 
The areas in the world where there is considerable afla-
toxin contamination of foods coincide with the areas where
primary liver cancer rates are high. The epoxide product of
aflatoxin AFB1 is known to be genotoxic and is formed in the
liver.80 It damages DNA, causing G:C base pairs to become
T:A. GST enzymes can repair this damage with varying effi-
ciency between genotypes. Recent studies have shown that
aflatoxins can damage the p53 gene, which is an important
regulator of normal growth.67 Damage to p53 DNA can lead
to increased proliferation of abnormal cells and formation
of cancers.
The synergistic effect of hepatitis virus infection and afla-
toxin exposure might be explained by hepatitis virus increas-
ing the production of the enzyme (CYP1A2) that produces
the genotoxic metabolite of aflatoxin.81 It is also possible that
the hepatitis virus increases the number of G:C to T:A trans-
versions, or that it inhibits nucleotide repair, or that it acts
as a tumour promoter.
The evidence is ample and consistent and is supported
by strong evidence for mechanisms operating in
humans. A dose response is apparent from both cohort
and case-control studies. The evidence that aflatoxins
and aflatoxin-contaminated foods are a cause of liver
cancer is convincing.
4.1.6  Comparison with previous report
The previous report concluded that dietary fibre/non-starch
polysaccharides possibly protect against cancers of the pan-
creas, colorectum, and breast. The previous report also con-
cluded that wholegrain cereals possibly decrease the risk of
stomach cancer and that refined cereals possibly increase the
risk of oesophageal cancer. 
Since the mid-1990s, evidence for a protective effect of
dietary fibre against colorectal and oesophageal cancer risk
has become somewhat stronger. The finding of the previous
report, suggesting that the degree of refinement (other than
relative amounts of dietary fibre) may be a factor in modi-
fication of the risk of some cancers, was not found. 
The previous report classified bananas as plantains. Here
they are classified as fruits. The previous report considered
dietary fibre separately from cereals (grains) and other plant
foods. Here, dietary fibre is considered in the context of cere-
als (grains) and other plant foods. 
4.1.7 Conclusions
The Panel concludes: 
The direct evidence that cereals (grains), roots, tubers, or
plantains affect the risk of any cancer remains unimpressive. 
However, foods containing dietary fibre probably protect
against colorectal cancer; and there is limited evidence sug-
gesting that such foods protect against oesophageal cancer.
Dietary fibre is mostly found in cereals, roots and tubers, and
also in vegetables, fruits, and pulses (legumes) (see chapter
Figure 4.1.3 Aflatoxins and liver cancer;
cohort studies
Qian 1994 Men 5.00 (2.11–11.85)
Wang 1996 3.80 (1.11–12.96)
Yu 1997 Men 6.00 (1.22–29.49)
Sun 1999 Men 4.52 (1.57–13.01)
51 2 6
 Relative risk (95% CI)
Relative risk, highest vs lowest exposure category
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4.2). All of these are highest in dietary fibre when in whole
or minimally processed forms. 
Foods high in dietary fibre may also have a protective
effect indirectly because they are relatively low in energy
density. See chapters 6.1, 7.3, 7.9, and 8 for discussion of
the role of energy density in weight gain, overweight, and
obesity, and of weight gain, overweight, and obesity in the
risk of some cancers, including those of the oesophagus and
colorectum. 
The evidence that foods contaminated with aflatoxins are
a cause of liver cancer is convincing. Cereals (grains) and
peanuts (see chapter 4.2) are the foods most commonly
infested by these fungal toxins. Contamination is most wide-
spread in countries with hot, damp climates and poor stor-
age facilities. 
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Vegetables and fruits are generally low in energy density
(with a few exceptions) and, when consumed in variety,
are sources of many vitamins, minerals, and other
bioactive compounds (phytochemicals). Many non-starchy
vegetables, including salad vegetables and fruits, may be
eaten raw and may also be cooked. Pulses (legumes) are
high in protein. Traditional diets all over the world
combine cereals (grains) with pulses (legumes) and, in
this way, ensure sufficient protein of adequate quality,
usually with small amounts of animal foods. Nuts and
seeds are concentrated sources of numerous
micronutrients and of essential fatty acids. All these foods
are sources of dietary fibre. Many herbs and spices have
potent pharmacological as well as culinary properties. 
Consumption of vegetables and fruits is very variable:
high around the Mediterranean littoral and some tropical
countries; low in many low-income countries, including
some in which fruits are abundant. Consumption of pulses
(legumes) is also very variable: beans and chickpeas and
their products are basic foods in a number of Latin
American, Middle Eastern, and Asian countries, but pulses
are insignificant in typical North American and most
European diets. Consumption of nuts, seeds, herbs, and
spices also varies. Traditional Middle Eastern and Indian
cuisines use a great variety of herbs and spices; garlic,
usually classified as a herb, is consumed in remarkable
quantities in some countries. 
In general, the Panel judges that findings from cohort
studies conducted since the mid-1990s have made the
overall evidence, that vegetables or fruits protect against
cancers, somewhat less impressive. In no case now is the
evidence of protection judged to be convincing. However,
in a substantial number of cases, a judgement of probable
is justified. Evidence on legumes (pulses), nuts, seeds, and
(with two exceptions) herbs and spices remains
insubstantial. 
The Panel judges as follows: 
Non-starchy vegetables probably protect against cancers of
the mouth, pharynx, and larynx, and those of the
oesophagus and stomach. There is limited evidence
suggesting that they also protect against cancers of the
nasopharynx, lung, colorectum, ovary, and endometrium.
Allium vegetables probably protect against stomach
cancer. Garlic (an allium vegetable, commonly classed as a
herb) probably protects against colorectal cancer. There is
limited evidence suggesting that carrots protect against
cervical cancer; and that pulses (legumes), including soya
and soya products, protect against stomach and prostate
cancers. Fruits in general probably protect against cancers
of the mouth, pharynx, and larynx, and those of the
oesophagus, lung, and stomach. There is limited evidence
suggesting that fruits also protect against cancers of the
nasopharynx, pancreas, liver, and colorectum. There is
limited evidence suggesting that chilli is a cause of
stomach cancer.
Fruits and non-starchy vegetables are generally low
energy-dense foods. For a discussion of the effect of such
foods and drinks on weight gain, overweight, and obesity,
and the role of weight gain, overweight, and obesity in the
risk of some cancers, see Chapters 6, 7, and 8.
Evidence that vegetables and fruits protect against some
cancers is supported by evidence on foods containing
various micronutrients, found especially in vegetables,
fruits, and pulses (legumes), and nuts and seeds, as well
as in cereals, roots, tubers, and other plant foods. Foods
containing folate probably protect against pancreatic
cancer, and there is limited evidence suggesting that these
foods also protect against oesophageal and colorectal
cancers. Foods containing carotenoids probably protect
against cancers of the mouth, pharynx, and larynx, and
also lung cancer. Foods containing the carotenoid beta-
carotene probably protect against oesophageal cancer; and
foods containing lycopene probably protect against
prostate cancer. Foods containing vitamin C probably
protect against oesophageal cancer. There is limited
evidence suggesting that foods containing quercetin
protect against lung cancer.
Evidence also relevant to chapter 4.1 is grouped here.
Foods containing selenium (also found in animal foods)
probably protect against prostate cancer; and there is
limited evidence suggesting that they protect against
stomach and colorectal cancers. There is limited evidence
suggesting that foods containing pyridoxine protect
against oesophageal and prostate cancers; and that foods
containing vitamin E protect against oesophageal and
prostate cancers. 
The strongest evidence, here corresponding to
judgements of ‘probable’, shows that non-starchy
vegetables and also fruits probably protect against cancers
of the mouth, larynx, pharynx, oesophagus, and stomach,
and that fruits also probably protect against lung cancer;
and that allium vegetables, and garlic specifically,
probably protect against stomach cancer. The case that
vegetables, fruits, and pulses (legumes) may be protective
against cancers of some sites is supported by evidence on
foods containing micronutrients found in these and other
plant foods. Thus, foods containing carotenoids probably
protect against cancers of the mouth, pharynx, larynx, and
lung; foods containing beta-carotene and also vitamin C
probably protect against oesophageal cancer; foods
containing selenium and also lycopene probably protect
4.2  Vegetables, fruits, pulses (legumes),
nuts, seeds, herbs, spices
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VEGETABLES,1 FRUITS,1 PULSES (LEGUMES), NUTS, SEEDS, HERBS, SPICES, 
AND THE RISK OF CANCER
In the judgement of the Panel, the factors listed below modify the risk of cancer. Judgements are graded according to the strength of the evidence.
DECREASES RISK INCREASES RISK
Exposure Cancer site Exposure Cancer site
Convincing
Probable Non-starchy vegetables1 Mouth, pharynx, larynx 
Oesophagus 
Stomach
Allium vegetables1 Stomach
Garlic1 Colorectum
Fruits1 Mouth, pharynx, larynx
Oesophagus 
Lung
Stomach
Foods containing folate2 Pancreas
Foods containing Mouth, pharynx, larynx
carotenoids2 Lung
Foods containing Oesophagus
beta-carotene2
Foods containing Prostate
lycopene2 3
Foods containing Oesophagus
vitamin C2 4
Foods containing Prostate
selenium2 5
Limited — Non-starchy vegetables1 Nasopharynx Chilli1 Stomach
suggestive Lung
Colorectum
Ovary
Endometrium 
Carrots1 Cervix
Fruits1 Nasopharynx 
Pancreas
Liver
Colorectum
Pulses (legumes)7 Stomach 
Prostate 
Foods containing folate2 Oesophagus 
Colorectum
Foods containing Oesophagus 
pyridoxine2 8
Foods containing Oesophagus 
vitamin E2 6 Prostate
Foods containing Lung
selenium2 5 Stomach
Colorectum
Foods containing Lung
quercetin2
Substantial
effect on risk Foods containing beta-carotene9: prostate; skin (non-melanoma)
unlikely
1 Judgements on vegetables and fruits do not include those preserved by salting and/or pickling.
2 Includes both foods naturally containing the constituent and foods which have the constituent added (see chapter 3.5.3).
3 Mostly contained in tomatoes and tomato products. Also fruits such as grapefruit, watermelon, guava, and apricot.
4 Also found in some roots and tubers — notably potatoes. See chapter 4.1. 
5 Also found in cereals (grains) and in some animal foods. See chapters 4.1 and 4.3.
6 Also found in plant seed oils. See chapter 4.5.
7 Including soya and soya products.
8 Vitamin B6. Also found in cereals. See chapter 4.1. 
9 The evidence is derived from studies using supplements and foods containing beta-carotene: see chapter 4.10. 
For an explanation of all the terms used in the matrix, please see chapter 3.5.1, the text of this section, and the glossary.
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against prostate cancer; and foods containing folate
probably protect against pancreatic cancer. Also see
chapter 4.1 for the evidence that foods containing dietary
fibre, found in plant foods (particularly when in whole or
relatively unprocessed forms), probably protect against
colorectal cancer.
Vegetables and fruits (including berries), nuts and seeds, and
herbs and spices, where they grow and can be cultivated,
have always been part of human diets. Gatherer–hunters and
pastoral peoples probably consumed more than relatively
impoverished urban dwellers: for them, vegetables were the
main sources of many vitamins, and fruits were a main
source of energy, from sugar (also found in wild honey).
They are consumed abundantly as part of many long-estab-
lished traditional cuisines, around the Mediterranean littoral,
the Middle East, in many Asian countries, and the Pacific
islands, where substantial amounts of meat, dairy products,
and other animal foods are traditionally consumed only occa-
sionally. In contrast, monotonous ‘poverty’ diets include few
of these foods.
Globally, consumption of these foods is lower than now
generally recommended. Vegetables and fruits are sometimes
seen as relatively expensive. Well stocked supermarkets usu-
ally now display a variety of local and imported fresh veg-
etables and fruits, although supplies in smaller stores are
more variable. Consumption of fresh vegetables and fruits in
many tropical countries in Africa and Latin America is low:
on average people in Brazil, for example, consume roughly
the same as people in Britain. The explanation may be that
in Africa, many rural communities are obliged to grow cash
crops that displace gardens, and that in Latin America knowl-
edge of the value — and pleasure — of many indigenous
vegetables and fruits has been lost. Many programmes in
tropical countries are now dedicated to regaining this knowl-
edge.1
Even before the discovery of vitamins as essential nutri-
ents beginning in the early 20th century, vegetables and
fruits have been recommended as ‘protective foods’. Early
reports concerned with nutritional deficiencies paid less
attention to pulses (legumes), nuts, and seeds, even though
these plant foods contain protein, and nuts and seeds are
nutrient- and also energy-dense, perhaps because they are
not much consumed in the countries where most such
reports were compiled. Instead, as already mentioned, pri-
ority was given to energy- and nutrient-dense foods of ani-
mal origin. By the 1980s, most reports concerned with
prevention of chronic diseases recommended relatively high
intakes of vegetables and fruits and sometimes also pulses
(legumes), either because these foods were seen as nour-
ishing substitutes for energy-dense fatty or sugary foods, or
else because they were identified as positively protective
against cardiovascular disease.2 Evidence that vegetables 
and fruits might be protective against some cancers emerged
in the 1990s.3 A common recommendation has been for at
least five portions (or at least 400 g) of vegetables and fruits
a day.4
Non-starchy root vegetables such as carrots are included
here. Chapter 4.1 includes dietary fibre, only found naturally
in plant foods. Chapter 4.1 also includes aflatoxins, which
also contaminate pulses (legumes), notably peanuts, nuts
and seeds, and other plant foods. The micronutrients includ-
ed here, as contained in vegetables, fruits, pulses (legumes),
nuts and seeds, are also found in other plant foods, and some
also in animal foods. 
4.2.1  Definitions, sources
Vegetables and fruits are defined in this Report by their culi-
nary use, and are grouped for discussion below as vegeta-
bles and fruits, pulses (legumes), nuts and seeds, and herbs,
spices, and condiments. 
Vegetables and fruits
Vegetables are the edible parts of plants, usually including
fungi. Typical examples include cultivated or gathered
leaves, roots, stalks, bulbs, and flowers. Some foods are culi-
nary vegetables but are classified botanically as fruits; these
include cucumbers, peppers, squash, and tomatoes. Non-
starchy vegetables are included here, while starchy root veg-
etables are considered in chapter 4.1. Non-starchy vegetables
can be further divided into green, leafy vegetables, such as
spinach and lettuce; cruciferous vegetables (the cabbage
family), for example, bok choy, broccoli, cabbage, and water-
cress; and allium vegetables, such as onions, garlic, and
leeks.
A fruit is the seed-containing part of the plant; but only
those that are eaten as fruits are included in the culinary def-
inition, for example, apples, bananas, berries, figs, grapes,
mangoes, and melons. This also includes citrus fruits such
as oranges, grapefruits, lemons, and limes; and also dried
fruits, such as apricots, figs, and raisins.
Pulses (legumes)
Leguminous plants produce their fruits as pods and are con-
sidered here separately. The dried, edible seeds of this fam-
ily are often called pulses, although this term is used
interchangeably with legumes. They include beans, lentils,
peas, and peanuts (groundnuts). The dried forms, which
have matured and dried on the plant, are eaten most wide-
ly. But some varieties are eaten as a green vegetable, such
as peas; the pods are sometimes eaten like this too, for exam-
ple, green beans and runner beans. Some legumes can also
be sprouted (germinated) and eaten, such as beanspouts.
Nuts and seeds
Nuts are edible seeds surrounded by a tough, dry shell. This
definition includes true nuts (such as hazelnuts and chest-
nuts), as well as seeds that most people think of as nuts
(including Brazil nuts, macadamia nuts, and cashews). Other
seeds commonly eaten include sunflower, sesame, pumpkin,
and poppy seeds. Nuts and seeds are processed for their oil,
ground into pastes, used as ingredients, or eaten raw or
roasted as snack foods. Cereals (grains) are also the seeds
of plants, but these are discussed separately in this Report
(see chapter 4.1). Seeds, like nuts, have a relatively high oil
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content, and the oils produced from them are considered in
chapter 4.4.
Herbs, spices, and condiments
Herbs and spices, which are generally used to flavour or pre-
serve foods, are of plant origin, although a very small num-
ber of animal products are classed as spices (such as
ambergris). Definitions of herbs and spices vary, but herbs
are usually the fresh or dry leaves or whole plant, while
spices are produced from other parts of the plant, such as
the seeds, and are usually dried.5 Many different parts of
plants are used as herbs or spices, such as the leaves (sage,
bay, or basil), stems (ginger, lemongrass), bark (cinnamon),
rhizomes (ginger), roots (horseradish), flower buds (cloves),
stamens (saffron), seeds (mustard, cumin), kernels (nut-
meg), and fruits (peppers). 
A condiment is a substance that adds taste to other foods;
the term is often used for sauces added at the table, which
are usually of plant origin. Examples include vinegars,
ketchups, chutneys, harissa, mustard, and soy sauce. Salt is
neither a herb nor a spice, although it is used as a condiment
(see chapter 4.5).
Vegetables, fruits, pulses (legumes), nuts,
and seeds are sources of a wide variety of
micronutrients and other bioactive com-
pounds. Foods containing several of these
constituents have been identified in the sys-
tematic literature reviews, on which this
chapter is based, as being associated with
cancer risk. These are carotenoids (includ-
ing beta-carotene and lycopene), folate,
vitamin C, vitamin D, vitamin E, quercetin,
pyridoxine, and selenium. Mechanisms by
which they might affect cancer risk are dis-
cussed in chapter 4.2.5. However, it is not
possible to ascribe the association between
these foods and lower cancer risk to a
causal effect of specific compounds with
confidence, as each food contains a com-
plex mixture of different constituents, all of
which might also contribute to any effect.
Carotenoids are found in varying con-
centrations in all vegetables, particularly
those that are red or orange. They are a
family of more than 600 fat-soluble
red/orange pigments that comprise xan-
thophylls (such as lutein) and carotenes
(such as alpha- and beta-carotene, and
lycopene). Some carotenoids, most impor-
tantly beta-carotene, can be converted by
the body to retinol and are sometimes
called pro-vitamin A carotenoids. These
compounds tend to be the main dietary
source of vitamin A in low-income coun-
tries. 
Only about half of the 50 or so
carotenoids in human diets can be absorb-
ed. They have antioxidant and other bioac-
tivities that are discussed in chapter 4.10.
Sources of carotenoids include spinach,
kale, butternut squash, pumpkin, red (bell)
peppers, carrots, tomatoes, cantaloupe
melon, and sweet potatoes. 
Beta-carotene is found in yellow, orange,
and green fruits and green, leafy vegeta-
bles including carrots, spinach, lettuce,
tomatoes, sweet potatoes, broccoli, can-
taloupe melon, oranges, and winter squash
(pumpkin). 
As a rule of thumb, the greater the inten-
sity of the colour of the fruit or vegetable,
the more beta-carotene it contains. 
The most concentrated source of
lycopene is tomatoes, but it is also present
in watermelon, red (bell) peppers, pink or
red grapefruit, pink-fleshed guava, and
persimmons. 
The B-vitamin folate is a family of com-
pounds essential for human health. Folic
acid, the synthetic form, is used to fortify
manufactured cereal products, spreads,
and, in some countries, flour or grains.
Folates are involved in a number of meta-
bolic pathways, especially in the synthesis
of purines and pyrimidines, which are
important for DNA synthesis and cell repli-
cation (also see chapter 4.2.5.4). Sources of
dietary folate include liver, beans, spinach,
broccoli, romaine lettuce, chicory, oranges,
and papaya.
Vitamin C (ascorbic acid) is a water-solu-
ble vitamin. Humans, like a small number of
other animals, cannot synthesise vitamin C,
so it is an essential part of diets. Vitamin C
is essential for collagen synthesis and also
has antioxidant activity. Severe deficiency
causes scurvy. It is added to many foods,
including bread and soft drinks, in small
amounts as an antioxidant preservative.
Natural dietary sources are vegetables,
tubers, and fruits, including red/yellow
(bell) peppers, kiwi fruits, broccoli, papaya,
citrus fruits, strawberries, and potatoes, but
it is destroyed by heat or contact with the
air (for instance, when vegetables are
chopped), or lost into cooking water.
Vitamin E is a fat-soluble vitamin and a
potent antioxidant that occurs as eight dif-
ferent forms: alpha- and gamma-toco-
pherol are the most common. The most
important dietary sources of vitamin E are
vegetable oils such as palm, sunflower,
corn, soya bean, and olive oils. Nuts, sun-
flower seeds, and wheatgerm are also
sources. Wholegrains, fish, peanut butter,
green, leafy vegetables, and fortified
breakfast cereals also contain this vitamin. 
Pyridoxine is one of a group of water-
soluble compounds collectively known as
vitamin B6. This vitamin is involved in neu-
rotransmitter synthesis, red blood cell for-
mation and function, niacin (vitamin B3)
formation, steroid hormone function, and
nucleic acid synthesis (also see chapter
4.2.5.5).15 Food sources include bananas,
fish, poultry, liver, potatoes eaten with the
skin, green, leafy vegetables, beans, pulses
(legumes), nuts, wholegrains, and fortified
breakfast cereals.
Selenium is a mineral element that
occurs in different chemical forms. It is
toxic in large amounts, but is essential in
the diet at trace levels. It is present at vary-
ing concentrations in different soils; and
since plants take up selenium from the soil,
these levels determine the amount present
in vegetables. Thus selenium deficiency is
more prevalent in regions where the soil
selenium content is low. Selenium is a com-
ponent of the amino acids selenocysteine
and selenomethionine, which are inte-
grated into proteins to form selenopro-
teins. Selenoproteins include antioxidant
enzymes such as glutathione peroxidases,
thioredoxin reductase, which is important
for DNA synthesis, and iodothyronine deio-
dinase, which is important for the synthe-
sis of thyroid hormones.16 Dietary sources
of selenium include brazil nuts, fish, whole-
grains, wheatgerm, and sunflower seeds.
Quercetin is a flavonoid, which is a type
of polyphenol; it is not an essential dietary
component. Many studies in cultured cells
and animals suggest that quercetin has
antioxidant activity, which could give rise
to a range of biological activities, including
reducing inflammation (also see chapter
4.2.5.9). Quercetin is found in apples,
green and black tea, onions, raspberries,
red wine, red grapes, citrus fruits, leafy,
green vegetables, cherries, elderberries,
broccoli, blueberries, cranberries, and
bilberries.
Box 4.2.1 Micronutrients and other bioactive compounds and cancer risk 
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4.2.2   Composition
Vegetables and fruits
The composition of fruits and vegetables depends both on
species and on subtype, as well as on the environmental,
farming, production, and storage conditions. These include
factors such as sun exposure, soil quality, agricultural prac-
tices, harvesting time, ripeness, length of time between har-
vest and consumption, and preservation and preparation
methods. For instance, the outer leaves of lettuces can have
higher levels of some micronutrients than the inner leaves;
and harvested, unripe fruit that ripens in transit may have
lower levels of nutrients than fruits ripened on the plant 
(box 4.2.1).6
Vegetables and fruits contain vitamins, minerals, dietary
fibre, and other bioactive compounds, such as phytochemi-
cals (box 4.2.2). This is a collective term for a variety of plant
components that often perform important functions in the
plant, such as providing colour, flavour, or protection, but
are not essential in the human diet. They include salicylates,
flavonoids, glucosinolates, terpenes, lignans, and
isoflavones. All of these groups of compounds have been
shown either in humans or in laboratory experiments to have
potentially beneficial health effects when they are included
in diets. However, the bioavailability of these compounds 
is variable (box 4.2.3) and their ultimate heath effects
uncertain. 
Plant cell walls are the main source of dietary fibre, and
all whole fruits and vegetables (but not their juices) contain
varying amounts of fibre (box 4.2.4). Most vegetables and
fruits are low energy-dense foods, although there are excep-
tions, for example, avocados, nuts, and seeds. 
Some families of fruits and vegetables have characteristic
components that may confer a particular health benefit (or
risk) to the whole family. For instance, cruciferous vegeta-
bles are sources of glucosinolates and their products isoth-
iocyanates and indoles. Allium vegetables and others, such
as chicory and Jerusalem artichokes, store energy as inulin
(chains of fructose sugars) rather than starch (chains of glu-
cose sugars). The body cannot digest inulin, which is called
a prebiotic — a substance that is claimed to have health ben-
efits by promoting the growth of certain types of gut bacte-
ria. Allyl sulphides and allicin in garlic are distinctive flavour
molecules that give vegetables of the onion family their
‘sting’ (box 4.2.3). Green, leafy vegetables are sources of
folate, and tomatoes have high levels of lycopene. All of
these components, as well as other phytochemicals (box
Plants contain a wide range of biologically active compounds,
some of which are known as phytochemicals. There may be as
many as 100 000 different compounds, which determine par-
ticular properties in plants, and in the fruits and vegetables they
produce, such as flavour and colour. Phytochemicals are classi-
fied according to their chemical structure and functional char-
acteristics, and include salicylates, phytosterols, saponins,
glucosinolates, polyphenols, protease inhibitors, monoterpenes,
phytoestrogens, sulphides, terpenes, and lectins.
It is widely believed that the health benefits of diets high in
fruits and vegetables are likely to be due partly to the presence
of phytochemicals. For instance, several act as antioxidants, pre-
venting oxidative damage to cells, proteins, and DNA. It is like-
ly that other bioactive phytochemicals have yet to be identified,
and those that are known may have additional properties in the
body that are not yet understood. But it is thought that nutri-
ents, phytochemicals, and other, as yet unknown, bioactive com-
ponents act together to influence physiological responses. 
Although many phytochemicals are bioactive, they are not
essential in the diet and there is no daily requirement, so they
are not classed as nutrients. Humans have developed tastes for
some phytochemicals, such as the hot flavours of mustard oil,
bitter alkaloids, and irritating capsaicins. There is genetically
inherited variation in sensitivity to some tastes, for example, the
bitter taste of isothiocyanates in cruciferous vegetables such as
cabbage.
Box 4.2.2 Phytochemicals
While some vegetables, often termed
‘salad vegetables’, are commonly eaten
raw, many are cooked before they are
eaten. In most cases, whether a vegetable
is eaten raw depends on personal choice.
Most forms of cooking reduce the total
nutrient content of vegetables, although
the degree to which this happens varies
between nutrients and with cooking meth-
ods. However, cooking also increases the
bioavailability of some nutrients.12
Therefore, although raw vegetables have
higher amounts of nutrients overall, the
body may absorb more of a nutrient from
the cooked vegetable. 
For instance, carotenoid absorption in
the small intestine is relatively inefficient
(5–50 per cent); the bioavailability of
carotenes is increased by cooking and
pureeing vegetables, particularly by
adding oil, because these compounds are
fat soluble.13 Similarly, processing tomatoes
increases the bioavailability of lycopene,
another carotenoid: it is four times more
bioavailable from tomato paste than from
fresh tomatoes. Thus processed tomato
products such as pasteurised tomato juice,
soup, sauce, and ketchup provide the most
bioavailable lycopene. Cooking and crush-
ing tomatoes (as in the canning process)
and including them in oil-rich dishes (such
as pasta sauce or pizza) greatly increases
lycopene absorption from the digestive
tract.
The biological response to garlic can also
be influenced by the way that it is
processed. Peeling and chopping garlic
releases an enzyme, alliinase, which is
known to promote the formation of some
sulphur compounds that are not only odor-
iferous but may provide some health ben-
efits. Heating garlic without peeling
inactivates this enzyme and has been
found to substantially reduce or eliminate
the active properties. If garlic is peeled or
chopped and allowed to stand for 15–20
minutes, the active agents that are formed
are not destroyed by normal cooking pro-
cedures.14
The ways in which vegetables and fruits
are produced and stored may affect nutri-
ent levels as much as cooking, or more. For
example, nutrient levels tend to fall rapid-
ly after harvest. 
Box 4.2.3 Preparation of vegetables and nutrient bioavailability
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4.2.2), have been shown to have potentially beneficial effects
in laboratory experiments, as detailed in the evidence in
chapter 4.2.5 (also see Chapter 2).7-9
Pulses (legumes)
Dry pulses are seeds and are higher in protein than most
other plant foods. Soya beans and peanuts contain 37 g per
100 g and 26 g per 100 g protein dry weight respectively,
although, on average, pulses contain around 20 g per 100 g
protein dry weight.10 These foods are typically high in car-
bohydrates and non-starch polysaccharides (dietary fibre),
and are generally low in fat. Soya beans and peanuts are
exceptions, being relatively high in fat with 8 g per 100 g
and 47 g per 100 g fat, respectively (mostly mono- and
polyunsaturated fatty acids). They also contain oligosac-
charides that are not digested in the gut but are fermented
by bacteria in the colon. Soya beans are distinct from other
legumes in that they have a high content of bioactive
isoflavones, or phytoestrogens, which have hormone-like
effects in the body. They are also good sources of saponins
and phytosterols, which decrease cholesterol absorption.
Many legumes contain deguelin, which has been shown to
have anti-tumour effects in laboratory experiments.11 Most
pulses are virtually indigestible and inedible before cooking;
immature legumes that are eaten green have higher levels
of sugar and lower levels of non-digestible polysaccharides
than dried pulses.
Nuts and seeds
Other seeds and nuts are also relatively high in protein and
fat; some contain as much as 60 g fat per 100 g. They are
therefore energy-dense foods (see Chapter 8), as well as
being nutrient-dense. Weight-for-weight, nuts provide more
calories than either meat or cereals (grains), although chest-
nuts are the exception as they are relatively low in fat. Most
nuts contain mainly monounsaturated fatty acids, although
the exceptions are coconuts, which contain a high propor-
tion of saturated fatty acids, and walnuts and pecans, which
contain mostly polyunsaturated fatty acids (see chapter
4.5.2). Nuts and seeds are high in dietary fibre (box 4.2.4),
especially when they are eaten with their skins or hulls; the
fibre content is typically 5–11 g per 100 g. Nuts and seeds
are also high in vitamins and minerals, particularly the B vit-
amins, vitamin E, and folate; and the seed coats contain phe-
nolic compounds.
Herbs and spices
Nearly all herbs and spices contain aromatic compounds,
which are volatile molecules that are usually fat- rather than
water-soluble. The flavour compounds may make up as much
as 15 g per 100 g of a spice by weight, although herbs con-
tain much lower levels — typically around 1 g per 100 g.
Many plants have evolved to contain these compounds
because they act as deterrents to herbivores. Some of these
aromatic compounds may be bioactive, although possibly not
at the levels found in most diets. Isothiocyanates are respon-
sible for the spicy/hot flavour of mustard and horseradish,
produced from glucosinolates in cruciferous plants. Chives
and garlic (allium vegetables) contain the distinctive sul-
phides discussed above. Terpenoids are common components
in herbs and spices, providing distinctive flavours. Examples
include monoterpenes, such as geranial in lemon grass, and
linalool in bergamot; sesquiterpenes, such as bisabolene in
ginger; triterpenoids, such as the saponin glycrrhizic acid,
found in liquorice root; and tetraterpenoids, such as the
carotenoid, lycopene. 
4.2.3 Consumption patterns 
Fruits and vegetables
The global average for vegetable consumption (based on
availability and not including vegetable oils) is 2.6 per cent
of total daily energy intake.17 It is generally highest in North
Africa, the Middle East, parts of Asia, the USA and Cuba, and
in southern Europe. Although consumption levels are similar
in countries of high and low economic status, vegetables rep-
resent a greater proportion of daily energy intake in the low-
income countries. Intakes range from 5.3 per cent in parts of
Asia to as little as 0.2 per cent in sub-Saharan Africa. On aver-
age, the availability of vegetables is increasing globally.
The global average for fruit consumption (based on avail-
ability) is 2.7 per cent of total daily energy intake. Fruit con-
sumption is generally higher than vegetable consumption,
but it shows a greater degree of variability. Fruit consump-
tion is higher in high-income countries, although it repre-
sents a similar percentage of total available dietary energy
The concept of dietary fibre arose from observations of the low
prevalence of colon cancer, diabetes, and coronary heart disease
in parts of Africa amongst people whose diets were high in
unrefined carbohydrates and whose stools were typically bulky,
and often or sometimes semisolid. Considerable efforts have
been dedicated to characterising the dietary components of
what has come to be called dietary fibre that might confer
health benefit. Naturally occurring dietary fibre is only derived
from plant foods. Pulses (legumes) and minimally processed
cereals are particularly concentrated sources, but vegetables and
fruits also contain significant amounts. Dietary fibre isolated
from plant cell walls and synthetic forms are increasingly enter-
ing the food supply.
High intakes of dietary fibre, variously defined, have been
associated with reduced risk of cardiovascular disease as well as
of some cancers. Definitions of dietary fibre vary. Some are
based on chemical analyses of the components of plant cell
walls, such as non-starch polysaccharide, others on physiologi-
cal effects — the carbohydrates that enter the large bowel hav-
ing escaped digestion in the small intestine being defined as
dietary fibre. The latter definition includes oligosaccharides and
resistant starch. The World Health Organization and Food and
Agriculture Organization have recently proposed that only poly-
saccharides which form part of plant cell walls should be regard-
ed as dietary fibre and that the health benefits of resistant
starch and oligosaccharides are more appropriately considered
separately.
Box 4.2.4 Foods containing dietary fibre
This box also appears as box 4.1.2 in the previous section
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to that seen in low-income countries. Intakes are highest in
some parts of Africa, the Middle East, southern Europe, and
Oceania, and lowest in other parts of Africa and Asia. Fruit
consumption also tends to be low in north-eastern Europe.
Intakes range from as much as 20 per cent of daily energy
in parts of Africa to as little as 0.5 per cent in parts of Asia.
The availability of fruit has increased globally in recent
decades, although there was a slight decrease in the 1990s.
Most countries have national recommendations for the
daily amount of vegetables and fruits that need to be eaten
to maintain optimal health (Chapter 10). These vary, but
they tend to recommend three or more servings per day of
vegetables and two or more servings per day of fruits; a serv-
ing is about 80 g (or half a US cup). In most high-income
countries for which data were available, daily consumption
of vegetables fell short of this target, although this is not due
to lack of availability; indeed, availability is high due to the
wide use of refrigeration. Fruit consumption tended to be
closer to national targets. Seasonal availability influences
overall availability, although less so in high-income countries
where vegetables and fruits are more likely to be imported.
Pulses (legumes)
Globally, pulses supply 2 per cent of total energy intake
(based on availability) and 3.5 per cent of daily protein
intake.17 The highest availability is in parts of Africa, South
America, Asia, and the Middle East. In these areas, pulses
are a dietary staple, and can account for as much as 20 per
cent of daily energy intake and 50 per cent of protein intake.
In societies with high intakes of meat and other foods of ani-
mal origin, pulses are less important in diets, and are usu-
ally consumed infrequently or in small amounts. Peanuts and
soya beans account for most of the legume products eaten
around the world.
Soya bean availability per person represents 0.5 per cent
of daily energy intake globally, but it is notably high in parts
of Asia, and higher than average in parts of Africa and
Central America. In parts of Asia, soya beans account for up
to 4.9 per cent of daily energy availability and 15 per cent
of protein.
Pulses are eaten in a variety of ways around the world; for
instance, Japanese and Chinese bean curd (tofu), Chinese
mung bean sprouts, Mexican chilli and refried beans, Indian
dahl, Middle Eastern falafel and hummus, Indonesian cul-
tured soya bean cakes (tempeh), Cuban black beans and rice,
Boston baked beans, French cassoulet, Brazilian feijoada,
Swedish pea soup, and US peanut butter. Soya beans are par-
ticularly versatile and their products are a common feature
in manufactured foods, although they are not commonly
eaten whole. Soya foods include soya drinks and flour, tofu,
tempeh, textured vegetable protein, and the many products
that can be prepared from these foods. Fermented soya beans
produce soy sauce and miso. Soya bean oil is also used wide-
ly (see chapter 4.5.3).
Nuts and seeds
Nuts and seeds were an important part of human diets before
the advent of agriculture and they remain locally important
in a few areas. Globally, tree nuts supply 0.4 per cent of daily
energy availability. The highest availability is in the Middle
East and parts of Europe, and the lowest is in South America
and parts of Africa; intakes range from 3 per cent of total
energy in parts of the Middle East to virtually zero in many
low-income countries.
Coconuts represent 0.5 per cent of daily energy availabil-
ity globally, although coconuts can be locally important in
tropical islands, for instance in parts of Oceania, Asia (Sri
Lanka and Indonesia), the Caribbean, and in the African
islands. In parts of Oceania, for example, coconuts provide
as much as 20 per cent of energy in the diet.
Sunflower, rape, mustard, and sesame seeds together sup-
ply 0.2 per cent of daily energy intake globally. There are
fewer data available for seeds than for many other foods,
although sesame seed intake is relatively high in parts of
Africa and Asia, providing a maximum of 3.9 per cent of
energy in parts of central Africa. Oils from seed crops are
widely used (see chapter 4.5.3).
Herbs, spices, and condiments
Although spices are consumed in small amounts to flavour
food, they are such a regular feature of some diets that they
account for a measurable quantity of daily energy intake.
Worldwide, spices provide 0.3 per cent of available dietary
energy and in parts of Asia they constitute as much as 1.8
per cent. Herbs and spices tend to be part of the tradition-
al diet in the areas from which they originate, and many tra-
ditional cuisines are characterised by the use of herbs, spices,
and condiments. Most are now available worldwide,
although their use still varies greatly in different parts of the
world. Many herbs and spices are believed to have medici-
nal or tonic value and have been used in this way at least
since the times of the earliest medical records. Many mod-
ern pharmaceuticals are derived from herbs and other plants. 
Many herbs and some spices are biologically very potent:
the modern pharmacopoeia lists drugs, many of which have
been isolated from herbs, sometimes known as ‘plants with
healing powers’. There are some in vivo experimental data
for potentially beneficial effects in the cases of turmeric, saf-
fron, ginger, pepper, garam masala (a herb and spice mix),
and also eugenol and myristin, constituents of a number of
herbs and spices. 
Conversely, it is at least theoretically possible that some
condiments have adverse effects. Two examples are hot chilli
juices and harissa, a fiery condiment; both are consumed in
substantial quantities in Mexico and the Mahgreb countries
of North Africa, respectively, and both irritate the mouth and
throat. 
4.2.4  Interpretation of the evidence
4.2.4.1 General
For general considerations that may affect interpretation of
the evidence, see chapter 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7. 
‘Relative risk’ (RR) is used in this Report to denote ratio
measures of effect, including ‘risk ratios’, ‘rate ratios’, ‘haz-
ard ratios’, and ‘odds ratios’.
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4.2.4.2 Specific 
Considerations specific to vegetables, fruits, pulses
(legumes), nuts, seeds, herbs, and spices include:
Patterns and ranges of intake. Most studies of consumption
of vegetables, fruits, and pulses (legumes) have been con-
ducted in populations that have relatively homogeneous
diets. The limited data on nuts, seeds, herbs, spices, and
condiments come mainly from a few human case-control
studies and some experimental animal studies. 
Classification. There is no general agreement on classifica-
tion. Some studies have included cereals such as corn, and
tubers such as potatoes, as vegetables, and plantains as fruit.
Broccoli and green peppers are included as ‘green vegetables’
in some studies, while only leafy greens are included in this
category in others; tomatoes are considered ‘yellow-orange
vegetables’ in some but not in others. Some studies report
results only for broad categories (for example, ‘all vegetables’
or ‘all fruits’), whereas others have reported results for more
narrowly defined categories (for example, ‘raw vegetables’,
‘green vegetables’, ‘citrus fruits’) or for individual food items
(for example, ‘spinach’, ‘carrots’, ‘tomatoes’). In some stud-
ies, vegetables and fruits have been categorised according to
botanical classification; in others, categorisation has been
according to culinary usage. In this report, the terms ‘veg-
etables’ and ‘fruits’ are used according to their culinary def-
inition. Some studies have included pulses as vegetables
whereas others have classified these as a separate entity or
not at all. Many older studies have not differentiated
between retinol and carotenoids. Vitamin E intakes are dif-
ficult to quantify since much comes from the vegetable oils
used in food preparation, and intakes within populations are
usually homogenous because of the widespread occurrence
of vitamin E in commonly consumed foods.
Measurement. Assessment of selenium intake is problemat-
ic because the content of selenium in foods depends to a
large extent on the soil selenium content of the area in which
the foods were grown. Blood and toenail levels of selenium
are thought to be fairly accurate indicators of intake and
have been used in several studies. 
Confounding. Smokers consume fewer vegetables and fruits
than non-smokers.18 19 Fat intake inversely correlates with
vegetable and, particularly, fruit intake in the USA.20 Recent
studies of the effects of fruits and vegetables in cancers
thought to be caused by smoking have controlled for the
effect of smoking. Folate intake is correlated with intake of
non-starchy polysaccharide (dietary fibre). 
Reporting bias. Studies using self-reporting tend to over-
report vegetable and fruit consumption. Where an effect
exists, results from such studies are liable to underestimate
the extent to which vegetables and fruits modify the risk of
cancer. 
4.2.5  Evidence and judgements 
The full systematic literature review (SLR) is contained on
the CD included with this Report.
4.2.5.1 Non-starchy vegetables
Mouth, pharynx, and larynx 
Thirty-one case-control studies21-50 and 3 ecological studies51-
53 investigated non-starchy vegetables and mouth, pharynx,
or larynx cancers; 1 cohort study54 and 6 case-control stud-
ies33 39 45 55-57 investigated non-starchy vegetables and fruits;
23 case-control studies investigated raw vegetables24 27 28 33
36-43 45 47 50 58-65; 1 cohort study,66 14 case-control studies,24
26-29 39 41 43 45-47 50 63 67 and 1 ecological study68 investigated
cruciferous vegetables; 1 cohort study66 and 10 case-control
studies24 26-29 39 47 61 67 69 investigated green, leafy vegetables;
3 cohort studies66 70 71 and 18 case-control studies23 24 26-29 39
41-43 46 49 50 63 65 72-75 investigated carrots; and 1 cohort study66
and 12 case-control studies26-29 39-43 46 50 58 62 65 investigated
tomatoes.
Non-starchy vegetables
Most studies showed decreased risk with increased intake of
non-starchy vegetables. Twenty-two studies reported com-
parisons of high against low intake (figure 4.2.1).22 23 25 26 29-
31 33 35-46 49 50 Of these, 19 showed decreased risk for the
highest intake group,22 25 26 30 31 33 35-44 46 49 50 which was sta-
tistically significant in 13.22 25 30 31 35 37 38 40 42 43 46 49 50 The
other 3 studies showed non-significant increased risk.23 29 45
Figure 4.2.1 Non-starchy vegetables and mouth, pharynx,
and larynx cancer; case-control studies
Notari 1987 0.42 (0.25–0.71)
Franco 1989 1.70 (0.92–3.16)
Oreggia 1991 0.19 (0.05–0.68)
Franceschi 1991 0.80 (0.55–0.68)
Franceschi 1992 0.40 (0.20–0.80)
Zheng 1993 1.73 (0.79–3.78)
Kune 1993 0.30 (0.11–0.85)
De Stefani 1994 0.40 (0.19–0.85)
Takezaki 1996 0.80 (0.59–1.08)
Esteve 1996 0.61 (0.45–0.81)
Levi 1998 0.14 (0.08–0.23)
De Stefani 1999 0.50 (0.29–0.87)
Franceschi 1999 0.50 (0.33–0.76)
De Stefani 1999 0.57 (0.30–1.08)
Garrote 2001 0.78 (0.40–1.52)
Bosetti 2002 0.17 (0.11–0.27)
Marchioni 2003 0.86 (0.54–1.38)
Lissowska 2003 0.17 (0.07–0.27)
Rajkumar 2003 0.44 (0.28–0.69)
Sanchez 2003 0.54 (0.34–0.86)
Gaud 2004 1.40 (0.71–2.76)
De Stefani 2005 0.60 (0.33–1.10)
Relative risk (95% CI)
Relative risk, highest vs lowest exposure category
1 50.2 0.5 2
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The remaining studies showed no consistent association,
probably due to varying exposure definitions and study
design.21 24 27 28 32 34 47 48 Meta-analysis was possible on 4 case-
control studies, giving a summary effect estimate of 0.72
(95% confidence interval (CI) 0.63–0.82) per 50 g/day, with
moderate heterogeneity (figure 4.2.2). All studies adjusted
for sex, smoking, and alcohol consumption.
A dose-response relationship is apparent from the four
case-control studies that could be meta-analysed (figure
4.2.3). There is some suggestion that the greatest effect
appears to be with the first increment. That is, any increase
above the lowest levels of vegetable consumption confers a
protective effect. However, it is not clear that the effect con-
tinues in a linear fashion with increased dose.
Of the three ecological studies, one (Hong Kong) study
found a significant negative association between vegetable
consumption and cancer incidence51; the other two
(international) found no significant association with cancer
mortality.52 53
Non-starchy vegetables and fruits
A cohort study that reported results for non-starchy vegeta-
bles and fruits in combination reported a statistically signif-
icant protective effect in the highest consumers (0.55, 95%
CI 0.32–0.95).54 All six case-control studies looking at the
same exposure group reported reduced risk estimates in sim-
ilar comparisons,33 39 45 55-57 which were statistically signifi-
cant in four.33 39 55 57 All of these studies adjusted for smoking
and alcohol consumption.
Raw vegetables
Twenty-three case-control studies reported separate risk esti-
mates for raw vegetable consumption.24 27 28 33 36-43 45 47 50 58-
65 All of these reported comparisons of risk between high and
low intake groups, which produced reduced risk estimates
in 2224 27 28 33 36-43 45 47 50 58 60-65; 16 of these were statistical-
ly significant.24 33 36-40 42 43 47 50 60-63 65 No studies reported sta-
tistically significant increased risk estimates. Meta-analysis
of 7 case-control studies gave an effect estimate of 0.71 (95%
CI 0.59–0.86) per 50 g/day, with moderate heterogeneity.37
39 42 45 59 62 65 These studies also provided evidence of a dose-
response relationship. The heterogeneity could be partially
explained by variable exposure definitions. These results are
consistent with data for non-starchy vegetables.
Cruciferous vegetables
One cohort study,66 14 case-control studies,24 26-29 39 41 43 45-
47 50 63 67 and 1 ecological study68 reported separate risk esti-
mates for cruciferous vegetable consumption.
The single cohort study showed a non-significant increased
risk for increased intake of cauliflower and a non-significant
decreased risk for cabbage.66 Four case-control studies
showed statistically significant decreased risk with increased
intake, either overall or in specific subgroups.24 29 43 47 One
study showed statistically significant increased risk associ-
ated with eating kimchi or pickled cabbage.67 The other nine
studies showed inconsistent and non-significant associa-
tions.26-28 39 41 45 46 50 63 The ecological study showed a sta-
tistically significant decreased risk.68
Green, leafy vegetables
One cohort study66 and 10 case-control studies24 26-29 39 47 61
67 69 reported separate risk estimates for green, leafy veg-
etable consumption.
The single cohort study showed no effect for the highest
intake group of lettuce when compared to the lowest.66 Nine
case-control studies showed decreased risk with increased
intake,24 26 27 29 39 47 61 67 69 which was statistically significant
in four.24 39 61 69 One study showed non-significant increased
risk.28
Carrots
Three cohort studies66 70 71 and 18 case-control studies23 24
26-29 39 41-43 46 50 63 65 72-75 investigated non-starchy root veg-
etables and mouth, larynx, or pharynx cancers. There was
variation in the exposure classification in studies. Most
Figure 4.2.3 Non-starchy vegetables and mouth,
pharynx, and larynx cancer; case-control
studies: dose response
De Stefani 1994
Levi 1998
De Stefani 2000
Bosetti 2002
0 200100 300 400
Non-starchy vegetables (g/day)
Figure 4.2.2 Non-starchy vegetables and mouth, pharynx,
and larynx cancer; case-control studies
De Stefani 1994 0.53 (0.26–1.09)
Levi 1998 0.62 (0.53–0.74)
De Stefani 2000 0.82 (0.64–1.05)
Bosetti 2002 0.75 (0.70–0.81)
Summary estimate 0.72 (0.63–0.82)
Relative risk (95% CI)
Relative risk, per 50 g/day
10.5 0.75 1.5
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assessed carrots, but some looked at ‘tubers and carrots’ or
‘non-starchy root vegetables’ or ‘yellow/orange vegetables’.
One cohort study, looking at ‘tubers and carrots’, report-
ed a non-significant increased risk when comparing high
against low intakes, with a wide confidence interval (1.9,
95% CI 0.6–6.0).66 Another that reported on ‘carotene-rich
fruits and vegetables’ found a non-significant reduced risk
when comparing the highest intake group against the low-
est (0.50, p value for linear trend 0.10).70 The third, which
evaluated yellow/orange vegetables in postmenopausal US
women, reported a significant reduced risk for the same com-
parison (0.58, 95% CI 0.39–0.87).71
All of the 18 case-control studies reported comparisons of
risk between high- and low-intake groups.23 24 26-29 39 41-43 46
49 50 63 65 72-75 Sixteen reported reduced risk estimates,23 26-29
39 41-43 50 63 65 72-75 6 of which were statistically significant.49
72 75 The other 2 were non-significant in the direction of
increased risk.24 27 28 39 43 46 The majority of studies were
hospital-based and analysed carrots as a separate exposure.
Tomatoes
One cohort study66 and 12 case-control studies26-29 39-43 46 50
58 62 65 investigated tomatoes and mouth, larynx, or pharynx
cancers.
The cohort study reported a non-significant increased risk
when comparing the highest intake group against the low-
est, with a wide confidence interval (1.7, 95% CI 0.8–3.7).66
Of the 12 case-control studies,26-29 39-43 46 50 58 62 65 10 report-
ed reduced risk estimates,26 29 39-43 46 50 58 62 65 5 of which were
statistically significant.26 29 39 40 62 Only 2 reported an
increased risk, which was non-significant.27 28 These studies
were also the only studies not to adjust for both smoking and
alcohol intake.
The general mechanisms through which vegetables could
plausibly protect against cancers of the mouth, larynx, and
pharynx are outlined below. 
Although all of the studies mentioned here adjust for
smoking behaviour and nearly all adjust for alcohol, the rel-
ative risk of smoking is large (particularly when combined
with alcoholic drinks). It is therefore difficult to eliminate
confidently the possibility of residual confounding with ways
of life associated with smoking: for instance, smokers con-
sume fewer vegetables than non-smokers.
A substantial amount of consistent evidence on non-
starchy vegetables, including specific subtypes, mostly
from case-control studies, shows a dose-response
relationship. There is evidence for plausible
mechanisms. Non-starchy vegetables probably protect
against mouth, pharynx, and larynx cancers. 
The Panel is aware that since the conclusion of the SLR, two
cohort76 77 and two case-control studies78 79 have been pub-
lished. This new information does not change the Panel judge-
ment (see box 3.8).
Oesophagus
Five cohort studies,70 80-83 37 case-control studies22 40 60 84-115
and 6 ecological studies51 52 116-119 investigated non-starchy
vegetables and oesophageal cancer. Eight case-control stud-
ies investigated vegetable and fruit consumption (com-
bined)95 104 107 114 120-123; 16 case-control studies investigated
raw vegetables40 60 85 95-97 103 109 113 114 124-129; 1 cohort study66
and 5 case-control studies86 93 107 124 125 investigated crucif-
erous vegetables; 1 cohort study82 and 8 case-control stud-
ies86 101 103 107 109 111 129 130 investigated allium vegetables; 1
cohort study66 and 11 case-control studies86 96 98 111 124 127 131-
135 investigated green, leafy vegetables; 1 cohort study66 and
9 case-control studies58 62 109 111 113 129-132 136 investigated
tomatoes.
Non-starchy vegetables
Data suggest an association with reduced risk. Of the five
cohort studies, three reported decreased risk when compar-
ing the highest intake group against the lowest, one of which
was statistically significant (0.66, 95% CI 0.44–0.99, non-
starchy vegetables82; 0.5, p value for linear trend 0.1, yel-
Figure 4.2.4 Non-starchy vegetables and oesophageal
cancer; cohort and case-control studies
Cohort
Hiryama 1990 1.06 (0.91–1.24)
Yu 1993 0.66 (0.44–0.99)
Guo 1999 0.80 (0.62–1.53)
Tran 2005 1.02 (0.85–1.18)
Case control
Cook-Mozalfari 1979 Men 0.85 (0.58–1.25)
Cook-Mozalfari 1979 Women 0.81 (0.49–1.33)
Notani 1967 1.06 (5.70–1.64)
Brown 1968 0.70 (0.39–1.20)
Jun-lao 1989 1.50 (0.19–1.89)
De Stefani 1990 0.56 (0.31–1.02)
Ren 1991 2.57 (1.25–5.27)
Negni 1991 0.20 (0.09–0.45)
Sammon 1992 1.44 (0.62–2.10)
Ho 1994 0.60 (0.30–1.35)
Sammon 1998 2.30 (1.06–4.89)
Lauroy 1998 0.24 (0.11–3.54)
De Stefani 1999 0.50 (0.29–0.87)
Takazaki 2000 0.60 (0.45–0.78)
De Stefani 2000 0.64 (0.34–1.20)
Levi 2000 0.19 (0.11–0.33)
Nayor 2000 0.53 (0.36–0.87)
Cheng 2000 0.56 (0.22–1.34)
Bosets 2000 0.79 (0.47–1.32)
Takezaki 2001 0.81 (0.40–1.43)
Terry 2001 0.60 (0.38–5.35)
Zhany 2001 1.94 (1.22–2.85)
Chen 2002 0.62 (0.26–1.35)
Cnuk 2002 10.10 (4.42–23.09)
Xibin 2003 0.44 (0.21–0.34)
Li 2003 0.76 (0.55–1.19)
Hung 2004 0.50 (0.31–0.82)
De Stefani 2005 0.53 (0.27–1.00)
Yang 2005 0.62 (0.32–1.18)
Relative risk (95% CI)
Relative risk, highest vs lowest exposure category
1 50.2 0.5 2
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low/orange vegetables70; and 0.8, 95% CI 0.60–1.0 and p
value for trend 0.08, stated as not statistically significant,
non-starchy vegetables80). The other two reported a non-
significant increased risk (1.06, 95% CI 0.91–1.24, non-
starchy vegetables81; and 1.02, 95% CI 0.88–1.19, fresh
non-starchy vegetables83) (figure 4.2.4). 
Most (29) of the case-control studies published decreased
risk estimates when comparing the highest intake group
against the lowest,40 60 85-90 94-99 101-105 107-109 111-115 which were
statistically significant in 14 (figure 4.2.4).40 88 89 94 97-99 101
102 104 105 109 Five studies reported statistically significant
increased risk.84 91 93 100 106 110 Meta-analysis was possible on
5 of the case-control studies, giving a summary effect
estimate of 0.87 (95% CI 0. 72–1.05) per 50 g/day incre-
ment, with high heterogeneity (figure 4.2.5). A potential
cause of heterogeneity is the disparate nature of the expo-
sure definition in different studies, some of which included
pickled and cured vegetables, cooked or uncooked
vegetables.
Two of the ecological studies reported a statistically sig-
nificant, positive association between vegetable consumption
and cancer incidence116 117; one reported a statistically sig-
nificant, negative association between vegetable consump-
tion and cancer incidence51; and the other three reported no
significant association between vegetable consumption and
cancer mortality.52 118 119
The Panel is aware that data from the European
Prospective Investigation into Cancer and Nutrition (EPIC;
521 457 participants from 10 European countries; 65 cases
of adenocarcinomas of the oesophagus), published after the
conclusion of the SLR,140 showed a non-significant reduced
risk (0.72, 95% CI 0.32–1.64) per 100 g/day increase in veg-
etable consumption (adjusted for several variables including
smoking and alcohol, red meat, and processed meat).
Non-starchy vegetables and fruits
Eight case-control studies investigated vegetable and fruit
consumption (combined) and oesophageal cancer. All
reported a decreased risk with increased consumption.95 104
107 114 120-123 Six of these were statistically significant.95 104 107
114 120 121
Raw vegetables
Sixteen case-control studies investigated raw vegetables and
oesophageal cancer.40 60 85 95-97 103 109 113 114 124-129
All of these studies reported associations with decreased
risk, which were statistically significant in 10.40 60 85 95 97 109
113 126 127 129 Dose-response meta-analysis was possible on five
studies, giving a summary effect estimate of 0.69 (95% CI
0.58–0.83) per 50 g/day increment (figures 4.2.6 and 4.2.7).
This exposure category could be less disparate than other
vegetable groupings, as it is clear that preserved vegetables
are not included and variation in cooking methods is
removed. This may account for the lack of heterogeneity in
direction of effect in this subcategory of vegetables.
Figure 4.2.5 Non-starchy vegetables and oesophageal
cancer; case-control studies
Jun-Lao Li 1989 1.08 (1.03–1.14)
De Stefani 2000 0.81 (0.66–0.99)
Levi 2000 0.66 (0.58–0.74)
Cheng 2000 0.90 (0.74–1.11)
De Stefani 2005 0.94 (0.86–1.02)
Summary estimate 0.87 (0.72–1.05)
Relative risk (95% CI)
Relative risk, per 50 g/day
1 20.5 0.75 1.5
Figure 4.2.7 Raw vegetables and oesophageal cancer;
case-control studies: dose response
Castelletto 1994
Cheng 2000
De Stefani 2000
Levi 2000
Sharp 2001
De Stefani 2003
0 200100 300
Non-starchy vegetables (g/day)
Figure 4.2.6 Raw vegetables and oesophageal cancer;
case-control studies
De Stefani 2000 0.38 (0.21–0.69)
Levi 2000 0.64 (0.57–0.72)
Cheng 2000 0.83 (0.68–1.02)
Sharp 2001 0.84 (0.75–0.95)
De Stefani 2003 0.60 (0.48–0.76)
Summary estimate 0.69 (0.58–0.83)
Relative risk (95% CI)
Relative risk, per 50 g/day
10.25 0.75 1.50.5
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Non-starchy root vegetables and tubers
One cohort study66 and six case-control studies114 122 128 132
136 141 142 reported separate risk estimates for consumption of
non-starchy root vegetables and tubers.
The single cohort study showed a non-significant increased
risk for the highest intake group when compared to the low-
est, after adjustment.66 All six case-control studies showed
non-significant decreased risk with increased intake.114 122 128
132 136 141 142
Cruciferous vegetables 
One cohort study66 and five case-control studies86 93 107 124 125
reported separate risk estimates for consumption of crucif-
erous vegetables.
The single cohort study showed a non-significant
decreased risk for increased intake of cauliflower or swede
and a non-significant increased risk for cabbage, after adjust-
ment.66 Three case-control studies showed decreased risk
with increased intake,93 107 124 which was statistically signif-
icant in two.93 124 One study showed a non-significant
increased risk125; and one study showed a non-significant
increased risk in women and a non-significant decreased risk
in men.86
Allium vegetables 
One cohort study82 and eight case-control studies86 101 103 107
109 111 129 130 reported separate risk estimates for allium
vegetable consumption.
The single cohort study showed that garlic intake had no
effect on risk.82 Four case-control studies showed non-sig-
nificant decreased risk with increased intake.101 103 107 130 Two
studies showed non-significant increased risk.86 111 One study
showed a statistically significant decreased risk for garlic and
that onions/leeks had no effect on risk109; and one study
showed a statistically significant reduced risk for onions and
a non-significant increased risk for garlic.129
Green, leafy vegetables 
One cohort study66 and 11 case-control studies86 96 98 111 124
127 131-135 reported separate risk estimates for green, leafy veg-
etable consumption.
The single cohort study showed no effect for the highest
intake group of lettuce when compared to the lowest.66 Ten
case-control studies showed decreased risk with increased
intake,96 98 111 124 127 131-135 which was statistically significant
in five.96 127 132-134 One study showed a non-significant
increased risk in women and a non-significant decreased risk
in men.86
Tomatoes
One cohort study66 and nine case-control studies58 62 109 111
113 129-132 136 reported separate risk estimates for consumption
of tomatoes.
The single cohort study showed a non-significant increased
risk for the highest intake group of lettuce, when compared
to the lowest, after adjustment.66 Eight case-control studies
showed decreased risk with increased intake,58 62 109 111 113 129
131 132 136 which was statistically significant in two.62 129 One
study showed no effect on risk.130
The general mechanisms through which vegetables could
plausibly protect against oesophageal cancer are outlined
below. 
There is more evidence, including on vegetable
subtypes, from case-control studies than from cohort
studies, but both are moderately consistent and there
is some evidence for a dose-response relationship.
There is evidence for plausible mechanisms. Non-
starchy vegetables probably protect against
oesophageal cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort140 and two case-control studies78 143 have been pub-
lished. This new information does not change the Panel judge-
ment (see box 3.8).
Stomach 
Ten cohort studies,71 80 140 144-150 45 case-control studies,109
151-195 and 19 ecological studies51 52 116-119 196-209 investigated
total vegetables. Eleven cohort studies,71 144 150 210-218 21 case-
control studies,89 165 169 178 179 188 191 219-232 and 8 ecological
studies233-240 investigated green-yellow vegetables; 6 cohort
studies70 140 144 146 150 241, 13 case-control studies,162 174 175 179
180 187 223 227 229 230 232 242 243 and 2 ecological studies202 240
investigated green, leafy vegetables; 3 cohort studies70 146 241
and 19 case-control studies58 109 129 152 156 164 171 172 174 232 243-
251 investigated tomatoes; 2 cohort studies150 214 and 6 case-
control studies157 165 169 226 228 243 investigated white or pale
vegetables; 6 cohort studies,146 148 214 252-254 25 case-control
studies,109 129 161 162 167 172 174 183 184 191 219 225 226 243 247 248 250 255-
264and 3 ecological studies202 208 238 investigated raw vegeta-
bles; 5 cohort studies144 146 148 253 265 and 6 case-control
studies158 161 162 164 257 266 267 investigated non-starchy veg-
etables and fruits. 
Non-starchy vegetables
Of 12 independent estimates from the 10 cohort studies that
investigated non-starchy vegetable consumption, none was
statistically significant.71 80 140 144-150 Seven studies showed
non-significant reduced risk71 140 144-147 150 and 2 reported
non-significant increased risk.80 149 One study showed non-
significant increased risk in women and non-significant
decreased risk in men.148 Most effect estimates were close to
1. Meta-analysis was possible on 9 independent estimates
from 7 cohort studies, giving a summary effect estimate of
0.98 (95% CI 0.91–1.06) per 100 g/day, with moderate het-
erogeneity (figure 4.2.8).
Of 45 case-control studies that reported on non-starchy
vegetable consumption, 28 reported statistically significant
decreased risk.109 151-153 156-160 163 164 168 169 171 173 176-179 181 182
184 185 187 190 192 The majority of the 17 remaining studies that
reported no significant effect on risk were in the direction of
decreased risk.155 162 165-167 170 172 174 183 191 194 195 Four studies
showed non-significant increased risk,180 188 189 193 1 study
showed no effect on risk,154 and 1 study stated that there was
no significant association.175 One study showed non-signif-
icant decreased risk in women and non-significant increased
risk in men186; and 1 study showed statistically significant
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decreased risk in men and non-significant increased risk in
women.161 No studies reported statistically significant
increased risk. Meta-analysis was possible on 20 studies, giv-
ing a summary effect estimate of 0.70 (95% CI 0.62–0.79)
per 100 g/day, with high heterogeneity (figure 4.2.8). This
heterogeneity tended to reflect differences in size, rather
than direction, of effect. 
A dose-response relationship was apparent from case-
control but not cohort data.
Results from ecological studies reporting on non-starchy
vegetable consumption were mixed, with almost as many
studies reporting increased risk as reported decreased 
risk.51 52 116-119 196-209
Green-yellow vegetables
Eight of the 11 cohort studies that reported on green-yellow
vegetable consumption showed decreased risk,71 144 150 210 211
214-217 statistically significant in 4.150 210 215 216 Two other stud-
ies showed non-significant increased risk212 213 and 1 other
study reported no statistically significant association.218
Meta-analysis was possible on 6 independent estimates from
5 studies, giving a summary effect estimate of 0.63 (95% CI
0.48–0.82) per 100 g/day, with no heterogeneity (figure
4.2.9).
Of the 21 case-control studies that reported on green-
yellow vegetable consumption, 16 showed decreased risk,89
165 169 178 179 191 219 220 222-228 230-232 statistically significant in
12.89 165 169 178 179 191 220 222 223 226 231 232 The remaining 5 stud-
ies reported increased risk,111 188 221 229 1 of which was sta-
tistically significant.221 Meta-analysis was possible on 12
independent estimates from 11 studies, giving a summary
effect estimate of 0.59 (95% CI 0.46–0.75) per 100 g/day,
with high heterogeneity (figure 4.2.9).
All of the studies adjusted for age and sex; none was
adjusted for infection with Helicobacter pylori. Nine studies
were maximally adjusted, seven of which reported a
significant negative association with higher consumption of
green-yellow vegetables, and the other two reported no
significant association.
A dose-response relationship was apparent from both
Figure 4.2.8 Non-starchy vegetables and stomach cancer;
cohort and case-control studies
Cohort
Chyou 1990 Men 0.76 (0.53–1.10)
Guo 1994 1.05 (0.93–1.18)
Botterweck 1998 0.92 (0.78–1.09)
McCullough 2001 Men 0.98 (0.84–1.02)
McCullough 2001 Women 1.16 (1.00–1.34)
Fujino 2002 Men 1.12 (0.93–1.34)
Fujino 2002 Women 1.03 (0.77–1.36)
Kobayashi 2002 0.86 (0.72–1.02)
Gonzalez 2006 0.91 (0.66–1.28)
Summary estimate 0.98 (0.91–1.06)
Case control
Risch 1985 0.84 (0.73–0.97)
You 1988 0.81 (0.75–0.86)
De Stefani 1990 0.40 (0.27–0.60)
Menik 1992 0.36 (0.16–0.80)
Hansson 1993 0.60 (0.46–0.79)
Cornee 1995 0.85 (0.57–1.28)
De Stefani 1998 0.39 (0.32–0.48)
Ji 1998 Men 0.86 (0.82–0.90)
Ji 1998 Women 0.94 (0.86–1.01)
Ward 1999 0.22 (0.11–0.43)
Mathew 2000 0.52 (0.18–1.46)
De Stefani 2001 0.89 (0.60–1.32)
Takezaki 2001 0.47 (0.26–0.81)
Sriamporn 2002 0.86 (0.56–1.33)
Hara 2003 1.06 (0.84–1.33)
Sipetic 2003                              0.07 (0.03–0.15)
Suh 2003 1.04 (0.89–1.22)
Lagiou 2004 0.51 (0.39–0.68)
Lissowska 2004 0.90 (0.74–1.09)
Boccia 2005 1.09 (0.56–2.12)
Nan 2005 0.90 (0.66–1.25)
Summary estimate 0.70 (0.62–0.79)
1 20.5 0.75 1.5
Relative risk (95% CI)
Relative risk, per 100 g/day
Figure 4.2.9 Green-yellow vegetables and stomach
cancer; cohort and case-control studies
Cohort
Chyou 1990 Men 0.74 (0.52–1.05)
Kasum 2002 Women 0.57 (0.19–1.75)
Kobayashi 2002 0.56 (0.33–0.94)
Ngoan 2002 0.41 (0.18–0.94)
Khan 2004 Men 0.66 (0.11–3.89)
Khan 2004 Women 0.18 (0.02–2.13)
Summary estimate 0.63 (0.48–0.82)
Case control
Lee 1990 0.94 (0.68–1.29)
Cai 1991 0.44 (0.38–0.50)
Negri 1991 0.24 (0.13–0.44)
Hoshiyama and Sasaba 1992 0.49 (0.32–0.74)
Ji 1998 Men 0.77 (0.69–0.86)
Ji 1998 Women 0.89 (0.77–1.04)
Ward 1999 0.33 (0.24–0.46)
Hamada 2002 1.09 (0.41–2.93)
Nishimoto 2002 0.62 (0.33–3.43)
Hara 2003 1.59 (0.73–3.43)
Ito 2003 Women 0.55 (0.38–0.81)
Lissowska 2004 0.28 (0.12–0.66)
Summary estimate 0.59 (0.46–0.75)
Relative risk (95% CI)
Relative risk, per 100 g/day
1 20.5
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cohort and case-control data on green-yellow vegetable
consumption (figure 4.2.10).
Five out of the eight ecological studies that reported on
green-yellow vegetable consumption showed decreased risk
with increased consumption,236-240 two showed no associa-
tion,233 234 and one study showed increased risk.235
This exposure included green-yellow vegetables, green
vegetables, yellow vegetables, yellow-orange vegetables, car-
rots and pumpkins, and high-carotenoid vegetables. 
Green, leafy vegetables 
Four cohort studies showed non-significant decreased 
risk with increased intake70 144 146 150; two studies showed
non-significant increased risk.140 241 Meta-analysis was pos-
sible on four cohort studies, giving a summary effect estimate
of 0.85 (95% CI 0.58–1.25) per 100 g/day, with no hetero-
geneity.140 144 146 150
Nine case-control studies showed decreased risk with
increased intake,179 187 223 227 229 230 232 242 243 which was sta-
tistically significant in three,223 232 243 and in men, but not
women, in a fourth study.227 Two further studies showed
non-significant increased risk174 180; one study showed no
effect on risk162; and one study stated that there was no sig-
nificant association.175 Meta-analysis was possible on six
case-control studies, giving a summary effect estimate of
0.90 (95% CI 0.70–1.16) per 100 g/day, with no hetero-
geneity.162 179 180 187 229 230
One ecological study showed statistically significant
decreased risk240 with high intake, the other showed non-
significant increased risk.202
One cohort study146 and 15 case-control studies152 156 164
167 172 231 243-246 261 268-271 also reported separately on lettuce
and salad leaves. The single cohort study showed a non-
significant decreased risk with increased intake. The effect
estimate was 0.88 (95% CI 0.38–2.60) per 50 g/day.146
Twelve case-control studies showed decreased risk with
increased intake of lettuce or salad leaves,152 156 164 167 231 243
246 261 268-271 which was statistically significant in 7.156 243 246
261 268-270 Two studies showed non-significant increased
risk.172 245 One study showed no effect on risk.244 Meta-
analysis was possible on 5 case-control studies that investi-
gated lettuce or salad leaves, giving a summary effect
estimate of 0.43 (95% CI 0.24–0.77) per 50 g/day, with high
heterogeneity.152 231 268-270 Heterogeneity was related
primarily to the size, and not the direction, of the effect.
Tomatoes
Two cohort studies showed a non-significant increased 
risk with increased intake.146 241 One study stated that there
was a non-significant decreased risk (unquantified).70
The effect estimates were 1.81 (95% CI 0.85–3.85) per 100
g/day,146 and 1.1 (95% CI 0.76–1.60) for women and 
1.19 (95% CI 0.88–1.61) for men (both for the highest
Figure 4.2.11 White or pale vegetables and stomach
cancer: cohort and case-control studies
Cohort
Kobayashi 2002 0.52 (0.23–1.18)
Khan 2004 Men 0.63 (0.09–4.12)
Khan 2004 Women 0.15 (0.01–2.34)
Summary estimate 0.49 (0.24–1.01)
Case control
Risch 1985 0.29 (0.07–1.15)
Cai 1991 0.45 (0.34–0.60)
Hoshiyama and Sasaba 1992 0.86 (0.32–1.09)
Summary estimate 0.57 (0.32–1.02)
Relative risk (95% CI)
Relative risk, per 100 g/day
1 20.5
Figure 4.2.10 Green-yellow vegetables and stomach
cancer; cohort and case-control studies:
dose response
Cohort
Chyou 1990 Men
Kasum 2002 Women
Kobayashi 2002
Ngoan 2002
Khan 2004 Men
Khan 2004 Women
Case control
Lee 1990
Cai 1991
Negri 1991
Hoshiyama and Sasaba 1992
Ji 1998 Men
Ji 1998 Women
Ward 1999
Hamada 2002
Nishimoto 2002
Hara 2003
Ito 2003 Women
Lissowska 2004
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intake group when compared to the lowest).241
Most case-control studies showed decreased risk with
increased intake, which was statistically significant in 10.58
109 152 156 164 171 232 246-248 No studies showed statistically sig-
nificant increased risk. Meta-analysis was possible on 6 case-
control studies, giving a summary effect estimate of 0.40
(95% CI 0.19–0.82) per 100 g/day, with high hetero-
geneity.109 152 171 232 244 250
White or pale vegetables
This incorporates a wide range of vegetables. For example,
in Japan white vegetables such as daikon (radish) are com-
monly consumed. Descriptions used for this exposure were
white vegetables, pale green or light green vegetables, and
raw chicory.
Both cohort studies showed non-significant decreased risk
with increased intake.150 214 Meta-analysis was possible on
both studies, giving a summary effect estimate of 0.49 (95%
CI 0.24–1.01) per 100 g/day, with no heterogeneity (figure
4.2.11).
All six case-control studies showed decreased risk with
increased intake,157 165 169 226 228 243 which was statistically sig-
nificant in three.165 169 243 Meta-analysis was possible on three
studies, giving a summary effect estimate of 0.57 (95% CI
0.32–1.02) per 100 g/day, with high heterogeneity, which
was caused by varying size, not direction of the effect (figure
4.2.11).
Raw vegetables
Of seven independent estimates from six cohort studies that
reported on raw vegetables, four reported non-significant
reduced risk,146 214 253 254 two reported non-significant
increased risk,214 252 and the other reported a significant
increased risk.148 Two of the increased risk estimates, includ-
ing the one that reached statistical significance, were strat-
ified for women only. Meta-analysis was possible on four
estimates from three studies (not including the one that was
statistically significant), giving a summary effect estimate of
0.80 (95% CI 0.54–1.18) per 100 g/day, with no hetero-
geneity (figure 4.2.12).
Of the 25 case-control studies that reported on raw veg-
etables, 21 reported decreased risk,109 129 161 162 167 172 174 183
184 191 219 225 226 243 247 248 250 255 256 258 260 261 264 which was sta-
tistically significant in 13.129 161 172 174 225 226 243 247 248 256 260 261
264 None of the remaining 4 studies that reported increased
risk reached statistical significance.257 259 262 263 Meta-analy-
sis was possible on 14 independent estimates from 13 case-
control studies, giving a summary effect estimate of 0.50
(95% CI 0.38–0.65) per 100 g/day, with moderate hetero-
geneity (figure 4.2.12).
A dose-response relationship was apparent from case-
control but not cohort data (figure 4.2.13).
Of the three ecological studies, two reported statistically sig-
nificant reduced risk208 238 and one reported a non-significant
increased risk with increased raw vegetable consumption.202
Figure 4.2.12 Raw vegetables and stomach cancer;
cohort and case-control studies
Cohort
Botterweck 1998 0.51 (0.05–4.73)
Galanis 1998 0.81 (0.53–1.23)
Khan 2004 Men 0.63 (0.16–2.51)
Khan 2004 Women 2.03 (0.14–29.46)
Summary estimate 0.80 (0.54–1.18)
Case control
Jedrychowski 1981 0.10 (0.02–0.41)
Jedrychowski 1986 1.56 (0.12–20.74)
Buiatti 1989 0.56 (0.45–0.71)
Caggon 1989 0.13 (0.01–2.88)
Kato 1990 Men 0.59 (0.38–0.91)
Kato 1990 Women 0.86 (0.48–1.48)
Hoshiyama and Sasaba 1992 0.44 (0.29–0.68)
Ramon 1993 0.35 (0.16–0.78)
Cornee 1995 0.27 (0.10–0.72)
Huang 1999 0.77 (0.62–0.94)
De Stefani 2001 0.46 (0.16–1.34)
Sriamporn 2002 0.40 (0.01–15.73)
Lee 2003 0.11 (0.04–0.27)
Lissowska 2004 0.82 (0.52–1.28)
Summary estimate 0.50 (0.38–0.65)
Relative risk (95% CI)
Relative risk, per 100 g/day
1 20.5
Figure 4.2.13 Raw vegetables and stomach cancer;
case-control studies: dose response
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Non-starchy vegetables and fruits
All five cohort studies showed decreased risk for the high-
est intake group when compared to the lowest,144 146 148 253
265 which was statistically significant in two,253 265 and in
men, but not women, in a third study.148 Meta-analysis was
possible on two cohort studies, giving a summary effect esti-
mate of 0.81 (95% CI 0.58–1.14) per 100 g/day.146 253 All
six case-control studies showed decreased risk with increased
intake,158 161 162 164 257 266 267which was statistically significant
in four.158 162 164 257 Meta-analysis was possible on two case-
control studies, giving a summary effect estimate of 0.79
(95% CI 0.63–0.99) per 100 g/day.162 267
The stomach is a particularly unusual chemical environ-
ment and it is possible that, in addition to the general mech-
anisms described below, specific mechanisms apply, for
instance, in relation to nitrosamine formation.
A substantial amount of evidence is available,
including on specific subtypes, particularly green-
yellow vegetables, with a dose-response relationship in
case-control, but not cohort data. There is evidence for
plausible mechanisms. Vegetables probably protect
against stomach cancer. 
Nasopharynx 
Five case-control studies272-276 and two ecological studies51
277 investigated non-starchy vegetables and nasopharyngeal
cancer; a further four case-control studies investigated green
vegetables.278-281 Preserved vegetables were excluded from
all categories.
Eight of the case-control studies reported reduced risk
when comparing high against low intake groups,272 273 275 276
278-281 which was statistically significant in three of the non-
starchy vegetable studies272 275 276 and in two of the green
vegetable studies.279 280 One other study stated that there was
no significant association.274 All studies were based in China.
The ecological studies produced mixed results. One
showed significant correlations between the consumption 
of fresh vegetables and reduced risk of nasopharyngeal car-
cinoma after adjusting for age (r2 = -0.77, p = 0.009 among
men and r2 = -0.75, p = 0.013 among women).51 The second
study showed an increasing risk with increases 
in local consumption of non-starchy vegetables (r2 = 2.36).277
This study did not report any adjustments for potential
confounding variables or whether the finding was signifi-
cant.
The general mechanisms through which vegetables could
plausibly protect against nasopharyngeal cancer are outlined
below. 
The evidence for non-starchy vegetables is sparse but
generally consistent. There is limited evidence
suggesting that non-starchy vegetables protect against
nasopharyngeal cancer.
Lung 
Seventeen cohort studies,282-300 27 case-control studies,301-331
and 6 ecological studies52 116 332-335 investigated total veg-
etables and lung cancer (some studies did not separate non-
starchy vegetables from this grouping); in addition, there
was 1 relevant pooling project publication.336 Three cohort
studies337-339 and 1 case-control study321 investigated non-
starchy vegetables specifically; 5 cohort studies285 292 299 340
341 and 17 case-control studies65 301 307 312 320-322 326 330 342-350
investigated green, leafy vegetables (excluding cruciferous);
2 cohort studies investigated non-starchy root vegetables and
tubers289 291; and 6 cohort studies,285 289 293 299 339 341 21 case-
control studies,65 261 304 307 313 320-322 325-327 342 344 346-348 351-358
and 1 ecological study333 investigated carrots specifically.
Total vegetables
Out of 19 effect estimates from 17 cohort studies, 14 showed
reduced risk with higher levels of vegetable consumption,282
283 286-289 291-297 299 300 which was statistically significant in 3286
297 299 300 and in women only in another285; 1 reported no
effect on risk,298 2 showed increased risk,284 290 none of which
was statistically significant, and 2 showed non-significant
increased risk in men but not women.285 296 Meta-analysis
was possible on 10 studies, all of which adjusted for smok-
ing, giving a summary effect estimate of 0.95 (95% CI
0.92–0.98) per 80 g serving/day, with no heterogeneity.282
283 285-287 292 296 297 300 Two studies did not adjust for smoking,
1 of which showed a non-significant lower vegetable intake
in cases than in controls,295 and the other reported no effect
on risk.298
Pooled analysis from 8 cohort studies (over 430 000 par-
ticipants, followed up for 6 to 16 years, more than 3200 lung
cancer cases) showed a non-significant reduced risk when
comparing high against low intake groups (0.88, 95% CI
0.78–1.00), with a p value for trend of 0.12.336
Out of 27 case-control studies, 17 showed reduced risk
with higher levels of vegetable consumption,301-304 306-312 314
316 317 319 322 325-331 which was statistically significant in 8303
304 306 308-310 314 316 319 325-328; 7 studies showed non-significant
increased risk305 313 315 318 320 323 324 and 1 study showed no
effect on risk.321 Meta-analysis was possible on 10 studies,
all of which adjusted for smoking, giving a summary effect
estimate of 0.67 (95% CI 0.53–0.86) per serving/day, with
high heterogeneity.303 308 309 313 316 317 323 325 326 328 329 Three
studies did not adjust for smoking, all of which showed
statistically significant decreased risk.306 316 319
A dose-response relationship was apparent from both
cohort and case-control data.
Most of the ecological studies are suggestive of an associ-
ation between increased vegetable consumption and
decreased risk.
Non-starchy vegetables
All three cohort studies reported non-significant reduced risk
when comparing highest and lowest vegetable intakes, with
effect estimates of 0.9 (lung cancer mortality, 95% CI
0.61–1.33),337 0.75 (95% CI 0.41–1.37),338 and 0.54 (p value
for trend 0.2, squamous and small-cell carcinomas only)
when comparing the highest with the lowest intake
groups.339 The single case-control study reported a non-
significant increased risk when comparing high and low
vegetable intakes.321
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Green, leafy vegetables
All five cohort studies reported reduced risk when compar-
ing high to low intake groups,285 292 299 340 341 which was sta-
tistically significant in one.299 Dose-response meta-analysis
was possible on three cohort studies, giving a summary effect
estimate of 0.91 (95% CI 0.89–0.93) per serving/day, with
no heterogeneity.285 340 The two non-included studies report-
ed high-versus-low effect estimates of 0.89 (95% CI
0.66–1.19)292 and 0.45 (95% CI 0.26–0.78).299 All five
cohort studies adjusted for smoking.
Of the 17 case-control studies, 12 reported decreased risk65
301 307 320 321 326 330 342 343 345-348 (reaching statistical significance
in 2343 345 348 and 5 reported non-significant increased risk.312
322 344 349 350 Dose-response meta-analysis was possible on 8
case-control studies, giving a summary effect estimate of
0.96 (95% CI 0.91–1.02) per serving/day, with moderate-
to-high heterogeneity.65 322 326 343 346-349 Some of this hetero-
geneity may be due to variation in exposure classification,
with some studies listing ‘green vegetables’ being included
in this category.
Total non-starchy root vegetables and tubers
Both cohort studies reported reduced risk with increased con-
sumption,289 291 with effect estimates of 0.56 (95% CI
0.36–0.88)289 when comparing the highest with the lowest
intake groups, and 0.70 (95% CI 0.53–0.93) when compar-
ing the third highest quartile with the lowest (the highest
intake group had a non-significant decreased risk).291 Both
studies adjusted for smoking.
Carrots 
All six cohort studies reported reduced risk,285 289 293 299 339 341
which was statistically significant in one (0.4, p value for
trend 0.003).341 The other, non-significant, risk estimates
ranged from 0.61 to 0.82.285 289 293 299 339
Twenty of the 21 case-control studies showed decreased
risk when comparing high against low intake groups,65 261 304
307 313 321 322 325-327 342 344 346-348 351-358 which was statistically
significant in 8.261 304 321 325 327 346 347 351 353 356-358 One study
reported no effect.320 Meta-analysis on studies that adjusted
for smoking was possible on 11 studies, giving a summary
effect estimate of 0.81 (95% CI 0.73–0.89), per serving/day
increment, with high heterogeneity.65 307 313 322 325-327 347 348 351
352 354-357
There was some evidence of publication bias for both
cohort and case-control studies.
The single ecological study reported lower mean intake of
carrots in an area of high lung cancer risk.333
The general mechanisms through which vegetables could
plausibly protect against lung cancer are outlined below. 
A substantial amount of evidence is available but some
studies were not adjusted for smoking. A dose-
response relationship is apparent from both cohort and
case-control studies. There is limited evidence
suggesting that non-starchy vegetables protect against
lung cancer.
Colorectum
Seventeen cohort studies81 359-379 and 71 case-control 
studies investigated non-starchy vegetables and colorectal
cancer.
Of 20 effect estimates from 17 cohort studies that report-
ed comparisons of the highest and lowest intake groups, 11
were in the direction of reduced risk,81 362 364 366 371-374 376-378
3 of which were statistically significant.81 366 371 377 One study
showed non-significant decreased risk in women and non-
significant increased risk in men.360 The other 8 reported
non-significant increased risk.359 361 363 365 367-370 375 One study
stated that there was no significant association.379 Meta-
analysis was possible on 9 independent estimates from 6
studies, giving a summary effect estimate of 1.00 (95% CI
0.90–1.11) per 2 servings/day increment, with moderate to
high heterogeneity.360 362-364 366 370
Because of the abundant prospective data from cohort
studies, case-control studies were not summarised.
The general mechanisms through which vegetables could
plausibly protect against colorectal cancer are outlined
below. 
A substantial amount of evidence is available but it is
inconsistent. There is limited evidence suggesting that
non-starchy vegetables protect against colorectal
cancer.
The Panel is aware that since the conclusion of the SLR, three
case-control studies78 261 380 have been published. This new
information does not change the Panel judgement (see box
3.8).
Ovary 
Five cohort studies,381-385 eight case-control studies,89 386-392
and two ecological studies393 394 investigated non-starchy
vegetables, and three cohort studies381-383 and two case-
control studies395 396 investigated green, leafy vegetables. 
Non-starchy vegetables
All of the cohort studies reported decreased risk with
increased vegetable consumption.381-385 Meta-analysis was
possible on four cohort studies, giving a summary effect esti-
mate of 0.64 (95% CI 0.33–0.97) for an increase of one serv-
ing/day, with no heterogeneity.381 383-385 The study that could
not be included reported an effect estimate of 0.76 (95% CI
0.42–1.37) for the highest intake group when compared with
the lowest.382
Pooled analysis from 12 cohort studies (over 560 000 par-
ticipants, followed up for 7 to 22 years, more than 2100 lung
cancer cases) showed a non-significant reduced risk when
comparing high against low intake groups (0.90, 95% CI
0.78–1.04), with a p value for trend of 0.06.397
All of the case-control studies reported reduced risk,89 
386-392 which was statistically significant in five.89 386 387 391 392
One ecological study reported a non-significant positive
regression/correlation between continents393 and the 
other reported a negative regression/correlation between
countries.394
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Green, leafy vegetables
All three cohort studies reported decreased risk with
increased green, leafy vegetable consumption.381-383 Meta-
analysis was possible on two cohort studies, giving a sum-
mary effect estimate of 0.96 (95% CI 0.88–1.03) per two
servings/day, with no heterogeneity.381 383 The third cohort
study reported a statistically significant reduced risk (0.44,
95% CI 0.25–0.79) when comparing the highest and lowest
intake groups.382
Both case-control studies reported reduced risk from
increased consumption of green, leafy vegetables,395 396 one
of which was statistically significant.396
The general mechanisms through which vegetables could
plausibly protect against ovarian cancer are outlined below. 
Evidence from cohort and case-control studies is
sparse. There is limited evidence suggesting that non-
starchy vegetables protect against ovarian cancer.
The Panel is aware that since the conclusion of the SLR one
case-control study78 has been published. This new information
does not change the Panel judgement (see box 3.8).
Endometrium
Ten case-control studies investigated non-starchy vegetable
consumption.398-407 Seven case-control studies investigated
cruciferous vegetables and endometrial cancer.398-400 405 407-410
Of the 10 studies that reported on non-starchy vegetables,
7 showed decreased risk when comparing the highest with
the lowest intake groups,400-405 407 which was statistically sig-
nificant in 5.400 402-404 407 Two reported a non-significant
increased risk398 406 and the other showed no effect on risk.399
Meta-analysis was possible on 8 studies, giving a summary
estimate of 0.90 (95% CI 0.86–0.95) per 100 g of vegetable
intake/day, with low heterogeneity.399 401-407 A dose-response
relationship was apparent from these data.
Five out of the seven case-control studies that investigat-
ed cruciferous vegetables reported reduced risk when com-
paring high to low intake groups,399 405 407-410 which was
statistically significant in one.405 The other two studies
reported non-significant increased risk.398 400 Meta-analysis
was possible on five studies, giving a summary effect esti-
mate of 0.79 (95% CI 0.69–0.90) per 100 g/day, with no het-
erogeneity.399 405 407 409 410 The two studies that could not be
included suggested increased risk, though not statistically
significant.398 400
A dose-response relationship is apparent from case-control
data.
The general mechanisms through which vegetables could
plausibly protect against endometrial cancer are outlined
below. Cruciferous vegetables contain glucosinolates. Certain
hydrolysis products of glucosinolates, including indoles and
isothiocyanates, have shown anti-carcinogenic properties in
laboratory experiments and in diets in live experiments in
animals.411 The human genotype of glutathione S-transferase
has been shown to have a significant role in the metabolism
of these phytochemicals and may therefore influence poten-
tial anti-cancer properties.412
Evidence comes from case-control studies only. 
There is limited evidence suggesting that non-starchy
vegetables protect against endometrial cancer.
General mechanisms — non-starchy vegetables 
Also see Chapter 2. Non-starchy vegetables provide a pletho-
ra of potentially cancer-preventive substances, including sev-
eral antioxidant nutrients (such as carotenoids and vitamin
C), dietary fibre, as well as phytochemicals (such as glu-
cosinolates, dithiolthiones, indoles, chlorophyll, flavonoids,
allylsulphides, and phytoestrogens). Phytochemicals might
influence cancer risk through their antioxidant activities,
modulation of detoxification enzymes, stimulation of the
immune system, antiproliferative activities, and/or modula-
tion of steroid hormone concentration and hormone metab-
olism, to name a few possible mechanisms. Non-starchy
vegetables are also a source of folate, which plays an impor-
tant role in synthesis and methylation of DNA. Abnormal
DNA methylation has been linked to aberrant gene expres-
sion and also to cancers at several sites, and may be partic-
ularly important in rapidly dividing tissues. It is difficult to
unravel the relative importance of each constituent and like-
ly that a protective effect may result from a combination of
influences on several pathways involved in carcinogenesis.
Carrots are a source of carotenoids, particularly alpha-
carotene and beta-carotene, as well as other vitamins and
phytochemicals with potentially protective effects. Tomatoes
are a source of vitamin C and carotenoids, particularly
lycopene. Potential mechanisms of inhibition include the
antioxidant properties of carotenoids and ligand-dependent
signalling through retinoid receptors (see chapter 4.2.5.3). 
There is a complex mixture of phytochemicals present in
whole vegetables and these may have additive and syner-
gistic effects responsible for anti-cancer activities. 
4.2.5.1.1  Allium vegetables  
Stomach 
Two cohort studies,413 414 27 case-control studies,109 129 152 162
164 171 178 182 185 187 191 194 195 232 243-245 247 248 251 266 270 415-419 and
2 ecological studies202 208 investigated allium vegetables and
stomach cancer; 1 cohort study,413 16 case-control studies,109
129 182 184 195 232 246 247 251 262 418 420-422 and 2 ecological studies203
208 investigated garlic and stomach cancer. There was also 1
relevant intervention study that combined allitridium and
selenium supplements.423 424
Allium vegetables
Both cohort studies reported decreased risk,413 414 which was
statistically significant in one.413 Meta-analysis was possible
on both, giving a summary effect estimate of 0.55 (95% CI
0.35–0.87) per 100 g/day, with no heterogeneity (figure
4.2.14).413 414
Twenty of the case-control studies showed reduced risk
when comparing high with low intake groups,129 152 162 164 171
178 182 185 187 191 194 195 232 243 247 248 270 416 418 419 which was sta-
tistically significant in 12.129 152 162 164 182 187 194 243 248 270 416 418
Four studies showed increased risk,109 245 266 415 which was sta-
tistically significant in 2,245 and the remaining 3 reported no
significant effect on risk.244 251 417 Meta-analysis was possible
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on 14 studies, giving a summary effect estimate of 0.59 (95%
CI 0.47–0.74) per 100 g/day, with high heterogeneity 
(figure 4.2.14).109 129 152 162 171 178 182 187 191 194 232 247 270 416
Both ecological studies reported statistically significant
decreased risk with increased consumption.202 208
A statistically significant dose-response relationship is
apparent from cohort and case-control data.
Garlic
The single cohort study, which was specific to supplemen-
tary garlic, showed a non-significant increased risk when
comparing garlic supplement use versus no supplement use
(1.29, 95% CI 0.62–2.67).413
Fifteen of the case-control studies showed decreased risk
when comparing highest to lowest intake groups,109 129 182 184
195 232 246 247 251 418 420-422 which was statistically significant in
seven.129 182 232 246 247 418 420 422 One study showed a non-
significant increased risk.262 Meta-analysis was possible on
five studies, giving a summary effect estimate of 0.41 
(95% CI 0.23–0.73) per serving/day.109 129 182 232 421
One ecological study showed statistically significant
decreased risk with increased intake208; the other showed no
significant association.203
Intervention study
The double-blind, randomised trial had an intervention dura-
tion of 3 years, and a 5- and 10-year follow-up, and more
than 5000 participants, all of whom had been identified as
being at increased risk of stomach cancer. The intervention
was a combined selenium/allitridium supplement.423 424 The
5-year follow-up suggested that the intervention was
effective in reducing stomach cancer incidence in men (0.36,
95% CI 0.14–0.92) but not in women (1.14, 95% CI
0.22–5.76).423 The statistically significant protective effect
for men had dissipated at the 10-year follow-up.424 (Also see
chapter 4.2.5.8.)
Allium vegetables are high in flavonols and organosulphur
compounds. They also, particularly garlic, have antibiotic
properties. Although this may act directly against H pylori
(a known cause of stomach cancers), a study in humans has
not shown this effect.425 It is also possible that antibacteri-
al effects of garlic might inhibit the secondary colonisation
of the stomach after H pylori-induced atrophy. At present,
there is no evidence to support or refute this mechanism. An
animal study provides evidence that dietary garlic can reduce
the severity of H pylori-associated gastritis.426
The evidence, though not copious and mostly from
case-control studies, is consistent, with a dose-
response relationship. There is evidence for plausible
mechanisms. Allium vegetables probably protect
against stomach cancer.
Colorectum 
Garlic
Two cohort studies361 362 and six case-control studies427-435
investigated garlic consumption.
Both cohort studies reported non-significant decreased risk
when comparing the highest with the lowest intake groups,
with effect estimates of 0.77 (95% CI 0.51–1.16)361 and 0.68
(95% CI 0.46–1.01) (figure 4.2.15).362
All six case-control studies showed decreased risk for the
highest consumers of garlic,427-435 which was statistically sig-
nificant in three (figure 4.2.16).431 432
There is considerable preclinical evidence with model car-
cinogens and transplantable tumours that supports an anti-
cancer effect of garlic and some of its allyl sulphur
components. Animal studies demonstrate that allyl sulphides
effectively inhibit colon tumour formation and also can
inhibit cell growth in the laboratory.436-439
Figure 4.2.14 Allium vegetables and stomach cancer;
cohort and case-control studies
Cohort
Dorant 1996 0.55 (0.35–0.88)
Gonzalez 2006 0.31 (0.01–11.69)
Summary estimate 0.55 (0.35–0.87)
Case control
Haenszel 1972 0.49 (0.33–0.72)
Trichopoulos 1985 0.23 (0.16–0.35)
You 1988 0.32 (0.17–0.59)
Buiatti 1989 0.85 (0.72–1.00)
Hansson 1993 0.79 (0.47–1.34)
Ji 1998 Men 0.66 (0.43–1.02)
Ji 1998 Women 0.69 (0.38–1.24)
Gao 1999 0.00 (0.00–0.02)
De Stefani 2001 0.29 (0.11–0.81)
Munoz 2001 0.70 (0.61–0.80)
Takezaki 2001 1.45 (0.74–2.82)
Sipetic 2003 0.40 (0.20–0.80)
Lissowka 2004 0.86 (0.67–1.10)
Nan 2005 0.49 (0.28–0.84)
Zickute 2005 0.91 (0.71–1.16)
Summary estimate 0.59 (0.47–0.74)
Relative risk (95% CI)
Relative risk, per 100 g/day
1 20.5
Figure 4.2.15 Garlic and colon cancer; cohort studies
Giovannucci 1994 Men 0.77 (0.51–1.16)
Steinmetz 1994 Women 0.68 (0.46–1.01)
Relative risk (95% CI)
Relative risk, highest vs lowest exposure category
1 50.2 0.5 2
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The evidence, though not copious and mostly from
case-control studies, is consistent, with a dose-
response relationship. There is evidence for plausible
mechanisms. Garlic probably protects against
colorectal cancer.
The Panel is aware that since the conclusion of the SLR, one
case-control study78 has been published. This new information
does not change the Panel judgement (see box 3.8).
In addition to this judgement, data on garlic have
contributed to the evidence base for allium vegetables and
stomach cancer (also see chapter 7.5). 
4.2.5.1.2 Carrots
Cervix
Five case-control studies440-444 and one ecological study445
investigated carrots and cervical cancer.
Case-control studies were consistent in showing reduced
risk for the highest levels of consumption, which was sta-
tistically significant in three.440-442 All studies used hospital-
based controls and none adjusted for human papilloma virus
status. The single ecological study showed non-significant
increased risk with high intake of carrots.445
Some carotenoids, including beta-carotene and alpha-
carotene, which are found at high levels in carrots, are pre-
cursors of vitamin A. They also have properties independent
of their pro-vitamin A activity. Carotenoids are recognised
antioxidants and low blood levels of dietary antioxidants are
associated with human papilloma virus persistence.446
The evidence, from case-control studies only, is sparse
but consistent. There is limited evidence suggesting
that carrots protect against cervical cancer.
Data on carrots have contributed to the evidence base for
non-starchy vegetables and mouth, pharynx, and larynx can-
cers (chapter 7.1) and lung cancer (chapter 7.4). Also see
chapter 4.2.5.1.
4.2.5.2 Fruits
Mouth, pharynx, and larynx
One cohort study,447 35 case-control studies21 22 24-26 28 30-33 35
36 39-50 59-61 63 64 67 69 72 74 448-450 and 2 ecological studies52 68
investigated fruits and mouth, pharynx, and larynx cancers;
and 1 cohort study,66 23 case-control studies23 26-29 31 33 34 37-
39 41-43 45-47 50 63 65 75 451 452 and 1 ecological study52 investigated
citrus fruits. In addition, 1 cohort study54 and 6 case-control
studies33 39 45 55-57investigated non-starchy vegetables and
fruits in combination (also see evidence on non-starchy
vegetables, chapter 4.2.5.1).
General fruits
The single cohort study, which adjusted for smoking,
showed a non-significant decreased risk for the highest when
compared to the lowest intake groups, with an effect esti-
mate of 0.82 (95% CI 0.64–1.04) (figure 4.2.17).447
Most (32) of the case-control studies reported decreased
risk associated with higher intake of fruits,24-26 28 30-33 35 36 39-
48 50 59-61 63 64 69 72 74 448 450 which was statistically significant
in 17.26 31 32 35 39-43 46-48 50 63 64 69 72 448 No study reported sta-
tistically significant increased risk. Meta-analysis was possi-
ble on 7 studies (all of which adjusted for smoking), giving
a summary effect estimate of 0.72 (95% CI 0.59–0.87) per
100 g/day, with high heterogeneity (figure 4.2.17).30 39 42 44
45 69 72 Heterogeneity came from the varying size, not direc-
tion, of effect.
One ecological study showed a weak inverse correlation
between fruits and oral cancer.68 The other observed inverse
correlations among women for fruit and both oral and laryn-
geal cancers and positive correlations among men for the
same two sites.52
Figure 4.2.17 Fruits and mouth, pharynx, and larynx
cancer; cohort and case-control studies
Cohort
Chyou 1995 0.82 (0.64–1.04)
Summary estimate 0.82 (0.64–1.04)
Case control
La Vecchia 1991 0.59 (0.41–0.86)
De Stefani 1994 0.58 (0.30–1.12)
De Stefani 2000 0.66 (0.52–0.85)
Bosetti 2002 0.92 (0.88–0.97)
Marchioni 2003 0.96 (0.86–1.08)
Gaudet 2004 0.90 (0.74–1.10)
Kapil 2005 0.17 (0.10–0.31)
Summary estimate 0.72 (0.59–0.87)
Relative risk (95% CI)
Relative risk, per 100 g/day
10.750.1 0.5 1.5
Figure 4.2.16 Garlic consumption and colorectal cancer;
case-control studies
Huetal 1991 0.21 (0.04–0.98)
Le Marchand 1997 Men 0.80 (0.54–1.19)
Le Marchand 1997 Women 0.90 (0.59–1.37)
Franceschi 1998 0.90 (0.80–1.01)
Levi 1999 0.39 (0.21–0.71)
Kamel 2002 0.83 (0.44–1.55)
Relative risk (95% CI)
Relative risk, highest vs lowest exposure category
1 50.2 0.5 2
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Citrus fruits
The single cohort study, which was specific to oranges and
was adjusted for smoking, showed a non-significant
decreased risk for the highest when compared to the lowest
intake groups, with an effect estimate of 0.50 (95% CI
0.30–1.00), with a p value for trend of 0.03.66 This risk esti-
mate was for cancers of the upper aerodigestive tract.
Twenty-two of the case-control studies showed decreased
risk associated with higher intake of fruits,23 27-29 31 33 34 37-39
41-43 45-47 50 63 65 75 451 452 which was statistically significant in
13.23 27-29 31 33 37 39 42 43 47 50 75 The 23rd study showed no effect
on risk.26 Meta-analysis was possible on 7 studies (all of
which adjusted for smoking), giving a summary effect esti-
mate of 0.76 (95% CI 0.66–0.87) per 50 g/day, with high
heterogeneity (figure 4.2.18).23 29 37 39 42 45 65 Heterogeneity
came from the varying size, not direction, of effect.
A dose-response relationship was apparent from case-
control but not cohort data for both general and citrus fruits
(figures 4.2.19 and 4.2.20). There is some suggestion that
the greatest effect appears to be with the first increment.
That is, some fruit consumption confers a protective effect
compared to none. However, it is not clear that the effect
continues in a linear fashion with increased doses.
One ecological study found no significant association
between citrus fruit consumption and cancer mortality in
men or women.52
Studies that reported on combined intake of non-starchy
vegetables and fruits showed evidence of an association with
decreased risk (see chapter 4.2.5.1).
The general mechanisms through which fruits could plau-
sibly protect against mouth, pharynx, and larynx cancer are
outlined below. 
The evidence, including on fruit subtypes, though
mostly from case-control studies, is consistent, with a
dose-response relationship. There is evidence for
plausible mechanisms. Fruits probably protect against
mouth, pharynx, and larynx cancers.
The Panel is aware that since the conclusion of the SLR, two
cohort studies76 77 and one case-control study79 have been pub-
lished. This new information does not change the Panel judge-
ment (see box 3.8).
Oesophagus
Four cohort studies,80 82 83 447 36 case-control studies22 40 60
84 86 87 89 94-96 98-100 102 104 108-110 112-115 125-129 134-136 138 453-456 and
7 ecological studies52 68 116 118 119 234 457 458 investigated fruits
and oesophageal cancer; 1 cohort study,66 16 case-control
Figure 4.2.18 Citrus fruits and mouth, pharynx, and
larynx cancer; case-control studies
Franco 1989 0.72 (0.56–0.93)
Zheng 1993 0.45 (0.31–0.66)
Levi 1998 0.88 (0.82–0.95)
De Stefani 2000 0.27 (0.14–0.52)
Bosetti 2002 0.91 (0.85–0.97)
Pisa 2002 0.71 (0.51–0.99)
Gaudet 2004 0.89 (0.73–1.10)
Summary estimate 0.76 (0.66–0.87)
Relative risk (95% CI)
Relative risk, per 50 g/day
10.750.5 1.5 2
Figure 4.2.19 Fruits and mouth, pharynx, and larynx
cancer; case-control studies: dose response
LaVecchia 1991
De Stefani 1994
De Stefani 2000
Bosetti 2002
Marchioni 2003
Gaudet 2004
Kapil 2005
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Figure 4.2.20 Citrus fruits and mouth, pharynx, and larynx
cancer; case-control studies: dose response
Franco 1989
Zheng 1993
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studies,33 85 86 88 90 97 105 111 113 124 125 128 130 132 133 136 459 and 1
ecological study52 investigated citrus fruits.
General fruits
All of the cohort studies reported reduced risk with higher
intakes of fruit,80 82 83 447 which was statistically significant
in two.83 447 One study reported a statistically significant
dose-response relationship, with a risk estimate of 0.68
(95% CI 0.53–0.88) per 100 g/day after adjustment for
smoking.447 The other three reported risks for the highest
intake groups relative to the lowest, with risk estimates of
0.8 (95% CI 0.7–0.9; not adjusted for smoking),83 0.9 (95%
CI 0.8–1.1; adjusted for smoking),80 and 0.99 (95% CI
0.85–1.15; not adjusted for smoking).82
Thirty-two of the case-control studies reported reduced
risk for the highest intake groups when compared to the low-
est (figure 4.2.21),22 40 60 84 86 87 89 95 96 98 99 102 104 108-110 113-115
125-129 134-136 138 453-456 which was statistically significant in
24.40 60 84 86 87 89 95 96 102 104 110 113-115 127 134-136 138 454-456 One
study reported statistically significant increased risk,100 one
reported no effect on risk,112 and one reported no statistically
significant association.94 Meta-analysis was possible on eight
studies, giving a summary effect estimate of 0.56 (95% CI
0.42–0.74) per 100 g/day, with high heterogeneity (figure
Figure 4.2.21 Fruits and oesophageal cancer; cohort
and case-control studies
Cohort
Yu 1993 0.99 (0.85–1.15)
Chyou 1995 0.65 (0.39–1.08)
Guo 1999 0.90 (0.77–1.06)
Tran 2005 0.80 (0.70–0.91)
Case control
Notani 1987 0.99 (0.63–1.57)
Victoria 1987 0.66 (0.50–0.88)
Nakachi 1988 Women 0.23 (0.12–0.45)
Nakachi 1988 Men 0.31 (0.22–0.44)
Brown 1988 0.50 (0.29–0.87)
Jun-lao 1989 1.00 (0.82–1.22)
De Stefani 1990 0.33 (0.21–0.52)
Negri 1991 0.30 (0.21–0.42)
Tavani 1993 0.40 (0.19–0.85)
Tavani 1994 0.30 (0.11–0.85)
Castelletto 1994 0.70 (0.31–1.57)
Hanaoka 1994 0.50 (0.18–1.39)
Srivastava 1995 3.15 (1.29–7.72)
Gimeno 1995 0.55 (0.33–0.94)
Zhang 1997 0.40 (0.16–0.98)
De Stefani 1999 0.30 (0.17–0.52)
Wang 1999 0.51 (0.27–0.98)
Gao 1999 0.75 (0.36–1.56)
Cheng 2000 0.08 (0.01–0.56)
Nayar 2000 0.96 (0.45–2.05)
De Stefani 2000 0.18 (0.09–0.37)
Takezaki 2000 0.70 (0.52–0.94)
Phukan 2001 0.30 (0.04–2.17)
Terry 2001 0.60 (0.36–0.99)
Wolfgarten 2001  0.32 (0.12–0.89)
Takezaki 2001 0.91 (0.48–1.73)
Sharp 2001 0.64 (0.25–1.65)
Zhang 2001 0.64 (0.42–0.97)
Onuk 2002 7.10 (3.21–15.73)
Lik 2003 0.08 (0.06–0.11)
Hung 2004 0.60 (0.40–0.90)
Yang 2005 0.42 (0.19–0.91)
De Stefani 0.21 (0.10–0.44)
Relative risk (95% CI)
Relative risk, highest vs lowest exposure category
1 50.2 0.5 2
Figure 4.2.22 Fruits and oesophageal cancer;
case-control studies
Jun-lao 1989 1.52 (0.47–4.91)
Hanaoke 1994 0.30 (0.13–0.67)
Castelletto 1994 0.33 (0.13–0.80)
Gao 1999 0.38 (0.01–20.03)
De Stefani 2000 0.53 (0.42–0.67)
Wolfgarten 2001 0.40 (0.27–0.59)
Sharp 2001 0.84 (0.74–0.96)
De Stefani 2005 0.59 (0.49–0.71)
Summary estimate 0.56 (0.42–0.74)
Relative risk (95% CI)
Relative risk, per 100 g/day
10.750.5 1.50.2
Figure 4.2.23 Citrus fruits and oesophageal cancer;
cohort and case-control studies
Cohort
Kjaerheim 1998 0.50 (0.27–0.91)
Case control
Brown 1988 0.50 (0.29–0.87)
Cheng 1992 0.10 (0.04–0.26)
Castelletto 1994 1.60 (0.81–3.15)
Cheng 1995 Non-smokers 0.39 (0.16–0.97)
Cheng 1995 Never drinkers 0.59 (0.23–1.52)
Zhang 1997 0.70 (0.29–1.71)
Launoy 1998 0.54 (0.33–0.89)
Levi 2000 0.22 (0.09–0.54)
Bosetti 2000 0.42 (0.25–0.71)
Terry 2000 0.90 (0.50–1.61)
Chen 2002 0.48 (0.21–1.10)
De Stefani 2005 0.28 (0.15–0.54)
Relative risk (95% CI)
Relative risk, highest vs lowest exposure category
1 50.2 0.5 2
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4.2.22). Heterogeneity may be partially explained by differ-
ential adjustment for confounders between studies.
All seven ecological studies reported reduced risk with
increased intake,52 68 116 118 119 234 457 458 which was statistically
significant in one.68 458
Citrus fruits
The single cohort study, which was specific to oranges and
was adjusted for smoking, showed a non-significant
decreased risk for the highest when compared to the lowest
intake groups, with an effect estimate of 0.50 (95% CI
0.30–1.00), with a p value for trend of 0.03.66 This risk esti-
mate was for cancers of the upper aerodigestive tract; 22 out
of 71 cases were oesophageal cancers.
Fifteen of the case-control studies reported decreased risk
for the highest intake groups when compared to the lowest,33
85 86 88 90 97 105 111 113 124 125 130 132 133 136 459 which was statisti-
cally significant in 10 (figure 4.2.23).33 85 86 88 97 105 113 132 133
136 459 The other study reported a non-significant increased
risk.128 Meta-analysis was possible on six studies, giving a
summary effect estimate of 0.70 (95% CI 0.56–0.88) per 
50 g/day, with high heterogeneity (figure 4.2.24).33 97 128 130
132 133 Four of these studies adjusted for smoking.33 97 128 132
133 Heterogeneity may be partially explained by differential
adjustment for confounders between studies.
The single ecological study reported a non-significant
increased risk.52
The general mechanisms through which fruits could plau-
sibly protect against cancer are outlined below. 
The evidence, including on fruit subtypes, though
mostly from case-control studies, is consistent, with a
dose-response relationship. There is evidence for
plausible mechanisms. Fruits probably protect against
oesophageal cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort study140 and two case-control studies143 460 have been
published. This new information does not change the Panel
judgement (see box 3.8).
Lung
Twenty-five cohort studies,214 216 282-300 337 339 360 461-467 32
case-control studies,261 303-306 308-318 320-322 324 326-328 330 331 343 346
349 350 352 355 357 358 468-472 and 7 ecological studies52 116 332-334
473 474 investigated fruits and lung cancer.
Twenty of the cohort studies showed decreased risk for the
highest intake groups when compared to the lowest,214 216 282-
289 291-294 296 297 299 300 337 461-467 which was statistically signifi-
cant in four.216 289 292 300 461 464 Four studies showed
non-significant increased risk290 295 339 360 and the other report-
ed no statistically significant association.298 Meta-analysis was
possible on 14 cohort studies, giving a summary effect esti-
mate of 0.94 (95% CI 0.90–0.97) per 80 g serving/day, with
low heterogeneity (figure 4.2.25). All but one of these stud-
ies adjusted for smoking.462
Pooled analysis from 8 cohort studies (over 430 000 par-
ticipants, followed up for 6 to 16 years, more than 3200 lung
Figure 4.2.24 Citrus fruits and oesophageal cancer;
case-control studies
Cheng 1992 0.46 (0.39–0.55)
Castelletto 1994 1.22 (0.79–1.89)
Cheng 1995 Never drinkers 0.65 (0.48–0.89)
Cheng 1995 Non-smokers 0.57 (0.43–0.75)
Levi 2000 0.75 (0.67–0.84)
Terry 2000 0.97 (0.84–1.13)
De Stefani 2005 0.62 (0.49–0.78)
Summary estimate 0.70 (0.56–0.88)
Relative risk (95% CI)
Relative risk, per 50 g/day
10.750.2 0.5 1.5 2
Figure 4.2.25 Fruits and lung cancer; cohort and
case-control studies
Cohort
Alavanja 2004 (pesticide applicators) 0.89 (0.59–1.35)
Alavanja 2004 (applicator spouses) 0.65 (0.28–1.51)
Breslow 2000 0.92 (0.71–1.18)
Feskanich 2000 (HPFS) Men 1.05 (0.94–1.17)
Feskanich 2000 (NHS) Women 0.94 (0.87–1.02)
Fraser 1991 0.47 (0.32–0.69)
Fu 1997 0.94 (0.67–1.32)
Holick 2002 0.94 (0.89–1.00)
Jansen 2004 0.84 (0.65–1.09)
Miller 2002 0.96 (0.86–1.07)
Olson 2002 0.91 (0.86–0.96)
Shibata 1992 0.99 (0.87–1.14)
Skuladottir 2004 0.95 (0.86–1.05)
Takezaki 2003 0.63 (0.24–1.63)
Vorrips 2000 0.92 (0.86–0.98)
Summary estimate 0.94 (0.90–0.97)
Case control
Axelsson 1996 0.77 (0.46–1.28)
Brennan 2000 1.08 (0.52–2.28)
De Stefani 2002 0.84 (0.66–1.06)
Gao 1993 0.45 (0.30–0.67)
Hu  2002 1.04 (0.85–1.27)
Ko 1997 1.00 (0.54–1.84)
Kreuzer 2002 0.79 (0.45–1.39)
Lagiou 2004 0.79 (0.60–1.04)
Pawlega 1997 0.01 (0.00–0.24)
Rachtan 2002 0.49 (0.32–0.75)
Raunoi-Ravina 2002 1.19 (0.74–1.91)
De Stefani 1999 0.67 (0.54–0.82)
Suzuki 1994 1.33 (0.56–3.18)
Swanson 1997 0.91 (0.76–1.09)
Summary estimate 0.80 (0.68–0.94)
Relative risk (95% CI)
Relative risk, per serving/day
10.05 2
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cancer cases) showed a statistically significant reduced risk for
the highest intake group when compared to the lowest (0.77,
95% CI 0.67–0.87), with a p value for trend of < 0.001.336
Twenty-one case-control studies showed decreased risk for
the highest intake groups when compared to the lowest,261
303 305 306 308 309 311 312 315 317 318 320-322 324 327 328 331 343 346 349 350
355 357 358 468 469 472 which was statistically significant in 7.261
309 311 324 327 343 346 357 358 468 472 Three studies reported no effect
on risk310 316 330 352 and 8 showed increased risk,304 313 314 326
470 471 which was statistically significant in 3.304 326 470 Meta-
analysis was possible on 14 case-control studies, giving a
summary effect estimate of 0.80 (95% CI 0.68–0.94) per
serving/day, with moderate heterogeneity (figures 4.2.25
and 4.2.26). All but 2 of these studies adjusted for smoking,
and exclusion of these 2 studies did not significantly alter
the meta-analysis.316 352
Of the seven ecological studies, four reported non-
significant decreased risk in areas of higher fruit consump-
tion,52 332 473 474 one reported no consistent association,334 and
two reported non-significant increased risk.116 333
The general mechanisms through which fruits could plau-
sibly protect against cancer are outlined below. In addition,
flavonoids found in fruit directly inhibit expression of
CYP1A1 (a cytochrome P450 enzyme that helps to
metabolise toxins), resulting in decreased DNA damage.475
Elevated CYP1A1 activity has been associated with increased
risk of lung cancer, primarily in smokers.476 The protective
association of flavonoids is associated with specific CYP1A1
genotypes, which supports the importance of flavonoids and
potentially explains heterogeneous results.476 477
The evidence is ample and consistent. A dose-response
relationship is apparent from both cohort and case-
control studies and there is evidence for plausible
mechanisms operating in humans. The evidence that
fruits protect against lung cancer is convincing.
The Panel is aware that since the conclusion of the SLR, one
case-control study478 has been published. This new information
does not change the Panel judgement (see box 3.8).
Stomach 
Sixteen cohort studies,71 80 144-147 149 150 213-217 252-254 414 51
case-control studies,89 109 129 151 154 156 158-163 167-169 174-176 178-180
182 184-187 189-191 193 195 219 221 222 224-227 229 230 246 255-258 260 261 264
270 479-482 and 23 ecological studies52 116 118 119 197 198 200-202 204-
209 234 236-240 483-485 investigated fruits.
Ten cohort studies reported decreased risk for the highest
intake groups when compared to the lowest,71 80 144 146 150 214-
217 253 254 which was statistically significant in one,253 and in
women only in a second study.216 Six studies showed
increased risk,145 147 149 213 214 252 414 which was statistically sig-
nificant in one.213 Meta-analysis was possible on eight stud-
ies, giving a summary effect estimate of 0.95 (95% CI
0.89–1.02) per 100 g/day, with low heterogeneity (figure
4.2.27).
One of the cohort studies considered in the meta-analysis
above (EPIC, more than 521000 participants in over 10
European countries) reported results stratified by H pylori
status. The effect estimate for the H pylori-negative group
was 0.72 (95% CI 0.39–1.33) and 0.98 (95% CI 0.81–1.2)
for the positive group.140
Forty case-control studies showed decreased risk for the
highest intake groups when compared to the lowest,89 109 151
156 158-160 162 163 167-169 174 176 178-180 184 186 187 189-191 195 219 221 222
225 226 229 230 246 256-258 260 261 264 270 479-481 which was statistical-
ly significant in 25.89 109 151 158-160 162 163 167-169 174 176 178 186 187
190 191 221 222 226 229 246 256 261 264 479 481 Seven showed increased
risk,129 161 182 185 193 224 482 which was statistically significant
in two.182 193 One study showed non-significant increased risk
in men and non-significant decreased risk in women.227 Two
studies showed no effect on risk154 255 and the remaining one
reported that there was no significant association.175 Meta-
analysis was possible on 26 studies, giving a summary effect
estimate of 0.67 (95% CI 0.59–0.76) per 100 g/day, with
Figure 4.2.26 Fruits and lung cancer; cohort and
case-control studies; dose response
Cohort
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Takezaki 2003
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Swanson 1997
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Stefani 1999
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high heterogeneity (figure 4.2.27).
A dose-response relationship is apparent from case-control
but not cohort data. There is statistically significant hetero-
geneity between study types. 
Eighteen ecological studies showed decreased risk with
increased intake of fruits,116 118 197 200 201 204-208 234 237-239 484 485
which was statistically significant in eight.204-208 237 Four stud-
ies showed increased risk with increased intake,52 118 119 202
239 240 which was statistically significant in one.240 Two stud-
ies showed non-significant decreased risk in women and
non-significant increased risk in men209 236; one study
showed non-significant decreased risk in men and non-
significant increased risk in women198; and one study
showed non-significant increased risk in white men and
Japanese men and women, and non-significant decreased
risk in white women.483
The stomach is a particularly unusual chemical environ-
ment and it is possible that, in addition to the general mech-
anisms described below, specific mechanisms apply, for
instance, in relation to nitrosamine formation.486 It is also
plausible that bioactive constituents in fruit would protect
against H pylori-induced damage, particularly inflammation,
which is implicated in the development of stomach cancers.
The evidence is ample and more consistent with a
dose-response relationship for case-control studies
than for cohorts. There is evidence for plausible
mechanisms. Fruits probably protect against stomach
cancer.
The Panel is aware that since the conclusion of the SLR, three
case-control studies487-489have been published. This new infor-
mation does not change the Panel judgement (see box 3.8).
Nasopharynx 
Six case-control studies investigated general fruits and
nasopharyngeal cancers274 275 281 490-492; a further five case-
control studies investigated citrus fruits.273 278-281 Preserved
fruits were excluded from all categories.
Of the six case-control studies that investigated general
fruits, four reported decreased risk for the highest intake
groups when compared to the lowest,275 281 491 492 which was
statistically significant in two.275 491 The other two studies
reported that there was no significant effect on risk, with-
out further detail.274 490 All five of the case-control studies
that investigated citrus fruits reported decreased risk for the
highest intake groups when compared to the lowest,273 278-
281 four of which were statistically significant.273 278-280
Preserved fruits were excluded as they introduced sub-
stantial heterogeneity.
The general mechanisms through which fruits could plau-
sibly protect against nasopharyngeal cancer are outlined
below. In addition, it is possible that active constituents in
fruit could act directly on Epstein-Barr virus infection.493
The evidence, from case-control studies only, is sparse.
There is limited evidence suggesting that fruits protect
against nasopharyngeal cancer.
Pancreas
Six cohort studies,214 216 252 494-496 16 case-control studies,219
497-511 and 8 ecological studies52 197 485 512-515 investigated
fruits and pancreatic cancer.
All six cohort studies showed decreased risk for the high-
est intake groups when compared to the lowest,214 216 252 494-
496 which was statistically significant in one.496 Meta-analysis
was possible on three cohort studies, giving a summary effect
estimate of 0.92 (95% CI 0.81–1.04) per 100 g/day, with no
heterogeneity.216 494 495
Eleven case-control studies showed decreased risk for the
highest intake groups when compared to the lowest,219 497 498
500 501 503-509 511 which was statistically significant in four,503
Figure 4.2.27 Fruits and stomach cancer; cohort and
case-control studies
Cohort
Chyou 1990 0.95 (0.84–1.07)
Botterweck 1998 0.92 (0.83–1.02)
Galanis 1998 0.68 (0.51–0.92)
Fujino 2002 Men 1.01 (0.90–1.13)
Fujino 2002 Women 1.12 (0.85–1.49)
Kobayashi 2002 0.75 (0.55–1.00)
Ngoan 2002 0.94 (0.28–1.19)
Khan 2004 Men 1.14 (0.28–4.70)
Gonzalez 2006 1.04 (0.91–1.19)
Summary estimate 0.95 (0.89–1.02)
Case control
Jedrychowski 1981 0.71 (0.53–0.95)
Jedrychowski 1986 0.98 (0.66–1.47)
You 1988 0.61 (0.48–0.79)
Burr 1989 Men 0.53 (0.32–0.89)
Burr 1989 Women 0.39 (0.15–0.97)
Coggon 1989 0.48 (0.07–3.45)
De Stefani 1990 0.42 (0.30–0.61)
Kato 1990 Men 0.89 (0.65–1.22)
Kato 1990 Women 0.85 (0.49–1.50)
Lee 1990 1.05 (0.79–1.39)
Wu-Williams 1990 Men 0.64 (0.37–1.11)
Hoshiyama 1992 0.54 (0.41–0.70)
Memik 1992 0.57 (0.36–0.90)
Cornee 1995 0.75 (0.67–0.99)
De Stefani 1998 0.49 (0.42–0.58)
Ji 1998 Men 0.49 (0.37–0.80)
Ji 1998 Women 0.55 (0.37–0.80)
Gao 1999 5.46 (0.36–17.98)
Huang 1999 0.93 (0.80–1.08)
Ward 1999 0.90 (0.55–1.47)
Mathew 2000 0.90 (0.55–1.47)
De Stefani 2001 0.65 (0.53–0.79)
Takezaki 2001 0.60 (0.37–0.97)
Nishimoto 2002 0.74 (0.62–1.06)
Lee 2003 0.36 (0.18–0.73)
Sipetic 2003 0.17 (0.07–0.32)
Suh 2003 0.80 (0.69–0.92)
Lissowska 2004 0.65 (0.47–0.91)
Boccia 2995 2.06 (1.10–3.84)
Summary estimate 0.67 (0.59–0.76)
Relative risk (95% CI)
Relative risk, per 100 g/day
10.5 2
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504 508 511 and in men but not women in a fifth study,506 and
in women but not men in a sixth.501 One study reported a sta-
tistically significant increased risk for men and a statistically
significant decreased risk for women.510 No other study
reported statistically significant increased risk. Meta-analysis
was possible on eight case-control studies, giving a summa-
ry effect estimate of 0.89 (95% CI 0.82–0.98) per 100 g/day,
with high heterogeneity.497 498 502 503 505 506 508 510 Heterogeneity
could be partly explained by proxy reporting, poor study qual-
ity, and varying adjustment for known confounders.
A dose-response relationship is apparent from case-control,
but not cohort data.
Ecological studies show no consistent association.52 197 485
512-515
The general mechanisms through which fruits could plau-
sibly protect against pancreatic cancer are outlined below. 
The evidence is inconsistent. There is limited evidence
suggesting that fruits protect against pancreatic cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort study516 has been published. This new information does
not change the Panel judgement (see box 3.8).
Liver cancer
One cohort study216 517 and five case-control studies89 518-521
investigated fruits and liver cancer.
The single cohort study showed non-significant decreased
risk for the highest intake groups when compared to the low-
est (0.98, 95% CI 0.75–1.21).216 517
Four case-control studies showed decreased risk for the
highest intake groups when compared to the lowest,89 518 520
521 which was statistically significant in two.89 518 One study
showed non-significant increased risk.519 Heterogeneity
could be partly explained by poor study quality and varying
adjustment for known confounders.
The general mechanisms through which fruits could plau-
sibly protect against liver cancer are outlined below. In addi-
tion, grape extracts and auraptene (from citrus fruit) have
shown protective effects against the development of hepa-
tocellular carcinoma in rats.522-525
The evidence is sparse and inconsistent. There is
limited evidence suggesting that fruits protect against
liver cancer. 
The Panel is aware that since the conclusion of the SLR, one
case-control study526 has been published. This new information
does not change the Panel judgement (see box 3.8).
Colorectum
Twenty cohort studies214 216 359-372 374-376 378 379 527-529 and 57
case-control studies investigated fruits and colorectal cancer.
Thirteen cohort studies showed decreased risk with
increased intake,214 216 360-364 366 371 374-376 378 which was sta-
tistically significant in two.360 364 No studies reported statis-
tically significant increased risk. Meta-analysis was possible
on eight cohort studies, giving a summary effect estimate of
0.97 (95% CI 0.92–1.03) per serving/day, with high het-
erogeneity.360 362-364 366 370 529 When results were stratified by
sex, a statistically significant decreased risk was apparent in
women (0.81, 95% CI 0.85–0.98 per serving/day based on
five studies), with low heterogeneity. 
Because of the abundant prospective data from cohort
studies, case-control studies were not summarised.
The mechanism for this sex difference is unknown. There
is speculation the mechanism could be related to the (part-
ly understood) explanation for protective effects observed in
postmenopausal women provided with hormone replace-
ment therapy. Another possibility is that the result could be
artifactual if men are poorer at reporting their diets than
women.
The general mechanisms through which fruits could plau-
sibly protect against colorectal cancer are outlined below.
There is a substantial amount of evidence but it is
inconsistent. There is limited evidence suggesting that
fruits protect against colorectal cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort530 and five case-control studies 261 380 531-533 have been
published. This new information does not change the Panel
judgement (see box 3.8).
General mechanisms — fruits 
Fruits, in particular citrus fruits, are sources of vitamin C and
other antioxidants, such as phenols and flavonoids, as well
as potentially bioactive phytochemicals. Vitamin C traps free
radicals and reactive oxygen molecules, protecting against
oxidation damage. It also regenerates other antioxidant
vitamins such as vitamin E.534 Vitamin C also inhibits 
the formation of carcinogens and protects DNA from 
mutagenic attack.535
Beta-carotene and other carotenoid antioxidants are also
found in fruits. Some fruits contain high levels of flavonoids,
including apples (quercetin) and grapefruit (naringin).
Flavonoids have antioxidant effects and can also inhibit
carcinogen-activating enzymes. Flavonoids can also alter the
metabolism of other dietary agents. For instance, quercetin
directly inhibits expression of CYP1A1 (a cytochrome P450
enzyme that helps to metabolise toxins), resulting in
decreased DNA damage.475 The phytochemical antioxidants
contained in fruit could reduce free-radical damage gener-
ated by inflammation. A single study reported that apples
given in physiological quantities inhibited carcinogen-
induced mammary cancer in rodents in a dose-response
manner.536
There is a complex mixture of phytochemicals present in
whole vegetables and these may have additive and syner-
gistic effects responsible for anti-cancer activities. 
4.2.5.3 Foods containing carotenoids
Mouth, pharynx, and larynx 
Two cohort studies537 538 investigated total serum carotenoids
and two case-control studies539 540 investigated total dietary
carotenoids and mouth, pharynx, and larynx cancers. 
Ten case-control studies investigated pro-vitamin A caro-
tenoids.26-29 47 48 450 451 541-544 Three cohort studies investigat-
ed serum alpha-carotene537 538 545; one cohort study
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investigated dietary alpha-carotene71; three cohort studies537
538 545 and two case-control studies546 547 investigated serum
beta-carotene; one cohort study71 and seven case-control
studies34 35 67 74 540 548 549 investigated dietary beta-carotene.
One cohort study71 and four case-control studies62 450 540 543
548 investigated dietary lycopene; one cohort study538 and
one case-control study547 investigated serum lycopene. 
Total carotenoids
The two cohort studies both showed decreased risk,537 538
one was statistically significant for the highest serum levels
of total carotenoids when compared to the lowest (0.33, 
p value for trend 0.05; not adjusted for smoking and
alcohol); and 0.22 (95% CI 0.05–0.88; adjusted for smok-
ing and alcohol).537
The two case-control studies showed decreased risk for the
highest intake group when compared to the lowest,539 540
which was statistically significant in men but not women in
one study539 and statistically significant for all in the other.540
Both case-control studies adjusted for smoking.
Pro-vitamin A carotenoids
Nine case-control studies reported decreased risk,26-29 47 48 450
541-544 which was statistically significant for five studies.29 48
541-543 One other study reported decreased risk for men and
increased risk for women but neither was statistically sig-
nificant.451 All studies adjusted for smoking.
Alpha-carotene
All four cohort studies reported decreased risk for the highest
intake group or serum level compared to the lowest,71 537 538
545 which was statistically significant in three,71 537 545
although one of the latter reported a separate estimate
specific to oral cancers, which suggested a non-significant
increased risk.545 Only one study adjusted for smoking.537
The effect estimates were 0.62 (95% CI 0.41–0.94) 
for dietary alpha-carotene,71 and 0.48 (laryngeal cancers, 
p value for trend 0.18), 1.26 (oral cancers, p value for 
trend 0.54),545 0.20 (95% CI 0.05–0.75; adjusted for smok-
ing),537 and 0.37 (p value for trend 0.06) for serum levels.538
These tended to be based on a relatively small number 
of cases.
Beta-carotene
The single cohort study that investigated dietary beta-
carotene intake reported that there was no significant asso-
ciation, but provided no further details.71 All three cohort
studies that investigated serum levels showed decreased risk
for the highest group when compared to the lowest,537 538 545
which was statistically significant in one.537 The effect esti-
mates were 0.10 (95% CI 0.02–0.46; adjusted for smok-
ing),537 0.42 and 0.88 for oral/oropharyngeal and laryngeal
cancers, respectively (not adjusted for smoking),545 and 0.5
(p value for trend 0.17), which was attenuated after adjust-
ment for smoking (0.69).538
Five case-control studies reported decreased risk,34 35 74 540
549 which was significant in two.35 549 One study reported
non-significant increased risk548 and one study reported a sig-
nificant increased risk.67
Lycopene
One cohort study71 and four case-control studies62 450 540 543
548 investigated dietary lycopene and mouth, larynx, and
pharynx cancers; one cohort study538 and one case-control
study547 investigated serum lycopene.
One cohort study reported a non-significant decreased risk
for the highest serum lycopene levels when compared to the
lowest (0.61; p value for trend 0.37).538 The other stated that
there was no relationship between dietary lycopene and
risk.71
All four case-controls that investigated dietary lycopene
reported decreased risk for the highest intake groups when
compared to the lowest,62 450 540 543 548 which was statistical-
ly significant in two.62 548 The single case-control that inves-
tigated serum lycopene reported contrary results, showing
that levels were significantly higher in cases than controls.547
The general mechanisms through which foods containing
carotenoids could plausibly protect against mouth, pharynx,
and larynx cancer are outlined below. 
There is a considerable amount of evidence, and
though it is for different carotenoid types, it is
generally consistent, with a dose-response
relationship. There is evidence for plausible
mechanisms. Foods containing carotenoids probably
protect against mouth, pharynx, and larynx cancers.
The Panel is aware that since the conclusion of the SLR, one
cohort study76 has been published. This new information does
not change the Panel judgement (see box 3.8).
Lung 
Eleven cohort studies,284 286 288 289 298 299 341 550-555 16 case-con-
trol studies,306-308 310 311 321 322 327 330 342 344 350 352 556-561 and 1
ecological study333 investigated total dietary carotenoids and
lung cancer; 4 cohort studies298 562-566 and 5 case-control
studies567-571 investigated total serum or plasma carotenoids;
7 cohort studies,286 289 293 341 552 566 572 573 8 case-control stud-
ies,306 308 320 321 327 350 560 574 and 1 ecological study333 inves-
tigated dietary beta-cryptoxanthin; 6 cohort studies563-566
575-577 and 1 case-control study578 investigated serum or
plasma beta-cryptoxanthin.
Figure 4.2.28 Carotenoids and lung cancer;
cohort studies
Shekelle 1981 0.97 (0.95–0.99)
Wright 2004 0.99 (0.97–1.01)
Summary estimate 0.98 (0.96–0.99)
 Relative risk (95% CI)
1 1.050.75
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Dietary carotenoids
All 11 cohort studies showed decreased risk of lung cancer
for the highest intake group when compared to the lowest,284
286 288 289 298 299 341 550-555 which was statistically significant in
three.286 550 553 Meta-analysis was possible on two cohort
studies, giving a summary effect estimate of 0.98 (95% CI
0.96–0.99) per 1000 µg/day, with no heterogeneity (figure
4.2.28).553 554 All cohort studies adjusted for smoking. 
Twelve of the case-control studies showed decreased risk
of lung cancer for the highest intake group when compared
to the lowest,306-308 310 311 321 322 327 330 344 350 352 556 559-561 which
was statistically significant in seven (figure 4.2.29).306-308 321
322 327 344 556 560 Three studies reported increased risk,342 557 558
which was statistically significant in one,557 and one report-
ed no effect on risk.350 Heterogeneity was high, which may
be partially explained by varying adjustment for known
confounders. Four case-control studies did not adjust for
smoking.306 352 556-558
The single ecological study showed an association between
increased carotenoid intake and decreased lung cancer
risk.333
Serum or plasma or carotenoids
All four of the cohort studies showed decreased risk of lung
cancer for the highest serum or plasma levels when com-
pared to the lowest,298 562-566 which was statistically signifi-
cant in three.298 562 563 Effect estimates were 0.27 (95% CI
0.1–0.7; adjusted for age, sex, smoking habits, alcohol drink-
ing, and cholesterol),563 0.57 (95% CI 0.35–0.93; adjusted
for age, smoking habits, and the intake of other nutrients,
foods, and supplements),298 1.84 (low compared to high; p
value for trend 0.033; adjusted for age and smoking),562 and
0.84 (95% CI 0.48–1.47; adjusted for age and smoking).566
All five of the case-control studies showed decreased 
risk of lung cancer for the highest serum or plasma levels
when compared to the lowest567-571; one was statistically
significant.568
Dietary beta-cryptoxanthin
All seven cohort studies showed decreased risk with
increased intake of beta-cryptoxanthin,286 289 293 341 552 566 572
573 which was statistically significant in one.293 566 Meta-
analysis was possible on two studies, giving a summary effect
estimate of 0.98 (95% CI 0.96–1.00) per 10 µg/day, with no
heterogeneity.286 572
Pooled analysis from 7 cohort studies (almost 400 000 par-
ticipants, followed up for 7 to 16 years, more than 3100 lung
cancer cases) showed a statistically significant decreased risk
when comparing high against low intake groups (0.76, 95%
CI 0.67–0.89), p value for trend < 0.001.579
Six case-control studies showed increased risk for the high-
est intake groups when compared to the lowest,306 308 321 327
560 574 which was statistically significant in four.306 308 327 560
Two studies showed non-significant increased risk.320 350
The single ecological study showed an association between
increased intake and increased risk.333
Serum or plasma beta-cryptoxanthin
Five cohort studies showed decreased risk with increased
intake,563-566 575 576 which was statistically significant in
three.563 566 575 One study showed statistically significant
increased risk.577 Meta-analysis was possible on two studies
(including the latter described study), giving a summary
effect estimate of 0.95 (95% CI 0.69–1.29) per 0.05 µmol/l,
with high heterogeneity.563 577
The single case-control study showed a non-significant
decreased risk with increased consumption.578
Data on beta-carotene supplements (see chapter
4.10.6.4.2) provide convincing evidence that high-dose
supplements have a contrasting effect, at least in smokers,
increasing the risk of lung cancer. Data on dietary beta-
carotene (15 cohort studies, a pooled analysis, 32 case-
control studies, 2 ecological studies) and serum or plasma
beta-carotene (13 cohort studies, 16 case-control studies, 1
ecological study) showed no consistent evidence of an asso-
ciation. The full SLR is contained on the CD included with
this Report.
The general mechanisms through which foods containing
carotenoids could plausibly protect against lung cancer are
outlined below. 
There is a substantial amount of evidence available
from both cohort and case-control studies. A clear
dose-response relationship is apparent from cohort
studies. Foods containing carotenoids probably protect
against lung cancer.
Figure 4.2.29 Carotenoids and lung cancer; cohort and
case-control studies
Cohort
Bandera 1997 0.75 (0.61–0.93)
Chow 1992 0.80 (0.52–1.24)
Holick 2002 0.84 (0.72–0.98)
Knekt 1999 0.92 (0.60–1.41)
Michaud 2000 (HPFS) Men 0.64 (0.37–1.12)
Michaud 2000 (NHS) Women 0.69 (0.46–1.03)
Neuhouser 2003 0.90 (0.62–1.32)
Yong 1997 0.74 (0.52–1.06)
Case control
Bond 1987 1.18 (0.73–1.91)
Brennan 2000 0.80 (0.62–1.03)
Candelora 1992 0.30 (0.12–0.73)
Darby 2001 0.74 (0.57–0.97)
Dorgon 1993 0.83 (0.66–3.11)
Fontham 1988 0.88 (0.70–1.11)
Garcia 1995 1.45 (0.68–3.11)
Mohr 1999 0.60 (0.36–1.00)
Nyberg 1998 0.43 (0.20–0.91)
Samet 1985 0.77 (0.54–1.09)
De Stefani 1999 0.43 (0.29–0.64)
Wright 2003 0.61 (0.41–0.91)
 Relative risk (95% CI)
Relative risk, highest vs lowest exposure category
10.05 2
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Oesophagus
Three cohort studies537 545 580 and one case-control study581
investigated serum beta-carotene; 10 case-control studies
investigated dietary beta-carotene and oesophageal cancer95
107 125 141 548 582-587; one cohort study70 and three case-
control studies86 585 587 investigated dietary pro-vitamin A
carotenoids. 
Serum beta-carotene
One of the cohort studies showed decreased risk for the high-
est levels when compared to the lowest, which was statisti-
cally significant after adjusting for smoking (0.11, 95% CI
0.04–0.34).537 Another cohort study showed no effect on risk
(RR 1.0) and was specific for squamous cell carcinoma.580
Another study reported a non-significant association but did
not provide further details.545
The single case-control study showed that serum beta-
carotene levels were non-significantly lower in cases than
controls.581
Dietary beta-carotene
Nine of the case-control studies showed decreased risk for
the highest intake group when compared to the lowest,95 107
125 141 582-587 which was statistically significant in six.95 141 582-
585 One study reported a non-significant increased risk (fig-
ure 4.2.30).548
Dietary pro-vitamin A carotenoids
The single cohort study showed a non-significant decreased
risk for the highest intake group when compared to the
lowest, with an effect estimate of 0.70 (95% CI 0.29–1.71)
(figure 4.2.30).70
All case-control studies showed decreased risk for the high-
est intake group when compared to the lowest,86 585 587 which
was statistically significant in one585 and in men, but not
women, in another (figure 4.2.30).86
The general mechanisms through which foods containing
carotenoids, including beta-carotene, could plausibly protect
against oesophageal cancer are outlined below. 
There is a substantial amount of consistent evidence
available from both cohort and case-control studies.
Foods containing beta-carotene probably protect
against oesophageal cancer.
Prostate
Five cohort studies,588-594 9 case-control studies,595-608 and 3
ecological studies609-611 investigated tomatoes; 3 cohort stud-
ies590 591 612-615 and 14 case-control studies595 596 598 599 601 602
606 616-625 investigated dietary lycopene; 6 cohort studies576
594 626-630 and 2 case-control studies596 608 619 investigated
serum or plasma lycopene.
Tomatoes
Three of the cohort studies showed decreased risk for the
highest intake groups when compared to the lowest,588 591
592 which was statistically significant in two.591 592 One study
showed a non-significant increased risk589 and one study
reported that there was no statistically significant associa-
tion.594 Meta-analysis was possible on four of the cohort
studies, giving a summary effect estimate of 0.69 (95% CI
0.43–1.08) per serving/day, with moderate heterogeneity.588
589 591 592 One of these studies reported an effect estimate of
0.24 (95% CI 0.13–0.47) per 15 g/day for cumulative intake
of tomato sauce.591 Two of the cohort studies reported on
advanced or aggressive prostate cancer.590 591 594 One report-
ed a risk estimate of 0.11 (95% CI 0.02–0.70) per increase
in serving/day for tomato sauce590 and the other found no
statistically significant association.594
Seven of the case-control studies showed decreased risk
for the highest intake groups when compared to the low-
est,595 598-600 602 603 608 which was statistically significant in
one.602 One study reported non-significant increased risk597
and the other stated that there was no significant associa-
tion without further details.606 Meta-analysis was possible on
five relatively high quality studies595 597-600 and two relatively
low quality ones.602 603 The former gave a summary effect
estimate of 0.97 (95% CI 0.91–1.03) per serving/day, with
no heterogeneity; the latter gave a summary effect estimate
of 0.33 (95% CI 0.04–2.74) per serving/day, with high
heterogeneity.
The three ecological studies showed no consistent 
association.609-611
Dietary lycopene
Two cohort studies showed non-significant decreased risk for
the highest intake groups when compared to the lowest,590
614 the other study showed non-significant increased risk.613
Meta-analysis was possible on all three cohort studies, giv-
ing a summary effect estimate of 0.97 (95% CI 0.64–1.45)
per 5 mg/day, with low heterogeneity (figures 4.2.31 and
Figure 4.2.30 Beta-carotene and oesophageal cancer;
cohort and case-control studies
Cohort
Zheng 1995 0.70 (0.29–1.71)
Case control
Decarli 1987 0.23 (0.12–0.45)
Brown 1988 0.80 (0.45–1.43)
Graham 1990 0.66 (0.36–1.22)
Valsecchi 1992 2.50 (1.67–3.74)
Tavani 1993 0.50 (0.22–1.12)
Tavani 1994 0.40 (0.19–0.85)
Hu 1994 0.70 (0.37–1.31)
Launoy 1998 0.61 (0.31–1.20)
De Stefani 1999 0.60 (0.40–0.90)
Franceschi 2000 0.30 (0.17–0.52)
Mayne 2001 0.43 (0.29–0.63)
Chen 2002 0.60 (0.31–1.15)
 Relative risk (95% CI)
Relative risk, highest vs lowest exposure category
10.2 20.5 0.75 51.5
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4.2.32). One of these studies also reported cumulative mea-
sures of lycopene consumption, which is a robust measure
of long-term consumption.590 The effect estimate was 0.95
(95% CI 0.92–0.99) per 5 mg/day. All studies were fully
adjusted.
Two of the cohort studies reported separately on advanced
or aggressive cancer, giving estimates of 0.89 (95% CI
0.28–2.84) per 5 mg /day613 and 0.57 (95% CI 0.37–0.87)
for the highest intake groups when compared to the lowest.591
Nine case-control studies showed decreased risk for the
highest intake groups when compared to the lowest,595 598 602
606 616 617 619 621 624 which was statistically significant in one.602
Five studies reported non-significant increased risk.596 599 601
620 625 Meta-analysis was possible on six relatively high qual-
ity case-control studies595 598 599 601 616 617 and three relative-
ly low quality ones.602 619 620 The former gave a summary
effect estimate of 0.995 (95% CI 0.95–1.04) per 5 mg/day,
with no heterogeneity and the latter gave a summary esti-
mate of 0.56 (95% CI 0.23–1.36) per 5 mg/day, with high
heterogeneity (figures 4.2.31 and 4.2.32).
Serum or plasma lycopene
Five cohort studies showed a non-significant reduced risk for
the highest intake groups when compared to the lowest576
626-628; the other study showed a non-significant increased
risk.629 Meta-analysis was possible on four cohort studies,
giving a summary estimate of 0.96 (95% CI 0.926–0.999)
per 10 µg/l, with no heterogeneity.576 626 627 All cohort stud-
ies were fully adjusted.
Both case-control studies of serum or plasma lycopene
showed a statistically significant reduced risk for the high-
est intake groups when compared to the lowest.596 619
Lycopene is most bioavailable from cooked and pureed
tomatoes. The best measures of systemic exposure are there-
fore studies on tomato sauce, particularly of cumulative con-
sumption, or on serum or plasma lycopene. The Panel also
gave emphasis to studies on advanced or aggressive cancers,
which may be better linked to prognosis than studies that
include early stage or latent disease, or screening-detected
disease.
The general mechanisms through which foods containing
carotenoids, including lycopene, could plausibly protect
against prostate cancer are outlined below. In addition,
amongst the common carotenoids, lycopene is thought to be
the most efficient antioxidant in the body.631
There is a substantial amount of consistent evidence,
in particular on tomato products, from both cohort and
case-control studies. There is evidence for plausible
mechanisms. Foods containing lycopene probably
protect against prostate cancer.
The Panel is aware that since the conclusion of the SLR, two
cohort studies632 633 and one case-control study634 have been
published. This new information does not change the Panel
judgement (see box 3.8).
Prostate
Also see chapter 4.10.6.4.2 for evidence on beta-carotene
supplements. Six cohort studies147 360 591 594 613 635 636 and 21
case-control studies595 598 599 602 616 617 619-621 624 625 637-648 inves-
tigated dietary beta-carotene and prostate cancer. 
Ten cohort studies576 594 626 628-630 635 649-652 and five case-
control studies584 596 608 619 653 investigated serum or plasma
beta-carotene.
Figure 4.2.32 Dietary lycopene and prostate cancer; cohort
and case-control studies: dose response
Cohort
Parker 1999
Giovanucci 2002
Schuurman 2002
Case control
McCann 2005
Hodge 2004
Key 1997
Jain 1999
Cohen 2000
Norrish 2000
0 421 3 5
Dietary lycopene (mg/day)
Figure 4.2.31 Lycopene and prostate cancer; cohort and
case-control studies
Cohort
Schuurman 2002 1.01 (0.46–2.22)
Parker 1999 0.01 (0.00–2.26)
Giovanucci 2002 0.99 (0.95–1.02)
Summary estimate 0.97 (0.64–1.45)
Case control
McCann 2005 0.99 (0.79–1.22)
Hodge 2004 0.93 (0.81–1.05)
Norrish 2000 0.70 (0.35–1.38)
Cohen 2000 0.96 (0.79–1.16)
Jain 1999 1.01 (0.96–1.06)
Key 1997 1.05 (0.13–8.85)
Summary estimate 1.00 (0.95–1.04)
Relative risk (95% CI)
Relative risk, per 5 mg/day
10.125 20.5 84
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Dietary beta-carotene
Three cohort studies showed non-significant increased risk
with increased intake.594 635 636 Three studies showed no
effect on risk.360 591 613 Meta-analysis was possible on all six
cohort studies, giving a summary effect estimate of 1.00
(95% CI 0.99–1.01) per 700 µg/day, with no hetero-
geneity.360 591 594 613 635 636
Two cohort studies reported results separately for
advanced/aggressive prostate cancer.594 613 Meta-analysis
was possible on both studies, giving a summary effect esti-
mate of 0.97 (95% CI 0.88–1.06) per 700 µg/day, with no
heterogeneity.
Fourteen case-control studies showed decreased risk with
increased intake,595 599 602 616 617 619-621 625 637 638 642 646 648 which
was statistically significant in two relatively low quality stud-
ies.602 646 648 Four studies showed no effect on risk624 639 644
645 and three studies showed non-significant increased
risk.598 640 641 Meta-analysis was possible on nine relatively
high quality595 598 599 616 617 637-640 and six relatively low qual-
ity case-control studies,602 619 620 624 641 642 giving summary
effect estimates of 0.99 (95% CI 0.98–1.00) and 0.98 (95%
CI 0.94–1.01) per 700 µg/day, with no and moderate het-
erogeneity, respectively. 
Serum or plasma beta-carotene
Five cohort studies showed decreased risk with increased
intake,576 626 628 649 651 652 which was statistically significant in
one.649 Four studies showed non-significant increased risk.594
626 629 635 Meta-analysis was possible on seven cohort stud-
ies, giving a summary effect estimate of 1.00 (95% CI
0.91–1.09) per 10 µg beta-carotene/100 ml, with moderate
heterogeneity.576 626 629 635 649
Four case-control studies showed decreased risk with
increased intake,584 608 619 653 which was statistically signifi-
cant in one relatively low quality study.653 One study showed
non-significant increased risk.596
It is unlikely that foods containing beta-carotene have
a substantial effect on the risk of prostate cancer. 
The Panel is aware that since the conclusion of the SLR, two
cohort studies632 633 have been published. This new information
does not change the Panel judgement (see box 3.8).
Skin 
Also see chapter 4.10.5.1 for evidence on beta-carotene sup-
plements. Two cohort studies654 655 and seven case-control
studies656-663 investigated dietary beta-carotene and skin can-
cer. Three cohort studies655 664-666 and one case-control
study657 investigated beta-carotene from food and supple-
ments combined; eight cohort studies545 630 651 655 667-672 and
three case-control studies584 673 674 investigated serum or plas-
ma beta-carotene.
Dietary beta-carotene
Both cohort studies showed non-significant increased risk
with increased intake, both for basal cell carcinoma.654 655 One
case-control study showed a non-significant decreased risk of
basal cell carcinoma for the highest intake group when com-
pared to the lowest662; one showed a non-significant
increased risk of squamous cell carcinoma.658 659 Three 
case-control studies showed decreased risk of melanoma for
the highest intake group when compared to the lowest,657 661
663 which was statistically significant in two.657 663
Two studies showed non-significant increased risk of mela-
noma.656 660
Beta-carotene from foods and supplements
Two cohort studies showed increased risk of basal cell car-
cinoma for the highest intake group when compared to the
lowest.655 665 One cohort study showed non-significant
increased risk of squamous cell carcinoma.666 One cohort
study showed a non-significant increased risk of
melanoma.664 One case-control study showed a statistically
significant decreased risk of melanoma for the highest intake
group when compared to the lowest.657
Serum or plasma beta-carotene
Two studies showed decreased risk for skin cancer of unspec-
ified type with increased serum or plasma beta-carotene,669
671 which was statistically significant in one.669 One cohort
study showed non-significant decreased risk of non-
melanoma skin cancer.667 One cohort study (fully adjusted)
showed a non-significant decreased risk for basal cell carci-
noma672; two showed a non-significant increased risk630 655;
and one a non-significant increased risk in women and a
non-significant decreased risk in men.651 Two studies
showed non-significant decreased risk on squamous cell car-
cinoma.668 672 Two studies showed decreased risk of
melanoma, which was statistically significant in one545 670;
and one study showed non-significant increased risk.630
Meta-analysis was possible on both cohort studies that inves-
tigated squamous cell carcinoma, giving a summary effect
estimate of 0.99 (95% CI 0.98–1.00) per µg beta-
carotene/100 ml, with no heterogeneity.668 672 Meta-analy-
sis was possible on two cohort studies that investigated
melanoma, giving a summary effect estimate of 0.90 (95%
CI 0.78–1.03) per µg beta-carotene/100 ml, with moderate
heterogeneity.545 670
One case-control study showed a statistically significant
decreased risk of non-melanoma skin cancer, which, at 0.999
per µg/100 ml (95% CI 0.999–0.999), was close to no
effect.673 One case-control study showed non-significant
increased risk of basal cell carcinoma for the highest intake
group when compared to the lowest.584 The same study
showed non-significant increased risk of squamous cell car-
cinoma and non-significant increased risk of melanoma.584
One additional study showed non-significant decreased risk
of melanoma.674
It is unlikely that foods containing beta-carotene have
any substantial effect on the risk of non-melanoma
skin cancer. 
General mechanisms — foods containing carotenoids
Carotenoids are antioxidants, which can prevent lipid oxi-
dation and related oxidative stress. Oxidative stress induced
by free radicals causes DNA damage. Base mutation, single-
and double-strand breaks, DNA cross-linking, and chromo-
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somal breakage and rearrangement can all occur if this ini-
tial damage is left unrepaired. This damage could plausibly
be prevented or limited by dietary antioxidants found in
fruits and vegetables.675
Many of the carotenoids, including beta-carotene, are also
retinoid (vitamin A) precursors. The pro-vitamin A
carotenoids may be converted to retinol where they function
in cellular differentiation, immunoenhancement, and acti-
vation of carcinogen-metabolising enzymes.580 676
Lycopene is the most potent carotenoid antioxidant, has
an antiproliferative effect, reduces plasma low-density
lipoprotein cholesterol, improves immune function, and
reduces inflammation.
4.2.5.4 Foods containing folate
Foods naturally containing folates are vegetables, fruits, and
liver, but increasingly foods such as breakfast cereals are for-
tified with folic acid.
Pancreas
Three cohort studies,677 678 two case-control studies,509 679
and one ecological study515 investigated folate from foods
and/or supplements, and pancreatic cancer.
One cohort study reported a statistically significant
reduced risk for the highest intake groups (without specify-
ing the source of folate) when compared to the lowest677; one
reported no effect on risk in men678 and the other reported
a non-significant increased risk in women.678 Meta-analysis
was possible on all three cohort studies, giving a summary
effect estimate of 0.94 (95% CI 0.80–1.11) per 100 µg/day,
with high heterogeneity.677 678
When these results were stratified according to dietary or
supplemental folate, this heterogeneity was removed. Two
cohort studies reported separately on dietary folate.678 Both
reported non-significant decreased risk; meta-analysis was
possible on both, giving a summary effect estimate of 0.86
(95% CI 0.73–1.00) per 100 µg/day, with no heterogeneity
(figure 4.2.33). All three cohort studies reported separately
on supplemental folate, showing non-significant increased
risk, with no heterogeneity.677 678
In addition, one of the cohort studies included a nested
case-control study investigating blood folate levels. This
reported a statistically significant decreased risk for the high-
est levels when compared to the lowest, with an effect esti-
mate of 0.45 (95% CI 0.24–0.82).680
The Panel is aware of an additional cohort study, published
after the conclusion of the literature review, which showed
a statistically significant decreased risk for the highest intake
groups when compared to the lowest.681 The effect estimate
was 0.25 (95% CI 0.11–0.59) for dietary folate and 0.33
(95% CI 0.15–0.72) for total folate (combining dietary and
supplemental sources). No association was observed with
folate supplements only.
One of the case-control studies reported a statistically sig-
nificant reduced risk for the highest intake groups when com-
pared to the lowest.679 The other reported a non-significant
decreased risk in women and no effect on risk in men.509
The ecological study showed a statistically significant
decreased risk in areas of high folate intake.515
The possible differential effect between folate from foods
and from supplements could be explained by folate serving
as a marker for fruit and vegetable intake, by a different
metabolic effect of the folic acid in supplements, or by con-
founders associated with supplement use.
The general mechanisms through which foods containing
folate could plausibly protect against pancreatic cancer are
outlined below. 
The evidence available is sparse but a dose-response
relationship was apparent from cohort studies. There is
limited evidence suggesting that foods containing
folate protect against pancreatic cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort study681 has been published. This new information does
not change the Panel judgement (see box 3.8).
Oesophagus
Eight case-control studies investigated dietary folate113 124 125
136 548 583 585 587 and two case-control studies investigated red
cell and/or plasma folate.682-684
All eight case-control studies that investigated dietary
folate reported decreased risk for the highest intake groups
when compared to the lowest,113 124 125 136 548 583 585 587 which
was statistically significant in two.583 587 Most studies adjust-
ed for smoking and alcohol.
Both case-control studies that investigated red cell and/or
plasma folate reported that levels were lower (statistically
significant) in cases than controls.682-684 One study was
adjusted for smoking and alcohol.684
The general mechanisms through which foods containing
folate could plausibly protect against oesophageal cancer are
outlined below. In addition, folate may reduce human papil-
loma virus proliferation in cells.685
The evidence, from case-control studies only, is sparse.
There is limited evidence suggesting that folate
protects against oesophageal cancer.
The Panel is aware that since the conclusion of the SLR, one
case-control study78 has been published. This new information
does not change the Panel judgement (see box 3.8).
Figure 4.2.33 Folate and pancreatic cancer;
cohort studies
Skinner 2004 Women 0.85 (0.63–1.15)
Skinner 2004 Men 0.86 (0.71–1.04)
Summary estimate 0.86 (0.73–1.00)
Relative risk (95% CI)
1 20.5 1.50.75
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Colorectum
Nine cohort studies investigated dietary folate and colorec-
tal cancer.686-694 Two cohorts investigated serum folate.694 695
Seven cohort studies that investigated dietary folate
showed decreased risk for the highest intake groups when
compared to the lowest, 686-690 692 693 which was statistically
significant in one.689 Two cohort studies reported non-
significant increased risk.691 694 Meta-analysis was possible on
four studies, giving a summary effect estimate of 0.84 (95%
CI 0.76–0.93) per 100 µg/day, with low heterogeneity 
(figure 4.2.34).686 689 692 696
One study of serum folate levels showed statistically sig-
nificant decreased risk for the highest intake groups when
compared to the lowest, with an effect estimate of 0.52 (95%
CI 0.27–0.97).695 The other showed a non-significant
decreased risk for colon cancer (0.96, 95% CI 0.4–2.3) and
a non-significant increased risk for rectal cancer incidence
(2.94, 95% CI 0.84–10.33).694
Because of the abundant prospective data from cohort
studies, case-control studies were not summarised.
A published meta-analysis of seven cohort studies and nine
case-control studies reported a statistically significant
decreased risk of colorectal cancer for the highest dietary
folate intake when compared to the lowest (0.75, 95% CI
0.64–0.89).697
The general mechanisms through which foods containing
folate could plausibly protect against colorectal cancer are
outlined below. In addition, folate intake is also strongly cor-
related with intake of dietary fibre, which probably prevents
colorectal cancer (also see chapter 7.1).
The evidence from cohort studies is plentiful, with a
dose-response relationship, but there is unexplained
inconsistency. Residual confounding from dietary fibre is
possible. There is limited evidence suggesting that foods
containing folate protect against colorectal cancer.
The Panel is aware that since the conclusion of the SLR, four
cohort698-701 and two case-control studies380 702 have been
published. This new information does not change the Panel
judgement (see box 3.8).
General mechanisms — foods containing folate 
Also see Chapter 2. Folate plays an important role in the syn-
thesis and methylation of DNA.703 Abnormal DNA methyl-
ation leading to aberrant gene expression has been
demonstrated in several types of cancer. Folate deficiency
may produce misincorporation of uracil instead of thymine
into DNA. The effects of folate deficiency and supplemen-
tation on DNA methylation are gene- and site-specific, and
appear to depend on cell type, target organ, stage of trans-
formation, and degree and duration of folate depletion.
Animal studies have shown that dose and timing of folate
intervention are critical in determining its effect: excep-
tionally high folate doses, and intervention after the forma-
tion of microscopic neoplastic foci, may promote rather than
suppress colorectal carcinogenesis, at least in the animal
models studied.704
There is a known interaction between folate and alcohol
and the risk of some cancers. 
4.2.5.5  Foods containing pyridoxine (vitamin B6)
Oesophagus
Six case-control studies investigated foods containing pyri-
doxine and oesophageal cancer.88 125 548 583 585 587
All six studies showed decreased risk for the highest intake
groups when compared to the lowest,88 125 548 583 585 587 which
was statistically significant in four.88 125 583 585 All studies
adjusted for alcohol and five adjusted for smoking.
Together with folate and cobalamin (B12), vitamin B6 is
involved in one-carbon metabolism and thus is important for
DNA synthesis, repair, and methylation. 
The evidence, from case-control studies only, was
sparse. There is limited evidence suggesting that
pyridoxine protects against oesophageal cancer.
The Panel is aware that since the conclusion of the SLR, one
case-control study78 has been published. This new information
does not change the Panel judgement (see box 3.8).
4.2.5.6 Foods containing vitamin C
Oesophagus
One cohort study,70 19 case-control studies,86 88 94 95 104 105 107
113 120 121 124 125 136 548 583 585-587 705-707 and 3 ecological stud-
ies118 203 708 investigated vitamin C and oesophageal cancer.
The single cohort study reported a non-significant reduced
risk for the highest intake groups when compared to the low-
est after adjustment for smoking, with an effect estimate of
0.70 (95% CI 0.3–1.7).70
Eighteen of the case-control studies showed decreased risk
for the highest intake groups when compared to the lowest,86
88 94 95 104 105 107 113 120 121 124 136 548 583 585-587 705-707 which was
statistically significant in 13 (figure 4.2.35).86 88 95 104 105 113
120 121 136 548 583 585 705 707 Three studies showed a non-signifi-
cant increased risk, all specific to adenocarcinoma.124 125 706
None of the ecological studies reported a statistically sig-
nificant association.118 203 708
Figure 4.2.34 Dietary folate intake and colorectal cancer;
cohort studies
Giovannucci 1998 Women 0.91 (0.76–1.10)
Su 2001 Women 0.93 (0.72–1.19)
Su 2001 Men 0.69 (0.52–0.90)
Konings 2002 Men 0.81 (0.64–1.03)
Konings 2002 Women 0.90 (0.63–1.29)
Larsson 2005 Women 0.77 (0.60–0.98)
Summary estimate 0.84 (0.76–0.93)
Relative risk (95% CI)
10.5 1.50.75 2
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It is biologically plausible that vitamin C should protect
against cancer. It traps free radicals and reactive oxygen mol-
ecules, protecting against lipid peroxidation, reducing
nitrates, and stimulating the immune system.586 709 Moreover,
it can recycle other antioxidant vitamins such as vitamin E.534
Vitamin C has also been shown to inhibit formation of car-
cinogens and protect DNA from mutagenic attack.535
However, evidence supporting a specific mechanism in the
oesophagus is limited.586
A substantial amount of consistent evidence is
available, from both cohort and case-control studies.
Foods containing vitamin C probably protect against
oesophageal cancer.
The Panel is aware that since the conclusion of the SLR, one
case-control study710 has been published. This new information
does not change the Panel judgement (see box 3.8).
4.2.5.7  Foods containing vitamin E
Oesophagus
One cohort study,70 nine case-control studies,86 88 95 105 125 548
583 585 587 and one ecological study708 investigated dietary vit-
amin E and oesophageal cancer. Three cohort studies537 545
711 and four case-control studies581 682 683 712 investigated
serum vitamin E.
Dietary vitamin E
The single cohort study showed decreased risk for the high-
est intake groups when compared to the lowest, with an effect
estimate of 0.8 (95% CI 0.3–2.0; adjusted for smoking).70
Eight case-control studies reported decreased risk for the
highest intake groups when compared to the lowest,86 88 95
105 125 548 583 585 which was statistically significant in seven86
88 95 105 548 583 585; the other study reported no effect on risk.587
All studies adjusted for alcohol and all but one also adjust-
ed for smoking.
The single ecological study reported no association.708
Serum vitamin E
All three cohort studies showed decreased risk for the high-
est intake groups when compared to the lowest,537 545 711
which was statistically significant in two. The effect estimates
were 0.63 (95% CI 0.44–0.91) for alpha-tocopherol 
(the same study showed no significant association with
serum gamma-tocopherol),711 and 0.39 (95% CI 0.19–0.80)
for gamma-tocopherol.537 The third cohort study found lower
mean values in cases than controls (8.52 vs 10.21 mg/l),
which was not statistically significant.545 The two former
studies were maximally adjusted.537 711
Two case-control studies reported that cases had higher
plasma vitamin E than controls,682 683 statistically significant
in one.683 One study reported statistically significant lower
levels in cases than those in controls712; and another report-
ed no significant difference.581 None of these studies was well
adjusted.
The general mechanisms through which foods containing
vitamin E could plausibly protect against oesophageal cancer
are outlined below. 
Much of the evidence on vitamin E, mostly from case-
control studies, was of poor quality. There is limited
evidence suggesting that foods containing vitamin E
protect against oesophageal cancer.
Prostate 
Two cohort studies,147 613 650 713 13 case-control studies,595 599
601 604 607 616 619-621 625 637 714-717 and 1 ecological study708 inves-
tigated dietary vitamin E and prostate cancer; 4 cohort stud-
ies629 630 718-722 and 1 case-control study716 investigated serum
vitamin E; 8 cohort studies576 626 627 629 635 650 652 713 718 723-725
and 2 case-control studies619 653 investigated serum or plas-
ma alpha-tocopherol; 6 cohort studies576 626 627 629 650 718 724
and 1 case-control study619 investigated serum gamma-
tocopherol.
Dietary vitamin E
Most studies showed non-significant decreased risk, although
there is heterogeneity in the direction of effect reported and
effect estimates are usually very close to 1 (no effect). One
cohort study reported an effect size of 0.96 (0.75–1.2) per
10 mg/day for advanced/aggressive prostate cancer.613 Meta-
analysis was possible on seven relatively good quality case-
control studies, giving a summary effect estimate of 1.04
(95% CI 0.99–1.11) per 10 mg/day, with low hetero-
geneity.595 599 601 616 637 714 715 Dietary studies produce no
consistent effect.
Serum or plasma alpha-tocopherol
Seven cohort studies showed decreased risk for the highest
Figure 4.2.35 Vitamin C and oesophageal cancer;
case-control studies
Mettlin 1981 0.42 (023–0.77)
Tuyns 1983 Men 0.63 (0.50–0.79)
Tuyns 1983 Women 0.56 (0.20–0.91)
Brown 1988 0.50 (0.27–0.91)
Barone 1992 0.40 (0.10–1.55)
Kabat 1993 0.53 (0.22–1.25)
Hu 1994 0.60 (0.31–1.15)
Launoy 1998 0.40 (0.20–0.79)
De Stefani 1999 0.70 (0.52–0.94)
De Stefani 1999 0.50 (0.31–0.82)
Terry 2000 0.60 (0.38–0.95)
De Stefani 2000 0.14 (0.06–0.35)
Franceschi 2000 0.40 (0.24–0.65)
Mayne 2001 0.53 (0.36–0.79)
Zhang 1997 1.30 (0.48–3.49)
Chen 2002 0.60 (0.30–1.20)
 Relative risk (95% CI)
Relative risk, highest vs lowest exposure category
10.2 20.5 5
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intake groups when compared to the lowest,576 626 629 635 650
652 713 718 723-725 which was statistically significant in one.576
One cohort study showed no effect on risk.627 Meta-analysis
was possible on seven cohort studies, giving a summary
effect estimate of 0.99 (95% CI 0.97–1.00) per mg/l, with
no heterogeneity.576 626 713 723-725
Both case-control studies showed decreased risk for the
highest intake groups when compared to the lowest,619 653
which was statistically significant in one.653
Serum gamma-tocopherol
All six cohort studies showed decreased risk for the highest
intake groups when compared to the lowest,576 626 627 629 650
718 724 which was statistically significant in two.650 724 Meta-
analysis was possible on all six cohort studies, giving a sum-
mary effect estimate of 0.90 (95% CI 0.81–0.996) per mg/l,
with moderate heterogeneity.
The single case-control study showed non-significant
decreased risk for the highest intake groups when compared
to the lowest.619
The general mechanisms through which foods containing
vitamin E could plausibly protect against prostate cancer 
are outlined below. Vitamin E has also been shown to 
inhibit the growth of human prostate tumours induced in
mice.726
The evidence, mostly from case-control studies, was
inconsistent. There is limited evidence suggesting that
foods containing vitamin E protect against prostate
cancer.
The Panel is aware that since the conclusion of the SLR, two
cohort studies632 633 have been published. This new information
does not change the Panel judgement (see box 3.8).
General mechanisms — foods containing vitamin E
Vitamin E is an antioxidant that has been reported to pre-
vent DNA damage, enhance DNA repair, prevent lipid per-
oxidation, and prevent activation of carcinogens such as
nitrosamines. Vitamin E protects vitamin A and selenium in
the body. In addition to acting as a free-radical scavenger,
vitamin E enhances the body’s immune response, which may
play a role in cancer defences.727
4.2.5.8  Foods containing selenium
Data from selenium levels in serum or nails can be inter-
preted more robustly than dietary data because they are less
prone to certain sources of error; serum data are a short-term
reflection of intake; levels in nails are cumulative and reflect
long-term intake. 
It is not possible to rule out residual confounding between
selenium levels and healthy lifestyles. Individuals with high-
er selenium levels may be more likely to be following sev-
eral strategies to improve their health, including taking 
supplements.
It is plausible that an effect attributed to selenium could
only be apparent in areas of selenium deficiency. 
Lung 
Two cohort studies,288 464 two case-control studies,469 557 and
two ecological studies728 729 investigated dietary selenium
and lung cancer. 
Ten cohort studies,463 575 577 730-738 seven case-control stud-
ies,570 571 739-743 and four ecological studies729 744-746 investi-
gated plasma or serum selenium; three cohort studies747-749
investigated selenium levels in nails.
Dietary selenium
One cohort study showed non-significant decreased risk for
the highest intake group when compared to the lowest.464
One cohort study showed non-significant increased risk in
non-smokers and non-significant decreased risk in
smokers.288 Both case-control studies showed a non-signifi-
cant increased risk for the highest intake group when com-
pared to the lowest.469 557 One ecological study showed
statistically significant decreased risk in high-intake areas,728
the other showed no consistent association.729
Plasma or serum selenium
Seven cohort studies showed decreased risk for the highest
selenium levels when compared to the lowest,463 575 731-734 
736-738 which was statistically significant in two.733 737 Four
studies showed increased risk,577 730 735 738 which was statis-
tically significant in two.735 738 Meta-analysis was possible on
four cohort studies, giving a summary effect estimate of
0.969 (95% CI 0.940–0.999) per 10 µg/l, with low hetero-
geneity.577 731 733 736
Six case-control studies showed decreased risk for the
highest levels when compared to the lowest,570 739-743 which
was statistically significant in four.739 740 742 743 One study
showed non-significant increased risk.571
One ecological study showed statistically significant
decreased risk in areas of high plasma selenium729; the oth-
ers showed no consistent effect.729 744-746
Nails
Two cohort studies showed decreased risk for the highest
selenium levels when compared to the lowest,748 749 which
was statistically significant in one.749 One study showed non-
significant increased risk.747
The general mechanisms through which selenium could
plausibly protect against lung cancer are outlined below.
The evidence available is sparse. There is limited
evidence to suggest that foods containing selenium
protect against lung cancer. 
Prostate 
One cohort,713 750 7 case-control studies,599 601 639 715 716 751 752
and 2 ecological studies729 753 754 investigated dietary sele-
nium; 12 cohort studies652 730 732 755-765 and 4 case-control
studies716 741 752 754 766 767 investigated serum or plasma sele-
nium; and 3 cohort studies,615 724 768 3 case-control studies,717
769 770 and 1 ecological study771 investigated levels in nails.
Further to this, 1 randomised controlled trial772 773 and 2
cohorts612 628 713 investigated selenium supplements (see
chapter 4.10.6.4.5).
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Dietary selenium
One cohort study showed a statistically significant decreased
risk. The effect estimate was 0.66 (95% CI 0.44–0.98) per
50 µg/day.713 This study did not adjust for confounders.
Two case-control studies showed non-significant decreased
risk for the highest intake groups when compared to the low-
est751 752; five showed increased risk,599 601 639 715 716 one of
which was statistically significant.715 Meta-analysis was pos-
sible on three studies, giving a summary effect estimate of
1.07 (95% CI 0.92–1.25) per increase in 50 µg/day, with no
heterogeneity.599 601 639
The two ecological studies reported that increasing
selenium intake was associated with decreasing prostate
cancer levels.729 753 754
Serum or plasma selenium
Eight cohort studies that investigated serum or plasma sele-
nium showed decreased risk for the highest intake groups
when compared to the lowest,652 732 755-759 761 763 764 which was
statistically significant in two. Four reported non-significant
increased risk.730 760 762 765 Meta-analysis was possible on nine
of these studies, giving a summary effect estimate of 0.95
(95% CI 0.89–1.00) per 10 µg/l, with moderate hetero-
geneity (figure 4.2.36).732 755 757 758 761 762 764 765
Two of these 12 cohort studies reported separately on
advanced/aggressive cancer.730 755 758 Both showed decreased
risk for the highest intake groups when compared to the low-
est, which was statistically significant in one.758 Meta-analy-
sis was possible on both, giving a summary effect estimate
of 0.87 (95% CI 0.79–0.97) per 10 µg/l, with no hetero-
geneity (figure 4.2.37).755 758
A dose-response relationship is apparent from the studies
on advanced or aggressive disease (figure 4.2.38).
All four of the case-control studies showed decreased risk
for the highest intake groups when compared to the low-
est,716 741 752 766 767 which was statistically significant in
three.741 752 767
Nails
Two cohort studies investigated selenium levels in nails for
all prostate cancer. Both showed non-significant decreased
risk for the highest intake groups when compared to the low-
est. Meta-analysis was possible on both studies, giving a sum-
mary effect estimate of 0.91 (95% 0.81–1.02) per 100 ng/g,
with moderate heterogeneity.724 768
Two cohort studies investigated selenium levels in nails for
advanced or aggressive prostate cancer. Both showed statis-
tically significant decreased risk for the highest intake groups
when compared to the lowest. Meta-analysis was possible on
both studies, giving a summary effect estimate of 0.80 (95%
0.69–0.91) per 100 ng/g, with no heterogeneity.615 768
One case-control study showed non-significant decreased
risk for the highest intake groups when compared to the low-
est,770 one showed no effect on risk717 and the other showed
a non-significant increased risk.769
The single ecological study reported a non-significant asso-
ciation.771
These data are supported by data on supplements, which
have been shown to decrease prostate cancer risk (see chap-
ter 4.10.6.4.5). 
There is no significant heterogeneity within the meta-
Figure 4.2.36 Selenium (in plasma or serum) and
prostate cancer; cohort studies
Nomura 2000 0.89 (0.40–0.99)
Li 2004 0.95 (0.89–1.01)
Knekt 1990 0.99 (0.78–1.24)
Goodman 2001 1.01 (0.93–1.11)
Brooks 2001 0.77 (0.65–0.89)
Ringstad 1988 0.99 (0.97–1.01)
Willett 1983 0.64 (0.37–1.12)
Virtamo 1987 1.16 (0.82–1.65)
Salonen 1984 1.03 (0.63–1.70)
Summary estimate 0.95 (0.89–1.00)
 Relative risk (95% CI)
10.5 2
Figure 4.2.37 Selenium (in serum or plasma) and
advanced or aggressive prostate cancer;
cohort studies
Nomura 2000 0.80 (0.64–1.00)
Li 2004 0.89 (0.80–1.00)
Summary estimate 0.87 (0.79–0.97)
 Relative risk (95% CI)
10.5 2
Figure 4.2.38 Selenium (in serum or plasma) and advanced
or aggressive prostate cancer;
cohort studies: dose response
Li 2004
Nomura 2000
8 12 1610 14
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analyses of advanced/aggressive cancer. The low to moder-
ate heterogeneity observed for other outcomes and different
study types may be explained by the variable inclusion of
latent cancers in the outcome and by variations in study
quality.
The general mechanisms through which foods containing
selenium could plausibly protect against prostate cancer are
outlined below. In addition, selenoproteins are involved in
testosterone production, which is an important regulator of
both normal and abnormal prostate growth.774 775
The evidence from cohort and case-control studies is
consistent, with a dose-response relationship. There is
evidence for plausible mechanisms. Foods containing
selenium probably protect against prostate cancer.
Stomach 
One case-control study776 and five ecological studies238 729 777-
779 investigated dietary selenium and stomach cancer. Three
cohort studies,731 732 736 nine case-control studies,738 741 754 
780-785 and three ecological studies236 729 786 investigated blood
selenium. One cohort study787 and one case-control study788
investigated selenium in toenails or hair. In addition, one
randomised controlled trial and one combined trial investi-
gated selenium supplements.423 424
Dietary selenium
The single case-control study showed that dietary selenium
was not significantly associated with risk of stomach
cancer.776
Most ecological studies showed that low selenium levels
were associated with increased stomach cancer risk,238 777-779
one of which was statistically significant.779
Blood selenium
All three cohort studies that investigated blood selenium lev-
els showed decreased risk for the highest levels when com-
pared to the lowest,731 732 736 which was statistically
significant in men in one study.732 Meta-analysis was possi-
ble on all three, giving a summary effect estimate of 0.89
(95% CI 0.78–1.00) per 0.1 µmol/l, with moderate hetero-
geneity.731 732 736
All nine case-control studies showed statistically significant
decreased risk for the highest levels when compared to the low-
est.738 741 754 780-785 Meta-analysis was possible on six of these,
giving a summary effect estimate of 0.44 (95% CI 0.35–0.55)
per 0.1 µmol/l, with high heterogeneity.741 754 782-785
This heterogeneity was caused by varying size, not direction,
of effect.
All three ecological studies reported inverse associations
between blood or plasma selenium and stomach cancer
mortality,236 729 786 which were statistically significant in
two.236 786
A dose-response relationship is apparent from case-control
but not cohort data.
Two additional cohort studies, both from China, stratified
results according to tumour location.789 790 The apparent pro-
tective effect was strengthened for cardia cancers, but dis-
appeared for proximal. 
Nails and hair
The single cohort study that investigated selenium in nails
showed statistically significant decreased risk for the high-
est levels when compared to the lowest in men, but not
women. The effect estimates were 0.4 in men (95% CI
0.17–0.96; 72 cases) and 1.68 in women (95% CI 0.43–6.54;
20 cases).787
The single case-control study found that mean hair
selenium levels were significantly lower in the 15 stomach
cancer cases than in controls.788
The general mechanisms through which foods containing
selenium could plausibly protect against stomach cancer are
outlined below. In addition, selenoproteins with powerful
antioxidant activity may provide protection against the
inflammatory effect of H pylori, which can lead to gastric
cancer in infected individuals.791
A substantial amount of evidence was available on
selenium, from dietary questionnaires, as well as
blood, nails, and hair, mostly from case-control
studies. There is limited evidence suggesting that foods
containing selenium protect against stomach cancer.
Colorectum
Fifteen case-control studies investigated dietary selenium
and colorectal cancer.738 785 792-795
Dietary, serum or plasma, toenail selenium
Meta-analysis was possible on six independent effect esti-
mates from five case-control studies, giving a summary effect
estimate of 0.86 (95% CI 0.78–0.95) per 10 µg/dl serum,
with high heterogeneity.785 792-795 All of these studies report-
ed decreased risk, which was statistically significant in four
of the five studies.792-795 The heterogeneity is therefore
derived from varying size, but not direction of effect. The
remaining 10 studies reported non-significant decreased
risk.738 These data are supported by limited evidence sug-
gesting that there is also a protective effect from selenium
supplements (see chapter 4.10.6.4.5).
The general mechanisms through which foods containing
selenium could plausibly protect against colorectal cancer are
outlined below.
A substantial amount of data was available, from case-
control studies only. There is limited evidence
suggesting that foods containing selenium protect
against colorectal cancer.
General mechanisms — foods containing selenium 
Dietary selenium deficiency has been shown to cause a lack
of selenoprotein expression. Twenty-five selenoproteins
have been identified in animals and a number of these have
important anti-inflammatory and antioxidant properties.796
Four are glutathione peroxidises, which protect against
oxidative damage to lipids, lipoproteins, and DNA. These
enzymes are rapidly degraded during selenium deprivation.
Three are thioredoxin reductases and, amongst other func-
tions, these regenerate oxidised ascorbic acid to its active
antioxidant form. 
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Selenoproteins appear to reach their maximal levels
relatively easily at normal dietary selenium intake and 
not to increase with selenium supplementation. It is, how-
ever, plausible that supraphysiological amounts of selenium
might affect programmed cell death, DNA repair, carcinogen
metabolism, immune system, and anti-angiogenic effects.797
4.2.5.9  Foods containing quercetin
Lung 
Two cohort studies147 798 and three case-control studies327 477
799 investigated foods containing quercetin and lung cancer.
Both cohort studies showed statistically significant
decreased risk for the highest intake groups when compared
to the lowest.147 798 The effect estimates were 0.63 (95% CI
0.52–0.78)147 and 0.42 (95% CI 0.25–0.72).798 Both studies
adjusted for smoking. 
Two case-control studies showed decreased risk for the
highest intake groups when compared to the lowest,327 477
which was statistically significant in one.327 One study
reported non-significant increased risk.799 The effect esti-
mates were 0.58 (95% CI 0.39–0.85),327 0.7 (95% CI
0.4–1.1),477 and 1.89 (95% CI 0.72–4.92).799 The latter study
may have been over-adjusted.
Quercetin is a flavonoid. It is an antioxidant and also
directly inhibits expression of CYP1A1 (a cytochrome P450
enzyme that helps to metabolise toxins), resulting in
decreased formation of DNA adducts.475 Elevated CYP1A1
activity has been associated with increased risk of lung can-
cer, primarily in smokers.476 The evidence for CYP1A1/
flavonoid interactions is supported by the observation that
protective associations of flavonoids are associated with
specific CYP1A1 genotypes.476 477
The evidence available is sparse and inconsistent.
There is limited evidence suggesting that foods
containing quercetin protect against lung cancer.
4.2.5.10  Pulses (legumes) 
Studies conducted in Western countries, as most cohorts
have been, are likely to have limited power to detect an asso-
ciation between pulses, and particularly soya intake, and
cancer risk because consumption tends to be low. 
Stomach 
Three cohort studies,144 146 241 22 case-control studies,109 157
161 162 165 175 179 180 185-187 190 219 224 243 244 247 249-251 270 271 482
2 cross-sectional studies,196 800 and 16 ecological studies116-
119 197 198 200-203 208 209 236 238 239 801 investigated pulses
(legumes) and stomach cancer. Two cohort studies,802 803
9 case-control studies,109 129 159 178 184 194 226 229 262 and 2 eco-
logical studies208 804 investigated soya and soya products.
Pulses (legumes)
All three cohort studies reported decreased risk with increased
intake of pulses (legumes),144 146 241 which was statistically
significant in one.146 Meta-analysis was possible on two
studies, giving a summary effect estimate of 0.93 (95% CI
0.82–1.05) per 20 g/day, with moderate heterogeneity.144 146
Twelve case-control studies showed decreased risk for the
highest intake groups when compared to the lowest,109 157 161
165 179 185-187 190 219 247 249 250 271 which was statistically signifi-
cant in six.109 161 165 179 190 249 Six studies reported increased
risk,162 224 243 251 270 482 which was statistically significant in
two.224 243 270 The remaining four studies reported no effect
on risk,180 244 or stated that there was no significant effect
on risk.175 Meta-analysis was possible on eight studies, giv-
ing a summary effect estimate of 0.93 (95% CI 0.87–0.99)
per 20 g/day, with moderate to high heterogeneity.157 162 179
180 186 187 247 249
A dose-response relationship is apparent from case-control
but not cohort data. 
One ecological study reported a statistically significant
association, so that higher soya consumption was associated
with lower stomach cancer risk.208 The other 15 reported no
significant association.116-119 197 198 200-203 209 236 238 239 801
Soya and soya products
Both cohort studies showed decreased risk for the highest
intake groups when compared to the lowest,802 803 which was
statistically significant in one.803 The effect estimates were
0.60 (44 cases, 95% CI 0.40–1.10)802 and 0.86 (121 cases,
95% CI 0.77–0.96) per 20 g/day.803 The smaller study was
not adjusted for any confounders.
All nine case-control studies showed decreased risk for the
highest intake groups when compared to the lowest,109 129 159
178 184 194 226 229 262 which was statistically significant in five.129
159 178 184 226 Meta-analysis was possible on seven studies, giv-
ing a summary effect estimate of 0.82 (95% CI 0.72–0.94)
per 20 g/day, with high heterogeneity.109 129 159 178 194 226 229
Heterogeneity is derived from the size, and not the direction,
of the effect.
A dose-response relationship is apparent from case-control
data, as well as from one of the two cohort studies.
Both ecological studies reported statistically significant
inverse relationships, with stomach cancer risk decreasing in
areas of increased soya consumption.208 804
The general mechanisms through which pulses (legumes),
soya and soya products could plausibly protect against stom-
ach cancer are outlined below. In addition, laboratory exper-
iments have shown that genistein slows down the
development of stomach cancers promoted by sodium chlo-
ride by increasing apoptosis, and lowering cell proliferation
and blood vessel growth.805 Additionally, in a rodent model,
a diet containing miso inhibited N-nitrosamine-induced
stomach tumours.806
The evidence, mostly from case-control studies, is
inconsistent. There is limited evidence suggesting that
pulses (legumes), including soya and soya products,
protect against stomach cancer.
Prostate 
Three cohort studies,589 592-594 11 case-control studies,595 597
599-601 604 608 617 620 624 715 and 6 ecological studies116 118 609 807-
809 investigated pulses (legumes) and prostate cancer. Four
cohort studies,597 810-813 4 case-control studies,603 715 814-816
and 2 ecological studies804 808 investigated soya and soya
products.
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Pulses (legumes)
Two cohort studies reported statistically significant decreased
risk with increased intake589 592; the third study reported that
there was no significant association.594 The reported effect
estimates were 0.93 (95% CI 0.87–0.996)589 and 0.817 (95%
CI 0.714–0.934)592 per serving/week. The latter was specif-
ic to beans and lentils. 
Eight of the case-control studies showed decreased risk
with increased intake,595 597 599 608 617 620 624 715 which was sta-
tistically significant in two.597 624 One study showed a non-
significant increased risk604 and the other reported no effect
on risk.600 One study showed a non-significant increased risk
for dried beans and lentils and a non-significant decreased
risk with fresh beans and lentils.601 Meta analysis was pos-
sible on four relatively good quality case-control studies, giv-
ing a summary effect estimate of 0.97 (95% CI 0.95–0.98)
per serving/week, with no heterogeneity.595 597 599 601
A dose-response relationship is apparent from two of the
cohort studies, as well as case-control data.
The five ecological studies generally fail to show a clear
relationship between consumption of pulses and prostate
cancer risk; correlations range from -0.15 to -0.63.116 118 609
807-809
Soya and soya products
The cohort studies reported a wide range of results based on
different specific exposures.810-813 One study, which report-
ed on soya and soya products, showed a non-significant
decreased risk for the highest intake groups when compared
to the lowest, with an effect estimate of 0.79 (95% CI
0.53–1.18).810 One study reported a statistically significant
decreased risk with increased intake of soya milk (0.93, 95%
CI 0.87–0.99) per serving/week and a non-significant
decreased risk with increased intake of vegetarian soya prod-
ucts (0.93, 95% CI 0.85–1.01) per serving/week.813 One
reported no association between soya bean paste soup intake
and prostate cancer.811 The final study reported non-signif-
icant harmful effects for miso soup and foods cooked in soy
sauce, with effect estimates of 1.05 (95% CI 0.94–1.18) and
1.06 (0.474, 2.39) respectively per serving/day.812
All four case-control studies showed non-significant
decreased risk with increased intake.597 603 715 814-816 Meta
analysis was possible on two case-control studies, giving a
summary effect estimate of 0.98 (95% CI 0.95–1.00).597 715
The two ecological studies reported no clear relationship
between soya consumption and prostate cancer.804 808
Heterogeneity is likely to be derived from the wide vari-
ety in specific foods being investigated.
The general mechanisms through which pulses (legumes),
soya and soya products could plausibly protect against
prostate cancer are outlined below. In addition, phytoestro-
gens in pulses and soya can have an androgenic effect, poten-
tially inhibiting testosterone-induced growth of the prostate.
The evidence, mostly from case-control studies, is
inconsistent. There is limited evidence suggesting that
pulses (legumes), including soya and soya products,
protect against prostate cancer.
General mechanisms — pulses (legumes) 
Pulses (legumes), particularly soya foods, contain various
compounds that may have anti-cancer effects, including pro-
tease inhibitors, saponins, and phytoestrogens, such as genis-
tein and daidzein, which are found in high concentrations
in soya.817 These compounds could plausibly influence
oestrogen metabolism. They have also been shown to have
antioxidant effects, inhibit the growth of blood vessels to a
tumour, and may influence apoptosis and cell growth.818
4.2.5.11  Nuts and seeds 
The evidence was too limited in amount, consistency, or
quality to draw any conclusions
4.2.5.12  Herbs and spices
Garlic can be classified as a herb or as an allium vegetable.
Data on garlic have contributed to the evidence base for alli-
um vegetables and stomach cancer (see chapter 4.2.5.1.1)
and garlic also probably protects against colorectal cancer
(see chapter 4.2.5.1.1).
4.2.5.12.1 Chilli
Stomach 
Fourteen case-control studies investigated chilli use and
stomach cancer.171 175 176 180 182 187 189 219 246 247 259 415 819-821
Nine studies showed increased risk for the highest intake
groups when compared to the lowest,175 176 180 187 189 219 259
415 820 821 which was statistically significant in four,175 180 259
821 statistically significant in men but not women in a fifth
study,219 and statistically significant in non-drinkers of alco-
hol, but not alcohol drinkers, in a sixth.176 Four studies
showed decreased risk,171 182 246 247 which was statistically sig-
nificant in three.182 246 247 One study reported no significant
effect on risk.819
Chilli may be used to disguise ‘off ’ flavours in foods, there-
fore these data may be confounded by socioeconomic sta-
tus, the availability of refrigeration, and H pylori infection.
Some constituents of chilli are irritants which could there-
fore plausibly increase inflammation in the stomach.
The evidence, from case-control studies only, is
inconsistent. There is limited evidence suggesting that
chilli is associated with an increased risk of stomach
cancer.
4.2.4  Comparison with previous report
The previous report concluded that the evidence that diets
high in vegetables and fruits protect against cancers of the
mouth, pharynx, oesophagus, lung, and stomach was con-
vincing; and that the evidence that diets high in vegetables
protect against colorectal cancer was also convincing. The
previous report also judged that diets high in vegetables and
fruits probably protected against cancers of the larynx, pan-
creas, breast, and bladder. The panel also noted a pattern
whereby diets high in vegetables and fruits possibly pro-
tected against cancers of the cervix, ovary, endometrium,
and thyroid; and that diets high in vegetables possibly pro-
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tected against cancers of the liver, prostate, and kidney. 
Since the mid-1990s, a number of cohort studies have
somewhat weakened the overall evidence for the protective
effects of vegetables and fruits. A number of judgements of
probable protective effects are made for non-starchy veg-
etables and for fruits (mouth, pharynx, larynx, oesophagus,
stomach, and (fruits only) lung). In general, the reason for
this is that the more recent cohort studies failed to show the
effect seen in case-control studies.
The previous report also made judgements on types of veg-
etables and fruits in a footnote, while choosing not to enter
these into the matrix. The evidence that green vegetables
protected against lung and stomach cancer was judged con-
vincing; and probable for mouth and oesophageal cancer.
The evidence that cruciferous vegetables protected against
colorectal and thyroid cancer was judged probable. The evi-
dence that allium vegetables protected against stomach can-
cer was judged probable. The evidence that raw vegetables
and citrus fruits protected against stomach cancer was
judged convincing. These classifications are somewhat dif-
ferent from those made in this Report, but mostly also gen-
erated more confident judgements than are made here. 
Vitamins, minerals, and other bioactive constituents of
foods and drinks were assessed as such in the previous
report, whereas here they are assessed either as contained
in foods and drinks or (see chapter 4.10) as supplements.
The previous report judged that carotenoids (in food) prob-
ably protected against lung cancer; that vitamin C (in food)
probably protected against stomach cancer; and that these
vitamins and vitamin E possibly protected against cancers of
a number of sites. 
The previous panel regretted the lack of evidence on puls-
es (legumes), nuts, seeds, herbs, and spices, and made no
significant judgements. Since then, evidence on soya and its
products, and on garlic (as well as allium vegetables in gen-
eral) and chilli, has increased and allowed some judgements. 
The previous report judged that aflatoxin contamination
was a probable cause of liver cancer. Since then, the overall
evidence, particularly on the underlying mechanisms, has
strengthened. 
The previous report emphasised evidence on vegetables
and on fruits as a whole, while noting evidence on categories
of vegetables and fruits. This Report has not made any sep-
arate judgement on raw vegetables and fruits. The previous
report classified bananas as plantains. Here they are classi-
fied as fruits. The previous report considered micronutrients
and phytochemicals contained in foods of plant origin in sep-
arate chapters. Here, the evidence has been characterised in
terms of foods containing specified micronutrients, and they
are considered together with vegetables and fruits, pulses
(legumes), nuts and seeds, and other plant foods. Similarly,
the previous report considered dietary fibre separately from
cereals (grains) and other plant foods. Here, dietary fibre is
considered in the context of cereals (grains) and other plant
foods, including those assessed in this section. 
4.2.7  Conclusions
The Panel concludes:
Findings from cohort studies conducted since the mid-1990s
have made the overall evidence that vegetables, or fruits,
protect against cancers, somewhat less impressive. In no case
now is evidence of protection judged to be convincing.
However, there is evidence that some types of vegetables,
and fruits in general, probably protect against a number of
cancers. The few judgements on legumes (pulses), nuts,
seeds, and (with two exceptions) herbs and spices, reflect the
small amount of epidemiological evidence. 
Non-starchy vegetables probably protect against cancers of
the mouth, pharynx, and larynx, and those of the oesopha-
gus and stomach. There is limited evidence suggesting that
they also protect against cancers of the nasopharynx, lung,
colorectum, ovary, and endometrium. Allium vegetables prob-
ably protect against stomach cancer. Garlic (an allium veg-
etable, commonly classed as a herb) probably protects against
colorectal cancer.
Fruits in general probably protect against cancers of the
mouth, pharynx, and larynx, and of the oesophagus, lung,
and stomach. There is limited evidence suggesting that fruits
also protect against cancers of the nasopharynx, pancreas,
liver, and colorectum.
There is limited evidence suggesting that carrots protect
against cervical cancer; and that pulses (legumes), including
soya and soya products, protect against stomach and prostate
cancers. There is limited evidence suggesting that chilli is a
cause of stomach cancer.
Fruits and non-starchy vegetables are low energy-dense
foods. For a discussion of the effect of such foods and drinks
on weight gain, overweight, and obesity, and the role of
weight gain, overweight, and obesity in the risk of some can-
cers, see Chapters 6, 7, and 8.
Evidence that vegetables, fruits, and pulses protect against
some cancers is supported by evidence on various micronu-
trients, which act as markers for consumption of vegetables,
fruits, and pulses (legumes), and other plant foods. Foods
containing folate probably protect against pancreatic cancer,
and there is limited evidence suggesting that these also pro-
tect against oesophageal and colorectal cancers. Foods con-
taining carotenoids probably protect against cancers of the
mouth, pharynx, and larynx, and also lung cancer. Foods con-
taining the carotenoid beta-carotene probably protect against
oesophageal cancer; and foods containing lycopene, found in
tomatoes and also fruits such as watermelon, guavas, and
apricots, probably protect against prostate cancer. Foods con-
taining vitamin C, found in some vegetables, citrus and other
fruits, and potatoes, probably protect against oesophageal
cancer. There is limited evidence suggesting that foods con-
taining quercetin, such as apples, tea, and onions, protect
against lung cancer.
Evidence on foods containing other micronutrients 
is grouped here, for ease of reference. Foods containing
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selenium probably protect against prostate cancer; there 
is limited evidence suggesting that they protect against
stomach and colorectal cancers. There is limited evidence
suggesting that foods containing the B vitamin pyridoxine
protect against oesophageal and prostate cancers; and that
foods containing vitamin E protect against oesophageal and
prostate cancers. 
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These animal foods are sources of protein and
micronutrients. The amount and nature of the fat content
of meat, poultry, and fish depends on methods of rearing,
processing, and preparation, as well as the type of animal.
Production and consumption of red meat and processed
meat generally rise with increases in available income.
Consumption of beef and products made with beef is still
increasing, notably in China and other middle- and low-
income countries. In many countries, poultry is now also
intensively reared and consumption has increased greatly.
Much fish is now farmed. 
In general, the Panel judges that the evidence on red meat
and processed meat is stronger than it was in the mid-1990s.
Epidemiological evidence on other methods of preserving
and preparing meats and other animal foods is sparse; the
overall evidence remains suggestive, at most. The evidence
on poultry, fish, and eggs is generally insubstantial.
The Panel judges as follows:
The evidence that red meats and processed meats are a
cause of colorectal cancer is convincing. Cantonese-style
salted fish is a probable cause of nasopharyngeal cancer.
This finding does not apply to any other type of fish
product. Cantonese-style salted fish is also subject to
fermentation.
There is limited evidence suggesting that fish, and also
foods containing vitamin D, protect against colorectal
cancer. There is limited evidence suggesting that red meat
is a cause of cancers of the oesophagus, lung, pancreas
and endometrium; that processed meat is a cause of
cancers of the oesophagus, lung, stomach and prostate;
and that foods containing iron are a cause of colorectal
cancer.  There is also limited evidence that animal foods
that are grilled (broiled), barbecued (charbroiled), or
smoked, are a cause of stomach cancer. 
4.3  Meat, poultry, fish, and eggs 
MEAT, POULTRY, FISH, EGGS, AND THE RISK OF CANCER
In the judgement of the Panel, the factors listed below modify the risk of cancer. Judgements are graded according to the strength of the evidence.
DECREASES RISK INCREASES RISK
Exposure Cancer site Exposure Cancer site
Convincing Red meat1 Colorectum
Processed meat2 Colorectum
Probable Cantonese-style Nasopharynx
salted fish3
Limited — Fish Colorectum Red meat1 Oesophagus
suggestive Foods containing Colorectum Lung
vitamin D4 7 Pancreas
Endometrium
Processed meat2 Oesophagus 
Lung 
Stomach
Prostate
Foods containing iron4 5 Colorectum
Smoked foods6 Stomach
Grilled (broiled) or Stomach
barbecued (charbroiled) 
animal foods6
Substantial
effect on risk None identified
unlikely
1 The term ‘red meat’ refers to beef, pork, lamb, and goat from domesticated animals. 
2 The term ‘processed meat’ refers to meats preserved by smoking, curing, or salting, or addition of chemical preservatives. 
3 This style of preparation is characterised by treatment with less salt than typically used, and fermentation during the drying process due to relatively high outdoor
temperature and moisture levels. This conclusion does not apply to fish prepared (or salted) by other means.
4 Includes both foods naturally containing the constituent and foods which have the constituent added (see chapter 3.5.3).
5 Although red and processed meats contain iron, the general category of ‘foods containing iron’ comprises many other foods, including those of plant origin.
6 The evidence is mostly from meats preserved or cooked in these ways. 
7 Found mostly in fortified foods and animal foods.
For an explanation of all the terms used in the matrix, please see chapter 3.5.1, the text of this section, and the glossary.
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Red meat can be relatively high in animal fats. For a
discussion of the role of animal fats on cancer, see chapter
4.4 and Chapter 7. Meat can also be energy dense. For
discussion on the role of energy-dense foods on weight
gain, overweight, and obesity, and the role of weight gain,
overweight, and obesity in the risk of some cancers, see
Chapters 6 and 8.
The strongest evidence, corresponding to judgements of
‘convincing’ and ‘probable’, shows that red meat and
processed meat are causes of colorectal cancer, and that
Cantonese-style salted fish is probably a cause of
nasopharyngeal cancer. The Panel also notes limited
evidence suggesting that red meat and processed meat are
causes of other cancers. 
It is generally, though not universally, agreed that humans
evolved as omnivores, and that healthy diets usually include
foods of plant and of animal origin — including meat, poul-
try, fish, and eggs, as well as milk and other dairy products. 
Most people who do not eat meat, flesh, or any food of ani-
mal origin do so for religious or ethical reasons. Impoverished
communities eat little flesh and meat is reserved for feasts.
Partly because meat-eating is a sign of prosperity and partly
because many people enjoy eating meat, poultry, and fish,
production and consumption generally rise as available
income increases. Consumption of beef is, for example, now
increasing very rapidly in China, and consumption of ‘burg-
ers’ made from beef is increasing worldwide. 
Early reports concerned with nutritional deficiencies iden-
tified meat, poultry, and fish as good sources of protein, iron,
and other nutrients, and eggs as a ‘complete food’, especially
for children. By contrast, in the second half of the 20th cen-
tury, reports on meat, poultry, fish, and eggs tended to focus
on red meat as a source of fat and saturated fatty acids and
on eggs as a source of dietary cholesterol in the causation
of coronary heart disease. These reports promoted poultry
and fish as better choices than red meat, either because they
contain less fat and saturated fatty acids or, in the case of
oily fish, they contain unsaturated fats identified as protec-
tive. Little attention has been given to flesh from wild ani-
mals and birds, despite this being known to have a different
nutritional profile — lower in total fat and higher in unsat-
urated fatty acids. On the other hand, since the mid-1990s
more attention has been given in epidemiological studies to
processed meat as a cause or possible cause of cancers of
some sites. 
For discussion of the role of red meat and processed meat
in energy-dense foods and drinks, the effect of energy-dense
foods and drinks on weight gain, overweight, and obesity,
and the role of weight gain, overweight, and obesity in the
risk of some cancers, see Chapters 6 and 8.
In this Report, methods of production, preservation, pro-
cessing, and preparation (including cooking), that are sole-
ly or mainly to do with meat and other animal foods, are
included here. Processed meat as a category is included here.
The mineral iron is also covered here, although it is also
found in plant foods. 
4.3.1  Definitions and sources
Meat and poultry
In this Report, meat includes all animal flesh apart from fish
and seafood. Meat can be further classed as either red meat,
which generally refers to flesh from animals that have more
red than white muscle fibres (in this Report, beef, goat, lamb,
and pork), or poultry, which usually has more white than red
muscle fibres (from birds such as chickens, guinea fowl, and
turkeys). Meat can also be categorised by dividing it into
meats from skeletal muscles or the internal organs (offal,
such as the brain, liver, heart, intestines, and tongue). Meat
can also be divided according to whether the animal was
domesticated or wild. Most meats consumed around the
world today are from domesticated animals. ‘Wild’ meats,
that is from non-domesticated or free-ranging species, are a
significant source of protein and energy among some popu-
lations. Some non-domesticated animals, such as deer or buf-
falo, are also farmed. However, the evidence presented in
this chapter applies only to meat from domesticated animals.
Some meats are processed in various ways (box 4.3.1).
Fish
This Report uses the culinary definition of fish, which
includes shellfish. There are more than 27 000 species of salt
and freshwater fish; many more crustaceans, bivalves, and
cephalopods can also be eaten. Fish and shellfish are the only
foods that, globally, are still obtained in significant quanti-
ties from the wild. But many species are on the verge of com-
mercial extinction and aquaculture is increasing worldwide.
For instance, more than a third of the salmon eaten world-
wide is farmed. Like meat, fish is also processed, for instance
by drying, salting, and smoking. 
Eggs
Eggs are the ova of animals and in this Report mean only
What is ‘processed meat’? The question is important because, as
shown here, the evidence that processed meat is a cause of
colorectal cancer is convincing.
In the broad sense of the word, most meat is processed — cook-
ing is a process. But as commonly used, the term ‘processed meat’
refers to meats (usually red meats) preserved by smoking, curing,
or salting, or by the addition of preservatives. Meats preserved
only by refrigeration, however they are cooked, are usually not
classified as ‘processed meat’. 
There is no generally agreed definition of ‘processed meat’. The
term is used inconsistently in epidemiological studies. Judgements
and recommendations are therefore less clear than they could be. 
Ham, bacon, pastrami, and salami are processed meats. So are
sausages, bratwursts, frankfurters, and ‘hot dogs’ to which nitrites
or nitrates or other preservatives are added (box 4.3.2). Minced
meats sometimes fall inside this definition, often if they are pre-
served chemically, but not always. The same point applies to ‘ham-
burgers’. Given the importance of this issue, transnational
burger caterers should specify the methods they use to process
their products.
Box 4.3.1 Processed meat
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those of birds; because they are generally eaten before they
have been fertilised, they do not contain an embryo. Eggs
are eaten both on their own and as an ingredient in a vari-
ety of baked goods, sauces, and other composite foods.
Chicken eggs are most commonly eaten, although people
also eat duck, ostrich, and quail eggs. Fish eggs (roe) and
turtle eggs are not included here.
4.3.2 Composition
Meat and poultry
Meat contains around 20–35 per cent protein by weight. The
fat content by weight ranges from less than 4 per cent in lean
poultry to 30–40 per cent in fatty meat from domesticated,
farmed animals. About 50 per cent of the fatty acids in lean
meat are monounsaturated fatty acids, while saturated fatty
acids make up around 40–50 per cent (see chapter 4.4.2).
Poultry contains a lower proportion of saturated fatty acids
(30–35 per cent) and a higher proportion of polyunsaturat-
ed fatty acids (15–30 per cent compared with 4–10 per cent).1
There are differences between meats from domesticated ani-
mals and wild meats. Wild animals are typically more mature,
leaner, and contain a greater variety of aromatic compounds
than farmed animals. They will have received no medication
and their diets will have been uncontrolled. Wild animals are
not only lower in fat, but also have a higher proportion of
polyunsaturated fatty acids than farmed varieties and a lower
proportion of saturated fatty acids.
Two iron-containing components of muscle tissue, myo-
globin and cytochromes, give meat its red colour. It also con-
tains relatively high levels of B vitamins, particularly B6
(pyridoxine) and B12, as well as vitamin D, and provides
readily absorbable iron, zinc, and selenium. Eating red meat
increases levels of N-nitroso compounds in the body (box
4.3.2), which may be partially due to its high haem content
(box 4.3.3). If meat is cooked over an open flame, at high
temperatures, and charred or ‘well done’, heterocyclic
amines or polycyclic aromatic hydrocarbons can be formed
(box 4.3.4). 
Vitamin D is a fat-soluble vitamin that plays a critical role
in calcium and bone metabolism and in controlling cell dif-
ferentiation. Low levels may lead to osteomalacia or, in chil-
dren, rickets and possibly osteoporosis, with increased
fracture risk. Most vitamin D is derived from the action of
sunlight on the skin. Foods such as milk or fat spreads (see
chapter 4.9) may be fortified, and then become the major
dietary source of vitamin D; natural sources include sardines
and other oily fish, meat, and eggs.
Fish
Fish has similar levels of protein to meat. It has a fat by
weight content of between 0.5 per cent in low-fat fish such
as cod or skate to as much as 20 per cent in oily fish such
as Atlantic salmon or eels. Fat from fish contains lower lev-
els of saturated fatty acids (around 20–25 per cent) than
meat. 
Fish oils from saltwater fish contain long-chain n-3 fatty
acids (see chapter 4.4.2). Wild fish have a lower fat content
than farmed fish, with a higher proportion of n-3 fatty acids.
Only marine algae and phytoplankton produce these fatty
acids, so the fish that feed on them are the primary dietary
sources. These fatty acids are essential to the development
and function of the brain and retina; they also reduce inflam-
mation, blood clotting, and cholesterol production. The body
Iron deficiency is the most common and widespread nutritional
disorder in the world. It is most common among children and
premenopausal women, and results in iron deficiency anaemia.
Haem iron is found only in foods of animal origin, such as
meat and meat products, fish, and blood products. Non-haem
iron is found in plant foods, such as lentils, beans, leafy veg-
etables, tofu, chickpeas, black-eyed peas, figs, and apricots. The
amount of dietary iron needed to meet the body’s requirements
depends on its bioavailability from the diet. This varies with the
diet, as well as factors related to the consumer such as their iron
status. Iron from animal sources is better absorbed than iron
from plant sources, but non-haem iron absorption is enhanced
when the body’s iron status is low, or when iron-rich foods are
eaten together with vitamin-C rich foods or with meat. 
Iron has a central role in metabolism. It is involved in oxida-
tive metabolism within cells and is a component of a number
of enzymes. Free iron can also catalyse the generation of free
radicals, which cause oxidative damage to specific cell compo-
nents including DNA, protein, and membrane lipids. Iron metab-
olism and transport are strictly regulated to reduce the
likelihood of cells being exposed to free iron and so to oxida-
tive damage; most iron in living tissues is bound to proteins, such
as transferrin and ferritin, which prevent its involvement in free-
radical generation. Also see chapter 4.10.
Box 4.3.3 Foods containing iron
Nitrate occurs naturally in plants; levels vary between species
and with different soil conditions and the amount of fertiliser
used. In high-income countries, vegetables account for 70–97
per cent of dietary nitrate intake.2 Between 5 and 20 per cent
of the nitrate in diets is converted by the body into nitrite, a sub-
stance that is also found in some vegetables (notably potatoes).
Nitrite is used to preserve processed meats (it is extremely toxic
to bacteria) and gives cured meats their recognisable colour and
flavours. The addition of nitrite and nitrate to food is regulat-
ed and monitored in most countries. 
Nitrite can react with the degradation products of amino
acids to form N-nitroso compounds (nitrosamines or
nitrosamides). These may be formed in meat during the curing
process or in the body (particularly in the stomach) from dietary
nitrite (or nitrate). 
Several N-nitroso compounds are known human or animal
carcinogens.3 There is concern that nitrite, from processed meats
for example, nitrates in vegetables, and preformed nitrosamines
may be involved in carcinogenesis, particularly in the stomach
(see Chapter 2). Dietary nitrates and nitrites are probable human
carcinogens because they are converted in the body to N-nitroso
compounds.3
Box 4.3.2 Nitrates, nitrites, and 
N-nitroso compounds
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can convert alpha-linolenic acid (found in plant foods and
essential in the diet) to eicosapentaenoic acid and docoso-
hexanoic acid, which are found in fish oils, but the rates of
conversion are low.
Fish contain lower levels of B vitamins, iron, and zinc than
meat and poultry, but oily fish are a source of retinol and vit-
amin D. Fish are also a source of calcium if the bones are
eaten with the flesh, for example, when canned.
Fish and shellfish have the potential to accumulate pollu-
tants that are washed into rivers and oceans, and these tend
to accumulate in their fat. These pollutants can include
heavy metals and organic compounds, some of which are
known carcinogens. Farmed fish are exposed to veterinary
medicines, and some environmental toxins may reach high
concentrations in their food. But farmed fish are less likely
than wild fish to become contaminated with environmental
pollutants. The balance of risks and benefits of eating fish
at various stages of the life course needs to be determined.
Also see chapter 4.9.
Eggs
Eggs, like meat, poultry, and fish, contain all the essential
amino acids needed by humans. A typical large hen’s egg has
roughly equal weights of protein and fat, with 60 per cent
of the energy coming from fat. A typical large shelled egg
contains 6 g protein; 1 g carbohydrate; 4.5 g fat (2.0 g
monounsaturated, 0.5 g polyunsaturated, and 1.5 g satu-
rated fatty acids); and about 200 mg cholesterol. It also con-
tains retinol, folate, thiamin, riboflavin, vitamin B12,
vitamin D, and iron. The yolk’s colour comes from
carotenoids, and contains all of the fat and cholesterol and
most of the iron, thiamin, and retinol. The white is 90 per
cent water and is virtually fat free, containing mainly pro-
tein, with some vitamins, and traces of glucose.
In Asia, eggs containing 2–3 week old chick fetuses may
occasionally be included in diets. There is no nutritional dif-
ference between these and unfertilised eggs, except that fer-
tilised eggs contain additional calcium absorbed from the
shell. 
4.3.3  Consumption patterns
Meat and poultry
Globally, meat accounts for about 8 per cent of total energy
availability, 18 per cent of dietary protein, and 23 per cent
of dietary fat. Meat consumption is considerably higher in
high-income countries (10 per cent of total energy intake
compared with 7 per cent in low-income countries), and is
particularly high in the USA, parts of South America, some
parts of Asia, northern Europe, and most of Oceania.
Consumption is particularly low in most of Africa and other
parts of Asia where vegetarian ways of life are commonplace.
Bangladesh has the lowest level of intake (0.6 per cent) and
Mongolia the highest (28 per cent).7
As a general rule, meat consumption increases with eco-
nomic development. Worldwide, between 1961 and 2002,
meat consumption per person doubled, with pork and poul-
try showing the greatest increases; in Japan it increased
nearly six-fold. Globally, overall energy availability increas-
ed in the same period by just 12 per cent. Consumption of
meat and other animal foods from wild and undomesticat-
ed animals is low on a global basis, but these foods are
important parts of diets within many middle- and low-
income countries, as well as being delicacies in high-income
countries. 
Fish
Worldwide, fish (including shellfish) account for 1 per cent
of available dietary energy; these foods are particularly
important in island and coastal communities. For instance,
in the Maldives, marine fish account for 15 per cent of
dietary energy, but in some landlocked, low-income coun-
tries, this figure is practically zero. In general, fish con-
sumption is highest in Asia and Oceania. Freshwater fish
provide a relatively small proportion of dietary energy (0.3
per cent), but they are a more important source of dietary
energy in low-income countries, and are particularly impor-
tant in regions with large lakes and rivers. Salting is a tra-
ditional method of preserving raw fish throughout much of
the world (box 4.3.5).
Heterocyclic amines are formed when muscle meats such as
beef, pork, fowl, and fish are cooked. High cooking tempera-
tures cause amino acids and creatine (a chemical found in mus-
cles) to react together to form these chemicals. So far, 17
different heterocyclic amines have been identified as being
formed by cooking muscle meats and which may pose a cancer
risk (also see Chapter 2). 
Temperature is the most important factor in the formation of
these chemicals. Frying, grilling (broiling), and barbecuing (char-
broiling) produce the largest amounts because these cooking
methods use very high temperatures. Oven roasting and bak-
ing involve lower temperatures, so meats cooked in this way are
lower in heterocyclic amines, but gravy made from meat drip-
pings contains substantial amounts. Meats that are partially
cooked in a microwave oven before being cooked by other
higher-temperature methods also have lower levels of these
chemicals.4
Polycyclic aromatic hydrocarbons (PAHs) are a group of over
100 different chemicals formed when organic substances like
tobacco or meat are burnt incompletely. Grilling (broiling) and
barbecuing (charbroiling) meat, fish, or other foods with intense
heat over a direct flame results in fat dropping on the hot fire;
this produces PAHs that stick to the surface of food. The more
intense the heat, the higher the level of contamination; using
wood creates more PAHs than charcoal. Cereals contaminated
with PAHs are also a common source of these chemicals in the
diet. Levels in cereals are considerably lower than in grilled
meats, but their overall contribution to diets is larger.5 Taken
together, cereals and meat and meat products account for more
than 50 per cent of dietary levels of these chemicals. Intakes are
thought to be relatively high in Europe, particularly in north-
ern Europe, although measures are only available from a few,
generally high-income, countries.6
Box 4.3.4 Heterocyclic amines and poly-
cyclic aromatic hydrocarbons
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Eggs
Worldwide, eggs provide 1.2 per cent of available food ener-
gy. Egg consumption is highest in the Far East, North
America, and Europe, ranging from nearly 3 per cent in these
areas to virtually zero in many African countries; it is sig-
nificantly higher in high-income countries. Preserved eggs
(pickled, salted, or cured) are traditional in some cultures.
4.3.4 Interpretation of the evidence
4.3.4.1 General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7.
‘Relative risk’ (RR) is used in this Report to denote ratio
measures of effect, including ‘risk ratios’, ‘rate ratios’, ‘haz-
ard ratios’, and ‘odds ratios’.
4.3.4.2 Specific 
Some considerations specific to meat, poultry, fish, and eggs
include: 
Classification. ‘Fish’ is a broad classification. Different fish
have different nutritional profiles and biological effects, one
obvious example being white fish and oily fish. These are
often not distinguished in epidemiological studies. 
Terminology. As yet, there is no agreed definition for
‘processed meat’. Some studies count minced meat, or ham,
bacon, and sausages as processed meats; others do not. See
the footnote to the matrix and box 4.3.1.
Confounding. People who consume large amounts of meat
and processed meats tend to consume less poultry, fish, and
vegetables, and vice versa. So an apparent effect of meat and
processed meat could possibly be due, at least in part, to low
intakes of these other foods. 
Production, processing, patterns. Practically all the evidence
relates to these foods as preserved, processed, or prepared
(cooked) in some way. Evidence on meat, poultry, and
increasingly on fish, is practically all from these foods as pro-
duced industrially. There is very little evidence on wild ani-
mals and birds, despite the quantity and nature of their body
fat, and other aspects of their nutritional profile, being dif-
ferent. Epidemiological evidence on specific methods of
preservation, processing, and preparation/cooking of meat,
poultry, and fish is mostly patchy, despite some of these being
known to generate carcinogens established as such in exper-
imental studies. Also see chapter 4.9. 
4.3.5  Evidence and judgements 
The full systematic literature review (SLR) is contained on
the CD included with this Report.
4.3.5.1 Meat 
4.3.5.1.1 Red meat 
Some studies may have included processed meats in their
classification of red meat intake.
Colorectum
Sixteen cohort studies8-24 and 71 case-control studies inves-
tigated red meat and colorectal cancer.
All of the cohort studies that reported analyses of risk for
the highest intake group when compared to the lowest
showed increased risk (figure 4.3.1),8-24 which was statisti-
cally significant in four (one of these was specific to rapid-
acetylator genotypes).9 10 12 18 23 Meta-analysis was possible
Salting is a traditional method of preserving raw fish through-
out much of the world. The freshness of the fish and the salt-
ing and drying conditions vary considerably between regions,
although fish are usually dried outside, in direct sunlight. This
results in varying levels of fermentation and/or insect infesta-
tion. Salted fish is a component of diets typical of Asia, Africa,
and parts of the Mediterranean.
Depending on the precise conditions, salt-preserved fish may
also undergo fermentation. The degree of fermentation that
occurs depends on the freshness of the raw fish, the amount of
salt used, the outdoor temperature, and the duration of the dry-
ing process. In general, excluding the factor of freshness, salt-
ed fish is less likely to be fermented in the northern part of
China compared with the southern part of China (where
nasopharyngeal cancer is more common). Cantonese-style salt-
ed fish is characterised by using less salt and a higher degree of
fermentation during the drying process, because of the rela-
tively high outdoor temperature and moisture levels.
Cantonese-style salted fish are a traditional part of the diet
in southern China, Taiwan, Malaysia, and Singapore.
Box 4.3.5 Cantonese-style salted fish
Figure 4.3.1 Red meat and colorectal cancer;
cohort studies
Philips 1975 2.70 (1.60–4.55)
Slattery 2001 Women 1.04 (0.62–1.75)
Kato 1997 Women 1.23 (0.68–2.22)
Singh 1998 1.41 (0.90–2.21)
Pietinen 1999 Men 1.20 (0.80–1.80)
Jarvinen 2001 1.50 (0.77–2.93)
Tiemersma 2002 Men 2.70 (1.09–6.66)
Tiemersma 2002  Women 1.20 (0.51–2.84)
Wei 2003 Men 1.35 (0.80–2.27)
Wei 2003 Women 1.31 (0.73–2.36)
Chen 2003 1.48 (0.85–2.59)
English 2004 1.40 (1.02–1.93)
Norat 2004 1.17 (0.92–1.49)
Relative risk (95% CI)
Relative risk, highest vs lowest exposure category
1 50.2 0.5 2
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on seven studies that measured red meat intake in ‘times per
week’ and three studies that measured grams per day. The
summary effect estimates were 1.43 (95% confidence inter-
val (CI) 1.05–1.94) per times/week and 1.29 (95% CI
1.04–1.60) per 100 g/day, respectively (figures 4.3.2 and
4.3.3). There was moderate heterogeneity in the former
analysis and low heterogeneity in the latter.
A dose-response relationship is apparent from cohort data
(figure 4.3.4).
These data are supported by a recently published meta-
analysis of 15 prospective studies, which reported a sum-
mary effect estimate of 1.28 (95% CI 1.18–1.39) per 120
g/day.25
Because of the abundant prospective data from cohort
studies, case-control studies were not summarised.
The general mechanisms through which red meat could
plausibly cause cancer are outlined below. In addition,
dietary haem iron induces colonic cytotoxicity and hyper-
proliferation.26
A substantial amount of data from cohort and case-
control studies showed a dose-response relationship,
supported by evidence for plausible mechanisms
operating in humans. Red meat is a convincing cause
of colorectal cancer.
The Panel is aware that since the conclusion of the SLR, six
cohort27-32 and four case control studies33-36 have been pub-
lished. This new information does not change the Panel judge-
ment (see box 3.8).
Oesophagus
Twelve case-control studies37-50 investigated red meat and
oesophageal cancer.
Eight studies reported increased risk for the highest intake
group when compared to the lowest,37-39 41-45 49 50 which was
statistically significant in five.37 41 42 45 Three studies reported
non-significant decreased risk38 40 46; one study reported 
no significant effect on risk,47 48 but did not provide further
details. Most of these studies adjusted for smoking and
alcohol.
The general mechanisms through which red meat could
plausibly cause cancer are outlined below. 
There is limited evidence, from case-control studies,
some of which were poor quality, suggesting that red
meat is a cause of oesophageal cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort study51 has been published. This new information does
not change the Panel judgement (see box 3.8).
Lung 
One cohort study52 and nine case-control studies53-62 inves-
tigated red meat and lung cancer.
Figure 4.3.2 Red meat and colorectal cancer;
cohort studies
Willet 1990 Women 1.81 (1.17–2.80)
Bostick 1994 Women 0.96 (0.80–1.14)
Giovannucci 1994 Men 2.20 (1.24–3.91)
Singh 1998 4.51 (0.38–53.27)
Chen 1998 Men, NAT rapid 2.57 (0.78–8.84)
Chen 1998 Men, NAT slow 0.88 (0.45–1.75)
Tiemersma 2002 Men 3.44 (0.83–14.18)
Tiemersma 2002 Women          1.42 (0.22–9.00)
English 2004 1.23 (0.88–1.73)
Summary estimate 1.43 (1.05–1.94)
 Relative risk (95% CI)
Relative risk, per time/week
1 50.2 0.5 2 9
Figure 4.3.3 Red meat and colorectal cancer;
cohort studies
Pietinen 1999 1.05 (0.74–1.48)
Norat 2005 1.49 (0.91–2.43)
Larsson 2005 Women 1.43 (1.05–0.95)
Summary estimate 1.29 (1.05–1.59)
Relative risk (95% CI)
Relative risk, per 100 g/day
1 50.2 0.5 2
Figure 4.3.4 Red meat and colorectal cancer; cohort
studies: dose response
Kinlen 1983 Men
Kinlen 1983  Women
Giovannucci 1994 Men
Bostick 1994
English 2004
0 105 15
Red meat (times/week)
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The single cohort study showed increased risk for the high-
est intake group when compared to the lowest, with an effect
estimate of 1.6 (95% CI 1.0–2.6; p value for trend < 0.014),
based on 158 cases.52
Seven case-control studies showed increased risk for the
highest intake group when compared to the lowest,53-58 60 61
which was statistically significant in four.54 55 60 61 One study
reported non-significant decreased risk59 and one study
showed no effect on risk.62 All except the latter study adjust-
ed for smoking.
The general mechanisms through which red meat could
plausibly cause cancer are outlined below.
There is limited evidence, mostly from inconsistent
case-control studies, suggesting that red meat is a
cause of lung cancer.
Pancreas
Seven cohort studies63-69 and four case-control studies46 70-72
investigated red meat and pancreatic cancer.
Six cohort studies showed increased risk for the highest
intake group when compared to the lowest,63-65 67-69 which
was statistically significant in one,64 and two of the studies
also had statistically significant tests for trend.65 67 One study
reported a non-significant increased risk that was very close
to no effect.66 Meta-analysis was possible on two studies, giv-
ing a summary effect estimate of 1.00 (95% CI 0.95–1.05)
per 20 g/day, with no heterogeneity.63 66 However, the two
included studies were not typical. The effect estimates for the
highest intake group when compared to the lowest in the
other five cohort studies were 1.45 (95% CI 1.19–1.76),64
1.73 (95% CI 0.99–2.98; with a statistically significant test
for trend),65 2.4 (95% CI 1–6.1; with a statistically signifi-
cant test for trend),67 1.1 (95% CI 0.9–1.2),68 and 1.4 (95%
CI 0.4–4.8) for men and 2.7 (95% CI 0.8–8.9) for women.69
All of the case-control studies showed increased risk for
the highest intake group when compared to the lowest,46 70-
72 which was statistically significant in three.46 71 72 Meta-
analysis was possible on three case-control studies, giving a
summary effect estimate of 1.11 (95% CI 1.08–1.15) per 20
g/day, with no heterogeneity.46 71 72
The general mechanisms through which red meat could
plausibly cause cancer are outlined below. In addition, both
the secretory function of the pancreas and cell turnover with-
in the pancreas are altered by the types of foods eaten.73
Amino acids and fatty acids stimulate more pancreatic secre-
tions than do carbohydrates.74
Evidence from cohort studies is less consistent than
that from case-control studies. There is limited
evidence suggesting that red meat is a cause of
pancreatic cancer.
Endometrium
One cohort study75 and seven case-control studies46 76-81
investigated red meat and endometrial cancer.
The single cohort study showed a non-significant increased
risk for the highest intake group when compared to the low-
est, with an effect estimate of 1.10 (95% CI 0.70–1.73).75
Five case-control studies showed increased risk for the
highest intake group when compared to the lowest,46 76-79
which was statistically significant in two.77 78 Two studies
showed non-significant reduced risk.80 81 Meta-analysis was
possible on six studies, giving a summary effect estimate of
1.20 (95% CI 1.03–1.39) per 50 g red meat/day, with mod-
erate heterogeneity.46 76-80
The general mechanisms through which red meat could
plausibly cause cancer are outlined below.
The evidence, mostly from case-control studies, is
sparse. There is limited evidence suggesting that red
meat is a cause of endometrial cancer.
The Panel is aware that since the conclusion of the SLR, one
case-control study82 has been published. This new information
does not change the Panel judgement (see box 3.8). 
General mechanisms
There are several potential underlying mechanisms for an
association between red meat consumption and cancer,
including the generation by stomach and gut bacteria of
potentially carcinogenic N-nitroso compounds. Some red
meats are also cooked at high temperatures, resulting in the
production of heterocyclic amines and polycyclic aromatic
hydrocarbons (box 4.3.4). Haem promotes the formation 
of N-nitroso compounds and also contains iron. Free iron can
lead to production of free radicals (box 4.3.3). Iron overload
also activates oxidative responsive transcription factors,
pro-inflammatory cytokines, and iron-induced hypoxia
signalling.83
Figure 4.3.5 Processed meat and colorectal cancer;
cohort studies
Philips 1975 2.05 (1.50–4.06)
Goldbohm 1994 Men 1.84 (0.85–3.97)
Goldbohm 1994 Women 1.66 (0.82–2.36)
Bostick 1994 Women 1.51 (0.72–3.17)
Gaard 1996 Women 3.50 (1.02–11.95)
Gaard 1996  Men 1.98 (0.70–5.59)
Kato 1997 Women 1.09 (0.59–2.02)
Pietinen 1999 Men 1.20 (0.75–1.92)
Tiemersma 2002  Men 1.00 (0.51–1.95)
Tiemersma 2002 Women 0.80 (0.43–1.50)
Flood 2003 Women 0.97 (0.73–1.28)
Wei 2003 Men 1.27 (0.87–1.85)
Wei 2003 Women 1.32 (0.95–1.83)
English 2004 1.50 (1.11–2.02)
Chao 2005  Men 1.11 (0.80–1.54)
Chao 2005 Women 1.16 (0.85–1.58)
Norat 2005 1.42 (1.09–1.85)
 Relative risk (95% CI)
Relative risk, highest vs lowest exposure category
1 20.50.2 5
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4.3.5.1.2 Processed meat
The variation in definitions for processed meat used by dif-
ferent studies (see chapter 4.3.1) is likely to contribute to
the observed heterogeneity.
Colorectum
Fourteen cohort studies8-10 14-19 21 27 69 84 85 and 44 case-control
studies investigated processed meat and colorectal cancer.
Twelve cohort studies showed increased risk for the high-
est intake group when compared to the lowest (figure
4.3.5),8-10 14-19 21 27 69 85 which was statistically significant in
three.9 14 15 85 One study reported non-significant decreased
risk and one study reported that there was no effect on risk.84
Meta-analysis was possible on five studies, giving a summary
effect estimate of 1.21 (95% CI 1.04–1.42) per 50 g/day,
with low heterogeneity (figures 4.3.6 and 4.3.7). What het-
erogeneity there is could be explained by the disparity in cat-
egory definitions between studies, as well as by improved
adjustment for confounders in recent studies. A dose-
response relationship was also apparent from cohort studies
that measured in times/day (figure 4.3.8).
The majority of case-control studies showed increased risk
with increasing intake of processed meat. Because of the
abundant prospective data from cohort studies, case-control
studies were not summarised.
These data are supported by a recently published meta-
analysis of 14 cohort studies, which reported a summary
effect estimate of 1.09 (95% CI 1.05–1.13) per 30 g/day.25
The general mechanisms through which processed meat
could plausibly cause cancer are outlined below.
There is a substantial amount of evidence, with a dose-
response relationship apparent from cohort studies.
There is strong evidence for plausible mechanisms
operating in humans. Processed meat is a convincing
cause of colorectal cancer.
The Panel is aware that since the conclusion of the SLR, five
cohort28 30 32 86 87 and two case-control studies36 88 have been
published. This new information does not change the Panel
judgement (see box 3.8).
Oesophagus
Two cohort studies89 90 and eight case-control studies40 41 43
44 49 50 91-94 investigated processed meat and oesophageal
cancer.
Both cohort studies showed non-significant increased risk
for the highest intake groups when compared to the lowest.89
90 The effect estimates were 1.24 (95% CI 0.73–2.1)90 and
1.6 (95% CI 0.4–6.9).89 Both analyses adjusted for age,
smoking, and alcohol.
Six case-control studies showed increased risk for the high-
est intake groups when compared to the lowest,43 44 49 50 91-
93 which was statistically significant in one.93 Two studies
showed non-significant reduced risk.40 41 94
The general mechanisms through which processed meat
could plausibly cause cancer are outlined below.
Figure 4.3.6 Processed meat and colorectal cancer;
cohort studies
Goldbohm 1994 1.69 (1.10–2.58)
Pietinen 1999 0.99 (0.79–1.24)
Chao 2005 Men 1.40 (1.04–1.88)
Chao 2005 Women 1.14 (0.64–2.05)
Norat 2005 1.30 (0.93–1.80)
Larsson 2005 Women 1.13 (0.85–1.51)
Summary estimate 1.21 (1.04–1.42)
Relative risk (95% CI)
Relative risk, per 50 g/day
1 50.2 0.5 2
Figure 4.3.7 Processed meat and colorectal cancer;
cohort studies: dose response
Choa 2005 Men
Choa 2005 Women
Goldbohm 1994 Men
Goldbohm 1994 Women
0 200100 300
Processed meat (g/day)
Figure 4.3.8 Processed meat and colorectal cancer;
cohort studies: dose response
Giovannucci 1994 Men
Bostick 1994 Women
English 2004
0 0.40.2 10.6 0.8
Processed meat (times/day)
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There is limited evidence, mostly from case-control
studies, suggesting that processed meat is a cause of
oesophageal cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort study51 has been published. This new information does
not change the Panel judgement (see box 3.8).
Lung 
Four cohort studies52 69 95 96 and 10 case-control studies33 55-
57 59 97-104 investigated processed meat and lung cancer.
Three cohort studies reported non-significant increased
risk for the highest intake group when compared to the low-
est.69 95 96 One study reported no effect on risk.52 95 Meta-
analysis was possible on two of the studies, giving a
summary effect estimate of 1.03 (95% CI 0.92–1.16) per
serving/week, with no heterogeneity.52 All four cohort stud-
ies adjusted for smoking.
Six case-control studies reported increased risk for the
highest intake group when compared to the lowest,33 56 57 59
99 100 102-104 which was statistically significant in two.100 102
Four studies reported non-significant decreased risk.55 97 98 101
All of the studies adjusted for smoking.
The general mechanisms through which processed meat
could plausibly cause cancer are outlined below.
There is limited, inconsistent evidence suggesting that
processed meat is a cause of lung cancer.
Stomach cancer 
Eight cohort studies,51 69 105-110 21 case-control studies,49 111-
132 1 cross-sectional study,133 and 1 ecological study134 inves-
tigated processed meat and stomach cancer.
Five cohort studies showed increased risk for the highest
intake group when compared to the lowest,51 106-108 110 which
was statistically significant in one.51 Two studies reported
non-significant decreased risk105 109; and one showed no
effect on risk in men and non-significant decreased risk in
women.69 Meta-analysis was possible on all eight cohort
studies, giving a summary effect estimate of 1.02 (95% CI
1.00–1.05) per 20 g/day, with no heterogeneity.
Thirteen case-control studies showed increased risk for the
highest intake group when compared to the lowest,49 113 117
119-121 124-132 which was statistically significant in seven.120 125
128-132 Three studies showed decreased risk,118 122 123 which
was statistically significant in one118; and one showed no
effect on risk.116 Four other studies reported no significant
difference between mean intakes in cases and controls.111 112
114 115 Meta-analysis was possible on nine studies, giving a
summary effect estimate of 1.13 (95% CI 1.01–1.25) per 
20 g/day, with high heterogeneity.49 117-119 121 123 128-130
A dose-response relationship is apparent from case-control
but not cohort data.
The single ecological study reports a statistically significant
correlation between increased processed meat and stomach
cancer risk.134
The general mechanisms through which processed meat
could plausibly cause cancer are outlined below.
The evidence is inconsistent. There is limited evidence
suggesting that processed meat is a cause of stomach
cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort135 and two case-control studies136 137 have been pub-
lished. This new information does not change the Panel judge-
ment (see box 3.8).
Prostate 
Four cohort studies138-141 and six case-control studies142-147
investigated processed meat and prostate cancer.
All four cohort studies showed increased risk for the high-
est intake group when compared to the lowest,138-141 which
was statistically significant in two.139 141 Meta-analysis was
possible on all four cohort studies, giving a summary effect
estimate of 1.11 (95% CI 0.995–1.25) per serving/week,
with high heterogeneity. Heterogeneity was caused by vary-
ing size, not direction, of effect.
Two of these studies reported separately on advanced 
or aggressive cancer. Both showed increased risk with
increasing intake of processed meat,138 141 which was statis-
tically significant in one.141 Meta-analysis was possible on
both studies, giving a summary effect estimate of 1.09 (95%
CI 0.98–1.22) per serving/week, with moderate hetero-
geneity.
Four case-control studies showed non-significant
decreased risk with increasing intake of processed meat143-
145 147; two showed non-significant increased risk.142 146 Meta-
analysis was possible on five case-control studies, giving a
summary effect estimate of 1.01 (95% CI 0.98–1.04) per
serving/week, with low heterogeneity.143-147 The general
mechanisms through which processed meat could plausibly
cause cancer are outlined below.
There is limited evidence from sparse and inconsistent
studies suggesting that processed meat is a cause of
prostate cancer. 
The Panel is aware that since the conclusion of the SLR, two
cohort studies148 149 have been published. This new information
does not change the Panel judgement (see box 3.8).
General mechanisms
Nitrates are produced endogenously at the low pH in the
stomach and are added as preservatives to processed meats,
both of which may contribute to N-nitroso compound pro-
duction and exposure. N-nitroso compounds are suspected
mutagens and carcinogens.150 Many processed meats also
contain high levels of salt and nitrite. Some processed meats
are also cooked at high temperatures, resulting in the pro-
duction of heterocyclic amines and polycyclic aromatic
hydrocarbons. Red meat contains haem iron. Haem promotes
the formation of N-nitroso compounds and also contains
iron. Free iron can lead to production of free radicals (box
4.3.3). 
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4.3.5.2 Poultry 
The evidence was too limited in amount, consistency, or
quality to draw any conclusions.
4.3.5.3  Fish, shellfish
Colorectum
Nineteen cohort studies8-10 14-18 21 23 69 85 151-161 and 55 case-
control studies investigated fish and colorectal cancer.
Nine cohort studies showed decreased risk for the highest
intake group when compared to the lowest,8 15-17 21 69 85 154
157 158 160 which was statistically significant in two.15 16 Eight
studies showed non-significant increased risk.9 10 18 23 151-153
155 156 159 One study showed no effect on risk14 and one study
reported that there was no statistically significant associa-
tion.161 Meta-analysis was possible on seven cohort studies,
giving a summary effect estimate of 0.96 (95% CI 0.92–1.00)
per serving/week, with low heterogeneity.8 9 14 18 21 158 160
Because of the abundant prospective data from cohort
studies, case-control studies were not summarised.
Heterogeneity may be partially explained by varying def-
initions of fish in different studies that included fresh and/or
salted or dried fish. It is also possible that high fish intake
is associated with low meat intake, which is a potential con-
founder that has not been adjusted for.
It is biologically plausible that fish n-3 polyunsaturated
fatty acids (PUFAs) protect against cancer. Fish oils reduce
tumours in animal studies.162 Likely mechanisms are thought
to revolve around their role in reduction of n-6 PUFA-derived
eicosanoid biosynthesis (eicosanoids promote inflammation)
and direct inhibition of COX-2 (cyclooxygenase-2, an enzyme
involved in the production of prostaglandins), which is also
implicated in the cancer process (see Chapter 2). This mech-
anism, though plausible, is not well supported.163 Alternative
suggestions include the relatively high selenium or vitamin
D content of fish.
A substantial amount of data is available but the
results are inconsistent, and residual confounding by
meat could not be excluded. There is limited evidence
suggesting that eating fish protects against colorectal
cancer.
The Panel is aware that since the conclusion of the SLR, six
cohort28 30 164 165 and two case-control studies33 166 have been
published. This new information does not change the Panel
judgement (see box 3.8).
4.3.5.3.1  Cantonese-style salted fish
Nasopharynx
One cohort study167 and 21 case-control studies161-188 inves-
tigated Cantonese-style salted fish (box 4.3.5) intake in
adults and nasopharyngeal cancer. Sixteen case-control stud-
ies168 170-174 177-179 181 188-193 investigated intake in childhood
and 10 case-control studies168 171-174 177 188 189 194 195 investi-
gated intake in infancy (less than 3 years).
Adult intake
The single cohort study showed increased risk for the high-
est intake group when compared to the lowest. Intake was
assessed in the 1960s, 1970s, and 1980s. The p value for
trend for the association between each decade’s intake and
increased risk was < 0.001, 0.014, and 0.21, respectively.
Seventeen of the case-control studies showed increased
risk for the highest intake group when compared to the low-
est,169-178 182-188 which was statistically significant in nine.170
172 173 176 178 182 185-188 One study showed a non-significant
decreased risk168; three studies reported that there was no
association.179-181 Meta-analysis was possible on nine stud-
ies, giving a summary effect estimate of 1.28 (95% CI
1.13–1.44) per serving/ week, with high heterogeneity (fig-
ure 4.3.9). Heterogeneity was related to size, and not direc-
tion, of effect. 
Figure 4.3.9 Salted fish and nasopharyngeal cancer;
case control
Yuan 2000 1.73 (0.66–4.52)
Lee 1994 1.17 (0.85–1.61)
Zheng 1994 2.50 (1.63–3.85)
Sriamporn 1992 1.35 (1.06–1.72)
Yu 1989 1.10 (1.00–1.21)
Yu 1986 1.31 (1.13–1.51)
Weiming 1995 1.71 (1.08–2.70)
Cai 1996 1.06 (1.00–1.02)
Zou 1999 1.32 (1.13–1.54)
Summary estimate 1.28 (1.13–1.44)
Relative risk (95% CI)
Relative risk, per time/week
1 50.1
Figure 4.3.10 Salted fish and nasopharyngeal cancer;
case-control studies
Ward 2000 0.80 (0.52–1.24)
Yuan 2000 1.82 (0.86–3.86)
Armstrong 1998 4.22 (2.23–7.99)
Lee 1994 4.40 (0.72–26.76)
Zheng 1994 4.07 (0.36–45.80)
Zheng 1994b   17.20 (2.28–104.79)
West 1993 1.30 (0.67–2.52)
Sriamporn 1992 2.50 (1.20–5.20)
Yu 1989 1.80 (0.90–3.60)
Yu 1986 7.50 (0.88–63.89)
Ning 1990 2.20 (1.30–3.71)
Ye 1995 5.00 (1.27–19.72)
Ye 1995b 2.00 (0.88–4.56)
Cai 1996 1.32 (0.98–1.77)
Chen 1994 5.51 (1.74–17.44)
Wang 1993 8.99 (1.60–50.44)
Zou 1999 3.04 (1.66–5.69)
 Relative risk (95% CI)
Relative risk, highest vs lowest exposure category
10.01 100
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Childhood intake
Fifteen case-control studies that investigated the intake of
salted fish at 10 years of age showed increased risk for the
highest intake group when compared to the lowest,168 170 172-
174 177-179 181 188-193 which was statistically significant in 8170
172 173 177-179 188 190 (figure 4.3.10). One study showed a non-
significant decreased risk.171 Meta-analysis was possible on
9 studies,171 173 174 177 178 181 188-190 giving a summary effect
estimate of 1.35 (95% CI 1.14–1.60) per serving/week, with
high heterogeneity. Heterogeneity was related to size, and
not direction, of effect.
Nine case-control studies that investigated the intake of
salted fish at 3 years of age showed increased risk for the
highest intake group when compared to the lowest,171-174 177
188 189 194 195 which was statistically significant in five.172 173
177 188 195 One study showed no effect on risk.168 Meta-analy-
sis was possible on five studies,171 173 174 177 189 giving a sum-
mary effect estimate of 1.42 (95% CI 1.11–1.81) per
serving/week, with moderate heterogeneity. Heterogeneity
was related to size, and not direction, of effect.
A dose-response relationship is apparent from case-control
data (figure 4.3.11). Cohort and case-control data suggest a
delayed and/or cumulative effect from eating Cantonese-
style salted fish.
General mechanisms 
Evidence suggests that high intake of nitrate and nitrosamine
from salted fish accounts for some of this increased risk of
nasopharyngeal cancer development. Nitrosamines are
known mutagens and animal carcinogens that induce gene
mutation. The N-nitrosamines are a large group of com-
pounds with a common carcinogenic mechanism.150 Salted
fish has been shown to contain N-nitrosamines, with the
highest levels in salted fish from areas with the highest mor-
tality from nasopharyngeal cancer.196 197 The variation in
nitrosamine content of salted fish may contribute to hetero-
geneity in assigning risk to salted fish consumption in dif-
ferent geographic locations. There is also some evidence that
genotype interacts with the risk associated with salted fish
intake, particularly the gene for the cytochrome P450
enzyme, CYP2E1.192 198
Evidence from several case-control studies is
consistent and shows a dose-response effect. There is
evidence for plausible mechanisms. Cantonese-style
salted fish is probably associated with increased risk of
nasopharyngeal cancer. 
4.3.5.4 Eggs
The evidence was too limited in amount, consistency, or
quality to draw any conclusions.
4.3.5.5  Foods containing vitamin D
Colorectum
Eleven cohort studies17 24 154 199-210 and 17 case-control stud-
ies investigated total vitamin D and/or dietary vitamin D and
colorectal cancer. Four cohort studies investigated plasma or
serum vitamin D.22 210-212
Dietary vitamin D
Twelve estimates from 11 cohort studies reported analyses
of the highest intake groups compared to the lowest.17 154 199-
206 Six of these showed non-significant decreased risk154 199-
202 205; 2 studies reported no effect on risk17 205; and 4 studies
show non-significant increased risk.203 204 206 Meta-analysis
was possible on 9 studies that investigated dietary vitamin
D, giving a summary effect estimate of 0.99 (95% CI
0.97–1.00) per 100 IU/day, with moderate heterogeneity.17
154 199 202 204-206 209 210 
Serum or plasma vitamin D
All four cohort studies showed non-significant decreased risk
for the highest intake groups when compared to the lowest.22
210-212 Effect estimates were 0.73 (stated as non-signifi-
cant)211; 0.4 (95% CI 1–1.4; serum 25-hydroxyvitamin D)
and 1.1 (95% CI 0.4–3.2; serum 1,25 hydroxyvitamin D)212;
0.6 (95% CI 0.3–1.1; serum 25-hydroxyvitamin D) and 0.9
(95% CI 0.5–1.7; serum 1,25 hydroxyvitamin D)210; and 0.53
(95% CI 0.27–1.04).22
Because of the abundant prospective data from cohort
studies, case-control studies were not summarised.
The effects of vitamin D and calcium are strongly interre-
lated because both are growth restraining, both induce dif-
ferentiation and apoptosis in intestinal cells, and calcium-
mediated effects are strongly dependent on vitamin D lev-
els. Data from observational studies are probably hampered
by the fact that total levels of the biologically active form are
not only dependent on diet but also on supplements and UV
exposure of the skin. 
Figure 4.3.11 Salted fish and nasopharyngeal cancer;
case-control studies: dose response
Zou 1999
Cai 1996
Ye 1995
Yu 1986
Yu 1989
Sriamporn 1992
Zheng 1994b
Lee 1994
Yuan 2000
0 42 86
Salted fish, times/week
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The evidence on vitamin D was inconsistent. There is
limited evidence suggesting that foods containing
vitamin D, or better vitamin D status, protect against
colorectal cancer.
The Panel is aware that since the conclusion of the SLR, two
case-control studies166 213 have been published. This new infor-
mation does not change the Panel judgement (see box 3.8).
4.3.5.6  Foods containing iron
Colorectum
Four cohort studies214-217 and 23 case-control studies inves-
tigated iron intake and colorectal cancer. One cohort study
investigated haem iron intake.218
The four cohort studies showed increased risk for the high-
est intake group when compared to the lowest,214-216 218
which was statistically significant in two.214 218 Effect esti-
mates were 1.17 (95% CI 0.6–2.3)216; 3.35 (95% CI
1.74–6.46; colon cancer)214; and 2.18 (95% CI 1.24–3.86;
proximal colon cancer).218 One study reported a non-signif-
icant higher intake in cancer cases (18.4 mg) than in con-
trols (17.4 mg).215 The other reported that mean iron intakes
were similar between male colon cancer cases, rectal cancer
cases, and male sub-cohort cases (13.2, 13.3, and 13.2 mg
per day, respectively), and between female colon cancer
cases, rectal cancer cases, and female sub-cohort cases (11.4,
11.6, and 11.7 mg/day, respectively).217
Data suggest that the effect may be limited to proximal
cancer cases and attenuated in distal cancer. Two studies
reported results separately for proximal and distal colon can-
cer cases.214-218 The effect estimates for the former were 1.44
(95% CI 1.23–1.69)214 and 2.18 (95% CI 1.24–3.86),218 and
1.03 (95% CI 0.8–1.32)214 and 0.90 (95% CI 0.45–1.81) for
the latter.218
Because of the abundant prospective data from cohort
studies, case-control studies were not summarised.
It is biologically plausible that iron increases colorectal
cancer risk due to its catalytic activity on the formation of
reactive oxygen species. Haem promotes the formation of N-
nitroso compounds and also contains iron. Free iron can lead
to production of free radicals (box 4.3.3). However, this role
has not been confirmed in animal studies. Another hypoth-
esis is that dietary haem induces colonic cytotoxicity and
hyperproliferation.26 Iron overload also activates oxidative
responsive transcription factors, proinflammatory cytokines,
and iron-induced hypoxia signalling.83
The evidence is sparse, of poor quality, and
inconsistent. There is limited evidence suggesting that
foods containing iron are in general a cause of
colorectal cancer. (Also see chapter 4.3.5.1.1 for
evidence on red and processed meat, which are
classified as convincing causes of colorectal cancer.)
The Panel is aware that since the conclusion of the SLR, two
cohort studies87 219 have been published. This new information
does not change the Panel judgement (see box 3.8).
4.3.5.7  Smoked foods
Stomach 
Seventeen case-control studies116 118 220-235 and two ecological
studies236 237 investigated smoked foods and stomach cancer.
Fourteen case-control studies showed increased risk for the
highest intake group when compared to the lowest,118 220 221
224-235 which was statistically significant in 11.118 224-234 One
study reported non-significant decreased risk222 and 2 stud-
ies reported no effect on risk.116 223 More than half of the
effect estimates were greater than 1.5. None of the studies
adjusted for infection with Helicobacter pylori.
One ecological study reported a statistically significant
increased risk with higher intake of smoked foods236; the
other reported decreased risk, though one constituent of
smoked food (3,4-benzopyrene) was associated with
increased risk.237
Heterogeneity may be partly explained by variation
between studies in the definition of smoked foods — some
were specific to smoked meats and most included meats.
Smoked foods, particularly meats, may contain polycyclic
aromatic hydrocarbons, depending on the fuel burned to
produce the smoke.238 Smoked meats are also often salted
or cured, meaning that they are likely to raise endogenous
production of N-nitroso compounds in the stomach (box
4.3.4). 
There is limited evidence from case-control and
ecological studies, some of which were of poor quality,
that smoked foods are causes of stomach cancer.
The Panel is aware that since the conclusion of the SLR, three
case-control studies136 137 239 have been published. This new
information does not change the Panel judgement (see box
3.8).
4.3.5.8  Grilled (broiled) or barbecued
(charbroiled) animal foods
Stomach 
Three cohort studies240-242 and 12 case-control studies inves-
tigated grilled (broiled) and barbecued (charbroiled) foods
and stomach cancer.
Two cohort studies showed increased risk for the highest
intake group when compared to the lowest,240 242 which was
statistically significant in one.242 One study reported a non-
significant reduced risk.241 Effect estimates were 1.67 (p
value for trend < 0.05)242; 1.77 (95% CI 0.59–5.33) for
grilled (broiled) fish and 2.08 (95% CI 0.97–4.46) for grilled
(broiled) meat240; and 0.84 (95% CI 0.55–1.29).241 None of
the studies adjusted for H pylori infection.
Eight case-control studies showed increased risk for the
highest intake group when compared to the lowest,126 129 130
233 243 245-247 which was statistically significant in seven. One
study reported a statistically significant decreased risk121;
two studies reported non-significant decreased risk220 248;
and one study stated that there was no significant effect on
risk.244
Charring or cooking meats over open flame generates het-
erocyclic amines and polycyclic hydrocarbons, which may
cause cancer (box 4.3.4). 
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There is limited, inconsistent evidence, mostly from
case-control studies, that grilled (broiled) or
barbecued (charbroiled) animal foods are causes of
stomach cancer.
4.3.6 Comparison with previous report
The panel responsible for the previous report judged that
diets relatively high in red meat were probable causes of col-
orectal cancer, and noted a pattern whereby red meat was a
possible cause of cancers of the pancreas, breast, prostate,
and kidney. 
The previous report considered methods of production,
preservation, processing, and preparation (including cook-
ing). Cured meats were judged to be a possible cause of col-
orectal cancer; and grilled, barbecued, and fried meats, and
other foods to be a possible cause of colorectal cancer; and
grilling (broiling) and barbecuing (charbroiling) to be a pos-
sible cause of stomach cancer. Processed meat was not iden-
tified as such. The evidence on Cantonese-style salted fish
was judged to be convincing for nasopharyngeal cancer. The
panel noted that the risk was highest when this food is eaten
frequently in early childhood. This Report concluded the evi-
dence to be probable, in view of the paucity of prospective
data 
Since the mid-1990s, the results of cohort studies have
strengthened the evidence on red meat and processed meat
as causes of colorectal cancer. 
4.3.7 Conclusions
The Panel concludes: 
The evidence on red meat and processed meat is stronger
than in the mid-1990s. Epidemiological evidence on other
methods of preserving and preparing meats and other ani-
mal foods is sparse, and the overall evidence remains sug-
gestive, at most. The evidence on poultry, fish, and eggs is
generally insubstantial.
The evidence that red meats and processed meats are 
a cause of colorectal cancer is convincing. Cantonese-style
salted fish is a probable cause of nasopharyngeal cancer.
This finding does not apply to any other type of fish 
product. Cantonese-style salted fish is also subject to
fermentation.
There is limited evidence suggesting that fish, and also
foods containing vitamin D, protect against colorectal can-
cer. There is limited evidence suggesting that red meat is a
cause of cancers of the oesophagus, lung, pancreas and
endometrium; that processed meat is a cause of cancers of
the oesophagus, lung, stomach and prostate; and that foods
containing iron are a cause of colorectal cancer.  There is also
limited evidence that foods that are grilled (broiled), bar-
becued (charbroiled), and smoked are a cause of stomach
cancer. The evidence comes mostly from meat preserved or
prepared in these ways. 
Meat, as mentioned above, is likely to be relatively high
in animal fats. For discussion of the role of animal fats on
cancer, see chapter 4.4. Meat may also be energy dense. For
discussion on the role of energy-dense foods on weight gain,
overweight, and obesity, and the role of weight gain, over-
weight, and obesity in the risk of some cancers, see Chapters
6 and 8.
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Milk and products made from milk, such as cheese, butter,
ghee, and yoghurt, have been consumed ever since suitable
animals were domesticated. Whole milk and cheese and
yoghurt made from whole milk have a high proportion of
energy from fat and from protein, although the absolute
concentrations in liquid milk are lower than those in cheese
due to the higher water content. They also contain a
number of vitamins, including retinol and riboflavin, and
minerals, particularly calcium. In countries where
consumption of milk and dairy products is high, these are
the main sources of calcium. Low-fat dairy products retain
all of the protein, the water-soluble vitamins, and the
mineral content. However, the fat-soluble vitamins are
significantly reduced. Low-fat milk or whole milk is
sometimes fortified with vitamins A and D.
Until the late 19th century, milk from animals was used as
a substitute for human milk for feeding infants. Adults did
not usually consume such milks; if they did, it was in low
amounts. Populations that kept milk-giving animals
consumed other dairy products. From the early 20th
century, a number of factors were responsible for cow’s milk
becoming almost a staple food in the USA and some
European countries. These included the industrialisation of
cattle farming; the identification of milk as a basic food,
especially for children; and the development of refrigeration
techniques and ultra-heat treated packaging. Dried milk is
now a common ingredient in many processed foods. 
Overall, the Panel judges that the evidence on milk and
dairy products, and on calcium, shows that their impact
on the risk of cancer varies in different tissues. 
The Panel judges as follows: 
Milk probably protects against colorectal cancer. There is
limited evidence suggesting that milk protects against
bladder cancer. There is limited evidence suggesting that
cheese is a cause of colorectal cancer. Diets high in
calcium are a probable cause of prostate cancer; and there
is limited evidence suggesting that high consumption of
milk and dairy products is a cause of prostate cancer. 
The strongest evidence, corresponding to judgements of
‘convincing’ and ‘probable’, shows that milk probably
protects against colorectal cancer, and that diets high in
calcium are a probable cause of prostate cancer.
Milk and dairy products are important components of diets
in some but not all parts of the world. Until recently in his-
tory, milk from several ruminant animals was used as a par-
tial substitute for or in addition to human milk; but these
milks were usually consumed infrequently and, if at all, later
in childhood or by adults. In countries where milk-giving
animals were raised, their products were consumed in the
form of cheese, butter, ghee, and in fermented form as
yoghurts or in combination with alcoholic drinks. 
4.4  Milk and dairy products
MILK, DAIRY PRODUCTS, AND THE RISK OF CANCER
In the judgement of the Panel, the factors listed below modify the risk of cancer. Judgements are graded according to the strength of the evidence.
DECREASES RISK INCREASES RISK
Exposure Cancer site Exposure Cancer site
Convincing
Probable Milk1 4 Colorectum Diets high in calcium2 3 Prostate   
Limited — Milk1 Bladder Milk and dairy products2 Prostate
suggestive Cheese4 Colorectum 
Substantial
effect on risk None identified
unlikely
1 Milk from cows. Most data are from high-income populations, where calcium can be taken to be a marker for milk/dairy consumption. The Panel judges that a higher
intake of dietary calcium is one way in which milk could have a protective effect.
2 Effect only apparent at high calcium intakes (around 1.5 g/day or more). Evidence for milk and dairy products (but not calcium) was derived only from data for
countries with populations that have high calcium and dairy consumption.
3 Includes diets that naturally contain calcium and that contain foods fortified with calcium. See box 4.10.1.
4 Although both milk and cheese are included in the general category of dairy products, their different nutritional composition and 
consumption patterns may result in different findings.
For an explanation of all the terms used in the matrix, please see chapter 3.5.1, the text of this section, and the glossary.
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From the late 19th century, consumption of cow’s milk
greatly increased in the USA, the UK, and some other
European countries. This was a result of a massive increase
in dairy farming supported by new techniques such as con-
densation, drying, and cooling. In the 20th century,
consumption was further boosted by pasteurisation and
doorstep delivery, the decline of breastfeeding, and the com-
mon view that modified cow’s milk is a suitable food for
infants and an excellent food for young children. Dried milk
is a mainstay of programmes of food aid to impoverished
countries. However, populations living outside North America
and northern Europe have until recently consumed little milk
as such, and dairy products consumed are in the form of
yoghurt or products derived from it. This may be due to the
limited capacity to digest lactose beyond infancy observed in
these populations. Yoghurt is fermented, which lowers lactose
concentration, and is therefore better tolerated. 
Reports in the early part of the 20th century of different
forms of malnutrition in young children, which documented
a requirement for high amounts of animal protein to cure
these conditions, supported the categorisation of milk, eggs,
and meat as protective foods. By contrast, reports published
since the 1960s have identified whole milk and dairy prod-
ucts, which have a high proportion of energy from fat and sat-
urated fatty acids, as foods that contribute to the pathogenesis
of coronary heart disease. More recently, some reports con-
cerned with the prevention of osteoporosis in Western pop-
ulations have recommended high intakes of calcium. 
This chapter is concerned with milk and its products. The
evidence on milk is on milk from cows, and the evidence on
cheese is from all sources. It does not consider human milk
or infant formula. For human milk, see chapter 4.11. Nor does
it consider soya drinks or other plant-derived alternatives. For
soya drinks, see chapter 4.2. For butter, see chapter 4.5.
Calcium is included here because in countries where milk
and dairy products are important in diets, these are the main
sources of what is a generally high intake of calcium. Dietary
calcium also comes from bones when these are consumed
(small or tinned fish, for example, and in stews), egg shells,
and from some plant foods. In many countries, plant foods
are the main source of calcium. See chapters 4.1, 4.2, and 4.4.
4.4.1  Definitions, sources
Milk is produced by all mammal species to suckle their
young. It has evolved to be the ideal nourishment for mam-
malian infants of each species and, in normal conditions,
contains all the nutrients they need at that stage of their
lives. Although all mammal species produce milk, only a few
are employed widely as milk producers, and they are all
ruminants. Milk from other species must be modified before
feeding to infants to allow for their limited capacity to
metabolise and excrete nitrogenous compounds and salts in
early life. 
Ruminant animals have a large, multichambered stomach
that contains microbes, which allows them to ferment cel-
lulose and extract nutrients from green and dried grasses.
Some species or breeds (notably European cows) have been
bred to produce copious amounts of milk. Around the world,
other bovine animals used to supply milk include zebu cows
in Asia, water buffalo in Asia and some parts of Europe, and
yaks, although usually only in the mountainous regions in
Asia. Goats and sheep are also important and widespread
milk-producing animals, as well as camels, which live in arid
climates around the world. In some areas of the world, other
animals such as horses, old- and new-world camels, and rein-
deer are locally important. 
Fresh milk can be consumed raw (untreated) or, as is com-
mon in many high-income countries, pasteurised (see chap-
ter 4.9.3). Milk is also commonly processed into a wide
variety of foods including cream, concentrated milks,
cheese, fats such as butter and ghee, and fermented foods
such as yoghurt.
4.4.2  Composition
Milk and dairy products in whole form have a high propor-
tion of energy from fat and protein, and contain some vita-
mins and minerals.1 The precise composition varies between
species and breeds, and with the nature of their feed. Sheep
and yak milks are particularly high in protein; buffalo, sheep,
and yak milks are high in fat. Typical whole cow’s milk con-
tains 3.4 g protein and 3.6 g fat per 100 g.1 Reduced fat
(semi-skimmed) and low-fat (skimmed) milks are produced
from whole milk, and the foods made from these milks have
a correspondingly lower fat and fat-soluble vitamin content
than those made from whole milk.
Around two thirds of the fatty acids in cow’s milk are sat-
urated. Polyunsaturated fatty acids make up less than 4 per
cent of milk fat (see chapter 4.5.2). Fat accounts for half of
the energy in whole milk. Milk contains all the essential
amino acids in the appropriate proportions for humans (see
chapter 4.10.1). 
The only significant carbohydrate found in milk is the
disaccharide lactose. Milk products such as cheese and
yoghurt contain varying amounts of lactose. Hard cheeses
contain only traces, soft cheeses 2–3 per cent, yoghurts 4 per
cent, compared to 5 per cent found in whole milk; this is
because cheese and yoghurt have been fermented by bacte-
ria used in the production of these foods. 
Milk, cheese, and yoghurt contain high levels of calcium
(box 4.4.1). They are also sources of riboflavin and vitamin
B12, and full-fat dairy products are sources of retinol, and
to a lesser extent, other fat-soluble vitamins. Milk also con-
tains several growth factors and hormones, though these are
probably digested in the stomach. However, milk consump-
tion has been shown to elevate circulating levels of insulin-
like growth factor.
4.4.3  Consumption patterns
Consumption of milk and dairy products throughout the
world is highly variable. The overall global average of around
5 per cent of available dietary energy2 conceals wide varia-
tions. The range is from 10–15 per cent of dietary energy in
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the USA and some European countries to less than 0.5 per
cent in some African and Asian countries. 
4.4.4  Interpretation of the evidence
4.4.4.1  General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7 
‘Relative risk’ (RR) is used in this Report to denote ratio
measures of effect, including ‘risk ratios’, ‘rate ratios’, ‘haz-
ard ratios’, and ‘odds ratios’.
4.4.4.2 Specific
Patterns and ranges of intake. Most studies are carried out
in high-income countries where consumption of cow’s milk
and its products is high, and where the main dairy product
consumed is milk. 
Classification. Studies usually do not make any distinction
between dairy products, such as cheeses from different
sources and with different compositions. 
4.4.5  Evidence and judgements
The full systematic literature review (SLR) is contained on
the CD included with this Report.
4.4.5.1  Milk and dairy products
Prostate 
Ten cohort studies,4-15 13 case-control studies,16-29 and 2 eco-
logical studies30 31 investigated milk and dairy products and
prostate cancer; 16 cohort studies,5-8 10 12 14 32-40 11 case-con-
trol studies,21 26 27 41-51 and 11 ecological studies30 31 52-61
investigated milk.
Milk and dairy products
Seven cohort studies showed increased risk with increased
intake of milk and dairy products,4 6 8-11 13 15 which was
statistically significant in two.6 10 Two studies showed non-
significant decreased risk5 12 14; and one study showed no
effect on risk.7 Meta-analysis was possible on eight studies,
giving a summary effect estimate of 1.06 (95% confidence
interval (CI) 1.01–1.11) per serving/day, with moderate
heterogeneity.4-12
Five of these cohort studies reported separately on
advanced/aggressive prostate cancer.5 7 9 10 12 Two studies
showed increased risk with increased intake of milk and
dairy products,9 10 which was statistically significant in one.9
Three studies showed non-significant decreased risk.5 7 12
Meta-analysis was possible on four studies, giving a sum-
mary effect estimate of 1.00 (95% CI 0.94–1.06) per serv-
ing/day, with low heterogeneity.5 7 10 12 The study that could
not be included in the meta-analysis was inconsistent with
this result, reporting an effect estimate of 2.35 (95% CI
1.29–4.26) per serving/day increase (dry weight).9
Eight case-control studies showed increased risk with
increased intake of milk and dairy products,16 19-21 23 24 26 28
which was statistically significant in one. 28 Four studies
showed non-significant decreased risk17 18 22 25 27; and one
study reported that there was no statistically significant
effect on risk.29 Meta-analysis was possible on five relative-
ly high-quality studies, giving a summary effect estimate of
1.03 (95% CI 0.99–1.07) per serving/day, with low hetero-
geneity.16-20
One ecological study showed no significant association,
with an age-adjusted correlation coefficient of -0.49.30 One
other ecological study reported no statistically significant
effect.31
There are many separate exposures being measured with-
in this broad category, which may explain the observed het-
erogeneity. 
A dose-response relationship is apparent from cohort data
on all prostate cancer, but not from cohort data on
advanced/aggressive prostate cancer or case-control data.
Milk
Six cohort studies showed increased risk with increased
intake of milk,6 8 33 36 37 39 which was statistically significant
in one.6 Three studies showed no effect on risk32 34 35 and one
study showed non-significant decreased risk.14 The remain-
ing six studies did not report quantified results, but stated
results were not statistically significant.5 7 10 12 38 40 Meta-
analysis was possible on eight studies, giving a summary
effect estimate of 1.05 (95% CI 0.98–1.14) per serving/day,
with low heterogeneity.6 8 14 32-36
Six studies reported separately on advanced/aggressive
prostate cancer.7 12 33 36 39 40 Three studies showed increased
risk with increased intake of milk, with effect estimates of
1.30 (95% CI 1.04–1.61) per serving/day36; 2.8 (in men
aged 72.5 years or less, for the highest intake groups com-
pared to the lowest, with no CI reported)33; and an increased
risk with a p value for trend of 0.005.39 Three studies did
not report quantified results but stated that there was no sig-
nificant association.7 12 40
In countries with high intakes of milk and dairy products, these
are the main source of calcium. Most of the epidemiological
studies reviewed here are from those countries. 
Calcium is found in plant as well as in animal foods, but it is less
easily absorbed. Other animal sources include small fish (when
eaten with their bones) and meat (when rendered on the bone in
stews). Plant sources include green vegetables, nuts, and pulses
(legumes).1 3
Calcium is the most abundant mineral in the body and is the
major mineral constituent of bones. It is central to a variety of
functions in the body, such as bone metabolism, nerve and mus-
cle activity, and the control of cell differentiation and prolifer-
ation. Calcium metabolism is controlled by various factors,
including vitamin D and related hormonal compounds formed
by the liver and kidney, necessary for the absorption of calcium
from foods, and its regulation in the body.
Box 4.4.1 Foods containing calcium
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Seven case-control studies showed increased risk with
increased intake of milk,27 41-44 47-51 which was statistically
significant in three (including the single relatively high qual-
ity study).41 43 44 47 Two studies showed non-significant
decreased risk21 45; one study reported no effect on risk46 and
one study stated that there was no significant association but
did not present results.26 Meta-analysis was possible on six
relatively low quality studies, giving a summary effect esti-
mate of 1.08 (95% CI 0.98–1.19) per serving/day, with mod-
erate heterogeneity.21 27 42-45
Ten ecological studies reported correlations in the direc-
tion of increased risk.31 52 54-61 One study did not provide a
quantified result, but stated there was no statistically sig-
nificant association.53 One study showed a non-significant
decreased risk in areas of increased intake.30
Milk could plausibly cause prostate cancer through the
actions of calcium (see chapter 4.4.5.1.1). Also, consump-
tion of milk increases blood levels of insulin-like growth fac-
tor-1, which has been associated with increased prostate
cancer risk in some studies.62 63
The evidence is inconsistent from both cohort and
case-control studies. There is limited evidence
suggesting that milk and dairy products are a cause of
prostate cancer.
The Panel is aware that since the conclusion of the SLR, two
cohort studies64 65 and one case-control study66 have been pub-
lished. This new information does not change the Panel judge-
ment (see box 3.8). 
4.4.5.1.1  Milk
Colorectum
Thirteen cohort studies67-82 and 36 case-control studies inves-
tigated milk and colorectal cancer. Fifteen cohort studies72-
77 79 80 82-101 and 58 case-control studies investigated dietary
calcium.
Milk
Nine cohort studies showed decreased risk with increased
intake of milk,67 69 70 72 74 75 77 80-82 which was statistically sig-
nificant in two.67 80 Two studies showed non-significant
increased risk69 71 78 79 and two studies showed non-signifi-
cant increased risk in women and non-significant decreased
risk in men.68 73 76 Meta-analysis was possible on four stud-
ies, giving a summary effect estimate of 0.94 (95% CI
0.85–1.03) per serving/day, with low heterogeneity (figures
4.4.1 and 4.4.2).72 73 76 81
In addition, there was a pooled analysis from 10 cohort
studies which included 534 536 participants with 4992 cases
of colorectal cancer. Milk intake was related to a statistical-
ly significant reduced risk of colorectal cancer (relative risk
(RR) 0.78; 95% CI 0.69–0.88) for the highest intake group
when compared to the lowest.102
Dietary calcium  
Eleven studies showed decreased risk with increased intake
of calcium,76 79 82 84 85 90-93 99 which was statistically significant
in three.84 85 90 One study showed non-significant increased
risk74; one study showed non-significant increased risk in
women and non-significant decreased risk in men73; and two
studies showed non-significant decreased risk of colon can-
cer and non-significant increased risk of rectal cancer.88 89
Meta-analysis was possible on 10 cohort studies giving a sum-
mary effect estimate of 0.98 (95% CI 0.95–1.00) per 200
mg/day, with low heterogeneity (figure 4.4.3).72 73 76 77 79 83
87 90 98 99 When meta-analysis was restricted to eight studies
that reported results separately for colon cancer, a summary
effect estimate of 0.95 (95% CI 0.92–0.98) per 200 mg/day
was produced, with no heterogeneity.72 73 76 77 83 87 89 90
Dose-response plot
Figure 4.4.4 shows the dose-response curve for dietary cal-
cium intake and colorectal cancer incidence. 
In addition, there was a pooled analysis from 10 cohort
studies which included 534 536 participants with 4992 
cases of colorectal cancer. Dietary calcium intake was 
related to a statistically significant reduced risk of colorec-
tal cancer (RR 0.86; 95% CI 0.78–0.95) for the highest
Figure 4.4.2 Milk and colorectal cancer: cohort studies:
dose response
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Figure 4.4.1 Milk and colorectal cancer; cohort studies
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intake group when compared to the lowest.102
Because of the abundant prospective data from cohort
studies, case-control studies were not summarised.
Dietary calcium intake can be interpreted as a marker of
dairy intake only in those populations (usually European,
Australian, or from the Americas) that consume relatively
regular and large amounts of milk and dairy products. Other
dietary sources of calcium include vegetables, nuts, pulses,
and fish or meat cooked on the bone (box 4.4.1).
The general mechanisms through which milk could plau-
sibly protect against cancer are outlined below.
The evidence on milk from cohort studies is reasonably
consistent, supported by stronger evidence from
dietary calcium as a dietary marker. There is evidence
for plausible mechanisms. Milk probably protects
against colorectal cancer.
The Panel is aware that since the conclusion of the SLR, three
cohort80 103 104 and three case-control studies66 105 106 have been
published. This new information does not change the Panel
judgement (see box 3.8).
Bladder cancer 
Five cohort studies,34 107-111 14 case-control studies,48 112-124
and 1 ecological study56 investigated milk and bladder
cancer.
All five cohort studies showed decreased risk with
increased intake of milk,34 107-111 which was statistically sig-
nificant in one.108 Meta-analysis was possible on four stud-
ies, giving a summary effect estimate of 0.82 (95% CI
0.67–0.99) per serving/day, with moderate heterogeneity.34
108-110
Seven case-control studies showed decreased risk with
increased intake of milk,48 112 115-117 121 122 which was statis-
tically significant in four.115 117 121 122 Four studies showed
non-significant increased risk,113 114 120 123 and three studies
stated that there was no significant association.118 119 124
Meta-analysis was possible on three relatively high-quality
case-control studies, giving a summary effect estimate of
1.00 (95% CI 0.87–1.14) per serving/day, with high het-
erogeneity.113-115
A dose-response relationship is apparent from cohort, but
not case-control data.
The single ecological study reported a correlation of 0.45
between milk consumption and death from bladder cancer.56
The general mechanisms through which milk could plau-
sibly protect against cancer are outlined below.
The evidence is inconsistent and comes mainly from
evidence on dietary calcium. There is limited evidence
suggesting that milk protects against bladder cancer.
General mechanisms — milk
The probable effect of milk in reducing cancer risk is likely
to be mediated at least in part by calcium. Calcium from diet
is an import micronutrient, and intracellular calcium direct-
ly influences cell growth and apoptosis. Calcium may also
bind to bile and fatty acids, preventing them from damag-
ing the intestinal lining.125 Milk includes many bioactive con-
stituents, however, which may also play a role.
4.4.5.1.2  Cheese
Colorectum
Eleven cohort studies67 68 70 72 74 78-80 82 126-128 and 25 case-
control studies investigated cheese and colorectal cancer.
Eight cohort studies showed increased risk with increased
intake of cheese, none of which was statistically significant.67
68 70 72 74 79 80 126 127 Two studies reported non-significant
decreased risk78 82 and one study reported that there was no
significant association.128 Two meta-analyses were possible
Figure 4.4.4 Dietary calcium and colorectal cancer;
cohort studies: dose response
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Figure 4.4.3 Dietary calcium and colorectal cancer:
cohort studies
Stemmermann, 1990 Men 0.98 (0.91-1.06)
Bostick 1993 Women 0.95 (0.87-1.02)
Martinez 1996 Women 0.95 (0.89-1.01)
Kearney 1996 Men 0.95 (0.85-1.05)
Gaard 1996 Men 0.86 (0.68-1.09)
Gaard 1996 0.98 (0.71-1.36)
Tangrea 1997 Men 1.00 (0.92-1.08)
Terry 2002 Women >=55 years 0.85 (0.75-0.96)
Terry 2002 Women <55 years 0.97 (0.80-1.19)
McCullough 2003 Men 0.95 (0.88-1.02)
McCullough 2003 Women 1.02 (0.93-1.11)
Koh 2004 1.00 (1.00-1.00)
Lin 2005 Women 0.99 (0.90-1.10)
Summary estimate 0.98 (0.95-1.00)
10.5 2
Relative risk (95% CI)
Relative risk, per 200 mg/day
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on three and two cohort studies, respectively, giving sum-
mary effect estimates of 1.14 (95% CI 0.82–1.58) per serv-
ing/day72 79 126 and 1.11 (95% CI 0.88–1.39) per 50 g/day,80
82 both with low heterogeneity.
Because of the abundant prospective data from cohort
studies, case-control studies were not summarised.
No specific mechanism has been identified but cheese
could plausibly cause colorectal cancer through the indirect
mechanisms connected to saturated fats. Saturated fats
intake increases insulin production and expression of insulin
receptors on colonic cells.129 Saturated fats can also induce
expression of certain inflammatory mediators associated
with carcinogenesis.130
Epidemiological evidence for cheese intake is consistent-
ly in contrast to the probable protective effect from milk. 
The evidence is inconsistent. There is limited evidence
suggesting that cheese is a cause of colorectal cancer.
The Panel is aware that since the conclusion of the SLR, two
cohort studies66 103 104 and one case-control study66 have been
published. This new information does not change the Panel
judgement (see box 3.8).
4.4.5.2  Diets high in calcium
For evidence on calcium supplements, see chapter
4.10.6.4.4.
Calcium is a good marker for dairy intake in Western diets.
In areas outside the USA, Europe, and Oceania, dairy prod-
ucts are not as widely consumed and the range of calcium
intake is smaller (see also box 4.4.1). 
Prostate 
Nine cohort studies,4-8 10 11 131-133 12 case-control studies,18 19
23 24 134-144 and 2 ecological studies145 146 investigated dietary
calcium and prostate cancer.
Seven cohort studies showed increased risk with increased
intake of dietary calcium,4-7 10 11 131 133 which was statistical-
ly significant in three.6 10 133 Two studies showed non-signif-
icant decreased risk, including the only unadjusted study.8
132 Meta-analysis was possible on eight cohort studies, giv-
ing a summary effect estimate of 1.27 (95% CI 1.09–1.48)
per g/day, with moderate heterogeneity.5-8 10 11 131-133
Four of these cohort studies reported separately on
advanced/aggressive prostate cancer.5 7 10 133 Three studies
showed increased risk with increased intake of milk and
dairy products,7 10 133 which was statistically significant in
one.133 One study showed non-significant decreased risk.5
Meta-analysis was possible on all four studies, giving a sum-
mary effect estimate of 1.32 (95% CI 1.05–1.64) per g/day,
with moderate heterogeneity.5 7 10 133
Six case-control studies showed non-significant decreased
risk with increased intake of dietary calcium.18 134 136 138-140
143 144 Five studies showed increased risk,19 23 24 135 137 141
which was statistically significant in one19 138; and one other
study showed no effect on risk.142 Meta-analysis was possi-
ble on three relatively high-quality studies, giving a summary
effect estimate of 1.16 (95% CI 0.64–2.14) per gram of
calcium/day, with high heterogeneity.18 19 134
A dose-response relationship was apparent from cohort but
not case-control data.
One ecological study from Germany showed a significant
increased risk of prostate cancer with higher calcium
intakes.146 Another study from Taiwan reported a non-
significant decreased risk with higher calcium intakes.145
High calcium intake downregulates the formation of 1,25
dihydroxy vitamin D(3) from vitamin D, thereby increasing
cell proliferation in the prostate.7 Prostate cancer tumours
in rats treated with 1,25 dihydroxy vitamin D(3) were sig-
nificantly smaller and presented smaller numbers of lung
metastases.147
The evidence, from both cohort and case-control
studies, is substantial and consistent with a dose-
response relationship. There is evidence for plausible
mechanisms. Diets high in calcium are a probable
cause of prostate cancer.
The Panel is aware that since the conclusion of the SLR, two
cohort studies64 65 have been published. This new information
does not change the Panel judgement (see box 3.8).
4.4.6  Comparison with previous report
The previous report judged that milk and dairy products pos-
sibly increase the risk of prostate and kidney cancer. Calcium
was judged possibly not to affect the risk of colorectal can-
cer. Since the mid-1990s, more evidence has emerged on
prostate cancer, and that for kidney cancer is now incon-
clusive.
4.4.7  Conclusions
The Panel concludes:
The evidence on the relationship between milk and dairy
products, and also diets high in calcium, and the risk of can-
cer, points in different directions. 
Milk probably protects against colorectal cancer; there is
limited evidence suggesting that milk protects against blad-
der cancer. But there is limited evidence suggesting that
cheese is a cause of colorectal cancer. 
Diets high in calcium are a probable cause of prostate can-
cer; there is limited evidence suggesting that high con-
sumption of milk and dairy products is a cause of prostate
cancer. 
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Fats and oils are the most energy-dense constituents of
food supplies and diets. Their contribution to total dietary
energy increases with industrialisation and urbanisation.
Meat from most industrially bred animals is higher in fat
than that from wild animals, and such meat fats, together
with fat from milk and dairy products, are a major source
of fat in most high-income countries. Many processed
foods contain substantial amounts of oils from plant
sources. Production and consumption of animal fats and
oil from plant sources have greatly increased in recent
decades, most of all in China and elsewhere in Asia. 
In general, the Panel judges that there is only limited
evidence suggesting that diets relatively high in fats and
oils (in total, or any type) are in themselves a cause of any
cancer. This judgement contrasts with those of some
earlier reports, which concluded from evidence then
available that diets high in fats and oils might be a
substantial cause of some cancers. Overall, the evidence
does not suggest that diets relatively high in fats and oils
might protect against the risk of any cancer. 
The Panel judges as follows: 
There is limited evidence suggesting that total fat is a
cause of lung cancer, and of postmenopausal breast
cancer; that animal fat is a cause of colorectal cancer; 
and that consumption of butter is a cause of lung cancer.
The Panel stresses that the principal cause of lung 
cancer is tobacco smoking.
The evidence on fats and oils does not justify any
judgement of ‘convincing’ or ‘probable’. For discussion of
the role of fats and oils in energy-dense foods and drinks,
the effect of energy-dense foods and drinks on weight
gain, overweight, and obesity, and the role of weight gain,
overweight, and obesity in the risk of some cancers, see
Chapters 6 and 8. 
Fats or oils may be an intrinsic part of the plant or animal,
as contained in the germ of cereals (grains) and the tissues
of animals, or extracted and added to food in manufacture,
cooking, or at the table. 
Production and consumption of fats and oils in general
rises with industrialisation and urbanisation, and in partic-
ular with the extent to which animal production is intensi-
fied, milk and dairy products are consumed, and processed
foods include extracted oils. Availability and price are also
key factors. In lower-income countries, average population
consumption of fat may amount to less than 15 per cent,
though usually to 20–30 per cent of total energy; in high-
income countries, usually to 30–40 per cent. On a global
basis, and most notably in China and elsewhere in Asia, pro-
duction and consumption of animal fats and plant oils are
increasing. 
Early reports issued in the context of food insecurity in
industrialised countries, including Europe and North
America, recommended maintenance and even an increase
in consumption of fats and oils. In the second half of the 20th
century, reports on fats, oils, and chronic diseases tended to
focus on the possible role of diets relatively high in fats and
oils in the causation of obesity, type 2 diabetes, coronary
4.5  Fats and oils
FATS, OILS, AND THE RISK OF CANCER
In the judgement of the Panel, the factors listed below modify the risk of cancer. Judgements are graded according to the strength of the evidence.
DECREASES RISK INCREASES RISK
Exposure Cancer site Exposure Cancer site
Convincing
Probable
Limited — Total fat Lung
suggestive Breast (postmenopause)
Foods containing animal fats1 Colorectum
Butter Lung
Substantial
effect on risk None identified
unlikely
1 Includes both foods naturally containing the constituent and foods that have had the constituent added (see Chapter 3). 
For an explanation of all the terms used in the matrix, please see chapter 3.5.1, the text of this section, and the glossary.
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heart disease, and cancers of some sites. In recent decades,
more attention has been given to issues of the nutritional
quality of fats and oils. Distinctions are made between rela-
tively saturated (including hydrogenated) fats, such as from
meat, milk, and their products, or from hydrogenated oils in
baked goods and many other processed foods; relatively
monounsaturated oils, notably olive oil; and relatively
polyunsaturated oils, from seeds, nuts, fish, and other
sources, some of which — like vitamins — are essential to
human health and life. These distinctions are to some extent
reflected in the studies reviewed here. 
For discussion of the role of fats and oils in energy-dense
foods and drinks, the effect of energy-dense foods and drinks
on weight gain, overweight, and obesity, and the role of
weight gain, overweight, and obesity in the risk of some can-
cers, see Chapters 6 and 8. 
In this Report, fats and oils are classified as foods. This sec-
tion also covers dietary cholesterol, as well as total fat and
individual fatty acids as dietary constituents. Food process-
es affecting the composition of fats and oils, such as hydro-
genation, are also covered here. 
4.5.1  Definitions and sources
Dietary fat is mostly made up of triglycerides (three fatty acid
molecules attached to a glycerol backbone). Triglycerides are
lipids, a class of hydrocarbon-containing organic compounds,
which also includes cholesterol. Lipids are used by plants,
animals, and humans as a means of storing energy, as struc-
tural components of cell membranes, and as precursors of
important hormones. 
Fatty acids are classified as either ‘saturated’ or ‘unsatu-
rated’, depending on their chemical structure (see chapter
4.5.2), and these differences determine their shape and phys-
ical properties. Fats high in saturated fatty acids are gener-
ally solid at room temperature, whereas those rich in
unsaturated fatty acids are liquid. Trans-fatty acids, formed
in a process called hydrogenation (box 4.5.1), are physical-
ly more like saturated fats (harder at lower temperatures),
and have similar effects on the body.
The term ‘fats’ is often used for fats and for oils. Fats can
be classified according to their source, use, or chemical com-
position. Those that are solid or semisolid at ambient tem-
perature are generally high in saturated fatty acids and are
often of animal origin; and oils, which are from plant and
marine sources, are liquid at ambient temperature in their
places of origin. Palm oil and coconut oil, which are relatively
high in saturated fatty acids, are semisolid in temperate cli-
mates but liquid in the tropics, where coconut and other
palm trees grow (also see chapter 4.5.2).
Fats and oils are eaten as part of animal and plant foods,
are contained in manufactured foods, used for cooking, and
may be added at the table. Animal fats include tallow, lard,
and suet, produced as part of the slaughtering process, and
butter. Margarine and other fat spreads are made from fish
and plant oils. Plant oils are extracted from oily fruits (such
as olives), seeds (such as rape and sunflower), nuts (such
as walnuts), and other sources. 
A small amount of dietary fat is essential to allow absorp-
tion of fat-soluble vitamins (A, D, E, and K) and to provide
the essential fatty acids that cannot be made by the body.
Fat also helps food to taste more interesting and be more
palatable, for instance in terms of its texture. Linoleic acid
and alpha-linolenic acid are the two essential fatty acids, and
are found in vegetables, nuts, and seed oils; lower levels are
also found in meat, eggs, and dairy products. Oily fish also
contain long-chain unsaturated fatty acids, which influence
inflammatory processes in the body.1 For instance, eicos-
apentaenoic and docosahexaenoic acids, and related fatty
acids, are precursors to prostaglandins, which are hormone-
like compounds with diverse effects, including roles in blood
vessel dilation and constriction, blood clotting, and inflam-
mation.
Cholesterol is found only in foods of animal origin, such
as cheese, butter, meat, seafood, and egg yolks. Most of the
cholesterol in the body is manufactured in the liver, rather
than coming from these dietary sources.1 The proportion and
types of saturated and unsaturated fatty acids eaten in the
diet are more important influences on cholesterol meta-
bolism than the amount of dietary cholesterol.
4.5.2  Composition
The properties of fats and oils are determined by the length
and structure of the fatty acids they contain. Liquid oils tend
to be higher in unsaturated fatty acids, whereas more solid
fats have more saturated fatty acids. 
Whether or not a fatty acid is saturated depends on the
chemical bonds that join together the chain of carbon atoms
that forms the backbone of the molecule. Saturated fatty
acids have only single bonds, whereas unsaturated fatty acids
have at least one double bond between two adjacent carbon
atoms. Monounsaturated fatty acids have only one double
bond; polyunsaturated fatty acids have two or more double
bonds. The position of the first double bond along the car-
bon chain is denoted by an ‘n’. Thus linoleic acid is ‘n-6’ and
alpha-linolenic acid is ‘n-3’. These were previously known as
‘omega-6’ and ‘omega-3’ fatty acids. 
Saturated fatty acids are long and straight, forming well
ordered, relatively solid structures. But each of the double
bonds in an unsaturated fatty acid causes the carbon chain
to kink; and the more kinks, the less well they pack togeth-
er, which means they form less solid structures. So, saturat-
ed fats are usually solid at room temperature and
unsaturated fats are liquid (oils). Trans-fatty acids are unsat-
urated fatty acids formed by a process called hydrogenation,
which removes and reconfigures the double bonds, making
the carbon chain less kinked. Plant oils can be turned into
saturated fats by this process, which, when only partially
complete, also leads to production of trans-fatty acids (box
4.5.1).
Fats from ruminants (cattle and sheep) contain more
saturated fatty acids than pork or poultry fats. Fats 
from under the skin have a smaller proportion of saturated
fatty acids than fats stored around the organs. Beef 
suet is the hardest culinary fat, while chicken, duck, and
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goose fats are semiliquid at room temperature. 
In general, the amount and type of body fat carried by ani-
mals and poultry depend on how they live, and this deter-
mines the fat content of their meat, unless some of it has
been removed during processing. Wild and free-living land
animals and birds are lean, and much of their fat is unsatu-
rated; domesticated animals and birds carry more fat, which
is higher in saturated fatty acids. Indeed, they are often bred
to be more fatty, so that their meat is more succulent.
4.5.3  Consumption patterns  
Consumption of total fats and oils varies greatly throughout
the world. Average intake of total fat is highest (30–40 per
cent of total energy) in most urbanised and industrialised
regions such as Europe, North America, Australia, and New
Zealand, where people consume relatively more meat and
milk and their products. By contrast, fat usually accounts for
only 20–30 per cent of total energy in lower-income parts of
the world, for instance in Africa, Asia, and Latin America;
this may be even lower in rural areas, where people consume
low levels of added fats or oils (for instance, from processed
foods). However, in general, consumption of fats — and in
particular plant oils — is increasing in middle- and low-
income countries. (Also see Chapter 1.) 
Higher amounts of separated animal fats (as distinct from
the fats that are naturally components of foods of animal ori-
gin) are consumed in high-income countries. Availability is
typically highest in North America, northern Europe,
Australia, and New Zealand — as much as 10 per cent in
parts of northern Europe, compared with less than 0.5 per
cent in much of Africa and Asia.3
More plant oils are also consumed in high-income coun-
tries; availability is highest in North America, southern
Europe and some parts of the Middle East, and lowest in
parts of Asia and Africa. Greece has the highest level of con-
sumption — almost 20 per cent of dietary energy — com-
pared with 1.4 per cent in Laos. 
Soya bean oil is the most widely consumed oil in the
world, particularly in North America, as well as in some
Asian and African countries. Sunflower seed oil is the sec-
ond most widely consumed vegetable oil (particularly in
Europe, South Africa, Argentina, Chile, and New Zealand)
and palm oil the third (particularly in some African, Asian,
and Latin American countries, as well as in Australia). Olive
oil is the most widely consumed oil in southern Europe (par-
ticularly in Greece, Italy, and Spain). Rapeseed oils are most
common in northern Europe and Canada, while groundnut
oil is common in some African countries. 
The industrial revolution brought significant changes to
food supplies, methods of food production, and hence peo-
ple’s diets (see chapter 1.1.3). Before then, it is thought that
the amounts of n-6 and n-3 oils in diets had been roughly
equal. But with the move to urban–industrial ways of life,
vegetable oils (which are predominantly n-6) became cheap
and widely available. The ratio of n-6 to n-3 fatty acids is
now thought to be between 10 and 20 to 1 in many high-
income countries.4
The World Health Organization recommends limiting aver-
age fat intake for populations to between 15 and 30 per cent
of total daily energy intake, and saturated fatty acids to less
than 10 per cent.5 In higher-income countries, fat con-
sumption as a percentage of total energy has been decreas-
ing for some time. However, this is no longer the case in
some countries such as the USA, where the percentage of
energy from fat has started to increase again.
4.5.4  Interpretation of the evidence
4.5.4.1 General
For general considerations that may affect interpretation 
of the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7.
‘Relative risk’ (RR) is used in this Report to denote ratio
measures of effect, including ‘risk ratios’, ‘rate ratios’, ‘haz-
ard ratios’, and ‘odds ratios’.
The main single factor that has increased
production and consumption of total fat
and saturated fatty acids throughout the
world, and therefore the energy density of
food supplies, is the industrial process of
hydrogenation, invented at the beginning
of the 20th century.2 The hydrogenation
process was at first used mostly for the
manufacture of margarine, but it is now
used in the manufacture of many pro-
cessed foods supplied and consumed
throughout the world. 
Complete hydrogenation converts the
unsaturated fatty acids in oils of plant and
marine origin into saturated fatty acids.
This process has two commercial benefits.
First, it greatly extends ‘shelf-life’: oils high
in unsaturated fatty acids become rancid,
whereas fats high in saturated fatty acids
‘keep’ for very much longer. Second, it
enables conversion of whatever plant and
marine oils are cheapest at the time into a
uniform, reliable ingredient and product. 
Partial hydrogenation produces trans-
fatty acids, which, although chemically
unsaturated, physiologically behave more
like saturated fatty acids. For instance, high
levels in the diet increase the risk of coro-
nary heart disease. Biscuits and other baked
goods may contain as much as 25 per cent
or more of their fats in trans form. Small
amounts of trans-fats are also naturally
found in milk and butter. 
Because of the evidence on coronary
heart disease, regulatory authorities in
many countries now require food manu-
facturers to list trans-fatty acid content on
nutrition labels of processed foods.
Hydrogenated fats found in foods, and
labelled as such, are hydrogenated to a
variable extent and may therefore contain
unspecified amounts of trans-fatty acids.
This may not be clear on labels where a dec-
laration of trans-fatty acid content is not
required.
The Panel notes that any effect of trans-
fatty acids specifically on the risk of any
cancer is not known. 
Box 4.5.1 Hydrogenation and trans-fatty acids 
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4.5.4.2 Specific 
Some considerations specific to fats and oils are as follows. 
Patterns and ranges of intake. In high-income countries
where most studies are undertaken, average consumption of
fats and oils is relatively high and variation in consumption
is not great. 
Classification. Studies tend to use classifications relevant to
coronary heart disease, some of which may not be relevant
to cancer. Thus, they examine not only animal and vegetable
fats; meat, fish, and dairy fats; but also saturated and unsat-
urated fatty acids; monounsaturated and polyunsaturated
fatty acids; n-3 and trans-fatty acids; and oleic, linoleic, and
other individual fatty acids. This makes aggregation and
analysis of intakes of fats and oils as a whole, problematic. 
Study design. Practically all studies have analysed con-
sumption of fats and oils as an issue of quantity (percentage
of total energy intake) rather than nutritional quality (effect
of different types of fats and oils). But oils are complex mix-
tures of nutrients and other bioactive compounds, some of
which may have harmful effects on cancer risk and others
beneficial effects. 
Reporting bias. The use of questionnaires to record con-
sumption of fats and oils may change behaviour. As people
become more conscious of what they consume, they tend to
under-report true consumption of foods and drinks they
regard as unhealthy, including fats and oils. So studies using
questionnaires may disproportionately underestimate con-
sumption of fats and oils. 
4.5.5  Evidence and judgements
The relationship between the risk of cancer and fat and oil
intake may be assessed as weight of fat consumed or adjust-
ed for total energy intake, so that fat is assessed as a pro-
portion of total dietary energy.6 Where this is the case, this
has been stated below.
The full systematic literature review (SLR) is contained on
the CD included with this Report.
4.5.5.1 Total fats 
Lung 
Nine cohort studies,7-15 17 case-control studies,16-32 and 4
ecological studies33-36 investigated total fat and lung cancer.
(Also see chapter 7.4.)
Six cohort studies showed non-significant increased risk for
the highest intake group when compared to the lowest.7 8 10
11 13 14 Three studies showed decreased risk,9 12 15 which was
statistically significant in one.15 Meta-analysis was possible on
two cohort studies, with a summary effect estimate of 1.01
(95% confidence interval (CI) 0.94–1.09) per 10 g fat/day,
with high heterogeneity.11 12 Six of the studies adjusted for
smoking, including the two studies in the meta-analysis and
not including the statistically significant reduced risk.7-12
Pooled analysis from 8 cohort studies (over 430 000 partici-
pants, followed up for 6 to 16 years, more than 3100 lung can-
cer cases) showed a non-significant increased risk of 1.01 (95%
CI 0.98–1.05) per 5 per cent daily energy intake from fat.37
Twelve of the case-control studies showed increased risk for
the highest intake group when compared to the lowest,16 17 19-
21 23 25 27-29 31 32 which was statistically significant in 
five.16 17 19-21 25 31 No studies reported statistically significant 
reduced risk. Most (12) of these studies adjusted for 
smoking.16 19-22 24 25 27 30-32
The ecological studies reported mixed results, most of which
were not statistically significant.33-35 One study reported a sta-
tistically significant decreased risk with increased fat intake.36
Although no evidence for plausible mechanisms was found,
based on the epidemiological evidence, there is limited evi-
dence suggesting that total fat is a cause of lung cancer.
The mixed results from cohort studies contrast with
the more consistent results from other studies. Overall,
there is limited evidence suggesting that consumption
of total fat is a cause of lung cancer. The Panel
emphasises that the principal cause of lung cancer is
smoking tobacco. 
Breast (all ages) 
Nineteen cohort studies,38-60 49 case-control studies,61-118 and
10 ecological studies119-128 investigated total fat intake and
breast cancer.
Breast (premenopause)
Total fat intake for all ages, and also for premenopausal
breast cancer, did not give any overall indication of effect. 
Breast (postmenopause) 
Nine cohort studies38 40 43 45 50-52 57-59 and 16 case-control stud-
ies62-65 75 79 85 86 96-98 101 102 109 110 112 116 reported results specif-
ically for postmenopausal breast cancer. 
Six cohort studies showed increased risk with increasing
fat intake,38 40 45 50-52 59 which was statistically significant in
three.38 51 52 Three studies reported non-significant reduced
risk.40 43 57 58 Meta-analysis was possible on five cohort stud-
ies, giving a summary estimate of 1.06 (95% CI 0.99–1.14)
per 20 g/day, with moderate heterogeneity.38 43 45 50 51
Pooling project data (7329 invasive postmenopausal
breast cancer cases among 351 821 women) showed a
reduced risk, with an estimate of 0.96 (95% CI 0.86–1.08)
per 25 g increase in energy-adjusted total fat. Menopausal
status was not an effect modifier on these data.129 130
Eleven case-control studies showed increased risk with
increasing fat intake,62 64 65 75 85 86 96-98 102 109 110 112 which was
statistically significant in three.97 109 112 Five studies showed
decreased risk,63 64 79 101 116 which was statistically significant
in one.64 Meta-analysis was possible on seven control stud-
ies, giving a summary estimate of 1.11 (95% CI 1.06–1.16),
with no heterogeneity.62 63 65 75 97 102 109
There is also evidence on percentage energy from fat. There
are four cohort studies131-134; three reported decreased risk.131
133 134 The other study reported non-significant increased
risk.132 There were two case-control studies; both reported a
non-significant decreased risk.135 136
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There is interest in the varying role that different types of
individual fatty acids might have on breast cancer risk but
there are insufficient data to draw any conclusions. There are
mechanistic data connecting polyunsaturated fatty acids and
peroxidation. 
Higher endogenous oestrogen levels after menopause are
a known cause of breast cancer.137 138 Dietary fat is relative-
ly well established as a cause of increased endogenous
oestrogen production.139 Low-fat diets are usually associat-
ed with high fibre consumption, which may reduce oestro-
gen concentration by decreasing intestinal reabsorption. In
premenopausal women, there is little evidence that serum
oestrogen levels are associated either with fat consumption
or with breast cancer risk.
An alternative mechanism by which dietary fat could influ-
ence steroid hormone levels is that increased serum-free fatty
acids could displace oestradiol from serum albumin, thus
increasing free oestradiol concentration.140 However, the
serum concentration of sex hormone-binding globulin is a
more important determinant of the proportion of oestradiol
that can enter the breast epithelial cells. Sex hormone-bind-
ing globulin decreases with increasing body mass index and
insulin resistance. 
Energy-dense diets (among other factors) lower the age
of menarche. Early menarche is an established risk factor for
breast cancer.
Evidence from prospective epidemiological studies of
different types shows inconsistent effects on the whole,
while case-control studies show a significant positive
association. Mechanistic evidence is speculative.
Overall, there is limited evidence suggesting that
consumption of total fat is a cause of postmenopausal
breast cancer.
4.5.5.1.1 Butter
Lung
Two cohort studies8 141 and eight case-control studies142-149
investigated butter and lung cancer. (Also see chapter 7.4.)
One cohort study showed statistically significant increased
risk, with a summary estimate of 1.8 (95% CI 1.0–3.0) for
the highest intake group when compared to the lowest.8 The
other cohort study showed non-significant decreased risk in
three independent estimates: 0.92 (95% CI 0.65–1.30) for
men; 0.90 (95% CI 0.46–1.77) for women; and 0.94 (95%
CI 0.62–1.42) for non-smokers.141 Both studies adjusted for
smoking.
Seven case-control studies showed increased risk for the
highest intake group when compared to the lowest,143-149
which was statistically significant in three.143 145 149 One study
showed a non-significant decreased risk.142 Most studies
adjusted for smoking.142 143 145-149
Although no evidence for plausible mechanisms was found,
based on the epidemiological evidence, there is limited evi-
dence suggesting that butter is a cause of lung cancer.
There is a limited amount of inconsistent evidence
suggesting that consumption of butter is a cause of
lung cancer.
4.5.5.2  Foods containing animal fat
The evidence here refers to animal fats as foods, for instance,
lard, suet, or dripping, and not to estimated amounts con-
tained within other foods (such as meat and milk and their
products, or baked goods).
Colorectum
Five cohort studies investigated animal fats and colorectal
cancer.150-154 (Also see chapter 7.9.)
Three studies showed increased risk with increasing intake
of animal fats,150 151 153 which was statistically significant in
one,150 and statistically significant when comparing the sec-
ond highest intake to the lowest intake group, but not when
comparing the highest to lowest, in another study.151 One
study reported no effect on risk152 and another showed non-
significant increased risk in men and non-significant
decreased risk in women.154 Meta-analysis was possible on
three studies, giving a summary effect estimate of 1.13 (95%
CI 0.92–1.38) per 20 g/day, with moderate heterogeneity.150
152 154
Because of the abundant prospective data from cohort
studies, case-control studies were not summarised.
There is a limited amount of fairly consistent evidence
suggesting that consumption of foods containing
animal fat is a cause of colorectal cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort study155 has been published. This new information does
not change the Panel judgement (see box 3.8).
4.5.6  Comparison with previous report
The panel responsible for the previous report judged it pos-
sible that diets relatively high in total fat, and/or in satu-
rated/animal fat, were causes of cancers of the lung,
colorectum, breast, endometrium, and prostate. That panel
noted a pattern whereby diets relatively high in fat could
increase the risk of some cancers, and pointed out that fats
and oils are energy-dense, and agreed that energy-dense
diets increase the risk of obesity, itself a risk factor for some
cancers. 
The previous report judged that diets high in dietary cho-
lesterol were a possible cause of cancers of the lung and pan-
creas. The overall evidence now does not support an
association.
Since the mid-1990s, the results of cohort studies have
overall tended to weaken the evidence on fats and oils as
direct causes of cancer.
4.5.7 Conclusions
The Panel concludes:
Findings from cohort studies conducted since the mid-1990s
have made the overall evidence associating fats and oils with
the risk of any cancer somewhat less impressive. 
There is limited evidence suggesting that total fat is a
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cause of lung cancer or postmenopausal breast cancer; that
foods containing animal fat are a cause of colorectal cancer;
and that butter is a cause of lung cancer. The Panel stresses
that the main cause of lung cancer is smoking tobacco. 
Fats and oils are the most energy-dense constituents of
foods. For discussion of the effect of energy-dense foods on
weight gain, overweight, and obesity, and the role of weight
gain, overweight, and obesity in the risk of some cancers, see
Chapters 6, 7, and 8. 
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Sugars are sweeteners and, in some forms, also a
preservative and a bulking agent. Free sugars in the solid
state or as syrups are ingredients in many processed foods
and drinks. Nutritionally, sugars supply energy and
nothing else. Sugars added to food were a luxury until
sugar from cane became a major international cash crop,
beginning in the 16th century. Consumption of added
sugars, from beet as well as cane, and syrups increased
rapidly in industrialised countries in the 19th and 20th
centuries. High-fructose corn syrups are now also used
extensively. Overall consumption of sugars is increasing
worldwide, particularly in lower-income countries. In
recent decades, and in many countries, consumption of
added sugars, notably in the form of sugary drinks,
accounts for a substantial proportion of energy intake. 
Salt (sodium chloride) is also a preservative. The
sodium and chloride in salt are essential nutrients in small
amounts. In nature, foods are generally low or very low in
sodium. Like sugar, salt historically was scarce and a
precious commodity; the Romans paid their labourers in
salt, thus the word ‘salary’ (from ‘sal’ for salt).
Consumption of salt, in the form of many processed,
salted, and salty foods, or of salt added in cooking and at
table, remains variable. Consumption of salt, and salty and
salt-preserved foods, is high in some maritime nations
such as Japan, Portugal, and other Portuguese-speaking
countries. In inland regions, such as landlocked African
countries, consumption has been very low. 
Overall, the Panel judges that the evidence on salt 
is confined to stomach cancer, and that on sugars is
limited.
The Panel judges as follows: 
Salt is a probable cause of stomach cancer. Salt-preserved
foods are also a probable cause of stomach cancer. There
is limited evidence suggesting that sugars are a cause of
colorectal cancer. Within the remit of this Report, the
strongest evidence, corresponding to judgements of
‘convincing’ and ‘probable’, shows that salt, and also salt-
preserved foods, are probably causes of stomach cancer. 
‘Extrinsic’, mainly refined, sugars amount to a substantial
part of most industrialised food supplies. Sugars and syrups
manufactured from cane, beet, and corn are profitable cash
crops and are ingredients in many processed foods and
drinks. 
There is reason to believe that humans have evolved with
a built-in desire for sweet foods. It has also been proposed
that humans have a specific appetite for salt that might have
evolved because sodium is scarce in nature. In any case, as
sugars and salt become readily available and increasingly
cheap, consumption tends to rise. In industrialised settings,
sugars and salt are mostly consumed, not in food prepara-
tion or at the table, but as ingredients of processed foods. 
Reports concerned with undernutrition have often, and
still do, recommend substantial consumption of sugars and
fats; their energy density enables quick weight gain, and the
SUGARS AND SALT, AND THE RISK OF CANCER
In the judgement of the Panel, the factors listed below modify the risk of cancer. Judgements are graded according to the strength of the evidence.
DECREASES RISK INCREASES RISK
Exposure Cancer site Exposure Cancer site
Convincing
Probable Salt1 Stomach
Salted and salty foods Stomach
Limited — Foods containing sugars2 Colorectum
suggestive
Substantial 
effect on risk None identified
unlikely
1 ‘Salt’ here means total salt consumption, from processed foods, including salty and salted foods, and also salt added in cooking and at the table. 
2 ‘Sugars’ here means all ‘non-milk extrinsic’ sugars, including refined and other added sugars, honey, and as contained in fruit juices and syrups. 
It does not include sugars naturally present in whole foods such as fruits. It also does not include lactose as contained in animal or human milk. 
For an explanation of all the terms used in the matrix, please see chapter 3.5.1, the text of this section, and the glossary.
4.6 Sugars and salt
142
P A R T  2  •  E V I D E N C E  A N D  J U D G E M E N T S
taste preference promotes energy consumption. By contrast,
reports concerned with prevention of chronic diseases fre-
quently recommend restraint in consumption of sugars. One
reason for this is that sugars are the dietary cause of dental
caries. Sugars in the amounts typically consumed in many
industrialised countries have also been identified as a cause
of obesity, and therefore also indirectly of obesity-related dis-
ease. Reports concerned with nutritional deficiencies often
recommend the iodisation of salt supplies, to prevent goitre.
Reports concerned with the prevention of chronic diseases
frequently highlight that salt intakes are usually greatly in
excess of requirements, and recommend substantial decreas-
es in salt consumption to prevent hypertension and cardio-
vascular disease, especially stroke. 
For sugared drinks, see chapter 4.7. For the contribution
of sugar to weight gain, overweight, and obesity in drinks
or through energy density of foods, see Chapter 8. For salt-
ed animal products, including Cantonese-style salted fish, see
chapter 4.3. 
Non-caloric chemical sweeteners are included here.
4.6.1  Definitions, sources
4.6.1.1  Sugars
Sugars here means all sugars in the diet. These are mainly
but not only ‘extrinsic sugars’, which include sucrose (com-
monly called sugar), maltose, lactose, glucose, and fructose;
in foods and drinks, including juices and milk, and in honey
and syrups, including high-fructose corn syrup; refined sug-
ars added to food in processing, preparation (cooking), and
at the table. ‘Intrinsic’ sugars are those naturally present in
whole foods such as fruits. 
Sugars are now cheap and are used widely as sweeteners,
preservatives, and bulking agents. They also often have the
function of making processed starches, fats, and other ingre-
dients more palatable. Also see box 4.6.1
Sucrose is refined from sugar beet and sugar cane. Maltose
and glucose are refined predominantly from corn. High-fruc-
tose corn syrup comprises a mixture of glucose with fructose,
commonly in close to equal amounts, and is now used in
great quantity in food and drink manufacture, particularly in
the USA. 
The amount of sugars in manufactured foods and drinks
varies. Sugared drinks are about 10 per cent by weight added
sugars, and up to 100 per cent of their energy comes from
sugars. Sugars are often added to fruit juices. Jams and other
preserves are about 60 per cent sugars. Cakes, biscuits (cook-
ies), and other baked goods contain starches, fats, and sug-
ars in varying proportions. Most chocolate and much
confectionery are high in sugars. It is often supposed that
almost all added sugars are contained in obviously sweet
foods: this is not so. Breakfast cereals may contain anything
from negligible amounts to 50 per cent sugars. Yoghurts may
contain anything between 0 to 20 per cent sugars; and ready-
to-eat desserts even more. Many canned products include
added sugars. Savoury processed foods, such as soups, pick-
les, bread, and buns, often contain significant amounts of 
sugars.
4.6.1.2  Salt
The term ‘salt’, in common usage, refers to sodium chloride.
It is now a cheap commodity. Like sugar, salt is a preserva-
tive and a flavour enhancer. Both salt and sugar trap free
water from foods, thus preventing microbial proliferation
and spoilage. Salt is found in some rocks and dissolved in
seawater, and can be extracted from seawater by evapora-
tion. Both sodium and chloride are essential components of
the diet in small amounts. 
Usually most salt in diets is contained in processed foods,
with only a relatively small amount added in cooking or at
the table (box 4.6.2). Some traditional diets include sub-
stantial amounts of salt-preserved foods, including salted
meat, fish, vegetables, and sometimes also fruits; and also
salted foods such as bacon, sausages, and ham, which con-
tain from 3 to 5 g of salt per 100 g. Industrialised diets include
many processed foods that are not salt-preserved but con-
tribute substantial amounts of salt to the diet, even if they
do not seem salty, as well as more obviously salty foods such
as potato crisps (chips), salted nuts, and other salty snack
foods. Most of the sodium consumed in urban environments
comes from salt added to processed foods, and thus is beyond
the control of typical consumers. Many foods such as bread,
soups, breakfast cereals, and biscuits may contain substantial
amounts of salt; anything from 1 to 4 g per 100 g.
4.6.2  Composition
4.6.2.1  Sugars 
Sugars are simple carbohydrates, and provide 3.75 kilo-
calories per gram (see chapter 4.10.1). Sugars are single
molecules such as glucose, fructose, and galactose (mono-
saccharides), or two molecules bound together (disaccha-
rides) such as sucrose (fructose and glucose), lactose
(glucose and galactose), or maltose (two glucose molecules). 
The body metabolises different sugars at different rates;
for instance, fructose is absorbed and metabolised more
slowly than either glucose or sucrose. It is also slightly sweet-
er than glucose or sucrose, and thus is able to replace them
in lower total amounts. Non-caloric chemical sweeteners pro-
duce a sweet taste, but are not sugars (box 4.6.3). 
There is no dietary requirement for sugars. The World
As indicated in chapter 4.6.4, it is particularly difficult to mea-
sure and assess the overall effect of sugars as possible modifiers
of the risk of any disease, including cancer. This is partly because
of inconsistency in the classification of sugars. Sometimes ‘sugar’
is equated with sucrose, which has been the chief sugar in
human diets, but now is less so. Some studies investigate only
‘packet’ sugar purchased for use in the home; this is in general
a relatively small and diminishing proportion of total sugars con-
sumed. Other studies include sugars as found naturally in fruits
and milk.
Box 4.6.1 Sugar, sugars, sugary foods, 
and drinks 
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Health Organization recommends that average consumption
of sugars by populations should be less than 10 per cent of
total energy.1
4.6.2.2  Salt
Pure salt, as sodium chloride, contains no metabolisable
energy. Formulated, granulated table salts often include
additives, such as anti-caking agents, which prevent salt crys-
tals from sticking together; potassium iodide, included to
prevent iodine deficiency; traces of other sodium compounds
(carbonate or thiosulphate); and also sugar, to stabilise the
potassium iodide. Sea salt may be refined to almost pure
sodium chloride, or unrefined, in which case they may
include traces of other minerals, algae, and a few salt-toler-
ant bacteria. Salt may also be flavoured, for example with
celery or garlic. 
Sodium is essential for the body to function normally. It
is a major electrolyte in extracellular fluid. The body’s sodi-
um content and its concentration in body fluids are con-
trolled homeostatically to very precise limits; excess sodium
is excreted in the urine. Sodium is also involved in regula-
tion of osmolarity, acid-base balance, and the membrane
potential of cells. The daily requirement for sodium has been
estimated at around 500 mg for adults. On a pragmatic basis,
WHO recommends restricting average salt consumption for
populations to less than 5 g per day.1
4.6.3  Consumption patterns
4.6.3.1  Sugars 
Sugars supply on average around 8 per cent of dietary ener-
gy worldwide. This figure disguises a wide range of intakes
in different parts of the world. Diets in high-income coun-
tries contain roughly twice the amount of sugars as those in
lower-income countries. In North America and some
European countries, average consumption is around 15–17
per cent of dietary energy, with a fairly wide range around
this average. In the USA, in the last decades of the 20th cen-
tury, many processed foods were reformulated to contain less
fat but more sugars. In some parts of Asia, consumption is
negligible, although globally sugar supplies are increasing
rapidly. Children in high-income countries usually obtain a
higher proportion of their daily energy from sugar than
adults.11
Consumption of sugars has generally increased over the
last century, particularly in high-income countries, and also
more recently in many countries undergoing economic tran-
sition in Asia, Africa, the Middle East, and Latin America. 
4.6.3.2  Salt
The use of salt as a preservative has generally decreased as
industrial and domestic use of refrigeration has increased
(box 4.6.4). But diets containing few salt-preserved foods
may nevertheless be high in salt. 
The average adult daily intake of salt worldwide varies
from less than 6 g to 18 g. Very high levels of intake are
found in Japan, some parts of China, Korea, Portugal, Brazil,
and other Portuguese-speaking countries, where diets con-
tain substantial amounts of salt-preserved, salt-pickled, salt-
ed, or salty foods. The average adult intake is around 9–12
g per day in high-income countries, including Europe and
North America.
4.6.4  Interpretation of the evidence
4.6.4.1  General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7.
‘Relative risk’ (RR) is used in this Report to denote ratio
measures of effect, including ‘risk ratios’, ‘rate ratios’, ‘haz-
ard ratios’, and ‘odds ratios’.
4.6.4.2  Specific
Classification. Studies of sugars may be of total sugars; of
As indicated in chapter 4.6.4.2, it is difficult to measure salt
intake, or the contribution from separate sources (salty, salted,
or salt-preserved foods). The most reliable estimates come from
measuring the amount of sodium excreted in the urine. 
Salt is itself readily identified, although it is sometimes com-
bined in studies with other sodium compounds. Some studies
investigate only salt added in cooking or at the table, but this
is usually a small proportion of total salt consumption. Results
from such studies are liable to produce different results, com-
pared with those from studies that have examined total salt con-
sumption. 
It has been thought that any effect of salt on stomach can-
cer (see chapter 4.6.5.2) is principally the result of regular
consumption of salted and salt-preserved foods, rather than salt
as such. This is partly because such foods are a substantial part
of traditional Japanese and other Asian diets, where incidence
of stomach cancer has been and still is high. However, the inci-
dence of this cancer is also high in countries where traditional
diets contain substantial amounts of salty as distinct from salt-
preserved foods; and the concentration of salt in many
processed foods consumed in Europe and North America
approaches that of salt-preserved foods.
Box 4.6.2 Salt, and salty, salted, and
salt-preserved foods 
Chemical sweeteners such as saccharin, cyclamates, and aspar-
tame have been thought to be possible causes of cancer. This is
because some animal studies have shown that very high doses
of saccharin, in particular, increase the incidence of bladder can-
cer in rats. In common with many chemical additives, some sweet-
eners can be shown to be carcinogenic in experimental settings
in massive amounts, far greater than humans could consume in
foods and drinks. 
The evidence from epidemiological studies does not suggest
that chemical sweeteners have a detectable effect on the risk of
any cancer. 
Box 4.6.3 Chemical sweeteners
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sugars added at the table; of sugary foods and/or drinks; of
sucrose; or of added sugars generally; and may or may not
include those sugars naturally present in foods. Studies using
such varying classifications are difficult to compare.
Similarly, studies of salt may be of salt added in cooking
and/or at the table; of salty or salted foods; or of salt con-
sumption as a whole. These studies are also difficult to com-
pare. See box 4.6.1 and box 4.6.2. 
Measurement. Measurement of salt intake is notoriously dif-
ficult, and is best done by measuring the excretion of sodi-
um in urine over a 24-hour period. But this method has only
rarely been used.
Study design. See Classification. Also studies may under-
estimate the amounts of sugars and of salt in foods and
drinks consumed outside the home. 
Reporting bias. Added sugars are generally regarded as
unhealthy, and studies that depend on self-reporting may dis-
proportionately underestimate the consumption of sugars.
4.6.5  Evidence and judgements 
The full systematic literature review (SLR) is contained on
the CD included with this Report.
The relationship between the intake of sugars and the risk
of cancer is often adjusted for total energy intake, meaning
that sugars are assessed as a proportion of total dietary ener-
gy.12 Where this is the case, this has been stated.
4.6.5.1  Sugars 
Colorectum
One cohort study13 and 7 case-control studies14-20 investi-
gated sugars as foods and colorectal cancer. Seven cohort
studies21-27 and 16 case-control studies investigated sugars
as nutrients, defined as sucrose or fructose.
Sugars as foods
The single cohort study stated that there was no association
between usually adding sugar to cereals and colorectal
cancer.13
All seven case-control studies showed increased risk with
increased sugar intake,14-20 which was statistically significant
in two.17 18 The classification of ‘sugars as foods’ varied con-
siderably between studies.
Sugars as nutrients
Four cohort studies reported on total sugar intake.21 22 25 26 One
study reported a non-significant increased risk for the highest
intake group when compared to the lowest, with an effect esti-
mate of 1.03 (95% confidence interval (CI) 0.73–1.44).22 One
study reported a non-significant lower sugar intake in cases
than controls.21 Two cohort studies stated that there was no
association between sugar intake and risk.25 26
Three cohort studies reported on sucrose intake.23 24 27 Two
cohort studies showed non-significant increased risk when
comparing the highest intake group against the lowest.23 27
Effect estimates were 1.45 (95% CI 0.88–2.39)23 and 1.30
(95% CI 0.99–1.69) in men.27 One study reported a non-
statistically significant decreased risk (0.89 (95% CI
0.72–1.11) in women).27
Freezing and cooling by use of natural ice
and snow is a method of food preservation
traditionally available only in cold climates
or in winter in temperate climates. Natural
ice refrigeration on an industrial scale first
developed in the late 19th century, when
refrigerated containers used in trains,
ships, and then later trucks, greatly
increased the production and consumption
of red meat. Domestic freezing, chilling,
and refrigeration on a mass scale is a phe-
nomenon mostly of the second half of the
20th century. 
Today, much perishable food is sold
frozen or chilled. Together with the
growth of industrial refrigeration, domes-
tic refrigerators began to be used in the
USA, Australia, and New Zealand on any
scale in the 1920s, and in Europe and Japan
mostly since the 1950s. In Japan, for exam-
ple, households possessing refrigerators
increased from 9 per cent in 1960 to 91 per
cent in 1970, and 99 per cent in 2004.
Supermarkets with freezers, chill cabinets,
and domestic refrigerators are now com-
monplace in the cities and towns of tropi-
cal countries; poorer rural communities still
rely on drying, fermenting, salting, bot-
tling, tinning, and other methods of food
preservation, as well as their own gardens
and farms. It is unlikely that refrigeration
itself has any direct effect on the risk of
cancer. Its effects are indirect. 
Refrigeration: 
• Enables consumption of fresh perishable
foods including seasonal vegetables and
fruits all year round, as well as of fresh
meat. 
• Reduces microbial and fungal
contamination of perishable foods,
notably cereals (grains) and pulses
(legumes).
• Reduces the need for and use of salting,
smoking, curing, and pickling as
methods of preserving vegetables,
fruits, and meat. 
It can therefore be said that refrigeration
(including freezing and chilling) indirectly
influences risk of those cancers, the 
risk of which is affected by the above 
factors.
Evidence amounting to a judgement of
‘convincing’ or ‘probable’ for such factors
is summarised in earlier sections of this
chapter, and in Chapter 7, and relates to
cancers of the mouth, pharynx, larynx,
nasopharynx, oesophagus, lung, stomach,
pancreas, liver, and colorectum. 
In particular, many studies have noted a
reciprocal relationship between use of
refrigeration and consumption of salt and
foods preserved with salt. Meta-analysis of
eight case-control studies2-9 has shown a
significant association between the use of
refrigeration (usually as gauged by poss-
ession of a domestic refrigerator) and
reduced risk of stomach cancer. 
The one cohort study10 identified mea-
sured effects in the Netherlands over a 
25-year period, in which almost the entire
population had access to commercial and
domestic refrigeration, and did not find
any association. 
Box 4.6.4 Refrigeration
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Three cohort studies reported separate results for fruc-
tose23 24 27; one reported a significant increased risk in men
of 1.37 (95% CI 1.05–1.78).27 Two other studies reported
non-significant decreased risk.23 27
Because of the abundant prospective data from cohort
studies, case-control studies were not summarised.
In most, though not all, animal experiments, sucrose and
fructose are associated with increased colonic proliferation and
aberrant crypt foci. These sugars may interfere with levels of
blood glucose and/or triglycerides, either directly or through
hormones like insulin and others (also see Chapter 2).28
The evidence is hard to interpret. There is limited
evidence suggesting that sugar is a cause of colorectal
cancer. 
4.6.5.2  Salt 
Stomach 
Three cohort studies,10 29 30 21 case-control studies,2 4 31-48
and 12 ecological studies49-60 investigated total salt use and
stomach cancer. Two cohort studies10 61 and 13 case-control
studies4 9 39 43 62-71 investigated salt added at the table; 1
cohort study72 and 8 case-control studies4 39 73-78 investigat-
ed sodium intake.
Total salt use
Two cohort studies showed increased risk with increased salt
intake,10 30 which was statistically significant in one study in
men but not women.30 One study showed statistically sig-
nificant decreased risk.29 Meta-analysis was possible on two
cohort studies, giving a summary effect estimate of 1.08
(95% CI 1.00–1.17) per 1 g/day, with moderate hetero-
geneity (figure 4.6.1). The study that could not be included
was inconsistent with this summary, with an effect estimate
of 0.53 (95% CI 0.31–0.91) for the highest intake group
when compared to the lowest; however, this study did not
adjust for other factors.29 The two cohort studies that report-
ed increased risk used much more detailed questionnaires to
assess salt intake (150 compared to 27 items). They also
adjusted for a greater number of confounders than the study
that reported decreased risk.
Twelve of the case-control studies showed increased risk
with increased salt intake,2 32 34 35 39 40 42-46 which was statis-
tically significant in six.32 40 42-45 None of the studies showed
statistically significant decreased risk. Most other studies
reported either risk estimates close to 1.0 or reported that
there was no statistical association. Meta-analysis was pos-
sible on eight case-control studies, giving a summary effect
estimate of 1.01 (95% CI 0.99–1.04) per 1 g/day, with high
heterogeneity (figure 4.6.1).
A dose-response relationship was apparent from cohort but
not case-control data.
Seven ecological studies reported increased risk with
increased salt intake,49 52-55 57 58 which was statistically sig-
nificant in four.53 54 57 58 The remaining five studies reported
either a decreased risk with increased salt intake50 56 59 60 or
no association,51 none of which was statistically significant.
Stomach cancer rates are highest in those areas of the world,
such as parts of Asia and Latin America, where diets are tra-
ditionally salty due to the regular consumption of meat, fish,
vegetables, and other foods preserved by salting, as well as
of salty foods.
Salt added at the table
Both cohort studies reported that there was no significant
effect, and estimates were close to one (1.0) (95% CI
0.6–1.6)61 and 0.9 (95% CI 0.56–1.44).10
Twelve case-control studies showed increased risk for the
highest intake group when compared to the lowest,4 9 39 43 62-
64 66-71 which was statistically significant in eight.4 9 43 62-64 67
One other study reported similar intakes in cases and
control.65
Sodium
The single cohort study showed a non-significant decreased
risk.72
Six case-control studies showed increased risk for the high-
est intake group when compared to the lowest,39 73-77 which
was statistically significant in three.39 74 77 Two studies
showed decreased risk, which was statistically significant in
both.4 78 Meta-analysis was possible on five studies, giving
a summary effect estimate of 1.18 (95% CI 1.02–1.38) per
1 g/day, with high heterogeneity.39 74-76 78
Interaction with Helicobacter pylori infection
Two case-control studies that investigated total salt use also
investigated the potential for interaction with H pylori infec-
tion (also see box 7.5.1).79 80 One study was suggestive of a
multiplicative effect on risk for high salt use and H pylori pos-
itive status79; the other stated that there was no association.80
Salt intake may be inversely related to the availability of
refrigeration both within and between populations. Salt-
Figure 4.6.1 Total salt use and stomach cancer; cohort
and case-control studies
Cohort
Van de brandt 2003 1.07 (0.97–1.18)
Tsugane 2004 Men 1.14 (1.08–1.21)
Tsugane 2004 Women 1.01 (0.92–1.11)
Summary estimate 1.08 (1.00–1.17)
Case control
You 1988 1.00 (0.99–1.01)
Nazario 1993 1.17 (1.08–1.27)
Ramon 1993 1.36 (1.01–1.82)
Ye 1998 1.03 (0.99–1.07)
Setiawan 2000 1.02 (0.99–1.04)
Munoz 2001 0.96 (0.93–1.00)
Tsukino 2004 0.98 (0.88–1.10)
Setiawan 2005 1.00 (0.86–1.16)
Setiawan 2005 0.96 (0.99–1.04)
Summary estimate 1.01 (0.99–1.04)
 Relative risk (95% CI)
Relative risk, per g/day
1 20.5 0.75 1.5
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preserved foods may be eaten more by those to whom
refrigeration is not available.
There is evidence from laboratory experiments that high
salt intake damages the lining of the stomach.81 It has also
been shown to increase endogenous N-nitroso compound
formation.82 In addition, a high salt diet has been shown to
have a synergistic interaction with gastric carcinogens.82 It
may only contribute to gastric cancer in subjects who have
H pylori infections and are also exposed to a chemical
carcinogen. 
There is a substantial amount of evidence from studies
on total salt use, salt added at the table, and sodium
intake. For total salt use, a dose-response relationship
was apparent from cohort but not case-control studies.
For sodium intake, a dose-response was also apparent
from case-control studies. The mechanistic evidence is
strong. Salt is a probable cause of stomach cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort83 and two case-control studies84 85 have been published.
This new information does not change the Panel judgement (see
box 3.8).
4.6.5.2.1 Salted and salty foods
Stomach 
Four cohort studies86-89, 17 case-control studies4 6-8 33 41 45 90-
99 and 1 ecological study100 investigated salted or salty foods
and stomach cancer.
Three cohort studies showed non-significant increased 
risk with increased salt intake.86 88 89 One study reported 
that there was no association.87 Meta-analysis was possible
on three cohort studies, giving a summary effect estimate 
of 1.32 (95% CI 0.90–1.95) per one serving/day with 
no heterogeneity (figure 4.6.2).
Eleven case-control studies showed increased risk for the
highest intake groups when compared to the lowest,6-8 41 45
91 94-98 which was statistically significant in seven.6-8 45 94-96
Two studies showed non-significant decreased risk.4 99 Four
studies reported either the same intakes in cases and con-
trols or no statistical association.33 90 92 93 Meta-analysis was
possible on four case-control studies, giving a summary effect
estimate of 5.2 (95% CI 2.49–10.83) per one serving/day,
with high heterogeneity (figure 4.6.2).
A dose-response relationship is apparent from case-control,
but not cohort data (figure 4.6.3).
Heterogeneity may be partly explained by variation
between studies in the precise foods being assessed.
The single ecological study showed non-significant
decreased risk in areas of increased salt consumption.100
The mechanisms through which salt could plausibly cause
stomach cancer are given above.
The evidence from both case-control and cohort
studies is consistent. A dose-response relationship is
apparent from case-control but not cohort studies.
There is robust evidence for mechanisms operating in
humans. Salted and salty foods are a probable cause of
stomach cancer.
Figure 4.6.3 Salted/salty foods and stomach cancer; cohort
and case-control studies: dose response
Cohort
Galanis 1998
Ngoan 2002
Khan 2004 Men
Khan 2994 Women
Case control
Demirer 1990
Hirayama 1992 Men
Hirayama 1992 Women
Ward 1999
Sriamporn 2002
0 10.6 1.40.2 0.4 0.8 1.2
Salted/salty foods (serving/day)
Figure 4.6.2 Salty/salted foods and stomach cancer;
cohort and case-control studies
Cohort
Galaris 1998 1.14 (0.61–2.13)
Ngoan 2002 1.21 (0.68–2.16)
Khan 2004 Men 1.76 (0.58–5.32)
Khan 2004 Woman 6.01 (0.85–42.61)
Summary estimate 1.32 (0.90–1.95)
Case control
Demirer 1990 116.86 (13.16–1037.90)
Hirayama 1992 Men 2.85 (2.13–3.81)
Hirayama 1992 Women 3.53 (2.34–5.34)
Ward 1999 113.13 (3.76–3403.01)
Sriamporn 2002 3.98 (0.65–24.22)
Summary estimate 5.20 (2.49–10.83)
Relative risk (95% CI)
Relative risk, per serving/day
1 20.5 6
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The Panel is aware that since the conclusion of the SLR, two
case-control studies84 85 have been published. This new infor-
mation does not change the Panel judgement (see box 3.8).
4.6.6  Comparison with previous report
The judgement of the previous report on sugars and col-
orectal cancer was in effect similar to that in this Report. 
The previous report judged that salt and also salting are
probable causes of stomach cancer. This judgement is also
much the same as that in this Report. 
4.6.7  Conclusions
The Panel concludes:
Salt is a probable cause of stomach cancer. Salted and salty
foods are also a probable cause of stomach cancer. There is
limited evidence suggesting that sugars are a cause of col-
orectal cancer. 
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Water is essential. Without water, people die in a matter of
days. As well as adequate supplies of water, a major public
health issue throughout the world is the safety of domestic
and other water. Water quality may be compromised by
chemical or microbiological contamination.
Fruit juices made from fruits or fruit pulps are often
concentrated for storage and transport, then diluted with
water to produce the final product. Sugar and other
ingredients are frequently added in this final
reconstitution process. Soft drinks are usually made from
water, sugar, colourings, flavourings, and mixtures of
herbs and other ingredients, to give a distinctive taste and
character. Consumption of branded, carbonated soft
drinks, and cola drinks in particular, has increased greatly
in the 20th century, and continues to increase throughout
the world. The rise is most marked in lower income
groups.
Tea and coffee are now the main hot drinks consumed
worldwide. Both contain stimulants and other bioactive
constituents, and many people add milk and sugar. A great
variety of herbal infusions are also drunk, including maté,
the traditional hot drink in parts of South America. 
Overall, the Panel judges that the direct evidence relating
non-alcoholic drinks to cancer is contamination of water
supplies with inorganic arsenic and irritation of the oral
cavity by maté, and possibly by other very high-
temperature drinks. For evidence relating sugared soft
drinks to body fatness, see Chapter 8.
The Panel judges as follows:
The evidence that inorganic arsenic in drinking water is a
cause of lung cancer is convincing. Water contaminated in
this way is probably a cause of skin cancer. Arsenic and
arsenic compounds are recognised carcinogens. There is
limited evidence suggesting that water contaminated in
this way is a cause of cancers of the kidney and bladder.
Maté, a herbal infusion, as drunk traditionally in parts
of Latin America, is probably a cause of oesophageal
cancer. Damage caused by the very high temperature of
the drink, rather than by the herb itself, is judged to be
responsible. There is limited evidence suggesting that
maté is a cause of cancers of the mouth, pharynx, and
larynx, for the same reason. There is also limited evidence
suggesting that high-temperature drinks are a cause of
oesophageal cancer.
It is unlikely that coffee has any substantial effect on the
risk of cancer either of the pancreas or of the kidney.
Within the remit of this Report, the strongest evidence,
corresponding to judgements of ‘convincing’ or ‘probable’,
shows that inorganic arsenic in drinking water is a cause
WATER, FRUIT JUICES, SOFT DRINKS, HOT DRINKS, AND THE RISK OF CANCER
In the judgement of the Panel, the factors listed below modify the risk of cancer. Judgements are graded according to the strength of the evidence.
DECREASES RISK INCREASES RISK
Exposure Cancer site Exposure Cancer site
Convincing Arsenic in drinking water1 Lung 
Probable Arsenic in drinking water1 Skin
Maté2 Oesophagus  
Limited — Arsenic in drinking water1 Kidney
suggestive Bladder
Maté2 Mouth, pharynx, larynx
High-temperature drinks Oesophagus  
Substantial
effect on risk Coffee: pancreas; kidney
unlikely
1 The International Agency for Research on Cancer has graded arsenic and arsenic compounds as class 1 carcinogens. The grading for this entry applies specifically to
inorganic arsenic in drinking water.
2 As drunk traditionally in parts of South America, scalding hot through a metal straw. Any increased risk of cancer is judged to be caused by epithelial damage
resulting from the heat, and not by the herb itself. 
For an explanation of all the terms used in the matrix, please see chapter 3.5.1, the text of this section, and the glossary.
4.7  Water, fruit juices and other soft
drinks, and hot drinks
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of lung cancer and probably a cause of skin cancer. Maté is
probably a cause of oesophageal cancer. It is unlikely that
coffee has any substantial effect on the risk of either
cancer of the pancreas or of the kidney. 
Chapter 4.7 concerns all non-alcoholic drinks. 
Water, including that contained in drinks and foods, is an
invariable part of all diets. Bottled spring and mineral waters
are consumed by people who can afford them. Juices made
from fruits and water, often sweetened (at first with honey
and then sugar), have been drunk throughout history.
Cordials, squashes, and other drinks made mainly from
colourings and flavourings, with some fruit juices, herbs, or
other ingredients added, started to become popular from the
beginning of the 19th century. Carbonated sweet drinks
(sometimes known as sodas) such as cola were first mass-
manufactured in the USA and are now commonly consumed
throughout the world. 
Tea was cultivated and drunk in China for over a thousand
years. Then, from the 18th century, it became commonly
drunk in Britain, and was cultivated in India and other coun-
tries, and drunk in other parts of the world. The original teas
were green and drunk without adding milk or sugar.
Manufacture of black teas came later; from the 19th centu-
ry, teas became the main hot stimulant drink in Britain,
almost always drunk with milk and often with sugar added.
Coffee was cultivated in and exported to many parts of the
world from the 19th century; it remains the main cash crop
in a number of tropical countries such as Ethiopia and Brazil.
Coffee is the main hot stimulant drink in the Americas, many
European countries, and also in the Arab world. In some
parts of the world, coffee is usually drunk black, with or
without sugar; in other countries, milk or cream is often
added. Chocolate is also consumed as a beverage.
Reports concerned with infectious diseases, especially of
childhood, usually emphasise the importance of safe water
supplies. Reports concerned with the prevention of chronic
diseases sometimes specify sugared soft drinks as contribu-
tors to overweight and obesity. They occasionally recom-
mend substantial consumption of water as healthy in itself
and preferable to soft or alcoholic drinks. 
Contaminants of water, and also of foods and other drinks,
are grouped here with water. High-temperature foods are
grouped here with high-temperature drinks. 
For the relationship between sugared drinks and body fat-
ness, see Chapter 8. 
4.7.1  Definitions, sources
4.7.1.1  Water
Water comes from rain, underground aquifers accessed by
wells, springs, and freshwater lakes and rivers. 
People cannot live without water, which is vital for the nor-
mal functioning of the body. Even mild dehydration (water
loss of 1–2 per cent of the body weight) can produce symp-
toms such as dry mouth and headaches. Stopping all fluid
intake may cause death in days, the number depending on
the health of the individual and external conditions such as
temperature and humidity. 
Water can be used as a vehicle to provide fluoride and can
contribute to intakes of essential elements, calcium, iron,
and copper, depending on its origin and the piping materi-
als used.
The water content of the body is around 70 per cent: men’s
bodies contain a higher proportion of water than those of
women because women have more body fat, which has min-
imal amounts of water. Adults produce an average of around
1.5 litres of urine each day and lose an additional litre of
water through breathing, from the skin by evaporation or
sweating, and in the faeces. Approximately 80 per cent of
water intake comes from drinks; food provides the other 20
per cent.
Tap water quality is regulated in most countries based on
World Health Organization guidelines for drinking water
that includes tap water and bottled water.1
Around the world, ground, rain, and river waters are also
drunk, often without first being treated to secure safety. More
than 1 billion people (around 15 per cent of the world’s pop-
ulation) lack access to safe, clean water2 and are at risk of
exposure to water-borne contaminants and infectious dis-
eases. Arsenic, the bacterium Helicobacter pylori, and para-
sitic schistosomes are among the many contaminants that
may be found in water supplies. In many low-income coun-
tries, access to clean water is limited for the low-income
segments of the populations and those living in rural areas.
4.7.1.2  Fruit juices
Fruit juices include liquids extracted from whole or pulped
fruits. Commercially prepared fruit juices may be pasteurised
to extend shelf-life, and concentrated at source to be recon-
stituted before packaging, closer to the point of sale.
4.7.1.3  Soft drinks
The term ‘soft drinks’ is used for a wide range of coloured
and flavoured non-alcoholic drinks, usually sold in cans, car-
tons, or bottles. They may be carbonated (such as cola drinks
or lemonade) or still (such as fruit squashes). Some soft
drinks are milk-based (milkshakes and yoghurt drinks).
Depending on the ingredients, some soft drinks may be mar-
keted with health claims, and are sometimes known as ‘func-
tional drinks’ (also see box 4.10.2).
4.7.1.4  Hot drinks
The most common hot drinks currently consumed are tea
and coffee. These are infusions (brewed using boiling water)
usually drunk hot, sometimes very hot (box 4.7.1). Coffee
is made from ground, roasted coffee beans — the dried seeds
of coffee plant berries. The beans naturally contain caffeine.
Decaffeinated coffees are produced by various processes,
using water, organic solvents, steam, or by interfering with
the expression of the gene coding for caffeine. Instant cof-
fee comprises the soluble solids derived from dried, double-
brewed coffee. Coffee is a large bush native to Ethiopia,
cultivated in many hot and humid climates. The main cof-
fee-exporting countries are Brazil, Vietnam, and Colombia. 
Although many herbal infusions are known as teas, tea is
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specifically the infusion of the dried leaves of the plant
Camellia sinensis. Green tea is made from leaves that have
first been cooked, pressed, and dried. To produce black tea,
the fresh leaves are withered, rolled repeatedly, allowed to
turn deep brown, and then air-dried until they are dark in
colour. Tea leaves contain caffeine and theophylline.
Decaffeinated teas are produced using similar processes to
those used for coffee. Most tea is grown in Asia. 
Maté is a type of herbal tea prepared from the dried leaves
of the plant Ilex paraguariensis that has stimulant properties
similar to the other methylxanthine-containing drinks (cof-
fee and tea).
Herbal and other teas are also consumed cold. Iced teas
are popular in the USA and some other countries: these are
sugared and considered here as soft drinks.
4.7.2  Composition 
4.7.2.1  Water
Water is a molecule comprising hydrogen and oxygen: chem-
ically, H2O. Rainwater may contain traces of air pollutants;
water from underground aquifers may contain traces of min-
erals from surrounding rocks and other surfaces. Ground
water may also be contaminated with natural minerals as
well as with various industrial and agricultural chemicals,
some of which are carcinogenic in laboratory conditions (box
4.7.2). Mineral water from springs and other sources con-
tains higher trace amounts of various minerals and other
substances, often detectable to taste. Some spring water is
naturally carbonated. Bottled water is either still or car-
bonated, sometimes artificially. The safety of water in terms
of chemical and microbial contamination is well regulated
by the WHO programme on chemical safety, but unfortu-
nately, monitoring and surveillance in most countries are
limited.
Arsenic residues can arise from agricultural, mining, and
industrial practices, or may occur naturally from volcanic
activity. WHO guidelines recommend that levels of arsenic
in drinking water should not exceed 10 µg/l.4 Levels of
arsenic in affected areas may range from tens to hundreds,
or even thousands, of micrograms per litre. In unaffected
areas, levels are typically less than 10 µg/l. Inorganic arsenic
(arsenate or arsenite) is the form that predominantly cont-
aminates drinking water.
Arsenic is classified as a human carcinogen by the
International Agency for Research on Cancer. Drinking water
contaminated with arsenic is also classed separately as a
human carcinogen.5
The bacterium H pylori is found in water supplies conta-
minated with faeces. It is an established necessary cause of
distal stomach cancer (see box 7.5.1).
Chronic schistosomiasis (infestation with schistosomes) is
a known cause of bladder and liver cancer (see chapters
7.16 and 7.8).6 It is caused by contact with water contam-
inated by parasite eggs. 
Constant mechanical irritation of epithelial surfaces causes
inflammation, which predisposes to the development of cancer
(see Chapter 2). It has also been suggested that foods and drinks
with chemically irritant components may be a cause of cancers
of those sites with which they come into direct contact. Again,
there is not much evidence for this theory, with the possible
exception of chilli and stomach cancer (see chapter 4.2). 
There is, however, some evidence that some thermally hot
(and therefore irritant) drinks are a cause of cancers of those
sites with which they come into direct contact. As shown in this
section, maté, the herbal infusion, is probably a cause of cancer
of the oesophagus, and there is limited evidence suggesting that
it is also a cause of other cancers of the oral cavity. This is prob-
ably not because of any carcinogen in the herb itself, but
because of the way the infusion is traditionally drunk in the
pampas region within the southern cone of Latin America, in
northern Argentina, Paraguay, and southern Brazil. It is drunk
extremely hot from a gourd through a metal straw, which is
often kept rested in the mouth, rather like the stem of a tobac-
co pipe.3 There is no substantive evidence that maté prepared
in the style of tea, loose or in sachets (bags), affects the risk of
cancer. 
There is also limited evidence suggesting that various other
very hot drinks and foods are a cause of cancer of the oesoph-
agus when they are consumed regularly. The implications of this
evidence, while so far not strong, suggest that more research
may be warranted (see chapter 4.7.5.6). 
Box 4.7.1 High-temperature, and irritant
drinks and foods
Water contaminants that are causes of cancer are inorganic
arsenic (reviewed here) and Helicobacter pylori and schistosomes
(see Chapter 7). 
Many other contaminants of water are identified as or have
been thought to be carcinogenic, usually as a result of animal
and other experiments, or else as a result of industrial accidents
or gross overuse. These include herbicides and pesticides, fer-
tilisers that contain and release nitrates, and disinfectants that
also produce potentially toxic contaminants such as chlorinat-
ed and brominated organic compounds. They also include chem-
icals deliberately added to drinking water as public health
measures, notably chlorine and fluoride. 
These and other industrial, agricultural, and other chemicals
are the subject of tests and regulations for toxicity and safety
in use. Nevertheless, they are often popularly believed to be sig-
nificant causes of cancer. This subject is controversial and is like-
ly to remain so. 
Currently there is no substantial epidemiological evidence
that any of these substances, singly or in combination, as cur-
rently regulated and usually consumed in water, or in foods and
other drinks, has any significant effect on the risk of any can-
cer. The Panel considers that the evidence is insufficient to con-
clude that usual intakes of industrial, agricultural, and other
chemicals have an effect on the risk of human cancer. Toxicity
and carcinogenicity of pollutants as a result of industrial acci-
dents or overuse are outside the scope of this Report.
Box 4.7.2 Contamination of water, and of
foods and other drinks
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4.7.2.2  Fruit juices
Bottled or canned or otherwise packaged fruit juices are
made from the fruits they contain or from fruit pulp. As well
as added water, they usually also contain some added sug-
ars, preservatives, and other additives. They often contain
trivial amounts of dietary fibre. Fruit and vegetable juices
have different nutritional properties from whole fruits and
vegetables. For these reasons, the international ‘at least five
a day’ campaign to encourage people to eat more fruits and
vegetables (at least five portions per day) recommends that
juices only count as one portion per day, irrespective of the
amount consumed.
4.7.2.3  Soft drinks 
Soft drinks are made from water, colourings, flavourings, and
herbal or other ingredients. They may or may not contain
fruit juice. They also contain either sugars or, in ‘diet’ form,
chemical sweeteners (see chapter 4.6 and box 4.6.3). They
may or may not be carbonated. The original formulations of
cola drinks contained stimulants from the coca and cola
plants. Soft drinks may also include yoghurt and other milk
derivatives, as yoghurt drinks or fruit ‘smoothies’, and also
added vitamins and minerals. ‘Sports’ drinks contain sugars,
electrolytes, and other additives. 
4.7.2.4  Hot drinks
The main hot drinks are tea (usually black tea but also green
tea, which is often preferred in China) and coffee. Both con-
tain various antioxidants and phenolic compounds, some of
which have been shown to have anti-cancer properties in lab-
oratory conditions.7 They both also contain caffeine (and the
related compound theophylline in tea). There is more caffeine
in tea leaves than in coffee beans, but brewed coffee contains
more caffeine than brewed tea. Caffeine and theophylline are
bioactive, quickening reaction times, relieving fatigue, and
stimulating the cardiovascular and central nervous systems.
Tea and coffee, when drunk without adding milk, cream,
sugar, lemon, or honey, contain no energy and trivial
amounts of some micronutrients; the bioactive chemicals
they contain are mentioned above. When these drinks are
consumed frequently, both may be substantial dietary
sources of some of these bioactive constituents. Thus, coffee
is a major source of some antioxidants in the US diet.8
4.7.3  Consumption patterns
4.7.3.1  Water
Environmental conditions, health, activity levels, and other
factors determine the amount of water needed, but there is
no international recommendation for daily consumption.
The Institute of Medicine in the USA recommends 2.7 litres
per day total water for women and 3.7 litres for men. The
UK’s Food Standards Agency estimates that most people 
need to drink at least 1.2 litres of fluids per day. More 
than half of the world’s population has access to drinking
water through taps in their homes or outside. Tap 
water should be regulated to meet international quality
guidelines, such as those prepared by WHO.9
Most people who do not have access to clean drinking
water live in Asia, sub-Saharan Africa, and some parts of
Latin America. High concentrations of arsenic in drinking
water have been found in areas of Bangladesh, China, and
West Bengal (India), and also in more localised areas of
Argentina, Australia, Chile, Mexico, Taiwan, China, the USA,
and Vietnam. In many of these regions, the drinking water
source is groundwater naturally contaminated by arsenic-
rich geological formations.10
4.7.3.2  Fruit juices
There is little information on the general or local consump-
tion of fruit juices. 
4.7.3.3  Soft drinks
In 2004, global consumption of soft drinks was estimated at
480 000 million litres (including bottled water),11 of which
cola and other carbonated drinks accounted for 40 per cent.
In terms of sales, carbonated drinks are the largest single cat-
egory. World sales of cola drinks continue to rise, as do more
recently, sales of bottled waters, fruit juices, and ‘function-
al drinks’. The USA is the biggest per capita consumer of soft
drinks, followed by Mexico and Chile. The USA alone
accounts for more than a 20 per cent share of the global
total. Asia is the fastest growing market for soft drinks: sales
are increasing at around 3.5 per cent each year.
Average consumption of soft drinks in the USA is around
a 12-ounce can (about 350 ml) per person/day. Older chil-
dren consume about this amount, and sometimes more. Most
of these drinks are sugared. At this level, soft drinks con-
tribute a substantial proportion of total sugars intake. 
4.7.3.4  Hot drinks
After water, tea and coffee are the most commonly con-
sumed drinks in the world. There are various different meth-
ods of preparing these hot drinks depending on culture and
personal preference. Coffee consumption is high in northern
Europe and North America. Low-income countries export
most of the world’s coffee; high-income countries consume
approximately seven times as much (per capita) as low-
income countries. 
Average worldwide consumption of tea is around 0.5 kg
per person/year; this is exceeded significantly in several
Asian countries (notably, China, India, and Japan), and in
the UK and Ireland. Worldwide, black tea is the most popu-
lar type, although green tea is more commonly drunk in Asia.
Maté, as traditionally prepared, is drunk almost exclusively
in parts of South America. 
4.7.4  Interpretation of the evidence
4.7.4.1  General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7. 
‘Relative risk’ (RR) is used in this Report to denote ratio
measures of effect, including ‘risk ratios’, ‘rate ratios’, ‘hazard
ratios’, and ‘odds ratios’.
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4.7.4.2  Specific
Classification. Different types of tea, coffee, and soft drinks
are consumed in different cultures. The ways in which tea
and coffee are prepared and drunk also vary. For coffee, this
includes the degree of roasting, the methods of brewing
(which determine the strength and composition), and the
different substances added. Similarly, tea may be consumed
with or without milk and in different strengths. Associations
seen in one population but not another may reflect some
aspect of the drink as consumed in that population rather
than the drinks themselves. In some studies, fruit juices and
bottled waters are included in the definition of soft drinks. 
Measurement. Fluid intake is best estimated from urine
collection, but this is rarely done. Instead, estimates are
usually made from food frequency questionnaires. 
Confounding. In interpreting the results of epidemiological
studies of all types of drink, confounding by other habits
should be considered. For example, heavy consumers of soft
drinks, tea, or coffee may also be smokers and drinkers of
alcohol. 
People who are physically active often consume more liq-
uid than those who are not. Physical activity is therefore a con-
founder of the relationship between the volume of fluid drunk
and cancer risk, but may not be adequately adjusted for.
Reporting bias. Soft and cola drinks are often identified as
unhealthy, and studies that depend on self-reporting may
disproportionately underestimate consumption. 
4.7.5  Evidence and judgements
The full systematic literature review (SLR) is contained on
the CD included with this Report. 
4.7.5.1 Water  
The evidence was too sparse or inconsistent to draw any con-
clusion about the relationship between water quantity and
cancer risk.
4.7.5.1.1  Water-borne contaminants: arsenic
Ecological studies based on known arsenic concentrations in
water may be interpreted more robustly than for many other
dietary exposures.
Lung 
Two cohort studies,12-17 2 case-control studies18 19 and 12
ecological studies20-30 investigated arsenic in drinking water
and lung cancer.
Both cohort studies showed statistically significant
increased risk of lung cancer for the highest intake group
compared to the lowest.12-17 Although meta-analysis was not
possible, both studies reported that a dose-response rela-
tionship was apparent. One study (in Taiwan) based in a
population with endemic black foot disease, a manifestation
of arsenicosis, reported an effect estimate of 3.29 (95% con-
fidence interval (CI) 1.60–6.78) for average arsenic level in
well water.13 The other study reported a quantified effect
estimate, which was 3.66 (95% CI 1.81–7.03), but this study
(based in Japan) did not adjust for smoking.17
Both case-control studies showed increased risk of lung
cancer for the highest intake group compared to the lowest,18
19 which was statistically significant in one.19 The other study
did not report confidence intervals. Effect estimates were
3.0118 and 8.9 (95% CI 4.0–19.6).19
Ecological studies were made in populations from
Argentina,27 Belgium,21 Chile,29 China,23 Switzerland,20 and
Taiwan,22-26 30 as well as worldwide.28 Eight studies showed
increased risk of lung cancer with increasing levels of arsenic
in drinking water,21-25 27 29 30 which was statistically signifi-
cant in four.24 27 29 30 Two studies showed decreased risk,20 26
which was statistically significant in one.26 One study report-
ed different inconsistent results for men and women (corre-
lation coefficients of -0.51 for men and 0.07 for women).28
One study showed that measures to lower arsenic levels in
drinking water by using tap water rather than well water
were associated with a fall in lung cancer rates in a region
of Taiwan with endemic black foot disease.25
The general mechanisms through which arsenic could
plausibly cause cancer are outlined below. In addition, sol-
uble arsenic in drinking water induces lung cancers in ani-
mal models and causes chronic lung disease.5
The evidence is ample and consistent, both from
cohort and case-control as well as ecological studies.
There is a dose-response relationship and the effect
size is relatively large. There is robust evidence for
mechanisms. The evidence that arsenic is a cause of
lung cancer is convincing.
Skin 
Two cohort studies,31 32 5 case-control studies,33-37 1 cross-
sectional study,38 and 11 ecological studies20 22 24 27 29 30 39-43
investigated arsenic in drinking water and skin cancer.
Both cohort studies showed non-significant increased risk
with increasing levels of arsenic in the water31 32; however,
for one study the increased risk was apparent in women but
not in men.32 Effect estimates were 1.82 (95% CI 0.5–4.66)
for women and 0.83 (95% CI 0.17–2.43) for men in Utah,32
and 1.21 (95% CI 1.00–1.47) per 100 µg/l.31
Two case-control studies measured arsenic levels in toe-
and fingernails.36 37 Such measures are less subject to error
and bias than some other methods to assess actual exposure
to a carcinogen. One study reported a significant increased
risk for melanoma with a risk estimate of 1.65 (95% CI
1.27–2.14) per 100 ng/g36; the other study reported non-sig-
nificant increased risk 1.02 (95% CI 0.90–1.17) per 100 ng/g
for basal cell carcinoma and 1.12 (95% CI 0.95–1.32) for
squamous cell carcinoma.37
Two case-control studies that reported on dietary arsenic
showed increased risk with increased intake,33 35 which was
statistically significant in one.33 One study reported a non-
significant decreased risk.34
The cross-sectional study showed a statistically significant
increased risk, with a partially adjusted effect estimate of
5.04 (95% CI 1.07–23.8) for > 0.71 versus 0 parts per mil-
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lion average arsenic content in water.38
All 11 ecological studies reported increased risk for skin
cancer with increased arsenic exposure,20 22 24 27 29 30 39-43
which was statistically significant in 4,24 29 30 40 41 and statis-
tically significant in women but not in men in 127; and sig-
nificant in men but not women in another study.20 The effect
increased with age (cumulative exposure), where that was
measured, and the reported effect estimates were usually
large, more than half being greater than 2.5. 
The general mechanisms through which arsenic could
plausibly cause cancer are outlined below. 
The evidence is consistent, from cohort, case-control
and ecological studies. There is robust mechanistic
evidence. Arsenic is a probable cause of skin cancer.
Kidney 
Three cohort studies,32 44 45 one time-series study,46 and nine
ecological studies20 22 24 27 29 30 40 47 48 investigated arsenic in
drinking water and kidney cancer.
All three cohort studies showed increased risk for the high-
est intake levels compared to the lowest,32 44 45 which was
statistically significant in one.45 Effect estimates were 1.49
(95% CI 0.67–3.31; adjusted for smoking),44 2.82 (95% CI
1.29–5.36),45 and 1.13 (women; confidence intervals not
reported) and 1.43 (men; confidence intervals not report-
ed).32
The single time-series study reported a statistically signif-
icant decreased risk in kidney cancer following the installa-
tion of a tap water supply system in an arsenic-endemic area
of Taiwan.46
All nine ecological studies showed increased risk with
higher levels of arsenic in drinking water,20 22 24 27 29 30 40 47 48
which was statistically significant in six.24 27 30 40 48
The general mechanisms through which arsenic could
plausibly cause cancer are outlined below. In addition,
arsenic in drinking water is well absorbed in the gastro-
intestinal tract, and both inorganic arsenic and its methyl-
ated metabolites are excreted in urine.49 Arsenic can modify
the urinary excretion of porphyrins in animals and humans.50
The evidence is sparse. There is limited evidence
suggesting that arsenic is a cause of kidney cancer.
Bladder 
Six cohort studies,14 17 32 44 45 51 1 time-series study,52 7 case-
control studies,18 53-60 and 11 ecological studies20 22 24 29 30 40
47 48 61-64 investigated arsenic in drinking water and bladder
cancer.
Four cohort studies showed increased risk for the highest
intake levels compared to the lowest,14 17 44 45 which was sta-
tistically significant in two.17 45 One study showed non-sig-
nificant decreased risk.32 The single cohort study that
measured arsenic levels in finger- or toenails reported an
effect estimate of 1.05 (95% CI 0.85–1.29) per 100 ng/g.51
Three case-control studies showed increased risk for the
highest intake levels compared to the lowest,18 56-59 which
was statistically significant in one.18 Two studies showed
non-significant decreased risk,53 55 two studies showed no
effect on risk,54 60 including the single case-control study that
measured arsenic levels in finger- or toenails.60
Six ecological studies showed increased risk with higher
levels of arsenic in drinking water; all were statistically
significant.22 24 29 30 40 62 64 Two studies reported decreased
risk,47 61 which was statistically significant in one.47 One
study showed a non-significant decreased risk in men and a
non-significant increased risk in women.20 Two studies did
not provide quantified results.48 63
The general mechanisms through which arsenic could
plausibly cause cancer are outlined below. In addition,
arsenic in drinking water is well absorbed in the gastro-
intestinal tract, and both inorganic arsenic and its methyl-
ated metabolites are excreted in urine.49 Arsenic can modify
the urinary excretion of porphyrins in animals and humans.50
The evidence is inconsistent. There is limited evidence
suggesting that arsenic is a cause of bladder cancer.
General mechanisms — arsenic
Arsenic is carcinogenic to humans and causes chromosomal
abnormalities.10 It can result in changes in the methylation
of oncogenes or tumour-suppressor genes. It also interferes
with the activities of several enzymes of the haem biosyn-
thetic pathway. Exposure to arsenite or arsenate results in
generation of reduced oxygen species (free radicals) in lab-
oratory animals and human cells. Arsenic biotransformation
is thought to deplete cells of reduced glutathione, leading
to a state of oxidative stress, characterised by decreased scav-
enging of free radicals, which can directly damage DNA and
induce cell proliferation.65
There are several compounds suspected to modulate the
chronic environmental toxicity of arsenic –- variables that
may either enhance or suppress its genotoxicity and car-
cinogenicity. Among them are nutritional factors like sele-
nium and zinc, as well as drinking water co-contaminants
like antimony.66
4.7.5.2 Soft drinks
The evidence was too limited in amount, consistency, or
quality to draw any conclusions
4.7.5.3 Fruit juices
The evidence was too limited in amount, consistency, or
quality to draw any conclusions.
4.7.5.4 Coffee
Pancreas
Eighteen cohort studies,67-83 37 case-control studies,77 84-119
and 11 ecological studies120-130 investigated coffee and pan-
creatic cancer.
Seven cohort studies showed increased risk for the high-
est intake groups when compared to the lowest,67 68 71 72 78
80 which was statistically significant in two.72 80 Seven stud-
ies showed non-significant decreased risk.69 70 73 75 79 81 83 Two
studies stated that there was no significant effect on risk.77
82 One study reported a non-significant increased risk in men
and decreased risk in women76; and one study reported a
non-significant increased risk in women and a non-signifi-
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cant decreased risk in men.74 Meta-analysis was possible on
eight cohort studies, giving a summary effect estimate of
1.00 (95% CI 0.94–1.07) per cup/day, with low hetero-
geneity (figure 4.7.1).
Some, though not all, of the cohort studies suggest a J-
shaped dose-response relationship. An effect at high levels
of coffee consumption cannot be excluded.
Case-control studies reported inconsistent results.77 84-119
Eighteen studies reported increased risk,84-87 89-91 94 97 99 102-
106 112 114 116 119 of which nine were statistically significant.85
87 94 102 112 114 Eleven studies reported decreased risk,77 92 93 95
96 101 107 109 111 113 118 which was statistically significant in
one.118 Three studies showed no effect on risk88 98 and one
study stated there was no significant effect on risk.110 Four
other studies reported different effects in men and women;
however none was statistically significant.100 108 115 117 Meta-
analysis was possible on 26 studies, giving a summary effect
estimate of 1.04 (95% CI 1.01–1.07) per cup/day, with mod-
erate heterogeneity (figures 4.7.1 and 4.7.2). Studies that
did not adjust for smoking behaviour were more likely to
report increased risk. Confounding with smoking could not
be excluded.
The ecological studies overall showed an increased mor-
tality between coffee consumption and pancreatic cancer.120-
130 Correlation coefficients ranged from +0.15122 to
+0.59.124 125
There is ample evidence, including prospective data,
which is consistent and with low heterogeneity, and
which fails to show an association. It is unlikely that
coffee has any substantial effect on the risk of
pancreatic cancer.
Figure 4.7.1 Coffee and pancreatic cancer; cohort and
case-control studies
Cohort
Snowdon 1984 0.98 (0.69–1.40)
Zheng 1993 Men 0.93 (0.81–1.08)
Shibata 1994 1.13 (0.79–1.62)
Stensvold 1994 Men 0.97 (0.83–1.14)
Stensvold 1994 Women 1.08 (0.85–1.37)
Harnack 1997 Women 1.24 (1.02–1.49)
Michaud 2001 Men 0.86 (0.74–1.00)
Michaud 2001 Women 0.96 (0.87–1.07)
Lin 2002 Men 1.14 (0.92–1.41)
Lin 2002 Women 0.86 (0.58–1.26)
Stolzenberg-Solomon 2002 Men 1.05 (0.94–1.17)
Summary estimate 1.00 (0.94–1.07)
Case control
Elinder 1981 0.85 (0.66–1.09)
MacMahon 1981 1.13 (1.05–1.23)
Wynder 1983 Men 1.01 (0.93–1.10)
Wynder 1983 Women 1.00 (0.90–1.10)
Gold 1985 1.06 (0.89–1.26)
Mack 1986 1.20 (1.07–1.34)
La Vechhia 1987 1.06 (0.89–1.27)
Gorham 1988 1.15 (0.98–1.35)
Falk 1988 Men 1.09 (1.03–1.16)
Falk 1988 Women 1.06 (0.97–1.15)
Clavel 1989 Women 2.00 (1.22–3.28)
Olsen 1989 All respondents 0.97 (0.87–1.08)
Clavel 1989 Men 1.32 (0.91–1.92)
Cuzick 1989 0.93 (0.83–1.05)
Farrow 1990 Men 1.03 (0.94–1.13)
Jain 1991 1.00 (1.00–1.00)
Ghadirian 1991 0.99 (0.93–1.05)
Bueno de Mesquita 1992 0.78 (0.61–1.00)
Stefanati 1992 1.14 (0.80–1.62)
Lyon 1992 1.15 (1.02–1.30)
Zatonski 1993 0.53 (0.27–1.02)
Kalapothaki 1993 0.85 (0.68–1.06)
Sciallero 1993 1.02 (0.84–1.24)
Partanen 1995 0.97 (0.92–1.03)
Gullo 1995 1.25 (1.12–1.40)
Silverman 1998 Men 1.05 (0.98–1.13)
Silverman 1998 Women 1.03 (0.94–1.13)
Villeneuve 2000 Men 1.05 (0.94–1.17)
Villeneuve 2000 Women 0.99 (0.88–1.12)
Kreiger 2001 Women 1.00 (0.77–1.32)
Summary estimate 1.04 (1.01–1.07)
 Relative risk (95% CI)
Relative risk, per cup/day
1 1.20.8 20.5
Figure 4.7.2 Coffee and pancreatic cancer;
cohort studies: dose response
Snowdon 1984
Zheng 1993
Shibata 1994
Stensvold 1994 Men
Stensvold 1994 Women
Honack 1997 Women
Michaud 2001 Men
Michaud 2001 Women
Lin 2002 Men
Lin 2002 Women
Stolzenberg-Solomon
2002 Men
0 6 102 4 8
Coffee (cups/day)
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Kidney 
Five cohort studies,73 74 131-134 18 case-control studies,135-152 and
1 ecological study153 investigated coffee and kidney cancer.
Two cohort studies showed non-significant decreased risk
for the highest intake groups when compared to the lowest.73
131 One study showed non-significant increased risk133; one
study stated that there was no association132 134; and anoth-
er study showed non-significant increased risk in women and
non-significant decreased risk in men.74 Effect estimates were
0.15 (95% CI 0.02–1.16),73 0.87 (95% CI 0.66–1.16) per
cup/day,131 2.69 (95% CI 0.89–8.1),133 and 0.7 (no CI; men)
and 1.2 (no CI; women) for highest versus lowest categories
of exposure.74
The case-control studies reported inconsistent results, only
one of which was statistically significant (in women but not
in men).146 Seven studies showed non-significant decreased
risk for the highest intake groups when compared to the low-
est.135-138 140 142 143 145 Four studies showed non-significant
increased risk141 144 149 152; one study reported no effect on risk;
four studies stated that there was no association147 148 150 151;
and two studies showed increased risk in women, which was
statistically significant in one,146 and non-significant decreased
risk in men.139 146 Only four of the best quality case-control
studies were able to be meta-analysed, giving a summary esti-
mate of 0.99 (95% CI 0.96–1.01) (figure 4.7.3).
The ecological study reported correlation of incidence of
0.62 for men and 0.4 for women.153
There is substantial evidence both from cohort and
case-control studies, which is consistent and of low
heterogeneity, and which fails to show an association.
It is unlikely that coffee has a substantial effect on the
risk of kidney cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort study154 has been published. This new information does
not change the Panel judgement (see box 3.8).
4.7.5.5 Tea
The evidence was too limited in amount, consistency, or
quality to draw any conclusions. 
4.7.5.6 Herbal teas, infusions
4.7.5.6.1 Maté 
Oesophagus
Eight case-control studies155-163 and one ecological study164
investigated maté and oesophageal cancer.
Seven case-control studies showed increased risk for the
highest intake groups when compared to the lowest (figure
4.7.4)155-159 161-163 which was statistically significant in
four.155 157 159 161 One study showed non-significant decreased
risk.160 Meta-analysis was possible on five studies, all adjust-
ing for smoking, giving a summary effect estimate of 1.16
(95% CI 1.07–1.25) per cup/day, with moderate hetero-
geneity relating to size but not direction of effect (figure
4.7.5). The two studies not included in the meta-analysis did
not adjust for smoking; both reported non-significant
increased risk.156 159
The single ecological study showed a non-significant
relationship between increased maté consumption and
oesophageal cancer mortality.164
The general mechanisms through which maté could plau-
sibly cause cancer are outlined below.
The evidence, from case-control studies, is consistent
and a dose-response relationship is apparent. There is
robust evidence for plausible mechanisms. Regular
consumption of maté, as drunk in the traditional style
in South America, is a probable cause of oesophageal
cancer.
Mouth, pharynx, and larynx 
Six case-control studies investigated maté and mouth,
pharynx, and larynx cancers.165-170
All six case-control studies showed increased risk for the
highest intake groups when compared to the lowest,165-170
which was statistically significant in four.165 167-169
The general mechanisms through which maté could plau-
sibly cause cancer are outlined below.
The evidence is sparse. There is limited evidence
suggesting that maté is a cause of mouth, pharynx, and
larynx cancers. 
General mechanisms — maté
Maté is typically drunk scalding hot through a metal straw.
This produces heat damage in the mouth, pharynx, larynx,
and oesophagus. Repeated damage of this nature can lead
to cancer (also see Chapter 2). Chemical carcinogenesis from
constituents of maté has also been postulated.171 172
4.7.5.7 High-temperature foods and drinks 
Oesophagus
Three cohort studies173-176 and 15 case-control studies162 177-
196 investigated hot foods or drinks and oesophageal cancer.
Two cohort studies showed increased risk for consuming
high-temperature foods or drinks,173 174 which was statisti-
cally significant in one.174 The other study stated that there
was no association for hot drinks.175 176 Effect estimates were
1.44 (95% CI 0.91–2.26; hot food),173 and 1.5 (95% CI
1.1–2.0; men; hot tea) and 1.8 (95% CI 1.1–2.9; women;
Figure 4.7.3 Coffee and kidney cancer;
case-control studies
Mattioli 2002 0.89 (0.63–1.26)
Yuan 1998 0.98 (0.95–1.01)
McLaughlin 1984 1.00 (0.95–1.04)
Kreiger 1993 0.99 (0.94–1.04)
Summary estimate 0.99 (0.96–1.01)
Relative risk (95% CI)
Coffee (cups/day)
1 20.5
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hot tea).174 Both these studies adjusted for smoking.
Seven case-control studies investigated food tempera-
ture162 178-183 189-191; seven investigated hot drinks177 182 184-186
188 192 193; and four investigated high-temperature hot drinks
and soups combined.191 194-196 For high-temperature food, six
studies showed increased risk,162 178-183 187 189 191 which was
statistically significant in three162 179 180 187 189; one study
showed non-significant decreased risk.190 For hot drinks, five
studies showed increased risk,177 182 185 186 188 which was sta-
tistically significant in four177 185 186; two studies showed no
significant association192 193; one study showed non-signifi-
cant decreased risk.184 For hot drinks and soups combined,
all four studies showed increased risk,191 194-196 which was
statistically significant in two.194 195 Several studies did not
adjust for smoking or alcohol.177 180 182 186 194 195
High-temperature foods and/or drinks produce heat dam-
age in the mouth, pharynx, larynx, and oesophagus.
Repeated damage of this nature can lead to cancer (also see
chapter 2.4.1.3).
The evidence is inconsistent. There is limited evidence
suggesting that high-temperature drinks are a cause of
oesophageal cancer.
4.7.6  Comparison with previous report
Water was not reviewed in the previous report, which had
little to say about contaminants in water and did not review
arsenic contamination. The previous report did not review
soft drinks as such. 
The previous report judged that green tea possibly protects
against stomach cancer, but this was not supported by the
current review. The previous report judged that black tea
probably has no relationship with cancers of the stomach,
pancreas, and kidney. This time the evidence was judged too
limited to draw a clear conclusion. The judgements of the
previous report on coffee were practically the same as in this
Report, except that the previous report judged that drinking
more than five cups per day was a possible cause of bladder
cancer. The evidence now indicates that coffee is unlikely to
have a substantial effect on risk of this cancer. The previous
report judged it possible that maté and other very hot drinks
increase the risk of oesophageal cancer. Since the mid-1990s,
a greater body of consistent data has been published on
maté.
Skin cancer was not reviewed in the previous report.
4.7.7  Conclusions
The Panel concludes:
The evidence that inorganic arsenic in drinking water is a
cause of lung cancer is convincing. Water contaminated in
this way is probably a cause of skin cancer. There is limited
evidence suggesting that water contaminated in this way is
a cause of cancers of the kidney and bladder.
Maté is probably a cause of oesophageal cancer when
drunk scalding hot through a metal straw, as traditional in
parts of South America. The temperature is judged to be
responsible for any increased risk of cancer. There is limited
evidence suggesting that maté as drunk traditionally is a
cause of cancers of the mouth, pharynx, and larynx. There
is limited evidence suggesting that high-temperature drinks
are a cause of oesophageal cancer.
It is unlikely that coffee has a substantial effect on the risk
of cancer either of the pancreas or of the kidney.
Figure 4.7.5 Maté and oesophageal cancer;
case-control studies
Vassallo 1995 Men 1.26 (1.18–1.35)
Vassallo 1995 Women 1.43 (1.20–1.69)
De Stefani 1990 1.17 (1.12–1.22)
Rolon 1995 1.04 (0.95–1.13)
Sewram 2003 1.17 (1.09–1.25)
De Stefani 2003 1.04 (1.00–1.08)
Summary estimate 1.16 (1.07–1.25)
Relative risk (95% CI)
Relative risk, per cup/day
1 1.750.95 1.4
Figure 4.7.4 Maté and oesophageal cancer;
case-control studies
Victora 1987 1.47 (0.67–3.25)
Sewram 2003 1.62 (1.01–2.61)
Castelletto 1994 1.70 (1.00–2.89)
De Stefani 2003 3.50 (1.39–8.82)
De Stefani 1990 12.21 (3.78–39.42)
Dietz 1998 5.48 (0.96–31.44)
Rolon 1995 0.90 (0.44–1.86)
Vassallo 1985 Men 4.80 (1.90–12.11)
Vassallo 1985 Women 34.60 (4.88–245.40)
Relative risk (95% CI)
Relative risk, highest vs lowest exposure category
1 50.2 20.5 3510
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Many plant and some animal foods can be fermented to
produce alcoholic drinks; alcohol has been made this way
for thousands of years.
The main alcoholic drinks consumed, in ascending order
of alcohol (ethanol) content, are beers and ciders; wines;
wines ‘fortified’ with spirits; and spirits (liquors) and
liqueurs. The alcohol content of the many different drinks
within each of these categories varies. 
Alcoholic drinks induce changes in mood; they also
produce physical effects such as loss of coordination. In
most countries they are the legal ‘intoxicant’ of choice,
used as a social and professional lubricant; however,
certain cultures forbid the drinking of alcohol. 
With industrialisation and urbanisation, and the ready
availability of alcoholic drinks (which may or may not be
taxed), consumption tends to rise. 
Alcohol relaxes people’s social inhibitions, but it is
addictive; dependency on alcohol can seriously affect
people’s personal and professional lives. 
It has been known for a long time that prolonged high
consumption of alcohol is a cause of cirrhosis of the liver,
though not all people are equally susceptible. Knowledge
of its other ill-effects is more recent. 
Overall, the Panel judges that alcoholic drinks are a
cause of cancers of a number of sites and that, in general,
the evidence is stronger than it was in the mid-1990s. The
evidence does not show any ‘safe limit’ of intake. The
effect is from ethanol, irrespective of the type of drink.
Ethanol is classified by the International Agency for
Cancer Research as a human carcinogen. 
The Panel judges as follows:
The evidence that alcoholic drinks are a cause of cancers
of the mouth, pharynx, and larynx, oesophagus,
colorectum (men), and breast is convincing. They are
probably a cause of liver cancer, and of colorectal cancer
in women. It is unlikely that alcoholic drinks have a
substantial adverse effect on the risk of kidney cancer.
In final summary, the evidence is that alcoholic drinks
are a cause of cancers of the mouth, pharynx, and larynx;
the oesophagus; the colorectum in men, and the breast;
and probably of liver cancer and colorectal cancer in
women. It is unlikely that alcoholic drinks have a
substantial adverse effect on the risk of kidney cancer.
Chapter 4.8 concerns all alcoholic drinks. 
Alcoholic drinks have been popular in most societies ever
4.8  Alcoholic drinks
ALCOHOLIC DRINKS, AND THE RISK OF CANCER
In the judgement of the Panel, the factors listed below modify the risk of cancer. Judgements are graded according to the strength of the evidence.
DECREASES RISK INCREASES RISK
Exposure Cancer site Exposure Cancer site
Convincing Alcoholic drinks Mouth, pharynx and
larynx
Oesophagus
Colorectum (men)1
Breast (pre- and
postmenopause)
Probable Alcoholic drinks Liver2
Colorectum (women)1
Limited —
suggestive
Substantial
effect on risk Alcoholic drinks (adverse effect): kidney3
unlikely
1 The judgements for men and women are different because there are fewer data for women. Increased risk is only apparent above a threshold of 30 g/day of ethanol
for both sexes.
2 Cirrhosis is an essential precursor of liver cancer caused by alcohol. The International Agency for Research on Cancer has graded alcohol as a class 1 carcinogen for
liver cancer. Alcohol alone only causes cirrhosis in the presence of other factors. 
3 The evidence was sufficient to judge that alcoholic drinks were unlikely to have an adverse effect on the risk of kidney cancer; it was inadequate to draw a
conclusion regarding a protective effect.
For an explanation of all the terms used in the matrix, please see chapter 3.5.1, the text of this section, and the glossary.
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since the effects on mood of the fermented products of plant
foods and some animal foods were discovered, probably in
Palaeolithic or even earlier times. 
Ethanol is the active ingredient in alcoholic drinks; the con-
centration varies, depending on the type of drink. In the past,
beers were made from grains, ciders from fruits, mead from
honey, and brews from milk; these were followed by wines,
generally made from grapes and with higher concentrations
of ethanol. The process of distillation was a later invention,
which produced more highly concentrated alcoholic drinks
made from grains, fruits, sugar, and other substrates. 
Alcohol is liable to be addictive. Its specific effects are to
induce a mood of euphoria and disinhibition, which may be
dangerous. Much domestic and other violence, and many
reckless and violent incidents, and crimes such as arson,
wounding, homicide, and car crashes, are alcohol-related. 
Reports concerned with food, nutrition, and the preven-
tion of disease have often excluded alcohol. This is because
alcohol is also a drug, the impact of which is behavioural and
social, as well as biological. More recently, alcoholic drinks
have been included in such reports because of the evidence
that low to moderate consumption protects against coronary
heart disease (but not cerebrovascular disease), and also
because of the evidence on cancer, given that ethanol is a
human carcinogen. 
4.8.1 Definitions and sources
Alcohol is the common term for ethanol, one of a family of
alcohols, produced in nature when sugar molecules are bro-
ken down to release energy by yeasts. This process of fer-
mentation is used to produce alcoholic drinks. Alcohol is a
source of dietary energy (see chapter 4.10.1). It also acts as
a drug, affecting both mental and physical responses (alco-
hol intoxication). Alcoholic drinks include beers, wines, and
spirits. Other alcoholic drinks that may be locally important
include fermented milks, fermented honey-water (mead),
and fermented apples (cider).
Most alcoholic drinks are manufactured industrially. Some
are made domestically or illegally, as ‘moonshine’ or ‘hooch’. 
4.8.1.1 Beers
Beer, ale, and lager are traditionally produced from barley;
today other cereal grains are used. Beer contains between 3
and 7 per cent alcohol. The grain starches are converted to
sugars and then fermented by yeasts. The term ‘beer’ in this
Report includes ales and lagers. 
4.8.1.2 Wines
Wines are usually produced from grapes and contain
between around 9 to 15 per cent alcohol; they are crushed
to produce juice and must, which is then fermented. The
colour of the grapes and the length of fermentation deter-
mine the colour and strength of the final product. Grape
vines grow best in temperate regions. Wines can also be pro-
duced from other fruits and from rice (sake). Here, wine is
taken to mean grape wines. Wines may be fortified with spir-
its (see chapter 4.8.2.2) to produce drinks of alcohol con-
tent between about 16 and 20 per cent.
4.8.1.3 Spirits/liquors 
Spirits are usually produced from cereal grains and some-
times from other plant foods. They are distilled, to give a
drink with a higher concentration of ethanol than either
beers or wines — around 35–50 per cent or higher. Some of
the most globally familiar spirits are brandy (distilled wine),
whisky and gin (distilled from grains), rum (from molasses),
aguardente also known as cachaça (from sugar), vodka
(sometimes from grain, sometimes potatoes), and tequila
and mescal (from agave and cactus plants). Spirits and
liqueurs are also made from fruits. 
4.8.2 Composition 
Alcohol has an energy content of 7 kilocalories per gram, and
is metabolised in the liver. On average, blood alcohol levels
reach a maximum between 30 and 60 minutes after
drinking an alcoholic drink, and the body can metabolise
10–15 g alcohol per hour.
Alcohol alters the way the central nervous system func-
tions. Very high alcohol consumption (where blood alcohol
reaches 0.4 per cent) can be fatal, as can long-term, regu-
lar, high intakes. 
4.8.2.1 Beers
There are many varieties of beer, with different compositions.
Their alcohol content ranges from around 3 to 7 per cent by
volume; beers generally contain a variety of bioavailable
phenolic and polyphenolic compounds, which contribute to
the taste and colour, many of which have antioxidant prop-
erties. Beer is also a source of magnesium, potassium,
riboflavin, folate, and other B vitamins. 
4.8.2.2 Wines
The composition of wine depends on the grape varieties
used, as well as the growing conditions and the wine-making
methods, which may vary between vineyards. The alcohol
content ranges from around 9 to 15 per cent by volume. Red
wines contain high levels of phenolic and polyphenolic com-
pounds (up to a total of around 800–4000 mg/l), particu-
larly resveratrol, derived from the grape skins. Like those in
beer, these phenolic compounds add taste and colour. White
wines contain fewer phenolics. Red wine has been shown to
have antioxidant activity in laboratory experiments. Wine
also contains sugars (mainly glucose and fructose), volatile
acids (mainly acetic acid), carboxylic acids, and varying lev-
els of calcium, copper, iron, magnesium, potassium, and vit-
amins B1, B2, B6, and C. Wines may be flavoured with herbs
and fortified with spirits (see chapter 4.8.2.3) to produce
drinks of alcohol content between about 16 and 20 per cent.
4.8.2.3 Spirits/liquors 
The alcohol content of spirits/liquors and liqueurs is usual-
ly between 35 and 50 per cent by volume, but can be even
higher. Distilled drinks may have herbs and other ingredi-
ents added to give them their distinctive character.
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4.8.3 Consumption patterns
Much of the information on average consumption of alco-
holic drinks, internationally and nationally, is not informa-
tive. Within almost all populations, consumption varies
widely, usually as a function of availability, price, culture or
religion, and dependency. In general, men consume sub-
stantially more alcoholic drinks than women. In countries
where considerable amounts of alcoholic drinks are produced
domestically and by artisanal methods, overall consumption
will (if only for this reason) be underestimated. In many
countries, alcohol is a public health problem. This is not so
much because of the average level of intake, but because a
minority of the population, which in high-income countries
includes an increasing number of young people, drink alco-
hol excessively (‘binge’ drinking). 
Worldwide, alcoholic drinks supply an average of 2.3 per
cent of total dietary energy. This ranges from around 10 per
cent in some northern European countries, to (as recorded)
practically zero in Islamic countries. Average consumption
is nearly four times higher in high-income compared with
low-income countries, and tends to be highest in Europe,
North America, and Oceania. Consumption varies within
countries: many people do not consume alcoholic drinks,
some drink occasionally and others consume 15–25 per cent
or more of their dietary energy as alcohol. 
Alcoholic drinks are illegal in Islamic countries. In coun-
tries where these drinks are legal, there are often restrictions
on price and availability to adults, and in particular to young
people. 
Many countries recommend restriction of alcohol intake
for health reasons. In the USA, men are advised not to exceed
two drinks per day and women one drink per day. In the UK,
the government advises men not to exceed 3–4 units per day
and women 2–3 units per day. One US ‘drink’ is equivalent
to about 15 g ethanol, almost two UK units; a unit is 10 ml
or 8 g of pure ethanol.
4.8.3.1  Beers
Beers are the most widely consumed alcoholic drinks world-
wide. They provide an average of 1 per cent of dietary ener-
gy, with a peak of more than 6 per cent in parts of northern
Europe. People living in Europe, North America, and
Oceania tend to drink the most beer. 
4.8.3.2  Wines
Wines provide an average of 0.2 per cent of dietary energy
worldwide. They are drunk mainly in Europe, Australasia,
and the Americas, with highest levels of consumption in
western and southern Europe.
4.8.3.3  Spirits/liquors 
There are few data on average consumption of spirits/liquors. 
4.8.4  Interpretation of the evidence
4.8.4.1  General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7. 
‘Relative risk’ (RR) is used in this Report to denote ratio
measures of effect, including ‘risk ratios’, ‘rate ratios’, ‘haz-
ard ratios’, and ‘odds ratios’.
4.8.4.2 Specific
Confounding. At high levels of consumption, the effects of
alcohol are heavily confounded by other behaviours, such as
smoking tobacco.
Reporting bias. Self-reporting of consumption of alcoholic
drinks is liable to underestimate consumption, sometimes
grossly, because alcohol is known to be unhealthy and un-
desirable, and is sometimes drunk secretly. Heavy drinkers
usually underestimate their consumption, as do drinkers of
illegal or unregulated alcoholic drinks. 
Measurement. In recent years, the strength and serving size
of some alcoholic drinks have increased. For example, in the
UK, wine is commonly served in 250 ml glasses as opposed
to the standard 125 or 175 ml glass. In addition, alcohol con-
tent of drinks varies widely. Studies that measure consump-
tion in terms of number of drinks may be referring to very
different amounts of alcohol (also see box 4.8.1).
4.8.5 Evidence and judgements
The full systematic literature review (SLR) is contained on
the CD included with this Report.
4.8.5.1 Alcoholic drinks
There are two different measures of exposure: the number
of alcoholic drinks per time period and/or ethanol intake in
grams or millilitres per time period. The former measure is
likely to be less precise because the size and strength of each
drink are unknown.
The Panel judges that alcoholic drinks are or may be a cause of
various cancers, irrespective of the type of alcoholic drink. The
causal factor is evidently alcohol (ethanol) itself. There is no sig-
nificant evidence that alcohol protects against any cancer. The
extent to which alcoholic drinks are a cause of various cancers
depends on the amount of alcohol drunk. 
Epidemiological studies commonly identify the type of alco-
holic drink consumed. Some of the evidence reviewed in chap-
ter 4.8.5 does appear to show that some types of drink seem to
have different effects. For example, for cancers of the mouth,
pharynx, and larynx, the evidence is stronger for consumption
of beer and spirits than for wine. Here is the possibility of resid-
ual confounding: wine drinkers in many countries tend to have
healthier ways of life than beer or spirit drinkers.
Apparent discrepancies in the strength of evidence may also
be due partly to variation in the amounts of different types of
alcoholic drinks consumed. In general, the evidence suggests
similar effects for different types of alcoholic drink. 
Box 4.8.1 Types of alcoholic drink
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Mouth, pharynx, and larynx 
Five cohort studies,1-6 89 case-control studies,7-93 and 4 eco-
logical studies94-97 investigated alcoholic drinks and mouth,
pharynx, and larynx cancers.
Total alcoholic drinks 
All five cohort studies showed increased risk for the highest
intake group when compared to the lowest (figure 4.8.1),1-6
which was statistically significant in four.1 2 4 6 Meta-analy-
sis was possible on two studies, giving a summary effect esti-
mate of 1.24 (95% confidence interval (CI) 1.18–1.30) per
drink/week, with no heterogeneity (figures 4.8.2 and
4.8.3).1 2 All cohort studies adjusted for smoking.
Almost all of the case-control studies showed increased risk
for the highest intake group when compared to the lowest
(figure 4.8.1),7-19 21-32 34-70 72-93 which was statistically signif-
icant in more than half (as can be seen from the high to low
Figure 4.8.2 Alcoholic drinks and mouth, pharynx, and
larynx cancer; cohort and case-control studies
Cohort
Kjaerheim 1998 1.26 (1.10–1.44)
Boeing 2002 1.24 (1.18–1.30)
Summary estimate 1.24 (1.18–1.30)
Case control
Martinez 1969 1.02 (1.01–1.04)
Martinez 1969 Men 1.03 (1.01–1.05)
Elwood 1984 1.05 (1.04–1.06)
Brownson 1987 1.02 (1.02–1.03)
Blot 1988 1.05 (1.04–1.06)
Blot 1988 Women 1.04 (1.02–1.06)
Falk R 1989 1.02 (1.00–1.04)
Merletti 1989 Men 1.01 (0.99–1.04)
Merletti 1989 Women 1.10 (0.99–1.22)
La Vecchia 1991 1.03 (1.01–1.02)
Choi1991 Men 1.17 (1.08–1.04)
Choi 1991 Women  1.03 (0.89–1.18)
Franceschi 1992 1.02 (1.01–1.03)
Mashberg 1993 1.01 (1.00–1.01)
Negri 1993 1.02 (1.02–1.03)
Day 1993 White 1.05 (1.04–1.06)
Day 1993 Black 1.05 (1.03–1.06)
Ng 1993 Men 1.02 (1.01–1.04)
Ng 1993 Women 1.07 (0.99–1.02)
Su 1998 Men 1.18 (1.03–1.36)
Franceschi 1999 1.03 (1.02–1.03)
Hayes 199 Men 1.03 (1.03–1.04)
Zavras 2001 1.02 (1.00–1.04)
Garrote 2001 1.02 (1.01–1.03)
Dal Maso 2002 1.02 (1.01–1.03)
Pisa 2002 1.04 (1.01–1.06)
Lissowska 2002 1.04 (1.01–1.08)
Pelucchi 2003 1.03 (1.02–1.03)
Castellsague 2004 1.01 (1.01–1.02)
Altieri 2004 1.03 (1.02–1.03)
Peters 2005 1.04 (1.03–1.05)
Summary estimate 1.03 (1.02–1.04)
Relative risk (95% CI)
Relative risk, per drink/week
1 1.50.5 0.75 2
Figure 4.8.1 Alcoholic drinks and mouth, pharynx, and
larynx cancer; cohort and case-control studies
Cohort
Gronbaek 1998 11.70 (4.91–27.87)
Kjaerheim 1998 3.20 (1.64–6.25)
Boeing 2002 9.22 (2.75–30.25)
Case control
Maier 1992 9.00 (5.21–15.54)
Wynder 1976 22.10 (7.83–62.36)
Herity 1982 5.60 (2.99–12.48)
Elwood 1984 7.70 (3.16–18.76)
Zagraniski 1986 4.00 (1.80–8.89)
De Stefani 1987 9.30 (3.49–24.81)
Brownson 1987 4.55 (2.81–8.37)
Blot 1988 Men 8.50 (5.41–14.32)
Blot 1988 Women 9.10 (3.92–21.12)
Tuyns 1988 2.56 (1.81–3.62)
Franco 1989 8.50 (2.48–29.15
Falk 1989 2.12 (0.89–5.04)
Sankaranarayanan 1989 a 6.25 (0.76–51.16)
Sankaranarayanan 1989 b 3.15 (0.74–13.12)
Merletti 1989 Men 2.10 (0.62–7.07)
Merletti 1989 Women 3.40 (0.90–12.87)
Zheng 1990 1.59 (1.05–2.41)
Sankaranarayanan 1990 a 7.69 (3.56–16.62)
Sankaranarayanan 1990 b 8.18 (2.79–23.97)
La Vecchia 1991 3.50 (2.03–7.11)
Choi 1991 Men 3.42 (1.77–6.60)
Choi 1991 Women 1.48 (0.12–18.14)
Zheng 1990 Men 0.80 (0.52–1.22)
Franceschi 1992 3.00 (1.38–6.51)
Zheng 1992 Men 1.56 (0.97–2.50)
Gonzalo 1992 4.64 (0.41–52.39)
Mashberg 1993 7.10 (4.12–12.25)
Day 1993 White 5.50 (5.72–13.54)
Day 1993 Black 16.60 (6.28–44.95)
Ng 1993 Men 4.36 (1.39–13.68)
Ng 1993 Women 2.62 (0.51–13.40)
Hedberg 1994 3.10 (1.21–7.95)
Rao 1994 1.51 (1.12–2.04)
Guo 1995 2.25 (1.23–4.13)
Takezaki 1996 Men 3.40 (1.18–9.77)
Takezaki 1996 Women 2.30 (1.58–3.58)
Zheng 1997 1.17 (0.58–2.35)
Sandersson 1997 20.80 (11.42–37.87)
Dosemeci 1997 1.60 (0.72–3.58)
Pintos 1998 4.10 (2.80–6.00)
Rao 1998 1.38 (1.00–1.91)
Wasnik 1998 1.84 (1.02–3.32)
Su 1998 Men 5.14 (0.95–27.81)
Smith 1998 2.57 (1.22–5.42)
Franceschi 1999 11.90 (6.22–22.77)
Rao 1999 1.53 (1.10–2.14)
Hayes 1999 Men 7.70 (3.31–17.93)
Zavras 2001 4.90 (1.20–19.95)
Brown 2001 60.40 (20.98–173.86)
Schlecht 2001 2.70 (0.90–8.11)
Garrote 2001 5.73 (1.77–18.53)
Zang 2001 4.80 (3.47–6.64)
Dal Maso 2002 4.30 (1.92–9.61)
Pisa 2002 4.00 (0.87–18.33)
Petridou 2002 2.02 (1.11–3.68)
Uzcudun 2002 3.50 (2.36–6.11)
Lissowska 2003 4.25 (1.07–16.90)
Pelucchi 2003 5.80 (3.79–8.88)
Sanchez 2003 3.28 (1.80–5.99)
Llewellyn 2004 Men 1.60 (0.81–3.15)
Llewellyn 2004 Women 1.60 (0.60–4.23)
Castellsague 2004 10.29 (4.57–23.17)
Relative risk (95% CI)
Relative risk, highest vs lowest exposure category
1 50.2 20.5
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comparison plot).8-19 21 23-25 28-32 34-36 40-48 52 54-57 59-67 70 72-75 77-
86 89-91 93 No studies reported statistically significant contra-
dictory results. Meta-analysis was possible on 25 studies,
giving a summary effect estimate of 1.03 (95% CI 1.02–1.04)
per drink/week, with high heterogeneity (figures 4.8.2 and
4.8.4).17 21 26 27 32 34 35 40-42 52 57 60 62 65 67 69 75 78-80 83-85 89
Heterogeneity related to the size, and not the direction, of
effect, and is largely explained by varying design and qual-
ity of studies.
A continuous curvilinear dose-response relationship was
apparent from cohort and case-control data with no obvious
threshold (figures 4.8.3 and 4.8.4). 
There was some evidence of publication bias as a result of
small studies that did not report a significant association
being unpublished. However, such small studies may suffer
from issues of quality.
Ecological studies tended to show increased risk with
increased consumption.94-97
Beers
Two cohort studies,1 6 27 case-control studies,25 26 32 33 36 42 47
58 62 64 65 68 79 83-85 98-105 and 4 ecological studies94-96 106 report-
ed separately on beer drinking. 
Both cohort studies showed statistically significant
increased risk with increased intake; both studies adjusted
for smoking.1 6 Almost all case-control studies also showed
increased risk,25 26 32 33 36 42 47 58 62 64 65 68 83-85 98-104 which was
statistically significant in many.36 42 47 62 68 83-85 98-102 Meta-
analysis was possible on six case-control studies, giving a
summary effect estimate of 1.06 (95% CI 1.03–1.08), with
high heterogeneity. Most studies adjusted for smoking. The
ecological studies did not show any consistent or statistically
significant effect.94-96 106
Wines
Twenty-six case-control studies25 26 32 33 42 58 62 64 65 68 79 83-85 98
99 101 102 104 105 107-109 and four ecological studies94-96 110 report-
ed separately on wine drinking.
Most of the case-control studies showed increased risk with
increased intake,25 32 33 58 62 64 68 79 84 85 101 102 105 107-109 which
was statistically significant in less than half.32 33 58 62 68 79 85
108 109 Five studies showed decreased risk,26 65 83 98 99 which
was statistically significant in one.98 99 Meta-analysis was
possible on 11 case-control studies, giving a summary effect
estimate of 1.02 (95% CI 1.01–1.03), with high hetero-
geneity.32 33 62 68 79 83-85 102 105 109 All studies adjusted for smok-
ing. All four ecological studies showed statistically significant
increased risk.94-96 110
Spirits
One cohort study,1 35 case-control studies,19 25 26 28 31-33 36 38
42 47 49 50 58 62 64 65 68 79 83-85 98 100-102 104 105 108 109 111-113 and 5 eco-
logical studies94-96 106 114 reported separately on spirits.
The single cohort study showed a non-significant increased
risk with increased intake.1 Almost all case-control studies
Figure 4.8.3 Alcoholic drinks and mouth, pharynx, and
larynx cancer; cohort  studies: dose response
Kjaerheim 1998
Boeing 2002
0 155 10
Alcoholic drinks (drinks/week)
Figure 4.8.4 Alcoholic drinks and mouth, pharynx,
and larynx cancer; case-control studies:
dose response
Martinez 1969 Men
Martinez 1969 Women
Elwood 1984
Brownson 1987
Blot 1988 Men
Blot 1988 Women
Falk 1989
Merletti 1989 Men
Merletti 1989 Women
Choi 1991 Men
Choi 1991 Women
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Franceschi 1992
Day 1993 Black
Day 1993 White
Mashberg 1993
Negri 1993
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Francechi 1999
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Zavras 2001
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Peters 2005
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showed increased risk, which was statistically significant 
in many. Meta-analysis was possible on nine case-control
studies, giving a summary effect estimate of 1.03 (95% 
CI 1.04–1.05), with high heterogeneity. Most studies
adjusted for smoking. One ecological study reported a sig-
nificant increased risk; the others tended to show non-
significant increased risk in men and non-significant
decreased risk in women. 
The general mechanisms through which alcohol could
plausibly cause cancer are outlined below. In addition, alco-
hol acts as a synergistic carcinogen with tobacco. Tobacco
may induce specific mutations in DNA that are less efficiently
repaired in the presence of alcohol. Alcohol may also func-
tion as a solvent, enhancing penetration of other carcino-
genic molecules into mucosal cells. 
There is ample and consistent evidence, both from
case-control and cohort studies, with a dose-response
relationship. There is robust evidence for mechanisms
operating in humans. The evidence that alcoholic
drinks are a cause of mouth, pharynx, and larynx
cancers is convincing. Alcohol and tobacco together
increase the risk of these cancers more than either
acting independently. No threshold was identified.
The Panel is aware that since the conclusion of the SLR, one
cohort115 and four case-control studies116-119 have been pub-
lished. This new information does not change the Panel judge-
ment (see box 3.8).
Oesophagus
Eight cohort studies,1 3 120-125 56 case-control studies,33 61 67
80 126-182 and 10 ecological studies2 94 95 114 183-189 investigat-
ed alcoholic drinks and oesophageal cancers.
Total alcoholic drinks
Eight cohort studies,1 3 120-125 56 case-control studies,33 61 67
80 126-137 139-182 and 10 ecological studies2 94 95 114 183-189 report-
ed on total alcoholic drinks. 
Six cohort studies showed increased risk for the highest
intake group when compared to the lowest (figure 4.8.5),1
3 120-122 124 which was statistically significant in four,1 120 122
124 and in men, but not in women in a fifth study.121 Two
studies showed non-significant decreased risk.123 125 Effect
estimates for all studies are shown in the high to low forest
plot (figure 4.8.5). Four studies did not adjust for smok-
ing.122-125
Most case-control studies showed increased risk for the
highest intake group when compared to the lowest (figure
4.8.5),33 61 67 80 126 128-137 139 141-148 150-166 169 170 172 174 175 177-182
which was statistically significant in 25.33 61 67 80 128 129 132 133
135 137 139 141 145 147 148 150 152 153 155-166 170 172 174 175 178-180 182
A few studies showed decreased risk, but none was statisti-
cally significant.140 149 167 168 171 173 176 Meta-analysis was pos-
sible on 20 case-control studies, giving a summary effect
estimate of 1.04 (95% CI 1.03–1.05) per drink/week, with
high heterogeneity (figures 4.8.6 and 4.8.7).33 61 67 131 133 137
144 149 150 156 157 160 161 170 178-182 Heterogeneity is related pre-
dominantly to size, rather than direction, of effect and may
Figure 4.8.5 Alcoholic drinks and oesophageal cancer;
cohort and case-control studies
Cohort
Kono 1987 14.46 (3.00–69.70)
Hirayama 1990 2.28 (1.96–2.65)
Yu 1993 0.50 (0.21–1.20)
Zheng 1995 1.40 (0.62–3.18)
Kinjo 1998 Men 2.40 (1.77–3.25)
Kjaerheim 1998 Women 3.20 (1.64–6.25)
Khjo 1998 Women 2.00 (0.62–6.43)
Sakata 2005 2.40 (1.20–4.80)
Tran 2005 0.92 (0.82–1.03)
Case control
Jozala 1983 26.70 (6.87–10.374)
Tuyns 1982 2.72 (1.03–7.16)
Rossi 1982 13.08 (4.55–37.61)
Tuyns 1983 Men 101.03 (109.9–928.52)
Tuyns 1983 Women 11.04 (1.08–112.57)
Adelhardt 1985 2.95 (1.12–7.76)
Decarli 1987 10.43 (4.37–24.90)
La Vecchia 1989 3.60 (0.93–13.99)
Franceschi 1990 0.90 (0.57–1.42)
De Stefani 1990 Men 5.27 (2.71–10.24)
De Stefani 1990 Women 1.89 (0.71–5.00)
Sankaranarayaran 1991 Men 2.33 (1.52–3.56)
Choi 1991 Men 9.14 (3.79–22.06)
Valsecchi 1992 9.30 (5.11–16.93)
Wang 1992 Men 2.10 (1.06–4.15)
Cheng 1992 11.45 (6.66–19.69)
Tavani 1993 2.30 (0.99–5.34)
Kabat 1993 Men 10.90 (4.88–24.32)
Kabat 1993 Women 13.20 (6.08–28.68)
Parkin 1994 0.80 (0.59–1.08)
Castelletto 1994 8.00 (3.01–21.27)
Hanaoka 1994 6.59 (2.51–17.33)
Tavani 1994 5.40 (1.39–20.91)
Gao 1994 Men 1.40 (1.07–1.84)
Gao 1994 Women 0.60 (0.24–1.53)
Brown 1994 White Men 16.10 (6.68–38.79)
Brown 1994 Black Men 26.90 (11.89–60.85)
Vaughan 1995 9.50 (4.02–22.43)
Cheng 1995 1.50 (0.99–2.27)
Srivastava 1995 3.70 (1.50–9.11)
Gimeno 1995 4.40 (1.86–10.40)
Cheng 1995 Non-smokers 14.43 (3.60–57.82)
Vizcaino 1995 0.90 (0.69–1.18)
Nandakumar 1996 Men 1.80 (1.20–2.70)
Garidou 1996 1.26 (1.09–1.45)
Gammon 1997 7.40 (4.00–13.69)
Dietz 1998 8.60 (3.82–19.38)
Tao 1999 1.54 (0.86–2.76)
Gao 1999 0.78 (0.38–1.62)
Bosetti 2000 12.35 (8.37–18.22)
Levi 2000 15.65 (6.81–35.96)
Nayar 2000 7.81 (3.28–5.61)
Takezaki 2000 8.50 (5.56–13.00)
Takezaki 2001 0.75 (0.46–1.22)
Wu 2001 0.70 (0.47–1.04)
Sharp 2001 0.86 (0.25–2.95)
Dal Maso 2002 13.80 (4.00–47.60)
Gao 2002 1.48 (0.78–2.81)
Boonyaphiphat 2002 5.84 (3.15–10.83)
Engel 2003 9.40 (4.60–19.20)
Chita 2004 men 3.50 (1.72–7.10)
Wang 2004 3.45 (1.73–6.88)
Lee 2005 7.60 (5.20–11.10)
Yang 2005 6.71 (1.92–23.42)
Trivers 2005 1.08 (0.81–1.44)
Relative risk (95% CI)
Relative risk, highest vs lowest exposure category
10.2 20.5 5 10
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be partially explained by the variation in measurement of
alcohol intake, variation in the outcome measured
(oesophageal or upper aerodigestive tract), or by inadequate
adjustment for smoking in some studies. There is a trend for
smaller effect estimates from more recent publications, which
could be due to improved methods of adjustment for con-
founders. Not all studies adjusted for smoking.
There is some evidence of publication bias; with smaller
studies tending to report larger effects. 
The ecological studies were not consistent.2 94 95 114 183-189
Two reported statistically significant results, both in the
direction of increased risk.94 186
Beers
One cohort study,4 15 case-control studies,103 129 143 144 159 170
173 176 190-197 and seven ecological studies94 95 106 184 187 198 199
reported separately on beer drinking.
The single cohort study showed statistically significant
increased risk with increased intake after adjustment for
smoking.4 All case-control studies with the exception of
two173 176 also showed increased risk, which was statistical-
ly significant in seven.103 129 144 159 170 191 193 195-197 Meta-analy-
sis was possible on five case-control studies, giving a
summary effect estimate of 1.05 (95% CI 1.03–1.07), with
high heterogeneity.144 159 170 193 197 About half of the studies
did not adjust for smoking. The ecological studies were
inconsistent and one reported a statistically significant result,
which was in the direction of increased risk.94
Wines
Ten case-control studies,143 144 159 161 170 173 190 194 195 one cross-
sectional study,200 and five ecological studies94 95 106 184 198
reported separately on wine drinking.
All but one of the case-control studies showed increased
risk with increased intake,144 which was statistically
significant in seven.159 161 170 190 195 About half of the studies
adjusted for smoking. The single cross-sectional study
showed non-significant increased risk.200 Most ecological
Figure 4.8.6 Alcoholic drinks and oesophageal cancer;
cohort and case-control studies
Cohort
Kjaerheim 1998 1.26 (1.10–1.44)
Case control
Tuyns 1983 Men 1.12 (1.07–1.17)
Tuyns 1983 Women 1.04 (1.00–1.09)
Decarli 1987 1.04 (1.03–1.05)
La Vecchia 1989 1.01 (0.99–1.03)
Franceschi 1990 1.02 (1.01–1.04)
De Stefani 1990 Men 1.04 (1.03–1.06)
De Stefani 1990 Women 1.13 (0.99–1.29)
Sankaranarayanan 1991 Men 1.02 (1.01–1.03)
Cheng 1992 1.08 (1.07–1.09)
Tavani 1993 1.03 (1.00–1.06)
Tavani 1994 1.02 (1.00–1.04)
Hanaoka 1994 1.24 (1.14–1.33)
Brown 1994 Black men 1.04 (1.03–1.04)
Brown 1994 White men 1.03 (1.05–1.07)
Castelletto 1994 1.05 (1.03–1.07)
Gammon 1997 1.07 (1.05–1.08)
Bosetti 2000 1.03 (1.03–1.03)
Takezaki 2001 1.00 (0.96–1.04)
Sharp 2001 1.00 (0.95–1.05)
Boonyaphiphat 2002 1.05 (1.04–1.07)
Dal Maso 2002 1.03 (1.02–1.04)
Lee 2005 0.99 (0.97–1.00)
Yang 2005 1.05 (1.03–1.06)
Summary estimate 1.04 (1.03–1.05)
Relative risk (95% CI)
Relative risk, per drink/week
1 1.50.8 1.25
Figure 4.8.7 Alcoholic drinks and oesophageal cancer;
case-control studies: dose response
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studies were in the direction of increased risk.94 106 184 198
Spirits
One cohort study,4 15 case-control studies,139 143-145 159 170 173
181 190 191 194-196 201 202 one cross-sectional study,200 and five eco-
logical studies94 95 106 184 198 reported separately on spirits.
The single cohort study showed statistically significant
increased risk with increased intake after adjustment for
smoking.4 All of the case-control studies also showed
increased risk, which was statistically significant in eight.139
144 145 191 194 195 201 202 Most studies adjusted for smoking. The
single cross-sectional study showed non-significant increased
risk.200 The ecological studies were inconsistent and two
reported statistically significant results; both were in the
direction of increased risk.94 106
The general mechanisms through which alcohol could
plausibly cause cancer are outlined below. In addition, alco-
hol acts as a synergistic carcinogen with tobacco. Tobacco
may induce specific mutations in DNA that are less efficiently
repaired in the presence of alcohol. Alcohol may also func-
tion as a solvent, enhancing penetration of other carcino-
genic molecules into mucosal cells. 
There is ample and consistent evidence, both from
cohort and case-control studies, with a dose-response
relationship. There is robust evidence for mechanisms
operating in humans. The evidence that alcoholic
drinks are a cause of oesophageal cancer is convincing.
No threshold was identified.
The Panel is aware that since the conclusion of the SLR, one
cohort203 and four case-control studies204-207 have been pub-
lished. This new information does not change the Panel judge-
ment (see box 3.8).
Colorectum
Twenty-four cohort studies investigated alcoholic drinks and
colorectal cancer.124 208-235 Thirteen cohort studies214 216 219 227
230 232 236-251 and 41 case-control studies investigated ethanol
intake and colorectal cancer.
Total alcoholic drinks
Eighteen cohort studies showed increased risk for the high-
est intake group when compared to the lowest,124 209 210 212-
217 220-223 225-228 233-235 which was statistically significant in
four.209 210 216 227 One study showed non-significant increased
risk in men and non-significant decreased risk in women.211
219 Two studies reported no effect on risk218 231 and three
studies reported decreased risk; none was statistically sig-
nificant.208 224 229 230 232 Meta-analysis was possible on six
cohort studies, giving a summary effect estimate of 1.01
(95% CI 0.95–1.08) per drink/day, with no heterogeneity
(figure 4.8.8). 
Alcohol (as ethanol)
Eleven of the cohort studies showed increased risk for the
highest intake group when compared to the lowest (figure
4.8.9),214 216 219 227 230 232 237 239-251 which was statistically sig-
nificant in six.219 227 230 240 244 245 251 One study reported no
effect on risk for men and non-significant decreased risk for
women,238 and one study reported no statistically significant
association.236 Meta-analysis was possible on nine cohort
studies, of which one reported on colorectal cancer and eight
reported on colon cancer, giving a summary effect estimate
of 1.09 (95% CI 1.03–1.14) per 10 g/day, with moderate het-
erogeneity(figures 4.8.10 and 4.8.11).
In a separate meta-analysis of nine studies for rectal can-
cer, the summary effect estimate was 1.06 (95% CI
1.01–1.12) per 10 g/day, with low heterogeneity (figure
4.8.12). It is apparent from the meta-analysis that the report-
ed effect for men was larger and more often statistically sig-
nificant than for women. Stratified meta-analyses for
colorectal cancer gave summary effect estimates of 1.09
(95% CI 1.02–1.15) for seven studies for men, and 1.00
(95% CI 0.89–1.40) for three studies for women. There was
no statistically significant difference with cancer site. There
was, however, apparent sexual dimorphism, with a larger
effect in men than in women, which explains the bulk of the
observed heterogeneity. 
Figure 4.8.8 Alcoholic drinks and colorectal cancer;
cohort studies
Kato 1999 Women 1.00 (0.82–1.22)
Ford 1997 0.97 (0.82–1.15)
Schoen 1999 1.24 (0.91–1.69)
Chen 2001 Men 1.26 (0.79–2.01)
Flood 2002 Women 1.02 (0.85–1.21)
Pedersen 2003 1.00 (0.91–1.09)
Summary estimate 1.01 (0.95–1.08)
 Relative risk (95% CI)
Relative risk, per drink/day
10.2 20.5 5
Figure 4.8.9 Ethanol and colorectal cancer; cohort studies
Slattery 1990  Men 2.21 (0.81–6.05)
Slattery 1990 Women 1.66 (0.78–3.52)
Goldbohm 1994 1.10 (0.32–3.81)
Glynn 1996 Men 3.60 (1.27–10.18)
Chyou 1996 Men 1.39 (1.05–1.84)
Murata 1996 Men 3.20 (1.53–6.70)
Harnack 2002 Women 1.08 (0.72–1.62)
Wei 2003  Men 1.55 (1.05–2.28)
Wei 2003 Women 1.14 (0.86–1.52)
Relative risk (95% CI)
Relative risk, highest vs lowest exposure category
10.2 20.5 5
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When data were analysed separately for drink type (beers,
wines, or spirits), they became insufficient to draw any firm
conclusions.
Pooled analysis from 8 cohort studies (over 475 000 par-
ticipants, followed up for 6 to 16 years, more than 4600 col-
orectal cancer cases) showed a significant increased risk for
the highest intake group when compared to the lowest, with
an effect estimate of 1.41 (95% CI 1.16–1.72) for those who
consumed 45 g/day or greater.252 No increased risk was
observed below intakes of 30 g/day. No significant hetero-
geneity was observed by sex or cancer site.
In addition, a published meta-analysis of 27 studies report-
ed a statistically significant increased risk, with a summary
effect estimate of 1.10 (95% CI 1.05–1.14) per two
drinks/day.
Because of the abundant prospective data from cohort
studies, case-control studies were not summarized.
The general mechanisms through which alcohol could
plausibly cause cancer are outlined below. In addition, the
association between alcohol intake and colorectal cancer risk
is modified by acetaldehyde dehydrogenase and alcohol
dehydrogenase genetic status.253 254 Alcohol may induce
folate deficiency in the colon and rectum, possibly by reduc-
ing absorption of folate or by inhibition of critical enzymes.
Also, alcohol may disrupt one-carbon metabolism (see
Chapter 2). Intestinal bacteria, because of their high alco-
hol dehydrogenase activity, can oxidise ethanol in colorec-
tal tissue to produce levels of acetaldehyde up to 1000-fold
higher than that in blood. 
The more elevated risk related to alcohol intake among
men compared with women may be because of the gener-
ally lower consumption of alcohol among women. That is,
it is possible that men exhibit a greater range in the amount
of alcohol drunk, which makes effects easier to detect. Also,
preferred beverages may differ between the sexes, or there
may be hormone-related differences in alcohol metabolism
or susceptibility to alcohol.
There is ample and generally consistent evidence from
cohort studies. A dose-response is apparent. There is
evidence for plausible mechanisms. The evidence that
consumption of more than 30 g/day of ethanol from
alcoholic drinks is a cause of colorectal cancer in men
is convincing, and probably also in women.
The Panel is aware that since the conclusion of the SLR, four
cohort255-258 and four case-control studies259-262 have been pub-
lished. This new information does not change the Panel judge-
ment (see box 3.8).
Breast 
Eleven cohort studies,183 263-271 31 case-control studies272-310
and 2 ecological studies311 312 investigated total alcoholic
drinks and breast cancer at all ages. Four cohort studies313-
316 and 19 case-control studies289 302 317-333 investigated alco-
holic drinks. Twenty-five cohort studies,315 334-364 29 case-
Figure 4.8.10 Ethanol and colon cancer; cohort studies
Wu 1987 1.18 (1.06–1.31)
Kreger 1992 Men 1.00 (0.92–1.09)
Kreger 1992 Women 0.88 (0.71–1.10)
Goldbohm 1994 Men 1.08 (0.95–1.23)
Goldbohm 1994 Women 1.07 (0.90–1.29)
Giovanucci 1995 Men, >646 µg/day folate intake 1.02 (0.64–1.61)
Chyou 1996 Men 1.17 (1.06–1.28)
Murata 1994 Men 1.12 (0.94–1.28)
Colbert 2001 Men 1.03 (0.96–1.12)
Harnack 2002 Women 1.05 (0.80–1.38)
Nakaya 2005 Men 1.25 (1.06–1.47)
Summary estimate 1.09 (1.03–1.14)
Relative risk (95% CI)
Relative risk, per 10 g/day
10.2 20.5 5
Figure 4.8.11 Ethanol and colon cancer incidence;
cohort studies: dose response
Goldbohm 1994 Men
Goldbohm 1994 Women
Chyou 1996 Men
0 402010 30
Ethanol  (g/day)
Figure 4.8.12 Ethanol and colorectal cancer; cohort studies
Kreger 1992 Men 0.98 (0.83–1.15)
Kreger 1992 Women 0.81 (0.48–1.37)
Goldbohm 1994 Men 1.08 (0.92–1.27)
Goldbohm 1994 Women 1.05 (0.78–1.39)
Chyou 1996 Men 1.11 (1.07–1.16)
Murata 1996 1.14 (0.93–1.39)
Colbert 2001 Women 0.99 (0.90–1.07)
Hamack 2002 0.94 (0.54–1.65)
Nakaya 2005 1.15 (0.92–1.44)
Summary estimate 1.06 (1.01–1.12)
Relative risk (95% CI)
Relative risk, per 10 g/day
10.2 20.5 5
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control studies,280 282 317 318 332 333 365-391 and 4 ecological
studies392-395 investigated ethanol intake.
Total alcoholic drinks 
Six cohort studies showed increased risk for the highest
intake group of total alcoholic drinks when compared to the
lowest,263 264 267-271 which was statistically significant in
three.267 269 270 Three studies showed non-significant
decreased risk265 266; one study showed no effect on risk.183
Meta-analysis was possible on three cohort studies, giving a
summary effect estimate of 1.07 (95% CI 0.89–1.29) per five
times/week, with no heterogeneity (figures 4.8.13 and
4.8.14).263 271
Two cohort studies reported separately on premenopausal
breast cancer.264 268 Both showed increased risk for the high-
est intake group when compared to the lowest, which was
statistically significant in one.268 Three cohort studies
reported separately on postmenopausal breast cancer.264 268
269 Two showed increased risk for the highest intake group
when compared to the lowest,264 269 which was statistically
significant in one.269 The other study showed non-significant
decreased risk.268
Four additional cohort studies investigated alcoholic
drinks.313-316 All four showed non-significant increased risk
for breast cancer at unspecified ages. One study also report-
ed statistically significant increased risk for postmenopausal
breast cancer and non-significant decreased risk for pre-
menopausal breast cancer.315
Most of the 22 case-control studies that reported on all-
age breast cancer and total alcoholic drinks showed
increased risk for the highest intake group when compared
to the lowest,273 274 280 282-285 287 288 290 295 297 301-303 305-309 318
which was statistically significant in seven.273 284 285 306 318
A few studies showed decreased risk, none was statistically
significant.276 291 295 298 302 304 Meta-analysis was possible on
10 case-control studies reporting on breast cancer at all ages,
giving a summary estimate of 1.05 (95% CI 1.03–1.07) for
an increment of five times/week, with high heterogeneity
(figures 4.8.13 and 4.8.14).274 276 284 286 287 296 306 307 No het-
erogeneity was apparent with menopausal status. Twelve
case-control studies reported separately on premenopausal
breast cancer.272 275 277-279 281 282 292-294 297 299 300 306 310 318 Ten
showed increased risk,272 275 277 279 281 292-294 299 300 306 318 which
was statistically significant in two.272 281 294 299 300 306 One
study showed no effect on risk297 and the other study showed
non-significant decreased risk.278 282 310 Six studies reported
separately on postmenopausal breast cancer.277 278 281 282 289
297 306 310 Five of these showed increased risk,278 281 282 289 306
310 which was statistically significant in one.306 The other
study reported non-significant decreased risk.297
In addition, 19 case-control studies investigated alcoholic
drinks.289 302 318-323 325-331 333 Most showed increased risk for
the highest intake group when compared to the lowest,
which was statistically significant in six.302 318 321 323 327 329
Two studies showed non-significant decreased risk317 324; one
study showed no effect on risk.332 Four studies reported sep-
arate results for premenopausal breast cancer.318 320 322 333 Of
these, two studies showed non-significant increased risk,318
333 one showed statistically significant increased risk in
Figure 4.8.13 Alcoholic drinks and breast cancer; cohort
and case-control studies
Cohort
Wu 1999 1.38 (0.84–2.26)
Wu 1999 1.08 (0.78–1.50)
Byrne 1996 0.99 (0.77–1.28)
Summary estimate 1.07 (0.89–1.29)
Case control
La Vecchia 1989 1.10 (1.07–1.13)
Baumgartner 2002 1.07 (0.82–1.38)
Katsoyannis 1994 1.05 (0.97–1.12)
Kinney 2000 1.03 (0.92–1.15)
Lash 2000 1.01 (0.86–1.19)
Rosenberg 1990 0.97 (0.86–1.10)
Viladiu 1996 0.97 (0.93–1.11)
Freudenheim 1995 0.94 (0.79–1.13)
Sneyd 1991 0.94 (0.81–1.09)
Baughmater 2002 0.90 (0.79–1.03)
Summary estimate 1.05 (1.03–1.07)
Relative risk (95% CI)
Relative risk, per 5 times/week
10.2 2 4 61.50.5
Figure 4.8.14 Alcoholic drinks and breast cancer; cohort
and case-control studies: dose response
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parous women,322 and one showed non-significant decreased
risk.320 Seven studies reported separately on postmenopausal
breast cancer.289 318 320-322 326 333 All seven studies showed
increased risk for the highest intake group when compared
to the lowest, which was statistically significant in three,318
321 333 and in oestrogen-sensitive cancers in a fourth study.326
Both ecological studies showed statistically significant,
positive associations.311 312
When data were analysed separately for drink type (beers,
wines, or spirits), they became insufficient to draw any firm
conclusions.
Alcohol (as ethanol)  
Twelve cohort studies investigated ethanol intake and all-age
breast cancer.315 336 338-341 343-350 352-354 361-364 Eight cohort stud-
ies showed increased risk for the highest intake group when
compared to the lowest,315 336 338-341 343 344 346-348 350 352-354 361
362 which was statistically significant in six.338 341 344 350 352 354
361 Four studies showed decreased risk,345 349 363 364 which was
statistically significant in one.364 Meta-analysis was possible
on nine cohort studies, giving a summary effect estimate of
1.10 (95% CI 1.06–1.14) per 10 g/day, with high hetero-
geneity (figure 4.8.15). Heterogeneity could be partly
explained by differential adjustment for age and reproduc-
tive history.
Seven cohort studies reported separately on pre-
menopausal breast cancer.315 340 343 347 348 352-354 361 Six stud-
ies showed increased risk,340 343 347 348 352-354 361 which was
statistically significant in three.340 348 352 One study showed
a non-significant decreased risk.315 Meta-analysis was possi-
ble on five studies, giving a summary estimate of 1.09 (95%
CI 1.01–1.17) per 10 g/day, with moderate heterogeneity.315
340 343 347 352 Eighteen cohort studies reported separately on
postmenopausal breast cancer.315 334 335 337 339 340 342 347 348 351-
361 Fifteen studies showed increased risk,315 335 337 339 342 347
348 351 353-361 which was statistically significant in seven.315 335
337 339 342 347 357-359 Three studies showed non-significant
decreased risk.334 340 352 Meta-analysis was possible on 11
studies, giving a summary effect estimate of 1.08 (95% CI
1.05–1.10) per 10g/day, with moderate heterogeneity.315 334
335 339 340 347 352 355 358-360
Pooled analysis from 6 cohort studies (over 320 000 par-
ticipants, followed up for up to 11 years, more than 4300
breast cancer cases) showed a significant increased risk with
increasing intake, with an effect estimate of 1.09 (95% CI
1.04–1.03) per 10 g/day.396 No significant heterogeneity was
observed by menopausal status.
A separate pooled analysis of 53 case-control studies (more
than 58 000 cases and more than 95 000 controls) showed
a significant increased risk with increasing intake, with an
effect estimate of 7.1 per cent increased risk (95% CI
5.5–8.7%; p < 0.00001) per 10 g/day.397 No significant het-
erogeneity was observed by menopausal status.
Eighteen case-control studies investigated ethanol intake
and all-age breast cancer.280 282 317 318 332 365-371 374 378 379 381 383
384 386 387 390 391 Twelve case-control studies showed increased
risk for the highest intake group when compared to the low-
est,280 318 332 365 367-369 374 379 381 383 384 386 387 391 which was sta-
tistically significant in five.280 318 368 369 374 381 384 Five studies
showed decreased risk,317 366 370 371 378 390 which was statisti-
cally significant in one378; and one study showed no effect
on risk.282 Meta-analysis was possible on seven case-control
studies, giving a summary effect estimate of 1.06 (95% CI
1.04–1.09) per 10 g/day, with moderate heterogeneity
(figure 4.8.16). 
When case-control data were analysed separately by
menopausal status, the meta-analysis for premenopausal
breast cancer was consistent with that for all ages (1.08
(95% CI 1.04–1.13) per 10 g/day; nine studies),317 318 369 
373 376 377 380 383 389 but the meta-analysis for postmeno-
pausal breast cancer was not (1.00 (95% CI 0.98–1.01) 
per 10 g/day; 10 studies).318 369 372 373 375 380 382 383 385 388
All four ecological studies showed statistically significant
positive associations.392-395
The general mechanisms through which alcohol could
plausibly cause cancer are outlined below. In addition, most
experimental studies in animals have shown that alcohol
intake is associated with increased breast cancer risk. Alcohol
interferes with oestrogen pathways in multiple ways,
Figure 4.8.15 Ethanol and breast cancer; cohort studies
Holmberg 1995 4.32 (1.34–13.89)
Rissanen 2003 2.33 (1.28–4.24)
Dumeaux 2004 1.41 (1.21–1.64)
Willett 1987 1.19 (1.11–1.29)
Lin 2005 1.15 (1.03–1.28)
Hines 2000 1.08 (0.88–1.33)
Rohan 2000 1.03 (0.98–1.09)
Oodman 1997 0.86 (0.67–1.11)
Schatzkin 1989 0.64 (0.43–0.94)
Summary estimate 1.10 (1.06–1.14)
Relative risk (95% CI)
Relative risk, per 10 g/day
10.2 5 10 15
Figure 4.8.16 Ethanol and breast cancer;
case-control studies
Bowlin 1997 1.44 (1.11–1.86)
Rohan 1988 1.21 (0.99–1.48)
Harvey 1987 1.10 (1.02–1.18)
Brandt 2004 1.08 (0.94–1.23)
Ferraroni 1998 1.06 (1.03–1.09)
Trentham-Dietz 2000 1.05 (1.00–1.11)
Webster 1983 1.01 (0.95–1.08)
Summary estimate 1.06 (1.04–1.09)
Relative risk (95% CI)
Relative risk, per 10 g/day
10.2 1.5 20.5
168
P A R T  2  •  E V I D E N C E  A N D  J U D G E M E N T S
influencing hormone levels and oestrogen receptors.398
There is an interaction between folate and alcohol affect-
ing breast cancer risk: increased folate status partially
mitigates the risk from increased alcohol consumption.399
There is ample, generally consistent evidence from
case-control and cohort studies. A dose-response
relationship is apparent. There is robust evidence for
mechanisms operating in humans. The evidence that
alcoholic drinks are a cause of premenopausal and
postmenopausal breast cancer is convincing. No
threshold was identified.
The Panel is aware that since the conclusion of the SLR, one
case-control study400 has been published. This new information
does not change the Panel judgement (see box 3.8).
Liver 
Fifteen cohort studies120 208 220 227 401-422 and 33 case-control
studies158 423-460 investigated alcoholic drinks and liver can-
cer. Fourteen cohort studies6 120 227 244 403 404 409 410 412 416 422
461-468 and 21 case-control studies158 427 431 434 436 440 446 452 456
459 469-485 investigated ethanol intake.
Total alcoholic drinks
Data are available from 15 cohort studies.120 208 220 227 401-422
Eleven cohort studies showed increased risk for the highest
intake group when compared to the lowest,120 220 227 401-404 407-
410 413 414 416 417 420 422 which was statistically significant in
two.120 401 Two studies showed non-significant decreased
risk.405 406 412 418 419 Two studies stated that there was no sig-
nificant difference but did not provide further data.411 415 421
Heterogeneity is partially explained by differences in
whether and how studies have adjusted for hepatitis virus
status. The effect estimates of eight studies are given in the
high to low comparison forest plot (figure 4.8.17). 
Data are available from 33 case-control studies.158 423-460
Twenty-eight case-control studies showed increased risk for
the highest intake group when compared to the lowest,158 423-
432 434-448 451-456 460 which was statistically significant in 12 (one
of these studies reported a non-significant decreased risk in
women, but a statistically significant increased risk in
men440).158 423 427 429-432 434 439 440 442 444 446 447 454-456 Two studies
showed non-significant decreased risk.449 Three studies stat-
ed that there was no significant effect on risk.433 450 457-459 Meta-
analysis was possible on five studies, giving a summary effect
estimate of 1.18 (95% CI 1.11–1.26) per drink/week, with
high heterogeneity (figure 4.8.18).158 425 434 449 460
A dose-response relationship is apparent from case-control
but not cohort data.
Alcohol (as ethanol) 
Ten cohort studies showed increased risk for the highest
intake group when compared to the lowest,6 120 244 403 404 409
410 416 422 461 465-468 which was statistically significant in five
(one of these studies reported a non-significant increased risk
in women, but a statistically significant increased risk in
men461).6 120 244 416 461 465 468 Three studies in men with cir-
rhosis showed non-significant decreased risk.227 412 462 463 One
study stated that there was no significant effect on risk.464
Meta-analysis was possible on six cohort studies, giving a
summary effect estimate of 1.10 (95% CI 1.02–1.17) per 10
g/day or 10 ml/day, with no heterogeneity (figure 4.8.19).
Twenty case-control studies showed increased risk for the
highest intake group when compared to the lowest,158 427 431
434 436 440 446 452 456 469 470 472-475 477-479 481-485 which was statisti-
cally significant in 12.158 427 431 434 440 446 456 474 475 477-479 481 483-
485 One study showed non-significant decreased risk.476
Meta-analysis was possible on 14 case-control studies, giv-
ing a summary effect estimate of 1.17 (95% CI 1.09–1.25)
per 10 g/day or 10 ml/day, with high heterogeneity (figure
Figure 4.8.17 Alcoholic drinks and liver cancer:
cohort and case-control studies
Cohort
Kono 1987 2.36 (1.04–5.35)
Hirayama 1989 1.89 (1.40–2.55)
Ross 1992 1.10 (0.46–2.60)
Goodman 1995 Men 1.11 (0.72–1.71)
Goodman 1995 Women 1.25 (0.78–1.99)
Mutu 1989 1.50 (0.42–5.31)
Yu 1999 1.39 (0.68–2.14)
Evans 2002 Men 0.90 (0.90–1.01)
Evans 2002 Women 0.57 (0.29–1.18)
Wang 2003 HBsAg positive 1.29 (0.78–2.10)
Wang 2003 HBsAg negative 2.00 (0.89–4.51)
Case control
Stemhagen 1983 Men 1.30 (0.64–2.63)
Stemhagen 1983 Women 1.63 (0.92–2.89)
Inaba 1984 3.62 (1.68–7.79)
Austin 1986 2.60 (1.26–5.35)
Harris 1988 Men 1.28 (0.69–2.39)
La Vecchia 1988 1.43 (0.83–2.46)
Harris 1988 Women 1.93 (0.66–5.63)
Tsukuma 1990 Men 2.60 (1.70–3.99)
Olubuyide 1990 Men 1.70 (0.90–3.21)
Olubuyide 1990 Women 1.40 (0.04–50.00)
Hiyama 1990 8.00 (1.30–49.36)
Qureshi  1990 3.04 (0.31–29.54)
Yu 1991 Anti-HCV negative 2.10 (1.20–3.69)
Choi 1991 Men 2.46 (1.16–5.22)
Yamaguchi 1993 HBsAg negative 2.70 (1.81–4.02)
Newton 1996 1.20 (0.50–2.89)
Wang 1996 1.28 (0.98–1.67)
Braga 2000 Men 1.68 (1.14–2.48)
Braga 2000 Women 1.30 (0.42–4.01)
Mukaiya 1998 2.31 (1.20–4.42)
Mandishona 1998 2.00 (0.49–8.10)
Kuper 2000 1.90 (0.91–3.96)
Yu 2002 1.38 (0.68–2.81)
Donato 2002 Men 2.70 (1.09–6.71)
Donato 2002 Women 0.90 (0.33–2.49)
Munaka 2003 1.45 (0.81–2.60)
Tsai 2004 2.55 (1.50–4.33)
0.2 0.5 1 2 5
Relative risk (95% CI)
Relative risk, highest vs lowest exposure category
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4.8.20). Heterogeneity may be due to the inclusion of stud-
ies that reported alcoholic behaviour.
A dose-response relationship is apparent from cohort and
case-control data (figure 4.8.21).
Beers
Two cohort studies6 486 and five case-control studies425 435 444
452 473 479 reported separately on beer drinking.
Both cohort studies showed statistically significant
increased risk with increased intake.6 486 Four case-control
studies also showed increased risk,425 435 444 452 479 which was
statistically significant in three.435 444 452 479 One study report-
ed no effect on risk.473
Wines
Three cohort studies6 410 486 and one case-control study425
reported separately on wine drinking.
One cohort study showed non-significant increased risk
with increased intake.410 Two studies stated that there was
no significant effect on risk.6 486 The single case-control study
showed non-significant increased risk.425
Figure 4.8.18 Alcoholic drinks and liver cancer;
case-control studies
Austin 1986 HBsAg 1.07 (0.86–1.33)
Lu 1988 0.89 (0.77–1.02)
Choi 1991 1.30 (1.19–1.41)
Yu 1991 1.39 (1.08–1.79)
Mukaiya 1998 1.21 (1.01–1.44)
Summary estimate 1.18 (1.11–1.26)
Relative risk (95% CI)
Relative risk, per drink/week
10.7 1.51.20.8
Figure 4.8.19 Ethanol and liver cancer; cohort studies
Oshima 1984 1.24 (1.03–1.50)
Ross 1992 1.20 (0.88–1.63)
Murata 1996 0.99 (0.85–1.16)
Miyakawa 1996 HBV-carrier 0.96 (0.62–1.48)
Khan 2000 1.09 (1.00–1.20)
Sharp 2005 1.26 (0.82–1.93)
Summary estimate  1.10 (1.02–1.17)
Relative risk (95% CI)
Relative risk, per 10 g/day
10.2 520.5
Figure 4.8.20 Ethanol and liver cancer; case-control studies
Infante 1980 Cirrhotic 5.01 (2.42–10.37)
Infante 1980 Non-cirrhotic 6.10 (2.20–16.93)
Yu 1983 1.12 (1.00–1.26)
Inaba 1984 1.81 (1.27–2.59)
Tsukuma 1990 1.17 (1.09–1.29)
Mayans 1990 1.19 (1.09–1.29)
Yamaguchi 1993 Men 1.11 (1.06–1.15)
Arico 1994 0.93 (0.87–1.00)
Pyong 1994 Men 1.40 (1.16–1.69)
Shin 1996 1.05 (0.97–1.15)
Zhang 1998 1.05 (0.95–1.17)
Mukaiya 1998 1.28 (1.05–1.57)
Kuper 2000 1.04 (0.96–1.13)
Hassan 2002 1.16 (1.03–1.30)
Gelatti 2005 1.28 (1.19–1.38)
Summary estimate 1.17 (1.09–1.25)
Relative risk (95% CI)
Relative risk, per 10 g/day
10.2 520.5
Figure 4.8.21 Ethanol and liver cancer; cohort studies:
dose response
Sharp 2005
Ross 1992
Oshima 1984
Murata 1996
Miyakawa 1996 HBV-carrier
Khan 2000
0 20 40 60 80 100
Ethanol (g/day)
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Spirits
Two cohort studies6 486 and five case-control studies425 444 469
472 479 487 reported separately on spirits.
Both cohort studies showed no significant effect on risk.6
486 All case-control studies showed increased risk,425 444 469 472
479 487 which was statistically significant in one444 479; and one
case-control study showed statistically significant increased
risk for consumption of illicit liquor.487
Several studies used participants judged to be at high risk
of developing liver cancer, that is, people who already had
liver cirrhosis. These results are particularly hard to interpret
as cirrhosis status affects drinking behaviour. Also the can-
cer disease path may be different in people with cirrhosis.
Assessment of some studies was hampered by poor expo-
sure assessment, and not all studies adjusted for known con-
founders such as hepatitis B or C virus.
The general mechanisms through which alcohol could
plausibly cause cancer are outlined below. In addition, reg-
ular, high levels of alcohol consumption are known to cause
liver damage. Tumour promotion has been linked to inflam-
mation in the liver through alcohol-associated fibrosis and
hepatitis.488 489 Alcohol consumption, even at moderate lev-
els, is associated with increases in levels of circulating hepati-
tis C virus RNA in carriers. Hepatitis C virus infection is
highly prevalent among alcoholics with chronic liver disease
and appears to accelerate the course of alcoholic liver disease
(see chapter 7.8).
There is ample, generally consistent evidence from
both cohort and case-control studies. A dose-response
relationship is apparent. Alcohol is a cause of cirrhosis
that predisposes to liver cancer, but the factors that
determine why some people are susceptible to
cirrhosis are not known. Alcoholic drinks are a
probable cause of liver cancer. No threshold was
identified.
The Panel is aware that since the conclusion of the SLR, one
case-control study490 has been published. This new information
does not change the Panel judgement (see box 3.8).
Kidney 
Three cohort studies491-493 and 16 case-control studies308 494-
509 investigated alcoholic drinks and kidney cancer. Four
cohort studies6 492 510-513 and five case-control studies503 504
514-516 investigated ethanol intake.
Total alcoholic drinks
Two cohort studies showed non-significant increased risk for
the highest intake group when compared to the lowest.491 493
One study showed a statistically significant decreased
risk.492 None of the studies was adjusted for smoking; effect
estimates were 1.42 (95% CI 0.69–2.9),493 1.7 (95% CI
0.8–3.5) for women491 and 1.2 (95% CI 0.5–2.6) for men,491
and 0.62 (95% CI 0.41–0.94).492
Seven case-control studies showed decreased risk for the
highest intake group when compared to the lowest,308 494 496
499 501-504 of which one was statistically significant494and one
was statistically significant in women but not in men.504
Three studies showed no effect on risk495 497 509; three stud-
ies stated that there was no significant association505-507; two
studies showed non-significant increased risk498 500; one
study showed a non-significant decreased risk in men and a
non-significant increased risk in women.508 Meta-analysis
was possible on two studies that adjusted for smoking, giv-
ing a summary effect estimate of 0.92 (95% CI 0.71–1.20)
per serving/day, with moderate heterogeneity (figure
4.8.22).496 498
Alcohol (as ethanol)
All four cohort studies showed decreased risk with increased
ethanol intake,6 492 510-513 which was statistically significant
in one.510 512 Meta-analysis was possible on two unadjusted
studies, giving a summary effect estimate of 0.48 (95% CI
0.26–0.90) per serving/day, with no heterogeneity.492 511
Three case-control studies showed non-significant
decreased risk with increased ethanol intake.504 514 516 One
study showed no effect on risk,515 and one study stated no
significant association.503 Meta-analysis was possible on two
unadjusted studies, giving a summary effect estimate of 0.90
(95% CI 0.77–1.05) per serving/day, with no heterogeneity
(figure 4.8.23).514 515
There is no known mechanism through which alcohol
could decrease kidney cancer risk.
It is unlikely that alcohol increases the risk of kidney
cancer, though a protective effect cannot be excluded.
Figure 4.8.22 Ethanol and kidney cancer;
case-control studies
Yuan 1998 1.01 (0.97–1.05)
Parker 2002 0.76 (0.53–1.07)
Summary estimate 0.92 (0.71–1.20)
Relative risk (95% CI)
Relative risk, per unit/day
1 20.5
Figure 4.8.23 Alcoholic drinks and kidney cancer;
case-control studies
Mattioli 2002 0.90 (0.76–1.04)
Lindblad 1997 1.00 (0.39–2.59)
Summary estimate 0.90 (0.77–1.05)
Relative risk (95% CI)
Relative risk, per unit/day
10.25 420.5
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The Panel is aware that since the conclusion of the SLR, one
cohort study517 has been published. This new information does
not change the Panel judgement (see box 3.8).
General mechanisms
Evidence suggests that reactive metabolites of alcohol, such
as acetaldehyde, may be carcinogenic. Additionally, the
effects of alcohol may be mediated through the production
of prostaglandins, lipid peroxidation, and the generation of
free-radical oxygen species. Alcohol also acts as a solvent,
enhancing penetration of carcinogens into cells. Alcohol has
been demonstrated to alter retinoid status in rodent studies
and, as a result, cellular growth, cellular differentiation, and
apoptosis are adversely altered. For all these pathways,
genetic polymorphisms might also influence risk.398
Lastly, heavy consumers of alcohol may have diets
deficient in essential nutrients, making tissue susceptible to
carcinogenesis.
4.8.6 Comparison with previous report
In general, the evidence that alcohol is a cause of a number
of cancers has become stronger since the mid-1990s. 
The previous report did not find any distinctions between
different types of alcoholic drink. This finding is upheld. 
The previous report identified a threshold of modest
consumption of alcoholic drinks, below which no effect on
cancer risk was observed, with the exception of breast can-
cer. Current evidence does not identify a generally ‘safe’
threshold. 
Current evidence strengthens the previous judgements on
colorectal and breast cancers. 
4.8.7 Conclusions
The Panel concludes:
Evidence that alcoholic drinks of any type are a cause of
various cancers has, on the whole, strengthened. 
The evidence that alcoholic drinks are a cause of cancers
of the mouth, pharynx, and larynx, oesophagus, colorectum
(men), and breast is convincing. They are probably a cause
of colorectal cancer in women, and of liver cancer. It is
unlikely that alcoholic drinks have a substantial adverse
effect on the risk of kidney cancer.
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Practically all food and drink is changed before it is
consumed, for instance by peeling or cooking. The
majority of foods and drinks consumed by most people
around the world are now modified in many more ways.
Products on sale in supermarkets, small shops, and other
retail outlets are chilled, pasteurised, canned, bottled,
vacuum packed, or otherwise packaged. Most contain a
number of ingredients, some of which are also processed.
The use of ingredients such as modified starches, added
sugars, hydrogenated fats, and also additives used as
bulking aids, preservatives, colours, flavours, sweeteners,
and for other purposes, is common. In general, rises in
consumption of fats, oils, and added sugars occur because
of their increased use in processed foods and drinks.
Animal and plant products both contain traces of
agricultural chemicals. Methods of industrial and domestic
food preparation and cooking change the nature of food as
eaten. 
It is possible that processing and/or preserving methods
may alter the nature of food. Different methods of food
preservation and processing may be protective, causative,
or neutral in their effects on the risk of cancer.
It is for this reason that the Panel decided that, as far as
practically possible, the evidence on methods of food
production, preservation, processing, and preparation
(including cooking) should be summarised and judged in
the context of the relevant foods and drinks. Most of this
evidence is to be found in the previous sections of
Chapter 4. 
This section summarises other information and findings
concerning the ways in which foods and drinks are
changed before consumption. These include where data
from animal and other experimental studies are not
supported by evidence from epidemiological studies. Such
studies are often carried out for the purposes of
establishing regulations for the safety in use of chemicals
known to be toxic, but may use levels of exposure far
higher than occur in foods and drinks. 
In line with its general criteria for judgement, the Panel
decided to make no judgements on experimental findings
alone that are not supported by epidemiological or other
evidence. Nevertheless, the Panel concurs that, in general,
it seems reasonable to conclude that the changes made to
foods and drinks within well regulated, modern food
systems, and made to foods and drinks as usually
prepared and cooked, are of themselves unlikely to modify
the risk of cancer significantly. For this reason, no matrix
showing Panel judgements is included in this section. 
In line with its general criteria for judgement, the Panel
has decided to make no judgements on experimental
findings from studies using doses of substances at levels
far above those found in foods and drinks, many if not
most of which are conducted to guide toxicological
regulations. The Panel also concurs that changes made to
processed foods and drinks within well regulated, modern
food systems are of themselves unlikely to modify the risk
of cancer significantly. For this reason, no matrix showing
Panel judgements is included in this section. Those aspects
of food production, preservation, processing, and
preparation that have been examined in epidemiological
as well as experimental settings are discussed and judged
in earlier sections of Chapter 4.
This section summarises some of the general methods by
which foods and drinks may be changed during their pro-
duction, preservation, processing, and preparation (includ-
ing cooking) that may be relevant to the risk of cancer.
Almost all foods and drinks are altered — processed, in a
general sense of the word — before being consumed. 
Reports concerned with the prevention of chronic diseases
often mention the added nutritional value of lightly
processed cereals (grains), and of vegetables and fruits. But
they may not make much distinction between foods and
drinks as such, and as modified in production, preservation,
processing, and preparation. Previous reports concerned with
cancer have concluded that some methods of food and drink
modification can produce carcinogens in experimental set-
tings, and that this might reasonably influence cancer risk.
Storage conditions that allow contamination of cereals
(grains) and other plant foods by aflatoxins, and the prepa-
ration of fish Cantonese-style by salting and fermentation,
have previously been identified as causes of cancer.
This section covers aspects of food production, preserva-
tion, processing, and preparation that are sometimes thought
to be relevant to the risk of cancer, but where experimental
information (when this exists) is not supported by epidemi-
ological evidence or where there is no such evidence. Where
the evidence for foods or drinks is sufficient to judge that
they may cause or protect against any cancer, this is sum-
marised and judged in earlier sections of this chapter. For
example, see chapter 4.1 for the Panel’s findings on aflatoxin
contamination; for processed meat and also cooking meth-
ods, see chapter 4.3; for salting, see chapter 4.6. 
4.9.1 Production
Modern food systems (box 4.9.1) involve various aspects of
food production that have some potential to modify the risk
of cancer. A clear benefit of these systems of production, dis-
tribution, and retail sale, with chilling used at all stages, is
4.9  Food production, preservation,
processing, and preparation
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the all-year round supply of fresh vegetables and fruits (see
chapter 4.2). 
The industrialised farming methods that are part of most
modern food systems in most countries use various tech-
nologies to maximise production. These include the use of
fertilisers, pesticides, and herbicides on food crops; and of
veterinary drugs in rearing livestock and in aquaculture.
Fertilisers play a part in determining nutrient levels in plants,
as well as potentially modifying concentrations of other
bioactive microconstituents. Residues of these and other
chemicals applied to crops are washed from soils by the 
rain and can contaminate water supplies. See boxes 4.9.2
and 4.9.3. 
Methods or consequences of food production, where epi-
demiological evidence shows or suggests an effect on the risk
of cancer, are summarised and judged earlier in this chapter.
These are fungal contamination (chapter 4.1), hot drinks 
and foods (chapter 4.7), and arsenic contamination 
(chapter 4.7). 
4.9.1.1  Pesticides and herbicides
The use of synthetic pesticides and herbicides has increased
vastly since the middle of the 20th century. Nearly 2500
tonnes of these chemicals were used worldwide in 2001.1
The chlorinated pesticide dichloro-diphenyl-trichloro-
ethane (DDT) has been banned from use in many countries.
Other organochlorine pesticides are now largely being
replaced with organophosphorus and carbamate pesticides.
These newer types are less persistent in the environment,
and have not been found to be carcinogenic in experimen-
tal settings. 
In many countries, the use of pesticides and herbicides is
regulated to minimise residues in foods and drinks, and there
are internationally recommended maximum residue limits
(box 4.9.3). The use of persistent organic pollutants
(organochlorine pesticides, furans, dioxins, and polychlori-
nated biphenyls) will be banned by 2025 under the United
Nations Environment Programme’s Stockholm Convention,
which entered into force in May 2004. 
Many of these contaminants have the potential to accu-
mulate within food systems, and residues of pesticides and
herbicides that have been banned from use, or are being
phased out, may still be present in foods eaten today. Some
contaminants, such as heavy metals and persistent organic
compounds, tend to be deposited in fatty tissues and are not
easily metabolised or excreted. They accumulate in living
creatures, in amounts higher than background levels (for
instance, in the soil). Dietary exposure increases with each
step up the food chain, as predators consume prey contam-
inated with these residues. 
There are theoretical grounds for concern, which are con-
stantly reviewed by international and national regulatory
bodies. However, there is no epidemiological evidence that
current exposures are causes of cancers in humans, and so
the Panel has made no judgements. Nevertheless, a precau-
tionary approach is wise for women of reproductive age,
since vulnerability during embryonic phases of development
is increased, and early exposure may result in increased risk
at later stages in life.
4.9.1.2 Veterinary drugs
Industrial animal production, as distinct from ‘organic’ farm-
ing (box 4.9.2), requires constant use of antimicrobial drugs
to treat and prevent infectious diseases, and promote growth.
Residues of these antimicrobials can be found in foods and
drinks, normally at levels lower than internationally recom-
mended maximum residue limits (box 4.9.3). When anti-
microbials have been found to be carcinogenic in animals,
their licence for that use has been withdrawn.
Hormonal anabolic agents are used in animal husbandry
in some countries, including the USA, to prevent and ter-
minate pregnancy in cows and to promote growth. Their use
has been banned in other countries as well as in the
European Union. Hormones designed to stimulate milk pro-
duction include bovine somatotropin and porcine soma-
totropin. Many hormones have been found to be multisite
carcinogens in experimental settings.2 These include oestro-
gens, classed as group 1, human carcinogens, by the
International Agency for Research on Cancer (IARC), prog-
Food systems involve the production, preservation, processing,
and preparation (including cooking) of food. Gatherer–hunters
take food as it is found in nature and modify it by the use of fire.
Pastoralists modify the animals that are a source of their food
through breeding. Agriculture improves plants for human food
use, by selective breeding and planting, and animals too are sub-
ject to selective breeding. In Egypt, selectively bred wheat was
ground into flour, kneaded with water and other ingredients,
and baked into bread as early as 4000 years ago. 
Thousands of years before industrialisation, most food and
drink consumed by the majority of people was modified in some
way in its production. This included preservation by drying, and
later other methods such as salting, fermenting, pickling, curing,
spicing, and freezing in cold climates; and various methods of
preparation and cooking, including boiling and roasting. 
Food systems were transformed as part of the industrial and
later, the technological revolution. But this was not the point at
which foods and drinks became modified for the first time.
Rather, many new processes were developed such as sterile bot-
tling and canning. Then, beginning in the late 19th century, steel
roller mills were devised for the mass-manufacture of white flour
and thus white bread; refrigerated transport using railways and
ships made possible the industrial production and international
export of meat and dairy products. In the 20th century, com-
mercialisation of the hydrogenation process to turn liquid oils
into solid fats made margarine manufacture a big business, and
the mass manufacture of soft drinks developed.
What is now known as ‘conventional’ farming, making exten-
sive use of chemical fertilisers, herbicides, and pesticides, and
feed concentrates for animals, developed mainly in the second
half of the 20th century. More recent developments in food sys-
tems include the use of containers to transport foods and drinks
nationally and internationally; the development of supermar-
kets, of which the biggest are now transnational; and the increas-
ing concentration of food producers, manufacturers, retailers,
and caterers.
Box 4.9.1 Food systems
174
P A R T  2  •  E V I D E N C E  A N D  J U D G E M E N T S
estins (IARC group 2B, possible human carcinogens), and
also testosterone (IARC group 1, human carcinogens).
The toxicity of antimicrobial drugs is constantly reviewed
by international and national regulatory bodies. The Panel
notes the findings on hormonal anabolic agents and also the
lack of epidemiological evidence. Because there is no sup-
porting epidemiological or other evidence, the Panel made
no judgements.
4.9.1.3 Genetic modification 
Plant breeding is a process of genetic exchange which is often
undertaken with the purpose of acquiring traits that are
either beneficial to humans or increase yield. More recently,
the use of new technologies of genetic modification, intrin-
sic to agriculture and animal husbandry from their begin-
nings, has raised great public interest and controversy. Many
crops are now genetically modified by means of gene trans-
fer within and between species. Potential uses of modern
genetic modification technology in food production include
changing nutritional composition (for example, beta-
carotene in ‘golden rice’); increasing the hardiness of crops;
improving pest or disease resistance; and increasing herbi-
cide tolerance in crop plants (to allow the use of generic
herbicides). 
Not all genetic modifications include transgenes, in which
a gene from one species is transferred across species, or even
kingdoms — that is to say, from plants to animals. Some
genetic modifications involve only inactivating existing
genes. For example, tomatoes have been genetically modi-
fied to render inactive the enzyme that softens the tomato
once ripe; thus, the tomato remains hard despite being ripe.
This is beneficial for transport and storage purposes.
The production and use of transgenic and genetically mod-
ified foods for humans or animal consumption are regulat-
ed in most but not all countries. The regulations require that
all genetically modified foods be of equivalent safety as 
the food they are replacing, both nutritionally and
toxicologically. 
Any effect of genetically modified foods on risk of human
disease might be a result of changes in the types of chemi-
cal pesticides or herbicides used, rather than of genetic mod-
ification itself. Genetically modified crops may require less
use of pesticides and herbicides.  
Any effect of modern methods of genetic modification of
foods on the risk of cancer is unknown. Because there is no
supporting epidemiological or other evidence, the Panel
made no judgements.
There is too little evidence to draw any conclusion about
the association between methods of production and risk of
cancer.
4.9.2  Preservation
Methods of preserving foods have probably been in use since
before recorded history began. Gatherer–hunter and peas-
ant–agricultural food systems (see chapter 1.1) include
various techniques to preserve foods, which remain in use,
such as drying, underground storage, fermenting, smoking,
and salting. A range of other methods of preservation accom-
panies, and is part of, industrialisation and urbanisation.
These include canning, bottling, refrigeration, heat treat-
ment, and irradiation. 
Methods of food preservation, where epidemiological evi-
dence shows or suggests an effect on the risk of cancer, are
summarised and judged earlier in this chapter. These are
refrigeration (box 4.6.4); processing meat (‘processed meat’
refers to red meats preserved by smoking, curing, or salting,
or by the addition of chemicals, see box 4.3.1 in chapter 4.3);
preserving fish Cantonese-style (see box 4.3.5 in chapter
4.3); and salting (chapter 4.6).
4.9.2.1 Drying
Drying is an ancient method used to preserve cereals
(grains), pulses (legumes), fruits, and other plant foods. It
is also used to preserve meat and fish, often as part of anoth-
er preservation process such as salting (see box 4.3.5 in chap-
ter 4.3). Freeze-drying, where the food is frozen and the
water extracted, has been in commercial use since the mid-
20th century, and is used to preserve fruits, herbs, meat, fish,
milk, eggs, coffee, and other foods. 
4.9.2.2  Fermenting
Fermentation is an ancient method used to preserve many
foods and drinks. It may originally have been discovered by
So-called ‘organic’ farming is essentially a reversion to, or revival
of, methods of agriculture that were the standard until the intro-
duction of farming systems dependent on chemical fertilisers,
pesticides, and biocides, in the second half of the 20th century. 
Organic farming avoids or largely excludes the use of synthetic
fertilisers and pesticides, plant growth regulators, and livestock
feed additives. Farmers tend to rely on crop rotation, crop
residues, animal manures, and mechanical cultivation to main-
tain soil productivity, and to supply plant nutrients and control
weeds, insects, and other pests. Organic farming is intended to
be indefinitely sustainable. 
This type of farming has become well established within
Europe and is expanding at a steady rate. More than 10 per cent
of farms in Austria, Switzerland, and several other countries use
organic methods. 
The retail market for organic farming in high-income countries
has grown about 20 per cent each year since the early 1990s due
to increasing consumer demand. Production and distribution
have become correspondingly large scale. The variety and avail-
ability of processed organic food has increased dramatically, and
the cost — which was initially high — is continuing to fall.
Claims that foods produced by organic methods are biologi-
cally or nutritionally superior to food produced by intensive
methods are not supported by clinical or epidemiological evi-
dence, but some food compositional data indicates higher con-
centrations of some constituents like vitamin C and dietary fibre.
There is evidence that organic products contain fewer residues
from chemicals employed in conventional agriculture. However,
the subject remains a matter of controversy.
Box 4.9.2 ‘Organic’ farming
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accident, because foods ferment as a result of the action of
bacteria or moulds (yeasts). Fermentation has special fea-
tures. It characteristically changes the sensory and nutri-
tional qualities of foods and drinks: for example, bacterial
fermentation turns milk into yoghurt and cabbage into kim-
chi (a staple food in Korea) and sauerkraut. Fermentation
by yeasts turns sugar into alcohol, and so is an essential part
of the process by which cereals (grains), vegetables, fruits,
and other plant foods are the basis for beers, wine, and
spirits.  
4.9.2.3  Canning, bottling
Bottling and canning were first developed around 1800. The
process involves heating or cooking fruits, vegetables, meats,
and other foods in containers, then sealing them while still
hot. Glass bottles were first used, and then cans. 
4.9.2.4  Pasteurisation 
Heat can be used to preserve milk and fruit juices by pas-
teurisation, which kills many micro-organisms. This involves
various methods of rapid heating to a specific temperature,
maintaining that temperature for a set period of time, fol-
lowed by rapid cooling.  
4.9.2.5  Chemical preservation 
Chemical preservative additives are added to perishable
processed foods. Antimicrobials inhibit the growth of bac-
teria and fungi. Antioxidants reduce the rate at which lipids
are oxidised through exposure to air, which leads to rancid-
ity. A third type blocks the natural ripening processes that
continue to occur in plant foods following harvest. The most
commonly used antimicrobial preservatives are benzoates,
nitrites (see box 4.3.2 in chapter 4.3), and sulphites. There
are internationally specified limits for levels of chemical
preservatives in foods and drinks. 
4.9.2.6  Irradiation
Irradiation was first patented at the beginning of the 20th
century as a means of preserving food using ionising radia-
tion. The process has been tested extensively, but there is
considerable public suspicion over the safety of irradiated
foods. For example, 2-alkylcyclobutanones, which interact
with DNA in laboratory settings, are found exclusively in
irradiated foods.
Methods of preservation tend to improve food security and
enable more reliable availability of food, but may have
adverse effects too. Some methods of food preservation such
as drying are almost certainly benign, and others like fer-
mentation may have some beneficial effects. The toxicity of
preservatives and preservation methods is constantly
reviewed by international and national regulatory bodies.
Because experimental data are not supported by epidemio-
logical or other evidence, the Panel made no judgements. 
There is too little evidence to draw any conclusion about
the association between methods of preservation and risk of
cancer.
4.9.3 Processing
Food processing transforms basic ingredients into manufac-
tured foods and drinks. In the broad sense of the word, food
production, processing, preservation, and preparation are
methods of processing. The term ‘processing’ here is used to
refer to techniques and technologies other than methods of
preservation that are used by manufacturers of industrialised
processed foods. The processes that take place in kitchens
(commercial or domestic) are considered in chapter 4.9.4. 
Methods of food processing, where there is evidence that
they may affect the risk of cancer, are summarised and
judged earlier in this chapter. These are hydrogenation
(chapter 4.5); refining (chapters 4.1 and 4.6); and the pro-
duction of alcohol by fermentation (chapter 4.8). 
4.9.3.1 Additives
Many if not most processed foods contain additives. These
may be synthetic, ‘nature-identical’, or natural. As well as
preservatives, these include bulking aids, colours, flavours,
solvents, and many other categories. For general issues of
toxicity in use, see box 4.9.3. Additives mentioned here are
some of those where issues of carcinogenicity have arisen
(also see box 4.9.4).
Flavours 
Alkenylbenzenes are a group of naturally occurring flavours,
some of which have been found to cause liver cancer in
Any chemicals that have a useful function in the production,
processing, or preservation of foods or drinks may nevertheless
be toxic, and possibly mutagenic or carcinogenic. For this rea-
son, food additives and contaminants, such as traces of chemi-
cals used in industrial agricultural production, are subject to
international and national surveillance and regulations. 
They are a cause for concern and vigilance because some, and
in particular agricultural chemicals, are known to be toxic in
experimental settings, though at levels well above those found
in foods and drinks. 
There is little epidemiological evidence on the possible effects
of contaminants and additives as present in foods and drinks. 
Because contaminants and additives are subject to interna-
tional and national regulation, there is a vast amount of toxi-
cological information from experiments on laboratory animals
and other settings. Failing any other method, it seems reason-
able to observe the effects of food additives and contaminants
on laboratory animals at levels greatly in excess of any likely to
be present in foods and drinks; and based on several assump-
tions and judgements, to set limits for safety in use. When such
limits are used as regulatory limits, they are also subject to sur-
veillance and special investigation when any chemical present
in foods and drinks seems to be a cause for special concern. 
This area remains controversial. Theoretically, it would be
ideal if food supplies contained no trace of any toxic substance,
including those that are or may be mutagenic or carcinogenic.
However, some foods in nature contain carcinogens and the
issue is not confined to methods of industrial food processing. 
Box 4.9.3 Regulation of additives and
contaminants
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rodents at levels vastly higher than normal human dietary
intakes.3
Colours 
About 50 colour compounds are permitted for use in foods.4
The number varies in different countries. Various azo dyes
and other colours found to be carcinogenic in experimental
settings have been withdrawn from use. 
Those dyes now regulated for use in food are judged by
UN and other expert committees not to be carcinogenic in
the amounts found in foods and drinks. The xanthene colour
erythrosine and ammonia caramel (a class 3 carcinogen,
according to IARC) cause cancers in rats given high doses,
but are judged to be safe as now used.10
Solvents
Around 20 solvents are permitted for food use.4 Two —
dichloromethane and trichloroethylene — once used wide-
ly for decaffeinating coffee and tea, have been classified by
IARC as possibly and probably carcinogenic to humans,
respectively. The Joint FAO/WHO Expert Committee on Food
Additives has recommended that use of these solvents should
be restricted, and that levels in food should be as low as tech-
nologically possible.10 These solvents are now generally not
used for decaffeination.
4.9.3.2  Packaging
Foods and drinks can become contaminated with traces of
chemicals that migrate from packaging materials such as
plastic wrappings and bottles, and metal cans. Migration
from food-contact materials can occur during the processing,
storage, and preparation of food. The polymers used in plas-
tic packaging are biologically inert, but their monomers such
as vinyl chloride, acrylonitrile, and acrylamide can and do
migrate into foods. Plasticisers such as phthalates, used in
the manufacture of these polymers, can also migrate into
foods and drinks. These are mutagenic or carcinogenic in
experimental animals. Nonylphenol and bisphenol-A, used
in packaging, mimic the action of oestrogens in the body.
Synthetic oestrogens in the diet are not readily excreted and
may therefore accumulate in the body. 
The potential effects of industrial food-processing meth-
ods and of additives and contaminants in foods and drinks
on carcinogenicity are constantly reviewed by international
and national regulatory bodies. In view of the lack of sup-
porting epidemiological or other evidence, the Panel made
no judgements. There is too little evidence to draw any con-
clusion about the association between methods of preserva-
tion and risk of cancer.
4.9.4  Preparation
‘Preparation’ here means domestic cooking or the cooking
done in industrial kitchens, by caterers for indirect or direct
sale.
Methods of food preparation, where epidemiological evi-
dence shows or suggests an effect on the risk of cancer, are
summarised and judged earlier in this chapter. These are
grilling (broiling) and barbecuing (charbroiling) animal
foods (chapter 4.3), and carcinogenic compounds generat-
ed by cooking these foods in a flame or at very high tem-
peratures (see box 4.3.4 in chapter 4.3), and ‘fast foods’
(Chapter 8). 
4.9.4.1  Industrial cooking
Ready-to-heat and ready-to-eat dishes sold in supermarkets
and other retail outlets are a massively increasing market.
Like ‘fast foods’ sold for immediate consumption, these are
usually energy dense (see Chapter 8). Intense and prolonged
industrial cooking of starch-based foods such as crisps
(chips), French fries (chips), and other snack foods, gener-
ates acrylamides, classified by IARC as ‘probably carcinogenic
to humans’. At the time when this Report was completed,
acrylamides were the subject of special surveillance and
study. 
4.9.4.2  Steaming, boiling, stewing
These are methods of cooking at up to 100°C. Some labile
water-soluble vitamins are destroyed or lost in this process. 
4.9.4.3  Baking, roasting
These are methods of cooking at up to 200°C, but not on a
direct flame. During baking, the high temperatures are usu-
ally reached only on the surface of the food, while the inner
parts often remain below 100°C. Traditional forms of roast-
ing usually involve basting foods with oils or fats.
In the early 1940s, people who lived where drinking water sup-
plies had higher naturally occurring fluoride levels were found
to have less dental caries than people who lived in areas with
lower naturally occurring fluoride levels. This finding is supported
by more recent studies.5
Where natural fluoride levels are low, fluoride compounds are
sometimes added to water supplies in order to reduce dental
caries in the general population. 
Most cities in the USA now fluoridate their water supplies;
most of Europe does not. The advisability of fluoridation is dis-
puted: fluoride can have adverse effects at doses not much above
that recommended for prevention of dental caries, and excess
can cause dental fluorosis and bone fragility.
Studies in experimental animals have identified an increased
risk of osteosarcomas (bone cancers) when exposed to water con-
taining high concentrations of fluoride. A report published in the
USA in 2006 considered all the available evidence on fluoride and
osteosarcoma and found the overall evidence to be tentative and
mixed, and made no recommendations for revising current avail-
able fluoride levels in drinking water.6 A study published later in
2006 suggested an association between drinking fluoridated
water and osteosarcoma in adolescent men.7 However, prelimi-
nary analysis of a second set of cases from the same study does
not replicate the findings.8 The US Centers for Disease Control
and Prevention continues to support community water fluori-
dation as a safe and effective public health measure to prevent
and control tooth decay. 
These findings are not the basis for any judgement.9
Box 4.9.4 Water fluoridation
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4.9.4.4  Microwaving
Microwaving exposes food to temperatures up to 200°C.
Microwaves are a form of electromagnetic radiation. They
cause vibration of water molecules, which produces heat.
There is no evidence that microwaves have any specific effect
on food composition beyond that of heat. 
4.9.4.5  Frying, grilling (broiling), barbecuing
(charbroiling)
Also see box 4.3.4 in chapter 4.3. Frying, grilling (broiling),
and barbecuing (charbroiling) generate temperatures of up
to 400°C, and sometimes use a direct flame to cook food.
These methods create high levels of carcinogenic com-
pounds. For any cooking involving wood fires, the type of
wood used can also be an important factor in determining
which chemicals contaminate the food. Hardwoods such as
oak and hickory burn cleanly; others such as mesquite gen-
erate copious quantities of polycyclic aromatic hydrocarbons.
Because of the experimental evidence of carcinogen pro-
duction, it is prudent not to consume burned or charred
foods frequently or in large amounts. Industrial food prepa-
ration methods are regulated. Because there is no support-
ing epidemiological or other evidence, the Panel made no
judgements.
There is too little evidence to draw any conclusion about
the association between methods of preparation and risk of
cancer.
4.9.5  Interpretation of the evidence
4.9.5.1  General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7.
Aspects of food production, preservation, processing, and
preparation (including cooking), where epidemiological evi-
dence enables judgements to be made, are summarised, with
Panel judgements, in previous sections of this chapter. 
4.9.5.2  Specific
Measurement. It is practically impossible to measure small
amounts of additives and trace amounts of contaminants in
foods and drinks except by analysis. Epidemiological stud-
ies using usual methods of dietary assessment are therefore
generally uninformative. 
Terminology. The terms used for different types of cooking
vary around the world. ‘Broiling’ in the USA is called ‘grilling’
in other countries. ‘Barbecuing’ may mean grilling in flame
or slow cooking near smoking embers. Results of studies in
these areas need to be interpreted with care, given that car-
cinogenic compounds are particularly generated when meat
and other animal and plant foods are cooked in a flame, and
even more so when they are burned or charred. 
Study design. Practically all studies of the topics covered in
this section are laboratory experiments on animals. They are
commonly carried out to assess toxicity to determine safety
in use, as a basis for food safety regulations. The relevance
of such work to the actual levels consumed of substances
identified in this section is obscure. Also, it is commonly
agreed, as in this Report, that information from animal and
other experimental settings, which is unsupported by evi-
dence from epidemiological studies, is not a sound basis for
firm judgements. 
Confounding. Studies commonly report the difficulty in sep-
arating out specific methods of processing or cooking, when
foods are characteristically processed and prepared in a num-
ber of different ways.
4.9.6  Evidence and judgements
The Panel decided to make no judgements on experimental
findings of toxicity that are not supported by epidemiologi-
cal or other evidence. 
The evidence considered by the Panel is in the systemat-
ic literature review (SLR). Because the Panel made no judge-
ment on the isolated experimental data, this evidence is not
summarised separately here.
The full SLR is contained on the CD included with this
Report.
4.9.7  Comparison with previous report
In general, the previous report found that information from
animal and other experimental settings unsupported by epi-
demiological evidence, was not a basis for judgement. In this
respect, the view of the Panel responsible for this Report is
similar. The findings of the previous report on food additives,
microbial contaminants, salt and salted foods, salted fish
(Cantonese-style), cured meats, and the grilling and barbe-
cuing of meat, fish, and other foods, were all contained in
a chapter on food processing. The previous panel’s judge-
ments were mostly similar to those made here, with the
important exception of processed meat, which was not con-
sidered separately from smoked and cured meats by the pre-
vious report. The judgements of this Report on these subjects
are made in previous sections of this chapter. 
4.9.8  Conclusions 
The Panel concludes:
The Panel decided to make no judgements on isolated exper-
imental findings that were not supported by epidemiologi-
cal or other evidence.
It is not possible to make any definitive judgement in the
absence of epidemiological evidence. Nevertheless, the Panel
concurs that, in general, it seems reasonable to conclude that
the changes made to foods and drinks within well regulat-
ed, modern food systems, and those made to foods and
drinks as usually prepared and cooked, are of themselves
unlikely to modify the risk of cancer significantly. 
There are important exceptions to this tentative conclusion
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and in these cases, the Panel’s judgements and conclusions
are found in the relevant earlier sections of this chapter.
These judgements and conclusions are made in those sec-
tions wherever epidemiological and other evidence justifies
a judgement of a protective or causative effect, using the
agreed criteria, for aspects of food production (including
contamination), processing, preservation, and preparation
(including cooking). 
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Nutritional science conventionally divides foods and
drinks into their chemical constituent parts, such as water,
carbohydrates, fats, proteins, vitamins, and minerals.
Their biological functions are then explored, singly or in
combination. It is now increasingly agreed by the nutrition
science community that research and also public health
can additionally benefit from a more integrated approach,
in which the emphasis is placed on foods and drinks. In
this Report, the evidence, its summaries, and the Panel’s
judgements are food-based, wherever possible. 
Here, the evidence on macronutrients, micronutrients
(isolated in the form of supplements), and bioactive
constituents of plant foods (also known as
phytochemicals) is summarised and judged. 
Overall, the Panel judges that the evidence that dietary
macronutrients specifically affect the risk of cancer is
unimpressive. The evidence, based on observational data
and randomised controlled trials of supplements, that
certain vitamins and minerals affect the risk of specific
cancers is, in some cases, impressive. 
The Panel judges as follows:
The evidence that high-dose beta-carotene supplements
are a cause of lung cancer in tobacco smokers is
convincing. There is limited evidence suggesting that high-
dose retinol supplements are a cause of lung cancer in
tobacco smokers. 
Calcium probably protects against colorectal cancer. At
specific doses, selenium probably protects against prostate
cancer. 
It is unlikely that beta-carotene has a substantial effect
on the risk of either prostate cancer or non-melanoma
skin cancer.
There is limited evidence suggesting that retinol at
specific doses protects against squamous cell carcinoma of
the skin. There is also limited evidence suggesting that
alpha-tocopherol protects against prostate cancer, and that
selenium at specific doses protects against colorectal and
lung cancer. There is limited evidence suggesting that
selenium supplements are a cause of skin cancer.
Within the remit of this Report, the strongest evidence,
4.10  Dietary constituents 
and supplements
DIETARY CONSTITUENTS AND SUPPLEMENTS, AND THE RISK OF CANCER
In the judgement of the Panel, the factors listed below modify the risk of cancer. Judgements are graded according to the strength of the evidence.
DECREASES RISK INCREASES RISK
Exposure Cancer site Exposure Cancer site
Convincing Beta-carotene Lung
supplements1
Probable Calcium2 Colorectum
Selenium3 Prostate
Limited — Retinol4 Skin5 Retinol supplements1 Lung
suggestive Alpha-tocopherol2 Prostate Selenium supplements2 Skin
Selenium3 Lung3
Colorectum6
Substantial 
effect on risk Beta-carotene7: prostate; skin (non-melanoma)
unlikely
1 The evidence is derived from studies using high-dose supplements (20 mg/day for beta-carotene; 25 000 international units/day for retinol) in smokers.
2 The evidence is derived from studies using supplements at a dose of 200  µg/day.
3 The evidence is derived from studies using supplements at 200 µg/day. Selenium is toxic at high doses. 
4 The evidence is derived from studies using supplements at a dose of 25 000 international units/day. 
5 Applies only to squamous cell carcinoma.
6 The evidence is derived from studies using supplements at a dose of 200 µg/day. Selenium is toxic at high doses.
7 The evidence is derived from studies using supplements (at doses of 20, 30, 50 mg for prostate, and doses of 30, 50 mg/day for skin), and foods containing 
beta-carotene: see  chapter 4.2. 
For an explanation of all the terms used in the matrix, please see chapter 3.5.1, the text of this section, and the glossary.
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corresponding to judgements of ‘convincing’ or ‘probable’,
shows that high-dose beta-carotene supplements in
tobacco smokers are a cause of lung cancer; that calcium
probably protects against colorectal cancer; and that
selenium probably protects against prostate cancer. It is
unlikely that beta-carotene, or foods containing it, have a
substantial effect on the risk of either prostate or skin
(non-melanoma) cancer. The Panel emphasises that this
evidence and these judgements relate to these
micronutrients only at the specified doses. 
Nutrition science in its conventional form as a biological dis-
cipline was created in the early 19th century following the
identification of carbohydrates, fats, and proteins. As nutri-
ents, these all supply energy and are essential for tissue struc-
ture and function, and physical and mental growth and
development. Later research has divided these macronutri-
ents into many constituent parts such as monosaccharides
and polysaccharides (including non-starch polysaccharides
or ‘dietary fibre’); saturated and unsaturated fatty acids
(which themselves have many fractions); and amino acids.
Many of these constituents of the main nutrients are known
to have different metabolic, physiological, biochemical, and
other effects, in isolation or combination. 
Beginning in the early 20th century, a series of substances
that do not supply energy were identified also as being vital
to life, typically in very small amounts: these are vitamins,
minerals, and trace elements. More recently a large number
of other substances that are not nutrients, in the sense of
being essential components of metabolic processes or cell
structure, have been identified as bioactive. Because these
are contained in plants, they are commonly known as
phytochemicals. 
Reports concerned with specifying recommended dietary
(or daily) amounts or reference values for nutrients, by their
nature, are structured accordingly. Compilations of the chem-
ical composition of foods, used as standard references in epi-
demiological studies of food, nutrition, and the risk of
diseases including cancer, also specify macro- and micro-
constituents of foods and drinks, to varied degrees of com-
pleteness and accuracy. 
Reports concerned with nutritional deficiencies charac-
teristically make recommendations for the relevant micro-
constituents. Increasingly though, they often now make
recommendations for dietary patterns, diets, and foods and
drinks that are high in the microconstituents with which they
are concerned. So a report on vitamin A deficiency may spec-
ify foods high in carotenoids and retinol, and may also rec-
ommend methods of agriculture that emphasise such foods.
Reports concerned with prevention of chronic diseases were
initially structured in terms of dietary constituents, with only
secondary reference to foods. But following a general inter-
national agreement that food-based dietary guidelines are
more useful, and often better reflect the science, such reports
now give more emphasis to foods and drinks, both in their
analysis of evidence and in their recommendations. 
The policy of this Report is to always emphasise foods and
drinks. Thus, earlier sections of this chapter include sum-
maries and judgements of the evidence on dietary fibre, vit-
amins, minerals, and trace elements as contained in foods,
and also on fats, oils, sugars, salt, and alcohol as foods. Also
see chapters 4.1 to 4.8. This section is concerned with macro-
nutrients and micronutrients as such, and with non-nutrient
bioactive constituents of food (phytochemicals). 
4.10.1  Macronutrients
Chemically, macronutrients are classified as carbohydrates,
fats, and proteins, and these categories have many sub-
classifications. Diets need to include adequate amounts 
of macronutrients for physical and mental growth and devel-
opment, and for maintenance of normal tissue structure and
function. All macronutrients supply energy. Alcohol also
supplies energy, but there is no requirement for it. Also see
chapter 4.8. 
4.10.1.1  Carbohydrates
Carbohydrates consist of monosaccharide sugars, or larger
molecules of these units joined together: disaccharides (two
units), oligosaccharides (a few), or polymers (many). For
instance, glucose is a monosaccharide and starch is a poly-
mer of glucose units. Polysaccharides are sometimes called
‘complex’ carbohydrates and sugars ‘simple’ carbohydrates. 
Carbohydrates are generally the largest single source of
energy in diets. They supply around 4 kilocalories per gram.
They form part of important structural components in the
body and, in the form of glucose, are the principal and pre-
ferred energy source for metabolism. They also play major
roles in several essential cellular and physiological process-
es. Non-starch polysaccharides are the characterising feature
of dietary fibre. 
Glycaemic index and glycaemic load are terms used to
characterise foods and diets based on their effects on blood
glucose levels. Also see box 4.1.3 in chapter 4.1.
Cereals (grains) and products made from them (such as
breads, pastas, and breakfast cereals), as well as starchy roots
and tubers, are all high in carbohydrates. These foods con-
tain a mixture of complex and simple carbohydrates and
other nutrients. Until recently, starches have been the main
source of carbohydrate in human diets. With industrialisa-
tion and urbanisation, sugars have been added in increas-
ing quantities in food preparation and as an ingredient in
processed foods. Diets consumed in some high-income
countries now may contain roughly as much carbohydrate
in the form of sugars as they do starches. Diets high in com-
plex carbohydrates are usually associated with lower preva-
lence of obesity, heart disease, and type 2 diabetes. 
For summaries and judgements on dietary fibre, see chap-
ter 4.1. For summaries and judgements on sugars, see
chapter 4.6. For food processing, see chapter 4.9. 
4.10.1.2  Fat
Fats in diets are mostly made up from triglycerides — three
fatty acid molecules attached to a glycerol backbone.
Triglycerides are lipids, a class of organic compounds char-
acterised by their solubility in organic solvents (such as ether
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and chloroform); they are usually insoluble in water. The
body stores excess energy as lipids in the form of body fat
(also known as adipose tissue). Lipids also form part of the
structural components of cellular membranes as well as
being precursors of important hormones. 
Dietary fats include solid fats and liquid oils. Their phys-
ical form at a particular temperature is determined by the
chemical structure of their constituent fatty acids. Fats with
a high proportion of ‘saturated’ fatty acids are solid or semi-
solid at ambient temperatures; those with a higher amount
of ‘unsaturated’ fatty acids are more likely to be oils. The dif-
ferent degrees of saturation produce various effects in the
body. Diets high in saturated fatty acids (and also trans-fatty
acids) (see chapter 4.5 and box 4.5.1) increase circulating
blood concentrations of cholesterol and the risk of cardio-
vascular disease. The World Health Organization recom-
mends limiting total fat to between 15 and 30 per cent of
total daily energy intake and saturated fatty acids to less than
10 per cent.1
Fats are the most concentrated energy source, supplying
around 9 kcal per gram. They also carry the fat-soluble vit-
amins (see chapter 4.10.2.1). The body can make all but two
of the fatty acids it needs — linoleic acid and alpha-linolenic
acid, known as the ‘essential’ fatty acids. Both are found in
vegetables, nuts, and seeds and their oils, in varying quan-
tities. They are also found in meat, eggs, and dairy products,
but at lower levels. The long-chain fatty acids found in oily
fish (eicosapentaenoic and docosahexaenoic acids) can be
made to a limited extent in the body, where they play a role
in inflammation.2 These and related fatty acids are precur-
sors to prostaglandins; these hormone-like compounds have
other diverse effects, including roles in blood vessel dilation
and constriction, blood clotting, and transmission of nerve
impulses.
Nuts, seeds, meat, oily fish, whole milk and dairy prod-
ucts, cooking oils and fats, spreadable fats, and a wide range
of manufactured foods all contain varying amounts and types
of fats. Those from animal sources usually have a higher pro-
portion of saturated fatty acids, and these are common in
processed foods. 
For summaries and judgements on fats and oils as foods,
see chapter 4.5. For summaries and judgements on foods
that are or may be high in fats, see chapters 4.3 and 4.4. 
4.10.1.3 Proteins
Proteins are large organic molecules made up of amino acids
arranged in a chain. Short chains are called peptides, for
instance di- and tripeptides (made up of two and three
amino acids respectively). Longer chains are known as
oligopeptides, and long chains as polypeptides. Proteins are
fundamental structural and functional elements within every
cell in the body.
Many proteins are enzymes that catalyse biochemical reac-
tions and are vital to metabolism. Others have structural or
mechanical functions, such as the proteins in the cytoskele-
ton, which give cells their shape and strength. They are also
important in cell signalling, immune responses, cell adhe-
sion, and the cell cycle.
Proteins supply around 4 kcal per gram. They are digest-
ed into their constituent amino acids, which are then
absorbed into the blood. The body has the ability to make
some amino acids, but others, so called essential amino
acids, must be obtained from foods and drinks. 
Dietary sources of protein include meats, milk and
cheese, pulses (legumes), nuts, and cereals (grains) and
products made from them, such as breads. Animal proteins
from eggs, milk, and meat contain all the essential amino
acids in the proportions needed by humans; soya protein is
the only plant food to do so. Other plant protein sources have
differing proportions of various essential amino acids, so
diets without animal foods or soya need to include a vari-
ety of plant protein sources to provide enough of the essen-
tial amino acids. 
For summaries and judgements on foods that contain
proteins, see chapters 4.1, 4.2, 4.3, and 4.4. 
4.10.2 Micronutrients
Micronutrients are essential constituents of diets needed in
small quantities compared with macronutrients, and are not
sources of energy. These are vitamins, minerals, and trace
elements. Deficiency of any dietary constituents classified as
a micronutrient causes debility, disease, and eventually
death. 
Many processed foods are ‘fortified’ with synthetic vita-
mins and minerals (box 4.10.1). Others contain various
microconstituents such as phytochemicals, and sometimes
other ingredients such as bacteria and ‘prebiotic’ polysac-
charides; these products are sometimes termed ‘functional
foods’ (box 4.10.2). Both types of product are often marketed
with health claims relating to these added constituents or to
the whole food.
4.10.2.1  Vitamins
Vitamins are organic molecules, classed as fat- or water-
soluble, that are needed for metabolism but cannot be made
in the body and so must be supplied in the diet. They have
different specific functions in the body. For example, vitamin
K is needed for blood clotting and vitamin C for the pro-
duction of collagen in connective tissue. 
Vitamins A (retinol), D, E, and K are fat-soluble and can
only be digested, absorbed, and transported in conjunction
with dietary fats. So they are found mainly in fatty foods
such as liver and oily fish, milk and dairy products, animal
fats (such as butter), and vegetable oils. The main sources
of vitamin A are plant foods containing the retinol precur-
sors known as carotenoids, which are converted by the body
to retinol (see box 4.2.1 in chapter 4.2). Preformed retinol,
which is absorbed better than carotenes in plant foods, is
found only in animal products, of which liver is a particu-
larly rich source. Fat-soluble vitamins are stored in the liver
and in body fat stores. For this reason, they do not need to
be consumed every day. For the same reason, some are toxic
in high doses. 
Vitamin C and the B vitamins are water-soluble. The B
group includes thiamin (vitamin B1), riboflavin (B2), niacin
(B3), pyridoxine (vitamin B6), biotin, pantothenic acid,
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folate, and cobalamin (vitamin B12). Excess amounts of
water-soluble vitamins are generally not toxic because they
are excreted in the urine rather than stored in the body. This
also means that they generally have to be consumed more
frequently than fat-soluble vitamins. Plant foods are impor-
tant sources of water-soluble vitamins: for example, cereals
(grains), vegetables, fruits, some roots and tubers, and puls-
es (legumes). They can be destroyed by heat or exposure to
the air, or lost by leaching during cooking, for instance when
vegetables are boiled (see chapter 4.9.4). 
4.10.2.2  Minerals, trace elements 
Minerals are inorganic substances. Most foods contain sig-
nificant amounts of one or more minerals, and these com-
pounds have many specific functions in the body. Some are
essential components of enzymes and other proteins (as
‘cofactors’, such as iron). They are also involved in main-
taining normal cell function (sodium, potassium, calcium),
and for structure (calcium in bones and teeth). Others
include magnesium, phosphorus, and sulphur.
Trace elements are minerals needed by the body in very
small amounts. Whether a mineral is defined as a trace ele-
ment is somewhat arbitrary: iron, zinc, and copper are min-
erals that may or may not be identified as trace elements.
Others include iodine, selenium, chromium, fluoride, boron,
cobalt, manganese, molybdenum, and silicon. 
4.10.3  Phytochemicals 
Phytochemicals are bioactive constituents of plant foods not
identified as nutrients because they are not essential in the
sense of being vital to life itself. Unlike vitamins and miner-
als, people do not suffer diseases when their diets are low
in phytochemicals. However, consuming them may have ben-
eficial effects on health or active roles in the prevention of
diseases. Also see box 4.2.2 in chapter 4.2. 
Various phytochemicals have been shown to have anti-
oxidant, anti-carcinogenic, anti-inflammatory, immunomod-
ulatory, and antimicrobial effects in laboratory experiments.
But it is not yet clear whether consuming these compounds
produces these or other effects in the body.
Phytochemicals have various chemical structures and are
grouped into families on this basis. They include flavonoids,
isoflavones (phytoestrogens), glucosinolates, terpenes,
organosulphur compounds, saponins, capsaicinoids, and
phytosterols. Many vegetables, fruits, pulses (legumes),
herbs, and teas are high in phytochemicals.
4.10.4  Supplements
Vitamins, minerals, trace elements, and other bioactive sub-
stances are available as supplements, usually in pill or pow-
der form. These began to be manufactured and marketed
after their functions were identified, and claims made for
their general benefits in prevention of disease and promo-
tion of well-being. 
Many dietary supplements are classed as foods, although
Functional foods are so-called because they are believed or
claimed to have special qualities, such as promoting well-being
or protecting against disease. What marks them out from ‘nor-
mal’ foods is that they are specifically formulated, manufactured,
and marketed as being ‘functional’ in specified ways, for which
claims are made. Some fortified products, such as breakfast cere-
als and yoghurts, are positioned as functional foods. 
The ingredients in functional foods claimed to have special
qualities may be added fractions of macronutrients, such as
amino acids or fatty acids, or vitamins, minerals, or trace ele-
ments. Very often the ‘functional’ ingredients will be known or
claimed to be bioactive in other ways: these include phyto-
chemicals, herbal extracts, and commensal bacteria. 
Box 4.10.2 Functional foods
Food ‘fortification’ refers to the addition of
nutrients, often in synthetic form, to foods,
so that the food contains more of the nutri-
ents added. The term ‘enrichment’ is some-
times also used.
The United Nations and other interna-
tional organisations are responsible for
major food fortification programmes,
designed in particular to reduce rates of
deficiency of vitamin A, iodine, iron, and
other nutrients, mostly within low-income
countries. But common foods have been
fortified in many countries since the early
20th century. For example, in some coun-
tries margarine and other fat spreads, or
milk, have been fortified with vitamins A
and D. White flour, and therefore white
bread and other products made from it, is
commonly fortified with some B vitamins,
and also sometimes with calcium and iron. 
The term ‘fortification’ in these and
other examples may refer to the partial
replacement of nutrients otherwise absent
or depleted by food-processing methods.
Or it may refer to the addition of nutrients
to levels not found in the food in whole
form; for example, the addition of calcium
to white bread in the UK is to levels high-
er than those found in wholegrain breads;
and salt may not contain iodine. 
Many common processed foods and
drinks, including some that would other-
wise be low in nutrients, are now fortified
with various combinations of synthetic
nutrients. These include breakfast cereals,
biscuits (cookies) and other baked goods,
dried milk, milk-based products, and soft
drinks, and even confectionery. Many such
products are designed to be consumed by
children. 
In an increasing number of countries,
the nutrients consumed in fortified foods
and drinks amount to a substantial and
growing proportion of total consumption
of these nutrients. For example, since 1998
in the USA, grain has been fortified with
folic acid, the synthetic equivalent of
folate, as a public health measure designed
to reduce the incidence of neural tube
defects in the fetus. As a result, it is esti-
mated that over one third of all intake of
this nutrient in the USA comes from this
source, as well as from fortified breakfast
cereals.3
Box 4.10.1 Food fortification
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some may be regulated medicinal products. Manufacturers
of food supplements may market their products using health
claims, although in some countries such as the UK, medici-
nal claims that the product can prevent, cure, or treat a dis-
ease may not be made. Herbal products may be permitted
to make certain claims based on their history of being used
for a particular condition. The regulatory status of dietary
supplements varies from country to country. 
Some nutrients such as water-soluble vitamins have been
thought to be harmless at pharmacological doses; but there is
now evidence, including some summarised and judged in this
Report, that this is not always the case. Other nutrients, includ-
ing fat-soluble vitamins and all minerals and trace elements,
are known to be toxic at pharmacological doses; some of these,
selenium being one example, are known to be toxic at rela-
tively low pharmacological levels (also see box 4.10.3). 
Expert reports issued by United Nations agencies and
national governments specify levels of nutrients agreed to
protect against deficiency diseases, and also (sometimes)
agreed to be safe in use. 
Many people take dietary supplements. Their use is high-
er in high-income countries. In the UK, 35 per cent of respon-
dents reported taking dietary supplements. Around 50 per
cent of people in the USA take supplements in some form. 
4.10.5  Interpretation of the evidence
4.10.5.1 General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7. 
‘Relative risk’ (RR) is used in this Report to denote ratio
measures of effect, including ‘risk ratios’, ‘rate ratios’, ‘haz-
ard ratios’, and ‘odds ratios’.
4.10.5.2 Specific
These specific points apply only to trials using micronutri-
ent supplements. 
Measurement. The results of supplement trials can be
assumed only to apply to levels and forms of the micro-
nutrient present in the supplement. 
Study design. Randomised controlled trials (RCTs) using
nutrient supplements provide strong evidence. But the evi-
dence can only be taken to apply to supplements at the doses
and in the form given, under the specific experimental con-
ditions. The doses used in trials are often pharmacological,
in which case they cannot be taken as directly relevant to
the nutrients as contained in foods and diets. Supplements
in synthetic forms are sometimes but not always chemical-
ly identical to the nutrient as found in food, and so may have
different biochemical effects. This may also be because of the
level of the dose, because the nutrient is given in isolation
or separated from the nutritional matrix as found in foods,
or for other reasons. 
Confounding. In trials using supplements given in combi-
nations, it is not possible to attribute any effect to an indi-
vidual nutrient. 
4.10.6  Evidence and judgements
The full systematic literature review (SLR) is contained on
the CD included with this Report.
4.10.6.1  Carbohydrates
For the evidence on foods containing carbohydrate, includ-
ing dietary fibre, see chapter 4.1. For the evidence on sugars
as a food, see chapter 4.6. 
4.10.6.2  Fats
For the evidence on foods containing substantial amounts of
fats and oils, see chapters 4.3 and 4.4. For the evidence 
on fats and oils as foods, see chapter 4.5. 
4.10.6.3  Proteins
The evidence from the SLRs did not suggest that proteins
specifically modify the risk of cancers of any sites. For the
evidence on foods containing protein, see chapters 4.1, 4.3,
and 4.4. 
4.10.6.4  Vitamin supplements 
The evidence presented here is derived from studies of vit-
amins and beta-carotene (a vitamin A precursor) in supple-
ment form only. Microconstituents in supplement form may
have very different effects according to form, dosage, com-
bination with other nutrients, interaction with diets as a
whole, and other factors. 
The effects of bioactive substances vary with the quantities con-
sumed. The amounts of nutrients and other substances in diets
depend on the nature and quantity of the foods and drinks that
taken together make up diets. 
The amounts of nutrients and other substances contained in
dietary supplements, in this context usually referred to as doses,
may or may not be at levels that can be found in diets. Lower
amounts, at levels about the same as those that can be found
in diets, are known as ‘physiological doses’. Higher amounts, at
levels above any that can be found in diets, are known as ‘phar-
macological doses’, or sometimes as ‘mega-doses’. 
Evidence from trials and studies using supplements are often
difficult to compare. One reason for this is that both human and
animal studies use supplements in different combinations and
concentrations. A nutrient that has one effect at a relatively low
or physiological dose may have a different effect at a higher or
pharmacological dose. For instance, a nutrient that may evi-
dently be protective at a lower or physiological dose may be
toxic or pathogenic at a higher dose. 
Randomised controlled trials using various doses of micro-
nutrients have produced evidence of the effects of these
supplements in modification of the risk of cancers of some sites.
This evidence is summarised and judged in chapter 4.10.6. 
Box 4.10.3 Levels of supplementation 
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4.10.6.4.1  Retinol 
Skin 
Two RCTs investigated retinol supplements and skin cancer
(table 4.10.1).4 5
Both trials included only participants at risk of develop-
ing non-melanoma skin cancer. The retinoid skin cancer pre-
vention (actinic keratoses) trial (SKICAP-AK) included
people with a history of precancerous lesions (actinin ker-
atoses); the retinoid skin cancer prevention (squamous cell
carcinoma/basal cell carcinoma) trial (SKICAP-S/B) includ-
ed people with a history of non-melanoma skin cancer. SKI-
CAP-AK showed non-significant increased risk for basal cell
carcinoma, with an effect estimate of 1.14 (95% confidence
interval (CI) 0.91–1.43), but it did show a statistically sig-
nificant decreased risk for squamous cell carcinoma 0.68
(95% CI 0.51–0.92), comparing intervention to placebo.5
SKICAP-S/B produced no evidence of effect for either basal
cell carcinoma (106 cases intervention group: 110 cases
placebo group) or squamous cell carcinoma (41 cases each
in intervention and placebo group).4
Meta-analysis was possible on both trials, giving summary
effect estimates of 1.10 (95% CI 0.90–1.34) for basal cell car-
cinoma and 0.93 (95% CI 0.70–1.23) for squamous cell
carcinoma.
The mechanism of anti-tumour action of the retinoids is
not completely known but retinol is known to bind to cell
receptors with promotion of differentiation, alteration of
membranes, and immunological adjuvant effects.6
The evidence is sparse and studies were conducted on
a narrowly defined population group (people at risk of
developing skin cancer). There is limited evidence
suggesting that retinol supplements protect against
squamous cell skin cancer.
The Panel is aware that since the conclusion of the SLR, one
case-control study7 has been published. This new information
does not change the Panel judgement (see box 3.8).
Lung 
Two trials (one an RCT, the other a non-randomised trial),8-11
two cohort studies,12 13 and two case-control studies14 15
investigated retinol or vitamin A supplements and lung
cancer (table 4.10.2).
The single RCT was the Beta-Carotene and Retinol
Efficacy Trial (CARET) trial (table 4.10.2) among current
and former smokers (some of whom were asbestos workers)
who were given retinyl palmitate and beta-carotene, or
placebo. It showed statistically significant increased risk of
all lung cancers in the treated subjects, with an effect esti-
mate of 1.28 (95% CI 1.04–1.57). The risk of death from
lung cancers was 1.46 (95% CI 1.07–2.00).9 The risk was
especially elevated in those who had the intervention as well
as exposure to either asbestos or heavy smoking, although
neither subgroup analysis was statistically significant. At
follow-up (5 years after trial termination), the effect was
reduced and no longer statistically significant, with an effect
estimate of 1.12 (95% CI 0.97–1.31).8
The other trial, which was not randomised, gave retinol
or beta-carotene to asbestos-exposed people and used a
matched comparison group, giving an adjusted effect esti-
mate of 0.67 (95% CI 0.33–1.37).11
One cohort study was stratified according to smoking sta-
tus (current, former, and never).12 In current smokers, high-
dose vitamin A supplements (synthetic beta-carotene or
retinol) were associated with an increased risk, with an effect
estimate of 3.42 (with no CI or value for trend reported),
when compared to no supplements. Men who never smoked
showed a non-significant decreased risk.12 The other cohort
study showed no effect on risk for men and non-significant
decreased risk in women. Effect estimates were 1.0 (95% CI
0.66–1.51) for men and 0.65 (95% CI 0.39–1.06) for
women, when comparing supplement use to non-use.13 One
case-control study showed a non-significant increased risk
with supplement use,14 the other showed no effect on risk.15
It is possible that the potential protective associations pre-
sent at dietary intake amounts of vitamins are lost or
reversed by pharmacological supplementation and the high-
er levels that this may supply.
The evidence is sparse and inconsistent. There is
limited evidence suggesting that high-dose retinol
Table 4.10.1 Retinol supplements and 
skin cancer; trials
Trial Number of Intervention Length of Length of 
name participants intervention follow-up
SKICAP-AK 2297 with 25000 IU 5 years 3.8 years
Moon 1997 moderate  retinol or 
risk of skin placebo daily
cancer
SKICAP-S/B 525 with  25000 IU 3 years 3 years
Levine 1997 high risk of  retinol, 5–10 mg 
skin cancer isotretinoin or 
placebo daily
Table 4.10.2 Vitamin A supplements and 
lung cancer; trials
Trial Number of Intervention Length of Length of 
name participants intervention follow-up
Beta- 18 314 at 30 mg beta- 4 years 5 years
Carotene high risk of carotene and (trial ended 
and Retinol developing 25 000 IU early)
Efficacy lung cancer retinyl palmitate
Trial 
(CARET)
Goodman
2004
Omenn 1996
Western 1203 Annual supplies Maximum –
Perth participants, of vitamin A of 4 years
asbestos 996 (either synthetic 
workers comparison beta-carotene or
Musk 1998 subjects retinol), help in 
quitting smoking, 
and dietary advice
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supplements are a cause of lung cancer in current
smokers.
4.10.6.4.2 Beta-carotene 
Lung 
Five RCTs8-10 16-20 and one cohort study21 investigated beta-
carotene supplements and lung cancer (table 4.10.3).
Four studies showed increased risk with a beta-carotene
intervention,16 17 19 20 which was statistically significant in
two (during the trial, not at follow-up; smokers).8-10 16 17 One
study showed a non-significant decreased risk.18 Meta-
analysis was possible on three trials, giving a summary effect
estimate of 1.10 (95% CI 0.89–1.36) for beta-carotene sup-
plementation versus none, with moderate heterogeneity (fig-
ure 4.10.1). Two trials could not be included in the
meta-analysis. One trial reported an effect estimate of 1.50
(95% CI 0.43–5.28) for those taking beta-carotene compared
to those taking retinol from a total of 10 lung cancers in all
participants.20 The other RCT was the CARET trial (table
4.10.3) among current and former smokers (some of whom
were asbestos workers) who were given retinyl palmitate and
beta-carotene, or placebo. It showed statistically significant
increased risk of all lung cancers in the treated subjects, with
an effect estimate of 1.28 (95% CI 1.04–1.57). The risk of
death from lung cancers was 1.46 (95% CI 1.07–2.00).9 The
risk was especially elevated in those who had the interven-
tion as well as exposure to either asbestos or heavy smok-
ing, although neither subgroup analysis was statistically
significant. At follow-up (five years after trial termination),
the effect was reduced and no longer statistically significant,
with an effect estimate of 1.12 (95% CI 0.97–1.31).8
One cohort study showed non-significant increased risk for
beta-carotene supplementation compared to none in women.
The other study showed non-significant decreased risk in
men. Effect estimates were 1.23 (95% CI 0.55–2.76;
women) and 0.82 (95% CI 0.36–1.85; men).21
There is a marked interaction between beta-carotene,
heavy smoking and genotype.22 23 When beta-carotene sup-
plementation among those without the glutathione-S-trans-
ferase variant GSTM1 who smoked more than 42 cigarettes
per day was compared to beta-carotene supplementation
among those without GSTM1 who smoked less than 37 cig-
arettes per day, a RR of 6.01 (95% CI 1.90–19.08) was
observed.22 After adjusting for age and smoking habits, an
RR of 3 (95% CI 1.3–7.1) was observed for the Arg/Arg
genotype when 545 µg/l of serum beta-carotene was com-
pared to 45 µg g/l.23 Glutathione-S transferase 1 and 2 are
carcinogen-detoxifying enzymes. People without or with less
active forms of these enzymes, due to genetic variation, are
less able to metabolise toxins than others and have higher
risk of cancer, particularly if they are smokers or exposed to
regular doses of toxins through another source. 
It is possible that the protective association present at
dietary intake amounts of carotenoids is lost or reversed by
pharmacological supplementation and the higher levels that
this may supply. In one animal study, low-dose beta-carotene
was protective against smoking-induced changes in p53,
while high doses promoted these changes.24 A second expla-
nation could be the complex nature of naturally occurring
carotenoids and the possibility that the protective associa-
tions are not due to the specific agent used in supplement
studies, but rather to other carotenoids present in dietary
exposure25 or other associated dietary or health related
behaviours.
There is strong evidence from good quality trials,
consistent with cohort studies. An interaction between
smoking, genetics, and beta-carotene is apparent. The
evidence that beta-carotene supplements cause lung
cancer in current smokers is convincing.
Table 4.10.3 Beta-carotene supplements and 
lung cancer; trials
Trial Number of Intervention Length of Length of 
name participants intervention follow-up
Physicians’ 22 071 50 mg beta- 13 years –
Health Study carotene taken 
(PHS) on alternate days
Cook 2000
Women’s 39 876 50 mg of beta- 2 years 4 years
Health Study carotene taken 
(WHS) on alternate days
Lee 1999
ATBC study 29 133 20 mg of beta- 5–8 years 6–8 years
(male carotene only
smokers) or with 50 mg of 
Virtamo 2003 alpha-tocopherol
Albanes 1996
Western 1024 30 mg/day Up to 5 years –
Perth beta-carotene or
asbestos 25 000 IU/day 
workers retinol
de Klerk 1998
Beta- 18 314 at 30 mg beta- 4 years 5 years
Carotene high risk of carotene and (trial ended 
and Retinol developing 25 000 IU early)
Efficacy lung cancer retinyl palmitate
Trial 
(CARET)
Goodman
2004
Omenn 1996
Figure 4.10.1 Beta-carotene supplements and lung
cancer; trials
Virtamo 2003 (ATBC) Men 1.17 (1.02–1.34)
Cook 2000 (PHS) Men 0.90 (0.68–1.18)
Lee 1999 (Women’s Health Study) 1.43 (0.83–2.48)
Summary estimate 1.10 (0.89–1.36)
 Relative risk (95% CI)
Relative risk, intervention group vs control group
1 20
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Prostate 
See also chapter 4.2.5.3 for evidence on foods containing
beta-carotene. Three RCTs9 10 16 18 26 and two cohort studies27
28 investigated beta-carotene supplements (table 4.10.4).
Two trials showed a non-significant increased risk for beta-
carotene supplementation compared to none9 10 16; the other
showed no effect on risk.18 Effect estimates were 1.26 (95%
CI 0.98–1.62) for the 1985 to 1993 follow-up period,16 1.01
(95% CI 0.80–1.27),9 10 and 1.0 (95% CI 0.9–1.1).18
One cohort study showed a non-significant increased risk
for beta-carotene supplementation compared to none27;
the other stated that there was no significant association.28
The single reported effect estimate was 1.17 (95% CI
0.85–1.61).27
There is no evidence for any mechanism of action.
There is strong evidence from good quality trials, and
from cohort studies, which consistently fails to
demonstrate a protective effect. Beta-carotene
supplements are unlikely to have a substantial
protective effect against prostate cancer. The evidence
is too limited to draw a conclusion on a harmful effect. 
Skin 
See also chapter 4.2.5.3 for evidence on foods containing
beta-carotene. Four RCTs19 29-32 and one cohort study33 inves-
tigated beta-carotene supplements (table 4.10.5).
Non-melanoma skin cancer
Three RCTs investigated non-melanoma skin cancer as an
outcome.29 31 32 Two trials showed non-significant increased
risk for beta-carotene supplementation compared to 
none31 32; one trial showed a non-significant decreased risk.29
The results are shown in the forest plot, separated for basal
cell carcinoma and squamous cell carcinoma (figure 4.10.2).
Meta-analysis was possible on all three trials, giving a
summary effect estimate of 1.00 (95% CI 0.94–1.07) for
basal cell carcinoma and 1.01 (95% CI 0.95–1.06) for squa-
mous cell carcinoma.
The single cohort study showed a non-significant
decreased risk for beta-carotene supplementation compared
to none. The effect estimate was 0.42 (95% CI 0.12–1.47).33
Table 4.10.4 Beta-carotene supplements and 
prostate cancer; trials
Trial Number of Intervention Length of Length of 
name participants intervention follow-up
Beta- 18 314 at 30 mg beta- 4 years 5 years
Carotene high risk of carotene and (trial ended 
and Retinol developing 25 000 IU early)
Efficacy lung cancer retinyl palmitate
Trial 
(CARET)
Omenn 1996
Goodman 
2004
Physicians’ 22 071 50 mg beta- 13 years –
Health carotene taken 
Study (PHS) on alternate days
Cook 2000
ATBC Study 29133 20 mg of beta- 5–8 years 6–8 years
(male carotene only or
smokers) with 50 mg of 
Virtamo 2003 alpha-tocopherol
Heinonen 1998
Table 4.10.5 Beta-carotene supplements and 
skin cancer; trials
Trial Number of Intervention Length of Length of 
name participants intervention follow-up
Nambour 1621 Four treatment 4.5 years –
Skin Cancer groups: daily 
Prevention application of 
Trial sunscreen and 
Green 1999 beta-carotene 
supplementation 
(30 mg per day); 
sunscreen plus 
placebo tablets; 
beta-carotene only; 
or placebo only
Beta- 1805 (with 50 mg daily 5 years 1–5 years
Carotene history of
Trial non-melanoma
Greenberg skin cancer)
1990
Physicians’ 22 071 50 mg beta- 12 years
Health Study carotene taken 
(PHS) on alternate days
Frieling 2000
Hennekens
1999
Women’s 39 876 50 mg of beta- 2 years 4 years
Health Study carotene taken 
(WHS) on alternate days
Lee 1999
Figure 4.10.2 Beta-carotene supplements and non-
melanoma skin cancer; trials
Basal cell carcinoma
Greenberg 1990 1.04 (0.89–1.21)
Green 1999 1.04 (0.79–1.37)
Frieling 2000 0.99 (0.92–1.06)
Summary estimate 1.00 (0.94–1.07)
Squamous cell carcinoma
Greenberg 1990 1.22 (0.87–1.72)
Green 1999 1.35 (0.84–2.18)
Frieling 2000 0.97 (0.84–1.13)
Summary estimate 1.01 (0.95–1.06)
Relative risk (95% CI)
Relative risk, intervention group vs control group
1 20.5
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Melanoma skin cancer
The Women’s Health Study19 and Physicians’ Health Study30
investigated melanoma skin cancer as an outcome. Both
trials stated that there was no significant effect from beta-
carotene supplementation compared to none.19 30
There is no evidence for any mechanism of action.
There is strong evidence from good quality trials that
consistently fail to show an effect. It is unlikely that
beta-carotene has a substantial effect on the risk of
non-melanoma skin cancer.
4.10.6.4.3 Alpha-tocopherol 
Prostate 
One RCT investigated alpha-tocopherol supplements and
prostate cancer (table 4.10.6).16 26
The ATBC (Alpha-Tocopherol Beta-Carotene) trial was a
large RCT of male smokers given 50 mg of alpha-tocopherol
and 20 mg of beta-carotene (see table 4.10.6 for details). It
showed a statistically significant decreased risk for alpha-toco-
pherol supplements, with an effect estimate of 0.66 (95% CI
0.52–0.86) for use compared to non-use. Prostate cancer was
not a prior-stated outcome for this trial.16 26
Data on dietary, serum, or supplemental vitamin E or
alpha-tocopherol levels were suggestive of decreased risk,
though generally not statistically significant. Data on
gamma-tocopherol provided evidence of an association with
decreased risk. 
Vitamin E exists in eight different forms or isomers: four
tocopherols and four tocotrienols. There is an alpha, beta,
gamma, and delta form of each. Each form has slightly dif-
ferent biological properties but all are antioxidants. Alpha-
tocopherol is thought to be the most biologically active
isomer of vitamin E. It inhibits proliferation, can directly acti-
vate certain enzymes, and exerts transcriptional control on
several genes.34 Vitamin E has also been shown to inhibit the
growth of human prostate tumours induced in mice.35
The evidence is sparse. There is limited evidence that
alpha-tocopherol supplements protect against prostate
cancer in smokers.
4.10.6.4.4 Calcium 
Colorectum 
Seven cohort studies investigated calcium supplements 
and colorectal cancer.36-43 Three trials44-49 and four cohort
studies50-53 investigated calcium supplements and colorectal
adenomas.
Six cohort studies showed decreased risk for calcium sup-
plements when compared to none,36-41 43 which was statis-
tically significant in one.40 One study showed non-significant
increased risk.42 The effect estimates can be seen in the for-
est plot, apart from one study which reported an effect esti-
mate of 0.76 (95% CI 0.56–0.98) for the highest intake
group compared to the lowest (figure 4.10.3).43
Pooled analysis from 10 cohort studies (with over 534 000
participants followed up for 6 to 16 years, 4992 cases of col-
orectal cancer) presented results for calcium from food
sources and total calcium which includes supplements. A
larger effect was seen for total calcium (0.78, 95% CI
0.69–0.88) than for calcium from food sources (0.86, 95%
CI 0.78–0.95).54
Because of the abundant prospective data from cohort
studies, case-control studies were not summarised.
Adenomas
Two RCTs showed decreased risk of adenomas with calcium
supplementation,44-48 which was statistically significant in
one.44-47 Effect estimates were 0.81 (95% CI 0.67–0.99; 1200
mg calcium; adenoma incidence)44 and 0.66 (95% CI
0.38–1.17; 4 g calcium; adenoma recurrence).48
One additional trial showed a reduced risk of new ade-
noma growth during a 3-year intervention of a daily mix-
ture of beta-carotene 15 mg, vitamin C 150 mg, vitamin E
75 mg, selenium 101 µg, and calcium (1.6 g daily) as car-
bonate (p value 0.035), though with no statistically signifi-
cant effect on the growth of pre-existing adenomas.49
Three cohort studies showed decreased risk with calcium
supplementation,50-52 which was statistically significant for
one.50 One study reported no significant association.53 Meta-
Table 4.10.6 Alpha-tocopherol supplements and 
prostate cancer; trials
Trial Number of Intervention Length of Length of 
name participants intervention follow-up
ATBC Study 29 133 20 mg of beta- 5–8 years 6–8 years
(male carotene only or 
smokers) with 50 mg of 
Virtamo 2003 alpha-tocopherol
Heinonen 1998
Figure 4.10.3 Calcium supplements and colorectal
cancer; cohort studies
Bostick 1993 Women 0.66 (0.43–1.02)
Kampman 1994 0.95 (0.50–1.79)
Wu 2002 Men 0.70 (0.43–1.14)
McCullough 2003 Men 0.60 (0.33–1.10)
McCullough 2003 Women 0.73 (0.30–1.76)
Feskanich 2004 Women 0.87 (0.69–1.11)
Lin 2005 Women 1.30 (0.90–1.87)
 Relative risk (95% CI)
Relative risk, highest vs lowest exposure category
1 50.2 20.5
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analysis was possible on two of these studies, giving a sum-
mary effect estimate of 0.91 (95% CI 0.85–0.98) per 200
mg/day.50 52 The other study that gave quantified results
reported an effect of 0.76 (95% CI 0.42–1.38).51
Calcium is an import micronutrient and intracellular
calcium is a pervasive second messenger acting on many
cellular functions, including cell growth. It has been widely
demonstrated that calcium has direct growth-restraining, and
differentiation- and apoptosis-inducing action, on normal
and tumour colorectal cells.55
There is generally consistent evidence from several
cohort studies, and evidence from trials for colorectal
adenomas. There is evidence for plausible
mechanisms. Calcium probably protects against
colorectal cancer. 
4.10.6.4.5  Selenium 
Prostate 
One RCT56 57 and two cohort studies27 58 investigated sele-
nium supplements and prostate cancer (table 4.10.7).
The RCT was conducted in men with a history of skin can-
cers. Prostate cancer was not a prior stated outcome and was
assessed as a secondary endpoint. Out of 974 participants,
approximately half were randomised to receive 200 µg of
selenium daily. There were 13 cases of prostate cancer in 
the selenium group and 35 cases in the control group, giv-
ing an effect estimate of 0.37 (95% CI 0.20–0.70) for sup-
plement use compared to non-use, after a mean of 4.5 years
of the intervention and a mean of 6.5 years follow-up.56 The
effect was strongest in those with the lowest levels of sele-
nium at the start of the trial.57
Both cohort studies showed non-significant decreased risk
with selenium supplementation.27 58 Effect estimates were
0.94 (95% CI 0.57–1.55)27 and 0.91 (95% CI 0.57–1.48)58
for use versus non-use.
Dietary selenium data are supportive of an effect (see
chapter 4.2.5.8).
The general mechanisms through which selenium could
plausibly protect against cancer are outlined below. In addi-
tion, selenoproteins are involved in testosterone production,
which is an important regulator of both normal and abnor-
mal prostate growth.
There is strong evidence from trials and cohort studies.
Selenium probably protects against prostate cancer.
Lung 
One RCT investigated selenium supplements and lung can-
cer (table 4.10.8).59
The Nutritional Prevention of Cancer (NPC) Trial consist-
ed of more than 1300 participants enrolled from several der-
matology practices who were treated with 200 µg of
selenium. The trial showed a non-significant decreased risk
with supplementation, with an effect estimate of 0.74 (95%
CI 0.44–1.24) after a mean of 4.5 years of the intervention
and a mean of 7.9 years follow-up, adjusted for age and
smoking. Subgroup analysis indicated that this risk differed
according to baseline plasma selenium level, with an effect
estimate of 0.42 (95% CI 0.18–0.96) for those in the lowest
tertile compared to no apparent effectiveness for individu-
als in the higher tertiles of plasma selenium.59 This suggests
that selenium supplementation may decrease cancer risk in
those who are deficient in dietary selenium, but that this
effect may not extend to those whose intake of selenium is
within the recommended levels.
The general mechanisms through which selenium could
plausibly protect against cancer are outlined below.
The evidence is sparse. There is limited evidence
suggesting that selenium protects against lung cancer.
Skin 
One RCT60-62 and one cohort study33 investigated selenium
supplements and skin cancer (table 4.10.9).
The Nutritional Prevention of Cancer Trial (see above)
showed a non-statistically significant increased risk of total
non-melanoma skin cancer with supplementation, with an
effect estimate of 1.18 (95% CI 0.49–2.85). Subgroup analy-
sis showed an effect estimate of 1.14 (95% CI 0.93–1.39) for
Table 4.10.7 Selenium supplements and 
prostate cancer; trials
Trial Number of Intervention Length of Length of 
name participants intervention follow-up
NPC Trial 974 men  200 µg  Mean Mean
Clark 1998 with a   selenium   4.5 years 6.5 years
Duffield- history of daily (primary
Lillico 2003 non-melanoma endpoint was
skin cancers skin cancer)
Table 4.10.8 Selenium supplements and lung
cancer; trials
Trial Number of Intervention Length of Length of 
name participants intervention follow-up
NPC Trial 1312 200 µg  Mean Mean
Reid 2002 people with selenium 4.5 years 7.9 years
a history of daily (primary
non-melanoma endpoint was 
skin cancers skin cancer)
Table 4.10.9 Selenium supplements and 
skin cancer; trials
Trial Number of Intervention Length of Length of 
name participants intervention follow-up
NPC Trial 1312 200 µg  Mean Mean
Combs 1997 people with selenium 4.5 years 6.4 years
Clark 1996 a history of daily (primary
Duffield- non-melanoma endpoint was
Lillico 2002 skin cancers skin cancer)
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squamous cell carcinoma and 1.10 (95% CI 0.95–1.28) for
basal cell carcinoma.61
The single cohort study stated that there was no statisti-
cally significant association.33
The evidence is sparse and no plausible mechanisms
have been identified. There is limited evidence
suggesting that selenium supplements are a cause of
skin cancer.
Colorectum
One RCT60 62 and one cohort study63 investigated selenium
supplements and colorectal cancer (table 4.10.10). 
The single trial included 1312 participants who were ran-
domised to receive 200 µg selenium or a placebo. There were
8 colorectal cancer cases in the intervention group and 19
in the control group, giving an effect estimate of 0.36 (p
value for trend 0.025) for use versus non-use.60 A hazard
ratio of 0.46 (95% CI 0.21–1.02) is given after a further 2.5
years follow-up.62
The single cohort study showed non-significant decreased
risk, with an effect estimate of 0.60 (95% CI 0.27–1.32) for
use versus non-use.63
Dietary selenium data are supportive of an effect (see
chapter 4.2.5.8).
The general mechanisms through which selenium could
plausibly protect against cancer are outlined below.
The evidence is sparse. There is limited evidence to
suggest that selenium protects against colorectal
cancer.
General mechanisms
Dietary selenium deficiency has been shown to cause a lack
of selenoprotein expression. Twenty-five selenoproteins
have been identified in animals, and a number of these have
important anti-inflammatory and antioxidant properties.64
Four are glutathione peroxidises, which protect against
oxidative damage to lipids, lipoproteins, and DNA. These
enzymes are rapidly degraded during selenium deprivation.
Three are thioredoxin reductases and, amongst other func-
tions, these regenerate oxidised ascorbic acid to its active
antioxidant form. 
Selenoproteins appear to reach their maximal levels
relatively easily at normal dietary selenium intake and 
not to increase with selenium supplementation. It is,
however, plausible that supraphysiological amounts of
selenium might affect programmed cell death, DNA repair,
carcinogen metabolism, immune system, and anti-angio-
genic effects.65
4.10.7  Comparison with previous report 
This Report associates nutrients and dietary constituents
with foods and drinks wherever possible; and findings and
judgements on these as contained in foods and drinks are
found in previous sections of this chapter. The previous
report included a whole chapter on dietary constituents. It
found that starch (probably when it is the staple of poverty
diets) possibly protected against colorectal cancer but was
possibly a cause of stomach cancer. The evidence from the
SLRs undertaken for this Report did not reproduce these
findings. 
The previous report noted that trials using supplements of
various micronutrients such as beta-carotene, vitamin E, and
multiple vitamins and minerals had produced mixed results.
But it did not make formal judgements as a result of these
trials, although one of the report’s recommendations was
that dietary supplements are probably unnecessary, and pos-
sibly unhelpful, for reducing cancer risk. RCTs published
since the mid-1990s have strengthened the evidence on the
relationship of some dietary supplements and the risk of can-
cers of some sites. 
For comparisons with the previous report concerning
dietary constituents here identified as foods (such as sugars,
fats and oils, and alcohol) or foods which contain certain
constituents (such as dietary fibre, vitamins, minerals, and
trace elements), see chapters 4.1 to 4.8. 
4.10.8 Conclusions
The Panel concludes:
The evidence that the use of high-dose beta-carotene
supplements in tobacco smokers is a cause of lung cancer is
convincing. There is limited evidence suggesting that high-
dose retinol supplements are a cause of lung cancer in 
this group. The principal cause of lung cancer is smoking
tobacco.
Calcium probably protects against colorectal cancer. At
specific doses, selenium probably protects against prostate
cancer.
There is limited evidence suggesting that retinol at specific
doses protects against squamous cell carcinoma of the skin.
There is also limited evidence suggesting that alpha-toco-
pherol protects against prostate cancer; and also that sele-
nium at specific doses protects against colorectal cancer (at
a level of 200 µg/day, the dose used in the studies on which
this judgement is based).
There is limited evidence suggesting that selenium sup-
plements are a cause of skin cancer. It is unlikely that beta-
carotene supplements, or foods containing it, have a
substantial effect on the risk of either prostate cancer or skin
(non-melanoma) cancer.
Table 4.10.10 Selenium supplements and
colorectal cancer; trials
Trial Number of Intervention Length of Length of 
name participants intervention follow-up
NPC Trial 1312  200 µg  Mean Mean
Combs 1997 people with selenium 4.5 years 6.4 years
Duffield- a history of daily (primary
Lillico 2002 non-melanoma endpoint was
skin cancers skin cancer)
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The nature, quality, quantities, and proportions of
different foods and drinks in diets, and the frequency with
which they are habitually consumed, constitute dietary
patterns. Populations, communities, and families may
share similar dietary patterns, which are determined by
various factors such as the ecological niche they inhabit,
physical environments in which they live, or by tradition,
culture, religion, or choice. Dietary patterns, as well as
patterns of physical activity, have co-evolved with humans
over millennia and are intimately related to long-term
survival of the species within a given environment. The
changes in environment including diets and activity
patterns over the past century are likely to have affected
the risk of chronic diseases, including cancer. Indeed, the
impact of food and nutrition on health is not generally
determined by individual foods and drinks, specific dietary
constituents, or the ways in which foods are modified, for
example by processing or cooking. No food or drink is an
elixir and few are poisons, unless they are contaminated
with pathogenic micro-organisms. It is dietary patterns,
with physical activity levels and other factors that
influence nutritional requirements, that determine
nutritional status and other health outcomes that are of
interest to this Report. 
Dietary patterns are difficult to characterise and are an
infrequent subject for epidemiological and experimental
investigations which, by their reductionist approach,
typically address specific foods and dietary components.
This precisely focused approach may overlook the
significance of diets as a whole. There is now increasing
interest in the examination of the impact of dietary
patterns on well-being and disease outcomes, including
the risk of cancer. 
The Panel notes that existing studies of specific dietary
patterns use different definitions and that the evidence
they have produced is unclear. Currently, given the agreed
criteria for grading evidence in this Report, no judgements
can be made on any possible relationship between dietary
patterns, as defined in the literature, and the risk of
cancer. For this reason, no matrix showing Panel
judgements is included in this section. However, a
narrative summary provides an analysis of existing
evidence relating dietary patterns and cancer-related
outcomes.
For most populations at most times, food systems determine
dietary patterns; traditionally, these systems have themselves
been largely determined by climate and terrain. Until recent-
ly in history, diets have been mostly made up from locally
available plant and animal sources, as gathered, hunted,
reared, cultivated, preserved, processed, prepared, and con-
sumed. The current dietary patterns of subsistence farmers
around the world, in East Africa, Mexico, India, and China
for instance, differ mostly not as a matter of communal or
family choice, but because different staple crops flourish in
different parts of the world. The same applies to communi-
ties that live near rivers, lakes, and seas: their dietary pat-
terns are different from those of inland populations largely
because fish and seafood are available. Traditional diets in
the territories on or close to the Mediterranean littoral are
typically high in vegetables, fruits, fish, and seafood. The
dietary patterns of pastoralist populations, especially those
living in Arctic climates, are high in meat and animal foods.
The extreme example of imposed dietary patterns are
‘poverty’ or ‘deficiency’ diets, consumed by impoverished
communities. 
One characteristic of human civilisation is food culture: the
development of dietary patterns throughout or within soci-
eties as part of general culture. It is thought that dietary pat-
terns have acquired a cultural dimension based on the fact
that they have evolved with human populations providing
advantages for survival within a given ecological setting.
Thus food cultures sometimes have become an expression of
some system of belief.
Dietetics, in its original form as a general philosophy of
the well-led life, was developed in Greece and then later in
western Europe (for example, by the School of Salerno, from
the 12th century). Scholars and teachers of dietetics rec-
ommended various dietary regimes, which involved dietary
patterns selected as a matter of choice. These were often sim-
ple or frugal, and not just for personal well-being and free-
dom from disease, but also as an expression of virtue.1 More
recently, people began to adopt certain dietary patterns in
the belief that these could protect against disease. 
The urban–industrial food systems that generate the foods
and drinks now purchased and consumed by most people in
the world are characterised by the increased use of tech-
nology in production, manufacture, processing, distribution,
and sale. Another key feature is globalisation. Spices have
been transported from Asia to Europe for thousands of years;
sugar has been shipped around the world for half a millen-
nium; similarly, the export of tropical fruits, meat, and tea
became subject to major intercontinental trade in the 19th
century. Very many if not most foods, or their ingredients,
now travel long distances before reaching their point of sale.
Globalised food systems are now shaping dietary patterns in
all continents.2 3
This chapter summarises some of the dietary patterns that
might modify the risk of cancer. Breastfeeding is also men-
4.11  Dietary patterns
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tioned here in this context. For evidence and judgement on
lactation, see Chapter 6; on being breastfed in relation to
weight gain, overweight, and obesity, see Chapter 8. 
4.11.1  Traditional and industrial dietary
patterns 
Dietary patterns are determined by many factors. This first
group includes some traditional and industrial dietary pat-
terns, determined mainly by climate and terrain, material
resources, technology, and culture. 
4.11.1.1  Mediterranean 
The traditional food systems of the territories on or near the
Mediterranean littoral, in southern-most Europe, the Middle
East, and northern-most Africa, are the fount of a number
of great cuisines. These were developed by peoples, often
from the East, who settled in successive waves within what
is now Spain, southern France and Italy, former Yugoslavia,
Greece, Turkey, Cyprus, Crete, Lebanon, Israel, Palestine,
Egypt, Libya, Algeria, Tunisia, and Morocco. The Med-
iterranean dietary patterns that have since evolved general-
ly have some common aspects. 
Traditional Mediterranean diets are broadly characterised
by high consumption of breads and other cereal foods usu-
ally made from wheat, and of vegetables and fruits, fish,
cheese, olive oil, tree nuts (almonds and walnuts), and (in
non-Islamic countries) wine. Extensive use is made of many
herbs and spices. Meat is also consumed, but often only on
relatively special occasions or in small amounts in combi-
nation with other foods in everyday dishes. Coffee, drunk
with added sugar (in modern times), is the traditional hot
drink. Desserts may also be sweet but overall consumption
of sugar is low. 
Since the second half of the 20th century, much attention
has been given to the ‘Mediterranean’ diet. This interest is
because of evidence associating the dietary patterns of the
populations living in this region with low incidence of coro-
nary heart disease.4 It is usually thought that this associa-
tion is causal, and that the reasons include high consumption
of fresh foods, dietary fibre, vegetables, fruits, and fish; mod-
est consumption of alcoholic drinks; and low intakes of sat-
urated fatty acids. In addition, historically, habitual levels of
physical activity have been high.
Recommendations published since the early 1980s on
food, nutrition, and the prevention of cancer have similari-
ties with those for the prevention of coronary heart disease.
Mediterranean dietary patterns might therefore also be pro-
tective against cancer, either generally or of specific sites. 
Traditional Mediterranean dietary patterns are gradually
becoming less common as the food supplies of the countries
of the Mediterranean littoral become increasingly ‘western’
or ‘globalised’. 
4.11.1.2  Asian 
Traditional Asian cuisines are very diverse. But traditional
Asian dietary patterns do have some qualities in common,
certainly those of southern and eastern Asian countries
including India, Sri Lanka, Thailand, Cambodia, Vietnam,
China, and Korea. 
Such traditional Asian dietary patterns are of low energy
density. The staple cereal (grain) is usually rice, which is also
usually the main source of energy. Traditionally, rice paddy
is often also used to breed fish. The amounts of vegetables,
fruits, and fish in diets vary; consumption is relatively low
in impoverished communities, and often high in those that
are more prosperous. In the more affluent centres of civili-
sation, traditional Indian and Chinese cuisines have been
and often remain extremely diverse. But they are almost
always made up mainly from foods of plant origin, again
with very extensive use of herbs and spices. As in the
Mediterranean region, large amounts of meat are usually
reserved for special occasions. Japan is a maritime nation,
and so the traditional dietary pattern is high in fish and
seafood and in salt and salt-preserved foods. The maritime
regions of other Asian countries have the same dietary pat-
terns. Traditionally, most alcoholic drinks consumed in Asia
are made from grains. Most foods are cooked at low tem-
peratures (steaming, boiling), although some high-temper-
ature methods are also used (stir-frying, deep-frying,
roasting). Tea is the traditional hot drink in China, India, Sri
Lanka, and Japan. Consumption of fat and sugars is tradi-
tionally low. 
As with Mediterranean dietary patterns, and probably for
broadly the same nutritional reasons, traditional southern
and eastern Asian dietary patterns are associated with rela-
tively low rates of obesity, type 2 diabetes, coronary heart
disease, and some cancers. However, those that are high in
salt are associated with elevated rates of hypertension and
stroke. Traditional Asian dietary patterns remain the norm
in rural and impoverished regions of southern and eastern
Asia, but are now gradually becoming increasingly ‘western’
or ‘globalised’ in the urban and more prosperous parts of
these countries.
These generalisations do not apply to the countries of
northern Asia, including those of the former USSR. 
4.11.1.3  Plant-based 
Plant-based diets are mainly but not necessarily solely made
up from foods of plant origin. Characteristically, cereals
(whole or minimally processed grains) and other starchy
foods, vegetables and fruits, pulses (legumes), herbs and
spices, plant oils, and other foods and ingredients of plant
origin are the basis of almost all everyday foods and meals.
Meat, poultry, fish, milk and dairy products, animal fats, and
other foods and ingredients of animal origin are consumed,
usually in small amounts on normal days, but often abun-
dantly on special and feast days. Consumption of alcoholic
drinks is also usually reserved for special social occasions. 
It is estimated that the dietary patterns of most of the
world’s population — perhaps around 4 billion people — are
plant-based. Traditional Mediterranean and southern and
eastern Asian dietary patterns (summarised above) are plant-
based, as are the dietary patterns of most rural communi-
ties in middle- and low-income countries. Most populations
that consume plant-based diets do not do so from choice, but
because for them, animals are valuable and animal foods are
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relatively costly. In some traditions (see chapters 4.11.1.1
and 4.11.1.2), plant-based or vegetarian diets are consumed
as an expression of philosophy of life or of religion. These
cultures, teachings, or faiths often also include periodic peri-
ods of fasting. 
The nutritional profiles of plant-based dietary patterns are
very variable, depending largely on the degree of variety of
the foods consumed, though their energy density is gener-
ally low. Traditional plant-based cuisines from all over the
world combine cereals (grains) and other starchy foods with
beans and other pulses (legumes) as the staple foods. When
food supplies are secure they are generally adequate in ener-
gy, and also in protein, unless reliant on very low-protein
starchy staples such as cassava (manioc). Plant-based diets
may be of relatively low energy density, but not necessarily
so. Most of the fatty acids in plant-based diets are unsatu-
rated. Levels of vitamins, minerals, trace elements, and phy-
tochemicals vary, again depending on the degree of variety
in diets. 
Obesity, type 2 diabetes, coronary heart disease, cancers
of some sites, and other chronic diseases have been rare or
uncommon in those parts of the world where traditional
dietary patterns are plant-based. Such diets are now com-
monly advocated and consumed by health-conscious people
in high-income countries, partly on this basis. These diets are
also increasingly popular because of the epidemiological and
other evidence that components of plant-based dietary pat-
terns are potentially protective against various chronic dis-
eases including some cancers. 
4.11.1.4  ‘Western’ 
The dietary patterns sometimes classified as ‘western’ have
been generated by industrialised food systems, at first in
western Europe, then in the USA. These patterns have also
evolved in countries settled mostly by British and western
European peoples, including those of the white populations
of South Africa, Australia, New Zealand, and enclaves else-
where in the world. This broad generalisation does not apply
to some countries of Latin America, but in general represents
the emerging dominant pattern observed in urban centres of
the region.
‘Western’ dietary patterns are energy dense, and are
increasingly made up from processed foods.5 They are high
in meat, milk and other dairy products, fatty or sugary foods
such as processed meats, pastries, baked goods, confec-
tionery, sugared and often also alcoholic drinks, with vari-
able amounts of vegetables and fruits. The starchy staple
foods are usually breads, cereal products, or potatoes. A fea-
ture of the global ‘nutrition transition’ (see chapter 1.2.1) is
that ‘western’ dietary patterns are becoming ‘exported’ glob-
ally with accelerating speed.
‘Western’ diets defined in this way are associated with
overweight and obesity, type 2 diabetes, cardiovascular dis-
ease, stroke, some cancers, and other chronic diseases.
However, the term ‘western diet’ is potentially confusing:
variations of such diets consumed within ‘western’ countries
can and do have very different nutritional profiles. 
4.11.2  Cultural dietary patterns 
These dietary patterns are strongly influenced by cultural
factors. These include ethical and religious beliefs, and
beliefs about health. The distinction is somewhat arbitrary:
these patterns are also influenced by climate and terrain,
material resources, and technology. 
4.11.2.1  Vegetarian and vegan diets
Plant-based dietary patterns need not be vegetarian, except
in a loose sense; but vegetarian diets are generally plant-
based. The distinction is more one of attitude than nutri-
tional profile. Typically, vegetarians are at least as concerned
about the ethics and environmental effects of consuming
(and producing) animal foods as they are with their own
well-being and protection against disease. 
There are many types of vegetarian dietary patterns, and
all exclude red meat and processed meat made from red
meat. However, people whose intention is to be vegetarian
may occasionally eat these meats; and many if not most will
consume some foods containing ingredients derived from
animals that supply red meat, perhaps inadvertently.
Lacto-ovo vegetarians consume milk and dairy products
and also eggs. Vegans consume no foods of animal origin,
although some are stricter than others about what they eat.
People who avoid red meats may consume poultry and fish,
and are sometimes termed ‘semi-vegetarian’. The dietary
practices of a number of religions are plant-based or vege-
tarian. Hindus are often vegetarian. Jains are vegan.
Rastafarians are semi-vegetarian. Zen macrobiotic food is
mostly vegetarian, although the main emphasis is on whole
foods. For Seventh-day Adventists, see chapter 4.11.5.5. 
Taken together, vegetarian dietary patterns are heteroge-
neous, as is the nutritional profile of most types of vegetar-
ian diets. Studies of some vegetarians have identified lower
rates of obesity and cardiovascular disease, and all-cause
mortality. But people who are the subjects of such studies in
high-income countries, who are vegetarian as a matter of
belief or choice, are frequently of higher socioeconomic sta-
tus compared with the general population. They are also less
likely to smoke and more likely to be physically active (also
see chapter 4.11.5.4). 
4.11.2.2  Religious 
Seventh-day Adventists are a Christian denomination of
about 14 million people who, among other ways of life as
part of their faith, are sparing in their consumption of meat
and meat products; about half are lacto-ovo vegetarians.
Most avoid hot condiments and spices, tea and coffee, and
alcoholic drinks. Smoking is proscribed. The effect of
Seventh-day Adventist ways of life on well-being and health
has been the subject of a large number of studies. Rates of
chronic diseases are generally lower among Adventists, and
this is usually attributed to be their generally healthy ways
of life.
Several other religions enjoin their adherents to refrain
from consumption of certain foods or beverages — for
instance, Islam forbids consumption of pork and alcohol,
Judaism pork and other foods, and Hinduism beef.
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4.11.2.3 ‘Healthy’ 
People who are conscious of the effects of food and nutri-
tion on well-being, and on the risk of disease, may choose
to consume ‘healthy’ diets. Such diets are featured in very
many popular television programmes, newspapers, maga-
zines, and books. However, there are as many ‘healthy’
dietary patterns as there are concepts of what constitutes a
healthy diet; and for many people a ‘healthy’ diet is seen as
a diet regime designed to reduce excess body fat. In the USA,
the ‘Healthy Diet Indicator’6 and also the ‘Healthy Eating
Index’ are used to assess how well people adhere to the
Dietary Guidelines for Americans. 
4.11.3  Other dietary patterns 
4.11.3.1  Meal frequency
One hypothesis about food, nutrition, and cancer is that risk
may be modified by meal patterns. The times of day at which
food is eaten vary greatly in different populations.
Gatherer–hunters and pastoralists often consume most of
their food once a day only, or may not eat large amounts of
food every day. Settled agriculturalists may consume two
meals at different times of the day, depending on their work. 
In urban settings, having three meals a day has been a
common pattern. Some may be light meals and some more
substantial, but the time of day at which each type is eaten
varies in different parts of the world, and also within coun-
tries. Some people choose to eat lighter meals or snacks more
frequently throughout the day, rather than having three
meals. A feature of globalised food supplies and other aspects
of modern cultures is the decline of the family meal; instead,
an increasing amount of food is eaten alone in the form of
quick meals or snacks, in fast-food outlets, in the street, or
at home. 
4.11.3.2  Breastfeeding 
Being breastfed is a type of dietary pattern for infants. In fact
it is the only pattern for healthy individuals based on a sin-
gle food which provides all known essential nutrients for a
given period of life. For a general summary of lactation and
breastfeeding, see chapter 6.3. For being breastfed, see
Chapter 8. 
4.11.4  Interpretation of the evidence
4.11.4.1  General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7. 
‘Relative risk’ (RR) is used in this Report to denote ratio
measures of effect, including ‘risk ratios’, ‘rate ratios’, ‘haz-
ard ratios’, and ‘odds ratios’.
4.11.4.2  Specific
Classification. A major limitation with most studies of dietary
patterns is that there is no general agreement on just what
constitutes any dietary pattern. For example, ‘healthy’ diets
vary substantially; different types of diets are termed ‘vege-
tarian’; and there are various types of ‘Mediterranean’ diet.
In general, there is considerable scope for variation within
any dietary pattern. 
Confounding. Patterns of diet are interrelated with other
habitual behaviour that may affect the risk of cancer, such
as smoking or physical activity; people who habitually con-
sume any type of diet for the sake of their health or for rea-
sons of belief, may also modify other aspects of their way of
life. This is likely to confound results that appear to show
associations with the risk of cancer. 
Study design. The analysis of conventional epidemiological
studies tends to focus on specific foods and drinks and spe-
cific aspects of diets, rather than the overall pattern. 
Reporting bias. People who habitually consume or who try
to follow types of diets in the belief that these are healthy
may, in studies relying on self-reporting, provide inaccurate
records. They may overestimate their consumption of foods
like vegetables, fruits, and other foods they believe to be
healthy, and underestimate or fail to report consumption of
foods and drinks they believe to be unhealthy. This type of
reporting bias is a general issue with studies relying on self-
reporting, but may be a special issue here. Studies of 
specific dietary patterns undertaken by scientists who them-
selves follow these patterns may be seen as biased for this
reason.
4.11.5  Evidence and judgements
Epidemiological research concerned with food, nutrition, and
the risk of cancer, characteristically examines individual
foods and dietary constituents. 
There is a growing body of epidemiological work on
dietary patterns; these were within the terms of reference of
the systematic literature reviews (SLRs) whose findings are
the primary basis for the Panel judgements in this Report.
However, the evidence on dietary patterns examined in this
way, relative to cancers of individual sites, does not permit
conclusions to be drawn and the Panel decided not to make
any judgements. Also see chapter 4.11.4.2. 
In the case of dietary patterns, evidence from the SLRs has
been supplemented by an informal narrative literature
review, and the results are summarised here. 
The full SLR is contained on the CD included with this
Report.
4.11.5.1  Mediterranean dietary patterns
In a Swedish cohort study, a 2-point increase in a
‘Mediterranean’ diet score was associated with a 16% (95%
confidence interval (CI) 1%–29%) reduced risk of cancer
mortality in women aged 40–49, but not among younger
women.7
An intervention trial investigated the recurrence of colo-
rectal adenomas. This showed that the ‘Mediterranean’ diet
(characterised by high consumption of vegetables, fruit, lean
194
P A R T  2  •  E V I D E N C E  A N D  J U D G E M E N T S
meat, fish, and olive oil) was associated with a reduced risk
of recurrence of colorectal adenomas in women (RR 0.30
(95% CI 0.09–0.98), but not in men. 8
4.11.5.2  Asian dietary patterns
A Japanese cohort study9 showed significant associations
between certain dietary patterns and the risk of stomach can-
cer. These were for a ‘traditional’ Japanese dietary pattern
in men (RR 2.88, 95% CI 1.76–4.72) and in women (RR
2.40, 95% CI 1.76–4.72); and for a ‘healthy’ dietary pattern
in women (RR 0.56, 95% CI 0.32–0.96) but not in men.
There was no association found with the ‘western’ dietary
pattern. In the same Japanese cohort,10 ‘traditional’ and
‘western’ dietary patterns were both positively associated
with colon cancer risk in women, but not in men: ‘traditional’
RR 2.06 (95% CI 1.10–3.84) and ‘western’ RR 2.06 (95% CI
1.10–4.45).
The narrative review did not identify any other studies on
Asian dietary patterns and the risk of cancer. 
For evidence and judgements on salt, salting, and salted
food, and the risk of stomach cancer, see chapter 4.6 and
chapter 7.5.
4.11.5.3  ‘Western’ dietary patterns
The narrative review identified several studies that have used
data from large cohorts, mostly undertaken in the USA, to
derive various types of ‘western’ dietary patterns from
dietary intake information. This is done by combining key
components of diets into what is then identified as types of
dietary pattern that may be related to the risk of cancer risk.
Some case-control and ecological studies have also been car-
ried out. 
Analysis of data from the Health Professionals Follow-Up
Study found no association between a ‘western’ dietary pat-
tern and prostate cancer risk. In the study, this pattern was
characterised as being high in refined cereals (grains), red
and processed meats, fat, and sweets.11 Similarly, for breast
cancer, another large cohort study reported no association
between a ‘western’ dietary pattern and breast cancer risk.12
A ‘drinker’ dietary pattern, characterised as being high in
beer, wine, and spirits, was identified as being associated
with a moderately increased risk of breast cancer (RR 1.27,
95% CI 1.06–1.52). 
A case-control study from Uruguay reported an association
with increased breast cancer risk and a ‘western’ diet; asso-
ciations with decreased risk were found for ‘traditional’,
‘stew’, and ‘healthy’ dietary patterns.13 Another case-control
study from Uruguay reported an association with increased
stomach cancer risk and a ‘starchy’ pattern; associations with
decreased risk were found for ‘healthy’ and ‘mixed’ patterns.14
A Swedish case-control study found that a diet high in
meat, red meat, high-fat dairy products, high-fat gravy, and
sweets was significantly associated with increased risk of gas-
tric cardia adenocarcinoma and oesophageal adenocarcino-
ma. It also found that a ‘drinker’ pattern (high intakes of
beer, spirits/liquor, and French fries) was significantly asso-
ciated with the risk of squamous cell carcinoma of the
oesophagus.15
One of the first studies to investigate diet and cancer using
factor analysis was a Japanese study looking at gallblad-
der/biliary tract cancer mortality using data collected
between 1958 and 1975.16 Western-style diets high in foods
with high levels of fats and proteins were associated with
decreased risk. For breast cancer mortality in Japan, anoth-
er ecological study found that westernised diets high in both
animal and saturated fats were associated with increased
risk.17
Another Japanese cohort study showed no association
between a western dietary pattern and stomach cancer risk.9
For colon cancer risk in the same Japanese cohort, ‘western’
as well as ‘traditional’ dietary patterns were associated with
increased colon cancer risk in women, RR 2.06 (95% CI
1.10–3.84) and RR 2.06 (95% CI 1.10–4.45) respectively,
but not in men.10
Three dietary patterns were identified from analysis of a
Swedish cohort: ‘healthy’, including wholegrains, vegetables,
fruits, tomatoes, poultry, and fish; ‘western’, including
refined grains, fried potato, meat, processed meat, high-fat
dairy products, margarine/butter, sweets and soft drinks;
and ‘drinker’, including beer, wine, spirits, and snacks. The
only pattern significantly associated with increased risk of
renal cell carcinoma was the ‘drinker’ pattern (RR 0.56, 95%
CI 0.34–0.95).18
An analysis of the Nurses’ Health Study cohort also
showed no evidence of an association between breast can-
cer risk and either a ‘prudent’ or a ‘western’ dietary pattern.19
Similarly, no associations were reported between these
dietary patterns and pancreatic cancer in a US cohort study.20
Two ‘western’ dietary patterns were identified from a US
cohort. These were a ‘prudent’ type, characterised as being
high in wholegrains, vegetables, fruits, low-fat dairy prod-
ucts, poultry, and fish; and a ‘typical’ type, characterised as
being high in refined cereals (grains), red and processed
meats, high-fat dairy products, sweets, and desserts. Neither
was associated with overall breast cancer risk. However, 
the typical western pattern was associated with higher risk
of breast cancer among smokers (RR 1.44, 95% 
CI 1.02–2.03).21
A Canadian case-control study identified an association
between prostate cancer risk and a ‘processed’ dietary pat-
tern, characterised as being high in refined cereals (grains),
white bread, onions and tomatoes, red meat, processed meat,
organ meats, vegetable oil and juice, soft drinks, and bottled
water. No significant associations were found with ‘healthy
living’, ‘traditional western’, or ‘beverages’ patterns.22
A case-control study conducted in central Italy identified
a ‘vitamin-rich’ as well as a ‘traditional’ dietary pattern; both
were strongly associated with decreased risk of stomach
cancer.23
For colon cancer, a case-control study reported a protec-
tive effect of a ‘prudent’ western dietary pattern and
increased risk with a ‘typical’ western pattern.24 Another
reported a protective effect of a western ‘physical activity’
pattern.25
Analysis of data from the French European Prospective
Investigation into Cancer and Nutrition (EPIC) cohort
showed a significant association between two ‘western’
dietary patterns and increased risk of colorectal cancer. The
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first, RR 1.39 (95% CI 1.00–1.94), included cereal products,
potatoes, processed meat, eggs, cheese, butter, sweets, cakes,
pizzas and pies, and sandwiches. The second was a ‘drinker’
pattern, RR 1.42 (95% CI 1.10–1.83), including processed
meat, alcoholic beverages, sandwiches, and snacks. A ‘meat-
eater’ pattern, including meat, poultry, and margarine, was
non-significantly associated with increased risk of colorectal
cancer, RR 1.58 (95% CI 0.98–2.53).26
In an Italian cohort study, four dietary patterns were iden-
tified: ‘western’, ‘canteen’, ‘prudent’, and ‘salad vegetables’.
The ‘salad vegetables’ pattern was associated with lower risk
of breast cancer, (RR 0.66, 95% CI 0.47–0.95).27 Another US
cohort study reported no association between either a
‘vegetable–fish/poultry–fruit’ or a ‘beef/pork–starch’ pattern
and postmenopausal breast cancer. But it found a significant
association with decreased risk of invasive breast cancer and
a ‘traditional southern’ pattern, including legumes, salad,
and a low intake of mayonnaise salad dressing (RR 0.78,
95% CI 0.65–0.95).28
In the Netherlands Cohort Study on Diet and Cancer, fac-
tor analysis identified five types of western dietary patterns.
Both the ‘salad vegetables’ and the ‘sweet foods’ patterns
were associated with decreased risk of lung cancer: RR 0.75
(95% CI 0.55–1.01) and RR 0.62 (95% CI 0.43–0.89),
respectively. The other three patterns were not significantly
associated with lung cancer risk. These were ‘pork, processed
meats, and potatoes’, ‘brown for white bread substitution’,
and ‘cooked vegetables’.29
One study found that associations between dietary pat-
terns and colorectal cancer were not consistent across
European countries. As part of the Dietary Patterns and
Cancer (DIETSCAN) project, factor analysis of three
European cohorts identified five dietary patterns. Two of
these, ‘vegetables’ and ‘pork, processed meats, and potatoes’,
were common across all three cohorts. The second dietary
pattern was associated with increased risk of colon cancer
in one cohort of women (RR 1.62, 95% CI 1.12–2.34), and
with increased risk of rectal cancer in one cohort of men (RR
2.21, 95% CI 1.07–4.57). Neither pattern was associated
with the risk of colorectal cancer in the third cohort.30
For thyroid cancer, a case-control study showed that var-
ious western dietary patterns of ‘fruits’, ‘raw vegetables’, and
‘mixed raw vegetables and fruits’ were associated with
reduced risk of thyroid cancer (RR 0.68, 0.71, and 0.73,
respectively). However, a pattern of ‘fish and cooked veg-
etables’ was associated with an increased risk (RR 2.79).31
Another case-control study showed that a ‘dessert’ pattern
and a ‘beef ’ pattern were associated with increased risk of
kidney cancer. A ‘juices’ factor was associated with increased
risk of this cancer in men and an ‘unhealthy’ pattern with
increased risk in women.32
One case-control study from Uruguay reported an associ-
ation with increased risk of oral and pharyngeal cancers and
a ‘stew’ pattern, characterised by cooked vegetables, potato
and sweet potato, and boiled meat. It also found a decreased
risk of these cancers associated with a ‘vegetables and fruits’
pattern, characterised by raw vegetables, citrus fruits, other
fruits, liver, fish, and desserts.33
A case-control study of pancreatic cancer risk showed no
association with ‘western’ and western ‘drinker’ patterns, but
an association with decreased risk and a ‘fruits and vegeta-
bles’ pattern.34
A Canadian case-control study found that four dietary pat-
terns were associated with increased risk of kidney cancer:
a ‘dessert’ pattern in both men and women; a ‘beef ’ pattern
and a ‘juices’ pattern in men; and an ‘unhealthy’ pattern
among women. 
4.11.5.4  Vegetarian dietary patterns
The narrative review identified several studies that have
investigated the relationship between vegetarian diets and
the risk of cancer. These often did not adjust for potentially
confounding factors. One study found that when adjusted for
age only, women who said they consumed vegetarian diets
seemed to increase the risk of breast cancer (1.65, 95% CI
1.01–2.7) (vegetarian versus non-vegetarian).35
Plausible biological mechanisms have been identified by
which vegetarian diets might specifically reduce the risk of
cancers of the colon, breast, and prostate (also see chapter
4.2). Any effect of vegetarian diets is likely to be due not only
to the exclusion of meat, but also to the inclusion of a larg-
er number and wider range of plant foods, containing an
extensive variety of potential cancer-preventive substances. 
4.11.5.5  Seventh-day Adventist diets 
The SLRs identified a number of cohort studies on the rela-
tionship between Seventh-day Adventist diets — and also
general ways of life — and the risk of cancer. Two investi-
gated oesophageal cancer,36 37 seven stomach cancer,37-43 two
kidney cancer,37 42 one breast cancer44 and three prostate can-
cer.37 41 45 For oesophageal, kidney, breast and prostate 
cancer, results were mixed and usually not statistically sig-
nificant, although they were slightly suggestive of reduced
risk. 
For stomach cancer, meta-analysis of five cohort studies37-40
42 gave a summary effect estimate of 0.60 (95% CI
0.44–0.80), with low heterogeneity, with non-included stud-
ies also reporting reduced risks. None of the studies that
reported reduced risk was adjusted for known confounding
factors such as smoking. 
As not smoking is a feature of Seventh-day Adventism, the
Panel concluded that data on the dietary patterns associated
with this faith are limited and no conclusion can be reached
for any cancer site.
No conclusions can be based on this evidence, because the
data are too limited and not comparable across studies. 
4.11.5.6  Meal frequency 
The SLRs identified 20 case-control studies46-65 that investi-
gated irregular eating and stomach cancer. All but 1 report-
ed increased risk estimates and 15 were statistically
significant. Meta-analysis of 16 case-control studies50-65 gave
a summary effect estimate of 2.76 (95% CI 2.10–3.64) for
irregular as opposed to regular eating (p < 0.001), but with
high heterogeneity.
However, the reference period was generally some years
before cancer diagnosis. Irregular eating can be taken to
mean frequent snacking or small meals, or missing main
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meals. But none of these studies defined ‘irregular eating’ or
quantified the frequency with which meals might be
skipped. 
Eight case-control studies investigated meal frequency and
colorectal cancer.66-80 Most showed increased risks with
increased frequency of meals. Meta-analysis of 11 estimates
from 7 of these studies67-69 76 78-80 gave a summary effect esti-
mate of 1.10 (95% CI 1.02–1.19), with high heterogeneity.
This evidence is also unclear. No cohort studies have been
identified as examining meal frequency. People who have
stomach or colorectal problems are likely to eat irregularly.
There is also high probability of confounding, as regular eat-
ing patterns are associated with generally healthy behaviour. 
The significance of these findings on meal frequency and
stomach and colorectal cancer is unclear, in part because of
the high probability of confounding. For this reason, no
judgement is made. 
4.11.5.7  Being breastfed
The SLRs produced no evidence on any relationship between
having been breastfed and the risk of cancer in adult life.
However, the reviews did produce evidence on the relation-
ship between lactation and cancer in women, and also
between having been breastfed and the risk of overweight
and obesity in childhood and thereafter. See chapters 6.3.3
and 8.8.3. 
4.11.6  Comparison with previous report
The previous report reviewed evidence on vegetarian and
mostly-vegetarian dietary patterns of various types, includ-
ing Seventh-day Adventist and macrobiotic diets. The report
concluded that various types of vegetarian dietary pattern
seem to decrease the incidence of cancer in general, as well
as of some specific sites. It also concluded that semi-vege-
tarian diets that include small amounts of meat and foods
of animal origin may also be beneficial. This conclusion was
not made as a formal judgement. 
The previous report identified ‘poverty’ or ‘deficiency’ pat-
terns of diet. These are monotonous, very high in refined
cereal foods (such as rice), with only small amounts of other
foods. This was partly in response to its finding that refined
cereals (grains) were a possible cause of oesophageal can-
cer and that starch was a possible cause of stomach cancer.
In explanation, the panel responsible for that report con-
cluded that any increase in the risk of cancer here was like-
ly to be caused by poverty/deficiency dietary patterns, not
by the specific food or dietary constituent. 
The first recommendation of the previous report was in
effect for: ‘nutritionally adequate and varied diets, based pri-
marily on foods of plant origin’. This was based partly on the
evidently protective effects of vegetables and fruits, and also
on the general balance of evidence. The panel emphasised
that ‘plant-based diets’ do and may include relatively mod-
est amounts of foods of animal origin.
4.11.7 Conclusions
The Panel concludes:
Currently, no firm judgements can be made on any possible
relationship between dietary patterns and the risk of cancer. 
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Physical activity
Physical activity is any form of movement using skeletal
muscles. Until very recently in history, people necessarily
engaged in regular, moderate, and at least occasional
vigorous, physical activity. However, with urbanisation and
industrialisation, general levels of physical activity have
declined. Machines now do most of the work previously
done by hand; driving and using public transport have
largely replaced walking and cycling. While people in
higher income countries and in urban settings in most
countries may engage in some active forms of recreation,
they remain largely inactive, and many spend much time
in sedentary recreations, such as watching television and
using home computers. 
In general, the Panel judges that the evidence on
physical activity and the risk of cancer, which has
continued to accumulate since the early 1990s, shows or
suggests that regular, sustained physical activity protects
against cancers of some sites. These include colon cancer
and female hormone-related cancers, independently of
other factors such as body fatness. 
The Panel judges as follows. The evidence that physical
activity protects against colon cancer is convincing.
Physical activity probably protects against postmenopausal
breast cancer; the evidence suggesting that it protects
against premenopausal breast cancer is limited. Physical
activity probably protects against cancer of the
endometrium. The evidence suggesting that physical
activity protects against cancers of the lung and pancreas
is limited. 
The Panel is impressed by the overall consistency of the
evidence and concludes that relatively high levels of
physical activity protect, or may protect, against cancers of
the colon, breast (postmenopause), and endometrium. To
prevent these cancers, the overall evidence supports the
message that the more physically active people are the
better; however, this excludes extreme levels of activity. 
The Panel also agrees that since physical activity protects
against overweight, weight gain, and obesity, it also
protects against cancers for which the risk is increased by
these factors (see Chapter 8). 
The evidence assembled for this Report gives an account
of the beneficial effects of higher compared to lower levels
of physical activity. However, the Panel further agrees that
the evidence can equally be interpreted as showing that
sedentary ways of life increase or may increase the risk of
these cancers. Most people in urbanised, industrialised,
C H A P T E R  5
and mechanised settings throughout the world now lead
these sedentary ways of life. 
Finally, the Panel agrees that the evidence assembled and
judged in this chapter supports the general hypothesis that
people have evolved and adapted to be physically active
throughout life. The Panel also agrees, therefore, that
sedentary ways of life are unhealthy. It is aware of current
trends and also projections (summarised in Chapter 1)
showing that average physical activity levels are
continuing to decrease throughout the world. 
Within the remit of this Report, the strongest evidence,
corresponding to judgements of ‘convincing’ and
‘probable’, shows that physical activity of all types protects
against cancers of the colon, and also of the breast
(postmenopause) and endometrium. 
This chapter does not address the social or
environmental (or underlying and basic) determinants of
physical activity and its general decline; this is the subject
of an associated report to be published in late 2008.
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Since the emergence of Homo sapiens around 250 000 years
ago, and until very recently in history, people have usually
been regularly physically active from early childhood
throughout life unless prevented by disability or infirmity.
Gatherer–hunter (and pastoral) and peasant–agricultural
communities have to be physically active to sustain their
ways of life. This includes building and maintaining
dwellings; raising families; seeking food security and feed-
ing infants, dependants, the disabled, and elders; and trav-
elling to find water, game, precious items, and better land.
Walking, as well as activities undertaken with hand tools
such as gathering, hunting, growing, harvesting, grinding,
cooking, cleaning, building, and fighting, all require a regu-
lar and substantial amount of energy from food. 
Throughout history, manual workers in and around cities
have also been physically active, by the nature of their occu-
pations. These range from those who built pyramids in
Egypt, Mexico, and elsewhere, and fortifications in Asia,
Latin America, and Europe, to the working-class labourers
of industrialised countries. Such labourers built houses,
sewers, bridges, canals, railways, roads, served in armies and
navies, and worked in mines and factories, ‘by the sweat of
their brow’, and still do so, throughout the world. 
In modern times, the story of urbanisation and of indus-
trialisation is one in which machines are increasingly used
to do the work previously done by hand. Early factory and
farm machinery still involved sustained, moderate or vigor-
ous physical activity, as did housework; and most people
walked or (later) cycled to work. In the first half of the 20th
century, most occupations in high-income countries required
physical activity and only a minority of households owned
cars or televisions. In middle- and low-income countries at
that time, almost all occupations were physically active.
In the second half of the 20th century this all began to
change, at first gradually and then more rapidly. Now, at the
beginning of the 21st century, most occupations in urban
areas throughout the world are sedentary. Household tasks
are mostly mechanised; much food is purchased already pre-
pared; most journeys (even short ones) are made by car or
public transport; and for young people, television viewing
and the use of computers have often largely replaced active
recreation.
In public health terms, given the known benefits of regu-
lar, sustained physical activity, this shift in whole populations
from being active to sedentary is one of the most ominous
phenomena of recent decades. This is not confined to high-
income countries or urban areas. The ways of life of most
people in most countries are now sedentary, with the major
exception of peasant farmers and manual labourers, mostly
in Asia and Africa but also elsewhere. 
General levels of physical activity in high-income coun-
tries, and more recently in most other countries, have
dropped and continue to drop. It is in this special context
that the Panel commissioned systematic literature reviews
(SLRs) of the primary evidence on physical activity and
cancer. 
5.1  Definitions
Physical activity is any movement using skeletal muscles. For
people with sedentary ways of life, light physical activity
includes standing, walking around an office or home, and
shopping and food preparation. Recreation time may involve
light, moderate, or vigorous physical activity depending on
the nature and intensity of activities, hobbies, and pursuits.
Most people with active ways of life are moderately or vig-
orously physically active at work (manual labour) or at home
(household work by hand), and are moderately physically
active in transport (walking, riding, and cycling). People
with sedentary occupations can be as physically active as
people engaged in manual labour, but usually only if they
engage in regular moderate and occasional vigorous physi-
cal activity away from work.1
Sitting, standing, and other light physical activity intrin-
sic to normal waking life, such as stretching, fidgeting, and
maintaining posture, are all forms of physical activity.
Exercise and other forms of physical training are types of
recreational physical activity. These may be aerobic, such as
PHYSICAL ACTIVITY, AND THE RISK OF CANCER
In the judgement of the Panel, physical activity1 modifies the risk of the
following cancers. Judgements are graded according to the strength of
the evidence.
DECREASES RISK INCREASES RISK
Convincing Colon2
Probable Breast
(postmenopause)
Endometrium
Limited — Lung
suggestive Pancreas
Breast (premenopause)
Substantial 
effect on risk None identified
unlikely
1 Physical activity of all types: occupational, household, transport, 
and recreational.
2 Much of the evidence reviewed grouped colon cancer and rectal cancer 
together as ‘colorectal’ cancer. The Panel judges that the evidence is
stronger for colon than for rectum.
For an explanation of the terms used in the matrix, 
please see chapter 3.5.1, the text of this chapter, 
and the glossary.
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running, cycling, dancing, and other activities that increase
oxygen uptake and improve cardiovascular function, among
other things; or anaerobic, such as resistance training using
weights, which increases muscle strength and mass.1
Physical activity increases energy expenditure and so is a
factor in energy balance (see chapter 8.3.3). The intensity
of physical activity can be categorised according to the
degree to which it increases energy expenditure above basal
metabolism. A table showing the intensity of physical activ-
ity involved in different forms of movement is included in
Chapter 12.
5.2  Types and levels of physical activity
5.2.1  Types of physical activity
Conventionally, and for the purposes of this Report, overall
physical activity is classified into four types. These are: 
• Occupational (at work)
• Household (in the home) 
• Transport (such as travelling to and from work)
• Recreational (leisure).
Much of the evidence summarised and judged below uses
these classifications. They also highlight differences between
various ways of life. Populations and communities where
physical activity at work and at home depends on hand tools
and walking (or riding or cycling) are overall physically
active or very active, even without recreational activity.
Conversely, people whose ways of life at work and at home
are sedentary, and who use mechanised transport, will be
overall sedentary, unless they engage in substantial amounts
of moderate and perhaps some vigorous physical recreational
activity away from work. In general, in high-income coun-
tries recreational activity accounts for a greater proportion
of an overall lower level of physical activity.2
Physical activity can also be classified by intensity: vigor-
ous, moderate, light, or sedentary (see boxes 5.1 and 5.2).
It is the combination of frequency, intensity, and duration
that determines total physical activity levels. A person may
use the same total amount of energy in 1 hour of light phys-
ical activity as they do in 30 minutes of moderate activity
or 20 minutes of vigorous activity.
5.2.2  Levels of physical activity
For many years, planners responsible for keeping specified
population groups (such as builders, soldiers, schoolchild-
ren, or office workers) healthy and productive have compiled
estimates of the food or energy needed by these groups. Such
estimates consistently show that some people need almost
as much energy from food for physical activity as they do
for the basic functions of vital organs and the assimilation
of food. These are people who are moderately physically
active for roughly half of their waking day, are engaged in
light work or sitting or resting for most of the rest of their
waking hours, and are occasionally vigorously physically
active.4
In physically active populations where energy from food
is not freely available, people tend to be lean, and also small.
Below critical levels, as has been observed in Asia and in
Europe, food scarcity makes regular, sustained physical work
difficult and even impossible.5 6
5.2.2.1 Energy costs of ways of life
The energy requirements of healthy adults are determined
largely by their habitual physical activity levels (PALs). PALs
are the ratio of a person’s daily total energy expenditure
(TEE) to their basal energy expenditure, and thus take into
account the greater energy required for performing the same
task with a higher body mass.2 7
A sustained PAL of 1.2 corresponds roughly to a bedrid-
den state. People whose occupations are exceptionally active,
such as miners, woodcutters, soldiers, and athletes, may
need more energy for physical activity than for their basic
functions. This translates into habitual PALs above 2.0. Such
unusual people are mostly young adults, and these levels of
physical activity are not sustained throughout life. PALs
above 2.4 can only be sustained over a long period of time
by unusually physically fit people. Also see Chapter 12.
In general, in high-income countries in the first decade of
the 21st century, average levels of physical activity usually
account for about 20 to 30 per cent of TEE, but for extreme-
The total amount of energy a person uses
during a particular activity is determined
by a combination of the duration and
intensity of the activity. Metabolic equiva-
lents (METs) describe intensity relative to a
person’s resting metabolic rate. The ener-
gy costs of any particular activity vary,
depending on a person’s basal energy
expenditure and their age, sex, size, skill,
and level of fitness. MET values take these
factors into account. 
High total energy expenditure can be
produced by performing low-intensity
activity for a long duration or high-inten-
sity activity for a shorter duration.
However, these two different types of
activity may have different physiological
effects. The intensity of physical activity is
therefore sometimes stratified into levels,
such as vigorous (≥ 6 METs), moderate
(3–5.9 METs), or light (<3 METs). METs can
be used to describe the intensity of single
activities, equivalent to the physical activ-
ity ratio (PAR), or the overall level of activ-
ity over a day, equivalent to the physical
activity level (PAL).
Vigorous physical activity can also be
defined as that which increases heart and
breathing rates up to 80 per cent or more
of their maximum (the point at which
anaerobic metabolism is needed to provide
energy). Moderate physical activity increas-
es heart rate to around 60–75 per cent of
its maximum (and the energy requirement
can usually be met by aerobic metabolism
using the body’s stores of glycogen and
then fats). Light physical activity has only
minor effects on heart and breathing
rates. Sedentary activity (or inactivity)
involves no noticeable effort: heart and
breathing rates are not raised perceptibly
above ‘resting’ levels.3 Also see 5.2.2.1.
Box 5.1 Energy cost and intensity of activity
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ly sedentary people this may be as little as 15 per cent.2 8 9
See box 5.2. 
The combined contribution of multiple types of physical
activity can also be characterised in terms of metabolic equiv-
alent (MET)-hours. METs are usually converted to MET-hours
per day or per week, which are calculated as the sum of the
MET level for each activity multiplied by the duration the
activity was performed.
5.3  Interpretation of the evidence
5.3.1  General
For general considerations, see chapters 3.3 and 3.5 and
boxes 3.1, 3.2, 3.6, and 3.7. Relative risk (RR) is used in this
Report to denote ratio measures of effect, including risk
ratios, rate ratios, hazard ratios, and odds ratios.
5.3.2  Specific 
Some considerations specific to physical activity are as
follows. 
Patterns and ranges. Large studies of physical activity are
mainly undertaken in high-income countries. Such studies
tend to pay most attention to voluntary recreational activity
and may therefore have limited relevance to populations in
lower-income countries. In these countries, overall activity
levels may be higher and physical activity is mostly of the
type classed as occupational, household, or transport. 
The evidence summarised in section 5.4 of this chapter
generally suggests that the more physically active people are,
the better, but with one cautionary note. At levels well above
what people at any level of fitness are accustomed to, and
well above the ranges reviewed in this Report, vigorous phys-
ical activity has a suppressive effect on immune function. This
not only increases vulnerability to infectious agents but also
to DNA damage. Also see chapter 2.4.1.3. 
Classification. There is currently no generally agreed clas-
sification of different levels of overall physical activity, with
quantified degrees of activity corresponding to terms such as
‘active’ and ‘sedentary’.
Measurement. Physical activity is rarely measured precise-
ly. Ideally, studies would record the frequency, intensity, and
duration of people’s physical activity over an extended period
— day and night. But studies are generally not designed to
obtain this information. Objective measures such as pedome-
ters and microcomputer sensors are not often used in large
studies. Instead, questionnaires are most frequently used. 
Terminology. Analysis of studies shows that what is meant
by and included as ‘physical activity’ varies. 
Study design. Different methods of measuring physical
activity are reported in the literature, making comparison
between studies difficult.
Confounding. In high-income countries, people who are
physically active also tend to be health conscious and so, for
example, are more likely to be non-smokers and to choose
diets they believe to be healthy. This may confound findings
that show associations with the risk of cancer.
Reporting bias. Questionnaires measure some forms of phys-
ical activity more accurately than others. Thus, people tend
to recall vigorous and recreational, and other voluntary activ-
ities, with relative accuracy. However, these activities are gen-
erally performed for relatively short periods of time and may
amount to a smaller than perceived proportion of a person’s
total physical activity. 
5.4  Evidence and judgements
Studies examining physical activity and cancer were includ-
ed in the SLRs. There is evidence, both epidemiological and
mechanistic, that physical activity may protect against cancer
The evidence judged in this chapter shows
that higher rather than lower levels of
physical activity protect, or may protect,
against a number of cancers. Most studies
of physical activity are carried out in high-
income countries with low average levels
of occupational, household, and transport
physical activity (characterised as sedentary
ways of life). 
What are now regarded as high levels of
physical activity in urbanised and industri-
alised settings correspond roughly to what
were average levels of physical activity in
most (including high-income) countries
until well into the second half of the 20th
century.4 Since then, occupations have
generally become more sedentary:
machines do more household work; more
people drive or ride in cars or buses than
cycle or walk; and for children as well as
adults, active recreation has been largely
replaced by watching television or other
sedentary pursuits. 
This Report has a global perspective, and
the Panel agrees that the evidence assessed
in this chapter can, with equal validity, be
judged inversely. This means that relative-
ly low levels of physical activity — as now
typical in high-income countries and in
urban–industrial settings in all continents
and most countries throughout the world
— are or may be a cause of cancers of the
colon, breast (postmenopause), and
endometrium. Also, these low levels are, or
may be, a cause of weight gain, over-
weight, or obesity, which themselves are
causes of some cancers. The evidence
judged in this chapter supports the gener-
al theory that the human species has
evolved and adapted to be physically
active throughout life, and therefore that
sedentary ways of life are unhealthy. 
Evidence that sedentary ways of life
increase the risk of diseases other than can-
cer is summarised in Chapters 8 and 10.
Box 5.2 Sedentary ways of life
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in general. Large studies carried out in the USA have shown
that physical inactivity is associated with higher overall can-
cer incidence and mortality.10-12 These studies are support-
ed by studies on animals.13 Mechanistic reasons why
physical activity may protect against cancer (or why seden-
tary living may promote cancer) include healthier levels of
circulating hormones and the ability of the more active body
to consume more food and nutrients without gaining weight
(see Chapter 2). Mechanisms by which physical activity may
protect against colorectal cancer and female hormone-relat-
ed cancers are summarised in the following sections. 
Evidence from the literature on physical activity and can-
cer in general indicates that the relationship between phys-
ical activity and health is continuous: that is, there does not
appear to be a threshold below or above which no effect is
found.14 15 This implies that, in general, the more physical-
ly active people are, the better, within the range examined.
The Panel agrees that this general judgment is supported by
the evidence on physical activity and cancer, which is sum-
marised, assessed, and judged below.
The full SLRs are contained on the CD included with this
Report.
5.4.1  Colorectal 
Eleven cohort studies investigated total physical activity and
colon or colorectal cancer.16-26 Twelve cohort studies inves-
tigated occupational physical activity21 25 27-36 and 24 inves-
tigated recreational activity.10 17 21 25-27 29 30 34 37-51 Five cohort
studies investigated frequency of physical activity,10 16 26 50 52
and seven investigated intensity of physical activity.22 26 34 37
46 51 53 Case-control studies that investigated physical activ-
ity can be found in the full SLRs. Also see chapter 7.9.
Total physical activity
Of the 11 cohort studies considered, 816-22 26 reported
decreased risk for the highest physical activity groups when
compared to the lowest. This was significant overall in three
studies17-19 and in two additional studies in men but not in
women.16 26 One cohort study reported non-significant
increased risk for the lowest physical activity groups when
compared to the highest.25 Meta-analysis was not possible on
these studies due to the heterogeneity with which physical
activity was measured. Six studies were included in a highest
versus lowest analysis, shown in figure 5.4.1. Three studies
investigated cancer of the rectum, with mixed results.17 18 21
Occupational 
Of the 12 cohort studies considered, 6 compared highest to
lowest occupational activity groups.21 25 27-30 All reported
decreased risk, which was significant in two27 30 and bor-
derline significant in one.25 Six cohort studies compared
sedentary occupational activity to high occupational activi-
ty31-36 and all reported increased risk for sedentary activity.
This was significant in three studies.32 33 35 Five studies that
investigated colorectal cancer are included in a highest ver-
sus lowest plot, shown in figure 5.4.2. Five studies that inves-
tigated rectal cancer are examined in a separate highest
versus lowest plot, shown in figure 5.4.3. 
Recreational 
Of the 24 cohort studies considered, 22 compared highest
to lowest physical activity groups. All but two of these stud-
ies reported decreased risk, which was significant in seven
studies.21 25 26 30 38 41 46 The Health Professionals Follow-Up
Study reported an RR of 0.53 (95% confidence interval (CI)
0.32–0.88) comparing men in the highest quintile of physi-
cal activity to men in the lowest quintile, with evidence of
a dose-response relationship (p for trend = 0.03). In the
highest quintile, men reported a median of 47 MET-hours of
activity a week; in the lowest quintile, the median was 0.9
MET-hours.41
Five studies examined rectal cancer separately, comparing
highest with lowest physical activity groups: two reported non-
significant decreased risk,25 27 one reported significant
increased risk,30 and two reported non-significant increased
risk.30 41 Fourteen studies that examined colorectal cancer are
included in a highest versus lowest plot, shown in figure 5.4.4. 
A published meta-analysis of 19 cohort studies reported
significant decreased risk of colon cancer for men with high
levels of occupational activity, and also for men and women
with high levels of recreational activity. Nine of these stud-
ies examined dose response; a significant inverse trend was
reported in six studies. Physical activity was not associated
with decreased risk of cancer of the rectum.54
Walking
Two cohort studies examined measures of walking. A sig-
nificant increased risk was found in men who reported a
‘slower walking pace than others’ compared to those who
said they had a ‘faster walking pace than others’.39 In a study
that examined time spent walking, decreased risk was report-
ed in men who walked for more than 60 minutes a day com-
pared to men who walked for less than 20 minutes a day,
but this was not significant.51
Figure 5.4.1 Total physical activity and colorectal cancer;
cohort studies
Wu 1987 Men 0.89 (0.50–1.59)
Wu 1987 Women 0.40 (0.20–0.80)
Lee 1991 Men 1.02 (0.65–1.60)
Thune 1996 Men <45 yrs 2.23 (0.88–5.66)
Thune 1996 Women <45 yrs 0.62 (0.31–1.24)
Thune 1996 Men ≥45 yrs 0.66 (0.40–1.09)
Thune 1996 Women ≥45 yrs 0.66 (0.33–1.33)
Pietinen 1999 Men 0.47 (0.31–0.71)
Schoen 1999 0.80 (0.43–1.50)
Nilsen 2001 Men 0.54 (0.37–0.79)
Nilsen 2001 Women 0.81 (0.54–1.22)
0.2 0.5 2 51
Relative risk (95% CI)
Relative risk, highest vs lowest exposure category
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Frequency 
Of the five cohort studies assessed, three reported decreased
risk for the highest frequency of physical activity when com-
pared to the lowest.16 26 50 In two of these studies, this find-
ing was significant in men but not in women.16 26 One study
reported non-significant increased risk comparing highest
with lowest frequency of activity.44 Another study, comparing
lowest with highest frequency of activity, reported non-sig-
nificant increased risk in women but no association in men.10
Intensity 
Six cohort studies investigated intensity of physical activity,
of which five reported an association between increased
intensity and decreased risk. Four reported decreased risk
comparing high with low intensity of physical activity,26 37 46
51 which was significant in all but one study.51 One study
reported a significant increased risk comparing low with high
intensity of physical activity,34 and another study reported
no association.53
Mechanisms
There are a number of mechanisms by which physical activ-
ity may protect against colorectal cancer. These include a
reduction in insulin resistance, the beneficial effect of phys-
ical activity on body fatness (see Chapter 6), the effects on
endogenous steroid hormone metabolism, and reduced gut
transit time.55 56
There is abundant epidemiological evidence from
prospective studies showing lower risk of colorectal
cancer with higher overall levels of physical activity, as
well as with greater frequency and intensity, and there
is evidence of a dose-response effect. There is little
heterogeneity, except that the effect is not as clear for
rectal cancer as it is for colon cancer. There is plausible
evidence for mechanisms operating in humans. The
evidence that higher levels of physical activity, within
the range studied, protects against colon cancer, is
convincing. 
The Panel is aware that since the conclusion of the SLR, four
cohort56A–56D and four case control studies56E-56H have been pub-
lished. This new information does not change the Panel judge-
ment (see box 3.8).
Figure 5.4.3 Occupational physical activity and rectal
cancer; cohort studies
Severson 1989 1.23 (0.71–2.14)
Suadicani 1993 Men 0.77 (0.44–1.47)
Thune 1996 Men 1.00 (0.69–1.45)
Thune 1996 Women 0.80 (0.30–2.14)
Colbert 2001 Men 0.50 (0.26–0.97)
Wei 2003 Men 0.95 (0.56–1.61)
0.2 0.5 2 51
Relative risk, highest vs lowest exposure category
Relative risk (95% CI)
Figure 5.4.4 Recreational physical activity and colorectal
cancer; cohort studies
Severson 1989 Men 0.66 (0.49–0.88)
Lee 1991 Men 0.95 (0.64–1.12)
Suadicani 1993 Men 0.77 (0.38–1.57)
Bostick 1994 Women 0.95 (0.66–1.36)
Giovannucci 1995 Men 0.53 (0.32–0.88)
Thune 1996 Men, high BMI 1.05 (0.69–1.59)
Thune 1996 Women, high BMI 0.93 (0.49–1.75)
Thune 1996 Men, low BMI 1.36 (0.74–2.51)
Thune 1996 Women, low BMI 0.45 (0.25–0.82)
Lee 1994 Men 1.10 (0.73–1.66)
Ford 1999 0.90 (0.62–1.29)
Wannamethee 2001 0.90 (0.80–1.35)
Nilsen 2001 Men 0.69 (0.50–0.95)
Nilsen 2001 Women 1.12 (0.93–1.52)
Malila 2002 Men 0.92 (0.60–1.24)
Tiemersma 2002 0.67 (0.46–0.96)
Wei 2003 Women 0.73 (0.53–1.01)
Sanjoaquin 2004 0.82 (0.49–1.37)
0.2 0.5 2 51
Relative risk (95% CI)
Relative risk, highest vs lowest exposure category
Figure 5.4.2 Occupational physical activity and colorectal
cancer; cohort studies
Severson 1989 Men 0.72 (0.52–1.00)
Suadicani 1993 Men 0.69 (0.39–1.23)
Thune 1996 Men 0.82 (0.59–1.14)
Thune 1996 Women 0.69 (0.34–1.41)
Wei 2004 0.71 (0.52–0.96)
Norat 2005 Men 0.43 (0.33–0.55)
Norat 2005 Women 0.51 (0.38–0.69)
Relative risk (95% CI)
0.2 0.5 2 51
Relative risk, highest vs lowest exposure category
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5.4.2  Breast 
Six cohort57-62 studies and eight case-control studies63-70
investigated total physical activity and breast cancer. Five
cohort studies10 71-74 and seven case-control studies75-81 inves-
tigated occupational activity. Fourteen cohort studies10 58 72
74 82-91 and 11 case-control studies67 76 77 81 92-98 investigated
recreational activity. Also see chapter 7.10.
5.4.2.1  Menopause status unspecified
Total physical activity
Two cohort studies59 60 and four case-control studies64-66 70
did not specify menopausal status.
One cohort study reported non-significant increased risk
for the highest activity group when compared to the lowest.59
The other reported non-significant decreased risk.60
All four case-control studies reported decreased risk for the
highest activity group when compared to the lowest. This
was significant in one study66 and in a second study in
Hispanic (but not in non-Hispanic) women.70
Occupational 
Five cohort studies10 71-74 and two case-control studies76 81 did
not specify menopausal status.
Two cohort studies reported decreased risk comparing high
with low physical activity72 74; this was significant in one
study.72 Another cohort study reported a borderline increased
risk comparing sedentary activity with high activity,73 and
two analyses of the NHANES Epidemiologic Follow-up Study
reported no significant associations.10 71
Both case-control studies reported non-significant
decreased risk for the highest activity group when compared
to the lowest.76 81
Recreational 
Six cohort studies72 74 82 86 87 89 and six case-control studies76
81 92-94 98 did not specify menopausal status. 
Three cohort studies reported decreased risk for the high-
est activity group when compared to the lowest72 82 87; this
was significant in one study.72 Two studies reported no asso-
ciation74 86 and one study reported non-significant increased
risk.89 The effect estimates were RR 0.63 (95% CI
0.42–0.95),72 RR 0.80 (95% CI 0.58–1.12),87 RR 0.73 (95%
CI 0.46–1.14),82 RR 1.0 (95% CI 0.64–1.54),74 and RR 1.24
(95% CI 0.83–1.82).89
All six case-control studies reported decreased risk with
increased physical activity, which was significant in five stud-
ies.76 81 92 93 98 Meta-analysis was possible on these five stud-
ies, giving a summary effect estimate of RR 0.90 (95% CI
0.88–0.93) per 7 MET-hours per week (figure 5.4.5), with
high heterogeneity. The heterogeneity was related to the size
but not the direction of effect.
Mechanisms
There are a number of mechanisms by which physical activ-
ity may protect against breast cancer in general. These
include the beneficial effect of physical activity on body fat-
ness (see Chapter 6), effects on endogenous steroid hormone
metabolism, and a possible strengthening of the immune sys-
tem. Physical activity may reduce levels of circulating oestro-
gens and androgens.
The Panel’s judgment is given not on breast cancer in gen-
eral, but separately for premenopausal and postmenopausal
breast cancer. See 5.4.2.2 and 5.4.2.3. 
5.4.2.2  Premenopause
Total physical activity
Two cohort studies58 61 and six case-control studies64-69
reported results for premenopausal breast cancer.
One cohort study reported non-significant but slightly
increased risk for the highest activity group when compared
to the lowest (RR 1.04; 95% CI 0.82–1.33).58 The other
study reported no association.61
Five case-control studies reported decreased risk for the
highest activity group when compared to the lowest64 66 67 69
77; this was significant in two.66 69 One study reported non-
significant increased risk.68
Occupational 
Three cohort studies10 72 73 and six case-control studies75-80
reported results for premenopausal breast cancer.
Two cohort studies reported decreased risk for the high-
est activity group compared to the lowest10 72; this was sig-
nificant in one study (RR 0.48; 95% CI 0.24–0.95).72 One
study reported that there was no association.73
Two case-control studies reported non-significant
decreased risk for the highest activity group when compared
to the lowest.75 76 No associations were reported in the other
four studies.77-80
Recreational
Four cohort studies58 72 82 84 and six case-control studies67 76
77 81 95 96 reported results for premenopausal breast cancer.
Two cohort studies reported non-significant decreased risk
for the highest activity group when compared to the lowest.58
72 Two studies reported non-significant increased risk.82 84
The effect estimates were RR 0.71 (95% CI 0.45–1.12),58 RR
0.53 (95% CI 0.25–1.14),72 RR 1.19 (95% CI 0.43–3.3),84
and RR 1.83 (95% CI 0.77–4.31).82
Figure 5.4.5 Recreational physical activity and breast
cancer; case-control studies
Bernstien 2005 0.94 (0.90–0.97)
Verloop 2000 0.92 (0.85–0.99)
Matthews 2001 0.86 (0.82–0.91)
Ueji 1998 0.85 (0.76–0.95)
Yang 2003 0.69 (0.57–0.83)
Summary estimate 0.90 (0.88–0.93)
Relative risk (95% CI)
0.6 0.8 1.21
Relative risk per 7 MET-hours per week
205
C H A P T E R  5  •  P H Y S I C A L  A C T I V I T Y
Four case-control studies76 81 95 96 reported decreased risk
with increased physical activity; this was significant in two
studies,81 95 neither of which could be included in the meta-
analysis. One study reported no association with risk,67 and
another reported non-significant increased risk.77 Meta-
analysis was possible on four case-control studies,67 76 77 96
giving a summary effect estimate of 1.00 (95% CI 0.97–1.04)
per 7 MET-hour per week, with low heterogeneity. 
There is ample evidence from prospective studies, but
it is inconsistent. There is limited evidence suggesting
that physical activity protects against premenopausal
breast cancer. 
5.4.2.3  Postmenopause
Total physical activity
Two cohort studies57 62 and six case-control studies64 66 67 69
70 77 reported results for postmenopausal breast cancer.
Both cohort studies reported decreased risk for the highest
activity group when compared to the lowest.57 62 Effect esti-
mates were RR 0.43 (95% CI 0.19–0.96)62 and RR 0.20 (95%
CI 0.5–1.0),57 comparing highly active with inactive women.
Five case-control studies reported decreased risk for the
highest activity group when compared to the lowest64 66 67 70
77; this was significant in three studies.66 70 77 One study
reported non-significant increased risk.69
Occupational 
Five cohort studies10 72-74 85 and four case-control studies75
77-79 reported results for postmenopausal breast cancer.
All five cohort studies reported decreased risk for the high-
est activity group when compared to the lowest; this was sig-
nificant in one study.73 The effect estimates were RR 0.85
(95% CI 0.57–1.28)74 and RR 0.78 (95% CI 0.52–1.18)72
for high compared to low occupational activity. The effect
estimates were RR 1.5 (95% CI 0.70–2.80)10 and RR 1.3
(95% CI 1.1–1.7),73 comparing sedentary to non-sedentary
occupations. 
Three case-control studies reported decreased risk for the
highest activity group when compared to the lowest75 77 79;
this was significant in one study.79 One study reported sig-
nificant increased risk.78
Recreational 
Eleven cohort studies10 72 74 82-85 87 88 90 91 and six case-control
studies67 76 77 81 94 97 reported results for postmenopausal
breast cancer.
Nine cohort studies reported decreased risk for the high-
est activity group when compared to the lowest10 72 82-85 87 88
90; this was significant in two.82 84 Two of the studies report-
ed non-significant increased risk.74 91 Meta-analysis was pos-
sible on three studies, giving a summary effect estimate of
RR 0.97 (95% CI 0.95–0.99) per 7 MET-hours per week, with
no heterogeneity. This is shown in figure 5.4.6.
Meta-analysis was possible on five of the case-control stud-
ies, giving a summary effect estimate of RR 0.97 (95% CI
0.95–1.00) per 7 MET-hours per week, with moderate het-
erogeneity. This is shown in figure 5.4.7.
There is ample evidence from prospective studies
showing lower risk of postmenopausal breast cancer
with higher levels of physical activity, with a dose-
response relationship, although there is some
heterogeneity. There is little evidence on frequency,
duration, or intensity of activity. There is robust evidence
for mechanisms operating in humans. Physical activity
probably protects against postmenopausal breast cancer. 
The Panel is aware that since the conclusion of the SLR, one
case-control study98A has been published. This new information
does not change the Panel judgement (see box 3.8). 
5.4.3  Endometrium 
Two cohort studies99 100 and four case-control studies101-104
investigated total physical activity and cancer of the
endometrium. Three cohort studies105-107 and 10 case-con-
trol studies102-104 108-114 investigated occupational activity.
Four cohort studies107 115-117 and 10 case-control studies
Figure 5.4.6 Recreational physical activity and
postmenopausal breast cancer;
cohort studies
McTiernan 2003 0.97 (0.95–1.00)
Patel 2003 0.97 (0.94–1.00)
Dirx 2001 0.97 (0.94–1.00)
Summary estimate 0.97 (0.95–0.99)
Relative risk (95% CI)
0.6 0.8 1.21
Relative risk per 7 MET-hours per week
Figure 5.4.7 Recreational physical activity and
postmenopausal breast cancer; case-control
studies
John 2003 1.04 (0.97–1.11)
Friedenreich 2001 1.02 (0.94–1.11)
Carpenter 2003 0.97 (0.95–1.00)
Moradi 2000 0.92 (0.86–0.97)
Ueji 1997 0.90 (0.76–1.07)
Summary estimate 0.97 (0.95–1.00)
Relative risk (95% CI)
0.6 0.8 1.21
Relative risk per 7 MET-hours per week
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investigated recreational activity.102-104 108-111 118-120 Also see
chapter 7.12.
Total physical activity 
One cohort study reported non-significant decreased risk for
the highest activity group when compared to the lowest (RR
0.8; 95% CI 0.5–1.1).99 The other study reported no associ-
ation when comparing any vigorous activity to none (RR
0.99; 95% CI 0.8–1.2).121
All four case-control studies reported decreased risk for the
highest activity group when compared to the lowest; this was
significant in one.101
Occupational 
All three cohort studies reported significant decreased risk for
the highest activity group when compared to the lowest. Effect
estimates are shown in figure 5.4.8. 
Seven case-control studies reported decreased risk for the
highest activity group when compared to the lowest,102 104 109-
111 113 114 statistically significant in three.102 104 113 Three stud-
ies reported non-significant increased risk.103 108 112 All three
cohort studies and eight of the case-control studies were
included in a highest versus lowest analysis, most of which
showed reduced risk with highwe activity (figure 5.4.8).
Recreational 
Three cohort studies reported decreased risk for the highest
activity group when compared to the lowest107 115 116; this
was significant in two studies.115 116 One study reported non-
significant increased risk.117 See figure 5.4.9.
Nine case-control studies reported decreased risk for 
the highest activity group when compared to the lowest,102
104 108-111 118-120 statistically significant in three.109 119 120 These
studies are included in figure 5.4.9. Another study (not
included in this figure) reported no significant association.103
Mechanisms
As with breast cancer, there are a number of mechanisms by
which physical activity may protect against cancer of the
endometrium. These include the beneficial effect of physi-
cal activity on body fatness (see Chapter 6); effects on
endogenous steroid hormone metabolism; and a possible
strengthening of the immune system. Also, high levels of
physical activity are associated with lower levels of circulat-
ing oestrogens and androgens in postmenopausal women.14
There is generally consistent evidence, mostly from
case-control studies, showing lower risk of cancer of
the endometrium with higher levels of physical activity.
There is evidence for mechanisms operating in
humans. Physical activity probably protects against
cancer of the endometrium. 
5.4.4  Lung 
Five cohort studies investigated total physical activity25 51 122-
124 and two investigated non-recreational activity.10 125 Four
cohort studies25 126-128 and two case-control studies112 129
investigated occupational activity. Eleven cohort studies10 25
51 126-128 130-134 and four case-control studies135-138 investigat-
ed recreational activity. Another two cohort studies
investigated a physical activity measure that did not fit into
Figure 5.4.9 Recreational physical activity and
endometrial cancer; cohort and
case-control studies
Cohort
Terry 1999 0.10 (0.03–0.39)
Folsom 2003 1.05 (0.83–1.32)
Furberg 2003 0.71 (0.34–1.49)
Schouten 2004 0.54 (0.34–0.85)
Case control
Levi 1993 0.53 (0.25–1.11)
Sturgeon 1993 0.83 (0.49–1.41)
Hirose 1996 0.60 (0.38–0.94)
Olsen 1997 0.67 (0.42–1.08)
Jain 2000 0.64 (0.45–0.91)
Moradi 2000 0.77 (0.59–1.00)
Littman 2001 0.83 (0.59–1.16)
Matthews 2005 0.76 (0.51–1.14)
Trentham-Dietz 2006 0.65 (0.49–0.86)
2 310.50.1
Relative risk (95% CI)
Relative risk, highest vs lowest exposure category
Figure 5.4.8 Occupational physical activity and
endometrial cancer; cohort and
case-control studies
Cohort
Moradi 1998 0.76 (0.67–0.86)
Weiderpass 2001 0.77 (0.66–0.90)
Furberg 2003 0.49 (0.22–0.91)
Case control
Levi 1993 0.67 (0.45–0.99)
Shu 1993 1.11 (0.68–1.81)
Sturgeon 1993 0.50 (0.31–0.80)
Kalandidi 1996 0.41 (0.18–0.91)
Goodman 1997 0.70 (0.47–1.03)
Olson 1997 1.19 (0.76–1.87)
Moradi 2000 0.77 (0.46–1.28)
Matthews 2005 0.86 (0.63–1.18)
2 310.5
Relative risk (95% CI)
Relative risk, highest vs lowest exposure category
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these categories.31 126 Also see chapter 7.4.
Total physical activity
Four of the five cohort studies reported decreased risk for the
highest activity group compared to the lowest25 51 123 124; this
was significant in two.123 124 The other study reported non-
significant decreased risk in people under the age of 63, RR
0.84 (95% CI 0.69–1.03) per 20 hours a week; and non-sig-
nificant increased risk in people aged 63 and over, RR 1.11
(95% CI 0.95–1.29) per 20 hours a week.122 The effect esti-
mates were RR 0.61 (95% CI 0.41–0.89),123 RR 0.74 (95%
CI 0.59–0.93),124 RR 0.70 (95% CI 0.48–1.01),25 and RR 0.76
(95% CI 0.40–1.43),51 comparing highest to lowest activity
groups. All cohort studies were adjusted for smoking.
Non-recreational activity
Two cohort studies reported increased risk with inactivity
(sedentary living)10 125; this was significant in one.10 In one
study of men, the effect estimate was RR 2.0 (95% CI
1.2–3.5)10; in the other study, the estimates were RR 1.26
(95% CI 0.71–2.24) for men and RR 1.41 (95% CI 0.59–3.35)
for women.125 Both studies were adjusted for smoking.
Other physical activity
Two cohort studies reported on other measures of physical
activity.31 126 The Whitehall Study in England reported non-
significant increased risk of lung cancer mortality compar-
ing low to high transport-related physical activity.31 The
other study reported decreased risk in both men and women,
which was significant in men, comparing high to low occu-
pational and recreational activity combined.126 Both studies
were adjusted for smoking.
Occupational 
Two cohort studies reported non-significant increased risk for
the highest activity group to the lowest.127 128 The effect esti-
mates were RR 1.23 (95% CI 0.95–1.59) in a cohort of male
non-smokers in Finland,127 and RR 1.13 (95% CI 0.63–2.05)
for men and 1.80 (95% CI 0.75–4.31) for women in the sec-
ond cohort.128 Another two cohort studies reported non-sig-
nificant decreased risk comparing high to low activity.25 126
The effect estimates were RR 0.88 (95% CI 0.62–1.22) in a
cohort of men and women,25 and in another cohort were RR
0.79 (95% CI 0.30–2.12) for women and RR 0.99 (95% CI
0.70–1.41) for men.126 All studies were adjusted for smoking.
One case-control study reported non-significant increased
risk for the highest activity group when compared to the low-
est112; the other reported non-significant decreased risk.129
Recreational
Ten cohort studies reported decreased risk comparing the
highest activity group compared to the lowest25 51 126-128 130-
134; this was significant in five studies. One study reported
non-significant increased risk.10 Effect estimates were RR
1.11 (95% CI 0.71–1.74),10 RR 0.90 (95% CI 0.83–0.97),128
RR 0.97 (95% CI 0.88–1.07),127 RR 0.27 (95% CI 0.15–0.49,
unadjusted for smoking),130 RR 0.45 (95% CI 0.17–1.18),131
RR 0.80 (95% CI 0.71–0.90),132 RR 0.50 (95% CI 0.29–0.87,
unadjusted for smoking),134 RR 0.73 (95% CI 0.54–0.98),126
RR 0.81 (95% CI 0.58–1.13),51 and RR 0.8 (95% CI
0.6–1.06).25 One study reported that mean hours per week
of sports activity were lower in cases (0.70) than in controls
(1.10).133 The exposure examined varied, with some studies
analysing leisure-time activities, sports, or exercise, and one
examining endurance skiers. All but the two studies specified
above were adjusted for smoking.
All four case-control studies reported a significant
decreased risk comparing high to low levels of activity.135-138
Mechanisms
No mechanisms were identified by which physical activity
might have a specific effect on the risk of lung cancer. The
possibility could not be dismissed that people with pulmonary
disease, who are at increased risk of lung cancer, might
reduce their level of physical activity.
The association between physical activity and lung cancer
is complex. Unlike many other cancers, lung cancer is not
positively associated with body mass index (BMI). The Panel
is aware that the observed association between physical activ-
ity and lung cancer may be a reflection of reverse causation
due to chronic lung disease. 
There is evidence from prospective and case-control
studies showing lower risk of lung cancer with higher
levels of physical activity, but there is no evidence of
plausible mechanisms. The relationship between activity,
BMI, and lung cancer makes the evidence difficult to
interpret. There is limited evidence suggesting that
physical activity protects against lung cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort study138A has been published. This new information does
not change the Panel judgement (see box 3.8).
5.4.5  Pancreas 
Three cohort studies44 139 140 and one case-control study141
investigated total physical activity and pancreatic cancer.
Three cohort studies139 142 143 and two case-control studies129
144 investigated occupational activity. Nine cohort studies31 139
140 142 145-149 and three case-control studies150-152 investigated
recreational activity. Four cohort studies (in three publica-
tions) investigated walking,140 145 146 while two investigated
transportation activity.140 145 Five cohort studies (in four pub-
lications) 140 146 149 153 and one case-control study141 investi-
gated vigorous activity. Four cohort studies (in three
publications)140 145 146 and one case-control study141 investi-
gated moderate activity. Also see chapter 7.6.
Total physical activity
Two cohort studies reported non-significant decreased risk for
the highest activity group compared to the lowest.44 139
Another cohort study reported non-significant increased
risk.140 The single case-control study reported decreased risk,
significant in men but not women.141
Occupational 
One cohort study reported significant increased risk for peo-
ple who reported that they felt ‘worn out’ after work.139 One
study stated they found no significant association143; and one
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study reported non-significant decreased risk for moderate
or heavy work compared to sedentary jobs.142 Both case-con-
trol studies reported decreased risk for the highest activity
group when compared to the lowest129 144; this was signifi-
cant in one study.144
Recreational 
Five cohort studies reported non-significant decreased risk
for the highest activity group when compared to the low-
est.139 142 145-147 Four cohort studies reported non-significant
increased risk.31 140 148 149 Meta-analysis was possible on three
cohort studies, giving a summary effect estimate of RR 0.98
(95% CI 0.91–1.05) per 10 MET-hours per week, with no
heterogeneity. All three case-control studies reported
decreased risk for the highest activity group compared to the
lowest150-152; this was significant in one.150
Walking
Three cohort studies reported decreased risk for the highest
activity group compared to the lowest140 146; this was signif-
icant in two.146 The effect estimates were RR 0.48 (95% CI
0.24–0.97) for women in the Nurses’ Health Study146; RR
0.45 (95% CI 0.26–0.80) for men in the Health Professionals
Follow-up Study146; and RR 0.99 (95% CI 0.64–1.51) in a
study of pancreatic cancer mortality.140 The Whitehall Study
reported increased risk of pancreatic cancer mortality for
slow compared to fast walkers (RR 1.1; 95% CI
0.20–5.10).145
Vigorous 
Three cohort studies reported non-significant decreased risk
for the highest activity group compared to the lowest.140 146
149 Two studies reported non-significant increased risk.146 153
The single case-control study reported non-significant
decreased risk.141
Moderate 
Two cohort studies reported increased risk for the highest
activity group compared to the lowest140 149; this was signif-
icant in one.149 Two cohort studies reported decreased risk,146
which was significant in one.146 The single case-control study
reported non-significant increased risk in men and no asso-
ciation in women.141
Mechanisms
Mechanisms by which physical activity may protect against
cancer of the pancreas include reduced insulin resistance and
reduced gut transit time, which has beneficial effects on bile
content and secretion and general pancreatic activity.154
There is evidence from prospective studies showing
lower risk of pancreatic cancer with higher levels of
various types of physical activity, but it is rather
inconsistent. There is limited evidence suggesting that
physical activity protects against pancreatic cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort study154A has been published. This new information does
not change the Panel judgement (see box 3.8).
5.4.6  Prostate 
Two studies showed that higher levels of physical activity
were associated with lower risk specifically of advanced or
aggressive prostate cancer.155 156 Also see chapter 7.14.
In the Health Professionals Follow-Up Study, a strong inverse
association between vigorous physical activity and advanced
prostate cancer was seen in men 65 years or older: RR 0.33
(95% CI 0.17–0.62) for more than 29 MET-hours compared
to none. No association was seen in younger men.155
In the American Cancer Society Cancer Prevention Study
II Nutrition Cohort, high levels of recreational physical activ-
ity were associated with decreased risk of aggressive
prostate cancer: RR 0.69 (95% CI 0.52–0.92) for more than
35 MET-hours per week compared to no physical activity. No
association was found between recreational physical activi-
ty and overall prostate cancer.156
Mechanisms
Several mechanisms have been proposed for how physical
activity may decrease the risk of prostate cancer. Exercise
may reduce prostate cancer risk by reducing levels of testos-
terone and insulin. Acute exercise may promote the forma-
tion of free radicals. In people who exercise consistently, this
may induce the production of enzymes, such as superoxide
dismutase, that protect against oxidative stress. These
enzymes may also protect against cancer, since dietary
antioxidants have been linked to reduced cancer risk.
The Panel has noted the evidence presented here that
physical activity is associated with reduced risk of
advanced or aggressive cancer of the prostate, but has
not made a formal judgement. 
5.5  Comparison with previous report
The panel responsible for the previous report judged that the
evidence that physical activity protects against cancer of the
colon was convincing. Evidence for cancer of the rectum was
judged to be unimpressive. Physical activity was judged to
be possibly protective against cancers of the lung and of the
breast. The previous report mentioned epidemiological,
experimental, and mechanistic evidence suggesting that
physical activity is generally protective against cancer, and
in particular against colon cancer and female hormone-relat-
ed cancers. The panel responsible for that report also con-
cluded that all types of physical activity were probably
beneficial and that people should remain physically active
throughout life. 
5.6  Conclusions
The Panel concludes:
The evidence that physical activity protects against colon
cancer is convincing. Physical activity probably protects
against postmenopausal breast cancer, whereas the evidence
suggesting that it protects against premenopausal breast can-
cer is limited. Physical activity probably protects against can-
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cer of the endometrium. The evidence suggesting that phys-
ical activity protects against cancers of the lung and pancreas
is limited. 
The Panel notes the overall consistency of the evidence. The
Panel emphasises that, taken together, the evidence suggests
that all types and degrees of physical activity are or may be
protective, excluding extreme levels of activity: the evidence
for any specific type or degree of physical activity is limited.
The evidence is consistent with the message that the more
physically active people are, the better. 
The Panel also agrees that physical activity, which promotes
healthy weight, would be expected to protect against cancers
whose risk is increased by overweight, weight gain, and obe-
sity, and conversely that sedentary living increases or may
increase the risk of the specified cancers (see Chapters 6 and
8). Most people in urbanised and industrialised settings, not
only in high-income countries but throughout the world,
now lead sedentary ways of life.
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The size and shape of the human body, the rates at
which humans grow from conception to adult life,
and human physical and mental development are
all determined by interrelated genetic and
environmental, including nutritional, factors. 
Specifically, human nutrition, the degree to which
the body’s needs are met by the nature, quality, and
quantity of the foods consumed, has a fundamental
effect on health and well-being, and also on the
body’s ability to resist diseases. These include not
only infectious diseases but also chronic diseases,
one of which is cancer. 
The Panel decided that the evidence apparent in
the literature concerned with body composition,
growth, and development, including breastfeeding
(lactation), was likely to prove of special interest.
For this reason, the independent systematic
literature reviews, on which the evidence and
judgements in this chapter are based, have covered
these areas more thoroughly than has previously
been attempted. 
The three related sections of this chapter pay
special attention to degree of body fatness, rates of
growth and their outcomes, and also to lactation in
relation to the risk of cancer throughout the life
course. The first of these sections, which focuses on
body composition, is complemented by Chapter 8
on determinants of weight gain, overweight, and
obesity. 
The findings of the systematic literature reviews
are summarised and judged within each section. The
matrices that are part of the introduction of each
section display the Panel’s judgements, which are
developed or qualified when necessary in
footnotes. Introductory passages also summarise
relevant context. Other passages review issues of
interpretation of the literature and compare the
findings of this with the previous report. For
convenience, and also throughout this Report, the
Panel’s summary judgements are repeated at the
end of each section. 
The picture that emerges is impressive: much
more so than that based on the evidence gathered
in the mid-1990s using the then agreed
methodology. Its implications are also impressive.
Some of the most persuasive evidence in the whole
field of food, nutrition, and physical activity
indicates that the basis for prevention of cancer
should be a whole life course approach, starting at
the beginning of life, or even in maternal
preparation for pregnancy.
Body composition, growth,
and development
C H A P T E R  6
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A key reason for the success of Homo sapiens is our
adaptability. Humans have evolved to survive and flourish
in almost all environments and circumstances which,
during the 250 000 years of our species’ existence, have
usually included occasional or regular food scarcity and
insecurity. We have built-in defences against starvation: our
own stores of fat that are used in times of need. 
Food insecurity remains endemic, particularly in Africa
and Asia. But many people in the world now have access to
more than enough to eat and drink and are also relatively
physically inactive (see Chapter 5). As a result, stores of
body fat tend to increase. What is now a pandemic of
overweight and obesity can be seen as a response to
circumstances of plenty. One consequence, in the context of
reduction in rates of nutritional deficiencies and infections
of childhood and early life, and the ageing of human
populations, is an increase in the rates of chronic diseases.
These include cancer.
Overall, the Panel judges that evidence on the degree of
body fatness and the risk of cancers of a number of sites is
strong and generally consistent. The Panel emphasises that
the risk of cancer is modified, not only by obesity, as
usually defined, but by overweight as well, and even by
degrees of body fatness generally regarded as healthy.
The Panel judges as follows: 
The evidence that greater body fatness is a cause of
adenocarcinoma of the oesophagus, and cancers of the
pancreas, colorectum, breast (postmenopause),
endometrium, and kidney, is convincing. Greater body
fatness is probably a cause of cancer of the gallbladder.
There is limited evidence suggesting that greater body
fatness is a cause of liver cancer. The evidence that greater
abdominal (central) fatness is a cause of colorectal cancer
is convincing; and greater abdominal fatness is probably a
cause of cancers of the pancreas, breast (postmenopause),
and endometrium. By contrast, greater body fatness
probably protects against premenopausal breast cancer.
BODY FATNESS, AND THE RISK OF CANCER
In the judgement of the Panel, the factors listed below modify the risk of cancer. Judgements are graded according to the strength of the evidence.
DECREASES RISK INCREASES RISK
Exposure Cancer site Exposure Cancer site
Convincing Body fatness Oesophagus1
Pancreas
Colorectum
Breast (postmenopause)
Endometrium
Kidney
Abdominal fatness Colorectum
Probable Body fatness Breast (premenopause) Body fatness Gallbladder2
Abdominal fatness Pancreas
Breast (postmenopause) 
Endometrium
Adult weight gain Breast (postmenopause)  
Limited — Body fatness Liver
suggestive Low body fatness Lung
Substantial 
effect on risk None identified
unlikely
1 For oesophageal adenocarcinomas only.
2 Directly and indirectly, through the formation of gallstones.
For an explanation of all the terms used in the matrix, please see chapter 3.5.1, the text of this section, and the glossary.
6.1  Body fatness 
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The Panel notes that there is limited evidence suggesting
that low body fatness (underweight) is a cause of lung
cancer, but residual confounding with smoking and lung
disease cannot be ruled out. 
See Chapter 8 for judgements on physical activity and
sedentary ways of life, the energy density of foods and
drinks, breastfeeding, other factors, and the risk of weight
gain, overweight, and obesity. 
Within the remit of this Report, the strongest evidence,
corresponding to judgements of ‘convincing’ and
‘probable’, shows that greater body fatness and greater
abdominal fatness are causes of cancer of the colorectum;
that greater body fatness is additionally a cause of cancers
of the oesophagus (adenocarcinoma), pancreas, breast
(postmenopause), endometrium, and kidney; and
(probably) gallbladder. It also shows that greater
abdominal fatness is probably a cause of cancers of the
pancreas, breast (postmenopause), and endometrium; but
that greater body fatness probably protects against
premenopausal breast cancer.
Body fatness and organ mass and composition, commonly
assessed by body size measurements, are key factors influ-
encing health and well-being throughout the life course. 
The main concern of nutrition science, since its beginnings
and until the mid-20th century, has been to protect popula-
tions against the consequences of malnutrition in the ‘clas-
sic’ sense of the word. That is undernutrition, which
increases vulnerability to infectious diseases, especially in
infancy and childhood, and results in people who are small
and weak, unable to be productive, and with low life
expectancy.1 This remains a central public health priority for
middle- and low-income countries.2
In the final two decades of the 20th century and into this
century, a different and imperative public health nutrition
concern has emerged: weight gain, overweight, and obesi-
ty. At first, it was generally assumed that societies whose
babies are big, whose children grow fast, and whose adults
are heavy and tall, were healthy. Compared to societies with
inadequate nutrition and poor public health provision, such
populations are indeed physically stronger, more productive,
have longer lives, and are generally healthier.
This said, since the 1980s, a series of reports based on a
rapidly increasing evidence base have concluded that popu-
lations of high-income countries, and now also populations
of many middle- and low-income countries, are becoming
overweight to an extent that is bad for health. These coun-
tries are almost exclusively those experiencing social, eco-
nomic, and nutritional transition. The nutritional transition
is characterised by a shift from ‘traditional’ diets that are low
in fat and high in fibre to high-energy ‘Western’ diets that are
high in fat and low in fibre. It is now generally accepted that
obesity, but also overweight short of obesity, increases the risk
of a number of major chronic diseases including insulin resis-
tance, hyperlipidaemia, hypertension and stroke, type 2 dia-
betes, and coronary heart disease, as well as cancers of some
sites.3 In this chapter, the evidence on body fatness and can-
cer is summarised and judged. Also see Chapter 8.
In this Report, the term ‘body fatness’ refers to the degree
of body fatness across the whole range, not only the con-
ventional categories of overweight and obesity. 
6.1.1  Definitions and patterns
6.1.1.1  Body fatness
Excess energy from food is stored as fat in the body in adi-
pose tissue. The amount of this body tissue varies more from
person to person than any other type (such as muscle, bone,
or blood). The size and location of these fat stores also vary
considerably between populations, people, and over the
course of a person’s life. Excess body fat is a cause of a num-
ber of chronic diseases and reduces life expectancy (also see
Chapter 8). 
Since the 1980s, typical body compositions have changed,
with a worldwide increase in average body fatness and in
overweight and obesity. This change is most notable in high-
income countries, and in industrial and urban environments
in many if not most countries (see chapters 1.1.3 and 1.2.2).
In several low-income countries, high levels of body fatness
exist alongside undernutrition in the same communities and
even in the same families.3
Body fatness is difficult to measure directly or accurately.
However, because body fatness is the most variable deter-
minant of weight, several weight-based measures are used
as markers of body fatness. The most common is the body
mass index (BMI), a measure of weight adjusted for height.
BMI is calculated as weight in kilograms divided by height
in metres squared (kg/m2). In most circumstances, BMI has
been shown to be reliably linked to body fatness.4 But this
method does not always provide an accurate measure:
unusually muscular and lean people (such as manual work-
ers and power athletes) have a relatively high BMI, even if
they have relatively little body fat. See table 6.1.1 and also
Chapter 8. 
A BMI of between 18.5 and 24.9 is generally regarded as
‘healthy’ or ‘normal’ (healthy or normal body fatness). This
is roughly equivalent to 15–20 per cent body fat in adult
men and 25–30 per cent in adult women.5 The ‘underweight’
or ‘thin’ range is a BMI below 18.5 (low body fatness). Above
25 (high body fatness), there are common gradings for over-
weight, obesity, and extreme (‘morbid’) obesity. The risk of
type 2 diabetes and high blood pressure increases with BMI
with no clear threshold, but with a marked increase in risk
as BMI approaches 25.3 The ideal average BMI for popula-
tions has been estimated to be 21–22.6
The principal cut-off points shown in table 6.1.1 have
been agreed by the World Health Organization and are based
on the risks associated with being underweight, overweight,
or obese (see Chapter 8). However, the healthy ranges of
BMI vary between populations. The additional cut-off points
take this into account and are recommended for reporting
purposes, with a view to facilitating international compar-
isons.
The principal BMI cut-offs are based on data primarily
derived from populations of European origin living in high-
income countries, so they may not apply globally. Different
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BMI cut-off points have been proposed to classify overweight
and obesity in different populations, due to different body
composition and the relation of BMI to risk in these popu-
lations. However, these have not become universally accept-
ed.7 8 A WHO expert consultation on BMI in Asian
populations recommended that the principal BMI cut-off
points (table 6.1.1) should be retained as the international
classification.9 However, it also recommended that addi-
tional cut-off points of 23, 27.5, 32.5, and 37.5 kg/m2
should be added to the international classification and, for
reporting purposes, countries should use all categories (that
is, 18.5, 23, 25, 27.5, 30, and 32.5 kg/m2; and in many pop-
ulations, 35, 37.5, and 40 kg/m2) with a view to facilitat-
ing international comparisons. The principal and additional
cut-off points are shown in table 6.1.1. 
At equivalent BMIs, many Asian populations have a high-
er body fat content, whereas Maori people and Pacific
Islanders have more lean tissue and less fat.4 10 11 Many Asian
expert groups and health ministries now define the upper
limit of ‘acceptable’ as a BMI of below 23, whereas the equiv-
alent cut-off point for China is 24. It is unlikely that the
excess risk in these populations at relatively low BMIs
reflects only differences in body fat — there are probably
other related metabolic changes, for instance, those induced
by fetal and early childhood nutritional differences. WHO
has recognised that Asian populations may choose a BMI
cut-off of 23 because of the greater susceptibility of these
groups of people to type 2 diabetes and perhaps other com-
plications of excess weight gain.9 Mexican people have also
been shown to be at greater risk, so Latin American popu-
lations may also be considered as more sensitive to the
effects of weight gain than white people of European
origin.12
6.1.1.2  Body fat distribution
Fat is not distributed equally around the body. It accumu-
lates subcutaneously (beneath the skin) around the muscles
of the upper arm, buttocks, belly, hips, and thighs. It also
accumulates intra-abdominally or viscerally (around the
organs). Fat stores can be categorised as ‘peripheral’ (not
around the trunk) or ‘abdominal’ (also called ‘central’). The
pattern of fat stores is determined largely by genetic factors,
with a typically different pattern in men and women, which
tends to change with age. Women tend to store more sub-
cutaneous fat around their hips, buttocks, and thighs than
men, producing a body profile known as a ‘pear shape’ (or
‘gynoid’ pattern of fat distribution). Men are more likely to
store fat around their abdomen, producing an ‘apple shape’
(or ‘android’ pattern). 
The size of peripheral fat stores can be used as a measure
of total body fatness, although the proportion of total to
abdominal fat varies between people. Waist circumference
is a measure that includes both subcutaneous and the more
metabolically active intra-abdominal fat stores. The size 
of intra-abdominal fat stores predicts the risk of chronic dis-
eases, such as metabolic disorders and cardiovascular
disease, better than overall indicators of body fatness, such
as subcutaneous fat measures or BMI.13 The size of these fat
stores also influences several hormone systems, such as
insulin, as well as those involved in the body’s response to
inflammation, both of which may play a role in cancer
processes (box 2.4).14 15
Crude estimates of excess abdominal fat can be made by
measuring either waist circumference or by calculating the
ratio of this measurement to hip circumference (the ‘waist 
to hip’ ratio), although this ratio is no longer recommended
as a useful indicator of abdominal obesity. Waist circumfer-
ence is a better single indicator. As is the case for BMI, the
cut-off points for excess waist measurements for Asian and
Mexican populations are usually lower than those suggest-
ed by WHO as suitable for people of European origin. This
is because these non-white populations have a greater risk
of disease with only modest increases in intra-abdominal fat.
The WHO reference values for waist circumferences of 94 cm
(37 inches) in men and 80 cm (31.5 inches) in women (on
a population basis) are based on their rough equivalence to
a BMI of around 25, whereas waist circumferences of 102 cm
(40.2 inches) in men and 88 cm (34.6 inches) in women are
equivalent to a BMI of around 30.16  17 For Asian populations,
cut-offs for waist circumferences of 90 cm for men and 80
cm for women have been proposed.18
6.1.1.3  Adult weight gain 
Increases in body weight during adulthood depend mostly
on accumulation of fat rather than lean tissue, and there-
fore any change may better reflect fatness than adult
attained weight itself, which is more dependent on lean
mass. For this reason, evidence of associations specifically
between weight gain in adulthood and cancers was sought
Table 6.1.1 The international classification of adult
underweight, overweight, and obesity
A body mass index (BMI) of between 18.5 and 24.9 is generally regarded
as ‘acceptable’ or ‘normal’. The ‘underweight’ or ‘thin’ range is a BMI of
below 18.5. Above 25, the common gradings for overweight and obesity
are as shown below: 
Classification BMI (kg/m2)
Principal Additional
cut-off points cut-off points
Underweight <18.50 <18.50
Severe thinness <16.00 <16.00
Moderate thinness 16.00–16.99 16.00–16.99
Mild thinness 17.00–18.49 17.00–18.49
Normal range 18.50–24.99 18.50–22.99
23.00–24.99
Overweight ≥25.00 ≥25.00
25.00–27.49
27.50–29.99
Obese ≥30.00 ≥30.00
Obese class I 30.00–34-99 30.00–32.49
32.50–34.99
Obese class II 35.00–39.99 35.00–37.49
37.50–39.99
Obese class III ≥40.00 ≥40.00
Adapted with permission from WHO.3
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in the systematic literature reviews that informed the Panel’s
judgements. 
6.1.2  Interpretation of the evidence 
6.1.2.1  General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7.
6.1.2.2  Specific 
Some considerations specific to body fatness are as follows. 
Classification. The system of classifying underweight, ‘nor-
mal’ weight, overweight, and degrees of obesity as discrete
ranges of BMI, is in general use. However, as shown in this
chapter and also Chapter 8, the relationship between body
fatness and cancer is continuous across the range of BMI. For
this reason, the Panel has chosen to use the term ‘body fat-
ness’ rather than ‘overweight’ or ‘obesity’. 
Measurement. BMI is not a perfect marker of body fatness.
More precise techniques such as underwater weighing, mag-
netic resonance imaging, computerised tomography, or dual-
energy X-ray absorptiometry are rare in large-scale
epidemiological studies due to their difficulty and expense.
Abdominal fatness is usually measured either using the waist
to hip ratio or the waist circumference alone. There is a lack
of consensus on how abdominal fatness is best measured,
and measurement error is more likely than for some other
anthropometric measures such as height and weight. The
currently proposed maximum ‘cut-off ’ points for ‘healthy’
waist circumferences (94 cm or 37 inches for men; 80 cm or
31.5 inches for women) and for ‘healthy’ waist to hip ratios
(1.0 for men; 0.8 for women) are based almost exclusively
on studies of cardiovascular or type 2 diabetes risk in white
populations in high-income countries. It is not known
whether they can be applied to other ethnic groups or out-
comes. The relationship between waist circumference and
the size of intra-abdominal fat stores (as opposed to subcu-
taneous abdominal fat stores) may vary between different
ethnic groups.18 As body fatness tends to increase with age
in most populations, and is characteristically higher in
women than in men, it is important that studies take into
account both age and sex. Measurement of change in weight
tends to be more precise than static measures such as weight
or BMI.
Reporting bias. Objective measures of height and weight, and
therefore BMI, are reliable. However, many studies rely on
self-reporting, which is liable to introduce bias. Although
reported and actual weights are correlated, weight tends to
be under-reported, especially by overweight and obese peo-
ple. BMIs calculated from self-reported data will therefore
tend to be lower than from more objective measures.
6.1.3  Evidence and judgements 
The full systematic literature review (SLR) is contained on
the CD included with this Report.
There are several general mechanisms through which body
fatness and abdominal fatness could plausibly influence can-
cer risk. For example, increasing body fatness raises the
inflammatory response, increases circulating oestrogens, and
decreases insulin sensitivity. The physiological effects of obe-
sity are described in more detail in Chapter 8. The effects of
body fatness-related hormonal changes and inflammation on
cancer processes are detailed in box 2.4. Additional site-
specific mechanisms are described with the evidence for 
each cancer site in the following sections.
6.1.3.1  Body fatness
Oesophagus
Three cohort studies19-21 and eight case-control studies22-29
investigated body fatness (as measured by BMI) and
oesophageal adenocarcinomas.
All three cohort studies showed increased risk for the high-
est body fatness, as measured by BMI, when compared to the
lowest (figure 6.1.1); this was statistically significant in both
sexes in one study21 and in men but not women in two oth-
ers.19 20 Effect estimates were 2.58 in men (95% confidence
interval (CI) 1.81–3.68; p < 0.001) and 2.06 in women (95%
CI 1.25–3.39; p = 0.002)21; 2.40 in men (95% CI 1.30–4.42)
and 1.57 in women (95% CI 0.51–4.84)20; and 1.76 in men
(95% CI 1.03–3.02) and 2.13 in women (95% CI
0.97–4.71).19 The latter study was adjusted for smoking and
alcohol but the other two were not. 
Seven case-control studies22-25 27-29 showed increased risk
for the highest body fatness group, as measured by BMI, when
Figure 6.1.1 BMI and oesophageal adenocarcinoma;
cohort and case-control studies
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compared to the lowest (figure 6.1.1). This was statistically
significant in five studies,22-24 28 29 and in men but not women
in a sixth.25 One study showed non-significant decreased
risk.26 Meta-analysis was possible on four case-control
studies (all of which showed increased risk), giving an effect
estimate of 1.11 (95% CI 1.07–1.15) per kg/m2, with mod-
erate heterogeneity (figure 6.1.2). This would produce an
increased risk of 55 per cent for each 5 kg/m2, assuming a
linear relationship, although a curvilinear dose-response 
relationship cannot be ruled out.
A dose-response relationship is apparent from case-control
data (figure 6.1.3). Cohort data show a statistically signifi-
cant trend in men and are suggestive of a similar trend in
women.
Studies that investigated body fatness, as measured by BMI,
and all types of oesophageal cancer or squamous cell carci-
nomas showed inconsistent results. Only when results were
stratified by cancer type did a consistent pattern emerge, and
then only for adenocarcinomas.
An association between body fatness and increased risk of
oesophageal adenocarcinoma is consistent, with known geo-
graphical and time trends for both BMI and adenocarcinomas.
The general mechanisms through which body fatness
could plausibly influence cancer risk are outlined in 6.1.3
(also see box 2.4). 
The epidemiology is consistent, with evidence of a
dose-response relationship. There is evidence for
plausible mechanisms that operate in humans. The
evidence that greater body fatness is a cause of
oesophageal adenocarcinoma is convincing.
The Panel is aware that since the conclusion of the SLR, two
cohort30 31 and five case-control studies32-36 have been pub-
lished. This new information does not change the Panel judge-
ment (see box 3.8).
Pancreas 
Twenty-three cohort studies37-58 and 15 case-control stud-
ies59-73 investigated body fatness (as measured by BMI) and
pancreatic cancer.
Thirteen cohort studies showed increased risk with
increased body fatness,37 38 40 43 44 46 47 49 51 54 55 57 which was
statistically significant in four.47 49 54 55 Two studies showed
increased risk in both sexes42 50; this was statistically signif-
icant in women but not in men in one study,42 and in men
but not women in the other.50 One study showed increased
risk in both black and white men, which was significant for
white men only.56 Two studies showed non-significant
increased risk in women and non-significant decreased risk
in men.45 52 One study showed statistically significant
increased risk in men and non-significant decreased risk in
women.39 Three studies showed non-significant decreased
risk41 48 53 and one study stated that there was no significant
association.58 Meta-analysis was possible on 17 cohort stud-
ies, giving a summary effect estimate of 1.14 (95% CI
1.07–1.22) per 5 kg/m2, with moderate heterogeneity (fig-
ure 6.1.4). Most studies adjusted for smoking, with no appar-
ent difference between people who smoked and those that
did not.
Five case-control studies showed increased risk with
increased body fatness,62-66 which was statistically significant
in one,66 and in men but not women in another study.64 Five
studies showed decreased risk,61 68-71 which was statistical-
ly significant in one.69 Two studies showed non-significant
decreased risk in men and a non-significant increased risk
in women.59 72 One study showed a statistically significant
increased risk in men and a non-significant decreased risk
in women.67 One study showed non-significant decreased
Figure 6.1.2 BMI and oesophageal cancer;
case-control studies
Brown 1995
Chow 1998 Men
Chow 1998 Women
Chen 2002
Engel 2003
Summary estimate
1.20 (1.12–1.29)
1.11 (1.05–1.17)
1.08 (0.99–1.17)
1.08 (1.03–1.13)
1.11 (1.05–1.16)
1.11 (1.07–1.15)
Case control
Relative risk (95% CI)
0.5 0.75 1.5 21
Relative risk, per 1 kg/m2
Figure 6.1.3 BMI and oesophageal cancer; case-control
studies: dose response
Brown 1995
Chow 1998 Men
Chow 1998 Women
Chen 2002
Engel 2003
10 15 25 3520 30
BMI (kg/m2 )
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risk in both sexes when interviewed indirectly, a non-signif-
icant decreased risk in women when interviewed directly,
and a non-significant increased risk in men.60 One study stat-
ed that there was no significant association.73 Meta-analysis
was possible on 13 case-control studies, giving a summary
effect estimate of 1.00 (95% CI 0.87–1.15) per 5 kg/m2, with
high heterogeneity (figure 6.1.4).
A dose-response relationship was apparent from cohort but
not case-control data (figure 6.1.5). Although meta-analysis
assumes a linear relationship, some cohort studies are sug-
gestive of a curvilinear relationship, though not conclusive-
ly so.
The general mechanisms through which body fatness
could plausibly influence cancer risk are outlined in 6.1.3
(also see box 2.4).
There is ample epidemiological evidence, which is
generally consistent, and there is a dose-response
relationship. There is evidence for plausible mechanisms
that operate in humans. The evidence that greater body
fatness is a cause of pancreatic cancer is convincing.
The Panel is aware that since the conclusion of the SLR, two
cohort studies30 74 have been published. This new information does
not change the Panel judgement (also see box 3.8). 
Colorectum
Sixty cohort studies42 45 50 54-58 75-142 and 86 case-control stud-
ies investigated body fatness (as measured by BMI) and can-
cers of the colon and rectum.
Most of the cohort studies showed increased risk with
increased body fatness,42 45 50 54 56-58 75 77 80-82 84-88 91-100 102-104
106 108-115 118-120 122 124-127 132 137 139 142 which was statistically
significant in approximately half of these studies.42 50 54 56-58
75 77 84-88 92-95 99 103 104 109 111 114 115 118-120 124 126 127 132 137 139 142
Relatively few studies showed lower risk with increased body
fatness76 83 90 107 116; this was statistically significant in only
one.83 One study showed no effect on risk78 and three stat-
ed that there was no association.79 89 101 Meta-analysis was
possible on 28 cohort studies, giving a summary effect esti-
mate of 1.03 (95% CI 1.02–1.04) per kg/m2, with moderate
heterogeneity (figure 6.1.6). This would produce an
increased risk of 15 per cent for each 5 kg/m2, assuming a
Figure 6.1.4 BMI and pancreatic cancer; cohort and
case-control studies
Cohort
Friedman 1993 1.10 (1.00–1.22)
Shibata 1994 1.19 (0.68–2.06)
Gapstur 2000 Men 1.90 (1.27–2.84)
Michaud 2001 Men 1.28 (0.98–1.66)
Michaud 2001 Women 1.16 (0.98–1.37)
Stolzenberg 2002 Men 0.85 (0.65–1.10)
Calle 2003 Men 1.13 (1.00–1.29)
Calle 2003 Women 1.28 (1.14–1.43)
Lee 2003 1.02 (0.78–1.34)
Batty 2005 Men 1.08 (0.76–1.53)
Kuriyama 2005 Men 0.96 (0.42–2.19)
Kuriyama 2005 Women 1.10 (0.60–1.99)
Larsson 2005 1.22 (0.89–1.62)
Navarro Silvera 2005 Women 1.22 (1.05–1.41)
Navarro Silvera 2005 0.96 (0.88–1.05)
Patel 1.42 (1.18–1.70)
Rapp 2005 Men 1.61 (1.08–2.41)
Rapp 2005 Women 1.10 (0.86–1.40)
Sinner 2005 Women 1.04 (0.90–1.21)
Lukanova 2006 Men 0.70 (0.31–1.58)
Lukanova 2006 Women 1.09 (0.68–1.74)
Summary estimate 1.14 (1.07–1.22)
Case control
Bueno de Mesquita 1990 Men 0.89 (0.56–1.42)
Bueno de Mesquita 1990 Women 1.02 (0.71–1.47)
Howe 1990 Men – Direct interview 1.38 (0.76–2.50)
Howe 1990 Women – Direct interview 0.79 (0.49–1.27)
Howe 1990  Men – Indirect interview 0.89 (0.63–1.26)
Howe 1990 Women – Direct interview 0.83 (0.61–1.14)
Ghadirian 1991 0.87 (0.56–1.36)
Zatonski 1991 1.22 (0.92–1.61)
Ji 1996 Men 1.40 (0.99–1.97)
Ji 1996 Women 1.26 (0.87–1.84)
Silverman 1998 Men 1.37 (1.05–1.80)
Silverman 1998 Women 1.21 (0.94–1.55)
Kreiger 2007 Women 1.09 (0.82–1.47)
Pan 2004 1.17 (1.06–1.29)
Eberle 2005 Men 1.57 (1.21–2.05)
Eberle 2005 Women 0.96 (0.75–1.24)
Fryzek 2005 0.98 (0.82–1.18)
Lin 2005 0.23 (0.16–0.33)
Pezzilli 2005 0.99 (0.80–1.21)
Rousseau 2005 0.88 (0.66–1.17)
Summary estimate 1.00 (0.87–1.15)
Relative risk (95% CI)
21.510.750.5
 Relative risk, per 5 kg/m2
Figure 6.1.5 BMI and pancreatic cancer; cohort and
case-control studies: dose response
Cohort
Friedman 1993
Shibata 1994
Gapstur 2000
Michaud 2001
Michaud 2001
Stolzenberg-Soloman 2002
Calle 2003 Men
Calle 2003 Women
Lee 2003
Batty 2005 Men
Kuriyuma 2005 Men
Kuriyuma 2005 Women
Larsson 2005 Men
Larsson 2005 Women
Navarro Silvera 2005 Women
Nothings 2005
Patel 2005
Rapp 2005 Men
Rapp 2005 Women
Sinner 2005 Women
Lukanova 2006 Women
Case control
Bueno de Mesquita 1990 Men
Bueno de Mesquita 1990 Women
Howe 1990 Indirect interview Men
Howe 1990 Indirect interview Women
Ghadirian 1991
Zatonski 1991
Ji 1996 Men
Ji 1996 Women
Silverman 1998 Men
Silverman 1998 Women
Kreiger 2001 Women
Pan 2004
Eberle 2005 Men
Eberle 2005 Women
Fryzek 2005
Lin 2005
Pezzili 2005
Rousseau 2005 Men
30 352015 2510 40
BMI (kg/m2)
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linear relationship, although a curvilinear dose-response
relationship cannot be ruled out.
When stratified according to cancer site, data suggest a
larger increased risk and are more consistent for colon can-
cer (figure 6.1.7) than for rectal cancer (figure 6.1.8), or for
colorectal cancer as a whole (figure 6.1.6). A clear dose-
response relationship was apparent from cohort data for
colorectal cancer (figure 6.1.9).
Because of the abundant prospective data from cohort
studies, case-control studies were not summarised.
The general mechanisms through which body fatness
could plausibly influence cancer risk are outlined in 6.1.3
(also see box 2.4). 
There is abundant and consistent epidemiological
evidence with a clear dose response, and evidence for
plausible mechanisms that operate in humans. The
evidence that greater body fatness is a cause of
colorectal cancer is convincing.
The Panel is aware that since the conclusion of the SLR, seven
cohort30 31 52 143-146 and two case-control studies147 148 have been
published. This new information does not change the Panel
judgement (also see box 3.8). 
Figure 6.1.7 BMI and colon cancer, cohort studies
Wu 1987 Men 2.23 (0.70–7.10)
Wu 1987 Women 1.33 (0.60–2.92)
Gerhardsson 1988 1.00 (0.54–1.84)
Chute 1991 Women 1.50 (0.82–2.76)
Lee 1992 Men 1.52 (1.06–2.17)
Le Marchand 1992 Men 1.40 (1.09–1.79)
Moller 1994 Men 1.30 (1.00–1.69)
Moller 1994 Women 1.20 (1.01–1.42)
Chyou 2006 Men 1.38 (1.01–1.89)
Gaard 1997 Men 1.64 (0.92–2.92)
Gaard 1997 Women 1.02 (0.53–1.97)
Singh 1998 Men 2.63 (1.12–6.15)
Singh 1998 Women 1.05 (0.63–1.75)
Robsahm 1999 Men 1.39 (1.34–1.44)
Robsahm 1999 Women 1.07 (0.99–1.15)
Ford 1999  Men 2.95 (0.99–8.76)
Ford 1999 Women 2.74 (1.04–7.23)
Folsom 2000 Women 1.70 (1.20–2.40)
Terry 2001 Women 1.21 (0.86–1.70)
Nilsen 2001 Men 1.11 (0.73–1.68)
Nilsen 2001 Women 1.11 (0.71–1.74)
Terry 2002 Women 0.95 (0.67–1.34)
Kmet 2003 Women 2.20 (1.22–3.97)
Saydah 2003 1.79 (1.02–3.14)
Shimizu 2003 Men 2.11 (1.26–3.53)
Shimizu 2003 Women 1.22 (0.69–2.15)
Wei 2003 Men 1.85 (1.26–2.72)
Samanic 2004 Men 1.47 (1.39–1.55)
Mclnnis 2004 Men 1.70 (1.07–2.71)
More 2004 1.60 (1.01–2.53)
Relative risk (95% CI)
Relative risk, highest vs lowest exposure category
52152
Figure 6.1.8 BMI and rectal cancer, cohort studies
Le Marchand 1992 Men 0.80 (0.52–1.24)
Moller 1994 Men 1.00 (0.71–1.41)
Moller 1994 Women 1.20 (0.93–1.04)
Chyou 1996 Men 0.63 (0.38–1.04)
Gaard 1997 Men 1.61 (0.76–3.43)
Gaard 1997 Women 0.64 (0.31–1.33)
Robsahm 1999 Men 1.16 (1.06–1.26)
Robsahm 1999 Women 1.03 (0.93–1.14)
Terry 2001 Women 1.32 (0.83–2.09)
Schloss 1997 Women 1.35 (0.88–2.08)
Saydah 2003 1.64 (0.68–3.95)
Wei 2003 Men 1.03 (0.49–2.15)
Wei 2003 Women 1.56 (1.01–2.41)
Shimizu 2003 Men 0.83 (0.42–1.64)
Shimizu 2003 Women 0.83 (0.35–1.98)
Samanic 2004 Men 1.23 (1.14–1.33)
5210.50.2
Relative risk (95% CI)
Relative risk, highest vs lowest exposure category
Figure 6.1.6 BMI and colorectal cancer; cohort studies
Wu 1987 Men 1.23 (0.98–1.54)
Wu 1987 Women 1.04 (0.92–1.18)
Klatsky 1988 1.48 (1.22–1.79)
Kreiger 1992 Men 1.09 (1.00–1.18)
Kreiger 1992 Women 1.03 (0.99–1.08)
Suadcani 1993 Women 0.90 (0.84–0.98)
Giovannucci 1995 Women 1.05 (1.01–1.10)
Chyou 1996 Men 1.06 (1.03–1.10)
Thune 1996 Men 1.02 (1.00–1.04)
Thune 1996 Women 0.99 (0.95–1.04)
Martinez 1997 Women 1.02 (1.00–1.05)
Tulinius1997 Men 1.04 (1.00–1.08)
Singh 1998 Men 1.09 (0.98–1.21)
Singh 1998 Women 1.00 (0.95–1.07)
Ford 1999 1.10 (0.92–1.32)
Schoen 1999 1.02 (0.98–1.07)
Kalo 1999 Women 1.01 (0.98–1.05)
Nilsen 2001 Men 1.00 (0.98–1.03)
Nilsen 2001 Women 1.01 (0.97–1.04)
Terry 2001 Women age 55–76 1.09 (1.02–1.16)
Terry 2001 Women age 40–54 1.04 (0.99–1.08)
Colbeit 2001 Women 1.00 (0.97–1.03)
Nielsen 2002 Men 1.06 (1.01–1.11)
Nielsen 2002 Women 1.01 (0.98–1.05)
Kmet 2003 Women 1.04 (0.99–1.10)
Sadah 2003 1.06 (0.90–1.24)
Shimizu 2003 Men 1.05 (1.00–1.10)
Shimizu 2003 Women 1.27 (1.08–1.50)
Koh 2004 1.06 (0.98–1.14)
Moore 2004 Men age 55–79 1.02 (0.95–1.09)
Moore 2004 Women age 55–79 1.14 (1.01–1.28)
Moore 2004 Men age 30–54 1.05 (1.01–1.10)
Moore 2004 Women age 30–54 1.01 (0.92–1.11)
Madnnis 2004 Men 1.04 (1.01–1.08)
Lin 2004 Men 1.04 (0.99–1.10)
Kuriyama 2005 Men 1.05 (1.00–1.10)
Kuriyama 2005 Women 1.05 (1.02–1.07)
Oh 2005 Men 1.05 (1.01–1.08)
Rapp 2005 Men 1.01 (0.99–1.03)
Rapp 2005 Women 1.01 (0.99–1.03)
Pischon 2006 Men 1.03 (1.02–1.04)
Pischon 2006 Women 1.04 (1.01–1.08)
Summary estimate 1.03 (1.02–1.04)
21.510.750.5
 Relative risk (95% CI)
Relative risk, per 1 kg/m2
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Breast 
Forty-three cohort studies,42 45 50 122 149-204156 case-control
studies,66 205-359 and 2 ecological studies360 361 investigated
body fatness (as measured by BMI) and breast cancer. 
Age unspecified
Twenty-six cohort studies45 50 152-154 161 162 164 166 168 171 172 179 181
188 191 192 194-197 201-204 and 73 case-control studies investigat-
ed body fatness,66 205 207-209 211-215 219 221 222 224 225 228-230 232 234-
236 238-240 243-245 251 252 254 255 257 259-261 263-267 269 270 273 276-278 281 282
285 289-292 294-296 298-301 304-306 309 310 313 314 316-319 321-326 329 332 334-
337 341-344 347-356 359 (as measured by BMI) and breast cancer at
all ages, or where menopausal status was unspecified.
Sixteen cohort studies showed increased risk with
increased body fatness,45 50 152-154 162 164 166 168 171 173 179 181 184
186 188 191 192 201 203 204 which was statistically significant in
three.162 171 179 201 Eight studies showed decreased risk,161 172
173 184 186 194-197 202 which was statistically significant in two.173
196 197 Two studies showed no effect on risk.50 204 Meta-analy-
sis was possible on 16 cohort studies, giving a summary
effect estimate of 1.01 (95% CI 1.00–1.02) per 2 kg/m2, with
moderate heterogeneity (figure 6.1.10).
Forty-seven case-control studies showed increased risk
with increased body fatness66 208 211 213 215 221 222 224 230 232 235
236 239 240 251 252 254 255 257 260 261 265-267 269 276 277 281 282 285 294-296
298-301 305 306 309 310 313 314 316-319 323-326 329 332 334-337 341 343 344 347-
350 352-356 359; this was statistically significant in 2266 208 211 222
230 232 235 254 255 269 277 285 295 296 298 316-318 329 332 334 336 337 341 349
352 353 359; 4 studies showed no effect on risk207 245 278 351; and
the remaining 22 showed decreased risk,205 209 212 214 219 225
228 229 234 238 243 244 259 263 264 270 273 289-292 304 321 322 342 349 which
was statistically significant in 4 studies.214 263 264 291 One of
Figure 6.1.10 BMI and breast cancer (age unspecified);
cohort and case-control studies
Cohort
Galanis 1998 1.11 (1.05–1.18)
Mills 1989 1.11 (1.01–1.22)
Key 1999  1.07 (1.00–1.08)
Wolk 1998 1.04 (1.00–1.08)
Silvera 2005 1.03 (0.99–1.07)
Byrne 1996 1.02 (0.90–1.16)
Overvad 1991 1.01 (0.85–1.21)
Tornberg 1994 1.01 (0.97–1.05)
Rapp 2005 1.00 (0.98–1.03)
Zhang 2003 1.00 (0.96–1.05)
Vatten 1992 0.96 (0.93–0.99)
Wu 1999 0.96 (0.82–1.11)
Wu 1999 0.94 (0.80–1.12)
Kilkkinen 2004  0.92 (0.85–1.00)
Rissanen 2003 0.90 (0.81–1.01)
Knekt 1996 0.88 (0.79–0.99)
Summary estimate 1.01 (1.00–1.02)
Case control
Henquin 1994 1.34 (1.05–1.71)
Henquin 1994 1.34 (0.91–1.96)
Hietanen 1994 1.29 (0.92–1.82)
Young 1989 1.15 (1.06–1.24)
Kato 1992 1.14 (1.06–1.24)
Zhu 2005 1.14 (1.05–1.24)
Talamini 1984 1.12 (1.03–1.21)
Wenten  2001 1.11 (1.03–1.20)
Hirose  1999 1.10 (1.06–1.15)
Malin 2005 1.10 (1.05–1.16)
Tung 1999 1.10 (1.01–1.20)
Eid 1998 1.10 (0.89–1.36)
Thomas 1996 1.09 (1.02–1.17)
Potischman 1990 1.08 (0.96–1.22)
Yoo 2001 1.08 (1.04–1.12)
Bonilla-Fernandez 2003 1.08 (0.98–1.19)
Dai 2002 1.07 (1.03–1.12)
Shu 2001 1.07 (1.03–1.12)
Do 2003 1.07 (1.04–1.11)
Richardson 1991 1.07 (0.98–1.17)
Pietinen 2001 1.07 (0.98–1.16)
Joensuu 1992 1.07 (0.97–1.17)
Viladiu 1996 1.06 (0.98–1.16)
Sarin 1985 1.06 (0.90–1.24)
Shrubsole 2001 1.05 (1.01–1.10)
Lopez-Carillo 1997 1.05 (0.95–1.17)
Hsieh 1990 1.05 (1.03–1.07)
Toti 1986 1.05 (1.00–1.10)
Zheng 2000 1.04 (0.93–1.17)
Holmberg 1994 1.04 (0.94–1.15)
Challier 1998 1.04 (0.95–1.15)
Trentham-Dietz 2000 1.04 (1.02–1.06)
Silva 2004 1.04 (0.97–1.11)
Newcomb 1994 1.03 (1.01–1.05)
Okobia 2005 1.03 (0.93–1.14)
Swanson 1989 1.03 (1.00–1.06)
Ingram 1991 1.02 (0.94–1.12)
Fioretti 1999 1.02 (0.96–1.08)
Adebamowo 2003 1.00 (0.92–1.09)
Gerber 1988 1.00 (0.90–1.10)
Friedenreich 2001 0.99 (0.97–1.02)
Sonnichsen 1990 0.99 (0.86–1.13)
Adami 1977 0.99 (0.89–1.09)
Zheng 2000 0.98 (0.87–1.12)
Hislop 1986 0.97 (0.91–1.04)
McCredie 1998 0.97 (0.92–1.03)
Moorman 2001 0.97 (0.92–1.03)
Furberg 1999 0.97 (0.94–1.01)
Ferranoni 1991 0.97 (0.88–1.06)
Coates 1999 0.96 (0.94–0.98)
Kuru 2002 0.96 (0.90–1.01)
Chie 1998 0.95 (0.80–1.14)
Bagga 2002 0.95 (0.85–1.07)
Wenten 2001 0.95 (0.89–1.02)
Drewnowski 2000 0.94 (0.86–1.01)
Petrek 1993 0.92 (0.81–1.04)
Zheng 2000 0.91 (0.83–1.01)
Bouchardy 1990 0.90 (0.86–0.94)
Mendonca 1999 0.90 (0.81–1.00)
Ueji 1997 0.90 (0.78–1.03)
Agurs-Collins 1998 0.89 (0.82–0.98)
Ibarluzea 2004 0.84 (0.77–0.90)
Summary estimate 1.02 (1.02–1.03)
21.510.5
Relative risk, per 2 kg/m2
Relative risk (95% CI)
Figure 6.1.9 BMI and colorectal cancer; cohort studies:
dose response
Lee 1975 Men
Saydah 2003
Blondon 2000 Men
Kritchevsky 1984 Women
Ford 1999 Women
Chyou 1996 Men
Bostick 1994 Women
Bostick 1994 Women
Koh 2004
10 4020 30
BMI (kg/m2)
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these studies showed significant increased risk with
increased body fatness in Hispanic-American people but non-
significant decreased risks among white-American people.349
Meta-analysis was possible on 62 case-control studies, giv-
ing a summary effect estimate of 1.02 (95% CI 1.02–1.03)
per 2 kg/m2, with high heterogeneity (figure 6.1.10). 
The two ecological studies showed no consistent
association.360 361
Postmenopause
Twenty-four cohort studies42 45 50 122 149-151 155-159 162 163 165 167
169 170 174 175 178 180 182-185 187-195 199 200 and 56 case-control stud-
ies investigated body fatness,66 205-208 214 220 224-227 231 233 237 239
241 242 244 246-250 253-259 261-263 268 271 274 275 279-283 286-288 293 295-297
302 304 308 311 315 321 322 327 329 331 333 336-341 345 349 352 357-359 (as mea-
sured by BMI) and postmenopausal breast cancer.
Nineteen cohort studies showed increased risk with
increased body fatness,42 45 50 122 149 151 155-159 162 163 165 167 174
175 180 183-185 187-194 199 200 which was statistically significant in
seven.42 45 149 158 162 163 174 175 180 183 189 192 Five studies showed
decreased risk,150 169 170 178 182 195 which was statistically sig-
nificant in one.150 Meta-analysis was possible on 17 studies,
giving a summary effect estimate of 1.03 (95% CI 1.01–1.04)
per 2 kg/m2, with high heterogeneity (figure 6.1.11). This
would produce an increased risk of 8 per cent for each 
5 kg/m2, assuming a linear relationship, although a curvi-
linear dose-response relationship cannot be ruled out.
Heterogeneity may be explained partially by failure to adjust
for hormone replacement therapy (HRT) use. Three major
studies that reported results stratified for HRT status all
found statistically significant increased risk with increasing
body fatness only in women not taking HRT. 
Pooled analysis from seven cohort studies (more than 
337 000 participants, followed up for up to 11 years, with
more than 4300 breast cancer cases) showed a significant
increased risk of postmenopausal breast cancer with
increased body fatness. The effect estimate was 1.07 
(95% CI 1.02–1.11) per 4 kg/m2.362
Most case-control studies showed increased risk with
increased body fatness,66 205 207 208 220 224-227 233 237 239 241 246-250
253-258 261 262 271 274 275 279-283 286-288 293 295-297 302 308 311 315 327 329
331 333 336-341 345 349 352 357-359 which was statistically significant
in approximately half of these studies.66 220 227 233 237 241 246 253-
258 261 275 280 283 293 295 296 302 308 315 329 333 336 338-341 352 359 Meta-
analysis was possible on 48 studies, giving a summary effect
estimate of 1.05 (95% CI 1.05–1.06) per 2 kg/m2, with mod-
erate heterogeneity (figure 6.1.12). This would produce an
increased risk of 13 per cent for each 5 kg/m2, assuming a
linear relationship, although a curvilinear dose-response
Figure 6.1.11 BMI and postmenopausal breast cancer;
cohort studies
Sonnenschein 1999 1.20 (1.08–1.34)
Toniolo 1994 1.20 (1.05–1.39)
Galanis 1998 1.09 (1.01–1.16)
Gapstur 1992  1.08 (1.04–1.13)
Wirfalt 2004 1.07 (1.00–1.15)
Saadatian-Elahi 2002 1.07 (0.95–1.19)
Barrett-Connor 1993 1.06 (0.80–1.41)
Tornberg 1994  1.05 (1.01–1.09)
Tulinius 1997 1.04 (0.98–1.10)
Tehard 2004 1.03 (1.00–1.07)
Van den Brandt  1.03 (0.97–1.09)
Huang 1997 1.02 (0.99–1.05)
Rissanen 2003  1.01 (0.85–1.21)
Manjer 2001 0.97 (0.88–1.07)
Kaaks 1998 0.97 (0.86–1.09)
Jumaan 1999 0.95 (0.87–1.03)
Summary estimate 1.03 (1.01–1.04)
21.510.5
Relative risk (95% CI)
Relative risk, per 2 kg/m2
Figure 6.1.12 BMI and postmenopausal breast cancer;
case-control studies
Chie 1996 1.31 (0.80–2.13)
Hu 1997 1.25 (0.95–1.63)
Zhu 1996 1.21 (0.89–1.64)
Hirose 2003 1.18 (1.13–1.24)
Park 2000 1.18 (1.13–1.24)
Hansen 1997 1.17 (0.95–1.43)
Rattanamongkolg 2002 1.15 (1.05–1.25)
Zhu 2005 1.15 (1.01–1.30)
Yoo 2001 1.14 (1.08–1.21)
Talamini 1984 1.13 (1.02–1.25)
Tung 1999 1.13 (1.01–1.25)
Lopez-Carrillo 1997 1.13 (0.97–1.32)
Graham 1991 1.11 (1.04–1.19)
Chow 2005 1.10 (1.01–1.19)
Magnusson 1998 1.09 (1.06–1.12)
Rosenburg 1990 1.08 (0.99–1.18)
Trentham-Dietz 2000 1.08 (1.06–1.10)
Toti 1986 1.08 (1.02–1.14)
Harris 1992 1.08 (1.00–1.16)
Taioli 1995 1.07 (1.00–1.16)
Kohlmeier 1997 1.07 (1.01–1.13)
Li 2000 1.06 (1.00–1.13)
Newcomb 1999 1.06 (1.04–1.09)
Shoff 2000 1.06 (1.04–1.09)
Swanson 1989 1.06 (1.01–1.11)
Trentham-Dietz 1997  1.06 (1.04–1.08)
Dorn 2003 1.06 (1.01–1.11)
Carpenter 2003 1.06 (1.02–1.10)
Li 2003 1.06 (1.01–1.10)
Hsieh 1990 1.05 (1.03–1.07)
Fioretti 1999 1.05 (0.97–1.13)
Franceschi 1996 1.05 (1.02–1.07)
Terry 2002 1.05 (1.02–1.07)
Ng 1997 1.04 (0.94–1.16)
Hall 2000 1.04 (0.96–1.13)
Adebamowo 2003 1.04 (0.94–1.15)
Van’t Veer 1989 1.04 (0.88–1.22)
Marubini 1988 1.03 (0.91–1.17)
Helmrich 1983 1.03 (0.99–1.06)
McCann 2004 1.02 (0.99–1.05)
Adami 1977 1.01 (0.91–1.13)
Hislop 1986 1.01 (0.92–1.10)
Hall 2000 1.00 (0.96–1.04)
Sonnichsen 1990 1.00 (0.98–1.02)
Friedenreich 2002 1.00 (0.96–1.04)
Petrek 1993 0.97 (0.85–1.11)
De Vasconcelos 2001 0.94 (0.85–1.03)
Adams-Campbell 1996  0.90 (0.83–0.98)
Summary estimate 1.05 (1.05–1.06)
1.510.8 2
Relative risk (95% CI)
Relative risk, per 2 kg/m2
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relationship cannot be ruled out. Heterogeneity may be par-
tially explained by differential adjustment between studies.
A dose-response relationship is apparent from cohort and
case-control data (figure 6.1.13, figure 6.1.14).
The general mechanisms through which body fatness
could plausibly influence cancer risk are outlined in 6.1.3
(also see box 2.4). 
There is abundant and consistent epidemiological
evidence and a clear dose response, with robust
evidence for mechanisms operating in humans. The
evidence that greater body fatness is a cause of
postmenopausal breast cancer is convincing.
The Panel is aware that since the conclusion of the SLR, one
cohort363 and one case-control study364 have been published.
This new information does not change the Panel judgement
(also see box 3.8).
Premenopause
Twenty cohort studies45 122 149 150 155 162 167 170 174-178 184 185 188-
192 195-198 and 59 case-control studies66 205-208 210 214 216-218 223-
227 231 233 237 239 241 242 247-250 253-259 261-263 268 269 272 281 282 284 286-290
293 297 302-304 306-308 311 312 320-322 324-330 336-341 343-346 349 352 357-359
investigated body fatness (as measured by BMI) and pre-
menopausal breast cancer.
Thirteen cohort studies showed decreased risk with
increased body fatness,45 149 150 167 170 174-176 184 185 189 191 192 195-
198 which was statistically significant in seven.149 150 167 176 184
192 195-198 Four studies showed non-significant increased
risk.155 162 188 190 Three studies showed no effect on risk.122
177 178 Meta-analysis was possible on 14 studies, giving a
summary effect estimate of 0.94 (95% CI 0.92–0.95) per 
2 kg/m2, with moderate heterogeneity (figure 6.1.15). This
would produce a decreased risk of 15 per cent for each 
5 kg/m2, assuming a linear relationship, although a curvi-
linear dose response cannot be ruled out.
Egger’s test for publication bias suggested some over-
representation of studies showing a protective effect on
premenopausal breast cancer of increasing BMI.
Pooled analysis from 7 cohort studies (more than 337 000
participants, followed up for up to 11 years, with more than
4300 breast cancer cases) showed a significant decreased risk
of premenopausal breast cancer with increased body fatness.
The effect estimate was 0.89 (95% CI 0.81–0.97) per 4
kg/m2.365
Most case-control studies showed decreased risk with
increased body fatness,205 206 214 216-218 223-225 231 233 237 239 241 242
247-250 259 262 263 268 281 282 284 286-290 293 297 302-304 311 324-328 330 338-
341 349 which was statistically significant in approximately one
third of these studies.214 218 223 231 237 250 262 268 303 304 326 327 330
Figure 6.1.13 BMI and postmenopausal breast cancer;
cohort studies: dose response
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Figure 6.1.14 BMI and premenopausal breast cancer;
case-control studies: dose response
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Meta-analysis was possible on 51 case-control studies,205-208
216 218 223 226 231 233 239 241 242 247-250 256 258 259 261 262 272 281 282 284
286-290 297 302-304 306-308 311 312 320-322 324-329 336 338-341 343-346 352 357
359 giving a summary effect estimate of 0.97 (95% CI
0.96–0.97) per 2 kg/m2, with moderate heterogeneity. 
A dose-response relationship was apparent from cohort
(figure 6.1.16) and case-control data.
There is no single, well-established mechanism through
which body fatness could prevent premenopausal breast can-
cer. According to the oestrogen plus progesterone theory,
overweight premenopausal women would be protected
because they would be more frequently anovulatory and
therefore less exposed to endogenous progesterone.
However, this theory is not well supported by recent studies,
which suggest that natural progesterone could be pro-
tective.365 Normal levels of natural progesterone are likely 
to be protective and women who are well nourished, or
perhaps overnourished, who may become slightly over-
weight in adulthood, may be protected by their natural
fertile condition. Another possible mechanism is that the
increased adipose tissue-derived oestrogen levels in over-
weight children could induce early breast differentiation and
eliminate some targets for malignant transformation.366
Anovulation and abnormal hormone profiles are commonly
associated with obesity.367 The age-specific pattern of asso-
ciation of breast cancer with BMI, therefore, is largely
explained by its relationship with endogenous sex hormone
levels.
Breast cancer diagnosed postmenopause is much more
common. Therefore, throughout life, a decreased risk of
premenopausal breast cancer would be expected to be
outweighed by an increased risk of postmenopausal 
breast cancer (also see chapter 7.10).
There is a substantial amount of consistent
epidemiological evidence, with a dose response, but
the mechanistic evidence is speculative. Greater body
fatness probably protects against premenopausal
breast cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort363 and one case-control study364 have been published.
This new information does not change the Panel judgement
(also see box 3.8).
Endometrium
Twenty-three cohort studies,45 50 52 55 122 137 168 192 368-385 41
case-control studies,254 386-455 and 2 cross-sectional studies456-
458 investigated body fatness (as measured by BMI) and
endometrial cancer. Three cohort studies168 376 382 and 6 case-
control studies254 409 416 422 424 425 441 investigated BMI mea-
sured as a young adult.
Twenty-two cohort studies showed increased risk with
increased body fatness,50 52 55 122 137 168 192 368-370 373-377 380-383
which was statistically significant in 16.384 One small study
showed non-significant decreased risk.376 382 Meta-analysis
was possible on 15 cohort studies, giving a summary effect
estimate of 1.52 (95% CI 1.35–1.72) per 5 kg/m2, with high
heterogeneity (figure 6.1.17).
Nearly all of the case-control studies showed increased risk
with increased body fatness, most of which were statistical-
ly significant.254 387-390 392 394-409 411-438 440-443 446 453 454 One
Figure 6.1.15 BMI and premenopausal breast cancer;
cohort studies
Galanis 1998  1.09 (0.96–1.25)
Toniolo 1994 1.09 (0.96–1.23)
Manjer 2001 1.00 (0.89–1.13)
Tulinius 1997 1.00 (0.92–1.09)
Karaks 1998 0.99 (0.89–1.10)
Sonnenschein 1999 0.95 (0.84–1.07)
Huang 1997 0.95 (0.91–0.98)
Saadatien-Elahi 2002 0.94 (0.83–1.07)
Vatten 1992 0.94 (0.90–0.98)
Tehard 2004 0.93 (0.87–0.99)
Weiderpass 2004 0.92 (0.88–0.96)
Ahlgren 2004 0.92 (0.88–0.96)
Tornberg 1994 0.86 (0.80–0.92)
Rissanen 2003 0.75 (0.62–0.90)
Summary estimate 0.94 (0.92–0.95)
1.510.5
Relative risk (95% CI)
Relative risk, per 2 kg/m2
Figure 6.1.16 BMI and premenopausal breast cancer;
cohort studies: dose response
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study showed no effect on risk after adjustment for waist cir-
cumference, but the unadjusted result showed a statistical-
ly significant increased risk.455 No studies showed decreased
risk with increased body fatness. Meta-analysis was possible
on 28 case-control studies, giving a summary effect estimate
of 1.56 (95% CI 1.45–1.66) per 5 kg/m2, with high hetero-
geneity (figure 6.1.17). Heterogeneity was predominantly
the result of variation in the size of effect, rather than direc-
tion of effect.
A dose-response relationship is apparent from cohort and
case-control data (figures 6.1.17 and 6.1.18). There was no
evidence of effect modification by menopause, smoking, or
oestrogen-use status.   
Both cross-sectional studies reported an association
between higher BMI and increased risk of endometrial
cancer.456-458
The general mechanisms through which body fatness
could plausibly influence cancer risk are outlined in 6.1.3
(also see box 2.4). 
BMI as a young adult
All three cohort studies showed increased risk with increased
body fatness, which was statistically significant in two.376 382
Meta-analysis was possible on all three cohort studies, giv-
ing a summary effect estimate of 1.31 (95% CI 1.12–1.54)
per 5 kg/m2, with no heterogeneity.168 376 382
Four case-control studies showed non-significant increased
risk with increased body fatness,409 416 424 425 441 and two
showed non-significant decreased risk.254 422 Meta-analysis
was possible on all six case-control studies, giving a summary
effect estimate of 1.10 (95% CI 0.95–1.27) per 5 kg/m2, with
low heterogeneity.254 409 416 422 424 425 441
A dose-response relationship was apparent from cohort but
not case-control data.
There is abundant consistent epidemiological evidence
with a clear dose response, and robust evidence for
mechanisms operating in humans. The evidence that
greater body fatness is a cause of endometrial cancer is
convincing.
Figure 6.1.17 BMI and endometrial cancer; cohort and
case-control studies
Cohort
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Rapp 2005 1.48 (1.29–1.71)
Silvera 2005 1.75 (1.56–1.96)
Lukanova 2006 1.85 (1.33–2.57)
Summary estimate 1.52 (1.35–1.72)
Case control
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Swanson 1993 1.25 (1.07–1.47)
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Parazzini 1995 1.59 (1.44–1.76)
Gruber 1996 1.73 (1.57–1.91)
Kalandidi 1996 1.93 (1.48–2.51)
Goodman 1997 1.99 (1.62–2.44)
Geraci 1998 1.47 (0.96–2.24)
Hachisuga 1998 1.46 (1.17–1.81)
Hose 1999 1.65 (1.18–2.29)
Beard 2000 1.34 (1.06–1.69)
Salazar-Martinez 2000 1.44 (1.09–1.90)
Weiderpass 2000 1.69 (1.50–1.89)
Newcomer 2001 1.58 (1.44–1.74)
Petitlou 2002 2.12 (1.37–3.27)
Augustin 2003 1.29 (1.08–1.54)
Hom-Ross 2003 1.16 (1.08–1.25)
Augustin 2003 2.10 (1.27–3.48)
Trentham-Dietz 2005 1.69 (1.54–1.84)
Xu 2005 1.78 (1.54–2.06)
Okamura 2006 1.74 (1.02–2.97)
Summary estimate  1.56 (1.45–1.66)
Relative risk (95% CI)
Relative risk, per 5 kg/m2
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Figure  6.1.18 BMI and endometrial cancer; cohort studies:
dose response
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The Panel is aware that since the conclusion of the SLR, one
cohort study146 and one case control study459 have been pub-
lished. This new information does not change the Panel judge-
ment (also see box 3.8).
Kidney 
Seventeen cohort studies42 45 57 122 279 460-473 and 20 case-
control studies66 474-502 investigated body fatness (as mea-
sured by BMI) and kidney cancer.
Fifteen cohort studies showed increased risk with
increased body fatness42 45 57 122 279 460-468 470-472; this was sta-
tistically significant in seven studies,57 122 460 461 465 466 468 472
and in women but not men in another.42 Two studies stated
that there was no statistically significant association.469 473 No
cohort studies showed decreased risk. Meta-analysis was pos-
sible on seven cohort studies that adjusted for smoking, giv-
ing a summary effect estimate of 1.31 (95% CI 1.24–1.39)
per 5 kg/m2, with low heterogeneity (figure 6.1.19)
Eighteen case-control studies66 474-493 495-497 499-502 showed
increased risk with increased body fatness; this was statisti-
cally significant in 14 studies,66 474 476-478 480-483 485 487 488 490-
493 495-497 500 and in men but not women in another.501 One
study showed no effect on risk498 and another (where the
controls were not drawn from the same population as the
cases, making it a relatively low-quality study) showed a
non-significant decreased risk.494 Meta-analysis was possible
on two case-control studies that adjusted for smoking and
eight unadjusted case-control studies. This gave summary
effect estimates of 2.05 (95% CI 1.43–2.92) per 5 kg/m2,
with low heterogeneity, and 1.42 (95% CI 1.17–1.72) per 5
kg/m2, with high heterogeneity, respectively (figure 6.1.19).
A dose-response relationship is apparent from cohort and
case-control data (figure 6.1.20).
The general mechanisms through which body fatness
could plausibly influence cancer risk are outlined in 6.1.3
and box 2.4; in addition, laboratory studies point to a poten-
tial role for insulin and leptin in renal cell carcinoma.503 504
There is abundant and consistent epidemiological
evidence with a dose-response relationship and
evidence of plausible mechanisms. The evidence that
greater body fatness is a cause of kidney cancer is
convincing.
The Panel is aware that since the conclusion of the SLR, three
cohort studies30 52 142 and one case-control study505 have been
published. This new information does not change the Panel
judgement (also see box 3.8).
Gallbladder 
Five cohort studies,42 45 56 58 141 201 seven case-control stud-
ies,506-514 and two cross-sectional studies515-517 investigated
body fatness (as measured by BMI) and gallbladder cancer. 
Most cohort studies showed increased risk with increased
body fatness. For two studies, results for the whole cohort
showed statistically significant increased risk.42 201 One study
reported significant increased risk for women and non-
significant increased risk for men,141 while another report-
ed statistically significant increased risk for women and
non-significant decreased risk for men.45 One study report-
ed a significant increased risk for white men and a non-
significant decreased risk for black men.56 Meta-analysis was
possible on four cohort studies, giving a summary effect
estimate of 1.23 (95% CI 1.15–1.32) per 5 kg/m2, with 
moderate heterogeneity (figure 6.1.21).
Most case-control studies showed increased risk with
increased body fatness,506 507 509 510 513 514 which was
Figure 6.1.19 BMI and kidney cancer; cohort and
case-control studies
Cohort
Chow 2000 1.37 (1.18–1.59)
Flaherty 2005 1.52 (1.00–2.31)
Oh 2005 1.43 (1.22–1.67)
Hiatt 1994 1.18 (0.82–1.70)
Van Dijk 2004 1.27 (1.23–1.31)
Bjorge 2004 1.28 (1.24–1.33)
Gamble 1996 2.53 (1.12–5.68)
Summary estimate 1.31 (1.24–1.39)
Case control
Mattioli 2002 2.74 (1.40–5.32)
Boeing 1997 1.83 (1.21–2.76)
Summary estimate 2.05 (1.43–2.92)
410.25 20.5
Relative risk (95% CI)
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Figure  6.1.20 BMI and kidney cancer; cohort and
case-control studies: dose response
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statistically significant in three.506 510 513 Two studies showed
decreased risk,511 512 which was statistically significant in
one.512 One study showed no effect on risk in men, but a sta-
tistically significant increased risk in women.508 Meta-analy-
sis was possible on all seven case-control studies,506-514 giving
a summary effect estimate of 1.19 (95% CI 0.81–1.75) per
5 kg/m2, with high heterogeneity. Heterogeneity could be at
least partly attributed to differences in the study participants’
ethnicity or sex, or to the number of adjustments made in
the study. In addition, there was variation according to
whether BMI was derived from direct measurements or self-
reports of weight and height, as well as in the outcome mea-
sured. For example, one cohort and one case-control study
reported biliary tract cancer as opposed to gallbladder can-
cer specifically, and some studies reported incidence while
others reported mortality.
The general mechanisms through which body fatness
could plausibly influence cancer risk are outlined in 6.1.3
(also see box 2.5). In addition, obesity is a known cause of
gallstone formation and having gallstones increases the risk
of gallbladder cancer (see chapter 7.7), possibly through bile
cholesterol supersaturation leading to cholesterol-based gall-
stones. High cholesterol in the bile is not necessarily relat-
ed to dietary cholesterol — it can also be caused by insulin
resistance, which can be caused by obesity. Insulin resistance
can independently increase cholesterol synthesis in the liver
and decrease cholesterol absorption.518 Bile cholesterol lev-
els are also gender-linked: women excrete more cholesterol
in bile than men. 
Owing to the link between gallstones and gallbladder can-
cer, the Panel reviewed the dietary causes of having gall-
stones, especially in relation to body fatness. BMI increased
the risk of having gallstones in a linear fashion.519 Waist cir-
cumference was associated with gallstone risk in men, inde-
pendently of BMI,520 and insoluble fibre in the diet showed
a protective effect.521 Gallstone formation is strongly asso-
ciated with dieting, especially where it involves rapid weight
loss — such as seen with very low-energy diets and bariatric
surgery.522 523 Rapid weight loss is also a common feature of
weight cycling. Weight cycling is associated with obesity and
independently associated with gallstones; people who are
more severe weight cyclers have a higher risk of gallstones.524
There is a substantial amount of generally consistent
epidemiological evidence with some evidence of a dose
response. There is evidence for several plausible
mechanisms. Greater body fatness is a probable cause
of gallbladder cancer, directly and also indirectly
through the formation of gallstones. 
Liver
Six cohort studies42 44 54-57 525 and two case-control studies
investigated body fatness526 527 (as measured by BMI), or
obesity, and liver cancer.
Five cohort studies showed increased risk for the highest
body fatness group compared to the lowest.42 44 54 55 57 This
was statistically significant in two studies,54 57 and in men
but not women in another two.42 55 One cohort study showed
a statistically significant increased risk in white men and a
significant decreased risk in black men.56 Effect estimates
were 1.68 in women (95% CI 0.93–3.04) and 4.52 in men
(95% CI 2.94–6.94)42; 1.44 in white men (95% CI
1.28–1.61) and 0.68 in black men (95% CI 0.49–0.94)56;
1.56 in men (95% CI 1.15–2.12)57; 3.88 in men (95% CI
0.96–15.69)44; 1.9 in both sexes (95% CI 1.5–2.5)54; and
1.70 in women (95% CI 0.95–3.05) and 3.60 in men (95%
CI 2.08–6.24).55
Neither case-control study showed any statistically signif-
icant association.526 527
The general mechanisms through which body fatness
could plausibly influence cancer risk are outlined in 6.1.3
(also see box 2.4). 
The epidemiological evidence shows some
inconsistencies, and the mechanistic evidence is
speculative. There is limited evidence suggesting that
greater body fatness is a cause of liver cancer.
The Panel is aware that since the conclusion of the SLR, two
cohort studies30 528 have been published. This new information
does not change the Panel judgement (see box 3.8).
Lung 
Twenty-one cohort studies,42 57 76 88 122 144 529-545 24 case-con-
trol studies,546-573 and 1 ecological study574 investigated body
fatness (as measured by BMI) and lung cancer.
Twenty cohort studies showed decreased risk with
increased body fatness42 57 76 88 122 529-545; this was statistical-
ly significant in 12 studies,42 76 122 531 533-535 540 542 543 545 and in
women but not men in another study.536 One study showed
no effect on risk.144 Meta-analysis was possible on 14 cohort
studies,57 88 122 144 530 532 534 535 537 538 540 543-545 giving a summary
effect estimate of 0.98 (95% CI 0.98–0.99) per kg/m2, with
high heterogeneity. This would produce a decreased risk of
Figure 6.1.21 BMI and gallbladder cancer; cohort studies
Calle 2003 Men 1.38 (1.05–1.82)
Calle 2003 Women 1.28 (1.14–1.43)
Samanic 2004 Black Men 0.97 (0.58–1.64)
Samanic 2004 White Women 1.22 (1.05–1.42)
Kuriyama 2005 Men 0.42 (0.04–4.77)
Kuriyama 2005 Women 1.91 (1.16–3.13)
Engeland 2005 Men age 45–74 1.10 (0.99–1.23)
Engeland 2005 Men age 20–44 1.15 (0.92–1.44)
Engeland 2005 Women age 20–44 1.37 (1.24–1.50)
Engeland 2005 Women age 45–74 1.19 (1.13–1.25)
Summary estimate 1.23 (1.15–1.32)
1 50.25 20.5
Relative risk (95% CI)
Relative risk, per 5 kg/m2
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5 per cent for each 5 kg/m2, assuming a linear relationship,
although a curvilinear dose-response relationship cannot be
ruled out. When meta-analysis was restricted to the 10 stud-
ies that adjusted for smoking, the effect estimate and CIs
remained the same, but with low heterogeneity.57 88 144 530 534
537 538 540 544 Heterogeneity was caused by variation in the size
but not the direction of the effect.
Begg’s and Egger’s tests suggested publication bias; that
is, the smaller the study, the stronger the protective associ-
ation observed. Smaller studies, with results of weak or no
association, appear to have been less likely to be published.
Twenty-two case-control studies showed decreased risk
with increased body fatness,546-560 562-570 572 573 which was sta-
tistically significant in nine.548 550 551 553 557 563 564 566 567 570 572
Two studies showed increased risk,561 571 which was statisti-
cally significant in one.561 Meta-analysis was possible on 10
case-control studies,546 550 554 555 557 566-568 570 572 giving a sum-
mary effect estimate of 0.98 (95% CI 0.98–0.99) per kg/m2,
with low heterogeneity. The effect estimate was unchanged
when three studies that did not adjust for smoking were
excluded from the analysis.546 568 572
The single ecological study showed a non-significant asso-
ciation between increased body fatness and decreased risk.574
Smoking is the principal cause of lung cancer and may also
be associated with lower BMI. There is a high potential for
confounding due to cigarette smoking, and residual con-
founding is therefore possible. In addition, it is possible that
people with undiagnosed lung cancer may lose weight, so
giving a spurious association (reverse causation).
There is no known mechanism through which greater body
fatness could plausibly protect against lung cancer, or
through which low body fatness could increase risk.
Although the epidemiological evidence suggests an
inverse relationship, this could be caused by
confounding by cigarette smoking or reverse causation
due to weight loss from undiagnosed cancer. There is
limited evidence suggesting that low body fatness is a
cause of lung cancer.
6.1.3.2  Abdominal fatness
Colorectum
Seven cohort studies87 92 97 115 118 137 142 and two case-control
studies investigated waist circumference and colorectal
cancer. Six cohort studies82 87 92 97 115 137 142 and four case-
control studies investigated waist to hip ratio.
Waist circumference
All seven cohort studies showed increased risk with increased
waist circumference, which was statistically significant in
six.87 97 115 118 137 142 Meta-analysis was possible on four cohort
studies, giving a summary effect estimate of 1.05 (95% CI
1.03–1.07) per 2.5 cm (1 inch), with moderate heterogeneity
(figure 6.1.22). Both case-control studies reported increased
risk with increased waist circumference. 
Waist to hip ratio
All six cohort studies showed increased risk with increased
waist to hip ratio, which was statistically significant in 
five.87 97 115 137 142 Meta-analysis was possible on five cohort
studies, giving a summary effect estimate of 1.30 (95% CI
1.17–1.44) per ratio increment of 0.1, with moderate het-
erogeneity (figure 6.1.23). Most case-control studies report-
ed increased risk with increased waist circumference.
Because of the abundant prospective data from cohort
studies, case-control studies were not summarised.
The general mechanisms through which body fatness and
abdominal fatness could plausibly influence cancer risk are
outlined in 6.1.3 (also see box 2.4). Many of these, such as
increased circulating oestrogens and decreased insulin sen-
sitivity, are particularly associated with abdominal rather
than overall body fatness.
There is ample, consistent epidemiological evidence
with a clear dose response and robust evidence for
mechanisms that operate in humans. The evidence
that abdominal fatness is a cause of colorectal cancer
is convincing.
Figure 6.1.22 Waist circumference and colorectal cancer;
cohort studies
Giovanucci 1995 Men 1.10 (1.04–1.15)
Folsom 2000 1.03 (1.01–1.05)
Maclnnis 2004 1.08 (1.04–1.13)
Pischon 2006 Men 1.04 (1.04–1.13)
Pischon 2006 Women 1.03 (1.01–1.06)
Summary estimate 1.05 (1.03–1.07)
Relative risk (95% CI)
1 1.20.8 1.10.9
Relative risk, per inch
Figure 6.1.23 Waist to hip ratio and colorectal cancer;
cohort studies
Giovanucci 1995 Men 1.72 (1.10–2.68)
Martinez 1997 Women 1.27 (0.97–1.66)
Folsom 2000 Women 1.16 (1.03–1.29)
Maclnnis 2004 1.68 (1.27–2.22)
Pischon 2006 Women 1.27 (1.11–1.46)
Pischon 2006 Men 1.30 (1.08–1.55)
Summary estimate 1.30 (1.17–1.44)
Relative risk (95% CI)
1 50.2 20.5
Relative risk, per 0.1 increment
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The Panel is aware that since the conclusion of the SLR, three
cohort studies31 142 143 have been published. This new infor-
mation does not change the Panel judgement (see box 3.8). 
Pancreas
Three cohort studies investigated waist circumference and
pancreatic cancer.46 74 Two cohort studies investigated waist
to hip ratio51 74 and one investigated patterns of weight gain.49
Waist circumference
All three cohort studies showed increased risk with increased
waist circumference, which was statistically significant in one.
Effect estimates were 1.32 (95% CI 0.73–2.37) per 20 cm (7.9
inches) in women,46 1.74 (95% CI 1.00–3.01) per 20 cm (7.9
inches) in men,46 and 1.13 (95% CI 1.01–1.26) per 10 cm
(3.9 inches).74 The latter study was published after the cut-
off date for inclusion in the SLR. However, the Panel was
aware of the study and agreed to include it in its considera-
tion of this exposure.
Waist to hip ratio
Both cohort studies showed increased risk with increased waist
circumference, which was statistically significant in one. Effect
estimates were 1.12 (95% CI 0.81–1.55; high versus low)51
and 1.24 (95% CI 1.04–1.48) per ratio increment of 0.1.74 The
latter study was published after the cut-off date for inclusion
in the SLR. However, the Panel was aware of the study and
agreed to include it in its consideration of this exposure.
Patterns of weight gain
The single cohort study showed a statistically significant
increased risk with a self-reported tendency to abdominal
(central) weight gain, when compared to peripheral weight
gain. The effect estimate was 1.45 (95% CI 1.02–2.07).49
The general mechanisms through which abdominal fatness
could plausibly influence cancer risk are outlined in 6.1.3
(also see box 2.4). 
There is a substantial amount of epidemiological
evidence, generally consistent, and there is evidence for
plausible mechanisms. Abdominal fatness is a probable
cause of pancreatic cancer.
Breast (postmenopause)
Eight cohort studies157 159 170 174 180 187 199 575-577 and three case-
control studies207 242 304 investigated waist circumference and
postmenopausal breast cancer. Eight cohort studies157 159 163
170 174 180 187 189 199 575 576 and eight case-control studies241 242
247 248 297 304 308 321 investigated waist to hip ratio.
Waist circumference
All eight cohort studies showed increased risk with increased
waist circumference, which was statistically significant in
two.157 180 199 Meta-analysis was possible on four cohort stud-
ies,159 170 575 577 giving a summary effect estimate of 1.05 (95%
CI 1.00–1.10) per 8 cm (3.1 inches), with no heterogeneity.
All three case-control studies showed increased risk with
increased waist circumference, which was statistically sig-
nificant in two.207 242
Waist to hip ratio
Six cohort studies showed increased risk with increased waist
to hip ratio,157 159 163 170 174 180 187 199 575 which was statistical-
ly significant in four.163 170 187 199 575 Two studies showed non-
significant decreased risk.189 576 Meta-analysis was possible
on five cohort studies, giving a summary effect estimate of
1.19 (95% CI 1.10–1.28) per ratio increment of 0.1, with
moderate heterogeneity (figure 6.1.24).
Five case-control studies showed increased risk with
increased waist to hip ratio,242 247 297 308 321 which was statis-
tically significant in three.242 297 308 Three studies showed
non-significant decreased risk.241 248 304 Meta-analysis was
possible on seven case-control studies, giving a summary
effect estimate of 1.07 (95% CI 1.00–1.14) per ratio incre-
ment of 0.1, with moderate heterogeneity (figure 6.1.24).
The general mechanisms through which abdominal fatness
could plausibly influence cancer risk are outlined in 6.1.3
(also see box 2.4). Many of these, such as increased circu-
lating oestrogens and decreased insulin sensitivity, are par-
ticularly associated with abdominal rather than overall 
body fatness.
There is a substantial amount of epidemiological
evidence but some inconsistency. There is robust
evidence for mechanisms that operate in humans.
Abdominal fatness is a probable cause of
postmenopausal breast cancer.
Figure 6.1.24 Waist to hip ratio and postmenopausal breast
cancer; cohort and case-control studies
Cohort
Kaaks 1998 2.04 (1.17–3.53)
Wirfalt 2004 1.49 (1.11–2.01)
Gapstur 1992 1.18 (1.05–1.31)
Huang 1999 1.15 (1.02–1.30)
Sonnenschein 1999 0.99 (0.69–1.40)
Summary estimate 1.19 (1.10–1.28)
Case control
Attanamongkolg 2002 1.68 (1.13–2.49)
Hall 2000 White women 1.34 (1.00–1.81)
Hall 2000 Black women 1.34 (0.90–2.00)
Friedenreich 2002 1.32 (1.10–1.58)
Sonnichsen 1990 1.0 (0.92–1.12)
Franceschi 1996 0.97 (0.86–1.10)
Hansen 1997 0.81 (0.44–1.51)
Petrek 1993 0.76 (0.41–1.42)
Summary estimate 1.07 (1.00–1.14)
1 20.25 3 4
 Relative risk (95% CI)
Relative risk, per 0.1 increment
227
C H A P T E R  6 •  B O D Y  C O M P O S I T I O N ,  G R O W T H ,  A N D  D E V E L O P M E N T
Endometrium
One cohort study137 and four case-control studies419 455 578 579
investigated waist circumference and endometrial cancer.
One cohort study137 368 373 374 376 and six case-control stud-
ies388 404 423 424 446 455 578-580 investigated waist to hip ratios.
Waist circumference
The single cohort study showed a statistically significant
increased risk for the highest waist circumference group
when compared to the lowest. The effect estimate was 4.2
(95% CI 2.8–6.2).137
All four case-control studies showed statistically significant
increased risk for the highest waist circumference group
when compared to the lowest.419 455 578 579 Three studies
adjusted for BMI.419 455 579
Waist to hip ratio
The single cohort study showed a statistically significant
increased risk for the highest waist circumference group
when compared to the lowest.137 368 373 374 376 The effect esti-
mate was 1.96 (95% CI 1.43–2.71) or 1.33 (95% CI
1.18–1.51) per ratio increment of 0.1 (figure 6.1.25).373 An
earlier report from the same study adjusted for BMI, which
reduced the effect estimate and made it non-significant: 1.2
(95% CI 0.8–1.9; high versus low).137
Five case-control studies showed increased risk with
increased waist to hip ratio,388 404 423 424 455 578 579 which was
statistically significant in two.404 423 424 455 578 580 One study
showed non-significant decreased risk.446 Meta-analysis was
possible on four case-control studies, giving a summary effect
estimate of 1.45 (95% CI 1.00–2.09) per ratio increment of
0.1, with high heterogeneity (figure 6.1.25). All four of these
case-control studies were adjusted for BMI.
The general mechanisms through which abdominal fatness
could plausibly influence cancer risk are outlined in 6.1.3
(also see box 2.4). Many of these, such as increased
circulating oestrogens and decreased insulin sensitivity, are
particularly associated with abdominal rather than overall
body fatness.
There is a substantial amount of generally consistent
epidemiological evidence, but limited prospective
data. There is evidence for plausible mechanisms.
Greater abdominal fatness is a probable cause of
cancer of the endometrium.
6.1.3.3 Adult weight gain
Breast (postmenopause) 
Seven cohort studies158 159 167 193 576 581-586 and 17 case-con-
trol studies217 220 225 231 241 242 255 274 280 283 315 318 327 338 339 349 359
587-591 investigated adult weight gain and postmenopausal
breast cancer. 
All seven cohort studies showed increased risk with
increasing amounts of weight gained in adulthood, which
was statistically significant in two.159 167 581 583 586 Two cohort
studies stratified results according to whether or not partic-
ipants were using HRT.158 576 584 Both studies showed a
statistically significant increased risk in women not using
HRT. Studies of weight gain and premenopausal breast can-
cer showed no overall effect on risk. 
The full SLR is contained on the CD included with this
Report.
Thirteen case-control studies showed increased risk with
increasing amounts of weight gained in adulthood,217 220 225
231 241 242 255 280 283 315 318 327 338 339 349 587 589-591 which was sta-
tistically significant in 11.217 220 242 255 280 283 315 318 338 339 349 587
589-591 No studies reported significant decreased risk. Meta-
analysis was possible on six case-control studies, giving a
summary effect estimate of 1.05 (95% CI 1.04–1.07) per 
5 kg (11 lbs) gained, with high heterogeneity (figure 6.1.26).
Figure 6.1.25 Waist to hip ratio and endometrial cancer;
cohort and case-control studies
Cohort
Folsom 2003 1.33 (1.18–1.51)
Case control
Elliott 1990 2.13 (0.94–4.83)
Austin 1991 1.01 (0.74–1.38)
Goodman 1997 1.22 (1.00–1.49)
Xu 2005 2.03 (1.63–2.53)
Summary estimate 1.45 (1.00–2.09)
210.5 3
Relative risk (95% CI)
Relative risk, per 0.1 increment
Figure 6.1.26 Weight gain and postmenopausal breast
cancer; cohort and case-control studies
Cohort
Brestom 2001 1.11 (0.99–1.24)
Folsom 1990 1.11 (1.03–1.20)
Huang 1997 1.05 (1.02–1.08)
Barnes-Josiah 1995 1.03 (1.02–1.03)
Summary estimate 1.03 (1.02–1.04)
Case control
Jemstrom 1999 1.28 (1.05–1.55)
Chie 1998 1.09 (0.84–1.40)
Trentham-Dietz 1.07 (1.05–1.09)
Friedenreich 2002 1.06 (1.01–1.11)
Franceschi 1996 1.04 (1.00–1.07)
Trentham-Dietz 2000 0.97 (0.93–1.01)
Summary estimate 1.05 (1.04–1.07)
1.510.5
Relative risk (95% CI)
Relative risk, per 5 kg gained
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Heterogeneity may be explained by failure to separate
postmenopausal participants using HRT.
There is ample, consistent epidemiological evidence
from both cohort and case-control studies. A dose
response was apparent from case-control and cohort
studies. Adult weight gain is a probable cause of
postmenopausal breast cancer.
6.1.4  Comparison with previous report
The previous report used different terminology. It conclud-
ed that the evidence that ‘high body mass’ was a cause of
cancer of the endometrium was convincing, and that high
body mass was probably a cause of cancers both of the breast
(postmenopause) and the kidney. In the previous report, the
evidence that high body mass was a cause of cancers of the
colon and gallbladder was judged to be possible. Since that
time, several cohort studies and other epidemiological and
other evidence have greatly strengthened the evidence on
body fatness, and specifically on overweight and obesity.
Also, the distinction between adenocarcinomas and squa-
mous cell carcinomas has identified a clear relationship
between body fatness and adenocarcinomas of the oesoph-
agus. The previous report did not make any judgements
specifically on abdominal fatness. 
The previous report did not include judgements on body
fatness and pancreatic cancer, although it did conclude that
high energy intake was a possible cause of this cancer.592 It
also noted data from correlation and animal studies sug-
gesting that high energy intake might increase the risk of
cancer in general, without making any judgement.
6.1.5  Conclusions
The Panel concludes: 
The evidence that greater body fatness is a cause of cancers
of various sites is more impressive now than it was in the
mid-1990s. 
The evidence that greater body fatness is a cause of can-
cers of the oesophagus (adenocarcinoma), pancreas, col-
orectum, breast (postmenopause), endometrium, and kidney
is convincing. Greater body fatness is probably a cause of
gallbladder cancer , both directly, and indirectly through the
formation of gallstones. There is also limited evidence sug-
gesting that greater body fatness is a cause of liver cancer.
The evidence that abdominal fatness is a cause of colorectal
cancer is convincing; and abdominal fatness is probably a
cause of cancers of the pancreas, breast (postmenopause),
and endometrium. By contrast, greater body fatness proba-
bly protects against cancer of the breast diagnosed before the
menopause. The Panel notes that there is limited evidence
suggesting that low body fatness (underweight) is a cause
of cancer of the lung, but residual confounding with smok-
ing and lung disease cannot be ruled out. See chapters 7.4
and 7.10, and Chapter 8 for discussion of the role of ener-
gy density in weight gain, overweight, and obesity.
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Growth in childhood is a predictor of age at sexual
maturity and eventual adult attained height. Food quantity
and quality, and the extent of infections and infestations
during crucial periods of growth, are critical in determining
speed of growth. Rate of growth has metabolic and
hormonal effects, which can trigger lifelong consequences.
Since the recognition of the vital importance of nutrition
to human health and welfare, public health nutrition policy
has emphasised the need for birth weights and rates of
growth within ranges defined as those most likely to ensure
physical and mental development in childhood, and good
health in adult life. Such policies are essential. New
standards based on the ‘ideal’ pattern of growth of healthy,
breastfed infants have now been agreed by the World
Health Organization.
Overall, the Panel judges that evidence on the factors that
lead to greater adult attained height, or its consequences,
and the risk of cancers of a number of sites, is strong,
consistent, and impressive. The Panel emphasises that
greater adult attained height, meaning how tall people are
as adults, is unlikely directly to modify the risk of cancer. It
is a marker for genetic, environmental, hormonal, and
nutritional factors affecting growth during the period from
preconception to completion of linear growth. 
The Panel concludes:
The evidence that the factors that lead to greater adult
attained height, or its consequences, increase the risk of
cancers of the colorectum and breast (postmenopause) is
convincing; and they probably also increase the risk of
cancers of the pancreas, breast (premenopause), and ovary.
There is limited evidence suggesting that the factors that
lead to greater adult attained height, or its consequences,
increase the risk of endometrial cancer. 
In addition, the factors that lead to greater birth weight,
or its consequences, are probably a cause of
premenopausal breast cancer. 
A major question for future research is: what are 
the factors that determine height in adult life? And, given
the theme of this Report, what is the relative importance 
of genetic and environmental factors, what is the role 
of nutrition, and when in the life course are nutritional
factors most relevant? Weighing such evidence, given 
that adequate birth weight and growth are essential for
good health in infancy and childhood, and throughout 
life, is a major challenge for the biological and nutritional
sciences. 
Within the remit of this Report, the strongest evidence,
corresponding to judgements of ‘convincing’ and
‘probable’, shows that the factors that lead to greater adult
attained height, or its consequences, are a cause of cancers
of the colorectum and breast (postmenopause), and
probably also of cancers of the pancreas, breast
(premenopause), and ovary. In addition, the factors that
lead to greater birth weight, or its consequences, probably
increase the risk of premenopausal breast cancer. 
GROWTH AND DEVELOPMENT, AND THE RISK OF CANCER
In the judgement of the Panel, the factors listed below modify the risk of cancer. Judgements are graded according to the strength of the evidence.
DECREASES RISK INCREASES RISK
Exposure Cancer site Exposure Cancer site
Convincing Adult attained height1 Colorectum 
Breast (postmenopause)
Probable Adult attained height1 Pancreas 
Breast (premenopause)
Ovary
Greater birth weight Breast (premenopause)  
Limited — Adult attained height1 Endometrium 
suggestive
Substantial 
effect on risk None identified
unlikely
1 Adult attained height is unlikely to directly modify the risk of cancer. It is a marker for genetic, environmental, hormonal, and also nutritional factors affecting
growth during the period from preconception to completion of linear growth (see 6.2.1.3).
For an explanation of all the terms used in the matrix, please see chapter 3.5.1, the text of this section, and the glossary.
6.2  Growth and development
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Linear growth, from preconception to adulthood, influences
health and well-being throughout life, as do body composi-
tion and shape. 
Standards for birth weight and growth developed by
expert panels for relevant United Nations agencies, and
approved by UN member states, form the basis for nation-
al, municipal, and local paediatric health policies and pro-
grammes throughout the world. The WHO/UNU Multicentre
Growth Reference Study (MGRS) of healthy, breastfed
children is the basis for the WHO 2006 growth standards for
children aged 0–5 years.593
However, no growth standard has been validated in terms
of lifelong risk for chronic diseases, including cancer. As with
body weight (see chapter 6.1), policies and programmes con-
cerned with the physical and mental development of infants
and children, and growth until adulthood, have focused on
the need to protect populations against the consequences of
inadequate nutrition and retarded growth. This remains a
central public health priority for middle- and low-income
countries. 
In the 1990s, increasing concern, based on emerging evi-
dence, was expressed by the scientific community in this
field.594 The concern has been that the agreed standards had
‘overshot the mark’ for optimum growth and health. For sev-
eral reasons, the agreed growth standards for the first peri-
od of life seemed to have been set unnecessarily and
unhelpfully high. This perception was heightened by evi-
dence of rapidly increasing rates of childhood overweight
and obesity, which tend to track into adult life (see box 8.3).
As a result, new standards based on breastfed children were
agreed and ratified, and issued in 2005, as guides to opti-
mum growth.593
This is the general context in which the Panel has exam-
ined the evidence on growth and development, and the risk
of cancer. 
6.2.1  Definitions and patterns 
Growth increases metabolic capacity and also the ability to
cope with environmental challenge. From a single cell at con-
ception, human growth progresses through embryogenesis
and fetal development, involving cellular multiplication and
differentiation in both structure and function. At birth, the
body’s tissues and organs are highly organised and regulat-
ed. The timing and order of these processes are determined
by the selective expression of genes, which is both innate and
modifiable by the wider environment, including the avail-
ability of oxygen, energy, and nutrients. Nutrients also act
by regulating hormones, growth factors, binding proteins,
and receptors, and their activity.
For every tissue or organ, adverse environmental influ-
ences during critical periods of development, such as limit-
ed energy or nutrients, can restrict development and future
capacity for function. The timing, severity, and duration of
any adverse exposure will determine the extent and pattern
of any restriction in capacity. 
Growth can be divided into three phases: fetal–infant,
childhood, and puberty.595 During the first period, growth is
most sensitive to the availability of energy and nutrients.
Brain growth is protected more effectively than growth in
stature, which is protected more effectively than weight. So
the timing of an adverse influence on growth tends to be
reflected in a person’s body shape, both as a child and as an
adult. For instance, for lean tissue to be deposited efficient-
ly and effectively, the appropriate pattern of nutrients must
be available in a timely way. 
If any nutrients are limited but energy intake is adequate
— or more than adequate — a person will be predisposed
to excess body fatness. This is because their energy intake
will exceed the nutrients available in the body for laying
down lean tissue, so the excess energy is stored as fat. People
who were of low birth weight have a greater tendency to
store fat, in particular abdominally.
6.2.1.1  Birth weight
A baby’s size and shape at birth indicates the extent and
quality of intra-uterine growth and development. Birth
weight can be measured simply and reliably, whereas head
circumference, which marks growth of the brain, and length,
which marks linear growth, are more difficult to measure reli-
ably. Within the usual range, heavier (and longer) babies
tend to become taller children and adults. 
Birth weight predicts the risk of death and of various dis-
eases in infancy and later in life. Very low birth weight —
less than 2.5 kg (5.5 lbs) for boys and 2.4 kg (5.3 lbs) for
girls — increases the risk of perinatal death and disease, or
death in infancy and young childhood, usually because of
increased vulnerability to infection and infestation. It is well
established, at least in high-income countries, that smaller
size at birth, and at 1 year of age, predicts increased risk of
chronic disease such as cardiovascular disease and type 2
diabetes during adult life.596 This is due to a reduced capac-
ity to cope with the stress of environmental challenges, such
as a poor diet (including excess energy) and physical inac-
tivity. Very high birth weight may also be associated with
increased risk — for instance, maternal diabetes or poor glu-
cose homeostasis can cause higher birth weight as well as
increased risk of diabetes in the infant.597 These findings
have been shown to be independent of smoking or socio-
economic status, although they may be accentuated in 
the presence of these additional stress factors.598
The extent to which body fatness is a factor in any rela-
tionship between low birth weight and disease in later life
remains unclear. The associations described above are
strongest when low birth weight, or restricted fetal growth,
is followed by rapid growth during early childhood.599-602
Such effects can be experimentally induced in animals, lend-
ing weight to the observed associations in humans being
causal. 
6.2.1.2  Infant and prepubertal growth
The fetal–infant growth phase slows during the second half
of the first year of life. The childhood phase of growth
becomes established at 6–18 months. Any delay in the onset
of this growth phase tends to lead to shorter stature during
childhood. Over an extended period of time, growth in
height and weight is a smooth process, although there may
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be growth spurts or times of little change over shorter peri-
ods. Growth, through the formation of new tissue, requires
a dietary supply of energy (about 5 kilocalories per gram of
new tissue) and macronutrients such as amino acids and
fatty acids, as well as vitamins, minerals, and trace elements.
Each individual factor is vital; if any are limited they will con-
strain normal growth and development. 
At any age, therefore, normal development requires
appropriate genetic, hormonal, and nutritional factors to
support growth. These in turn require adequate quantity and
quality of food, and minimal exposure to food and environ-
mental toxicants, infection, and psychosocial stress. As an
infant gets older, the body is increasingly able to cope with
environmental challenge. 
The pattern and timing of any nutrient shortfall deter-
mines the pattern of constrained growth. Patterns of growth
failure are highly variable, comprising the differential effects
on linear growth (stunting), weight (underweight and wast-
ing), or on specific tissues. Thus stunting may be due to a
period of slow growth or a delay to the onset of the child-
hood phase of growth. If growth has been constrained as the
result of an adverse circumstance, which is then removed,
there is a drive towards returning to the growth pattern
established previously or to the genetically determined
growth pattern. This ‘catch-up’ growth may be in height or
weight, or some combination of the two; the term is often
used without defining what type of growth is involved.
However, ‘catch-up’ in linear growth after malnutrition is
rare beyond the first 2–3 years of life.
In the first 6 months of life, infants who are breastfed and
then weaned appropriately to mixed diets grow differently
from those fed on formula. This is partly related to the
increased risk of infection for formula-fed infants and part-
ly due to the different compositions of human milk and for-
mula feed. Normal child growth (under optimal
environmental conditions) from birth to 5 years is specified
in the WHO Child Growth Standards.593
Throughout the world, particularly in high- and middle-
income countries, and in urban areas generally, childhood
obesity and type 2 diabetes are becoming more common.
Childhood overweight and obesity often persists into adult
life. This exposes people to the hormonal and physiological
consequences of being overweight or obese earlier in adult
life, increasing their risk of related health problems at a rel-
atively young age (also see box 8.3). 
6.2.1.3  Adult attained height 
Genetic and early life environmental factors, even before
birth, are important in determining adult height. The envi-
ronmental determinants of height attained in adulthood are
highlighted by the variation between generations in adop-
tion and migrant studies, where children are moved from a
poor or limited nutritional background to an area of high or
even overnutrition.603 Adult height is also linked to birth
weight, rate of growth, and age of puberty. Periods of peak
growth (such as in infancy and adolescence) are particular-
ly important in determining adult height.
Adult height increases as populations become less vulner-
able to undernutrition, infestation, and infection, and as food
supplies become more secure; it continues to increase when
food is abundant (also see chapter 1.1). This trend has now
slowed or even stopped in most high-income countries.
Increases in height between generations are generally due
to increased leg, rather than spine, length. Leg length is
linked to prepubertal growth, particularly to infancy (below
the age of 5); after this age, trunk growth becomes more
prominent.604 605
Growth hormones, insulin-like growth factors, and sex
hormone binding proteins all define the biological activity
of the respective hormones. These in turn impact on height,
growth, sexual maturation (boxes 6.2.1 and 6.2.2), fat stor-
age, and many processes relevant to cancer (box 2.4). It is
therefore plausible that nutritional factors that impinge on
height could also influence cancer risk, with adult height act-
ing as a marker of that early life experience, in the same way
that taller people have a decreased risk of cardiovascular dis-
eases, at least in high-income countries.606-608
Therefore, both birth weight and adult attained height are
markers of an aggregated fetal and childhood experience;
they are clearly also surrogates for important nutritional
exposures, which impact on several hormonal and metabol-
ic axes, and which influence cancer risk (also see Chapter 2).
6.2.2. Interpretation of the evidence
6.2.2.1 General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7. 
6.2.2.2 Specific 
Some considerations specific to growth and development are
as follows. 
Measurement. Weight at birth is usually recalled accurately
by parents. As well as full height, proxy measures may be
used in some studies, including leg length, sitting height, or
a ratio of these two. The ratio between overall height and
limb length varies with genetic background and nutritional
experience over the life course. 
6.2.3 Evidence and judgements 
The full systematic literature review (SLR) is contained on
the CD included with this Report.
As indicated in 6.2.1.3, there are several general mecha-
nisms through which the factors that lead to greater adult
attained height, or its consequences, could plausibly influ-
ence cancer risk. However, adult attained height is unlikely
to directly modify the risk of cancer. It is a marker for genet-
ic, environmental, hormonal, and also nutritional factors
affecting growth during the period from preconception to
completion of linear growth. For example, adult height is the
result of several stages of growth from fetal life through
childhood. These are all influenced by nutrition, particular-
ly in infancy, which in turn affects hormone levels, and there-
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fore many processes relevant to cancer (box 2.4). Site-spe-
cific mechanisms are described with the evidence for each
cancer site.
6.2.3.1 Adult attained height
Colorectum
Twenty-one cohort studies58 80 82-84 87 88 91 93 108 109 115 117 119 120
124 126 133 140 142 621-625 and 16 case-control studies investigat-
ed adult attained height and cancer of the colon and rectum.
Eighteen cohort studies showed increased risk with
increased adult attained height58 80 82-84 87 88 109 115 117 120 124
126 142 622-625; this was statistically significant in six,58 80 87 124
623 624 and in another study in men, but not in women.108 119
621 One study showed non-significant increased risk in 
men and no effect on risk in women.140 Two studies showed
no effect on risk.91 93 133 Meta-analysis was possible on 12
cohort studies, giving a summary effect estimate of 1.09
(95% CI 1.06–1.12) per 5 cm (2 inches), with no hetero-
geneity (figure 6.2.1).
A dose-response relationship was apparent from cohort
data.
Because of the abundant prospective data from cohort
studies, case-control studies were not summarised.
The general mechanisms through which the factors that
lead to greater adult attained height, or its consequences,
could plausibly influence cancer risk are outlined in 6.2.1.3
(also see box 2.4). Many of these, such as early-life nutri-
tion, altered hormone profiles, and the rate of sexual matu-
ration, could plausibly increase cancer risk
There is ample prospective epidemiological evidence,
which is consistent, and there is a clear dose response,
with evidence for plausible mechanisms operating in
humans. The evidence that factors that lead to greater
Early menarche is an established risk factor
for breast cancer. From pooling project
data, based on information from 322 647
women, 4827 breast cancer cases occurred
during follow-up, and the fully adjusted
risk due to late menarche (at 15 years or
above compared with under 12 years of
age) was 0.72 (95% confidence interval (CI)
0.62–0.82).613
A meta-analysis of 21 epidemiological
studies (including both case-control and
cohort) reported a risk reduction of about
9 per cent (95% CI 7–11) for each addition-
al year of age at menarche. There was also
a statistically significant gradient of risk
when breast cancer was diagnosed early or
before menopause, and a risk of about 4
per cent (95% CI 2–5) for later diagnoses.614
A large cohort study (100 000 partici-
pants) reported a 7 per cent per year
decrease in breast cancer risk with increas-
ing age of menarche for premenopause
cases (p < 0.05). Compared to those who
had their first period at 11 or younger,
women experiencing menarche at 15 years
or older had a risk of 0.66 (95% CI
0.45–0.97). There was no statistically signif-
icant effect for postmenopause cases.615
Menarche marks the start of the cyclic
production of oestrogen by the ovaries.
Therefore early menarche means that a
woman is exposed to more oestrogen over
the course of her lifetime.616 This is likely to
be the mechanism by which age at menar-
che influences breast cancer risk. As well as
a longer lifetime exposure to oestrogen,
early menarche may be associated with
increased oestrogen levels during the
whole period of adolescence and early
adulthood.617
The first onset of breast development in
girls occurs about two years before menar-
che. The years preceding menarche are
characterised by a sharp increase in adren-
al androgens and the associated appear-
ance of the first pubic and axillary hairs,
and the first enlargement of the breasts. 
At this age, adrenal androgens play an
important role in inducing hypothalamic
changes leading to menarche.618 In adult-
hood, both before and after menopause,
high serum androgen levels are associated
with increased breast cancer risk.619 620
Consequently, nutritional exposures in early
life that influence sexual maturation in
women are also likely to have an indirect
impact on later breast cancer risk.
Box 6.2.2 Age at menarche and risk of breast cancer
Sexual maturity is the biological capability
to have children. In girls, this is charac-
terised by ovulatory cycles and/or menar-
che, the onset of menstruation. In boys,
pubertal stages are less easy to charac-
terise, and indirect markers (secondary sex
characteristics) are used, such as the age of
appearance of pubic hair. As a conse-
quence, there are more data for sexual
maturation in girls than boys. 
There is considerable variation in the
age of sexual maturity, both between and
among populations. In high-income coun-
tries, the average age of menarche ranges
from 12–13 years; this has dropped by
around 3 years over the last 150 years,
although the change has now generally
halted.609 In low-income countries, and
particularly among the most disadvan-
taged populations, the average age of
menarche may be as high as 16.610 These
trends show the impact of environmental
influences on age at menarche. 
Adrenal sex hormone production nor-
mally rises at around 6 years of age
(adrenarchy) and coincides with a rise in
BMI (adiposity rebound). Growth hor-
mone, insulin-like growth factors, and sex
hormone binding proteins all define the
biological activity of the respective hor-
mones. 
Children with an early adiposity
rebound have earlier sexual maturation
and higher risk of later obesity. 
Nutrition, birth weight, rates of growth,
body fatness, and age of sexual maturity
are all connected. The effects of these
factors may be different in either sex, 
with increased body fatness lowering 
the age at menarche but slowing male
sexual maturation.611 Conversely, early
menarche increases the risk of adult
obesity. 
Undernutrition delays the onset of
puberty in both boys and girls.612 Regular,
intense physical activity can delay menar-
che or cause menstruation to stop in later
life. The combination of low birth weight
and rapid growth in early childhood also
accelerates the development of sexual
maturity.
Box 6.2.1 Sexual maturity
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adult attained height, or its consequences, are a cause
of colorectal cancer is convincing. The causal factor is
unlikely to be tallness itself, but factors that promote
linear growth in childhood. 
The Panel is aware that since the conclusion of the SLR, three
cohort studies31 141 145 have been published. This new infor-
mation does not change the Panel judgement (see box 3.8).
Breast 
Thirty-three cohort studies,122 150 151 155-157 161 162 164 166 168 170-
172 174-176 178 180 181 183 185-187 189-191 193 196 198-200 203 577 626-637 56
case-control studies,205 206 208 214 217 218 220 221 224 225 231 234 241 242
247 248 253 254 256 257 259 261 262 269 272 274 279 280 283 290 297 303 304 306 308
312-314 318 319 323-327 331 333 336 338 339 341 342 346 349 352 588 638-647 and
3 ecological studies361 625 648 investigated adult attained height
and breast cancer.
Age unspecified
Twenty cohort studies122 150 161 162 164 166 168 171 172 181 186 191 196
203 627-630 632 634-637 and 29 case-control studies205 208 214 218 221
224 225 234 248 254 259 261 262 269 290 297 306 313 314 318 319 323 324 336 341
342 349 352 638 641 646 647 investigated adult attained height and
breast cancer at all ages, or unspecified menopausal status.
Thirteen cohort studies showed increased risk with greater
adult attained height,122 161 162 164 168 171 191 196 628 629 632 634-637
which was statistically significant in nine.122 161 162 168 191 196
632 634-637 Four studies showed no effect on risk,172 181 186 630
and two showed decreased risk,150 166 203 627 which was sta-
tistically significant in one study.150 Another study showed
varying effects in different age groups.633 Meta-analysis was
possible on 14 cohort studies, giving a summary effect esti-
mate of 1.09 (95% CI 1.07–1.12) per 5 cm (2 inches), with
low heterogeneity (figure 6.2.2).
Twenty-two case-control studies showed increased risk
with greater adult attained height,205 208 218 221 224 234 248 254 259
261 262 290 297 318 319 323 324 341 342 349 352 638 641 647 which was sta-
Figure 6.2.1 Height and colorectal cancer;
cohort studies
Albanes 1988 Men 1.19 (0.98–1.45)
Albanes 1988 Women 1.17 (0.96–1.43)
Suadini 1993 Men 1.07 (0.86–1.34)
Bostick 1994 Women 1.11 (0.97–1.26)
Thune 1996 Men 1.06 (0.97–1.16)
Thune 1996 Women 1.04 (0.89–1.21)
Tangrea 1997 Men 1.03 (0.88–1.20)
Hebert 1997 Men 1.05 (0.97–1.15)
Kato 1997 Women 0.99 (0.84–1.18)
Shimizu 2003 Men 1.30 (1.08–1.56)
Shimizu 2003 Women 1.18 (0.92–1.51)
Maclnnis 2004 Men 1.10 (0.94–1.27)
Giovannucci 2004 Men 1.12 (1.04–1.21)
Otani 2005 Men 1.04 (0.95–1.13)
Otani 2005 Women 1.00 (0.88–1.14)
Pischon 2006 Men 1.08 (1.01–1.17)
Pischon 2006 Women 1.14 (1.06–1.23)
Summary estimate 1.09 (1.06–1.12)
210.5 1.50.75
Relative risk (95% CI)
Relative risk, per 5 cm
Figure 6.2.2 Height and breast cancer (age unspecified);
cohort and case-control studies
Cohort
Nilsen 2001 1.44 (1.10–1.88)
Hoyer 1998 1.17 (1.00–1.36)
Palmer 2001 1.15 (1.03–1.29)
Galanis 1998 1.13 (1.02–1.24)
Vatten 1992 1.13 (1.06,–1.20)
Tulinius 1997 1.10 (1.05–1.15)
Tornberg 1988 1.10 (1.05–1.15)
Palmer 2001 1.10 (1.04–1.16)
Tryggvadottir 2002 1.09 (1.03–1.15)
Nilsen 2001 1.09 (0.79–1.50)
Goodman 1997 1.03 (0.88–1.21)
Key 1999 1.01 (0.90–1.13)
Overvad 1991 1.00 (0.77–1.31)
Kilkinnen 2004 1.00 (0.85–1.17)
Drake 2001 1.00 (0.87–1.14)
Nilsen 2001 0.99 (0.72–1.38)
Wu 2005 0.98 (0.83–1.15)
Nilsen 2001 0.95 (0.68–1.32)
Nilsen 2001 0.80 (0.58–1.10)
Summary estimate 1.09 (1.07–1.12)
Case control
Bruning 1992 1.22 (1.06–1.42)
Ziegler 1996 1.18 (1.06–1.31)
Ueji 1997 1.15 (0.93–1.41)
Lebamowo 2003 1.15 (1.03–1.28)
Hu 1997 1.12 (0.95–1.31)
Challier 1998 1.11 (0.98–1.25)
Wenten 2001 1.08 (0.94–1.25)
Swanson 1989 1.08 (1.03–1.14)
Shu 2001 1.08 (1.00–1.15)
Hirose 1999 1.06 (1.00–1.11)
Adami 1977 1.05 (0.89–1.25)
Hsieh 1990 1.04 (0.91–1.07)
Wenten 2001 1.03 (0.91–1.17)
Silva 2004 1.03 (0.90–1.17)
Yoo 2001 1.02 (0.93–1.11)
McCredie 1998 1.02 (0.95–1.09)
Hislop 1986 1.02 (0.93–1.11)
Tung 1999 1.02 (0.88–1.17)
Drewnowski 2000 1.01 (0.85–1.20)
Zhang 1996 0.99 (0.96–1.02)
Chie 1998 0.97 (0.79–1.18)
Potischman 1990 0.96 (0.80–1.16)
Kato 1992 0.95 (0.86–1.05)
Bouchardy 1990 0.94 (0.88–1.01)
Toti 1986 0.89 (0.82–0.97)
Sarlin 1985 0.88 (0.58–1.34)
Summary estimate 1.03 (1.01–1.04)
210.1 3 4
Relative risk (95% CI)
Relative risk, per 5 cm
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tistically significant in seven.208 218 224 261 297 324 647 Seven stud-
ies showed decreased risk,214 225 269 306 313 314 336 646 which was
statistically significant in one.336 Meta-analysis was possible
on 25 case-control studies, giving a summary effect estimate
of 1.03 (95% CI 1.01–1.04) per 5 cm (2 inches), with mod-
erate heterogeneity (figure 6.2.2).
A dose-response relationship was apparent from cohort
and case-control data.
All three ecological studies showed increased risk with
greater adult attained height.361 625 648
Postmenopause
Twenty-two cohort studies122 151 155-157 162 168 170-172 174 175 178
180 183 185 187 189-191 193 199 200 577 626 631 634 636 637 and 34 case-con-
trol studies205 206 208 214 217 220 224 225 231 241 242 247 253 256 257 259 261
274 280 283 297 304 308 318 327 331 333 338 339 341 352 588 638-640 642 643 646
647 investigated adult attained height and postmenopausal
breast cancer.
Twenty-one cohort studies showed increased risk with
greater adult attained height,122 151 155-157 162 168 170-172 174 175
178 180 183 185 187 189-191 193 577 626 631 634 636 637 which was statisti-
cally significant in 12.122 155 162 168 171 172 175 178 183 191 193 577 626
631 636 One study showed no effect on risk.200 Meta-analysis
was possible on 15 cohort studies, giving a summary effect
estimate of 1.11 (95% CI 1.09–1.13) per 5 cm (2 inches),
with no heterogeneity (figure 6.2.3).
Pooled analysis from 7 cohort studies (more than 337 000
participants, followed up for up to 11 years, with more than
4300 breast cancer cases) showed a statistically significant
increased risk of postmenopausal breast cancer with greater
adult attained height. The effect estimate was 1.07 (95% CI
1.03–1.12) per 5 cm (2 inches).362
Twenty-two case-control studies showed increased risk
with greater adult attained height,205 208 214 217 224 231 242 253 256
257 259 261 279 280 283 297 318 331 338 339 352 588 638-640 642 643 647 which
was statistically significant in 11.208 217 224 253 256 261 297 318 338
339 639 Nine studies showed non-significant decreased risk.206
220 225 241 274 304 327 333 341 646 Two studies showed no effect on
risk.308 Another study showed non-significant increased risk
in white women and no effect on risk in black women.247
Meta-analysis was possible on 27 case-control studies, giv-
ing a summary effect estimate of 1.02 (95% CI 1.01–1.03)
per 5 cm (2 inches), with high heterogeneity (figure 6.2.3).
A dose-response relationship was apparent from cohort
and from case-control data.
The general mechanisms through which the factors that
lead to greater adult attained height, and its consequences,
could plausibly influence cancer risk are outlined in 6.2.1.3
(also see box 2.5). Many of these, such as early-life nutri-
tion, altered hormone profiles, and the rate of sexual matu-
ration, could plausibly increase cancer risk.
There is abundant prospective epidemiological
evidence, which is generally consistent, with a clear
dose response, and evidence for plausible mechanisms
operating in humans. The evidence that factors that
lead to greater adult attained height, or its
consequences, are a cause of postmenopausal breast
cancer is convincing. The causal factor is unlikely to be
tallness itself, but factors that promote linear growth
in childhood.
The Panel is aware that since the conclusion of the SLR, one
cohort study649 has been published. This new information does
not change the Panel judgement (see box 3.8).
Figure 6.2.3 Height and postmenopausal breast cancer;
cohort and case-control studies
Cohort
Manjer 2001 1.21 (1.05–1.40)
Toniolo 1994 1.20 (1.00–1.44)
Mattisson 2004 1.19 (1.08–1.30)
Vatten 1990 1.18 (0.99–1.41)
Barrett-Connor 1993 1.17 (0.76–1.81)
Van den Brandt 1997 1.17 (1.08–1.27)
Galanis 1998 1.16 (1.03–1.31)
Tryggvaddottir 2002 1.21 (1.03–1.22)
Tulinius 1997 1.10 (1.00–1.22)
Tornberg 1998 1.10 (1.07–1.13)
Saadatien-Elahi 2002 1.10 (0.88–1.37)
Sonnenschein 1999 1.09 (0.95–1.25)
Kaaks 1998 1.08 (0.85–1.38)
Palmer 2001 1.04 (0.94–1.14)
Wirfalt 2004 1.00 (0.88–1.13)
Summary estimate 1.11 (1.09–1.13)
Case control
Chie 1996  2.35 (1.26–4.37)
Lebamowo 2003 1.40 (1.10–1.78)
Ng 1997 1.27 (1.05–1.53)
Shu 2001 1.24 (1.08–1.42)
Ziegler 1996 1.18 (0.94–1.49)
Hansen 1997 1.17 (0.80–1.72)
Hall 2000 1.16 (1.00–1.34)
Radimer 1993 1.13 (0.98–1.31)
Terry 2002 1.13 (1.08–1.18)
De Vasconcelos 2001 1.12 (0.90–1.40)
Li 2003 1.11 (1.03–1.21)
Hislop 1986 1.09 (0.98–1.22)
Magnusson 1998 1.08 (1.03–1.14)
Hirose 1995 1.08 (0.99–1.17)
Trentham-Dietz 1997 1.07 (1.041.11)
Adami 1977 1.07 (0.96–1.19)
Yoo 2001 1.06 (1.01–1.10)
Hsieh 1990 1.05 (0.93–1.18)
Li 2000 1.02 (0.94–1.10)
Friedenreich 2002 1.00 (0.86–1.16)
Hall 2000 1.00 (0.84–1.16)
Rattanamongkolg 2002 0.98 (0.96–1.01)
Carpenter 2003 0.98 (0.95–1.00)
Tung 1999 0.97 (0.76–1.25)
Petrek 1993 0.97 (0.76–1.25)
Franceschi 1996 0.97 (0.91–1.03)
Jams-Campbell 1996 0.90 (0.76–1.08)
Taioli 1995 0.88 (0.75–1.03)
Summary estimate 1.02 (1.01–1.03)
210.1 4
Relative risk (95% CI)
Relative risk, per 5 cm
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Premenopause
Seventeen cohort studies122 155 162 170 175 176 178 185 189-191 196 198
626 631 634 636 637 and 38 case-control studies205 206 208 214 217 224
225 231 241 242 247 248 253 256 257 259 261 272 290 297 303 304 308 312 318 324-
327 339 341 346 352 588 638 640 644-647 investigated adult attained
height and premenopausal breast cancer.
Eleven cohort studies showed increased risk with greater
adult attained height,122 155 162 170 175 176 191 196 626 631 634 637
which was statistically significant in two.196 634 637 Six stud-
ies showed non-significant decreased risk.178 185 189 190 198 636
Meta-analysis was possible on 11 cohort studies, giving a
summary effect estimate of 1.09 (95% CI 1.05–1.14) per 5
cm (2 inches), with low heterogeneity (figure 6.2.4).
Pooled analysis from 7 cohort studies (more than 337 000
participants, followed up for up to 11 years, with more than
4300 breast cancer cases) showed a non-significant increased
risk of premenopausal breast cancer with greater adult
attained height. The effect estimate was 1.02 (95% CI
0.96–1.10) per 5 cm (2 inches).362
Twenty-three case-control studies showed increased risk
with greater adult attained height,206 208 214 217 224 231 242 247 256
257 290 297 304 312 318 324-326 339 341 346 638 644 646 647 which was sta-
tistically significant in five.217 290 325 326 339 Thirteen studies
showed non-significant decreased risk.205 225 248 253 259 261 272
303 308 327 640 645 Two studies showed no effect on risk.241 352
588 Meta-analysis was possible on 31 case-control studies,
giving a summary effect estimate of 1.04 (95% CI 1.02–1.06)
per 5 cm (2 inches), with moderate heterogeneity (figure
6.2.4).
A dose-response relationship was apparent from cohort
and from case-control data.
The general mechanisms through which factors associat-
ed with adult attained height could plausibly cause cancer
are outlined in 6.2.1.3 (also see box 2.5). Many of these,
such as early-life nutrition, altered hormone profiles, and the
rate of sexual maturation, could plausibly increase cancer
risk.
There are fewer data for premenopausal than for
postmenopausal breast cancer. The epidemiological
evidence is generally consistent with a dose response
and evidence for plausible mechanisms. Greater adult
attained height or factors that lead to it are probably a
cause of premenopausal breast cancer. The causal
factor is unlikely to be tallness itself, but factors that
promote linear growth in childhood.
The Panel is aware that since the conclusion of the SLR, one
cohort study649 has been published. This new information does
not change the Panel judgement (see box 3.8).
Pancreas
Eight cohort studies,40 41 53 58 122 650-652 12 case-control stud-
ies,60-63 67 70 73 653-657 and 1 ecological study625 investigated
adult attained height and pancreatic cancer.
Six cohort studies showed increased risk with greater adult
attained height,40 41 53 122 650 652 which was statistically sig-
nificant in one.40 One study showed no effect on risk.651
Another stated that there was no significant association.58
Meta-analysis was possible on six cohort studies, giving a
summary effect estimate of 1.11 (95% CI 1.05–1.17) per 5
cm (2 inches), with low heterogeneity (figure 6.2.5).
The Panel is aware of a further study, published after the
conclusion of the SLR, from the European Prospective
Investigation into Cancer and Nutrition. This reported a sta-
tistically significant increased risk for the highest adult
Figure 6.2.4 Height and premenopausal breast cancer;
cohort and case-control studies
Cohort
Palmer 2001 1.17 (1.08–1.26)
Tulinius 1997 1.16 (0.95–1.41)
Vatten 1992 1.16 (1.06–1.27)
Tornberg 1988 1.11 (0.98–1.26)
Kaaks 1998 1.09 (0.93–1.29)
Galanis 1998 1.04 (0.86–1.25)
Manjer 2001 0.99 (0.87–1.14)
Tryggvadottir 2002 0.99 (0.79–1.24)
Sonnenschein 1999 0.99 (0.84–1.16)
Saadatian-Elahi 2002 0.98 (0.80–1.21)
Toniolo 1994 0.92 (0.78–1.09)
Summary estimate 1.09 (1.05–1.14)
Case control
Hall 2000 1.28 (1.00–1.63)
Tung 1999 1.25 (0.97–1.60)
Petrek 1993 1.24 (0.99–1.54)
Ng 1997 1.19 (0.91–1.55)
Adebamowo 2003 1.16 (1.00–1.34)
Ziegler 1996 1.15 (1.02–1.31)
McCredie 1996 1.15 (1.02–1.30)
Adams-Campbell 1996 1.12 (0.89–1.42)
Swanson 1996 1.12 (1.06–1.18)
De Vasconcelos 2001 1.11 (0.77–1.61)
Swanson 1997 1.10 (1.02–1.18)
Friedenreich 2002 1.09 (0.96–1.22)
Verla-Tebit 2005 1.08 (0.99–1.18)
Trentham-Dietz 1997 1.08 (1.02–1.14)
Shu 2001 1.05 (0.95–1.16)
McCredie 1998 1.03 (0.95–1.11)
Sanderson 2002 1.02 (0.88–1.18)
Franceschi 1996 1.00 (0.92–1.10)
Yoo 2001 1.00 (0.91–1.10)
Hsieh 1990 0.99 (0.94–1.05)
Radimer 1993 0.98 (0.83–1.17)
Peacock 1999 0.97 (0.90–1.04)
Hirose 1995 0.96 (0.89–1.03)
Hall 2000 0.95 (0.77–1.17)
Adami 1977 0.95 (0.59–1.42)
Taioli 1995 0.94 (0.77–1.15)
Rattanamonkolg 2002 0.93 (0.80–1.09)
Hislop 1986 0.92 (0.80–1.05)
Kumar 2005 0.91 (0.75–1.12)
Hansen 1997 0.82 (0.45–1.49)
Ursin 1994 0.62 (0.11–3.63)
Summary estimate 1.04 (1.02–1.06)
210.1 3 4
Relative risk (95% CI)
Relative risk, per 5 cm
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altered hormone profiles, and the rate of sexual maturation,
could plausibly increase cancer risk.
There is ample prospective epidemiological evidence,
though there is some inconsistency. There is evidence
for a dose-response relationship and evidence for
plausible mechanisms. Greater adult attained height or
factors that lead to it are probably a cause of
pancreatic cancer. The causal factor is unlikely to be
tallness itself, but factors that promote linear growth
in childhood.
Ovary
Seven cohort studies,168 658-663 nine case-control studies,254 657
664-670 and two ecological studies625 671 investigated adult
attained height and ovarian cancer.
All seven cohort studies showed increased risk with greater
adult attained height, which was statistically significant in
four.168 659 661 663 Meta-analysis was possible on three cohort
studies, giving a summary effect estimate of 1.15 (95% CI
1.08–1.21) per 10 cm (3.9 inches), with low heterogeneity
(figure 6.2.7).
Seven case-control studies showed non-significant
increased risk with greater adult attained height.254 664 666-670
Two studies showed decreased risk,657 665 which was statis-
tically significant in one.665 Meta-analysis was possible on
seven case-control studies, giving a summary effect estimate
of 0.96 (95% CI 0.87–1.05) per 10 cm (3.9 inches), with
moderate heterogeneity (figure 6.2.7). Heterogeneity origi-
nated from one relatively large hospital-based study. The
confidence intervals of all other studies were large and over-
lapped the null effect.
A dose-response relationship was apparent from cohort
Figure 6.2.5 Height and pancreatic cancer; cohort and
case-control studies
Cohort
Ogren 1996 1.00 (0.81–1.24)
Tulinius 1997 Men 1.19 (0.97–1.45)
Tulinius 1997 Women 1.31 (0.97–1.77)
Michaud 2001 Women 1.21 (1.02–1.34)
Stolzenberg-Solomon 2002 Men 1.04 (0.92–1.17)
Song 2003 Men 1.07 (0.95–1.20)
Giovanucci 2004 Men 1.07 (0.94–1.22)
Summary estimate 1.11 (1.05–1.17)
Case control
Sarles 1979 Men 1.00 (0.74–1.35)
Howe 1990 Men – Direct interview 1.26 (0.95–1.68)
Howe 1990 Women –
Direct interview 1.04 (0.71–1.51)
Howe 1990 Men –
    Indirect interview 1.04 (0.88–1.24)
Howe 1990 Women –
Indirect interview 1.05 (0.84–1.32)
Ghadirien 1991 1.05 (0.83–1.32)
La Vecchia 1991 Men 1.05 (0.93–1.19)
La Vecchia 1991 Women 1.13 (0.97–1.33)
Zatorski 1991 0.89 (0.77–1.03)
Bueno de Mesquita 1992 Men 0.99 (0.83–1.19)
Bueno de Mesquita 1992 Women 1.46 (1.17–1.82)
Kalapothaki 1993 0.99 (0.83–1.18)
Ji 1996 Men 0.80 (0.68–0.94)
Ji 1996 Women 1.00 (0.79–1.27)
Eberle 2005 Men 0.96 (0.86–1.06)
Eberle 2005 Women 1.00 (0.89–1.12)
Pezzi 2005 1.01 (0.92–1.10)
Summary estimate 1.02 (0.96–1.07)
Relative risk, per 5 cm
0.5 1.51 20.75
 Relative risk (95% CI)
Figure  6.2.6 Height and pancreatic cancer;
cohort studies: dose response
Ogren 1996
Tulinius 1997 Men
Tulinius 1997 Women
Michaud 2001 Women
Stolzenberg-Solomon 2002 Men
Song 2003 Men
Giovannucci 2004 Men
165155 180170 175160
 Height (cm)
attained height group when compared to the lowest, with an
effect estimate of 1.74 (95% CI 1.20–2.52).74
Five case-control studies showed increased risk with
greater adult attained height,60 61 70 654 657 which was statis-
tically significant in women, but not men, in one.654 Four
studies showed decreased risk,62 63 67 655 which was statisti-
cally significant in men, but not women, in one.63 Two stud-
ies showed no effect on risk653 656 and another stated that
there was no significant association.73 Meta-analysis was pos-
sible on 10 case-control studies, giving a summary effect esti-
mate of 1.02 (95% CI 0.96–1.07) per 5 cm (2 inches), with
moderate heterogeneity (figure 6.2.5).
A dose-response relationship was apparent from cohort
data (figure 6.2.6), but not from case-control data.
The single ecological study showed an association between
greater adult attained height and increased pancreatic can-
cer incidence, which was statistically significant in men.625
The general mechanisms through which the factors that
lead to greater adult attained height, and its consequences,
could plausibly influence cancer risk are outlined in 6.2.1.3
(also see box 2.4). Many of these, such as early-life nutrition,
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data, but not from case-control data.
Both ecological studies showed an association between
greater adult attained height and increased cancer inci-
dence.625 671
The general mechanisms through which the factors that
lead to greater adult attained height, and its consequences,
could plausibly influence cancer risk, are outlined in 6.2.1.3
(also see box 2.4). Many of these, such as early-life nutri-
tion, altered hormone profiles, and the rate of sexual matu-
ration, could plausibly increase cancer risk.
There is some inconsistency, but the better quality
epidemiological data show a clearer effect, with a
dose-response relationship. There is evidence for
plausible mechanisms operating in humans. Adult
attained height or factors that lead to it are probably a
cause of ovarian cancer. The causal factor is unlikely to
be tallness itself, but factors that promote linear
growth in childhood. 
The Panel is aware that since the conclusion of the SLR, one
cohort study672 and one case-control study673 have been pub-
lished. This new information does not change the Panel judge-
ment (see box 3.8).
Endometrium
Ten cohort studies,168 369 371 372 375 379 382 385 674 675 16 case-
control studies,254 389 396 402 404 409 416 419 420 422-424 434-437 446 453
578 579 657 676 677 and one ecological study625 investigated 
adult attained height and endometrial cancer.
Seven cohort studies showed increased risk with greater
adult attained height,168 369 372 375 379 382 674 which was statis-
tically significant in one.379 One study showed significant
increased risk for postmenopausal women and non-signifi-
cant decreased risk for premenopausal women.371 One study
showed non-significant increased risk for metastatic
endometrial cancer and non-significant decreased risk for
non-metastatic endometrial cancer.675 One study reported no
significant difference but gave no further information.385
Meta-analysis was possible on four cohort studies,372 375 382
674 giving a summary effect estimate of 1.17 (95% CI
0.96–1.42) per 10 cm (3.9 inches), with no heterogeneity.
Eight of the case-control studies showed increased risk
with greater adult attained height,254 389 396 404 416 420 422 435-
437 446 453 579 676 677 which was statistically significant in one.435
Two studies that showed decreased risk, which was not sta-
tistically significant in either case.402 434 578 Five other stud-
ies reported non-significant associations.409 419 423 424 657
Meta-analysis was possible on 11 case-control studies,254 402
416 419 420 422 435 436 455 579 676 giving a summary effect estimate
of 1.10 (95% CI 1.00–1.21) per 10 cm (3.9 inches), with
moderate heterogeneity.
The general mechanisms through which the factors that
lead to greater adult attained height, or its consequences,
could plausibly influence cancer risk are outlined in 6.2.1.3
(also see box 2.4). Many of these, such as early-life nutri-
tion, altered hormone profiles, and the rate of sexual mat-
uration, could plausibly increase cancer risk.
Although there is generally consistent evidence for
prospective epidemiological data, there is some
inconsistency in the evidence between cohort and
case-control studies, and the mechanistic evidence is
speculative. There is limited evidence that greater
adult attained height or factors that lead to it are a
cause of endometrial cancer. The causal factor is
unlikely to be tallness itself, but factors that promote
linear growth in childhood. 
6.2.3.2 Greater birth weight
Breast (premenopause)
Six cohort studies150 319 678-681 and four case-control studies312
644 682 683 investigated birth weight and premenopausal breast
cancer.
All six cohort studies showed increased risk with greater
birth weight, which was statistically significant in three.150
679 680 Meta-analysis was possible on four cohort studies, giv-
ing a summary effect estimate of 1.08 (95% CI 1.04–1.13)
per kg (2.2 lbs), with high heterogeneity (figure 6.2.8).
Three case-control studies showed increased risk with
greater birth weight,644 682 683 which was statistically signif-
icant in one.682 Another study showed non-significant
decreased risk.312
The general mechanisms through which the factors that
lead to greater birth weight, or its consequences, could plau-
sibly influence cancer risk are outlined in 6.2.1.1. Many of
these, such as long-term programming of hormonal systems,
could plausibly increase cancer risk.
There is general consistency amongst the relatively few
epidemiological studies, with some evidence for a dose
response. The mechanistic evidence is speculative.
Figure 6.2.7 Height and ovarian cancer; cohort and
case-control studies
Cohort
Schouten 2003 1.42 (1.08–1.87)
Engeland 2003 1.14 (1.08–1.22)
Andersaon 2004 1.07 (0.89–1.28)
Summary estimate 1.15 (1.08–1.21)
Case control
Zhang 2005 1.26 (0.88–1.80)
Hirose 1999 1.12 (0.67–1.88)
Mori 1998 1.11 (0.67–1.88)
Polychronopoulou 1993 1.09 (0.75–1.59)
Kuper 2002 1.06 (0.75–1.59)
Cramer 1984 1.05 (0.79–1.39)
Del Maso 2002 0.81 (0.70–0.93)
Summary estimate 0.96 (0.87–1.05)
0.5 1.51 2
Relative risk (95% CI)
Relative risk, per 10 cm
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Greater birth weight or factors that lead to greater
birth weight are probably a cause of premenopausal
breast cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort363 and one case-control study684 have been published.
This new information does not change the Panel judgement (see
box 3.8).
6.2.4  Comparison with previous report
The previous report used different terminology from this
Report. It concluded that the evidence that rapid growth
leads to earlier menarche (itself an established risk factor for
breast cancer), and that greater adult attained height increas-
es the risk of breast cancer, was convincing. It also concluded
that greater adult height was a possible cause of colorectal
cancer. 
In general, evidence that the factors that lead to greater
adult attained height, or its consequences, increase the risk
of cancers of some sites, including colorectal and breast, has
become stronger since the mid-1990s.
6.2.5 Conclusions
The Panel concludes: 
The evidence that the factors that lead to greater adult
attained height (meaning relative tallness), or its conse-
quences, are a cause of cancers of various sites, is more
impressive now than it was in the mid-1990s. 
The evidence that the factors that lead to greater adult
attained height, or its consequences, increase the risk of
colorectal cancer and postmenopausal breast cancer is
convincing; and they probably increase the risk of cancers
of the pancreas, breast (premenopause), and ovary. There is
limited evidence suggesting that the factors that lead to adult
attained height, or its consequences, increase the risk of
endometrial cancer. Greater adult attained height is unlike-
ly to directly modify the risk of cancer. It is a marker for
genetic, environmental, hormonal, and also nutritional fac-
tors affecting growth during the period from preconception
to completion of linear growth. 
The factors that lead to greater birth weight, or its conse-
quences, are probably a cause of premenopausal breast
cancer.
Figure 6.2.8 Birth weight and premenopausal breast
cancer; cohort studies
De Stavola 2000 1.79 (1.04–3.09)
McCormack 2005 1.52 (1.13–2.05)
Silva 2004 1.39 (0.86–2.26)
Ahlgren 2004 1.07 (1.02–1.12)
Summary estimate 1.08 (1.04–1.13)
21 3
Relative risk (95% CI)
Relative risk, per kg
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Human milk is the natural, complete food for infants 
until around 6 months of age. There is no completely
adequate substitute. Breastfeeding is natural both for 
the mother and her child, although some women find 
that they are unable to or do not want to breastfeed.
Lactation is the process by which the mother produces 
her milk. 
The Panel judges as follows: 
Evidence on lactation, breastfeeding by the mother, and
her risk of breast cancer at all ages thereafter, is strong
and consistent. It is supported by strong evidence for
plausible biological mechanisms.  
The Panel concludes that lactation protects against both
premenopausal and postmenopausal breast cancer. An
implication of this finding, together with those in the
earlier sections of this chapter, and also as summarised
and judged in Chapter 8, is that more emphasis should be
given to factors acting throughout the life course that
modify the risk of cancer. There is limited evidence
suggesting that lactation protects against cancer of the
ovary.
Within the remit of this Report, the strongest evidence,
corresponding to the judgement of ‘convincing’, shows
that lactation — breastfeeding by the mother — protects
her against breast cancer at all ages thereafter.
Human milk gives infants the best start in life. The view
sometimes expressed in the past, that infant formula may in
normal circumstances be a complete substitute for human
milk, is no longer held.685-687
The main focus of attention on breastfeeding and human
milk, throughout almost all of the last century, has been on
its benefits for the infant and young child during the peri-
od of breastfeeding, and then into the stage of weaning, and
perhaps up to 5 years of age. This remains a central part of
public health nutrition science, policy, and practice.687
It is only recently that researchers and those concerned
with public health policies have paid substantial attention
to the effects of being breastfed on the health of the child
in later life, and on the effects of lactation on the health of
the mother.687 688 Thus, the previous report did not investi-
gate what was then the small evidence base on breastfeed-
ing and cancer risk (see 6.3.4). 
As shown in the previous two sections of this chapter, it
is becoming increasingly evident that early-life environment,
including food and nutrition, is of fundamental importance
to health and well-being throughout the life course. This has
important implications for overall judgements and recom-
mendations designed to promote health and prevent disease,
and for public policy. These aspects are discussed in Part 3
of this Report, and in an accompanying report on policy
implications, to be published in late 2008.689
6.3.1  Definition and patterns
In this Report, the term ‘lactation’ refers to the process by
which the mother produces milk to breastfeed. While lac-
tating women may express their milk for their own or anoth-
er child, or for storage in human milk banks, lactation is
usually synonymous with breastfeeding.
Breastfeeding provides a complete source of nourishment
for newborns and young infants, and human milk also con-
tains immunologically active components. The UN global
strategy for infant and young child feeding recommends
LACTATION, AND THE RISK OF CANCER
In the judgement of the Panel, the factors listed below modify the risk of cancer. Judgements are graded according to the strength of the evidence.
DECREASES RISK INCREASES RISK
Exposure Cancer site Exposure Cancer site
Convincing Lactation Breast (pre- and postmenopause)
Probable
Limited — Lactation Ovary
suggestive
Substantial 
effect on risk None identified
unlikely
For an explanation of all the terms used in the matrix, please see chapter 3.5.1, the text of this section, and the glossary.
6.3 Lactation 
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exclusive breastfeeding up to 6 months for the health of both
mother and child.687
A mother’s breasts change during pregnancy to prepare for
lactation, although milk is not produced until after the baby
is born. Pituitary hormones promote milk production after
birth, with suckling acting as the stimulus to let down milk
and to continue its production. During breastfeeding, men-
struation reduces and often stops (amenorrhea). In almost
all mammals, including humans, lactation induces a period
of infertility, which increases birth spacing. Babies tend to
be weaned earlier in high-income countries. It is recom-
mended that solid foods are not introduced until the infant
is around 6 months old. With decreased suckling, lactation
slows and then stops, and this is usually accompanied by a
return to normal menstruation.
Breastfeeding was almost universal at the beginning of the
20th century. It declined in the mid-1900s, but has been
increasing since the 1970s.690 However, disparity remains
with socioeconomic status of mothers.691 In some low-
income countries, high socioeconomic class or education
level of mothers is associated with reduced breastfeeding,
whereas the opposite is true in many high-income coun-
tries.692 Older mothers and those educated to a higher level
are more likely to breastfeed in high-income countries.693 694
In Africa, more than 95 per cent of infants are breastfed,
often for a long duration, although exclusivity is low and the
rising prevalence of HIV may reduce breastfeeding.695 Also
see chapter 4.11.
6.3.2  Interpretation of the evidence
6.3.2.1 General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and  3.5, and boxes 3.1, 3.2,
3.6 and 3.7. 
6.3.2.2 Specific 
Some considerations specific to breastfeeding and lactation
are as follows. 
Patterns and ranges of duration. Most studies have been car-
ried out in high-income countries where, since the second half
of the 20th century and until recently, duration of breast-
feeding — exclusive or not — has usually been brief. Therefore
the findings of these studies may be of limited relevance to
areas of the world where breastfeeding practices differ. 
Classification. Reports (as distinct from studies) concerned
with chronic diseases have not usually considered breast-
feeding or other factors specific to infancy and childhood,
despite what is now the general agreement that the out-
comes of early life experience tend to track into adult life.
Also, there is no agreed classification for duration and exclu-
sivity of breastfeeding. 
Measurement. Studies reporting on breastfeeding use the
term with different meanings. Some studies have simply dis-
tinguished between ‘ever’ and ‘never’, which means that
results from minimal amounts of breastfeeding — exclusive
or not — are combined with results from extended and exclu-
sive breastfeeding.
6.3.3  Evidence and judgements
The full systematic literature review (SLR) is contained on
the CD included with this Report.
The principal mechanism through which lactation or breast-
feeding could plausibly influence cancer risk is the hormonal
influence of the associated period of amenorrhea and infer-
tility. This decreases lifetime exposure to menstrual cycles
and therefore alters hormone levels, particularly androgens,
which can influence cancer risk (box 2.4). Site-specific mech-
anisms are described with the evidence for each cancer site
discussed below.
Breast
One cohort study636 696 and 37 case-control studies207 208 219
244 249 254 264 294-297 302 354 355 591 697-720 investigated ever having
breastfed, as compared to never having breastfed, and breast
cancer. Five cohort studies164 177 721-724 and 55 case-control
studies213 215 216 229 232 244 246 254 262 273 279 281 290-292 295 296 299-302
306 312 318 335 337 340 349 355 356 697 699 701-705 707 712-714 717 725-748 inves-
tigated the total duration of lactation.
Ever compared to never
The single cohort study showed a statistically significant
decreased risk for ever having breastfed when compared to
never. The effect estimate, which was adjusted for repro-
ductive factors, was 0.95 (95% CI 0.91–0.99) per month of
breastfeeding, based on 1120 cases (age unspecified). A sta-
tistically significant decreased risk was observed for pre-
menopausal breast cancer, 0.76 (95% CI 0.59–0.99) per
month of breastfeeding, but not for postmenopausal breast
cancer, 0.96 (95% CI 0.91–1.01) per month of breastfeed-
ing.636 696
Twenty-eight case-control studies investigated breast can-
cer (age unspecified).207 208 219 244 254 264 294 295 354 355 591 697 700
703-708 710-713 715-720 Twenty-four of these showed decreased
risk for ever having breastfed when compared to never,207 208
219 244 254 264 294 295 302 354 355 591 700 703-707 710-713 715-720 which was
statistically significant in 10 studies.244 264 294 707 713 716 717 719
720 Four studies showed non-significant increased risk.219 302
697 708
Sixteen case-control studies investigated premenopausal
breast cancer.207 208 244 249 295 297 355 698 699 701 702 705 707 709 712 714
716 718 Fourteen of these showed decreased risk for ever hav-
ing breastfed when compared to never,244 249 295 297 355 698 701
702 705 707 709 712 714 716 718 which was statistically significant in
four.295 297 698 714 716 Two studies showed non-significant
increased risk.207 208 699
Fourteen case-control studies investigated postmenopausal
breast cancer.244 296 355 698 699 701 702 707 709 712-714 716 718 Ten of
these showed decreased risk for ever having breastfed when
compared to never,244 249 295 296 355 698 701 702 705 707 709 712-714 716
718 which was statistically significant in six.296 698 701 707 716 Four
studies showed non-significant increased risk.249 295 699 705
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Total duration
Four cohort studies showed decreased risk with increased
total duration of lactation,164 177 721-723 which was statistical-
ly significant in two.177 721 One study showed no effect on
risk.724 Meta-analysis was possible on four cohort studies,
giving a summary effect estimate of 0.98 (95% CI 0.97–1.00)
per 5 months of total breastfeeding, with no heterogeneity
(figure 6.3.1). There was no clear difference when results
were stratified according to menopause status.
Pooled analysis from 47 epidemiological studies in 30
countries (more than 50 000 controls and nearly 97 000
breast cancer cases) showed a statistically significant
decreased risk breast cancer with duration of lactation. There
was an estimated reduction in risk of 4.3 per cent (95% CI
2.9–5.8; p < 0.0001). Menopausal status was not an effect
modifier.749
Forty-four case-control studies investigated breast cancer
(age unspecified).215 229 232 244 254 262 273 281 290-292 295 299-302 306
318 335 337 340 349 355 356 697 703-705 707 712 713 717 725-727 730 734-738 740-
745 747 748 Thirty-five of these showed decreased risk with
increased total duration of lactation,215 229 244 254 262 273 281 290
295 299-302 306 318 335 337 349 355 356 703-705 707 713 717 725-727 729 734 736
737 742-745 747 748 which was statistically significant in 18 stud-
ies.215 244 254 273 281 300 337 349 705 707 713 717 726 727 736 737 743 747 748
Six studies showed non-significant increased risk291 292 697 730
735 738 740 741 and three studies showed no effect of risk.232 340
712 Meta-analysis was possible on 37 case-control studies,
giving a summary effect estimate of 0.98 (95% CI 0.97–0.98)
per 5 months of total breastfeeding, with moderate hetero-
geneity (figure 6.3.1).
Twenty-six case-control studies investigated pre-
menopausal breast cancer.216 244 254 281 290 295 312 337 355 699 701
702 705 707 712-714 728-732 739 741 743 745 746 748 Twenty-four studies
showed decreased risk with increased total duration of lac-
tation,216 244 254 281 290 295 312 337 355 699 701 702 705 707 712-714 728 729
731 732 739 743 745 746 748 which was statistically significant in
eight.254 295 707 713 714 732 739 745 746 One study showed no effect
on risk741 and one study reported non-significant increased
risk.730 Meta-analysis was possible on 19 case-control stud-
ies, giving a summary effect estimate of 0.98 (95% CI
0.97–0.98) per 5 months of total breastfeeding, with mod-
erate heterogeneity.216 244 254 281 295 312 355 701 702 712-714 729-732 741
743 745 746 748
Twenty-three case-control studies investigated post-
menopausal breast cancer.213 216 244 246 254 279 281 295 296 337 355
699 701 702 705 707 712-714 728 730 731 739 741 743 748 Fourteen showed
decreased risk with increased total duration of lactation,213
216 244 246 279 281 296 337 355 699 701 705 707 713 714 728 745 746 748 which
was statistically significant in three.213 337 701 707 Two studies
showed no effect on risk739 743 and seven reported non-sig-
nificant increased risk.254 295 702 712 730 741 745 746 Meta-analysis
was possible on 18 case-control studies, giving a summary
effect estimate of 0.99 (95% CI 0.98–1.00) per 5 months of
total breastfeeding, with low heterogeneity.244 246 254 279 281 296
355 701 702 712 714 730 731 739 741 743 745 746
The general mechanisms through which lactation could
plausibly protect against cancer are outlined in 6.3.3. In
addition to the hormonal effects of amenorrhea, the strong
exfoliation of the breast tissue during lactation, and the mas-
sive epithelial apoptosis at the end of breastfeeding, could
contribute to risk decrease by elimination of cells with poten-
tial initial DNA damage.
There is abundant epidemiological evidence from both
prospective and case-control studies, which is
consistent and shows a dose-response relationship.
Figure 6.3.1 Total duration of lactation and breast
cancer (age unspecified); cohort and
case-control studies
Cohort
Michels 1996 1.00 (0.97–1.02)
Kvale 1987 0.97 (0.94–0.99)
Goodman 1997 0.96 (0.85–1.09)
Li 2005 0.96 (0.82–1.13)
Summary estimate 0.98 (0.97–1.00)
Case control
Schecter 1997 1.12 (0.9–1.36)
Chie WeiChu 1997 1.02 (0.97–1.07)
Siskind 1989 1.02 (0.96–1.08)
Abramson 1966 1.02 (0.90–1.15)
Mendoca 1999 1.02 (0.94–1.10)
Wrensch 2003 1.00 (0.87–1.15)
Trentham-Dietz 2000 1.00 (0.95–1.05)
Do 2003 1.00 (0.96–1.04)
Tessaro 2003 0.99 (0.93–1.06)
Newcomb 1994 0.99 (0.97–1.01)
Thomas 1993 0.99 (0.98–1.00)
Coogan 1999 0.99 (0.96–1.01)
Gao Yu Tang 2000 0.99 (0.95–1.03)
Shu 2001 0.98 (0.95–1.00)
Lai FuMing 1996 0.98 (0.93–1.03)
Yavari 2005 0.97 (0.94–0.99)
McCredie 1998 0.96 (0.92–1.01)
Tao 1988 0.96 (0.94–0.99)
Hu 1997 0.96 (0.91–1.02)
Zheng 2001 0.96 (0.91–1.01)
Kuru 2002 0.95 (0.93–0.98)
Layde 1989 0.95 (0.93–0.97)
Lopez-Carillo 1997 0.95 (0.92–0.99)
Wenten 2001 0.95 (0.88–1.02)
Romieu 1996 0.95 (0.92–0.97)
Hirose 1999 0.94 (0.90–0.98)
Furberg 1999 0.94 (0.89–0.99)
Olaya-Contreras 1999 0.94 (0.88–0.99)
Park 2000 0.93 (0.86–1.01)
Zheng 2000 0.93 (0.87–1.00)
Potischman 1990 0.93 (0.80–1.07)
Yuan 1988 0.93 (0.88–0.98)
Wenten 2001 0.92 (0.84–1.00)
Haring 1992 0.91 (0.78–1.06)
Brandt 2004 0.90 (0.82–0.99)
Becher 2003 0.90 (0.82–0.98)
Lee 2004 0.87 (0.79–0.86)
Summary estimate 0.98 (0.97–0.98)
1.410.8 1.2
Relative risk (95% CI)
Relative risk, per 5 months
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There is robust evidence for plausible mechanisms that
operate in humans. The evidence that lactation
protects against both premenopausal and
postmenopausal breast cancer is convincing.
Ovary
One cohort study750 and 10 case-control studies254 751-760
investigated lactation and ovarian cancer.
The single cohort study showed non-significant decreased
risk with increased total duration of lactation. The effect esti-
mate was 0.79 (95% CI 0.25–2.56) for five or more children
breastfed compared with never breastfeeding. However, this
study was relatively small, with only 97 cases.750
Seven case-control studies showed decreased risk with
increased total duration of lactation,254 753 754 756-760 which
was statistically significant in three.753 756 759 760 Three stud-
ies showed non-significant increased risk.751 752 755 Meta-
analysis was possible on six case-control studies, giving a
summary effect estimate of 0.96 (95% CI 0.93–0.99) per 
6 months of total breastfeeding, with high heterogeneity 
(figure 6.3.2).
A dose-response relationship is apparent from case-control
data, but cohort data are insufficient.
As described in 6.3.2, substantial heterogeneity could be
expected when assessing breastfeeding when, for example,
exclusivity of breastfeeding is not always assessed.
The general mechanisms through which lactation could
plausibly protect against cancer are outlined in 6.3.3. There
is evidence that the reduced number of menstrual cycles
associated with breastfeeding protects against some cancers. 
There are sparse prospective epidemiological data,
though some evidence for a dose response. The
mechanistic evidence is speculative. There is limited
evidence suggesting that lactation protects against
ovarian cancer.
The Panel is aware that since the conclusion of the SLR, one
case-control study761 has been published. This new information
does not change the Panel judgement (see box 3.8).
6.3.4  Comparison with previous report
The previous report noted evidence that breastfeeding
(meaning lactation) protected against breast cancer, but it
did not review the literature or make a judgement. 
6.3.5  Conclusions
The Panel concludes: 
The evidence on lactation and breast cancer — the most
common female hormone-related cancer — is impressive.
Much of this has been published since the mid-1990s.
The evidence that lactation protects against breast cancer,
at all ages, is convincing. There is limited evidence suggest-
ing that lactation protects against ovarian cancer.
Figure 6.3.2 Total duration of lactation and ovarian cancer;
case-control studies
Booth 1989 1.09 (0.95–1.24)
Chiaffarino 2005 1.03 (0.97–1.10)
Yen 2003 0.96 (0.92–1.00)
Hirose 1999 0.90 (0.72–1.13)
Greggi 2000 0.84 (0.78–0.91)
Zhang 2004 0.80 (0.69–0.94)
Summary estimate 0.96 (0.93–0.99)
21 1.50.5
Relative risk (95% CI)
 Relative risk, per 6 months
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Every year an estimated 11 million people are
diagnosed with cancer (excluding skin cancers) and
nearly 7 million people are recorded as dying from
cancer. Projections for 2030 predict that these
figures will double. Cancer is increasing at rates
faster than the increase in global population. It is
becoming more common in high-income but also —
and most of all — in middle- and low-income
countries, absolutely and also relative to other
diseases. 
The scientific community is convinced that
inherited high susceptibility to cancer accounts for
only a small proportion of cases. Although we are
all more or less susceptible to various diseases,
most adult cancers are caused mainly by
environmental factors. This means that most
cancers are at least in theory preventable. 
One important cause of cancer is smoking, or
other exposure to, tobacco. Infection, infestation,
solar radiation, and other factors are also
important. Food and nutrition, physical activity,
body composition, and other associated factors are
also individually and collectively important
modifiers of cancer risk. But there is a difference.
Smoking and exposure to tobacco, and these other
factors, are all causes of cancer. By contrast, this
and the previous chapters show that food and
nutrition, and physical activity can protect against
cancer. When we are able to do so, we can choose
ways of life that protect both ourselves and the
next generation against cancer. So our nutritional
state — what we eat and drink, how active we are,
and how much body fat we carry — not only as
adults but also from and before birth, vitally affects
our risk of many cancers.
This chapter follows those on foods and drinks,
physical activity, and body composition, growth,
and development. Its purpose is to summarise the
evidence derived from independently commissioned
and presented systematic literature reviews (SLRs),
and the Panel’s judgements and conclusions, as they
relate to cancers of 17 sites. Together, these amount
to roughly 80 per cent of the incidence of, and
deaths from, all cancers worldwide. Evidence on a
number of other cancers is also summarised briefly,
based on narrative reviews. 
The sequence of the sections of this chapter
corresponds roughly with the body’s systems, or
with sites that have anatomical, metabolic,
hormonal, or other features in common, and
generally follows the sequence of the previous
report. 
The structure of all the sections, where evidence
derives from these systematic reviews, is identical.
After brief introductions, matrices display the
Panel’s judgements. In this chapter, the Panel’s
judgements also include the ‘Limited — no
conclusion’ category, where evidence is, in the
Panel’s view, of such poor quality, or too sparse,
confused, or conflicting, to allow a conclusion.
Footnotes to these matrices include important
explanations or qualifications. 
Then follow subsections on trends, incidence, and
survival; pathogenesis; and other established
causes. The next subsection concerns interpretation
of the evidence, in which issues and problems
related to specific cancer sites are summarised. 
‘Evidence and judgements’ are the central
subsections throughout this chapter. Here, the
evidence from the SLRs, reported more extensively
with graphics in Chapters 4, 5, and 6, is also
summarised. The sequence of these subsections is
the same as that of Chapters 4–6. The strongest
evidence on protection from cancer comes first,
followed by the strongest evidence on causation,
and so on. Within each passage, summaries of the
statistically most powerful epidemiological studies
come first, followed by other epidemiological
studies, and then summaries of the experimental
literature and evidence of biological plausibility.
This is followed by the Panel’s judgements, which
take into account matters of quality and
interpretation. 
Then follows a subsection comparing the
judgements of this Report with those of the
previous report, with indications of why these
differ when they do. All sections conclude with the
Panel’s judgements for each cancer site.
Cancers
C H A P T E R  7
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Cancers of the mouth, pharynx, and larynx, taken together,
are the seventh most commonly occurring types of cancer
worldwide. These cancers are three times more common in
men than in women. Over 550 000 cases were recorded in
2002, accounting for around 5 per cent of cancer cases
overall. In general, the rates of these cancers are
decreasing. These cancers tend to recur. Survival rates are
variable and average around 50 per cent at 5 years.
Cancers of the mouth, pharynx, and larynx are the seventh
most common cause of death from cancer. 
Overall, the Panel judges that food and nutrition play an
important role in the prevention and causation of cancers
of the mouth, pharynx, and larynx. 
The Panel judges as follows: 
The evidence that alcoholic drinks are a cause of cancers
of the mouth, pharynx, and larynx is convincing. The risk
is multiplied when drinkers of alcohol also smoke tobacco. 
Non-starchy vegetables, fruits, and also foods containing
carotenoids probably protect against these cancers. 
There is limited evidence suggesting that maté, a herbal
infusion traditionally drunk scalding hot through a metal
straw in parts of South America, is a cause of oral cancer. 
The main single cause of these cancers is smoking
tobacco. It has been estimated that up to half of these
cancers are preventable by appropriate diets and
associated factors. 
In final summary, the strongest evidence, corresponding
to judgements of “convincing” and “probable”, shows that
alcoholic drinks are a convincing cause of these cancers;
and that non-starchy vegetables, fruits, and foods
containing carotenoids are probably protective.
There are several different tissues and organs in and around
the mouth, pharynx, and larynx. These include the lips, the
tongue, the inside lining of the cheeks (buccal mucosa), the
floor of the mouth, the gums (gingiva), the palate, and the
salivary glands. The pharynx (or throat) is the muscular cav-
ity leading from the nose and mouth to the larynx, which
includes the vocal cords. 
Ninety per cent of cancers of the mouth, pharynx, and lar-
ynx are squamous cell carcinomas, the type discussed here.
Cancers of the oropharynx (including the tonsils) and the
hypopharynx are also included. For cancer of the nasopharynx,
the cavity from the back of the mouth to the nose, see 7.2.
FOOD, NUTRITION, PHYSICAL ACTIVITY, AND
CANCERS OF THE MOUTH, PHARYNX, AND LARYNX
In the judgement of the Panel, the factors listed below modify the risk of
cancers of the mouth, pharynx, and larynx. Judgements are graded
according to the strength of the evidence.
DECREASES RISK INCREASES RISK
Convincing Alcoholic drinks
Probable Non-starchy
vegetables1
Fruits1
Foods containing
carotenoids2
Limited — Maté3
suggestive
Limited — Cereals (grains) and their products; starchy roots,
no conclusion tubers, and plantains; dietary fibre; pulses (legumes);
meat; poultry; fish; eggs; milk and dairy products;
total fat; animal fats; plant oils; coffee; tea; frying;
grilling (broiling) and barbecuing (charbroiling);
protein; vitamin A; retinol; thiamin; riboflavin;
niacin; folate; vitamin C; vitamin E; calcium; iron;
selenium; body fatness; energy intake
Substantial 
effect on risk None identified
unlikely
1 Judgements on vegetables and fruits do not include those preserved by
salting and/or pickling.
2 Includes both foods naturally containing the constituent and foods which
have the constituent added (see chapter 3.5.3).
3 As drunk traditionally in parts of South America, scalding hot through a
metal straw. Any increased risk of cancer is judged to be caused by epithelial
damage resulting from the heat, and not by the herb itself. 
For an explanation of all the terms used in the matrix, 
please see chapter 3.5.1, the text of this section, 
and the glossary.
7.1  Mouth, pharynx, and larynx
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7.1.1  Trends, incidence, and survival
Rates of cancers of the mouth and pharynx (age adjusted)
are stable or decreasing in many high-income countries.
There was a sharp increase between 1950 and 1980 in sev-
eral European countries, such as Germany and France,
although this has since reached a plateau and started to
decrease. Laryngeal cancer rates appear to have been
generally stable or decreasing since 1970.1
Age-adjusted incidence rates of oral cancers range from
20–40 per 100 000 people in parts of south-central Asia,
Europe, Oceania, and southern Africa, to less than 3 per
100 000 in parts of eastern Asia, northern and western
Africa, and Central America. Pharyngeal cancers (other than
those of the nasopharynx) follow broadly similar incidence
patterns, although the overall incidence is lower, with highs
of more than 10 per 100 000 in south-central Asia and west-
ern Europe, to a low of less than 1 per 100 000 in northern
Africa. Age-adjusted incidence rates of laryngeal cancer
range from more than 10 per 100 000 in South America,
south-central and western Asia, and southern, central, and
western Europe to less than 1 per 100 000 in many African
countries.2 Rates are higher in men than in women by
approximately three to one.2 In the USA, rates are higher
among African-American people than in white people.3
Risk increases with age, and diagnoses of these three types
of cancer are most common in people aged 50 or over.4
Although cure rates are high for early-stage cancers of the
mouth, pharynx, and larynx, second primary tumours are rel-
atively common at these sites.5 More than 60 per cent of
patients do not seek medical advice until the disease is at an
advanced stage; in these cases, long-term survival rates are
poor, especially if the cancer site is inaccessible.4 Five-year
survival rates are around 60 per cent in the USA and 50 per
cent in the UK.3 6 These cancers account for just over 5 per
cent of all cancer incidence, but just under 5 per cent of all
cancer deaths.2 Also see box 7.1.1.
7.1.2  Pathogenesis
Mouth, pharynx, and larynx cancers, like other types, are the
result of genetic alterations that lead to small, localised
lesions in the mucous membranes that grow in an abnormal
way (dysplasia). These lesions may then progress to carci-
noma in situ, and then become invasive cancers. 
Exposure to carcinogens, such as those in tobacco, can be
prolonged and consistent. The mouth and pharynx are
directly exposed to both inhaled carcinogens and those that
are ingested by drinking and chewing — including, in the
case of chewing tobacco and betel quid, when it is spat out
after chewing. Chronic damage and inflammation caused by
stomach acid are also implicated; some studies have found
that laryngopharyngeal reflux (where stomach acid flows
upwards to the larynx and/or pharynx) is associated with
laryngeal cancers.7 8
Cancers of the mouth, pharynx, and larynx frequently
show multiple, independent, malignant foci — with second
primary cancers occurring relatively frequently. This phe-
nomenon occurs when an entire region of tissue is repeat-
edly exposed to carcinogens. Around 90 per cent of oral
cancers occur after exposure to tobacco or alcohol, or a com-
bination of both.9
7.1.3  Other established causes 
7.1.3.1  General
(Also see chapter 2.4.)
Throughout this chapter, this section lists factors outside the
scope of this Report, identified as established causes of can-
cer by the World Health Organization International Agency
for Research on Cancer, and other authoritative bodies.
These factors are as listed in chapter 2.4: tobacco use; infec-
tious agents; radiation; industrial chemicals; and some med-
ications. Other diseases may also increase the risk of cancer.
In the same way, life events that modify the risk of cancer
— causative and protective — are also included. 
‘Established’ effectively means ‘beyond reasonable doubt’
— roughly the equivalent of the judgement of ‘convincing’
used in this Report. Occasionally, authoritative findings that
perhaps fall short of ‘established’ are also included here. 
Where possible, a note of interactive or multiplicative
effects with food, nutrition, and the other factors covered by
this Report is added, as is any indication of scale or relative
importance. The factors here are almost all causative, where-
as much of the evidence on food, nutrition, physical activi-
ty, and related factors shows or suggests protection against
cancer. 
7.1.3.2  Specific
Other diseases. There is substantial evidence that gastric
reflux increases the risk of oral cancers.
The cancer incidence rates and figures given in this Report are
those reported by cancer registries, now established in many
countries. These registries record cases of cancer that have been
diagnosed. However, many cases of cancer are not identified or
recorded: some countries do not have cancer registries; regions
of some countries have few or no records; records in countries
suffering war or other disruption are bound to be incomplete;
and some people with cancer do not consult a physician.
Altogether, this means that the actual incidence of cancer is high-
er than the figures given here. 
The cancer survival rates given in this chapter and elsewhere
are usually overall global averages. Survival rates are generally
higher in high-income countries and other parts of the world
where there are established services for screening and early
detection of cancer and well established treatment facilities.
Survival also is often a function of the stage at which a cancer is
detected and diagnosed. The symptoms of some internal cancers
are often evident only at a late stage, which accounts for rela-
tively low survival rates. In this context, ‘survival’ means that the
person with diagnosed cancer has not died 5 years after diag-
nosis. Also see chapter 9.
Box 7.1.1 Cancer incidence and survival
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Tobacco use. Smoking, and other use of and exposure to
tobacco, is the most important cause of oral cancers, includ-
ing those of the mouth, pharynx, and larynx. These factors
are estimated to cause around 60 per cent per cent of all
laryngeal cancers. While alcoholic drinks are an independent
cause of these cancers, risk is multiplied if drinkers smoke
tobacco and if smokers drink .10 Chewing of betel quid (with
or without added tobacco) also causes oral cancers.11
Infection and infestation. Human papilloma viruses (HPVs)
are a cause of oral cancers.12-14
7.1.4  Interpretation of the evidence
7.1.4.1  General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7.
‘Relative risk’ is used in this Report to denote ratio mea-
sures of effect, including ‘risk ratios’, ‘rate ratios’, ‘hazard
ratios’, and ‘odds ratios’.
7.1.4.2  Specific 
Considerations specific to cancers of the mouth, pharynx,
and larynx include: 
Classification. Some studies did not report separately on can-
cers of the mouth, pharynx, or larynx, but grouped these
cancers with others as ‘head and neck cancers’ or ‘upper
aerodigestive tract cancers’. The term ‘head and neck can-
cer’ includes all of these sites plus cancers of the middle ear,
the nasal cavity, and the paranasal sinuses. The term ‘upper
aerodigestive tract cancer’ includes all head and neck can-
cers and oesophageal cancer (see 7.3).
Confounding. High-quality studies adjust for smoking but
may still be subject to residual confounding. Because of the
size of the effect of smoking, and the tendency for the diets
of smokers to be low in vegetables and fruits, and for smok-
ers to have relatively lower body mass indices, residual con-
founding is a particular concern for these exposures.
Wherever possible, detailed stratification of the data accord-
ing to smoking status was obtained.
7.1.5  Evidence and judgements 
In total, 238 publications were included in the systematic lit-
erature review (SLR) for cancers of the mouth, pharynx, and
larynx. Fuller summaries of the epidemiological, experi-
mental, and mechanistic evidence are in Chapters 4–6. 
The full SLR is contained on the CD included with this
Report.
7.1.5.1  Non-starchy vegetables 
(Also see chapter 4.2.5.1.)
A total of 31 case-control studies and 3 ecological studies
examined non-starchy vegetables. Other groupings exam-
ined were non-starchy vegetables and fruits (in combination)
(1 cohort, 6 case-control); raw vegetables (23 case-control);
cruciferous vegetables (1 cohort, 14 case-control, and 1 eco-
logical); green, leafy vegetables (1 cohort, 10 case-control);
carrots (3 cohort, 18 case-control); and tomatoes (1 cohort,
12 case-control). Most of the studies for the exposures
grouped under non-starchy vegetables showed a decreased
risk with increased intake. Meta-analysis showed a 28 per
cent decreased risk per 50 g per day (figure 4.2.2). The 
dose-response relationship suggested that the greatest effect
was produced by the first increment; that is, that some
vegetable consumption confers a protective effect com-
pared with none (figure 4.2.3). However, it is not clear that
the effect continues in a linear fashion. It is possible that 
this is an artificial phenomenon produced by residual
confounding due to smoking. There is some unexplained
heterogeneity.
This is a wide and disparate category, and many different
plant food constituents are represented that could contribute
to a protective effect of non-starchy vegetables. These include
dietary fibre, carotenoids, folate, selenium, glucosinolates,
dithiolthiones, indoles, coumarins, ascorbate, chlorophyll,
flavonoids, allylsulphides, flavonoids, and phytoestrogens,
some of which are potentially antioxidants. Antioxidants trap
free radicals and reactive oxygen molecules, protecting
against oxidation damage. It is difficult to unravel the rela-
tive importance of each constituent and is likely that any pro-
tective effect may result from a combination of influences on
several pathways involved in carcinogenesis.
A substantial amount of consistent evidence on non-
starchy vegetables, including specific subtypes mostly
from case-control studies, shows a dose-response
relationship. There is evidence for plausible
mechanisms. Non-starchy vegetables probably protect
against mouth, pharynx, and larynx cancers. 
The Panel is aware that since the conclusion of the SLR, two
cohort15 16 and two case-control studies17 18 have been pub-
lished. This new information does not change the Panel judge-
ment. Also see box 3.8. 
7.1.5.2  Fruits 
(Also see chapter 4.2.5.2.)
A total of 1 cohort study, 35 case-control studies, and 2 eco-
logical studies investigated fruits. Other groupings examined
were citrus fruits (1 cohort, 23 case-control, 1 ecological),
and non-starchy vegetables and fruits (in combination) 
(1 cohort, 6 case-control). Most studies showed decreased
risk. Meta-analysis showed a 18 per cent decreased risk per
100 g per day for general fruits, or 24 per cent per 50 g per
day for citrus fruits (figures 4.2.17 and 4.2.18). The dose-
response relationship suggested that the greatest effect was
produced by the first increment; that is, that some fruit con-
sumption confers a protective effect compared to none.
However, it is not clear that the effect continues in a linear
fashion (figures 4.2.19 and 4.2.20). It is possible that this is
an artificial phenomenon produced by residual confounding
due to smoking. 
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Studies that reported on combined intake of non-starchy
vegetables and fruits showed evidence of an association with
decreased risk (see 7.1.5.1).
Fruits are sources of vitamin C and other antioxidants such
as carotenoids, phenols, and flavonoids, as well as other
potentially bioactive phytochemicals. Antioxidants trap free
radicals and reactive oxygen molecules, protecting against
oxidation damage. It is difficult to unravel the relative impor-
tance of each constituent, and is likely that any protective
effect may result from a combination of influences on sev-
eral pathways involved in carcinogenesis.
The evidence, including that on fruit subtypes, though
mostly from case-control studies, is consistent, with a
dose-response relationship. There is evidence for
plausible mechanisms. Fruits probably protect against
mouth, pharynx, and larynx cancers.
The Panel is aware that since the conclusion of the SLR, two
cohort studies15 16 and one case-control study18 have been pub-
lished. This new information does not change the Panel judge-
ment. Also see box 3.8.
7.1.5.3  Foods containing carotenoids 
(Also see chapter 4.2.5.3.)
Two cohort studies investigated total serum carotenoids, 10
case-control studies investigated pro-vitamin A carotenoids,
and 2 case-control studies investigated total dietary
carotenoids. Other groupings examined were dietary alpha-
carotene (1 cohort); serum alpha-carotene (3 cohort);
dietary beta-carotene (1 cohort, 7 case-control); serum beta-
carotene (3 cohort, 2 case-control); dietary lycopene (1
cohort, 4 case-control); and serum lycopene (1 cohort, 1
case-control). All of the serum studies and most of the
dietary studies showed decreased risk with increased mea-
sures of carotenoids. Meta-analysis was not possible.
Information comes predominantly from dietary sources, not
supplements; therefore no effect can be attributed to
carotenoids separate from foods.
In trials, carotenoids have been effective at reducing cel-
lular damage within the mouth, which may act as a precur-
sor to cancers in this region. Carotenoids are antioxidants.
Oxidative damage is linked to the formation of tumours
through several mechanisms. Oxidative stress damages DNA.
This might be prevented or limited by dietary antioxidants
found in fruits and vegetables. 
There is a considerable amount of evidence, and
though it is for different carotenoid types, it is
generally consistent, with a dose-response
relationship. There is evidence for plausible
mechanisms. Foods containing carotenoids probably
protect against mouth, pharynx, and larynx cancers.
The Panel is aware that since the conclusion of the SLR, one
cohort study15 has been published. This new information does
not change the Panel judgement. Also see box 3.8.
7.1.5.4  Maté 
(Also see chapter 4.7.5.6.1.)
Six case-control studies were examined. All reported
increased risk from drinking maté, which was statistically sig-
nificant in four.
There is some biological plausibility. Maté is a herbal infu-
sion traditionally drunk very hot through a metal straw. This
produces heat damage in the mouth, pharynx, and larynx.
Repeated damage of this nature could lead to cancer.
Chemical carcinogenesis from constituents of maté has also
been postulated.19 20
The evidence is sparse. There is limited evidence
suggesting that maté is a cause of mouth, pharynx, and
larynx cancers. 
7.1.5.5  Alcoholic drinks
(Also see chapter 4.8.5.1.) 
Five cohort studies, 89 case-control studies, and 4 ecologi-
cal studies investigated alcoholic drinks. All cohort studies
and nearly all case-control studies showed increased risk.
Meta-analysis of cohort data showed a 24 per cent increased
risk per drink/week; case-control data showed a 3 per cent
increased risk per drink/week (figure 4.8.2). The cohort
studies showed a curvilinear dose-response relationship. 
It is biologically highly plausible that alcoholic drinks are
a cause of mouth, pharynx, and larynx cancers. IARC clas-
sifies alcohol as a Class 1 carcinogen. Reactive metabolites
of alcohol such as acetaldehyde can be carcinogenic. There
is also an interaction with smoking. Tobacco may induce spe-
cific mutations in DNA that are less efficiently repaired in the
presence of alcohol. Alcohol may also function as a solvent,
enhancing penetration of other carcinogenic molecules into
mucosal cells. Additionally, the effects of alcohol may be
mediated through the production of prostaglandins, lipid
peroxidation, and the generation of free radical oxygen
species. High consumers of alcohol may also have diets 
low in essential nutrients, making tissues susceptible to
carcinogenesis.
There is ample and consistent evidence, both from
case-control and cohort studies, with a dose-response
relationship. There is robust evidence for mechanisms
operating in humans. The evidence that alcoholic
drinks are a cause of mouth, pharynx, and larynx
cancers is convincing. Alcohol and tobacco together
increase the risk of these cancers more than either
acting independently. No threshold was identified.
The Panel is aware that since the conclusion of the SLR, one
cohort15 and four case-control studies21-24 have been published.
This new information does not change the Panel judgement.
Also see box 3.8.
7.1.5.6  Other exposures
Other exposures were evaluated. However, the data were
either of too low quality, too inconsistent, or the number of
studies too few to allow conclusions to be reached. These
were as follows: cereals (grains) and their products; starchy
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roots, tubers, and plantains; pulses (legumes); foods con-
taining dietary fibre; meat; poultry; fish; eggs; milk and dairy
products; total fat; foods containing animal fat; plant oils;
coffee; tea; frying, grilling (broiling), and barbecuing; pro-
tein; vitamin A; retinol; thiamin; riboflavin; niacin; folate;
vitamin C; vitamin E; iron; calcium; selenium; energy intake;
and body fatness. 
Fourteen case-control studies examined body fatness, as
measured by body mass index (BMI). Meta-analysis pro-
duced a statistically significant decreased risk with increased
BMI, and a dose-response relationship, but reverse causality
was implicated. That is, cancers of the mouth, pharynx, and
larynx cause significant weight loss, often before diagnosis.
Smoking is also associated with low BMI. For these reasons,
the data were judged insufficient to allow any conclusion to
be drawn.
7.1.6  Comparison with previous report
The main differences between this Report and the previous
report are summarised here, together with any reasons for
these differences. When the findings here and in the previ-
ous report are similar, this is usually not mentioned. Minor
differences are not always mentioned. 
7.1.6.1  General
The criteria used by the previous report for gauging the
strength of the evidence were not identical to the criteria
used for this Report. In particular, a judgement of ‘convinc-
ing’ causal association was not conditional on supportive evi-
dence from prospective studies. This Report does make that
requirement. It also emphasises the special importance of
randomised controlled trials when applied appropriately,
especially where the results are positive. In these respects,
the criteria used for this Report are more stringent. See box
3.8 in chapter 3.
7.1.6.2  Specific
The previous report separated cancers of the mouth and
pharynx from cancer of the larynx. The panel responsible for
the previous report judged the evidence that vegetables and
fruits protect against cancers of the mouth and pharynx to
be convincing. It also judged that these foods probably pro-
tect against cancer of the larynx. Vitamin C was judged to
be possibly protective against cancers of the mouth and lar-
ynx. There is still little information from cohort studies,
which weakens the evidence base. 
Evidence accumulated since the mid-1990s confirms the
previous judgement that the evidence that alcoholic drinks
are a cause of oral cancers is convincing. And in the previ-
ous report, the evidence that maté is a cause of oral cancers
was judged possible for cancers of the mouth and pharynx.
7.1.7  Conclusions
The Panel concludes:
The evidence that alcoholic drinks are a cause of cancers of
the mouth, pharynx, and larynx is convincing. The risk is
multiplied when drinkers of alcohol also smoke tobacco. 
Non-starchy vegetables, fruits, and foods containing
carotenoids probably protect against these cancers. 
There is limited evidence suggesting that maté, a herbal
infusion, when drunk scalding hot through a metal straw, as
is traditional in some parts of South America, is a cause of
oral cancer.
The main cause of these cancers is smoking and other use
of and exposure to tobacco.
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7.2  Nasopharynx
Cancer of the nasopharynx is the 23rd most common type
of cancer worldwide. About 80 000 cases were recorded in
2002, accounting for less than 1 per cent overall. In most
parts of the world, this cancer is rare. It is relatively
common on and near the southern Chinese littoral, and
among communities who have migrated from that part of
China to other countries. It is twice as common in men as
in women. It is the 20th most common cause of death
from cancer. 
Overall, the Panel judges that there is a specific role for
Cantonese-style salted fish in the causation of cancer of
the nasopharynx.
The Panel judges as follows: 
Cantonese-style salted fish is probably a cause of
nasopharyngeal cancer. This judgement does not apply to
fish salted or fermented by any other method. 
There is limited evidence suggesting that non-starchy
vegetables and fruits protect against this cancer. 
Other causes of this cancer include tobacco smoking and
infection with the Epstein-Barr virus. 
In final summary, the strongest evidence, corresponding
to judgements of “convincing” and “probable”, shows that
Cantonese-style salted fish is a probable cause of this
cancer.
The nasopharynx is the top portion of the pharynx, the mus-
cular cavity leading from the nose and mouth to the larynx. 
Cancers in this area arise predominantly from epithelial
cells, with squamous cell carcinomas being the most com-
mon. Carcinomas constitute 75–90 per cent of nasopharyn-
geal cancers in low-risk populations, and virtually 100 per
cent in high-risk populations.25 Nasopharyngeal squamous
cell carcinomas are included here; other types are not.
7.2.1  Trends, incidence, and survival
Age-adjusted rates of nasopharyngeal cancer are decreasing
in areas of high incidence, such as Hong Kong and
Singapore.25
This cancer is predominantly a disease of low-income
countries, with overall rates more than three times higher in
middle- to low- than in high-income countries. Incidence is
also higher in certain ethnic groups — for instance Chinese
and also Malay and Filipino people living in south-eastern
Asia.
Around the world, age-adjusted incidence rates range
from 20–30 per 100 000 people in parts of Hong Kong and
south-eastern Asia, to less than 1 per 100 000 across most
of the Americas and Europe. 
This cancer also occurs in northern Africa, parts of the
Middle East, and Micronesia and Polynesia. However, the
highest rates are among Cantonese people who live in the
central region of Guangdong Province in southern China,
which includes Hong Kong.25 Migrant populations from this
province carry the risk levels of the original population, but
this decreases over generations.26 Rates are approximately
twice as high in men as in women.2
The age profile of nasopharyngeal cancer is different in
areas of high compared with low incidence. Risk increases
with age in most of the world, but in Guangdong Province
it peaks between the ages of 45 and 54. In populations
where there is a moderate incidence of this cancer, risk
peaks in young adults.25 Overall 5-year survival rates are
around 50 per cent.27 Also see box 7.1.1.
There are two variants of nasopharyngeal squamous cell
carcinoma: keratinising and non-keratinising. The non-ker-
atinising variant can be further divided into differentiated
or undifferentiated. In North America, the proportions of
each are 25, 12, and 63 per cent, respectively. In southern
China, the distribution is different: 2, 3, and 95 per cent.27
FOOD, NUTRITION, PHYSICAL ACTIVITY, 
AND CANCER OF THE NASOPHARYNX
In the judgement of the Panel, the factors listed below modify the risk of
cancer of the nasopharynx. Judgements are graded according to the
strength of the evidence.
DECREASES RISK INCREASES RISK
Convincing
Probable Cantonese-style
salted fish1
Limited — Non-starchy vegetables2
suggestive Fruits2
Limited — Cereals (grains) and their products; nuts and seeds;
no conclusion herbs, spices, and condiments; meat; fish; shellfish
and seafood; eggs; plant oils; tea; alcohol; salted
plant food; Chinese-style pickled cabbage; pickled
radish; pickled mustard leaf; Chinese-style preserved
salted eggs; fermented tofu and soya products
Substantial 
effect on risk None identified
unlikely
1 This style of preparation is characterised by treatment with less salt than
typically used, and fermentation during the drying process due to relatively
high outdoor temperature and moisture levels. This conclusion does not
apply to fish prepared (or salted) by other means. 
2 Judgements on vegetables and fruits do not include those preserved by
salting and/or pickling.
For an explanation of all the terms used in the matrix, 
please see chapter 3.5.1, the text of this section, 
and the glossary.
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7.2.2  Pathogenesis
Variation in the distribution of keratinising squamous cell
carcinoma and the two forms of non-keratinising carcinoma
in North America and southern China, together with the dif-
ferent age profiles in the two regions, suggests that differ-
ent disease paths may occur in high-incidence populations.
Patches of dysplasia are the first recognisable precancer-
ous lesions; latent infection with the Epstein-Barr virus (see
box 7.2.1) leads to severe dysplasia. The subsequent genet-
ic and chromosomal changes in these lesions lead to inva-
sive carcinoma.28
7.2.3  Other established causes 
(Also see chapter 2.4 and 7.1.3.1.) 
Tobacco use. Smoking tobacco is a cause of nasopharyngeal
cancer.
Occupational exposure. Occupational exposure to formalde-
hyde is also a cause of this cancer.33-35
Infectious agents. Epstein-Barr virus infection is a cause of
nasopharyngeal cancer (see box 7.2.1).30 It may be neces-
sary but is not a sufficient cause. 
7.2.4  Interpretation of the evidence
7.2.4.1  General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7. 
‘Relative risk’ is used in this Report to denote ratio mea-
sures of effect, including ‘risk ratios’, ‘rate ratios’, ‘hazard
ratios’, and ‘odds ratios’.
7.2.4.2  Specific 
Considerations specific to cancer of the nasopharynx and to
Cantonese-style salted fish, include: 
Classification. The term ‘salted’ is an incomplete and perhaps
misleading term, given that the fish is also fermented. See
the footnote of the matrix for this section, and also 7.2.5.3.
Confounding. It is not possible to exclude a genetic compo-
nent. Those at highest risk are Cantonese-speaking commu-
nities living in or originally from Guangdong Province. 
Production, preservation, processing, preparation. The
method of salting or the type of fish salted varies between
regions. The presence of nitrates and nitrosamines (see box
4.3.2) in the fish also varies.
7.2.5  Evidence and judgements 
In total, 74 publications were included in the SLR for
nasopharyngeal cancer. Fuller summaries of the epidemio-
logical, experimental, and mechanistic evidence are to be
found in Chapters 4–6.
The full SLR is contained on the CD included with this
Report.
7.2.5.1  Non-starchy vegetables 
(Also see chapter 4.2.5.1.)
Five case-control studies and two ecological studies investi-
gated non-starchy vegetables; a further four case-control
studies investigated green vegetables. Preserved vegetables
were excluded from all categories. Nearly all of the studies
showed decreased risk with increased intake.
This is a wide and disparate category, and many different
plant food constituents are represented that could contribute
to a protective effect of non-starchy vegetables. These
include dietary fibre, carotenoids, folate, selenium, glucosi-
nolates, dithiolthiones, indoles, coumarins, ascorbate,
chlorophyll, flavonoids, allylsulphides, flavonoids, and phy-
toestrogens, some of which are potentially antioxidants.
Antioxidants trap free radicals and reactive oxygen mole-
cules, protecting against oxidation damage. It is difficult to
unravel the relative importance of each constituent and it 
is likely that any protective effect may result from a
combination of influences on several pathways involved in
carcinogenesis.
The evidence on non-starchy vegetables is sparse but
generally consistent. There is limited evidence
suggesting that non-starchy vegetables protect against
nasopharyngeal cancer.
7.2.5.2  Fruits 
(Also see chapter 4.2.5.2.)
Most adults are infected with the Epstein-Barr virus, but rela-
tively few will ever develop the cancers of which this virus is a
contributory or necessary cause. Other factors beyond infection
with the virus are needed to lead to the development of can-
cer. Environmental factors including some dietary factors are
thought to render precancerous epithelial cells sensitive to
Epstein-Barr virus infection, which then triggers malignancy.29
Epstein-Barr virus is a DNA virus of the herpes family. It pri-
marily infects B lymphocytes (white blood cells that produce
antibodies), though it can also infect epithelial cells. Infection
usually occurs in childhood and does not usually produce symp-
toms, but in adults it can cause infectious mononucleosis or glan-
dular fever. It is particularly associated with undifferentiated
nasopharyngeal carcinoma, the most prevalent type.30 31
In nasopharyngeal carcinoma, all of the tumour cells carry
viral DNA in a monoclonal form. This means that Epstein-Barr
virus infection must have occurred quite early in the cancer
process, before rapid growth.32 It is not normally possible to
detect Epstein-Barr virus infection in non-cancerous nasopha-
ryngeal cells.31
Box 7.2.1 Epstein-Barr virus
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Six case-control studies investigated general fruits and a
further five case-control studies investigated citrus fruits.
Preserved fruits were excluded from all categories. Most of
the studies for general fruits and all of the studies for citrus
fruits showed a decreased risk. 
This is a wide and disparate category, and many different
plant food constituents are represented that could contribute
to a protective effect of fruits. These include dietary fibre,
carotenoids, folate, selenium, glucosinolates, dithiolthiones,
indoles, coumarins, ascorbate, chlorophyll, flavonoids, allyl-
sulphides, flavonoids, and phytoestrogens, some of which are
potentially antioxidants. Antioxidants trap free radicals and
reactive oxygen molecules, protecting against oxidation dam-
age. It is difficult to unravel the relative importance of each
constituent and likely that a protective effect may result from
a combination of influences on several pathways involved in
carcinogenesis. In addition, some components of citrus fruits
have been shown directly to inhibit Epstein-Barr virus acti-
vation.36
The evidence, from case-control studies only, is sparse.
There is limited evidence suggesting that fruits protect
against nasopharyngeal cancer.
7.2.5.3  Cantonese-style salted fish 
(Also see chapter 4.3.5.3.1.)
One cohort study and 21 case-control studies of adult diets
were examined. The single cohort study and most of the
case-control studies showed increased risk with higher
intake. Meta-analysis showed a 28 per cent increased risk per
time eaten per week (figure 4.3.9). There is some hetero-
geneity, not all readily explained. Childhood diet data impli-
cate an increased risk with early-life exposure. 
Cantonese-style salted fish is dried in natural conditions
outdoors. As prepared on the southern Chinese littoral, it is
characterised by treatment with less salt than used on the
northern littoral; it is also subject to fermentation during the
drying process in the warm, damp climate of southern China. 
The high content of nitrate and nitrosamines may account
for some of the increased risk associated with salted fish
intake. Nitrosamines are known mutagens and animal car-
cinogens that induce gene mutation. The direct role of
nitrosamines in the carcinogenic process is supported by the
increased risk for nasopharyngeal cancer development in
people who have a variant allele of CYP2E1. This enzyme is
expressed in the nasopharynx and is involved in the meta-
bolic activation of nitrosamines to carcinogenic adducts.37
Additional evidence has suggested a component of salted 
fish may contain Epstein-Barr virus-activating substances,
although the specific agents of action have not been
identified.38
Evidence from several case-control studies is
consistent and shows a dose-response effect. There is
evidence for plausible mechanisms. Cantonese-style
salted fish is probably a cause of nasopharyngeal
cancer. 
7.2.5.4  Other exposures 
Other exposures were evaluated. However, the data were
either of too low quality, too inconsistent, or the number of
studies too few to allow conclusions to be reached. These
were as follows: cereals (grains) and their products; nuts and
seeds; meat; fish; shellfish and seafood; eggs; herbs, spices,
and condiments; tea; alcohol; plant oils; salted plant foods;
Chinese-style pickled cabbage; pickled radish; pickled mus-
tard leaf; Chinese-style preserved salted eggs; and ferment-
ed tofu/soya products.
7.2.6  Comparison with previous report
7.2.6.1  General
See 7.1.6.1, and box 3.8.
7.2.6.2  Specific
The previous report judged the evidence that Cantonese-style
salted fish is a cause of nasopharyngeal cancer to be con-
vincing. No further cohort studies have been conducted since
the mid-1990s.
7.2.7  Conclusions
The Panel concludes:
Cantonese-style salted fish is probably a cause of nasopha-
ryngeal cancer. This does not apply to fish salted or
fermented by any other method. 
There is limited evidence suggesting that non-starchy
vegetables, and also fruits, protect against this cancer. 
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7.3  Oesophagus 
Cancer of the oesophagus is the eighth most common type
of cancer worldwide. Around 460 000 cases occurred in
2002, accounting for over 4 per cent overall. There are two
common types of oesophageal cancer, adenocarcinoma
and squamous cell carcinoma, which have different
patterns of occurrence. In general this cancer is not
increasing, except for adenocarcinomas, which are
increasing in high-income countries. Oesophageal cancer
is twice as common in men as in women. It is usually fatal
and is the sixth most common cause of death from cancer. 
Overall, the Panel judges that food and nutrition and
body fatness play an important role in the prevention and
causation of cancer of the oesophagus. 
The Panel judges as follows: 
The evidence that alcoholic drinks are a cause of cancer of
the oesophagus is convincing. The risk is multiplied when
drinkers of alcohol also smoke tobacco. The evidence that
greater body fatness is a cause of oesophageal
adenocarcinoma is also convincing. Maté, a herbal
infusion, when drunk scalding hot through a metal straw,
as is traditional in parts of South America, is probably a
cause of this cancer.
Non-starchy vegetables, fruits, and foods containing
beta-carotene and/or vitamin C probably protect against
oesophageal cancer. 
There is limited evidence suggesting that foods
containing dietary fibre, folate, pyridoxine, or vitamin E
protect against this cancer, and that red meat, processed
meat, and high-temperature drinks are causes of this
cancer. 
See chapter 8 for evidence and judgements on factors
that modify the risk of body fatness, including physical
activity and sedentary ways of life, the energy density of
foods and drinks, and breastfeeding.
Other causes of this cancer include smoking tobacco and
chewing betel quid. It has been estimated that most cases
of oesophageal cancer are preventable by appropriate diets
and associated factors, together with not smoking. 
In final summary, the strongest evidence, corresponding
to judgements of “convincing” and “probable”, shows that
alcoholic drinks and body fatness are a cause of this
cancer (adenocarcinoma only); that non-starchy
vegetables, fruits, and foods containing beta-carotene
and/or vitamin C are probably protective; and that maté,
as traditionally drunk in parts of South America, is
probably a cause of this cancer.
The oesophagus is the muscular tube through which food
passes from the pharynx to the stomach. 
The oesophagus is lined over most of its length by squa-
mous epithelial cells, where squamous cell carcinomas occur.
The portion just above the gastric junction (where the
oesophagus meets the stomach) is lined by columnar
FOOD, NUTRITION, PHYSICAL ACTIVITY, AND
CANCER OF THE OESOPHAGUS
In the judgement of the Panel, the factors listed below modify the risk of
cancer of the oesophagus. Judgements are graded according to the
strength of the evidence.
DECREASES RISK INCREASES RISK
Convincing Alcoholic drinks
Body fatness1
Probable Non-starchy Maté4
vegetables2
Fruits2
Foods containing 
beta-carotene3
Foods containing 
vitamin C3
Limited — Foods containing Red meat6
suggestive dietary fibre3 Processed meat7
Foods containing High-temperature 
folate3 drinks
Foods containing
pyridoxine3 5
Foods containing
vitamin E3
Limited — Cereals (grains) and their products; starchy roots,
no conclusion tubers, and plantains; pulses (legumes); soya and
soya products; herbs, spices, and condiments;
poultry; fish; eggs; milk and dairy products; total
fat; saturated fatty acids; monounsaturated fatty
acids; polyunsaturated fatty acids; sugary foods and
drinks; salt; salting; fermenting; pickling; smoked
and cured foods; nitrates and nitrites; frying;
grilling (broiling) and barbecuing (charbroiling);
protein; vitamin A; retinol; thiamin; riboflavin;
calcium; iron; zinc; pro-vitamin A carotenoids; 
beta-cryptoxanthin; Seventh-day Adventist diets;
adult attained height; energy intake
Substantial 
effect on risk None identified
unlikely
1 For oesophageal adenocarcinomas only.
2 Judgements on vegetables and fruits do not include those preserved by
salting and/or pickling.
3 Includes both foods naturally containing the constituent and foods which
have the constituent added (see chapter 3.5.3). Dietary fibre is contained in
plant foods (see box 4.1.2 and chapter 4.2).
4 As drunk traditionally in parts of South America, scalding hot through a
metal straw. Any increased risk of cancer is judged to be caused by epithelial
damage resulting from the heat, and not by the herb itself. 
5 Vitamin B6.
6 The term ‘red meat’ refers to beef, pork, lamb, and goat from domesticated
animals. 
7 The term ‘processed meat’ refers to meats preserved by smoking, curing, 
or salting, or addition of chemical preservatives.
For an explanation of all the terms used in the matrix, 
please see chapter 3.5.1, the text of this section, 
and the glossary.
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epithelial cells, from which adenocarcinomas can develop.4
Adenocarcinoma of the oesophagus shows similarities with
adenocarcinoma of the gastric cardia (see 7.5). Each type
accounts for around half of all cases and both types are
included in this Report.
7.3.1  Trends, incidence, and survival
Age-adjusted rates of oesophageal squamous cell carcinomas
are generally declining, although in some high-income
regions, overall rates of oesophageal cancer are increasing.
For instance, the incidence of oesophageal adenocarcinoma
is rising rapidly in Europe and North America.39 In the USA,
adenocarcinomas in white men increased fivefold between
1974 and the end of the 20th century, making it the fastest
increasing cancer studied in that country.40
Oesophageal cancer is, however, mainly a disease of low-
income countries, occurring around four times more com-
monly in low- to middle- than in high-income countries.
Around the world, age-adjusted incidence rates range from
more than 20 per 100 000 people in parts of eastern and
southern Africa and eastern and south-central Asia to less
than 5 per 100 000 in northern, western, and middle Africa,
Central America, and south-eastern Asia. Localised peaks in
incidence have been reported to exceed 100 per 100 000. For
instance, in rural Linxian, China, oesophageal cancer is the
leading cause of death.41 In the USA, rates are higher among
African-American people than in white people. Worldwide,
rates are higher in men than in women, by around five to
two. In most populations, risk increases with age, with few
cases diagnosed in people under 40.
Oesophageal cancer does not usually produce symptoms
at the early stages, so the disease is generally at an advanced
stage when diagnosed. Survival rates are poor: around 10
per cent at 5 years.3 6 This type of cancer accounts for a lit-
tle over 4 per cent of all cancer incidence, but almost 6 per
cent of all cancer deaths worldwide. Also see box 7.1.1.
7.3.2  Pathogenesis
The epithelial cells lining the oesophagus are exposed direct-
ly to carcinogens in food. Repeated exposures, for instance,
to burns from very high-temperature drinks or irritation from
the direct action of alcohol, may cause inflammation.
The role of irritation and inflammation in the development
of oesophageal cancer is supported by the finding that gas-
tro-oesophageal reflux (where stomach acid flows upwards
to the oesophagus) increases the risk of adenocarcinomas by
as much as 40-fold.42 Barrett’s oesophagus is a probable
intermediate stage between gastro-oesophageal reflux dis-
ease, with repeated gastro-oesophageal reflux, and devel-
oping oesophageal adenocarcinoma.43 Barrett’s oesophagus
is an acquired condition in which squamous cells are
replaced by columnar epithelial cells; autopsy studies sug-
gest that it usually remains undiagnosed.44 The increasing
use of endoscopes to investigate abdominal symptoms has
resulted in the earlier detection of a small proportion of ade-
nocarcinomas in people with Barrett’s oesophagus.4
Some people have an abnormally strong lower
oesophageal sphincter (a condition called oesophageal
achalasia), which means swallowed food is retained in the
oesophagus. It causes a 15-fold increase in the risk of squa-
mous cell carcinomas, which may be due to chronic irrita-
tion of the lining of the oesophagus or its increased contact
with food-borne carcinogens.45 46
Tylosis A is the late-onset, inherited familial disease where
the outer horny layer of the skin thickens, affecting the palms
and soles (hyperkeratosis). Palmar and plantar hyperker-
atosis is the single proven genetic abnormality associated
with a 25 per cent lifetime incidence of squamous cell can-
cer of the oesophagus.47
7.3.3  Other established causes 
(Also see chapter 2.4 and 7.1.3.1.) 
Other diseases. Gastric reflux and oesophageal achalasia
both increase the risk of, and thus can be seen as a cause of,
this cancer. Barrett’s oesophagus can be seen as a precan-
cerous condition.
Tobacco use. Smoking is a cause both of oesophageal squa-
mous cell carcinoma and of adenocarcinomas, increasing the
risk approximately twofold.10 39 Smoking is estimated to
cause around 40 per cent of all cases. Chewing betel quid
(on its own and also with tobacco quid) is also a cause of
oesophageal cancers.11
Infectious agents. HPV (see box 7.13.1) is also a cause of this
cancer, and is estimated to be a cause of almost 25 per cent
of squamous cell carcinomas. Like other infectious agents, it
may be a necessary cause but is not a sufficient cause. It may
also play a role in the divergent geographical distributions
of this cancer.48
7.3.4  Interpretation of the evidence
7.3.4.1  General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7. 
‘Relative risk’ is used in this Report to denote ratio mea-
sures of effect, including ‘risk ratios’, ‘rate ratios’, ‘hazard
ratios’, and ‘odds ratios’.
7.3.4.2  Specific 
Considerations specific to cancer of the oesophagus include: 
Classification. There are different types of oesophageal can-
cer. Squamous cell carcinomas have different geographical
and time trends from adenocarcinomas. Each follows a dif-
ferent disease path, and may have different associated risk
factors. However, there were only sufficient data to conduct
separate analyses for body fatness. Therefore the ratio of
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squamous cell carcinomas to adenocarcinomas in each study
is a potential cause of heterogeneity in all other summaries.
The oesophageal-gastric junction and gastric cardia are also
lined with columnar epithelial cells. Cancers in these areas
are often grouped with oesophageal cancers, although they
may also be classed as stomach cancers (see 7.5).4 Different
approaches or definitions in different studies are another
potential source of heterogeneity.
Confounding. Smoking is the main single cause of this can-
cer. High-quality studies adjust for smoking.
7.3.5  Evidence and judgements
In total, 262 publications were included in the SLR for
oesophageal cancer. Fuller summaries of the epidemiologi-
cal, experimental, and mechanistic evidence are to be found
in Chapters 4–6.
The full SLR is contained on the CD included with this
Report.
7.3.5.1  Foods containing dietary fibre
(Also see chapter 4.1.5.3.)
One cohort study, nine case-control studies, and two eco-
logical studies investigated dietary fibre. Most were sugges-
tive of a relationship with decreased oesophageal cancer
incidence. Data come predominantly from dietary sources,
not supplements; therefore no specific effect can be attrib-
uted specifically to dietary fibre itself, which is interpreted
simply as a marker of consumption of foods containing it.
It is not clear whether there is an as yet unknown mech-
anism through which dietary fibre could exert a direct effect
on oesophageal cancer, or whether the effect is mediated
through other constituents of the foods (such as cereals
(grains), vegetables, and fruits) that contain dietary fibre.
There is limited evidence, from sparse and inconsistent
case-control studies only, suggesting that foods
containing dietary fibre protect against oesophageal
cancer.
7.3.5.2  Non-starchy vegetables 
(Also see chapter 4.2.5.1.)
A total of 5 cohort studies, 37 case-control studies, and 6 eco-
logical studies investigated non-starchy vegetables. Other
groupings examined were vegetable and fruit consumption
(combined) (8 case-control), raw vegetables (16 case-con-
trol), cruciferous vegetables (1 cohort, 5 case-control), alli-
um vegetables (1 cohort, 8 case-control), green, leafy
vegetables (1 cohort, 11 case-control), and tomatoes (1
cohort, 9 case-control). All of the studies of raw vegetables
and most of the other studies showed decreased risk with
increased intake. Meta-analysis of case-control data showed
a 31 per cent decreased risk per 50 g of raw vegetables per
day (figures 4.2.6 and 4.2.7). Raw vegetables have a more
consistent definition than non-starchy vegetables, which may
include preserved vegetables and a variety of cooking meth-
ods, leading to increased heterogeneity.
This is a wide and disparate category, and many different
plant food constituents are represented that could contribute
to a protective effect of non-starchy vegetables. These
include dietary fibre, carotenoids, folate, selenium, glucosi-
nolates, dithiolthiones, indoles, coumarins, ascorbate,
chlorophyll, flavonoids, allylsulphides, flavonoids, and phy-
toestrogens, some of which are potentially antioxidants.
Antioxidants trap free radicals and reactive oxygen mole-
cules, protecting against oxidation damage. It is difficult to
unravel the relative importance of each constituent and it is
likely that any protective effect may result from a combina-
tion of influences on several pathways involved in carcino-
genesis.
There is more evidence, including on vegetable
subtypes, from case-control studies than from cohort
studies, but both are moderately consistent, and there
is some evidence for a dose-response relationship.
There is evidence for plausible mechanisms (see
chapter 4.2.5.1). Non-starchy vegetables probably
protect against oesophageal cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort49 and two case-control studies17 50 have been published.
This new information does not change the Panel judgement.
Also see box 3.8.
7.3.5.3  Fruits 
(Also see chapter 4.2.5.2.)
A total of 4 cohort studies, 36 case-control studies, and 7
ecological studies investigated fruits; and 1 cohort study, 16
case-control studies, and 1 ecological study investigated cit-
rus fruits. All of the cohort studies and most of the other
studies showed decreased risk with increased intake. Meta-
analysis of case-control data showed a 22 per cent decreased
risk per 50 g of fruit per day, and 30 per cent decreased risk
per 50 g of citrus fruit per day (figures 4.2.22 and 4.2.24).
A dose-response relationship was apparent. Heterogeneity
could not be fully explained.
Fruits are sources of vitamin C and other antioxidants,
such as carotenoids, phenols, and flavonoids, as well as other
potentially bioactive phytochemicals. Antioxidants trap free
radicals and reactive oxygen molecules, protecting against
oxidation damage. 
It is difficult to unravel the relative importance of each
constituent and it is likely that any protective effect may
result from a combination of influences on several pathways
involved in carcinogenesis.
The evidence, including that on fruit subtypes, though
mostly from case-control studies, is consistent, with a
dose-response relationship. There is evidence for
plausible mechanisms. Fruits probably protect against
oesophageal cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort49 and two case-control studies50 51 have been published.
This new information does not change the Panel judgement.
Also see box 3.8.
256
P A R T  2  •  E V I D E N C E  A N D  J U D G E M E N T S
7.3.5.4  Foods containing folate 
(Also see chapter 4.2.5.4.)
Eight case-control studies investigated dietary folate and two
case-control studies investigated red-cell and plasma folate.
All studies showed a relationship with decreased cancer inci-
dence. Data come predominantly from dietary sources, not
supplements; therefore no effect can be attributed to folate
separate from foods.
Folate plays an important role in the synthesis, repair, and
methylation of DNA. Abnormal DNA methylation has been
linked to aberrant gene expression and to cancers at sever-
al sites. Folate may also reduce HPV proliferation in cells.
The evidence, from case-control studies only, is sparse.
There is limited evidence suggesting that folate
protects against oesophageal cancer.
The Panel is aware that since the conclusion of the SLR, one
case-control study52 has been published. This new information
does not change the Panel judgement. Also see box 3.8.
7.3.5.5  Foods containing pyridoxine (vitamin B6)
(Also see chapter 4.2.5.5.)
Six case-control studies investigated foods containing pyri-
doxine and oesophageal cancer.
All six studies showed a relationship between pyridoxine
consumption and reduced risk of oesophageal cancer, with
none reporting contrary results.
Together with folate and cobalamin (vitamin B12), vita-
min B6 is involved in one-carbon metabolism and is impor-
tant for DNA synthesis, repair, and methylation.
The evidence, from case-control studies only, was
sparse. There is limited evidence suggesting that
pyridoxine protects against oesophageal cancer.
The Panel is aware that since the conclusion of the SLR, one
case-control study52 has been published. This new information
does not change the Panel judgement. Also see box 3.8.
7.3.5.6  Foods containing vitamin C 
(Also see chapter 4.2.5.6.)
One cohort study, 19 case-control studies, and 3 ecological
studies investigated vitamin C. The single cohort study and
nearly all of the case-control studies showed decreased risk
with increased intake.
Vitamin C traps free radicals and reactive oxygen mole-
cules, protecting DNA from mutagenic attack, protecting
against lipid peroxidation, reducing nitrates, and stimulat-
ing the immune system.
A substantial amount of consistent evidence is
available, both from cohort and from case-control
studies. Foods containing vitamin C probably protect
against oesophageal cancer.
The Panel is aware that since the conclusion of the SLR, one
case-control study53 has been published. This new information
does not change the Panel judgement. Also see box 3.8.
7.3.5.7  Foods containing vitamin E
(Also see chapter 4.2.5.7.)
One cohort study, nine case-control studies, and one eco-
logical study investigated dietary vitamin E; three cohort
studies and four case-control studies investigated serum vit-
amin E. All cohort studies and most case-control studies
showed decreased risk with increased intake; serum case-
control data were inconsistent.
Vitamin E is a family of eight compounds collectively
referred to as tocopherols. They can act as antioxidants and
free radical scavengers; however, few animal studies support
an anti-cancer effect.
Much of the evidence on vitamin E, mostly from case-
control studies, was of poor quality. There is limited
evidence suggesting that foods containing vitamin E
protect against oesophageal cancer.
7.3.5.8  Foods containing beta-carotene 
(Also see chapter 4.2.5.3.)
Ten case-control studies investigated dietary beta-carotene;
three cohort studies and one case-control study investigat-
ed serum beta-carotene; and one cohort study and three
case-control studies investigated dietary pro-vitamin A
carotenoids. Most of these studies showed a relationship 
with decreased risk. 
Data come predominantly from dietary sources, not sup-
plements; therefore no effect can be attributed to carotenoids
separate from foods.
Carotenoids are antioxidants, which can prevent lipid oxi-
dation and related oxidative stress. Some, such as beta-
carotene, are also pro-vitamin A carotenoids.
There is a substantial amount of consistent evidence
available from both cohort and case-control studies.
Foods containing beta-carotene probably protect
against oesophageal cancer.
7.3.5.9  Red meat
(Also see chapter 4.3.5.1.1.)
Twelve case-control studies investigated red meat. Most were
suggestive of increased risk.
There are several potential underlying mechanisms for a
positive association of red meat consumption with
oesophageal cancer, including the generation of potentially
carcinogenic N-nitroso compounds (see box 4.3.2). Some
meats are also cooked at high temperatures, resulting in the
production of heterocyclic amines and polycyclic aromatic
hydrocarbons (see box 4.3.4). Red meat contains haem iron.
Free iron can lead to the production of free radicals (see box
4.3.3).
There is limited evidence, from case-control studies,
some of which were poor quality, suggesting that red
meat is a cause of oesophageal cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort study54 has been published. This new information does
not change the Panel judgement. Also see box 3.8.
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7.3.5.10  Processed meat
(Also see chapter 4.3.5.1.2.)
Two cohort studies and eight case-control studies investi-
gated processed meat. Both cohort studies were suggestive
of increased risk; case-control data were inconsistent. The
definition of processed meat varies (see box 4.3.1), which
may increase heterogeneity.
Nitrates are produced endogenously in gastric acid and are
added as preservatives to processed meats (see box 4.3.2).
This may contribute to production of N-nitroso compounds
and increased exposure. These compounds are suspected
mutagens and carcinogens.55
Many processed meats also contain high levels of salt and
nitrite. Meats cooked at high temperatures can contain het-
erocyclic amines and polycyclic aromatic hydrocarbons (see
box 4.3.4). Haem promotes the formation of N-nitroso com-
pounds and also contains iron. Free iron can lead to the pro-
duction of free radicals (see box 4.3.3).
There is limited evidence, mostly from case-control
studies, suggesting that processed meat is a cause of
oesophageal cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort study54 has been published. This new information does
not change the Panel judgement. Also see box 3.8.
7.3.5.11  Maté
(Also see chapter 4.7.5.6.1.)
Eight case-control studies and one ecological study investi-
gated maté. Most were suggestive of an increased incidence
with higher maté consumption. Meta-analysis of case-
control data showed a 16 per cent increased risk per cup/
day (figure 4.7.5). A dose-response relationship was 
apparent.
There is some biological plausibility. Maté is a tea-like
beverage typically drunk very hot through a metal straw. 
This produces heat damage in the oesophagus. Repeated
damage of this nature can lead to cancer (see chapter
2.4.1.3). Chemical carcinogenesis from constituents of maté
has also been postulated.19 20
The evidence from case-control studies is consistent
and a dose-response relationship is apparent. There is
robust evidence for plausible mechanisms. Regular
consumption of maté, as drunk in the traditional style
in South America, is a probable cause of oesophageal
cancer.
7.3.5.12  High-temperature foods and drinks
(Also see chapter 4.7.5.7.)
Three cohort studies and 15 case-control studies investigat-
ed high-temperature foods and drinks. Most were suggestive
of a relationship between them and increased incidence of
oesophageal cancer but many were inadequately adjusted for
alcohol and smoking.
High-temperature foods and drinks can produce heat dam-
age in the oesophagus. Repeated damage of this nature can
predispose to the development of oesophageal cancer.
The evidence is inconsistent. There is limited evidence
suggesting that high-temperature drinks are a cause of
oesophageal cancer.
The Panel is aware that since the conclusion of the SLR, two
case-control studies50 51 have been published. This new infor-
mation does not change the Panel judgement. Also see box 3.8.
7.3.5.13  Alcoholic drinks 
(Also see chapter 4.8.5.1.)
Eight cohort studies, 56 case-control studies, and 10 eco-
logical studies investigated alcoholic drinks. Most studies
showed a relationship between increased consumption and
increased cancer incidence. Meta-analysis of case-control
data showed a 4 per cent increased risk per drink/week (fig-
ure 4.8.6). A dose-response relationship is apparent from
case-control data, with no clear threshold.
It is biologically highly plausible that alcoholic drinks are
a cause of oesophageal cancer. Reactive metabolites of alco-
hol such as acetaldehyde can be carcinogenic. Tobacco may
induce specific mutations in DNA that are less efficiently
repaired in the presence of alcohol. Alcohol may also func-
tion as a solvent, enhancing penetration of other carcino-
genic molecules into mucosal cells. Additionally, the effects
of alcohol may be mediated through the production of
prostaglandins, lipid peroxidation, and the generation of free
radical oxygen species. Lastly, heavy consumers of alcohol
may have diets low in essential nutrients, making tissues sus-
ceptible to carcinogenesis.
There is ample and consistent evidence, both from
cohort and case-control studies, with a dose-response
relationship. There is robust evidence for mechanisms
operating in humans. The evidence that alcoholic
drinks are a cause of oesophageal cancer is convincing.
No threshold was identified.
The Panel is aware that since the conclusion of the SLR, one
cohort56 and four case-control studies50 51 53 57 have been pub-
lished. This new information does not change the Panel judge-
ment. Also see box 3.8.
7.3.5.14  Body fatness 
(Also see chapter 6.1.3.1.)
A sufficient number of studies investigated BMI to allow
squamous cell carcinomas and adenocarcinomas to be
analysed separately. While results were inconsistent for squa-
mous cell carcinomas and for all oesophageal cancers,
adenocarcinomas, when analysed separately, showed a con-
sistent increased risk with greater BMI. Three cohort stud-
ies and eight case-control studies investigated body fatness,
as measured by BMI and adenocarcinomas. All of the cohort
studies and most of the case-control studies showed
increased risk with increased BMI. Meta-analysis of case-con-
trol data showed a 55 per cent increased risk per 5 kg/m2
(figure 6.1.2). A dose-response relationship is apparent. This
is consistent with known geographical and time trends for
both BMI and adenocarcinomas.
It is biologically plausible that body fatness is a cause of
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oesophageal cancer. High body fatness is associated with
increased gastro-oesophageal reflux and Barrett’s oesopha-
gus. It also directly affects levels of many circulating hor-
mones, such as insulin, insulin-like growth factors, and
oestrogens, creating an environment that encourages car-
cinogenesis and discourages apoptosis (see box 2.4) Body
fatness stimulates the body’s inflammatory response, which
may contribute to the initiation and progression of several
cancers (see chapter 2.4.1.3).
The epidemiology is consistent with evidence of a
dose-response relationship. There is evidence for
plausible mechanisms that operate in humans. The
evidence that greater body fatness is a cause of
oesophageal adenocarcinoma is convincing.
The Panel is aware that since the conclusion of the SLR, two
cohort58 59 and five case-control studies51 53 60-62 have been pub-
lished. This new information does not change the Panel judge-
ment. Also see box 3.8.
7.3.5.15  Other exposures
Other exposures were evaluated. However, the data were
either too sparse, too inconsistent, or the number of studies
too few to allow conclusions to be reached. These were as
follows: cereals (grains) or their products; starchy roots,
tubers, and plantains; pulses (legumes); soya and soya prod-
ucts; herbs, condiments or spices; poultry; fish; eggs; milk
and dairy products; sugary foods and drinks; fermenting;
pickling; salt; salting; smoked and cured foods; nitrates and
nitrites; frying, grilling (broiling), and barbecuing; total fat;
saturated fatty acids; monounsaturated fatty acids; polyun-
saturated fatty acids; protein; vitamin A; retinol; pro-vitamin
A carotenoids; beta-cryptoxanthin; thiamin; riboflavin; iron;
calcium; zinc; energy intake; adult attained height; and
Seventh-day Adventist diets.
7.3.6  Comparison with previous report
7.3.6.1  General
See section 7.1.6.1 of this chapter, and box 3.8 in chapter 3.
7.3.6.2  Specific
The previous report judged the evidence that vegetables and
fruits protect against oesophageal cancer to be convincing.
Data published since then have been somewhat less consis-
tent.
At the time of the previous report, the evidence on body
fatness was unclear, because data on adenocarcinomas was
inadequate and not analysed separately.
The previous report judged it possible that carotenoids or
vitamin C protect against this cancer. The evidence base for
foods containing these nutrients is now stronger. The previ-
ous report judged it possible that maté and other very hot
drinks cause oesophageal cancer. The evidence on maté is
now stronger.
7.3.7  Conclusions
The Panel concludes:
The evidence that alcoholic drinks and body fatness (ade-
nocarcinomas only) are causes of cancer of the oesophagus
is convincing. The risk is multiplied when drinkers of alco-
hol also smoke tobacco. 
Non-starchy vegetables, fruits, and foods containing beta-
carotene and/or vitamin C probably protect against
oesophageal cancer. 
Maté, a herbal infusion, when drunk scalding hot through
a metal straw as is traditional in South America, is probably
a cause of this cancer.
There is limited evidence suggesting that foods contain-
ing dietary fibre, folate, pyridoxine, or vitamin E protect
against this cancer; and that red meat, processed meat, and
high temperature drinks are causes of this cancer.
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7.4  Lung 
Cancer of the lung is the most common type of cancer
worldwide (excluding non-melanoma skin cancer). Around
1.4 million cases were recorded in 2002, accounting for
over 12 per cent of all cancers. Three-quarters of all cases
occur in men. The disease is most common in high-income
countries and is increasing in some low-income countries
such as China. It is almost always fatal, and is the chief
cause of death from cancer: nearly 18 per cent of all
deaths from cancer are from this type. 
Overall, the Panel emphasises that the principal cause of
lung cancer is smoking tobacco.
The Panel judges as follows: 
The evidence that arsenic in drinking water and (in
smokers only) pharmacological doses of beta-carotene are
a cause of this cancer is convincing. 
Fruits, and also foods containing carotenoids, probably
protect against lung cancer.
There is limited evidence suggesting that non-starchy
vegetables, selenium and foods containing it, foods
containing quercetin, and physical activity protect against
lung cancer. 
There is also limited evidence suggesting that red meat,
processed meat, total fat, butter, pharmacological doses of
retinol (smokers only), and low body fatness are causes of
lung cancer. 
In final summary, the strongest evidence, corresponding
to judgements of “convincing” and “probable”, shows that
arsenic in drinking water and pharmacological doses of
beta-carotene (smokers only) are causes of lung cancer;
and that fruits and foods containing carotenoids probably
protect against this cancer. 
The lungs are part of the aerodigestive system. They contain
hundreds of lobules, and each lobule contains a bronchiole,
its branches, and clusters of alveoli. This is where carbon
dioxide (a product of respiration) is removed from the blood
and replaced with oxygen, to fuel further respiration, pro-
ducing energy.
About 90–95 per cent of lung cancers are either small-cell
carcinoma or non-small-cell carcinoma. The latter has three
major subtypes: squamous cell carcinoma, adenocarcinoma,
and large-cell carcinoma.4 Squamous cell carcinomas account
for 30–35 per cent, adenocarcinomas 30–45 per cent, and
large-cell carcinomas about 9 per cent of all lung cancers.
Small cell lung cancer (SCLC) accounts for 10–15 per cent
of all lung cancers; this form is considered a distinct clinical
pathological entity due to its characteristic aggressive biol-
ogy, diffuse nature, propensity for early metastasis, and over-
all poor prognosis. Mesothelioma, which affects the pleura
(layer of cells covering the lung and chest cavity), is almost
always caused by previous exposure to asbestos.
FOOD, NUTRITION, PHYSICAL ACTIVITY, 
AND CANCER OF THE LUNG
In the judgement of the Panel, the factors listed below modify the risk of
cancer of the lung. Judgements are graded according to the strength of
the evidence.
DECREASES RISK INCREASES RISK
Convincing Arsenic in drinking
water1
Beta-carotene
supplements2
Probable Fruits3
Foods containing 
carotenoids4
Limited — Non-starchy vegetables3 Red meat7
suggestive Foods containing Processed meat8
selenium4 Total fat 
Foods containing Butter
quercetin4
Retinol supplements2
Selenium5
Low body fatness
Physical activity6
Limited — Cereals (grains) and their products; starchy tubers;
no conclusion dietary fibre; pulses (legumes); poultry; fish; eggs;
milk and dairy products; total fat; animal fats; plant
oils; soft drinks; coffee; tea; alcohol; preservation,
processing, and preparation; carbohydrate; protein
vitamin A; thiamin; riboflavin; niacin; vitamin B6;
folate; vitamin C; vitamin E; multivitamins; calcium;
copper; iron; zinc; pro-vitamin A carotenoids;
lycopene; flavonoids; culturally-defined diets; 
body size, shape, and composition (except low 
body fatness); energy intake
Substantial 
effect on risk None identified
unlikely
1 The International Agency for Research on Cancer has graded arsenic and
arsenic compounds as Class 1 carcinogens. The grading for this entry applies
specifically to inorganic arsenic in drinking water.
2 The evidence is derived from studies using high-dose supplements 
(20 mg/day for beta-carotene; 25 000 international units/day for retinol)
in smokers.
3 Judgements on vegetables and fruits do not include those preserved by
salting and/or pickling.
4 Includes both foods naturally containing the constituent and foods which
have the constituent added (see chapter 3.5.3).
5 The evidence is derived from studies using supplements at a dose of 
200 µg/day.
6 Physical activity of all types: occupational, household, transport, and
recreational.
7 The term ‘red meat’ refers to beef, pork, lamb, and goat from domesticated
animals.
8 The term ‘processed meat’ refers to meats preserved by smoking, curing, 
or salting, or addition of chemical preservatives.
For an explanation of all the terms used in the matrix, 
please see chapter 3.5.1, the text of this section, 
and the glossary.
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7.4.1  Trends, incidence, and survival 
Smoking and other exposure to tobacco smoke are the prin-
cipal causes of lung cancer. The trend and incidence patterns
are explained largely by these exposures. Age-adjusted rates
of lung cancer are decreasing in many high-income countries
due to decreased smoking. Global and regional trends in inci-
dence have mirrored the prevalence of smoking, with a time
lag of around 35 years.63 Lung cancer was rare until the end
of the 19th century, with only 140 cases reported in the
world literature before 1898, and only 374 by 1912.63
Incidence peaked in most high-income countries in the sec-
ond half of the 20th century, and later for women than men. 
The relative incidence of the various types of lung cancer
is gradually changing. Between 1980 and 2000, the pro-
portion of squamous cancers decreased as the proportion of
adenocarcinomas increased, possibly due to changes in
smoking habits or products.64 Adenocarcinoma is now the
most frequently diagnosed type in the USA and Japan; while
it is also showing signs of increasing in Europe, squamous
cell carcinoma continues to be the predominant type.
Lung cancer is mainly a disease of high-income countries,
where the smoking epidemic began earlier, and overall rates
are nearly double those in middle- to low-income countries.
Around the world, age-adjusted incidence ranges from more
than 60 per 100 000 people in North America and across
much of Europe, to less than 5 per 100 000 in much of mid-
dle Africa. Within Europe, rates are highest in eastern
European countries. In the USA, rates are higher among
African-American people than in white people. Worldwide,
rates are higher in men than in women, by around three to
one. The incidence of lung cancer increases with age. Rates
will continue to rise in middle- and low-income countries as
tobacco smoking increases.
The early stages of lung cancer do not usually produce symp-
toms, so the disease is generally at an advanced stage when it
is diagnosed. Survival rates are poor, around 10 per cent at 
5 years, and are usually higher in women than men.3 6 SCLC
has a worse prognosis than non-SCLC (a survival rate of only
around 5 per cent at 5 years), because SCLC has a tenden-
cy to metastasise (spread) early, and surgery is not usually
successful.4 65 Lung cancer accounts for somewhat over 12
per cent of all cancer incidence, but for nearly 18 per cent
of all cancer deaths. Also see box 7.1.1.
7.4.2  Pathogenesis
Carcinogens in tobacco smoke, or other inhaled particles
such as coal tar or asbestos, can interact directly with the
DNA of lung cells. Because the whole lung is exposed to
inhaled carcinogens, several sites may accumulate different
cancerous changes, leading to multiple cancers originating
in different types of cell.4
Inflammation may also play a role in the development of
lung cancer, with cancerous changes occurring as a response
to chronic exposure to irritants and repeated injury.
Columnar epithelial cells are replaced with stratified squa-
mous epithelial cells, which may also increase cancer risk.
The division of these new cells increases, and this eventual-
ly is followed by dysplasia of the lung mucosa. When this
process involves the full thickness of the mucosa, these dys-
plastic lesions become carcinoma in situ. Further invasion to
the depth of the basement membrane, and the subsequent
infiltration of the underlying stroma by malignant cells, sig-
nals invasive cancer. This process may take 10–20 years.4
People with adenocarcinomas may have an associated his-
tory of chronic lung disease, such as scleroderma, rheuma-
toid disease, sarcoidosis, or tuberculosis.4
7.4.3  Other established causes 
(Also see chapter 2.4 and section 7.1.3.1.)
Tobacco use. Smoking is the principal cause of lung cancer; it
is estimated to be responsible for 85 per cent of all types of this
cancer.66 In populations with a history of long-term cigarette
use, the proportion has reached 90 per cent.10 Involuntary
exposure to tobacco smoke (‘passive smoking’) is also a cause
of lung cancer, including in people who have never smoked.10
Industrial chemicals. Carcinogens that are causes of lung can-
cer include aluminium; arsenic; asbestos (both lung cancer
and mesothelioma); chloromethyl methyl ether and/or bis-
chloromethyl ether; coal-tar fumes; erionite (mesothe-
lioma); pollutants from iron and steel founding; untreated
mineral oils; mustard gas; soot; talc containing asbestiform
tremolite; and vinyl chloride.67
7.4.4  Interpretation of the evidence 
7.4.4.1  General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7.
‘Relative risk’ is used in this Report to denote ratio mea-
sures of effect, including ‘risk ratios’, ‘rate ratios’, ‘hazard
ratios’, and ‘odds ratios’.
7.4.4.2  Specific 
Considerations specific to cancer of the lung include: 
Measurement. Due to low survival rates, both incidence and
mortality can be assessed. Low survival times and rates
decrease the reliability of case-control studies, which often
rely on proxy reporting.
Confounding. Smoking tobacco is the predominant cause of
lung cancer, and smokers tend also to have less healthy diets,
more sedentary ways of life, and to be leaner than non-smok-
ers. Therefore a central task in assessing the results of dietary
studies is to evaluate the degree to which observed associations
in smokers may be due to confounding/residual confounding
by cigarette smoking; that is, not a direct result of the dietary
exposure examined. A high proportion of the studies assessed
below are appropriately adjusted for smoking.
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7.4.5  Evidence and judgements
In total, 561 publications were included in the SLR for lung
cancer. Fuller summaries of the epidemiological, experi-
mental, and mechanistic evidence are to be found in
Chapters 4–6.
The full SLR is contained on the CD included with this
Report.
7.4.5.1  Non-starchy vegetables
(Also see chapter 4.2.5.1.)
A total of 17 cohort studies, 27 case-control studies, and 6
ecological studies investigated total vegetables. Other group-
ings examined were non-starchy vegetables specifically (3
cohort, 1 case-control); green, leafy vegetables, excluding
cruciferous (5 cohort, 17 case-control); non-starchy root veg-
etables and tubers (2 cohort); and carrots (6 cohort, 21 case-
control, 1 ecological). Most studies showed decreased risk
with increased intake. Data are particularly consistent when
stratified for carrots. A pooled analysis of 8 cohort studies
(more than 430 000 participants, followed up for 6–16 years,
with more than 3200 lung cancer cases) showed a non-sig-
nificant decreased risk for the groups that ate the most veg-
etables. There was considerable heterogeneity, not all
readily explained. 
This is a wide and disparate category, and many different
plant food constituents are represented that could contribute
to a protective effect of non-starchy vegetables. These include
dietary fibre, carotenoids, folate, selenium, glucosinolates,
dithiolthiones, indoles, coumarins, ascorbate, chlorophyll,
flavonoids, allylsulphides, flavonoids, and phytoestrogens,
some of which are potentially antioxidants. Antioxidants trap
free radicals and reactive oxygen molecules, protecting
against oxidation damage. It is difficult to unravel the rela-
tive importance of each constituent and it is likely that any
protective effect may result from a combination of influences
on several pathways involved in carcinogenesis.
A substantial amount of evidence is available but some
studies were not adjusted for smoking. A dose
response is apparent from both cohort and case-
control studies. There is limited evidence suggesting
that non-starchy vegetables protect against lung
cancer.
7.4.5.2  Fruits
(Also see chapter 4.2.5.2.)
Twenty-five cohort studies, 32 case-control studies, and 7
ecological studies investigated fruit consumption. Most of
these showed decreased risk with increased intake. Meta-
analysis of cohort data showed a 6 per cent decreased risk
per 80 g serving/day; meta-analysis of case-control data
showed a 20 per cent decreased risk per serving/day (figure
4.2.25). A pooled analysis of 8 cohort studies (more than 430
000 participants, followed up for 6–16 years, with more than
3200 lung cancer cases) showed a 23 per cent decreased risk
for the groups that ate the most fruit. There is considerable
heterogeneity, perhaps explained by the broad and disparate
nature of this category.
Fruits are sources of vitamin C and other antioxidants,
such as carotenoids, phenols, and flavonoids, as well as other
potentially bioactive phytochemicals. Antioxidants trap free
radicals and reactive oxygen molecules, protecting against
oxidation damage. In addition, flavonoids found in fruit
directly inhibit the expression of a cytochrome P450
enzyme. This helps to metabolise toxins and has been asso-
ciated with increased risk of lung cancer, primarily in smok-
ers.68 It is difficult to unravel the relative importance of each
constituent, and it is likely that any protective effect may
result from a combination of influences on several pathways
involved in carcinogenesis.
The evidence is ample and consistent. A dose-response
relationship is apparent from both cohort and case-
control studies and there is evidence for plausible
mechanisms operating in humans. The evidence that
fruits protect against lung cancer is convincing.
The Panel is aware that since the conclusion of the SLR, one
case-control study69 has been published. This new information
does not change the Panel judgement. Also see box 3.8.
7.4.5.3  Foods containing carotenoids 
(Also see chapter 4.2.5.3.)
A total of 11 cohort studies, 16 case-control studies, and 1
ecological study investigated total dietary carotenoids; 4
cohort studies and 5 case-control studies investigated serum
or plasma carotenoids. Other groupings examined were
dietary beta-cryptoxanthin (7 cohort, 8 case-control, 1 eco-
logical), and serum/plasma beta-cryptoxanthin (6 cohort, 1
case-control). Nearly all cohort studies and most case-con-
trol studies showed decreased risk with increased intake.
Meta-analysis of cohort data showed a 2 per cent decreased
risk per 1 mg dietary carotenoid intake per day, or per 
10 µg beta-cryptoxanthin intake per day (figure 4.2.28). A
pooled analysis of 7 cohort studies (almost 400 000 partic-
ipants, followed up for 7–16 years, with more than 3100
lung cancer cases) showed a 24 per cent decreased risk for
the groups that consumed the most beta-cryptoxanthin.
Several case-control studies did not adjust for smoking. Data
come predominantly from dietary sources, not supplements;
therefore no effect can be attributed to carotenoids separate
from foods.
Carotenoids are antioxidants, which can prevent lipid oxi-
dation and related oxidative stress. Some, such as beta-
carotene, are also pro-vitamin A carotenoids.
There is a substantial amount of evidence available
from both cohort and case-control studies. A clear
dose-response relationship is apparent from cohort
studies. Foods containing carotenoids probably protect
against lung cancer.
7.4.5.4  Foods containing selenium 
(Also see chapter 4.2.5.8.)
Two cohort studies, 2 case-control studies, and 2 ecological
studies investigated dietary selenium; 10 cohort studies, 7
case-control studies, and 4 ecological studies investigated
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plasma or serum selenium; and 3 cohort studies investigat-
ed selenium levels in nails. Most studies showed decreased
risk with increased intake. Meta-analysis of cohort data on
plasma or serum selenium produced evidence of decreased
risk with a clear dose-response relationship.
Dietary selenium deficiency has been shown to cause a
lack of selenoprotein expression. Twenty-five selenoproteins
have been identified in animals and a number of these have
important anti-inflammatory and antioxidant properties.
Four are glutathione peroxidases, which protect against
oxidative damage to biomolecules such as lipids, lipopro-
teins, and DNA. Three are thioredoxin reductases and,
among other functions, these regenerate oxidised ascorbic
acid to its active antioxidant form.
The evidence available is sparse. There is limited
evidence to suggest that foods containing selenium
protect against lung cancer. 
7.4.5.5  Foods containing quercetin
(Also see chapter 4.2.5.9.)
Two cohort studies and three case-control studies investi-
gated quercetin intake. Both cohort studies showed statisti-
cally significant decreased risk for the highest intake groups.
Data from case-control studies were more heterogeneous.
Quercetin is a flavonoid which directly inhibits expression
of a cytochrome P450 enzyme that helps to metabolise tox-
ins, resulting in decreased DNA damage in laboratory exper-
iments.70
The evidence available is sparse and inconsistent.
There is limited evidence suggesting that foods
containing quercetin protect against lung cancer.
7.4.5.6  Red meat 
(Also see chapter 4.3.5.1.1.)
One cohort study and nine case-control studies investigated
red meat. The single cohort study and most of the case-con-
trol studies showed increased risk with increased intake.
Red meat contains haem iron (see box 4.3.3). Free iron can
lead to the production of free radicals. When cooked at high
temperatures, red meat can also contain heterocyclic amines
and polycyclic aromatic hydrocarbons (see box 4.3.4).
There is limited evidence, mostly from inconsistent
case-control studies, suggesting that red meat is a
cause of lung cancer.
7.4.5.7  Processed meat
(Also see chapter 4.3.5.1.2.)
Four cohort studies and 10 case-control studies investigated
processed meat, most of which showed increased risk with
increased intake.
N-nitroso compounds are suspected mutagens and car-
cinogens that are found in processed meats, and produced
in the stomach from nitrates, including those used to pre-
serve meats.55 Many processed meats also contain high lev-
els of salt and nitrite (see box 4.3.2). When cooked at high
temperatures, meats can also contain heterocyclic amines
and polycyclic aromatic hydrocarbons (see box 4.3.4). Haem
promotes the formation of N-nitroso compounds and also
contains iron. Free iron can lead to production of free radi-
cals (see box 4.3.3).
There is limited, inconsistent evidence suggesting that
processed meat is a cause of lung cancer.
7.4.5.8  Total fat
(Also see chapter 4.5.5.1.)
Nine cohort studies, 17 case-control studies, and 4 ecologi-
cal studies investigated total fat intake. Most studies showed
increased risk with increased intake, although cohort data
were less suggestive of an effect, and few studies were sta-
tistically significant. No evidence for plausible mechanisms
was found. 
The mixed results from cohort studies contrast with
the more consistent results from other studies. Overall,
there is limited evidence suggesting that consumption
of total fat is a cause of lung cancer. The Panel
emphasises that the principle cause of lung cancer is
smoking tobacco.
7.4.5.9  Butter
(Also see chapter 4.5.5.1.1.)
Two cohort studies and eight case-control studies investi-
gated butter consumption. Most studies showed increased
risk with increased intake, but cohort data were inconsistent.
No evidence for plausible mechanisms was found. 
There is a limited amount of inconsistent evidence
suggesting that consumption of butter is a cause of
lung cancer.
7.4.5.10  Arsenic in drinking water
(Also see chapter 4.7.5.1.1.)
Two cohort studies, 2 case-control studies, and 12 ecologi-
cal studies investigated arsenic in drinking water. All cohort
and case-control studies, and most ecological studies,
showed a relationship between increased levels of arsenic in
drinking water and increased incidence. Meta-analysis was
not possible, but effect estimates tended to be large (an
increased risk of over 300 per cent for the highest levels).
Soluble arsenic in drinking water induces lung cancers in
animal models.71 In humans, arsenic is a chromosomal muta-
gen (an agent that induces mutations involving more than
one gene, typically large deletions or rearrangements). It can
also act as a synergistic co-mutagen. Arsenic exposure also
causes chronic lung disease.71 The Joint FAO/WHO Expert
Committee on Food Additives has set a provisional tolerable
weekly intake of 0.015 mg/kg of body weight.72
The evidence is ample and consistent, from cohort and
case-control as well as ecological studies. There is a
dose-response relationship, and the effect size is
relatively large. There is robust evidence for
mechanisms. The evidence that arsenic in drinking
water is a cause of lung cancer is convincing.
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7.4.5.11  Retinol supplements (in smokers)
(Also see chapter 4.10.6.4.1.)
Two trials (one randomised controlled, one non-randomised),
two cohort studies, and two case-control studies investigat-
ed retinol or retinol supplements. The single randomised con-
trolled trial, performed in current and former smokers only,
showed a statistically significant increased risk with a high-
dose supplement. There was a suggestion of further elevat-
ed incidence in heavy smokers and asbestos workers. The
non-randomised trial was inconclusive. One cohort, also strat-
ified by smoking status, showed a relationship with increased
incidence only in current smokers. All other studies failed to
stratify by smoking status and were inconclusive.
It is possible that some protective effect present at dietary
intake amounts of vitamins is lost or reversed by the higher
levels supplied by pharmacologic supplementation.
The evidence is sparse and inconsistent. There is
limited evidence suggesting that high-dose vitamin A
supplements are a cause of lung cancer in current
smokers.
7.4.5.12  Beta-carotene supplements (in smokers)
(Also see chapter 4.10.6.4.2.)
Four randomised controlled trials and two cohort studies
investigated beta-carotene supplements. Of these, one ran-
domised controlled trial was performed in smokers. This
study showed a statistically significant increased risk of 17
per cent with a daily 20 mg beta-carotene supplement. It also
suggested that heavy smoking elevated the risk further.
Other trials and studies, either in non-smokers or not strat-
ified according to smoking status, were inconclusive.
There is a marked interaction between beta-carotene,
heavy smoking, and glutathione S-transferase (GST) geno-
type. GST is a carcinogen-detoxifying enzyme (see chapter
2.5). Beta-carotene supplementation among people without
GSTM1 (one of the variants of the GST gene) who smoked
more than 42 cigarettes per day was compared to beta-
carotene supplementation among those without GSTM1 who
smoked less than 37 cigarettes per day. A relative risk of 6.01
(95% confidence interval 1.90–19.08) was observed. 
It is possible that a protective association present at dietary
intake amounts of carotenoids is lost or reversed by the high-
er levels that pharmacological supplementation may supply.
In one animal study, low-dose beta-carotene was protective
against smoking-induced changes in the tumour-suppressor
p53 gene (see box 2.2), while high doses promoted these
changes.73 A second explanation could relate to disturbance
of the complex nature of naturally occurring carotenoids. It
is possible that the protective associations are not due to the
specific agent used in supplement studies, but rather to other
carotenoids present in dietary exposure,74 or other associat-
ed dietary or health-related behaviour.
There is strong evidence from good-quality trials,
consistent with cohort studies. An interaction between
smoking, genotype, and beta-carotene is apparent. The
evidence that beta-carotene supplements cause lung
cancer in current smokers is convincing.
7.4.5.13  Selenium supplements
(Also see chapter 4.10.6.4.5.)
One randomised controlled trial investigated selenium sup-
plements and lung cancer.
The single trial of more than 1300 participants given 
200 µg/day of selenium for 13 years showed a non-signifi-
cant decreased risk with supplementation, adjusted for age
and smoking. Subgroup analysis indicated that this risk dif-
fered according to baseline plasma selenium level, with a sta-
tistically significant decreased risk for those with the lowest
initial plasma selenium. This is suggestive that selenium sup-
plementation may decrease cancer risk in those who have
poor selenium status, but that this effect may not extend to
those who do not.
Dietary selenium deficiency has been shown to cause a
lack of selenoprotein expression. Twenty-five selenoproteins
have been identified in animals and a number of these have
important anti-inflammatory and antioxidant properties.
Four are glutathione peroxidases, which protect against
oxidative damage to biomolecules such as lipids, lipopro-
teins, and DNA. Three are thioredoxin reductases and,
among other functions, these regenerate oxidised ascorbic
acid to its active antioxidant form.
The evidence is sparse. There is limited evidence
suggesting that selenium protects against lung cancer.
7.4.5.14  Physical activity
(Also see chapter 5.4.4.)
In total, 5 cohort studies investigated total physical activi-
ty; 2 cohort studies investigated non-recreational activity; 4
cohort studies and 2 case-control studies investigated occu-
pational activity; and 11 cohort studies and 4 case-control
studies investigated recreational activity. Overall, most
studies showed decreased risk with increased physical activ-
ity. No studies showed a statistically significant increased
risk. Of the categories analysed, consistent protective rela-
tionships were reported for total physical activity, non-recre-
ational activity, and recreational activity. Increased
heterogeneity in occupational physical activity may be due
to either the extreme variation in exposure definition, or the
generally lower levels of occupational activity, meaning that,
as a percentage of daily activity, occupational activity is of
reduced importance in many high-income countries (where
these studies were generally performed).
Sustained, moderate physical activity raises metabolic rate
and increases maximal oxygen uptake. In the long term,
regular periods of such activity increase the body’s metabolic
efficiency and capacity (the amount of work that it can
perform), as well as reducing blood pressure and insulin
resistance.
There is evidence from prospective and case-control
studies showing lower risk of lung cancer with higher
levels of physical activity, but there is no evidence of
plausible mechanisms. The relationship between activity,
BMI, and lung cancer makes the evidence difficult to
interpret. There is limited evidence suggesting that
physical activity protects against lung cancer.
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The Panel is aware that since the conclusion of the SLR, one
cohort study75 has been published. This new information does
not change the Panel judgement. Also see box 3.8. 
7.4.5.15  Body fatness 
(Also see chapter 6.1.3.1.)
Twenty-one cohort studies, 24 case-control studies, and 1
ecological study investigated body fatness, as measured by
BMI. Nearly all of the cohort and case-control studies showed
decreased risk with increased BMI. Meta-analysis of cohort
and case-control data provided evidence of a statistically sig-
nificant reduced risk, with no heterogeneity in cohort data.
Smoking is the principal cause of lung cancer and may also
be associated with lower BMI. There is a high potential for
confounding due to tobacco smoking, and residual con-
founding is therefore possible. In addition, it is possible that
people with undiagnosed lung cancer may lose weight, so
giving a spurious association (reverse causation).
There is no known mechanism through which greater body
fatness could plausibly protect against lung cancer, or
through which low body fatness could increase risk.
Although the epidemiological evidence suggests an
inverse relationship, this could be caused by
confounding by cigarette smoking or reverse causation
due to weight loss from undiagnosed cancer. There is
limited evidence suggesting that low body fatness is a
cause of lung cancer.
7.4.5.16  Other exposures
Other exposures were evaluated. However, the data were
either of too low quality, too inconsistent, or the number of
studies too few to allow conclusions to be reached. These
were as follows: cereals (grains) or their products; starchy
tubers; pulses (legumes); meat; poultry; fish; eggs; animal
fats; milk and dairy products; soft drinks; coffee; tea; alco-
hol; processing, preservation, and preparation; carbohydrate;
dietary fibre; total fat; protein; vitamin A; retinol; pro-vita-
min A carotenoids; lycopene; thiamin; riboflavin; niacin; vit-
amin B6; folate; vitamin C; vitamin E; multivitamins; iron;
zinc; copper; calcium; selenium; flavonoids; energy intake;
plant oils; body size, shape, and composition (except low
body fatness); and culturally defined diets.
7.4.6  Comparison with previous report
7.4.6.1  General
See section 7.1.6.1 of this chapter, and box 3.8 in chapter 3.
7.4.6.2  Specific
The previous report judged the evidence that vegetables and
fruits protect against lung cancer to be convincing. Evidence,
particularly from cohort studies published since the mid-
1990s, is more consistent for fruits than for vegetables. 
The findings of the previous report for carotenoids, and for
pharmaceutical doses of beta-carotene given to smokers,
were identical to the current findings (for foods containing
carotenoids), although the previous report did not include a
matrix entry for beta-carotene supplements. The previous
report did not review arsenic.
7.4.7  Conclusions 
The Panel concludes:
The evidence that arsenic in drinking water and (in smok-
ers only) pharmacological doses of beta-carotene are caus-
es of lung cancer is convincing. 
Fruits, and also foods containing carotenoids, probably
protect against lung cancer. 
There is limited evidence suggesting that non-starchy veg-
etables, selenium and foods containing it, foods containing
quercetin, and physical activity protect against lung cancer. 
There is also limited evidence suggesting that red meat,
processed meat, total fat, butter, pharmacological doses of
retinol (in smokers only), and low body fatness are causes
of lung cancer. 
Smoking tobacco is the main cause of lung cancer.
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7.5  Stomach 
Cancer of the stomach is the fourth most common type of
cancer worldwide. Almost one million cases were recorded
in 2002. Two out of three cases occur in men. Overall, it is
decreasing rapidly in high-income countries, but remains
very common elsewhere in the world. It is usually fatal
and is the second most common cause of death from
cancer. 
Overall, the Panel judges that food and nutrition play an
important role in the prevention and causation of stomach
cancer.
The Panel judges as follows: 
Non-starchy vegetables, including specifically allium
vegetables, as well as fruits probably protect against
stomach cancer. 
Salt, and also salt-preserved foods, are probably causes
of this cancer.
There is limited evidence suggesting that pulses
(legumes), including soya and soya products, and also
foods containing selenium protect against stomach cancer. 
There is also limited evidence suggesting that chilli,
processed meat, smoked foods, and grilled (broiled) and
barbecued (charbroiled) animal foods are causes of
stomach cancer.
Infection with the bacterium Helicobacter pylori is
established as a necessary cause of almost all cases of
stomach cancer. It has been estimated that most cases 
of this cancer are preventable by appropriate diets and
associated factors. 
In final summary, the strongest evidence, corresponding
to judgements of “convincing” and “probable”,shows that
non-starchy vegetables, allium vegetables, and fruits
protect against stomach cancer; and that salt and also
salt-preserved foods are causes 
of this cancer.
The stomach is the sac-like part of the digestive system
between the oesophagus and the small intestine. The body
of the stomach is lined by a mucous membrane consisting
of columnar epithelial cells and glands, surrounded by
muscle.
There are two main types of stomach cancer. Distal gastric
cancers (those of the lower portion of the stomach) are the
predominant type. The other type is cancer of the gastric
cardia or of the gastro-oesophageal junction.4 The latter are
sometimes grouped with oesophageal adenocarcinomas.
Distal gastric cancers may be classified depending on their
appearance under the microscope as intestinal or diffuse
(from mucus-producing cells). The former is more common
and predominates in areas of high incidence; the latter has
a poorer prognosis, tends to occur at a younger age, and may
also occur in the cardia.76 More than 95 per cent of gastric
cancers are adenocarcinomas.77
7.5.1  Trends, incidence, and survival
Age-adjusted rates of stomach cancer are decreasing, and in
2002 (in many countries) were half what they were 30 years
earlier. However, during the same period, two types of can-
cer affecting the upper (proximal) section of the stomach —
those of the gastro-oesophageal junction and gastric cardia
FOOD, NUTRITION, PHYSICAL ACTIVITY, 
AND CANCER OF THE STOMACH
In the judgement of the Panel, the factors listed below modify the risk of
cancer of the stomach. Judgements are graded according to the strength
of the evidence.
DECREASES RISK INCREASES RISK
Convincing
Probable Non-starchy Salt2
vegetables1 Salted and salty
Allium vegetables1 foods
Fruits1
Limited — Pulses (legumes)3 Chilli1
suggestive Foods containing Processed meat5
selenium4 Smoked foods6
Grilled (broiled) 
or barbecued
(charbroiled) animal
foods6
Limited — Cereals (grains) and their products; dietary fibre;
no conclusion potatoes; starchy roots, tubers, and plantains; nuts
and seeds; herbs, spices, and condiments; meat
(unprocessed); poultry; eggs; milk and dairy
products; fats and oils; total fat; fatty acid
composition; cholesterol; sugars; sugar (sucrose);
fruit juices; coffee; tea; alcohol; dietary nitrate and
nitrite, N-nitrosodimethylamine; drying or dried
food; protein; thiamin; riboflavin; vitamin C;
vitamin D; multivitamin/mineral supplements;
calcium; iron; selenium supplements; carotenoids;
culturally defined diets; meal frequency; eating
speed; body fatness; energy intake
Substantial 
effect on risk None identified
unlikely
1 Judgements on vegetables and fruits do not include those preserved by
salting and/or pickling.
2 ‘Salt’ here means total salt consumption, from processed foods, including
salty and salted foods, and also salt added in cooking and at the table. 
3 Including soya and soya products.
4 Includes both foods naturally containing the constituent and foods which
have the constituent added (see chapter 3.5.3).
5 The term ‘processed meat’ refers to meats preserved by smoking, curing, 
or salting, or addition of chemical preservatives. 
6 The evidence is mostly from meats preserved or cooked in these ways.
For an explanation of all the terms used in the matrix, 
please see chapter 3.5.1, the text of this section, 
and the glossary.
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— increased, notably in high-income countries.78 The
decline in stomach cancer incidence is likely to have been
due partly to the increased availability of refrigeration (see
box 4.6.4). This has had the effect of increasing availability
and consumption of fresh foods such as vegetables and fruits,
and decreasing consumption of foods preserved by salt and
other relevant methods.79 80
Age-adjusted incidence rates range from more than 60 per
100 000 people in Japan and other countries in eastern Asia,
to less than 10 per 100 000 in much of Africa and North
America. Chile and other Latin American countries, as well
as Portugal and eastern Europe, have moderately high rates
of 30 per 100 000. Rates are also higher in some ethnic
groups, for instance, Asian and Pacific Islanders living in the
USA, and African-American, and Hispanic-American people;
rates are also twice as high in men as women. Rates of dif-
ferent types of stomach cancer also vary, both geographically
and between ethnic groups. Cancers affecting the lower (dis-
tal) section of the stomach are most common in low- to mid-
dle-income countries and in people of African origin;
proximal tumours are predominant in high-income countries
and in white people.78 Risk increases with age; stomach can-
cer is rarely diagnosed in people under 50.
The 5-year survival rate for stomach cancer is approxi-
mately 20 per cent.3 6 Survival rates are higher in countries
which have screening programmes that lead to early detec-
tion, and where distal cancer (which has a better prognosis)
predominates.81 Stomach cancer accounts for nearly 9 per
cent of all cancer incidence, but somewhat over 10 per cent
of all cancer deaths worldwide. Also see box 7.1.1.
7.5.2  Pathogenesis
Changes in the stomach mucosa, brought about by a variety
of environmental factors and ageing, can eventually lead to
atrophic gastritis. The chronic form of this condition, and the
resulting changes in the characteristics of the stomach cells,
appear to be precursor conditions to the development of dis-
tal stomach cancer.4 Food carcinogens can also potentially
interact directly with the epithelial cells that line the stom-
ach. However, cancer can also develop without these pre-
cursors, particularly when the bacterium H pylori is present
in the stomach (see box 7.5.1).81
Three independent cohort studies have shown the pro-
gression of gastritis from the non-atrophic to the atrophic
form. Epidemiological studies of atrophic gastritis have also
shown an association with dietary factors, especially a high
intake of salt (mostly in the form of salty and salted foods).90
N-nitrosamines are known carcinogens produced in the
stomach from nitrate in foods, and via nitrite from endoge-
nous nitric oxide production in chronic inflammation (see
box 4.3.2). They may be potential causes of stomach can-
cer92 (see chapter 2.4.2.6).
Cancers of the gastric cardia show many similarities to
oesophageal cancer (see 7.3.1). There is a clear association
between Barrett’s oesophagus and adenocarcinoma of the
lower (distal) oesophagus and of the gastric cardia, caused
by chronic acid damage.
The diffuse type of distal stomach cancers (those that
develop from mucus-producing cells) show some genetic pre-
disposition, with an increased risk for people with blood
group A. Genetic predisposition is thought to be a factor in
5–10 per cent of diffuse cancers.93 Stomach cancer is part of
the spectrum of cancers associated with the germ line mis-
match repair (MMR) gene alterations that give rise to hered-
itary nonpolyposis colorectal cancer (HNPCC).77 Also see
chapter 7.9.2.
7.5.3  Other established causes 
(Also see chapter 2.4 and 7.1.3.1.) 
Infection and infestation. The bacterium H pylori is an
important cause of distal stomach cancers (see box 7.5.1).
Also, Epstein-Barr virus is carcinogenic to humans and has
been linked to stomach cancers (particularly gastric lym-
phoepithelial carcinomas and a smaller proportion of gastric
adenocarcinomas) in some studies.30
Industrial chemicals. Industrial exposure to ethylene oxide
is carcinogenic to humans and has led to increased risk of
stomach cancer in some studies.94
H pylori is a bacterium that lives in the human stomach. Infection
does not usually produce symptoms, and spreads through saliva
and faecal material. Prevalence increases with age, but differs
dramatically among populations.82 In the USA, prevalence is less
than 20 per cent at 20 years old and about 50 per cent at 50
years, which may be typical of high-income countries,83 while in
Korea, it is 50 per cent at 5 years and 90 per cent at 20 years,
and in Japan it reaches 85 per cent by middle age.84
H pylori colonises the gastric mucosa and elicits both inflam-
matory and immune lifelong responses, including the release of
various bacterial and host-dependent cytotoxic substances.85
H pylori infection greatly reduces the bioavailability of vitamin
C. This may play a role in the development of stomach cancer in
the presence of dietary and other factors that are a cause of this
cancer. In studies of precancerous lesions or gastric atrophy, erad-
ication of H pylori promoted regression of these cancer precur-
sors.86-88
Some people develop stomach cancer without apparent infec-
tion with H pylori. Reported percentages of non-cardia cancers
that test positive for H pylori range from approximately 60 to 95
per cent, averaging around 86 per cent,89 but those with distal
stomach cancer who test negative for H pylori may have under-
gone a loss of infection associated with the atrophic gastritis, and
consequently a decline in antibody titre. It can be regarded as a
necessary cause for those stomach cancers arising in the distal
region of the stomach.90
The longer the time of infection, and the greater the impact
on the gastric mucosa, the more likely it is that stomach cancer
will develop and take a severe form. The exact site of the can-
cer is most likely to be where the mucosa is most affected.91
Those who develop extensive gastritis and gastric atrophy are at
increased risk of developing cancer.81
Box 7.5.1 Helicobacter pylori  
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7.5.4  Interpretation of the evidence 
7.5.4.1 General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7.
‘Relative risk’ is used in this Report to denote ratio mea-
sures of effect, including ‘risk ratios’, ‘rate ratios’, ‘hazard
ratios’, and ‘odds ratios’.
7.5.4.2 Specific 
Considerations specific to cancer of the stomach include the
following. 
Classification. Most evidence relates to distal stomach can-
cers, although cancers of the gastric cardia and gastro-
oesophageal junction might be included in an outcome of
‘stomach cancer’. It is now well recognised that proximal and
distal stomach cancers are quite different, but relatively few
studies stratified results on the basis of subsite. For many
early studies, most stomach cancer was probably distal in ori-
gin, so the lack of stratification was less important. As the
incidence and overall proportion of proximal cancer have
increased in recent years in high-income countries, there is
a greater likelihood that the general term ‘stomach cancer’
will represent a combination of the two subsites and there-
fore results will be less informative.
Measurement. Owing to low survival rates, both incidence
and mortality can be assessed. Low survival times and rates
decrease the reliability of case-control studies, which often
rely on proxy reporting.
Confounding. H pylori infection is a necessary cause of dis-
tal stomach cancer. This has only been established relative-
ly recently. Only recent studies have incorporated H pylori
status into their design and have adjusted or stratified for
infection.
7.5.5  Evidence and judgements 
In total, 722 publications were included in the SLR for stom-
ach cancer. Fuller summaries of the epidemiological, exper-
imental, and mechanistic evidence are to be found in
Chapters 4–6.
The full SLR is contained on the CD included with this
Report.
7.5.5.1  Non-starchy vegetables 
(Also see chapter 4.2.5.1.)
A total of 10 cohort studies, 45 case-control studies, and 19
ecological studies investigated total vegetables. Other group-
ings examined were green-yellow vegetables (11 cohort, 21
case-control, 8 ecological); green, leafy vegetables (6 cohort,
13 case-control, 2 ecological); tomatoes (3 cohort, 19 case-
control); white or pale vegetables (2 cohort, 6 case-control);
raw vegetables (6 cohort, 25 case-control, 3 ecological); or
non-starchy vegetables and fruits (5 cohort, 6 case-control).
Most studies showed decreased risk with increased intake.
However, cohort data were less consistent than case-control
data. Meta-analysis of cohort data showed a 19 per cent
decreased risk per 50 g green-yellow vegetables/day; no other
subcategory analyses were statistically significant. Case-con-
trol data showed a 15 per cent decreased risk per 50 g veg-
etables/day (figures 4.2.8. and 4.2.9); a 21 per cent
decreased risk per 50 g green-yellow vegetables/day; a 57 per
cent decreased risk per 50 g green, leafy vegetables/day; a
30 per cent decreased risk per 50 g tomatoes/day; and a 25
per cent decreased risk per 50 g raw vegetables/day (figure
4.2.12). There was unexplained heterogeneity.
This is a wide and disparate category, and many different
plant food constituents are represented that could contribute
to a protective effect of non-starchy vegetables. These include
dietary fibre, carotenoids, folate, selenium, glucosinolates,
dithiolthiones, indoles, coumarins, ascorbate, chlorophyll,
flavonoids, allylsulphides, flavonoids, and phytoestrogens,
some of which are potentially antioxidants. Antioxidants trap
free radicals and reactive oxygen molecules, protecting
against oxidation damage. It is difficult to unravel the rela-
tive importance of each constituent and it is likely that any
protective effect may result from a combination of influences
on several pathways involved in carcinogenesis.
A substantial amount of evidence is available,
including on specific subtypes, particularly green-
yellow vegetables, with a dose-response relationship in
case-control, but not cohort, data. There is evidence
for plausible mechanisms. Non-starchy vegetables
probably protect against stomach cancer.
The Panel is aware that since the conclusion of the SLR, one
case-control study95 has been published. This new information
does not change the Panel judgement. Also see box 3.8.
7.5.5.2  Allium vegetables
(Also see chapter 4.2.5.1.1.)
A total of 2 cohort studies, 27 case-control studies, and 2
ecological studies investigated allium vegetables; and 1
cohort study, 16 case-control studies, and 2 ecological stud-
ies investigated garlic. There was also one relevant inter-
vention study that combined allitridium (a garlic extract
containing triallylsulphides) and selenium supplements.
Most of the studies showed decreased risk with increased
intake. Meta-analysis of cohort data showed a 23 per cent
decreased risk per 50 g allium vegetables/day. Meta-analy-
sis of case-control data showed a 20 per cent decreased risk
per 50 g allium vegetables/day (figure 4.2.14), and a 59 per
cent decreased risk per serving of garlic/day. The single trial
of combined selenium and allitridium supplements showed
a statistically significant decreased risk in men but not
women, after 5 years of follow-up.
Allium vegetables, particularly garlic, have antibiotic prop-
erties. Although this may act directly against H pylori, stud-
ies in humans have not shown this effect. It is also possible
that antibacterial effects of garlic might inhibit the secondary
colonisation of the stomach after H pylori-induced atrophy.
At present, there is no evidence to support or refute this idea.
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The evidence, though not copious and mostly from
case-control studies, is consistent, with a dose-
response relationship. There is evidence for plausible
mechanisms. Allium vegetables probably protect
against stomach cancer.
7.5.5.3  Fruits
(Also see chapter 4.2.5.2.)
Sixteen cohort studies, 51 case-control studies, and 23 eco-
logical studies investigated fruits. Most studies showed
decreased risk with increased intake, but there was unex-
plained heterogeneity. Cohort studies suggested a non-sig-
nificant relationship with decreased risk. Meta-analysis of
case-control data showed a 17 per cent decreased risk per
50 g fruits per day (figure 4.2.27).
Fruits are sources of vitamin C and other antioxidants,
such as carotenoids, phenols, and flavonoids, as well as other
potentially bioactive phytochemicals. Antioxidants trap free
radicals and reactive oxygen molecules, protecting against
oxidation damage. In addition, flavonoids found in fruits
directly inhibit the expression of a cytochrome P450 enzyme,
which helps to metabolise toxins and has been associated
with increased risk of lung cancer, primarily in smokers.68 It
is difficult to unravel the relative importance of each con-
stituent and it is likely that a protective effect may result from
a combination of influences on several pathways involved in
carcinogenesis.
The evidence is ample and more consistent, with a
dose-response relationship, for case-control studies
than for cohorts. There is evidence for plausible
mechanisms. Fruits probably protect against stomach
cancer.
The Panel is aware that since the conclusion of the SLR, three
case-control studies95-97 have been published. This new infor-
mation does not change the Panel judgement. Also see box 3.8.
7.5.5.4   Pulses (legumes) including soya and soya
products
(Also see chapter 4.2.5.10.)
A total of 3 cohort studies, 22 case-control studies, and 
16 ecological studies investigated pulses (legumes) and
stomach cancer; and 2 cohort studies, 9 case-control stud-
ies, and 2 ecological studies investigated soya and soya prod-
ucts. All of the cohort studies and most of the case-control
studies showed decreased risk with increased intake.
Ecological studies showed decreased risk for soya and soya
products, but were inconsistent for pulses (legumes). 
Meta-analysis of cohort studies showed a non-significant
relationship with decreased risk. Meta-analysis of case-con-
trol studies produced evidence for a relationship with
decreased risk.
Pulses (legumes), particularly soya, contain high levels of
isoflavones that have shown anti-cancer properties in labo-
ratory experiments. Saponins and other bioactive con-
stituents of soya (and to a lesser extent, other pulses) may
also have anti-cancer properties, although these are less well
demonstrated.
The evidence, mostly from case-control studies, is
inconsistent. There is limited evidence suggesting that
pulses (legumes), including soya and soya products,
protect against stomach cancer.
7.5.5.5  Foods containing selenium
(Also see chapter 4.2.5.8.)
One case-control study and 5 ecological studies investigated
dietary selenium; 3 cohort studies, 9 case-control studies and
3 ecological studies investigated blood selenium; and 1 cohort
study and 1 case-control study investigated selenium in toe-
nails or hair. All of the studies for blood, nail, or hair seleni-
um levels showed decreased risk with increased selenium
intake. Meta-analysis of cohort data showed a non-significant
decreased risk, and meta-analysis of case-control data pro-
duced statistically significant evidence of decreased risk. 
Dietary selenium deficiency has been shown to cause a
lack of selenoprotein expression. Twenty-five selenoproteins
have been identified in animals and a number of these have
important anti-inflammatory and antioxidant properties.
Four are glutathione peroxidases, which protect against
oxidative damage to biomolecules such as lipids, lipopro-
teins, and DNA. Three are thioredoxin reductases, which,
among other functions, regenerate oxidised ascorbic acid to
its active antioxidant form. Selenoproteins with powerful
antioxidant activity may provide protection against the
inflammatory effect of H pylori that can lead to gastric can-
cer in infected individuals.
A substantial amount of evidence was available on
selenium, from dietary questionnaires as well as blood,
nails, and hair, mostly from case-control studies. There
is limited evidence suggesting that foods containing
selenium protect against stomach cancer.
7.5.5.6  Chilli
(Also see chapter 4.2.5.12.1.)
Fourteen case-control studies investigated chilli use. Most of
these reported increased risk with increased use, although
results were heterogeneous and data were not suitable for
meta-analysis.
Anecdotally, chilli may be used to disguise ‘off ’ flavours in
foods, so these data may be confounded by socioeconomic
status, the availability of refrigeration, and H pylori infection.
Some constituents of chilli are irritants, which could there-
fore plausibly increase inflammation in the stomach (also see
chapter 2.4.1.3).
The evidence, from case-control studies only, is
inconsistent. There is limited evidence suggesting that
chilli is associated with an increased risk of stomach
cancer.
7.5.5.7  Processed meat
(Also see chapter 4.3.5.1.2.)
Eight cohort studies, 21 case-control studies, 1 cross-sec-
tional study, and 1 ecological study investigated processed
meat. Most of these showed increased risk with higher
intake. Meta-analysis of cohort data showed a non- signifi-
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cant relationship with increased risk. Meta-analysis of case-
control data produced evidence of a statistically significant
dose-response relationship. Heterogeneity is likely to be
caused by the diverse nature of definitions for processed
meat in different studies.
Nitrates are produced endogenously in gastric acid, and are
added as preservatives to processed meats. They may con-
tribute to N-nitroso compound production and exposure. N-
nitroso compounds are suspected mutagens and carcinogens
(see box 4.3.2).55 Many processed meats also contain high
levels of salt and nitrite. Meats cooked at high temperatures
can contain heterocyclic amines and polycyclic aromatic
hydrocarbons (see box 4.3.4). Haem promotes the formation
of N-nitroso compounds and also contains iron. Free iron can
lead to the production of free radicals (see box 4.3.3).
The evidence is inconsistent. There is limited evidence
suggesting that processed meat is a cause of stomach
cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort98 and two case-control studies95 99 have been published.
This new information does not change the Panel judgement.
Also see box 3.8.
7.5.5.8  Smoked foods
(Also see chapter 4.3.5.7.)
Seventeen case-control studies and two ecological studies
investigated smoked foods. Most of these showed increased
risk with increased intake, with none reporting statistically
significant reduced risk.
Definitions of smoked foods varied between studies,
although most included smoked meats and/or fish. Smoked
foods are often salted. High rates of mortality from stomach
cancer are found in countries such as Iceland, Hungary, and
Latvia, where diets include a regular intake of meat and/or
fish preserved by smoking. 
Smoked foods, particularly meats, may contain polycyclic
aromatic hydrocarbons, depending on the fuel burned to pro-
duce the smoke.100 (Also see box 4.3.4.) Smoked meats are
also often salted or cured, meaning that they are likely to
raise endogenous production of N-nitroso compounds in the
stomach (see box 4.3.2). These are suspected causes of stom-
ach cancer.
There is limited evidence from case-control and
ecological studies, some of which were of poor quality,
that smoked foods are causes of stomach cancer.
The Panel is aware that since the conclusion of the SLR, three
case-control studies95 96 99 have been published. This new infor-
mation does not change the Panel judgement. Also see box 3.8.
7.5.5.9  Grilled (broiled) or barbecued
(charbroiled) animal foods
(Also see chapter 4.3.5.8.)
Three cohort studies and 12 case-control studies investigat-
ed grilled (broiled) or barbecued (charbroiled) foods (these
were predominantly meats or fish, although not all studies
specified the foods studied). Most studies showed increased
risk with increased intake.
Cooking methods involving grilling above a heat source
and barbecuing can produce marked differences in levels of
carcinogens in foods cooked in these ways (see chapter
4.9.4). For example, fat dripping on hot surfaces can form
polycyclic aromatic hydrocarbons and heterocyclic amines
(see box 4.3.4), while oven grilling prevents this from hap-
pening, resulting in much lower levels of these compounds
in the cooked foods.
There is limited, inconsistent evidence, mostly from
case-control studies, that grilled (broiled) or
barbecued (charbroiled) animal foods are causes of
stomach cancer.
7.5.5.10  Salt 
(Also see chapter 4.6.5.2.)
Three cohort studies, 21 case-control studies, and 12 eco-
logical studies investigated total salt use. Other groupings
examined were salt added at the table (2 cohort, 13 case-con-
trol) and sodium intake (1 cohort, 8 case-control). Most stud-
ies showed increased risk with increased intake, but there is
some unexplained heterogeneity. Meta-analysis of case-con-
trol data showed an 18 per cent increased risk per gram of
sodium per day; the meta-analyses for total salt indicated
increased risk but were not statistically significant (figure
4.6.1).
Assessment of salt intake is complicated as the small pro-
portion added during preparation or at the table is very vari-
able and difficult to quantify. Higher-quality studies, which
are better adjusted, tend to report a greater or more signif-
icant effect. However, residual confounding is possible: salt
intake may be inversely related to the availability of refrig-
eration in a population, and so to socioeconomic status,
which is itself related to stomach cancer risk. 
Salt has been shown to directly damage the stomach lin-
ing in animal trials. It has also been shown to increase
endogenous N-nitroso compound formation (see box 4.3.2).
Salt may enhance the action of carcinogens in the stomach.
In addition, salt intake may facilitate H pylori infection.101
There is a substantial amount of evidence from studies
on total salt use, salt added at the table, and sodium
intake. For total salt use, a dose-response relationship
was apparent from cohort but not case-control studies.
For sodium intake, a dose response was also apparent
from case-control studies. The mechanistic evidence is
strong. Salt is a probable cause of stomach cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort102 and two case-control studies95 99 have been published.
This new information does not change the Panel judgement.
Also see box 3.8.
7.5.5.11  Salted and salty foods
(Also see chapter 4.6.5.2.1.)
Four cohort studies, 17 case-control studies, and 1 ecologi-
cal study investigated salty or salted foods. Nearly all of the
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studies showed increased risk with increased intake. Meta-
analysis of cohort data showed a non-significant increased
risk; meta-analysis of case-control data showed a 5.2-fold
increased risk per serving per day (figure 4.6.2).
Heterogeneity may be partly explained by variation between
studies in the precise foods being assessed.
As stated above, assessment of salt intake is complicated.
Again, higher-quality studies report a greater or more sig-
nificant effect.
Again, salt has been shown to directly damage the stom-
ach lining in animal trials. It has also been shown to increase
endogenous N-nitroso compound formation (see box 4.3.2). 
The evidence, both from case-control and cohort
studies, is consistent. A dose-response relationship is
apparent from case-control but not cohort studies.
There is robust evidence for mechanisms operating in
humans. Salted and salty foods are probable causes of
stomach cancer.
The Panel is aware that since the conclusion of the SLR, two
case-control studies95 99 have been published. This new infor-
mation does not change the Panel judgement. Also see box 3.8.
7.5.5.12  Other exposures
Other exposures were evaluated. However, the data were
either of too low quality, too inconsistent, or the number of
studies too few to allow conclusions to be reached. These
were as follows: cereals (grains) and their products; starchy
roots, potatoes, and other tubers; plantains; nuts and seeds;
herbs, spices, and condiments; meat; poultry; eggs; fats and
oils; milk and dairy products; sugar; fruit juices; coffee; tea;
alcohol; nitrosodimethylamine/dietary nitrate/nitrite; drying
or dried food; dietary fibre; sugars; total fat; fatty acid com-
position; cholesterol; protein; carotenoids; thiamin;
riboflavin; vitamin C; vitamin D; multivitamin/mineral sup-
plements; selenium supplements; iron; calcium; energy
intake; body fatness; culturally defined diets; meal frequen-
cy; and eating speed.
7.5.6  Comparison with previous report
7.5.6.1  General
See 7.1.6.1, and box 3.8.
7.5.6.2  Specific
The previous report judged the evidence that vegetables and
fruits protect against stomach cancer to be convincing. Since
then, the evidence from cohort studies has been rather equiv-
ocal, whereas evidence from case-control studies remains
strong and consistent. Previously, the compounds found in
allium vegetables were judged possibly to protect against
stomach cancer; more recent evidence for allium vegetables
is stronger. 
The previous report found the evidence that refrigeration
protects against stomach cancer to be convincing. Also see
box 4.6.4.
Before the mid-1990s there were no published trials of
selenium supplements. Two trials are now available, as well
as increased numbers of cohort and case-control studies, but
the evidence is still limited and only suggestive of a protec-
tive effect.
7.5.7  Conclusions 
The Panel concludes:
Non-starchy vegetables, and specifically allium vegetables,
as well as fruits probably protect against stomach cancer. 
Salt and salt-preserved foods are probably causes of this
cancer. 
There is limited evidence suggesting that pulses (legumes)
including soya and soya products and foods containing sele-
nium protect against stomach cancer. 
There is also limited evidence suggesting that chilli,
processed meat, smoked foods, and grilled (broiled) and bar-
becued (charbroiled) animal foods are causes of stomach
cancer.
Infection with the bacterium H pylori is a necessary but
not sufficient cause of stomach cancer.
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7.6  Pancreas 
Cancer of the pancreas is the thirteenth most common
type of cancer worldwide. About 230 000 cases were
recorded in 2002, accounting for around 2 per cent of
cancers overall. The incidence is somewhat more
common in men than in women. It is generally
increasing, particularly in high-income countries, 
where it is most frequent. It is rare in Africa and Asia.
This cancer is almost always fatal and is the ninth most
common cause of cancer death. 
Overall, the Panel is impressed by the strength of the
evidence that body fatness, abdominal fatness, and the
factors that lead to greater adult attained height, or its
consequences, are causes of cancer of the pancreas. 
The Panel judges as follows: 
The evidence that body fatness is a cause of cancer of 
the pancreas is convincing; abdominal fatness is probably
a cause of this cancer.
Foods containing folate probably protect against 
this cancer. 
The factors that lead to greater adult attained height, 
or its consequences, are probably a cause of pancreatic
cancer. 
It is unlikely that coffee has any substantial effect on
the risk of this cancer.
There is limited evidence suggesting that fruits and
physical activity protect against this cancer, and that red
meat is a cause of this cancer. 
See chapter 8 for evidence and judgements on factors
that modify the risk of body fatness and abdominal
fatness, including physical activity and sedentary ways 
of life, the energy density of foods and drinks, and
breastfeeding. 
Tobacco smoking is an established cause of 
this cancer.
In final summary, the strongest evidence,
corresponding to judgements of “convincing” and
“probable”, shows that body fatness and (probably)
abdominal fatness are both causes of cancer of the
pancreas, and that the factors that lead to greater adult
attained height, or its consequences, are probably also a
cause of this cancer. Foods containing folate are probably
protective. It is unlikely that coffee has any substantial
effect on the risk of this cancer.
The pancreas is an elongated gland located behind 
the stomach. It contains two types of tissue, exocrine 
and endocrine. The exocrine pancreas produces digestive
enzymes that are secreted into the small intestine. Cells in
the endocrine pancreas produce hormones including insulin
and glucagon, which influence glucose metabolism. 
Over 95 per cent of pancreatic cancers are adenocarci-
nomas of the exocrine pancreas, the type included in this
Report.
7.6.1  Trends, incidence, and survival 
Age-adjusted rates of pancreatic cancer have been general-
ly stable since the 1970s, following an approximate three-
fold rise over the preceding 50 years in the countries for
which data are available.103 104
This is mainly a disease of high-income countries, where
overall rates are nearly three times higher than in middle-
and low-income countries. Around the world, age-adjusted
incidence rates range from 10–15 per 100 000 people in
parts of northern, central, and eastern Europe to less than
1 per 100 000 in areas of Africa and Asia, although rates are
FOOD, NUTRITION, PHYSICAL ACTIVITY, 
AND CANCER OF THE PANCREAS
In the judgement of the Panel, the factors listed below modify the risk of
cancer of the pancreas. Judgements are graded according to the strength
of the evidence.
DECREASES RISK INCREASES RISK
Convincing Body fatness
Probable Foods containing Abdominal fatness 
folate1 Adult attained
height2
Limited — Fruits3 Red meat5
suggestive Physical activity4
Limited — Cereal (grains) and their products; dietary fibre;
no conclusion vegetables; pulses (legumes); soya and soya
products; processed meat; poultry; fish; eggs; milk
and dairy products; total fat; butter; plant oils;
margarine; cholesterol; sugar (sucrose); black tea;
green tea; alcohol; nitrate and nitrite; total
carbohydrate; folic acid supplements; vitamin C;
vegetarianism; age at menarche; lactation; energy
intake
Substantial 
effect on risk Coffee
unlikely
1 Includes both foods naturally containing the constituent and foods which
have the constituent added (see chapter 3.5.3).
2 Adult attained height is unlikely directly to modify the risk of cancer. It is a
marker for genetic, environmental, hormonal, and also nutritional factors
affecting growth during the period from preconception to completion of
linear growth (see chapter 6.2.1.3).
3 Judgements on vegetables and fruits do not include those preserved by
salting and/or pickling. 
4 Physical activity of all types: occupational, household, transport, and
recreational.
5 The term ‘red meat’ refers to beef, pork, lamb, and goat from domesticated
animals.
For an explanation of all the terms used in the matrix, 
please see chapter 3.5.1, the text of this section, 
and the glossary.
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relatively high in some countries in these areas, for exam-
ple, Japan and Korea. In the USA, rates are higher among
African-American people than in white people.3 The risk of
pancreatic cancer increases with age, with most diagnoses
made in people between the ages of 60 and 80.
The early stages of this cancer do not usually produce
symptoms, so the disease is generally advanced when it is
diagnosed. Survival rates are therefore low — around 4 per
cent at 5 years. This cancer accounts for around 2 per cent
of all cancer incidence, but somewhat over 3 per cent of all
cancer deaths.4 Also see box 7.1.1.
7.6.2  Pathogenesis
The ductal cells in the head of the pancreas are exposed to
pancreatic secretions, as well as bile, and environmental car-
cinogens can reach these cells through those fluids or in the
blood (see 7.7).
The pancreas is relatively inaccessible to routine medical
examination, so the progression of this cancer through pre-
cursor lesions is not well understood. However, inflamma-
tion is implicated in this process through chronic pancreatitis,
which is a risk factor for pancreatic cancer. The role of infec-
tion with H pylori (see box 7.5.1) is the subject of ongoing
research.105 Conditions that lead to high insulin levels in pan-
creatic secretions, such as insulin resistance and type 2 dia-
betes, may increase the risk of this cancer.106
More than 90 per cent of pancreatic cancer cases are spo-
radic (due to spontaneous rather than inherited mutations),
although a family history increases risk, particularly where
more than one family member is involved.105 Around 75–90
per cent of pancreatic cancer cases involve a point mutation
in the K-ras oncogene107 (see box 2.2 in chapter 2).
7.6.3  Other established causes
(Also see chapters 2.4 and 7.1.3.1.) 
Tobacco use. Approximately 25 per cent of cases of pancre-
atic cancer are attributable to tobacco smoking. 
7.6.4  Interpretation of the evidence 
7.6.4.1  General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7. 
‘Relative risk’ is used in this Report to denote ratio mea-
sures of effect, including ‘risk ratios’, ‘rate ratios’, ‘hazard
ratios’, and ‘odds ratios’.
7.6.4.2  Specific 
Considerations specific to cancer of the pancreas include: 
Measurement. Owing to very low survival rates, both inci-
dence and mortality can be assessed. Low survival times and
rates decrease the reliability of case-control studies, which
often rely on proxy reporting.
Confounding. High-quality studies adjust for smoking.
7.6.5  Evidence and judgements
In total, 318 publications were included in the SLR for this
cancer. Fuller summaries of the epidemiological, experi-
mental, and mechanistic evidence are in Chapters 4–6.
The full SLR is contained on the CD included with this
Report. 
7.6.5.1  Fruits
(Also see chapter 4.2.5.2.)
Six cohort studies, 16 case-control studies, and 8 ecological
studies investigated fruits. All cohort studies and most other
studies showed decreased risk with increased intake. Meta-
analysis of cohort data showed a non-significant decreased
risk. Meta-analysis of case-control data showed a statistically
significant decreased risk. 
Fruits are sources of vitamin C and other antioxidants,
such as carotenoids, phenols, and flavonoids, as well as other
potentially bioactive phytochemicals. Antioxidants trap free
radicals and reactive oxygen molecules, protecting against
oxidation damage. In addition, flavonoids found in fruit
directly inhibit the expression of the cytochrome P450
enzyme, which helps to metabolise toxins and has been asso-
ciated with increased risk of lung cancer, primarily in smok-
ers.68 It is difficult to unravel the relative importance of each
constituent and is likely that a protective effect may result
from a combination of influences on several pathways
involved in carcinogenesis.
The evidence is inconsistent. There is limited evidence
suggesting that fruits protect against pancreatic cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort study108 has been published. This new information does
not change the Panel judgement. Also see box 3.8.
7.6.5.2  Foods containing folate 
(Also see chapter 4.2.5.4.)
Three cohort studies, two case-control studies, and one eco-
logical study investigated folate from foods and/or folic acid
from supplements. Meta-analysis of all three cohort studies
showed a non-significant decreased risk, with high hetero-
geneity. When stratified according to the source, both dietary
studies showed a non-significant decreased risk, and three
studies of supplements showed a non-significant increased
risk. One cohort study also analysed serum folate levels,
showing a significant decreased risk of 55 per cent for the
highest levels compared with the lowest. Both the case-con-
trol studies and the ecological study showed decreased risk
with increased intake. Folic acid supplements do not show
a protective effect. 
Folate plays an important role in the synthesis and repair
of DNA. There is a known interaction between folate and
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alcohol and the risk of some cancers (see chapter 4.8). Folate
intake is strongly correlated with intake of non-starchy poly-
saccharide or dietary fibre.
The evidence available is sparse but a dose-response
relationship was apparent from cohort studies. There is
limited evidence suggesting that foods containing
folate protect against pancreatic cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort study109 has been published. This new information does
not change the Panel judgement. Also see box 3.8.
7.6.5.3  Red meat
(Also see chapter 4.3.5.1.1.)
Seven cohort studies and four case-control studies investi-
gated red meat. Nearly all of the studies showed increased
risk with increased intake.
Red meat contains haem iron. Free iron can lead to the pro-
duction of free radicals (see box 4.3.3). When cooked at high
temperatures, red meat can also contain heterocyclic amines
and polycyclic aromatic hydrocarbons (see box 4.3.4).
Evidence from cohort studies is less consistent than
that from case-control studies. There is limited
evidence suggesting that red meat is a cause of
pancreatic cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort study110 has been published. This new information does
not change the Panel judgement. Also see box 3.8.
7.6.5.4  Coffee
(Also see chapter 4.7.5.4.)
Eighteen cohort studies, 37 case-control studies, and 11 eco-
logical studies investigated coffee. Analysis of cohort data
showed an effect estimate close to null with low hetero-
geneity. Data for case-control studies were less consistent.
There is ample evidence, including prospective data,
which is consistent and with low heterogeneity, and
which fails to show an association. It is unlikely that
coffee has a substantial effect on the risk of pancreatic
cancer.
7.6.5.5  Physical activity
(Also see chapter 5.4.5.)
A total of three cohort studies and one case-control study
investigated total physical activity; three cohort studies and
two case-control studies investigated occupational activity;
and nine cohort studies and three case-control studies inves-
tigated recreational activity. Several studies also examined
walking and transportation. Most of the studies showed
decreased risk with increased physical activity, though there
was heterogeneity in the direction of effect and no clear
dose-response relationship.
Sustained moderate physical activity raises the metabolic
rate and increases maximal oxygen uptake. In the long term,
regular periods of such activity increase the body’s metabolic
efficiency and capacity (the amount of work that it can per-
form), as well as reducing blood pressure and insulin resis-
tance. In addition, low levels of physical activity decrease
gastrointestinal transit times. This alters bile content and
secretion, as well as affecting pancreatic activity.111
There is evidence from prospective studies showing
lower risk of pancreatic cancer with higher levels of
various types of physical activity, but it is rather
inconsistent. There is limited evidence suggesting that
physical activity protects against pancreatic cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort study112 has been published. This new information does
not change the Panel judgement. Also see box 3.8.
7.6.5.6  Body fatness
(Also see chapter 6.1.3.1.)
Twenty-three cohort studies and 15 case-control studies
investigated body fatness, as measured by BMI. Most cohort
studies showed increased risk with increased body fatness,
but case-control studies were inconsistent. Meta-analysis of
cohort data showed a 14 per cent increased risk per 5 kg/m2
(figure 6.1.4). Heterogeneity appeared to be explained by a
number of studies failing to adjust for smoking, which is sep-
arately associated with both BMI and pancreatic cancer.
It is biologically plausible that body fatness is a cause of
pancreatic cancer. There is an established connection
between increasing BMI or body fatness and insulin resis-
tance and diabetes. The risk of this cancer is increased in
people with insulin resistance or diabetes. It also directly
affects levels of many circulating hormones, such as insulin,
insulin-like growth factors, and oestrogens, creating an envi-
ronment that encourages carcinogenesis and discourages
apoptosis (see box 2.4). Body fatness stimulates the inflam-
matory response, which may contribute to the initiation and
progression of several cancers (see chapter 2.4.1.3).
There is ample epidemiological evidence, which is
generally consistent, and there is a dose-response
relationship. There is evidence for plausible
mechanisms that operate in humans. The evidence
that greater body fatness is a cause of pancreatic
cancer is convincing.
The Panel is aware that since the conclusion of the SLR, two
cohort studies58 112 have been published. This new information
does not change the Panel judgement. Also see box 3.8.
7.6.5.7  Abdominal fatness
(Also see chapter 6.1.3.2.)
Three cohort studies investigated waist circumference, two
cohort studies investigated waist to hip ratio, and one cohort
study investigated patterns of weight gain, all of which
showed increased risk with increasing measures of abdom-
inal fatness. Half of all studies were statistically significant.
The general mechanisms through which abdominal fatness
could plausibly cause cancer are outlined in chapter 6.1.3
(also see box 2.4). The hormonal and other biological effects
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of being overweight or obese are outlined in chapter 8. Many
of these, such as increased circulating oestrogens and
decreased insulin sensitivity, are associated with abdominal
fatness independently of overall body fatness.
There is a substantial amount of epidemiological
evidence that is generally consistent, and there is
evidence for plausible mechanisms. Abdominal fatness
is a probable cause of pancreatic cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort study112 has been published. This new information does
not change the Panel judgement. Also see box 3.8.
7.6.5.8  Adult attained height
(Also see chapter 6.2.3.1.)
Eight cohort studies, 12 case-control studies, and 1 ecolog-
ical study investigated adult attained height. Most cohort
studies and the single ecological study showed increased risk
with greater adult attained height. Case-control studies were
inconsistent. Meta-analysis of cohort data showed an 11 per
cent increased risk per 5 cm of height (figure 6.2.5). There
was considerable heterogeneity in case-control data, not all
readily explained. However, the cohort studies showed a lin-
ear dose-response relationship (figure 6.2.6). 
The general mechanisms through which the factors that
lead to greater adult attained height, or its consequences,
could plausibly influence cancer risk are outlined in chapter
6.2.1.3 (for more detail see box 2.4). Many of these, such as
early-life nutrition, altered hormone profiles, and the rate of
sexual maturation, could plausibly increase cancer risk.
There is ample prospective epidemiological evidence,
though there is some inconsistency. There is evidence
for a dose-response relationship, and evidence for
plausible mechanisms. The factors that lead to greater
adult attained height, or its consequences, are
probably a cause of pancreatic cancer. The causal
factor is unlikely to be tallness itself, but factors that
promote linear growth in childhood.
The Panel is aware that since the conclusion of the SLR, one
cohort study112 has been published. This new information does
not change the Panel judgement. Also see box 3.8.
7.6.5.9  Other exposures
Other exposures were evaluated. However, the data were
either of too low quality, too inconsistent, or the number of
studies too few to allow conclusions to be reached. These
were as follows: cereals (grains) and their products; veg-
etables; pulses (legumes); soya and soya products; processed
meat; poultry; fish; eggs; milk and dairy products; butter;
margarine; black tea; green tea; alcoholic drinks;
nitrate/nitrite; total carbohydrate; dietary fibre; sucrose;
total fat; cholesterol; folic acid supplements; plant oils; ener-
gy intake; age at menarche; vegetarianism; and lactation.
In the case of alcoholic drinks, although low-to-moderate lev-
els of drinking were unlikely to have an effect on risk, it could
not be excluded that heavy drinking might have an effect.
7.6.6  Comparison with previous report 
7.6.6.1  General
See 7.1.6.1, and box 3.8 in chapter 3.
7.6.6.2  Specific
Apart from vegetables and fruits, the strongest evidence and
judgements here are remarkably different from the previous
report. Much of the evidence on body fatness, abdominal fat-
ness, attained adult height (tallness), and physical activity
is recent.
7.6.7  Conclusions
The Panel concludes:
The evidence that body fatness is a cause of cancer of the
pancreas is convincing; abdominal fatness is probably a
cause of this cancer. 
Foods containing folate (but not folic acid supplements)
probably protect against pancreatic cancer. 
The factors that lead to greater adult attained height, or
its consequences, are probably a cause of this cancer. Greater
height is unlikely to directly modify the risk of cancer; it is
a marker for genetic, environmental, hormonal, and also
nutritional factors affecting growth during the period from
preconception to completion of linear growth.
It is unlikely that coffee has any substantial effect on risk.
There is limited evidence suggesting that fruits and also
physical activity protect against this cancer, and that red
meat is a cause of this cancer.
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7.7  Gallbladder 
Cancer of the gallbladder accounts for somewhat over 
2 per cent of all cancer incidence and rates are generally
declining. The highest rates occur in eastern Asia and
eastern Europe, but it is rare in Africa. This cancer is
usually fatal and is the 17th most common cause of 
cancer death. 
The Panel judges as follows: 
Body fatness is probably a cause of cancer of the
gallbladder and people with gallstones are more likely to
develop gallbladder cancer. 
See chapter 8 for evidence and judgements on factors
that modify the risk of body fatness, including physical
activity and sedentary ways of life, the energy density of
foods and drinks, and breastfeeding. 
In final summary, the strongest evidence, corresponding
to judgements of “convincing” and “probable”, shows that
body fatness is probably a cause of gallbladder cancer,
both directly and indirectly, through the formation of
gallstones. 
The gallbladder is a small sac-like organ that forms part of
the biliary tract. Bile, produced in the liver, flows into the
gallbladder, where it is stored and concentrated until
released into the small intestine. 
More than 90 per cent of gallbladder cancers are adeno-
carcinomas, while only a small proportion are squamous cell
carcinomas.4
7.7.1  Trends, incidence, and survival 
Age-adjusted rates of gallbladder cancer are decreasing.1
Even in many of the countries where incidence had been rel-
atively high, such as in eastern Asia and eastern Europe, rates
have decreased and continued to fall, following a dramatic
rise in the 1970s and 1980s. 
There is no clear geographical pattern to the distribution
of gallbladder cancer. Age-adjusted incidence rates range
from 5–10 per 100 000 people in parts of eastern Asia and
eastern Europe to less than 1 per 100 000 in parts of Africa.
In the USA, rates are higher among both Native- and
Hispanic-American people than in white people.113 Around
most of the world, gallbladder cancer is slightly more com-
mon in women than men. In Japan and Korea, this trend is
reversed, with around 60 per cent of cases in men.103 Risk
increases with age, with more than two thirds of cases occur-
ring in people aged 65 years or older.114
Gallbladder cancer is usually advanced at diagnosis.
Survival rates are poor: at 5 years less than 12 per cent for
advanced disease, but this is much higher (by up to 20 per
cent) when the cancer is caught early. Gallbladder cancer
accounts for just over 2 per cent of all cancer incidence, and
the same proportion of all cancer deaths. Also see box 7.1.1.
7.7.2  Pathogenesis
The pathogenesis of gallbladder cancer is not well under-
stood, partly because it is often diagnosed at a late stage. 
Having gallstones increases the risk of this cancer. The
associated inflammation decreases the speed at which bile
empties from the gallbladder; gallstones may also have a
direct effect by blocking the transit of bile.115 Gallstones, like
gallbladder cancers, are more common in women than men,
and the risk of cancer is proportional to the size of the gall-
stones.116 However, other factors must also be involved: in
high-income countries up to 1 person in 10 has gallstones
(many asymptomatic),117 whereas gallbladder cancer is diag-
nosed in only around 1 in 50 000. 
Many toxins, whether they come from diet, smoke inhala-
tion, or other environmental sources (and their metabolic
products) are excreted and concentrated in the bile.
Early stages of the disease include plaque-like lesions and
small ulcerations in the mucosal lining of the gallbladder,
which are associated with chronic inflammation (cholecys-
titis). This may progress to carcinoma in situ, and then to
invasive tumours. This process probably takes at least 20
years (cholecystitis is seldom seen in people under 40),
hence the age profile of gallbladder cancer. Chronic inflam-
FOOD, NUTRITION, PHYSICAL ACTIVITY, 
AND CANCER OF THE GALLBLADDER
In the judgement of the Panel, the factors listed below modify the risk of
cancer of the gallbladder. Judgements are graded according to the
strength of the evidence.
DECREASES RISK INCREASES RISK
Convincing
Probable Body fatness1
Limited — 
suggestive
Limited — Peppers (capsicums); fish; coffee; tea; alcohol; 
no conclusion vitamin C.
Substantial 
effect on risk None identified
unlikely
1 Directly and indirectly, through the formation of gallstones.
For an explanation of all the terms used in the matrix, 
please see chapter 3.5.1, the text of this section, 
and the glossary.
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mation caused by other factors (such as in ‘porcelain gall-
bladder’ or from chronic bacterial infection) may be a nec-
essary stage in the development of gallbladder cancer,
although the evidence is not conclusive.4 118 119
A congenital deformity to the pancreatic ducts is associ-
ated with most gallbladder cancers in eastern Asia.120 This
may account for the different epidemiology in this region,
and could imply a distinct pathogenesis with different risk
factors. Mutations of the tumour-suppressor p53 gene are fre-
quent in gallbladder cancers (see box 2.2).121
7.7.3  Other established causes 
(Also see chapter 2.4 and 7.1.3.1 of this chapter.)
Other diseases. Having gallstones increases the risk of gall-
bladder cancer and can be identified as a cause of this can-
cer. 
Other causes are not established; see 7.7.2.
7.7.4  Interpretation of the evidence 
7.7.4.1  General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7. 
‘Relative risk’ is used in this Report to denote ratio mea-
sures of effect, including ‘risk ratios’, ‘rate ratios’, ‘hazard
ratios’, and ‘odds ratios’.
7.7.4.2  Specific
Considerations specific to cancer of the gallbladder include: 
Confounding. Having gallstones increases the risk of gall-
bladder cancer. Exposures with an apparent link to gall-
bladder cancer may act indirectly, through gallstones, or
directly, either after gallstone formation or in their absence.
It is not yet possible to separate these effects. See 7.7.7.
7.7.5  Evidence and judgements 
In total, 48 publications were included in the SLR for gall-
bladder cancer. Fuller summaries of the epidemiological,
experimental, and mechanistic evidence are to be found in
Chapters 4–6.
The full SLR is contained on the CD included with this
Report. 
7.7.5.1  Body fatness
(Also see chapter 6.1.3.1.)
Five cohort studies, seven case-control studies, and two
cross-sectional studies investigated body fatness, as mea-
sured by BMI. Most studies showed increased risk with
increased body fatness. Meta-analysis of cohort data showed
a 23 per cent increased risk per 5 kg/m2; meta-analysis of
case-control data showed a 19 per cent increased risk per 5
kg/m2. Heterogeneity could be partly attributed to differ-
ences in the study participants’ ethnicity or sex, or to the
number of adjustments made in the study.
Body fatness directly affects levels of many circulating hor-
mones, such as insulin, insulin-like growth factors, and
oestrogens, creating an environment that encourages car-
cinogenesis and discourages apoptosis (see box 2.4). It also
stimulates the body’s inflammatory response, which may
contribute to the initiation and progression of several can-
cers (see chapter 2.4.1.3). In addition, obesity is a known
cause of gallstone formation, and having gallstones increas-
es the risk of gallbladder cancer, possibly through bile cho-
lesterol supersaturation. 
Because having gallstones is a cause of gallbladder can-
cer, the Panel also reviewed the dietary causes of gallstones,
especially in relation to body fatness. Having a relatively high
BMI increases the risk of gallstones in a linear fashion; waist
circumference is associated with gallstone risk in men, inde-
pendently of BMI. Gallstone formation is associated with
repeated dieting, especially where it involves rapid weight
loss, such as that from very low-energy diets and bariatric
surgery.
There is a substantial amount of generally consistent
epidemiological evidence with some evidence of a
dose-response relationship. There is evidence for
several plausible mechanisms. Greater body fatness is
a probable cause of gallbladder cancer, directly and
also indirectly through the formation of gallstones. 
7.7.5.2  Other exposures
Other exposures were evaluated. However, the data were
either of too low quality, too inconsistent, or the number of
studies too few to allow conclusions to be reached. These
included capsicums, fish, coffee, tea, alcohol, and vitamin C.
7.7.6  Comparison with previous report
7.7.6.1  General
See 7.1.6.1, and box 3.8 of chapter 3.
7.7.6.2  Specific
Since publication of the previous report, the evidence that
body fatness is an indirect and a direct cause of gallbladder
cancer has strengthened.
7.7.7  Conclusions
The Panel concludes:
Greater body fatness is probably a cause of cancer of the gall-
bladder. People with gallstones are more likely to develop
gallbladder cancer.
277
C H A P T E R  7  •  C A N C E R S
7.8  Liver 
Cancer of the liver is the sixth most common type of
cancer worldwide. Around 625 000 cases were recorded in
2002, accounting for around 6 per cent of all cancers.
About half of all cases occur in China, and it is more
common in middle- and low-income countries. It is almost
always fatal, and is the third most common cause of death
from cancer, accounting for around 9 per cent of all
deaths. 
Overall, the Panel notes that toxic compounds are the
main causes of primary liver cancer related to foods and
drinks. 
The Panel judges as follows: 
The evidence that aflatoxins, which contaminate mostly
cereals (grains) and pulses (legumes) stored in hot, wet
conditions, are a cause of liver cancer is convincing.
Alcoholic drinks are probably a direct cause of this cancer.
There is limited evidence suggesting that fruits are
protective, and that body fatness is a cause of this cancer. 
Other causes of this cancer include infection with
hepatitis viruses B or C, the development of cirrhosis from
any cause, and infestation with liver flukes. 
In final summary, the strongest evidence, corresponding
to judgements of “convincing” and “probable”, shows that
aflatoxins, and probably alcoholic drinks, are causes of
liver cancer.
The liver is the body’s largest organ. It processes and stores
nutrients, and produces cholesterol and proteins such as
albumin, clotting factors, and the lipoproteins that carry cho-
lesterol. It also secretes bile and performs many metabolic
functions, including detoxification of several classes of car-
cinogen.
Different types of tumour occur in the liver. Each has
potentially different causes and natural history. Around
75–90 per cent of liver cancers are hepatocellular carcino-
ma. This starts in hepatocytes, which are the commonest
type of liver cell, and has various subtypes. Cholangio-
carcinomas account for 10–20 per cent of primary liver can-
cers. These cancers start in the small bile ducts (tubes that
carry bile to the gallbladder) within the liver. Hepato-
blastoma and angiosarcoma are less common types of liver
cancer. Hepatocellular carcinoma is the main type included
here. Secondary tumours of the liver are not included.
7.8.1  Trends, incidence, and survival
Age-adjusted rates of liver cancer are either increasing or sta-
ble in most countries for which data are available.6 122 However,
a recent report on trends in the USA between 1975 and 2001
suggested that these increases may now be reversing.3
This is predominantly a disease of middle- to low-income
countries, where overall rates are more than double those
in high-income countries. Around the world, age-adjusted
incidence rates range from more than 40 per 100 000 peo-
ple in eastern Asia and parts of Africa to less than 5 per
100 000 in the Americas and northern Europe.2 In the USA,
rates are higher among African-American and Hispanic-
American people, and Asian and Pacific Islanders, than in
white people.3 Globally, rates are higher in men than women
by five to two.
Risk tends to increase with age, although the disease
develops at a younger age (typically around the age of 40,
or below) in people living in Asia and Africa compared with
those in high-income countries.123
FOOD, NUTRITION, PHYSICAL ACTIVITY, 
AND CANCER OF THE LIVER
In the judgement of the Panel, the factors listed below modify the risk of
cancer of the liver. Judgements are graded according to the strength of
the evidence.
DECREASES RISK INCREASES RISK
Convincing Aflatoxins1
Probable Alcoholic drinks2
Limited — Fruits3 Body fatness
suggestive
Limited — Cereals (grains) and their products1; non-starchy
no conclusion vegetables; peanuts (groundnuts)1; fish; salted fish;
water source; coffee; tea
Substantial 
effect on risk None identified
unlikely
1 Foods that may be contaminated with aflatoxins include cereals (grains),
and also pulses (legumes), seeds, nuts, and some vegetables and fruits 
(see chapter 4.2). 
2 Cirrhosis is an essential precursor of liver cancer caused by alcohol. The
International Agency for Research on Cancer has graded alcohol as a Class 1
carcinogen for liver cancer. Alcohol alone only causes cirrhosis in the
presence of other susceptibility factors.
3 Judgements on vegetables and fruits do not include those preserved by
salting and/or pickling. 
For an explanation of all the terms used in the matrix, 
please see chapter 3.5.1, the text of this section, 
and the glossary.
278
P A R T  2  •  E V I D E N C E  A N D  J U D G E M E N T S
The early stages of liver cancer do not usually produce
symptoms, so the disease is generally advanced when it is
diagnosed. Survival rates are poor: at 5 years, approximately
5 per cent.124 This cancer accounts for almost 6 per cent of
all cancer incidence, but around 9 per cent of all cancer
deaths.2 Also see box 7.1.1.
7.8.2  Pathogenesis
Liver cancer generally follows cirrhosis, so any cause of cir-
rhosis — either viral (see box 7.8.1) or chemical — is like-
ly to increase cancer risk. Approximately 80 per cent of
hepatocellular carcinoma cases develop in cirrhotic livers.123
As for cancers at most sites, accumulated sequential
changes (see chapter 2.5), specifically in mature hepatocytes,
lead to the development of dysplastic nodules; over the
course of around 5 years, 30 per cent may develop into
tumours.125 Hepatocellular carcinoma cells show numerous
genetic changes, perhaps accumulated during cellular pro-
liferation, which is part of the normal liver repair process.126
The hepatitis B virus-related type (see box 7.8.1) appears to
be more genetically unstable than others.127 128
The liver is a common site for metastasis of tumours orig-
inating in other organs.
7.8.3  Other established causes 
(Also see chapter 2.4 and 7.1.3.1.) 
Other diseases. Cirrhosis of the liver increases the risk of, and
so can be seen as a cause of, liver cancer. 
Infection and infestation. Chronic viral hepatitis is a cause
of liver cancer (see box 7.8.1).130 Infestation with liver flukes
is a cause of cholangiocarcinoma. 
Medication. Oral contraceptives containing high doses of oestro-
gen and progesterone may be a cause of this cancer.90 133
7.8.4  Interpretation of the evidence 
7.8.4.1  General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7. 
‘Relative risk’ is used in this Report to denote ratio mea-
sures of effect, including ‘risk ratios’, ‘rate ratios’, ‘hazard
ratios’, and ‘odds ratios’.
7.8.4.2  Specific
Considerations specific to cancer of the liver include: 
Classification. Most of the data is on hepatocellular carci-
noma, the most well characterised (and most common) form
of liver cancer. However, different outcomes are reported for
unspecified primary liver cancer, compared with hepato-
cellular carcinoma or cholangiocarcinoma. This suggests
different causation and so may therefore be a cause of
heterogeneity.
Confounding. Hepatitis B and C viruses are possible con-
founders or effect modifiers; high-quality studies adjust for
them. Not all studies do so.
Measurement. Owing to low survival rates, both incidence
and mortality can be assessed. Low survival times and rates
decrease the reliability of case-control studies, which often
rely on proxy reporting.
7.8.5  Evidence and judgements
In total, 273 publications were included in the SLR for liver
cancer. Fuller summaries of the epidemiological, experi-
mental, and mechanistic evidence are to be found in
Chapters 4–6.
The full SLR is contained on the CD included with this
Report.
7.8.5.1  Fruits
(Also see chapter 4.2.5.2.)
One cohort study and five case-control studies investigated
fruits. The cohort study and most of the case-control stud-
Hepatitis B and hepatitis C viruses are causes of liver cancer. The
former appears to act directly by damaging cells and their DNA.
The latter shows an indirect effect, mediated by cirrhosis. For
both, there is potential for nutrition status to have an effect at
several stages: susceptibility to and duration of infection, liver
damage, DNA damage, and cancer progression.129
Around 7–8 per cent of the world’s population is estimated to
be infected with hepatitis B virus. It is mostly spread by blood
and sexual transmission. In endemic areas, the carrier rate may
be 10–20 per cent.130 It is often acquired at birth or in childhood,
and is endemic in areas of Africa and Asia. Chronic hepatitis B
virus carriers have a 100-fold greater chance of developing liver
cancer than non-carriers. Those infected in adulthood have a
lower risk of this cancer than those infected in childhood because
there is less time for the virus to cause inflammation.130
Vaccination against hepatitis B virus has been shown to reduce
the prevalence of liver cancer by 60 per cent.131
Liver cancer in hepatitis B virus carriers is not necessarily con-
nected with cirrhosis: up to 40 per cent of associated liver can-
cer cases are non-cirrhotic. Hepatitis B virus carries its genetic
code as DNA rather than RNA. Viral DNA can insert itself into liver
cells and alter their DNA. 
Around 3 per cent of the world’s population is estimated to
be infected with hepatitis C virus. It is more prevalent in high-
income countries. Approximately 80 per cent of these infections
become chronic, of which 15–20 per cent develops into cirrho-
sis. Of those, 1–4 per cent develops into liver cancer each year.
Interruption of the sequence of chronic hepatitis developing into
cirrhosis prevents liver cancer. Also, there is an interaction
between hepatitis C virus infection, liver cancer risk, and con-
sumption of alcoholic drinks.132 There is no vaccine against
hepatitis C. It is mostly spread by blood. 
Box 7.8.1 Hepatitis viruses 
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ies showed decreased risk with increased fruit intake. No
studies showed statistically significant increased risk.
Fruits are sources of vitamin C and other antioxidants,
such as carotenoids, phenols, and flavonoids, as well as other
potentially bioactive phytochemicals. Antioxidants trap free
radicals and reactive oxygen molecules, protecting against
oxidation damage. 
In addition, flavonoids found in fruit directly inhibit the
expression of a cytochrome P450 enzyme, which helps to
metabolise toxins and has been associated with increased
risk of lung cancer, primarily in smokers.68 It is difficult to
unravel the relative importance of each constituent and 
is likely that a protective effect may result from a com-
bination of influences on several pathways involved in
carcinogenesis.
The evidence is sparse and inconsistent. There is
limited evidence suggesting that fruits protect against
liver cancer. 
The Panel is aware that since the conclusion of the SLR, one
case-control study134 has been published. This new information
does not change the Panel judgement. Also see box 3.8.
7.8.5.2  Aflatoxins
(Also see chapter 4.1.5.4.)
Five cohort studies and seven case-control studies investi-
gated biomarkers of exposure to aflatoxins. All of the cohort
studies and most of the case-control studies showed
increased risk with elevated measures of exposure. Most
cohort studies showed significant dose-response relation-
ships, although the variety of measures used prevented meta-
analysis. Effect estimates ranged from a three- to sevenfold
increased risk for the highest measures of exposure.
There is strong mechanistic evidence through the meta-
bolic product of aflatoxin B1, which is known to be geno-
toxic and is formed in the liver. It directly damages DNA,
forming adducts. The activity of GST enzymes can result in
lower levels of adducts with varying efficiency between
genotypes. There is clear and consistent evidence that GST-
positive genotypes protect against the increased risk of liver
cancer from hepatitis infection combined with aflatoxin
exposure. This supports a causal role for aflatoxin B1 in
hepatocellular carcinoma.
The evidence is ample and consistent and is supported
by strong evidence for mechanisms operating in
humans. A dose-response relationship is apparent from
both cohort and case-control studies. The evidence that
aflatoxins and aflatoxin-contaminated foods are a
cause of liver cancer is convincing.
7.8.5.3  Alcoholic drinks
(Also see chapter 4.8.5.1.)
A total of 15 cohort studies and 33 case-control studies inves-
tigated alcoholic drinks, and 14 cohort studies and 21 case-
control studies investigated total ethanol intake. Most studies
showed increased risk with increased alcohol intake, with
none reporting statistically significant decreased risk. Meta-
analysis of cohort data showed a 10 per cent increased risk
per 10 g ethanol/day. Meta-analysis of case-control data
showed an 18 per cent increased risk per drink/week, or a
17 per cent increased risk per 10 g ethanol/day (figures
4.8.18–4.8.19). 
Heterogeneity in case-control studies may be explained by
alcoholic behaviour, by proxy reporting, or by failure to
adjust for hepatitis virus status. Several studies used partic-
ipants judged to be at high risk of developing liver cancer
(people who already had liver cirrhosis). These results are
particularly difficult to interpret as cirrhosis status affects
drinking behaviour. Also, the cancer disease path may be dif-
ferent in people with cirrhosis.
It is biologically highly plausible that alcoholic drinks are
a cause of liver cancer. Reactive metabolites of alcohol such
as acetaldehyde can be carcinogenic. DNA mutations may be
less efficiently repaired in the presence of alcohol. Alcohol
may also function as a solvent, enhancing penetration of
other carcinogenic molecules into cells. Additionally, the
effects of alcohol may be mediated through the production
of prostaglandins, lipid peroxidation, and the generation of
free radical oxygen species. Lastly, heavy consumers of alco-
hol may have diets low in essential nutrients, making tissues
susceptible to carcinogenesis. In addition, regular, high lev-
els of alcohol consumption are known to cause liver dam-
age. Tumour promotion has been linked to inflammation in
the liver through alcohol-associated fibrosis and hepatitis.
Alcohol consumption, even at moderate levels, is associat-
ed with increases in levels of circulating hepatitis C virus
RNA in carriers of this infection. This infection is highly
prevalent among alcoholics with chronic liver disease, and
appears to accelerate the course of alcoholic liver disease.
There is ample, generally consistent evidence from
both cohort and case-control studies. A dose-response
relationship is apparent. Alcohol is a cause of cirrhosis,
which predisposes to liver cancer, but the factors that
determine why some people are susceptible to
cirrhosis are not known. Alcoholic drinks are a
probable cause of liver cancer. No threshold was
identified.
The Panel is aware that since the conclusion of the SLR, one
case-control study135 has been published. This new information
does not change the Panel judgement. Also see box 3.8.
7.8.5.4  Body fatness
(Also see chapter 6.1.3.1).
Six cohort studies and two case-control studies investigated
body fatness, as measured by BMI, or obesity. All cohort stud-
ies showed increased risk with increased body fatness, except
in one subgroup of African-American men. There was sub-
stantial heterogeneity and none of the studies adjusted for
hepatitis virus status. The two case-control studies provid-
ed no clear evidence of any effect.
Body fatness directly affects levels of many circulating hor-
mones, such as insulin, insulin-like growth factors, and
oestrogens, creating an environment that encourages car-
cinogenesis and discourages apoptosis (see box 2.4). It stim-
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ulates the body’s inflammatory response, which may con-
tribute to the initiation and progression of several cancers
(see chapter 2.4.1.3).
The epidemiological evidence shows some
inconsistencies and the mechanistic evidence is
speculative. There is limited evidence suggesting that
greater body fatness is a cause of liver cancer.
The Panel is aware that since the conclusion of the SLR, two
cohort studies58 136 have been published. This new information
does not change the Panel judgement. Also see box 3.8.
7.8.5.5  Other exposures
Other exposures were evaluated. However, the data were
either of too low quality, too inconsistent, or the number of
studies too few to allow conclusions to be reached. These
were as follows: cereals (grains) and their products; non-
starchy vegetables; peanuts; fish; salted fish; water source;
coffee; and tea.
In cases of cereals (grains) and peanuts, there are data con-
necting these foods to liver cancer, but the Panel judges that
any causative factor is likely to be aflatoxins. 
7.8.6  Comparison with previous report 
7.8.6.1  General
See 7.1.6.1, and box 3.8 in chapter 3.
7.8.6.2  Specific
Since publication of the previous report, the evidence that
aflatoxin contamination of food is a cause of liver cancer is
stronger and now justifies a judgement of ‘convincing’.
7.8.7  Conclusions 
The Panel concludes:
The evidence is convincing that aflatoxins, which contami-
nate mostly cereals (grains) and pulses (legumes), usually
as a result of long storage in hot, wet conditions, are a cause
of liver cancer. 
Alcoholic drinks are probably a cause of liver cancer. 
There is limited evidence suggesting that fruits are pro-
tective, and that body fatness is a cause of this cancer.
7.9  Colon and
rectum
Cancers of the colon and rectum are the third most
common type worldwide. Around 1 million cases were
recorded in 2002, accounting for around 9 per cent
overall. Rates of this cancer increase with industrialisation
and urbanisation. It has been much more common in high-
income countries but is now increasing in middle- and
low-income countries. It remains relatively uncommon in
Africa and much of Asia. It is somewhat more common in
men than in women. It is fatal in just under half of all
cases and is the fourth most common cause of death from
cancer. 
Overall, the Panel judges that food and nutrition have a
highly important role in the prevention and causation of
cancers of the colon and rectum (here termed
colorectum). 
The Panel judges as follows: 
The evidence that physical activity protects against
colorectal cancer is convincing, although the evidence is
stronger for colon than for rectum. The evidence that red
meat, processed meat, substantial consumption of alcoholic
drinks (in men), body fatness and abdominal fatness, and
the factors that lead to greater adult attained height, or its
consequences, are causes of colorectal cancer is
convincing. Substantial consumption of alcoholic drinks is
probably a cause of this cancer in women. Foods containing
dietary fibre, and garlic, milk, and calcium probably protect
against this cancer.
There is limited evidence suggesting that non-starchy
vegetables, fruits, foods containing folate, fish, foods
containing vitamin D, and selenium and foods containing it
protect against colorectal cancer, and that foods containing
iron, cheese, foods containing animal fats, and foods
containing sugars are causes of this cancer.
See chapter 8 for evidence and judgements on factors
that modify the risk of body fatness and abdominal fatness,
including physical activity and sedentary ways of life, the
energy density of foods and drinks, and breastfeeding.
It has been estimated that this cancer is mostly
preventable by appropriate diets and associated factors. 
In final summary, the strongest evidence, corresponding
to judgements of “convincing” and “probable”,shows that
physical activity protects against colorectal cancer. The
evidence also shows that red meat and processed meat,
substantial consumption of alcoholic drinks (by men and
probably by women), body fatness and abdominal fatness,
and the factors that lead to greater adult attained height,
or its consequences, are causes of this cancer. Foods
containing dietary fibre, and also garlic, milk, and calcium,
probably protect against this cancer.
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The colon is the lower part of the intestinal tract. It extends
from the caecum to the rectum. In the colon, water and salts
are absorbed from undigested foods, and muscles move the
waste products towards the rectum. The colon contains a vast
population of many types of bacteria, which have potential-
ly important functions. These include the fermentation of
unabsorbed carbohydrate (non-starch polysaccharides and
resistant starch) to release energy and short chain fatty acids
that influence the health of the colonic mucosa. It may also
be infected with harmful types of bacteria. The colon is lined
with mucous membranes, and also contains lymphoid cells
that form part of the body’s immune defences. 
Approximately 95 per cent of colorectal cancers are ade-
nocarcinomas. Other types of cancer that can occur here
FOOD, NUTRITION, PHYSICAL ACTIVITY, AND CANCERS OF THE COLON AND THE RECTUM
In the judgement of the Panel, the factors listed below modify the risk of cancers of the colon and the rectum. Judgements are graded according to the
strength of the evidence.
DECREASES RISK INCREASES RISK
Convincing Physical activity1 2 Red meat3 4
Processed meat4 5
Alcoholic drinks (men)6
Body fatness
Abdominal fatness
Adult attained height7
Probable Foods containing dietary fibre8 Alcoholic drinks (women)6
Garlic9
Milk10 11
Calcium12
Limited — Non-starchy vegetables9 Foods containing iron4 8
suggestive Fruits9 Cheese10
Foods containing folate8 Foods containing animal fats8
Foods containing selenium8 Foods containing sugars15
Fish 
Foods containing vitamin D8 13
Selenium14
Limited — Cereals (grains) and their products; potatoes; poultry; shellfish and other seafood; other dairy products; total fat; fatty acid
no conclusion composition; cholesterol; sugar (sucrose); coffee; tea; caffeine; total carbohydrate; starch; vitamin A; retinol; vitamin C; vitamin E;
multivitamins; non-dairy sources of calcium; methionine; beta-carotene; alpha-carotene; lycopene; meal frequency; energy intake
Substantial 
effect on risk None identified
unlikely
1 Physical activity of all types: occupational, household, transport, and recreational.
2 Much of the evidence reviewed grouped colon cancer and rectal cancer together as ‘colorectal’ cancer. The Panel judges that the evidence is stronger for colon 
than for rectum.
3 The term ‘red meat’ refers to beef, pork, lamb, and goat from domesticated animals.
4 Although red and processed meats contain iron, the general category of ‘foods containing iron’ comprises many other foods, including those of plant origin.
5 The term ‘processed meat’ refers to meats preserved by smoking, curing, or salting, or addition of chemical preservatives.
6 The judgements for men and women are different because there are fewer data for women. Increased risk is only apparent above a threshold of 30 g/day of
ethanol for both sexes. 
7 Adult attained height is unlikely directly to modify the risk of cancer. It is a marker for genetic, environmental, hormonal, and also nutritional factors affecting
growth during the period from preconception to completion of linear growth (see chapter 6.2.1.3).
8 Includes both foods naturally containing the constituent and foods which have the constituent added (see chapter 3.5.3). Dietary fibre is contained in plant foods
(see box 4.1.2 and chapter 4.2).
9 Judgements on vegetables and fruits do not include those preserved by salting and/or pickling.
10 Although both milk and cheese are included in the general category of dairy products, their different nutritional composition and consumption patterns may 
result in different findings.
11 Milk from cows. Most data are from high-income populations, where calcium can be taken to be a marker for milk/dairy consumption. The Panel judges that a
higher intake of dietary calcium is one way in which milk could have a protective effect. 
12 The evidence is derived from studies using supplements at a dose of 1200 mg/day.
13 Found mostly in fortified foods and animal foods.
14 The evidence is derived from studies using supplements at a dose of 200 µg/day. Selenium is toxic at high doses.
15 ‘Sugars’ here means all ‘non-milk extrinsic’ sugars, including refined and other added sugars, honey, and as contained in fruit juices and syrups. It does not include
sugars naturally present in whole foods such as fruits. It also does not include lactose as contained in animal or human milks.
For an explanation of all the terms used in the matrix, please see chapter 3.5.1, the text of this section, and the glossary.
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include mucinous carcinomas and adenosquamous carcino-
mas.4 Adenocarcinomas are covered here. A systematic
review of colorectal adenomas was conducted to understand
the contribution of food, nutrition, and physical activity to
the pathogenesis of colorectal cancer, and contributed to
interpretation of the underlying mechanisms.
7.9.1  Trends, incidence, and survival
There is no clear trend in global age-adjusted rates of col-
orectal cancer. There has, however, been a rapid increase in
rates in high-income countries that have recently made the
transition from a relatively low-income economy, such as
Japan, Singapore, and eastern European countries. Rates
have at least doubled in many of these countries since the
mid-1970s.137 Colorectal cancer is mainly a disease of high-
income countries, where overall rates are nearly four times
higher than in middle- to low-income countries. Around the
world, age-adjusted incidence rates range from more than
40 per 100 000 people in North America, parts of Europe,
Australia, New Zealand, and Japan to less than 5 per
100 000 in much of Africa, Central America, and parts of
Asia.2 In the USA, rates are higher among African-American
people than in white people.3 This disease is slightly more
common in men than in women, by seven to five. Risk
increases with age until old age, when it levels off.6
Colorectal cancer often produces symptoms at an early
enough stage to make it treatable, meaning that survival
rates are relatively high. In addition, regular screening is
common in some countries such as the USA. The 5-year over-
all survival rate averages 50 per cent, with 55 per cent in
high-income countries and 39 per cent in middle- to low-
income countries.124 This cancer accounts for somewhat over
9 per cent of all cancer incidence, but around 8 per cent of
all cancer deaths. Also see box 7.1.1.
7.9.2  Pathogenesis
Carcinogens ingested as part of, or with, foods and drinks
can interact directly with the cells that line the colon and rec-
tum if they are not metabolised or absorbed in the small
intestine. Colorectal cancer can also develop from a back-
ground of inflammatory bowel disease (ulcerative colitis or
Crohn’s disease).138
Between 5 and 10 per cent of colorectal cancers are a con-
sequence of recognised hereditary conditions. The two major
ones are familial adenomatous polyposis (FAP) and
HNPCC139 (also see 7.5.2). A further 20 per cent of cases
occur in people who have a family history of colorectal can-
cer.139 People with FAP develop a large number of adenomas
at a relatively young age; if left untreated, nearly all will
develop colorectal cancer by the time they reach 40.140
On average, people develop HNPCC in their mid-40s140;
having this form of the disease increases the risk of a number
of other gastrointestinal cancers. HNPCC involves mutations
in DNA repair genes, a recognised step in the development
of many colorectal cancers.
There are two characterised pathways to colorectal cancer,
although they are likely to be linked — the ‘gatekeeper’ and
the ‘caretaker’ pathways.141 The gatekeeper pathway is
involved in 85 per cent of sporadic colorectal cancers, and
is the one associated with FAP.140 It involves the disruption
of genes that regulate growth, and for colorectal cancer, the
key one is the tumour-suppressor gene APC. The caretaker
pathway is characterised by disruption to genes that main-
tain genetic stability. It leads to 15 per cent of sporadic can-
cers, and is involved in the development of HNPCC.140
Several tumour-suppressor genes are mutated in this path-
way142 (also see box 2.2 in chapter 2).
7.9.3  Other established causes 
(Also see chapter 2.4 and 7.1.3.1.)
Other diseases. Inflammatory bowel disease (Crohn’s disease
and ulcerative colitis) increase the risk of, and so may be
seen as a cause of, colon cancer.
Medication. Non-steroidal anti-inflammatory drugs such as
aspirin and hormone replacement therapy in postmeno-
pausal women have been shown to decrease colon cancer
risk.143 144
7.9.4  Interpretation of the evidence 
7.9.4.1  General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7. 
‘Relative risk’ is used in this Report to denote ratio mea-
sures of effect, including ‘risk ratios’, ‘rate ratios’, ‘hazard
ratios’, and ‘odds ratios’.
7.9.4.2  Specific
Considerations specific to colorectal cancer include: 
Classification. Cancers in different parts of the colon and in
the rectum could have different pathogeneses and different
causal agents.
7.9.5  Evidence and judgements
In total, 752 publications were included in the SLR for can-
cers of the colon and rectum. Fuller summaries of the epi-
demiological, experimental, and mechanistic evidence are to
be found in Chapters 4–6.
The full SLR is contained on the CD included with this
Report. 
7.9.5.1  Foods containing dietary fibre
(Also see chapter 4.1.5.3.)
Sixteen cohort studies and 91 case-control studies investi-
gated dietary fibre. Most studies showed decreased risk with
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increased intake. Meta-analysis of cohort data showed a 10
per cent decreased risk per 10 g/day (see figure 4.1.1).
Heterogeneity may be caused by variation in the definition
of dietary fibre between studies. A pooled analysis of 8100
colorectal cancer cases among 730 000 participants, fol-
lowed up for 6–20 yeas, showed a non-significant decreased
risk for the groups that consumed the most dietary fibre.
Data come predominantly from dietary sources, not supple-
ments; therefore no effect can be attributed specifically to
fibre, which is interpreted simply as a marker of consump-
tion of foods containing it, although specific mechanisms
have been identified. 
Fibre exerts several effects in the gastrointestinal tract, but
the precise mechanisms for its probable protective role are
still not clearly understood. Fibre dilutes faecal content,
decreases transit time, and increases stool weight.
Fermentation products, especially short-chain fatty acids, are
produced by the gut flora from a wide range of dietary car-
bohydrates and mucins that reach the colon. Short-chain
fatty acids, such as butyrate, induce apoptosis, cell cycle
arrest, and differentiation in experimental studies. Fibre
intake is also strongly correlated with intake of folate, though
adjusting for this often does not affect the risk reduction
attributed to fibre.
A clear dose-response relationship is apparent from
generally consistent cohort studies, supported by
evidence for plausible mechanisms, but residual
confounding could not be excluded. Foods containing
dietary fibre probably protect against colorectal cancer.
The Panel is aware that since the conclusion of the SLR, seven
cohort studies145-151 and one case-control study152 have been
published. This new information does not change the Panel
judgement. Also see box 3.8.
7.9.5.2  Non-starchy vegetables
(Also see chapter 4.2.5.1.)
Seventeen cohort studies and 71 case-control studies inves-
tigated non-starchy vegetables. Although meta-analysis of
cohort data produced no evidence of an association, a com-
parison of the groups with the highest intakes against those
with the lowest was suggestive of an association.
This is a wide and disparate category, and many different
plant food constituents are represented that could contribute
to a protective effect of non-starchy vegetables. These include
dietary fibre, carotenoids, folate, selenium, glucosinolates,
dithiolthiones, indoles, coumarins, ascorbate, chlorophyll,
flavonoids, allylsulphides, flavonoids, and phytoestrogens,
some of which are potentially antioxidants. Antioxidants trap
free radicals and reactive oxygen molecules, protecting
against oxidation damage. It is difficult to unravel the rela-
tive importance of each constituent and it is likely that any
protective effect may result from a combination of influences
on several pathways involved in carcinogenesis.
A substantial amount of evidence is available but it is
inconsistent. There is limited evidence suggesting that
non-starchy vegetables protect against colorectal cancer.
The Panel is aware that since the conclusion of the SLR, three
case-control studies17 152 154 have been published. This new
information does not change the Panel judgement. Also see box
3.8.
7.9.5.3  Garlic
(Also see chapter 4.2.5.1.2.)
Two cohort studies and six case-control studies investigated
garlic. All studies reported decreased risk with increased
intake, with none reporting contrary results. Most studies did
not reach statistical significance, and meta-analysis was not
possible.
There is considerable preclinical evidence with model car-
cinogens and transplantable tumours that supports an anti-
cancer effect of garlic and some of its allyl sulphur
components. Animal studies demonstrate that allyl sulphides
effectively inhibit colon tumour formation, and also can
inhibit cell growth in laboratory experiments.
The evidence, though not copious and mostly from
case-control studies, is consistent, with a dose-
response relationship. There is evidence for plausible
mechanisms. Garlic probably protects against
colorectal cancer.
The Panel is aware that since the conclusion of the SLR, one
case-control study17 has been published. This new information
does not change the Panel judgement. Also see box 3.8.
7.9.5.4  Fruits
(Also see chapter 4.2.5.2.)
Twenty cohort studies and 57 case-control studies investi-
gated fruits. More than half of the cohort studies showed
decreased risk with increased intake. Meta-analysis of cohort
data produced no clear evidence of an overall association.
However, stratification by sex did show a statistically sig-
nificant decreased risk with increased intake among women,
but not men.
This difference could be hormone-related, speculating 
a connection with the protective effects observed in
postmenopausal women provided by hormone replacement
therapy. Another possibility is that this could be artefactual:
men may have not reported their diets as accurately as
women.
Because of the abundant prospective data from cohort
studies, case-control studies were not summarised.
Fruits are sources of vitamin C and other antioxidants,
such as carotenoids, phenols, and flavonoids, as well as other
potentially bioactive phytochemicals. Antioxidants trap free
radicals and reactive oxygen molecules, protecting against
oxidation damage. In addition, flavonoids found in fruit
directly inhibit the expression of a cytochrome P450
enzyme, which helps to metabolise toxins and has been asso-
ciated with increased risk of lung cancer, primarily in smok-
ers.68 It is difficult to unravel the relative importance of each
constituent and it is likely that a protective effect may result
from a combination of influences on several pathways
involved in carcinogenesis.
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There is a substantial amount of evidence but it is
inconsistent. There is limited evidence suggesting that
fruits protect against colorectal cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort147 153 155 and five case control studies152 154 156-158 have
been published. This new information does not change the
Panel judgement. Also see box 3.8.
7.9.5.5  Foods containing folate 
(Also see chapter 4.2.5.4.)
Nine cohort studies investigated dietary folate and two
cohort studies investigated serum folate. Most studies
showed decreased risk with increased intake. Meta-analysis
of cohort data produced evidence of decreased risk with a
clear dose-response relationship. Both studies that investi-
gated serum folate levels, which may be a more accurate and
precise measure than dietary estimates, showed decreased
risk for colon cancer, but not rectal cancer; this was statisti-
cally significant in one study. Data come predominantly from
dietary sources, not supplements; therefore no effect can be
attributed specifically to folate, which is interpreted simply
as a marker of consumption of foods containing it.
Folate plays an important role in the synthesis, repair, and
methylation of DNA. Abnormal DNA methylation has been
linked to aberrant gene expression and also to cancers at sev-
eral sites. Folate may also reduce HPV proliferation in cells
(also see box 7.13.1). In addition, folate intake is also strong-
ly correlated with intake of dietary fibre, which probably pro-
tects against colorectal cancer (see 7.9.5.1).
The evidence from cohort studies is plentiful, with a
dose-response relationship, but there is unexplained
inconsistency. Residual confounding from dietary fibre
is possible. There is limited evidence suggesting that
foods containing folate protect against colorectal
cancer.
The Panel is aware that since the conclusion of the SLR, four
cohort159-163 and two case control studies152 164 have been pub-
lished. This new information does not change the Panel judge-
ment. Also see box 3.8.
7.9.5.6  Foods containing selenium 
(Also see chapter 4.2.5.8.)
Fifteen case-control studies investigated dietary selenium, all
of which showed decreased risk with increased intake. Meta-
analysis of case-control data produced evidence of decreased
risk with increased serum selenium levels, showing a clear
dose-response relationship.
Dietary selenium deficiency has been shown to cause a
lack of selenoprotein expression. Twenty-five selenoproteins
have been identified in animals, and a number of these have
important anti-inflammatory and antioxidant properties.
Four are glutathione peroxidases, which protect against
oxidative damage to biomolecules such as lipids, lipopro-
teins, and DNA. Three are thioredoxin reductases, which
regenerate oxidised ascorbic acid to its active antioxidant
form, among other functions.
A substantial amount of data was available, from case-
control studies only. There is limited evidence
suggesting that foods containing selenium protect
against colorectal cancer.
7.9.5.7  Red meat
(Also see chapter 4.3.5.1.1.)
Sixteen cohort and 71 case-control studies investigated red
meat. Nearly all cohort studies showed increased risk with
higher intake. Meta-analysis of cohort data showed a 43 per
cent increased risk per time consumed/week (figure 4.3.2) or
a 15 per cent increased risk per 50 g/day (figure 4.3.3).
Heterogeneity could not be fully explained but some studies
could have included processed meats in the ‘red meat’ category.
There are several potential underlying mechanisms for a
positive association of red meat consumption with colorectal
cancer, including the generation of potentially carcinogenic
N-nitroso compounds (see box 4.3.2). Some meats are also
cooked at high temperatures, resulting in the production of
heterocyclic amines and polycyclic aromatic hydrocarbons
(see box 4.3.4). Red meat contains haem iron. Free iron can
lead to the production of free radicals (see box 4.3.3).
A substantial amount of data from cohort and case-
control studies showed a dose-response relationship,
supported by evidence for plausible mechanisms
operating in humans. Red meat is a convincing cause
of colorectal cancer.
The Panel is aware that since the conclusion of the SLR, six
cohort165-173 and four case-control studies154 156 157 174 have been
published. This new information does not change the Panel
judgement. Also see box 3.8.
7.9.5.8  Processed meat
(Also see chapter 4.3.5.1.2.)
Fourteen cohort studies and 44 case-control studies investi-
gated processed meat. Nearly all cohort studies showed
increased risk with higher intake. Meta-analysis of cohort
data showed a 21 per cent increased risk per 50 g/day (fig-
ure 4.3.6). Heterogeneity was low and explained by the dis-
parity in category definitions between studies, as well as by
improved adjustment for confounders in recent studies.
Nitrates are both produced endogenously in gastric acid
and added as preservatives to processed meats. They may
contribute to N-nitroso compound production and exposure.
These compounds are suspected mutagens and carcinogens
(see box 4.3.2).55 Many processed meats also contain high
levels of salt and nitrite. Meats cooked at high temperatures
can contain heterocyclic amines and polycyclic aromatic
hydrocarbons (see box 4.3.4). Haem promotes the formation
of N-nitroso compounds and also contains iron. Free iron can
lead to production of free radicals (see box 4.3.3).
There is a substantial amount of evidence, with a dose-
response relationship apparent from cohort studies.
There is strong evidence for plausible mechanisms
operating in humans. Processed meat is a convincing
cause of colorectal cancer.
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The Panel is aware that since the conclusion of the SLR, five
cohort153 165-169 171 173 175 and two case-control studies154 157 have
been published. This new information does not change the
Panel judgement. Also see box 3.8.
7.9.5.9  Fish
(Also see chapter 4.3.5.3.)
Nineteen cohort studies and 55 case-control studies investi-
gated fish. Most cohort studies showed decreased risk with
higher intake. Meta-analysis showed a non-significant
decreased risk. Heterogeneity may be partially explained by
varying definitions of fish in different studies to include fresh
and/or salted and dried fish. Also, high fish intake may be
associated with low meat intake, which is a potential con-
founder that has not been adjusted for.
Because of the abundant prospective data from cohort
studies, case-control studies were not summarised.
It is biologically plausible that long-chain fish n-3 polyun-
saturated fatty acids (PUFAs) protect against cancer (see
chapter 2.4.1.3). Fish oils reduce tumours in animal stud-
ies.176 Likely mechanisms are thought to include their role
in reduction of n-6 PUFA-derived eicosanoid biosynthesis
(eicosanoids influence inflammation) and direct inhibition
of cyclo-oxygenase-2, also implicated in the cancer process
This mechanism, though plausible, is not well supported.177
Alternative suggestions include the relatively high selenium
or vitamin D content of fish.
A substantial amount of data is available but the
results are inconsistent, and residual confounding by
meat could not be excluded. There is limited evidence
suggesting that eating fish protects against colorectal
cancer.
The Panel is aware that since the conclusion of the SLR, six
cohort147 165 167-169 171 178 and two case-control studies152 154 have
been published. This new information does not change the
Panel judgement. Also see box 3.8.
7.9.5.10  Foods containing vitamin D
(Also see chapter 4.3.5.5.)
Eleven cohort studies and 17 case-control studies investi-
gated total vitamin D and/or dietary vitamin D. Four cohort
studies investigated plasma or serum vitamin D. Most of the
studies of intake, and all of the studies of plasma or serum
vitamin D, showed decreased risk as measures of intake
increased.
The effects of vitamin D and calcium are strongly interre-
lated because both are growth restraining, both induce dif-
ferentiation and apoptosis in intestinal cells, and
calcium-mediated effects are strongly dependent on vitamin
D levels. Data from observational studies were limited by the
fact that levels of the biologically active form are not only
dependent on diet but also on supplements, and ultraviolet
(UV) exposure of the skin.
The evidence on vitamin D was inconsistent. There is
limited evidence suggesting that foods containing vitamin
D or vitamin D status protect against colorectal cancer.
The Panel is aware that since the conclusion of the SLR, two
case-control studies152 179 have been published. This new infor-
mation does not change the Panel judgement. Also see box 3.8.
7.9.5.11  Foods containing iron
(Also see chapter 4.3.5.6.)
Four cohort studies and 23 case-control studies investigated
iron intake. All cohort studies showed increased risk with
increased intake, which was statistically significant in two.
It is biologically plausible that iron increases colorectal can-
cer risk due to its catalytic activity on the formation of reac-
tive oxygen species. However, this role has not been
confirmed in animal studies. Another hypothesis relates to
dietary haem, which can induce colonic cytotoxicity and
hyperproliferation.180 Iron overload also activates oxidative
responsive transcription factors, pro-inflammatory cytokines
and iron-induced hypoxia signalling.181 Also see box 4.3.3.
The evidence is sparse, of poor quality, and
inconsistent. There is limited evidence suggesting that
foods containing iron are in general a cause of
colorectal cancer. (Also see chapter 4.3 for evidence
specifically on red and processed meat, which are
classified as convincing causes of colorectal cancer.)
The Panel is aware that since the conclusion of the SLR, two
cohort studies175 182 have been published. This new information
does not change the Panel judgement. Also see box 3.8.
7.9.5.12  Milk
(Also see chapter 4.4.5.1.2.)
Thirteen cohort studies and 36 case-control studies investi-
gated milk; 15 cohort studies and 58 case-control studies
investigated dietary calcium. Most cohort studies showed
decreased risk with increased intake. A pooled analysis of 10
cohort studies (nearly 5000 colorectal cancer cases among
more than 530 000 participants) showed a 15 per cent
decreased risk for the groups that drank the most milk, and
a 14 per cent decreased risk for the groups with the highest
dietary calcium intakes.183
Most of the evidence used here comes from Western coun-
tries, where dietary calcium intake can be taken as a mark-
er for dairy consumption.
Any effect of milk in reducing colorectal cancer risk is likely
to be mediated at least in part by calcium, which has direct
growth-restraining and differentiation- and apoptosis-inducing
actions on normal and tumour colorectal cells.184 Milk includes
many bioactive constituents, which may also play a role.
The evidence on milk from cohort studies is reasonably
consistent, supported by stronger evidence from dietary
calcium, as a dietary marker. There is evidence for
plausible mechanisms. Milk probably protects against
colorectal cancer.
The Panel is aware that since the conclusion of the SLR, three
cohort185-188 and three case-control studies154 158 189 have been
published. This new information does not change the Panel
judgement. Also see box 3.8.
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7.9.5.13  Cheese
(Also see chapter 4.4.5.1.2.)
Eleven cohort studies and 25 case-control studies investi-
gated cheese. Most cohort studies showed increased risk with
increased intake. Meta-analysis showed a non-significant
increased risk.
The potential mechanisms for the association of cheese
with cancers of the colon and rectum are unclear. Saturated
fatty acids can induce expression of inflammatory mediators
and stimulate increased insulin production.
The evidence is inconsistent. There is limited evidence
suggesting that cheese is a cause of colorectal cancer.
The Panel is aware that since the conclusion of the SLR, two
cohort studies185-188 and one case-control study189 have been
published. This new information does not change the Panel
judgement. Also see box 3.8.
7.9.5.14  Foods containing animal fats
(Also see chapter 4.5.5.2.)
Five cohort studies investigated animal fats. Most studies
showed increased risk with increased intake but there is
potential for residual confounding. Meta-analysis of cohort
data showed a non-significant increased risk. 
Diets high in fat lead to increased levels of bile acids in
the colon. Bile acids are metabolised by the bacterial flora
to deoxycholic acid, which can promote cancer in rodents.
The conversion of bile acids to secondary bile acids such as
deoxycholic acid is decreased by the lower pH induced by
short-chain fatty acids produced in diets high in non-starch
polysaccharides. Also, deoxycholic acid is less soluble at a
lower pH, which may limit its adverse effects.190
There is a limited amount of fairly consistent evidence
suggesting that consumption of foods containing
animal fats is a cause of colorectal cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort study167 has been published. This new information does
not change the Panel judgement. Also see box 3.8.
7.9.5.15  Foods containing sugars
(Also see chapter 4.6.5.1.)
A total of one cohort study and seven case-control studies
investigated sugars as foods. Seven cohort studies and 16
case-control studies investigated sugars as nutrients, defined
as total sugar, sucrose, or fructose. Most studies showed
increased risk with increased total sugars, sucrose, or fruc-
tose intake. Data were particularly suggestive for fructose.
In most, though not all, animal experiments, sucrose and
fructose are associated with increased colonic proliferation
and aberrant crypt foci, which are precursors of colon can-
cers (see chapter 2).
The evidence is sparse and inconsistent. There is
limited evidence suggesting that foods containing
sugars are a cause of colorectal cancer. 
7.9.5.16  Alcoholic drinks
(Also see chapter 4.8.5.1.)
Twenty-four cohort studies investigated alcoholic drinks; 13
cohort studies and 41 case-control studies investigated
ethanol intake. Nearly all cohort studies showed increased
risk with increased intake, with none reporting statistically
significant contrary results. Meta-analysis of cohort data
showed a 9 per cent increased risk per 10 g ethanol/day (fig-
ure 4.8.10). A pooled analysis of more than 4600 colorectal
cancer cases among more than 475 000 participants, fol-
lowed up for 6–16 years, showed a 41 per cent increased risk
for the groups that drank the most alcohol.191 There was
some suggestion of sexual dimorphism, with a possibly
greater effect in men than in women. This more elevated risk
may be because of the generally higher consumption of alco-
hol among men. Also, men and women may prefer different
types of alcoholic drinks, there may be hormone-related dif-
ferences in alcohol metabolism, or susceptibility to alcohol
may exist. Data also suggested a ‘J’-shaped dose-response
relationship, with low intake being associated with lower risk
compared with no intake. 
Because of the abundant prospective data from cohort
studies, case-control studies were not summarised.
Reactive metabolites of alcohol such as acetaldehyde can
be carcinogenic. There is also an interaction with smoking.
Tobacco may induce specific mutations in DNA that are less
efficiently repaired in the presence of alcohol. Alcohol may
also function as a solvent, enhancing penetration of other
carcinogenic molecules into mucosal cells. Additionally, the
effects of alcohol may be mediated through the production
of prostaglandins, lipid peroxidation, and the generation of
free radical oxygen species. Lastly, high consumers of alco-
hol may have diets low in essential nutrients, making tissues
susceptible to carcinogenesis.
There is ample and generally consistent evidence from
cohort studies. A dose-response relationship is
apparent. There is evidence for plausible mechanisms.
The evidence that consumption of more than about 
30 g per day of ethanol from alcoholic drinks is a cause
of colorectal cancer in men is convincing; and it is
probably a cause in women.
The Panel is aware that since the conclusion of the SLR, four
cohort studies159 192-194 and four case-control studies154 195-197
have been published. This new information does not change the
Panel judgement. Also see box 3.8.
7.9.5.17  Calcium
(Also see chapter 4.10.6.4.4.)
Seven cohort studies investigated calcium supplements. All
but one reported decreased risk with calcium supplementa-
tion. A pooled analysis of 10 cohort studies (nearly 5000 col-
orectal cancer cases among more than 530 000 participants,
followed up for 6–16 years) showed a 22 per cent decreased
risk for the groups with the highest calcium intakes (dietary
and supplemental sources).183 In addition, two randomised
controlled trials and four cohort studies investigated calci-
um supplements and the risk of adenomas. Both trials and
287
C H A P T E R  7  •  C A N C E R S
most of the cohort studies showed decreased risk with
supplementation.
Because of the abundant prospective data from cohort
studies, case-control studies were not summarised.
Calcium from diet is an important nutrient; intracellular
calcium is a pervasive second messenger acting on many cel-
lular functions including cell growth. Calcium has direct
growth-restraining and differentiation- and apoptosis-induc-
ing actions on normal and tumour colorectal cells.184
There is generally consistent evidence from several
cohort studies, and evidence from trials for colorectal
adenomas. There is evidence for plausible
mechanisms. Calcium probably protects against
colorectal cancer. 
7.9.5.18  Selenium
(Also see chapter 4.10.6.4.5.)
One randomised controlled trial and one cohort study inves-
tigated selenium supplements. The trial showed a statistically
significant decreased risk with a daily supplement of 200 g
of selenium. This was a relatively small study (1321 partici-
pants; 8 cases in the supplement group and 19 in the control
group) and colorectal cancer was a secondary outcome. The
cohort study showed non-significant decreased risk.
Dietary selenium deficiency has been shown to cause a
lack of selenoprotein expression. Twenty-five selenoproteins
have been identified in animals and a number of these have
important anti-inflammatory and antioxidant properties.
Four are glutathione peroxidases, which protect against
oxidative damage to biomolecules such as lipids, lipopro-
teins, and DNA. Three are thioredoxin reductases and,
among other functions, these regenerate oxidised ascorbic
acid to its active antioxidant form.
The evidence is sparse. There is limited evidence to
suggest that selenium protects against colorectal
cancer.
7.9.5.19  Physical activity
(Also see chapter 5.4.1.)
Eleven cohort studies investigated total physical activity; 12
cohort studies investigated occupational physical activity;
and 24 cohort studies investigated recreational activity. Most
studies reported an association between increased physical
activity and decreased cancer risk. Most studies were unsuit-
able for meta-analysis due to the disparate measures used
to assess physical activity. The data also suggested that the
effect was reduced or removed for rectal cancer. The evi-
dence, overall, was broad and consistent. A published meta-
analysis of 19 cohort studies reported a statistically
significant decreased risk for physical activity for colon can-
cer, but not for rectal cancer.
Sustained moderate physical activity raises the metabolic
rate and increases maximal oxygen uptake. In the long term,
regular periods of such activity increase the body’s metabolic
efficiency and capacity (the amount of work that it can per-
form), as well as reducing blood pressure and insulin resis-
tance. In addition, physical activity increases gut motility.
There is abundant epidemiological evidence from
prospective studies showing lower risk of colorectal
cancer with higher overall levels of physical activity, as
well as with greater frequency and intensity, and there
is evidence of a dose-response effect. There is little
heterogeneity, except that the effect is not as clear for
rectal cancer as it is for colon cancer. There is plausible
evidence for mechanisms operating in humans. The
evidence that higher levels of physical activity, within
the range studied, protect against colon cancer is
convincing. 
The Panel is aware that since the conclusion of the SLR, four
cohort198-201 and four case-control studies154 202-204 have been
published. This new information does not change the Panel
judgement. Also see box 3.8.
7.9.5.20  Body fatness
(Also see chapter 6.1.3.1.)
Sixty cohort studies and 86 case-control studies investigat-
ed body fatness, as measured by BMI. Most of the cohort
studies showed increased risk with increased body fatness.
Meta-analysis of cohort data showed a 15 per cent increased
risk per 5 kg/m2 (figure 6.1.6). Heterogeneity is explained
partially by sexual and geographical differences, and also by
cancer site. When stratified according to cancer site, data are
more consistent and suggest a larger increased risk for colon
cancer (figure 6.1.7) than for rectal cancer (figure 6.1.8).
Because of the abundant prospective data from cohort
studies, case-control studies were not summarised. 
Body fatness directly affects levels of many circulating hor-
mones, such as insulin, insulin-like growth factors, and
oestrogens, creating an environment that encourages car-
cinogenesis and discourages apoptosis. It also stimulates the
body’s inflammatory response, which may contribute to the
initiation and progression of several cancers. Also see chap-
ter 6.1.3 and box 2.4.
There is abundant and consistent epidemiological
evidence with a clear dose-response relationship, and
evidence for plausible mechanisms that operate in
humans. The evidence that greater body fatness is a
cause of colorectal cancer is convincing.
The Panel is aware that since the conclusion of the SLR, 15
cohort58 59 151 205-215 and 2 case-control studies216-218 have been
published. This new information does not change the Panel
judgement. Also see box 3.8. 
7.9.5.21  Abdominal fatness
(Also see chapter 6.1.3.2.)
Seven cohort studies and two case-control studies investi-
gated waist circumference; six cohort studies and four case-
control studies investigated waist to hip ratio. All cohort
studies showed increased risk with either increased waist cir-
cumference or increased waist to hip ratio. Meta-analysis was
possible on four cohort studies measuring waist circumfer-
ence and five cohort studies measuring waist to hip ratio.
This showed a 5 per cent increased risk per inch of waist cir-
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cumference, or a 30 per cent increased risk per 0.1 increment
of waist to hip ratio (figures 6.1.22 and 6.1.23).
The general mechanisms through which abdominal fatness
could plausibly influence cancer risk are outlined in chapter
6.1.3 (for more detail see box 2.4). The hormonal and other
biological effects of being overweight or obese are outlined
in chapter 8. Many of these, such as increased circulating
oestrogens and decreased insulin sensitivity, are associated
with abdominal fatness independently of overall body
fatness.
There is ample consistent epidemiological evidence
with a clear dose-response relationship and robust
evidence for mechanisms that operate in humans. The
evidence that abdominal fatness is a cause of
colorectal cancer is convincing.
The Panel is aware that since the conclusion of the SLR, three
cohort studies146 205 209 have been published. This new infor-
mation does not change the Panel judgement. Also see box 3.8. 
7.9.5.22  Adult attained height
(Also see chapter 6.2.3.1.)
Twenty-one cohort studies and 16 case-control studies
investigated adult attained height. Most cohort studies
showed increased risk with increased height. Meta-analysis
of cohort data showed a 9 per cent increased risk per 5 cm
of height (figure 6.2.1). 
Because of the abundant prospective data from cohort
studies, case-control studies were not summarised.
The general mechanisms through which the factors that
lead to greater adult attained height, or its consequences,
could plausibly influence cancer risk are outlined in chapter
6.2.1.3 (for more detail see box 2.4). Many of these, such as
early-life nutrition, altered hormone profiles, and the rate of
sexual maturation, could plausibly increase cancer risk. 
There is ample prospective epidemiological evidence,
which is consistent, and there is a clear dose-response
relationship, with evidence for plausible mechanisms
operating in humans. The evidence that the factors
that lead to greater adult attained height, or its
consequences, are a cause of colorectal cancer is
convincing. The causal factor is unlikely to be tallness
itself, but factors that promote linear growth in
childhood. 
The Panel is aware that since the conclusion of the SLR, four
cohort studies146 151 206 207 209 have been published. This new
information does not change the Panel judgement. Also see box
3.8.
7.9.5.23  Other exposures
Other exposures were evaluated. However, the data were
either of too low quality, too inconsistent, or the number of
studies too few to allow conclusions to be reached. These
were as follows: cereals (grains) or their products; potatoes;
poultry; shellfish and other seafood; dairy products other
than cheese or milk; non-dairy sources of calcium; coffee;
caffeine; tea; total carbohydrate; starch; sugar; total fat; fatty
acid composition; cholesterol; vitamin A; retinol; beta-
carotene; alpha-carotene; lycopene; vitamin C; vitamin E;
methionine; multivitamins; meal frequency; and energy
intake.
7.9.6  Comparison with previous report
7.9.6.1  General
See 7.1.6.1, and box 3.8 in chapter 3.
7.9.6.2  Specific
The previous report judged the evidence that vegetables pro-
tect against colorectal cancer to be convincing. The results
of cohort studies since then have generally not been sup-
portive of this judgement. 
Evidence that red meat and, in particular, processed meat
are causes of colorectal cancer is now stronger. 
The previous report noted the evidence showing that
greater adult height was a possible cause of colorectal can-
cer. The evidence now is stronger, as is that for body fatness
and for abdominal fatness. The previous report found that
frequent meals or snacks possibly increased the risk of col-
orectal cancer; this was not found here. 
The evidence that dietary fibre protects against colorectal
cancer is here judged to be stronger than it was previously.
Evidence that garlic, milk, and calcium supplements are
probably protective was not found previously.
7.9.7  Conclusions
The Panel concludes:
The evidence that physical activity protects against colorec-
tal cancer is convincing, although the evidence is stronger
for colon than for rectum. 
The evidence that red meat, processed meat, substantial
consumption (more than about 30 g per day ethanol) of alco-
holic drinks (by men, and probably by women), body fatness
and abdominal fatness, and the factors that lead to greater
adult attained height, or its consequences, are causes of col-
orectal cancer is convincing. 
Foods containing dietary fibre, as well as garlic, milk, and
calcium, probably protect against this cancer. 
There is limited evidence suggesting that non-starchy veg-
etables, fruits, foods containing folate, as well as fish, foods
containing vitamin D, and also selenium and foods contain-
ing it, protect against colorectal cancer, and that foods con-
taining iron, and also cheese, foods containing animal fats,
and foods containing sugars are causes of this cancer. 
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Cancer of the breast is the most common cancer in women
worldwide. Around 1.15 million cases were recorded in
2002, accounting for around 23 per cent of all cancers in
women (11 per cent overall). 
Observed rates of this cancer increase with
industrialisation and urbanisation, and also with facilities
for early detection. It remains much more common in
high-income countries but is now increasing rapidly in
middle- and low-income countries, including within Africa,
much of Asia, and Latin America. Breast cancer is fatal in
under half of all cases and is the leading cause of death
from cancer in women (fifth overall), accounting for 14
per cent of all cancer deaths worldwide. 
Breast cancer is hormone related, and the factors that
modify the risk of this cancer when diagnosed
premenopausally and when diagnosed (much more
commonly) postmenopausally are not the same. 
Overall, the Panel is impressed by the pattern of
evidence showing the importance of early life events,
including food and nutrition, as well as factors that affect
hormone status, in modification of the risk of breast
cancer.
FOOD, NUTRITION, PHYSICAL ACTIVITY, 
AND CANCER OF THE BREAST (PREMENOPAUSE)
In the judgement of the Panel, the factors listed below modify the risk of
cancer of the breast (premenopause). Judgements are graded according
to the strength of the evidence.
DECREASES RISK INCREASES RISK
Convincing Lactation Alcoholic drinks
Probable Body fatness Adult attained
height1
Greater birth weight
Limited — Physical activity2
suggestive
Limited — Cereals (grains) and their products; dietary fibre;
no conclusion potatoes; vegetables; fruits; pulses (legumes); soya
and soya products; meat; poultry; fish; eggs; milk
and dairy products; fats and oils; total fat;
vegetable fat; fatty acid composition, trans-fatty
acids; cholesterol; sugar (sucrose); other sugars;
sugary foods and drinks; coffee; tea; carbohydrate;
starch; glycaemic index; protein; vitamin A; riboflavin;
vitamin B6; folate; vitamin B12; vitamin C; vitamin
D; vitamin E; calcium; iron; selenium; carotenoids;
isoflavones; dichlorodiphenyldichloroethylene;
dichlorodiphenyltrichloroethane; dieldrin;
hexachlorobenzene; hexachlorocyclohexane; 
trans-nonachlor; polychlorinated biphenyls; dietary
patterns; culturally defined diets; adult weight
gain; energy intake; being breastfed
Substantial 
effect on risk None identified
unlikely
1 Adult attained height is unlikely directly to modify the risk of cancer. It is a
marker for genetic, environmental, hormonal, and also nutritional factors
affecting growth during the period from preconception to completion of
linear growth (see chapter 6.2.1.3).
2 Physical activity of all types: occupational, household, transport, and
recreational.
For an explanation of all the terms used in the matrix, 
please see chapter 3.5.1, the text of this section, 
and the glossary.
FOOD, NUTRITION, PHYSICAL ACTIVITY, AND
CANCER OF THE BREAST (POSTMENOPAUSE)
In the judgement of the Panel, the factors listed below modify the risk of
cancer of the breast (postmenopause). Judgements are graded according
to the strength of the evidence.
DECREASES RISK INCREASES RISK
Convincing Lactation Alcoholic drinks 
Body fatness  
Adult attained
height1
Probable Physical activity2 Abdominal fatness 
Adult weight gain
Limited — Total fat
suggestive
Limited — Cereals (grains) and their products; dietary fibre;
no conclusion potatoes; vegetables and fruits; pulses (legumes);
soya and soya products; meat; poultry; fish; eggs;
milk and dairy products; fats and oils; vegetable fat;
fatty acid composition; cholesterol; sugar (sucrose);
sugary foods and drinks; coffee; tea; carbohydrate;
starch; glycaemic index; protein; vitamin A; riboflavin;
vitamin B6; folate; vitamin B12; vitamin C; vitamin
D; vitamin E; calcium; iron; selenium; carotenoids;
isoflavones; dichlorodiphenyldichloroethylene;
dichlorodiphenyltrichloroethane; dieldrin;
hexachlorobenzene; hexachlorocyclohexane; trans-
nonachlor; polychlorinated biphenyls; dietary
patterns; culturally defined diets; birth weight;
birth length; energy intake; being breastfed
Substantial 
effect on risk None identified
unlikely
1 Adult attained height is unlikely directly to modify the risk of cancer. It is a
marker for genetic, environmental, hormonal, and also nutritional factors
affecting growth during the period from preconception to completion of
linear growth (see chapter 6.2.1.3).
2 Physical activity of all types: occupational, household, transport, and
recreational.
For an explanation of all the terms used in the matrix, 
please see chapter 3.5.1, the text of this section, 
and the glossary.
7.10  Breast 
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The Panel judges as follows: 
The evidence that lactation protects against breast cancer
at all ages is convincing. 
Physical activity probably protects against breast cancer
postmenopause, and there is limited evidence suggesting
that it protects against this cancer diagnosed
premenopause. The evidence that alcoholic drinks are a
cause of breast cancer at all ages is convincing. The
evidence that the factors that lead to greater adult
attained height, or its consequences, are a cause of
postmenopausal breast cancer is convincing, and these are
probably also a cause of breast cancer diagnosed
premenopause. 
The factors that lead to greater birth weight, or its
consequences, are probably a cause of breast cancer
diagnosed premenopause. Adult weight gain is probably a
cause of postmenopausal breast cancer. The evidence that
body fatness is a cause of postmenopausal breast cancer is
convincing, and abdominal body fatness is probably also a
cause. On the other hand, body fatness probably protects
against breast cancer diagnosed premenopause. There is
limited evidence suggesting that total dietary fat is a cause
of postmenopausal breast cancer. 
Life events that protect against breast cancer include
late menarche, early pregnancy, bearing children, and
early menopause, all of which have the effect of reducing
the number of menstrual cycles, and therefore lifetime
exposure to oestrogen. The reverse also applies. 
See chapter 8 for evidence and judgements on factors
that modify the risk of body fatness and abdominal
fatness, including physical activity and sedentary ways of
life, the energy density of foods and drinks, and
breastfeeding. 
In final summary, the strongest evidence, corresponding
to judgements of “convincing” and “probable”, shows that
lactation protects against breast cancer; that alcoholic
drinks are a cause of this cancer; that the factors that lead
to greater adult attained height, or its consequences, are a
cause of postmenopausal and probably also
premenopausal breast cancer; that factors that lead to
greater birth weight, or its consequences, are probably a
cause of premenopausal breast cancer; and that
abdominal body fatness and adult weight gain are
probably a cause of postmenopausal breast cancer. Body
fatness is a cause of postmenopausal breast cancer but
probably protects against premenopausal breast cancer.
Breast tissue comprises mainly fat, glandular tissue (arranged
in lobes), ducts, and connective tissue. Breast tissue develops
in response to hormones such as oestrogens, progesterone,
insulin, and growth factors. The main periods of development
are during puberty, pregnancy, and lactation. The glandular tis-
sue atrophies after menopause.
Breast cancers are almost all carcinomas of the epithelial cells
lining the ducts (the channels in the breast that carry milk to
the nipple).219 Premenopausal and postmenopausal breast can-
cers are considered separately in this Report. Although rare,
breast cancer can occur in men, but it is not included here.
7.10.1  Trends, incidence, and survival
Age-adjusted rates of breast cancer in women are increasing
in most countries, particularly in areas where the incidence
had previously been low, such as Japan, China, and south-
ern and eastern Europe.124 137
This is predominantly a disease of high-income countries,
where overall rates are nearly three times higher than in mid-
dle- to low-income countries. Around the world, age-adjust-
ed incidence rates range from 75–100 per 100 000 women
in North America, northern Europe, and Australia, to less than
20 per 100 000 in parts of Africa and Asia.2 In the USA, rates
are higher among white women than those from other eth-
nic groups, although mortality is highest in black women.3
Overall risk doubles each decade until the menopause,
when the increase slows down or remains stable. However,
breast cancer is more common after the menopause. Studies
of women who migrate from areas of low risk to areas of high
risk show that rates of breast cancer in migrants assume the
rate in the host country within one or two generations. This
shows that environmental factors are important in the pro-
gression of the disease.220
Breast cancers can often be detected at a relatively early
stage. In countries that provide or advocate screening, most
of these cancers are diagnosed when the disease is still at a
localised stage.221 Survival rates range from more than 90 to
less than 50 per cent, depending on the characteristics of the
tumour, its size and spread, and the availability of treatment.4
Average 5-year survival rates are higher in high-income coun-
tries: around 73 per cent, compared with 57 per cent in mid-
dle- to low-income countries. Breast cancer accounts for
nearly 23 per cent of all cancer incidence in women and 14
per cent of all cancer deaths (all sites except for skin (non-
melanoma) and in women only). Also see box 7.1.1.
7.10.2  Pathogenesis
Breast tissue, as well as hormones and hormone-receptor sta-
tus, varies at different stages of life. It is therefore possible
that individual risk factors will have different effects at dif-
ferent life stages (see 7.10.5). Early menarche, late
menopause, not bearing children, and late (over 30) first
pregnancy all increase breast cancer risk.220 222 The age when
breasts develop, and menopause, are both influenced by
nutrition, with overnutrition leading to early puberty and
late menopause; undernutrition delays puberty and advances
menopause (see chapter 6.2).
Hormones play an important role in breast cancer pro-
gression because they modulate the structure and growth of
epithelial tumour cells.4 Different cancers vary in hormone
sensitivity. Many breast cancers also produce hormones, such
as growth factors, that act locally, and these can both stim-
ulate and inhibit the tumour’s growth.223 224
Between 4 and 9 per cent of breast cancer cases are hered-
itary, and are usually caused by inherited mutations in either
the BRCA1 or BRCA2 gene.225 226 In addition, growth factor
receptor genes, as well as some oncogenes, are overexpressed
in many breast cancers4 (see box 2.2). 
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7.10.3  Other established causes 
(Also see chapter 2.4 and 7.1.3.1.)
Life events. As stated above, lifetime exposure to oestrogen,
influenced by early menarche, late natural menopause, not
bearing children, and late (over 30) first pregnancy all
increase the risk of, and may be seen as causes of, breast can-
cer.220 222 The reverse also applies: late menarche, early
menopause, bearing children, and early pregnancy all reduce
the risk of, and may be seen as protective against, breast can-
cer. Age of breast development and menopause are influ-
enced by nutrition, with high-energy diets promoting
earlier puberty and late menopause, and low-energy diets
delaying puberty and advancing menopause.
Radiation. Ionising radiation exposure from medical treat-
ment such as X-rays, particularly during puberty, increases
risk, even at low doses.227
Medication. Hormone replacement therapy is a cause of
breast cancer. The increased risk appears to disappear a few
years after cessation.144 Oral contraceptives containing both
oestrogen and progesterone cause a small, transient,
increased risk of breast cancer; the increased risk disappears
after cessation.133
7.10.4  Interpretation of the evidence
7.10.4.1  General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7.
‘Relative risk’ is used in this Report to denote ratio mea-
sures of effect, including ‘risk ratios’, ‘rate ratios’, ‘hazard
ratios’, and ‘odds ratios’.
7.10.4.2  Specific
Considerations specific to breast cancer include: 
Patterns. The preponderance of data from high-income
countries is a special issue with breast cancer. Breast cancer
is hormone related, and factors that modify risk have dif-
ferent effects on cancers diagnosed pre- and postmenopause. 
Classification. Because of the importance of menopause as
an effect modifier, studies should stratify for menopause sta-
tus. Many do not. 
Confounding. Hormone replacement therapy is an important
possible confounder in postmenopausal breast cancer. A few
studies also reported results separately for different hormone
receptor profiles within cancers. High-quality studies adjust
for age, number of reproductive cycles, age at which children
were born, and the taking of hormone-based medications.
7.10.5   Evidence and judgements
In total, 873 publications were included in the SLR for breast
cancer. Fuller summaries of the epidemiological, experi-
mental, and mechanistic evidence are to be found in
Chapters 4–6.
The full SLR is contained on the CD included with this
Report.
7.10.5.1  Alcoholic drinks
(Also see chapter 4.8.5.1.)
A total of 11 cohort studies, 31 case-control studies, and 2
ecological studies investigated alcoholic drinks; 25 cohort
studies, 29 case-control studies, and 4 ecological studies
investigated ethanol intake and all-age breast cancer.
Further studies investigated the relationship with alcoholic
drinks in either pre- or postmenopausal breast cancer. Most
studies showed increased risk with increased intake. Meta-
analysis of cohort data showed a 10 per cent increased risk
per 10 g ethanol/day; meta-analysis of case-control data
showed a 5 per cent increased risk per 5 drinks/week, and
a 6 per cent increased risk per 10 g ethanol/day (figures
4.8.13, 4.8.15, and 4.8.16). Menopausal status did not sig-
nificantly alter the association. Two pooled analyses also
showed statistically significant increased risks of 9 and 7 per
cent per 10 g ethanol/day. The first was based on 6 cohort
studies with more than 320 000 participants, followed up
for up to 11 years, with more than 4300 breast cancer cases.
The other analysed 53 case-control studies, with more than
58 000 cases and more than 95 000 controls.228 229
Reactive metabolites of alcohol, such as acetaldehyde,
may be carcinogenic. Additionally, the effects of alcohol may
be mediated through the production of prostaglandins, lipid
peroxidation, and the generation of free radical oxygen
species. Alcohol also acts as a solvent, enhancing penetra-
tion of carcinogens into cells. High consumers of alcohol
may have diets deficient in essential nutrients, making tis-
sues susceptible to carcinogenesis. In addition, most exper-
imental studies in animals have shown that alcohol intake
is associated with increased breast cancer risk. Alcohol inter-
feres with oestrogen metabolism and action in multiple
ways, influencing hormone levels and oestrogen receptors.
There is an interaction between folate and alcohol affect-
ing breast cancer risk: increased folate status partially mit-
igates the risk from increased alcohol consumption.230
There is ample, generally consistent evidence from
case-control and cohort studies. A dose-response
relationship is apparent. There is robust evidence for
mechanisms operating in humans. The evidence that
alcoholic drinks are a cause of premenopausal and
postmenopausal breast cancer is convincing. No
threshold was identified.
The Panel is aware that since the conclusion of the SLR, one
case-control study231 has been published. This new informa-
tion does not change the Panel judgement. Also see box 3.8.
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7.10.5.2  Lactation
(Also see chapter 6.3.3.)
One cohort study and 37 case-control studies investigated
ever having breastfed as compared to never having breast-
fed; and 5 cohort studies and 55 case-control studies inves-
tigated the total duration of lactation. The single cohort
study and most case-control studies showed decreased risk
(age unspecified) with ever having breastfed compared with
never. Most studies showed decreased risk with increasing
duration of breastfeeding. Meta-analysis of case-control data
showed a 3 per cent decreased risk per 5 months of total
breastfeeding (figure 6.3.1); meta-analysis of cohort data
showed a non-significant decreased risk. Pooled analysis
from 47 epidemiological studies in 30 countries (more than
50 000 controls and nearly 97 000 breast cancer cases)
showed a statistically significant decreased risk of breast can-
cer of 4.3 per cent for each 12 months of breastfeeding.
Menopause status was not an effect modifier.228 386
Lactation is associated with increased differentiation of
breast cells and with lower exposure to endogenous sex hor-
mones during amenorrhea accompanying lactation. In addi-
tion, the strong exfoliation of breast tissue during lactation,
and the massive epithelial apoptosis at the end of lactation,
could decrease risk by elimination of cells with potential
DNA damage.
There is abundant epidemiological evidence from both
prospective and case-control studies, which is
consistent and shows a dose-response relationship.
There is robust evidence for plausible mechanisms that
operate in humans. The evidence that lactation
protects against both premenopausal and
postmenopausal breast cancer is convincing.
7.10.5.3  Physical activity
(Also see chapter 5.4.2.)
Six cohort studies and 8 case-control studies investigated
total physical activity; 5 cohort studies and 7 case-control
studies investigated occupational activity; and 14 cohort
studies and 11 case-control studies investigated recreation-
al activity.
Menopause age unspecified
Most studies showed decreased risk with increased physical
activity. Meta-analysis of case-control data showed a 10 per
cent decreased risk per 7 MET-hours recreational activi-
ty/week (figure 5.4.5). 
Premenopause  
Data were inconsistent for most categories, but data on occu-
pational activity were suggestive of decreased risk.
Postmenopause
Nearly all of the cohort studies and most case-control stud-
ies showed decreased risk with increased physical activity.
Meta-analysis of cohort data showed a 3 per cent decreased
risk per 7 MET-hours recreational activity/week (figure 5.4.6).
Sustained moderate physical activity raises the metabolic
rate and increases maximal oxygen uptake. In the long term,
regular periods of such activity increase the body’s metabolic
efficiency and capacity (the amount of work that it can per-
form), as well as reducing blood pressure and insulin resis-
tance. In addition, it decreases levels of oestrogens and
androgens in postmenopausal women. Some trials have also
shown decreases in circulating oestrogens, increased men-
strual cycle length, and decreased ovulation in pre-
menopausal women with a high level of physical activity.
Premenopause: There is ample evidence from
prospective studies, but it is inconsistent. There is limited
evidence suggesting that physical activity protects
against premenopausal breast cancer. 
Postmenopause: There is ample evidence from
prospective studies showing lower risk of
postmenopausal breast cancer with higher levels of
physical activity, with a dose-response relationship,
although there is some heterogeneity. There is little
evidence on frequency, duration, or intensity of activity.
There is robust evidence for mechanisms operating in
humans. Physical activity probably protects against
postmenopausal breast cancer. 
The Panel is aware that since the conclusion of the SLR, one
case-control study232 has been published. This new information
does not change the Panel judgement. Also see box 3.8.
7.10.5.4  Body fatness
(Also see chapter 6.1.3.1.)
Forty-three cohort studies, more than 100 case-control stud-
ies, and 2 ecological studies investigated body fatness, as
measured by BMI. When grouped for all ages, data were
inconsistent. However, a consistent effect emerged when
they were stratified according to menopausal status. Most
studies showed a decreased risk for premenopausal breast
cancer and an increased risk for postmenopausal breast can-
cer with increased body fatness. For cancer diagnosed pre-
menopause, meta-analysis of cohort data showed a 15 per
cent decreased risk per 5 kg/m2; meta-analysis of case-con-
trol data showed a 15 per cent increased risk per 5 kg/m2.
For cancer diagnosed postmenopause, meta-analysis of
cohort data showed an 8 per cent increased risk per 5 kg/m2;
meta-analysis of case-control data showed a 13 per cent
increased risk per 5 kg/m2 (figures 6.1.11–6.1.16). 
Two pooled analyses showed statistically significant
increased risk for postmenopausal cancer. One of these also
showed a statistically significant decreased risk for pre-
menopausal breast cancer. One pooled analysis was based
on 7 cohort studies with more than 337 000 participants, fol-
lowed up for up to 11 years, with more than 4300 breast can-
cer cases. It showed a 14 per cent decreased risk per 5 kg/m2
for cancer diagnosed premenopause and a 9 per cent
increased risk per 5 kg/m2 for cancer diagnosed post-
menopause. The other pooled analysis, based on 53 case-
control studies with more than 58 000 cases and more than
95 000 controls, showed a 19 per cent increased risk per 5
kg/m2 for postmenopausal breast cancer.233 234
Body fatness directly affects levels of many circulating hor-
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mones, such as insulin, insulin-like growth factors, and
oestrogens, creating an environment that encourages car-
cinogenesis and discourages apoptosis (see box 2.4). It also
stimulates the body’s inflammatory response, which may
contribute to the initiation and progression of several can-
cers (see chapter 2.4.1.3). Adjusting for serum levels of
oestradiol diminishes or destroys the association with BMI,
suggesting that hormones are a predominant mechanism.235
There is no single well established mechanism through
which body fatness could prevent premenopausal breast can-
cer. According to the oestrogen plus progesterone theory,
overweight premenopausal women would be protected
because they would be more frequently anovulatory, and
therefore less exposed to endogenous progesterone.
However, this theory is not well supported by recent stud-
ies, which suggest that natural progesterone could be pro-
tective.236 Normal levels of natural progesterone are likely to
be protective, and well nourished, or perhaps overnourished
women, who may become slightly overweight in adulthood,
may be protected by their natural fertile condition. Another
possible mechanism is that the increased adipose tissue-
derived oestrogen levels in overweight children could
induce early breast differentiation and eliminate some tar-
gets for malignant transformation.237 Anovulation and
abnormal hormone profiles are commonly associated with
obesity.238 The age-specific pattern of association of breast
cancer with BMI, therefore, is largely explained by its rela-
tionship with endogenous sex hormone levels.
Breast cancer diagnosed postmenopause is much more
common. Therefore, throughout life, a decreased risk of pre-
menopausal breast cancer would be expected to be out-
weighed by an increased risk of postmenopausal breast
cancer.
Premenopause: There is a substantial amount of
consistent epidemiological evidence with a dose-
response relationship, but the mechanistic evidence is
speculative. Greater body fatness probably protects
against premenopausal breast cancer.
Postmenopause: There is abundant and consistent
epidemiological evidence and a clear dose-response
relationship with robust evidence for mechanisms
operating in humans. The evidence that greater body
fatness is a cause of postmenopausal breast cancer is
convincing.
The Panel is aware that since the conclusion of the SLR, one
cohort239 and one case-control study240 have been published.
This new information does not change the Panel judgement.
Also see box 3.8.
7.10.5.5  Adult attained height
(Also see chapter 6.2.3.1.)
Thirty-three cohort studies, 56 case-control studies, and 3
ecological studies investigated adult attained height.
Age unspecified
Twenty cohort studies and 29 case-control studies investi-
gated adult attained height and breast cancer at all ages, or
unspecified menopausal status. Most of the studies showed
increased risk. Meta-analysis of cohort data showed a 9 per
cent increased risk per 5 cm of height; meta-analysis of case-
control data showed a 3 per cent increased risk per 5 cm of
height (figure 6.2.2).
Premenopause  
Seventeen cohort studies and 38 case-control studies inves-
tigated adult attained height and premenopausal breast can-
cer. Most of the studies showed increased risk. Meta-analysis
of cohort data showed a 9 per cent increased risk per 5 cm
of height; meta-analysis of case-control data showed a 4 per
cent increased risk per 5 cm of height (figure 6.2.4). A
pooled analysis of 7 cohort studies (more than 337 000 par-
ticipants, followed up for up to 11 years, with more than
4300 breast cancer cases) showed a non-significant increased
risk with greater adult attained height.234
There are fewer data for premenopausal than for
postmenopausal breast cancer. The epidemiological
evidence is generally consistent, with a dose-response
relationship and evidence for plausible mechanisms.
The factors that lead to greater adult attained height,
or its consequences, are probably a cause of
premenopausal breast cancer. The causal factor is
unlikely to be tallness itself, but factors that promote
linear growth in childhood.
Postmenopause
Twenty-two cohort studies and 34 case-control studies inves-
tigated adult attained height and postmenopausal breast
cancer. Nearly all of the cohort studies and most of the case-
control studies showed increased risk, with no studies show-
ing statistically significant contrary results. Meta-analysis of
cohort data showed an 11 per cent increased risk per 5 cm
of height; meta-analysis of case-control data showed a 2 per
cent increased risk per 5 cm of height (figure 6.2.3). A
pooled analysis of 7 cohort studies (more than 337 000 par-
ticipants, followed up for up to 11 years, with more than
4300 breast cancer cases) showed a statistically significant
7 per cent increased risk per 5 cm of height.234 The ecolog-
ical studies provided supporting data.
The general mechanisms through which the factors that
lead to greater adult attained height, or its consequences,
could plausibly influence cancer risk are outlined in chapter
6.2.1.3 (for more detail see box 2.4). Many of these, such
as early-life nutrition, altered hormone profiles, and the rate
of sexual maturation, could plausibly increase cancer risk.
There is abundant prospective epidemiological
evidence, which is generally consistent, with a clear
dose-response relationship, and evidence for plausible
mechanisms operating in humans. The evidence that
the factors that lead to greater adult attained height,
or its consequences, are a cause of postmenopausal
breast cancer is convincing. The causal factor is
unlikely to be tallness itself, but factors that promote
linear growth in childhood.
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The Panel is aware that since the conclusion of the SLR, one
cohort study241 has been published. This new information does
not change the Panel judgement. Also see box 3.8.
7.10.5.6  Abdominal fatness (postmenopause)
(Also see chapter 6.1.3.2.)
Eight cohort studies and three case-control studies investi-
gated waist circumference and postmenopausal breast
cancer; eight cohort studies and eight case-control 
studies investigated waist to hip ratio. All of the waist-cir-
cumference studies and most of those on waist to hip ratio
showed increased risk with increased measures of abdomi-
nal fatness. Meta-analysis of cohort data showed a 19 per
cent increased risk per 0.1 increment in waist to hip ratio
(figure 6.1.24). 
The general mechanisms through which abdominal fatness
could plausibly cause cancer are outlined in chapter 6.1.3 (for
more detail see box 2.4). The hormonal and other biological
effects of being overweight or obese are outlined in chapter
8. Many of these, such as increased levels of circulating
oestrogens and decreased insulin sensitivity, are associated
with abdominal fatness independently of overall body fatness.
There is a substantial amount of epidemiological
evidence but some inconsistency. There is robust
evidence for mechanisms that operate in humans.
Abdominal fatness is a probable cause of
postmenopausal breast cancer.
7.10.5.7  Adult weight gain (postmenopause)
(Also see chapter 6.1.3.3.)
Seven cohort studies and 17 case-control studies investigat-
ed adult weight gain and postmenopausal breast cancer.
Nearly all of the studies showed increased risk with
increased weight gain in adulthood. Meta-analysis of case-
control data showed a 5 per cent increased risk per 5 kg
gained (figure 6.1.26). Heterogeneity may be explained by
failure to separate postmenopausal participants taking hor-
mone replacement therapy.
Body fatness directly affects levels of many circulating hor-
mones, such as insulin, insulin-like growth factors, and
oestrogens, creating an environment that encourages car-
cinogenesis and discourages apoptosis (see chapter 2.7.1.3).
It also stimulates the body’s inflammatory response, which
may contribute to the initiation and progression of several
cancers.
There is ample, consistent epidemiological evidence
from both cohort and case-control studies. A dose-
response relationship was apparent from case-control
and cohort studies. Adult weight gain is a probable
cause of postmenopausal breast cancer.
7.10.5.8  Greater birth weight (premenopause)
(Also see chapter 6.2.3.2.)
Six cohort studies and four case-control studies investigat-
ed birth weight. All cohort studies and most case-control
studies showed increased risk with greater birth weight, with
none reporting statistically significant contrary results.
Meta-analysis of cohort data showed an 8 per cent increased
risk per kg (figure 6.2.8).
The general mechanisms through which the factors that
lead to greater birth weight, or its consequences, could
plausibly influence cancer risk are outlined in chapter
6.2.1.1. Many of these, such as long-term programming of
hormonal systems, could plausibly increase cancer risk.
Greater birth weight raises circulating maternal oestrogen
levels and may increase insulin-like growth factor (IGF)-1
activity; low birth weight raises both fetal and maternal lev-
els of IGF-1 binding protein. The action of both oestrogens
and IGF-1 are thought to be important in fetal growth and
mammary gland development, and play a central, synergis-
tic role in the initiation and promotion of breast cancer.242
Animal experiments also provide evidence that exposure to
oestrogens during fetal and early postnatal development can
increase the risk of mammary cancers.243
There is general consistency amongst the relatively few
epidemiological studies, with some evidence for a
dose-response relationship. The mechanistic evidence
is speculative. The factors that lead to greater birth
weight, or its consequences, are probably a cause of
premenopausal breast cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort study239 and one case-control study244 have been pub-
lished. This new information does not change the Panel judge-
ment. Also see box 3.8.
7.10.5.9  Total fat (postmenopause)
(Also see chapter 4.5.5.1.)
Nine cohort studies and 16 case-control studies investigat-
ed total fat intake and postmenopausal breast cancer. Most
studies showed increased risk with increased intake. Meta-
analysis of cohort data showed a non-significant increased
risk; meta-analysis of case-control data showed a statistically
significant increased risk. A pooled analysis (more than
350 000 participants and more than 7300 breast cancer
cases) showed an overall non-significant decreased risk with
increased fat intake. Menopausal status did not significant-
ly alter the result.245
Higher endogenous oestrogen levels after menopause are
a known cause of breast cancer.235 246 Dietary fat may also
increase endogenous oestrogen production.247
Evidence from prospective epidemiological studies of
different types on the whole shows inconsistent effects,
while case-control studies show a significant positive
association. Mechanistic evidence is speculative.
Overall, there is limited evidence suggesting that
consumption of total fat is a cause of postmenopausal
breast cancer.
7.10.5.10  Other exposures
For premenopausal breast cancer, other exposures were eval-
uated. However, the data were either of too low quality, too
inconsistent, or the number of studies too few to allow con-
clusions to be reached. These were as follows: cereals
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(grains) and their products; potatoes; vegetables; fruits;
pulses (legumes); soya and soya products; meat; poultry;
fish; eggs; fats and oils; vegetable fat; sugar; sugary foods
and drinks; milk and dairy products; coffee; tea; carbohy-
drate; starch; dietary fibre; sugars; total fat; fatty acid com-
position; trans-fatty acids; cholesterol; protein; vitamin A;
carotenoids; folate; riboflavin; vitamin B6; cobalamin;
vitamin C; vitamin D; vitamin E; iron; calcium; selenium;
isoflavones; dieldrin; trans-nonachlor; dichlorodiphenyl-
trichloroethane; dichlorodiphenyldichloroethylene; poly-
chlorinated biphenyls; hexachlorocyclohexane; hexachloro-
benzene; energy intake; adult weight gain; adult attained
height; dietary patterns; culturally defined diets; glycaemic
index; and being breastfed. 
For postmenopausal breast cancer other exposures were
evaluated. However, the data were either of too low quali-
ty, too inconsistent, or the number of studies too few to allow
conclusions to be reached. These were as follows: cereals
(grains) and their products; potatoes; vegetables and fruits;
pulses; soya and soya products; meat; poultry; fish; eggs; fats
and oils; sugar; sugary drinks and foods; milk and dairy
products; coffee; tea; carbohydrate; starch; dietary fibre; veg-
etable fat; fatty acid composition; cholesterol; protein; vita-
min A and carotenoids; riboflavin; vitamin B6; vitamin B12;
folate; vitamin C; vitamin D; vitamin E; isoflavones; iron;
calcium; selenium; dieldrin; trans-nonachlor; dichloro-
diphenyltrichloroethane; dichlorodiphenyldichloroethylene;
polychlorinated biphenyls; hexachlorocyclohexane; hexa-
chlorobenzene; energy intake; birth length; culturally
defined diets; dietary patterns; glycaemic index; being
breastfed; and birth weight. 
There is considerable speculation around a biologically
plausible interaction of soya and soya products with breast
cancer development, due to their high phytoestrogen con-
tent. Data on pulses (legumes) were sparse and inconsistent,
and there were insufficient studies available on soya con-
sumption to allow a conclusion to be reached.
7.10.6  Comparison with previous report
7.10.6.1  General
See 7.1.6.1, and box 3.8.
7.10.6.2  Specific
One of the most striking differences between the two reports
is the finding here on lactation. The previous report men-
tioned studies indicating that breastfeeding may protect
against breast cancer, but it did not review or judge this
evidence. 
The previous report found that high body mass probably
increases the risk for breast cancer diagnosed after the
menopause, while this Report found the evidence for body
fatness to be convincing. While the previous report made no
judgement on high body mass and premenopausal breast
cancer, this Report found that greater body fatness probably
decreases the risk. The previous report judged the evidence
to be convincing that rapid growth, together with greater
adult height, are causes of breast cancer. This Report does
not make a judgement on rates of growth. The previous
report did not make judgments on birth weight. 
The previous report judged it probable that vegetables and
fruits decrease breast cancer risk. Cohort findings since then
have been equivocal.
7.10.7  Conclusions
The Panel concludes:
The evidence that lactation protects against breast cancer at
all ages therafter is convincing. Physical activity probably
protects against postmenopausal breast cancer, and there is
limited evidence suggesting that it protects against pre-
menopausal breast cancer. The evidence that alcoholic drinks
are a cause of breast cancer at all ages is convincing. The
evidence that the factors that lead to greater attained adult
height or its consequences are a cause of postmenopausal
breast cancer is convincing; these are probably a cause of
premenopausal breast cancer.
The factors that lead to greater birth weight or its conse-
quences are probably a cause of breast cancer diagnosed pre-
menopause. Adult weight gain is probably a cause of
postmenopausal breast cancer. The evidence that body fat-
ness is a cause of postmenopausal breast cancer is convinc-
ing, and abdominal body fatness is probably a cause of this
cancer. On the other hand, body fatness probably protects
against breast cancer diagnosed premenopause. There is lim-
ited evidence suggesting that total dietary fat is a cause of
postmenopausal breast cancer. 
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7.11  Ovary 
Ovarian cancer is the seventh most common cancer in
women (and the 16th most common cancer overall)
worldwide. Around 200 000 cases were recorded in 2002,
accounting for around 4 per cent of all new cases of
cancer in women (2 per cent overall). It is most frequent
in high-income countries. This cancer is usually fatal, and
is the seventh most common cause of cancer death in
women worldwide (15th overall). 
The Panel judges as follows: 
The factors that lead to greater adult attained height, or
its consequences, are probably a cause of cancer of the
ovary. There is limited evidence suggesting that non-
starchy vegetables, and also lactation, protect against this
cancer. 
Life events that protect against ovarian cancer include
late menarche, bearing children, and early menopause, all
of which have the effect of reducing the number of
menstrual cycles, and therefore lifetime exposure to
oestrogen. 
In final summary, the strongest evidence, corresponding
to judgements of “convincing” and “probable”, shows that
the factors that lead to greater adult attained height, or its
consequences, are probably a cause of cancer of the ovary.
The ovaries are the sites of egg production in women. They
are also the main source of the hormones oestrogen and prog-
esterone.
There are three types of ovarian tissue that can produce
cancers: epithelial cells, which cover the ovary; stromal cells,
which produce hormones; and germ cells, which become
eggs. Many different types of ovarian cancers can occur.
About 85–90 per cent of ovarian cancers are carcinomas,4 the
type included here.
7.11.1  Trends, incidence, and survival 
There is no clear global trend in ovarian cancer incidence.
Rates appear to be high in high-income countries, and ris-
ing in countries undergoing economic transition.137 For
instance in Japan, there was a fourfold increase in the age-
adjusted mortality rate (from 0.9 to 3.6 per 100 000 women)
between 1950 and 1997.248
Ovarian cancer rates are nearly three times higher in high-
than in middle- to low-income countries. Around the world,
age-adjusted incidence rates range from more than 10 per
100 000 women in Europe and North America, to less than
5 per 100 000 in parts of Africa and Asia. But rates are rel-
atively high elsewhere in Asia, for example in Singapore and
the Philippines.2 In the USA, rates are higher among white
women than in those from other ethnic groups; rates are also
higher in Jewish women of Ashkenazi descent.3 249
Risk increases with age, although the rate of increase slows
after the menopause, with most ovarian cancers occurring
after menopause. Only 10–15 per cent of cases occur before
the menopause, although germ cell cancers peak in women
aged between 15 and 35.4
Ovarian cancer often has no symptoms at the early stages,
so the disease is generally advanced when it is diagnosed.
The 5-year survival rate ranges from approximately 30 to 50
per cent.3 6 This cancer accounts for about 7 per cent of all
cancer incidence and 4 per cent of cancer deaths in women
worldwide. Also see box 7.1.1.
7.11.2  Pathogenesis
The pathogenesis of this disease is not well characterised,
although various mechanisms have been suggested. Over
many cycles of ovulation, the ovarian surface epithelium
undergoes repeated disruption and repair. The epithelial cells
FOOD, NUTRITION, PHYSICAL ACTIVITY, 
AND CANCER OF THE OVARY
In the judgement of the Panel, the factors listed below modify the risk of
cancer of the ovary. Judgements are graded according to the strength of
the evidence.
DECREASES RISK INCREASES RISK
Convincing
Probable Adult attained
height1
Limited — Non-starchy vegetables2
suggestive Lactation
Limited — Dietary fibre; fruits; pulses (legumes); meat; 
no conclusion poultry; fish; eggs; milk and dairy products; total
fat; cholesterol; coffee; tea; alcohol; carbohydrate;
lactose; protein; vitamin A; folate; vitamin C; 
vitamin E; recreational activity; body fatness;
abdominal fatness; weight change; energy intake
Substantial 
effect on risk None identified
unlikely
1 Adult attained height is unlikely directly to modify the risk of cancer. It is a
marker for genetic, environmental, hormonal, and also nutritional factors
affecting growth during the period from preconception to completion of
linear growth (see chapter 6.2.1.3).
2 Judgements on vegetables and fruits do not include those preserved by
salting and/or pickling.
For an explanation of all the terms used in the matrix, 
please see chapter 3.5.1, the text of this section, 
and the glossary.
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are stimulated to proliferate, which increases the probabili-
ty of spontaneous mutations. Alternatively, following ovula-
tion, these cells may become trapped within the connective
tissue surrounding the ovary, which can lead to the forma-
tion of inclusion cysts. If this happens, the epithelial cells are
subjected to a unique pro-inflammatory microenvironment,
which may increase the rate of DNA damage.
Most ovarian cancers occur spontaneously, although 5–10
per cent of cases develop due to a genetic predisposition.104
The latter, involving dysfunctional BRCA1 or BRCA2 genes
(see chapter 2.4.1.1), produces high-grade carcinomas, with
a poorer prognosis.250
7.11.3  Other established causes
(Also see chapter 2.4 and 7.1.3.1.)
Life events. The risk of ovarian cancer is affected by the num-
ber of menstrual cycles during a woman’s lifetime. Not bear-
ing children increases the risk of, and may be seen as a cause
of, ovarian cancer. The reverse also applies: bearing children
reduces the risk of, and may be seen as protective against,
ovarian cancer.251-253 There is also substantial evidence that,
as with breast cancer, early menarche and late natural
menopause increase the risk of, and may be seen as causes
of, ovarian cancer. The reverse also applies: late menarche
and early menopause reduce the risk of, and may be seen as
protective against, ovarian cancer.251-253
Medication. Oral contraceptives protect against this cancer.133
7.11.4  Interpretation of the evidence
7.11.4.1 General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7.
‘Relative risk’ is used in this Report to denote ratio mea-
sures of effect, including ‘risk ratios’, ‘rate ratios’, ‘hazard
ratios’, and ‘odds ratios’.
7.11.4.2 Specific
Considerations specific to cancer of the ovary include: 
Patterns. Because ovarian cancer is hormone related, factors
that modify risk might have different effects at different
times of life. If so, this might partly explain heterogeneous
results. 
Confounding. High-quality studies adjust for age, number of
reproductive cycles, age at which children were born, and the
taking of hormone-based medications.
Classification. There are different histological subtypes of
ovarian cancer, which may have independent risk factors and
disease progression patterns. Most studies combine these
subtypes.
7.11.5  Evidence and judgements
In total, 187 publications were included in the SLR for ovar-
ian cancer. Fuller summaries of the epidemiological, exper-
imental, and mechanistic evidence are to be found in
Chapters 4–6.
The full SLR is contained on the CD included with this
Report. 
7.11.5.1  Non-starchy vegetables
(Also see chapter 4.2.5.1.)
A total of five cohort studies, eight case-control studies, and
two ecological studies investigated non-starchy vegetables;
three cohort studies and two case-control studies investi-
gated green, leafy vegetables. All showed decreased risk with
increased intake, with none reporting contrary results. Meta-
analysis of cohort data showed a statistically significant
decreased risk for non-starchy vegetables, with a clear dose-
response relationship. A pooled analysis of 12 cohort stud-
ies (more than 560 000 participants, followed up for 7–22
years, with more than 2100 ovarian cancer cases) showed a
non-significant decreased risk for the highest intake group
of non-starchy vegetables.254
This is a wide and disparate category, and many different
plant food constituents are represented that could contribute
to a protective effect of non-starchy vegetables. These
include dietary fibre, carotenoids, folate, selenium, glucosi-
nolates, dithiolthiones, indoles, coumarins, ascorbate,
chlorophyll, flavonoids, allylsulphides, flavonoids, and phy-
toestrogens, some of which are potentially antioxidants.
Antioxidants trap free radicals and reactive oxygen mole-
cules, protecting against oxidation damage. It is difficult to
unravel the relative importance of each constituent and it is
likely that any protective effect may result from a combina-
tion of influences on several pathways involved in
carcinogenesis.
Evidence from cohort and case-control studies is
sparse. There is limited evidence suggesting that non-
starchy vegetables protect against ovarian cancer.
The Panel is aware that since the conclusion of the SLR, one
case-control study17 has been published. This new information
does not change the Panel judgement. Also see box 3.8. 
7.11.5.2  Adult attained height 
(Also see chapter 6.2.3.1.)
Seven cohort studies, nine case-control studies, and two eco-
logical studies investigated adult attained height. All cohort
studies and most other studies showed increased risk with
greater adult attained height. Meta-analysis of cohort data
showed an 8 per cent increased risk per 5 cm of height (fig-
ure 6.2.7); meta-analysis of case-control data showed no sta-
tistically significant relationship. Heterogeneity in the latter
was derived almost entirely from one study.
The general mechanisms through which the factors that
lead to greater adult attained height, or its consequences,
could plausibly influence cancer risk are outlined in chapter
6.2.1.3 (see box 2.4). Many of these, such as early-life
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nutrition, altered hormone profiles, and the rate of sexual
maturation, could plausibly increase cancer risk.
There is some inconsistency, but the better quality
epidemiological data show a clearer effect, with a
dose-response relationship. There is evidence for
plausible mechanisms operating in humans. The
factors that lead to greater adult attained height, or its
consequences, are probably a cause of ovarian cancer.
The causal factor is unlikely to be tallness itself, but
factors that promote linear growth in childhood. 
The Panel is aware that since the conclusion of the SLR, one
cohort study255 and one case-control study256 have been pub-
lished. This new information does not change the Panel judge-
ment. Also see box 3.8.
7.11.5.3  Lactation
(Also see chapter 6.3.3.)
One cohort study and 10 case-control studies investigated
lactation, most of which showed an association with
reduced risk. Meta-analysis of case-control data showed sta-
tistically significant decreased risk with increased accumu-
lated lifetime duration of breastfeeding, with a clear
dose-response relationship. Substantial heterogeneity is par-
tially explained by variation in the assessment of breast-
feeding when, for example, exclusivity of breastfeeding is not
always assessed.
Lactation delays the return of menstruation and ovulation
after childbirth. The general mechanisms through which lac-
tation could plausibly protect against cancer are outlined in
chapter 6.3.3. There is evidence that the reduced number of
menstrual cycles associated with breastfeeding protect
against some cancers.
There are sparse prospective epidemiological data,
though some evidence for a dose-response
relationship. The mechanistic evidence is speculative.
There is limited evidence suggesting that lactation
protects against ovarian cancer.
The Panel is aware that since the conclusion of the SLR, one
case-control study257 has been published. This new information
does not change the Panel judgement. Also see box 3.8.
7.11.5.4  Other exposures
Other exposures were evaluated. However, the data were
either of too low quality, too inconsistent, or the number of
studies too few to allow conclusions to be reached. These
were as follows: pulses (legumes); fruits; meat; poultry; fish;
eggs; milk and dairy products; coffee; tea; alcohol; carbo-
hydrate; dietary fibre; lactose; total fat; cholesterol; protein;
vitamin A; folate; vitamin C; vitamin E; recreational activi-
ty; energy intake; body fatness; weight change; and abdom-
inal fatness.
7.11.6   Comparison with previous report
7.11.6.1  General
See 7.1.6.1, and box 3.8 in chapter 3.
7.11.6.2  Specific
The finding here on adult attained height is new.
7.11.7  Conclusions
The Panel concludes:
The factors that lead to greater adult attained height, or its
consequences, are probably a cause of cancer of the ovary. 
There is limited evidence suggesting that non-starchy veg-
etables, and also lactation, protect against this cancer.
299
C H A P T E R  7  •  C A N C E R S
Endometrial cancer is the eighth most common cancer in
women (and the 17th most common cancer overall)
worldwide. Around 200 000 cases were recorded in 2002,
accounting for around 4 per cent of all new cases of
cancer in women (2 per cent overall). It is most frequent
in high-income countries. Around three quarters of women
with this cancer survive for 5 years. It is the 13th most
common cause of cancer death in women worldwide (21st
overall). 
Overall, the Panel is impressed by the pattern of evidence
showing the importance of physical activity and body
fatness, as well as factors that affect hormone status, in
modification of the risk of endometrial cancer. 
The Panel judges as follows: 
The evidence that body fatness is a cause of cancer of the
endometrium is convincing; abdominal fatness is probably
a cause. Physical activity probably protects against this
cancer. There is limited evidence suggesting that non-
starchy vegetables protect against endometrial cancer, and
that red meat, and also the factors that lead to greater
adult attained height, or its consequences, are causes of
this cancer. 
Life events that protect against endometrial cancer
include bearing children and early menopause, which have
the effect of reducing the number of menstrual cycles and
therefore lifetime exposure to oestrogens. The reverse also
applies. 
See chapter 8 for evidence and judgements on factors
that modify the risk of body fatness and abdominal
fatness, including physical activity and sedentary ways of
life, the energy density of foods and drinks, and
breastfeeding.
In final summary, the strongest evidence, corresponding
to judgements of “convincing” and “probable”, shows that
body fatness and probably abdominal fatness are causes of
endometrial cancer, and that physical activity is protective.
The endometrium is the lining of the uterus. It is subject to
a process of cyclical change during the fertile years of a
woman’s life.
The majority of cancers that occur in the body of the womb
are endometrial cancers, mostly adenocarcinomas,4 the type
included here.
7.12.1  Trends, incidence, and survival
Age-adjusted rates of endometrial cancer are increasing in
countries undergoing transition from low- to high-income
economies, although there is no clear, overall trend in high-
income countries. 
This is mainly a disease of high-income countries, where
overall rates are nearly five times higher than in middle- to
low-income countries. Around the world, age-adjusted inci-
dence rates range from more than 15 per 100 000 women
in North America and parts of Europe to less than 5 per
100 000 in most of Africa and Asia. In the USA, rates are
higher in white women than among those from other eth-
nic groups, although mortality rates are higher in black
women.3 258 Risk increases with age, with most diagnoses
made postmenopause.
Endometrial cancer often produces symptoms at relative-
ly early stages, so the disease is generally diagnosed early.
At around 73 per cent, the overall 5-year survival rate is rel-
atively high, although it is lower in middle- than in high-
income countries (67 compared with 82 per cent).124 259
Endometrial cancer accounts for almost 2 per cent of all
cancer incidence (around 4 per cent in women), but just
under 1 per cent of all cancer deaths (nearly 2 per cent in
women). Also see box 7.1.1.
FOOD, NUTRITION, PHYSICAL ACTIVITY, 
AND CANCER OF THE ENDOMETRIUM
In the judgement of the Panel, the factors listed below modify the risk of
cancer of the endometrium. Judgements are graded according to the
strength of the evidence.
DECREASES RISK INCREASES RISK
Convincing Body fatness
Probable Physical activity1 Abdominal fatness
Limited — Non-starchy vegetables2 Red meat3
suggestive Adult attained height4
Limited — Cereals (grains) and their products; dietary fibre; 
no conclusion fruits; pulses (legumes); soya and soya products;
poultry; fish; eggs; milk and dairy products; total
fat; animal fats; saturated fatty acids; cholesterol;
coffee; alcohol; carbohydrates; protein; retinol;
vitamin C; vitamin E; beta-carotene; lactation;
energy intake
Substantial 
effect on risk None identified
unlikely
1 Physical activity of all types: occupational, household, transport, 
and recreational.
2 Judgements on vegetables and fruits do not include those preserved by
salting and/or pickling.
3 The term ‘red meat’ refers to beef, pork, lamb, and goat from
domesticated animals.
4 Adult attained height is unlikely directly to modify the risk of cancer. It is a
marker for genetic, environmental, hormonal, and also nutritional factors
affecting growth during the period from preconception to completion of
linear growth (see chapter 6.2.1.3).
For an explanation of all the terms used in the matrix, 
please see chapter 3.5.1, the text of this section, 
and the glossary.
7.12  Endometrium
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7.12.2  Pathogenesis
Type 1 endometrial tumours are oestrogen driven, account
for around 80 per cent of endometrial cancers, and have a
favourable prognosis.260 They follow a clear development
pathway, starting with endometrial hyperplasia (an increase
in the number of cells), and are relatively well differentiat-
ed. Type 2 tumours are less common, accounting for around
10 per cent of endometrial cancers. Most are associated with
endometrial atrophy (wasting), tend to metastasise, and
have a less favourable prognosis.
Up to 70 per cent of endometrial cancers are reported in
women who have no recognised risk factors — such as those
that might disrupt endocrine (hormone) processes.4 Some
studies have shown that polycystic ovary syndrome and
insulin sensitivity, which are both components of metabolic
syndrome, may play a role in the pathogenesis of endome-
trial cancer, perhaps through hormonal disruption.261
The tumour-suppressor gene PTEN is also involved in 
the development of endometrial cancers.260 Also see also 
box 2.2. 
7.12.3  Other established causes 
(Also see chapter 2.4 and 7.1.3.1.)
Life events. Not bearing children increases the risk of, and
may be seen as a cause of, endometrial cancer.262 The reverse
also applies: bearing children reduces the risk of, and may
be seen as protective against, endometrial cancer.258-261 There
is also substantial evidence that, as with breast and ovarian
cancer, late natural menopause increases the risk of, and may
be seen as a cause of, endometrial cancer. The reverse also
applies: early menopause reduces the risk of, and may be
seen as protective against, this cancer.133
Medication. Oral contraceptives protect against this can-
cer.133 Oestrogen-only hormone replacement therapy is a
cause of this cancer,144 as is tamoxifen.
7.12.4  Interpretation of the evidence
7.12.4.1 General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7. 
‘Relative risk’ is used in this Report to denote ratio mea-
sures of effect, including ‘risk ratios’, ‘rate ratios’, ‘hazard
ratios’, and ‘odds ratios’.
7.12.4.2 Specific
Considerations specific to cancer of the endometrium
include: 
Patterns. Because endometrial cancer is hormone related,
factors that modify risk might have different effects at dif-
ferent times of life. 
Confounding. High-quality cohort studies eliminate women
who have had hysterectomies from ‘at-risk’ populations.
High-quality case-control studies assess the levels of hys-
terectomies in control groups. 
7.12.5  Evidence and judgements
In total, 282 publications were included in the SLR for
endometrial cancer. Fuller summaries of the epidemiologi-
cal, experimental, and mechanistic evidence are to be found
in Chapters 4–6.
The full SLR is contained on the CD included with this
Report.
7.12.5.1  Non-starchy vegetables
(Also see chapter 4.2.5.1.)
Ten case-control studies investigated non-starchy vegetables,
and seven case-control studies investigated cruciferous veg-
etables. Most studies showed decreased risk with increased
intake. Meta-analysis of case-control data produced evidence
of decreased risk with non-starchy or cruciferous vegetable
intake, with a clear dose-response relationship. There were
no cohort data.
This is a wide and disparate category, and many different
plant food constituents are represented that could contribute
to a protective effect of non-starchy vegetables. These
include dietary fibre, carotenoids, folate, selenium, glucosi-
nolates, dithiolthiones, indoles, coumarins, ascorbate,
chlorophyll, flavonoids, allylsulphides, flavonoids, and phy-
toestrogens, some of which are potentially antioxidants.
Antioxidants trap free radicals and reactive oxygen mole-
cules, protecting against oxidation damage. 
It is difficult to unravel the relative importance of each
constituent and it is likely that any protective effect may
result from a combination of influences on several pathways
involved in carcinogenesis.
Evidence comes from case-control studies only. There
is limited evidence suggesting that non-starchy
vegetables protect against endometrial cancer.
7.12.5.2  Red meat
(Also see chapter 4.3.5.1.1.)
One cohort study and seven case-control studies investigat-
ed red meat. Most studies showed increased risk with high-
er intake. Meta-analysis of case-control data produced
evidence of increased risk with higher intake, with a clear
dose-response relationship.
There are several potential underlying mechanisms for a
positive association of red meat consumption with endome-
trial cancer, including the generation of potentially carcino-
genic N-nitroso compounds (see box 4.3.2). 
Some meats are also cooked at high temperatures, result-
ing in the production of heterocyclic amines and polycyclic
aromatic hydrocarbons (see box 4.3.4). Red meat contains
haem iron. Free iron can lead to the production of free rad-
icals (see box 4.3.3).
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The evidence, mostly from case-control studies, is
sparse. There is limited evidence suggesting that red
meat is a cause of endometrial cancer.
The Panel is aware that since the conclusion of the SLR, one
case-control study263 has been published. This new information
does not change the Panel judgement. Also see box 3.8.
7.12.5.3  Physical activity
(Also see chapter 5.4.3.)
Two cohort studies and 4 case-control studies investigated
total physical activity; 3 cohort studies and 10 case-control
studies investigated occupational activity; and 4 cohort stud-
ies and 10 case-control studies investigated recreational
activity. Nearly all of the cohort studies and most of the other
studies showed decreased risk with increased physical activ-
ity. Although meta-analysis was not possible due to the wide
variety in measures used, comparisons of high with low
activity levels showed a consistent association with
decreased risk (figures 5.4.8 and 5.4.9).
Sustained moderate physical activity raises the metabolic
rate and increases maximal oxygen uptake. In the long term,
regular periods of such activity increase the body’s metabolic
efficiency and capacity (the amount of work that it can per-
form), as well as reducing blood pressure and insulin resis-
tance. In addition, physical activity has been found to affect
serum levels of oestradiol, oestrone, and androgens in post-
menopausal women, even after adjusting for BMI. More gen-
erally, effects on oestrogen metabolism may operate directly,
or through decreasing body fat stores. Physical activity is also
known to have favourable effects on insulin resistance, which
may also result in decreased risk of endometrial cancer.
Physical activity also results in decreased risk of diabetes and
high blood pressure, which are risk factors for endometrial
cancer.
There is generally consistent evidence, mostly from
case-control studies, showing lower risk of cancer of
the endometrium with higher levels of physical activity.
There is evidence for mechanisms operating in
humans. Physical activity probably protects against
cancer of the endometrium. 
7.12.5.4  Body fatness
(Also see chapter 6.1.3.1.)
Twenty-three cohort studies, 41 case-control studies and 
2 cross-sectional studies investigated body fatness, as mea-
sured by BMI. Three cohort studies and six case-control stud-
ies investigated BMI as a young adult. Nearly all of the
studies showed increased risk with increased body fatness,
more than half of which were statistically significant. Meta-
analysis of cohort data showed an overall 52 per cent
increased risk per 5 kg/m2, or a 31 per cent increased risk
per 5 kg/m2 as a young adult; meta-analysis of case-control
data showed an overall 56 per cent increased risk per 5
kg/m2, with a non-significant increased risk for BMI as a
young adult (figures 6.1.17 and 6.1.18). Heterogeneity exist-
ed in the size, but not direction, of the effect.
Body fatness directly affects levels of many circulating hor-
mones, such as insulin, insulin-like growth factors, and
oestrogens, creating an environment that encourages car-
cinogenesis and discourages apoptosis (see box 2.4). It also
stimulates the body’s inflammatory response, which may
contribute to the initiation and progression of several can-
cers (see chapter 2.4.1.3).
There is abundant, consistent epidemiological
evidence with a clear dose-response relationship, and
robust evidence for mechanisms operating in humans.
The evidence that greater body fatness is a cause of
endometrial cancer is convincing.
The Panel is aware that since the conclusion of the SLR, one
cohort study215 and one case-control study264 have been pub-
lished. This new information does not change the Panel judge-
ment. Also see box 3.8.
7.12.5.5  Abdominal fatness
(Also see chapter 6.1.3.2.)
One cohort study and four case-control studies investigated
waist circumference; one cohort study and six case-control
studies investigated waist to hip ratio. Both cohort studies
and most case-control studies showed statistically significant
increased risk with increased abdominal fatness. Meta-analy-
sis of case-control data showed a non-significant increased
risk.
The general mechanisms through which abdominal fatness
could plausibly cause cancer are outlined in chapter 6.1.3
(for more detail see box 2.4). The hormonal and other bio-
logical effects of being overweight or obese are outlined in
chapter 8. Many of these, such as increased circulating
oestrogens and decreased insulin sensitivity, are associated
with abdominal fatness independently of overall body
fatness.
There is a substantial amount of generally consistent
epidemiological evidence, but limited prospective
data. There is evidence for plausible mechanisms.
Greater abdominal fatness is a probable cause of
endometrial cancer.
7.12.5.6  Adult attained height
(Also see chapter 6.2.3.1.)
Ten cohort studies, 16 case-control studies and 1 ecological
study investigated adult attained height. Most studies
showed increased risk with greater adult attained height.
Meta-analysis of cohort and case-control data showed non-
significant increased risk. 
The general mechanisms through which the factors that
lead to greater adult attained height, or its consequences,
could plausibly influence cancer risk are outlined in chapter
6.2.1.3 (for more detail see box 2.4). Many of these, such
as early-life nutrition, altered hormone profiles, and the rate
of sexual maturation, could plausibly increase cancer risk.
Although there is generally consistent evidence for
prospective epidemiological data, there is some
inconsistency in the evidence between cohort and
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case-control studies, and the mechanistic evidence is
speculative. There is limited evidence that greater
adult attained height, or the factors that lead to it, are
a cause of endometrial cancer. The causal factor is
unlikely to be tallness itself, but factors that promote
linear growth in childhood. 
7.12.5.7  Other exposures
Other exposures were evaluated. However, the data were
either of too low quality, too inconsistent, or the number of
studies too few to allow conclusions to be reached. These
were as follows: cereals (grains) and their products; fruits;
pulses (legumes); tofu and soya; poultry; fish; eggs; milk and
dairy products; coffee; alcohol; carbohydrates; dietary fibre;
total fat; animal fats; saturated fatty acids; cholesterol; pro-
tein; retinol; beta-carotene; vitamin C; vitamin E; energy
intake; and lactation.
7.12.6  Comparison with previous report
7.12.6.1  General
See 7.1.6.1, and box 3.8 in chapter 3.
7.12.6.2  Specific
The finding here on physical activity is new. The evidence
on body fatness and on abdominal fatness (not considered
separately in the previous report’s matrices) has strength-
ened.
7.12.7  Conclusions
The Panel concludes:
The evidence that body fatness is a cause of cancer of the
endometrium is convincing; abdominal fatness is probably
also a cause. 
Physical activity probably protects against this cancer. 
There is limited evidence suggesting that non-starchy veg-
etables protect against endometrial cancer, and that red
meat, and also the factors that lead to greater adult attained
height, or its consequences, are causes of this cancer. 
7.13  Cervix 
Cervical cancer is the second most common cancer in
women worldwide. Around half a million cases were
recorded in 2002, accounting for around 10 per cent of all
new cases of cancer in women (5 per cent overall). It is
most common in Africa, some parts of Asia including
India, and in Latin America. It is most common in
relatively young women. Five-year survival rates are
around 50 per cent. It is the third most common cause of
cancer death in women. 
Overall, the Panel notes that food and nutrition and
associated factors are not significant factors in
modification of the risk of cancer of the cervix, although
general nutritional status may affect a woman’s
vulnerability to infection. 
Life events that protect against cervical cancer include
having relatively few sexual partners. The reverse also
applies. Infection with HPV is a necessary cause of this
cancer, and smoking tobacco increases risk. 
The Panel judges as follows: 
There is limited evidence suggesting that carrots protect
against cervical cancer. 
In final summary, there is no strong evidence,
corresponding to judgements of “convincing” and
“probable”, to conclude that any aspect of food, nutrition,
and physical activity modifies the risk of cervical cancer.
The cervix is the neck of the womb. The part of the cervix
inside the cervical canal is called the endocervix. The part on
the outside is the ectocervix. Most cervical cancers start where
these two parts meet. There are two main types, squamous
cell carcinoma and adenocarcinoma. Occasionally, mixed car-
cinomas, with features of both types, occur. Approximately
80 per cent of cervical cancers are squamous cell carcinomas,
with most of the rest being adenocarcinomas.265 Both types
of cervical cancer are covered in this Report.
7.13.1  Trends, incidence, and survival
Age-adjusted rates of cervical cancer are decreasing, partic-
ularly in high- and middle-income countries, although there
are insufficient data to derive trends in low-income countries.
In high-income countries, the incidence of adenocarcinomas
has increased since the 1970s, both absolutely and relative
to squamous cell carcinomas. The prevalence appears to be
increasing disproportionately in young women.266
Cervical cancer is predominantly a disease of low-income
countries, with overall rates nearly twice as high in middle-
to low- as in high-income countries. Around the world, age-
adjusted incidence rates range from more than 40 per
100 000 women in parts of Africa, South America, and
Melanesia, to less than 10 per 100 000 in North America and
parts of Asia. However, rates are relatively high elsewhere
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in Asia, for example in India and Bangladesh. In the USA,
rates are higher among both African-American and Hispanic-
American women than in white women. The incidence of
many cancers rises with age, but cervical cancer peaks in
younger women, between the ages of 30 and 45.6 However,
mortality does not follow the same pattern, and rises with
age. Most women in high-income countries, and to varying
degrees in other countries, have access to preventive
screening programmes that are designed to detect precan-
cerous lesions. If these are identified and removed, the inci-
dence of this cancer is reduced. After a screening programme
was implemented in the UK in 1988, cervical cancer inci-
dence (age-standardised rate) has fallen by nearly 60 per
cent.6 It is generally well accepted that better access to cer-
vical screening programmes worldwide would decrease both
the incidence and mortality rates for this cancer.267 More
recently vaccination against HPV has become a preventive
option.
The overall 5-year survival rate is approximately 50 per
cent: 61 per cent in high-income countries compared with
41 per cent in middle- to low-income countries.124 This can-
cer accounts for somewhat over 4 per cent of all cancer inci-
dence (around 10 per cent in women) but only around 4 per
cent of all cancer deaths (just over 9 per cent in women).
Also see box 7.1.1.
7.13.2  Pathogenesis
Virtually all cervical cancers are associated with HPV
infection (see box 7.13.1), and a woman’s nutrition 
status may influence her susceptibility to this infection.268
However, the majority of women with HPV do not develop
cervical cancer. Therefore, HPV infection is a necessary but
not a sufficient cause of cervical cancer. Women become sus-
ceptible to developing cervical cancer following HPV infec-
tion, but other environmental factors are required for the
cancer to develop. 
These factors may include toxins such as polycyclic aro-
matic hydrocarbons (see box 4.3.4) from tobacco smoke,
food, or other environmental sources, which have been
found in the mucus lining the cervix.269
FOOD, NUTRITION, PHYSICAL ACTIVITY, 
AND CANCER OF THE CERVIX
In the judgement of the Panel, the factors listed below modify the risk of
cancer of the cervix. Judgements are graded according to the strength of
the evidence.
DECREASES RISK INCREASES RISK
Convincing
Probable
Limited — Carrots1
suggestive
Limited — Non-starchy vegetables; fruits; milk; retinol; vitamin E;
no conclusion alcoholism2; body fatness; adult attained height.
Substantial 
effect on risk None identified
unlikely
1 Judgements on vegetables and fruits do not include those preserved by
salting and/or pickling.
2 Although data suggest that alcoholism is related to increased risk, the Panel
concludes that this is likely to be due to factors other than alcohol intake
itself.
For an explanation of all the terms used in the matrix, 
please see chapter 3.5.1, the text of this section, 
and the glossary.
Human papilloma viruses (HPVs) are com-
mon. They infect squamous epithelia and
generate warts. They are passed by direct
contact; genital HPV infections are sexual-
ly transmitted. HPV infection rates are
higher in women who have had a higher
number of sexual partners (particularly
male partners); do not use barrier methods
of contraception; and who started having
sex at a younger age.
There are more than 100 types of HPV.
All can interfere with host-cell machinery
that prevents cells from growing and
replicating excessively, which are some of
the cellular mechanisms that help protect
the body against cancer development.
Low-risk HPVs cause genital warts; high-
risk HPVs cause squamous intra-epithelial
lesions that can progress to invasive squa-
mous cell carcinoma. The majority of
human cervical cancers are associated with
high-risk HPV infections. Four subtypes of
this virus account for 80 per cent of all cer-
vical cancer. 
HPV infection tends to remain dormant,
and with repeated infection, the HPV
genome becomes integrated within the
host cell genome and some cells may
become cancerous. 
Most HPV infections do not become per-
sistent, and most persistent HPV infections
do not lead to cancer. However, HPV infec-
tion is demonstrably present in 99 per cent
of women with cervical cancer, and may be
present but undetected in the remainder.
HPV is a necessary while not sufficient
cause of cervical cancer.
There are several stages at which foods
or nutrition status could influence pro-
gression. Dietary factors influence suscep-
tibility to infection; infection can alter
nutrition status; diet may affect the likeli-
hood of infections becoming persistent;
and dietary factors have been shown to
alter DNA stability and repair.
Unfortunately, there is a shortage of epi-
demiological evidence specific to HPV at
each of these stages. There is some limit-
ed evidence that eating vegetables and
fruits can protect against persistence.268
There is also evidence that folate can
reduce persistence and independently
reduce the risk of precancerous lesions in
high-risk-HPV infected women.270-272
Box 7.13.1 Human papilloma viruses
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7.13.3  Other established causes 
(Also see chapter 2.4 and 7.1.3.1.)
Life events. Early sexual experience and a relatively high
number of sexual partners increase the risk and severity of
HPV infection, and may be seen as indirect causes of cervi-
cal cancer.220 222
Tobacco use. Smoking tobacco makes a woman twice as like-
ly to develop cervical cancer.10 Tobacco by-products have been
found in the cervical mucus of women who smoke. The effect
of smoking is independent of that of viral infection.10 273
Infectious agents. HPV infection (see box 7.13.1) is a nec-
essary but not sufficient cause of cervical cancer.273 274
Medication. Dethylstilboestrol (a synthetic oestrogen, now
withdrawn) used by women during pregnancy is a cause of
vaginal and cervical clear-cell adenocarcinoma in their
daughters.275
7.13.4  Interpretation of the evidence
7.13.4.1  General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7.
‘Relative risk’ is used in this Report to denote ratio mea-
sures of effect, including ‘risk ratios’, ‘rate ratios’, ‘hazard
ratios’, and ‘odds ratios’.
7.13.4.2  Specific
Considerations specific to cancer of the cervix include: 
Confounding. High-quality studies adjust for HPV infection.
Early studies that failed to adjust for HPV status have
reduced validity.
7.13.5  Evidence and judgements
In total, 154 publications were included in the SLR for cer-
vical cancer. Fuller summaries of the epidemiological,
experimental, and mechanistic evidence are to be found in
Chapters 4–6.
The full SLR is contained on the CD included with this
Report.
7.13.5.1  Carrots
(Also see chapter 4.2.5.1.3.)
Five case-control studies and one ecological study investi-
gated carrots. All of the case-control studies showed
decreased risk for the highest levels of intake compared with
the lowest, statistically significant in three. The case-control
studies all used hospital-based controls and none adjusted for
HPV status. The single ecological study showed non-signifi-
cant increased risk with high intake of carrots.
Some carotenoids, including beta-carotene and alpha-
carotene, which are found at high levels in carrots, are pre-
cursors of vitamin A. They also have properties independent
of their pro-vitamin A activity. Carotenoids are recognised
antioxidants, and low blood levels of dietary antioxidants are
associated with HPV persistence.276
The evidence, from case-control studies only, is sparse
but consistent. There is limited evidence suggesting
that carrots protect against cervical cancer.
7.13.5.2  Other exposures
Other exposures were evaluated. However, the data were
either of too low quality, too inconsistent, or the number of
studies too few to allow conclusions to be reached. These
were as follows: non-starchy vegetables; fruits; milk; retinol;
vitamin E; alcoholism; body fatness; and adult attained
height.
Although data suggest that alcoholism is related to
increased risk, the Panel concludes that this is likely to be due
to factors other than alcohol intake itself. 
7.13.5.3  Exposures as related to non-invasive
cancer outcomes
The following exposures were evaluated. However, the data
were either too sparse, too inconsistent, or the number of
studies too few to allow conclusions to be reached: vitamin
A (as beta-carotene, alpha-carotene, or retinol); folate; vit-
amin C; vitamin E; and lycopene. 
7.13.6  Comparison with previous report
7.13.6.1  General
See 7.1.6.1, and box 3.8 in chapter 3.
7.13.6.2  Specific
The previous report found that vegetables and fruits, and
carotenoids (not carrots specifically), and also vitamins C
and E possibly protect against cervical cancer.
7.13.7  Conclusions
The Panel concludes:
There is limited evidence suggesting that carrots protect
against cervical cancer. The evidence is too limited to con-
clude that any aspect of food, nutrition, and physical activ-
ity directly modifies the risk of this cancer.
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7.14  Prostate
Prostate cancer is the second most common cancer in men
(and the sixth most common cancer overall) worldwide.
Around 680 000 cases were recorded in 2002, accounting
for around 12 per cent of all new cases of cancer in men
(6 per cent overall). It is most commonly diagnosed in
high-income countries, where screening is common. Five-
year survival rates are around 60 per cent. It is the sixth
most common cause of cancer death in men worldwide. 
Overall, the Panel notes the impressive recent evidence
from cohort studies and trials demonstrating effects, or
absence of effect, of specific foods and nutrients on
prostate cancer. 
The Panel judges as follows: 
Foods containing lycopene, as well as selenium or foods
containing it, probably protect against prostate cancer.
Foods containing calcium are a probable cause of this
cancer. It is unlikely that beta-carotene (whether from
foods or supplements) has a substantial effect on the risk
of this cancer. There is limited evidence suggesting that
pulses (legumes) including soya and soya products, foods
containing vitamin E, and alpha-tocopherol supplements
are protective; and that processed meat, and milk and
dairy products are a cause of this cancer. 
In final summary, the strongest evidence, corresponding
to judgements of “convincing” and “probable”, shows that
foods containing lycopene, as well as selenium or foods
containing it, probably protect against prostate cancer,
and that foods containing calcium are a probable cause of
this cancer. It is unlikely that beta-carotene (whether from
foods or supplements) has a substantial effect on the risk
of this cancer.
The prostate is a walnut-sized gland in men that surrounds
the top of the urethra; it produces seminal fluid. Its growth
and function are controlled by male hormones such as
testosterone.
Almost all prostate cancers are adenocarcinomas,4 the type
included here.
7.14.1  Trends, incidence, and survival 
Age-adjusted incidence rates of prostate cancer increased dra-
matically between 1988 and 1992.137 This was largely
because of the increased availability of screening for prostate-
specific antigen (PSA) in men without symptoms of the dis-
ease. This test leads to the detection of many prostate cancers
that are small and/or would otherwise remain unrecognised,
and which may or may not develop further into higher stage
disease (see 7.14.2). Rates were already increasing before the
availability of PSA testing, and have continued to increase in
middle-income countries where screening is still not widely
available.124 This suggests that prostate cancer is influenced
FOOD, NUTRITION, PHYSICAL ACTIVITY, 
AND CANCER OF THE PROSTATE
In the judgement of the Panel, the factors listed below modify the risk of
cancer of the prostate. Judgements are graded according to the strength
of the evidence.
DECREASES RISK INCREASES RISK
Convincing
Probable Foods containing 
lycopene1 2
Foods containing Diets high in
selenium1 calcium4 5
Selenium3
Limited — Pulses (legumes)6
suggestive Foods containing Processed meat8
vitamin E1
Alpha-tocopherol7 Milk and dairy
products5
Limited — Cereals (grains) and their products; dietary fibre;
no conclusion potatoes; non-starchy vegetables; fruits; meat;
poultry; fish; eggs; total fat; plant oils; sugar
(sucrose); sugary foods and drinks; coffee; tea;
alcohol; carbohydrate; protein; vitamin A; retinol;
thiamin; riboflavin; niacin; vitamin C; vitamin D;
gamma-tocopherol; vitamin supplements;
multivitamins; iron; phosphorus; zinc; other
carotenoids; physical activity; energy expenditure;
vegetarian diets; Seventh-day Adventist diets; 
body fatness; abdominal fatness; birth weight;
energy intake
Substantial 
effect on risk Beta-carotene1 9
unlikely
1 Includes both foods naturally containing the constituent and foods which
have the constituent added (see chapter 3.5.3). 
2 Mostly contained in tomatoes and tomato products. Also fruits such as
grapefruit, watermelon, guava, and apricot.
3 The evidence is derived from studies using supplements at a dose of 
200 µg/day. Selenium is toxic at high doses.
4 Includes diets that naturally contain calcium and that contain foods
fortified with calcium. See box 4.10.1. 
5 Effect only apparent at high calcium intakes (around 1.5 g/day or more).
Evidence for milk and dairy products (but not calcium) was derived only
from countries with populations that have high calcium and dairy
consumption.
6 Including soya and soya products.
7 The evidence is derived from studies using supplements at a dose of 
50 mg/day.
8 The term ‘processed meat’ refers to meats preserved by smoking, curing, 
or salting, or addition of chemical preservatives.
9 The evidence is derived from studies using supplements at doses of 20, 30,
and 50 mg/day.
For an explanation of all the terms used in the matrix, 
please see chapter 3.5.1, the text of this section, 
and the glossary.
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by environmental factors. Although screening is increasingly
popular in many high-income countries, its value, for exam-
ple in reducing mortality, is controversial. There has been a
decline in incidence and mortality in several high-income
countries since the 1990s although rates remain higher than
those recorded before screening became available. This trend
may be due to elimination of early stage disease and
improved treatment.277
Prostate cancer is mainly a disease of high-income coun-
tries, where overall rates are nearly six times higher than in
middle- to low-income countries. Around the world, age-
adjusted incidence rates range from more than 100 per
100 000 men in North America, parts of the Caribbean, and
Oceania, to less than 10 per 100 000 in Melanesia and much
of Asia.2 This wide range is partly, but not entirely, attribut-
able to the increased availability of screening in high-income
countries. In the USA, rates are higher among African-
American men than in white men.3
Risk increases with age, rising sharply after 40. In most
high-income countries, incidence in men below 40 is typi-
cally less than 1 per 100 000, rising to more than 1000 per
100 000 in those aged 65 and over.278
Average survival for prostate cancer is relatively high
worldwide, although markedly more so in high-income coun-
tries. The 5-year survival rate is approximately 60 per cent
overall: 76 per cent in high-income countries compared with
45 per cent in middle- to low-income countries.124 This can-
cer accounts for around 6 per cent of all cancer incidence
(nearly 12 per cent in men) but around 3 per cent of all can-
cer deaths (almost 6 per cent in men; all sites except for non-
melanoma skin). Also see box 7.1.1.
7.14.2  Pathogenesis
The disease usually develops slowly and dysplastic lesions
may precede cancer by many years or even decades.
Extrapolations from autopsy studies suggest that most men
would have prostate cancer if they lived to be more than
100.278 The number of prostate cancers found incidentally
at autopsy, which had been asymptomatic and not a cause
of death, suggests that small, localised prostate cancers can
remain unrecognised for many years before progressing to a
clinically significant form. Men are more likely to die with,
rather than from, prostate cancer.279 280
The increased prostate cancer incidence in first-degree
male relatives of women who have early onset breast can-
cer suggests a genetic predisposition.281 Some studies pro-
pose that this may be linked to the BRCA genes.282
Growth factors, particularly IGF, as well as androgens have
also been implicated in the development of prostate cancers.
Serum levels of IGF-1 can be associated with prostate can-
cer independently of PSA levels.283 High levels of testos-
terone promote cell differentiation, which could protect
against the development of this cancer. Therefore, declining
levels of this hormone in older age may contribute to the
development of this cancer.284
7.14.3  Other established causes 
(Also see chapter 2.4 and 7.1.3.1.) 
There are no other established causes of prostate cancer.
7.14.4  Interpretation of the evidence
7.14.4.1  General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7. 
‘Relative risk’ is used in this Report to denote ratio mea-
sures of effect, including ‘risk ratios’, ‘rate ratios’, ‘hazard
ratios’, and ‘odds ratios’.
7.14.4.2  Specific
Considerations specific to cancer of the prostate include: 
Confounding. Screening is associated with relatively high
socioeconomic status and also with ‘health-conscious’ behav-
iour such as taking exercise or following dietary guidelines.
High-quality studies adjust for these factors. Some case-con-
trol studies use cases that have been detected by screening.
If so, it is important that control groups are also from a
screened population.
7.14.5  Evidence and judgements
In total, 558 publications were included in the SLR for
prostate cancer. Fuller summaries of the epidemiological,
experimental, and mechanistic evidence are to be found in
Chapters 4–6.
The full SLR is contained on the CD included with this
Report. 
7.14.5.1  Pulses (legumes) including soya and soya
products
(Also see chapter 4.2.5.10.)
A total of 3 cohort studies, 11 case-control studies, and 6 eco-
logical studies investigated pulses (legumes); 4 cohort stud-
ies, 4 case-control studies, and 2 ecological studies
investigated soya and soya products. Most studies showed
decreased risk with increased intake. Meta-analysis of case-
control data produced evidence of an association with
legume intake, with a clear dose-response relationship.
Pulses (legumes), particularly soya foods, contain various
compounds that may have anti-cancer effects. These com-
pounds could plausibly influence oestrogen metabolism. In
addition, phytoestrogens in pulses and soya can have an
androgenic effect, potentially inhibiting testosterone-induced
growth of the prostate.
The evidence, mostly from case-control studies, is
inconsistent. There is limited evidence suggesting that
pulses (legumes), including soya and soya products,
protect against prostate cancer.
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7.14.5.2  Processed meat
(Also see chapter 4.3.5.1.2.)
Four cohort studies and six case-control studies investigat-
ed processed meat. All cohort studies reported increased risk
with higher intake; and most case-control studies also
showed this effect.
Nitrates are both produced endogenously in gastric acid
and added as preservatives to processed meats (box 4.3.2).
They may contribute to N-nitroso compound production and
exposure. These compounds are suspected mutagens and
carcinogens.55
Many processed meats also contain high levels of salt and
nitrite. Meats cooked at high temperatures can contain het-
erocyclic amines and polycyclic aromatic hydrocarbons (box
4.3.4). Haem promotes the formation of N-nitroso com-
pounds and also contains iron. Free iron can lead to pro-
duction of free radicals (box 4.3.3).
There is limited evidence from sparse and inconsistent
studies suggesting that processed meat is a cause of
prostate cancer. 
The Panel is aware that since the conclusion of the SLR, two
cohort studies285 286 have been published. This new information
does not change the Panel judgement. Also see box 3.8.
7.14.5.3  Milk and dairy products
(Also see chapter 4.4.5.1.)
A total of 10 cohort studies, 13 case-control studies, and 2
ecological studies investigated milk and dairy foods; 16
cohort studies, 11 case-control studies, and 11 ecological
studies investigated milk. Most of the studies showed
increased risk with increased intake. Meta-analysis of cohort
data produced evidence of a clear dose-response relationship
between advanced/aggressive cancer risk with milk intake,
and between all prostate cancer risk and milk and dairy
products. 
Most other meta-analyses show non-significant increased
risk. Ecological studies consistently report a relationship in
the direction of increased risk between milk or dairy con-
sumption and prostate cancer.
High calcium intake downregulates the formation of 1,25-
dihydroxy vitamin D3 from vitamin D, thereby increasing cell
proliferation in the prostate.287 Prostate cancer tumours in
rats treated with 1,25-dihydroxy vitamin D3 were signifi-
cantly smaller, and presented smaller numbers of lung metas-
tases.288 Also, consumption of milk increases blood levels of
IGF-1, which has been associated with increased prostate
cancer risk in some studies.283 289
The evidence is inconsistent from both cohort and
case-control studies. There is limited evidence
suggesting that milk and dairy products are a cause of
prostate cancer.
The Panel is aware that since the conclusion of the SLR, two
cohort studies290 291 and one case-control study189 have been
published. This new information does not change the Panel
judgement. Also see box 3.8.
7.14.5.4  Diets high in calcium
(Also see chapter 4.4.5.2.)
Nine cohort studies, 12 case-control studies, and 2 ecolog-
ical studies investigated dietary calcium. Most cohort stud-
ies showed increased risk with increased calcium intake;
case-control studies were inconsistent. Meta-analysis of
cohort data showed an increased risk of 27 per cent per
g/day; meta-analysis of cohort data on advanced or aggres-
sive prostate cancer showed an increased risk of 32 per cent
per g/day. Meta-analyses of case-control data showed non-
significant increased risk.
Calcium can be taken to be a marker for dairy intake in
high-income populations. In areas outside the USA, Europe,
and Oceania, dairy products are not as widely consumed,
and the range of calcium intakes is smaller.
High calcium intake downregulates the formation of 1,25-
dihydroxy vitamin D3 from vitamin D, thereby increasing
cell proliferation in the prostate.287 Prostate cancer tumours
in rats treated with 1,25-dihydroxy vitamin D3 were signif-
icantly smaller and presented fewer lung metastases.288
The evidence, from both cohort and case-control
studies, is substantial and consistent, with a dose-
response relationship. There is evidence for plausible
mechanisms. Diets high in calcium are a probable
cause of prostate cancer.
The Panel is aware that since the conclusion of the SLR, two
cohort studies290 291 have been published. This new informa-
tion does not change the Panel judgement. Also see box 3.8.
7.14.5.5  Foods containing selenium 
(Also see chapter 4.2.5.8.)
A total of 1 cohort study, 7 case-control studies, and 2 eco-
logical studies investigated dietary selenium; 12 cohort
studies and 4 case-control studies investigated serum or
plasma selenium; and 3 cohort studies, 3 case-control stud-
ies, and 1 ecological study investigated levels in nails. Most
studies, including all of those that reported separately on
advanced/aggressive prostate cancer, showed decreased risk
with increased intake. Meta-analysis of cohort data on
advanced or aggressive prostate cancer showed a decreased
risk of 13 per cent per 10 µg selenium/litre of serum or 
plasma (figure 4.2.37), or 20 per cent per 100 ng selenium
per g of nail clippings. Meta-analyses of cohort data that
included all prostate cancer diagnoses showed non-signifi-
cant decreased risk. Case-control studies were inconsistent.
Dietary selenium deficiency has been shown to cause a
lack of selenoprotein expression. Twenty-five selenoproteins
have been identified in animals, and a number of these have
important anti-inflammatory and antioxidant properties.
Four are glutathione peroxidases, which protect against
oxidative damage to biomolecules such as lipids, lipopro-
teins, and DNA. Three are thioredoxin reductases; among
other functions, these regenerate oxidised ascorbic acid to
its active antioxidant form. 
In addition, selenoproteins are involved in testosterone
production, which is an important regulator of both normal
and abnormal prostate growth.
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The evidence from cohort and case-control studies is
consistent, with a dose-response relationship. There is
evidence for plausible mechanisms. Foods containing
selenium probably protect against prostate cancer.
7.14.5.6  Foods containing lycopene 
(Also see chapter 4.2.5.3.)
A total of 5 cohort studies, 9 case-control studies, and 3 eco-
logical studies investigated tomatoes; 3 cohort studies and
14 case-control studies investigated dietary lycopene; and 6
cohort studies and 2 case-control studies investigated serum
or plasma lycopene. Most of the studies showed decreased
risk with increased intake. Studies of cumulative lycopene
intake, or of tomato sauce products (from which lycopene is
highly bioavailable), showed statistically significant
decreased risk. Meta-analysis of cohort data on serum or
plasma lycopene, which are likely to be more precise and
accurate than dietary assessments, showed a 4 per cent
decreased risk per 10 µg lycopene/litre.
Lycopene is best absorbed from vegetables and fruits that
contain it after they are cooked and pureed. The best mea-
sures, that take the degree of absorption into account, are
therefore from studies on tomato sauce or serum/plasma
lycopene. The Panel also gave emphasis to studies on
advanced or aggressive cancers, which may be better linked
to prognosis than studies that include early stage or
unrecognised disease.
Lycopene is the most potent carotenoid antioxidant, has
an antiproliferative effect, reduces plasma low-density
lipoprotein cholesterol, improves immune function, and
reduces inflammation.
There is a substantial amount of consistent evidence,
in particular on tomato products, from both cohort and
case-control studies. There is evidence for plausible
mechanisms. Foods containing lycopene probably
protect against prostate cancer.
The Panel is aware that since the conclusion of the SLR, two
cohort studies292 293 and one case-control study294 have been
published. This new information does not change the Panel
judgement. Also see box 3.8.
7.14.5.7  Selenium 
(Also see chapter 4.10.6.4.5.)
One randomised controlled trial and two cohort studies
investigated selenium supplements. The randomised con-
trolled trial was conducted in 974 men with a history of skin
cancers, randomised to receive a daily supplement of 200 µg
selenium or a placebo. Prostate cancer was not a prior stat-
ed outcome, and was assessed as a secondary endpoint. The
trial showed a 63 per cent decreased risk from selenium sup-
plementation. Both cohort studies showed non-significant
decreased risk with selenium supplementation. 
Dietary selenium deficiency has been shown to cause a
lack of selenoprotein expression. Twenty-five selenoproteins
have been identified in animals and a number of these have
important anti-inflammatory and antioxidant properties.
Four are glutathione peroxidases, which protect against
oxidative damage to biomolecules such as lipids, lipopro-
teins, and DNA. Three are thioredoxin reductases; among
other functions, these regenerate oxidised ascorbic acid to
its active antioxidant form. In addition, selenoproteins are
involved in testosterone production, which is an important
regulator of both normal and abnormal prostate growth.
There is strong evidence from trials and cohort studies.
Selenium probably protects against prostate cancer.
7.14.5.8  Foods containing vitamin E
(Also see chapter 4.2.5.7.)
A total of 2 cohort studies, 13 case-control studies, and 1 eco-
logical study investigated dietary vitamin E; and 4 cohort
studies and 1 case-control study investigated serum vitamin
E. Other groupings examined were serum or plasma alpha-
tocopherol (8 cohort, 2 case-control) and serum gamma-
tocopherol (6 cohort, 1 case-control). Most studies showed
decreased risk with increased intake. Meta-analysis of
cohort data on serum gamma-tocopherol produced evidence
of an association with decreased risk, with a clear dose-
response relationship.
Vitamin E is an antioxidant that has been reported to pre-
vent DNA damage, enhance DNA repair, prevent lipid per-
oxidation, and prevent activation of carcinogens such as
nitrosamines. Vitamin E protects vitamin A and selenium in
the body. In addition to acting as a free-radical scavenger,
vitamin E enhances the body’s immune response, which may
play a role in cancer defences.
The evidence on vitamin E, mostly from case-control
studies, was inconsistent. There is limited evidence
suggesting that foods containing vitamin E protect
against prostate cancer.
The Panel is aware that since the conclusion of the SLR, two
cohort studies293 295 have been published. This new information
does not change the Panel judgement. Also see box 3.8.
7.14.5.9  Beta-carotene 
(Also see chapters 4.2.5.3 and 4.10.6.4.2.)
Six cohort studies and 21 case-control studies investigated
dietary beta-carotene; 10 cohort studies and 5 case-control
studies investigated serum or plasma beta-carotene; 3 ran-
domised controlled trials and 2 cohort studies investigated
beta-carotene supplements. Meta-analyses of 6 cohort stud-
ies and 15 case-control studies that investigated beta-
carotene from food and 7 cohort studies that investigated
serum or plasma beta-carotene produced evidence for there
being no association with prostate cancer risk. One ran-
domised controlled trial produced evidence of no associa-
tion; the other two showed that it was unlikely that
beta-carotene reduced incidence, but did not exclude an
effect of increasing incidence.
There is strong evidence from good quality trials 
and from cohort studies, which consistently fail 
to demonstrate a protective effect. Beta-carotene
supplements are unlikely to have a substantial
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protective effect against prostate cancer. The evidence
is too limited to draw a conclusion on a harmful 
effect. It is unlikely that beta-carotene or foods
containing it have a substantial effect on the risk of
prostate cancer. 
The Panel is aware that since the conclusion of the SLR, two
cohort studies293 295 have been published. This new information
does not change the Panel judgement. Also see box 3.8.
7.14.5.10  Alpha-tocopherol (vitamin E)
(Also see chapter 4.10.6.4.3.)
One randomised controlled trial investigated alpha-toco-
pherol supplements and prostate cancer. The large ran-
domised controlled trial of male smokers given daily
supplements of 50 mg of alpha-tocopherol and 20 mg of
beta-carotene showed a statistically significant 34 per cent
decreased risk for alpha-tocopherol supplements. Prostate
cancer was not a prior-stated outcome for this trial.
Vitamin E exists in eight different forms (isomers): four
tocopherols and four tocotrienols. There is an alpha, beta,
gamma, and delta form of each. Each form has slightly dif-
ferent biological properties but all are antioxidants. Alpha-
tocopherol is thought to be the most biologically active
isomer of vitamin E. It inhibits cell proliferation, can direct-
ly activate certain enzymes, and exerts transcriptional con-
trol on several genes. Vitamin E may have a direct effect on
prostate growth by decreasing cellular concentrations of
testosterone, which could impair differentiation.
The evidence is sparse. There is limited evidence that
alpha-tocopherol supplements protect against prostate
cancer in smokers.
7.14.5.11  Other exposures
Other exposures were evaluated. However, the data were
either of too low quality, too inconsistent, or the number of
studies too few to allow conclusions to be reached. These
were as follows: culturally defined diets (vegetarian,
Seventh-day Adventist); cereals (grains) and their products;
potatoes; fruit and (non-starchy) vegetables; poultry; meat;
fish; eggs; all fats; plant oils; sugar; confectionery; dietary
fibre; fat; protein; carbohydrate; coffee; tea; alcoholic drinks;
vitamin supplements; multivitamins; vitamin A; retinol;
carotenoids; thiamine; riboflavin; niacin; vitamin C; vitamin
D; vitamin E from foods; iron; zinc; phosphorus; physical
activity; energy intake; energy expenditure; body composi-
tion; size and shape; and birth weight.
7.14.6  Comparison with previous report 
7.14.6.1  General
See 7.1.6.1, and box 3.8 in chapter 3.
7.14.6.2  Specific
The findings here on foods containing lycopene and/or cal-
cium, and on selenium or foods containing it, are new,
reflecting the recent intense research interest in prostate can-
cer, including randomised controlled supplementation trials.
7.14.7  Conclusions
The Panel concludes:
Foods containing lycopene, as well as selenium and foods
containing it, probably protect against prostate cancer. Diets
high in calcium are a probable cause of this cancer. It is
unlikely that beta-carotene (whether from foods or supple-
ments) has a substantial effect on the risk of this cancer.
There is limited evidence suggesting that pulses (legumes)
including soya and soya products, foods containing vitamin
E, and alpha-tocopherol supplements are protective, and that
processed meat, and milk and dairy products are a cause of
this cancer.
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7.15  Kidney 
Cancer of the kidney is the 15th most common type
worldwide. Around 200 000 cases were recorded in 2002,
accounting for around 2 per cent of all cancers. Average
overall survival rates are around 50 per cent at 5 years. It
is the 16th most common cause of death from cancer. 
Overall, the Panel is impressed by the pattern of evidence
showing the importance of body fatness as a cause of
cancer of the kidney. 
The Panel judges as follows: 
The evidence that body fatness is a cause of this cancer is
convincing. It is unlikely that coffee has a substantial
effect, or that alcoholic drinks have an adverse effect, on
the risk of this cancer. There is limited evidence suggesting
that arsenic in drinking water is a cause of this cancer. 
Smoking is a cause of cancer of the kidney.
In final summary, the strongest evidence, corresponding
to judgements of “convincing” and “probable”,shows that
greater body fatness is a cause of kidney cancer; and that it
is unlikely that coffee has a substantial effect, or alcoholic
drinks an adverse effect, on the risk of this cancer.
The kidneys are at the back of the abdomen and outside the
peritoneal cavity. They filter waste products and water from
the blood, producing urine, which empties into the bladder
through the ureter. They are also important endocrine organs
concerned with salt and water metabolism, and convert vit-
amin D to its active form.
Renal cell carcinoma is the most common kidney cancer,
accounting for approximately 85 per cent. The majority of
these are adenocarcinomas,4 the type included here. Kidney
cancers also include transition cell carcinomas of the renal
pelvis, sarcomas, and Wilms’ tumour (nephroblastoma), a
childhood cancer. This section refers mainly to renal cell
carcinomas; some studies also examined transitional cell
carcinomas.
7.15.1  Trends, incidence, and survival 
Age-adjusted rates of kidney cancer are increasing world-
wide. Rates have doubled in many high-income countries
since the mid-1970s, with some of the largest increases in
countries in eastern Europe, for example, that are undergo-
ing profound economic transition.137
This is mainly a disease of high-income countries, where
rates are nearly five times higher overall than in middle- to
low-income countries. Around the world, age-adjusted inci-
dence rates range from 10–20 per 100 000 people in North
America, parts of Europe, and Australia to less than 2 per
100 000 in parts of Africa.2 In the USA, rates are higher
among African-American people than in white people.
Globally, rates are higher in men than in women, by five to
three.3 Risk increases with age, with most diagnoses made
in people between the ages of 60 and 80.296
Kidney cancer is diagnosed at an early stage in more than
half of cases. The 5-year survival rate is about 95 per cent
for early stage cancers, and about 20 per cent at the most
advanced stages.296 Overall, 5-year survival rates are more
than 50 per cent in high-income countries, but lower in mid-
dle- to low-income countries.3 6 This cancer accounts for
almost 2 per cent of all cancer incidence, and somewhat over
1 per cent of all cancer deaths. Also see box 7.1.1.
7.15.2  Pathogenesis
Urine contains many waste products from food, drinks, and
other environmental sources, and some of these are poten-
tial carcinogens, such as carcinogens from cigarette smoke,
and may play a role in kidney cancer. 
It is not clear whether benign renal adenomas are a pre-
cursor of renal cell carcinoma. They are similar histologically
and are frequently distinguished predominantly by their size.
Most adult kidney cancers are sporadic renal cell carcino-
FOOD, NUTRITION, PHYSICAL ACTIVITY, 
AND CANCER OF THE KIDNEY
In the judgement of the Panel, the factors listed below modify the risk of
cancer of the kidney. Judgements are graded according to the strength 
of the evidence.
DECREASES RISK INCREASES RISK
Convincing Body fatness
Probable
Limited — Arsenic in drinking
suggestive water1
Limited — Cereals (grains) and their products; vegetables; 
no conclusion fruits; meat; poultry; fish; eggs; milk and dairy
products; total fat; soft drinks; tea; alcoholic drinks
(protective effect)2; carbohydrate; protein; vitamin
A; retinol; vitamin C; vitamin E; beta-carotene;
flavonol; Seventh-day Adventist diets; physical
activity; body fatness at age 18–20; weight at age
18–20; birth weight; adult attained height; age at
menarche; energy intake.
Substantial 
effect on risk Coffee; alcoholic drinks (adverse effect)2
unlikely
1 The International Agency for Research on Cancer has graded arsenic and
arsenic compounds as Class 1 carcinogens. The grading for this entry
applies specifically to inorganic arsenic in drinking water.
2 The evidence was sufficient to judge that alcoholic drinks were unlikely to
have an adverse effect on the risk of kidney cancer; but it was inadequate
to draw a conclusion regarding a protective effect.
For an explanation of all the terms used in the matrix, 
please see chapter 3.5.1, the text of this section, 
and the glossary.
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mas, which can be divided into two main types. The con-
ventional (or clear cell) type accounts for 75 per cent; 12
per cent of cases are of the papillary form,296 which are less
likely to metastasise. In 60 per cent of conventional carci-
noma cases, there is a mutation in the von Hippel–Lindau
tumour suppressor gene (VHL) (see box 2.2).297 VHL disease
is also a cause of some familial kidney cancers.
7.15.3  Other established causes 
(Also see chapter 2.4 and 7.1.3.1.)
Tobacco use. Smoking is a cause of kidney cancer, increas-
ing the risk approximately twofold.10 The association is
stronger for cancers of the renal pelvis.298
Medication. Analgesics containing phenacetin are a cause of
cancer of the renal pelvis.299 Dialysis is a cause of kidney can-
cer, perhaps through its role in the development of acquired
renal cystic disease.300 301
7.15.4  Interpretation of the evidence 
7.15.4.1 General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7.
‘Relative risk’ is used in this Report to denote ratio mea-
sures of effect, including ‘risk ratios’, ‘rate ratios’, ‘hazard
ratios’, and ‘odds ratios’.
7.15.4.2 Specific
Considerations specific to cancer of the kidney include: 
Classification. The subtype of kidney cancer may also be
important. Papillary renal cell carcinomas may follow a dif-
ferent disease path from other renal cell carcinomas. Some
studies also included transitional cell carcinomas or looked
at both renal and urinary tract tumours.
Confounding. High-quality studies adjust for smoking.
7.15.5  Evidence and judgements
In total, 187 publications were included in the SLR for kid-
ney cancer. Fuller summaries of the epidemiological, exper-
imental, and mechanistic evidence are to be found in
Chapters 4–6.
The full SLR is contained on the CD included with this
Report.
7.15.5.1  Arsenic in drinking water
(Also see chapter 4.7.5.1.1.)
Three cohort studies, one time-series study, and nine eco-
logical studies investigated arsenic in drinking water. All
studies showed increased risk for the highest intake levels
compared with the lowest. Effect sizes, particularly from eco-
logical studies in areas of high exposure levels, tend to be
relatively large.
Arsenic is carcinogenic to humans and causes chromoso-
mal abnormalities.217 Arsenic biotransformation is thought
to lead to a state of oxidative stress. In addition, arsenic in
drinking water is well absorbed in the gastrointestinal tract,
and both inorganic arsenic and its methylated metabolites
are excreted in urine. Arsenic can modify the urinary excre-
tion of porphyrins in animals and humans.
The evidence is sparse. There is limited evidence
suggesting that arsenic in drinking water is a cause of
kidney cancer.
7.15.5.2  Coffee
(Also see chapter 4.7.5.4.)
Five cohort studies, 18 case-control studies, and 1 ecologi-
cal study investigated coffee. None of the cohort studies and
only 1 of the case-control studies reported a statistically sig-
nificant association. Meta-analysis of case-control data pro-
duced evidence of no association.
There is substantial evidence, both from cohort and
case-control studies, which is consistent and of low
heterogeneity, and which fails to show an association.
It is unlikely that coffee has a substantial effect on the
risk of kidney cancer.
The Panel is aware that since the conclusion of the SLR, one
cohort study302 has been published. This new information does
not change the Panel judgement. Also see box 3.8.
7.15.5.3  Alcoholic drinks
(Also see chapter 4.8.5.1.)
A total of 3 cohort studies and 16 case-control studies inves-
tigated alcoholic drinks; 4 cohort and 5 case-control studies
investigated ethanol intake. Studies showed no consistent
direction of effect. Meta-analysis of cohort data on ethanol
produced evidence of a dose-response relationship with
decreased risk; cohort data on alcoholic drinks were het-
erogeneous. Meta-analyses of case-control data showed non-
significant decreased risk.
It is unlikely that alcoholic drinks increase the risk of
kidney cancer, though a protective effect cannot be
excluded. 
The Panel is aware that since the conclusion of the SLR, one
cohort study302 has been published. This new information does
not change the Panel judgement. Also see box 3.8.
7.15.5.4  Body fatness
(Also see chapter 6.1.3.1.)
Seventeen cohort studies and 20 case-control studies inves-
tigated body fatness, as measured by BMI. Nearly all of them
showed increased risk with increased body fatness, with
none showing a statistically significant decreased risk. Meta-
analysis of cohort data showed a 31 per cent increased risk
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per 5 kg/m2; meta-analysis of case-control data showed a
205 (adjusted for smoking) or 42 (unadjusted) per cent
increased risk per 5 kg/m2 (figures 6.1.19 and 6.1.20).
There was little heterogeneity in the former two analyses;
the heterogeneity in the latter could be partially explained
by failure to adjust for smoking.
Body fatness directly affects levels of many circulating
hormones, such as insulin, insulin-like growth factors, and
oestrogens, creating an environment that encourages car-
cinogenesis and discourages apoptosis (box 2.4). It also
stimulates the body’s inflammatory response, which may
contribute to the initiation and progression of several can-
cers (see chapter 2.4.1.3). In addition, laboratory studies
point to a potential role for insulin and leptin in renal cell
carcinoma.303 304
There is abundant and consistent epidemiological
evidence with a dose-response relationship and evidence
of plausible mechanisms. The evidence that greater body
fatness is a cause of kidney cancer is convincing.
The Panel is aware that since the conclusion of the SLR, three
cohort studies58 213 305 and one case-control study306 have been
published. This new information does not change the Panel
judgement. Also see box 3.8.
7.15.5.5  Other exposures
Other exposures were evaluated. However, the data were
either of too low quality, too inconsistent, or the number
of studies too few to allow conclusions to be reached. These
were as follows: cereals (grains) or their products; vegeta-
bles; fruits; meat; poultry; fish; eggs; milk and dairy prod-
ucts; soft drinks; tea; alcoholic drinks (protective effect);
carbohydrate; total fat; protein; vitamin A; retinol; beta-
carotene; vitamin C; vitamin E; flavonol; physical activity;
energy intake; body fatness at age 18–20; weight at age
18–20; age at menarche; adult attained height; birth
weight; and Seventh-day Adventist diets.
7.15.6   Comparison with previous report 
7.15.6.1  General
See 7.1.6.1, and box 3.8.
7.15.6.2  Specific
The previous report judged that high body mass is proba-
bly a cause of kidney cancer. Since then the evidence for
body fatness has become stronger.
7.15.7  Conclusions 
The Panel concludes:
The evidence that body fatness is a cause of kidney cancer
is convincing. It is unlikely that coffee has a substantial
effect, or alcoholic drinks an adverse effect, on the risk of
this cancer. There is limited evidence suggesting that
arsenic in drinking water is a cause of this cancer.
7.16  Bladder
Cancer of the bladder is the 10th most common type
worldwide. Around 350 000 cases were recorded in 2002,
accounting for around 3 per cent of all cancers. It is most
common in high-income countries. Rates are much higher
in men than in women. Overall rates of this cancer are not
changing much. Average overall survival rates vary
depending on how soon the cancer is detected. It is the
11th most common cause of death from cancer. 
Overall, the Panel notes the evidence that food,
nutrition, and physical activity are not significant factors
in the development of cancer of the bladder.
The Panel judges as follows: 
There is limited evidence suggesting that milk protects
against bladder cancer; and that arsenic in drinking water
is a cause. 
Smoking tobacco and schistosomiasis are other causes
of this cancer. 
In final summary, the evidence is too limited to conclude
that any aspect of food, nutrition, and physical activity
directly modifies the risk of bladder cancer.
The bladder is a sac-like organ that is the reservoir for urine.
The inside of the bladder is lined by transitional epithelial
cells known as the urothelium. 
The term ‘urothelial cancers’ includes predominantly tran-
sition cell carcinomas of the bladder and cancers of the upper
part of the urinary tract. Transitional cell carcinoma is the
most common form, accounting for more than 90 per cent
of bladder cancers, the type mainly included here. Other
types (in order of incidence) include squamous cell carci-
nomas, adenocarcinomas, and small cell cancers.4
7.16.1  Trends, incidence, and survival
There is no clear global trend in bladder cancer incidence.
While rates increased in many countries during the 20th cen-
tury, this rise has generally slowed since the mid-1980s or
stopped.137 However, there are exceptions, such as in Japan
and countries in eastern Europe that are in economic tran-
sition.
Bladder cancer is predominantly a disease of high-income
countries, where overall rates are slightly more than three
times higher than in middle- to low-income countries.
Around the world, age-adjusted incidence rates range from
20–30 per 100 000 men in southern and western Europe and
North America to less than 1 per 100 000 in much of Middle
Africa and Asia.2 It is five times more common in men than
in women, and risk increases with age. In northern Africa
and parts of Asia, where schistosomiasis (a parasitic disease,
also known as bilharzia) is prevalent, bladder cancer rates
are high and squamous cell carcinomas of the bladder are
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the most common type. In Egypt, it is the most common can-
cer among men and the third most common among
women.307 In the USA, rates are higher in white people than
among other ethnic groups.3
Five-year survival rates vary according to the stage of the
cancer when it is diagnosed. They range from 63 to 88 per
cent in cases of superficial bladder carcinoma, and from 47
to 63 per cent in muscle-invasive bladder cancer.4 However,
recurrence rates for this cancer are relatively high.308 This dis-
ease accounts for just over 3 per cent of all cancer incidence,
and around 2 per cent of all cancer deaths. Also see box
7.1.1.
7.16.2  Pathogenesis
Dietary carcinogens, as well as those from tobacco smoke or
other environmental sources, are often excreted in the urine,
so the bladder lining is exposed to these toxins.
Urothelial cell carcinomas start as superficial bladder car-
cinomas. The majority have low rates of progression,
although they can occur at multiple sites. Low-risk lesions
may never progress, but they have a poor prognosis if they
become invasive cancers.
The superficial lesion that carries the highest risk, carci-
noma in situ, progresses to invasive cancer in more than 50
per cent of cases if it is not treated. These high-risk lesions
are often found with multiple papillary tumours, but
because they may involve different molecular changes, they
are likely to have a different natural history to low-risk
lesions.308
Squamous cell carcinoma may be caused by chronic
inflammation, for instance from latent schistosomiasis,
chronic infections, or long-term catheter use.
Mutations in the tumour-suppressor p53 gene, as well as
abnormalities in chromosome 9, are common in invasive
bladder cancer (see box 2.2). Inherited mutations of two
other genes, GSTM1 (glutathione S-transferase null) and
NAT2 (n-acetyltransferase; slow acetylation) also cause blad-
der cancer. NAT2 interacts with cigarette smoke, and may
be responsible for 20–46 per cent of bladder cancers.309
7.16.3  Other established causes 
(Also see chapter 2.4 and 7.1.3.1.)
Tobacco use. Smoking is a major cause of bladder cancer. It
is estimated that more than half of all cases in men and
around a third in women are caused by smoking.10 310
Infection and infestation. Infestation with schistosomes (par-
ticularly Schistosoma haematobium) is a cause of bladder
cancer, particularly squamous cell carcinomas.311 This is esti-
mated to be responsible for 10 per cent of bladder cancer
cases in middle- and low-income countries, and 3 per cent
of cases overall.312
Industrial chemicals. Occupational exposure to aromatic
amines, such as 2-naphthylamine (used in dyes), also
increases the risk of bladder cancer.313
7.16.4  Interpretation of the evidence
7.16.4.1 General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7. 
‘Relative risk’ is used in this Report to denote ratio mea-
sures of effect, including ‘risk ratios’, ‘rate ratios’, ‘hazard
ratios’, and ‘odds ratios’.
7.16.4.2 Specific
Considerations specific to cancer of the bladder include: 
Confounding. High-quality studies adjust for smoking.
FOOD, NUTRITION, PHYSICAL ACTIVITY, 
AND CANCER OF THE BLADDER
In the judgement of the Panel, the factors listed below modify the risk of
cancer of the bladder. Judgements are graded according to the strength
of the evidence.
DECREASES RISK INCREASES RISK
Convincing
Probable
Limited — Milk1 Arsenic in drinking 
suggestive water2
Limited — Cereals (grains) and their products; vegetables; fruits;
no conclusion pulses (legumes); meat; poultry; fish; eggs; total fat;
butter; dietetic foods; soft drinks; diet drinks; fruit
juices; coffee; tea; caffeine; alcohol; chlorinated
surface water; total fluid intake; sweeteners; frying;
carbohydrate; protein; vitamin A; folate; vitamin C;
vitamin E; multivitamin supplements; selenium; 
beta-carotene; alpha-carotene; lycopene; beta-
cryptoxanthin; lutein; zeaxanthin; flavonoids;
physical activity; body fatness; energy intake
Substantial 
effect on risk None identified
unlikely
1 Milk from cows. Most data are from high-income populations, where
calcium can be taken to be a marker for milk/dairy consumption. The Panel
judges that a higher intake of dietary calcium is one way in which milk
could have a protective effect.
2 The International Agency for Research on Cancer has graded arsenic and
arsenic compounds as Class 1 carcinogens. The grading for this entry applies
specifically to inorganic arsenic in drinking water.
For an explanation of all the terms used in the matrix, 
please see chapter 3.5.1, the text of this section, 
and the glossary.
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7.16.5   Evidence and judgements
In total, 349 publications were included in the SLR for blad-
der cancer. Fuller summaries of the epidemiological, exper-
imental, and mechanistic evidence are to be found in
Chapters 4–6.
The full SLR is contained on the CD included with this
Report.
7.16.5.1  Milk
(Also see chapter 4.4.5.1.1.)
Five cohort studies, 14 case-control studies, and 1 ecologi-
cal study investigated milk. All of the cohort studies and half
of the case-control studies showed decreased risk with
increased intake of milk. Meta-analysis of cohort data pro-
duced evidence of an association with decreased risk, with
a clear dose-response relationship. Meta-analysis of case-con-
trol data was inconclusive.
The possible effect of milk in reducing bladder cancer risk
is likely to be mediated at least in part by calcium, which has
direct growth-restraining and differentiation- and apoptosis-
inducing actions on normal and tumour cells.184 However,
milk includes many bioactive constituents, which may also
play a role.
The evidence is inconsistent and comes mainly from
evidence on dietary calcium. There is limited evidence
suggesting that milk protects against bladder cancer.
7.16.5.2  Arsenic in drinking water 
(Also see chapter 4.7.5.1.1.)
Six cohort studies, 1 time-series study, 7 case-control stud-
ies, and 11 ecological studies investigated arsenic in drink-
ing water. Most studies showed increased risk for groups
with the highest intakes when compared with the lowest. 
Soluble arsenic in drinking water induces lung cancers in
experimental animal models.71 In humans, arsenic is a chro-
mosomal mutagen (an agent that induces mutations involv-
ing more than one gene, typically large deletions or
rearrangements). It can also act as a synergistic co-mutagen.
Arsenic exposure also causes chronic lung disease.71 These
mechanisms may also apply to bladder cancer. The Joint
FAO/WHO Expert Committee on Food Additives has set a
provisional tolerable weekly intake of 0.015 mg per kg body
weight.72
The evidence is inconsistent. There is limited evidence
suggesting that arsenic is a cause of bladder cancer.
7.16.5.3  Other exposures
Other exposures were evaluated. However, the data were
either of too low quality, too inconsistent, or the number of
studies too few to allow conclusions to be reached. These
were as follows: cereals (grains) and their products; veg-
etables; fruits; pulses (legumes); meat; poultry; fish; eggs;
butter; dietetic foods; soft drinks; diet drinks; fruit juices;
coffee; caffeine; tea; alcohol; chlorinated surface water;
sweeteners; frying; carbohydrate; total fat; protein; vitamin
A; beta-carotene; alpha-carotene; lycopene; beta-cryptox-
anthin; lutein; zeaxanthin; folate; vitamin C; vitamin E; sele-
nium; multivitamin supplements; flavonoids; energy intake;
physical activity; body fatness; and total fluid intake.
7.16.6  Comparison with previous report 
7.16.6.1  General
See 7.1.6.1, and box 3.8.
7.16.6.2  Specific
The previous report judged that vegetables and fruits prob-
ably protect against bladder cancer. As with other sites, the
evidence for these foods is now considered to be weaker, in
this case, very much so. The previous finding that coffee
(more than five cups per day) is a possible cause of bladder
cancer was not found here.
7.16.7  Conclusions
The Panel concludes:
There is limited evidence suggesting that milk protects
against bladder cancer and that arsenic in drinking water is
a cause. 
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7.17  Skin 
Cancer of the skin in its various forms is the most common
type of cancer worldwide. Around 90 per cent of all skin
cancers are non-melanoma. Around 4 million cases were
recorded in 2002, but it is likely that many cases are not
referred, and this cancer is not included in the rankings in
this Report. Around 160 000 cases of melanoma skin
cancer were recorded in 2002, accounting for around 1.5
per cent of all cancers. Skin cancers are more common in
high-income countries and among light-skinned people.
Overall rates of this cancer are increasing. Survival rates
of melanoma are high and also depend on access to
treatment. Five-year survival rates for non-melanoma skin
cancer are more than 99 per cent. Melanoma is the 22nd
most common cause of death from cancer. 
Overall, the Panel emphasises that the main cause of skin
cancer is over-exposure to radiation from sunlight. 
The Panel judges as follows: 
Arsenic in drinking water is probably a cause of skin
cancer. There is limited evidence suggesting that retinol
protects against squamous cell carcinomas of the skin, and
that selenium is a cause of skin cancer. It is unlikely that
beta-carotene or foods containing it have a substantial
effect on the risk of non-melanoma skin cancer.
In final summary, the strongest evidence, corresponding
to judgements of “convincing” and “probable”, shows that
arsenic in drinking water is probably a cause of skin
cancer. It is unlikely that beta-carotene or foods containing
it have a substantial effect on the risk of non-melanoma
skin cancer.
The skin is the outer covering of the body. There are two
main types of skin cancer: melanoma and non-melanoma.
Non-melanoma is more common. The most common non-
melanoma tumours are basal cell carcinoma and squamous
cell carcinoma, which together account for 90 per cent of
skin cancers.4 Melanomas are nearly always pigmented and
usually develop from pigmented lesions such as moles.
Melanoma accounts for 4 per cent of skin cancers. Other skin
cancers such as Kaposi’s sarcoma and cutaneous lymphomas
are not included here. 
7.17.1  Trends, incidence, and survival
Age-adjusted rates of both melanoma and non-melanoma
skin cancers are increasing. Rates have doubled since the
mid-1950s in many high-income countries, particularly those
that already had high rates. This trend is restricted to coun-
tries where a high proportion of the population is fair-
skinned.137 The incidence of non-melanoma skin cancer is
also increasing.4 It is estimated that there are more than a
million new cases each year in the USA alone,314 and in
Australia the reported incidence is even higher.315
Skin cancer is mainly a disease of high-income countries,
where overall melanoma rates are more than 10 times higher
than in middle- to low-income countries. Age-adjusted inci-
dence rates range from more than 30 per 100 000 people in
Australia and New Zealand to less than 1 per 100 000 across
much of Africa and Asia. Rates are relatively high (around
15 per 100 000) in North America, Israel, and many north-
ern European countries.2 In the USA, rates are higher in
white people than among other ethnic groups.3 Non-
melanoma skin cancer is the most common cancer in the
world, and correlates with lighter skin colour and accumu-
lated sun exposure.316
Although both melanoma and non-melanoma skin cancer
incidence increases with age, melanoma causes a dispro-
portionate number of cancers in young and middle-aged
people.317 Melanomas are most common on exposed areas
of the body, and are relatively rare on areas that are usual-
ly covered by clothing.
FOOD, NUTRITION, PHYSICAL ACTIVITY, 
AND CANCER OF THE SKIN
In the judgement of the Panel, the factors listed below modify the risk of
cancer of the skin. Judgements are graded according to the strength of
the evidence.
DECREASES RISK INCREASES RISK
Convincing
Probable Arsenic in drinking 
water1
Limited — Retinol2 Selenium supplements3
suggestive
Limited — Potatoes; non-starchy vegetables; fruits; fish; eggs;
no conclusion milk; total fat; cholesterol; coffee; tea; alcohol;
protein; vitamin A; retinol (foods); folate; vitamin C;
vitamin D; vitamin E; multivitamins; selenium;
carotenoids; beta-carotene (melanoma); alpha-
carotene; lycopene; physical activity; body fatness;
energy intake
Substantial 
effect on risk Beta-carotene4 (non-melanoma)
unlikely
1 The International Agency for Research on Cancer has graded arsenic and
arsenic compounds as Class 1 carcinogens. The grading for this entry
applies specifically to inorganic arsenic in drinking water.
2 The evidence is derived from studies using supplements at a dose of 25 000
international units/day. Applies only to squamous cell carcinoma. 
3 The evidence is derived from studies using supplements at a dose of 
200 µg/day. 
4 The evidence is derived from studies using supplements at doses of 30, and
50 mg/day, and from foods containing beta-carotene. See chapter 4.2.
For an explanation of all the terms used in the matrix, 
please see chapter 3.5.1, the text of this section, 
and the glossary.
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Despite the considerably higher incidence of non-
melanoma skin cancer compared with melanoma (around 20
to 1 in the USA), this less common type accounts for 79 per
cent of skin cancer deaths.318 The 5-year survival rate is
between 80 and 90 per cent in high-income countries, but
just over half that in middle- to low-income countries.124 This
difference is partly due to a different, prevalent type of
melanoma (acral melanoma, on the soles of the feet), which
has a poorer prognosis. Melanoma accounts for somewhat
over 1 per cent of all cancer incidence, but only around 0.5
per cent of all cancer deaths. Non-melanoma skin cancers are
almost never fatal.319 Also see box 7.1.1.
7.17.2  Pathogenesis
The skin changes with age and is affected by hormonal influ-
ences and exposure to the sun and wind. Skin pigmentation
varies between individuals and its structure also differs,
depending, for instance, on whether it covers the lips, the
soles of the feet, or the eyelids. All of these aspects influence
skin cancer risk. Both melanoma and non-melanoma skin
cancers are thought to be caused largely by UV irradiation
mainly from sunlight. There is a clear relationship between
accumulated sun exposure and non-melanoma skin cancer,
but melanoma is more common in office workers than in out-
door workers, suggesting that damage from episodic expo-
sure and extreme occasional sun damage (blistering
sunburn) may be more important.4 The role of sun damage
is supported by the association between measures of sun sen-
sitivity and skin cancer incidence, which is higher in people
who have freckles and skin that burns without tanning, more
moles, blue eyes, and red hair.320 321
UV-damaged cells are usually removed by apoptosis (pro-
grammed cell death, see chapter 2.5.2) in a process involv-
ing the p53 protein. However, in non-melanoma skin cancer,
the p53 tumour-suppressor gene is often damaged by UVB
irradiation, so faulty cells are not removed from the skin.
Both UVB and UVA irradiation also have direct and indirect
effects on the cutaneous immune system, lowering the skin’s
cell-mediated immunity,322 which is another factor that may
influence carcinogenesis.
People who have a family history of melanoma may be pre-
disposed to this type of skin cancer, although only one major
inherited mutation has been found, and less than 2 per cent
of melanomas are attributable to this inherited mutation.323
7.17.3  Other established causes 
(Also see chapter 2.4 and 7.1.3.1.)
Radiation. Over-exposure to UV radiation (mainly from sun-
light) is the chief cause of both non-melanoma and
melanoma skin cancers.324 In the case of melanoma, the
main cause is episodic skin exposure involving severe sun-
burn, particularly in fair-skinned white people.317
Medication. Immune suppression in organ-transplant and
AIDS patients is also associated with an increased risk of skin
cancer (in addition to Kaposi’s sarcomas).325
Infection and infestation. HPV can cause squamous cell car-
cinomas, especially in immune-compromised people.325
7.17.4  Interpretation of the evidence
7.17.4.1 General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7.
‘Relative risk’ is used in this Report to denote ratio mea-
sures of effect, including ‘risk ratios’, ‘rate ratios’, ‘hazard
ratios’, and ‘odds ratios’.
7.17.4.2 Specific
Considerations specific to cancer of the skin include: 
Classification. Melanoma and non-melanoma cancers may
have different causes; this would explain heterogeneity in
studies that do not distinguish between these two types of
skin cancer. Non-melanoma skin cancer cases are common-
ly not recorded by cancer registries, and are therefore under-
estimated in many reports.
Confounding. High-quality studies adjust for sun exposure
and distinguish between cancer types.
7.17.5  Evidence and judgements 
In total, 167 publications were included in the SLR for skin
cancer. Fuller summaries of the epidemiological, experi-
mental, and mechanistic evidence are in Chapters 4–6.
The full SLR is contained on the CD included with this
Report.
7.17.5.1  Arsenic in drinking water 
(Also see chapter 4.7.5.1.1.)
Two cohort studies, 5 case-control studies, 1 cross-sectional
study, and 11 ecological studies investigated arsenic in drink-
ing water. Nearly all studies showed an association between
increased arsenic and skin cancer. Two case-control studies
used toenail and fingernail measurements, which are thought
to be more reliable than dietary estimates. These studies both
showed increased risk, which was statistically significant in
one. The single cross-sectional study and all ecological stud-
ies showed increased risk, with several reporting relatively
large and statistically significant effect estimates.
Soluble arsenic in drinking water induces lung cancers in
experimental animal models.71 In humans, arsenic is a chro-
mosomal mutagen (an agent that induces mutations involving
more than one gene, typically large deletions or rearrange-
ments). It can also act as a synergistic co-mutagen. Arsenic
exposure also causes chronic lung disease.71 These mechanisms
may also be applicable to skin cancer. The Joint FAO/WHO
Expert Committee on Food Additives has set a provisional tol-
317
C H A P T E R  7  •  C A N C E R S
erable weekly intake of 0.015 mg per kg body weight.72
The evidence is consistent, from cohort, case-control,
and ecological studies. There is robust mechanistic
evidence. Arsenic in drinking water is a probable cause
of skin cancer.
7.17.5.2  Retinol 
(Also see chapter 4.10.6.4.1.)
Two randomised controlled trials investigated retinol sup-
plements. Both trials included only participants at risk of
developing non-melanoma skin cancer, and both gave results
stratified according to this type. While neither trial report-
ed a statistically significant association to basal cell carci-
noma, one of the two studies did report a statistically
significant relationship with decreased squamous cell carci-
noma risk.
The mechanism of anti-tumour action of the retinoids is
not completely understood, but retinol is known to bind to
cell receptors with promotion of differentiation, alteration of
membranes, and immunological adjuvant effects.326
The evidence is sparse and studies were conducted on
a narrowly defined population group (people at risk of
developing skin cancer). There is limited evidence
suggesting that retinol supplements protect against
squamous cell skin cancer.
The Panel is aware that since the conclusion of the SLR, one
case-control study327 has been published. This new information
does not change the Panel judgement. Also see box 3.8.
7.17.5.3  Selenium supplements
(Also see chapter 4.10.6.4.5.)
One randomised controlled trial and one cohort study inves-
tigated selenium supplements. The trial showed a statisti-
cally significant increased risk of total non-melanoma skin
cancer with daily supplementation of 200 µg selenium.
Subgroup analysis indicated that this risk might differ
according to cancer type, with a statistically significant
increased risk for squamous cell carcinoma but not basal cell
carcinoma. The single cohort study stated that there was no
statistically significant association.
No plausible mechanisms for how selenium might increase
risk of skin cancer have been suggested. 
The evidence is sparse, and no plausible mechanisms
have been identified. There is limited evidence
suggesting that selenium supplements are a cause of
skin cancer.
7.17.5.4  Beta-carotene (non-melanoma)
(Also see chapters 4.2.5.3 and 4.10.6.4.2)
Four randomised controlled trials and one cohort study
investigated beta-carotene supplements; two cohort studies
and seven case-control studies investigated dietary beta-
carotene; three cohort studies and one case-control study
investigated beta-carotene from food and supplements com-
bined; and eight cohort studies and three case-control stud-
ies investigated serum or plasma beta-carotene. 
All three randomised controlled trials that investigated
beta-carotene supplement interventions against placebo with
respect to non-melanoma skin cancer reported results very
close to null. Meta-analysis of the three trials produced evi-
dence of no association. Two trials that investigated beta-
carotene supplement interventions against placebo with
respect to melanoma stated that there was no association
with risk.
Meta-analysis of cohort data on plasma or serum beta-
carotene and non-melanoma skin cancer, and cohort data
that investigated the same exposure in melanoma, showed
no clear association. No clear association was shown with
dietary beta-carotene.
There is strong evidence from good quality trials that
consistently fail to show an effect. It is unlikely that
beta-carotene has a substantial effect on the risk of
non-melanoma skin cancer. It is unlikely that foods
containing beta-carotene have any substantial effect
on the risk of non-melanoma skin cancer.
7.17.5.5  Other exposures
Other exposures were evaluated. However, the data were
either of too low quality, too inconsistent, or the number of
studies too few to allow conclusions to be reached. These
were as follows: potatoes; non-starchy vegetables; fruits;
fish; eggs; milk; coffee; tea; alcohol; foods containing sele-
nium; total fat; cholesterol; protein; vitamin A; retinol
(foods); beta-carotene (melanoma); alpha-carotene;
carotenes; lycopene; folate; vitamin C; vitamin D; vitamin
E; multivitamins; physical activity; energy intake; and body
fatness.
7.17.6  Comparison with previous report
Skin cancers were not reviewed in the previous report. 
7.17.7  Conclusions
The Panel concludes:
Arsenic in drinking water is probably a cause of skin cancer.
There is limited evidence suggesting that retinol protects
against squamous cell carcinomas of the skin and that sele-
nium is a cause of skin cancer. It is unlikely that beta-
carotene or foods containing it have a substantial effect on
the risk of non-melanoma skin cancer. The main cause of
skin cancer is over-exposure to UV radiation from sunlight.
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The Panel also considered other cancers, not generally
recognised to have a relationship to food, nutrition, and
physical activity. These are cancers of the thyroid gland
and testis, and cancers of the lymphoid and haemopoietic
systems, the musculoskeletal system, and the nervous
systems. 
Five narrative reviews were commissioned. This method
was not systematic, and the Panel decided not to make any
judgements regarding the causality of any associations in
the text or matrices. 
Some of the evidence that emerged may merit more
thorough investigation and further studies. 
The Panel noted as follows:
Some of these cancers are known to have as established
causes other diseases, tobacco use, radiation, infection, or
industrial chemicals, or else not to have established
causes. Some details are given in the following sections.
From the reviews commissioned, some evidence emerges.
Thyroid cancer. Non-cruciferous, non-starchy vegetables 
and fish show an association with decreased risk. Body fat-
ness and adult attained height show an association with
increased risk. 
Lymphoid and haemopoietic cancers. Vegetables and fruits
are associated with decreased risk. Alcoholic drinks have an
association with decreased risk. Meat, total fat, and body fat-
ness are associated with increased risk. Milk and dairy
products show an association with increased risk of non-
Hodgkin’s lymphoma. 
Other cancers. The evidence on food, nutrition, physical
activity, and cancers of the musculoskeletal and nervous sys-
tems is too limited to draw any conclusions.
7.18.1  Thyroid
Thyroid cancer is the 21st most common type worldwide. An
estimated 141000 cases occurred in 2002, accounting for
just over 1 per cent overall. This cancer type is the 23rd most
common cause of cancer death. It is more common in high-
income countries, with rates more than twice those of mid-
dle- to low-income countries. 
Thyroid cancer is not usually fatal, with a 5-year survival
rate of approximately 70 per cent.2 It is increasing in inci-
dence worldwide, although this may be partly explained by
changing diagnostic practices.124 137
Thyroid cancer rates peak between the ages of 25 and 55,
then decline and rise again in the elderly. This cancer is more
common in women than in men. Also see box 7.1.1.
Differentiated carcinomas account for 94 per cent of these
cancers (80 per cent papillary and 14 per cent follicular car-
cinomas). Medullary carcinoma and the highly aggressive
anaplastic carcinoma comprise the remainder.4
Exposure to ionising radiation, especially during child-
hood, is a cause of this cancer.328
7.18.1.1  Evidence 
The evidence from the narrative review is summarised below. 
7.18.1.1.1  Vegetables
One pooled analysis of 11 case-control studies (2241 cases
and 3716 controls) investigated consumption of vegetables.
It showed a statistically significant reduced incidence with
higher intakes of vegetable other than cruciferous types.
Cruciferous vegetables were not significantly associated with
reduced incidence.
Vegetables contain many potentially protective substances,
including several antioxidants, as well as phytochemicals
with antiproliferative capabilities. They are also a rich source
of folate, which plays an important role in the synthesis,
repair, and methylation of DNA.
7.18.1.1.2  Fish 
One pooled analysis of 13 case-control studies (2497 cases
and 4337 controls) and 2 case-control studies investigated
fish consumption. These were consistent in showing a sig-
nificantly reduced incidence with increased consumption in
areas of endemic iodine deficiency, but none in areas where
iodine intakes are high.
Fish is known to be an important natural source of iodine
in the diets of different populations, and therefore an asso-
ciation between fish intake and thyroid cancer risk may be
mediated by iodine.
7.18.1.1.3  Body fatness
One pooled analysis of 12 case-control studies (cases: 2056
women and 417 men; controls: 3358 women and 965 men)
and 1 cohort study investigated BMI or obesity. Obesity was
associated with a statistically significant increased incidence
in women, with a clear dose-response relationship. No asso-
ciation was observed in men (although this could have been
influenced by the relatively small number of cases). The
cohort study also showed a relationship with increased
incidence.
Body size might affect iodine requirement and therefore,
indirectly, influence thyroid cancer risk.
7.18.1.1.4  Adult attained height
One pooled analysis of 12 case-control studies (cases: 2056
women and 417 men; controls: 3358 women and 965 men)
investigated adult attained height. Greater height was asso-
ciated with a statistically significant increased incidence in
both women and men, with a clear dose-response relation-
ship. The effect was greater in men than in women.
Body size might affect iodine requirement and therefore,
indirectly, influence thyroid cancer risk. The association with
7.18  Other cancers
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height in both men and women may indicate a potential
influence of some growth factor or hormone during child-
hood or adolescence, but the potential role of growth fac-
tors on thyroid carcinogenesis is still poorly defined. 
7.18.1.2 Conclusions 
Thyroid cancer was reviewed in the previous report. It judged
that both iodine deficiency (probably) and iodine excess
(possibly) were causes of this cancer, and also that vegeta-
bles and fruits were possibly protective. 
The Panel concludes that the associations identified warrant
more investigation into food, nutrition, and thyroid cancer.
7.18.2  Testis
Cancer of the testis is the 19th most common type in men.
An estimated 49 000 cases occurred in 2002, accounting for
around 0.5 per cent overall. This cancer is increasing world-
wide, with rapid rises in many high-income countries and
some transition countries.124 Rates are more than five times
higher than in middle- to low-income countries.
Cancer of the testis is usually not fatal where chemother-
apy is available, with a 5-year survival rate of more than 90
per cent in high-income countries, but less than 60 per cent
in middle- to low-income countries.2 6 Also see box 7.1.1.
Most (95 per cent) testicular cancers are germ cell cancers,
with seminomas being the other main subtype.4
The most well established risk factor for testicular cancer
is the failure of one testis or both to descend into the nor-
mal position during fetal development.4 Rates peak in young
adulthood. 
7.18.2.1  Evidence
The evidence from the narrative review is summarised below. 
7.18.2.1.1  Milk and dairy products
Five case-control studies, one twin study, and four ecologi-
cal studies investigated milk and dairy consumption. All eco-
logical studies and two of the case-control studies showed
statistically significant relationships between increased milk
and dairy consumption and increased testicular cancer
incidence. 
None of the other studies reported statistically significant
associations, although non-significant associations were
heterogeneous.
There are no well established mechanisms through which
milk could influence testicular cancer development. Milk and
dairy products contain fat, protein, and calcium, all of which
may have an effect on testicular cancer risk.
7.18.2.2  Conclusions
Cancer of the testis was not reviewed in the previous report. 
The Panel concludes that the evidence does not warrant
significant investigation into food, nutrition, and testicular
cancer.
7.18.3  Lymphoid and haemopoietic
system
Cancers of the lympho-haemopoietic system are predomi-
nantly lymphomas (Hodgkin’s or non-Hodgkin’s), leuk-
aemias, and multiple myelomas. These cancers have
different non-dietary causes and there is no reason to believe
that they might be affected by food, nutrition, and physical
activity in the same ways. 
If taken together, this group of cancers would be the sixth
most common type worldwide. An estimated 749 000 cases
occurred in 2002, accounting for around 7 per cent overall.
Approximately 48 per cent of these cancers were lymphomas
(83 per cent non-Hodgkin’s; 17 per cent Hodgkin’s), and 
40 per cent were leukaemias, with multiple myelomas
accounting for the remaining 12 per cent.2
Non-Hodgkin’s lymphoma is the 11th most common cause
of cancer incidence. It is increasing in incidence world-
wide.124 Non-Hodgkin’s lymphoma is most frequent in high-
income countries, with rates more than twice those of
middle- to low-income countries. It is usually fatal, with a
5-year survival rate of less than 35 per cent.4 This is not a
single cancer, but a wide group of cancers (such as Burkitt’s
lymphoma and diffuse large B-cell lymphoma), each with a
distinct geographical distribution, development path, age
profile, and prognosis. 
Hodgkin’s lymphoma is the 25th most common type. It is
most frequent in high-income countries, where rates are
more than twice those of middle- to low-income countries.
It is not usually fatal, with a 5-year survival rate of approx-
imately 75 per cent in high-income countries and less than
60 per cent in middle- to low-income countries.2 4 This can-
cer occurs mainly in children, young adults, and the elder-
ly (tending to occur at a younger age or in old age in middle-
to low-income countries).124
Leukaemias are the 12th most common type and the 10th
most common cause of cancer death. They are gradually
increasing in incidence worldwide. They are most frequent
in high-income countries, with rates more than twice those
of middle- to low-income countries. Leukaemias are usual-
ly fatal, with a 5-year survival rate of approximately 40 per
cent in high-income countries, and less than 20 per cent in
middle- to low-income countries.124 However, childhood
leukaemias have a very high survival rate. This is not a sin-
gle cancer, but a wide group of both acute and chronic
leukaemias.
Multiple myeloma is the 24th most common type and the
19th most common cause of cancer death. It is gradually
increasing in incidence worldwide, and is most frequent in
high-income countries with rates more than three times high-
er than in middle- to low-income countries. It is usually fatal,
with a 5-year survival rate of less than 50 per cent in high-
income countries and less than 30 per cent in middle- to low-
income countries.2
Infection with Epstein-Barr virus (see box 7.2.1) is a risk
factor for developing Hodgkin’s lymphoma.329 HIV-1 infec-
tion, immune suppression (whatever the cause), and infec-
tion with Epstein-Barr and human T-cell leukaemia virus all
increase the risk of developing non-Hodgkin’s lymphoma.330
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Tobacco use, infection with human T-cell leukaemia virus,
radiation, and benzene are established causes of
leukaemia.10 67 328 331 Exposure to ionising radiation is a cause
of multiple myeloma. Also see chapter 2.4.
7.18.3.1  Evidence 
The evidence from the narrative review is summarised below. 
7.18.3.1.1  Vegetables and fruits
One cohort study and six case-control studies investigated
vegetables and fruits. The cohort study and five of the case-
control studies showed statistically significant associations
with increased vegetable and fruit intake and reduced inci-
dence of lymphoid and haemopoietic cancers. However, the
cohort study and two of the case-control studies reported on
non-Hodgkin’s lymphoma only. The sixth case-control study
reported increased incidence with consumption of ‘vegeta-
bles other than cruciferous, leafy, or yellow/orange’.
Vegetables and fruits contain many potentially protective
substances, including several antioxidants, as well as phy-
tochemicals with antiproliferative capabilities. They are also
a rich source of folate, which plays an important role in the
synthesis, repair, and methylation of DNA.
7.18.3.1.2  Milk and dairy products
One cohort study, nine case-control studies, and one eco-
logical study investigated milk and dairy products, with most
reporting on non-Hodgkin’s lymphoma. The cohort study, the
ecological study, and most of the case-control studies report-
ed statistically significant associations between increased
milk and dairy consumption and increased incidence.
There are no well established mechanisms by which milk
could increase lymphoma incidence. Hypotheses include cal-
cium restricting the bioavailability of vitamin D (this vitamin
promotes differentiation and apoptosis and inhibits cancer
cell growth in the laboratory). Alternatively, organochlorines
(which are potential carcinogens) may accumulate in dairy
fat. A final hypothesis is that bovine leukaemia virus might
transmit through milk to humans, although there is no direct
evidence for this.
7.18.3.1.3  Meat
One cohort study, seven case-control studies, and one eco-
logical study investigated meat or red meat. The cohort
study, the ecological study, and most of the case-control stud-
ies showed an association with increased incidence, with sev-
eral reaching statistical significance. A review article came
to the same conclusion.
There are no postulated mechanisms by which meat 
could increase the incidence of lymphoid and haemopoietic
cancers.
7.18.3.1.4  Fish
Two cohort studies and seven case-control studies investi-
gated fish and lymphoid and haematopoietic cancers. Most
studies showed a non-significant relationship with reduced
incidence. This reached statistical significance in two case-
control studies that reported results separately for non-
Hodgkin’s lymphoma.
One animal study has shown that fish oils can inhibit the
formation of lymphoid and haemopoietic cancers.
7.18.3.1.5  Fat 
Two cohort studies and four case-control studies investigat-
ed fat consumption. All showed statistically significant rela-
tionships with increased incidence. One case-control study
that reported separately on PUFAs described a significantly
reduced incidence for that fatty acid type, while confirming
a significant increased incidence for saturated fatty acids.
There are no postulated mechanisms by which fat could
increase lymphoid and haemopoietic cancers.
7.18.3.1.6  Alcoholic drinks
One pooled analysis of case-control studies representing 
15 175 participants, with 6492 non-Hodgkin’s lymphoma
cases, showed a statistically significant reduced incidence for
this type, particularly Burkitt’s lymphoma.
There are no postulated mechanisms by which alcohol
could decrease the incidence of lymphoid and haemopoiet-
ic cancers.
7.18.3.1.7  Body fatness 
Nine cohort studies and 11 case-control studies investigat-
ed BMI or obesity and non-Hodgkin’s lymphoma, leukaemia,
or multiple myeloma. In each case, most studies reported an
association with increased incidence, with several reporting
statistically significant relationships.
Obesity results in pathological states of inflammation and
altered immune responses, both of which are factors that can
influence lymphoid and haemopoietic cell function.
7.18.3.2 Conclusions 
These cancers were not reviewed in the previous report. 
The Panel concludes that more work into mechanisms that
might underlie the associations identified is warranted. A
more comprehensive and systematic review might also clar-
ify the epidemiology. The different cancer types should be
investigated separately unless there is reason to believe that
they have common causes.
7.18.4  Musculoskeletal system
Cancers of the musculoskeletal system are a diverse group,
including those of the bones, muscles, and related tissues,
all around the body. These include liposarcomas, fibrosar-
comas, osteosarcomas, and myosarcomas. 
These cancers are all uncommon or rare, each accounting
for less than 1 per cent — usually much less — of all can-
cers. There is no reason to think that they have causes in
common. 
The narrative review did not produce any findings. 
Because these cancers are uncommon, any study investi-
gating their possible links with food, nutrition, and physical
activity would be unlikely to be fruitful. Because they are
diverse, any investigation that grouped all of them together
would also be unlikely to show consistent results. 
321
C H A P T E R  7  •  C A N C E R S
7.18.4.1  Conclusions 
These cancers were not reviewed in the previous report. 
The Panel concludes that it is unlikely that any further inves-
tigation would be warranted. 
7.18.5  Nervous system
Cancers of the brain and central nervous system are the 18th
most common type worldwide. An estimated 189 000 cases
occurred in 2002, accounting for around 2 per cent overall.
These cancers are most frequent in high-income countries,
with rates more than twice those of middle- to low-income
countries. Brain tumours are relatively common among
childhood cancers. They are the 13th most common cause
of cancer death, and are usually fatal. The overall 5-year sur-
vival rate is less than 25 per cent, with higher rates for many
brain tumours that occur during childhood, and in high-
rather than in middle- to low-income countries.2 Also see box
7.1.1.
Tumours of neural tissue account for approximately half
of these cancers, with most of these being glioblastomas.4
Meningiomas are the other major type of central nervous sys-
tem tumour, with sellar tumours, cranial and spinal nerve
tumours, central nervous system lymphomas, and other rare
brain tumour types comprising the remainder.
The incidence of these cancers appears to be increasing
worldwide, although the trend is not entirely clear.124 The
causes of brain and central nervous system cancers have not
been well established. 
The narrative review did not produce any findings. 
Because these cancers are uncommon, any study investi-
gating their possible links with food, nutrition, and physical
activity would be unlikely to be fruitful. Because they are
diverse, any investigation that grouped all of them together
would also be unlikely to show consistent results.
7.18.5.1 Conclusions 
These cancers were not reviewed in the previous report. 
The Panel concludes that it is unlikely that any further inves-
tigation is warranted.
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This chapter examines food, nutrition, and physical
activity as factors that modify the risk of weight gain,
overweight, and obesity, which themselves influence
cancer risk.
The Panel agreed that as for the other systematic
literature reviews elsewhere in this Report, a review of the
epidemiological literature should be amplified by
consideration of established knowledge on mechanisms,
including basic thermodynamics and mechanisms of
energy input, output, and balance. 
As shown in Chapters 6 and 7 of this Report, the
evidence that obesity, weight gain, and also overweight
short of obesity increase the risk of a 
number of cancers, is more impressive than was the case
in the mid-1990s. Also, it is now generally agreed that the
rapid rise in the incidence of 
overweight and obesity is a public health nutrition
emergency worldwide. In most countries in Asia, Latin
America, and the Middle East, and some in Africa, chronic
diseases including obesity are now more prevalent than
nutritional deficiencies and infectious diseases. 
The Panel agreed therefore that any comprehensive
report on the prevention of cancer must also deal with the
prevention of overweight, obesity, and weight gain. Expert
reports that inform public health policy on cardiovascular
diseases have, for many years, accepted that factors
identified as causes of obesity are also causes of
cardiovascular diseases. The Panel agrees that the same
applies to cancer. So unless there is reason to think
otherwise, anything that modifies the risk of weight gain,
overweight, and obesity also modifies the risk of those
cancers whose risk is increased by weight gain,
overweight, and obesity.
The Panel judges that the evidence that regular and
sustained physical activity of all types protects against
weight gain, overweight, and obesity is convincing.
Correspondingly, the evidence that 
sedentary living is a cause of these conditions is also
convincing. Television viewing, a particular form of very
sedentary behaviour, which may be associated with
snacking on energy-dense foods, is probably also a cause. 
Low energy-dense foods — typically foods that are high
in fibre and bulky because of their water content — are
probably protective. Such foods include cereals (grains),
pulses (legumes), and vegetables and fruits, and are also
often micronutrient-dense, meaning high in vitamins,
Determinants of weight gain,
overweight, and obesity
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minerals, and other bioactive compounds.
Correspondingly, the Panel judges that high energy-dense
foods, in particular sugary drinks and ‘fast foods’, are
probably a cause of weight gain, overweight, and obesity.
Such foods are typically high in fats and/or sugars, contain
little water or dietary fibre, and are often low in
micronutrients. 
The Panel also judges that sustained breastfeeding
probably protects infants and young children against
overweight and obesity, which tend to track into later
childhood and adult life.
The Panel’s conclusions and judgements on the dietary
and associated determinants of weight gain, overweight,
and obesity also apply to cancers for which the risk is
increased by weight gain, overweight, and obesity, unless
there is reason to think otherwise. 
Within the remit of this Report, the strongest 
evidence, corresponding to judgements of ‘convincing’ and
‘probable’, shows that physical activity of all types protects
against weight gain, overweight, and obesity, whereas
sedentary living is causative; that low energy-dense foods
are probably protective and high energy-dense foods are
probably causative; that being breastfed is probably 
protective; and that sugary drinks, ‘fast foods’, and 
television watching are probably causative. 
Environmental factors (physical, economic, political, and
sociocultural) are extremely important in determining
health behaviour, including that which affects body
fatness. Such factors are the subject of a further report to
be published in late 2008.
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Recent and current research shows that degree of body fat-
ness (often characterised as overweight and obesity) is a
more important cause of cancer than was evident in the mid-
1990s.5 As stated in Chapters 6 and 7, the evidence that body
fatness is a cause of cancers of the oesophagus, pancreas,
colon and rectum, breast (postmenopause), endometrium,
and kidney is convincing; and it is probably a cause of can-
cer of the gallbladder. In addition, the evidence that abdom-
inal fatness is a cause of cancer of the colon is convincing;
and it is also probably a cause of cancers of the breast (post-
menopause) and endometrium. Body fatness probably pro-
tects against breast cancer that becomes evident before the
menopause.
Further, rates of overweight and obesity have greatly
increased since the 1990s, not only throughout high-income
countries, but also in urban and even rural areas of many if
not most middle- and many low-income countries; and not
only in adults, but also in children and young people. Obesity
in both childhood and adult life can now be seen more as a
disease of poverty than of affluence. In 2005, the World
Health Organization estimated the number of overweight
adults (age 15+) to be approximately 1.6 billion, with pro-
jections for 2015 increasing this figure to 2.3 billion.6
The evidence showing that body fatness is, or probably is,
a cause of a number of cancers, as well as a large number
of disorders and diseases (see 8.2.2), is impressive; and over-
weight and obesity are now pandemic, including among chil-
dren and young people. For these reasons, the Panel decided
to commission this chapter, and also decided that its assess-
ments and judgements should be based on the same princi-
ples underlying their assessments of the links between food,
nutrition, and physical activity with specific cancers.
The Panel agrees that any factor related to food, nutrition,
and physical activity that increases the risk of weight gain,
overweight, and obesity, can also be taken to increase the risk
of cancers associated with excess body fatness, unless there
is reason to think otherwise. Thus if regular, sustained phys-
ical activity of all types and regular consumption of low ener-
gy-dense foods protect against weight gain, overweight, and
obesity, then they would also be expected to protect indi-
rectly against those cancers identified in Chapter 7 as being
associated with body fatness.
Social and environmental (underlying and basic) factors
that modify the risk of weight gain, overweight, and obesi-
ty are critically important and the subject of an associated
report to be published in late 2008.7
8.1  Definitions
Humans take in energy from food and drinks, which is used
for the body’s natural processes and for physical activity.
People gain weight if they take in more energy than they use
and lose weight if they take in less energy than they use.
Excess energy is stored mostly as body fat, laid down at var-
ious sites around the body, regardless of whether the excess
energy comes from carbohydrates, fats, or proteins, or from
ethanol from alcoholic drinks. Conversely, with a deficiency
of energy, carbohydrates are initially released in the form of
FOOD, NUTRITION, PHYSICAL ACTIVITY, AND
WEIGHT GAIN, OVERWEIGHT, AND OBESITY
In the judgement of the Panel, the factors listed below modify the risk of
weight gain, overweight, and obesity. Judgements are graded according
to the strength of the evidence.
Factors that decrease risk promote appropriate energy intake,
and those that increase risk promote excess energy intake,
relative to the level of energy expenditure.
DECREASES RISK INCREASES RISK
Convincing Physical activity Sedentary living1
Probable Low energy-dense Energy-dense foods2 3
foods2 Sugary drinks5
Being breastfed4 ‘Fast foods’6
Television viewing7
Limited — 
suggestive 
Limited — Refined cereals (grains) and their products; starchy
no conclusion roots, tubers, and plantains; fruits; meat; fish; milk
and dairy products; fruit juices; coffee; alcoholic
drinks; sweeteners
Substantial 
effect on risk None identified
unlikely
1 Sedentary living comprises both high levels of physical inactivity and low
levels of physical activity (in terms of intensity, frequency, and duration).
Also see box 5.2.
2 The direct epidemiological evidence for low energy-dense foods is from
wholegrain cereals (grains) and cereal products, non-starchy vegetables,
and dietary fibre. The direct epidemiological evidence for energy-dense
foods is from animal fat and fast foods. These are interpreted as markers 
of the energy density of diets, based on compelling physiological and
mechanistic evidence (box 8.1). 
3 Some relatively unprocessed energy-dense foods (which tend to be eaten
sparingly), such as nuts, seeds, and some vegetable oils, are valuable sources
of nutrients. 
4 The evidence relates principally to obesity in childhood, but overweight and
obesity in children tend to track into adult life: overweight children are
liable to become overweight and obese adults. 
5 The evidence relates to all drinks containing added caloric sweeteners,
notably sucrose and high-fructose corn syrup. Fruit juices are also sugary
drinks and could have similar effects, but the evidence is currently limited.
6 ‘Fast foods’ characteristically are consumed often, in large portions, and are
energy dense (box 8.2).
7 Television viewing (box 8.4) is here identified as a sedentary activity (box
5.2). It is also associated with consumption of energy-dense foods (box 8.1).
The evidence relates specifically to childhood and adolescence, and is taken
also to apply to adults. 
For an explanation of all the terms used in the matrix, 
please see chapter 3.5.1, the text of this section, 
and the glossary.
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immediately available glycogen, followed by use of body fat
and of protein in the form of lean tissue. Balance (no weight
loss or gain) is achieved when energy input equals output,
over time. When body fat stores increase or decrease, there
is an accompanying change in lean body mass, with around
three quarters of progressive weight gain or loss represent-
ing changes in body fat stores.
As stated in Chapter 6, body mass index (BMI) is the con-
ventional indicator of body fatness, and takes account of both
height and weight. BMI is calculated as weight in kilograms
divided by height in metres squared (BMI = kg/m2). This
method does not always provide an accurate measure of
body fatness. Unusually lean but muscular people have a rel-
atively high BMI, even if they have little fat. The BMI crite-
ria for risk are now supplemented by measures of excess
abdominal fat, because this selective accumulation is a par-
ticular risk to health. But the BMI method provides a simple
measure of body fatness for most people, most of the time.8
See table 8.1 and also Chapter 6.
8.2  Trends and incidence 
Brief summaries of the worldwide trends in BMI are given
in Chapter 1. The more historical and detailed perspective
that follows provides an important evolutionary context for
interpretation of the clinical, epidemiological, and experi-
mental data reviewed.
8.2.1  Human evolution and adaptation 
Overweight and obesity became a public health issue only
relatively recently in human history. Before industrialisation,
underweight and weight loss, leading to debility caused by
shortage or deficiency of energy from food, were the main
nutritional issues.10 Food insecurity is still a feature of life
for the remaining gatherer–hunter and pastoralist commu-
nities, and for many agricultural communities in adverse
social or environmental circumstances. Periodic episodes of
food shortage are a defining characteristic of any type of
nomadic life. It is likely that the human species has evolved
A concept central to the Panel’s thinking,
assessments, and judgements in this chap-
ter is that of the energy density of foods
and drinks. 
Energy density describes the amount of
energy per unit weight of foods or diets.
The units of measure are kilocalories (kcal)
or kilojoules (kJ) per 100 grams (g). The
body derives energy from the macronutri-
ents in foods and drinks. The metabolis-
able energy of carbohydrate and protein is
around 4 kcal (17 kJ)/g; of fat, 9 kcal (38
kJ)/g; and of ethanol — from alcoholic
drinks — 7 kcal (29 kJ)/g. It follows that of
the macronutrients in pure form, fats and
oils are the most energy-dense, followed
by ethanol; and protein and carbohydrate
are least energy-dense.1 By contrast,
dietary fibre generates around 1.5 kcal (6.3
kJ)/g.2 Water, like all foods and drinks,
requires some energy for its absorption
and metabolism, but its energy value can,
for practical purposes, be counted as nil.
The energy density of foods and diets
varies depending on the water content
and concentration of the different
macronutrients, and of dietary fibre. In
general, low energy-dense foods and diets
are high in fibre, and also in water.
Therefore, in terms of weight, they are 
relatively ‘dilute’ in energy-providing
macronutrients. Cereals (grains) and veg-
etables cooked in water, and most fruits,
are examples of low energy-dense foods.
By contrast, high energy-dense diets tend
to contain fewer fibre-rich foods and to be
relatively concentrated in macronutrients.
Many processed foods are energy dense.
Energy-dense foods are usually high in fats
or oils, and/or processed starches and
added sugars. ‘Fast foods’ (box 8.2), certain
baked goods, and confectionery are exam-
ples of high energy-dense foods. The ener-
gy density of meat depends on the amount
of fat it contains and how it is cooked. Low
energy-dense foods are often high in vita-
mins and minerals and other bioactive con-
stituents. Processed, high energy-dense
foods are often low in micronutrients. 
There is no evidence that drinking a lot
of water with the consumption of energy-
dense foods mimics the intake of low 
energy-dense foods.
In general, people tend to consume
roughly the same amount of food from day
to day, measured by bulk and weight.
Several human clinical studies have shown
that high energy-dense diets can under-
mine normal appetite regulation — a
process that has been termed ‘passive over-
consumption’.3 4 Higher energy density
diets tend to lead to greater energy intake.
Energy consumed in drinks appears to be
less easily recognised by appetite control
systems than energy in foods. Drinks by
their nature are generally high in water
and so, compared to foods, have low ener-
gy density. However, altering the energy
density of drinks, for instance by adding
sugar, nevertheless does influence the over-
all amount of energy consumed, just as it
does for foods, even though the absolute
levels of energy density for drinks are lower
than that for foods. For this reason, caloric
drinks may play a special role in contribut-
ing to positive energy balance.
The Panel has given special emphasis to
the substantial body of robust experimen-
tal evidence, both in humans and in rele-
vant animal models, underpinned by the
principles of thermodynamics. To reach its
conclusions, the Panel interpreted the epi-
demiological findings in the light of this
experimental evidence. Thus, the Panel
notes the associations between specific
foods and food groups with weight gain,
overweight, and obesity, and has inter-
preted them, in the light of the experi-
mental evidence, as indicating a general
effect of energy density rather than as
several different specific effects of particu-
lar foods and drinks. The Panel concludes
that energy density is a probable causal
factor underlying the observed associations
with specific foods and food groups, 
and therefore has decided that energy
density is entered into the matrix as 
such. Similar principles apply to physical
activity although, unlike energy density,
epidemiological studies estimate this more
directly.
The evidence, compelling on physiolog-
ical grounds and supported by experimen-
tal and observational evidence, is for diets
with plenty of low energy-dense foods to
limit weight gain; and for diets with sub-
stantial amounts of high energy-dense
foods to promote weight gain — especial-
ly when there is frequent consumption of
large portions of energy-dense foods and
drinks. Although drinks are characteristi-
cally high in water and less energy dense
than foods, the same principles apply,
within the drink category.
Box 8.1 Energy density
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and adapted to favour the deposition of body fat in order
to survive food shortages.11 12
Famines still occur in regions of the world ravaged by wars
and droughts, particularly in Africa. In children, poor mater-
nal nutrition, inadequate and inappropriate feeding of
infants and young children, and recurrent infections still
cause millions of deaths every year. Therefore it is unlikely
that the United Nations Millennium Development Goal, to
halve the 1990 global rate of malnutrition in under-5s by
2015, will be achieved.13 14
In the past, people in most settled communities possibly
lived a large part of their lives in approximate energy
balance, with adults usually remaining lean, neither losing
nor gaining much weight from year to year. This pattern is
still evident in food-secure agricultural communities in
Africa, Asia, and Latin America, as well as in those urban
areas where ways of life involve a substantial amount of
physical labour and where energy-dense foods are scarce.
Historically, being overweight has been seen as a sign of
wealth, the ability to provide, and a social advantage. This
is still the case in countries where food insecurity remains
endemic or is a living memory. 
8.2.2  Obesity as a public health issue 
Even in the highest-income countries, obesity was uncom-
mon until the 19th century, except among wealthy people
who had access to plentiful amounts of food. But with indus-
trialisation and urbanisation in Europe, and then in North
America and other countries, issues of food insecurity dis-
appeared, food supplies became more plentiful, and food
generally became more energy dense (in particular, increas-
ingly processed and higher in fats and sugars). At the same
time, occupations gradually became more sedentary.15
Consequently, from the latter part of the 19th century,
overweight and obesity were not unusual among middle-
aged, middle-class adults in high-income countries; from the
middle of the 20th century, they became fairly common in
adults in high-income countries. In low-income countries,
and even most high-income countries, there has been a rapid
increase in the prevalence of obesity in the period from 1990
to the present. The rate of increase of the prevalence of obe-
sity globally has accelerated during this period.16
Although obesity was recognised as a public health prob-
lem in higher-income countries in the 1970s,17 18 until fair-
ly recently it was generally not taken seriously. It was
typically seen by health professionals and the public as being
caused by bad habits and weak will — obese patients would
simply be advised to follow a low-energy diet. Only in the
past decade has there been a growing and wide recognition
of the significance of the social and environmental forces that
influence the quality and quantity of food and drink con-
sumed and physical activity undertaken.19
Further, until recently, the causal role of obesity in increas-
ing the risk of other diseases was not well understood. Since
the 1980s, however, obesity has increasingly been recognised
The term ‘fast food’ is used in lay publica-
tions and in common discourse, as well as
in the scientific literature. It is also used as
a category in research studies of food,
nutrition, and the risk of diseases, includ-
ing cancer. In the literature, the term does
not refer to all foods that can be consumed
immediately or quickly, and certainly does
not refer to foods such as fruits. In gener-
al, the term refers to readily available,
energy-dense meals, snacks, foods, and
drinks. These tend to be consumed often
and are frequently offered in large portion
sizes. In the literature, the term usually
refers to ‘fast food’ served in transnation-
al restaurants and the many ‘fast foods’
created in each country and region that
imitate those served in such transnational
restaurants.
Studies assessed in this chapter (see 8.8)
show an association between the con-
sumption of ‘fast foods’ as defined in the
literature and a higher risk of weight gain
and obesity. These studies examined peo-
ple who ate at ‘fast-food’ restaurants or
from takeaway outlets: most of the foods
they consumed were high energy-dense
products. There is no plausible basis for
weight gain being caused by the speed
with which a food is prepared or made
available. Indeed, many foods can be pre-
pared speedily without also being energy
dense. These studies support the Panel’s
conclusion that the energy density of
foods and drinks is an important determi-
nant of body mass. 
Box 8.2 Fast food
Table 8.1 Body mass index as a measure of
body fatness
A body mass index (BMI) of between 18.5 and 24.9 is generally regarded
as ‘acceptable’ or ‘normal’. This is roughly equivalent to 15–20 per cent
body fat in adult men and 25–30 per cent in adult women.1 The ‘under-
weight’ or ‘thin’ range is a BMI of below 18.5. Above 25, the common
gradings for overweight and obesity are as follows: 
Classification BMI (kg/m2)
Principal Additional
cut-off points cut-off points
Normal range 18.50–24.99 18.50–22.99
23.00–24.99
Overweight ≥ 25.00 ≥ 25.00
25.00–27.49
27.50–29.99
Obese ≥ 30.00 ≥ 30.00
Obese class I 30.00–34.99 30.00–32.49
32.50–34.99
Obese class II 35.00–39.99 35.00–37.49
37.50–39.99
Obese class III ≥ 40.00 ≥ 40.00
Adapted with permission from WHO9
The principal cut-off points have been proposed to classify
overweight and obesity. The additional cut-off points are used in
some countries as useful public health references.9 Also see
chapter 6.1.1.
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as a disease in itself, and also as a cause of several disorders
and diseases (table 8.2). Many people who are obese suffer
several of these diseases, disorders, or disabilities. Obese peo-
ple, women in particular, are also more likely to experience
personal, social, and professional difficulties20 and reduced
opportunities for employment and advancement.21
Obesity also lowers life expectancy. It is estimated that at
40 years of age, an obese person can expect to live 6 to 7
years less than someone defined as being of ‘normal’ weight.
The UK government has suggested that the average life
expectancy of men living in England has fallen because 
so many are obese.22 23 It is also now generally accepted that,
to a lesser degree, overweight short of obesity as usually
defined is a cause of many of these pathologies (table 8.2).24
8.2.3  Obesity as a global pandemic 
Now, at the beginning of the 21st century, overweight and
obesity are common, and their prevalence is increasing rapid-
ly. WHO estimated in 2005 that 1.6 billion adults worldwide
were overweight, of whom 300 million were obese.25 About
one sixth of the adult population worldwide was overweight
and a further 7 per cent obese. The very rapid rise in over-
weight and obesity in children, together with a fast and
accelerating rise in type 2 diabetes in young people (box
8.3), are particularly striking.
Although the very rapid rise in obesity throughout the
world was not expected, there is now general agreement on
why obesity has become pandemic. The demographic, nutri-
tional, and epidemiological shifts that affected the popula-
tions of the first countries to be industrialised in the 19th
century are now occurring worldwide, and at a faster rate.
In 1975, of a global population of around 4 billion, about
35 per cent (or 1.4 billion people) lived in cities or urban
areas. In 2005, of a global population of 6.5 billion, about
49 per cent (or 3.2 billion people) lived in urban areas: so
in three decades the world’s urban population has more than
doubled. The projections for 2030 are a world population of
perhaps 8.2 billion, of which 60 per cent (or 4.9 billion peo-
ple) will live in urban areas: an increase of over three times
the 1975 figure within the space of one lifetime.34
Living in cities does not of itself predispose people to
weight gain, overweight, and obesity; this depends on how
people work and live, and what they eat and drink. Daily
Childhood overweight and obesity are
becoming increasingly common, not only
in high-income countries, but in industri-
alised areas in most countries around the
world.26 The most widely used definition of
childhood obesity is that of Cole et al.27
Ten per cent of the world’s children were
estimated to be overweight in 2000.
Recent evidence suggests that this problem
affects almost all countries and is escalat-
ing.28 In many countries, an additional 1
per cent of children are becoming over-
weight or obese every year. From the 1970s
to the end of the 1990s, the prevalence of
overweight and obesity in children dou-
bled or tripled in several large countries in
most regions, such as Canada and the
United States in North America; Brazil and
Chile in Latin America; Australia and Japan
in the Western Pacific region; and Finland,
France, Germany, Italy, and Spain in
Europe. Projections estimate that by 2010,
half of all school-age children will be over-
weight in the Americas, along with some
44 per cent of children in the eastern
Mediterranean region, and 35 per cent in
the European region (including the coun-
tries of the former Soviet Union) and in the
western Pacific region.29
Children who are overweight are liable
to remain overweight as adults or to
become obese.26 30 The likelihood of an
overweight or obese child becoming or
remaining obese in adulthood is increased
by their degree of body fatness and the age
at which they are assessed. Below about
the age of 10, the degree of overweight or
obesity is only partly related to adult fat-
ness, while by 18 years of age, obesity is
largely fixed.30 Even when adults are not
overweight, they may retain an increased
risk of morbidity and mortality from having
been overweight in adolescence.31
As with overweight and obesity in adult-
hood, childhood overweight and obesity
are causes of other chronic diseases. Most
of the consequences of obesity take years,
or even decades, to become clinically evi-
dent, but some are apparent in childhood.
Over half of overweight 5–10-year-old-chil-
dren have been reported to have one car-
diovascular disease risk factor, such as
high blood pressure, hyperlipidaemia, or
elevated insulin level.32 Children who are
even only moderately overweight have
elevated low-density lipoprotein choles-
terol levels. Type 2 diabetes, almost
unknown in early life until recently, is ris-
ing rapidly in children as obesity increases.
Some areas in the USA experienced a 10-
fold increase in this form of diabetes in
children between the 1980s and 1990s.33
Children who experienced growth
restriction or very low-energy diets in very
early life (and in utero), but who then
gained weight rapidly in infancy or early
childhood, are especially likely to become
obese and to develop type 2 diabetes as
children and as adults. 
Box 8.3 Body fatness in childhood 
Table 8.2 Approximate relative risk of physical
health problems associated with obesity
Relative risk Relative risk 2–3 Relative risk 1–2
greater than 3
Type 2 diabetes Coronary heart disease Cancer
Gallbladder disease Hypertension Reproductive 
hormone
abnormalities
Dyslipidaemia Osteoarthritis (knees) Polycystic ovary
syndrome
Insulin resistance Hyperuricaemia Impaired fertility
and gout
Breathlessness Low back pain
Sleep apnoea Increased risk of
anaesthesia 
complications
Fetal defects 
(associated with
maternal obesity)
Adapted with permission from WHO1
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ways of life for non-industrialised populations typically
involve relatively high levels of physical activity. This
includes manual labour and walking, even when food sup-
plies are secure and plentiful; and staple foods — cereals
(grains) or roots and tubers — which are almost always of
relatively low energy density (box 8.1). In contrast, ways of
life in industrialised cities are more likely to be sedentary.
Modern urban food supplies are increasingly processed, with
products that are relatively energy dense: low in dietary fibre
and relatively high in fats and oils, and refined starches and
sugars. Modern urban food supplies also include more meat
and energy-dense alcoholic and soft drinks. An additional
factor, in what has been termed this ‘obesogenic’ environ-
ment, is the ready availability and low price of very many
processed foods and drinks. This makes it easy for poor as
well as rich people to consume more energy than their bod-
ies require.20 35
Obesity is still more common in high-income countries,
where about 22 per cent of the adult population (185 mil-
lion people) are now obese, compared with less than 4 per
cent (115 million people) in middle- to low-income coun-
tries.36 However, of the six countries where more than 60 per
cent of the adult population are overweight or obese, while
three are higher income (the United States, Australia, 
and Great Britain), three are lower-income (Mexico, Egypt,
and South Africa).37 In middle- and low-income countries,
obesity, and the diseases caused by weight gain leading 
to obesity, coexist with diseases and disorders of undernutri-
tion in the same communities and families.38 See figures 8.1
and 8.2. 
In general, obesity is more common in women than in men,
although more men are overweight.1 Overweight and obesi-
ty rates usually increase up to middle age and then are lower
in old age. Obesity rates rise first in cities and urban areas;
rural communities are slower to show this increase.1 Of 38
nationally representative studies among the very lowest
income countries, women of child-bearing age were more
likely to be overweight than underweight, even in rural
areas.39
Obesity rates vary with socioeconomic status. In a cross-
country analysis, as national income rose, BMI increased
rapidly, then flattened, and eventually declined.40
It increased most rapidly until an annual income of about
$US 5000, and peaked at about $US 12500 for women and
$US 17000 for men. In countries whose gross national prod-
uct (GNP) per head is less than $US 2500, obesity in women
is more common among those with a high income.41 But
even in a number of countries with GNP per capita below
$US 2500, such as China, more women of lower compared
to higher socioeconomic status are overweight. As countries
use more money (measured by rises in national GNP), obe-
sity is increasingly becoming a disease of the poor.41
8.3  Regulation of body fatness 
As stated, the physiological cause of weight gain, over-
weight, and obesity is the consumption of more energy from
foods and drinks than is used. Therefore both dietary intake
and energy expended, and physical activity, are determinants
of energy balance. In particular, the systems responsible for
regulating appetite to match energy intake to expenditure
are crucial. This section summarises relevant points about
thermodynamics and the physiological mechanisms involved
in energy intake, expenditure, and balance. 
8.3.1  Thermodynamics
The first law of thermodynamics states that energy cannot
be created or destroyed, but only transformed. In humans
and other animals, energy is supplied by the metabolism of
Figure 8.1 Estimates of the prevalence of obesity and
overweight in selected countries
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Reproduced with permission from the American Journal of
Clinical Nutrition37
Figure 8.2 Estimates of the annual increases in
prevalence of overweight and obesity in
selected countries
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Clinical Nutrition37
Estimates are given by country for men and women, for three BMI
ranges: ≥ 25; ≥ 30; and 25–29.9. GDP = gross domestic product per
capita ($US). UK = United Kingdom. USA = United States of America.
Estimates are given by country for men and women, for three BMI
ranges: ≥ 25; ≥ 30; and 25–29.9. GDP = gross domestic product per
capita ($US). UK = United Kingdom. USA = United States of America.
328
P A R T  2  •  E V I D E N C E  A N D  J U D G E M E N T S
food, using up oxygen in the process. Of the energy the body
liberates from food, about 10 per cent is used in its diges-
tion, absorption, and metabolism. 
Energy expenditure can be measured in a calorimeter, a
sealed chamber designed for this purpose, either directly as
heat production or indirectly by measuring the amounts of
oxygen used and carbon dioxide produced. The amount of
energy metabolised can then be calculated. Studies using
calorimeters prove that the principles of thermodynamics,
manifest as energy balance, with weight loss and weight gain
as described in this chapter, apply both in humans and in ani-
mals.42 Such studies were the first to prove that restriction
of energy from food results in weight loss.43
Energy restriction to less than is expended will result in
weight loss, independent of the type of macronutrients sup-
plied in the diet. Recent trials,44-47 however, show that dif-
ferent macronutrients may have different effects on
metabolism, independent of their energy content. For
instance, low-carbohydrate diets cause the body to
metabolise carbohydrate stored in the body as glycogen; the
associated water excreted leads to loss of weight but not,
unless there is a deficit in total energy, of tissue. Foods high
in dietary fibre, such as wholegrain cereals and vegetables,
promote satiety and therefore may influence weight regula-
tion by improving appetite regulation and tending to con-
strain excess energy consumption.48
8.3.2  Energy intake and output
Human energy needs comprise the amount of energy used
to maintain the body’s functions (measured as basal meta-
bolic rate or BMR); to digest and assimilate food (diet-
induced thermogenesis); and to provide fuel for physical
activity. This energy comes originally from foods and
drinks, and is sourced by the body from stores of carbohy-
drate, fat, and protein. 
Human basal energy needs vary largely as a function of
the total mass of lean tissue, which in turn relates to sex, size,
and age. Physical activity levels vary from day to day, as does
energy intake from foods and drinks. Excess intake is stored;
these stores are used to meet the needs of a higher output
— as a result of extra physical activity, for example. In pre-
menopausal women, basal needs vary to some extent with
ovulatory and other cyclical hormonal changes.
Usually, body weight and energy stores balance over a
month or so. Short-term changes in weight are mostly caused
by fluctuations in the body’s store of water, not in stored
energy. Thus between meals and overnight, the short-term
stores of carbohydrate (glycogen in liver and muscles) are
mobilised and oxidised, with associated water. This causes
weight loss, but mostly of water. Longer-term changes in
weight, by contrast, are due to alterations in the body’s fat
tissue. Therefore substantial daily fluctuations in weight do
not reflect changes in energy stores, whereas consistent
weight gain (or weight loss) over a substantial period of time
does. In undernourished people with negligible fat stores,
weight loss reflects loss of lean tissue, used for energy. In
sedentary adults who are not undernourished, changes in
weight over a period of time reflect changes mainly in the
body’s stores of fat. 
8.3.3  Energy requirement and balance
The energy used to maintain the body’s functions (basal
metabolism) fuels many physiological processes. These
include maintenance of the balance of minerals within cells
and the electrical potential difference across membranes.
Energy is also required for processes such as DNA repair and
the production of new cells, and for the synthesis of proteins
and other structural and functional molecules. The assimi-
lation of food involves the production and secretion of var-
ious enzymes and hormones that control the flow of nutrient
molecules through different metabolic pathways. 
The regulation of these interrelated processes depends on
factors such as general health, age, and also genetic and
other factors that vary between people.49
Tissue deposition during growth in childhood, puberty,
and pregnancy and lactation, has additional energy costs.
Pregnant women have modestly increased energy require-
ments, but many are less physically active during pregnan-
cy. Lactating women require about an extra daily 750 kcal
(3150 kJ) of energy from food. 
The major energy cost above BMR comes from physical
activity (see Chapter 5).
For any given weight, BMR is largely a function of the pro-
portion of lean body mass to total body mass; this varies with
sex and age, and also health and nutrition status. In seden-
tary adults, lean mass (and so BMR) decreases with age:
older adolescents and young adults usually have higher ener-
gy requirements than middle-aged and elderly people. This
means that as they age, people need to consume less ener-
gy from foods and drinks if they are to stay in energy balance
and not gain weight. 
Energy requirements — the energy expended by the body
— vary between people. A small, lean, elderly man weigh-
ing 50 kg living in the tropics, who takes only light exercise,
might be in energy balance at around 1750 kcal (7350 kJ)
per day; whereas a young man weighing 80 kg, who is
extremely active as a manual labourer, is likely to need over
3500 kcal (14.6 MJ) per day. A sedentary, elderly woman
weighing 55 kg might be in energy balance at 1500 kcal
(6300 kJ) per day; whereas a young woman who trains with
weights daily might need up to 2750 kcal (11.5 MJ). Positive
energy balance means consuming more energy than is
expended, in which case, the body will gain weight — main-
ly as fat, but also as lean tissue, which increases BMR.
Negative energy balance means consuming less energy than
is expended, in which case the body will lose weight — again
mainly fat, but also lean tissue. This, together with other
adaptations such as reducing physical activity, tends to
mitigate weight loss. 
In obesity there is excess stored energy, mainly as fat but
also as lean tissue, which leads to increased energy expen-
diture, so that higher energy intake is needed to maintain
energy balance. 
As people gain weight and their BMR increases, they need
more energy from foods and drinks to maintain their
increased weight. Over time, a new balance may be
achieved, so that no more weight is gained, or the balance
may remain positive even at the heavier weight, so that
weight continues to be gained.50
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8.3.4  Appetite and weight control 
Humans have many physiological control systems to help
balance energy input and output. Underfeeding leads to
increased appetite. Eating a meal normally leads to satiation,
a feeling of fullness which stops the eating, and satiety, which
inhibits the desire to begin to eat. However, humans vary
with regard to the extent to which they are able to maintain
body weight over years or decades; some appear to main-
tain energy balance readily, others can only do so with dif-
ficulty. The maintenance of energy balance involves various
processes including satiety responses, appetite control sys-
tems, and other homeostatic mechanisms. In the main, the
control systems are most effective in responding to under-
feeding, by increasing appetite, and are less effective at
reducing intake with long-term overfeeding. Psychological,
social, and cultural factors are important underlying influ-
ences on dietary patterns and physical activity. 
Control seems to be least effective at relatively low levels
of physical activity, meaning that sedentary people tend to
gain weight more readily than active people. Conversely,
although high levels of physical activity increase energy
requirements and appetite, the likelihood of consuming 
more than is needed is lower. In addition, both increased
energy density51 and portion size appear to promote over-
consumption.52-54
In rodents, various mechanisms have been identified that
affect appetite control and weight. Some of these, involving
the hormones leptin and ghrelin, for example, may turn out
to be important for humans. But in humans, energy homeo-
stasis is most reliably achieved by relatively active ways of
life, together with low energy-dense diets. It is likely, in
humans at least, that energy homeostasis operates most
effectively within a range of physical activity and so also of
energy expenditure, to which humans have evolved since the
emergence of Homo sapiens about 250000 years ago, and to
which they are adapted.11 55
8.4  Other causes 
Genetic, social, and environmental factors over the life
course influence the prevalence of weight gain, overweight,
and obesity. A large number of genes are involved with com-
plex gene–gene and gene–environment interactions.
Estimates of the extent to which relative body mass is inher-
ited, derived from studies of identical (monozygotic) twins
or adopted children and their biological parents, are consis-
tently high, ranging between 64 and 84 per cent.56
Correspondingly, relatively high energy intake and/or rela-
tively low energy expenditure, as well as levels of habitual
physical activity, also tend to run in families.57-59
Genetically determined obesity, such as the single-gene
defects that cause Prader-Willi syndrome, Bardet-Biedl syn-
drome, and congenital leptin deficiency, is rare.
Polymorphisms, in particular chromosomal locations linked to
obesity in various populations, are now being investigated.60
The study of genetic determinants of weight gain is tending
to show that appetite regulation and spontaneous physical
activity, rather than metabolism, have the dominant role.56
8.5  Risks of overweight and obesity 
The risk of ill health and of death rises with increasing BMI, from
a point well below a BMI of 30 (figures 8.3 and 8.4).61-67
The effects of overweight and obesity in the USA have
been thought to be declining because of improvements in the
medical treatment of complications such as high blood pres-
sure, type 2 diabetes, and abnormal blood lipids. But large
Figure 8.3 Relationship between BMI and
risk of death
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Figures relate to US women who have never smoked
Relative risks of death were adjusted for: age; presence or
absence of a parental history of coronary heart disease;
menopausal status and hormone use; physical activity; and
alcohol consumption. Bars denote 95% confidence intervals.
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prospective studies with direct long-term monitoring of US
women show increases in death rates when BMI exceeds 25
(except in smokers who tend to be thin and die earlier than
non-smokers).67
Figure 8.3 shows relative risks for death among women
who had never smoked. The monotonic relationship held for
deaths from cancer and, more strongly, for deaths from car-
diovascular causes. For other deaths, the increased risk in the
leanest group was primarily due to chronic obstructive pul-
monary disease and cirrhosis.
When death rate is plotted graphically against BMI, U- or
J-shaped curves imply that having a low BMI both increas-
es the risk of death and reduces life expectancy. But care
needs to be taken to exclude the impact of smoking and of
undiagnosed diseases such as cancer, which can lead to unin-
tended weight loss well before a diagnosis is made.68
8.6  Method
As already stated (see Chapter 3), a full understanding of the
biological factors that modify the risk of chronic diseases
such as obesity requires a synthesis of several types of evi-
dence. Each type has advantages and disadvantages, and all
contribute to an overall picture. But there are special con-
siderations that need to be taken into account for weight
gain, overweight, and obesity. 
First, this chapter includes consideration of thermody-
namics, and the mechanisms of energy input, output, and
balance, to complement evidence from observational and
experimental studies. Evidence on the physiological mecha-
nisms, including robust experimental evidence in humans,
is abundant. Reliable evidence for mechanisms by which a
particular factor affects energy balance is an especially
important consideration when assessing and judging evi-
dence on biological causation. 
Next, clinical and epidemiological evidence in this area has
specific problems. Studies on obese subjects based on their
retrospective assessment (recall) of diet and physical activity
are prone to serious bias. Also, interventions that may work
in the short term are often ineffective in the longer term.
Further, even if specific interventions are shown to cause
weight loss, they are not necessarily the same factors that
caused the weight gain originally. Finally, because of the cru-
cial importance of environmental (economic, social, cultur-
al, and political) factors in determining weight-related
behaviour, interventions which focus on individual behav-
iour in isolation from the environment may fail to show long-
term impact.
The Panel therefore decided to exclude data from such stud-
ies that are inherently problematic from the systematic lit-
erature review (SLR) of the clinical and epidemiological
evidence. The literature review included trials or studies that
ran for, or included follow-up of, less than a year in the
review of underlying mechanisms. These were interpreted as
contributing to understanding of mechanisms underpinning
regulation of body fatness, though not in themselves as evi-
dence of long-term impact on body fatness. The failure of
interventions that are successful in the short term to trans-
late to the long term is probably due to the powerful influ-
ences of sociocultural and other environmental factors in
determining behaviour. Case-control studies were excluded,
due to the special bias inherent in retrospective dietary
reports related to weight gain. Trials that prescribed energy-
restricted diets as the intervention were also excluded; only
trials using ad libitum (unrestricted) diets as the interven-
tion were included. Studies in children under 5 years old
were also excluded. The restriction to include only studies
in free-living participants means that results from this SLR
are relatively robust and generalisable. 
8.7  Interpretation of the evidence
Energy balance and body composition
Measuring energy intake and expenditure in free-living par-
ticipants taking part in prospective observational studies is
complex. Interpretation of measures of energy intake per se
is problematic, due to inaccuracies in assessment and the
complexity of its relationships with body mass and physical
activity. Current techniques are not sufficiently precise to reli-
ably detect the small imbalances that lead to weight gain,
against a background of much higher levels of total energy
intake and expenditure. Studies addressing the effectiveness
of interventions designed to encourage weight loss are also
difficult to interpret from the point of view of what causes
weight gain in the first place. Interventions in free-living
populations tend to have relatively low compliance. 
Initial weight loss is hard to sustain in the long term, and
so long-term studies tend to show less weight loss than pre-
dicted by short-term interventions. While the causes of short-
term weight loss or maintenance can be identified and
understood physiologically, the causes of long-term weight
loss or maintenance may be different. Weight-loss trials were
included in the review and informed the judgements report-
ed here, but the causes of weight loss are not necessarily the
converse of the causes of weight gain and obesity.
Figure 8.4 Relationship between BMI and diabetes,
hypertension, and hypercholesterolaemia
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Several of the studies that contributed data to this report
used self-reported body weight, which correlates well with
measured body weight, although under-reporting is com-
mon, particularly among more overweight subjects. 
Self-reported information on food consumption has also
been used; this is prone to similar bias. Consumption of foods
or drinks regarded as ‘unhealthy’, for instance, those con-
taining fat, sugars, and alcohol, tend to be under-reported
more than others. 
Designs and reporting methods vary between studies, mak-
ing it difficult to combine data. For most of the exposures
assessed, many different measures are used. Study results can,
and have been compared, but meta-analysis was not usually
possible. Nevertheless, when epidemiological and trial data
are interpreted appropriately, and the results are assessed
together in the light of biological evidence, this research does
identify aspects of food and nutrition, and ways of life such
as being physically active, that are the most important deter-
minants of overweight, weight gain, and obesity.
Social (including economic and political) and environ-
mental factors are important determinants of behaviour,
including that which affects body fatness. Such factors are
the subject of a further report to be published one year after
this Report. 
Physical activity
Measurement of physical activity is complex (also see
Chapter 5). When exposure measurement is less precise than
outcome measurement, the apparent effect is attenuated.
Most cohort studies used subjective assessment methods.
Although all studies are prospective, some studies do not
allow reverse causality to be excluded. That is, a high BMI
at the start of the study may be a cause of decreasing phys-
ical activity and may also be independently associated with
an increased risk of weight gain. Although many studies
adjusted for potential confounders, the complexity of this
area makes residual confounding difficult to exclude.
Trials of physical activity interventions and cohort studies
that investigated the effects of physical activity on weight
gain vary greatly in size, length, follow-up, intervention
details, and study design, making comparisons problematic
and precluding meta-analysis. In the case of physical activ-
ity and obesity, cross-sectional data may also be valuable.69
More recent studies report an inverse relationship between
physical activity and weight gain. While this could be
explained by improvements in study design, publication bias
may be present. 
Being breastfed
The definition and classification of breastfeeding varied
between studies. Some studies included mixed feeding, per-
haps in a ‘predominantly breastfed’ group; some reported
mixed feeding separately to exclusive feeding. In other stud-
ies, it was unclear what level of exclusiveness was used. The
duration of exclusive breastfeeding varied and was not
always reported. Intervention trials of the effect of breast-
feeding are impossible for practical and ethical reasons.
Results may remain confounded, because in high-income
countries where most studies are undertaken, mothers 
from higher socio-economic groups tend to breastfeed for
longer periods, and it is difficult to correct for social class
completely. 
8.8  Evidence and judgements 
A total of 207 publications were included in the SLR for the
determinants of weight gain, overweight, and obesity. The
evidence from these studies is summarised here and is fol-
lowed by the Panel’s assessments and judgements.
The evidence included observational epidemiology, trials,
and mechanistic data, with particularly strong and robust
evidence in humans, including data from short-term trials,
which were interpreted as evidence of underlying mecha-
nisms rather than of long-term impact. Each of these types
of evidence is presented according to the particular expo-
sures in the matrix. The exposures in the matrix reflect the
Panel’s interpretation of the causal pathway by which the
exposures/interventions might influence the risk of obesity. 
The Panel agreed that in the particular case of weight gain,
overweight, and obesity, the epidemiological and trial evi-
dence on cereals (grains), on vegetables, and on foods high
in dietary fibre, should be interpreted in the light of, and as
a marker of, their low energy density. It also agreed that, cor-
respondingly, epidemiological and trial evidence on animal
fats should be interpreted on the basis of their high energy
The Panel decided to include evidence on
television viewing, which is a discrete and
measurable pastime associated with obesi-
ty. Subjective methods such as diaries or
questionnaires, and more objective meth-
ods such as accelerometers, pedometers, or
heart rate monitoring, can be used to mea-
sure relatively complex patterns of physical
activity. However, all such methods are
prone to imprecision and bias. On the
other hand, the time spent on single, sim-
ple activities such as viewing television can
be recalled more precisely, and it is rela-
tively straightforward to measure the num-
ber of hours someone spends watching
television. 
As shown in 8.8.8, watching television is
associated with the development of obesi-
ty (as well as with metabolic and cardio-
vascular pathology). Such adverse effects
are unlikely to be caused simply by the act
of watching television. Television watching
is a sedentary behaviour; the degree of
physical inactivity during television watch-
ing appears to be profound compared with
other sedentary activities such as reading,
or sitting and talking. Also, time spent
watching television displaces opportunities
for more active pursuits and increases
exposure to promotion of foods that may
promote weight gain. Further, watching
television may be accompanied by
relatively uninhibited consumption of
energy-dense foods, which may be eaten
in large portion sizes. Measuring the num-
ber of hours someone spends watching
television not only measures physical inac-
tivity, but also a collection of related
behaviour.70
Box 8.4 Television viewing
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density (box 8.1). Therefore, the Panel concludes that the epi-
demiological associations between specific foods, and weight
gain and obesity, were probably due to a general effect of
the relative energy density of such foods and drinks rather
than any other characteristic. 
The full SLR is contained on the CD included with this
Report.
8.8.1  Physical activity 
Three randomised controlled trials (RCTs)71-73 and 16
cohort studies74-89 investigated total physical activity and
weight maintenance or change in adults. Nine RCTs investi-
gated combined physical activity and diet interventions in
adults.90-100 Ten cohort studies101-110 and 1 case-cohort
study111 investigated occupational activity; 19 cohort stud-
ies.73 78 86 87 102 104 106 111-121 and 1 case-cohort study111 inves-
tigated recreational activity in adults; 2 cohort studies
investigated household activity86 122; 1 cohort study investi-
gated frequency of physical activity in adults107; 3 cohort
studies investigated intensity of physical activity in adults.78
102 123 Two long-term RCTs,124 125 3 short-term RCTs,126-128 and
15 cohort studies.129-145 investigated total physical activity in
children, and 4 cohort studies investigated frequency of phys-
ical activity in children.145-148
Total physical activity in adults 
Two trials showed at least one statistically significant
decreased measure of weight gain/body fatness with a phys-
ical activity intervention.71 73 One trial showed no effect on
weight maintenance.72 (See table 8.3.)
In the Schmitz trial, at 39 weeks, the intervention group
gained significantly more fat-free mass (0.89 kg, p = 0.009)
and lost more body fat (1.63 per cent, p = 0.006) compared
with controls.71 There was no statistically significant 
effect on weight or waist measurements. The Fogelholm 
trial showed lower weight regain and waist-circumference
measures in the moderate walking group than in either 
the control or high-intensity groups.73 The Borg trial showed
no statistically significant difference to weight mainte-
nance.72 However, resistance training attenuated the 
regain of body fat mass during the maintenance phase,
though not after follow-up.
Also see 8.8.4, 8.8.5, 8.8.6, and 8.8.7 for dietary interventions.
All nine trials showed a decreased risk of at least one mea-
sure of weight gain with interventions that included physi-
cal activity and diet advice. This tended to be removed or
attenuated as follow-up periods extended past 12 months
(table 8.4). 
The first Pound of Prevention trial showed that 82 per cent
of the intervention group maintained or lost weight, com-
pared with 56 per cent of the control group.90 The second
showed a statistically significant higher weight loss or main-
tenance in high-income women and men than in low-income
women from intervention, but no statistically significant dif-
ference overall between intervention and control.91 At 3
years, there was no statistically significant difference.92 In the
Women’s Healthy Lifestyle Project, the intervention group
showed statistically significant reductions in weight and
waist to hip ratio levels compared with baseline. The con-
trol group showed no statistically significant difference.93 94
In Leermarker’s trial,95 both intervention groups showed sta-
tistically significant reductions in weight (-1.6 kg, whereas
controls gained 0.2 kg; p < 0.01). (The 54-month follow-up
showed statistically significant lower increases in low-den-
sity lipoprotein cholesterol in the intervention group than in
the control group.95) In the Harrell trial, the intervention
group showed statistically significant lesser body fat than the
control group.96
The Patient-centred Assessment and Counselling for
Exercise trial showed no difference in BMI, but a non-signif-
icant lower percentage of body fat in the intervention group
compared with the control group.97 The Burke trial showed
no statistically significant effect on BMI, but fewer individu-
als in the high-intensity group became overweight or
obese.98 The Pritchard trial showed a statistically significant
greater weight loss in the diet than in the exercise group.99
However, dual energy X-ray absorptiometry scans showed
that 60 per cent of weight loss in dieters was fat tissue,
compared to 80 per cent in the exercise group, which also
showed better preservation of lean tissue. In the King trial,
the exercise-focused intervention showed statistically signif-
icant better weight maintenance than diet or control.100
Cohort studies in adults
All 16 cohort studies showed decreased risk
for at least one measure of weight gain,
overweight, or obesity with increased phys-
ical activity, which was statistically signifi-
cant in 12.74-85
Effect estimates (not all studies reported
effect estimates) were a 0.77 per cent
decrease in annual percentage change in
weight (95% confidence interval (CI)
0.53–1.01) per one-unit increase in physical
activity level89; a 0.32 kg/m2 greater increase
in BMI (95% CI 0.19–0.46) for not taking
exercise, compared to taking exercise in 
men, and a 0.30 kg/m2 (95% CI 0.16–0.44)
for the same comparison in women85; a 
0.03 kg/m2 decrease in BMI (95% CI
Table 8.3 Physical activity interventions in adults
Author Number of Intervention Length of Length of 
participants intervention follow-up
Schmitz 2003 56 women Strength-training 15 weeks 6 months
programme or control 
(aimed at weight loss)
Fogelholm 85 women who Moderate or high- 40 weeks 33 months
2000 had undergone intensity walking
a 12-week very programme (aimed at 
low-calorie diet weight-loss maintenance), 
or control
Borg 2002 90 men who Walking programme, 8 months 31 months
had undergone resistance training  
a 2-month very (aimed at weight-loss 
low-energy diet maintenance) or control
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0.005–0.0001; p = 0.049) per 1-unit increase in metabolic
equivalent (MET) hours per day83; a 0.91 kg decrease in men
(95% CI 0.42–1.4) per physical activity score unit and a 2.14
kg decrease in women (95% CI 1.35–2.93)81; a 0.12 kg
decrease (95% CI 0.07–0.16) per 0.10 MET change in phys-
ical activity level80; a 0.29 kg decrease (± 0.12 kg; p < 0.02)
per log physical activity score in women only79; a 0.38 cm
decrease in waist circumference (95% CI 0.16–0.60) for an
increase in vigorous physical activity from baseline of 25
MET hours per week (this effect was reduced to 0.19 cm
(95% CI 0.03–0.35 cm) after controlling for change in
BMI)78; a 2.98 kg decrease (95% CI 1.41–4.55) per 200 exer-
cise units in white women, and change in physical activity
was inversely associated with change in body weight in all
four race and sex subgroups (p < 0.0005)77; a 0.32 kg
decrease (95% CI 0.16–0.48; p < 0.0001) per 1-unit, with-
in-woman increase in sports/exercise scale86; a 0.41 kg/m2
decrease in current BMI (95% CI 0.02–0.81; p value for trend
0.042) per 1-unit increase in past sport participation75; a
1.09 risk of increased BMI (95% CI 1.01–1.17) for the inac-
tive group compared with the referent in the overweight, and
a 0.95 risk of increased BMI (95% CI 0.91–0.99) in the aver-
age compared to the active reference group in the overweight
subgroup.74 One study showed that the baseline physical
activity index was a significant predictor of weight gain (cor-
relation coefficient of 0.39; p value for trend < 0.05) and
fat mass gain (correlation coefficient of 0.40; p value for
trend < 0.05) when one outlier was removed (weight regain
of approximately 40 kg).82 One study stated that there was
a non-significant trend for lower increases in BMI with
increased physical activity.84
One study showed a non-significant association between
increased physical activity energy expenditure (correlation
coefficient of -0.03; p value for trend 0.77) and physical
activity level (correlation coefficient of -0.03; p value for
trend 0.80) and subsequent weight gain.88
Other physical activity assessments in adults
Two cohort studies showed a statistically significant
decreased risk of weight gain, overweight, or obesity with
increased occupational activity108 110; two studies showed
statistically significant decreased risk in women only102 105;
four studies showed no significant association103 104 107 109;
two studies had mixed results101 106; and one study showed
a statistically significant increased risk (exposure was ‘lift-
ing’).111 There was considerable heterogeneity. 
Six cohort studies showed a decreased risk of weight gain,
overweight, or obesity with increased recreational activity.73
86 118-121 Six studies showed no significant association87 102 104
111 115 116; five studies had mixed results,78 106 112-114 and one
study showed a statistically significant increased risk.118
One cohort study showed a statistically significant
decreased risk of weight gain, overweight, or obesity with
increased household activity.122 One study showed no sig-
nificant association.86
One cohort study showed no statistically significant asso-
ciation between frequency of physical activity and risk of
weight gain, overweight, or obesity.107
Two cohort studies showed a statistically significant
decreased risk of weight gain, overweight, or obesity with
increased frequency of high-intensity physical activity.78 102
One study showed no significant association.123
One cohort study showed a statistically significant
decreased risk of weight gain, overweight, or obesity with
Table 8.4 Diet and physical activity interventions in adults
Trial Number of Intervention Length of Length of 
participants intervention follow-up
Pound of Prevention 219 Monthly education newsletters, with and 12 months –
(Forster 1988) without incentives, monitoring postcards, 
optional education course. 
Advice on healthy diet and exercise
Pound of Prevention II 288 men, 594 high- Newsletters with and without lottery 12 months 3 years
(Jeffery 1997, 1999) income women, and incentives, or control
404 low-income women
Women’s Healthy 535 women Behavioural programme or control 5 years 6–54 months
Lifestyle Project
(Kuller 2001, Simkin-Silverman 1995)
Leermarkers 1998 67 sedentary men Clinic or home-based intervention or control – 4 months
Harrell 1996 1504 police trainees ‘Health and fitness programme’ or the 9 weeks –
usual training
Patient-centred Assessment 299 municipal service Intervention or control 9 months –
and Counselling for Exercise workers
(Proper 2003) Burke 2003 137 couples High- or low-intensity intervention or control 4 months 12 months
Pritchard 1997 58 overweight men A worksite programme comparing diet to – 12 months
exercise interventions
King 1989 90 men who had Comparing diet or exercise programmes – –
participated in a 1-year against control in maintenance of previous
weight-loss trial weight loss
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increased number of steps climbed in a day.87 One study
showed a statistically significant decreased risk of weight
gain, overweight, or obesity with increased routine, daily
physical activity level, and a non-significant decreased risk
with change in daily physical activity level.86
Both long-term trials showed statistically significant
decreased risk of at least one measure of weight gain, over-
weight, or obesity.124 125 However, one of the trials also
reported statistically significant lower BMIs in the control
group (table 8.5).125
Two short-term trials showed no statistically significant dif-
ference with physical activity interventions.127 128 One short-
term trial showed a decreased risk of weight gain,
overweight, or obesity with a dance-based physical activity
intervention, which was statistically significant in girls.126
The Mo-Suwan trial showed a non-significant decreased
prevalence of obesity in the intervention group (p = 0.057).
Girls had a statistically significant decreased risk of increas-
ing BMI of 0.32 (95% CI 0.18–0.56); boys had a non-sig-
nificant increased risk of 1.08 (95% CI 0.62–1.89). At 1 year,
the prevalence of obesity (defined by 95th skinfold percentile)
decreased by 2.7 per cent in the intervention group and
increased by 1.4 per cent in the controls.124 The Sallis trial
showed statistically significant lower BMI at 6 and 12
months (p value for trend < 0.05), but not at 18 months, in
the control group. However, boys in the specialist-led group
had thinner skinfold measurements at 6 and 12 months, but
not at 18 months. Girls in the control group had lower BMI
at each time point and this was statistically significant at 18
months (p < 0.01).125
The Flores trial showed a decreased risk of weight gain
with intervention, which was statistically significant in girls
only (BMI change -0.8 kg/m2 in intervention and 0.3 kg/m2
control). Boys showed similar, though non-significant,
trends.126 The Pangrazi trial showed no statistically signifi-
cant difference between the intervention and control
schools. However, girls showed a statistically significant
higher activity in two out of three of the interventions than
control girls.128 The Neumark-Stzainer trial showed no
statistically significant difference in BMI between the inter-
vention and control schools, with non-significant improve-
ments in several analyses.127
Twelve cohort studies showed decreased risk for at least
one measure of weight gain, overweight, or obesity with
increased physical activity in children, which was statistically
significant in 11 (including the 2 cohort studies that used
objective measures to assess physical activity).132-145 Three
studies stated that there was no statistically significant
association.129-131
General mechanisms
The general mechanisms through which physical activity
could plausibly protect against weight gain, overweight, and
obesity are outlined in 8.3 and in Chapter 5. In addition, an
important physiological consequence of physical activity is
fat oxidation, although this effect may be attenuated in obese
people. Regular exercise has been shown to increase fat 
oxidation in both healthy and obese people, a mechanism
that is thought to occur as a result of improved insulin 
sensitivity,149 although this effect may be attenuated in obese
people. Evidence has shown that physical activity could
potentially influence appetite control by: increasing the 
sensitivity of satiety signals; altering food choice or macro-
nutrient preference; and modifying the pleasure response to
food, which may elevate hunger, food intake, and body
weight. Short- and medium-term studies have, however,
shown that individuals can tolerate substantial negative
energy balance during sustained physical activity, thus result-
ing in weight loss. Eventually, food intake will increase to
compensate for the exercise-induced energy loss, although
the degree of compensation may vary greatly between
individuals.150
The epidemiological evidence on physical activity is
substantial and consistent. There is robust mechanistic
evidence, particularly in relation to its impact on
Table 8.5 Physical activity interventions in children
Author Number of Intervention Length of Length of 
participants intervention follow-up
Mo-Suwan 1998 292 kindergarten children Randomised by class (n=10) into exercise or 29–30 weeks 12 months
control group
Sallis 1993 549 school children Randomised by school to specialist-led or – 18 months
(mean age 9.25) teacher-led physical activity programme, or
control condition
Flores 1995 110 children Randomised by class to Dance for Health 12 weeks –
(mean age 12.6) or control conditions
Pangrazi 2003 606 children Randomised by school to usual physical 12 weeks –
(mean age 9.8) education, PLAY (Promoting Lifetime Activity 
for Youth) (intervention) and PLAY plus usual 
physical education and control (no physical 
education or PLAY)
Neumark-Sztainer 2003 201 physically inactive Randomised by school to multicomponent 24 weeks –
girls (mean age 14.9 physical education class or control.
(intervention) and Intervention included 8-week maintenance 
15.8 (control)) component of weekly meetings
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appetite regulation and energy balance. Overall, the
evidence that all types of physical activity protect
against weight gain, overweight, and obesity is
convincing. It has this effect by promoting appropriate
energy intake. Conversely, the evidence can be
interpreted as showing that sedentary living is a cause
of weight gain, overweight, and obesity.
The Panel is aware that since the conclusion of the SLR, nine
RCTs151-159 and four cohort studies160-163 have been published.
This new information does not change the Panel judgement (see
box 3.8).
8.8.2  Sedentary living
One RCT investigated physical inactivity in children164 (see
table 8.6) and three cohort studies investigated physical inac-
tivity in adults.87 122 165 In addition, one RCT164 and 16 cohort
studies129 143 147 166-178 investigated television viewing. These
data are summarised separately in 8.8.8. Television viewing
is a behaviour that usually involves being highly sedentary,
although other activities, such as snacking, are also associ-
ated with it (see box 8.4).
Sedentary living involves a high level of inactivity, with
low levels of activity. The data reviewed here relate to phys-
ical inactivity, which is only one component of sedentary liv-
ing. Somebody who is inactive for considerable periods of
time might also engage in regular, moderate, or vigorous
physical activity at other times, and therefore not be seden-
tary. The strong mechanistic evidence on the effects of
sedentary living, particularly in an environment with easy
access to frequent, large portions of high energy-dense foods,
contribute to the Panel’s judgement on sedentary living.
The single trial showed no significant relationship between
sedentary living and BMI. Post-intervention, BMI was
unchanged, but behaviour such as the number of children
watching more than 2 hours of television per day was sig-
nificantly lower in the intervention group, as was total num-
ber of hours watched.164
Two cohort studies showed increased risk of weight gain
with increased sitting time.122 165 One study stated that there
was no statistically significant relationship.87 Effect estimates
were 1.28 (95% CI 1.04–1.58) for the risk of becoming obese
in those sitting at work, or away from home, or driving for
more than 40 hours per week compared with less than 1
hour a week; 1.11 (95% CI 0.85–1.45) in those who spent
> 40 hours a week sitting at home compared with 0–1 hours
per week122; and 0.80 (95% CI 0.70–0.91) for the likelihood
of weight maintenance (vs weight gain) with a low (< 33
hours per week) compared with high (! 52 hours per week)
sitting time.165
The general mechanisms through which sedentary living
could plausibly cause weight gain, overweight, and obesity
are outlined above and in Chapter 5.
The epidemiological evidence that sedentary living
causes weight gain, overweight, and obesity is
relatively sparse, but there is robust mechanistic
evidence in humans. The Panel concludes that the
evidence that sedentary living causes weight gain,
overweight, and obesity is convincing. 
The Panel is aware that since the conclusion of the SLR, one
cohort study179 and one case-control study180 have been pub-
lished. This new information does not change the Panel judge-
ment (see box 3.8).
8.8.3  Being breastfed
Two published SLRs181 182 and three subsequent cohort
studies98 171 183 investigated being breastfed. 
The larger literature review included 61 studies that inves-
tigated being breastfed and later risk of obesity, of which 43
were cohort studies, 15 were cross-sectional studies, and 3
were case-control studies.182 It showed a statistically signif-
icant decreased risk of obesity with breastfeeding. Meta-
analysis was possible on 28 studies, giving a summary effect
estimate of 0.87 (95% CI 0.85–0.89) for breastfeeding com-
pared with formula feeding. 
Only two studies looked at adult obesity; the rest assessed
obesity in those under 18 years. This effect was attenuated,
but still statistically significant, when only the six studies that
adjusted for parental obesity, maternal smoking, and social
class were included, with an effect estimate of 0.93 (95% CI
0.88–0.99).182
The smaller literature review included 28 studies that
investigated being breastfed and risk of obesity in later child-
hood.181 It showed a statistically significant decreased risk
of obesity with breastfeeding. Meta-analysis was possible on
nine studies (two cohort studies and seven cross-sectional
studies), giving an adjusted summary effect estimate of 0.78
(95% CI 0.71–0.85) for breastfeeding compared with not.
The assessment of exposure to breastfeeding differed
between studies. One study compared children who were
mostly or only breastfed in their first 6 months with those
who were mostly or only formula-fed, while most of the stud-
ies compared children who were never breastfed with chil-
dren always breastfed. Again, the effect was attenuated
when only maximally adjusted studies were
included.
All three cohort studies published after the
conclusion of the above-mentioned litera-
ture reviews showed decreased risk of obe-
sity with breastfeeding.98 171 183 However, the
effect was not statistically significant when
fully adjusted in two studies,171 183 and one
study showed a decreased risk of obesity,
which was statistically significant in adoles-
cence but not adulthood.98 Effect estimates
Table 8.6 Sedentary behaviour interventions in children
Author Number of Intervention Length of Length of 
participants intervention follow-up
Dennison 176 children Randomised by daycare 12 weeks –
2004 from middle-  centre (n=18) into 
income families   intervention that addressed 
(mean age 4.0) nutrition, reducing sedentary 
behaviours, or control group
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were 0.70 (95% CI 0.54–0.91; minimally adjusted) but 1.22
(95% CI 0.87–1.71) in the final model171; and 0.15 (95% CI
0.03–0.72) for being obese in adolescence and 0.34 (95%
CI 0.12–1.01) for being obese in adulthood.98 One study
reported a regression coefficient of -0.30 (95% CI -0.053 to
-0.007; p value for trend 0.012) and BMI at age 8 years after
adjustment for sex.183 The study stated that breastfeeding
was not a statistically significant predictor of BMI after mul-
tivariate adjustment.
General mechanisms
Exclusively breastfed children show different growth patterns
from those of formula-fed infants (also see chapter 6.2).
Breastfed infants consume less total energy and less protein
than formula-fed infants.184 It is possible that the bioactive
factors in human milk could modulate energy metabolism,
a process in which leptin (present in human milk but not for-
mula) may be implicated. Alternatively, the effect of elevat-
ed protein intake and plasma insulin concentrations in
formula-fed babies could stimulate fat deposition and early
adipocyte development.
The epidemiological and mechanistic evidence that
being breastfed protects against overweight and
obesity is substantial and generally consistent. While
there are some issues to do with measurement and
confounding, there is evidence for plausible
mechanisms. Being breastfed is probably protective.
The epidemiological evidence relates to childhood
overweight and obesity; overweight children tend to
become obese adults.
The Panel is aware that since the conclusion of the SLR, three
cohort studies185-187 have been published. This new information
does not change the Panel judgement (see box 3.8).
8.8.4  Low energy-dense foods 
The Panel decided to group the epidemiological evidence 
on foods that are low in energy (box 8.1) into this general
category. This decision was informed by the mechanistic
evidence. 
Nutrition interventions
Fourteen randomised controlled trials investigated dietary
interventions and weight loss, and prevention of weight gain,
overweight, or obesity.45 188-200 Most trials increased the pro-
portion of low energy-dense foods and drinks in people’s
diets. However, the stated aims of trials varied and some may
not be directly relevant. In particular, low-carbohydrate diets
seem to lead to energy reduction with high energy density,
but the long-term health impact of such diets is not known
(see table 8.7).
All trials showed that restricted energy diets decreased the
risk of weight gain, overweight, and obesity. All trials also
showed that increasing the consumption of low energy-dense
foods and decreasing the consumption of high energy-dense
foods in diets decreased risk of weight gain, overweight, and
obesity. Some found that these varied approaches were more
effective than general energy restriction; some did not. 
Most trials with sufficient follow-up periods also showed 
that weight loss was not commonly maintained after the
intervention ended.
The Matvienko trial showed no significant difference from
analysis of the whole dataset, although participants with
higher initial BMI showed improved weight maintenance
with intervention, with statistically significant weight gain
in the control group.200 The Epstein trial showed non-
significant weight loss in both intervention groups, with a
non-significantly greater weight loss in the decreased fat and
sugar group.199 The Swinburn trial showed statistically 
significant weight loss with the low-fat diet at one year, but
no significant difference at five years.195 The Flemming trial
showed statistically significant weight loss with the low-fat
diet and calorie-controlled interventions.197 The Dansinger
trial showed statistically significant weight loss for all diets
and no significant difference between them.198 The Harvey-
Berino trial showed statistically significant greater weight
loss with calorie restriction than with the low-fat diet.196 The
Jeffery trial showed statistically significant greater weight
loss with the low-fat diet at the end of the intervention; after
follow-up, both groups had returned to their original
weights.194 The Sheppard trial showed statistically significant
greater weight loss in the low-fat diet group.193 The Shah
trial showed no statistically significant difference in weight
loss between the low-fat and low-calorie diets.192 The Foster
trial showed statistically significant greater weight loss for
the low carbohydrate diet at three and six months, but a non-
significant greater weight loss at one year.45 The Stern trial
showed a non-significant greater weight loss with the low-
carbohydrate diet than the calorie-restricted diet.191 The
Ebbeling trial showed statistically significant greater weight
loss with the reduced glycaemic load trial.190 The Simkin-
Silverman trial showed statistically significant greater weight
loss and/or maintenance for the intervention group.189 The
Toubro trial showed no significant difference between the
two weight-loss regimes, but did show statistically significant
maintenance (less regained weight) in the ad libitum main-
tenance regime than in the fixed energy group.188
8.8.4.1  Wholegrain cereals and cereal products
Four cohort studies investigated wholegrain cereals and
cereal products.
All four cohort studies showed decreased risk of weight
gain and/or obesity for the highest intake group when com-
pared with the lowest, which was statistically significant in
two.201-204 The two statistically significant results were both
from studies that investigated all food sources of whole-
grains. Effect estimates for higher wholegrain intake were
0.81 (95% CI 0.73–0.91; p value for trend 0.0002) for obe-
sity and 0.77 (95% CI 0.59–1.01; p value for trend 0.03) for
major weight gain204; decreased weight gain with greater
total wholegrain intake (p value for trend < 0.0001)203;
regression coefficients of -0.07 (95% CI -0.30 to 0.17) for
men and -0.20 (95% CI -0.49 to 0.09) for women for the
relationship between wholegrain bread intake and waist cir-
cumference202; and 0.91 (95% CI 0.79–1.05; p value for
trend 0.13) for the relationship between wholegrain break-
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fast cereal intake and risk of being overweight.201
Definitions of wholegrain foods remain contentious (see
box 4.1.1). 
Wholegrains (consisting of the grain endosperm, germ,
and bran) provide an abundant source of dietary fibre, resis-
tant starch, phytoestrogens, antioxidants, and other micronu-
trients (see chapter 4.1). The primary mechanism for an
effect on weight gain is through low-energy density.
However, there are other mechanisms through which whole-
grains may have a physiological effect on weight gain. For
instance, several studies have demonstrated a positive rela-
tion between wholegrain consumption and improved blood
insulin profiles, which could provide an indirect mechanism. 
Wholegrain cereals and cereal products are assessed
here as high-fibre foods and as a marker for low
energy-dense foods. For this reason, no separate
judgement is made for wholegrain cereals and cereal
products. 
8.8.4.2   Foods containing dietary fibre
Six cohort studies investigated foods containing fibre, four
in adults and two in children.115 173 203-206
Five cohort studies showed decreased risk of weight gain
and/or obesity for the highest intake group when compared
with the lowest,115 203-206 which was statistically significant
in three.203-205 One study (in children) showed a non-signif-
icant decreased risk in boys and a non-significant increased
risk in girls.173 Of the two studies that showed non-signifi-
cant decreased risk, one investigated the relationship
between infant diets and adolescent obesity.206 Effect esti-
mates in adults were 0.51 (95% CI 0.39–0.67; p value for
trend < 0.0001) for overweight and 0.66 (95% CI
0.58–0.74; p value for trend < 0.0001) for obesity204; 
p value for trend ! 0.001 for weight gain (no effect esti-
mate)205; 0.39 standard deviation (SD) g per day weight
change (± 0.2) for the highest intake group and 1.4 SD g
per day weight change (± 0.2) for the lowest, p value for
trend < 0.0001203; and the univariate model (adjusted for
retirement (yes/no); type of job (sedentary or active); inter-
action between retirement and type of job; age; smoking;
and the base level of the behaviour) showed a regression
coefficient of -0.31, p value for trend < 0.01, and the mul-
tivariable model (additionally adjusted for all other behav-
Table 8.7 Nutrition interventions
Author Number of Intervention Length of Length of 
participants intervention follow-up
Matvienko 2001 40 female young adults Nutrition education 4 months 16 months
Epstein 2001 26 children with at least one Increased vegetables and fruits of decreased 12 months –
obese parent – and their fat and sugar intake
families
Dansinger 2005 160 adults with one obesity- Low-carbohydrate diet, low-fat diet, calorie 12 months –
related comorbidity restriction, and macronutrient balance
Flemming 2002 100 otherwise healthy overweight High, moderate, and low-fat diet compared 12 months –
or obese adults with a calorie-controlled group
Harvey-Berino 1999 80 otherwise healthy overweight Low-fat diet or low-calorie diet 24 weeks –
or obese adults
Swinburn 2001 103 adults with one obesity- Low-fat diet or general dietary advice 12 months 5 years
related comorbidity
Jeffery 1995 74 moderately obese but Low-fat diet or low-calorie intervention 18 months –
otherwise healthy women
Sheppard 1991 303 women at increased Low-fat diet or other intervention 12 months –
risk of breast cancer
Shah 1996 122 overweight but otherwise  Low-fat diet or low-calorie diet 6 months 12 months 
healthy women (data only 
available for 75)
Foster 2003 63 obese but otherwise Low-carbohydrate diet (Atkins) compared 6 months 12 months
healthy people with low-calorie diet
Stern 2004 87 obese adults Low-carbohydrate diet or calorie-restricted 12 months –
diet
Ebbeling 2003 14 obese adolescents/ Reduced glycaemic load diet compared with 6 month intensive –
young adults reduced energy and reduced-fat diet phase + 6 month 
maintenance phase
Simkin-Silverman 1998 489 women, 50% were Meetings led by behavioural psychologists 18 months –
not over or underweight and nutritionists compared with control
at baseline
Toubro 1997 43 First randomised to rapid or slow weight-loss 12 months –
programmes, then re-randomised to a fixed 
energy or ad lib maintenance programme
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iours examined, including physical activity and dietary vari-
ables) showed a regression coefficient of -0.17, p value for
trend 0.10.115 Effect estimates in children were 0.78 (95%
CI 0.60–1.02) for adolescent obesity with the highest intake
group of fibre foods at 3 years old206; and regression coeffi-
cients of 0.0011 (95% CI -0.0073 to 0.0095; p value for trend
0.80) in girls and -0.0046 (95% CI -0.014 to 0.0046; p value
for trend 0.320) in boys.173
Residual confounding is possible, as indicated by the max-
imally adjusted cohort study above. People whose diets are
high in fibre from food often also have other habits regard-
ed as healthy, which may be difficult to characterise precisely.
On the other hand, there is considerable evidence for a spe-
cific effect of dietary fibre on satiety and on mechanisms
relating to appetite regulation, such as gastric emptying.48
Fibre from food has a low energy density, as it is not digest-
ed in the small bowel and can only undergo partial fermen-
tation in the large bowel. Fibre consumption may increase
satiation by increasing chewing, slowing gastric emptying
and elevating stomach distension, and stimulation of chole-
cystokinin. The increased viscosity of soluble fibre can reduce
the overall rate and extent of digestion, which may also
result in reduced energy from protein and fat and a blunted
post-prandial glycaemic and insulinaemic response to car-
bohydrates. Fibre-induced delayed absorption and the resul-
tant presence of macronutrients in the distal small intestine,
known as the ileal brake, mediate the release of several gut
hormones.207
The evidence on foods containing dietary fibre is
assessed here as a marker for low energy-dense foods,
although there are specific mechanisms beyond energy
density. For this reason, no separate judgement is
made for dietary fibre. 
8.8.4.3  Non-starchy vegetables 
Five cohort studies investigated non-starchy vegetables, four
in adults and one in children.114 208-211
All five cohort studies showed decreased risk of weight
gain and/or obesity for the highest group of non-starchy veg-
etables intake when compared with the lowest, which was
statistically significant in two.114 210 Effect estimates in adults
were 0.84 (95% CI 0.75–0.93; p value for trend < 0.0001)
for becoming obese and 0.76 (95% CI 0.59–0.99; p value for
trend 0.01) for major weight gain210; -0.12 kg/m2 mean
change in BMI (95% CI -0.22 to -0.02; p value for trend
0.012)114; regression coefficient of -0.05 (95% CI -1.24 to 
-0.63) with change in BMI211; and 0.99 (95% CI 0.87–1.13)
for weight gain.209 Weight and height were measured in the
two statistically significant studies, and were self-reported in
the two non-significant studies. The study in children showed
a statistically significant decreased risk of raised BMI z-scores
in boys (regression coefficient of -0.003, 95% CI -0.004 to
-0.001) but no relationship in girls.208
Increased consumption of non-starchy vegetables, which
are generally low in energy density, may result in a com-
pensatory decrease in the consumption of more energy-dense
foods. Most non-starchy vegetables tend to have a low gly-
caemic index and contain soluble dietary fibre, which may
result in slowed gastric emptying and increased satiety. Fruits
and vegetables contain high concentrations of a range of
important micronutrients such as antioxidants and phyto-
estrogens that may also have a beneficial influence upon the
energy homeostatic pathways.
Non-starchy vegetables are assessed here as high fibre
foods and as a marker for low energy-dense foods. For
this reason, no separate judgement is made for non-
starchy vegetables.
Overall, the epidemiological evidence that low
energy-dense foods protect against weight gain,
overweight, and obesity is substantial and generally
consistent. The mechanistic evidence, particularly that
on appetite regulation and energy balance, is
compelling. Taking all types of evidence together, low
energy-dense foods probably protect against weight
gain, overweight, and obesity. They have this effect by
promoting appropriate energy intake. 
The Panel is aware that since the conclusion of the SLR, two
RCTs,212 213 three cohort studies,179 214 215 and one case-cohort
study216 have been published. This new information does not
change the Panel judgement (see box 3.8).
8.8.5  Energy-dense foods 
The Panel decided to group the epidemiological evidence on
foods that are high in energy (box 8.1) into this general
category. This decision was informed by the mechanistic
evidence.
In addition to the evidence summarised below, several of
the trials reviewed in 8.8.4 investigated the effect of reduc-
ing intake of energy-dense foods and drinks, which gener-
ally decreased the risk of weight gain during the
intervention. The evidence on sugary drinks and ‘fast foods’
are also relevant to the judgement for this general category
(see 8.8.6 and 8.8.7).
8.8.5.1  Animal fats
Three cohort studies investigated animal fats, two in adults
and one in children.211 217 218
All three cohort studies showed increased risk of weight
gain for the highest intake group when compared to the low-
est, which was statistically significant in one study,218 and
in one analysis of data on children.217 Regression coefficients
in adults were 0.0032 (95% CI 0.0063–0.00006) linking ani-
mal fat intake and increased risk of weight gain (height and
weight were self-reported)218; and 4.85 (95% CI -3.5 to 13.2;
p value for trend 0.26) linking animal fat intake and weight
change (measured).211 The study in children (recording ani-
mal fat intake from 1 to 7 years of age) showed a statisti-
cally significant greater weight at 7 years for the highest
intake group of 29.3 kg (SD±2.0) compared with 23.7 kg
(SD±1.2) in the lowest (p value for trend < 0.05).217 When
animal fat intake was measured as g/1000 kcal, g/kg body
weight, or compared to Roher index (weight in g "
100/height in cm3), no statistically significant difference was
apparent.
As the most energy-dense macronutrient, there are several
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plausible mechanisms by which dietary fat could lead to pos-
itive energy balance and obesity. The efficiency of nutrient
use is higher for fat than carbohydrate or protein. When
energy balance is positive and fat is being stored, the stor-
age of this fat only requires a small degree of oxidation
(approximately 3 per cent of the energy stored). The high
energy density of fat may promote passive overconsumption.
Prolonged consumption of a high-fat diet may desensitise the
individual to a number of appetite controls. The palatabili-
ty of fat may induce voluntary overconsumption. 
The evidence on animal fats is assessed here as a
marker for energy-dense foods. For this reason, no
separate judgement is made for animal fats. 
High energy-dense foods are probably a cause of
weight gain, overweight, and obesity, particularly
when large portion sizes are consumed regularly. They
have this effect by promoting excess energy intake.
Also see entries on sugary drinks (8.8.6), ‘fast foods’
(8.8.7), and television viewing (8.8.8).
The Panel is aware that since the conclusion of the SLR, one
cohort219 and one case-control study180 have been published.
This new information does not change the Panel judgement (see
box 3.8).
8.8.6  Sugary drinks
The evidence on sugary drinks is reviewed separately due to
its independent effect on body fatness. It also contributes to
the judgement on energy-dense foods and drinks.
One RCT220 and four cohort studies investigated sugary
drinks.115 221-223 Two cohort studies were in adults115 223; the
trial and two other cohort studies were in children.221 222
The single trial included 644 children randomised by class
to receive teaching sessions to discourage consumption of
sugary, carbonated drinks or to control. After 12 months,
change in BMI z-score was non-significantly lower in the
intervention group, with a change of 0.7 (SD 0.2) compared
with 0.8 (SD 0.3) in the control group.220
Three cohort studies showed increased risk of weight gain
when frequency of sugary drink intake increased,115 222 223
which was statistically significant in two.115 222 One study
showed no association.221 This study was in children, and
investigated intake of ‘fruit drinks’, but excluded fruit juice,
soda (fizzy drinks), or diet soda. The effect estimates for the
two adult studies were mean weight gain of 4.69 kg for 1991
to 1995 and 4.20 kg for 1995 to 1999 in women who
increased their sugar-sweetened soft drink consumption, and
1.34 kg and 0.15 kg in women who decreased their con-
sumption223; regression coefficients of 0.20 (p value for trend
< 0.01) for the univariate model relating weight gain to
increase in intake of sugar-sweetened soft drinks and 0.12
(p value for trend 0.05) for the multivariable model (this
study also reported a statistically significant relationship with
increased waist circumference).115 The cohort study in chil-
dren that reported an effect estimate showed that BMI
increased by 0.24 kg/m2 (95% CI 0.10–0.30; p value for
trend 0.03) per sugary drink (not including fruit juice)/day
and the effect estimate for the frequency of obesity was 1.60
(95% CI 1.14–2.24; p value for trend 0.02), also per drink/
day.222
There is considerable variation in the definition of ‘sugary
drinks’ between studies. The study that reported no associ-
ation excluded fizzy drinks.
Studies have demonstrated that, when consumed as part
of a soft drink, the energy from sugars may not be compen-
sated for in the same way as when consumed as part of a
solid meal.224 Limited studies have shown that in adults,
short-term (10-week) intake of sugar-sweetened foods and
drinks (of which 80% were drinks) promoted weight gain,
whilst consumption of artificially sweetened foods resulted
in weight loss.28
The epidemiological and mechanistic evidence that
drinks containing added sugars, including sucrose and
high-fructose corn syrup, are a cause of weight gain,
overweight, and obesity is substantial and consistent.
Sugary drinks probably cause weight gain, overweight,
and obesity. Like energy-dense foods and drinks, they
have this effect by promoting excess energy intake. 
The Panel is aware that since the conclusion of the SLR, one
RCT,225 one cohort,226 and one case-control study180 have been
published. This new information does not change the Panel
judgement (see box 3.8).
8.8.7  ‘Fast foods’
The evidence on ‘fast foods’ is reviewed separately due to
their independent effect on body fatness. It also contributes
to the judgement on energy-dense foods and drinks.
Six cohort studies investigated ‘fast foods’ (see box 8.2),
four in adults and two in children.165 227-231
All six cohort studies showed increased risk of weight gain
with increased intake of ‘fast foods’, which was statistically
significant in four,165 227 229 230 and in women but not men in
an additional study.231 Effect estimates in adults were a
regression coefficient of 0.85 (95% CI 0.43–1.27; p value for
trend < 0.05) in low-income women and 0.39 (95% CI
0.15–0.64; p value for trend < 0.05) for the association
between number of ‘fast-food meals’ per week and BMI231;
a 0.85 (95% CI 0.75–0.96) chance of maintaining weight
(equivalent to a 15 per cent increased risk of weight gain)165;
a weight gain of 1.72 kg (95% CI 0.52–2.92; p value for
trend 0.005) greater for black people who visited ‘fast-food
restaurants’ frequently compared to those who visited infre-
quently, and 1.84 kg (95% CI 0.86–2.82; p value for trend
< 0.0013) greater for the same comparison in white peo-
ple230; and a 0.72 kg (95% CI 0.33–1.11; p value for trend
< 0.01) greater weight gain for people who visited fast-food
restaurants more than twice a week compared to those who
visited infrequently.229 One study in children showed a sta-
tistically significant greater increase in BMI z-scores of 0.82
for those who ate food from quick-service outlets more than
twice a week compared to 0.28 for those who never ate
quick-service foods (p value for trend 0.0023).227 One study
in children stated that there was a statistically significant
association between increased ‘takeaway food’ intake and
BMI at the age of 8, but that after multivariable adjustment
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there was no statistically significant relationship.228
The energy density of a food reflects the energy content
per unit weight (box 8.1). Many of the highly consumed
processed and ‘fast foods’ have a high energy density, often
due to a high content of fat and refined starches and sugars
and a correspondingly low water content.232
The evidence that ‘fast foods’ as defined in the
literature are a cause of weight gain, overweight, and
obesity is strong and consistent. This epidemiological
evidence reinforces the Panel’s judgement on energy-
dense foods. Other factors are that ‘fast foods’ are
promoted vigorously, are cheap, and are often
available in large portion sizes at low cost. ‘Fast foods’
probably cause weight gain, overweight, and obesity.
They have this effect by promoting excess energy
intake. 
The Panel is aware that since the conclusion of the SLR, two
cohort studies226 233 and one case-control study180 have been
published. This new information does not change the Panel
judgement (see box 3.8).
8.8.8  Television viewing
The evidence on television viewing is reviewed separately
due to its independent effect on body fatness. It also
contributes to the judgement on sedentary living (8.8.2)
and may be a marker for other behaviour, such as
consumption of energy-dense foods (box 8.1).70
One RCT234 and 16 cohort studies129 143 147 166-178 investi-
gated television viewing, all in children, adolescents, or young
adults. Some studies grouped other sedentary leisure-time
activities, such as playing videogames, together with televi-
sion viewing.
The single RCT showed a statistically significant decreased
risk of body fatness with decreased television viewing. The
trial included 198 children randomised by school into an
intervention or control group for six months. The interven-
tion aimed to reduce television, videotape, and videogame
use with supporting lessons, encouragement not to eat meals
whilst watching television, and a seven hours per week tele-
vision budget. The intervention group showed a 0.45 kg/m2
greater decrease in BMI (95% CI -0.73 to -0.17) than the con-
trol group. Statistically significant greater decreases were
also seen in skinfold measurement, waist circumference, and
waist to hip ratio. The intervention group showed statisti-
cally significant fewer hours of television viewing (p value
for trend < 0.001) and fewer meals eaten in front of the tele-
vision (p value for trend < 0.02).234
Ten cohort studies showed increased risk of weight gain
and/or obesity with increased television viewing,143 166-168 170-175
which were statistically significant in nine.143 166-168 170-174 Four
studies stated that there was no significant association129
176-178 and an additional study found an association with
videogame-playing in girls but not boys, but no association
with television viewing.147 One study showed a non-signifi-
cant decreased risk.169 Effect estimates (four studies did not
report effect estimates) were a regression coefficient of 0.029
(p value for trend < 0.001) for the relationship between
hours spent watching television and the risk of obesity (as
defined by triceps skinfolds on or above the 85th percentile)
and 0.14 (p value for trend < 0.001) for triceps skinfolds
on or above the 95th percentile174; regression coefficients of
0.037 (95% CI 0.011–0.058; p value for trend 0.001) for the
relationship between time spent watching television or play-
ing videogames in girls and 0.038 (95% CI 0.018–0.059; p
value for trend 0.001) for the same relationship in boys173;
correlation coefficient of 0.14 (95% CI 0.01–0.27; p value
for trend < 0.05) for the relationship between time spent
watching television and subscapular skinfold thickness (as
a measure of body fatness)143; a regression coefficient of
0.054 (p value for trend 0.82) for the relationship between
television viewing and BMI175; a regression coefficient of
0.48 (standard error 0.19; p value for trend 0.012) for rela-
tionship between television viewing in adolescence and BMI
at 26 years in a maximally adjusted model167; a regression
coefficient of 0.47 (SE 0.21; p value for trend 0.02) for the
relationship between television viewing and BMI166; a regres-
sion coefficient of 0.19 (p value for trend < 0.01) for the
relationship between time spent watching television or play-
ing videogames and BMI172; an effect estimate of 1.55 (95%
CI 1.13–2.12) for the group that watched the most televi-
sion when compared to the lowest.171 Watching television or
videos, playing computer games, or listening to audio tapes
was a positive predictor of body fat in 2 out of 4 models
investigating variables related to percentage body fat at age
8 years170; a regression coefficient of 0.05 (95% CI
0.02–0.07; p value for trend < 0.01) for the relationship
between time spent watching television and BMI168; and a
BMI of 19.5 kg/m2 (95% CI 19.3–19.7) in the group that
watched the most television compared to a BMI of 19.6
kg/m2 (95% CI 19.4–19.9) in the group that watched the
least.169
Television viewing is a form of very sedentary
behaviour. The epidemiological evidence is mostly
consistent and generally free of methodological issues.
Results from the intervention trial are impressive, and
there is evidence of a dose-response relationship.
Television viewing may also be associated with
consumption of energy-dense foods and drinks.
Studies were of children and adolescents, but these can
be taken to apply also to adults. Given that television
viewing is a sedentary behaviour, the mechanistic
evidence, particularly that on energy input, output,
and turnover, is compelling. Television viewing is
probably a cause of weight gain, overweight, and
obesity. It has this effect by promoting an energy intake
in excess of the relatively low level of energy
expenditure. 
8.8.9  Other exposures
The following exposures were evaluated: total fat, refined
cereals (grains)/cereal products, starchy roots, tubers and
plantains, fruits, fruit juices, fish, milk and dairy products,
alcoholic drinks, sweeteners, and coffee. However, the data
were either too low quality, too inconsistent, or the number
of studies too few to allow conclusions to be reached.
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8.9  Comparison with previous report
The panel responsible for the previous report made recom-
mendations on body mass and on weight gain, based on the
evidence that high body mass increases the risk of some can-
cers (also see Chapter 6). The report did not review the
determinants of weight gain, overweight, and obesity. 
8.10  Conclusions
The Panel concludes:
Throughout this Report, our conclusions and judgements
derive from a balance of different types of evidence, includ-
ing epidemiological, clinical trial, and mechanistic data (as
set out in Chapter 3). Compared to evidence on the factors
that modify the risk of cancer, there is more and better evi-
dence from clinical trials, and less from observational epi-
demiology, while there is a large and robust body of
experimental evidence in humans on mechanisms of energy
balance. Factors that increase (or decrease) risk of weight
gain do this through promoting (or discouraging) excess
energy intake. The interaction of energy density of diets and
level of physical activity is fundamental.
In light of this, we have taken an integrated approach in
our interpretation of the evidence relating to weight gain,
overweight, and obesity, much of which has focused on spe-
cific foods, drinks, and dietary constituents. The various
foods and dietary constituents have therefore been inter-
preted in the context of the energy density of foods and diets.
The evidence showing that regular, sustained physical
activity of all types protects against weight gain, overweight,
and obesity is convincing. Being breastfed is probably pro-
tective. While the evidence is from studies of infants and
young children, childhood overweight and obesity tend to
track into adult life. Low energy-dense foods, especially
those containing dietary fibre, are probably also protective.
The evidence that sedentary living is a cause of weight
gain, overweight, and obesity is convincing. Energy-dense
foods are probably also a cause. Sugary drinks (those con-
taining added caloric sweeteners, notably sucrose and high-
fructose corn syrup); ‘fast foods’ (which are readily available
and may be energy dense and frequently consumed, often
in large portions); and television viewing (a sedentary
behaviour associated with consumption of energy-dense
foods) are all probable causes of weight gain, overweight,
and obesity. 
The evidence reviewed in this chapter does not include the
important role played by sociocultural and other environ-
mental factors, which will be the subject of a further report
to be published in late 2008. Nevertheless, given the
evidence summarised in Chapter 7 on the role of body fat-
ness in causing various cancers, the factors identified here
should be considered to be additional, indirect causes of
those cancers. 
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Cancer survivors
Cancer survivors are people who are living with 
a diagnosis of cancer, including those who have 
recovered. 
Awareness of cancer survival has increased greatly
since the 1990s. So has the number of people living
with a diagnosis of cancer. The total number of
recorded cancer survivors in the world in 2002 was
estimated to be just under 25 million, and by 2050
may approach 70 million. 
The term ‘cancer survivor’ covers a very wide
variety of circumstances. Thus, the needs of people
currently undergoing therapy are likely to be
different from those of people whose metabolic
functions have been altered as a result of therapy
and from those of people who are evidently fully
recovered and whose functions are intact. 
Nevertheless, the Panel accepts the validity of the
concept of cancer survivor, welcomes the rising con-
sciousness that cancer is a disease best spoken of
and dealt with openly, and agrees that the best way
to improve quality of life and increase the chances
of prolonged life and recovery from cancer is when
cancer survivors take responsibility for themselves,
supported by associates, friends, and family, while
always also consulting their professional advisors
and making best use of available medical care sys-
tems and qualified social support. 
Correspondingly, we the Panel collectively have
accepted a special responsibility to give our best
advice, having examined the evidence derived from
systematic reviews of the scientific literature done
according to our agreed methodology, and also
from our knowledge of the whole range of evidence
and consideration of the precautionary principle
and best clinical and public health practice. 
Research on food, nutrition, physical activity, and
cancer survival is at an early stage. Overall, the
Panel agrees that it is not possible to make judge-
ments that apply specifically to cancer survivors,
based on the evidence reviewed for this Report. The
available evidence on cancer survivors has a number
of limitations: it is of variable quality; it is difficult
to interpret; and it has not yet produced any impres-
sive results. Definite general judgements are made
more problematic because of differences in the
health of cancer survivors at various stages;
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between cancers of various sites; and between the
effects of the many types of conventional and other
therapies used. 
The Panel notes as follows: 
Regular physical activity and other measures that
control body weight may help prevent recurrence, at
least of breast cancer. In any case, when able to do
so, cancer survivors are likely to gain general health
benefit, and a sense of control over their
circumstances, from regular physical activity. 
The evidence does not support the use of high-
dose supplements of microconstituents as a means
of improving outcome in people with a diagnosis of
cancer. Cancer survivors should consult their
physician and/or a qualified nutrition professional,
who can evaluate the safety and efficacy of specific
dietary supplements, and counsel an appropriate
action based on current research relevant to their
particular clinical situation.
In summary, evidence that some aspects of food,
nutrition, or physical activity specifically modify the
condition of cancer survivors is emerging, but is not
yet sufficiently developed to enable the Panel to
make judgements that apply specifically to cancer
survivors, as distinct from people without cancer. 
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The concept of ‘cancer survivor’ first gained currency in the
USA in the 1990s, particularly among advocacy groups
formed to give information, advice, and support to people
with cancer. The term here refers to people living with a diag-
nosis of cancer, including those believed to have recovered. 
Consciousness of cancer survival has increased greatly
since the 1990s, especially in high-income countries. This is
only partly because of the increase in numbers. Another rea-
son is that cancer is increasingly a disease spoken of open-
ly, and seen less as the visitation of a death sentence. 
Cancer survivors, and their families and friends, are
increasingly determined to take responsibility for living with
cancer. They do this individually and collectively, usually in
collaboration with their medical and surgical advisors, and
often with practitioners offering complementary and alter-
native therapies, regimens, and advice. 
Cancer survivors as an overall group, together with those
who are closest to them, are especially concerned to learn
about and act on helpful recommendations. These should be
least likely to do harm, and most likely to help limit the
progress of the cancer. They should also help prevent a recur-
rence of that or another cancer, and help prevent other dis-
eases, as well as improve the quality of survivors’ lives. This
places a special responsibility on professionals in this field,
to consider carefully what can be recommended. 
The Panel’s recommendations for cancer survivors are in
Part 3, Chapter 12. 
9.1  Definitions
The term ‘cancer survivors’ denotes all people who are living
with a diagnosis of cancer, and those who have recovered
from the disease. In this definition, then, cancer survival
begins at the point of diagnosis. 
Cancer survivors include the following population groups;
these are often not discrete, because people may fall into sev-
eral of the groups below. 
After diagnosis, before treatment
• People with cancer who have chosen to have treatment
• People with cancer who choose to have no treatment.
During treatment
• People being treated with modern conventional therapies
• Radiation
• Chemotherapy
• Surgery
• Combinations of radiation, chemotherapy, and surgery.
• People treated with therapies that are alternative or
complementary to conventional ones (box 9.1), usually
as well as, but sometimes instead of, conventional
therapies
• Naturopathy
• Radical diets (very low fat, raw food, other) 
• Energy restriction 
• Orthomolecular nutrition (including all forms of
supplementation)
• Gerson therapy, Hoxsey therapy, antineoplastons,
Coley’s toxins, other 
• Traditional therapies (Ayurvedic, Chinese herbal,
other) 
• Combinations of these, with or without conventional
therapy
• Other.
After treatment
• People whose treatment has been said to be successful,
and who have undamaged metabolic functions
• People whose treatment has been said to be successful,
and who have damaged metabolic functions
• People who have had parts of their digestive tract
surgically removed (mouth, oesophagus, stomach,
small intestine, colon)
• As above, also with colostomy, ileostomy
• Other.
People with secondary cancer or cancer of 
a different site
• Where treatment has been unsuccessful, and who have
undamaged metabolic functions
• Where treatment has been unsuccessful, and who have
damaged metabolic functions
• Those who have had parts of their digestive tract
surgically removed (mouth, oesophagus, stomach,
small intestine, colon)
• As above, also with colostomy, ileostomy
• Other
• People with metastasised or disseminated cancer, with 
or without cachexia
• People with terminal cancer. 
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After recovery 
• People who are alive 5–10 years after successful treatment
• People who are alive 10+ years after successful treatment
(including those who had cancer as a child). 
The definition of ‘cancer survivor’ here does not include peo-
ple living with a diagnosis of a benign tumour, or tumours
defined as premalignant, such as premalignant cervical
lesions or polyps in the colon. 
‘Cancer survivors’ as defined here also does not include
those living with people who are living with a diagnosis of can-
cer. Sometimes this wider definition is used, and from the pub-
lic, community, and family health points of view, issues that
concern cancer survivors are also of vital importance to their
partners, family members, and close friends.1 Such loved ones
are most likely to want to know what to do, and will seek pro-
fessional guidance, both for the person with diagnosed can-
cer, and also for themselves and family members.
This becomes most important practically when decisions
need to be made about family shopping and meal prepara-
tion, and eating out. Should the family member with cancer
be treated differently? Or should the whole family follow the
same recommendations and advice? These are not questions
of direct professional concern to cancer researchers, but do
concern physicians, and other health professionals, whose
responsibility includes passing on authoritative recommen-
dations, or else giving the best available advice and guidance. 
9.2  Occurrence
The number of cancer survivors has greatly increased in
recent decades, especially in high-income countries. This is
partly because the general prevalence of cancer continues to
rise, within a world population that is also rising. In addi-
tion, screening programmes for common cancers are identi-
fying many more cases, usually at relatively early stages. As
already stated, the rapid rise in the recorded incidence of
prostate cancer in recent years is largely because of increased
use of methods of detection (see chapter 7.14.1). Also, for
some cancers, medical and surgical treatments and follow-
up care are increasing the time that people live with cancer;
these interventions are also improving rates of recovery. In
the USA, estimates of the number of cancer survivors have
increased from around 3 million (1.5 per cent of the popu-
lation) in 1970 to over 10 million (close to 4 per cent of the
population) in 2002. The absolute number of cancer sur-
vivors aged 65 years and older is predicted to double in the
USA by the year 2050.1
Calculations of the type made in the USA have not been
made in Europe as a whole. European Union countries
together now have a larger population than the USA, but
given the overall differences between the two (somewhat
lower rates of screening, detection, and years of survival after
diagnosis in Europe), a rough guess of 5 million European
survivors (or 1 per cent of the population) seems reason-
able.2 In 2002, the total number of recorded cancer survivors
in the world was estimated to be just under 25 million.3
If prevalence of, and survival with, cancer worldwide con-
tinues to increase, and follows predictions made in the USA,
and given a further increasing global population, the number
of recorded cancer survivors worldwide in 2025 will approach
50 million, and in 2050 will approach 70 million. Such pro-
jections may be conservative, and also do not take into account
people with cancer that is not diagnosed or recorded.
Among cancer survivors in the USA in 2002, the most
common cancer diagnosed was breast cancer among women
(22 per cent), prostate cancer among men (18 per cent), and
colorectal cancer among men and women combined (10 per
cent).1 These figures are not proportional to incidence rates
because the average time of survival after diagnosis of dif-
ferent cancers varies. In Europe, breast cancer was the most
prevalent cancer in women (34 per cent), followed by colo-
rectal cancer (10 per cent). In men, colorectal cancer (15
per cent), prostate cancer (12 per cent), and lung cancer (10
per cent) were most prevalent.2
9.3  Interpretation of the evidence
9.3.1  General
For general considerations that may affect interpretation of
the evidence, see chapters 3.3 and 3.5, and boxes 3.1, 3.2,
3.6 and 3.7.
9.3.2  Specific
Nature of the field. The main problem faced by reviews of
cancer survivors, as indicated in 9.1, is the scale and het-
erogeneity of the field. The interventions reviewed were
studied in people with a number of different cancers, at dif-
ferent stages, and for different outcomes.
Classification. There are many groups of cancer survivors.
Some have been diagnosed but have not yet received treat-
ment. Others are undergoing treatments that have damag-
ing effects and which, for some, have damaged the physical
function of the body. Others have been overtly free from can-
cer for several or many years. As yet, there are no general-
ly agreed classifications of cancer survivors, or the different
stages of cancer survival, which makes comparisons of stud-
ies problematic. 
Study design. Studies should take into account and report
the stage of treatment participants are at, and give details
of this treatment. Studies need to have sufficient statistical
power to address the research question being examined.
Confounding. Clinical and pathological characteristics of the
cancer, such as tissue of origin, stage at diagnosis, and spe-
cific molecular characteristics, are the strongest predictors of
outcome, and are powerful confounding factors, especially
in observational studies. Cancer treatments and their conse-
quences may change the effects of interventions in ways that
are not well understood. Different cancers may be modified
in different ways by food, nutrition, and physical activity. 
This complexity is increased by the effects of treatment
and the disease itself, both of which can affect food
consumption, digestion, absorption, and metabolism, and
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also a person’s physical condition or behaviour. This is par-
ticularly important for studies that relate body fatness to can-
cer risk, as cancer often causes weight loss. In some cases,
surgery may have been performed to remove parts of the
gastrointestinal tract affected by cancer. Cancer often
results in loss of appetite, and cancer treatments may cause
nausea or a decreased ability to absorb nutrients from food.4
An important strength of randomised trials, provided they
are sufficiently large, is that confounding variables, both
known and unknown, will on average be distributed equal-
ly between the treatment and control groups, and will there-
fore not bias the study results (also see chapter 3.1.6).
9.4  Evidence and judgements
A systematic literature review (SLR) was undertaken to
assess the role of food, nutrition, and physical activity in the
case of cancer survivors. This review addressed the efficacy
of nutritional and physical activity interventions in cancer
survivors in relation to mortality, disease-free survival, can-
cer recurrence, secondary cancers, quality of life, and
adverse effects of treatment regimens.5
This SLR was designed differently from those on the caus-
es of cancer in people assumed to be free from the disease,
and used as the bases for judgements in previous chapters.
This decision was taken because the focus of the research
questions was not on causation, but on the efficacy of par-
ticular interventions. In addition, people with cancer are in
a clinical situation and will often be receiving, or will have
received, medical, surgical, or other treatments that may
affect their nutritional status; this limits the value of some
kinds of observational evidence. 
For these and other reasons, it was decided in the case of
cancer survivors to give pre-eminence to randomised con-
trolled trials (RCTs), which are least likely to be confound-
ed, and are best suited to investigate the relatively short-term
efficacy of specific interventions. The review undertaken was
of 53 nutritional intervention trials and 23 physical activity
trials. It assessed the quality of all the studies reviewed,
including the size of the study populations; the length of 
the interventions and of the follow-up programmes; the
methods used to ensure randomisation; and the methods of
statistical analysis.
There were usually insufficient numbers of any type of
study to allow useful combining of data for meta-analysis.
Overall, data were also insufficient to allow for separate
analyses of survivors before, during, and after treatment. The
Panel’s standard criteria used to grade the strength of evi-
dence, and the matrices used to record the Panel’s judge-
ments, used in previous chapters, were not used in the case
of cancer survivors. 
A narrative review of observational studies was also con-
ducted. As stated above, these are less suited in the study of
efficacy of treatments, and so in studies of cancer survivors
their results should be treated with caution. Also see 9.3. 
The full SLR is contained on the CD included with this
Report.
9.4.1  Randomised controlled trials
9.4.1.1  ‘Healthy’ diets
Food-based RCTs were defined as those using interventions
that offered advice about ‘healthy eating’ (variously defined)
or specific diets such as high-fibre diets and/or weight-loss
programmes. Twelve trials met the criteria for inclusion in
the review of food-based interventions. Study designs tend-
ed to be of poor quality, and insufficient information was
available about the methods used for randomisation and
blinding. Duration of interventions varied between seven
weeks and three years. 
Small trials conducted in Russia, the Netherlands, and
Poland reported on the effects of ‘healthy diet’ interventions
for breast cancer survivors, either during or after treatment,
and cancer recurrence. A reduced fat and energy diet
decreased the recurrence of breast cancer in the Russian
study.6 A study conducted both in the Netherlands and in
Conventional medicine is also known as
modern or Western medicine. It is allo-
pathic, meaning that it relies on diagnosis
of disease, by examinations and tests, and
treatment. With cancer, treatment includes
surgery, chemotherapy, and radiotherapy.
Conventional medicine is based on investi-
gation of the biology (including anatomy,
physiology, and biochemistry) of body
organs, tissues, and cells. It includes an
understanding of the pathological pro-
cesses that lead to disease, and testing of
interventions for efficacy and safety.
Conventional practitioners undergo exter-
nally validated and structured education
and training programmes, and continuing
professional development, and they are
subject to statutory regulation. 
Complementary and alternative medi-
cine includes many diverse medical and
healthcare systems, practices, and products
—  some traditional, some modern. Training
and regulation of providers exist, but 
often vary between therapies and nations.
Some orthodox scientific evidence is avail-
able regarding some of these therapies,
although the efficacy of many remains
unclear and often controversial.
These therapies include mind–body
interventions, such as meditation; biologi-
cally based treatments, such as radical
nutritional regimens, micronutrient sup-
plements, and herbal products; manipula-
tive and body-based techniques, such 
as massage and osteopathy; ‘energy
therapies’, such as the use of magnets or
therapeutic touch; and alternative medical
systems, such as traditional Chinese and
Ayurvedic medicine.
‘Integrative medicine’ is a recent
approach that uses some complementary
and alternative therapies within conven-
tional medicine. Physical activity pro-
grammes and dietary interventions are
commonly used in integrative medicine,
together with counselling.
Cancer survivors should consult their
physician or qualified health professional
before initiating any therapies that are
alternative or complementary to conven-
tional therapies. Cancer survivors should
keep all of the health professionals involved
in providing any treatment fully informed
of their choices in these areas.
Box 9.1 Conventional and unconventional therapies 
346
P A R T  2  •  E V I D E N C E  A N D  J U D G E M E N T S
Poland examined the effect of dietary advice and psycho-
logical support to achieve weight loss, but no significant
effect on breast cancer recurrence was reported, perhaps
because of the small size and limited power of the study.7
Six trials reported on the effect of ‘healthy diets’ on ‘quality
of life’. Of these, one study of people surviving breast, ovary,
prostate, or testicular cancers showed a positive effect, in a pro-
gramme that combined general dietary information with phys-
ical training and coping skills.8 A study of people surviving head
and neck or gastrointestinal cancers showed a beneficial effect
with a programme of dietary counselling compared to usual
care.9 The other studies reported no effect.10-13
Only one trial investigated food-based interventions and
side-effects of treatment. This study found that individual
nutritional advice, adapted to the patient’s own needs and
tastes, reduced adverse effects from radiotherapy in people
with head and neck cancers.14
Three small trials examined food-based interventions and
all-cause mortality. The studies were conducted in survivors
of non-melanoma skin cancer,15 colorectal or lung cancer,16
and breast, ovary, prostate, or testicular cancer.8 None of the
trials reported a significant association between the inter-
vention and all-cause mortality.
No conclusions can be derived from these results. 
The Panel is aware of two large, multicentre, randomised tri-
als of breast cancer survivors, the WINS study, published in
2006, and the WHEL study, published in 2007. The WINS trial
tested a dietary intervention to reduce fat intake in over 2000
women with early stage breast cancer. After 5 years of follow-
up, the women in the intervention group had a 24 per cent
reduced risk of recurrence compared with the control group (rel-
ative risk 0.76, 95% CI 0.60–0.98).17 However, these findings
cannot be easily translated into recommendations for breast
cancer survivors, for several reasons. First, women in the inter-
vention group had more extensive surgical procedures. Also,
they lost weight during the trial and it is possible that weight
loss was responsible for their improved outcome. Finally,
dietary fat reduction was most beneficial in women with oestro-
gen- or progesterone-receptor negative tumours, a finding that
may be due to chance.18
The WHEL study tested the effect of a dietary intervention high
in vegetables, fruits, and dietary fibre, and low in fat, in over 3000
women with early stage breast cancer. After 7.3 years of follow-
up, there was no difference in breast cancer recurrence, new breast
cancer, or all-cause mortality between the intervention and con-
trol groups.19 Unlike the WINS study, in the WHEL study women
in both the intervention group and the control group experienced
small increases in weight, and this may partially account for the
different results in these two trials.
9.4.1.2  Supplements
Data from 39 RCTs were assessed. The review included tri-
als on supplements of retinol,20-26 beta-carotene,27-30 vitamin
B6,31 32 vitamin C,31 32 multivitamins,27 33 34 vitamin E,35-37
selenium,35-38 and isoflavones.39 40 Additionally, single trials
of each of evening primrose oil,41 glutamine,42 and N-acetyl-
cysteine26 and nine trials of commercial supplements were
reviewed.43-51 Also see box 9.2.
Trial quality and number of participants tended to be
higher in supplement trials than in the dietary-intervention
trials. Compliance was monitored in the majority of trials,
and placebos were usually given to the control group.
However, the controls in all seven retinol trials and in five
of the nine commercial supplement interventions were given
‘usual treatment’ or an ‘unrestricted’ diet. 
There was considerable variation in the methods and
length and type of intervention used, and the overall quali-
ty of many studies was poor. Furthermore, the disparate vit-
amins and other bioactive substances used in these studies
make comparison difficult. Results were null or non-signifi-
cant in almost all cases.
Trials where data were sufficient and the exposures were
homogeneous enough to allow meta-analysis included those
examining retinol and all-cause or cancer mortality.
Comparing the intervention to usual treatment, the summary
estimate from four trials that examined all-cause mortality
was 0.97 (95% CI 0.83–1.13)23-26; from three trials that
examined cancer mortality, the summary estimate was 0.92
(95% CI 0.65–1.31).23 24 26
One small trial of bladder cancer survivors showed a sig-
nificant reduction in cancer recurrence. This trial compared
supplementation with a multivitamin plus a high-dose
combination of vitamins A, B6, C, and E and zinc against a
multivitamin alone.33
A larger trial designed to test the effect of 200 micrograms
per day of selenium supplementation on recurrent non-
melanoma skin cancer showed no effect on skin cancer, but
a protective effect on prostate cancer.36 37
Fifteen trials investigated types of supplementation and
side-effects of cancer treatment. One small study reported
higher treatment toxicity in survivors of haematological can-
cers with vitamin A supplementation (as retinol or beta-
carotene).23 No significant results were reported in the other
studies.27 29 31 32 34 35 38-40 48 56-58
The evidence from this review of trials does not show
that micronutrient supplements have any benefits in
cancer survivors. High-dose supplements may be
harmful. Some micronutrients and other bioactive
compounds are known to be toxic at high doses.
In the USA and in other high-income countries, the use of supple-
ments in physiological (low dose) and also pharmacological (high
dose) amounts is common among the general population and
also among cancer survivors. 
At least 50 per cent of the US population take vitamin and min-
eral supplements.52 Supplement use among US cancer survivors
has been shown in two studies published in 2004 to be similar to
the average, but high-dose supplements may be more commonly
used by cancer survivors.53 54 Survivors are also reported to be high
users of complementary and alternative medicines and other
treatments.55 Several hundred web sites promote high-dose sup-
plements with unsupported claims that they are active cancer
cures or can prevent recurrence. 
Box 9.2 Use of supplements by cancer survivors
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9.4.1.3  Physical activity
Twenty-three physical activity RCTs met the criteria for inclu-
sion in the review. Interventions ranged from simple advice
to increase physical activity, to enrolment in supervised exer-
cise programmes. These were mostly small trials and of short
duration. In half of the studies, compliance levels were
unclear, and the majority failed to record physical activity
levels in the control group, which severely limits their value.
Only three of the physical activity intervention trials
reported on mortality or cancer recurrence.8 59 60 None of
these studies reported significant effects. 
Twenty trials investigated quality of life outcomes with phys-
ical activity interventions. Nine of these trials were in survivors
of haematological cancer,61 lung cancer,62 prostate cancer,63
and in a combination of cancers.8 12 64-68. Eleven trials were in
breast cancer survivors.62-73 Two of the interventions in these
trials included nutrition components.12 64
The physical activity interventions, assessment instru-
ments, and outcomes studied were varied. The interventions
included many types of supervised or home-based exercise
programmes. Several studies assessed well-being and qual-
ity of life using a version of the Functional Assessment of
Cancer Therapy scale,69 although other questionnaires and
scales were also used. Quality of life outcomes included a
range of measures of physical, functional, and emotional
well-being, as well as measures of physical fitness. 
Of the 20 physical activity trials that investigated quality
of life, 18 reported a benefit from the intervention on at least
one of the outcome measures reported in the study. None of
the trials reported harmful effects of the physical activity
interventions on any of the outcomes studied.
Taken together, these trials provide some evidence for
the benefit of physical activity on post-treatment
quality of life in cancer survivors.
9.4.2  Observational data 
Three reviews that examined data from 26 observational
cohort or case-control studies met the criteria for inclusion
in the review of observational data.70-72
All of these compared breast cancer outcomes in cancer
survivors to ‘body fatness’, as measured by body mass index
(BMI) (see chapter 6.1). The results of these studies were
generally consistent. An overall increased risk of mortality
with increasing BMI was reported, although there was some
heterogeneity in study results. 
Of 21 studies that followed cases for at least 5 years, 12
showed statistically significant associations between higher
BMI and worse outcome, while others showed insignificant
results or were null. One study found that mortality risk
decreased as BMI increased. Physical activity was associat-
ed with an enhanced quality of life in cancer survivors.
While this information suggests that higher body 
fatness before diagnosis leads to a worse outcome, and
also that physical activity may be beneficial in breast
cancer survivors, it is nevertheless insufficient to
justify any firm judgement on body fatness specifically
in relation to cancer survivors.
The Panel is aware of two large observational studies that
investigated physical activity in breast cancer survivors. A study
of nearly 3000 breast cancer survivors in the Nurses’ Health
Study reported reduced risk of breast cancer mortality in
women who were physically active, compared with sedentary
women.73 In a second study of over 1200 women, physical
activity measured before diagnosis of breast cancer was asso-
ciated with reduced all-cause mortality; this association was
statistically significant in women who were overweight or obese
at diagnosis.74
9.5  Comparison with the previous report
The previous report did not include any review, assessment,
or recommendations directed at cancer survivors. The panel
responsible for that report stated that its recommendations
were especially important for population groups and people
most susceptible to cancer. 
9.6  Conclusions
The Panel concludes:
Research into the effects of food, nutrition, and physical
activity in cancer survivors is in its early stages. For this rea-
son, and also because of the scale and heterogeneity of the
field, the evidence reviewed here is inconclusive. 
Regular physical activity and other measures that control
weight may help prevent recurrence of breast cancer and
improve quality of life. When able to do so, cancer survivors
may gain general health benefit and a sense of control over
their circumstances from regular physical activity. 
The evidence does not support the use of high-dose
supplements of microconstituents as a means of improving
outcomes in people with a diagnosis of cancer. 
Cancer survivors should consult their physician and/or a
qualified nutrition professional who can evaluate the safety
and efficacy of specific dietary supplements, and offer advice
based on current research relevant to their particular clini-
cal situation.
As with all the chapters in Part 2 of this Report, the 
Panel’s recommendations for cancer survivors are in Part 3,
Chapter 12.
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Findings of other reports 
The assessments and judgements made by the Panel
shown in the preceding chapters are based on
evidence from systematic literature reviews of
original research studies, compiled according to
specified criteria, on food, nutrition, physical
activity, and the risk of cancer. However, the Panel
recognises that recommendations on food, nutrition,
and physical activity are also made in relation to
other diseases. These include recommendations
designed to control and prevent chronic diseases
other than cancer, and those designed to influence
the dietary and activity patterns of populations and
individuals. Recommendations that address
nutritional adequacy (prevention of deficiencies),
and prevention and management of infectious
diseases (vulnerability to which is affected by
nutritional status) should also be taken into account. 
The Panel has therefore decided that its
recommendations designed to control and prevent
the incidence of cancer, made in the following
chapters, should take into account the judgements
and recommendations of authoritative reports
related to the prevention and control of other
diseases. Any potential conflicts that might arise
between its own recommendations and others that
cover the same aspects of food, nutrition, and
physical activity are identified in this chapter.
As stated in its title, the present Report has a
global perspective. The importance of dietary issues
related to chronic diseases, relative to those for
nutritional adequacy and infectious diseases, varies
both between countries and between
subpopulations within countries. The approach taken
by this Report, to consider recommendations from
other reports, is particularly relevant for those parts
of the world now suffering the ‘double burden’ of
endemic deficiencies and infection — especially of
infancy and childhood — as well as increasing
incidence of cancers of various sites, and of other
chronic diseases. Nevertheless, people, as well as
public health authorities, need integrated messages.
In Chapter 12 we state whether any recommendation
is affected as a result of the findings of other such
reports. 
This chapter has also assembled the findings of
other recent reports on food, nutrition, physical
C H A P T E R  1 0
activity, and cancer. These show where judgements
and recommendations are consistent, and where
they have changed, as science has developed and as
views on relative weight of evidence from different
types of research have evolved. In addition,
comparisons have been made in Chapters 4 to 7
between the findings of this Report and the previous
report, published in 1997. 
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Dietary guidelines produced by expert bodies have been part
of national and international public health nutrition policies
since the early 20th century. At first, the recommended
dietary intakes for the planning of food supplies were
designed to prevent specific nutritional deficiencies. From
the 1960s, a different type of guidance began to emerge,
designed to prevent food and nutrition-related chronic
diseases, including heart disease and cancer. 
A previous review analysed the findings of 100 expert
reports published between 1961 and 1991 that include
guidelines and recommendations to prevent various chron-
ic diseases.1 Some of the landmark reports produced over
this period are ‘The Causes of Cancer’,2 ‘The US Surgeon
General’s Report on Nutrition and Health’,3 ‘Nutritional Goals
for Health in Latin America’,4 ‘Medical Aspects of Dietary
Fibre’ published by the Royal College of Physicians of
London,5 and ‘Diet and Health’ and ‘Diet, Nutrition, and
Cancer’ published by the US National Research Council.6 7
Towards the end of this 30-year period, dietary guidelines
to prevent chronic diseases tended to move the emphasis
away from dietary constituents (such as saturated fat or vit-
amins). Instead, the focus shifted to foods and drinks, and
sometimes to dietary patterns as a whole. 
The 1961–1991 review1 shows consistent agreement on
the types of diet recommended to protect against obesity, car-
diovascular disease (CVD), cancer of a number of sites, type
2 diabetes, gut disorders and diseases, osteoporosis, dental
caries, and other chronic diseases. Compared with diets typ-
ically consumed in high-income countries, the recommend-
ed diets are high in wholegrain or minimally processed
cereals (grains), vegetables and fruits, and are therefore high
in dietary fibre and bioactive microconstituents, relatively
high in fish, and contain lean meat. These recommended
diets are also correspondingly low in total fat and saturated
fatty acids, sugars, and salt; fatty and salty foods; sugary
foods and drinks in general; and alcoholic drinks. The review
also shows that the expert reports consistently recommend
regular, sustained, physical activity. 
However, almost without exception, expert reports on
chronic diseases treated these issues independently to those
of nutritional adequacy (and the prevention of nutritional
deficiencies), or of the prevention and management of infec-
tious diseases, notably of infancy and childhood, and vice
versa. The separate consideration of these issues usually
reflected the focus either on national concerns in high-
income societies, or the specific interests of specialists. 
10.1  Method 
This chapter is based on a systematic review of secondary
literature that examines recommendations for dietary and
physical activity produced since 1990 for the prevention of
a number of diseases. Therefore, this chapter carries forward
the work of the 1961–1991 review. The purpose is to give
an account of the recommendations of other reports and not
to assess the evidence therein. The full systematic literature
review is contained on the CD included with this Report. 
10.1.1 Diseases and exposures 
The diseases in this present review are categorised as nutri-
tional deficiencies, infectious diseases, chronic diseases other
than cancer, and cancer. These are diseases identified by the
United Nations and other authoritative bodies as being
causally linked with food, nutrition, and physical activity.
They are also identified as significant contributors to the
global burden of preventable disease in terms of prevalence
and cost. 
The ‘exposures’ covered in this review are those identified
in the report that preceded this one8 as convincing or prob-
able modifiers of cancer risk — together with those judged
by other reports to justify a recommendation designed to pre-
vent or control other diseases. The reports analysed include
recommendations on relevant foods and drinks (including
food production, preservation, processing, and preparation),
and dietary constituents, physical activity, and energy
balance. 
10.1.2 Reports reviewed
The reports reviewed were published between 1990 and 
31 December 2004 in the English language. To be included
in the review, reports needed to:
• Involve an expert panel
• Include an original review of relevant literature
• Include explicit disease-specific conclusions and
recommendations
• Base their conclusions on published peer-reviewed
literature specified as a bibliography.
This approach eliminated reports that simply restated pre-
vious recommendations. It also ensured that the review
included only reports with the main aim of developing or
updating nutrition-related recommendations. Reports 
commissioned by industry, business-interest organisations, or
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other interested parties were excluded.
The criteria used for and timing of this review meant that
some important reports were not included. The Panel is aware
of these exclusions and has supplemented the text where
such an omission would have given an incomplete picture. 
Of more than 10000 documents identified initially by data-
base searches, applying these criteria reduced the 
number to 207. All of these reports were read and 94 were
included in the review: 16 reports from international organ-
isations,8-23 39 from North American organisations,24-62 22
from the European Union,63-84 14 from Australasia,85-98
2 from India,99 100 and 1 report from South Africa.101 The
recommendations in the 113 that were finally excluded are
generally consistent with those in the included reports.
The Panel is aware that other important reports have been
published, which were either published subsequent to the
review for this chapter or did not meet the criteria for inclu-
sion. The organisations that produced these reports are: the
American Cancer Society,102 the International Agency for
Research on Cancer,103 the National Institute for Health and
Clinical Excellence,104 and the US Department of Health and
Human Services and the Department of Agriculture,105 and
the National Heart, Lung and Blood Institute and the World
Health Organization.106 106B The recommendations from
these reports were also taken into consideration during the
formulation of the recommendations for this Report.  
10.2  Interpretation of the data
Some caution is needed when interpreting the information
presented here. Most of the reports included have been com-
missioned by and for high-income countries and so reflect
the nutrition concerns of such countries. Producing these
reports is expensive and is likely to be beyond the means of
most individual middle- and low-income countries. Where a
recommendation is made for diets high in vegetables and
fruits, for example, this means high in relation to the diets
typical of high-income countries. Meeting such recommen-
dations might mean increases in intake in some countries and
maintaining already high intakes in others. Recommend-
ations for vegetables and fruits usually do not include pota-
toes, which are generally grouped with roots and tubers (see
chapter 4.1.1).
Many of these reports are concerned with what are now
pandemic diseases of the circulatory system (ischaemic heart
and cerebrovascular diseases and their determinants such as
obesity, high levels of blood fats, and high blood pressure).
Fewer reports are concerned specifically with cancer or dis-
eases of other systems of the body, although an increasing
number now link obesity with type 2 diabetes, and cancer. 
Only a minority of the reports reviewed attempt to be com-
prehensive, and the terms of reference of these reports may
be limited. For example, of the 15 reports addressing can-
cer, just 4 are concerned solely with cancers in general. Of
the rest, 4 focus on chronic diseases including cancer, 2 are
concerned only with colorectal cancer, 2 with vitamin sup-
plementation, 1 with oral health, 1 with children’s health,
and 1 with fats and oils. Also, some reports on cancer do not
review alcohol, food additives and contaminants, or breast-
feeding. For such reasons, most reports say nothing about
many of the aspects of food, nutrition, and physical activity
addressed in this Report. The summary below states where
there is significant disagreement between reports. The Panel
decided not to include a tabulated summary of the recom-
mendations from reports on cancer because, in view of our
own Report, this would be non-contributory.
Until recently, few reports have used a systematic approach
to assess the prevention of nutritional deficiencies in gener-
al. Although it has been established that vulnerability to
infectious diseases — especially of infancy and childhood —
is crucially affected by nutritional status, only in the past few
years has there been an extensive analysis and a coherent
approach to the recognition of the role of individual micronu-
trients such as vitamin A, zinc, and selenium in reducing life-
threatening infections, for example, of the respiratory and
gastrointestinal tracts, which continue to exact a huge bur-
den of disability and premature death.  
Many reports concerned with food, nutrition, and physi-
cal activity also stress the importance of not smoking or using
tobacco. This information is not included here. 
10.3  Nutritional deficiencies
10.3.1 Background
Undernutrition and hunger remain common in parts of the
world where populations are impoverished and food is inse-
cure, largely for social (including political and economic) and
environmental reasons. Global rates of malnutrition (inade-
quate energy intake) and micronutrient deficiencies remain
high, especially in low-income countries.
Many diseases are caused by deficiencies of specific or
combined essential nutrients. These diseases, when severe
and prolonged, can be fatal. In the 1990s, relevant UN agen-
cies specified that certain micronutrient deficiencies were the
most important global public health problems.107 108 Those
identified included deficiencies of iron (causing anaemia, las-
situde, and learning difficulties), iodine (causing goitre and
cretinism), and vitamin A (causing xerophthalmia, impaired
night vision, and eventually blindness).  
Infants, young children, and pregnant and lactating
women have been, and remain, the main focus of recom-
mendations designed to prevent and control nutritional 
deficiencies. Recommendations for combating specific defi-
ciencies include programmes of salt iodisation (iodine); con-
sumption of foods containing readily absorbable iron,
including meat and other foods of animal origin (iron); and
consumption of foods high in carotenoids or retinol (vitamin
A). Supplementation and fortification are also recommend-
ed.107 108 Other recommendations continue to promote exclu-
sive breastfeeding, as well as the supply of adequate and
varied weaning foods (preferably indigenous or local), and
water and food free from infectious agents. 
A number of trials and systematic analyses have assessed
the value of interventions with micronutrients. The results
are sometimes different when tested in African, Asian, or
Latin American children, and this probably reflects the
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different prevailing nutritional conditions. The results
emphasise the importance of ensuring that micronutrient
intakes are adequate and that dietary factors that enhance
micronutrient status form an important part of the diet of
both children and adults, with particular attention being paid 
to women before and during pregnancy. 
10.3.2 Introduction
Few reports concerning nutritional deficiencies qualified for
inclusion in this review. Of the 95 included, 2 make recom-
mendations on preventing rickets,28 52 4 on preventing iron
deficiency anaemia,11 13 51 92 and 4 on preventing vitamin A
deficiency.14 19 21 79 These reports come from 10 different
organisations: 1 from Europe, 6 from international agencies,
and 3 from North America. No reports were included whose
recommendations relate to malnutrition in general, or to
iodine deficiency. 
10.3.3 Foods and drinks 
Vegetables, fruits, pulses (legumes), nuts, seeds, herbs,
and spices. Three reports recommended that various 
vegetables and fruits — being those high in vitamin C 
and folates — should be included with meals to boost 
iron absorption and hence prevent iron deficiency 
anaemia.11 13 51 Another report recommended that the com-
plementary diets of infants and young children should include
vegetables and fruits high in vitamin A to prevent vitamin A
deficiency.21
Meat, fish, and eggs. One report recommended including
foods that are high in absorbable iron, such as lean meat, to
prevent iron deficiency anaemia.51
Dietary constituents and supplements. For vitamin C, folic
acid, and iron, see chapter 4.10. Also, one report recom-
mended that after the age of 6 months, infants receiving
breastmilk or cow’s milk as their main drink, or those con-
suming less than 500 ml/day of infant or follow-on formu-
la, should receive a vitamin A supplement to prevent vitamin
A deficiency.79 Two reports include recommendations for vit-
amin A supplementation,14 19 and two recommended vitamin
D to prevent rickets.28 52
Breastfeeding. One report recommended that mothers
should breastfeed exclusively for the first 4–6 months of their
child’s life to prevent iron deficiency in the child.19
10.3.4 Comparison of reports 
One difference in emphasis between these reports and those
on cancer (and other reports not included in the review) is
the stress given to the importance of extended, exclusive
breastfeeding (see 10.4.3), and the importance of safe water
supplies. 
Differences in recommendations for supplementation of
diets of infants and young children are not substantial. 
An apparent difference between these reports, and those
on cancer and other chronic diseases, is the recommenda-
tion to consume meat as a source of absorbable iron to pre-
vent anaemia. However, only modest amounts are proposed, 
and reports on cancer and other chronic diseases do 
not recommend diets without red meat. 
The Panel agrees that these matters of emphasis and
considerations should be taken into account in its
recommendations. See Chapter 12. Also see the Panel’s
conclusions in 10.7.
10.4  Infectious diseases
10.4.1 Background
Vulnerability to a number of common infectious diseases is
affected by nutritional status; this is especially important in
infants and young children.109 Interaction between nutrition
and infection occurs with ‘classic’ malnutrition — inadequate
energy from food — and also with deficiencies of a range of
vitamins and minerals. Relevant diseases include diarrhoeal
diseases, respiratory infections, measles, whooping cough,
and chickenpox.109 On a global basis, rates of dangerous
infectious diseases — especially of infancy and childhood —
remain high, particularly in low-income countries. Con-
versely, repeated infections impair nutritional status,
particularly during childhood.
The usual recommendations in previous reports concern-
ing food, nutrition, and infectious diseases of infants and
young children have been for exclusive breastfeeding, ade-
quate and varied weaning foods (preferably indigenous or
local), and water and food supplies free from infectious
agents.107
10.4.2 Introduction
Few reports concerned with infections qualified for inclusion
in the review. Of the 95 reports accepted, 3 included rec-
ommendations for the prevention or management of diar-
rhoea,10 17 91 3 for the management of HIV and AIDS,9 12 25
1 for the management of measles,85 and 1 for respiratory dis-
eases.91 These 7 reports were published by 6 organisations:
2 from Australasia, 3 from international agencies, and 1 from
North America. No reports were found that make dietary
recommendations to help prevent or manage dysentery,
malaria, or tuberculosis. 
10.4.3 Foods and drinks 
Cereals (grains), roots, tubers, and plantains. One report
recommended that people with HIV or AIDS should include
staple foods with every meal.9 This report specified refined
starchy foods such as white rice, maize meals, white bread,
noodles, and potatoes to avoid gastric aggravation.9
Vegetables, fruits, pulses (legumes), nuts, seeds, herbs,
and spices. One report recommended that people with HIV
or AIDS should eat a wide variety of vegetables, fruits, and
pulses (legumes) every day.9
Meat, fish, and eggs. One report recommended that 
people with HIV or AIDS should eat meat, poultry, and 
fish regularly.9 It advised that meat should be cooked 
thoroughly, and foods containing raw eggs avoided, to 
prevent diarrhoea.9
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Milk and dairy products. One report recommended that
people with HIV or AIDS should consume milk products
regularly.9
Fats and oils. One report recommended that people with
HIV or AIDS should include fats and oils in their diet to 
maintain their weight.9
Salt and sugar. One report recommended that people with
HIV or AIDS should include sugar and sugary foods in their
diet to maintain their weight.9
Water, fruit juices, soft drinks, and hot drinks. One report
recommended that people with HIV or AIDS should drink
plenty of clean and safe water. If in doubt, and during an
episode of diarrhoea, water should be boiled before use, and
coffee and tea avoided.9
Food production, processing, preservation, and prepara-
tion. Also see 10.5.3. Two reports made recommendations
on preventing diarrhoea: contaminated food and drink
should be avoided; clean utensils should be used during
preparation and serving; and food should be stored safely
and served immediately after preparation.10 17 One of these
reports also recommended that foods should be covered and
refrigerated where possible, for the same reason.17 Similarly,
another report recommended storing fresh food and leftovers
in a cool place or a refrigerator.9 Two reports recommended
that foods should be cooked thoroughly and leftovers reheat-
ed to a high temperature to prevent diarrhoea.9 17
Dietary constituents and supplements. One report rec-
ommended that some people with measles should receive
vitamin A supplements.85
Breastfeeding. Three reports recommended that women
should breastfeed exclusively for the first 4–6 months of their
child’s life to prevent the child having diarrhoea.10 17 91 Of
these, one further advised non-exclusive breastfeeding up to
2 years of age and beyond if possible.17 Another report made
the same recommendation to prevent respiratory disease in
the infant.91 Two reports recommended that women infect-
ed with HIV should avoid breastfeeding where possible to
prevent transmission of the virus to their child, and should
cease breastfeeding as soon as is feasible.12 25 One report
recommended that clean, nutritious weaning foods should
be introduced to an infant at 4–6 months of age, beginning
initially with soft mashed foods to prevent the child 
having diarrhoea.17
10.4.4 Physical activity 
One report recommended that people with HIV or AIDS
should take light exercise.9
10.4.5 Comparison of reports 
As with reports on nutritional deficiencies, one difference in
emphasis between these reports and those on cancer is the
stress given to the importance of extended, exclusive breast-
feeding and the importance of safe water supplies. 
The Panel agrees that these matters of emphasis should be
taken into account in its recommendations. On the impor-
tant issue of mothers with HIV or AIDS, the Panel endorses
the position of the WHO that ‘exclusive breastfeeding is rec-
ommended for HIV-infected women for the first 6 months
of life unless replacement feeding is acceptable, feasible,
affordable, sustainable and safe for them and their infants
before that time’. Also see Chapter 12.
Many of the specific recommendations to protect against
deficiencies and infections in these reports (and others) are
in harmony with those designed to prevent chronic diseases;
few are inconsistent. On salt and the prevention of goitre,
and meat/iron and the prevention of deficiency, and the pro-
motion of physical and mental health, see 10.5.7. 
The recommendations made by the Panel in Chapter 12,
when these take into account prevention of nutritional defi-
ciencies and infectious diseases, are based additionally on
the expert judgement of Panel members experienced in these
areas. Many such reports were excluded by the criteria for
inclusion for systematic review. These usually emphasise the
need for food security — the constant availability of ade-
quate, appropriate, and nourishing food. This fundamental
priority does not contradict the findings of reports concerned
with chronic diseases. Similarly, reports concerned with
deficiencies and infections, especially of infancy and child-
hood, emphasise the need for safe water (and safe water
supply and reliable sewage systems). This also does not
contradict the findings of reports concerned with chronic
diseases. 
10.5  Chronic diseases other than cancer
10.5.1 Background 
In general, chronic diseases such as obesity, type 2 diabetes,
and cardiovascular disease (CVD), as well as some cancers,
appear to have been uncommon, even in older people, until
recent history. With urbanisation and industrialisation, they
have become more prevalent, even among younger people.
It is now generally accepted that the main causes of chron-
ic diseases are environmental factors, including inappropri-
ate food and nutrition, and physical inactivity. 
Expert reports concerning the impact of unbalanced food
and nutrition on the risk of chronic diseases began to appear
in the 1970s.110 At first, these were concerned mostly with
coronary heart disease (CHD), which had become the most
common cause of total and premature mortality in various
high-income countries. Later reports began to consider other
chronic diseases, or chronic diseases in general. For exam-
ple, a report published by WHO in 1990 considered that a
number of diseases could be prevented by appropriate food
and nutrition. These include cerebrovascular disease, CHD,
dental caries, type 2 diabetes, obesity, osteoporosis, various
cancers, and various gut disorders.111
Forty-two reports published mostly in high-income coun-
tries between 1973 and 1988 were reviewed in 1990.111
These made recommendations for reducing the risk of chron-
ic diseases. They proposed that changes in consumption of
certain foods and drinks were causing the rise in chronic
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diseases, as was physical inactivity. They identified foods and
drinks relatively concentrated in total fat and saturated fatty
acids, sugar and salt, and alcohol, as well as diets low in rel-
atively unprocessed grains and other starchy foods, vegeta-
bles and fruits, and dietary fibre. Later reports noted that
obesity and type 2 diabetes in particular were becoming
more common in middle-income countries, and that these
diseases were no longer ‘diseases of affluence’.
More or less the same dietary recommendations were
made for the prevention of all of these chronic diseases,
including cancer.1 For high-income countries, this has been
summarised as diets with: ‘moderately low levels of fat, with
special emphasis on restriction of saturated fatty acids and
cholesterol; high levels of complex carbohydrates; only mod-
erate levels of protein, especially animal protein; and only
low levels of added sugars’.7
Global population average nutrient goals for the preven-
tion of chronic diseases were published by WHO in 1990 as
follows: total fats 15–30 per cent, saturated fats 0–10 per
cent, and polyunsaturated fatty acids 3–7 per cent of total
energy intake; cholesterol 0–300 g/day; sugar 0–10 per cent
of total energy intake; salt less than 6 g/day; starch/complex
carbohydrates 50–70 per cent of total energy intake; dietary
fibre 27–40 g/day; and dietary protein 10–15 per cent of
total energy intake.111
10.5.2 Introduction 
This section presents the recommendations made since 1990
on chronic diseases other than cancer. Of the 95 reports
reviewed, 60 made recommendations relating to the pre-
vention of obesity, type 2 diabetes, or CVD. These were pro-
duced by 34 different organisations: 6 from Australasia, 10
from Europe, 2 from India, 2 from international agencies, 13
from North America, and 1 from South Africa. Of these, 33
discussed the prevention of CVD in general,16 22 30 32 34 36 37
39-47 57 61-63 68 69 71 72 77 78 80 84 91 92 94 97 98 24 the prevention of
CHD,8 22 24 26 30 35 36 53 62 64 66 73 75 81 88 91-93 95-97 99-101 14 the
prevention of type 2 diabetes,22 30 31 45 53 57 62 69 76 77 88 89 91 92
8 the prevention of dyslipidaemia,16 30 53 57 77 87 91 98 16 the
prevention of hypertension,16 22 30 34 36 44 46 56 57 62 69 71 88 91 92
98 12 the prevention of overweight/obesity,8 16 18 22 27 53 62 69
76 91 92 98 and 11 the prevention of stroke,30 36 38 40 42 62 70 77 88
91 111 Nine reports included recommendations to prevent
osteoporosis22 23 33 48 58 59 88 91 92 and 10 to prevent dental
caries.22 49 50 52 53 65 69 74 91 92 Two reports referred to the
prevention of skeletal disorders in general30 82 and 3 to the
prevention of dental diseases in general.62 79 88 These have
been produced by 16 different organisations: 1 from
Australasia, 4 from Europe, 1 from an international agency,
and 10 from North America. Some 5 reports made recom-
mendations to prevent gut diseases and disorders, produced
by 4 organisations: 2 from Australasia, 1 from Europe, and
1 from North America. Of these, 3 referred to the prevention
of constipation,9 60 91 2 to the prevention of diverticular
disease,91 92 and 1 to the prevention of Crohn’s disease92 and
ulcerative colitis.92 Recommendations regarding food
intolerances were found in 4 reports,79 86 91 92 of which 1 was
concerned with lactose intolerance88 and 1 with coeliac
disease.92
10.5.3 Foods and drinks
Cereals (grains), roots, tubers, and plantains. Fourteen
reports recommended including wholegrain cereals in the
diet.16 18 24 36 40 41 43 66 70 78 91 92 95 98 Four of these recommended
that people should consume 3–6 servings per day to prevent
CVD,36 40 78 98 and those at risk of CVD should eat 6–12 serv-
ings per day.98 Three recommended that people should limit
their intake of refined carbohydrates, particularly from cere-
als (grains).36 41 98
Vegetables, fruits, pulses (legumes), nuts, seeds, herbs,
and spices. Sixteen reports recommended consuming rela-
tively high amounts of vegetables and fruits22 35 36 40 69 70 73
75 77 78 80 91 92 95 98 100 with 13 recommending at least 400 g
per day (at least 5 servings).22 35 36 40 69 73 75 77 78 83 95 98 100
Eleven reports recommended the consumption of pulses
(legumes).16 22 24 36 37 41 43 70 88 91 98
Meat, fish, and eggs. Eight reports recommended that con-
sumption of red meat should be moderated and lean meat
preferred (unspecified amount).16 24 40 41 66 78 98 101 Seven
reports recommended including fish in the diet.16 24 41 43 66 80
91 Nine reports recommended consuming oily fish.22 39 40 72
78 80 91 93 98 Eleven reports recommended that people should
consume 1–3 servings of fish a week.22 30 39 40 70 72 78 83 93 96 98
Two reports recommended that egg consumption should be
limited.16 98
Fats and oils. Twenty-five reports recommended that total
dietary fat intake should be limited.8 22 24 26 34 35 46 53 56 62 64 69
70 77 78 80 84 87 89 91 94 98-101 Thirty-three reports recommended
that intake of saturated fatty acids should be limited.8 16 22 24
26 30 31 34-36 40 41 43 53 56 62 63 66 69 70 76-78 80 88 89 91 94 95 98-101 Three
reports recommended that dietary fat intake should not be
restricted in children under 2 years of age.26 41 83 Seven reports
recommended moderate intake of polyunsaturated fatty
acid.24 30 35 66 70 80 93 One report recommended that if total fat
intake is restricted, people who are inactive and overweight
should still include some polyunsaturated fatty acids in their
diet to prevent CHD.98 One report recommended that n-6
fatty acids should form 5–8 per cent of energy intake to pre-
vent stroke,70 while another suggested they should form 4–8
per cent to prevent CVD.69 One report recommended that to
prevent CHD, linoleic acid should make up no more than 10
per cent of total energy, at a ratio of between 5:1 and 10:1
with alpha-linolenic acid.8 Five reports recommended the
consumption of n-3 fatty acids.70 72 80 91 93 Two reports rec-
ommended that eicosapentaenoic acid and docosahexaenoic
acid should be included in the diet.23 39 Nine reports recom-
mended restricting intake of trans-fatty acids.22 30 36 40 41 43 69
83 98 Three reports recommended restricting the combined
intake of trans- and saturated fatty acids.93 97 98 Four reports
recommended limiting the intake of hydrogenated, vegetable,
and partially hydrogenated fats.24 62 66 91 Three reports rec-
ommended restricting myristic acid intake (including coconut
products).66 91 101
Salt and sugar. Twenty reports recommended that salt
intake should be limited to no more than 6 g/day for
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adults,16 30 35 36 40 41 44 46 56 62 63 69-71 73 80 88 91 98 100 while anoth-
er recommended that people should consume less than 
5 g/day.22 Ten reports recommended that people should limit
their sodium intake.30 40 41 44 46 56 59 66 80 88 Seven reports rec-
ommended that consumption of sugary foods should be lim-
ited,36 41 62 69 91 92 98 with six specifying the prevention of
dental disease.22 62 65 74 79 92 Four of these reports made this
recommendation only in relation to dental disease.22 65 74 79
Ten reports recommended that the proportion of energy in
the diet from sugar should be limited (either total, added,
or non-milk extrinsic sugars).36 41 53 62 73 87 91 92 98 101
Milk and dairy products. Eleven reports recommended that
low-fat dairy products should be chosen in preference to
high-fat versions.16 24 36 40 41 46 56 66 83 98 101
Water, fruit juices, soft drinks, and hot drinks. Three
reports recommended that water should be chosen as a drink
to prevent overweight/obesity and dental damage.22 65 92 One
report recommended that individuals (particularly older peo-
ple) should consume between 1.5 and 2 litres of water each
day to prevent constipation.60 One report recommended that
people with HIV or AIDS should drink plenty of fluids to pre-
vent constipation.9 Three reports recommended that people
should limit their consumption of sugary drinks to prevent
dental damage.22 65 92 Three reports recommended against
using sugary drinks in babies’ bottles to prevent dental dam-
age.49 65 92 Two recommended that people should limit their
caffeine intake to no more than four cups of coffee per day
to prevent osteoporosis.48 59 One report recommended that
caffeine should be eliminated to prevent constipation.60
Alcoholic drinks. Sixteen reports recommended that men
should drink no more than two alcoholic drinks per day and
that women should drink no more than one.22 31 36 40 44 46 56
62 70 73 75 77 88 91 96 97 Two reports recommended that people
with dyslipidaemia should limit their intake of alcoholic
drinks.64 96 Five reports recommended that if people choose
to drink, they should do so only with meals.40 56 62 70 91 Five
reports recommended that alcohol intake should be limit-
ed.34 44 64 96 99 Three reports recommended that men should
drink no more than 21 units of alcohol/week (equivalent to
three drinks a day), and women no more than 14 (equiva-
lent to two drinks a day).73 75 76 One report recommended
avoiding high intakes of alcohol to prevent osteoporosis.23
Two reports recommended that alcohol should be eliminat-
ed completely to prevent constipation60 and stroke.70
Food production, processing, preservation, and prepara-
tion. Also see 10.4.3. Two reports recommended that food
should be grilled (broiled) or steamed, rather than fried.62 101
Dietary constituents and supplements. Eight reports rec-
ommended that carbohydrates should provide between 45
and 65 per cent of total energy intake as part of a healthy
diet.24 53 63 64 69 80 87 99 Three reports recommended including
complex carbohydrates in the diet.16 87 99 Fifteen reports rec-
ommended a diet relatively high in dietary fibre.9 16 35 36 40 41
53 60 63 64 69 70 95 98 101 Sixteen recommended restricting dietary
cholesterol intake.8 16 24 26 30 35 36 40 43 62 63 66 70 78 80 93 Thirteen
reports recommended that ‘at risk’ groups, and also people
with type 2 diabetes, should limit dietary cholesterol to less
than 200 mg/day to prevent CVD.30 34-36 40 41 43 44 46 63 64 99 101
These groups of people include those at risk of or with pre-
existing CVD, or those with elevated levels of low-density
lipoprotein (LDL) cholesterol. Two reports recommended
that there should be no restriction of dietary cholesterol for
children under 2 years of age.26 80 One report recommend-
ed that more than 400 micrograms/day of folate should be
consumed to prevent CVD.98 Three reports recommended the
consumption of vitamin D to prevent osteoporosis,22 48 59 and
another made this recommendation for preventing skeletal
disorders in general.82 One report recommended that chil-
dren with inflammatory bowel disease should have at least
400 international units (IU) of vitamin D per day to prevent
osteoporosis.58 Another report recommended that vitamin D
intakes for people with gastrointestinal diseases should be
800 IU/day to prevent osteoporosis.33 Various reports rec-
ommended that people should ensure that they have an ade-
quate intake of calcium,16 22 30 33 46 48 58 59 70 82 potassium,22 46
56 80 and magnesium.46 70 Three recommended that people
should brush their teeth with a fluoride toothpaste to pre-
vent dental damage.50 65 74 With regard to supplements, one
report recommended against the use of antioxidant supple-
ments to prevent CVD,43 while two recommended against
beta-carotene supplements.61 73 One report recommended
against using vitamin E supplements to prevent CHD,61 73 and
another to prevent CVD.47
Breastfeeding. One report recommended that women
should breastfeed to prevent dyslipidaemia in the infant.87
Two gave this advice as a means of preventing over-
weight/obesity in the infant,27 92 and one of these specified
exclusive breastfeeding for 6 months.92 Four reports recom-
mended that women should breastfeed exclusively for 6
months to prevent food intolerance in the infant,27 79 91 92 of
which two made this recommendation to prevent Crohn’s dis-
ease,27 92 and ulcerative colitis.27 92 One report also recom-
mended breastfeeding as a way of reducing the risk or
delaying the onset of coeliac disease92 in the infant. 
10.5.4 Physical activity
Twenty-four reports recommended that people should
undertake at least 30 minutes of moderate intensity physi-
cal activity on most days of the week.16 22 30 33-36 40 43 45 56 57
62 64 68 69 73 76 78 80 89 96 97 101 One of these recommended 60 min-
utes/day of moderate, or 30 minutes/day of vigorous activ-
ity,69 while two reports recommended 60 minutes/day of
moderate activity.22 53 Three reports recommended that chil-
dren and adolescents should perform 60 minutes of activity
on most days of the week.16 41 62 Seventeen reports recom-
mended that people should be physically active for general
good health and to prevent chronic diseases.9 16 23 27 30 34 40-
42 59 62 64 75 77 82 88 91 Two reports recommended that weight-
bearing activity should be included to prevent skeletal
disorders including osteoporosis.59 82 Four reports recom-
mended that people, especially children, should limit
sedentary activities.27 41 62 82 
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10.5.5 Growth, development, body composition 
Two reports recommended that people should avoid being
underweight to prevent skeletal disorders, including
osteoporosis.23 82
10.5.6 Weight gain, overweight, obesity
Fifteen reports recommended that a body mass index (BMI)
of less than 25 is healthy.35 36 38 40 41 43 46 56 62 69 80 91 96 98 101 Eight
of these reports specified a BMI range of 18.5–24.9.35 38 40 43
46 56 62 91 Two reports recommended a BMI range of 18.5–23
for Asian people.99 100 Twelve reports recommended that peo-
ple should achieve and maintain a healthy weight.16 18 23 34 41
46 62 69 82 91 98 111 Six reports recommended that people should
lose weight if they have a BMI of 25 or above.34 40 44 46 77 78
One report recommended that people who are overweight or
obese should lose 5–10 kg to prevent CHD.73 One recom-
mended that overweight people at risk of type 2 diabetes
should lose 5–10 per cent of their bodyweight to prevent this
disease.31 Nine reports recommended that men maintain a
waist circumference of no more than 40 inches (102 cm) and
women no more than 35 inches (89 cm).34-36 40 43 44 78 89 98 Two
recommended that Asian men should have a waist to hip ratio
of not more than 0.88; for Asian women this should not exceed
0.85.99 100 Three reports recommended that people should
limit their intake of energy-dense foods.36 62 89
10.5.7 Comparison of reports 
There is one significant difference between the reports that
focus specifically on cancer (see 10.6) and those concerned
with chronic diseases other than cancer. The discussion in a
number of these reports noted the evident protective effect
of modest alcohol consumption against CHD (but not cere-
brovascular disease or other chronic diseases). However, no
report included in this review explicitly recommended the
consumption of alcoholic drinks.
There are some significant differences — at least in empha-
sis — between reports that make recommendations to pre-
vent chronic diseases other than cancer, and those that make
recommendations for preventing cancer specifically. Reports
concerned with preventing chronic diseases other than can-
cer, particularly CVD, give more prominence to the impor-
tance of diets high in cereals (grains) — preferably
wholegrain or minimally processed — as well as diets high
in vegetables, fruits, and fish. High-fat milk and dairy prod-
ucts are judged to increase the risk of CVD, but these foods
are not thought to be a major factor in the development of
cancer.
The iodisation of salt supplies, which is necessary to prevent
goitre, need not be in conflict with recommendations on max-
imum levels of salt intake. Recommendations to limit con-
sumption of red meat need not conflict with recommendations
for iron intake to prevent clinical and subclinical deficiency,
and to promote physical and mental development. 
The Panel agrees that these differences and considerations
be taken into account in its recommendations which, when
they are based partly on findings on diseases other than can-
cer, are clearly identified as such. See Chapter 12. 
In general, the Panel notes the impressive consistency of find-
ings apparent from a systematic review of expert reports pub-
lished since 1990 on food, nutrition, physical activity, and the
prevention of chronic diseases, which reinforce the findings
of earlier, less formally conducted work. The main evidence-
based recommendations made by expert reports on cancer,
and by reports on chronic diseases other than cancer, are
mostly harmonious and often practically identical. This in-
cludes reports on obesity, type 2 diabetes, CVD, and disorders
of the digestive system, osteoporosis, and dental diseases.
10.6  Cancer
10.6.1 Background 
Throughout recorded history, cancer has been attributed —
at least in part — to food and nutrition, as well as to other
environmental factors. Until the beginning of the 20th
century, high consumption of meat and salt, and low
consumption of bulky plant foods, vegetables, and fruits
were thought to increase the risk of cancer in general. In the
first two thirds of the 20th century, a series of laboratory and
ecological studies found that energy restriction protected
against cancer in laboratory animals, and that diets low in
fibre and high in meat, fat, salt, salty foods, and/or alcoholic
drinks seemed to increase the risk of some cancers in
particular.15
From the late 1970s, reports began to be published that
summarised the scientific literature on food, nutrition, and
cancer, and provided dietary recommendations for the pre-
vention of cancer. Between 1977 and 1989, 12 such reports
were published in, or for, Canada (1), Europe (2), Japan (1),
Latin America (1), and USA (7). These reports have been
reviewed previously.1 They tended to recommend relatively
high consumption of cereals (grains), vegetables, and fruits
(and so of dietary fibre and micronutrients); relatively low
consumption of red meat, and smoked and cured meats; low
consumption of salted and salty foods; low or no consump-
tion of alcoholic drinks; maintenance of a healthy body
weight; and regular physical activity.
10.6.2 Introduction 
Following this work, this section presents the recommenda-
tions made for controlling and preventing cancer since 1990.
The order of the passages below follows that of the contents
of the present Report. Overall, of the 95 reports reviewed,
15 include recommendations on preventing cancer. These
reports have been produced by 12 different organisations: 1
from Australasia, 3 from Europe, 5 in or for North America,
and 3 from international agencies. There are no such reports
from middle- or low-income countries. Of the 15 reports, 12
present recommendations relating to the prevention of can-
cer in general8 15 22 29 47 61 62 67 83 88 91 92 and 11 of these also
make recommendations on preventing site-specific cancers.
These include cancers of the bladder (3)15 88 91; breast (7)15
29 62 67 88 91 92; 2 for cervix, endometrium, kidney, larynx, liver,
nasopharynx, oesophagus, pancreas, and stomach15 67; colon
and rectum (9)15 20 29 62 67 88 90-92; lung (3)15 47 67; mouth/phar-
ynx (3)15 65 67; and 1 for ovary and prostate.15 The recom-
mendations summarised in this section (10.6) are for
preventing cancer in general, unless stated otherwise. 
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Table 10.1 Recommendations to prevent food-related diseases
The table below summarises recommendations from reports published since 1991 for the management, control, and prevention of chronic diseases, nutritional 
deficiencies, and relevant infectious diseases. Recommendations related to cancer are not included here. Unless indicated otherwise, there is no disagreement 
between reports. To present the findings of the review more easily, recommendations have only been included if they are made in three or more reports. 
However, the Panel does not intend this as a measure of the quality of the recommendations themselves. For more detailed information, please refer to the 
appropriate sections in this chapter.
EXPOSURE RECOMMENDATIONS TO PREVENT OR MANAGE
Cereals (grains), roots, Include wholegrain cereals in the diet (unspecified amount) CVD,36 41 43 78 98 CHD16 24 66 91 92 95
tubers, and plantains
Suggested intake of 3–6 or more servings/day of wholegrain cereals CVD36 40 78 98
Foods high in iron should be eaten in combination with foods that enhance Iron deficiency anaemia11 13 51
rather than inhibit iron absorption: cereals (grains) should be consumed with 
meals of low iron content, and foods high in ascorbic acid, such as tubers, 
should be included with meals
Vegetables, fruits, pulses Include 400 g (5 or more servings)/day of vegetables and fruits CVD,36 40 69 77 78 80 98 111 CHD,35 40 73 75 95 100 111
(legumes), nuts, seeds, hypertension35 36 73 95 100 111
herbs, and spices
Include pulses (legumes) in the diet (unspecified amount) CVD,36 41 43 91 98 CHD16 24 88
Foods high in ascorbic acid, such as orange juice, carrots, and cauliflower, Iron deficiency anaemia11 13 51
should be included with meals
Meat, fish, and eggs Red meat consumption should be moderated and lean meat preferred CVD,16 40 41 78 98 CHD24 66 101
(unspecified amount)
Include fish in the diet (unspecified amount) CVD,16 41 43 80 CHD24 66 91
Consume between 1 and 3 servings/week of fish CVD,39 40 72 78 80 98 CHD22 30 40 93 96
Choose oily fish (unspecified amount) CVD,39 40 72 78 80 98 CHD22 36 91 93
Fats and oils Limit intake of hydrogenated/partially hydrogenated vegetable oils  CHD24 62 66 91
and hard margarines (unspecified amount)
Total dietary fat intake should be limited (unspecified amount) CVD46 77 84
Total dietary fat to provide no more than 35% of total energy CHD,8 53 66 overweight/obesity22 53 69
Total dietary fat to provide no more than 30% of total energy CVD,22 69 78 CHD24 26 34 35 62 64 101
Dietary fat intake should not be restricted In children under 2 years of age26 41 80
Limit/reduce intake of saturated fats (unspecified amount) CHD53 88 98
Intake of saturated fat should be no more than 10% of energy CVD16 22 36 40 41 63 69 78 80 94
CHD8 24 26 62 66 91 92 95 101
Intake of saturated fat should be no more than 7% of energy CVD,34 36 41 43 44 CHD,35 99 100 people with, 
or at risk of, CVD or with elevated LDL 
cholesterol (including those with 
diabetes)31 34-36 40 41 43 44
Intake of saturated fatty acid intake should be limited (unspecified amount) CHD53 88 98
Restrict intake of myristic acid (including coconut products) CHD66 91 101
Limit intake of dietary cholesterol to <300 mg/day CVD,16 36 40 43 63 78 CHD8 24 26 35 62 66 93
Limit intake of dietary cholesterol to <200 mg/day CVD in people with diabetes, people at 
risk of, or with pre-existing, CVD or those 
with elevated LDL cholesterol,34 36 41 43 44 63
CHD in people with diabetes, people at
risk of, or with pre-existing, CVD or those
with elevated LDL cholesterol35 64 101
Limit intake of polyunsaturated fatty acids to no more than 10% of energy CHD24 66 93 101
Limit intake of trans-fatty acids (unspecified amount) CVD36 40 41 43 98
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Table 10.1 Continued
EXPOSURE RECOMMENDATIONS TO PREVENT OR MANAGE
Salt and sugar Limit intake of sodium to no more than 100 mmol/day Hypertension30 46 56 80 88
Limit/reduce sodium intake (unspecified amount) CVD in children at risk of CVD and in 
adults with hypertension40 41 44 46
Limit/reduce consumption of salt and salted foods to no more CVD,16 36 40 41 63 69 71 80 91 CHD,35 73 80 100
than 6 g of salt/day hypertension,30 46 56 62 69 71 80 88 91 98
stroke40 70 80
Limit the proportion of energy in the diet from sugar (unspecified amount) CVD,36 41 98 overweight/obesity62 91 92
Limit consumption of sugary foods (unspecified amount) CVD,36 41 98 overweight/obesity62 69 91 92
Avoid consumption of sugary foods and drinks between meals Dental caries22 65 74 92
Limit sugar intake Dental caries22 65 74 91 92
Milk and dairy products Eat low-fat versions of dairy products in preference to high-fat versions CVD,16 36 40 43 46 80 98 CHD24 66 101
Water, fruit juices, soft Avoid using sugary drinks in baby bottles Dental disease49 65 92
drinks, and hot drinks
Alcoholic drinks Limit intake of alcoholic drinks to two drinks for men and  CVD,22 36 40 44 46 77 97 CHD,31 73 75 88 96
one drink for women per day hypertension,31 46 56 62 91 stroke31 40 62 70 77 91
If drinking, do so only with meals Hypertension,56 62 91 stroke40 62 70 91
Food production, Limit/reduce intake of refined carbohydrates/grain products and foods CVD36 41 98
processing, preservation,
and preparation
Dietary constituents and Include fibre in the diet (unspecified amount) CVD36 69 98
supplements
Brush teeth with fluoride toothpaste twice daily Dental caries50 65 74
Ensure an adequate intake of vitamin D Osteoporosis22 48 59
Ensure an adequate intake of calcium Osteoporosis22 33 48 58 59 88
Dietary patterns Encourage exclusive breastfeeding for first 4–6 months Diarrhoea10 17 91
Women should breastfeed exclusively for 6 months Food intolerances in the infant27 79 91 92
Physical activity Be physically active CVD,30 34 40-42 44 CHD,64 75 88 91
osteoporosis23 59 88
Minimum of 30 minutes of moderate-intensity physical activity on  CVD16 22 34 36 40 43 45 57 62 68 78 80
most days of the week CHD22 35 64 73 96 97 101
type 2 diabetes22 30 31 57 62 69 76 89
hypertension16 56 57 62
overweight/obesity16 57 62 69
60 minutes of physical activity for children and adolescents on CVD16 41 62
most days of the week
Weight gain, overweight, Achieve/maintain a healthy weight (unspecified) Type 2 diabetes22 62 69 91
and obesity hypertension34 46 62 98
Achieve/maintain a BMI of 18.5–24.9 kg/m2 Stroke,38 40 62 hypertension46 56 91
If BMI is ≥25 kg/m2, lose weight CVD34 40 44 46 77 78
Achieve/maintain a waist circumference of no more than 35 inches (89 cm)  CVD34-36 40 43 44 78 89 98
for women and 40 inches (102 cm) for men 
BMI, body mass index; CHD, coronary heart disease; CVD, cardiovascular disease; LDL, low density lipoprotein
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10.6.3 Foods and drinks 
Cereals (grains), roots, tubers, and plantains. Six reports
recommended diets high in cereals (grains),15 20 29 90-92 with
some emphasising relatively unprocessed grains. One rec-
ommended 600–800 g/day of a variety of cereals (grains),
pulses (legumes), roots, tubers, and plantains, stating that
this is based more on the evidence for other chronic
diseases.15
Vegetables, fruits, pulses (legumes), nuts, seeds, herbs,
and spices. Nine reports recommended diets relatively high
in vegetables and fruits,15 20 22 29 65 67 83 90 91 with five speci-
fying five or more portions a day.15 22 29 67 83 One report rec-
ommended the consumption of five portions of vegetables
and two portions of fruits each day.91 Four reports recom-
mended diets relatively high in pulses (legumes).15 29 88 91
Meat, fish, and eggs. Five reports recommended limiting 
red meat15 20 22 29 83; two of these advised opting for lean
varieties.22 29 Three reports recommended that meat should
be baked, grilled (broiled), or poached rather than fried or
flame grilled (charbroiled).15 22 29 One recommended minimal
intake of smoked and cured meats.15 Four recommended
choosing poultry15 20 22 29 and fish.15 20 22 29 One recommend-
ed limiting Cantonese-style fermented salted fish.22
Fats and oils. Three reports recommended limiting total fat
intake: upper limits vary between 15 and 30 per cent,15
25 and 30 per cent,15 90 and 30 and 35 per cent.8 Two rec-
ommended restricting saturated fatty acid intake to 10 per
cent or less of total energy intake.8 67 One recommended lim-
iting animal fats,15 and another limiting linoleic acid.53
Salt and sugar. Two reports recommended that consumption
of salt, salty, and salted foods should be limited to a total
intake of less than 6 g of salt/day.15 22 Two reports recom-
mended limiting sugars and refined carbohydrates.15 29 One
of these advised limiting sugars to less than 10 per cent of
total energy intake.15
Water, fruit juices, soft drinks, and hot drinks. One report
recommended drinking plenty of water to prevent cancers
of the colon and rectum and bladder.91 Two reports recom-
mended limiting sugars and syrups from sources such as soft
drinks.15 29 Another recommended avoiding very hot and
scalding drinks.22
Alcoholic drinks. Six reports recommended limiting alco-
holic drinks.15 22 29 62 91 92 When an amount was specified, this
was usually a maximum of 1–2 drinks per day.
Food production, processing, preservation, and prepara-
tion. (Also see meat, fish, and eggs.) Two reports recom-
mended avoiding contaminants (in particular aflatoxins and
mycotoxins).15 22 One of these recommended that perishable
foods should be refrigerated.15
Dietary constituents and supplements. One report
recommended diets high in dietary fibre/non-starch poly-
saccharides.83 Another recommended 1000–1200 mg/day of
calcium to prevent colorectal cancer.90 Two stated that
dietary supplements are unnecessary and possibly even
harmful.15 83
10.6.4 Physical activity 
Ten reports recommended regular, sustained physical activ-
ity.15 20 22 29 62 67 83 88 90 91 Those that specify the intensity and
duration, recommend moderate physical activity for around
30–60 minutes per day. 
10.6.5 Growth, development, body composition
One report recommended that women should breastfeed
exclusively to prevent them from developing breast cancer
— ideally until the child is 6 months old.91
10.6.6  Weight gain, overweight, obesity
Five reports recommended maintaining a BMI of between
18.5 and 24.9.15 29 67 83 91 One of these advised that people
should not gain more than 5 kg during their adult life.15 One
report recommended avoiding energy-dense foods.29
10.6.7 Comparison of reports 
There is no substantial disagreement between any of these
reports. The Panel also notes the general consistency with its
own findings and recommendations.
10.7  Conclusions
The Panel concludes: 
We are impressed by the similarity of the conclusions and rec-
ommendations in all types of expert report reviewed here.
For reports that recommended diets high in cereals (grains)
(preferably relatively unrefined), and in vegetables and
fruits, and pulses (legumes), no conflicting recommendations
were found. These reports also include recommendations for
diets low in red and processed meats; and correspondingly
high in dietary fibre and micronutrients, including bioactive
microconstituents; and low in fats, saturated fatty acids,
added sugars, salt, and alcoholic drinks. 
We are also impressed by the consistency between reports
on deficiencies and infections that stress the vital importance
of extended, exclusive breastfeeding for the sake of the child;
and reports on chronic diseases that make the same recom-
mendation, for the sake of both children and mothers. We
are also impressed by the agreement of the reports on the
benefits of all forms of regular, sustained physical activity,
and the corresponding risks of sedentary ways of life.
Evidence on micronutrient supplements is less clear. We
consider this largely reflects the clinical needs of populations
vulnerable to deficiencies.  
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Research issues 
The evidence of causal relationships between food,
nutrition, physical activity, body composition, and
cancer is and always will be incomplete. New
methods of research, and new issues to study, are
always being developed. However, this ongoing
work does not mean that the response to every
question is ‘more research is needed’. The previous
chapters in this Report show that in many areas, the
evidence of causal relationships is already strong
enough to justify public health goals and personal
recommendations, which are specified in Chapter 12.
This chapter outlines future strategic research
directions that the Panel sees as especially promising
to build on this current base of knowledge.
In many areas, as shown in the matrices
introducing each section of Chapter 7, the evidence
may be suggestive but inconclusive. These particular
areas are those in which new efforts to answer
research questions may be most likely to result in
findings that can advance scientific knowledge or
change public health practice. The research directions
identified here are often cross-cutting and
interdisciplinary. These could increase understanding
of the cancer process, and provide new evidence to
clarify and strengthen the recommendations made in
Chapter 12.
There are also many fields of study that are only
now beginning to be explored. These include
exposures in early life including before birth that
affect birth weight, growth in childhood, age at
menarche, and attained adult height. They also
include interactions between food and nutrition and
other factors, notably smoking, inflammation, and
infectious agents. There is as yet relatively little
epidemiological research on broad patterns of diets,
and the inter-relationship between elements of
diets: more understanding here will enable
recommendations to be made with increasing
confidence. 
More needs to be known about the levels of
exposure that are critical as modifiers of cancer risk,
and the extent to which risk is decreased or
increased at different levels. In some areas,
understanding will be improved by general
agreement on the nature and definition of
exposures; examples include physical activity,
C H A P T E R  1 1
processed meat, and breastfeeding. 
Until recently, epidemiological and experimental
research studies were typically carried out
separately, and with different objectives. But to be
convincing, epidemiological evidence, however
consistent, needs to be supported by concrete
evidence of biological mechanisms. A promising
development is an increased tendency for
epidemiologists and basic scientists to work as team
members, to mutual benefit. Future research should
encourage this. 
One broad category of research, not reviewed for
this Report, concerns the underlying social
(including economic and political) and broad
environmental determinants of patterns of food,
nutrition, and physical activity. This area is also
critical to the successful translation of the
knowledge of the causes of cancer into improved
health. This crucially important aspect of research is
contained in a separate report dedicated to this
topic to be published in late 2008. 
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11.1  Principles
The principles applied when identifying the research
questions specified here are as follows: 
Interdisciplinary
The research directions discussed here are focused not on
issues that are specific to separate disciplines, such as
epidemiology or cancer biology, but on interdisciplinary
issues and questions that concern the relationships
between cancer and food, nutrition, physical activity, and
obesity.
Important 
The benefit of conducting more research where the
evidence is already convincing and well understood is
likely to be small. Research that investigates areas where
the evidence is unclear is likely to be of especial value.
Research is also of most value when the results have a
large potential impact on the overall burden of disease.
This may be because the exposure under consideration has
a potentially profound effect on cancer risk or because the
cancer site in question is particularly common. 
Innovative
Research questions need to be practical and yet innovative,
which implies that they should not be constrained by
conventional wisdom. More innovative research is needed.
Investigators should be imaginative and collaborate across
disciplines, and be willing to engage in research
programmes most likely to benefit public health. 
11.2  Research issues
How can the evidence for specific nutritional or
physical activity exposures in relation to cancer be
strengthened?
Exposures judged ‘probable’ or ‘limited — suggestive’ in
the matrices of this Report are most promising as a focus
of further research when evidence is scant. Examples of
such exposures include calcium and dairy products as
related to cancer of the prostate; vitamin D and cancer of
the colon; folate and cancers of the oesophagus,
pancreas, and colorectum; and selenium and cancers of
the lung, colorectum, and prostate. Those already judged
convincing, by their very nature, are less likely to be
influenced by new research. Also, people are increasingly
using non-traditional therapies, and these should also be
a topic for more systematic research. 
Study design options include pooling of prospective
data (especially for rarer cancers), longer follow-up of
existing cohorts, investigations with biomarker
measurements of intake and biomarker endpoints, and
new randomised controlled trials (RCTs).
For exposures where strong evidence exists of a causal
relationship, what are the effect sizes with respect to
timing, dose, and duration of exposure?
The evidence currently available for various exposures
and cancer risk is limited in terms of timing, dose,
duration, and size of effect. This kind of evidence is
important for healthcare providers and policy-makers to
make informed decisions on public health programmes,
and for people to make better-informed choices. 
Study design options include pooling of prospective
data (especially for less common cancers), longer follow-
up of existing cohorts, and obtaining more information
on early life dietary exposures. This research direction
applies to a number of the questions addressed in this
Report. For example, more information on timing, dose,
and duration of exposure is needed on the effects of body
size and fatness at different times of life in relation to
future risk of breast cancer and colorectal cancer; the
effects of timing, dose, and duration of use of alcohol and
breast cancer risk; and detailed dose-response
Research findings continue to accumulate. This evidence needs
to be identified, analysed, and interpreted. The World Cancer
Research Fund International, together with the American
Institute for Cancer Research, the organisations responsible for
commissioning this Report, have now commissioned a process
of continuous updating of the literature. This will be the basis
for periodic updates of this Report’s findings. The process will
continue to make use of systematic literature reviews and is
being overseen by an international expert steering group,
including members of the Panel responsible for this Report.
Box 11.1 Updating the evidence
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information on red meat and processed meat in relation
to colorectal and other cancers.
How do environmental and genetic factors modify the
effects of exposures on cancer risk?
Further investigation into the presence of effect
modification is needed to deepen understanding of risk
among different population groups and to help health
professionals and policy-makers provide more precise
recommendations. Factors that should be studied as
potential effect modifiers include tobacco, exogenous
hormones, medications (such as non-steroidal anti-
inflammatory drugs), metabolising genes, genes
associated with various cancers, and other food,
nutrition, and body composition exposures. 
What mechanisms link foods and drinks, dietary
constituents, or other nutritional and physical activity
factors to cancer risk?
There is general agreement that nutritional factors, body
composition, and physical activity are important
determinants of cancer risk. However, it has been difficult
to identify with confidence the precise pathways whereby
such exposures influence the process of cancer
development. Inevitably, the impact of nutrition will
ultimately be at the level of DNA and gene expression,
but the ways in which this occurs, either via genetic
mutation or epigenetic events, is only now beginning to
be explored. There are many nutritional factors for which
epidemiological data suggest that a relationship exists,
but where complete understanding of the biological
pathways is lacking. Examples include adiposity, physical
activity, height, red meat, processed meat, vegetables,
alcoholic drinks, lactation, arsenic, dairy products, and
whole grains. 
Dietary constituents that are especially favourable to
this type of mechanistic investigation include beta-
carotene, calcium, vitamin D, folate, selenium, polycyclic
aromatic hydrocarbons, and dietary fibre. Intermediate
biological mechanisms potentially relevant to mechanistic
understanding include inflammation, insulin resistance,
growth factors, oxidation, gut flora, hormonal changes,
and various cellular metabolic and molecular processes.
Such mechanisms may vary by the histopathological and
molecular characteristics of the tumours. Intermediate
markers may clarify questions of causation and serve as
surrogate endpoints for observational and intervention
studies. 
Study designs that may be useful to examine these
questions include human metabolic studies with cancer-
related endpoints and metabolic studies added onto
existing nutrient RCTs. Intermediate endpoints should be
incorporated into large, prospective, observational or
intervention studies to better understand their links to
both nutritional factors and cancer endpoints.
Increasingly with greater understanding of the interplay
of nutritional state and genetic expression, programmes
of study that incorporate elements of different disciplines
and technologies should illuminate the fundamental
processes underpinning diet–cancer links.
Which genetic polymorphisms and nutritional
exposures that influence gene expression are useful for
understanding the relationship between nutrition or
physical activity and cancer?
Certain genetic polymorphisms (genetic variants that
appear in at least 1 per cent of the population) may
increase, while others may decrease, the extent to which
nutritional factors affect cancer risk. Studying
gene–nutrient interactions is likely to yield better results
as technology allows the simultaneous examination of
multiple gene–nutrient interactions, and as better
systems evolve for synthesising the large amounts of data
that are generated by these newer techniques. 
Genetic make up can impact the extent to which our
bodies respond to nutritional factors. Also, genes express
themselves (or switch on) to varying degrees depending
on the nutritional environment. Understanding the extent
to which nutrients affect gene expression in such a way as
to impact on both cancer risk itself and the
nutrient/cancer risk relationship is very important.
Examples of gene–nutrient interactions include N-
acetyl transferase and meat. In certain cases, genetic
polymorphisms (for example, MTHFR 677 TT for low
folate intake and LCT — lactase persistence — for dairy
food intake) can act as proxies for nutritional exposures.
This can be examined using a Mendelian randomisation
study design, controlling for confounding factors. For
example, the effects of folate may be demonstrated by
looking at the differences in cancer outcome between
people who have the MTHFR gene variant that mimics
low folate intake (MTHFR 677 TT) and people who do
not. Carrying this form of the gene is unlikely to be
related to other potential confounding factors such as
smoking or socioeconomic status. 
Does weight loss in overweight or obese people reduce
cancer risk?
Body fatness and weight gain increase the risk of several
cancers. But the effects of weight loss on cancer risk are
poorly understood. Study design options for investigating
this question include model systems with caloric
restriction and weight loss, human metabolic studies with
intermediate endpoints, and cohort studies with explicit
inquiries about intentional weight loss.
What are the relevant milestones in the timing of growth
and development that affect cancer risk and how can
they be modified by food, nutrition, and physical activity?
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Critical periods for exposure to factors that lead to
increased cancer risk during the life course should be
identified. For example, high birth weight and rapid
growth in height during adolescence are both associated
with an increased risk of breast cancer. Some countries
have extensive child and adolescent growth data that can
be examined in relation to cancer outcomes using
registries. 
How can factors related to food production, processing,
preservation, and cooking methods, which may affect
cancer risk, best be studied in humans? 
Current methods used to produce food are changing faster
than at any other point in history. It is most important to
understand how old and new methods might affect the
risk of cancer. In addition to changes in agricultural
practices, both rapid urbanisation and economic
globalisation have transformed food systems. Methods
used to evaluate the changes in cancer risk that might be
tied to these new patterns need to be developed. Relevant
factors may include exogenous hormone administration in
the production of meat, production of heterocyclic amines
and polycyclic aromatic hydrocarbons by high-temperature
cooking, use of food additives, use of pesticides, novel
processing methods, and storage conditions. 
How do food, nutrition, body composition, and 
physical activity affect outcomes in cancer survivors? 
The extent to which cancer survivors are similar to or
different from people without cancer, in terms of the
extent to which their cancer risk is sensitive to changes in
diet, body composition, and physical activity, needs to be
investigated. 
A number of further questions arise:
• Are any effects of food, nutrition, and physical activity
additive? 
• Are the type and the progression of the cancer
important in this regard? 
• Is the extent to which cancer survivors have had
exposure to chemotherapeutic or radiological
treatment important? 
There are two broad contexts for these questions: do diet,
nutrition, or physical activity before diagnosis affect
outcome after treatment? And do changes in these after
diagnosis and treatment affect outcome? 
In addition to RCTs among survivors, existing cohort
studies can examine some of these questions since there
are now fairly large numbers of cancer survivors in some
cohorts. Pooling of the data from these studies could be
valuable. Good information on clinical–pathological
factors and treatments is necessary in observational
studies because these potentially confounding factors
affect cancer prognosis and may be related to nutritional
exposures. 
How do relationships between food, nutrition, and
physical activity and cancer risk differ in various parts
of the world?
In areas of the world where patterns of cancer and
patterns of diet are different, the relationship between
nutrition and cancer risk can also vary. For example, in
middle- and low-income countries, the inverse relation
between body mass and premenopausal breast cancer is
usually not seen. It could be that there are factors such as
genes, body composition, or physical activity that modify
the effect of body mass on cancer risk in some
populations. 
How can measures of food, nutrition, physical activity,
and body composition, as they relate to cancer risk, be
improved?
Better ways of characterising and measuring the short-
and long-term exposures most relevant to determining
cancer risk are needed. These may include incorporating
new instruments in prospective studies, whether internet-
based or telephone-based recalls, dietary records, with, if
possible, strong validation studies using biomarkers. Also,
additional development of intake biomarkers, where
feasible, and their incorporation in large prospective
studies would be helpful. 
Finally, expanded investigation of dietary indexes and
patterns, which have the potential to capture the effect of
multiple, interconnected dietary factors, may further
enhance our understanding of nutrition and cancer.
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The culmination of the five-year process resulting in this Report is Chapter 12, in
which the Panel’s public health goals and personal recommendations are
specified. These are preceded by a statement of the principles that have guided
the Panel in its thinking. 
The goals and recommendations are based on judgements made by the Panel in
Part 2, as shown in the introductory matrices. Such judgements are of a
‘convincing’ or ‘probable’ causal effect, either of decreased or increased risk. 
Judgements of ‘convincing’ or ‘probable’ generally justify goals and
recommendations. These are proposed as the basis for public policies and for
personal choices that, if effectively implemented, will be expected to reduce the
incidence of cancer for people, families, and communities.
Eight general and two special goals and recommendations are specified. In each
case a general recommendation is followed by public health goals and personal
recommendations, together with footnotes when further explanation or
clarification is required. These are all shown in boxed text. The accompanying
text includes a summary of the evidence; justification of the goals and
recommendations; and guidance on how to achieve them. 
Reliable judgements are carefully derived from good evidence. But specific
public health and personal goals and recommendations do not automatically
follow from the evidence, however strong and consistent. The process of moving
from evidence to judgements and to recommendations has been one of the
Panel’s main responsibilities, and has involved much discussion and debate until
final agreement has been reached. The goals and recommendations here have
been unanimously agreed. 
Food, nutrition, body composition, and physical activity also affect the risk of
diseases other than cancer. Informed by the findings of other reports
summarised in Chapter 10, the goals and recommendations have therefore been
agreed with an awareness of their wider public health implications.
The goals and recommendations are followed by the Panel’s conclusions on the
dietary patterns most likely to protect against cancer. As conventionally
undertaken, epidemiological and experimental studies are usually sharply
focused. In order to discern the ‘big picture’ of healthy and protective diets, it is
necessary to integrate a vast amount of detailed information. This also has been
part of the Panel’s task. 
The main focus of this Report is on nutritional and other biological and
associated factors that modify the risk of cancer. The Panel is aware that, as with
other diseases, the risk of cancer is critically influenced by social, cultural,
economic, and ecological factors. Thus the foods and drinks that people consume
are not purely because of personal choice; often opportunities to access
adequate food or to undertake physical activity can be constrained, either for
reasons of ill health or geography, economics, or equally powerfully, by culture.
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There is a limit to what can be achieved by individuals, families, communities,
and health professionals.  
Identifying not only the nutritional and associated factors that affect the risk of
cancer but also the deeper factors enables a wider range of policy
recommendations and options to be identified. This is the subject of a separate
report to be published in late 2008. 
The members of the Panel and supporting secretariat, and the executives of the
WCRF global network responsible for commissioning this Report, have been
constantly reminded of the importance of their work during its five-year
duration. The public health goals and personal recommendations of the Panel
that follow are offered as a significant contribution towards the prevention and
control of cancer throughout the world. 
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This Report is concerned with food, nutrition,
physical activity, body composition, and the
prevention of cancer, worldwide. Chapter 12 is the
culmination of the Report. It explains the principles
that guide the Panel’s decisions; lists and explains
the Panel’s recommendations to prevent cancer; and
identifies appropriate dietary patterns. The
recommendations are in the form of a series of
general statements; public health goals designed to
be used by health professionals; and
recommendations for people — as communities,
families, and individuals — who can also be guided
by the goals. Footnotes are included when needed
for further explanation or clarity. 
Most cancer is preventable. The risk of cancers is
often influenced by inherited factors. Nevertheless,
it is generally agreed that the two main ways to
reduce the risk of cancer are achievable by most
well informed people, if they have the necessary
resources. These are not to smoke tobacco and to
avoid exposure to tobacco smoke; and to consume
healthy diets and be physically active, and to
maintain a healthy weight. Other factors, in
particular infectious agents, and also radiation,
industrial chemicals, and medication, affect the risk
of some cancers. 
The Panel notes that previous reports have
attributed roughly one third of the world’s cancer
burden to smoking and exposure to tobacco, and
roughly another one third to a combination of
inappropriate food and nutrition, physical
inactivity, and overweight and obesity. By their
nature, these estimates are approximations, but the
Panel judges that avoidance of tobacco in any form,
together with appropriate food and nutrition,
physical activity, and body composition, have the
potential over time to reduce much and perhaps
most of the global burden of cancer. This is in the
context of general current trends towards
decreased physical activity and increased body
fatness, and projections of an increasing and ageing
global population. 
The recommendations here are derived from the
evidence summarised and judged in Part 2 of this
Report. They have also taken into account relevant
dietary and associated recommendations made in
other reports commissioned by United Nations
agencies and other authoritative international and
national organisations, designed to promote
nutritional adequacy and prevent cardiovascular
and other chronic diseases. They therefore
contribute to diets that are generally protective,
and that also provide adequate energy and
nutrients. The recommendations can therefore be
the basis for policies, programmes, and choices that
should prevent cancer, and also protect against
deficiency diseases, infections especially of early
life, and other chronic diseases. 
Throughout its work, the Panel has also been
conscious that enjoyment of food and drink is a
central part of family and social life, and that food
systems that generate adequate, varied, and
delicious diets are one central part of human
civilisation. From the cultural and culinary, as well
as the nutritional point of view, the
recommendations here amount to diets similar to
cuisines already well established and enjoyed in
many parts of the world. 
Public health goals and
personal recommendations
C H A P T E R  1 2
369
C H A P T E R  1 2  •  P U B L I C  H E A L T H  G O A L S  A N D  P E R S O N A L  R E C O M M E N D A T I O N S
activity is most appropriate and enjoyable depends on indi-
vidual abilities and preferences, as well as the settings in
which populations, communities, families, and individuals
live.
The Panel has taken the same approach in considering the
recommendations altogether. As a whole, the recommen-
dations contribute to whole diets and overall levels of phys-
ical activity most likely to prevent cancer. This does not
imply one particular diet, or a specific form of physical activ-
ity, but rather key elements designed to be incorporated into
existing and traditional diets and ways of life around the
world. This is emphasised in section 12.3 of this chapter, on
patterns of food, nutrition, and physical activity.
12.1.3  Global 
This Report has a global perspective. It is therefore appro-
priate that the recommendations here are for people and
populations all over the world; that they apply to people
irrespective of their state of health or their susceptibility to
cancer; and that they include cancer survivors. 
Some factors that modify the risk of cancer are more com-
mon, and so of more concern, in some parts of the world
than others. It is possible that such factors might become
more widespread, but the recommendations on them in this
Report are in the context of their current local importance.
Just as people’s susceptibility to cancer varies, so will the
extent to which they will benefit from following these rec-
ommendations, though most people can expect to benefit
to some extent from each of them. 
Recommendations for whole populations are usually now
identified as also being of importance for people who, while
not being clinically symptomatic, have known risk factors
for disease. People at higher risk of various cancers include
smokers and people regularly exposed to tobacco smoke;
people infected with specific micro-organisms; overweight
and obese people; sedentary people; people with high
intakes of alcoholic drinks; people who are immunosup-
pressed; and those with a family history of cancer. Such peo-
ple are often at higher risk of diseases other than cancer.
The Panel agrees that the recommendations here apply to
these people. 
They also apply to cancer survivors, meaning people liv-
ing with a diagnosis of cancer, including those identified as
having recovered from cancer (see Chapter 9). This is sub-
ject to important qualifications, stated in the special rec-
ommendations for this group of people.
The recommendations presented in this chapter are
designed as the basis for policies, programmes, and
personal choices to reduce the incidence of cancer in
general. These are guided by a number of separate
principles and also by one overall principle, which is, 
that taken together, the recommendations provide an
integrated approach to establishing healthy patterns of
diet and physical activity, and healthy ways of life. 
In order to be useful both for health professionals who
advise on cancer, and for people who are interested in
reducing their own risk of cancer, the recommendations
are quantified wherever possible and appropriate. 
See box 12.1.
12.1.1  Integrated
The Panel, in making its recommendations, has been con-
cerned to ensure that most people in most situations
throughout the world will be able to follow its advice. The
recommendations are framed to emphasise aspects of food
and nutrition, physical activity, and body composition that
protect against cancer. They are also integrated with exist-
ing advice on promoting healthy ways of life, such as that
to prevent other diseases. At the same time, the Panel has
given special attention to making recommendations that can
form the basis for rational policies, effective programmes,
and healthy personal choices. 
12.1.2  Broad based
In assessing the evidence, making its judgements, and in
framing its recommendations, the Panel has, where appro-
priate, chosen to take a broad view. It has also agreed to base
its advice on foods and whole diets rather than on specific
nutrients. Thus, recommendations 4 and 5 concern plant
foods and animal foods in general, while their specific pub-
lic health goals and personal recommendations are mostly
concerned with vegetables and fruits, and then with red
meat and processed meat, where the evidence on cancer is
strongest. 
The same applies to physical activity. The evidence shows
that all types and degrees of physical activity protect or
probably protect against some common cancers. Recom-
mendation 2 therefore does not specify any particular phys-
ical activity (of which sport and exercise are 
one type). Rather, it recommends sustained physical activi-
ty as part of active ways of life. What type of physical 
12.1 Principles 
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12.1.4  Cancer in general
This Report is concerned with the prevention of cancer in
general. Evidence for particular cancer sites provided the
building blocks. A key task for the Panel was to take this spe-
cific evidence and formulate recommendations that would,
in general, lead to a lower burden from cancer regardless 
of site. 
This broad approach is appropriate from the public health
point of view. International agencies, national governments,
other policy-makers, health professionals, and people with-
in communities and families, and also as individuals, want
to know how to prevent cancer in general.
12.1.5  Designed to have major impact
Every case of cancer is important. But the responsibility of
those concerned with public health is to encourage policies,
programmes, and choices that will have the greatest impact. 
For this reason, the Panel has paid special attention to the
more common cancers; cancers where there is the most clear-
cut evidence of modification of risk by food, nutrition, phys-
ical activity, and body composition; and cancers that may
most readily be prevented by achievable recommendations.
Special attention has also been paid to those aspects of food
and nutrition, physical activity, and body composition that
seem most likely to prevent cancers of a number of sites. 
This matrix displays the Panel’s most confident judgements on the strength of the evidence causally relating food, nutrition, and physical
activity to the risk of cancer. It is a synthesis of all the matrices introducing the text of Chapters 4, 5, 6, 7, and 8 of this Report, but shows
only judgements of ‘convincing’ and ‘probable’, on which the following recommendations are based. It does not show a detailed
breakdown of the individual foods, drinks, and their constituents. The full matrix, which also includes judgements of ‘limited —
suggestive’, is on the fold-out section, which can be found inside the back cover of this Report.
In this matrix, the columns correspond to the cancer sites that are the subject of Chapter 7 and body fatness that is the subject of 
Chapter 8. The rows correspond to factors that the Panel judges to be ‘convincing’ or ‘probable’, either as protective against or causative
of cancer of the sites specified, or of weight gain, overweight, or obesity. Such judgements usually justify public health goals and
personal recommendations. The strength of the evidence is shown by the height of the blocks in this matrix — see the key. 
FOOD, NUTRITION, PHYSICAL ACTIVITY, AND THE PREVENTION OF CANCER 
OVERVIEW OF THE PANEL’S KEY JUDGEMENTS
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Summary of ‘convincing’ and ‘probable’ judgements
4 Evidence is from milk and studies using 
supplements for colorectum
5 Includes 'fast foods'
6 Convincing harm for men and probable harm for 
women for colorectum
7 The evidence is derived from studies using 
supplements for lung
8 Includes evidence on televison viewing
9 Judgement for physical activity applies to colon 
and not rectum
1 Includes evidence on foods containing 
carotenoids for mouth, pharynx, larynx; foods 
containing beta-carotene for oesophagus; foods
containing vitamin C for oesophagus
2 Includes evidence on foods containing 
carotenoids for mouth, pharynx, larynx and 
lung; foods containing beta-carotene for 
oesophagus; foods containing vitamin C for 
oesophagus
3 Includes evidence from supplements for 
prostate
371
C H A P T E R  1 2  •  P U B L I C  H E A L T H  G O A L S  A N D  P E R S O N A L  R E C O M M E N D A T I O N S
12.1.6  Prevention of other diseases taken into
account 
Chapter 10 of this Report is based on a systematic review of
secondary sources — other reports — on other diseases where
the risk is modified by food and nutrition and related factors.
These diseases are nutritional deficiencies; relevant infectious
diseases, especially diarrhoea and respiratory infections of
early childhood; and chronic diseases other than cancer.
As stated above, the recommendations here are designed
to prevent cancer as a whole. For similar reasons of public
health, the Panel, in considering and judging the secondary
evidence presented in Chapter 10, has made sure that the
recommendations here take the prevention of other diseases
into account. 
Often recommendations to prevent cancer are much the
same as recommendations to control or prevent other
diseases. When this is evidently so, the Panel has stated 
that its recommendations are supported or reinforced.
Occasionally, recommendations to prevent other diseases
include factors that evidently do not apply to cancer: for
example, saturated fatty acids, contained mostly in animal
foods, are accepted to be a cause of coronary heart disease,
but have no special relevance to the risk of cancer. 
There are also some cases where recommendations to pre-
vent other diseases conflict, or seem to conflict, with those
for cancer. One example is alcoholic drinks. While no report
on cardiovascular disease has ever recommended consump-
tion of alcoholic drinks, low levels of consumption of alco-
holic drinks are likely to protect against coronary heart
disease; whereas there is no evidence that alcoholic drinks
at any level of consumption have any benefit for any can-
cer. In cases like this, the Panel’s recommendations may be
modified to take such a conflict into account; this is clearly
indicated in the recommendations. 
Public health professionals who advise on
preventing cancer, including those respon-
sible for planning food supplies or exercise
programmes (for example, for schools, hos-
pitals, or canteens), or those working in
clinical settings, need to be able to give spe-
cific, actionable, and relevant advice that
includes prevention of cancer. 
To do this they need to know how much
of what foods and drinks, what levels of
body fatness, and how much physical activ-
ity are most likely to protect against cancer.
So do people in general, as members of
communities and families, as well as indi-
viduals. For these reasons, the personal 
and public health goals in each of the rec-
ommendations are quantified wherever
possible. 
Translation of an overall body of current
evidence into quantified recommendations
is a challenge for all expert panels respon-
sible for recommendations designed to
guide public policy, and professional and
personal decisions. This process is not and
cannot be ‘an exact science’. Within any
population, people differ from one anoth-
er, and there are differences between pop-
ulations as well. A single, numerical
recommendation is not able to encompass
these differing needs and so will necessar-
ily be imprecise. 
Furthermore, the evidence rarely shows
a clear point above or below which risk
changes suddenly. Rather, there is usually a
continuous relationship between the expo-
sure, be it body fatness, physical activity, or
level of consumption of a food or drink,
and cancer risk. The shape of this ‘dose
response’ may vary — sometimes it is a
straight line, or it may be curved, for
instance J-shaped or U-shaped. All of these
factors need to be taken into account. The
quantified recommendations are therefore
based on the evidence but are also a mat-
ter of judgement.
For example, the evidence on alcoholic
drinks and breast cancer, as shown in chap-
ters 4.8 and 7.10, does not show any ‘safe
threshold’. The risk evidently increases,
albeit modestly, at any level of intake of
any alcoholic drink. And there is no nutri-
tional need to consume alcohol. So in this
case, the appropriate recommendation
based solely on the evidence for breast can-
cer would be not to consume alcoholic
drinks; the quantified recommendation
would be zero. 
However, the integrated approach that
guides these recommendations means that
the Panel has taken into account evidence
for a likely protective effect of modest
amounts of alcohol against coronary heart
disease, and has not made this recommen-
dation based only on the evidence for can-
cer (see recommendation 6).
In addition, in some cases, there is evi-
dence for adverse effects unrelated to can-
cer risk that might help to quantify
recommendations. Physical activity is a case
in point. The evidence, as shown in
Chapters 5 and 7, shows that high levels of
all types of physical activity protect or may
protect against some cancers, and also that
low levels increase the risk of these cancers.
But there is also evidence (not derived from
the systematic literature reviews), that
above certain high levels, which vary
depending on people’s general state of fit-
ness, physical activity can provoke an unde-
sirable inflammatory response. 
The Panel also used such an approach in
considering the minimum limit for healthy
body mass index, which does not derive
from the evidence on cancer. The implica-
tion is that upper as well as lower limits
may need to be recommended. 
These quantified recommendations are
also guided by the ranges of foods and
drinks, physical activity, and body composi-
tion identified in the studies whose results,
taken together, form the basis for the
Panel’s judgements. High and low limits can
be set by simply following the ranges in the
studies themselves, mostly cohort studies.
The case for doing this is quite strong;
this prospective evidence provides a robust
basis for defining the dose response. On the
other hand, many studies have been carried
out among populations who have only a
rather narrow range of dietary intakes, lev-
els of physical activity, and degree of body
fatness, which makes detection of associa-
tions difficult. Further, these ranges may
not themselves be optimal, and this makes
it difficult to define what is healthy. In such
cases, a recommended range based only on
the results of such studies would be flawed.
Ecological studies, which often address a
much wider range of intakes, were also
part of this review and, though not central
to the judgement of causality, nevertheless
inform the quantification of the recom-
mendations. 
As well as considering the evidence from
studies on cancer, the Panel, in common
with others, has also used its collective
knowledge of other relevant considerations
in making the quantified recommendations
in this chapter. It has also taken into
account the ranges of intake of foods and
drinks, and the ranges of advisable body
composition and physical activity recom-
mended in other reports.
Box 12.1 Quantification
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12.1.7  Challenging 
The Panel emphasises that food and life should be enjoyed.
The Panel recognises that for many people, these recommen-
dations will involve change. People tend to enjoy ways of life
that they have become used to. However, when they change,
people often enjoy their new ways of life as much or more.
The Panel is aware of the importance of aspirational goals
and recommendations. To achieve substantial public and per-
sonal health gain, some of these need to be challenging. 
For many populations and people, especially in industri-
alised or urban settings, achieving all of these recommen-
dations will not be easy. Levels of physical activity within
societies that are basically sedentary, and energy density of
diets, are often well outside the ranges recommended here.
But the Panel believes that populations and people who
achieve these recommendations will not only reduce their
risk of cancer, as well as of other diseases, but are also like-
ly to improve their positive health and well-being.
Sometimes it may take time for people to achieve
changes. The Panel has taken this into account when
applying the evidence to framing these recommendations.
See box 12.2. 
Some people will not be able to follow some or all of these
recommendations because of their situation or circum-
stances. For such people, the recommendations as stated here
may be unattainable, but working towards them will also
reduce the risk of cancer, although to a lesser degree.
The evidence reviewed by the Panel more often than not does
not show thresholds of food and drink consumption, body fat-
ness, or physical activity below or above which the risk of can-
cer suddenly changes. In such cases, any change in the exposure
would be expected to lead to a change in cancer risk, whatev-
er the starting level, and no single point lends itself to being an
obvious recommended level. Recommendations might then sim-
ply state ‘the less the better’ or ‘the more the better’. However,
while that would be faithful to the evidence, it is less helpful
for people trying to implement change — the question arises
of how much more or less, or of what level should be a target. 
These judgements take account of several factors — the range
of foods and drinks consumed, the level of physical activity or
degree of body fatness found in the studies reviewed, or the
possibility of adverse effects at particularly high or low levels,
but also the precise nature of the relationship between them
and the risk of cancer. In some cases, this may be a relatively
straight line, in others it may be curved, for instance either U-
shaped or J-shaped. Therefore the Panel has chosen to make
quantified recommendations that in its judgement would result
in a real health gain, and are achievable yet challenging.
However, it would be wrong to interpret this as meaning that
any movement towards them, but which did not reach them,
was valueless. On the contrary, these recommendations should
act as a spur to change of any amount. While it is true that a
smaller change than recommended would lead to less reduction
in risk, any change at all would nevertheless provide at least
some benefit. 
A perceived inability to achieve the targets should not be a
disincentive to making changes to move in that direction. So a
change from eating two portions of vegetables daily to three,
or a reduction in body mass index from 29 to 27, while not meet-
ing the goals, would nevertheless be valuable.
Box 12.2 Making gradual changes
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The Panel’s goals and recommendations, the culmination
of five years of work, are guided by the principles above.
They are based on the best available evidence, which has
been identified, collected, analysed, displayed,
summarised, and judged systematically, transparently, and
independently. The public health goals are for populations
and are therefore principally for health professionals; the
recommendations are for people, as communities,
families, and individuals. The eight general
recommendations are followed by two special
recommendations. Together they are designed to be
integrated and to contribute to healthy dietary patterns,
healthy ways of life, and general well-being.
The Panel emphasises that the setting of recommendations is
not and cannot be ‘an exact science’. Recommendations
derive from judgements based on the best evidence but that
evidence and those judgements may still not be such that
only one possible recommendation would follow. Several
aspects of recommendations designed to improve health can
be questioned. The Panel believes nevertheless that its rec-
ommendations are as firmly based as the science currently
allows, and therefore represent a sound base for developing
policy and action. 
The 10 recommendations here derive from the evidence
on food, nutrition, and physical activity but not on their
wider socioeconomic, cultural, and other determinants. The
Panel is aware that patterns of diet and physical activity, as
well as the risk of diseases such as cancer, are also crucial-
ly influenced by social and environmental factors. These
broader factors, and recommendations designed as the basis
for policies and programmes that can create healthier soci-
eties and environments, are the subject of a further report
to be published in late 2008. 
The Panel has agreed that its recommendations normally
derive from evidence that justifies judgements of ‘convinc-
ing’ and ‘probable’, as shown in the top halves of the matri-
ces in the chapters and sections of Part 2. This means that
the evidence is sufficiently strong to make recommendations
designed as the basis for public health policies and
programmes. Therefore judgements that evidence is ‘limit-
ed — suggestive’ do not normally form the basis for recom-
mendations. 
As shown in the following pages, the goals and recom-
mendations themselves are boxed. They begin with a gen-
eral statement. This is followed by the public health goals
and the personal recommendations, together with any nec-
essary footnotes. These footnotes are an integral part of the
recommendations. The boxed texts are followed by passages
summarising the relevant judgements made by the Panel.
Then the specifications made in the public health goals and
personal recommendations are explained. This is followed by
passages of further clarification and qualification as neces-
sary: in special circumstances, the points made here are also
integral to the recommendations. Finally, guides showing
how people can sustain the recommendations are included.
The public health goals are for populations and so are pri-
marily for health professionals, and are quantified where
appropriate. ‘Population’ includes the world population,
national populations, and population groups such as school-
children, hospital patients, and staff who eat in canteens,
generally or in specific settings. The personal recommenda-
tions are for people as communities, families, and as indi-
viduals. This allows for the fact that decisions on the choice
of foods and drinks are often taken communally or within
families, or by the family members responsible for buying
and preparing meals and food, as well as by individuals.
Personal recommendations are best followed in conjunction
with public health goals. For example, the recommendation
that people walk briskly for at least 30 minutes every day is
RECOMMENDATIONS
BODY FATNESS
Be as lean as possible within the 
normal range of body weight
PHYSICAL ACTIVITY
Be physically active as part of everyday life
FOODS AND DRINKS THAT PROMOTE WEIGHT GAIN
Limit consumption of energy-dense foods
Avoid sugary drinks
PLANT FOODS
Eat mostly foods of plant origin
ANIMAL FOODS
Limit intake of red meat and avoid processed meat
ALCOHOLIC DRINKS
Limit alcoholic drinks
PRESERVATION, PROCESSING, PREPARATION
Limit consumption of salt
Avoid mouldy cereals (grains) or pulses (legumes)
DIETARY SUPPLEMENTS
Aim to meet nutritional needs through diet alone
BREASTFEEDING
Mothers to breastfeed; children to be breastfed
CANCER SURVIVORS
Follow the recommendations for cancer prevention
12.2 Goals and recommendations
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to enable them to increase their average physical activity
level (PAL) by about 0.1. 
The Panel concludes that the evidence that high body fat-
ness and also physical inactivity are causes of a number of
cancers, including common cancers, is particularly strong.
For this reason, the first three sets of goals and recommen-
dations are designed as a basis for policies, programmes, and
choices whose purpose is to maintain healthy body weights
and to sustain physical activity, throughout life. The remain-
ing five general recommendations are not in any order of pri-
ority; instead, they follow the order that their subjects
appear in the chapters in Part 2. After the eight general rec-
ommendations, there are two special recommendations, one
on breastfeeding and one for cancer survivors, that are tar-
geted at specific groups of people. 
These goals and recommendations are concerned with
food and nutrition, physical activity, and body fatness. Other
factors that modify the risk of cancer outside the remit of
this Report, such as smoking, infectious agents, radiation,
industrial chemicals, and medication, are specified in
Chapter 2 and throughout Chapter 7. 
The Panel emphasises the importance of not smoking and
of avoiding exposure to tobacco smoke.
RECOMMENDATION  1
BODY FATNESS
Be as lean as possible within 
the normal range1 of body weight
PUBLIC HEALTH GOALS
Median adult body mass index (BMI) to be 
between 21 and 23, depending on the 
normal range for different populations2
The proportion of the population that is overweight 
or obese to be no more than the current level, 
or preferably lower, in 10 years
PERSONAL RECOMMENDATIONS
Ensure that body weight through 
childhood and adolescent growth projects3 towards the
lower end of the normal BMI range at age 21
Maintain body weight within 
the normal range from age 21
Avoid weight gain and increases in 
waist circumference throughout adulthood
1 ‘Normal range’ refers to appropriate ranges issued by national governments or
the World Health Organization 
2 To minimise the proportion of the population outside the normal range
3 ‘Projects’ in this context means following a pattern of growth (weight and
height) throughout childhood that leads to adult BMI at the lower end of the
normal range. Such patterns of growth are specified in International Obesity
Task Force and WHO growth reference charts
Evidence
The evidence that overweight and obesity increase the risk
of a number of cancers is now even more impressive than
in the mid-1990s. Since that time, rates of overweight and
obesity, in adults as well as in children, have greatly
increased in most countries. 
The evidence that greater body fatness is a cause of cancers
of the colorectum, oesophagus (adenocarcinoma), endo-
metrium, pancreas, kidney, and breast (postmenopause) is
convincing. It is a probable cause of cancer of the gallblad-
der. Body fatness probably protects against premenopausal
breast cancer, but increases the risk of breast cancer overall.
This is because postmenopausal breast cancer is more com-
mon. The evidence that abdominal (central) fatness is a
cause of cancer of the colorectum is convincing; and it is a
probable cause of cancers of the pancreas and endometrium,
and of postmenopausal breast cancer. Adult weight gain is
a probable cause of postmenopausal breast cancer. Greater
birth weight is a probable cause of premenopausal breast
cancer. Also see Chapters 6 and 7. 
The evidence that the factors that lead to greater adult attained
height, or its consequences, increase the risk of cancers of the
colorectum and breast (postmenopause) is convincing; and they
probably also increase the risk of cancers of the pancreas, breast
(premenopause) and ovary. In addition, the factors that lead to
greater birth weight, or its consequences, are probably a cause
of premenopausal breast cancer. Also see chapter 6. 
The Panel has agreed that height and birth weight are them-
selves unlikely directly to modify the risk of cancer. They are
markers for genetic, environmental, hormonal, and nutritional
factors affecting growth during the period from preconception
to completion of linear growth. However, the precise mecha-
nisms by which they operate are currently unclear. In addition,
they are known to have different associations with other chron-
ic diseases such as cardiovascular disease. For these reasons, they
are not the subject of recommendations in this chapter. 
Understanding the factors that influence growth, and how
they might modify the risk of cancer and other chronic diseases,
is an important question for future research, including the rel-
ative importance of genetic and environmental factors, and
when in the life course nutritional factors might be most rele-
vant. Identifying optimal growth trajectories that protect
health not only in childhood but also throughout life is a major
challenge for the research and public health communities.
Greater birth weight, and adult attained height
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Justification
Maintenance of a healthy weight throughout life may be one
of the most important ways to protect against cancer. This
will also protect against a number of other common chron-
ic diseases. 
Weight gain, overweight, and obesity are now generally
much more common than in the 1980s and 1990s. Rates of
overweight and obesity doubled in many high-income coun-
tries between 1990 and 2005. In most countries in Asia and
Latin America, and some in Africa, chronic diseases includ-
ing obesity are now more prevalent than nutritional defi-
ciencies and infectious diseases. 
Being overweight or obese increases the risk of some can-
cers. Overweight and obesity also increase the risk of condi-
tions including dyslipidaemia, hypertension and stroke, type
2 diabetes, and coronary heart disease. Overweight in child-
hood and early life is liable to be followed by overweight and
obesity in adulthood. Further details of evidence and judge-
ments can be found in Chapters 6 and 8. Maintenance of a
healthy weight throughout life may be one of the most
important ways to protect against cancer.
Public health goals 
The points here are additional to those made in the footnotes
to the goals above. 
Median adult BMI for different populations to 
be between 21 and 23, depending on the normal range
To date, the range of normal weight has been usually iden-
tified as a BMI between 18.5 and 24.9; overweight and obe-
sity has been identified as a BMI of 25 or over 30, respectively.
However, the evidence that is the basis for this Report does
not show any threshold at a BMI of 25. The relationship
between BMI and risk of disease varies between different pop-
ulations (see chapter 8.4), and so the median population BMI
that accompanies lowest risk will vary. The Panel therefore rec-
ommends that the population median lies between 21 and 23,
which allows for this variation. Within any population, the
range of individual BMIs will vary around this.
The proportion of the population that is overweight or
obese to be no more than the current level,
or preferably lower, in 10 years
The context for this goal, which like the others specified here
is designed as a guide for national and other population poli-
cies, is the current general rapid rise in overweight and obe-
sity. The goal proposes a time-frame. Policy-makers are
encouraged to frame specific goals according to their own
circumstances. The implications of the goal for countries
where there is a current increasing trend are that over the
10-year period, the increase would stop, and then rates of
overweight and obesity would begin to drop. 
While it is clear that obesity itself is a cause of some can-
cers and of other diseases, it is also a marker for dietary and
physical activity patterns that independently lead to poor
health.
In the chart above, a BMI between 18.5 and 25 is highlighted.
A BMI between 18.5 and 25 has conventionally been regard-
ed as normal or healthy. BMIs under 18.5 represent under-
weight, which is unhealthy; BMIs between 25 and 30 are called
overweight; BMIs over 30 are called obesity; and BMIs over 40
are designated as extremely (morbidly) obese.
However, different cut-off points for overweight and obe-
sity have been agreed in some countries; these cut-offs usual-
ly specify overweight at BMI less than 25, and obesity at BMI
less than 30. Such specifications should be used for and by peo-
ple living in those countries. These are shown in dotted lines.
BMI is calculated using weight and height. Using the graph
above, a person who is 170 cm tall and weighs 68 kg has a BMI
within the normal range. To calculate BMI, divide weight (kg)
by height (m) squared. Therefore, a person who is 1.7 m tall
and who weighs 68 kg has a BMI of 23.5. 
It should be noted that BMI should be interpreted with cau-
tion, as in some cases it may be misleading, for instance in mus-
cular people such as manual workers and some athletes, and
older people, children, or people less than 5 feet tall (152 cm).
Box 12.3 Height, weight, and ranges of
body mass index (BMI)
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Personal recommendations 
The points here are additional to those made in the footnotes
to the recommendations above. 
Ensure that body weight through childhood and
adolescent growth projects towards the lower end of the
normal BMI range at age 21
Maintain body weight within 
the normal range from age 21
These two related recommendations emphasise the impor-
tance of prevention of excess weight gain, overweight, and
obesity, beginning in early life — indeed, in infancy and
childhood. As stated, the normal range of BMI is within 18.5
to 25, with some variation between countries; where the
agreed range is different this should be used as the guide.
See box 12.3. 
These recommendations do not mean that all healthy peo-
ple within the normal range of BMI need necessarily aim to
lower their BMI. However, people who have gained weight,
even within the normal range, are advised to aim to return
to their original weight. 
People above the normal range of BMI are recommended
to lose weight to approach the normal range. See ‘Guidance’
and also recommendations 2 and 3.
Avoid weight gain and increases in 
waist circumference throughout adulthood
There may be specific adverse effects from gaining weight
during adulthood (see chapter 6.1.1.3), and so maintenance
of weight within the normal range throughout adult life is
recommended.
The World Health Organization reference values for waist
circumferences of 94 cm (37 inches) in men and 80 cm (31.5
inches) in women (on a population basis) are based on their
rough equivalence to a BMI of around 25, whereas waist cir-
cumferences of 102 cm (40.2 inches) in men and 88 cm
(34.6 inches) in women are equivalent to a BMI of around
30. For Asian populations, cut-offs for waist circumferences
of 90 cm (35.4 inches) for men and 80 cm (31.5 inches) for
women have been proposed. 
Guidance
This overall recommendation can best be achieved by being
physically active throughout life, and by choosing diets
based on foods that have low energy density and avoiding
sugary drinks.
People who are already outside the normal BMI range should
seek advice from appropriately qualified professionals 
with a view to returning towards the normal range.
However, for weight control, recommendations 1, 2, and 3
can be followed. 
RECOMMENDATION  2
PHYSICAL ACTIVITY
Be physically active as part of everyday life
PUBLIC HEALTH GOALS
The proportion of the population that is sedentary1
to be halved every 10 years
Average physical activity levels (PALs)1 to be above 1.6
PERSONAL RECOMMENDATIONS
Be moderately physically active, equivalent 
to brisk walking,2 for at least 30 minutes every day
As fitness improves, aim for 60 minutes or more 
of moderate, or for 30 minutes or more of 
vigorous, physical activity every day2 3
Limit sedentary habits such as watching television
1 The term ‘sedentary’ refers to a PAL of 1.4 or less. PAL is a way of representing
the average intensity of daily physical activity. PAL is calculated as total energy
expenditure as a multiple of basal metabolic rate 
2 Can be incorporated in occupational, transport, household, or leisure activities 
3 This is because physical activity of longer duration or greater intensity is more
beneficial
Evidence 
The evidence that physical activity of all types protects
against cancer and also against obesity, and therefore indi-
rectly those cancers whose risk is increased by obesity, has
continued to accumulate since the early 1990s. 
The evidence that physical activity protects against colon
cancer is convincing. It probably protects against post-
menopausal breast cancer and endometrial cancer. Also see
Chapter 5. 
The evidence that physical activity protects against weight
gain, overweight, and obesity is convincing. The evidence
that sedentary living increases the risk of weight gain, over-
weight, and obesity is also convincing. Television viewing, a
form of very sedentary behaviour, is probably a cause of
weight gain, overweight, and obesity. Also see Chapter 8.
Justification
Most populations, and people living in industrialised and
urban settings, have habitual levels of activity below levels
to which humans are adapted. 
With industrialisation, urbanisation, and mechanisation,
populations and people become more sedentary. As with
overweight and obesity, sedentary ways of life have been
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usual in high-income countries since the second half of the
20th century. They are now common if not usual in most
countries. 
All forms of physical activity protect against some cancers,
as well as against weight gain, overweight, and obesity; cor-
respondingly, sedentary ways of life are a cause of these can-
cers and of weight gain, overweight, and obesity. Weight
gain, overweight, and obesity are also causes of some can-
cers independently of the level of physical activity. Further
details of evidence and judgements can be found in
Chapters 5, 6, and 8.
The evidence summarised in Chapter 10 also shows that
physical activity protects against other diseases and that
sedentary ways of life are causes of these diseases. 
Public health goals 
The points here are additional to those made in the footnotes
to the goals above. 
The proportion of the population that is sedentary 
to be halved every 10 years
As above, the context for this goal, which like the others spec-
ified here is designed as a guide for national and other pop-
ulation policies, is the current general rapid rise in sedentary
ways of life. Again as above, the goal proposes a time-frame.
Its achievement will require leadership from governments,
city planners, school boards, and others. Policy-makers are
encouraged to frame goals according to their specific cir-
cumstances. 
The recommendation takes account of the magnitude of
health gain expected from moving, even modestly, from
sedentary ways of life, compared to increasing the level of
activity for already active people. 
Average physical activity levels to be above 1.6
Average PALs for people in high income populations are
between around 1.4 and 1.6. PALs for people in the normal
range of BMI often average around 1.6. The Panel empha-
sises that the goal is to move above a PAL of 1.6. Levels of
1.7 and more are readily achieved by active and fit people.
See Chapter 5.
Personal recommendations 
The points here are additional to those made in the footnotes
to the recommendations above. 
Be moderately physically active, equivalent to brisk
walking for at least 30 minutes every day
As fitness improves, aim for 60 minutes or more of
moderate, or for 30 minutes or more of 
vigorous, physical activity every day
These recommendations are linked. The first derives from
the evidence on cancer. The second derives from the evi-
dence on overweight and obesity, themselves a cause of
some cancers. In making these two recommendations, the
Panel also recognises that for people who have been habit-
ually sedentary for some time, a first recommendation,
which is also meant to be intermediary, is sensible. Levels
of activity above those recommended here are likely to be
additionally beneficial, unless excessive, which may lead to
an acute inflammatory response indicated by muscle pain
and vulnerability to infections. 
Limit sedentary habits such as watching television
Watching television is a form of very sedentary behaviour.
Children may commonly watch television for more than
three hours a day, and are often also exposed to heavy mar-
keting of foods that are high in energy and of sugary drinks
on television. 
Table 12.1 How to achieve a healthy physical activity level (PAL)
This table provides guidance on the impact of specific periods of activity on overall physical activity levels. Increasing activity can be achieved in many
different ways. See Chapter 5.
The table lists some examples of the effect on average daily PAL of doing different activities for different periods of time. The estimates are approximate
and rounded.
So for a person with a PAL of 1.6, an extra 30 minutes daily of moderate activity would increase PAL to around 1.7.
Category Increase in daily PAL Increase in daily PAL Increase in daily PAL Increase in daily PAL Increase in daily PAL
(for an hour of  (for 20 minutes of (for 30 minutes (for 40 minutes (for an hour of 
activity a week) activity a day) of activity a day) of activity a day) activity a day)
Sedentary
Lying down quietly 0 0 0 0 0
Light
Walking slowly, 0.01 0.03 0.05 0.06 0.09
light gardening, housework
Moderate
Walking briskly, cycling, 0.03 0.07 0.10 0.13 0.20
dancing, swimming
Vigorous
Running, tennis, football 0.07 0.17 0.25 0.35 0.50
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Guidance
Most people can readily build regular moderate, and some
vigorous, physical activity into their everyday lives. 
Moderate physical activity can readily be built into everyday
life. It is not necessary to devote a continuous half hour every
day to moderate activity. With walking as an example, walk
briskly all or part of the way to and from work, or on local
errands, or at school; take a break for a walk in the middle
of the day or the evening; use stairs rather than the eleva-
tor. The same applies to other moderate activities.
The best choice of vigorous physical activity is that which
is most enjoyable for the family or the individual — be it
swimming, running, dancing, rowing, cycling, hill walking,
aerobic workouts, or team games such as football and bad-
minton. Resistance and balance training are also beneficial.
Some sports and recreations such as golf are not vigorously
active. A good test that activity is vigorous is that it involves
sweating and raises heart rate to 60–80 per cent of its max-
imum. 
People whose work is sedentary should take special care
to build moderate and vigorous physical activity into their
everyday lives. 
It is also important to avoid long periods of sedentary
behaviour, such as watching television. This behaviour is also
often associated with consumption of energy-dense food and
sugary drinks. 
A common misconception is that sport or exercise is the only
way in which to be physically active. Physical activity includes
that involved with transport (such as walking and cycling),
household (chores, gardening), and occupation (manual and
other active work), as well as recreational activity. 
See table 12.1 for guidance on how to achieve and main-
tain a healthy PAL. This table provides guidance on the
impact of specific periods of activity on overall PALs.
Increasing activity can be achieved in many different ways.
The table lists some examples of the effect on average daily
PAL of doing different activities for different periods of time.
The estimates are approximate and rounded. So for a per-
son with a PAL of 1.6, an extra 30 minutes daily of moder-
ate activity would increase their PAL to around 1.7.
RECOMMENDATION   3
FOODS AND DRINKS THAT 
PROMOTE WEIGHT GAIN
Limit consumption of energy-dense foods1
Avoid sugary drinks2
PUBLIC HEALTH GOALS
Average energy density of diets3 to be lowered 
towards 125 kcal per 100 g
Population average consumption of sugary drinks2
to be halved every 10 years
PERSONAL RECOMMENDATIONS
Consume energy-dense foods1 4 sparingly
Avoid sugary drinks2
Consume ‘fast foods’5 sparingly, if at all
1 Energy-dense foods are here defined as those with an energy content of more
than about 225–275 kcal per 100 g
2 This principally refers to drinks with added sugars. Fruit juices should also be
limited 
3 This does not include drinks
4 Limit processed energy-dense foods (also see recommendation 4). Relatively
unprocessed energy-dense foods, such as nuts and seeds, have not been shown
to contribute to weight gain when consumed as part of typical diets, and these
and many vegetable oils are valuable sources of nutrients 
5 The term ‘fast foods’ refers to readily available convenience foods that tend to 
be energy-dense and consumed frequently and in large portions
Evidence 
Evidence shows that foods and diets that are high in energy,
particularly those that are highly processed, and sugary drinks,
increase the risk of overweight and obesity. Some foods low
in energy density probably protect against some cancers.
Energy-dense foods and sugary drinks probably promote
weight gain, especially when consumed frequently and in
large portions. Correspondingly, low energy-dense foods,
(often relatively unprocessed) probably protect against weight
gain, overweight, and obesity. Specific types of low energy-
dense foods, such as vegetables and fruits and foods con-
taining dietary fibre, probably protect against some cancers.
Also see recommendation 4, Chapter 8, and box 12.4.
Justification
Consumption of energy-dense foods and sugary drinks is
increasing worldwide and is probably contributing to the
global increase in obesity.
This overall recommendation is mainly designed to prevent and
to control weight gain, overweight, and obesity. Further details
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of evidence and judgements can be found in Chapter 8.
‘Energy density’ measures the amount of energy (in kcal or
kJ) per weight (usually 100 g) of food. Food supplies that are
mainly made up of processed foods, which often contain sub-
stantial amounts of fat or sugar, tend to be more energy-dense
than food supplies that include substantial amounts of fresh
foods. Taken together, the evidence shows that it is not spe-
cific dietary constituents that are problematic, so much as the
contribution these make to the energy density of diets. 
Because of their water content, drinks are less energy-dense
than foods. However, sugary drinks provide energy but do not
seem to induce satiety or compensatory reduction in subse-
quent energy intake, and so promote overconsumption of
energy and thus weight gain.
Public health goals 
The points here are additional to those made in the footnotes
to the goals above. 
Average energy density of diets to be 
lowered towards 125 kcal per 100 g
Diets appropriately low in energy density are identified as
supplying around 125 kcal (or 525 kJ) per 100 g, excluding
any drinks. These of course will include foods whose energy
density is higher than this average. 
Population average consumption of sugary drinks
to be halved every 10 years
The context for this goal, which like others specified here is
designed as a guide for national and other population policies,
is the current general rapid rise in weight gain, overweight,
and obesity, especially in children and young people, and the
rapid rise in consumption of sugary drinks. As above, the goal
proposes a time-frame. Achievement of this challenging goal
implies support from regulatory authorities and from manu-
facturers of sugary drinks. Policy-makers are encouraged to
frame goals according to their specific circumstances.
Personal recommendations 
The points here are additional to those made in the footnotes
to the recommendations above. 
Consume energy-dense foods sparingly
Energy-dense foods are here defined as those supplying more
than about 225–275 kcal (950–1150 kJ) per 100 g. Foods nat-
urally high in dietary fibre or water, such as vegetables and
fruits, and cereals (grains) prepared without fats and oils, are
usually low in energy density. Non-starchy vegetables, roots and
tubers, and fruits provide roughly between 10 and 100 kcal per
100 g, and cereals (grains) and pulses (legumes) between
about 60 and 150 kcal per 100 g. Breads and lean meat, poul-
try, and fish usually provide between about 100 and 225 kcal
per 100 g. Most foods containing substantial amounts of fats,
oils, or added sugars, including many ‘fast foods’ as defined
here, as well as many pre-prepared dishes and snacks, baked
goods, desserts, and confectionery, are high in energy density.
This recommendation does not imply that all energy-dense
foods should be avoided. Some, such as certain oils of plant
origin, nuts, and seeds, are important sources of nutrients;
their consumption has not been linked with weight gain, and
by their nature they tend to be consumed sparingly. 
Avoid sugary drinks
This recommendation is especially targeted at soft drinks
(including colas, sodas, and squashes) with added sugars.
Consumption of such drinks, including in ‘super-sizes’, has
greatly increased in many countries. The evidence that such
drinks ‘fool’ the human satiety mechanism, thereby promoting
weight gain, is impressive. They are best not drunk at all. The
implication of this recommendation is to prefer water. Low-
energy soft drinks, and coffee and tea (without added sugar),
are also preferable. Fruit juices, even with no added sugar, are
likely to have the same effect and may promote weight gain,
and so they should not be drunk in large quantities.
Consume ‘fast foods’ sparingly, if at all
As already stated, ‘fast foods’ does not refer to all foods (and
drinks) that are readily available for consumption. The term
refers to readily available convenience foods that tend to be
energy-dense, and that are often consumed frequently and in
large portions. Most of the evidence on ‘fast foods’ is from
studies of such foods, such as burgers, fried chicken pieces,
French fries (chips), and fatty or sugary drinks, as served in
international franchised outlets. 
Guidance
Foods and diets that are low in energy density, and avoidance
of sugary drinks, are the best choices, in particular for peo-
ple who lead generally sedentary lives.
The recommendation above can be best achieved by replac-
ing energy-dense foods, such as fatty and sugary processed
foods and ‘fast foods’, with those of low energy density, such
as plant foods including non-starchy vegetables, fruits, and rel-
atively unprocessed cereals (grains) (see recommendation 4),
and replacing sugary drinks with unsweetened drinks such as
water, and unsweetened tea or coffee. 
The total energy content of diets is related not only to the
energy density of individual foods consumed, but also to the
frequency with which they are eaten and the portion size. The
physical capacity of the human stomach and digestive system
is limited. In general, people usually consume roughly the
same amount of food from day to day, measured by weight.
Energy-dense diets can undermine normal appetite regulation
and therefore lead to greater energy intake. 
Sugary drinks are a particular problem as these can 
be drunk in large quantities without a feeling of satiety. 
By replacing these foods and drinks with those of low energy
density, such as vegetables and fruits, relatively unprocessed
cereals (grains) and pulses (legumes), water and non-caloric
drinks, the risk of weight gain is reduced, which there-
fore would be expected to reduce the risk of developing some
cancers.
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RECOMMENDATION   4
PLANT FOODS
Eat mostly foods of plant origin 
PUBLIC HEALTH GOALS
Population average consumption of non-starchy1
vegetables and of fruits to be at least 600 g (21 oz) daily2
Relatively unprocessed cereals (grains) and/or pulses
(legumes), and other foods that are a natural source of
dietary fibre, to contribute to a population average 
of at least 25 g non-starch polysaccharide daily
PERSONAL RECOMMENDATIONS
Eat at least five portions/servings 
(at least 400 g or 14 oz) of a variety2 of 
non-starchy vegetables and of fruits every day 
Eat relatively unprocessed cereals (grains) 
and/or pulses (legumes) with every meal3
Limit refined starchy foods 
People who consume starchy roots or tubers4
as staples also to ensure intake of sufficient 
non-starchy vegetables, fruits, and pulses (legumes)
1 This is best made up from a range of various amounts of non-starchy vegetables
and fruits of different colours including red, green, yellow, white, purple, and
orange, including tomato-based products and allium vegetables such as garlic
2 Relatively unprocessed cereals (grains) and/or pulses (legumes) to contribute to
an average of at least 25 g non-starch polysaccharide daily
3 These foods are low in energy density and so promote healthy weight
4 For example, populations in Africa, Latin America, and the Asia-Pacific region
Evidence 
The evidence that diets high in vegetables and fruits protect
against cancer is overall less compelling than in the mid-
1990s. However, vegetables and fruits, and other foods con-
taining dietary fibre, probably protect against a number of
cancers. 
Non-starchy vegetables probably protect against cancers of
the mouth, pharynx, larynx, oesophagus, and stomach.
Allium vegetables in particular probably protect against can-
cer of the stomach. Garlic probably protects against cancers
of the colon and rectum. Fruits probably protect against can-
cers of the mouth, pharynx, larynx, oesophagus, lung, and
stomach. Also see chapter 4.2. 
Foods containing dietary fibre probably protect against
cancers of the colorectum. Foods containing folate probably
protect against cancer of the pancreas. Foods containing
carotenoids probably protect against cancers of the mouth,
pharynx, larynx, and lung; foods containing beta-carotene
probably protect against oesophageal cancer; and foods con-
taining lycopene probably protect against prostate cancer.
Foods containing vitamin C probably protect against
oesophageal cancer; and foods containing selenium proba-
bly protect against prostate cancer. It is unlikely that foods
containing beta-carotene have a substantial effect on the risk
of cancers of the prostate or skin (non-melanoma). It can-
not be confidently assumed that the effects of these foods
can be attributed to the nutrient specified, which may be act-
ing as a marker for other constituents in the foods. Also see
chapter 4.2.
Justification
An integrated approach to the evidence shows that most
diets that are protective against cancer are mainly made up
from foods of plant origin. 
Higher consumption of several plant foods probably protects
against cancers of various sites. What is meant by ‘plant-
based’ is diets that give more emphasis to those plant foods
that are high in nutrients, high in dietary fibre (and so in
non-starch polysaccharides), and low in energy density. 
Non-starchy vegetables, and fruits, probably protect
against some cancers. Being typically low in energy density,
they probably also protect against weight gain. Further
details of evidence and judgements can be found in
Chapters 4 and 8.
Non-starchy vegetables include green, leafy vegetables,
broccoli, okra, aubergine (eggplant), and bok choy, but not,
for instance, potato, yam, sweet potato, or cassava. Non-
starchy roots and tubers include carrots, Jerusalem arti-
chokes, celeriac (celery root), swede (rutabaga), and
turnips. 
The goals and recommendations here are broadly similar
to those that have been issued by other international and
national authoritative organisations (see Chapter 10). They
derive from the evidence on cancer and are supported by evi-
dence on other diseases. They emphasise the importance of
relatively unprocessed cereals (grains), non-starchy vegeta-
bles and fruits, and pulses (legumes), all of which contain
substantial amounts of dietary fibre and a variety of micronu-
trients, and are low or relatively low in energy density. These,
and not foods of animal origin, are the recommended cen-
tre for everyday meals.
Public health goals 
The points here are additional to those made in the footnotes
to the goals above. 
Population average consumption of non-starchy
vegetables and of fruits to be at least 600 g (21 oz) daily 
This goal represents amounts well above average population
intakes in almost all parts of the world. Non-starchy veg-
etables exclude starchy roots and tubers (such as potatoes
and potato products). 
In populations where most people consume at least 400 g
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of vegetables and fruits daily (see below), the average
consumption is likely to correspond roughly to at least 
600 g per day. 
Relatively unprocessed cereals (grains) and/or pulses
(legumes), and other foods that are a natural source of
dietary fibre, to contribute to a population average 
of at least 25 g non-starch polysaccharide daily 
All cereals (grains) and pulses (legumes) undergo some form
of processing before they can be consumed. Cooking is a form
of processing. This goal is designed to emphasise the value
of wholegrains, and generally of plant foods naturally con-
taining substantial amounts of dietary fibre. This does not
include processed foods with forms of dietary fibre added, for
which evidence of a protective effect is lacking. A total of 25
g of non-starch polysaccharide is roughly equivalent to 32 g
of dietary fibre. Also see box 4.1.2 in chapter 4.1.
Personal recommendations 
The points here are additional to those made in the footnotes
to the recommendations above. 
Eat at least five portions/servings 
(at least 400 g or 14 oz) of a variety of 
non-starchy vegetables and of fruits every day 
Eat relatively unprocessed cereals (grains) 
and/or pulses (legumes) with every meal
Limit refined starchy foods 
These three linked recommendations also relate to the pub-
lic health goals above. It is likely that there is further pro-
tective benefit from consuming more than five portions/
servings of non-starchy vegetables and fruits. The recom-
mendation on relatively unprocessed cereals (grains) and
pulses (legumes) is designed to ensure that these become a
feature of all meals. Refined starchy foods include products
made from white flour such as bread, pasta, pizza; white
rice; and also foods that are fatty and sugary, such as cakes,
pastries, biscuits (cookies), and other baked goods. 
People who consume starchy roots and tubers 
as staples to ensure intake of sufficient 
non-starchy vegetables, fruits, and pulses (legumes) 
In many parts of the world, traditional food systems are
based on roots or tubers, such as cassava, sweet potato, 
yam, or taro. Traditional food systems should be protected:
as well as their cultural value, and their suitability to local
climate and terrain, they are often nutritionally superior to
the diets that tend to displace them. However, monotonous
traditional diets, especially those that contain only small
amounts of non-starchy vegetables, fruits, and pulses
(legumes), are likely to be low in nutrients, which may
increase susceptibility to infection and so be relevant to the
risk of some cancers. 
Guidance
Maintaining plant-based diets is easily done by planning
meals and dishes around plant foods rather than meat and
other foods of animal origin.
Meat and other animal foods became centrepieces of meals
as a result of industrialisation, one consequence of which is
that meat becomes cheap. As stated above, foods of plant
origin are recommended to be the basis of all meals. A
healthy plate is one that is at least two thirds full of plant
foods; and instead of processed cereals and grains, whole-
grain versions are better choices. 
As stated in recommendation 3, vegetables and fruits are
generally low in energy density. Therefore, by consuming the
amount of vegetables and fruits recommended above, and
limiting the amount of energy-dense foods consumed, peo-
ple can reduce their risk of cancer directly, as well as the risk
of overweight and obesity. 
One portion of vegetables or fruits is approximately 80 g
or 3 oz. If consuming the recommended amount of vegeta-
bles and fruits stated above, average consumption will be at
least 400 g or 14 oz per day. 
Some plant foods are not the subject of goals or
recommendations. 
Nuts, seeds, plant oils. The evidence on nuts, seeds, and plant oils,
and the risk of cancer, is not substantial. However, nuts and seeds
are sources of dietary fibre, essential fatty acids, and vitamins
and minerals. Though they are energy-dense, and so should be
eaten sparingly, they have not been associated with weight gain.
Similarly, modest amounts of appropriate plant oils can be used
as the primary form of fat for use in cooking and food prepa-
ration. See chapter 4.2. 
Sugars. Sugars and also syrups in their various forms are refined
from cane, beet, or corn. The evidence on sugary drinks is strong
enough to generate goals and recommendations (3, above). The
evidence suggesting that foods containing substantial amounts
of added sugars increase the risk of colorectal cancer is limited,
and so the Panel has made no recommendation. However, the
general implication of the goals and recommendations made
here is that consumption of foods containing added sugars
would be limited. See chapter 4.6.
Other plant foods
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RECOMMENDATION  5
ANIMAL FOODS
Limit intake of red meat1 and 
avoid processed meat2
PUBLIC HEALTH GOAL
Population average consumption of red meat 
to be no more than 300 g (11 oz) a week, 
very little if any of which to be processed
PERSONAL RECOMMENDATION
People who eat red meat1
to consume less than 500 g (18 oz) a week, 
very little if any to be processed2
1 ‘Red meat’ refers to beef, pork, lamb, and goat from domesticated animals
including that contained in processed foods
2 ‘Processed meat’ refers to meat preserved by smoking, curing or salting, or
addition of chemical preservatives, including that contained in processed foods
Evidence
The evidence that red meat, and particularly processed
meat, is a cause of colorectal cancer is stronger now than it
was in the mid-1990s. 
The evidence that red meat is a cause of colorectal cancer is
convincing. The evidence that processed meat is a cause of
colorectal cancer is also convincing. Cantonese-style salted
fish (see chapter 4.3, box 4.3.5, and also box 12.5) is a prob-
able cause of nasopharyngeal cancer: this conclusion does
not apply to fish prepared (or salted) by other means. Milk
from cows probably protects against colorectal cancer. Diets
high in calcium are a probable cause of prostate cancer; this
effect is only apparent at high calcium intakes (around 1.5
g per day or more). Also see chapters 4.3 and 4.4. 
Justification
An integrated approach to the evidence also shows that
many foods of animal origin are nourishing and healthy if
consumed in modest amounts. 
People who eat various forms of vegetarian diets are at low
risk of some diseases including some cancers, although it is
not easy to separate out these benefits of the diets from other
aspects of their ways of life, such as not smoking, drinking
little if any alcohol, and so forth. In addition, meat can be
a valuable source of nutrients, in particular protein, iron,
zinc, and vitamin B12. The Panel emphasises that this over-
all recommendation is not for diets containing no meat —
or diets containing no foods of animal origin. The amounts
are for weight of meat as eaten. As a rough conversion, 300
g of cooked red meat is equivalent to about 400–450 g raw
weight, and 500 g cooked red meat to about 700–750 g raw
weight. The exact conversion will depend on the cut of meat,
the proportions of lean and fat, and the method and degree
of cooking, so more specific guidance is not possible.
Red or processed meats are convincing or probable caus-
es of some cancers. Diets with high levels of animal fats are
often relatively high in energy, increasing the risk of weight
gain. Further details of evidence and judgements can be
found in Chapters 4 and 8.
Public health goal
The points here are additional to those made in the footnotes
to the goal above. 
Population average consumption of red meat 
to be no more than 300 g (11 oz) a week, 
very little if any of which to be processed
This goal is given in terms of weekly consumption to encour-
age perception that red meat need not be a daily food. The
goal of 300 g or 11 oz a week corresponds to the level of
consumption of red meat at which the risk of colorectal can-
cer can clearly be seen to rise. The evidence on processed
meat is even more clear-cut than that on red meat, and the
data do not show any level of intake that can confidently be
shown not to be associated with risk.
Many animal foods are not the subject of goals or recommen-
dations. 
Poultry, fish. The evidence on poultry and the risk of cancer is
not substantial. The evidence suggesting that fish protects
against colorectal cancer is limited. (Cantonese-style salted fish
is a special case — see chapter 4.3.) However, people who eat
flesh foods are advised to prefer poultry, and all types of fish, to
red meat. Flesh from wild animals, birds, and fish, whose nutri-
tional profiles are different from those of domesticated and
industrially reared creatures, is also preferred. See chapter 4.3.
Eggs. The evidence on eggs and the risk of cancer is not sub-
stantial. There is no basis for recommending avoidance of eggs
to prevent cancer. See chapter 4.3.
Milk, cheese, other dairy products. The evidence on cow’s milk,
cheese, and foods high in calcium, and the risk of cancer, is hard
to interpret. The evidence on colorectal cancer and on prostate
cancer seems to be in conflict. After long discussion, the Panel
chose to make no recommendations here. See chapter 4.4.
Animal fats. The evidence suggesting that animal fats are a cause
of colorectal cancer is limited. Animal fats are high in energy and
the Panel integrated the limited evidence suggesting that ani-
mal fats are a cause of overweight and obesity into its findings
on energy-dense foods. The implication is that it is best to limit
consumption of animal fats, as part of meat and also as con-
tained in processed foods, in part because of the relation with
cardiovascular disease. See chapter 4.5.
Other animal foods 
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Personal recommendation
The points here are additional to those made in the footnotes
to the recommendation above. 
People who regularly eat red meat 
to consume less than 500 g (18 oz) a week, 
very little if any to be processed
This recommendation relates to the goal above. In popula-
tions where most people consume less than 500 g (18 oz) a
week, the population average is likely to correspond to no
more than roughly 300 g (11 oz) a week. 
Guidance
There are many ways to enjoy meat and other animal foods
as part of plant-based diets. 
For those who eat flesh foods, the amount of red meat con-
sumed can be limited by choosing poultry and fish instead.
It is better also to consume the lean parts of red meat. 
It is best that processed meats are avoided. They are gen-
erally energy-dense and can also contain high levels of salt
(see recommendation 7). They also tend to be preserved by
smoking, curing, or salting, or with the addition of chemi-
cal preservatives. Some of these methods of preservation are
known to generate carcinogens; while the epidemiological
evidence that these are causes of cancer is limited, it is a wise
precaution to avoid them. Processed meat includes ham,
bacon, pastrami, and salami. Sausages, frankfurters, and ‘hot
dogs’, to which nitrates/nitrites or other preservatives are
added, are also processed meats. Minced meats sometimes,
but not always, fall inside this definition if they are preserved
chemically. The same point applies to ‘hamburgers’. Fresh
meats that have simply been minced or ground and then
shaped and cooked are not considered to be ‘processed’. 
Substantial amounts of meat are not needed to sustain
adequate consumption of protein and iron. All flesh foods
are high in protein, and for people who consume varied diets
without any flesh foods, more than adequate protein can be
derived from a mixture of pulses (legumes) and cereals
(grains). Iron is present in many plant foods, as well as in
meat. 
RECOMMENDATION  6
ALCOHOLIC DRINKS
Limit alcoholic drinks1
PUBLIC HEALTH GOAL 
Proportion of the population drinking 
more than the recommended limits to be 
reduced by one third every 10 years1 2
PERSONAL RECOMMENDATION
If alcoholic drinks are consumed, 
limit consumption to no more than two drinks a day 
for men and one drink a day for women1 2 3
1 This recommendation takes into account that there is a likely protective effect
for coronary heart disease 
2 Children and pregnant women not to consume alcoholic drinks
3 One ‘drink’ contains about 10–15 grams of ethanol
Evidence 
The evidence that all types of alcoholic drink are a cause of
a number of cancers is now stronger than it was in the mid-
1990s.
The evidence that alcoholic drinks are a cause of cancers of
the mouth, pharynx, and larynx, oesophagus, and breast
(pre- and postmenopausal) is convincing. The evidence that
alcoholic drinks are a cause of colorectal cancer in men is
convincing. Alcoholic drinks are a probable cause of liver
cancer, and of colorectal cancer in women. It is unlikely that
alcoholic drinks have a substantial adverse effect on the risk
of kidney cancer. Also see chapter 4.8.
Justification
The evidence on cancer justifies a recommendation not to
drink alcoholic drinks. Other evidence shows that modest
amounts of alcoholic drinks are likely to reduce risk of coro-
nary heart disease. 
The evidence does not show a clear level of consumption of
alcoholic drinks below which there is no increase in risk of
the cancers it causes. This means that, based solely on the
evidence on cancer, even small amounts of alcoholic drinks
should be avoided. Further details of evidence and judge-
ments can be found in Chapter 4. In framing the recom-
mendation here, the Panel has also taken into account the
evidence that modest amounts of alcoholic drinks are likely
to protect against coronary heart disease, as described in
Chapter 10. 
The evidence shows that all alcoholic drinks have the same
effect. Data do not suggest any significant difference
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depending on the type of drink. This recommendation there-
fore covers all alcoholic drinks, whether beers, wines, spir-
its (liquors), or other alcoholic drinks. The important factor
is the amount of ethanol consumed. 
The Panel emphasises that children and pregnant women
should not consume alcoholic drinks. 
Public health goal 
The points here are additional to those made in the footnotes
to the goal above. 
Proportion of the population drinking 
more than the recommended limits to be 
reduced by one third every 10 years
The context for this goal, which like the others specified here
is designed as a guide for national and other population poli-
cies, is the current common rise in regular and heavy con-
sumption of alcoholic drinks, including among young
people. The focus of the goal is especially on those con-
suming above the recommended limits, rather than regular
modest drinkers. Again as above, the goal proposes a time-
frame. Achievement of this goal requires substantial support
from regulatory authorities, the manufacturers of alcoholic
drinks, and from the owners of bars and other locations
where alcoholic drinks are sold and consumed. Policy-makers
are encouraged to frame goals according to their specific
circumstances. 
Personal recommendation 
The points here are additional to those made in the footnotes
to the recommendation above. 
If alcoholic drinks are consumed,
limit consumption to no more than two drinks 
a day for men and one drink a day for women
Modest consumption of alcoholic drinks has been shown to
be protective against coronary heart disease compared to no
drinking, with higher levels of drinking in some cases show-
ing increased risk. Nevertheless, no authoritative body has
made specific recommendations for alcohol consumption to
avoid coronary heart disease because of the adverse biolog-
ical, behavioural, physical, social, and other effects of high-
er levels of consumption. 
For those who do consume alcoholic drinks, no more than
two drinks per day (men) and no more than one drink per
day (women) are the recommended limits. These limits are
expressed as amounts per day, because occasional heavy
drinking (say, at weekends) while at other times alcoholic
drinks are not consumed, is particularly likely to lead to
adverse outcomes.
Guidance
For those people who choose to consume alcoholic drinks,
the Panel endorses the advice of other authoritative bodies.
These generally advise an upper limit of around two drinks
per day for men and one for women. 
RECOMMENDATION  7
PRESERVATION, PROCESSING,
PREPARATION 
Limit consumption of salt1 
Avoid mouldy cereals (grains) or pulses (legumes)
PUBLIC HEALTH GOALS
Population average consumption of salt from 
all sources to be less than 5 g (2 g of sodium) a day
Proportion of the population consuming more than 6 g 
of salt (2.4 g of sodium) a day to be halved every 10 years
Minimise exposure to aflatoxins 
from mouldy cereals (grains) or pulses (legumes)
PERSONAL RECOMMENDATIONS
Avoid salt-preserved, salted, or salty foods; 
preserve foods without using salt1
Limit consumption of processed foods with added salt 
to ensure an intake of less than 6 g (2.4 g sodium) a day
Do not eat mouldy cereals (grains) or pulses (legumes)
1 Methods of preservation that do not or need not use salt include refrigeration,
freezing, drying, bottling, canning, and fermentation 
Evidence 
Some methods of food preservation, processing, and prepa-
ration affect the risk of cancer. The strongest evidence con-
cerns processed meats, preserved by salting, smoking,
pickling, addition of chemicals, and other methods (see rec-
ommendation 5, above); salt from all sources; and salt-pre-
served foods. 
Salt and salt-preserved foods are probably a cause of stom-
ach cancer: see chapter 4.6. 
The Panel judges that refrigeration, while not likely to have
any direct effect on the risk of cancer, indirectly protects
against some cancers because it affects consumption of foods
which themselves influence the risk of cancer. For instance,
it may increase the availability and nutrient content of fresh,
perishable foods (vegetables and fruits; meat; milk; see
chapters 4.2, 4.3, and 4.4); and decrease the need for
processed foods (preserved by salting, smoking, curing, and
pickling; see chapters 4.3 and 4.9). Also see recommenda-
tions 4 and 5, and box 4.6.4 in chapter 4.6. 
Some plant foods, notably cereals (grains) and pulses
(legumes), may be contaminated with aflatoxins, produced
by moulds (fungi) during storage in hot and humid condi-
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tions. The evidence that aflatoxins are a cause of liver can-
cer is convincing. Also see chapter 4.1.
Justification
The strongest evidence on methods of food preservation,
processing, and preparation shows that salt and salt-pre-
served foods are probably a cause of stomach cancer, and
that foods contaminated with aflatoxins are a cause of liver
cancer. 
Salt is necessary for human health and life itself, but at lev-
els very much lower than those typically consumed in most
parts of the world. At the levels found not only in high-
income countries but also in those where traditional diets are
high in salt, consumption of salty foods, salted foods, and
salt itself, is too high. The critical factor is the overall amount
of salt. 
Microbial contamination of foods and drinks and of water
supplies, remains a major public health problem worldwide.
Specifically, the contamination of cereals (grains) and puls-
es (legumes) with aflatoxins, produced by some moulds
when such foods are stored for too long in warm tempera-
tures is an important public health problem, and not only in
tropical countries. 
Salt and salt-preserved foods are a probable cause of some
cancers. Aflatoxins are a convincing cause of liver cancer.
Further details of evidence and judgements can be found in
Chapter 4.
Public health goals 
The points here are additional to those made in the footnotes
to the goal above. 
Population average consumption of salt from 
all sources to be less than 5 g (2 g of sodium) a day
Proportion of the population consuming more than 6 g 
of salt (2.4 g of sodium) a day to be halved every 10 years
The reason for these linked goals, which like the others spec-
ified above are designed as a guide for national and other
population policies, is the very high consumption of salt in
most countries. Again as above, one of the goals proposes a
time-frame. This time-frame implies a continuing effort into
the future to achieve levels that might seem difficult within
a single decade. Its achievement implies support from regu-
latory authorities and from the manufacturers of salty and
salted foods. Policy-makers are encouraged to frame goals
according to their specific circumstances. 
Minimise exposure to aflatoxins 
from mouldy cereals (grains) or pulses (legumes)
Personal recommendations 
The points here are additional to those made in the footnotes
to the recommendations above. 
Avoid salt-preserved, salted, or salty foods; 
preserve foods without using salt
Limit consumption of processed foods with added salt 
to ensure an intake of less than 6 g (2.4 g sodium) a day
For most people, these two linked recommendations are
designed to reduce salt consumption substantially. Usually
most salt in diets is contained in processed foods. Some such
foods are obviously salty. Others, bread for example, usual-
ly do not taste salty, but bread and other cereal products are
a major source of salt in high-income countries, together
with many other industrially processed foods that may not
appear ‘salty’. When preserving foods at home, methods that
minimise use of salt are recommended. Avoid the use of salt
at table. 
Do not eat mouldy cereals (grains) or pulses (legumes)
The prudent approach is to avoid consumption of any cere-
als (grains) or pulses (legumes) that may have been stored
Most methods of food preservation, processing, and preparation
are not the subject of goals or recommendations. Some of these
are of public interest and some are mentioned here. 
Drying, fermenting, canning, bottling. There is no good evidence
that these methods of food preservation in themselves have any
effect on the risk of cancer. When they do not involve the use of
salt, they are preferable to methods that do add salt. See chap-
ter 4.9.
Refrigeration. The epidemiological evidence associating use of
refrigeration with reduction of the risk of stomach cancer is sub-
stantial. The previous report judged this evidence to be convinc-
ing. The Panel responsible for this Report judged that the effect
of refrigeration as such on cancer risk was not likely to be direct-
ly causative. Nevertheless, the benefits of industrial and domes-
tic freezing, refrigeration, and chilling include availability of
perishable foods, including vegetables and fruits, all year round,
protection against microbial contamination, and reduced need to
preserve food by salting. In these respects, refrigeration is bene-
ficial. Also see box 4.6.4 in chapter 4.6. 
Additives, contaminants. There is little epidemiological evidence
on any relationship between food additives and contaminants,
whose use is subject to regulation, and the risk of cancer. Also see
chapter 4.9. 
Steaming, boiling, stewing, baking, roasting, frying, grilling (broil-
ing), barbecuing (charbroiling). While evidence suggesting that
grilled (broiled) and barbecued (charbroiled) animal foods are a
cause of stomach cancer is limited, there is evidence from exper-
imental settings showing that carcinogens are formed when
meats, animal foods, and some other foods are cooked at very
high temperatures, and most of all when they are exposed to
direct flame. While the epidemiological evidence that these are
causes of cancer is limited, it is a wise precaution to avoid foods
cooked in this way. This effect is not found when foods are cooked
by use of boiling water. Also see chapter 4.9.
Other methods of preservation 
and preparation 
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for a relatively long time in warm, ambient temperatures,
even if they show no visible signs of mould. 
Guidance
At all stages in the food chain, from production to purchase
and storage ready for food preparation, prefer methods of
food preservation, processing, and preparation that keep
perishable foods relatively fresh, and that do not involve the
use of salt. 
Salt is just one way to add savour to foods. Many herbs and
spices can be used instead. After a period of time of limit-
ing the use of salt, taste sensitivity to it increases, preference
decreases, and the natural savour of food becomes apparent.
Food labels give some guidance. Products advertised as
‘reduced salt’ may still be high in salt. 
Keep food fresh by use of refrigeration. Discard food show-
ing signs of mould (other than those such as some cheeses
manufactured by use of benign moulds). 
RECOMMENDATION  8
DIETARY SUPPLEMENTS
Aim to meet nutritional needs 
through diet alone1
PUBLIC HEALTH GOAL
Maximise the proportion of the population achieving
nutritional adequacy without dietary supplements 
PERSONAL RECOMMENDATION
Dietary supplements are not recommended 
for cancer prevention
1 This may not always be feasible. In some situations of illness or dietary
inadequacy, supplements may be valuable
Evidence 
Randomised controlled trials have produced strong evidence
that high-dose supplements of some nutrients modify the
risk of some cancers. 
The evidence that high-dose beta-carotene supplements are
a cause of lung cancer in smokers is convincing. Calcium
probably protects against cancers of the colorectum.
Selenium in high doses probably protects against prostate
cancer. It is unlikely that beta-carotene, or foods fortified
with this constituent, have a substantial effect on the risk of
cancers of the prostate or skin (non-melanoma). Also see
chapters 4.2 and 4.10.
Justification
The evidence shows that high-dose nutrient supplements
can be protective or can cause cancer. The studies that
demonstrate such effects do not relate to widespread use
among the general population, in whom the balance of risks
and benefits cannot confidently be predicted. A general rec-
ommendation to consume supplements for cancer preven-
tion might have unexpected adverse effects. Increasing the
consumption of the relevant nutrients through the usual diet
is preferred. 
The recommendations of this Report, in common with its
general approach, are food based. Vitamins, minerals, and
other nutrients are assessed in the context of the foods and
drinks that contain them. The Panel judges that the best
source of nourishment is foods and drinks, not dietary sup-
plements. There is evidence that high-dose dietary supple-
ments can modify the risk of some cancers. Although some
studies in specific, usually high-risk, groups have shown evi-
dence of cancer prevention from some supplements, this
finding may not apply to the general population. Their level
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of benefit may be different, and there may be unexpected
and uncommon adverse effects. Therefore it is unwise to rec-
ommend widespread supplement use as a means of cancer
prevention. Further details of evidence and judgements can
be found in Chapter 4.
In general, for otherwise healthy people, inadequacy of
intake of nutrients is best resolved by nutrient-dense diets
and not by supplements, as these do not increase consump-
tion of other potentially beneficial food constituents. The
Panel recognises that there are situations when supplements
are advisable. See box 12.4.
Public health goal
The points here are additional to that in the footnote above. 
Maximise the proportion of the population achieving
nutritional adequacy without dietary supplements 
In many parts of the world, nutritional inadequacy is endem-
ic. In cases of crisis, it is necessary to supply supplements of
nutrients to such populations or to fortify food to ensure at
least minimum adequacy of nutritional status. The best
approach is to protect or improve local food systems so that
they are nutritionally adequate. The same applies in high-
income countries, where impoverished communities and
families, vulnerable people including those living alone, the
elderly, and the chronically ill or infirm, are also liable to be
consuming nutritionally inadequate diets. In such cases of
immediate need, supplementation is necessary. See box 12.4. 
Personal recommendation
The points here are additional to that in the footnote above. 
Dietary supplements are not recommended 
for cancer prevention
This recommendation applies to self-administration of low
(physiological) as well as high (pharmacological) doses of
supplements, unless on the advice of a qualified health pro-
fessional who can assess potential risks and benefits. 
Guidance
Choose nutrient-rich foods and drinks instead of dietary sup-
plements.
This can be done by following all the recommendations
made here, in the context of appropriate general recom-
mendations on food, nutrition, physical activity, and body
composition, designed to protect against disease and to pro-
mote health and well-being. 
The Panel judges that the use of supplements as possible pro-
tection against colorectal and prostate cancer should not be rou-
tinely recommended.
In general, as already stated, with secure food supplies and
access to a variety of foods and drinks, when people follow the
recommendations here in the context of general dietary rec-
ommendations, supplements are normally unnecessary.
Furthermore, in diets, nutrients are present in combinations
often not found in ‘multi’-supplements, and with other bioac-
tive substances. 
The Panel recognises, however, that dietary supplements, in
addition to varied diets, may at times be beneficial for specific
population groups. Examples include vitamin B12 for people
over the age of 50 who have difficulty absorbing naturally occur-
ring vitamin B12, folic acid supplements for women who may
become or are pregnant, and vitamin D supplements for peo-
ple who are not exposed to sufficient sunlight or some people
(such as the elderly or people with dark skin) who do not syn-
thesise adequate vitamin D from sunlight. 
The Panel advises against self-administration of supplements as
protection against specific cancers. The findings on calcium and
selenium apply in specific settings and specific doses. A recom-
mendation for routine consumption in the general population
might show a different balance of risks and benefits. Advice for
individuals whose particular circumstances have been assessed
is best given in a clinical setting in consultation with an appro-
priately qualified professional. 
Box 12.4 When supplements are advisable
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This recommendation has a special significance. While
derived from the evidence on being breastfed, it also indi-
cates that policies and actions designed to prevent cancer
need to be directed throughout the whole life course, from
the beginning of life.
Public health goal 
The points here are additional to those made in the footnotes
to the goal above. 
The majority of mothers to breastfeed 
exclusively, for six months
Sustained, exclusive breastfeeding was the norm until the
development and marketing of infant formulas, which large-
ly replaced breastfeeding in high-income and then in most
countries by the second half of the 20th century. 
While the practice of breastfeeding and exclusive breast-
feeding has been increasing in many countries in recent
decades, in most countries now only a minority of mothers
exclusively breastfeed their babies until four months, and an
even smaller number until six months. 
This is the context for this goal, which like the others spec-
ified here, is designed as a guide for national and other
population policies. It does not imply that in any population
where over half of all mothers breastfeed exclusively for 
six months that the ultimate goal has been reached: the
greater the proportion, the better. Its achievement will
require increased support from regulatory authorities and
from the manufacturers of infant formulas. Policy-makers 
are encouraged to frame goals according to their specific
circumstances.
The Panel emphasises the importance of exclusive breast-
feeding (other than vitamin drops where locally recom-
mended), with no other sustenance, including water. 
There are special situations where breastfeeding is rec-
ommended with caution or is not advised. The main special
situation is when mothers have HIV/AIDS. On this, the UN
Global Strategy as revised in late 2006 states: ‘Exclusive
breastfeeding is recommended for HIV-infected women for
the first six months of life unless replacement feeding is
acceptable, feasible, affordable, sustainable, and safe for
them and their infants before that time.’
Personal recommendation 
The points here are additional to those made in the footnotes
to the recommendations above. 
Aim to breastfeed infants exclusively 
up to six months and continue 
with complementary feeding thereafter
This and the population goal are references to the UN Global
Strategy on Infant and Young Child Feeding, which is
endorsed by the Panel. None of the phrasing of the goals and
recommendations here is designed to modify the Strategy,
which allows for special circumstances, including those in
which mothers are not able to breastfeed their babies or may
otherwise be well advised not to do so. 
SPECIAL RECOMMENDATION 1
BREASTFEEDING 
Mothers to breastfeed; children to be breastfed1
PUBLIC HEALTH GOAL
The majority of mothers to breastfeed 
exclusively, for six months2 3
PERSONAL RECOMMENDATION
Aim to breastfeed infants exclusively2
up to six months and continue 
with complementary feeding thereafter3
1 Breastfeeding protects both mother and child 
2 ‘Exclusively’ means human milk only, with no other food or drink, including
water 
3 In accordance with the UN Global Strategy on Infant and Young Child Feeding 
Evidence 
The evidence on cancer supports the evidence on well-being,
positive health, and prevention of other diseases: at the
beginning of life, human milk is best. 
The evidence that lactation protects the mother against
breast cancer at all ages is convincing. There is limited evi-
dence suggesting that lactation protects the mother against
cancer of the ovary. Having been breastfed probably protects
children against overweight and obesity, and therefore those
cancers for which weight gain, overweight, and obesity are
a cause. Overweight and obesity in children tend to track
into adult life. Also see recommendation 1 and chapters 6.3,
7.10, and 8.  
Justification
The evidence on cancer as well as other diseases shows that
sustained, exclusive breastfeeding is protective for the moth-
er as well as the child. 
This is the first major report concerned with the prevention
of cancer to make a recommendation specifically on breast-
feeding, to prevent breast cancer in mothers, and to prevent
overweight and obesity in children. Further details of evi-
dence and judgements can be found in Chapters 6 and 8.
Other benefits of breastfeeding for mothers and their chil-
dren are well known. Breastfeeding protects against infec-
tions in infancy, protects the development of the immature
immune system, protects against other childhood diseases,
and is vital for the development of the bond between moth-
er and child. It has many other benefits. Breastfeeding is espe-
cially vital in parts of the world where water supplies are not
safe and where impoverished families do not readily have the
money to buy infant formula and other infant and young
child foods. 
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Guidance
On breastfeeding, the Panel endorses the UN Global
Strategy on Infant and Young Child Feeding. 
It is universally agreed, by UN agencies, national govern-
ments, health professionals, civil society organisations, and
the infant formula and milk industries, that human milk is
the best food for infants and young children. Therefore, this
Report recommends that mothers breastfeed exclusively, for
six months, as recommended in the Strategy. 
SPECIAL RECOMMENDATION  2
CANCER SURVIVORS1
Follow the recommendations 
for cancer prevention2
RECOMMENDATIONS
All cancer survivors3 to receive nutritional care 
from an appropriately trained professional
If able to do so, and unless otherwise advised, 
aim to follow the recommendations for 
diet, healthy weight, and physical activity2
1 Cancer survivors are people who are living with a diagnosis of cancer, including
those who have recovered from the disease
2 This recommendation does not apply to those who are undergoing active
treatment, subject to the qualifications in the text 
3 This includes all cancer survivors, before, during, and after active treatment 
Evidence
The available evidence on cancer survivors has limitations.
It is of variable quality; it is difficult to interpret; and it has
not yet produced impressive results. The evidence for this
review does not include the active treatment period. 
The term ‘cancer survivor’ denotes people in a very wide
range of circumstances. It is unlikely that specific recom-
mendations based on evidence applying to any one group
of people would apply to all cancer survivors. 
In no case is the evidence specifically on cancer survivors
clear enough to make any firm judgements or recommen-
dations that apply to cancer survivors as a whole, or to those
who are survivors of any specific cancer. 
Justification
Subject to the qualifications made here, the Panel has agreed
that its recommendations apply also to cancer survivors.
There may be specific situations where this advice may not
apply, for instance, where treatment has compromised gas-
trointestinal function.
If possible, when appropriate, and unless advised otherwise
by a qualified professional, the recommendations of this
Report also apply to cancer survivors. The Panel has made
this judgement based on its examination of the evidence,
including that specifically on cancer survivors, and also on
its collective knowledge of the pathology of cancer and its
interactions with food, nutrition, physical activity, and body
composition. In no case is the evidence specifically on can-
cer survivors clear enough to make any firm judgements or
recommendations to cancer survivors. Further details of evi-
dence and judgements can be found in Chapter 9.
Treatment for many cancers is increasingly successful, and
so cancer survivors increasingly are living long enough to
develop new primary cancers or other chronic diseases. The
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recommendations in this Report would also be expected to
reduce risk of those conditions, and so can also be recom-
mended on that account. 
Recommendations
In the special circumstances of cancer survivors, who until
they have recovered from the disease are in a clinical setting,
the Panel decided not to separate public health goals and per-
sonal recommendations. The points here are additional to
those made in the footnotes above. 
All cancer survivors to receive nutritional care from 
an appropriately trained professional
The circumstances of cancer survivors vary greatly. Given the
increased importance of food, nutrition, physical activity, and
body composition in cancer survival, people who have
received a diagnosis of cancer should consult an appropri-
ately trained health professional as soon as possible. The
advice received will be designed to take their personal situ-
ation and circumstances into account. 
People who are undergoing surgical, chemical, or radio-
therapy for cancer are likely to have special nutritional
requirements; as are people after treatment whose ability to
consume or metabolise food has been altered by treatment;
and people in the later stages of cancer whose immediate
need is to arrest or slow down weight loss. These are all clin-
ical situations where the advice of an appropriately trained
health professional is essential. 
The evidence does not support the use of high-dose sup-
plements of microconstituents as a means of improving out-
come. Cancer survivors should consult their physician and/or
a qualified nutrition professional, who can evaluate the safe-
ty and efficacy of specific dietary supplements, and counsel
appropriate action based on current research relevant to their
particular clinical situation.
All cancer survivors to aim to follow the recommendations
for diet, healthy weight, and physical activity
This general approach is for cancer survivors who are able,
and have not been advised otherwise, to follow the recom-
mendations of this Report. 
There is growing evidence that physical activity and other
measures that control weight may help to prevent cancer
recurrence, particularly breast cancer. These findings are in
line with the recommendations of this Report. Cancer sur-
vivors are also likely to gain health benefit, and a sense of
control, from regular physical activity at levels that they can
sustain. 
Guidance
The general purpose of the recommendations made in this
Report is to ‘stop cancer before it starts’. Crucial support will
be given to cancer survivors who decide to follow the over-
all recommendations made in this chapter, when the people
living closest to them also make this choice. As well as giv-
ing crucial support and improving the quality of life of the
cancer survivor, they will also be reducing their own risk of
cancer. 
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Those responsible for reports such as this are faced with a
number of challenges. Information, even from high-
income countries where most research is carried out, is
incomplete and often patchy, and that from many
countries is fragmentary. Most modern research in the
nutritional and other biological sciences is highly focused.
Many researchers address not just what foods affect the
risk of disease, but what specific agent or agents in the
food are responsible, or the exact biological pathway
involved. The amount of data produced by such studies is
multiplying and its sheer volume can obscure the general
view needed as a basis for public health goals and
personal recommendations. 
As a result, until relatively recently, expert reports
concerned with the prevention of disease tended to frame
their conclusions and recommendations in terms of
specific dietary constituents being the most relevant
factors modifying the risk of disease. Thus, since the
1960s, reports concerned with prevention of coronary
heart disease have recommended cuts in consumption of
saturated fats and of dietary cholesterol. Such
recommendations, while staying closer to the science as
usually carried out, and of value to planners of food
supplies and in the formulation of manufactured food, are
less effective as ways of encouraging healthy choices of
foods and drinks. People consume foods and drinks, rather
than nutrients. 
Also, what people eat and drink and how they behave
are only partly a matter of choice. Many other factors are
involved including income, climate, and culture. Although
food supplies are now becoming increasingly globalised,
the people of South India are not likely to move to meat-
based diets, nor will most people in the USA adopt lentils
as staple foods. 
More recently, some reports have adopted a food-based
approach to the prevention of disease and the promotion
of well-being. This has presented the expert panels
responsible for reports such as this one with another
challenge. This is to review, assess, and judge the evidence
in ways that respect its nature, yet at the same time also
seek to discern ‘the bigger picture’. A further challenge is
to identify healthy patterns of food, nutrition, and physical
activity that allow for — indeed encourage — the diversity
both of traditional and modern food systems and cuisines. 
12.3.1  The integrated approach 
Since its work began, five years before publication of this
Report, the Panel has used a broad, integrative approach.
This, while largely derived from conventional ‘reductionist’
research, has sought to find patterns of consumption of foods
and drinks, degrees of physical activity, and scale of body
composition that lead to recommendations designed to pre-
vent cancer at personal and population levels. 
This approach has proved to work. As recommendation 2
indicates, meticulous examination of the many studies on
physical activity and the risk of cancer shows that all types of
activity — occupational, transport, domestic, recreational —
do or may protect against some cancers. The type of activity
is evidently unimportant. Given the general tendency of pop-
ulations living in industrialised and urbanised societies to
become increasingly sedentary, this enables clear recommen-
dations designed to encourage increased levels of physical
activity. 
At a more detailed level, the same point applies to alco-
holic drinks, as indicated in recommendation 6. Many stud-
ies have been undertaken to examine the relationship of beer,
wine, and spirits (liquor) to the risk of cancer — and to other
diseases. Taken all together, these show that it is alcoholic
drinks in general — which is to say, the amount of ethanol
consumed — that are or may be a cause of some cancers.
Again, this enables the framing of clear recommendations
that take into account the effect of modest amounts of alco-
holic drinks on the risk of coronary heart disease. 
Recommendations 3, 4, and 5 also show how the inte-
grated approach stays with the science and, by looking for
patterns, can create broad public and personal health mes-
sages. After particularly careful discussions, the Panel agreed
that a key factor determining vulnerability to weight gain,
overweight, and obesity, and thus to those cancers whose risk
is increased in these ways, is not so much specific foods,
drinks, or nutrients, but the relative energy density of diets.
This is not an obvious conclusion from the studies whose
results form the basis for this judgement. Up to now, epi-
demiologists have rarely used energy density as a concept in
the design of their studies. 
Comparably, the vast amount of evidence on specific foods
and drinks does indeed show a more general pattern with
vegetables and fruits, and with red and processed meat. In
framing recommendations 4 and 5, the Panel agreed that rec-
ommendations on these types of food should be seen in the
broader context of plant and animal foods. This is not a new
conclusion. Plant-based diets, which is to say diets within
which foods of plant origin are more central than is typical
in industrialised and urbanised settings, are now common-
ly recognised as protective against some cancers. Again, the
judgement requires qualification, as has been done in the
footnotes and text. Many foods of animal origin are nour-
12.3  Patterns of food, nutrition, 
and physical activity 
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ishing, and only the evidence on red meat and on processed
meat is strong enough to justify specific recommendations.
Nevertheless, with such precautions, the Panel has agreed
that dietary patterns in which foods of plant origin are more
central, with red meat less so, are protective. 
12.3.2  Nutritional patterns 
The recommendations made in this Report do not specify
every major type of food and drink. In this sense they do
not, taken together, amount to whole diets. Nevertheless,
combined with the text that accompanies them, they are
likely to promote the nutritional adequacy of diets and
healthy body composition. For this and other reasons, they
will also be expected to help prevent nutritional deficien-
cies and related infectious diseases. 
Thus, a diet based on these recommendations is likely to
have modest fat content (through limiting energy-dense
foods), especially in saturated fatty acids (limiting red and
processed meat); to be relatively high in starch and fibre
(from emphasis on relatively unprocessed plant foods
including cereals (grains)), while being low in sugar (due
to limiting energy-dense foods and sugary drinks). Overall,
the macronutrient profile is likely to be similar to that rec-
ommended in authoritative reports concerned more gener-
ally with prevention of other chronic diseases. 
A number of the positive recommendations derive from
evidence on foods that contribute various micronutrients to
the diet. These, including relatively unprocessed cereals
(grains), vegetables and fruits, and pulses (legumes), as well
as various foods of animal origin, would be expected to sup-
ply ample vitamin A (mostly in the form of carotenoids),
folate, other B vitamins including vitamin B12, vitamin C,
vitamin E, selenium, iron, zinc, potassium, and indeed
sodium. 
12.3.3  Integration with national
recommendations 
In national settings, the recommendations of this Report will
be best used in combination with recommendations issued
by governments or on behalf of nations, designed to prevent
chronic and other diseases. Also see box 12.5. 
In the Panel’s judgement, based on its collective knowl-
edge of food, nutrition, physical activity, and disease pre-
vention, and also experience of national contexts, the
recommendations here are likely to be harmonious with
those designed to prevent disease in specific countries, which
take local and national dietary patterns, food cultures, and
social and other circumstances into account. 
Box 12.5 Regional and special circumstances
The goals and recommendations specified
in 12.2 are generally relevant worldwide. 
In three cases, evidence that is strong
enough to be the basis for goals and rec-
ommendations is of importance only in dis-
crete geographical regions. That is not to
say that if the same foods or drinks were
consumed elsewhere they would not have
the same effect, but rather that currently,
people in the rest of the world do not con-
sume them. These are the herbal drink
maté, probably a cause of oesophageal can-
cer; Cantonese-style salted fish, probably a
cause of nasopharyngeal cancer; and cont-
amination of water supplies with arsenic, a
cause of lung cancer and (probably) skin
cancer. The Panel considers that detailed
goals and recommendations in these cases
are most appropriately set by local and/or
regional regulatory authorities, other poli-
cy-makers, and health professionals in the
countries affected.
Maté
As stated in chapter 4.7 and elsewhere,
maté is a herbal infusion originally culti-
vated and drunk by the original inhabitants
in Argentina, Uruguay, and Rio Grande do
Sul in Brazil, where it is now adopted as a
staple drink. Reports on the prevention of
cancer have identified maté as a cause or
possible cause of cancers of the oral cavity
and oesophagus. The product is commonly
available in supermarkets in many coun-
tries, but the evidence shows that the causal
factor is maté drunk very hot through a
metal straw often left resting on the lip, the
form traditional within Latin America. It is
probable that the cause of cancer is not the
herb but the thermic effect. 
RECOMMENDATION
Avoid consumption of maté as drunk 
in parts of Latin America, very hot and
through a metal straw. 
Cantonese-style salted fish
Cantonese-style salted fish, as stated in
chapter 4.3 and elsewhere, is part of the
traditional diet consumed by people living
around the Pearl River Delta region in
southern China, and has been given to chil-
dren, even as part of a weaning diet. This
style of fish is prepared with less salt than
used on the northern Chinese littoral, is
allowed to ferment, and so is eaten in a
decomposed state. While it is also con-
sumed by communities of emigrants from
the Pearl River Delta in other countries, this
particular preparation of fish is not other-
wise an issue, and there is no good 
evidence that other forms of preserved fish
affect the risk of cancer. 
RECOMMENDATIONS
Avoid consumption of Cantonese-style
salted fish. 
Children not to eat this type of fish.
Arsenic in water
Contamination of water supplies with
arsenic is a different type of special case.
This may happen as a result of release of
industrial effluents, and also because of
geological and other environmental cir-
cumstances. High concentrations of arsenic
in drinking water have been found in areas
of Bangladesh, China, and West Bengal
(India); and also in more localised areas of
Argentina, Australia, Chile, Mexico, Taiwan,
China, the USA, and Vietnam. Arsenic is
classed as a carcinogen by the International
Agency for Research on Cancer. 
RECOMMENDATIONS
Avoid use of any source of water 
that may be contaminated with arsenic.
Authorities to ensure that 
safe water supplies are available 
where such contamination occurs.
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late 2008 will deal with the social and environmental fac-
tors that influence the risk of cancer, with appropriate rec-
ommendations.
12.3.4  General patterns 
The Panel has not been able to base its recommendations on
general patterns of food and nutrition, as stated above, on
evidence specifically directed towards that question. Reasons
for this, as summarised in chapter 4.9, are that relatively few
epidemiological studies examine diets in an integrated form;
and of these, most do not define the nature of such diets in
a way that can be compared with other studies. Those that
do, such as studies of Seventh-day Adventists, often exam-
ine the effects of whole ways of life, including factors that
may confound findings specifically on food, nutrition, and
physical activity. 
For the future, the Panel recommends that protocols be
agreed to enable well conducted epidemiological studies to
be carried out on patterns of food, nutrition, and of physi-
cal activity, using agreed definitions and methods that allow
comparisons and detailed analyses. 
A number of traditional and more modern food systems
generate a variety of climatically and culturally appropriate,
delicious, and nourishing cuisines that are harmonious with
the recommendations made here. These include the many
traditional cuisines of the Mediterranean littoral, and of
South-East and East Asia, and some diets devised since the
industrialisation and internationalisation of food systems.
The latter are often adaptations of traditional diets, enjoyed
by people in higher income countries as part of generally
healthy ways of life. 
12.3.5  Health, well-being, and ways of life 
Throughout our work we, the members of this Panel, have
been aware that prevention of cancer through changes to
food and nutrition, physical activity, and body composition
is a major global, regional, and national task; and also that
this work is one part of a greater task, to prevent disease and
to promote well-being throughout the world, sustainably and
equitably. 
As part of this task, integrated and comprehensive pro-
grammes should be developed on cancer prevention, togeth-
er with prevention of other chronic diseases, such as type 2
diabetes, cardiovascular diseases, osteoporosis, other chron-
ic diseases, and also nutrient deficiencies and relevant infec-
tious diseases, especially of early childhood. This approach,
broader than any now undertaken within the UN system,
would need to be coordinated by relevant international and
national organisations. 
All reports on the prevention of cancer must emphasise the
fundamental importance of tobacco control, as we do here.
The one habit that most unequivocally is a cause of cancer
is smoking, and other use of and exposure to tobacco. Partly
because of its addictive nature, and for other reasons, tobac-
co smoking is not a simple matter of personal choice. Its
reduction requires vigilant commitment from governments
and civil society at all levels. 
In general, ways of life — patterns of behaviour within
societies — are never just personal matters. In this Report,
we have concentrated our attention on nutritional and asso-
ciated factors that affect the risk of cancer, and our goals and
recommendations here for populations and for people are
framed accordingly. An associated report to be published in
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How this Report has been achieved 
This Report follows, develops, and replaces Food, Nutrition
and the Prevention of Cancer: a global perspective, the first
report commissioned by the World Cancer Research Fund
together with the American Institute for Cancer Research,
which was published in 1997. 
In 2001, WCRF and AICR agreed that it was time to com-
mission a new report. Since the mid 1990s, the amount of
scientific literature on this subject has dramatically
increased. New methods of analysing and assessing evidence
have been developed, facilitated by advances in electronic
technology. There is more evidence, in particular on over-
weight and obesity and on physical activity. Examining food,
nutrition, and physical activity in relation to cancer survivors
is a new field of study. The need for a new report was obvi-
ous, and a multilevel process involving global collaboration
was put in place. 
Commissioning this Report
The goal of this second Report, Food, Nutrition, Physical
Activity, and the Prevention of Cancer: a Global Perspective,
has been to identify, review, and assess all the relevant
research to date. It has used the most meticulous methods
for assessment and review in order to generate a compre-
hensive series of recommendations on food, nutrition, and
physical activity suitable for all societies and designed to
reduce the risk of cancer. The process has also been devised
as the basis for a continuous review that will keep the evi-
dence updated into the future.
The process was organised into overlapping stages,
designed to ensure objectivity and transparency as well as
separation between the collection of evidence and the busi-
ness of assessing and judging it. First, an expert task force
developed a method for systematic review of the voluminous
scientific literature. Second, research teams collected and
reviewed the literature based upon this methodology. Third,
an expert Panel assessed and judged this evidence and
agreed recommendations. The results are published in this
Report.  
The whole project has taken six years, with the launch and
distribution of the second Report taking place in November
2007. 
Agreeing the methodology
As a first stage, WCRF International developed an appro-
priate method for collecting, synthesising, analysing, and
reporting the evidence. In 2002, a Methodology Task Force
of experts in nutrition, cancer, epidemiology, methodology,
and statistics was convened. This Task Force drew on the
accumulated experience of existing techniques to develop a
unique new process. The methodology is described in a
Systematic Literature Review Specification Manual, which con-
tains the instructions for conducting the systematic reviews. 
The methods specified in the manual were tested at two
centres, one in the USA and the other in the UK, and as a
result the manual was modified. It has formed the basis of
all the reviews of the literature on food, nutrition, physical
activity, and the risk of cancer for all relevant cancer sites
and on weight gain, overweight, and obesity. 
Reviewing the literature
WCRF International then invited scientific centres to bid for
the work of systematic literature review (SLR), and con-
tracted with nine institutions in Europe and North America
to conduct reviews of the literature on all cancer sites where
evidence of links with food, nutrition, and associated factors
was already apparent, as well as that on determinants 
of overweight and obesity, and on authoritative reports con-
cerned with other diseases. The project team from each 
centre included expertise in epidemiology, nutrition, cancer,
mechanisms, statistics, and project management. Teams 
have been supported by a review coordinator — a member 
of the WCRF International Secretariat. All reviews have
included the relevant epidemiological and experimental
literature. 
Using the specification manual to ensure a comprehensive
and consistent approach to the analysis plus a common for-
mat for displaying the evidence, each centre undertook one
or more SLRs and produced a report on the evidence for each
cancer site. The reports were subject to peer review both at
the initial protocol stage and when the reports were sub-
mitted in complete form. They were then revised before
being summarised and submitted to the Panel. The system-
atic reviews present the findings of the review teams based
on the agreed protocol. They stop short of assessing or judg-
ing the strength and implications of the evidence.
Judging the evidence
The Panel of 21 experts was convened by WRCF
International in 2003 to develop the second Report.
Members of the Panel come from all the main continents and
from 11 countries. Its collective expertise includes nutrition,
Project process 
A P P E N D I X  A
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cancer, obesity, other chronic diseases, physical activity, epi-
demiology, biochemistry, statistics, public health, and pub-
lic policy. The Panel includes members of the Panel from the
first WCRF/AICR report and relevant World Health
Organization expert consultations, as well as observers from
the Methodology Task Force and the Mechanisms Working
Group and from six relevant United Nations and other inter-
national organisations. The Panel convened twice a year for
three- or four-day meetings between 2003 and 2007.
The Panel has been responsible for assessing the evidence
from the SLRs, for agreeing judgements based on their
assessments, and for agreeing a comprehensive set of rec-
ommendations. The Panel has also been responsible for iden-
tifying issues arising from this work that would be
appropriate topics for future research.
For the next stage, the Panel, supplemented by addition-
al expertise, examined the evidence on the determinants of
dietary and activity patterns, and of obesity, and the effec-
tiveness of interventions from personal to population level.
Publication of this separate report is due in late 2008.
Managing the project 
The second Report was commissioned by WCRF International
and has been funded and published by WCRF/AICR. WCRF
International set up a multilevel process to manage the pro-
ject, and an Executive Team was established with the specif-
ic responsibility of directing it. 
Executive Team: Executive body responsible for Report.
Composed of WCRF International and
AICR executives and advisors.
Secretariat: Manages the whole report process. 
Advisory Group: Guides the Executive Team and the
Panel on policy and strategic and
technical issues
The Secretariat has included WCRF International staff in the
UK, AICR staff in the USA, and consultants, including in the
following positions:
Project Director: Overall responsibility for the report
and its scientific content. Chair of
Executive Team. 
Chief Editor: Responsible for editorial quality of the
report. Chair of Advisory Group.
Project Manager: Responsible for day-to-day
management of the project; Chair of
Secretariat. 
Chapter Managers: Drive progress on chapters of the
report. 
In addition to the work of producing the second Report, a
Communications Strategy Group from within the WCRF
global network was set up to be responsible for all aspects
of the promotion of the report before, during, and after its
launch in November 2007. 
Keeping up to date 
This Report is meant to guide future scientific research, can-
cer prevention education programmes, and health policy
around the world. It provides a solid evidence base for pol-
icy-makers, health professionals, researchers, and informed
and interested people to draw on and work with.  
WCRF International has been mindful that the literature
is continually expanding, and has commissioned a continu-
ous review of the evidence. This process will be overseen by
an expert panel convened by WCRF International, responsi-
ble for assessing and judging the updated evidence as a basis
for recommendations and action to prevent cancer world-
wide. 
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In September 1997, the World Cancer Research Fund and its
affiliate in the USA, the American Institute for Cancer
Research, jointly published Food, Nutrition and the Prevention
of Cancer: a global perspective.
On publication, this 670-page WCRF/AICR report, in its
distinctive blue cover, and with its accompanying summary,
was immediately recognised as the most authoritative and
influential in its field. It became the standard text worldwide
for policy-makers in government at all levels, for civil soci-
ety and health professional organisations, and in teaching
and research for centres of academic excellence. 
Responsibility for the first report and its conclusions and
recommendations was taken by a panel of scientists con-
vened by WCRF/AICR, chaired by Professor John Potter.
Panel members came from Africa, Asia (India, China, Japan)
and Latin America, as well as Europe and the USA. The col-
lective knowledge of the panel included nutrition, cancer,
other chronic diseases, energy balance, epidemiology,
biochemistry, toxicology, statistics, public health, and public
policy.
Official observers came from the World Health
Organization, the International Agency for Research on
Cancer, the Food and Agriculture Organization of the United
Nations, and the US National Cancer Institute. The Panel,
supported by a WCRF Secretariat, held a series of seven
three-day meetings between 1993 and 1997.
Special features
The first report had a number of special features, adapted
and developed in this second Report. All its findings were
introduced and summarised in plain language, to make the
science and its significance as clear and accessible as possi-
ble. This facilitated its use as a tool for policy-makers at all
levels from international government to municipalities,
schools, and hospitals, as well as the standard basis for aca-
demic teaching and practice. 
The panel responsible for the first report concluded that
worldwide, around 4 million deaths each year are pre-
ventable by adoption of its recommendations. Part of the
purpose of the report was to show that prevention of cancer
by means of food, nutrition, and associated factors is as fea-
sible and crucial as prevention of coronary heart disease. Its
recommendations take into account prevention of other
chronic diseases, and also prevention of nutritional defi-
ciencies and food-related infectious diseases. 
The conclusions of the first report were based on method-
ical reviews of the epidemiological, experimental, and other
relevant expert literature. The judgements of the panel were
presented in the form of matrices, adapted for this second
Report. This matrix approach, in which judgements such as
‘convincing’ and ‘probable’ were displayed according to com-
mon specified criteria on the relative strength of evidence,
was pioneered in the first WCRF/AICR report. 
The 14 recommendations of the 1997 report are food
based. Taken together, they amount to whole diets judged
to give the best protection against cancer, other chronic dis-
eases, and also other food-related diseases. The first report
also included a chapter on the public policy implications of
its recommendations. As part of the second Report process,
this aspect is the subject of a separate report to be published
in late 2008. 
Impact and influence 
WCRF/AICR has a special commitment to ensure that the
work for which it is responsible has a global impact and that
its reports are placed in the right hands. Accordingly, over
30 000 copies of the first report and of its summary have
been distributed throughout the world, to policy-makers in
government, to health professional and civil society organi-
sations, to scientists responsible for research and prevention,
and to all other qualified and interested people. 
In addition, the report and its summary have been trans-
lated or adapted for a number of regions and countries,
including Latin America, China, Japan, India, Germany,
France, Italy, and the Asia-Pacific region.   
The report has had a powerful impact on cancer preven-
tion at all levels. Governments and authoritative organisa-
tions around the world use it to shape public health policy.
The 2003 WHO report, Diet, Nutrition and the Prevention of
Chronic Diseases, the scientific basis for the WHO Global
Strategy on Diet, Physical Activity and Health, adapted the
methods pioneered by WCRF to classify the strength of sci-
entific evidence and to display evidence-based judgements
in the form of matrices. 
Research scientists use the first report as a basis for their
work. Academics and public health educators use it as the
pre-eminent textbook. Having set the agenda in its field, it
is frequently cited in the academic and professional litera-
ture and at international scientific conferences. It has stim-
ulated debate about how best to engage in a systematic and
objective interpretation of the scientific data on food, nutri-
tion, and the prevention of cancer.
The first WCRF/AICR 
Expert Report 
A P P E N D I X  B
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Directly, and also indirectly through its influence on pro-
fessionals, it guides communities, families, and individuals
throughout the world as they make choices about their food
and nutrition, physical activity, and weight management.
The report has also been used as the basis for the research,
education, and associated programmes of the WCRF global
network in the USA, the UK, the Netherlands, China (Hong
Kong), and France, which together distribute tens of millions
of brochures and newsletters each year to assist their sup-
porters and to fulfil their missions. 
The first report laid solid foundations for this second
Report, which has developed its methods and made use of
the latest electronic technology in compiling, displaying, and
assessing the evidence. The overall purpose of both reports
has been, and will remain, that of WCRF and AICR: to pre-
vent cancer, worldwide. 
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Since its foundation in 1982, the World Cancer Research
Fund global network has been dedicated to the prevention
of cancer. All the members of the global network have the
same mission: to prevent cancer worldwide.   
Cancer is a global disease. Some types of cancer are more
common in the higher income countries of Europe, North
America, and elsewhere. Other types are more common in
Africa and Asia and other lower-income parts of the world;
and as shown in Chapter 1 of this Report, these are among
the many compelling reasons why it is necessary to study
cancer from a global perspective in order to understand how
best to prevent cancer in any one country. 
The WCRF global network consists of WCRF International
and its member organisations. These are national charities
based in the USA, the UK, the Netherlands, France, and Hong
Kong.
Each member organisation is supported by donations from
the public and is independent of government. Each is a sep-
arate legal entity, responsible to its own board and account-
able to the donors who support it. All member organisations
determine their own programmes, which are designed to be
most effective in national and local environments. Through
national education and research programmes, a primary goal
of the WCRF global network is to help promote changes that
will decrease rates of cancer incidence. WCRF International
provides each member with financial, operational, and sci-
entific services and support.
Education 
The extensive education programmes of the global network
encourage and enable individuals, families, and communi-
ties to make healthy choices. Until 2007, these were based
on the six Diet and Health Guidelines for Cancer Prevention,
developed from the recommendations made in the first
expert report published in 1997 (see Appendix B). 
All the global network’s education programmes reflect the
most current research and the latest scientific agreements.
A prime purpose of this second Report is to provide the basis
for the WCRF global network’s education programmes from
2007. 
All network member organisations produce a wide variety
of publications. Collectively, these are the most extensive in
their field. They include a quarterly newsletter, booklets,
brochures, and leaflets covering many themes, from the lat-
est information on antioxidants to suggestions for the quick
preparation of healthy meals. The emphasis is on easy tips
and support for individuals and their families to adopt
healthy ways of life. Public seminars and specific materials
for dieticians, scientists, parents, and children all ensure that
relevant information reaches these specific groups in appro-
priate formats and language. National websites provide 
an immediate and interactive communication tool with 
the facility for nutrition hot lines, recipe corners, and daily
tips, in addition to access to the wide range of educational
materials.
Research 
The global network funds research worldwide on the role of
food, nutrition, physical activity, and associated factors in the
causation and prevention of cancer. There are two research
grant programmes within the network. One is operated by
WCRF International in London; the other is based with the
American Institute for Cancer Research, a member of the net-
work, in Washington, DC. The programmes support epi-
demiological studies and basic laboratory research. In 2007,
the cumulative research funding by all members of the WCRF
global network amounts to over $US 105 million, support-
ing almost 800 projects and involving over a thousand sci-
entists from 23 countries. 
The research issues raised in Chapter 11 of this Report will
be the basis for setting new research priorities for the glob-
al network. 
Global impact
In its first year in 1982, AICR, with the agreement of the US
National Academy of Sciences, reprinted the pioneering NAS
report on Diet, Nutrition and Cancer and distributed it to pol-
icy-makers, opinion-formers, and health professionals
throughout the USA. The findings and recommendations of
the NAS report became the first basis for the education and
other programmes of AICR. 
Following the foundation of WCRF in the UK in 1990, the
decision was taken to commission a new report with a glob-
al perspective. This work took five years. The result was the
first report, published by WCRF together with AICR in 1997
(see Appendix B). With the development of the global net-
work, the science in the field, and new understanding of the
causes of cancer, the decision was taken in 2001 to com-
mission this second Report, which has also been a five-year
task. This Report will enable the global network to deliver
the most current and reliable advice on food, nutrition, phys-
ical activity, body composition, and associated factors, in
The World Cancer Research
Fund global network
A P P E N D I X  C
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order to reduce the risk of cancer. It replaces the 1997 report
as the leading work of reference and basis for action in the
field, throughout the world.
The global network is already committed to continue this
work by continuous updating and evaluation of the scien-
tific evidence. This commitment means that the network is
now able to offer the best and most reliable advice now and
also in the future. 
The global network is also proud of its work done in asso-
ciation with United Nations and other authoritative inter-
national and national organisations. This work is concerned
with the prevention of cancer, and also the prevention of
other diseases. The methods and findings of the first and
now this Report are offered as a basis for the work of other
organisations that are also committed to the prevention of
disease and the promotion of health and well-being, world-
wide. 
Our membership 
World Cancer Research Fund International is the association
that coordinates the global network. The greatest impact can
be achieved when allied organisations work together.
Founded in 1999 and based in London and the USA, WCRF
International maximises the potential of each member organ-
isation, and strengthens their work. The commissioning and
funding of this Report, and provision of the secretariat, is an
example of all members of the global network combining
together. This has required collaboration on a global basis,
in the interests of the network and all its members, and to
further their joint mission. 
Founded in 1982, The American Institute for Cancer
Research was the first organisation to focus exclusively on the
link between diet and cancer, and became the first member
of the WCRF global network. Located in Washington, DC,
AICR is now one of the largest cancer charities in the USA,
funding scientific research and offering a wide range of edu-
cation programmes.
World Cancer Research Fund UK became the second mem-
ber of the global network when it was established in 1990.
Based in London, it is the UK’s leading charity in the field of
diet, nutrition, and cancer prevention, and is responsible for
raising awareness of the diet and cancer link among scien-
tists, public health officials, media, and the general public.
Wereld Kanker Onderzoek Fonds (WCRF NL) began work
in 1994 in the Netherlands as the third member of the glob-
al network. Based in Amsterdam, it is the only Dutch char-
ity specialising in cancer prevention by means of food, nutri-
tion, physical activity, and associated factors, and has already
made a major contribution to the acceptance of this message
in the Netherlands. 
World Cancer Research Fund Hong Kong (WCRF HK) began
work in 2002. As traditional Chinese diets have been
replaced by more western diets, patterns of cancer incidence
are changing. WCRF HK is playing a vital role, especially in
working with government health departments in Hong Kong,
to disseminate education and research programmes on can-
cer prevention. 
Fonds Mondial de Recherche contre le Cancer (WCRF FR),
founded in 2004, is the latest member of the WCRF global
network. Based in Paris, WCRF FR is building its research
and education programmes, working with like-minded
organisations to disseminate the vital information to help
people to make healthy choices and so reduce their risk of
cancer. 
From its beginnings in the early 1980s, the WCRF global
network has consistently been a pioneer and a leader of
research and education on food, nutrition, physical activity,
and the prevention of cancer. The network has a special com-
mitment to creation of the most reliable science-based rec-
ommendations and their translation into messages that form
the basis for action by professionals, communities, families,
and individuals.
This work is being done for these organisations in the USA,
the UK, the Netherlands, France, and Hong Kong, and on
behalf of people in all countries. The global network will
remain one of the leaders of the international cancer pre-
vention movement, in the broader context of better person-
al and public health, worldwide. 
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Terms here are defined in the context of
this Report. Some terms may have other
meanings in other contexts. 
Absorption
The movement of nutrients and other food
constituents from the gut into the blood. 
Acid-base balance
The appropriate acidity of the blood and
tissues. Abnormal acid-base balance may
indicate a change in respiratory or metabolic
status.
Adduct (see DNA adduct)
Adenocarcinoma
Cancer of glandular epithelial cells.
Adenosine triphosphate (ATP)
The principal molecule used for storage and
transfer of energy in metabolic processes.
Adipose tissue
Body fat. Tissue comprising mainly cells
(adipocytes) containing triglyceride. It acts as
an energy reserve, provides insulation and
protection, and secretes metabolically active
hormones.
Adiposity rebound
The age at which body mass index (BMI)
increases after reaching a nadir at around 4–6
years of age. Earlier age of adiposity rebound
has been linked to later development of
obesity.
Adjustment
A statistical tool for taking into account the
effect of known confounders (see box 3.1).
Adrenarche
The period, typically between age 6 and 10
years, characterised by an increase in secretion
of androgens from the adrenal cortex.
Aerobic metabolism
The normal process of producing ATP as a
source of energy using oxygen.
Aflatoxins
Naturally-occurring mycotoxins that are
produced by many species of Aspergillus, a
fungus, most notably Aspergillus flavus and
Aspergillus parasiticus. Aflatoxins are toxic and
carcinogenic to animals, including humans (see
box 4.1.4).
Age-adjusted incidence
The number of events in a population, usually
expressed per 100,000 people, over a defined
period of time, adjusted for the varying
proportion of people in each age group
between populations and over time. It allows
for comparisons between countries with
different age structures (see box 7.1.1).
Alpha-linolenic acid
An essential n-3 polyunsaturated fatty acid
(C18:3 n3).
Amenorrhoea
The absence of menstruation.
Amino acid
An organic compound containing an amino
group and a carboxylic acid group. The basic
building blocks of proteins such as enzymes.
Anaerobic metabolism
The process of producing ATP as a source of
energy without oxygen, resulting in lactic acid
accumulation.
Androgen
Any masculinising sex hormone, such as
testosterone.
Angiogenesis
The process of generating new blood vessels.
Antioxidants
Any substance that inhibits oxidation or traps
or quenches reactive oxygen species
generated during metabolism.
Anthropometric measures
Measures of body dimensions.
ATP (see adenosine triphosphate)
Basal energy expenditure (see basal
metabolic rate)
Basal metabolic rate (BMR)
The amount of energy required to maintain
the essential body functions in resting and
fasting conditions, expressed as megajoules,
kilojoules, or kilocalories per minute, hour, or
day. 
Begg’s test
A statistical test for small study effects such as
publication bias.
Beta-glucans
Non-starch polysaccharides composed of
glucose subunits linked in such a way as to
render them indigestible by pancreatic
amylase. A major component of the cell wall
polysaccharides of oats (see non-starch
polysaccharides and dietary fibre).
Bias
In epidemiology, deviation of an observed
result from the true value in a particular
direction (systematic error) due to factors
pertaining to the observer or to study design
or analysis. See also selection bias.
Bile
A greenish-yellow fluid secreted by the liver
and stored in the gallbladder. Bile plays an
important role in the intestinal absorption of
fats. Bile contains cholesterol, bile salts, and
waste products such as bilirubin. 
Biliary tract
The biliary tract includes the bile ducts within
the liver, the common bile duct, which
connects the liver and gallbladder to the small
intestine, and the cystic duct, which connects
the gallbladder to the common bile duct.
Bioavailability
The degree to which a nutrient (or other
substance) can be absorbed and used by the
body. 
BMI (see body mass index)
BMR (see basal metabolic rate)
Body mass index (BMI)
Body weight expressed in kilograms divided by
the square of height expressed in metres (BMI
= kg/m2). It provides an indirect measure of
body fatness. Also called Quetelet’s Index.
Caffeine
An alkaloid found in coffee, tea, kola nuts,
chocolate, and other foods that acts as a
stimulant and a diuretic.
Cancer survivor
Any person who has received a diagnosis of
cancer 
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Cantonese-style salted fish
Fish that has been treated with varying
amounts of salt and dried in natural
conditions outdoors. It is characterised by
treatment with less salt than typically used
and is also subject to fermentation during
the drying process due to relatively high
outdoor temperature and moisture levels (see
box 4.3.5).
Carcinogen 
Any substance or agent capable of causing
cancer.
Carcinoma
Malignant tumour derived from epithelial
cells, usually with the ability to spread into the
surrounding tissue (invasion) and produce
secondary tumours (metastases).
Carcinoma in situ
The first stage of carcinoma in which the
malignant tumour has not spread beyond the
epithelium.
Cardiovascular disease
A group of diseases that involve the heart
and/or blood vessels (arteries and veins). While
the term technically refers to any disease that
affects the cardiovascular system, it is usually
used to refer to those related to
atherosclerosis. 
Case-control study 
An epidemiological study in which the
participants are chosen based on their disease
or condition (cases) or lack of it (controls) to
test whether past or recent history of an
exposure such as smoking, genetic profile,
alcohol consumption, or dietary intake is
associated with the risk of disease (see box
3.4). 
CE
Common Era — the period of measured time
beginning with the year one on the Gregorian
calendar. The notations CE and BCE (Before
Common Era) are alternative notations for AD
and BC, respectively.
Cell cycle
The sequence of stages that a cell passes
through between one cell division and the
next.
Cell signalling
Mechanisms whereby cells send messages to,
or respond to external stimuli from, other
cells.
Cerebrovascular disease
A group of diseases of the brain due to
damage to the blood vessels, in which an area
of the brain is transiently or permanently
affected by ischaemia or bleeding.
Cholesterol
The principal sterol in animal tissues,
synthesised in the body; an essential
component of cell membranes and the
precursor of the steroid hormones and
vitamin D. 
Chromatin
Mass of genetic material in the nucleus of a
cell, composed of DNA and proteins that
condense to form chromosomes. 
Chronic disease
A disease that develops or persists over a long
period of time. Includes noncommunicable
diseases such as cancer, cardiovascular
disease, and diabetes, and some infectious
diseases such as tuberculosis. 
CI (see confidence interval)
Coeliac disease
Intolerance to the gliadin fraction of the
protein gluten from wheat, rye, and barley.
The villi of the small intestine atrophy and
nutrient absorption from food is poor.
Stools are often bulky and contain a large
amount of unabsorbed fat. 
Cohort study 
A study of a (usually large) group of people
whose characteristics are recorded at
recruitment (and sometimes later), followed
up for a period of time during which
outcomes of interest are noted. Differences in
the frequency of outcomes (such as disease)
within the cohort are calculated in relation to
different levels of exposure to factors of
interest, for example smoking, alcohol
consumption, diet, and exercise. Differences
in the likelihood of a particular outcome are
presented as the relative risk comparing one
level of exposure to another (see box 3.4).
Compliance
The extent to which people such as study
participants follow an allocated treatment
programme. 
Computed tomography (CT)
A form of X-ray that produces cross-sectional
or other images of the body.
Confidence interval (CI)
A measure of the uncertainty in an estimate,
usually reported as 95% confidence interval
(CI), which is the range of values within which
there is a 95% chance that the true value lies.
For example the effect of smoking on the
relative risk of lung cancer in one study may
be expressed as 10 (95% CI 5–15). This means
that in this particular analysis, the estimate of
the relative risk was calculated as 10, and that
there is a 95% chance that the true value lies
between 5 and 15. 
Confounder
A variable, within a specific epidemiological
study, that is associated with an exposure, is
also a risk factor for the disease, and is not in
the causal pathway from the exposure to the
disease. If not adjusted for, this factor may
distort the apparent exposure–disease
relationship. An example is that smoking is
related both to coffee drinking and to risk of
lung cancer and thus, unless accounted for
(controlled) in studies, might make coffee
drinking appear falsely as a possible cause of
lung cancer (see box 3.1).
Confounding factor (see confounder)
Confounding variable (see confounder)
Cretinism
Underactivity of the thyroid gland
(hypothyroidism) in infancy, resulting in poor
growth, severe mental retardation, and
deafness.
CT (see computed tomography)
Curing
Various preservation and flavouring processes,
especially of meat or fish, by the addition of a
combination of salt, sugar, and either nitrate
or nitrite. Curing processes often involve
smoking. The addition of saltpetre (sodium
nitrate) gives a pinkish colour to meat.
Bacteria convert the nitrates in cured meats to
nitrites and nitrosamines, which are
potentially carcinogenic to humans (see box
4.3.2).
Cytotoxic
Poisonous to living cells.
Deoxyribonucleic acid (DNA) 
The double-stranded, helical molecular chain
found within the nucleus of each cell that
carries the genetic information.
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DEXA (see dual energy X-ray
absorptiometry)
Diabetes mellitus
A metabolic disorder involving impaired
metabolism of glucose due either to failure of
secretion of the hormone insulin (type 1
diabetes) or to impaired responses of tissues to
insulin (type 2 diabetes), which results in
complications including kidney failure,
blindness, and increased risk of
cardiovascular disease.
Dietary fibre 
Constituents of plant cell walls that are not
digested in the small intestine. Several
methods of analysis are used, which identify
different components. The many constituents
that are variously included in the definitions
have different chemical and physiological
features that are not easily defined under a
single term. The different analytical methods
do not generally characterise the physiological
impact of foods or diets. Non-starch
polysaccharides are a consistent feature and
are fermented by colonic bacteria to produce
energy and short chain fatty acids including
butyrate. The term dietary fibre is increasingly
seen as a concept describing a particular aspect
of some dietary patterns (see box 4.1.2). 
Dietary supplement 
A substance, often in tablet or capsule form,
which is consumed in addition to the usual
diet. Dietary supplements typically refer to
vitamins or minerals, though
phytochemicals or other substances may be
included. 
Differentiation
The process of development of cells to take on
the structural and functional characteristics
specific to a particular tissue. Also, the degree
to which tumour cells have the structure or
function of the organ from which the tumour
arose. Tumours can be described as well,
moderately, or poorly differentiated: well-
differentiated tumours appear similar to the
cells of the organ in which they arose; poorly
differentiated tumours do not. The degree of
differentiation is often of prognostic
significance.
Disaccharide
A carbohydrate composed of two
monosaccharides.
Diverticular disease
The presence of pouch-like hernias
(diverticula) through the muscle layer of the
colon, associated with a low intake of dietary
fibre and high intestinal pressure due to
straining. Faecal matter may be trapped in
these diverticula, causing them to become
inflamed, causing pain and diarrhoea
(diverticulitis). 
DNA (see deoxyribonucleic acid)
DNA adducts 
DNA adducts are compounds formed by the
reaction of a chemical with DNA, which may
damage the DNA. If repaired, some adducts
can be excreted and measured in the urine as a
marker of DNA damage. If not repaired, DNA
may function abnormally and may therefore
be a stage in carcinogenesis.
Docosahexaenoic acid (DHA)
A long-chain n-3 polyunsaturated fatty acid
(C22:6 n3). 
Dose response
A term derived from pharmacology that
describes the degree to which an effect
changes with the level of an exposure, for
instance the intake of a drug or food (see box
3.2).
Double bond
A covalent bond between two carbon atoms
each with one hydrogen atom, for instance in
fatty acids.
Dual energy X-ray absorptiometry (DEXA)
A means of measuring the density of different
body tissues such as bone or fat, using two X-
ray beams with differing energy levels.
Dyslipidaemia
Any disorder of lipoprotein metabolism
resulting in abnormal plasma concentrations
or forms of lipoprotein, such as high total or
low-density lipoprotein (LDL) cholesterol
or triglyceride, and low high-density
lipoprotein (HDL) cholesterol concentrations.
Dysplasia
Abnormal development of the cells of a tissue.
Ecological study 
A study in which differences in patterns of
exposure, for instance in consumption of a
particular nutrient or food, are compared at
aggregate level, with populations (rather than
individuals) as the unit of analysis (see box 3.4).
Egger’s test
A statistical test for small study effects such as
publication bias.
Eicosapentaenoic acid (EPA)
A long-chain n-3 polyunsaturated fatty acid
(C20:5 n3).
Effect modifier/effect modification
Effect modification (or effect-measure
modification) occurs when a measure of effect
for an exposure changes over levels of
another variable (the modifier) (see box 3.6). 
Emulsifier
A substance that promotes the formation of a
stable mixture, or emulsion, of two substances
that do not normally mix well (for example oil
and water). 
Endocrine
Referring to organs or glands that secrete
hormones into the blood.
Energy 
Energy, measured as calories or joules, is
required for all metabolic processes. Fats,
carbohydrates, proteins, and alcohol from
foods and drinks release energy when they are
metabolised in the body.
Energy adjustment
The use of statistical methods to ‘adjust’
intakes of a dietary factor under study for total
energy intake (see box 3.7).
Energy balance
The state in which the total energy absorbed
from foods and drinks equals total energy
expended. Also the degree to which intake
exceeds expenditure (positive energy balance)
or expenditure exceeds intake (negative
energy balance).
Enzyme
A protein that acts as a catalyst in living
organisms, promoting chemical reactions and
regulating the rate at which they proceed.
Epidemic
A widespread or rapidly spreading disease that
affects many individuals in a population at the
same time, markedly in excess of the number
normally expected. 
Epigenetic
Relating to the control of gene expression
through mechanisms that do not depend on
changes in the nucleotide sequence of DNA,
for example through methylation of DNA or
acetylation of histone.
Epithelial (see epithelium)
Epithelial-mesenchymal transition (EMT)
A disorder of cell differentiation where cells
assume a mesenchymal rather than an
epithelial phenotype. Cancer cells may have
phenotypic similarities to EMT.
Epithelium
The layer of cells covering internal and
external surfaces of the body, including the
skin and mucous membranes lining body
cavities such as the lung, gut, and urinary tract. 
Essential amino acid
An amino acid that is required for normal
cellular structure and metabolic function but
which humans cannot synthesise and so must
obtain from food.
Evidence
Information that helps to determine whether
a proposal or belief is true or valid, or false or
invalid. 
Exercise
A type of physical activity, often deliberate
such as sport, which improves fitness or health.
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Exposure
A factor to which an individual may be
exposed to varying degrees, such as intake of
a food, level or type of physical activity, or
aspect of body composition. 
Extracellular fluid
All body fluid not contained within cells.
Includes the fluid in blood vessels (plasma) and
between cells (interstitial fluid).
Factor analysis
A statistical technique used to examine the
structure underlying the interactions between
several variables.
Fat-free mass 
The mass of all body tissue excluding the lipid
components.
Fatty acid
A carboxylic acid with a carbon chain of
varying length, which may be either saturated
(no double bonds) or unsaturated (one or
more double bonds). Three fatty acids
attached to a glycerol backbone make up a
triglyceride, the usual form of fat in foods and
adipose tissue.
Fermentation
The anaerobic metabolic breakdown of
molecules such as glucose. Fermentation yields
energy in the form of lactate, acetate,
ethanol, or other simple product.
Fetal programming (see programming)
Food systems
The interconnected agricultural, ecological,
economic, social, cultural, and technological
systems involved in food production,
distribution, and consumption.
Forest plot
A simple visual representation of the amount
of variation between the results of the
individual studies in a meta-analysis. Their
construction begins with plotting the
observed exposure effect of each individual
study, which is represented as the centre of a
square. Horizontal lines run through this to
show the 95% confidence interval. Different
sized squares may be plotted for each of the
individual studies, the size of the box
increasing with the size of the study and the
weight that it takes in the analysis. The overall
summary estimate of effect and its confidence
interval can also be added to the bottom of
this plot, if appropriate, and this is
represented as a diamond. The centre of the
diamond is the pooled summary estimate and
the horizontal tips are the confidence intervals
(see box 3.3).
Fortification
The deliberate addition of nutrients to foods
or drinks as a means of increasing the level of
intake in a population (see box 4.10.1).
Functional food
Any food, similar in appearance to
conventional food, claiming to have specific
physiological effects that benefit health
and/or reduce the risk of disease. Products are
sometimes sold in medicinal forms (see box
4.10.2). 
Gene expression
The active production of the RNA and protein
that are coded for by a particular gene. In any
cell, not all genes are expressed (see
epigenetic).
Genetic modification
The manipulation of a living organism’s
genetic material by eliminating, modifying, or
adding copies of specific genes, often from
other organisms. Also known as ‘genetic
engineering’.
Germ cell (see germ line)
Germ line
Eggs and sperm and the cells that develop into
them, through which genetic information is
passed from generation to generation.
Genotype
The genetic makeup of a cell or organism.
GH (see growth hormone)
Gleason score
A quantitative measure of the degree of
differentiation of prostate cancers. High
Gleason scores, representing aggressive
disease, are associated with poor prognoses.
Whitemore and Jewett scales are used to
assess prostate cancer stage.
Glycaemic index 
A system for ranking foods containing
carbohydrates according to the effect of a
standard amount on blood glucose levels.
Foods that raise the blood sugar the most
have the highest glycaemic index (see box
4.1.3).
Glycaemic load 
The glycaemic index of a food multiplied by
the number of grams of carbohydrate in the
serving of food (see box 4.1.3). 
Glycerol 
A three-carbon molecule that forms the
backbone of triglyceride in fats (see fatty
acid).
Goitre
Enlargement of the thyroid gland, seen as a
swelling in the neck; may be hypothyroid, with
low production of thyroid hormone,
euthyroid (normal levels), or hyperthyroid
(excessive production). Deficiency of iodine is
one cause. 
Gross domestic product
The total market value of all the goods and
services produced within a nation in a given
year.
Growth hormone (GH)
Also known as somatotropin, a hormone
secreted by the pituitary gland that stimulates
secretion of growth factors from the liver and
so also protein synthesis and growth of the
long bones in the legs and arms. It also
promotes the breakdown and use of fatty
acids, rather than glucose, as an energy
source.
Haem
The part of the organic molecule haemoglobin
in red blood cells containing iron to which
oxygen binds for transport around the body. 
Herbicide
A pesticide used to kill or control the growth
of unwanted plants. Selective herbicides kill
certain targets while leaving a desired crop
relatively unharmed. Non-selective herbicides
kill every plant with which they come into
contact.
Heterocyclic amines 
A family of compounds formed from protein
and sugars in meat, chicken, and fish cooked
at very high temperatures by grilling (broiling)
or frying that have potential carcinogenic
effects (see box 4.3.4).
Heterogeneity
A measure of difference between the results
of different studies addressing a similar
question. In meta-analysis, the degree of
heterogeneity may be calculated statistically
using the I2 test.
High fructose corn syrup (HFCS)
A form of corn syrup that has undergone
enzymatic processing in order to increase its
fructose content. Used to sweeten soft drinks,
juices, ice cream, and many other processed
foods, especially in the USA (see box 4.6.1). 
High-income countries
Countries with a gross average annual
national product of more than an agreed
figure per head (in 2006 this was more than
$US 10 726). This term is less judgemental and
more descriptive than ‘economically
developed’ countries.
Homeostasis
The maintenance of biological conditions in a
stable state.
Hormone
A substance secreted by specialised cells that
affects the structure and/or function of other
cells or tissues in another part of the body.
Hydrogenation
The process by which unsaturated fatty acids
in vegetable oils are made more saturated by
the addition of hydrogen. This makes liquid
oils more solid at room temperature and more
resistant to oxidation, for instance in the
manufacture of margarines. Incomplete
hydrogenation can lead to the formation of
trans-fatty acids (see box 4.5.1). 
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Hyperkeratosis
Excessive thickening of the outer horny layer
of the skin, affecting the palms and soles. 
Hyperplasia
An increase in the number of cells in a tissue. 
Hypertension
High blood pressure; a risk factor for
cardiovascular and kidney disease.
Hypoxia
Abnormally low levels of oxygen in blood or
tissues.
IARC
International Agency for Research on Cancer
(www.iarc.fr). 
IGF binding proteins 
Proteins that bind to insulin-like growth
factors (which are implicated in the cancer
process, see Chapter 2) in the bloodstream.
Immune response
The production of antibodies or specialised
cells in response to foreign proteins or other
substances.
Incidence rates
The number of new cases of a condition
appearing during a specified period of time
expressed relative to the size of the
population, for example 60 new cases of
breast cancer per 100 000 women per year.
Inflammation
The immunologic response of tissues to injury
or infection. Inflammation is characterised by
accumulation of white blood cells that
produce several bioactive chemicals, causing
redness, pain, and swelling. 
Inflammatory bowel disease 
A term used to describe Crohn’s disease and
ulcerative colitis: both are characterised by
chronic inflammation of the gut. 
Insulin
A protein hormone secreted by the pancreas
that promotes the uptake and utilisation of
glucose, particularly in the liver and muscles.
Inadequate secretion of, or tissue response to,
insulin leads to diabetes mellitus.
Intrinsic sugars
Sugars naturally integrated into the cellular
structure of foods, for example those present
in unprocessed fruits and vegetables.
Intra-abdominal fat
Also known as visceral fat. Fat stored within
the abdomen surrounding the internal organs
(see adipose tissue).
In utero
In the uterus; refers to events that occur
before birth.
Invasive cancer
Tumours that spread into surrounding healthy
tissue.
Iron-deficiency anaemia
A low blood concentration of haemoglobin
due to a deficiency of iron, due either to
unusually high demands or low intake or
impaired absorption.
Irradiation 
Exposure to ionising radiation. Food
irradiation is used to disinfest, sterilise, or
preserve food.
Jewett scale (see Whitemore and Jewett
scales)
K-ras
One of a class of genes (proto-oncogenes)
which when mutated can malfunction to
become an oncogene, promoting the
transformation of normal cells into cancer cells
(see box 2.2). 
Lactation
The production and secretion of milk by the
mammary glands.
Lacto-ovo-vegetarian diet
A vegetarian diet characterised by the
inclusion of eggs and dairy products, but no
other animal products.
Latency 
The period of time between the onset of a
disease process and its detection or clinical
appearance.
Lean body mass
The mass of those parts of the body that are
not adipose tissue. Lean body mass includes
some lipid and is not synonymous with fat-
free mass.
Lesion
A general term for any abnormality of cells or
tissues, including those due to cancerous
change.
Linoleic acid
An essential n-6 polyunsaturated fatty acid
(C18:2 n6).
Lipids
Naturally occurring organic molecules that are
insoluble in water, including triglycerides;
fatty acids; phospholipids; lipoproteins;
carotenoids; cholesterol, which is a
precursor of steroid hormones and vitamin
D; and the other fat-soluble vitamins A, E, and
K. Lipids are an essential component of cell
membranes and many metabolic processes.
Low-density lipoprotein (LDL) cholesterol
A class of lipoproteins that is the major carrier
of cholesterol in the blood in humans. A high
blood LDL cholesterol concentration is a cause
of coronary artery disease.
Low-income countries
Countries with a gross average annual
national product of less than an agreed
figure per head (in 2006 this was $US 875).
This term is less judgemental and more
descriptive than ‘economically developing’
countries.
Lymphocyte
Several types of white blood cell, part of the
immune system, found in the blood and lymph
glands.
Macronutrient
Those nutrient components of the diet that
provide energy: carbohydrate, fat, and
protein; ethanol also provides energy but is
not a nutrient.
Magnetic resonance imaging (MRI)
A technique that produces images of parts of
the body using analysis of the behaviour of
water molecules within body tissues when
placed in a strong magnetic field.
Malignant
A tumour with the capacity to spread to
surrounding tissue or to other sites in the
body. 
Melanoma
Malignant tumour of the skin derived from
the pigment-producing cells (melanocytes).
Membrane potential
The difference in electrical charge across the
cell membrane.
Menarche 
The beginning of menstruation (see boxes 6.1
and 6.2).
MET (see metabolic equivalent)
Meta-analysis
The process of using statistical methods to
combine the results of different studies.
Metabolic equivalent (MET)
One MET equals the resting metabolic rate,
measured as the rate of oxygen consumption,
which is approximately 3.5 millilitres of oxygen
per kilogram body weight per minute.
Equivalent to physical activity ratio (see box
5.1).
Metabolic syndrome
A common cluster of a variety of several risk
factors for cardiovascular disease including
insulin resistance, abdominal obesity, high
blood pressure, and abnormal blood lipids.
Metastasis
The spread of malignant cancer cells to
distant locations around the body from the
original site. 
Micronutrients
Vitamins and minerals present in foods and
required in the diet for normal body function
in small quantities, conventionally of less than
1 g/day (see box 4.2.3).
Migrant study
A study of people who migrate from one
country to other countries with different
environments and cultural backgrounds. The
experience, such as mortality or disease
incidence, of the migrant group is compared
with that of people in their current country of
residence and in their country of origin. 
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Mineral
An inorganic compound in food required by
the body for normal function, such as calcium,
magnesium, and iron.
Monosaccharide 
Simple sugar consisting of a single sugar
molecule, such as glucose, fructose, and
galactose. They form the basis of
disaccharides such as sucrose, and of
oligosaccharides, starch, and non-starch
polysaccharides.
MRI (see magnetic resonance imaging)
Mucosal
Relating to mucous membranes.
Mutagens
Chemical compounds or physical agents
capable of inducing genetic mutations. 
Mycotoxins
Toxins produced by fungi (moulds), especially
Aspergillus flavus under tropical conditions
and Penicillium and Fusarium species under
temperate conditions (see box 4.1.4).
Neoplasm
A benign or malignant tumour.
Nested case-control study
A case-control study in which cases and
controls are drawn from the population of a
cohort study; often used for studies of
prospectively collected information or
biological samples.
Neurotransmitter
A chemical secreted by one nerve cell that
stimulates a response in a neighbouring nerve
cell.
Night blindness
A condition in which a person has impaired
vision in the dark, characteristic of vitamin A
deficiency.
Nitrate
A salt containing the nitrate ion, which
contains nitrogen and oxygen in proportion
1:3 (NO3). Derived from decomposing organic
material such as manure, plants, and human
waste, and a component of chemical fertilisers
(see box 4.3.2).
Nitrite
A salt containing the nitrite ion, which
contains nitrogen and oxygen in proportion
1:2 (NO2). Sodium nitrite is added to many
processed meats. Nitrites are also formed in
the body from nitrates in plant foods that are
eaten. When consumed, nitrites can lead to
the generation of N-nitroso compounds,
some of which are known carcinogens (see
box 4.3.2). 
Nitrosamines 
A group of chemicals formed by the reaction
of nitrites with amines; some nitrosamines
are carcinogens (see box 4.3.2). 
N-nitroso compound (see nitrosamines)
Non-caloric sweetener
A food additive that replicates the sweetness
of sugar but with negligible food energy (see
box 4.6.2).
Non-exercise activity thermogenesis
(NEAT)
The energy used in non-conscious or
spontaneous physical activity, such as
fidgeting and posture maintenance. 
Non-milk extrinsic sugars
Sugars not present within the cellular
structure of foods, apart from those in milk or
milk products. For example those added to
foods or in juices, syrups, or honey.
Non-starch polysaccharide
A carbohydrate comprising at least 10 simple
sugar molecules; a major component of plant
cell walls and the principal analytic fraction
characterising dietary fibre (see box 4.1.2).
Nucleic acid
The four building blocks of DNA – guanine,
thymine, cytosine, and adenine.
Nutrient 
A substance present in food and required by
the body for maintenance of normal structure
and function, and for growth and
development. Nutrients include
macronutrients (fat, protein, and
carbohydrate), which provide energy as well
as performing metabolic and structural
functions, and micronutrients (vitamins and
minerals), which do not provide energy but
are necessary for normal metabolic function. 
Obesity
Excess body fat to a degree that increases the
risk of various diseases. Conventionally
defined as a BMI of 30 kg/m2 or more.
Different cut-off points have been proposed
for specific populations.
Odds ratio
A measure of the risk of an outcome such as
cancer, associated with an exposure of
interest, used in case-control studies;
approximately equivalent to the relative risk.
Oligosaccharide
A compound comprising between 2 and 10
simple sugar molecules (monosaccharides).
Oncogene
A gene whose protein product contributes to
the transformation of normal cells into cancer
cells. Oncogenes result from the mutation of
normal genes called proto-oncogenes (see box
2.2).
Organic compounds
Any member of a large class of chemical
compounds whose molecules contain carbon
(and other elements), with exception of
carbides, carbonates, and carbon oxides. Most
occur naturally only in the bodies and
products of living organisms.
Organic farming
Agricultural production system without or
with only limited use of pesticides, synthetic
fertilisers, growth regulators, and livestock
feed additives (see box 4.9.2).
Osteomalacia
A disease due to vitamin D deficiency
characterised by inadequate bone
mineralisation, pain, and increased bone
fragility.
Osteoporosis
Loss of the tissues of bone (bone cells, mineral,
and protein) to an extent that increases the
risk of fracture.
Oxidative damage
Damage to cells or structures in cells caused by
oxidation, either by chemicals or by radiation.
Some oxidants are generated in the normal
course of metabolism. Oxidation of DNA is
one cause of mutation.
p53
A protein central to regulation of cell growth.
Mutations of the p53 gene are important
causes of cancer (see oncogene and box 2.2).
Pasteurisation
Partial sterilisation of foods at a
temperature that destroys microorganisms
such as bacteria, viruses, moulds, yeast, and
protozoa without major changes in the
chemistry of the food.
Pathogenesis
The origin and development of disease. The
mechanisms by which causal factors increase
the risk of disease.
Pedometer
An instrument that records the number of
steps taken.
Peer review
The scrutiny of scientific papers by one or
more suitably qualified scientists. 
Pentosan
A polysaccharide composed of pentose
sugars (with a ring comprising 5 carbon
atoms), for example arabans or xylans. 
Phenotype
The characteristics displayed by an organism;
this depends on both the genotype and
environmental factors.
Phosphorylation
Addition of phosphate groups to hydroxyl
groups on proteins, catalysed by a protein
kinase with ATP as phosphate donor. A key
process in cell signalling and energy
transfer.
Physical activity
Any movement using skeletal muscles. 
Physical activity level (PAL)
Energy expenditure per day as a multiple of
basal metabolic rate (BMR) (see box 5.2).
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Physical activity ratio (PAR)
The energy cost of an activity per minute
divided by the energy cost of basal
metabolic rate per minute. Thus, the energy
cost of sitting at rest is about 1.2; for walking
at a normal pace, 4; and for jogging, 7.
Phytochemicals
Compounds found in plants not required for
normal structure or function, which may
modify physiological functions and influence
health (see box 4.2.1). 
Point estimate
An estimate that is reported as a single value.
The precision of a point estimate is indicated
by the width of the confidence interval that
surrounds it.
Point mutation
Mutation of a single DNA base in a gene often
leading to a single peptide change in a
protein, which can influence its function.
Polycyclic aromatic hydrocarbons 
A family of chemical compounds, including
several known carcinogens, formed by
incomplete combustion of organic substances
such as wood, coal, diesel, fat, or tobacco (see
box 4.3.4).
Polymorphisms
Common variations (more than 1 per cent of
the population) in the DNA sequence of a
gene.
Polyphenol
Any of a group of chemical substances found
in plants that have more than one phenol
group per molecule; includes tannins, lignins,
and flavonoids.
Polysaccharide
A polymer composed of multiple subunits of
monosaccharides (simple sugars) linked
together. 
Polyunsaturated fatty acids
Fatty acids containing two or more double
bonds.
Pooled analysis (see pooling)
Pooling
In epidemiology, a type of study where
original individual-level data from two or
more original studies are obtained, combined,
and re-analysed.
Positive energy balance (see energy
balance)
Prebiotic
Dietary carbohydrate that reaches the colon,
where it promotes growth of beneficial
bacterial flora (see box 4.10.2).
Precursor
A chemical compound from which another
compound is formed.
Processed meat
Meat (usually red meat) preserved by
smoking, curing, or salting, or by the
addition of preservatives. Definitions vary
between countries and studies as to what
precisely is included (see box 4.3.1).
Programming
The process whereby events happening during
fetal life (fetal programming), such as growth
restriction, or in infancy can permanently
affect the structure and function of particular
organs, and so also metabolic processes.
Combined with other factors, this can in turn
alter the response to environmental
exposures and so susceptibility to disease.
Promoter region
The region of DNA in a gene which initiates
the transcription of DNA to RNA when the
enzyme RNA polymerase binds to it. 
Prostaglandins 
A range of hormones derived from essential
fatty acids. Among many other processes,
they influence blood pressure and
inflammation.
Publication bias
A bias in the overall balance of evidence in
the published literature due to selective
publication. Not all studies carried out are
published, and those that are may differ from
those that are not. Publication bias can be
tested for with either Begg’s or Egger’s
tests.
Randomised controlled trial (RCT)
A study in which a comparison is made
between one intervention (often a treatment
or prevention strategy) and another (control).
Sometimes the control group receives an
inactive agent (a placebo). Groups are
randomised to one intervention or the other,
so that any difference in outcome between the
two groups can be ascribed with confidence to
the intervention. Neither investigators nor
subjects usually know to which condition they
have been randomised; this is called ‘double-
blinding’ (see box 3.4).
RCT (see randomised controlled trial)
Reactive oxygen species
Oxygen-containing radical or reactive ion that
oxidises DNA (removes electrons); can be
hydroxyl radical (OH-), hydrogen peroxide
(H2O2) or superoxide radical (O2-).
Red meat
Meat from domesticated cattle, pigs, sheep,
and goats; not poultry and fish or meat from
wild animals.
Refined sugars
Sugars obtained by purification from plants
which contain it, principally sugar cane or
beet.
Relative risk (RR)
The ratio of the rate of disease or death
among people exposed to a factor, compared
to the rate among the unexposed, usually used
in cohort studies (see odds ratio). 
Resting metabolic rate
Metabolic rate in a fasting subject sitting
quietly (also see basal metabolic rate).
Reverse causation
The situation when an abnormal level of an
exposure is caused by the cancer or its
treatment, rather than the other way round.
For example if cancer causes weight loss, then
the finding that low BMI is associated with
increased risk may reflect weight loss due to
cancer rather than low weight causing cancer.
Ribonucleic acid (RNA)
The molecule created by RNA polymerase from
DNA (transcription) which carries the genetic
message to ribosomes (translation), where
proteins are made.
Rickets
Malformation of the bones in growing
children due to deficiency of vitamin D. In
adults the equivalent is osteomalacia.
RNA (see ribonucleic acid)
Salt iodisation
The practice of fortifying salt with iodide as a
means of ensuring adequate iodine intake.
Satiation
The development of fullness during eating
that limits the size of a meal consumed (see
satiety).
Satiety
The suppression of appetite after eating that
inhibits the starting of eating (see satiation).
Saturated fatty acids
Fatty acids that do not contain any double
bonds.
Selection bias
Bias arising from the procedures used to select
study participants and from factors influencing
participation. 
Single bond
A covalent bond between two carbon atoms,
each with two hydrogen atoms, for instance in
saturated fatty acids.
Single nucleotide polymorphism (SNP)
DNA sequence variation where a single
nucleotide in the DNA is altered. SNPs account
for 90% of all human genetic variation (see
polymorphism and point mutation).
SLR (see systematic literature review)
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Smoking (foods)
Smoking is the process of curing, cooking, or
seasoning food by exposing it for long periods
of time to the smoke from a wood fire. ‘Hot
smoking’ is a process that can be used to fully
cook raw meats or fish, while ‘cold smoking’ is
an hours- or days-long process that is generally
used to preserve or flavour foods (usually
meats or fish, but sometimes cheeses,
vegetables, fruits).
SNP (see single nucleotide polymorphism)
Socioeconomic status
A combined product of social and economic
status reflecting education level, personal
wealth, class, and associated factors. 
Solvent
Substances (usually liquid) capable of
dissolving or dispersing one or more other
substances.
Spontaneous physical activity (see non-
exercise activity thermogenesis)
Squamous cell carcinoma
A malignant cancer derived from squamous
epithelial cells. 
Stabiliser
One of a number of food additives, such as
agar or pectin (used in jam, for example), that
give foods a firmer texture. While they are not
true emulsifiers, they help to stabilise
emulsions.
Statistical significance
The probability that any observed result might
not have occurred by chance. In most
epidemiologic work, a study result whose
probability is less than 5% (p < 0.05) is
considered sufficiently unlikely to have
occurred by chance to justify the designation
‘statistically significant’ (see confidence
interval). 
Stem cell
A cell that can self-renew or give rise to a
lineage of more differentiated cells.
Sterilisation
The destruction of bacteria or other
microorganisms by heat, radiation, or
chemical means.
Steroid hormone
One of several hormones derived from
cholesterol and having a central effect on
growth and metabolism.
Supplement (see dietary supplement)
Systematic literature review (SLR)
A means of compiling and assessing published
evidence that addresses a scientific question
with a predefined protocol and transparent
methods (see box 3.5).
Testosterone
An androgenic steroid hormone and the
principal male sex hormone.
Thermodynamics
The branch of physics concerned with the
study of energy and its conversion between
different forms.
Thermogenesis
The process of heat production. In adults,
arising from the metabolic processes during
the digestion and assimilation of food and
during shivering.
Tocotrienol
A form of vitamin E. 
Total energy expenditure
The energy expended in a 24-hour period by
an individual or a group of individuals. It
reflects the average amount of energy spent
in a typical day, but may not be the exact
amount of energy spent each and every day.
Transcription
Synthesis of RNA from DNA by the enzyme
RNA polymerase. 
Transition cultures
Countries in the process of changing from one
predominant social/cultural structure to
another, for instance moving from lower-
income to higher-income status with the
accompanying changes that this implies. 
Translation
The process by which RNA carries the genetic
message from DNA to generate proteins in
the ribosome.
Tumour suppressor gene
A gene whose protein product inhibits tumour
formation (see also oncogene and box 2.2).
UICC
International Union Against Cancer
(www.uicc.org). 
Ulcerative colitis
A disease causing chronic inflammation of
the large intestine (colon). Together with
another disease of inflammation of the
intestines called Crohn’s disease, referred to as
inflammatory bowel disease.
Underwater weighing
A method for estimating the proportions of
body fat and lean mass. By comparing weight
underwater with weight on land, and taking
account of the different densities of fat and
lean tissue, the proportions of fat and lean can
be calculated. 
UVA/UVB
Ultraviolet light of different wavelengths.
UVA has relatively long wave lengths, UVB
relatively short.
Visceral fat (see intra-abdominal fat)
Waist to hip circumference ratio (WHR)
A measure of body shape indicating fat
distribution. 
Weight cycling
Repeated abnormal losses and regains of
weight, often the result of repeated diet
regimes. 
Whitemore and Jewett scales
A scale used to describe the stage of prostate
cancer.
WHO
World Health Organization (www.who.int).
Wholegrain
Cereal grain that retains the bran and germ as
well as the endosperm, in contrast to refined
grains that retain only the endosperm. All
components of the grain are retained in their
usual proportions, though the term
‘wholegrain’ may apply to products that
include other constituents, so that the
complete product comprises less than 100%
wholegrain (see box 4.1.1). 
WHR (see waist to hip circumference ratio)
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Abdominal fatness, 213–14, 225–7
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colorectal cancer, 225–6, 287–8
endometrial cancer, 227, 301
pancreatic cancer, 226, 273–4
Adaptation, weight gain, 324–5
Adaptive immunity, 38
Additives, 175–6, 385
Adipose tissue-derived oestrogen, 221
Adiposity rebound, early childhood, 232
Adrenal sex hormones, 232
Adult attained height, 231, 232–7
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body fatness, 39
breast cancer, 233–5, 293–4
colorectal cancer, 232–3, 288
endometrial cancer, 237, 301–2
obesity, 39
ovarian cancer, 236–7, 297–8
pancreatic cancer, 235–6, 274
thyroid cancer, 318–19
Aflatoxins, 70, 279
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liver cancer, 73
AIDS, 351–2
Alcohol, 39, 157–71
breast cancer, 165–8, 291
chronic disease, 354
colorectal cancer, 164–5, 286
composition, 158
consumption patterns, 159
definition, 158
evidence and judgements, 159–71
evidence interpretation, 159
kidney cancer, 170–1, 311
laryngeal cancer, 160–2
liver cancer, 168–70, 279
lymphoid and haemopoietic cancers, 320
mouth cancer, 160–2, 248
oesophageal cancer, 162–4, 257
pharyngeal cancer, 160–2
psychological effects, 157
public health goals, 383–4
recommendations, 383–4, 391
report comparisons, 171, 358
sources, 158
types, 159
Alkenylbenzenes, 175–6
Allium vegetables, 92–3, 267–8
colorectal cancer, 93–4
oesophageal cancer, 86
stomach cancer, 92–3
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Alpha-linolenic acid, 136
Alpha-tocopherol, 187
prostate cancer, 109, 308–9
Amenorrhea, 240
Animal fats
colorectal cancer, 286
weight gain determinants, 338–9
Animal products
consumption trends, 11–12
goals and recommendations, 382–3
see also Meat
Antigrowth signal insensitivity, 42
Antioxidants, 38
Apoptosis evasion, 44–6
Appetite, 329
Arsenic, 150, 152–4, 392
bladder cancer, 153, 314
kidney cancer, 153, 311
lung cancer, 152, 262, 316
skin cancer, 152–3, 316–17
Ascorbic acid (vitamin C), 78, 107–8, 256
Asian diets, 191, 194
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Aspergillus parasiticus, 70
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B
Bacteria, 40
Baking, 176
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mouth, pharynx, and larynx cancer, 161
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sources, 158
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Beta-cryptoxanthin, lung cancer, 102
Betel quid, oral cancers, 246
Binge drinking, 159
Biological pathways, 54–5
Biomarkers, 56, 363
Birth weight, 230
Black tea, consumption trends, 149
Bladder cancer, 153, 312–14
dairy products, 133
Egypt, 7
evidence and judgements, 314
evidence interpretation, 313
milk and dairy products, 133
previous report comparisons, 314
supplements, 346
trends, incidence, and survival, 312–13
Body composition, 210–42
Body fatness, 211–28
adult attained height, 39
assessment, 212
body mass index, 212, 325
breast cancer, 218–19, 292–3
Index
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classification, 214
colorectal cancer, 216–18, 287
definitions, 212–14
distribution, 213
endometrial cancer, 221–3, 301
evidence and judgements, 214–28
evidence interpretation, 214
gallbladder cancer, 223–4, 276
kidney cancer, 223, 311–12
liver cancer, 224–5, 279–80
lung cancer, 224–5, 264
lymphoid and haemopoietic cancers, 320
measurement, 214
oesophageal cancer, 257–8
pancreatic cancer, 215–16, 273
patterns, 212–14
previous report comparisons, 228
public health goals, 374–9
recommendations, 374–9
regulation, 327–9
reporting bias, 214
thyroid cancer, 318
Body mass index (BMI), 324, 375
body fatness, 212, 325
cancer survivors, 347
chronic diseases, 330
international trends, 13
principle cut-off points, 212–13
risk of death, 329
Boiling, 176, 385
Bottling, 175, 385
Brain growth, 230
Brain tumours, 321
Brazil, 28
Breakfast cereals, 68
Breast cancer, 289–95
abdominal fatness, 294
adult attained height, 233–5, 293–4
alcohol, 165–8, 291
birth weight, 294
body fatness, 218–19, 292–3
evidence and judgements, 291–5
evidence interpretation, 291
fat intake, 138, 294
inherited mutations, 290
international trends, 21
lactation, 240–1, 292
life events, 290
menarche, age of, 232
menopause status unspecified, physical activity, 204
pathogenesis, 290–1
physical activity, 204, 292
postmenopausal see Postmenopausal breast cancer
premenopausal see Premenopausal breast cancer
previous report comparisons, 295
radiation, 291
trends, incidence, and survival, 290
weight gain, 294
Western diets, 194
Breastfeeding, 193, 239–42, 331, 335–6
chronic disease, 354
dietary patterns in adulthood, 195–6
growth, 231
infectious diseases, 352
nutritional deficiencies, 351
public health goals, 388
recommendations, 388
urban-industrial food systems, 8
Broiling, 177
Butter, 139
colorectal cancer, 139
lung cancer, 139, 262
Butyrate, 43
C
Caffeine, sources, 151
Calcium, 43, 134, 187–8
colorectal cancer, 132–3, 286–7
foods containing, 131
prostate cancer, 134, 307
Cancer
common diagnoses, global, 17
hallmarks, 44
incidence measurement, 18–19
international trends, 17
other report findings, 355–8
outcomes, 56–7
principles of, 31
processes linked to, 33, 45
projected increase, 17
Cancer process, 30–46
carcinogen metabolism, 36–7
causes, 37–41
endogenous, 38–40
exogenous, 40–1
cellular, 32–6
nutritional influence, 41–6
principles of, 31–2
Cancer survivors, 342–7
definitions, 343–4
evidence interpretation, 344–5
judgements, 345–7
occurrence, 344
previous report comparisons, 347
public health goals, 389–90
recommendations, 389–90
supplement use, 346
Canning, 175, 385
Cantonese-style salted fish, 120, 392
nasopharyngeal cancer, 125–6, 252
Carbohydrates, 180
Carcinogenesis, 41–2
Carcinogens
cigarette smoke, 40
food, 41
metabolism, 36–7
Carotenoids, 78, 100–6
laryngeal cancer, 100–1
lung cancer, 101–2, 261
oesophageal cancer, 103
oral cancers, 100–1, 248
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pharyngeal cancer, 100–1
prostate cancer, 103–5
skin cancer, 105–6
Carrots
cervical cancer, 94, 304
endometrial cancer, 92
oral cancers, 83–4
stomach cancer, 91
Case-control studies, 50–1
Catch up growth, 231
Cell cycle, 43
Cell proliferation, 42–4
Cell signalling, 33
Cellular cancer prevention, 41
Cellular cancer processes, 32–6
Cereals (grains), 67–74, 180
chronic disease, 353
composition, 69
consumption patterns, 11, 70–1
definitions, 68
dominant indigenous crops, 6
evidence and judgements, 71–3
interpretation, 71
infectious diseases, 351
recommendations, 385
report comparisons, 73, 358
sources, 68
wholegrain, 68, 336–7
Cervical cancer, 302–4
carrots, 94, 304
evidence and judgements, 304
human papilloma viruses, 303
international trends, 21
life events, 304
pathogenesis, 303
previous report comparisons, 304
tobacco use, 304
trends, incidence, and survival, 302–3
Cheese, 133–4, 286, 382
Chemical preservation, 175
Chewing tobacco, 246
Childhood obesity, 10, 326
Children, 335
Chilli, 113, 268
China, 10–11
Cholesterol, 136
Chronic disease, 352–5
Chronic inflammatory conditions, 38
Cigarette smoke, 40
Citrus fruits, 95, 96–7
Coffee, 148, 149, 152
decaffeinated, 149
kidney cancer, 155, 311
pancreatic cancer, 153–4, 273
previous report comparisons, 156
sources, 149
Cohort studies, 51
Colon anatomy, 281
Colorectal cancer, 280–8
abdominal fatness, 225–6, 287–8
adult attained height, 232–3, 288
alcohol, 164–5, 286
animal fats, 286
animal products, 284–5
body fatness, 216–18, 287
butter, 139
calcium, 187–8, 286
cheese, 133–4, 286
dietary fibre, 71–2, 282–3
evidence and judgements, 282–8
evidence interpretation, 282
fish, 125, 285
folate, 107, 284
fruits, 100, 283–3
international trends, 20
iron, 127
meat, 120–1
Mediterranean diets, 193–4
milk and dairy products, 132–4, 285
nitrates, 284
pathogenesis, 282
physical activity, 202–3, 287
previous report comparisons, 288
processed meat, 123, 284–5
selenium, 111–12, 189, 284, 287
sugars, 144–5, 286
tobacco use, 286
trends, incidence, and survival, 282
vegetables, 91, 93–4, 283
vitamin D, 125–6, 285
waist circumference, 225
waist to hip ratio, 225
Western diets, 194
Colours, added, 176
‘Concentration’ biomarkers, 56
Contaminants, 175, 385
Conventional therapies, 345
Coronary heart disease (CHD), 352
CpG islands, 34
Crop availability differences, 11
Cruciferous vegetables, 37
endometrial cancer, 92
oesophageal cancer, 86
oral cancers, 83
Cultural dietary patterns, 192–3
Cyclin dependent kinases (CDKs), 42
CYP2EI, 37
Cytochrome P450, 36
D
Dairy products
bladder cancer, 133
chronic disease, 354
colorectal cancer, 132–3, 285
composition, 130
consumption patterns, 130–1
definition, 130
evidence and judgements, 131–4
evidence interpretation, 131
infectious diseases, 129–34, 352
lymphoid and haemopoietic cancers, 320
previous report comparisons, 134
prostate cancer, 307
recommendations, 382
sources, 130
testicular cancer, 319
see also Milk
Dansinger trial, 336, 337
Decaffeinated coffee, 149
Descriptive studies, 49
Development see Growth and development
Diallyl disulphide, 43
Dietary assessment methods, 55–6
Dietary constituents, 179–89
evidence and judgements, 183–9
interpretation, 183
previous report comparisons, 189
Dietary fibre, 71–2
aflatoxins, 72–3
colorectal cancer, 71–2, 282–3
foods containing, 69, 80
liver cancer, 73
oesophageal cancer, 72, 255
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weight gain determinants, 337–8
Dietary guidelines, 349
Dietary patterns, 190–6
characterisation, 190
cultural, 192–3
evidence and judgements, 193–6
previous report comparisons, 196
traditional, 191–2
Dietary Patterns and Cancer (DIETSCAN), 195
Dietary recommendations, 180
Dietetics, 190
Diethylstilboestrol, 304
Diet interventions, adult, 333
Diets, 5–10
Differentiation, 35
Disaccharides, 142
DNA, 31–2, 33
damage, 35–6
methylation, 34
repair, 35–6
Dose response, 52
‘Double blind’ RCT, 51
Dried milk, 130
Drink trends, 11–13
Drying, 174, 385
E
Ebbeling trial, 336, 337
Ecological studies, 22–5, 49–50
Effect modification, 56
Eggs, 382
composition, 119
consumption patterns, 120
definition, 117
infectious disease, 351
report comparisons, 358
sources, 117
Egypt, 6–7
Endometrial cancer, 299–302
abdominal fatness, 227, 301
adult attained height, 237, 301–2
body fatness, 221–3, 301
evidence and judgements, 300–2
meat, 122, 300–1
pathogenesis, 300
physical activity, 301
previous report comparisons, 302
trends, incidence, and survival, 299
vegetables, 92, 300
waist circumference, 227
waist to hip ratio, 227
Energy
costs, 200–1
density, 324
intake, 328
output, obesity, 328
requirement, 328
Energy adjustment, 57
Energy balance, 328
body composition and, 330–1
Energy-dense foods
public health goals, 379
recommendations, 379
weight gain determinants, 338
Energy restriction, 46, 328
Environmental factors, 4
Epigenetic regulation, 34
Epstein-Barr virus, 251, 319
Ethanol
breast cancer, 167–8
colorectal cancer, 164–5
definition, 158
kidney cancer, 170
liver cancer, 168–9
European Prospective Investigation into Cancer 
and Nutrition (EPIC), 194
Evidence evaluation, 48–62
assessment methods, 55–7
causation and risk, 57–8
epidemiological, 49–52
experimental, 52–5
interpretation issues, 50
judgement, coming to, 58–62
Evidence grading criteria, 60–1, 62
Extrinsic sugars, 141–2
F
Familial adenomatous polyposis (FAP), 38, 282
Famines, 325
Fast food, 325, 339–40, 379
Fats and oils, 135–40, 180–1
breast cancer, 138, 294
composition, 136–7
consumption, 135, 137
definitions, 136
evidence and judgements, 138–9
evidence interpretation, 137–8
lung cancer, 138, 262
lymphoid and haemopoietic cancers, 320
production, 135
purpose, 136
quality, 136
report comparisons, 139, 358
sources, 136
Fat stores, peripheral, 213
Fatty acids, 136
Fermenting, 174–5, 385
Fibre see Dietary fibre
Fish, 125, 382
chronic disease, 353
colorectal cancer, 125, 285
composition, 118–19
consumption patterns, 12, 119
definition, 117
lymphoid and haemopoietic cancers, 320
report comparisons, 128, 358
sources, 117
thyroid cancer, 318
Fish oil supplements, 43
Flavonoids, 37
Flavours, added, 175–6
Flemming trial, 336, 337
Flores trial, 334, 337
Folate, 36, 43, 78, 106–7
colorectal cancer, 107, 284
metabolism, 37
oesophageal cancer, 106–7, 256
pancreatic cancer, 272–3
Food balance sheets, 13
Food-based approach, 60–1
Food consumption measurement, 13
Food diary, 55
Food frequency questionnaires, 55
Food preparation, 176–7, 384–6
Food preservation methods, 174–5, 384–6
Food processing, 175–7, 384–6
Food production methods, 172–4
chronic disease, 354
evidence and judgements, 177
evidence interpretation, 177
infectious diseases, 352
report comparisons, 177, 358
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Food-related disease prevention, 356–7
Food supply measurement, 13
Food systems, 5–10, 173, 190
Food trends, 11–13
Forest plots, 53
Fortification, 182
Foster trial, 336, 337
Fruit(s)
chronic disease, 353
classification, 82
colorectal cancer, 100, 283–4
composition, 79
consumption patterns, 80–1
global consumption, 73
infectious diseases, 351
laryngeal cancer, 94–5
liver cancer, 100, 278–9
lung cancer, 97–9, 261
lymphoid and haemopoietic cancers, 320
nasopharyngeal cancer, 99, 251–2
nutritional deficiencies, 351
oesophageal cancer, 95–7, 255
oral cancers, 94–5, 247–8
pancreatic cancer, 99–100, 272
pharyngeal cancer, 94–5
recommended minimum daily amounts, 12
report comparisons, 114, 358
sources, 77
stomach cancer, 90, 98–9, 268
Fruit juices, 148–56
chronic disease, 354
composition, 151
consumption patterns, 151
definition, 149
evidence and judgements, 152–6
evidence interpretation, 151–2
sources, 149
Frying, 177
Functional foods, 182
G
G1 phase, cell cycle, 42
G2 phase, cell cycle, 42
Gallbladder cancer, 223–4, 275–6
Gallstones, 275
Gamma-tocopherol, 109
Garlic, 93–4, 267, 283
Gatherer–hunter food systems, 5–6, 68
Gene expression, 33–4
Gene–nutrient interactions, 362
Genetic material, 31–2
Genetic modification, 174
Genetic polymorphisms, 362
Glucose, 142
Glucosinolates, 37, 43, 92
Glutathione-S-transferases (GSTs), 36, 73
Glycaemic index, 69, 180
Glycaemic load, 69
Grains see Cereals (grains)
Green tea, 150
Grilling, 177, 269, 385
Growth and development, 210–42
definitions, 230–1
evidence and judgements, 231–8
evidence interpretation, 231
patterns, 230–1
prepubertal, 230–1
previous report comparisons, 238
Growth factors, 39, 306
Growth hormones, 231
Growth phases, 230
Growth signal autonomy, 42
GSTM1, 37
H
Haemopoietic cancers, 318–20
Harvey Berino trial, 336, 337
Health Professionals Follow-Up Study, 194
Healthy diets, 193
trials, 345–6
Height, adult attained see Adult attained height
Helicobacter pylori, 40
in drinking water, 150
salt, 145–6
stomach cancer, 20, 266
Hepatitis virus, 73, 278
liver cancer, 278
Herbicides, 173
Herbs, 78, 113
Hereditary nonpolypopsis colorectal cancer (HNPCC), 282
Heterocyclic amines, 41, 119
High birth weight, 230, 237–8
adult attained height, 374
breast cancer, 294
High fructose corn syrup, 141–2
High temperature food and drink, 155–6, 257
Histone structures, 33
HIV, 351–2
Hodgkin’s lymphoma, 319
Hormone replacement therapy (HRT), 219, 291
Hormones, 39–40, 290
Hot drinks, 148–56
chronic disease, 354
composition, 151
consumption patterns, 151
definition, 149–50
evidence and judgements, 152–6
evidence interpretation, 151–2
sources, 149–50
Household income surveys, 13
Human evolution, 324–5
Human feeding studies, 52–3
Human papilloma viruses, 303
cervical cancer, 303
Hydrogenation, 8, 136–7
I
Immune surveillance hypothesis, 38
India, 14–15
Indole-3-carbinol, 37
Industrial chemicals, 40–1
bladder cancer, 313
lung cancer, 260
stomach cancer, 266–7
Industrial cooking, 176
Industrial dietary patterns, 191–2
Industrial revolution, 7
Infant growth, 230–1
Infectious agents, 40, 351–2
bladder cancer, 313
stomach cancer, 266
Inferring causation, 57
Inflammation, 38–9
chronic conditions, 38
Inherited germ line mutations, 38
Inherited susceptibility, 244
Initiation, 41
Innate immunity, 38
Insulin, 43
Insulin-like growth factor 1 (IGF-1), 39
Insulin-like growth factors (IGF), 306
511
I N D E X
Interleukin 6 (IL-6), 39
International Agency for Research on Cancer (IARC), 49
International Classification of Disease (ICD) codes, 57
International variations and trends, 4–29
foods and drinks, activity, and body composition, 11–22
food systems and diets, 5–10
Intestinal bacteria, 165
In vitro studies, 53–4
Ionising radiation, 40
Iron, 118, 127, 285
colorectal cancer, 127
Irradiation, 175
Irritant drinks, 150
Isothiocyanates (ITCs), 37
J
Japan, 17–18
Judgement, 58–62
levels and types, 59
robust, basis for, 61–2
K
Kidney cancer, 310–12
alcohol, 170–1, 311
arsenic, 153, 311
body fatness, 223, 311–12
coffee, 155, 311
evidence and judgements, 311–12
evidence interpretation, 311
pathogenesis, 310–11, 313
previous report comparisons, 312
tobacco use, 311
trends, incidence, and survival, 310
Western diets, 195
L
Lactation, 239–42
breast cancer, 240–1, 292
definition, 239–40
evidence and judgements, 240–2
evidence interpretation, 240
ovarian cancer, 242, 298
patterns, 239–40
previous report comparisons, 242
total duration, 241–2
Lactose, 130
Landmark reports, 349
Laryngeal cancer, 245–9
alcohol, 160–2
carotenoids, 100–1
evidence and judgements, 247–9
fruits, 94–5
maté, 155
pathogenesis, 246
previous report comparisons, 249
trends, incidence and survival, 245–6
vegetables, 82–4
Leermarker’s trial, 332
Legumes see Pulses (legumes)
Leukaemia, 319
Life events
breast cancer, 290
cervical cancer, 304
ovarian cancer, 297
Life expectancy, by country, 9
Linoleic acid, 136
Liquors see Spirits/liquors
Literature reviews, systematic, 54
Live animal models, 5
Liver cancer, 277–80
aflatoxins, 73
alcohol, 168–70, 279
body fatness, 224–5, 279–80
dietary fibre, 73
evidence and judgements, 278–80
evidence interpretation, 278
fruits, 100, 278–9
hepatitis virus, 278
international trends, 20
pathogenesis, 278
previous report comparisons, 280
trends, incidence, and survival, 277–8
Low birth weight, 230
Low energy-dense food, 336
Lung cancer, 259–64
animal products, 262
arsenic, 152, 262, 316
beta-carotene, 185, 263
beta-cryptoxanthin, 102
body fatness, 224–5, 264
butter, 139, 262
carotenoids, 101–2, 261
China, 10–11
evidence interpretation, 260
fats and oils, 138, 262
fruits, 97–9, 261
industrial chemicals, 260
international trends, 19
meat, 121–2
pathogenesis, 260
physical activity, 206–7, 263–4
previous report comparisons, 264
processed meat, 124, 262
quercetin, 112, 262
retinol supplements, 184, 263
selenium, 109, 188, 261–3
tobacco use, 260
trends, incidence, and survival, 260
vegetables, 90–1, 261
Western diets, 195
Lycopene, 101, 103–4, 308
Lymphoid cancer, 318–20
M
Macronutrients, 180–1
Maltose, 142
Maté, 148, 392
laryngeal cancer, 155
oesophageal cancer, 155–6, 257
oral cancers, 155, 248
pharyngeal cancer, 155
sources, 150
Matvienko trial, 336, 337
Matrix approach, 58–9
Matrix metalloproteases (MMPs), 46
Meal frequency, 193, 195–6
Meat
chronic disease, 353
colorectal cancer, 120–1
composition, 118
consumption patterns, 119
definition, 117
endometrial cancer, 122
lung cancer, 121–2
lymphoid and haemopoietic cancers, 320
oesophageal cancer, 121
pancreatic cancer, 122
processed see Processed meat
red see Red meat
report comparisons, 128, 358
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sources, 117
Medications, carcinogenic, 41
Mediterranean diets, 191, 193–4
Melanoma skin cancer, beta-carotene supplementation, 187
Menarche, age of, breast cancer, 232
Meningiomas, 321
Meta-analysis, 51–2
Metabolic equivalents (METs), 200
Metastasis, 46
Methodology Task Force, 54, 55
Methylation of DNA, 34
Methylenetetrahydrofolate reductase (MTHFR) gene, 37
Mexico, 26
Micronutrients, 78, 181–3
Micro RNAs (miRNAs), 33–4
Microwaving, 177
Migrant studies, 22–5, 50
Milk, 129–34
bladder cancer, 133, 314
colorectal cancer, 285
composition, 130
consumption patterns, 130–1
definition, 130
evidence and judgements, 131–4
evidence interpretation, 131
lymphoid and haemopoietic cancers, 320
previous report comparisons, 134
products made from, 129
prostate cancer, 307
recommendations, 382
sources, 130
testicular cancer, 319
Minerals, 182
MONICA project, 13
Monosaccharides, 142
Monounsaturated fatty acids, 136
Morbid obesity, gradings, 212–13
Mortality measurement, 18–19
Mo-Suwan trial, 334
Moulds, 41
Mouth cancer, 245–9
alcohol, 160–2
carotenoids, 100–1
evidence and judgements, 247–9
evidence interpretation, 247
fruits, 94–5
maté, 155
pathogenesis, 246
previous report comparisons, 249
trends, incidence, and survival, 245–6
vegetables, 82–4
Western diets, 195
mRNA, 31
Multicentre Growth Reference Study (MGRS), 230
Multiple myeloma, 319
Musculoskeletal system cancers, 320–1
Mycotoxins, 70
N
n-3 fatty acids, 46
Nails, selenium
colorectal cancer, 111
lung cancer, 109
prostate cancer, 110–11
stomach cancer, 111
Nasopharyngeal cancer, 125–6, 250–2
Epstein-Barr virus, 251
evidence and judgements, 251–2
evidence interpretation, 251
fruits, 99, 251–2
pathogenesis, 251
previous report comparisons, 252
trends, incidence, and survival, 250
variants, 250
vegetables, 90
Nervous system cancers, 321
Nested case-control studies, 51
Nitrates, 118
colorectal cancer, 284
stomach cancer, 269
Nitrosamines
nasopharyngeal cancer, 252
stomach cancer, 266
N-nitroso compounds, 37, 41, 118
Non-Hodgkin’s lymphoma, 319
Non-melanoma skin cancer, 315–16
beta-carotene supplementation, 186–7, 317
Nucleotide excision repair, 36
Nurses Health Study, Western diets, 194
Nutrigenomics, 32
Nutritional deficiencies, other report findings, 350–1
Nutritional patterns, 392
Nutrition interventions, 337
Nutrition over life course, 34
Nutrition status, 56
Nuts and seeds
composition, 80
definition, 77–8
sources, 77–8
O
Obesity
adult attained height, 39
characteristics, 39
childhood, 10, 326
genetically determined, 329
global pandemic, 326–7
hormones and growth factors, 39
physical health problems, relative risk, 326
projected increases, 14
public health issue, 325–6
report findings, 355
see also Overweight
Obesity determinants see Weight gain determinants
Oesophageal cancer, 253–8
alcohol, 162–4, 257
animal products, 256–7
beta-carotene, 103
body fatness, 214–15, 257–8
carotenoids, 103, 256
classification, 254–5
dietary fibre, 72, 255
evidence and judgements, 255–8
evidence interpretation, 254–5
folate, 106–7, 256
fruits, 95–7, 255
high temperature food and drink, 155–6
international trends, 17–19
maté, 155–6, 257
meat, 121, 256
pathogenesis, 254
previous report comparisons, 258
processed meat, 123, 2573
pyridoxine (vitamin B6), 107, 256
tobacco use, 254
trends, incidence and survival, 254
vegetables, 84–6, 255
vitamin C, 107–8, 256
vitamin E, 108, 256
Western diets, 194
Oestradiol, fats and, 139
Oestrogen, 39, 139
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adipose tissue-derived, 221
Oils see Fats and oils
Oncogenes, 35
Oral combined contraceptive pill, 39
Organic farming, 174
Ovarian cancer, 296–8
adult attained height, 236–7, 297–8
evidence and judgements, 297–8
evidence interpretation, 297
lactation, 242
pathogenesis, 296–7
trends, incidence, and survival, 296
vegetables, 91–2
Overweight
children, 10, 326
determinants see Weight gain determinants
gradings, 212–13
increase estimates, 327
international trends, 13–14
prevalence estimates, 327
principal cut-off points, 212
rates, 323
risks, 329–30
Oxidative stress, 38
P
p53 gene, 44
Packaging, 176
Palm oil, 137
Pancreatic cancer, 271–4
abdominal fatness, 226, 273–4
adult attained height, 235–6, 274
body fatness, 215–16, 273
coffee, 153–4, 273
evidence and judgements, 272–4
evidence interpretation, 272
folate, 106
fruits, 99–100
meat, 122
pathogenesis, 272
physical activity, 207–8
previous report comparisons, 274
trends, incidence, and survival, 271–2
Western diets, 195
Pasteurisation, 175
Patient-centred Assessment and Counselling 
for Exercise (PACE) Trial, 332
Patterns, 391–3
integrated approach, 391–2
national recommendations, integration with, 392
regional and special circumstances, 392
Peasant-agricultural food systems, 6–7
Peripheral fat stores, 213
Personal recommendations, 373–90
alcohol, 384
animal foods, 383
body fatness, 375
breastfeeding, 388
cancer survivors, 390
food processing and preservation, 385
physical activity, 377
plant foods, 381
supplementation, 387
weight gain, 379
Pesticides, 173
Pharyngeal cancer, 245–9
alcohol, 160–2
carotenoids, 100–1
evidence and judgements, 247–9
evidence interpretation, 247
fruits, 94–5
maté, 155
pathogenesis, 246
previous report comparisons, 249
vegetables, 82–4
Western diets, 195
Phase I metabolising enzymes, 36
Phase II metabolising enzymes, 36
Phenacetin, 311
Phenolic compounds, 43
Physical activity, 198–209
achieving healthy levels, 377
breast cancer, 204, 292
cancer survivors, 347
colorectal cancer, 202–3, 287
definition, 15, 199–200
endometrial cancer, 205–6, 301
evidence and judgements, 201–8
evidence interpretation, 201
interventions
adult, 333
children, 334
lung cancer, 206–7, 263–4
measurements, 56
pancreatic cancer, 273
public health goals, 376–8
recommendations, 376–8
report comparisons, 208, 354
types and levels, 200–1
weight gain determinants, 332–5
Physical activity levels (PALs), 200–1
future influences, 16
international trends, 14–17
projected levels of inactivity, 15
urban-industrial food systems, 10
Phytochemicals, 79, 182–3
Phytoestrogens, 43, 46
Pituitary hormones, lactation, 240
Plantains see Roots, tubers, and plantains
Plant-based diets, 191–2
Plant foods, goals and recommendations, 380
Poland, 20–1
Polychlorinated biphenyls (PCBs), 40–1
Polycyclic hydrocarbons, 36, 41, 119
Polyunsaturated fatty acids, 130, 136
‘Portfolio’ approach, 58
Postmenopausal breast cancer, 292
abdominal fatness, 226
adult attained height, 234, 293
body fatness, 219–20
fats and oils, 138–9
physical activity, 205
waist circumference, 226
waist to hip ratio, 226
weight gain, 227–8
Western diets, 195
Poultry, 382
composition, 118
consumption patterns, 119
definition, 117
sources, 117
Pound of Prevention trial, 332
Premenopausal breast cancer, 292
adult attained height, 235, 293
body fatness, 220–1
fats and oils, 138
high birth weight, 237–8
physical activity, 204–5
Prepubertal growth, 230–1
Processed meat, 117, 123–4
colorectal cancer, 123, 284–5
lung cancer, 124, 262
oesophageal cancer, 123, 257
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prostate cancer, 307
stomach cancer, 124, 268–9
Progesterone, 221
Projections, 244
Promotion, 41–2
Prostate cancer, 305–9
alpha-tocopherol, 109, 187
beta-carotene, 105, 185, 308–9
calcium, 134, 307
carotenoids, 103–5
evidence and judgements, 306–9
evidence interpretation, 306
gamma-tocopherol, 109
international trends, 21–2
lycopene, 103–4
milk and diary products, 131–2
pathogenesis, 306
physical activity, 208
processed meat, 124
pulses, 113
report comparisons, 309
selenium, 109–10, 188
soya, 113
tomatoes, 103
trends, incidence, and survival, 305–6
vitamin E, 108–9
Western diets, 194
Prostate specific antigen (PSA), 305
Proteins, 180–1, 183
Pro-vitamin A carotenoids, 101, 103
Public health goals, 373–90
alcohol, 384
animal foods, 382
body fatness, 375
breastfeeding, 388
food processing/preservation, 385
physical activity, 377
plant foods, 380–1
principles of
broad based, 369
cancer, 370
challenging, need to be, 372
global, 369
gradual changes, 372
impact, 370
integrated, 369
other disease prevention, 371
quantification, 371
supplementation, 387
weight gain, 379
Pulses (legumes), 112–13
composition, 80
consumption patterns, 81
definition, 77
prostate cancer, 113, 306
sources, 77
stomach cancer, 112–13, 268
Pyridoxine (vitamin B6), 78, 107, 256
Q
Quantification of risk, 58
Quercetin, 78
lung cancer, 112, 262
R
Radiation, 40, 291, 316
Randomised controlled trials (RCT), 51, 345–7
Rapeseed oil, 137
Raw vegetables
oesophageal cancer, 85
oral cancers, 83
stomach cancer, 89
Reactive oxygen species, 38, 44
‘Recovery’ biomarkers, 56
Rectal cancer, 20, 22, 217
Red meat
colorectal cancer, 284
endometrial cancer, 300–1
lung cancer, 262
lymphoid and haemopoietic cancers, 320
oesophageal cancer, 256
pancreatic cancer, 273
Red wine, composition, 158
Refrigeration, 144, 385
Religious diets, 192
Renal cancer see Kidney cancer
Replicative potential, limitless, 42–4
Report findings, other, 348–58
cancer, 355–8
chronic disease (non-cancer), 352–5
comparisons, 355
data interpretation, 350
diseases and exposures, 349
infectious diseases, 351–2
method, 349–50
nutritional deficiencies, 350–1
obesity, 355
physical activity, 354
reports reviewed, 349–50
weight gain, 355
Research issues, 360–3
cancer survivors, 363
environmental and genetic factors, 362
evidence updating, 361
food production methods, 363
geographic variations, 363
growth and development, 362–3
measurement improvement, 363
nutrition linkage mechanisms, 362
principles, 361
weight loss, 362
Retinoic acid, 42
Retinol, 184–5
lung cancer, 184, 263
skin cancer, 184, 317
Risk quantification, 58
Roasting, 176
Roots, tubers, and plantains, 67–74
composition, 69
consumption patterns, 70–1
definitions, 68–9
evidence and judgements, 71–3
evidence interpretation, 71
oesophageal cancer, 86
previous report comparisons, 114
stomach cancer, 91
Ruminant animals, 130
S
Salt, 141–7
chronic disease, 353–4
composition, 143
consumption patterns, 143
definition, 142
evidence and judgements, 144–7
evidence interpretation, 143–4
report comparisons, 147, 358
sources, 142
stomach cancer, 269
Salted foods, 143
recommendations, 385
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stomach cancer, 146, 269–70
Saturated fats, 136
Schistosomiasis, 150, 313
Schmidtz trial, 332
Sedentary activity, 16, 201, 335
Seeds see Nuts and seeds
Selenium, 36, 78, 188–9
cancer survivors, 346
colorectal cancer, 111–12, 189, 284, 287
foods containing, 109
lung cancer, 109, 261–3
prostate cancer, 109–10, 307–8
skin cancer, 188–9, 317
stomach cancer, 111, 268
Seventh-day Adventist diets, 195
Sex hormones, 39, 232
Sexual maturity, 232
Shah trial, 336, 337
Sheppard trial, 336, 337
Silverman trial, 336
Skin cancer, 315–17
arsenic, 152–3, 316–17
beta-carotene, 105, 317
supplementation, 186–7
carotenoids, 105–6
evidence and judgements, 316–17
evidence interpretation, 316
pathogenesis, 316
previous report comparisons, 317
retinol supplements, 184, 317
selenium, 188–9, 317
trends, incidence, and survival, 315–16
Smoked foods, 127, 269
Sodium, 143, 145
Soft drinks, 148–56
chronic disease, 354
consumption patterns, 151, 152
definition, 149
evidence and judgements, 152–6
evidence interpretation, 151–2
sources, 149
Soft juices, composition, 151
Solvents, 176
South Africa, 8–9
Soya
prostate cancer, 113, 306
stomach cancer, 112–13
Soya bean oil, 137
Spain, 22–3
Spices, 78, 113
Spirits/liquors
composition, 158
laryngeal cancer, 161–2
liver cancer, 170
mouth cancer, 161–2
oesophageal cancer, 164
pharyngeal cancer, 161–2
sources, 158
Starchy foods, 69, 381
Steaming, 176, 385
Stem cells, 35
Steroid hormones, fats and oils, 139
Stewing, 176
Stomach cancer, 265–70
animal products, 268–9
chilli, 113, 268
China, 10
evidence and judgements, 267–70
evidence interpretation, 267
fruits, 90, 98–9, 268
grilled/barbecued meat, 127–8
Helicobacter pylori, 20, 266
industrial chemicals, 266–7
infectious agents, 266
international trends, 19–20
migrant mortality, 22
nitrates, 269
nitrosamines, 266
pathogenesis, 266
previous report comparisons, 270
processed meat, 124, 268–9
pulses (legumes), 112–13, 268
salt, 145–6
salted foods, 146, 269–70
selenium, 111, 268
smoked foods, 127
soya, 112–13
trends, incidence, and survival, 265–6
vegetables, 86–93, 267
Western diets, 194
Study design options, 361
Sucrose, 142
Sugars, 8, 141–7
chronic disease, 353–4
colorectal cancer, 144–5, 286
composition, 142–3
consumption patterns, 143
definition, 142
dietary requirement, 142–3
evidence and judgements, 144–7
evidence interpretation, 143–4
extrinsic, 141–2
manufactured foods, 142
previous report comparisons, 147
public health goals, 381
recommendations, 381
report comparisons, 358
sources, 142
Sugary drinks
public health goals and recommendations, 379
recommendations, 379
weight gain determinants, 339
Sunflower seed oil, 137
Sunlight, 40
Supplementation, 179–89
bladder cancer, 346
cancer survivors, 346
chronic disease, 354
evidence and judgements, 183–9
evidence interpretation, 183
infectious diseases, 352
levels, 183
nutritional deficiencies, 351
phytochemicals, 182–3
public health goals, 386–7
recommendations, 386–7
report comparisons, 189, 358
Surveillance, Epidemiology and End Results (SEER) programme, 57
Sustained angiogenesis, 46
Sweeteners, chemical, 143
Swinburn trial, 336, 337
Systematic literature reviews, 54
T
Tap water quality, 149
Tea, 148
consumption trends, 149, 152
previous report comparisons, 156
sources, 149–50
Television viewing, 331, 340
Telomeres, 42
Testicular cancer, 319
Theophylline, 151
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Therapies
conventional, 345
unconventional, 345
Thermodynamics, 327–8
Thyroid cancer, 318–19
adult attained height, 318–19
body fatness, 318
Western diets, 195
Tissue invasion, 46
Tobacco use, 40, 393
bladder cancer, 313
cervical cancer, 304
chewing, 246
colorectal cancer, 286
kidney cancer, 311
lung cancer, 260
oesophageal cancer, 254
oral cancers, 246–7, 248
Tomatoes
oesophageal cancer, 86
oral cancers, 84
prostate cancer, 103
stomach cancer, 88–9
Toubro trial, 336, 337
Trace elements, 182
Traditional dietary patterns, 191–2
Transcription factors, 33, 35
Trans-fatty acids, 136–7
Transport-related physical activity, 15
Trends see International variations and trends
Triglycerides, 136
Tubers see Roots, tubers, and plantains
Tumour suppressor genes, 35, 38
Tylosis A, 254
U
Undernutrition, 39, 232
United Kingdom, 18–19
United States of America, 24–5
Unsaturated fats, 136
Urban industrial food systems, 7–10
dietary patterns, 190
ill-effects, 9
UV-damaged cells, 316
UV radiation, 40
V
Vegan diets, 192
Vegetables
allium see Allium vegetables
chronic disease, 353
classification, 82
composition, 79
consumption patterns, 80–1
cruciferous see Cruciferous vegetables
definition, 77
endometrial cancer, 92
global consumption, 73
green leafy
oesophageal cancer, 86
oral cancers, 83
ovarian cancer, 92
stomach cancer, 88, 91
infectious diseases, 351
laryngeal cancer, 82–4
lymphoid and haemopoietic cancers, 320
mouth cancer, 82–4
nasopharyngeal cancer, 90
non-starchy
colorectal cancer, 283
endometrial cancer, 300
lung cancer, 90–1, 261
mouth cancer, 82–4, 247
nasopharyngeal cancer, 251
oesophageal cancer, 84–5, 255
ovarian cancer, 91–2, 297
stomach cancer, 86–7, 267
weight gain determinants, 338
nutrient bioavailability, 79
nutritional deficiencies, 351
ovarian cancer, 91–2
pharyngeal cancer, 82–4
preparation, 79
previous report comparisons, 114
raw see Raw vegetables
recommended minimum daily amounts, 12
report comparisons, 358
sources, 77
thyroid cancer, 318
Vegetarian diets, 192, 195
Veterinary drugs, 173–4
Viruses, 40
Vitamin(s), 130, 181–2, 183
Vitamin A, 42, 184–5
Vitamin C, 78, 107–8, 256
Vitamin D, 40
colorectal cancer, 125–6, 285
meat, 118
Vitamin E, 78
oesophageal cancer, 108, 256
prostate cancer, 108–9, 308
W
Waist circumference
colorectal cancer, 225
endometrial cancer, 227
pancreatic cancer, 226
postmenopausal breast cancer, 226
Waist to hip ratio
colorectal cancer, 225
endometrial cancer, 227
pancreatic cancer, 226
postmenopausal breast cancer, 226
Water, 148–56
chronic disease, 354
composition, 150
consumption trends, 149, 151
contamination, 150
definition, 149
evidence and judgements, 152–6
evidence interpretation, 151–2
fluoridation, 176
sources, 149
Weight control, 329
Weight gain
adult, 213–14, 227–8
breast cancer, 294
fast food, 339–40
pancreatic cancer, 226
public health goals, 378–9
recommendations, 378–9
report findings, 355
Weight gain determinants, 322–41
animal fats, 338–9
definitions, 323–4
evidence and judgements, 331–40
evidence interpretation, 330–1
incidence, 324–7
method, 330
physical activity, 332–5
previous report comparisons, 341
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trends, 324–7
Western diets, 192, 194–5
colorectal cancer, 194
kidney cancer, 195
lung cancer, 195
oesophageal cancer, 194
pharyngeal cancer, 195
stomach cancer, 194
White vegetables, stomach cancer, 88–9
Wholegrain cereals, 68, 336–7
Whole milk, composition, 130
Wines
composition, 158
consumption patterns, 159
laryngeal cancer, 161
liver cancer, 169
mouth cancer, 161
oesophageal cancer, 163–4
pharyngeal cancer, 161
sources, 158
Women’s Healthy Lifestyle Project, 332
World Bank Living Standards Measurement Study, 13
Y
Yoghurt, 130
